PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gazzeri, S; Gouyer, V; Vourc'h, C; Brambilla, C; Brambilla, E				Gazzeri, S; Gouyer, V; Vourc'h, C; Brambilla, C; Brambilla, E			Mechanisms of p16(INK4A) inactivation in non small-cell lung cancers	ONCOGENE			English	Article						p16(INK4A); lung cancer; protein expression; mutation methylation; homozygous deletion	KINASE-4 INHIBITOR GENE; TUMOR-SUPPRESSOR GENE; RB PROTEIN; SOMATIC MUTATIONS; CYCLE INHIBITION; P18 GENES; IN-VITRO; EXPRESSION; CARCINOMA; GROWTH	The cyclin-dependent kinase inhibitor p16 (p16(INK4A)/CDKN2/MTS1) is a potent inhibitor of the cyclin D-dependent phosphorylation of the retinoblastoma gene (Rb) product, the inactivation of which induces loss of Rb-dependent G1 arrest through inappropriate phosphorylation of the Rb protein. To analyse the role of po16(INK4A) as a tumor suppressor in the genesis of non small cell lung cancers (NSCLC) and correlate loss of p16(INK4A) protein expression to genetic or epigenetic mechanisms, we have performed a comprehensive study of p16 status in a series of 43 NSCLC. To this end, we have investigated p16(INK4A) protein expression with immunohistochemistry, deletions of the gene by FISH, and determined the methylation status of exon 1 alpha using a PCR-based methylation assay. Finally, possible mutations were studied by SSCP and subsequent sequencing, Twenty one of the 43 (49%) NSCLC studied exhibited an absence of p16(INK4A) nuclear staining. Of these, three (14%) had frameshift or missense mutations, seven (33%) displayed methylation of exon1 alpha and 10 (48%) displayed homozygous deletions, In total, 95% of the tumors with p16(INK4A) negative staining carried one of these three alternative genetic or epigenetic alterations. Furthermore, a high degree of chromosome 9 polysomy was found (58%) in those tumors with p16(INK4A) inactivation. Taken together these results suggest that deregulation of the p16 gene locus is a frequently occurring event in NSCLC through distinct mechanisms including rare point mutations, promotor methylation and frequent homozygous deletions. Furthermore, our data show that immunohistochemistry is a rapid and an accurate technique for screening of p16(INK4A) gene inactivation events that result in loss of protein expression.	Inst Albert Bonniot, Grp Rech Canc Poumon, F-38706 La Tronche, France; Inst Albert Bonniot, INSERM, U309, DYOGEN, F-38706 La Tronche, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Vourc'h, Claire/AAE-3119-2022; gazzeri, sylvie/U-4669-2019; VOURC'H, Claire/L-9319-2013; Brambilla, Elisabeth MP/L-8796-2013; Gouyer, Valérie/R-4984-2018; gazzeri, sylvie/M-1961-2013; VOURC'H, Claire/AAG-8576-2021	gazzeri, sylvie/0000-0001-5817-1839; VOURC'H, Claire/0000-0002-7276-9359; Gouyer, Valérie/0000-0002-4223-7060; gazzeri, sylvie/0000-0001-5817-1839; VOURC'H, Claire/0000-0002-7276-9359				ARAP W, 1995, CANCER RES, V55, P1351; BRAMBILLA E, 1992, HUM PATHOL, V23, P993, DOI 10.1016/0046-8177(92)90260-A; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; DURO D, 1995, ONCOGENE, V11, P21; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GOUYER V, 1994, INT J CANCER, V58, P818, DOI 10.1002/ijc.2910580612; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hittelman WN, 1996, J CELL BIOCHEM, P57; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JIN X, 1995, CANCER RES, V55, P3520; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kratzke RA, 1996, CANCER RES, V56, P3415; LI Y, 1994, CANCER RES, V54, P6078; Liggett WH, 1996, CANCER RES, V56, P4119; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Packenham JP, 1995, CLIN CANCER RES, V1, P687; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUESNEL B, 1995, BRIT J CANCER, V72, P351, DOI 10.1038/bjc.1995.337; Reed AL, 1996, CANCER RES, V56, P3630; ROCCHI M, 1991, GENOMICS, V9, P517, DOI 10.1016/0888-7543(91)90419-F; Rusin MR, 1996, INT J CANCER, V65, P734, DOI 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; STONE S, 1995, CANCER RES, V55, P2988; TAM SW, 1994, CANCER RES, V54, P5816; *WHO CLASS, 1981, HIST TYP LUNG TUM; Wiest JS, 1997, CANCER RES, V57, P1	46	154	161	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	1998	16	4					497	504		10.1038/sj.onc.1201559	http://dx.doi.org/10.1038/sj.onc.1201559			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484839				2022-12-17	WOS:000071739400008
J	del Peso, L; Hernandez-Alcoceba, R; Embade, N; Carnero, A; Esteve, P; Paje, C; Lacal, JC				del Peso, L; Hernandez-Alcoceba, R; Embade, N; Carnero, A; Esteve, P; Paje, C; Lacal, JC			Rho proteins induce metastatic properties in vivo	ONCOGENE			English	Article						Rho proteins; metastasis; dbl; ost; vav	GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; JNK/SAPK SIGNALING PATHWAY; TUMOR-CELL INVASION; ACTIN STRESS FIBERS; PHOSPHOLIPASE-D; RAS TRANSFORMATION; 3T3 CELLS; LYSOPHOSPHATIDIC ACID; ADP-RIBOSYLATION	Rho proteins have been implicated in the regulation of multiple signal transduction processes, Some of the members of this family, including the rho gene from Aplysia californica and the human genes (rhoA, rhoB and rac-1), are proto-oncogenes since when properly mutated they can induce cell transformation, and the generated rho-transformed cells are tumorigenic when inoculated into mice, In addition to their tumorigenic activity, there is evidence suggesting that Rho proteins mag contribute to the metastatic phenotype, However, all the experiments implicating Rho proteins or Rho-regulating proteins in the induction of metastatic potential are either indirect or have been performed in vitro. In this study, we investigated whether cells transformed by rho oncogenes do have metastatic potential in vivo. We present evidence that cells transformed by the Aplysia californica rho gene, when injected directly into the blood stream are able to efficiently colonize lungs and secondary organs, consistent with the acquisition of the metastatic potential, Moreover, tumors derived from subcutaneous injections of these rho-transformed cells are also able to metastasize in distant organs, a strong support to the hypothesis that Rho proteins play a role in the metastatic phenotype. Finally, cells transformed by the human oncogenes dbl, vav and ost, three well-known guanine exchange factors for members of the Rho family, or cells transformed by the activated human rac-1 or rhoA genes do also have metastatic potential when injected into the blood stream, These results demonstrate that signaling pathways regulated by Rho proteins play an important role in the acquisition of the metastatic phenotype in vivo.	CSIC, Inst Invest Biomed, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid, Spain.		del Peso, Luis/K-9391-2014; embade, Nieves/K-5190-2014; Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; embade, Nieves/0000-0001-9878-3290; Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979				AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, RAS SUPERFAMILY GTPA, P203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LP, 1993, P NATL ACAD SCI USA, V90, P6523, DOI 10.1073/pnas.90.14.6523; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DAVIES BR, 1993, ONCOGENE, V8, P999; Esteve P, 1995, ONCOGENE, V11, P2657; ESTEVE P, UNPUB; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JIMENEZ B, 1995, ONCOGENE, V10, P811; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; LEEUWEN FN, 1995, ONCOGENE, V11, P2215; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI JK, 1994, ANTI-CANCER DRUG DES, V9, P363; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PERONA R, 1997, GENE DEV, V15, P463; PERONA R, 1993, RAS SUPERFAMILY GTPA; PESO L, 1996, BIOCHEM J, V322, P519; PONTA H, 1994, EUR J CANCER, V30A, P1995, DOI 10.1016/0959-8049(94)00393-J; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WILLIGER BT, 1995, J BIOL CHEM, V270, P29656; ZHANG J, 1993, J BIOL CHEM, V268, P22251	61	154	159	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3047	3057						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444953				2022-12-17	WOS:000070968000005
J	Visconti, R; Cerutti, J; Battista, S; Fedele, M; Trapasso, F; Zeki, K; Miano, MP; deNigris, F; Casalino, L; Curcio, F; Santoro, M; Fusco, A				Visconti, R; Cerutti, J; Battista, S; Fedele, M; Trapasso, F; Zeki, K; Miano, MP; deNigris, F; Casalino, L; Curcio, F; Santoro, M; Fusco, A			Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF kappa B p65 protein expression	ONCOGENE			English	Article						NF kappa B; p65-p50; thyroid; carcinomas; antisense; oncogenes	C-MYC; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION ACTIVATOR; INHIBITS PROLIFERATION; MESSENGER-RNA; DNA-BINDING; REL FAMILY; SUBUNIT; DIFFERENTIATION; TRANSFORMATION	We have investigated the role of the NF kappa B complex in the process of thyroid carcinogenesis by analysing thyroid carcinoma cell lines, A significant increase in p65 NF kappa B mRNA and protein expression, compared to normal thyroid cultures or tissue, was found in all of the cancer cell lines, Conversely, only a modest increase in the p50 NF kappa B mRNA and protein was found in most, but not all carcinoma cell lines, The block of p65 protein synthesis with specific antisense oligonucleotides greatly reduced the ability of two undifferentiated carcinoma cell lines to form colonies in agar and reduced their growth rate, On the other hand, no effect was observed in the same cell lines when treated with p50 specific antisense oligonucleotides. These inhibitory effects seem to be mediated by the suppression of c-myc gene expression, since treatment with antisense oligonucleotides for p65 gene interfered negatively with c-myc gene expression, Our results indicate that activation of the NF kappa B complex by overexpression of p65 plays a critical role in the process of thyroid cell transformation.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,CNR,I-80131 NAPLES,ITALY; IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT INTERNAL MED 1,YAHATONISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; UNIV UDINE,DIPARTIMENTO PATOL & MED SPERIMENTALE & CLIN,I-33100 UDINE,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; University of Occupational & Environmental Health - Japan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Udine			Fedele, Monica/C-1417-2015; Casalino, Laura/C-1506-2015; Curcio, Francesco/K-4669-2014; Visconti, Roberta/C-5299-2009; Giuseppina, Miano Maria/B-9169-2015; Battista, Sabrina/AAY-2981-2020; Miano, Maria Giuseppina/AAX-8437-2020; Miano, Maria Giuseppina/E-9056-2011; Cerutti, Janete/D-3513-2014	Fedele, Monica/0000-0002-9171-1312; Casalino, Laura/0000-0002-2557-0443; Battista, Sabrina/0000-0001-5899-9759; Miano, Maria Giuseppina/0000-0003-1396-9673; Miano, Maria Giuseppina/0000-0003-1396-9673; Visconti, Roberta/0000-0001-7613-3801; de nigris, filomena/0000-0002-2322-1557; Fusco, Alfredo/0000-0003-3332-5197; Cerutti, Janete/0000-0003-0156-8274; CURCIO, Francesco/0000-0002-9070-4807				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Cerutti J, 1996, CLIN CANCER RES, V2, P119; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HARLOW E, 1989, IMMUNOBLOTTING LAB M; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J, 1989, MOL CLONING LAB MANU; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127	44	154	157	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1987	1994		10.1038/sj.onc.1201373	http://dx.doi.org/10.1038/sj.onc.1201373			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365245				2022-12-17	WOS:A1997YA87200013
J	Crespo, P; Bustelo, XR; Aaronson, DS; Coso, OA; LopezBarahona, M; Barbacid, M; Gutkind, JS				Crespo, P; Bustelo, XR; Aaronson, DS; Coso, OA; LopezBarahona, M; Barbacid, M; Gutkind, JS			Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav	ONCOGENE			English	Article						Vav; signal transduction; JNK; MAP kinases; GTP-binding proteins	GUANINE-NUCLEOTIDE EXCHANGE; DBL-ONCOGENE PRODUCT; RECEPTOR TYROSINE KINASE; GTP-BINDING PROTEINS; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; RAS; ACTIVATION; PHOSPHORYLATION	The protein product of the human vav oncogene, Vav, exhibits a number of structural motifs suggestive of a role in signal transduction pathways, including a leucine-rich region, a plekstrin homology (PH) domain, a cysteine-rich domain, two SH3 regions, an SH2 domain, and a central Dbl homology (DH) domain. However, the transforming pathway(s) activated by Vav has not yet been elucidated. Interestingly, DH domains are frequently found in guanine nucleotide-exchange factors for small GTP-binding proteins of the Ras and Rho families, and it has been recently shown that, whereas Ras controls the activation of mitogen activated kinases (MAPKs), two members of the Rho family of small GTPases, Rac 1 and Cdc42, regulate activity of stress activated protein kinases (SAPKs), also termed c-jun N-terminal kinases (JNKs). The structural similarity between Vav and other guanine nucleotide exchange factors for small GTP-binding proteins, together with the recent identification of biochemical routes specific for members of the Ras and Rho family of GTPases, prompted us to explore whether MAPK or JNK are downstream components of the Vav signaling pathways. Using the COS-7 cell transient expression system, we have found that neither Vav nor the product of the I,av proto-oncogene, proto-Vav, can enhance the enzymatic activity of a coexpressed, epitope tagged MAPK. On the other hand, we have observed that, whereas proto-Vav can slightly elevate JNK/SAPK activity, oncogenic Vav potently activates JNK/SAPK to an extent comparable to that elicited by two guanine-nucleotide exchange factors for Rho family members, Dbl and Ost. We also show that point mutations in conserved residues within the cysteine rich and DH domains of Vav both prevent its ability to activate JNK/SAPK and render Vav oncogenically inactive. In addition, we found that coexpression of the Rac-1 N17 dominant inhibitory mutant dramatically diminishes JNK/SAPK stimulation by Vav, as well as reduces the focus-forming ability of Vav in NIH3T3 murine fibroblasts. Taken together, these findings provide the first evidence that Rac-1 and JNK are integral components of the Vav signaling pathway.	NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,PRINCETON,NJ 08543	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Bristol-Myers Squibb			Bustelo, Xose R./AAD-2081-2022; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Bustelo, Xose R./0000-0001-9398-6072; Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P177; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	41	154	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					455	460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760286				2022-12-17	WOS:A1996VB32800002
J	Kunath, T; OrdonezGarcia, C; Turbide, C; Beauchemin, N				Kunath, T; OrdonezGarcia, C; Turbide, C; Beauchemin, N			Inhibition of colonic tumor cell growth by biliary glycoprotein	ONCOGENE			English	Article						biliary glycoprotein; BGP; carcinoembryonic antigen; CEA; growth inhibitor; tumor; colon carcinoma	ANTIGEN GENE FAMILY; INTERCELLULAR-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN; ECTO-ATPASE; ENDOGENOUS SUBSTRATE; CYTOPLASMIC DOMAIN; TYROSINE KINASE; EXPRESSION; RECEPTOR; MEMBER	Biliary glycoproteins (BGPs) are members of the carcinoembryonic antigen (CEA) family. These glycoproteins function in vitro as intercellular adhesion molecules and, in the mouse, serve as receptors for the mouse hepatitis viruses. In previous studies, BGP expression has been reported to be generally downregulated in colon and liver carcinomas of human, rat and mouse origins. We now demonstrate that introduction of murine Bgp1 cDNA isoforms into a mouse colonic carcinoma cell line, negative for endogenous Bgpl expression, significantly alters the growth properties of these cells. Cells bearing two Bgpl isoforms were growth-retarded and exhibited a reduced ability to form colonies in an in vitro transformation assay, when compared to parental or control neo(r) cells. Furthermore, tumor formation was inhibited by 80% when cells bearing a full-length Bgpl isoform were injected into BALB/c syngeneic mice, while cells expressing a Bgpl isoform lacking most of the intracytoplasmic domain produced tumors as readily as the parental cells. These results indicate that a biliary glycoprotein isoform is involved in negative regulation of colonic tumor cell growth, by a process which requires its intracytoplasmic domain. The precise mechanisms causing Bgp-dependent tumor growth inhibition remain, however, to be defined.	MCGILL UNIV, CTR CANC, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA	McGill University; McGill University; McGill University; McGill University				Kunath, Tilo/0000-0002-8805-7356				AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRATTAIN MG, 1980, CANCER RES, V40, P2142; CHEN W, 1991, J CELL BIOL, V114, P310; COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; KIMBALL PM, 1978, BRIT J CANCER, V37, P1015, DOI 10.1038/bjc.1978.147; KUPRINA NI, 1990, HISTOCHEMISTRY, V94, P179, DOI 10.1007/BF02440185; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SPORNS O, 1995, P NATL ACAD SCI USA, V92, P542, DOI 10.1073/pnas.92.2.542; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TURBIDE C, 1991, J BIOL CHEM, V266, P309; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; VLERNINCKX K, 1991, CELL, V66, P107; YOKOMORI K, 1992, J VIROL, V66, P6194, DOI 10.1128/JVI.66.10.6194-6199.1992	40	154	157	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2375	2382						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570189				2022-12-17	WOS:A1995TK70200022
J	DURO, D; BERNARD, O; DELLAVALLE, V; BERGER, R; LARSEN, CJ				DURO, D; BERNARD, O; DELLAVALLE, V; BERGER, R; LARSEN, CJ			A NEW-TYPE OF P16(INK4)/MTS1 GENE TRANSCRIPT EXPRESSED IN B-CELL MALIGNANCIES	ONCOGENE			English	Article						P(16INK4)/MTS1 GENE EXPRESSION; LYMPHOID PROLIFERATIONS; CYTOGENETICS	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; SHORT ARM; NONRANDOM ABNORMALITIES; LYMPHOMATOUS FEATURES; HOMOZYGOUS DELETIONS; CHROMOSOME-9; INTERFERON; TRANSLOCATION; ASSOCIATION	Chromosome band 9p21-22 is frequently altered by nonrandom abnormalities, mainly deletions, in hemopoietic malignancies of the lymphoid lineage. We have analysed a translocation t(9;14)(p21-p22;q11) in a B-cell type acute lymphoblastic leukemia. Location of the 14q11 breakpoint within the TCR-alpha/delta locus allowed the isolation of a fusion transcript composed of a 3' segment containing part of the constant region of the TCR-alpha gene and a 5' segment from chromosome 9, designated 0.18. This 0.18 segment was also part of cDNAs isolated from two tumoral B-cell lines (RPMI-8226, Raji). In both cases, 0.18 was juxtaposed 5' to a sequence corresponding to exons 2 and 3 of the p16(INK4)/MTS1 gene which is located on band 9p21-22. Unexpectedly, none of the two ATG codons found in 0.18 was in phase with that of the exons 2 and 3 of p16(INK4)/MTS1. Furthermore, in vitro translation product of a RPMI-8226 cDNA clone generated a product that was not immunoprecipitated by antibodies specific of the C-terminal end of the p16(INK4)/MTS1 protein. Evidence for similar transcripts in non tumoral lymphoid B cells (unstimulated peripheral blood lymphocytes (PBL) and lymphoblastoid cell lines) were obtained by using amplimers representative of the 0.18 segment and the p16(INK4)/MTS1 exon 2. Altogether, these data are consistent with the existence of a new type of p16(INK4)/MTS1 transcript whose significance is discussed.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; CNRS,SDI 16954,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P915; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CARROLL AJ, 1987, BLOOD, V70, P1962; CARROLL AJ, 1987, BLOOD, V69, P735; CHENG JQ, 1994, CANCER RES, V54, P5547; CHILCOTE RR, 1985, NEW ENGL J MED, V313, P286, DOI 10.1056/NEJM198508013130503; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN A, 1994, CANCER RES, V54, P344; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DURO D, 1994, CR ACAD SCI III-VIE, V317, P913; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEYMAN M, 1993, INT J CANCER, V54, P748, DOI 10.1002/ijc.2910540507; HUANG DP, 1994, CANCER RES, V54, P4003; ISSHIKI K, 1994, ONCOGENE, V9, P1649; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KOWALCZYK J, 1983, CANCER GENET CYTOGEN, V9, P383, DOI 10.1016/0165-4608(83)90086-9; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MATHIEUMAHUL D, 1986, J EXP MED, V163, P1308, DOI 10.1084/jem.163.5.1308; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MITELMAN F, 1991, CATALOG CHROMOSOME A; MORI T, 1994, CANCER RES, V54, P3396; MURPHY SB, 1989, BLOOD, V74, P409; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1992, CANCER RES, V52, P2523; ORLOW I, 1994, CANCER RES, V54, P2848; ROMANROMAN S, 1991, EUR J IMMUNOL, V21, P2848; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SOULARD M, 1991, EXP CELL RES, V193, P59, DOI 10.1016/0014-4827(91)90538-6; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TSAI YC, 1990, CANCER RES, V50, P44	44	154	166	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					21	29						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624129				2022-12-17	WOS:A1995RJ29500004
J	BRONDELLO, JM; MCKENZIE, FR; SUN, H; TONKS, NK; POUYSSEGUR, J				BRONDELLO, JM; MCKENZIE, FR; SUN, H; TONKS, NK; POUYSSEGUR, J			CONSTITUTIVE MAP KINASE PHOSPHATASE (MKP-1) EXPRESSION BLOCKS G1 SPECIFIC GENE-TRANSCRIPTION AND S-PHASE ENTRY IN FIBROBLASTS	ONCOGENE			English	Article						CELL CYCLE ENTRY; GENE TRANSCRIPTION; GROWTH CONTROL; MAP KINASE CASCADE; PHOSPHATASES	PROTEIN-TYROSINE-PHOSPHATASE; IMMEDIATE-EARLY GENE; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; C-FOS; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; COMPLEX-FORMATION; ENCODED PROTEIN; 3T3 CELLS	MAP kinase (mitogen activated protein kinase) represents a ubiquitously expressed family of kinases whose long term activation via phosphorylation is essential for the mitogenic response in fibroblasts. Two family members, p42 and p44 MAP kinase are cytosolic proteins in quiescent cells, but become nuclear following mitogenic stimulation, Inactivation of MAP kinases occurs via a specific phosphatase, MKP-1. Hence, we examined the localisation of this phosphatase, to determine the cellular site of MAP kinase inactivation, Transient transfection of CCL39 fibroblasts with epitope-tagged MKP-1 showed the protein to be entirely nuclear in both quiescent and mitogen stimulated cells, whereas a catalytically inactive mutant in which the essential cysteine was mutated to serine (MKP-1CS) was predominately cytoplasmic and again serum stimulation failed to alter the protein's localisation. Expression of either wild type or inactive MKP-1 did not alter the cytosolic localisation of p44 MAP kinase in quiescent cells nor the ability of MAP kinase to translocate to the nucleus following mitogen stimulation, Expression of wild type MKP-1 inhibited serum stimulated early (c-fos promoter) and late (dhfr promoter) transcriptional events as web as entry into S-phase. This inhibition was reversed by the co-expression of an active MAP kinase. We conclude that in the continual expression of MKP-1, the cellular localisation of MAP kinase is unaffected and that inactivation of MAP kinase by MKP-1 is a nuclear process leading to the inhibition of cell division.	CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE,FRANCE; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Cold Spring Harbor Laboratory			Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945				AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNET A, 1994, ONCOGENE, V9, P3379; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; EGAN SE, 1993, NATURE, V363, P35; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KWAK SP, 1993, J BIOL CHEM, V269, P3596; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MELOCHE S, 1992, MOL ENDOCRINOL, V63, P845; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WARNE PH, 1993, NATURE, V364, P1031; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	58	154	159	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1895	1904						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761091				2022-12-17	WOS:A1995QZ92600003
J	IWAMOTO, T; TANIGUCHI, M; ASAI, N; OHKUSU, K; NAKASHIMA, I; TAKAHASHI, M				IWAMOTO, T; TANIGUCHI, M; ASAI, N; OHKUSU, K; NAKASHIMA, I; TAKAHASHI, M			CDNA CLONING OF MOUSE RET PROTOONCOGENE AND ITS SEQUENCE SIMILARITY TO THE CADHERIN SUPERFAMILY	ONCOGENE			English	Note							CELL-ADHESION MOLECULE; GENE FAMILY; EXPRESSION; PROTOONCOGENE; NEUROBLASTOMA; IDENTIFICATION; UVOMORULIN; DISEASE	We report the nucleotide sequence of the mouse ret proto-oncogene (proto-ret) and the deduced amino acid sequence. It encodes a transmembrane tyrosine kinase of 1115 amino acids that shows 83% homology with the human proto-Ret protein. The amino acid sequence revealed that the structures of the extracellular domain as well as the tyrosine kinase domain are similar in human and mouse proto-Ret proteins. Interestingly, the extracellular domains of both human and mouse proto-Ret proteins contain a cadherin-related sequence that is known to be important for Ca2+-dependent homophilic binding of the cadherins. When we examined transcription of the proto-ret gene in a variety of mouse tissues, it was detected in lymph nodes of C3H/HeJ-gld/gld mice and in normal mouse spinal cord. Furthermore, its transcription was found in the Neuro-2a mouse neuroblastoma cell line but not in 13 other rodent cell lines surveyed. Western blot analysis showed that proto-Ret proteins are expressed as 140-kDa and 160-kDa glycoproteins in Neuro-2a cells.	NAGOYA UNIV,SCH MED,DEPT IMMUNOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University			TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; IKEDA I, 1990, ONCOGENE, V5, P1291; KUMA K, 1992, IN PRESS P JPN ACAD; KUMA K, 1992, IN PRESS MOL BIOL EV; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1990, ONCOGENE, V5, P1595; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIGUCHI M, 1992, ONCOGENE, V7, P1491	23	154	162	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1087	1091						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455936				2022-12-17	WOS:A1993KT22000035
J	LIU, C; PARK, M; TSAO, MS				LIU, C; PARK, M; TSAO, MS			OVEREXPRESSION OF C-MET PROTOONCOGENE BUT NOT EPIDERMAL GROWTH-FACTOR RECEPTOR OR C-ERBB-2 IN PRIMARY HUMAN COLORECTAL CARCINOMAS	ONCOGENE			English	Note							HUMAN GASTRIC-CARCINOMA; HUMAN-BREAST CANCER; EGF RECEPTOR; NEU ONCOGENE; TYROSINE KINASE; ENHANCED EXPRESSION; GENE AMPLIFICATION; HUMAN-COLON; CELL-LINE; PHOSPHORYLATION	The epidermal growth factor receptor (EGFR) and the protein products of c-erbB-2 and c-met proto-oncogenes belong to a family of growth factor receptors with tyrosine kinase activity. In human colonic carcinomas, the expression of the EGFR and c-erbB-2 have been studied at the protein level only, while c-met expression has not been reported. We have examined the mRNA expression of these genes in human normal colorectal mucosa and primary carcinomas. The results demonstrate that the normal mucosa shows highly variable levels of EGFR and c-erbB-2 mRNAs, but expresses consistently low amounts of c-met mRNA. Colorectal carcinomas did not express significantly higher levels of the EGFR and c-erbB-2 mRNAs than the normal mucosa. In contrast, c-met was consistently and significantly overexpressed (mean sixfold) in carcinomas as compared with normal mucosa. Seventy percent of paired normal-tumor specimens showed a tumor to normal c-met mRNA ratio of greater than 4. The expression of c-met mRNA was also enhanced in the adenomas, suggesting that overexpression of this proto-oncogene may have mechanistic significance in the early stages of human colorectal carcinogenesis.	MONTREAL GEN HOSP,DEPT PATHOL,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3G 1A4,QUEBEC,CANADA; LUDWIG INST CANC RES,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; McGill University; Ludwig Institute for Cancer Research			Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; 				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1988, CANCER RES, V48, P1238; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; COHEN JA, 1989, ONCOGENE, V4, P81; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEMILIA J, 1989, ONCOGENE, V4, P1233; Dukes CE, 1940, J PATHOL BACTERIOL, V50, P527, DOI 10.1002/path.1700500314; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLEY GG, 1989, ONCOGENE, V4, P963; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GREEN MR, 1985, J INVEST DERMATOL, V85, P239, DOI 10.1111/1523-1747.ep12276708; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; KAHN P, 1986, ONCOGENES GROWTH FAC; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KORETZ K, 1990, VIRCHOWS ARCH A, V416, P343, DOI 10.1007/BF01605295; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MCCLARE JT, 1988, STATISTICS; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; NANNEY LB, 1984, J INVEST DERMATOL, V82, P165, DOI 10.1111/1523-1747.ep12259731; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PARK M, 1986, CELL, V45, P894; PFEIFFER A, 1990, GASTROENTEROLOGY, V98, P961, DOI 10.1016/0016-5085(90)90020-2; ROTHBAUER E, 1989, KLIN WOCHENSCHR, V67, P518, DOI 10.1007/BF01719776; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TSAO MS, 1989, MOL CARCINOGEN, V2, P144, DOI 10.1002/mc.2940020307; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEIDNER U, 1990, CANCER RES, V50, P4504; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; YASUI W, 1988, CANCER RES, V48, P137; YONEMURA Y, 1989, ONCOLOGY, V46, P158	44	154	173	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					181	185						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741162				2022-12-17	WOS:A1992HC22700024
J	MANO, H; ISHIKAWA, F; NISHIDA, J; HIRAI, H; TAKAKU, F				MANO, H; ISHIKAWA, F; NISHIDA, J; HIRAI, H; TAKAKU, F			A NOVEL PROTEIN-TYROSINE KINASE, TEC, IS PREFERENTIALLY EXPRESSED IN LIVER	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; NUCLEOTIDE-SEQUENCE; HEMATOPOIETIC-CELLS; GROWTH-FACTOR; C-SRC; ONCOGENE; GENE; VIRUS; IDENTIFICATION; RECEPTOR	To identify protein-tyrosine kinases which play an important role in the process of hepatocarcinogenesis, we have screened a murine liver cDNA library with v-fps kinase domain as a probe. Using low stringency screening, we could isolate cDNAs of a putative protein-tyrosine kinase, tec (tyrosine kinase expressed in hepatocellular carcinoma). Nucleotide sequences of the cDNAs show that the C-terminal domain of its predicted protein has significant homology with that of the members of the src family. The tec gene is expressed mainly in liver and faintly in heart, kidney and ovary. Northern analysis further shows that in 2 out of 4 cell lines of human hepatocellular carcinoma (HCC) the tec gene is highly expressed compared to normal human liver. This is the first report showing a protein-tyrosine kinase which may be specifically involved in the cell growth of hepatocytes or in the step of hepatocarcinogenesis.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BLUMBERG BS, 1981, NEW ENGL J MED, V304, P782, DOI 10.1056/NEJM198103263041312; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; GU JR, 1988, CARCINOGENESIS, V9, P697, DOI 10.1093/carcin/9.5.697; HEINKOFF S, 1984, GENE, V28, P351; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOTARIO V, 1984, CANCER CELL, V2, P425; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; YANG SS, 1988, LEUKEMIA S, V2, P102	37	154	160	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1781	1786						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284097				2022-12-17	WOS:A1990ET43600007
J	ECCLES, DM; CRANSTON, G; STEEL, CM; NAKAMURA, Y; LEONARD, RCF				ECCLES, DM; CRANSTON, G; STEEL, CM; NAKAMURA, Y; LEONARD, RCF			ALLELE LOSSES ON CHROMOSOME-17 IN HUMAN EPITHELIAL OVARIAN-CARCINOMA	ONCOGENE			English	Note									WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; JAPANESE FDN CANC RES,TOSHIMA KU,TOKYO 170,JAPAN; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Japanese Foundation for Cancer Research; University of Edinburgh	ECCLES, DM (corresponding author), WESTERN GEN HOSP,IMPERIAL CANC RES FUND,EDINBURGH MED ONCOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Eccles, Diana/K-6327-2019	Eccles, Diana/0000-0002-9935-3169				DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; GREEN AR, 1988, BRIT J CANCER, V58, P115, DOI 10.1038/bjc.1988.176; LEE JH, 1989, CANCER RES, V49, P1220; LEE JH, 1989, CANCER GENET CYTOGEN, P243; MACKAY J, 1989, LANCET, V1, P154; Maniatis T., 1982, MOL CLONING; Nakamura Y, 1988, GENOMICS, V2, P302, DOI 10.1016/0888-7543(88)90018-3; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	11	154	154	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1599	1601						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250917				2022-12-17	WOS:A1990EK50200023
J	TAKAHASHI, M; BUMA, Y; HIAI, H				TAKAHASHI, M; BUMA, Y; HIAI, H			ISOLATION OF RET PROTO-ONCOGENE CDNA WITH AN AMINO-TERMINAL SIGNAL SEQUENCE	ONCOGENE			English	Note											TAKAHASHI, M (corresponding author), AICHI CANC CTR,RES INST,EXPTL PATHOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.		Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	5	154	157	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					805	806						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660074				2022-12-17	WOS:A1989AA66000018
J	SCHONTHAL, A; BUSCHER, M; ANGEL, P; RAHMSDORF, HJ; PONTA, H; HATTORI, K; CHIU, R; KARIN, M; HERRLICH, P				SCHONTHAL, A; BUSCHER, M; ANGEL, P; RAHMSDORF, HJ; PONTA, H; HATTORI, K; CHIU, R; KARIN, M; HERRLICH, P			THE FOS AND JUN/AP-1 PROTEINS ARE INVOLVED IN THE DOWN-REGULATION OF FOS TRANSCRIPTION	ONCOGENE			English	Article									UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	SCHONTHAL, A (corresponding author), KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,POSTFACH 3640,D-7500 KARLSRUHE 1,FED REP GER.		Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634; Schonthal, Axel/0000-0003-0662-5653				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1985, CANCER CELL, V3, P315; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BUSCHER M, 1988, ONCOGENE, V3, P301; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CURRAN T, 1984, CELL, V36, P259; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA M, 1986, MOL CELL BIOL, V7, P639; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P10; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHONTHAL A, 1988, IN PRESS COLD SPRING, V53; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; WILLIAMS JG, 1985, NUCLEIC ACID HYBRIDI	43	154	155	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					629	636						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2498806				2022-12-17	WOS:A1989U768800014
J	DREBIN, JA; LINK, VC; GREENE, MI				DREBIN, JA; LINK, VC; GREENE, MI			MONOCLONAL-ANTIBODIES SPECIFIC FOR THE NEU ONCOGENE PRODUCT DIRECTLY MEDIATE ANTI-TUMOR EFFECTS INVIVO	ONCOGENE			English	Article									HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV PENN,SCH MED,DEPT LAB MED,DIV IMMUNOL,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; University of Pennsylvania								BERG H, 1984, CELL, V36, P963; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1986, IMMUNOLOGY CANCER, P277; GREENE MI, 1979, AM J PATHOL, V95, P159; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HERLYN D, 1985, J IMMUNOL, V134, P1300; HOLLINGSWORTH MA, 1986, CANCER RES, V46, P2482; HOUGHTON AN, 1986, SEMIN ONCOL, V13, P165; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P117; JONES JF, 1980, J IMMUNOL, V125, P926; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MASUI H, 1984, CANCER RES, V44, P1002; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; PEPYS MB, 1972, NATURE-NEW BIOL, V237, P157, DOI 10.1038/newbio237157a0; REISFELD RA, 1986, SEMIN ONCOL, V13, P153; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROTH JA, 1986, J IMMUNOL, V136, P2305; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TROWBRIDGE IS, 1981, NATURE, V294, P171, DOI 10.1038/294171a0; VOLLMERS HP, 1985, CELL, V40, P547, DOI 10.1016/0092-8674(85)90203-X; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YOKOTA J, 1986, LANCET, V1, P765; YUNG YP, 1977, J IMMUNOL, V119, P1310	33	154	182	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					387	394						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2896329				2022-12-17	WOS:A1988M947200011
J	Kasinski, AL; Kelnar, K; Stahlhut, C; Orellana, E; Zhao, J; Shimer, E; Dysart, S; Chen, X; Bader, AG; Slack, FJ				Kasinski, A. L.; Kelnar, K.; Stahlhut, C.; Orellana, E.; Zhao, J.; Shimer, E.; Dysart, S.; Chen, X.; Bader, A. G.; Slack, F. J.			A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer	ONCOGENE			English	Article							MOUSE MODELS; MIR-34A; ACTIVATION; EXPRESSION; INITIATION; DELIVERY; TARGET; GROWTH; RAS	Targeted cancer therapies, although often effective, have limited utility owing to preexisting primary or acquired secondary resistance. Consequently, agents are sometimes used in combination to simultaneously affect multiple targets. MicroRNA mimics are excellent therapeutic candidates because of their ability to repress multiple oncogenic pathways at once. Here we treated the aggressive Kras; p53 non-small cell lung cancer mouse model and demonstrated efficacy with a combination of two tumor-suppressive microRNAs (miRNAs). Systemic nanodelivery of miR-34 and let-7 suppressed tumor growth leading to survival advantage. This combinatorial miRNA therapeutic approach engages numerous components of tumor cell-addictive pathways and highlights the ability to deliver multiple miRNAs in a safe and effective manner to target lung tissue.	[Kasinski, A. L.; Stahlhut, C.; Shimer, E.; Chen, X.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Kasinski, A. L.; Orellana, E.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Kelnar, K.; Zhao, J.; Dysart, S.; Bader, A. G.] Mirna Therapeut Inc, Austin, TX 78744 USA; [Slack, F. J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Yale University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Slack, FJ (corresponding author), Harvard Univ, Sch Med, Dept Pathol, BIDMC, 3 Blackfan Circle CLS412, Boston, MA 02115 USA.	abader@mirnarx.com; fslack@bidmc.harvard.edu	Orellana, Esteban/I-3653-2014; Kasinski, Andrea L/E-7951-2014; Kasinski, Andrea/AAF-3864-2021; Orellana, Esteban/N-8004-2019	Orellana, Esteban/0000-0003-4369-9416; Kasinski, Andrea/0000-0002-9602-7827; Orellana, Esteban/0000-0003-4369-9416; Stahlhut, Carlos/0000-0002-8472-7156; Slack, Frank/0000-0001-8263-0409	American Cancer Society [PF-11-244-01]; NIH [CA178091, CA131301]; Cancer Prevention Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE [R01CA131301, R00CA178091, K99CA178091, F32CA153885] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	ALK was supported by an American Cancer Society Fellowship (PF-11-244-01) and an NIH Pathway to Independence Award (CA178091). This work was supported by a grant to FJS from the NIH (CA131301) and by a commercialization grant from the Cancer Prevention Research Institute of Texas (CPRIT) to AGB.	Bader Andreas G., 2012, Frontiers in Genetics, V3, P120, DOI 10.3389/fgene.2012.00120; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Gatsonis CA, 2011, RADIOLOGY, V258, P243, DOI 10.1148/radiol.10091808; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kasinski AL, 2012, CANCER RES, V72, P5576, DOI 10.1158/0008-5472.CAN-12-2001; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lin PY, 2010, BRIT J CANCER, V103, P1144, DOI 10.1038/sj.bjc.6605901; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Singh M, 2010, NAT BIOTECHNOL, V28, P585, DOI 10.1038/nbt.1640; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Xue W, 2011, CANCER DISCOV, V1, P236, DOI 10.1158/2159-8290.CD-11-0073; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zhao J, 2013, MOL THER, V21, P1678, DOI 10.1038/mt.2013.148	34	153	160	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3547	3555		10.1038/onc.2014.282	http://dx.doi.org/10.1038/onc.2014.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25174400	Green Accepted			2022-12-17	WOS:000357434900007
J	Yan, L; Zhou, J; Gao, Y; Ghazal, S; Lu, L; Bellone, S; Yang, Y; Liu, N; Zhao, X; Santin, AD; Taylor, H; Huang, Y				Yan, L.; Zhou, J.; Gao, Y.; Ghazal, S.; Lu, L.; Bellone, S.; Yang, Y.; Liu, N.; Zhao, X.; Santin, A. D.; Taylor, H.; Huang, Y.			Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation	ONCOGENE			English	Article							EPITHELIAL-OVARIAN-CANCER; C-MYC ONCOGENE; NONCODING RNA; SIGNALING PATHWAY; H19; EXPRESSION; GROWTH; LET-7; METASTASIS; BINDING	The imprinted, developmentally regulated H19 long noncoding RNA has been implicated in the pathogenesis of diverse human cancers, but the underlying mechanisms have remained poorly understood. Here, we report that H19 promotes tumor cell migration and invasion by inhibiting let-7, a potent tumor suppressor microRNA that functions to posttranscriptionally suppress the expression of oncogenes that regulate cell growth and motility. We show that H19 depletion impairs, whereas its overexpression enhances the motility and invasiveness of tumor cells. These phenomena occur, at least in part through affecting let-7-mediated regulation of metastasis-promoting genes, including Hmga2, c-Myc and Igf2bp3. This H19/let-7-dependent regulation is recapitulated in vivo where co-expressions of oncogenes and H19 exist in both primary human ovarian and endometrial cancers. Furthermore, we provide evidence that the anti-diabetic drug metformin inhibits tumor cell migration and invasion, partly by downregulating H19 via DNA methylation. Our results reveal a novel mechanism underpinning H19-mediated regulation in metastasis and may explain why in some cases increased let-7 expression unexpectedly correlates with poor prognosis, given the widely accepted role for let-7 as a tumor suppressor. Targeting this newly identified pathway might offer therapeutic opportunities.	[Yan, L.; Zhao, X.] Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China; [Yan, L.; Zhou, J.; Gao, Y.; Ghazal, S.; Bellone, S.; Yang, Y.; Liu, N.; Santin, A. D.; Taylor, H.; Huang, Y.] Yale Univ, Sch Med, Yale Stem Cell Ctr, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06510 USA; [Zhou, J.] Zhejiang Univ, Sch Med, Affiliated Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Gao, Y.] Chinese Peoples Liberat Army Gen Hosp, Dept Gynecol & Obstet, Beijing 100853, Peoples R China; [Lu, L.] Yale Univ, Sch Med, Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT 06510 USA; [Liu, N.] Cent S Univ, Xiangya Hosp, Dept Obstet & Gynecol, Changsha, Hunan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Yale University; Zhejiang University; Chinese People's Liberation Army General Hospital; Yale University; Central South University	Huang, Y (corresponding author), Yale Univ, Sch Med, Yale Stem Cell Ctr, Dept Obstet Gynecol & Reprod Sci, 310 Cedar St LSOG 205C, New Haven, CT 06510 USA.	yingqun.huang@yale.edu	Zhou, Jichun/Q-8646-2019	Zhou, Jichun/0000-0002-0727-4034; Bellone, Stefania/0000-0001-5909-5292	State of Connecticut Stem Cell grant [09SCAYALE14]; Albert McKern Scholar Award [1063338]; National Natural Science Foundation of China [81202057, 81272858]	State of Connecticut Stem Cell grant; Albert McKern Scholar Award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Gil Mor for A2780 and Tara R127 cells. This work was supported by the following grants: the State of Connecticut Stem Cell grant 09SCAYALE14, Albert McKern Scholar Award 1063338, and funds from National Natural Science Foundation of China 81202057 and 81272858.	Akinyeke T, 2013, CARCINOGENESIS, V34, P2823, DOI 10.1093/carcin/bgt307; Bao B, 2012, CANCER PREV RES, V5, P355, DOI 10.1158/1940-6207.CAPR-11-0299; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bednar F, 2012, CANCER PREV RES, V5, P351, DOI 10.1158/1940-6207.CAPR-12-0026; BEHRENS BC, 1987, CANCER RES, V47, P414; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Cerezo M, 2013, MOL CANCER THER, V12, P1605, DOI 10.1158/1535-7163.MCT-12-1226-T; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fanale D, 2012, ONCOGENE, V31, P2121, DOI 10.1038/onc.2011.408; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Fu X, 2014, ONCOGENE, V33, P4296, DOI 10.1038/onc.2013.385; Gabory A, 2010, BIOESSAYS, V32, P473, DOI 10.1002/bies.200900170; Gao ZH, 2002, J CLIN ENDOCR METAB, V87, P1170, DOI 10.1210/jc.87.3.1170; Gou SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063969; Grayson DR, 2013, NEUROPSYCHOPHARMACOL, V38, P138, DOI 10.1038/npp.2012.125; Green JM, 2009, MOL CANCER THER, V8, P1385; Guo L, 2013, ONCOGENE, V32, P5272, DOI 10.1038/onc.2012.573; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Huang YQ, 2012, WIRES RNA, V3, P483, DOI 10.1002/wrna.1112; Jeng YM, 2008, HEPATOLOGY, V48, P1118, DOI 10.1002/hep.22459; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Liu Q, 2012, MOL BIOL REP, V39, P1239, DOI 10.1007/s11033-011-0854-7; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lu LG, 2011, BREAST CANCER RES TR, V126, P687, DOI 10.1007/s10549-010-1168-5; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Matouk I, 2013, INT J MOL SCI, V14, P4298, DOI 10.3390/ijms14024298; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Qian PX, 2011, CANCER RES, V71, P6463, DOI 10.1158/0008-5472.CAN-11-1322; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Riaz M, 2011, BREAST CANC RES TREA, V133, P12; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Samanta S, 2012, ONCOGENE, V31, P4689, DOI 10.1038/onc.2011.620; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sarfstein R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061537; Srivastava M, 2000, GENE DEV, V14, P1186; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Suvasini R, 2011, J BIOL CHEM, V286, P25882, DOI 10.1074/jbc.M110.178012; Tang ZQ, 2014, INT J CANCER, V134, P306, DOI 10.1002/ijc.28371; Tanos V, 2004, INT J GYNECOL CANCER, V14, P521, DOI 10.1111/j.1048-891x.2004.014314.x; Tanos V, 1999, EUR J OBSTET GYN R B, V85, P7, DOI 10.1016/S0301-2115(98)00275-9; Thornton JE, 2012, TRENDS CELL BIOL, V22, P474, DOI 10.1016/j.tcb.2012.06.001; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187; Toledano H, 2012, NATURE, V485, P605, DOI 10.1038/nature11061; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Wu BC, 2012, ONCOL REP, V28, P903, DOI 10.3892/or.2012.1890; Wurth R, 2013, CELL CYCLE, V12, P145, DOI 10.4161/cc.23050; Yin G, 2013, ONCOGENE, V32, P39, DOI 10.1038/onc.2012.33; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105; Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381; Zhao BT, 2014, CANCER LETT, V342, P43, DOI 10.1016/j.canlet.2013.08.030; Zhao SM, 2013, P NATL ACAD SCI USA, V110, P2916, DOI 10.1073/pnas.1222577110; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	70	153	170	4	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					3076	3084		10.1038/onc.2014.236	http://dx.doi.org/10.1038/onc.2014.236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25088204				2022-12-17	WOS:000356100500012
J	Pierotti, MA; Berrino, F; Gariboldi, M; Melani, C; Mogavero, A; Negri, T; Pasanisi, P; Pilotti, S				Pierotti, M. A.; Berrino, F.; Gariboldi, M.; Melani, C.; Mogavero, A.; Negri, T.; Pasanisi, P.; Pilotti, S.			Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects	ONCOGENE			English	Review						metformin; AMPK; mTORC; energetic metabolism; cancer treatment; chemoprevention	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; ABERRANT CRYPT FOCI; EARLY BREAST-CANCER; HIGH-ENERGY DIET; BCL-X-L; IN-VIVO; PANCREATIC-CANCER; DIABETIC-PATIENTS; LIFE-SPAN	Understanding the complexity of cancer and of the underlying regulatory networks provides a new paradigm that tackles cancer development and treatment through a system biology approach, contemporarily acting on various intersecting pathways. Cancer cell metabolism is an old pathogenetic issue that has recently gained new interest as target for therapeutic approaches. More than 70 years ago, Warburg discovered that malignant cells generally have altered metabolism with high rates of glucose uptake and increased glycolysis, even under aerobic condition. Observational studies have provided evidence that impaired metabolism, obesity, hyperglycemia and hyperinsulinemia may have a role in cancer development, progression and prognosis, and actually diabetic and obese patients have increased cancer risk. On the other hand, caloric restriction has been shown to prolong life span and reduce cancer incidence in several animal models, having an impact on different metabolic pathways. Metformin, an antidiabetic drug widely used for over 40 years, mimics caloric restriction acting on cell metabolism at multiple levels, reducing all energy-consuming processes in the cells, including cell proliferation. By overviewing molecular mechanisms of action, epidemiological evidences, experimental data in tumor models and early clinical study results, this review provides information supporting the promising use of metformin in cancer prevention and treatment. Oncogene (2013) 32, 1475-1487; doi:10.1038/onc.2012.181; published online 4 June 2012	[Pierotti, M. A.; Melani, C.] Ist Nazl Tumori, Fdn IRCCS, Sci Directorate, I-20133 Milan, Italy; [Berrino, F.; Pasanisi, P.] Ist Nazl Tumori, Fdn IRCCS, Dept Predict & Prevent Med, I-20133 Milan, Italy; [Gariboldi, M.; Mogavero, A.] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Mol Med, I-20133 Milan, Italy; [Gariboldi, M.; Mogavero, A.] Fdn Ist FIRC Oncol Mol, Milan, Italy; [Negri, T.; Pilotti, S.] Ist Nazl Tumori, Fdn IRCCS, Dept Pathol, Lab Mol Pathol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan	Pierotti, MA (corresponding author), Ist Nazl Tumori, Fdn IRCCS, Sci Directorate, Via Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it	Pasanisi, Patrizia/F-4908-2017; Melani, Cecilia/C-2756-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Berrino, Franco/AAC-2364-2020; Gariboldi, Manuela/K-4744-2016	Pasanisi, Patrizia/0000-0001-6278-3491; Melani, Cecilia/0000-0003-2734-739X; Pierotti, Marco Alessandro/0000-0002-7431-8332; Berrino, Franco/0000-0002-4858-1866; Negri, Tiziana/0000-0002-3528-7115; Gariboldi, Manuela/0000-0001-8406-165X	Ministero dell'Universita e della Ricerca [DO11/002]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [R10/029]	Ministero dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Ministero dell'Universita e della Ricerca with the MIUR 5 x 1000 grant no. DO11/002 and by the Associazione Italiana per la Ricerca sul Cancro (AIRC grant no. R10/029). MAP would like to thank Dr Mathias Christian Zohoungbogbo who first introduced him to metformin. The authors wish to thank Dr Daniela Majerna for editorial assistance.	Algire C, 2011, ONCOGENE, V30, P1174, DOI 10.1038/onc.2010.483; Algire C, 2008, ENDOCR-RELAT CANCER, V15, P833, DOI 10.1677/ERC-08-0038; Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Anisimov VN, 2008, CELL CYCLE, V7, P2769, DOI 10.4161/cc.7.17.6625; Anisimov VN, 2005, EXP GERONTOL, V40, P685, DOI 10.1016/j.exger.2005.07.007; Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824; Basen-Engquist K, 2011, CURR ONCOL REP, V13, P71, DOI 10.1007/s11912-010-0139-7; Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024; Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Bodmer M, 2012, AM J GASTROENTEROL, V107, P620, DOI 10.1038/ajg.2011.483; Bodmer M, 2012, CANCER EPIDEM BIOMAR, V21, P280, DOI 10.1158/1055-9965.EPI-11-0992-T; Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791; Bosco JLF, 2011, CANCER EPIDEM BIOMAR, V20, P101, DOI 10.1158/1055-9965.EPI-10-0817; Bowker SL, 2010, DIABETOLOGIA, V53, P1631, DOI 10.1007/s00125-010-1750-8; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Campagnoli C, 2012, CLIN BREAST CANCER, V12, P175, DOI 10.1016/j.clbc.2012.03.004; Campbell IW, 2007, METFORMIN GOLD STAND, P77; Cantrell LA, 2010, GYNECOL ONCOL, V116, P92, DOI 10.1016/j.ygyno.2009.09.024; Carling D, 2011, NAT CHEM BIOL, V7, P512, DOI [10.1038/NCHEMBIO.610, 10.1038/nchembio.610]; Cazzaniga M, 2009, CANCER EPIDEM BIOMAR, V18, P701, DOI 10.1158/1055-9965.EPI-08-0871; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Chiacchiera F, 2010, CELL CYCLE, V9, P1091, DOI 10.4161/cc.9.6.11035; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6; Currie CJ, 2012, DIABETES CARE, V35, P299, DOI 10.2337/dc11-1313; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Detaille D, 2002, BIOCHEM PHARMACOL, V63, P1259, DOI 10.1016/S0006-2952(02)00858-4; Donadon V, 2009, WORLD J GASTROENTERO, V15, P2506, DOI 10.3748/wjg.15.2506; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001057; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Galluzzi L, 2010, AGING-US, V2, P535, DOI 10.18632/aging.100202; Garrett CR, 2012, BRIT J CANCER, V106, P1374, DOI 10.1038/bjc.2012.71; Giannarelli R, 2003, DIABETES METAB, V29, pS28; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Goodwin PJ, 2011, BREAST CANCER RES TR, V126, P215, DOI 10.1007/s10549-010-1224-1; Goodwin PJ, 2008, CLIN BREAST CANCER, V8, P501, DOI 10.3816/CBC.2008.n.060; Gotlieb WH, 2008, GYNECOL ONCOL, V110, P246, DOI 10.1016/j.ygyno.2008.04.008; Green AS, 2010, BLOOD, V116, P4262, DOI 10.1182/blood-2010-02-269837; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hadad SM, 2010, J CLIN ONCOL, V28; Hadad S, 2011, BREAST CANCER RES TR, V128, P783, DOI 10.1007/s10549-011-1612-1; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Home PD, 2010, DIABETOLOGIA, V53, P1838, DOI 10.1007/s00125-010-1804-y; Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186; Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Hursting SD, 2007, CURR CANCER DRUG TAR, V7, P484; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018-007-7080-4; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jiralerspong S, 2009, J CLIN ONCOL, V27, P3297, DOI 10.1200/JCO.2009.19.6410; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414; Kisfalvi K, 2009, CANCER RES, V69, P6539, DOI 10.1158/0008-5472.CAN-09-0418; Kourelis TV, 2012, MED ONCOL, V29, P1314, DOI 10.1007/s12032-011-9846-7; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394; Lee MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-20; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; MacKenzie MJ, 2012, INVEST NEW DRUG, V30, P647, DOI 10.1007/s10637-010-9570-8; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Martin-Castillo B, 2010, ANN ONCOL, V21, P187, DOI 10.1093/annonc/mdp494; Martin-Castillo B, 2010, CELL CYCLE, V9, P1057, DOI 10.4161/cc.9.6.10994; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P4208, DOI 10.4161/cc.10.24.18487; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; MATTHAEI S, 1993, ENDOCRINOLOGY, V133, P304, DOI 10.1210/en.133.1.304; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Monami M, 2011, DIABETES CARE, V34, P129, DOI 10.2337/dc10-1287; Monami M, 2009, ACTA DIABETOL, V46, P279, DOI 10.1007/s00592-008-0083-2; Muti P, 2009, CELL CYCLE, V8, P2661, DOI 10.4161/cc.8.16.9226; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Ning JY, 2010, MOL ENDOCRINOL, V24, P1218, DOI 10.1210/me.2009-0474; Niraula S, 2010, CANC RES S, V70, P104; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Oliveras-Ferraros C, 2011, CELL CYCLE, V10, P1144, DOI 10.4161/cc.10.7.15210; Oliveria SA, 2008, DIABETES METAB SYND, V2, P47, DOI 10.1016/j.dsx.2007.11.002; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Phoenix KN, 2009, BREAST CANCER RES TR, V113, P101, DOI 10.1007/s10549-008-9916-5; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175; Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Roberts DL, 2010, ANNU REV MED, V61, P301, DOI 10.1146/annurev.med.080708.082713; Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229; Saito S, 2009, CANCER RES, V69, P4225, DOI 10.1158/0008-5472.CAN-08-2689; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Segal ED, 2011, BIOCHEM BIOPH RES CO, V414, P694, DOI 10.1016/j.bbrc.2011.09.134; Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558; Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49; Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x; Tzvetkov MV, 2009, CLIN PHARMACOL THER, V86, P299, DOI 10.1038/clpt.2009.92; Vazquez-Martin A, 2010, CURR MOL MED, V10, P674, DOI 10.2174/156652410792630625; Vazquez-Martin A, 2011, DRUG RESIST UPDATE, V14, P212, DOI 10.1016/j.drup.2011.04.003; Vazquez-Martin A, 2011, CELL CYCLE, V10, P1499, DOI 10.4161/cc.10.9.15423; Vazquez-Martin A, 2011, ONCOL REP, V25, P135, DOI 10.3892/or_00001052; Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131; Vazquez-Martin A, 2011, BREAST CANCER RES TR, V126, P355, DOI 10.1007/s10549-010-0924-x; Vazquez-Martin A, 2009, J CLIN ONCOL, V27, pE207, DOI 10.1200/JCO.2009.24.5456; Vazquez-Martin A, 2009, CELL CYCLE, V8, P88, DOI 10.4161/cc.8.1.7499; Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P4047, DOI 10.4161/cc.10.23.18151; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Yea SS, 2011, SCIENCE, V332, P1270, DOI 10.1126/science.1208071; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zakikhani M, 2010, BREAST CANCER RES TR, V123, P271, DOI 10.1007/s10549-010-0763-9; Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081; Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625; Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zeqiraj E, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000126; Zhou KX, 2011, NAT GENET, V43, P117, DOI 10.1038/ng.735; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18; Zhuang YX, 2011, MOL CANCER RES, V9, P603, DOI 10.1158/1541-7786.MCR-10-0343	145	153	161	1	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1475	1487		10.1038/onc.2012.181	http://dx.doi.org/10.1038/onc.2012.181			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22665053				2022-12-17	WOS:000316456000001
J	Zhu, G; Wang, Y; Huang, B; Liang, J; Ding, Y; Xu, A; Wu, W				Zhu, G.; Wang, Y.; Huang, B.; Liang, J.; Ding, Y.; Xu, A.; Wu, W.			A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells	ONCOGENE			English	Article						colon cancer; beta-catenin; PAK1; Rac1; phosphorylation	WNT SIGNALING PATHWAY; COLORECTAL-CANCER; PHOSPHORYLATION; PAK; EXPRESSION; KINASES; RAC1; LOCALIZATION; PROGRESSION; INHIBITION	P21-activated kinase 1 (PAK1) is associated with colon cancer progression and metastasis, whereas the molecular mechanism remains elusive. Here, we show that down-regulation of PAK1 in colon cancer cells reduces total beta-catenin level, as well as cell proliferation. Mechanistically, PAK1 directly phosphorylates beta-catenin proteins at Ser675 site and this leads to more stable and transcriptional active beta-catenin. Corroborating these results, PAK1 is required for full Wnt signaling, and superactivation of beta-catenin is achieved by simultaneous knockdown of adenomatous polyposis coli protein and activation of PAK1. Moreover, we show that Rac1 functions upstream of PAK1 in colon cancer cells and contributes to beta-catenin phosphorylation and accumulation. We conclude that a Rac1/PAK1 cascade controls beta-catenin S675 phosphorylation and full activation in colon cancer cells. Supporting this conclusion, overexpression of PAK1 is observed in 70% of colon cancer samples and is correlated with massive beta-catenin accumulation. Oncogene (2012) 31, 1001-1012; doi:10.1038/onc.2011.294; published online 8 August 2011	[Zhu, G.; Wang, Y.; Huang, B.; Liang, J.; Ding, Y.; Wu, W.] Tsinghua Univ, Prot Sci Lab, Minist Educ, Sch Life Sci, Beijing 100084, Peoples R China; [Xu, A.] Beijing Friendship Hosp, Beijing, Peoples R China	Tsinghua University; Capital Medical University	Wu, W (corresponding author), Tsinghua Univ, Prot Sci Lab, Minist Educ, Sch Life Sci, Qinghuayuan 1, Beijing 100084, Peoples R China.	wwu@mail.tsinghua.edu.cn			National Natural Science Foundation of China [30730048, 30921004]; Major Science Programs of China [2006CB943402, 2011CB943803]; Tsinghua University [2010THZ0]; Bayer Healthcare	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Science Programs of China; Tsinghua University; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals)	We thank Drs Ye-Guang Chen, Jonathan Chernoff, Raymond Habas, Alan Hall, Tianhui Hu, Edward Leof, Chaojun Li, Randy Moon, Christof Niehrs, Roel Nusse and Thomas Rudel for reagents. This work was supported by grants to WW from the National Natural Science Foundation of China (No. 30730048, 30921004), the Major Science Programs of China (2006CB943402, 2011CB943803), Tsinghua University Initiative Scientific Research Program (2010THZ0) and Bayer Healthcare.	Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bikkavilli RK, 2008, J CELL SCI, V121, P234, DOI 10.1242/jcs.021964; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; Hendriksen J, 2008, J CELL SCI, V121, P1793, DOI 10.1242/jcs.025536; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Huynh N, 2010, BBA-MOL CELL RES, V1803, P1106, DOI 10.1016/j.bbamcr.2010.05.007; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jacobs T, 2007, J NEUROSCI, V27, P8604, DOI 10.1523/JNEUROSCI.0765-07.2007; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lee SH, 2007, CANCER RES, V67, P11045, DOI 10.1158/0008-5472.CAN-07-0986; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lu ZM, 2004, CELL CYCLE, V3, P571; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Nheu T, 2004, CELL CYCLE, V3, P71; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Rennefahrt UEE, 2007, J BIOL CHEM, V282, P15667, DOI 10.1074/jbc.M700253200; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Segditsas S, 2008, EXP MOL PATHOL, V85, P201, DOI 10.1016/j.yexmp.2008.09.006; Sun J, 2009, ONCOGENE, V28, P3132, DOI 10.1038/onc.2009.167; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Valentini AM, 2003, CURR PHARM DESIGN, V9, P1932, DOI 10.2174/1381612033454216; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang Y, 2010, J BIOL CHEM, V285, P10890, DOI 10.1074/jbc.M109.058347; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wells CM, 2010, BIOCHEM J, V425, P465, DOI 10.1042/BJ20091173; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001	54	153	159	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					1001	1012		10.1038/onc.2011.294	http://dx.doi.org/10.1038/onc.2011.294			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21822311				2022-12-17	WOS:000300709700006
J	Bergamaschi, A; Katzenellenbogen, BS				Bergamaschi, A.; Katzenellenbogen, B. S.			Tamoxifen downregulation of miR-451 increases 14-3-3 zeta and promotes breast cancer cell survival and endocrine resistance	ONCOGENE			English	Article						breast cancer; tamoxifen; endocrine resistance; 14-3-3 zeta; miR-451; tumor suppressor	ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; MICRORNAS; DETERMINANTS; RALOXIFENE; MECHANISM; THERAPY; KINASE; GROWTH; RISK	Many estrogen receptor (ER)-positive breast cancers respond well initially to endocrine therapies, but often develop resistance during treatment with selective ER modulators (SERMs) such as tamoxifen. We have reported that the 14-3-3 family member and conserved protein, 14-3-3 zeta, is upregulated by tamoxifen and that high expression correlated with an early time to disease recurrence. However, the mechanism by which tamoxifen upregulates 14-3-3 zeta and may promote the development of endocrine resistance is not known. Our findings herein reveal that the tamoxifen upregulation of 14-3-3 zeta results from its ability to rapidly downregulate microRNA (miR)-451 that specifically targets 14-3-3 zeta. The levels of 14-3-3 zeta and miR-451 were inversely correlated, with 14-3-3 zeta being elevated and miR-451 being at a greatly reduced level in tamoxifen-resistant breast cancer cells. Of note, downregulation of miR-451 was selectively elicited by tamoxifen but not by other SERMs, such as raloxifene or ICI182,780 (Fulvestrant). Increasing the level of miR-451 by overexpression, which decreased 14-3-3 zeta, suppressed cell proliferation and colony formation, markedly reduced activation of HER2, EGFR and MAPK signaling, increased apoptosis, and, importantly, restored the growth-inhibitory effectiveness of SERMs in endocrine-resistant cells. Opposite effects were elicited by miR-451 knockdown. Thus, we identify tamoxifen downregulation of miR-451, and consequent elevation of the key survival factor 14-3-3 zeta, as a mechanistic basis of tamoxifen-associated development of endocrine resistance. These findings suggest that therapeutic approaches to increase expression of this tumor suppressor-like miR should be considered to downregulate 14-3-3 zeta and enhance the effectiveness of endocrine therapies. Furthermore, the selective ability of the SERM tamoxifen but not raloxifene to regulate miR-451 and 14-3-3 zeta may assist in understanding differences in their activities, as seen in the STAR (Study of Tamoxifen and Raloxifene) breast cancer prevention trial and in other clinical trials. Oncogene (2012) 31, 39-47; doi: 10.1038/onc.2011.223; published online 13 June 2011	[Katzenellenbogen, B. S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Coll Med Urbana Champaign, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	katzenel@uiuc.edu	Bergamaschi, Anna/D-2022-2009	Bergamaschi, Anna/0000-0001-8709-1766	Breast Cancer Research Foundation; NIH [P01AG024387, P50 AT006268]; Department of Defense [W81XWH-09-1-0398]; National Center for Complementary & Integrative Health [P50AT006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG024387] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by grants from the Breast Cancer Research Foundation (BSK) and the NIH (P01AG024387 and P50 AT006268, BSK), and a Postdoctoral Fellowship from the Department of Defense (W81XWH-09-1-0398, AB). We thank Dr Nancy Weigel, Baylor College of Medicine, for providing lysine-coated adenovirus.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bergamaschi A, 2009, P AM ASS CANC RES AN, V2, P2854; Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dore LC, 2008, P NATL ACAD SCI USA, V105, P3333, DOI 10.1073/pnas.0712312105; Dunn B K, 2001, Breast J, V7, P144, DOI 10.1046/j.1524-4741.2001.007003144.x; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Harfe BD, 2005, CURR OPIN GENET DEV, V15, P410, DOI 10.1016/j.gde.2005.06.012; Herman ME, 1996, J STEROID BIOCHEM, V59, P121, DOI 10.1016/S0960-0760(96)00114-8; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Lowery AJ, 2008, CLIN CANCER RES, V14, P360, DOI 10.1158/1078-0432.CCR-07-0992; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Oksvold MP, 2004, FEBS LETT, V569, P207, DOI 10.1016/j.febslet.2004.05.068; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Patrick DM, 2010, GENE DEV, V24, P1614, DOI 10.1101/gad.1942810; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Shan G, 2008, NAT BIOTECHNOL, V26, P933, DOI 10.1038/nbt.1481; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; Vogel VG, 2010, CANCER PREV RES, V3, P696, DOI 10.1158/1940-6207.CAPR-10-0076; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Yang JS, 2010, P NATL ACAD SCI USA, V107, P15163, DOI 10.1073/pnas.1006432107; Yu DN, 2010, GENE DEV, V24, P1620, DOI 10.1101/gad.1942110	42	153	167	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					39	47		10.1038/onc.2011.223	http://dx.doi.org/10.1038/onc.2011.223			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666713	Green Accepted			2022-12-17	WOS:000299176200004
J	Danese, S; Mantovani, A				Danese, S.; Mantovani, A.			Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer	ONCOGENE			English	Review						inflammation; colon cancer; chemokines	TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTORS; IKK/NF-KAPPA-B; BLOCKING TNF-ALPHA; COLON-CANCER; ULCERATIVE-COLITIS; COLORECTAL-CANCER; EPITHELIAL-CELLS; MOUSE MODEL; INTERLEUKIN-10-DEFICIENT MICE	Colon cancer represents a paradigm for the connection between inflammation and cancer in terms of epidemiology and mechanistic studies in preclinical models. Key components of cancer promoting inflammation include master transcription factors (for example, nuclear factor kappa B, STAT3), proinflammatory cytokines (for example, tumor necrosis factor, interleukin-6 (IL-6)), cyclooxygenase-2 and selected chemokines (for example, CCL2). Of no less importance are mediators that keep inflammation in check, including IL-10, transforming growth factor beta, toll-like receptor and the IL-1 receptor inhibitor TIR8/SIGIRR, and the chemokine decoy and scavenger receptor D6. Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies. Oncogene (2010) 29, 3313-3323; doi:10.1038/onc.2010.109; published online 19 April 2010	[Mantovani, A.] Ist Clin Humanitas IRCCS, Lab Inflammat & Immunol, I-20089 Milan, Italy; [Danese, S.] Div Gastroenterol, Inflammatory Bowel Dis Unit, Milan, Italy	IRCCS Humanitas Research Hospital	Mantovani, A (corresponding author), Ist Clin Humanitas IRCCS, Lab Inflammat & Immunol, Via Manzoni56, I-20089 Milan, Italy.	sdanese@hotmail.com; alberto.mantovani@humanitasresearch.it	Danese, Silvio/ABH-9571-2020; Mantovani, Alberto/HCI-7449-2022	Danese, Silvio/0000-0001-7341-1351; Mantovani, Alberto/0000-0001-5578-236X	Broad Medical Research Program,; Italian Ministery of Health (Ricerca Finalizzata) [72]; Bando Giovani Ricercatori; Fondazione Cariplo; Italian Association for Cancer Research (AIRC); European Community [518167]; Ministero dell'Istruzione dell'Universita e della Ricerca (Rome, Italy) [2002061255, RBIN04EKC]; Fondazione Cariplo (Milan, Italy); Fondazione Humanitas per la Ricerca (Rozzano, Italy)	Broad Medical Research Program,; Italian Ministery of Health (Ricerca Finalizzata); Bando Giovani Ricercatori; Fondazione Cariplo(Fondazione Cariplo); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); European Community(European Commission); Ministero dell'Istruzione dell'Universita e della Ricerca (Rome, Italy)(Ministry of Education, Universities and Research (MIUR)); Fondazione Cariplo (Milan, Italy)(Fondazione Cariplo); Fondazione Humanitas per la Ricerca (Rozzano, Italy)	This study was supported by grants from the Broad Medical Research Program, the Italian Ministery of Health (Ricerca Finalizzata 2006, n.72 and Bando Giovani Ricercatori), Fondazione Cariplo and the Italian Association for Cancer Research (My first AIRC Grant) to SD, and the European Community (INNOCHEM project 518167), the Ministero dell'Istruzione dell'Universita e della Ricerca (Rome, Italy; PRIN project 2002061255; FIRB project RBIN04EKCX) and Fondazione Cariplo (Milan, Italy; NOBEL project). This work was conducted in the context and with the support of the Fondazione Humanitas per la Ricerca (Rozzano, Italy).	Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Attiga FA, 2000, CANCER RES, V60, P4629; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Beaugerie L, 2009, LANCET, V374, P1617, DOI 10.1016/S0140-6736(09)61302-7; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Becker C, 2006, CYTOKINE GROWTH F R, V17, P97, DOI 10.1016/j.cytogfr.2005.09.004; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; Betti M, 2006, ANN ONCOL, V17, P235; Biancone L, 2009, GUT, V58, P1703, DOI 10.1136/gut.2008.176461; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bonecchi R, 2004, J IMMUNOL, V172, P4972, DOI 10.4049/jimmunol.172.8.4972; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Bos CL, 2006, CARCINOGENESIS, V27, P2371, DOI 10.1093/carcin/bgl071; Brint EK, 2004, NAT IMMUNOL, V5, P373, DOI 10.1038/ni1050; Burstein E, 2008, J CLIN INVEST, V118, P464, DOI [10.1172/JC134831, 10.1172/JCI34831]; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; CHOI PM, 1994, GUT, V35, P950, DOI 10.1136/gut.35.7.950; Chung YC, 2003, J SURG ONCOL, V83, P222, DOI 10.1002/jso.10269; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; D'Amico G, 2000, NAT IMMUNOL, V1, P387, DOI 10.1038/80819; de la Torre YM, 2007, P NATL ACAD SCI USA, V104, P2319, DOI 10.1073/pnas.0607514104; Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Fantini MC, 2009, GASTROENTEROLOGY, V136, P1308, DOI 10.1053/j.gastro.2008.12.053; Fukata M, 2008, ONCOGENE, V27, P234, DOI 10.1038/sj.onc.1210908; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Garlanda C, 2004, P NATL ACAD SCI USA, V101, P3522, DOI 10.1073/pnas.0308680101; Garlanda C, 2007, CANCER RES, V67, P6017, DOI 10.1158/0008-5472.CAN-07-0560; Garlanda C, 2009, TRENDS IMMUNOL, V30, P439, DOI 10.1016/j.it.2009.06.001; Garrett WS, 2009, CANCER CELL, V16, P208, DOI 10.1016/j.ccr.2009.07.015; Gasche C, 2004, ALIMENT PHARM THER, V20, P31, DOI 10.1111/j.1365-2036.2004.02045.x; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; GYDE S, 1982, GASTROENTEROLOGY, V83, P36; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; Jacoby RF, 2000, CANCER RES, V60, P5040; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; Kai H, 2005, ANTICANCER RES, V25, P709; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kundu JK, 2008, MUTAT RES-REV MUTAT, V659, P15, DOI 10.1016/j.mrrev.2008.03.002; Laghi L, 2009, LANCET ONCOL, V10, P877, DOI 10.1016/S1470-2045(09)70186-X; Li GP, 2002, BIOCHEM BIOPH RES CO, V299, P886, DOI 10.1016/S0006-291X(02)02707-9; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Mantovani A, 2004, J LEUKOCYTE BIOL, V75, P738, DOI 10.1189/jlb.1003473; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Matuk R, 2004, INFLAMM BOWEL DIS, V10, P352, DOI 10.1097/00054725-200407000-00005; Mazzucchelli L, 1996, J PATHOL, V178, P201, DOI 10.1002/(SICI)1096-9896(199602)178:2<201::AID-PATH440>3.0.CO;2-4; McLoughlin RM, 2003, J CLIN INVEST, V112, P598, DOI 10.1172/JCI200317129; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Murphy PM, 2000, PHARMACOL REV, V52, P145; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nakamura K, 2006, WORLD J GASTROENTERO, V12, P4628, DOI 10.3748/wjg.v12.i29.4628; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nibbs RJB, 2001, AM J PATHOL, V158, P867, DOI 10.1016/S0002-9440(10)64035-7; Nibbs RJB, 2007, J CLIN INVEST, V117, P1884, DOI 10.1172/JCI30068; NOACH LA, 1994, SCAND J GASTROENTERO, V29, P425, DOI 10.3109/00365529409096833; Noguchi M, 1998, GUT, V43, P203, DOI 10.1136/gut.43.2.203; Okayasu I, 2002, J GASTROEN HEPATOL, V17, P1078, DOI 10.1046/j.1440-1746.2002.02853.x; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Osawa E, 2006, INT J CANCER, V118, P2232, DOI 10.1002/ijc.21639; Oshima M, 2001, CANCER RES, V61, P1733; Pasparakis M, 2008, MUCOSAL IMMUNOL, V1, pS54, DOI 10.1038/mi.2008.53; PESKAR BM, 1987, DIGEST DIS SCI, V32, pS51, DOI 10.1007/BF01312464; Polentarutti N, 2003, EUR CYTOKINE NETW, V14, P211; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; REINECKER HC, 1995, GASTROENTEROLOGY, V108, P40, DOI 10.1016/0016-5085(95)90006-3; Rigby RJ, 2007, ONCOGENE, V26, P4833, DOI 10.1038/sj.onc.1210286; Roessner A, 2008, PATHOL RES PRACT, V204, P511, DOI 10.1016/j.prp.2008.04.011; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sinicrope FA, 2004, CANCER METAST REV, V23, P63, DOI 10.1023/A:1025863029529; Stolfi C, 2008, WORLD J GASTROENTERO, V14, P4434, DOI 10.3748/wjg.14.4434; Stolfi C, 2008, BIOCHEM PHARMACOL, V75, P668, DOI 10.1016/j.bcp.2007.09.020; Sun YJ, 2002, CANCER RES, V62, P6323; Szlosarek P, 2006, EUR J CANCER, V42, P745, DOI 10.1016/j.ejca.2006.01.012; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Vetrano S, 2010, GUT, V59, P197, DOI 10.1136/gut.2009.183772; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Waldner M, 2006, WORLD J GASTROENTERO, V12, P7233, DOI 10.3748/wjg.v12.i45.7233; Wang H., 2003, CYTOKINE HDB, V4th ed., P837; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012	114	153	158	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3313	3323		10.1038/onc.2010.109	http://dx.doi.org/10.1038/onc.2010.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20400974				2022-12-17	WOS:000278622700001
J	Levanon, K; Ng, V; Piao, HY; Zhang, Y; Chang, MC; Roh, MH; Kindelberger, DW; Hirsch, MS; Crum, CP; Marto, JA; Drapkin, R				Levanon, K.; Ng, V.; Piao, H. Y.; Zhang, Yi; Chang, M. C.; Roh, M. H.; Kindelberger, D. W.; Hirsch, M. S.; Crum, C. P.; Marto, J. A.; Drapkin, R.			Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis	ONCOGENE			English	Article						ovarian cancer; fallopian tube; primary cell culture; cancer biomarkers; DNA damage and repair	CELL-CYCLE; IN-VITRO; CANCER; DIFFERENTIATION; CARCINOMA; HE-4; PATHOGENESIS; RECEPTOR; OVIDUCT; MARKERS	Recent studies suggest that some serous ovarian carcinomas (SOCs) arise from the fallopian tube (FT) epithelium rather than the ovarian surface epithelium. This hypothesis places emphasis on the FT secretory epithelial cell as a cell-of-origin. Herein, we report the development of a novel ex vivo primary human FT epithelium culture system that faithfully recapitulates the in vivo epithelium, as shown by morphological, ultrastructural and immunophenotypic analyses. Mass spectrometry-based proteomics reveal that these cultures secrete proteins previously identified as biomarkers for ovarian cancer. We also use this culture system to study the response of the FT epithelium to genotoxic stress and find that the secretory cells exhibit a distinct response to DNA damage when compared with neighboring ciliated cells. The secretory cells show a limited ability to resolve the damage over time, potentially leaving them more susceptible to accumulation of additional mutagenic injury. This divergent response is confirmed with in situ studies using tissue samples, further supporting the use of this ex vivo culture system to investigate FT epithelial pathobiology. We anticipate that this novel culture system will facilitate the study of SOC pathogenesis, and propose that similar culture systems could be developed for other organ site-specific epithelia. Oncogene (2010) 29, 1103-1113; doi: 10.1038/onc.2009.402; published online 23 November 2009	[Levanon, K.; Ng, V.; Piao, H. Y.; Drapkin, R.] Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, Boston, MA 02115 USA; [Zhang, Yi; Marto, J. A.] Dana Farber Canc Inst, Dept Canc Biol, Ctr Prote, Boston, MA 02115 USA; [Chang, M. C.; Roh, M. H.; Kindelberger, D. W.; Hirsch, M. S.; Crum, C. P.; Drapkin, R.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Drapkin, R (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, JF215D,44 Binney St, Boston, MA 02115 USA.	ronny_drapkin@dfci.harvard.edu	Chang, Martin/J-2329-2016; Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Levanon, Keren/0000-0002-5122-064X	National Cancer Institute [P50 CA105009, K08 CA108748, R21 CA124688]; Ovarian Cancer Research Fund; Phi Beta Psi Sorority Charitable Trust; Fannie E. Ripple Foundation; Robert and Deborah First Fund; Randi and Joel Cutler Ovarian Cancer Research Fund; Columbia Hospital for Women Research Foundation; Marsha Rivkin Foundation Scientific Scholar Award; AACR-George and Patricia Sehl Fellowship; American Physicians Fellowship; Emmanuel G Rosenblatt Foundation; NATIONAL CANCER INSTITUTE [P50CA105009, R21CA124688, K08CA108748] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund; Phi Beta Psi Sorority Charitable Trust; Fannie E. Ripple Foundation; Robert and Deborah First Fund; Randi and Joel Cutler Ovarian Cancer Research Fund; Columbia Hospital for Women Research Foundation; Marsha Rivkin Foundation Scientific Scholar Award; AACR-George and Patricia Sehl Fellowship; American Physicians Fellowship; Emmanuel G Rosenblatt Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Phil Karp, Thomas Moninger and Drs Paola Vermeer and Joseph Zabner (University of Iowa) for their enthusiastic support and assistance in establishing the FT ex vivo culture system, Drs Steve Cannistra, Glenn Dranoff and David Livingston for thoughtful suggestions and comments on the paper and Drs Tom Benjamin and Dawei Li for the Sall2 antibody. Special thanks goes to the faculty, technicians, residents and fellows of the division of Women's and Perinatal Pathology in the Department of Pathology at the Brigham and Women's Hospital, Boston, MA, for the allocation of tissues. This work was supported by the National Cancer Institute [P50 CA105009, K08 CA108748 and R21 CA124688], Ovarian Cancer Research Fund (Individual Investigator Award and Program Project Development Award), Phi Beta Psi Sorority Charitable Trust, Fannie E. Ripple Foundation, Robert and Deborah First Fund, Randi and Joel Cutler Ovarian Cancer Research Fund, the Columbia Hospital for Women Research Foundation, Marsha Rivkin Foundation Scientific Scholar Award, AACR-George and Patricia Sehl Fellowship for Cancer Genetics Research and the American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G Rosenblatt Foundation Grant.	Ando H, 2000, HUM REPROD, V15, P1597, DOI 10.1093/humrep/15.7.1597; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bast RC, 2005, INT J GYNECOL CANCER, V15, P274, DOI 10.1111/j.1525-1438.2005.00441.x; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; Briton-Jones C, 2002, FERTIL STERIL, V77, P576, DOI 10.1016/S0015-0282(01)03216-2; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Comer MT, 1998, HUM REPROD, V13, P3114, DOI 10.1093/humrep/13.11.3114; CROW J, 1994, HUM REPROD, V9, P2224, DOI 10.1093/oxfordjournals.humrep.a138428; Crum CP, 2009, MOL ONCOL, V3, P165, DOI 10.1016/j.molonc.2009.01.004; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Folkins AK, 2009, GYNECOL ONCOL, V113, P391, DOI 10.1016/j.ygyno.2009.01.013; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hellstrom I, 2003, CANCER RES, V63, P3695; HENRIKSEN T, 1990, HUM REPROD, V5, P25, DOI 10.1093/oxfordjournals.humrep.a137034; Huang KC, 2006, INT J CANCER, V118, P2433, DOI 10.1002/ijc.21671; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; KERVANCIOGLU ME, 1994, BIOL CELL, V82, P103, DOI 10.1016/S0248-4900(94)80012-X; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kozak KR, 2005, PROTEOMICS, V5, P4589, DOI 10.1002/pmic.200500093; Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li DW, 2004, MOL CELL BIOL, V24, P3885, DOI 10.1128/MCB.24.9.3885-3893.2004; Liu H, 2007, PLOS GENET, V3, P996, DOI 10.1371/journal.pgen.0030091; Moore RG, 2009, GYNECOL ONCOL, V112, P40, DOI 10.1016/j.ygyno.2008.08.031; Okada A, 2004, J MOL ENDOCRINOL, V32, P615, DOI 10.1677/jme.0.0320615; Piek JMJ, 2001, HISTOPATHOLOGY, V38, P481, DOI 10.1046/j.1365-2559.2001.1163c.x; Ponten F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440; Rajagopal M, 2006, IN VITRO CELL DEV-AN, V42, P248; Rusiniak ME, 2000, CANCER RES, V60, P1824; Saridogan E, 1997, HUM REPROD, V12, P1500, DOI 10.1093/humrep/12.7.1500; Satir P, 2008, HISTOCHEM CELL BIOL, V129, P687, DOI 10.1007/s00418-008-0416-9; Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955	39	153	166	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1103	1113		10.1038/onc.2009.402	http://dx.doi.org/10.1038/onc.2009.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935705	Green Accepted			2022-12-17	WOS:000274912100002
J	Burdak-Rothkamm, S; Short, SC; Folkard, M; Rothkamm, K; Prise, KM				Burdak-Rothkamm, S.; Short, S. C.; Folkard, M.; Rothkamm, K.; Prise, K. M.			ATR-dependent radiation-induced gamma H2AX foci in bystander primary human astrocytes and glioma cells	ONCOGENE			English	Article						ATR; gamma H2AX; DNA damage; charged particle irradiation; targeted irradiation; bystander signalling	DOUBLE-STRAND BREAKS; CHARGED-PARTICLE MICROBEAM; MEDIATED INTERCELLULAR COMMUNICATION; IONIZING-RADIATION; REACTIVE OXYGEN; HUMAN FIBROBLASTS; IRRADIATED-CELLS; ALPHA-PARTICLES; HISTONE H2AX; GENOMIC INSTABILITY	Radiotherapy is an important treatment for patients suffering from high-grade malignant gliomas. Non-targeted ( bystander) effects may influence these cells' response to radiation and the investigation of these effects may therefore provide new insights into mechanisms of radiosensitivity and responses to radiotherapy as well as de. ne new targets for therapeutic approaches. Normal primary human astrocytes ( NHA) and T98G glioma cells were irradiated with helium ions using the Gray Cancer Institute microbeam facility targeting individual cells. Irradiated NHA and T98G glioma cells generated signals that induced gamma H2AX foci in neighbouring non-targeted bystander cells up to 48 h after irradiation. gamma H2AX bystander foci were also observed in co-cultures targeting either NHA or T98G cells and in medium transfer experiments. Dimethyl sulphoxide, Filipin and antitransforming growth factor (TGF)-beta 1 could suppress gamma H2AX foci in bystander cells, confirming that reactive oxygen species (ROS) and membrane-mediated signals are involved in the bystander signalling pathways. Also, TGF-beta 1 induced gamma H2AX in an ROS- dependent manner similar to bystander foci. ROS and membrane signalling-dependent differences in bystander foci induction between T98G glioma cells and normal human astrocytes have been observed. Inhibition of ataxia telangiectasia mutated (ATM) protein and DNA-PK could not suppress the induction of bystander gamma H2AX foci whereas the mutation of ATM- and rad3-related (ATR) abrogated bystander foci induction. Furthermore, ATR-dependent bystander foci induction was restricted to S-phase cells. These observations may provide additional therapeutic targets for the exploitation of the bystander effect.	Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2JR, Middx, England; Univ Oxford, Gray Canc Inst, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Burdak-Rothkamm, S (corresponding author), Mt Vernon Hosp, Gray Canc Inst, POB 100, Northwood HA6 2JR, Middx, England.	burdak-rothkamm@gci.ac.uk	Rothkamm, Kai/A-2164-2014; Prise, Kevin/N-7872-2015; Burdak-Rothkamm, Susanne/I-2553-2012	Rothkamm, Kai/0000-0001-7414-5729; Prise, Kevin/0000-0001-6134-7946; Burdak-Rothkamm, Susanne/0000-0002-3840-2844; Short, Susan/0000-0003-4423-7256				Ayache N, 2002, OSTEOARTHR CARTILAGE, V10, P344, DOI 10.1053/joca.2001.0499; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Azzam EI, 2000, CANCER RES, V60, P2623; Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; Belyakov OV, 2002, RADIAT PROT DOSIM, V99, P249, DOI 10.1093/oxfordjournals.rpd.a006775; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Gerashchenko BI, 2003, CYTOM PART A, V56A, P71, DOI 10.1002/cyto.a.10092; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Hu B, 2005, RADIAT RES, V164, P286, DOI 10.1667/RR3415.1; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Kosmidou I, 2002, AM J RESP CELL MOL, V26, P587, DOI 10.1165/ajrcmb.26.5.4598; Leach JK, 2001, CANCER RES, V61, P3894; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Maguire P, 2005, RADIAT RES, V163, P384, DOI 10.1667/RR3325; Mitchell SA, 2004, RADIAT RES, V161, P397, DOI 10.1667/RR3137; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Mothersill C, 2004, RADIAT RES, V161, P256, DOI 10.1667/RR3136; Mothersill CE, 2004, INT J RADIAT ONCOL, V58, P575, DOI 10.1016/j.ijrobp.2003.09.038; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Ryan KA, 2004, INFECT IMMUN, V72, P2123, DOI 10.1128/IAI.72.4.2123-2130.2004; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2003, CANCER RES, V63, P8437; SHAO C, 2006, IN PRESS RAD RES; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, RADIAT RES, V160, P318, DOI 10.1667/RR3044; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Souhami R, 2005, CANC ITS MANAGEMENT; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	48	153	159	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					993	1002		10.1038/sj.onc.1209863	http://dx.doi.org/10.1038/sj.onc.1209863			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909103				2022-12-17	WOS:000244245400005
J	Liu, L; Li, F; Cardelli, JA; Martin, KA; Blenis, J; Huang, S				Liu, L.; Li, F.; Cardelli, J. A.; Martin, K. A.; Blenis, J.; Huang, S.			Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways	ONCOGENE			English	Article						rapamycin; mTOR; S6K1; 4E-BP1; eIF4E; motility	TOP MESSENGER-RNAS; MAMMALIAN TARGET; ACTIN CYTOSKELETON; SIGNALING PATHWAY; INDUCED APOPTOSIS; INDUCED MIGRATION; BINDING PARTNER; GROWTH; PHOSPHORYLATION; TRANSLATION	Rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), inhibits tumor cell motility. However, the underlying mechanism is poorly understood. Here, we show that rapamycin inhibited type I insulin-like growth factor (IGF-I)-stimulated motility of a panel of cell lines. Expression of a rapamycin-resistant mutant of mTOR (mTORrr) prevented rapamycin inhibition of cell motility. However, cells expressing a kinase-dead mTORrr remained sensitive to rapamycin. Downregulation of raptor or rictor by RNA interference (RNAi) decreased cell motility. However, only downregulation of raptor mimicked the effect of rapamycin, inhibiting phosphorylation of S6 kinase 1 (S6K1) and 4E-BP1. Cells infected with an adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6K1, but not with an adenovirus expressing wild-type S6K1, or a control virus, conferred to resistance to rapamycin. Further, IGF-I failed to stimulate motility of the cells, in which S6K1 was downregulated by RNAi. Moreover, downregulation of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) by RNAi-attenuated rapamycin inhibition of cell motility. In contrast, expression of constitutively active 4E-BP1 dramatically inhibited IGF-I-stimulated cell motility. The results indicate that both S6K1 and 4E-BP1 pathways, regulated by TORC1, are required for cell motility. Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/ eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, FeistWeiller Canc Ctr, Shreveport, LA 71130 USA; Dartmouth Med Sch, Dept Surg, Lebanon, NH USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Dartmouth College; Harvard University; Harvard Medical School	Huang, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072; Martin, Kathleen/0000-0002-1748-0034				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Boffa DJ, 2004, CLIN CANCER RES, V10, P293, DOI 10.1158/1078-0432.CCR-0629-3; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cartwright JE, 2002, EXP CELL RES, V279, P219, DOI 10.1006/excr.2002.5616; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Gallicchio MA, 2003, J CELL PHYSIOL, V197, P131, DOI 10.1002/jcp.10352; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gomez-Cambronero J, 2003, FEBS LETT, V550, P94, DOI 10.1016/S0014-5793(03)00828-7; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hassid A, 1999, AM J PHYSIOL-HEART C, V277, pH1014, DOI 10.1152/ajpheart.1999.277.3.H1014; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kwon YS, 2005, INVEST OPHTH VIS SCI, V46, P454, DOI 10.1167/iovs.04-0753; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Martin KA, 2004, AM J PHYSIOL-CELL PH, V286, pC507, DOI 10.1152/ajpcell.00201.2003; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Poon M, 1996, J CLIN INVEST, V98, P2277, DOI 10.1172/JCI119038; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez Luis G., 2004, V294, P23; Rowinsky EK, 2004, CURR OPIN ONCOL, V16, P564, DOI 10.1097/01.cco.0000143964.74936.d1; Sakakibara K, 2005, AM J PHYSIOL-HEART C, V288, pH2861, DOI 10.1152/ajpheart.00561.2004; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Sekulic A, 2000, CANCER RES, V60, P3504; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Tai YT, 2003, CANCER RES, V63, P5850; TAKAISHI K, 1995, METHOD ENZYMOL, V256, P336; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wong AST, 2004, EXP CELL RES, V299, P248, DOI 10.1016/j.yexcr.2004.06.002; Yuan Q, 2000, AM J PHYSIOL-GASTR L, V278, pG49, DOI 10.1152/ajpgi.2000.278.1.G49; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197	60	153	166	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7029	7040		10.1038/sj.onc.1209691	http://dx.doi.org/10.1038/sj.onc.1209691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715128				2022-12-17	WOS:000241910500003
J	Li, X; Deng, W; Nail, CD; Bailey, SK; Kraus, MH; Ruppert, JM; Lobo-Ruppert, SM				Li, X; Deng, W; Nail, CD; Bailey, SK; Kraus, MH; Ruppert, JM; Lobo-Ruppert, SM			Snail induction is an early response to Gli1 that determines the effciency of epithelial transformation	ONCOGENE			English	Article						basal cell carcinoma; hedgehog; Snail; Gli1; epithelial cell; E-cadherin	BASAL-CELL CARCINOMAS; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; HAIR FOLLICLE MORPHOGENESIS; HEDGEHOG SIGNALING PATHWAY; SONIC-HEDGEHOG; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; TUMOR-SUPPRESSOR; REPRESSOR SNAIL	Gli family members mediate constitutive Hedgehog signaling in the common skin cancer, basal cell carcinoma (BCC). Snail/Snai1 is rapidly induced by Gli1 in vitro, and is coexpressed with Gli1 in human hair follicles and skin tumors. In the current study, we generated a dominant-negative allele of Snail, SnaZFD, composed of the zinc-finger domain and flanking sequence. In promoter -reporter assays, SnaZFD blocked the activity of wildtype Snail on the E-cadherin promoter. Snail loss-of-function mediated by SnaZFD or by one of several short hairpin RNAs inhibited transformation of RK3E epithelial cells by Gli1. Conversely, enforced expression of Snail promoted transformation in vitro by Gli1, but not by other genes that were tested, including Notch1, ErbB2, and N-Ras. As observed for Gli1, wild-type Snail repressed E-cadherin in RK3E cells and induced blebbing of the cytoplasmic membrane. Induction of a conditional Gli1 transgene in the basal keratinocytes of mouse skin led to rapid upregulation of Snail transcripts and to cell proliferation in the interfollicular epidermis. Established Gli1-induced skin lesions exhibited molecular similarities to BCC, including loss of E-cadherin. The results identify Snail as a Gli1-inducible effector of transformation in vitro, and an early Gli1-responsive gene in the skin.	Univ Alabama, Sch Med, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Lobo-Ruppert, SM (corresponding author), Univ Alabama, Sch Med, Dept Med, Room 570 WTI, Birmingham, AL 35294 USA.	sruppert@uab.edu		Kammerud, Sarah/0000-0002-4808-1618	NCI NIH HHS [R01 CA065686, P50 CA097247, CA65686, P50CA097247, P30CA13148, CA094030, P30 CA013148, P50 CA089019, R29 CA065686, CA89019, R01 CA094030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097247, P30CA013148, R29CA065686, R01CA094030, R01CA065686, P50CA089019] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aybar MJ, 2003, DEVELOPMENT, V130, P483, DOI 10.1242/dev.00238; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Bardelli A, 2003, CLIN CANCER RES, V9, P5607; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Callahan CA, 2001, CURR OPIN GENET DEV, V11, P541, DOI 10.1016/S0959-437X(00)00230-6; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Cunningham CC, 1997, J CELL BIOL, V136, P845, DOI 10.1083/jcb.136.4.845; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DEFIORE PP, 1987, SCIENCE, V237, P178; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Hay ED, 1995, ACTA ANAT, V154, P8; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Jamora C, 2005, PLOS BIOL, V3, P131, DOI 10.1371/journal.pbio.0030011; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Ling G, 2001, ONCOGENE, V20, P7770, DOI 10.1038/sj.onc.1204946; Louro ID, 2002, CANCER RES, V62, P5867; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Miller SJ, 1995, CLIN DERMATOL, V13, P527, DOI 10.1016/0738-081X(95)00062-K; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; PIZARRO A, 1994, BRIT J CANCER, V69, P157, DOI 10.1038/bjc.1994.26; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; SHEFFIELD JB, 1987, ANAL BIOCHEM, V166, P49, DOI 10.1016/0003-2697(87)90544-6; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	67	153	160	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					609	621		10.1038/sj.onc.1209077	http://dx.doi.org/10.1038/sj.onc.1209077			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16158046	Green Accepted			2022-12-17	WOS:000234897400012
J	Takada, Y; Murakami, A; Aggarwal, BB				Takada, Y; Murakami, A; Aggarwal, BB			Zerumbone abolishes NF-kappa B and I kappa B alpha kinase activation leading to suppression of antiapoptotic and metastatic gene expression, upregulation of apoptosis, and downregulation of invasion	ONCOGENE			English	Article						carcinogens; NF-kappa B; TNF; IKK; inflammation; apoptosis; metastasis	TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; P65 PHOSPHORYLATION; TRANSCRIPTIONAL REGULATION; GINGER SESQUITERPENE; DEPENDENT INDUCTION; SUBTROPICAL GINGER; ENDOTHELIAL-CELLS; CYCLIN D1; INHIBITOR	Zerumbone found in subtropical ginger Zingiber zerumbet Smith exhibits antiproliferative and antiinflammatory activityies but underlying molecular mechanisms are poorly understood. As several genes that regulate proliferation and apoptosis are regulated by nuclear factor (NF)-kappa B, we hypothesized that zerumbone mediates its activity through the modulation of NF-kappa B activation. We found that zerumbone suppressed NF-kappa B activation induced by tumor necrosis factor (TNF), okadaic acid, cigarette smoke condensate, phorbol myristate acetate, and H2O2 and that the suppression was not cell type specific. Interestingly, alpha-humulene, a structural analogue of zerumbone lacking the carbonyl group, was completely inactive. Besides being inducible, constitutively active NF-kappa B was also inhibited. NF-kappa B inhibition by zerumbone correlated with sequential suppression of the I kappa B alpha kinase activity, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, p65 nuclear translocation, and p65 acylation. Zerumbone also inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK but not that activated by the p65 subunit of NF-kappa B. NF-kappa B regulated gene products, such as cyclin D1, COX-2, MMP-9 ICAM-1, c-Myc, survivin, IAP1, IAP2, XIAP, Bcl-2, Bcl-x(L), Bfl-1/A1, TRAF1 and FLIP, were all downregulated by zerumbone. This downregulation led to the potentiation of apoptosis induced by cytokines and chemotherapeutic agents. Zerumbone's inhibition of expression of these NF-kappa B regulated genes also correlated with the suppression of TNF-induced invasion activity. Overall, our results indicated that zerumbone inhibits the activation of NF-kappa B and NF-kappa B regulated gene expression induced by carcinogens and that this inhibition may provide a molecular basis for the prevention and treatment of cancer by zerumbone.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Kyoto 6068502, Japan	University of Texas System; UTMD Anderson Cancer Center; Kyoto University	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd,Box 143, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844, P50 CA97007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DEV S, 1956, CHEM IND-LONDON, P1051; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hirschowitz E, 2002, GENE THER, V9, P81, DOI 10.1038/sj.gt.3301621; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kirana C, 2003, NUTR CANCER, V45, P218, DOI 10.1207/S15327914NC4502_12; Kitayama T, 1999, J ORG CHEM, V64, P2667, DOI 10.1021/jo981593n; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Morris KR, 2003, INFECT IMMUN, V71, P1442, DOI 10.1128/IAI.71.3.1442-1452.2003; Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048; Murakami A, 2004, INT J CANCER, V110, P481, DOI 10.1002/ijc.20175; Murakami A, 2003, BIOCHEM PHARMACOL, V66, P1253, DOI 10.1016/S0006-2952(03)00446-5; Murakami A, 2003, CANCER LETT, V195, P17, DOI 10.1016/S0304-3835(03)00058-2; Murakami A, 2003, MUTAT RES-FUND MOL M, V523, P151, DOI 10.1016/S0027-5107(02)00331-7; Murakami A, 2002, CARCINOGENESIS, V23, P795, DOI 10.1093/carcin/23.5.795; Murakami A, 1999, BIOSCI BIOTECH BIOCH, V63, P1811, DOI 10.1271/bbb.63.1811; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; OZAKI Y, 1991, CHEM PHARM BULL, V39, P2353, DOI 10.1248/cpb.39.2353; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shiraga M, 2002, CANCER RES, V62, P5967; Shishodia S, 2003, CANCER RES, V63, P4375; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; STEVE PO, 2002, J BIOL CHEM, V277, P35150; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka T, 2001, LIFE SCI, V69, P1935, DOI 10.1016/S0024-3205(01)01277-2; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weinstein IB, 2000, CARCINOGENESIS, V21, P857, DOI 10.1093/carcin/21.5.857; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	61	153	168	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6957	6969		10.1038/sj.onc.1208845	http://dx.doi.org/10.1038/sj.onc.1208845			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007145				2022-12-17	WOS:000232701700010
J	Berthou, S; Aebersold, DM; Schmidt, LS; Stroka, D; Heigl, C; Streit, B; Stalder, D; Gruber, G; Liang, CX; Howlett, AR; Candinas, D; Greiner, RH; Lipson, KE; Zimmer, Y				Berthou, S; Aebersold, DM; Schmidt, LS; Stroka, D; Heigl, C; Streit, B; Stalder, D; Gruber, G; Liang, CX; Howlett, AR; Candinas, D; Greiner, RH; Lipson, KE; Zimmer, Y			The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants	ONCOGENE			English	Article						Met receptor; activating mutation; receptor tyrosine kinase inhibitor	GROWTH-FACTOR RECEPTOR; GASTROINTESTINAL STROMAL TUMORS; PAPILLARY RENAL-CARCINOMAS; CHRONIC MYELOID-LEUKEMIA; FACTOR SCATTER FACTOR; TYROSINE KINASE; SOMATIC MUTATIONS; C-MET; CYTOGENETIC RESPONSES; IMATINIB MESYLATE	Point mutations constitute a major mode of oncogenic activation of the Met receptor tyrosine kinase. Met is aberrantly activated in many types of human malignancies and its deregulated activity is correlated with aggressive tumor traits such as abnormal proliferation and survival, leading to tumor growth, local invasion and metastasis. Here we report that the Met kinase inhibitor SU11274 differentially affects the kinase activity and subsequent signaling of various mutant forms of Met. Two Met variants tested, M1268T and H1112Y, were potently inhibited by 2 muM SU11274, while two other variants, L1213V and Y1248H, remained resistant under similar experimental conditions. Inhibition of the kinase altered cell proliferation, morphology and motility, while cells containing resistant mutants appeared unaffected by the compound. The basis for the sensitivity or resistance to SU11274 is discussed in terms of the position of the mutations predicted from a homology model.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Radiat Oncol, CH-3010 Bern, Switzerland; SAIC Frederick Inc, Basic Res Program, NCI Frederick, Ft Detrick, MD 21702 USA; Univ Bern, Inselspital, Dept Visceral Surg, CH-3010 Bern, Switzerland; SUGEN Inc, San Francisco, CA 94080 USA	University of Bern; University of Bern; University Hospital of Bern; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Bern; University Hospital of Bern; Pfizer	Zimmer, Y (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35-D-809, CH-3010 Bern, Switzerland.	yitzhak.zimmer@dkf5.unibe.ch	Aebersold, Daniel Matthias/C-2946-2013; Stroka, Deborah M/F-1806-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834; Lipson, Kenneth/0000-0001-8847-6051; Stroka, Deborah/0000-0002-3517-3871	PHS HHS [N01-C0-12400] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aebersold DM, 2003, ONCOGENE, V22, P8519, DOI 10.1038/sj.onc.1206968; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; de Silva MV, 2003, PATHOL ONCOL RES, V9, P13, DOI 10.1007/BF03033708; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Haddad R, 2001, ANTICANCER RES, V21, P4243; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Longati P, 2001, CURR DRUG TARGETS, V2, P41, DOI 10.2174/1389450013348920; Lorenzato A, 2002, CANCER RES, V62, P7025; Ma PC, 2003, CANCER RES, V63, P6272; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Miller M, 2001, PROTEINS, V44, P32, DOI 10.1002/prot.1069; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Park WS, 1999, CANCER RES, V59, P307; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sattler M, 2003, CANCER RES, V63, P5462; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; To CTT, 1998, ONCOL REP, V5, P1013; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Wang XY, 2003, MOL CANCER THER, V2, P1085	33	153	167	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5387	5393		10.1038/sj.onc.1207691	http://dx.doi.org/10.1038/sj.onc.1207691			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064724				2022-12-17	WOS:000222491600014
J	Weston, CR; Balmanno, K; Chalmers, C; Hadfield, K; Molton, SA; Ley, R; Wagner, EF; Cook, SJ				Weston, CR; Balmanno, K; Chalmers, C; Hadfield, K; Molton, SA; Ley, R; Wagner, EF; Cook, SJ			Activation of ERK1/2 by Delta Raf-1 : ER* represses bim expression independently of the JNK or PI3K pathways	ONCOGENE			English	Article						apoptosis; bim; ERK; Raf; JNK; PI3K	PROGRAMMED CELL-DEATH; BCL-2 FAMILY-MEMBER; C-JUN; BH3 DOMAIN; MOLECULAR-CLONING; CYCLE ARREST; PROTEIN BIM; APOPTOSIS; SURVIVAL; GENE	CC139 fibroblasts are one of several model systems in which the Raf --> MEK --> ERK1/2 pathway can inhibit apoptosis independently of the PI3K pathway; however, the precise mechanism for this protective effect is not known. Serum withdrawal from CC139 fibroblasts resulted in the rapid onset of apoptosis, which was prevented by actinomycin D or cycloheximide. Serum withdrawal promoted the rapid, de novo accumulation of BiMEL, a proapoptotic 'BH3-only' member of the Bcl-2 protein family. BiMEL expression was an early event, occurring several hours prior to caspase activation. In contrast to studies in neurons, activation of the JNK - cJun pathway was neither necessary nor sufficient to induce BiMEL expression. Selective inhibition of either the ERK pathway (with U0126) or the PI3K pathway (with LY294002) caused an increase in the expression of BiMEL. Furthermore, selective activation of the ERK1/2 pathway by DeltaRaf-1:ER*:ER* substantially reduced BiMEL expression, abolished conformational changes in Bax and blocked the appearance of apoptotic cells. The ability of DeltaRaf-1:ER* to repress Bim(EL) expression required the ERK pathway but was independent of the PI3K --> PDK --> PKB pathway. Thus, serum withdrawal-induced expression of BiMEL occurs independently of the JNK --> c-Jun pathway and can be repressed by the ERK pathway independently of the PI3K pathway. This may contribute to Raf- and Ras-induced cell survival at low serum concentrations.	Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England; Res IMP, A-1030 Vienna, Austria; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk		Balmanno, Kathryn/0000-0002-6417-3889; Wagner, Erwin F/0000-0001-7872-0196	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199, BBS/E/B/0000H457] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HILBERG F, 1992, ONCOGENE, V7, P2371; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; VASQUEZ F, 2000, BIOCHIM BIOPHYS ACTA, V1470, pM21; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	52	153	158	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1281	1293		10.1038/sj.onc.1206261	http://dx.doi.org/10.1038/sj.onc.1206261			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618753				2022-12-17	WOS:000181360900002
J	Liu, G; Chen, XB				Liu, G; Chen, XB			The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis	ONCOGENE			English	Article						FDXR; ROS; p53; p63; p73; apoptosis	COLORECTAL-CANCER CELLS; ADRENODOXIN REDUCTASE; CYCLE ARREST; TARGET GENES; DNA-DAMAGE; P21; INHIBITOR; BINDING; P73; P63	The p53 tumor suppressor protein, a transcription factor, induces cell cycle arrest and apoptosis via the upregulation of downstream target genes. Ferredoxin Reductase (protein, FR; gene, FDXR) transfers electron from NADPH to cytochrome P450 via ferredoxin in mitochondria. Here, we identified FDXR as a target gene of the p53 family, that is, p53, p63, and p73. We found that FDXR can be induced by DNA damage in cells in a p53-dependent manner and by a mutated form of p53 that is competent in inducing apoptosis. In addition, we identified a p53 response element located within the FDXR promoter that is responsive to wild-type p53, p63alpha, p63gamma, p73alpha, and p73beta. Furthermore, we showed that p53, p63alpha and p73alpha directly bind to the p53 response element in vivo and promote the accessibility of the FDXR promoter by increasing the acetylation of histones H3 and H4. To determine the role of FR in p53 tumor suppression, we generated cell lines that express FR using a tetracycline-regulated promoter. We found that overexpression of FR in lung H1299, breast MCF7, and colorectal HCT116 carcinoma cells have no effect on cell proliferation. However, we showed that FR increases the sensibility of H1299 and HCT116 cells to 5-fluorouracil-, doxorubicin- and H2O2- mediated apoptosis. Our data support a model of feed-forward loop for p53 activity, that is, various cellular stresses, including reactive oxygen species (ROS), activate p53, which induces the expression of FDXR; and the FDXR gene product, FR, in turn sensitizes cells to ROS-mediated apoptosis.	Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660, 1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		Liu, Gang/0000-0003-2615-131X; , Gang/0000-0002-6999-7633	NATIONAL CANCER INSTITUTE [R01CA076069, R29CA076069, R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [CA76069, R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1992, BIOCHEMISTRY-US, V31, P3500, DOI 10.1021/bi00128a026; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen J, 1996, ONCOGENE, V13, P1395; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; Chenery HJ, 1996, APHASIOLOGY, V10, P1, DOI 10.1080/02687039608248396; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMER RE, 1982, ARCH BIOCHEM BIOPHYS, V215, P478, DOI 10.1016/0003-9861(82)90106-0; MIYASHITA T, 1995, CELL, V80, P293; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; MUNGER K, 1989, J VIROL, V63, P4417; Nakayama T, 2000, IPAP CONFERENCE SER, V1, P7, DOI 10.1109/ROMAN.2000.892461; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	41	153	156	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7195	7204		10.1038/sj.onc.1205862	http://dx.doi.org/10.1038/sj.onc.1205862			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370809				2022-12-17	WOS:000178504600007
J	Shreeram, S; Sparks, A; Lane, DP; Blow, JJ				Shreeram, S; Sparks, A; Lane, DP; Blow, JJ			Cell type-specific responses of human cells to inhibition of replication licensing	ONCOGENE			English	Article						replication licensing; geminin; Cdt1	S-PHASE PROGRESSION; DNA-REPLICATION; MCM PROTEINS; IN-VIVO; CHECKPOINT; CYCLE; CHROMATIN; ORIGINS; COMPLEXES; DAMAGE	Replication origins are 'licensed' for a single initiation event by loading Mcm2-7 complexes during late mitosis and G1. Licensing is blocked at other cell cycle stages by the activity of cyclin-dependent kinases and a small protein called geminin. Here, we describe the effects of over-expressing a non-degradable form of geminin in various cell lines. Geminin expression reduced the quantity of Mcm2 bound to chromatin and blocked cell proliferation. U2OS (p53+/Rb+) cells showed an early S phase arrest with high cyclin E and undetectable cyclin A levels, consistent with the activation of an intra-S checkpoint. Saos2 (p53-/Rb-) cells showed an accumulation of cells in late S and G2/M with approximately normal levels of cyclin A, consistent with loss of this intra-S phase checkpoint. Geminin also induced apoptosis in both these cell lines. In contrast, IMR90 primary fibroblasts over-expressing geminin arrested in G1 with reduced cyclin E levels and no detectable apoptosis. A 'licensing checkpoint' may therefore act in primary cells to prevent passage into S phase in the absence of sufficient origin licensing. These results suggest that inhibition of the licensing system may cause cancer-specific cell killing and therefore represent a novel anticancer target.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Blow, JJ (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Dow St, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Sathyavageeswaran, Shreeram/0000-0002-6111-1818; Lane, David/0000-0003-0551-3545	Cancer Research UK [A2335] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Miura M, 1999, METH MOL B, V113, P577; Musahl C, 1998, EXP CELL RES, V241, P260, DOI 10.1006/excr.1998.4041; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Rowles A, 1999, J CELL SCI, V112, P2011; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Saudan P, 2000, EMBO J, V19, P4351, DOI 10.1093/emboj/19.16.4351; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Stoeber K, 2001, J CELL SCI, V114, P2027; Sun W, 2000, J CELL SCI, V113, P683; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; WOODWARD A, 2002, IN PRESS CHEMTRACTS	47	153	161	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6624	6632		10.1038/sj.onc.1205910	http://dx.doi.org/10.1038/sj.onc.1205910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242660	Green Accepted			2022-12-17	WOS:000178202300008
J	Crnogorac-Jurcevic, T; Efthimiou, E; Capelli, P; Blaveri, E; Baron, A; Terris, B; Jones, M; Tyson, K; Bassi, C; Scarpa, A; Lemoine, NR				Crnogorac-Jurcevic, T; Efthimiou, E; Capelli, P; Blaveri, E; Baron, A; Terris, B; Jones, M; Tyson, K; Bassi, C; Scarpa, A; Lemoine, NR			Gene expression profiles of pancreatic cancer and stromal desmoplasia	ONCOGENE			English	Article						pancreatic cancer; microarray; expression profiling; desmoplasia	GROWTH-FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; BREAST-CANCER; APOPTOSIS; PROTEINS; DECORIN; TUMORS; CELLS; ADENOCARCINOMA; IDENTIFICATION	Gene expression studies were undertaken in normal pancreas and pancreatic adenocarcinomas to determine new candidate genes that can potentially be used as markers of the disease. The characteristic desmoplastic stromal reaction of pancreatic adenocarcinoma greatly hampers expression studies in this tumour type, and usually necessitates time-consuming tissue microdissection for enrichment of the tumour cell population. We show that fine needle aspiration of cancer provides a fast and efficient way of obtaining samples highly enriched in tumour cells with sufficient yields of RNA. Using Atlas cancer cDNA arrays with 588 cancer-related genes, we describe gene expression profiles of normal pancreas, bulk pancreatic tumour tissues and pancreatic tumour aspirates containing more than 95% tumour cells. Analysis of bulk tissue specimens revealed differentially expressed genes belonging predominantly to the stromal component of the tumour. This contrasted with the results obtained from tumour-cell enriched samples. Several genes already described in pancreatic cancer (caspase 8, TIMP1, CD9, IL-13) were also differentially expressed in our study. Furthermore, we found dysregulated expression of genes not previously associated with pancreatic adenocarcinoma, such as Rac 1, GLG1, NEDD5, RPL-13a, RPS9 and members of the Wnt5A gene family. In summary, we present a panel of genes newly identified in the pathogenesis of pancreatic adenocarcinoma and demonstrate that fine needle aspirates of the tumour mass are a convenient source of material for gene expression studies in tumours accompanied by desmoplastic reactions.	Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Dept Canc Med, Mol Oncol Unit, London W12 0NN, England; Oxford Glycosci Proteome Discovery, Abingdon, Oxon, England; Univ Verona, Dept Surg, I-37100 Verona, Italy; Univ Verona, Dept Pathol, I-37100 Verona, Italy	Cancer Research UK; Imperial College London; University of Verona; University of Verona	Lemoine, NR (corresponding author), Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Dept Canc Med, Mol Oncol Unit, Hammersmith Campus, London W12 0NN, England.		Terris, Benoit/P-1497-2017; scarpa, aldo/K-6832-2016; Capelli, Patrizio/AEJ-5748-2022; Capelli, Patrizio/AAD-5108-2022	scarpa, aldo/0000-0003-1678-739X; Capelli, Patrizio/0000-0001-9434-3984; SALVIA, Roberto/0000-0002-3514-8473				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Asakura S, 1999, HUM PATHOL, V30, P195, DOI 10.1016/S0046-8177(99)90275-7; Aspinall RJ, 1999, ANN ONCOL, V10, P188, DOI 10.1023/A:1008315003875; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Bramhall SR, 1997, J PATHOL, V182, P347, DOI 10.1002/(SICI)1096-9896(199707)182:3<347::AID-PATH848>3.0.CO;2-J; Cardone A, 1997, PANMINERVA MED, V39, P174; Chen FW, 1998, MOL GENET METAB, V64, P271, DOI 10.1006/mgme.1998.2718; EMMERTBUCK MR, 1996, SCIENCE, V274, P988; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gress TM, 1998, DIGESTION, V59, P625, DOI 10.1159/000007567; Gress TM, 1996, ONCOGENE, V13, P1819; Gress TM, 1997, GENE CHROMOSOME CANC, V19, P97, DOI 10.1002/(SICI)1098-2264(199706)19:2<97::AID-GCC5>3.0.CO;2-V; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; HALVORSEN TB, 1989, J CLIN PATHOL, V42, P162, DOI 10.1136/jcp.42.2.162; Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784; IOZZO RV, 1995, CANCER RES, V55, P3495; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kohl R, 2000, J BIOL CHEM, V275, P15741, DOI 10.1074/jbc.M903271199; Kornmann M, 1999, ANTICANCER RES, V19, P125; Lemoine NR, 1997, DIGESTION, V58, P550, DOI 10.1159/000201500; Lohr M, 2001, CANCER RES, V61, P550; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ryu B, 2001, CANCER RES, V61, P1833; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Sirivatanauksorn Y, 1999, J PATHOL, V189, P150, DOI 10.1002/(SICI)1096-9896(199910)189:2<150::AID-PATH451>3.0.CO;2-G; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Virkajarvi N, 1998, HISTOPATHOLOGY, V33, P432, DOI 10.1046/j.1365-2559.1998.00553.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4	39	153	164	2	17	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7437	7446		10.1038/sj.onc.1204935	http://dx.doi.org/10.1038/sj.onc.1204935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704875				2022-12-17	WOS:000171894200018
J	Degos, L; Wang, ZY				Degos, L; Wang, ZY			All trans retinoic acid in acute promyelocytic leukemia	ONCOGENE			English	Article						differentiation; promyelocytic leukemia; retinoic acid	POLYMERASE CHAIN-REACTION; RECEPTOR-ALPHA; DIFFERENTIATION THERAPY; 15-17 TRANSLOCATION; TRANSRETINOIC ACID; COMPLETE REMISSION; CD56 EXPRESSION; PML GENE; CHEMOTHERAPY; FUSION	All trans retinoic acid (ATRA) is able to induce complete remission (CR) in almost all patients with acute promyelocytic leukemia (APL) through in vivo differentiation of APL blasts. However, it cannot eliminate the leukemic clone and to be effective must be used in combination with anthracycline-based chemotherapy. Experience accumulated over the last 10 years has clearly shown that the combination of ATRA and chemotherapy gives better survival in newly diagnosed APL than chemotherapy alone because of fewer relapses and a higher CR rate experienced by these patients. It is also strongly suggested that maintenance treatment with ATRA, and possibly in combination with low-dose chemotherapy, can further reduce the incidence of relapse. Overall, more than 90% of patients with newly diagnosed APL can achieve CR and about 75% can be cured by the combination of ATRA and chemotherapy.	Hop St Louis, Inst Univ Hematol, AP HP, F-75010 Paris, France; Shanghai Med Univ 2, Rui Jin Hosp, Shanghai Inst Hematol, Shanghai, Peoples R China	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Shanghai Jiao Tong University	Degos, L (corresponding author), Hop St Louis, Inst Univ Hematol, AP HP, 1 Ave Claude Vellefaux, F-75010 Paris, France.							Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Avvisati G, 1999, BLOOD, V94, p505A; AVVISATI G, 1991, ANN ONCOL, V2, P405; AVVISATI G, 1990, HEMOSTASIS CANC, P91; Beaumont M, 2000, BLOOD, V96, p321A; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BENNETT JM, 1980, ANN INTERN MED, V92, P261, DOI 10.7326/0003-4819-92-2-261; BERNARD J, 1959, Schweiz Med Wochenschr, V89, P604; BERNARD J, 1973, BLOOD, V41, P489, DOI 10.1182/blood.V41.4.489.489; BIONDI A, 1992, BLOOD, V80, P492; BREITMAN TR, 1981, BLOOD, V57, P1000; CAEN J, 1959, REV FR ETUD CLIN BIO, V4, P363; CAEN J, 1957, C EUR HEMAT KARGER, P502; CASSINAT B, 2001, SEMINARS HEMATOLOGY; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1986, LEUKEMIA RES, V10, P1301, DOI 10.1016/0145-2126(86)90337-1; CHOMIENNE C, 1986, LEUKEMIA RES, V10, P1079, DOI 10.1016/0145-2126(86)90052-4; CORNIC M, 1992, CANCER RES, V52, P3329; DOMBRET H, 1995, LEUKEMIA, V9, P19; Douer D, 1996, BLOOD, V87, P308, DOI 10.1182/blood.V87.1.308.bloodjournal871308; DUBOIS C, 1994, LEUKEMIA, V8, P1750; Fenaux P, 1999, BLOOD, V94, P1192, DOI 10.1182/blood.V94.4.1192.416k07_1192_1200; FENAUX P, 1993, BLOOD, V82, P3241; FENAUX P, 1992, BLOOD, V80, P2176; Fenaux P, 2000, LEUKEMIA, V14, P1371, DOI 10.1038/sj.leu.2401859; Ferrara F, 2000, J CLIN ONCOL, V18, P1295, DOI 10.1200/JCO.2000.18.6.1295; FRANKEL SR, 1992, ANN INTERN MED, V117, P293; GOLOMB HM, 1976, ARCH INTERN MED, V136, P825, DOI 10.1001/archinte.136.7.825; Guglielmi C, 1998, BRIT J HAEMATOL, V102, P1035, DOI 10.1046/j.1365-2141.1998.00871.x; HILLESTAD LK, 1957, ACTA MED SCAND, V159, P189, DOI 10.1111/j.0954-6820.1957.tb00124.x; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; KANAMARU A, 1995, BLOOD, V85, P1202, DOI 10.1182/blood.V85.5.1202.bloodjournal8551202; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; Lo Coco F, 1999, BLOOD, V94, P2225, DOI 10.1182/blood.V94.7.2225.419k03_2225_2229; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; MICLEA JM, 1994, LEUKEMIA, V8, P214; MUINDI J, 1992, BLOOD, V79, P299; Murray CK, 1999, J CLIN ONCOL, V17, P293, DOI 10.1200/JCO.1999.17.1.293; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RODEGHIERO F, 1990, BLOOD, V75, P2112; ROWLEY JD, 1977, LANCET, V1, P549; Schoch C, 1996, BRIT J HAEMATOL, V94, P493, DOI 10.1046/j.1365-2141.1996.d01-1829.x; Slack JL, 1997, J CLIN ONCOL, V15, P1786, DOI 10.1200/JCO.1997.15.5.1786; Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501; VAHDAT L, 1994, BLOOD, V84, P3843, DOI 10.1182/blood.V84.11.3843.bloodjournal84113843; Wang ZY, 1999, CHINESE MED J-PEKING, V112, P963; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1994, LEUKEMIA, V8, P929; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zhu J, 1999, LEUKEMIA, V13, P1062, DOI 10.1038/sj.leu.2401448	55	153	166	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7140	7145		10.1038/sj.onc.1204763	http://dx.doi.org/10.1038/sj.onc.1204763			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704842				2022-12-17	WOS:000171891900002
J	Belsches-Jablonski, AP; Biscardi, JS; Peavy, DR; Tice, DA; Romney, DA; Parsons, SJ				Belsches-Jablonski, AP; Biscardi, JS; Peavy, DR; Tice, DA; Romney, DA; Parsons, SJ			Src family kinases and HER2 interactions in human breast cancer cell growth and survival	ONCOGENE			English	Article						Src family kinases; heregulin; breast cancer; HER2/neu; cell growth; apoptosis	PROTEIN-TYROSINE KINASES; ERBB SIGNALING NETWORK; FACTOR RECEPTOR; C-SRC; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIATION FACTOR; NEU PROTOONCOGENE; EPITHELIAL-CELLS; OVARIAN-CANCER; A431 CELLS	Evidence from murine fibroblast models and human breast cancer cells indicates that c-Src and human EGF receptor (HER1) synergize to enhance neoplastic growth of mammary epithelial cells, To investigate whether interactions between c-Src and other HER members may also play a role in breast tumor progression, we characterized 13 human breast carcinoma cell lines and 13 tumor samples for expression of HER family members and c-Src and examined a subset of the cell lines for Src-dependent, heregulin (HRG)-augmented, anchorage-dependent and independent growth. By immunoblotting, we found that all cell lines overexpressed one or more HER family member, and 60% overexpressed c-Src, Seventy-five per cent of the tumor tissues overexpressed HER2, while 64% overexpressed c-Src, Colony formation in soft agar was enhanced by HRG in three of five cell lines tested, a response that correlated,vith the presence of a c-Src/HER2 heterocomplex, This result suggests that HRG may act through both HER2 and c-Src to facilitate anchorage-independent growth. In contrast, HRG had little effect on anchorage-dependent growth in any of the cell lines tested. PP1, a Src family kinase inhibitor, reduced or ablated HRG-dependent and independent soft agar growth or anchorage dependent growth, and triggered apoptosis in all cell lines tested. The apoptotic effect of PP1 could be partially or completely reversed by HRG, depending on the cell line. These results suggest that while Src family kinases may cooperate with HRG to promote the survival and growth of human breast tumor cells, they also function independently of HER2/HRG in these processes.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Lynchburg Coll, Biol Program, Lynchburg, VA 24501 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NCI NIH HHS [CA71449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; BERCHUCK A, 1990, CANCER RES, V50, P4087; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KAMEDA T, 1990, CANCER RES, V50, P8002; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPERS GJL, 1991, BRIT J CANCER, V64, P469, DOI 10.1038/bjc.1991.333; KERN JA, 1990, CANCER RES, V50, P5184; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; LINSLEY PS, 1980, J SUPRAMOL STR CELL, V14, P441, DOI 10.1002/jss.400140404; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MAGUIRE HC, 1992, PATHOBIOLOGY, V60, P117; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PIERCE JH, 1991, ONCOGENE, V6, P1189; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SAINSBURY JRC, 1987, LANCET, V1, P1398; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SEGATTO O, 1993, ONCOGENE, V8, P2105; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VILLANUEVA A, 1984, HISTOCHEMISTRY, V81, P103, DOI 10.1007/BF00495409; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	63	153	157	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1465	1475		10.1038/sj.onc.1204205	http://dx.doi.org/10.1038/sj.onc.1204205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313890				2022-12-17	WOS:000167595200007
J	Follenzi, A; Bakovic, S; Gual, P; Stella, MC; Longati, P; Comoglio, PM				Follenzi, A; Bakovic, S; Gual, P; Stella, MC; Longati, P; Comoglio, PM			Cross-talk between the proto-oncogenes Met and Ron	ONCOGENE			English	Article						Met; Ron; cross talk; scatter factors; tyrosine kinase	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; HGF RECEPTOR; C-MET; SIGNAL-TRANSDUCTION; MEDIATED TRANSFORMATION; GASTRIC-CARCINOMA; MET/HGF RECEPTOR	Scatter Factors control a complex genetic program known as 'invasive growth'. HGF (Scatter factor 1) and MSP (Scatter Factor 2) bind to tyrosine kinase receptors encoded by the proto-oncogenes MET and RON. Using the appropriate 'kinase inactive' mutant receptors, we show that ligand-induced activation of Met results in transphosphorylation of Roll, and Vice ver sn. Transphosphorylation is direct, as it occurs in Met or Ron receptors lacking the docking sites for signal transducers. Phosphate groups are transferred to the tyrosine phosphorylation sites responsible both for kinase up-regulation (Met: Y1234/Y1235 and Ron: Y1238/Y1239) and for generation of signal transducer docking sites (Met: Y1349/Y1356 and Ron Y1353/Y1360). The transphosphorylation specifically takes place for the receptor subfamily, as it is not observed between Met or Ron and ErbB1, ErbB2 or TrkA. Cross-linking experiments show that non-covalent Met-Roll complexes are present on the cell surface, before ligand-induced dimerization. Go-expression of a kinase inactive Ron receptor with naturally-occurring oncogenic Met mutants suppresses the transforming phenotype, suggesting a dominant negative role for the inefficient kinase partner. These data show that, while specific for their ligands, scatter factor receptors cross-talk and cooperate in intracellular signaling.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Follenzi, A (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy.		Comoglio, Paolo/G-6323-2011; Gual, Philippe/P-9833-2019	Gual, Philippe/0000-0001-7393-8356; Comoglio, Paolo/0000-0002-7056-5328; Follenzi, Antonia/0000-0001-9780-300X				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Banu N, 1996, J IMMUNOL, V156, P2933; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Blechman JM, 1995, ANN NY ACAD SCI, V766, P344, DOI 10.1111/j.1749-6632.1995.tb26685.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; DIRENZO MF, 1995, J ENDOCRINOL INVEST, V18, P134, DOI 10.1007/BF03349722; DIRENZO MF, 1991, ONCOGENE, V6, P1997; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FALETTO DL, 1992, ONCOGENE, V7, P1149; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GAUDINO G, 1995, ONCOGENE, V11, P2527; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LONGATI P, 1994, ONCOGENE, V9, P49; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899; Michieli P, 1996, ONCOGENE, V12, P775; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; TARTARE S, 1991, FEBS LETT, V295, P219, DOI 10.1016/0014-5793(91)81422-5; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Westermark B, 1989, CURR OPIN CELL BIOL, V1, P279, DOI 10.1016/0955-0674(89)90101-4; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	73	153	157	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3041	3049		10.1038/sj.onc.1203620	http://dx.doi.org/10.1038/sj.onc.1203620			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871856				2022-12-17	WOS:000087903900001
J	Gilmore, TD				Gilmore, TD			Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel	ONCOGENE			English	Review						v-Rel; Rel; NF-kappa B; malignant transformation; transcription factor; retroviral oncogene	VIRUS-STRAIN-T; NF-KAPPA-B; AVIAN RETICULOENDOTHELIOSIS VIRUS; CHICKEN SPLEEN-CELLS; TRANSFORMED LYMPHOID-CELLS; RECEPTOR FUSION PROTEIN; BONE-MARROW CELLS; C-REL; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION	The avian Rev-T retrovirus encodes the v-Rel oncoprotein, which is a member of the Rel/NF-kappa B transcription factor family. v-Rel induces a rapidly fatal lymphoma/leukemia in young birds, and v-Rel can transform and immortalize a variety of avian cell types irt vitro. Although Rel/NF-kappa B transcription factors have been associated with oncogenesis in mammals, v-Rel is the only member of this family that is frankly oncogenic in animal model systems. The potent oncogenicity of v-Rel is the consequence of a number of mutations that have altered its activity and regulation: for example, certain mutations decrease its ability to be regulated by I kappa B alpha, change its DNA-binding site specificity, and endow it with new transactivation properties. The study of v-Rel will continue to increase our knowledge of how cellular Rel proteins contribute to oncogenesis by affecting cell growth, altering cell-cycle regulation, and blocking apoptosis, This review will discuss biological and molecular activities of v-Rel, with particular attention to how these activities relate to structure-function aspects of the Rel/NF-kappa B transcription factors.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARBACID M, 1979, J VIROL, V30, P508, DOI 10.1128/JVI.30.2.508-514.1979; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARKETT M, 1999, UNPUB ONCOGENE; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BENATAR T, 1992, P NATL ACAD SCI USA, V89, P7615, DOI 10.1073/pnas.89.16.7615; BENATAR T, 1991, EUR J IMMUNOL, V21, P2529, DOI 10.1002/eji.1830211033; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHARMAN HP, 1979, J VIROL, V29, P1221, DOI 10.1128/JVI.29.3.1221-1225.1979; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen E, 1998, J BIOL CHEM, V273, P35201, DOI 10.1074/jbc.273.52.35201; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; CHEN ISY, 1982, CELL, V31, P111, DOI 10.1016/0092-8674(82)90410-X; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; CHEN L, 1988, P NATL ACAD SCI USA, V85, P549, DOI 10.1073/pnas.85.2.549; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; Enrietto P J, 1990, Semin Cancer Biol, V1, P399; EPINAT JC, 1999, IN PRESS ONCOGENE; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; Fujii M, 1996, ONCOGENE, V12, P2193; Fujii Masahiro, 1997, Leukemia (Basingstoke), V11, P402; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARRY RF, 1981, VIROLOGY, V113, P403, DOI 10.1016/0042-6822(81)90167-7; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; Gilmore TD, 1996, ONCOGENE, V13, P1367; GILMORE TD, 1995, DNA PROVIRUS, P109; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HODGSON J, 1995, J VIROL, V69, P1971, DOI 10.1128/JVI.69.3.1971-1979.1995; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HOEZLER JD, 1980, VIROLOGY, V100, P462; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HU SSF, 1981, J VIROL, V37, P899, DOI 10.1128/JVI.37.3.899-907.1981; HUNTER E, 1978, P NATL ACAD SCI USA, V75, P2708, DOI 10.1073/pnas.75.6.2708; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INUZUKA M, 1994, ONCOGENE, V9, P133; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1991, NEW BIOL, V3, P1005; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KELLER LH, 1979, INFECT IMMUN, V25, P694, DOI 10.1128/IAI.25.2.694-701.1979; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; KOCHEL T, 1992, ONCOGENE, V7, P567; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LAROSE RN, 1965, AVIAN DIS, V9, P604, DOI 10.2307/1588144; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; MALDONADO RL, 1971, J VIROL, V8, P813, DOI 10.1128/JVI.8.5.813-815.1971; MARMOR MD, 1993, J EXP MED, V177, P647, DOI 10.1084/jem.177.3.647; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MILLER CK, 1988, J VIROL, V62, P1219, DOI 10.1128/JVI.62.4.1219-1226.1988; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; MOSIALOS G, 1993, THESIS BOSTON U; MUSSMAN HC, 1971, AVIAN DIS, V15, P483, DOI 10.2307/1588725; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NOORIDALOII MR, 1981, NATURE, V294, P574, DOI 10.1038/294574a0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OLSON LD, 1967, AM J VET RES, V28, P1501; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PENTRENKO O, 1997, ONCOGENE, V15, P1671; PETERSON DA, 1971, AVIAN DIS, V15, P874, DOI 10.2307/1588878; PETRENKO O, 1995, GENE, V160, P305, DOI 10.1016/0378-1119(95)00210-W; PURCHASE HG, 1973, J NATL CANCER I, V51, P489; PURCHASE HG, 1975, CURR TOP MICROBIOL, P103; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; RUP BJ, 1979, J IMMUNOL, V123, P1362; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SARKAR S, 1993, ONCOGENE, V8, P2245; SASAKI T, 1989, AVIAN PATHOL, V18, P307, DOI 10.1080/03079458908418604; SCHAT KA, 1992, AVIAN DIS, V36, P432, DOI 10.2307/1591524; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SEVOIAN M, 1964, AVIAN DIS, V8, P336, DOI 10.2307/1587964; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIF S, 1993, ONCOGENE, V8, P2501; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SMARDOVA J, 1995, ONCOGENE, V10, P2017; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STORMS RW, 1992, VIROLOGY, V188, P765, DOI 10.1016/0042-6822(92)90531-S; SWIFT RA, 1985, J VIROL, V54, P869, DOI 10.1128/JVI.54.3.869-872.1985; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TAYLOR HW, 1971, AVIAN DIS, V15, P629, DOI 10.2307/1588849; TAYLOR HW, 1973, AVIAN DIS, V17, P794, DOI 10.2307/1589047; TAYLOR HW, 1973, AVIAN DIS, V17, P782, DOI 10.2307/1589046; TAYLOR HW, 1972, AVIAN DIS, V16, P330, DOI 10.2307/1588797; TEMIN HM, 1990, CELLULAR MOL BIOL HU, P175; THEILEN GH, 1996, J NATL CANCER I, V37, P731; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; TUNG HYL, 1988, BIOCHEM BIOPH RES CO, V152, P441; Walker AK, 1996, ONCOGENE, V12, P2515; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WITTER RL, 1981, AVIAN DIS, V25, P374, DOI 10.2307/1589930; WITTER RL, 1979, INT J CANCER, V23, P673, DOI 10.1002/ijc.2910230513; WITTER RL, 1979, INFECT IMMUN, V26, P90, DOI 10.1128/IAI.26.1.90-98.1979; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Xu X, 1997, ONCOGENE, V14, P1521, DOI 10.1038/sj.onc.1200985; XU X, 1995, VIROLOGY, V207, P362, DOI 10.1006/viro.1995.1095; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; ZHANG J, 1989, MOL CELL BIOL, V9, P4970, DOI 10.1128/MCB.9.11.4970; ZHANG J, 1991, VIROLOGY, V183, P457, DOI 10.1016/0042-6822(91)90975-H; ZHAO MK, 1999, IN PRESS GENE EXPRES; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	176	153	155	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	1999	18	49					6925	6937		10.1038/sj.onc.1203222	http://dx.doi.org/10.1038/sj.onc.1203222			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602467				2022-12-17	WOS:000083896500009
J	Sakamuro, D; Prendergast, GC				Sakamuro, D; Prendergast, GC			New Myc-interacting proteins: a second Myc network emerges	ONCOGENE			English	Review						neoplastic transformation; apoptosis; transcription; oncogene; tumor suppressor; proliferation	CELL-CYCLE PROGRESSION; TRANSCRIPTIONAL ACTIVATION DOMAIN; RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING PROTEIN; N-TERMINAL DOMAIN; C-MYC; IN-VIVO; TFII-I; TRANSACTIVATION DOMAIN; PHOSPHORYLATION SITES	Despite its intensive investigation for almost two decades, c-Myc remains a fascinating and enigmatic subject. A large and compelling body of evidence indicates that c-Myc is a transcription factor with central roles in the regulation of cell proliferation, differentiation, and apoptosis, but its exact function has remained elusive. In this review we survey recent advances in the identification and analysis of c-Myc-binding proteins, which suggest insights into the transcriptional roles of c-Myc but which also extend the existing functional paradigms. The C-terminal domain (CTD) of c-Myc mediates interaction with Max and physiological recognition of DNA target sequences, events needed for all biological actions. Recently described interactions between the CTD and other cellular proteins, including YY-1, AP-2, BRCA-1, TFII-I, and Miz-1, suggest levels of regulatory complexity beyond Max in controlling DNA recognition by c-Myc, The N-terminal domain (NTD), which includes the evolutionarily conserved and functionally crucial Myc Box sequences (MB1 and MB2), contains the transcription activation domain (TAD) of c-Myc as well as regions required for transcriptional repression, cell cycle regulation, transformation, and apoptosis, In addition to interaction with the retinoblastoma family protein p107, the NTD has been shown to interact with alpha-tubulin and the novel adaptor proteins Bin1, MM-1, Pam, TRRAP, and AMY-I, The structure of these proteins and their effects on c-Myc actions suggest links to the transcriptional regulatory machinery as well as to cell cycle regulation, chromatin modeling, and apoptosis, Investigations of this emerging NTD-based network may reveal how c-Myc is regulated and how it affects cell fate, as well as providing tools to distinguish the physiological roles of various Myc target genes.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Sakamuro, D (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							ADNANE J, 1995, ONCOGENE, V10, P381; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; ASKEW DS, 1991, ONCOGENE, V6, P1915; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bao JX, 1996, ONCOGENE, V12, P2171; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BERBERICH S, 1992, ONCOGENE, V7, P775; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BOUSSET K, 1993, ONCOGENE, V8, P3211; Bova GS, 1996, WORLD J UROL, V14, P338; Brizzio V, 1998, J CELL BIOL, V141, P567, DOI 10.1083/jcb.141.3.567; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cher ML, 1996, CANCER RES, V56, P3091; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Dropcho EJ, 1996, ANN NEUROL, V39, P659, DOI 10.1002/ana.410390516; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELLIOTT K, 1999, IN PRESS ONCOGENE; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MAO NC, 1999, IN PRESS GENOMICS; MARTEL C, 1995, ONCOGENE, V10, P2195; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Mori K, 1998, J BIOL CHEM, V273, P29794, DOI 10.1074/jbc.273.45.29794; MorrissKay GM, 1996, BIOESSAYS, V18, P785, DOI 10.1002/bies.950181004; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Negorev D, 1996, GENOMICS, V33, P329, DOI 10.1006/geno.1996.0205; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRENDERGAST GC, 1997, ONCOGENES TRANSCRIPT, P1; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; Ryan KM, 1997, BIOCHEM J, V325, P79, DOI 10.1042/bj3250079; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Steiner P, 1996, Prog Cell Cycle Res, V2, P73; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VASTRIK I, 1995, ONCOGENE, V11, P553; VRIZ S, 1992, MOL CELL BIOL, V12, P3548, DOI 10.1128/MCB.12.8.3548; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; YANO T, 1993, ONCOGENE, V8, P2741; Yin XY, 1998, ONCOGENE, V16, P2629, DOI 10.1038/sj.onc.1201777; Yuan J, 1998, ONCOGENE, V17, P1109, DOI 10.1038/sj.onc.1202036; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	150	153	157	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2942	2954		10.1038/sj.onc.1202725	http://dx.doi.org/10.1038/sj.onc.1202725			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378691				2022-12-17	WOS:000080387800005
J	Dennler, S; Huet, S; Gauthier, JM				Dennler, S; Huet, S; Gauthier, JM			A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3	ONCOGENE			English	Article						Smad; TGF beta; transcription; DNA-binding	TGF-BETA RECEPTOR; TUMOR-SUPPRESSOR SMAD4; MAD-RELATED PROTEIN; MICROSATELLITE INSTABILITY; INACTIVATION; SUPERFAMILY; ANTAGONIST; MUTATIONS; CANCER; GENE	Smad proteins are essential components of the signalling cascade initiated by members of the Transforming Growth Factor-beta family. TGF beta binding to heteromeric complexes of transmembrane Ser/Thr kinases induces Smad2 and Smad3 phosphorylation on their C terminus residues. This phosphorylation leads to oligomerization with Smad4, a common mediator of TGF-beta, activin and BMP signalling. The Smad complexes then translocate to the nucleus where they play transcription regulator roles. Even if they share 92% identity, the two TGF beta restricted Smad2 and Smad3 are not functionally equivalent. As we have previously shown, Smad3 acts as a transcription factor by binding to a TGF beta-responsive sequence termed CAGA box whereas Smad2 does not. Smad2 differs from Smad3 mainly in the N-terminal MH1 domain where it contains two additional stretches of amino acids that are lacking in Smad3. Here, we show that one of these domains corresponding to exon 3 is responsible for the absence of Smad2 transcriptional activity in CAGA box-containing promoters. Furthermore, in vitro studies indicate that this domain prevents Smad2 from binding to this DNA sequence. This suggests that Smad2 and Smad3 may have different subsets of target genes participating thus in distinct responses among TGF beta pleiotropic effects.	Lab Glaxo Wellcome, F-91951 Les Ulis, France	GlaxoSmithKline	Gauthier, JM (corresponding author), Lab Glaxo Wellcome, 25 Ave Quebec, F-91951 Les Ulis, France.							ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1998, MINER ELECTROL METAB, V24, P131, DOI 10.1159/000057360; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyazono K, 1997, INT J HEMATOL, V65, P97; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PARSONS R, 1995, CANCER RES, V55, P5548; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	34	153	159	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1643	1648		10.1038/sj.onc.1202729	http://dx.doi.org/10.1038/sj.onc.1202729			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102636				2022-12-17	WOS:000078770700016
J	Cairns, P; Evron, E; Okami, K; Halachmi, N; Esteller, M; Herman, JG; Bose, S; Wang, SI; Parsons, R; Sidransky, D				Cairns, P; Evron, E; Okami, K; Halachmi, N; Esteller, M; Herman, JG; Bose, S; Wang, SI; Parsons, R; Sidransky, D			Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers	ONCOGENE			English	Article						PTEN/MMAC1; bladder cancer; renal cell cancer; chromosome 10q; homozygous deletion	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; COWDEN SYNDROME; IDENTIFICATION; DISEASE; INACTIVATION; METHYLATION; ALLELOTYPE	A new tumor suppressor gene PTEN/MMAC1 was recently isolated at chromosome 10q23 and found to be inactivated by point mutation or homozygous deletion in glioma, prostate and breast cancer. PTEN/MMAC1 was also identified as the gene predisposing to Cowden disease, an autosomal dominant cancer predisposition syndrome associated with an increased risk of breast, skin and thyroid tumors and occasional cases of other cancers including bladder and renal cell carcinoma. We screened 345 urinary tract cancers by microsatellite analysis and found chromosome 10q to be deleted in 65 of 285 (23%) bladder and 15 of 60 (25%) renal cell cancers, We then screened the entire PTEN/MMAC1 coding region for mutation in 25 bladder and 15 renal cell primary tumors with deletion of chromosome 10q, Two somatic point mutations, a frameshift and a splicing variant, were found in the panel of bladder tumors while no mutation was observed in the renal cell carcinomas. To screen for homozygous deletion, we isolated two polymorphic microsatellite repeats from genomic BAC clones containing the PTEN/MMAC1 gene. Using these new informative markers, we identified apparent retention at the gene locus indicative of homozygous deletion of PTEN/MMAC1 in four of 65 bladder and 0 of 15 renal cell tumors with LOH through chromosome 10q, Identification of the second inactivation event in six bladder tumors with LOH of 10q implies that the PTEN/MMAC1 gene is occasionally involved in bladder tumorigenesis. However, the low frequency of biallelic inactivation suggests that either PTEN/MMAC1 is inactivated by other mechanisms or it is not the only target of chromosome 10q deletion in primary bladder and renal cell cancer.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Med, New York, NY 10032 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Columbia University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA.		Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Evron, Ella/0000-0002-1003-5042; Parsons, Ramon/0000-0002-6656-3514				CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1991, ONCOGENE, V6, P2305; Cairns P, 1997, CANCER RES, V57, P4997; ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HAIBACH H, 1992, AM J CLIN PATHOL, V97, P705, DOI 10.1093/ajcp/97.5.705; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; ISHIKAWA J, 1991, CANCER RES, V51, P5736; KNOWLES MA, 1994, CANCER RES, V54, P531; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORITA R, 1991, CANCER RES, V51, P5817; MORITA R, 1991, CANCER RES, V51, P820; REITER RE, 1993, CANCER RES, V53, P3092; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STARINK TM, 1986, CLIN GENET, V29, P222; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VANDERRIET P, 1994, CANCER RES, V54, P25; Wang SI, 1997, CANCER RES, V57, P4183	26	153	159	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	1998	16	24					3215	3218		10.1038/sj.onc.1201855	http://dx.doi.org/10.1038/sj.onc.1201855			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671402				2022-12-17	WOS:000074261300016
J	Klapper, LN; Vaisman, N; Hurwitz, E; PinkasKramarski, R; Yarden, Y; Sela, M				Klapper, LN; Vaisman, N; Hurwitz, E; PinkasKramarski, R; Yarden, Y; Sela, M			A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors	ONCOGENE			English	Article						signal transduction; tyrosine kinase; oncogene; Neu differentiation factor; epidermal growth factor; adenocarcinoma	NEU DIFFERENTIATION FACTOR; HUMAN MAMMARY-CARCINOMA; HUMAN-BREAST-CANCER; EXTRACELLULAR DOMAIN; NEU/ERBB-2 RECEPTOR; SIGNAL-TRANSDUCTION; GENE-PRODUCT; CELLS; ONCOGENE; TRANSFORMATION	ErbB-2 is an orphan receptor that belongs to a family of tyrosine kinase receptors for either epidermal growth factor (EGF) or Neu differentiation factor (NDF/ neuregulin), Because overexpression of the erbB-2 proto-oncogene is frequently associated with an aggressive clinical course of certain human adenocarcinomas, the encoded protein is an attractive target for immunotherapy. Indeed, certain monoclonal antibodies (mAbs) to ErbB-2 effectively inhibit tumor growth in animal models and in clinical trials, but the underlying mechanism is incompletely understood. To study this question, we generated a large battery of mAbs to ErbB-2, that were classified epitopically, Whereas most antibodies stimulated tyrosine phosphorylation of ErbB-2, their anti-tumor effect correlated with its accelerated endocytic degradation, One group of tumor-inhibitory mAbs (Class II mAbs) was elicited by the most antigenic site of ErbB-2, and inhibited in trans binding of NDF and EGF to their direct receptors. The inhibitory effect was due to acceleration of ligand dissociation, and it resulted in the reduction of the ability of ErbB-2 to transactivate the mitogenic signals of NDF and EGF, These results identify two potential mechanisms of antibody-induced therapy: acceleration of ErbB-2 endocytosis by homodimerization and blocking of heterodimerization between ErbB-2 and growth factor receptors.	WEIZMANN INST SCI, DEPT IMMUNOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT MOL CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012	Pinkas-Kramarski, Ronit/0000-0002-1000-369X	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1992, CANCER RES, V52, P2580; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; FENDLY BM, 1990, J BIOL RESP MODIF, V9, P449; GOLDENBERG DM, 1993, AM J MED, V94, P297, DOI 10.1016/0002-9343(93)90062-T; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1994, EUR J CANCER, V30A, P2186, DOI 10.1016/0959-8049(94)00365-C; GULLICK WJ, 1990, INT J CANCER, P55; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HELLSTROM KE, 1989, FASEB J, V3, P1715, DOI 10.1096/fasebj.3.6.2649402; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARK JB, 1989, CANCER RES, V49, P6605; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RUSSO C, 1983, J IMMUNOL METHODS, V65, P269, DOI 10.1016/0022-1759(83)90324-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STANCOVSKI I, 1992, J STEROID BIOCHEM, V43, P95, DOI 10.1016/0960-0760(92)90192-L; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STANCOVSKI I, 1994, REGULATORY MECH BREA, P161; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; TREPEL JB, 1990, CANCER RES, V50, P2773; TZAHAR E, 1996, IN PRESS MOL CELL BI; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	54	153	203	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	1997	14	17					2099	2109		10.1038/sj.onc.1201029	http://dx.doi.org/10.1038/sj.onc.1201029			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160890				2022-12-17	WOS:A1997WW80900012
J	WELCH, DR; CHEN, PC; MIELE, ME; MCGARY, CT; BOWER, JM; STANBRIDGE, EJ; WEISSMAN, BE				WELCH, DR; CHEN, PC; MIELE, ME; MCGARY, CT; BOWER, JM; STANBRIDGE, EJ; WEISSMAN, BE			MICROCELL-MEDIATED TRANSFER OF CHROMOSOME-6 INTO METASTATIC HUMAN C8161 MELANOMA-CELLS SUPPRESSES METASTASIS BUT DOES NOT INHIBIT TUMORIGENICITY	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; NM23 GENE; NEGATIVE REGULATION; NUDE-MICE; EXPRESSION; PROGRESSION; CANCER; PHENOTYPE; INVASION; GROWTH	Structural alterations of chromosome 6, including del(6q), are often associated with metastatic melanoma; therefore, we hypothesized that a metastasis-suppressor gene could be coded on human chromosome 6. Highly metastatic C8161 human malignant melanoma cells exhibit chromosomal changes typical of late-stage melanomas. Using microcell-mediated chromosome transfer, a copy of a normal human chromosome 6 was introduced into C8161. Three randomly selected hybrid clones (neo6/C8161.1, neo6/C8161.2 and neo6/C8161.3) were assayed for metastasis in athymic nude mice. All controls - parental C8161 cells, randomly-selected single cell clones, neo-transfected cell clones, neo11/CS161.2 and neo11/C8161.3 - were tumorigenic (270/272 mice) and metastatic (208/272 mice). neo6/C8161 hybrid cells were still tumorigenic (91/93 mice) but were not metastatic (0/195 mice). The presence of the added chromosomes was verified in cultured and tumor cells by amplification of polymorphic (CA), markers using PCR-RFLP. The neo6/C8161 hybrids display growth and morphological patterns of more differentiated cells than C8161. In Northern blot analysis an inverse relationship between metastatic ability and metastasis-suppressor gene, nm23-H1, expression is observed - with clone neo6/C8161.1 expressing the highest level of nm23 transcripts, neo6/C8161.2 and neo6/C8161.3 expressing intermediate levels, and barely detectable levels are seen in C8161. Collectively, these results suggest that a malignant melanoma metastasis-regulatory gene may be located on human chromosome 6. These results further demonstrate that tumorigenicity and metastatic ability are distinct phenotypes.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27514; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27514; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Irvine	WELCH, DR (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PATHOL,DIV EXPTL PATHOL,HERSHEY,PA 17033, USA.				NCI NIH HHS [R01-CA19401, R01-CA44470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044470, R01CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1991, CANCER RES, V51, P4815; ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P234; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOBROW M, 1974, NATURE, V251, P77, DOI 10.1038/251077a0; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHAMBERS AF, 1990, INVAS METAST, V10, P225; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; CLARK WH, 1991, CANCER METAST REV, V10, P83, DOI 10.1007/BF00049406; CONWAY K, 1992, CANCER RES, V52, P6487; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRACOPOLI NC, 1988, SEMIN ONCOL, V15, P541; DRACOPOLI NC, 1992, AM J HUM GENET, V54, pA51; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FLORENES VA, 1992, CANCER RES, V52, P6088; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1992, AM J HUM GENET, V54, pA51; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUAN XY, 1992, GENOMICS, V14, P680, DOI 10.1016/S0888-7543(05)80168-5; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; KJELDSEN L, 1992, BIOCHEM J, V287, P603, DOI 10.1042/bj2870603; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; LIOTTA LA, 1991, CANCER RES, V51, pS5054; MILLIKIN D, 1991, CANCER RES, V51, P5449; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4743, DOI 10.1093/nar/16.10.4743; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; NEGRINI M, 1992, CANCER RES, V52, P1297; NICHOLAS CD, 1991, P NATL ACAD SCI USA, V82, P1470; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; NICOLSON GL, 1993, HOSP PRAC, P43; PARMITER AH, 1988, MALIGNANT MELANOMA B, P43; RADINSKY R, 1992, CANCER RES, V52, P5808; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RODECK U, 1991, CANCER METAST REV, V10, P89, DOI 10.1007/BF00049407; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Sambrook J., 1989, MOL CLONING LAB MANU; SANFORD JA, 1987, SOMAT CELL MOLEC GEN, V13, P279, DOI 10.1007/BF01535210; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SCHLATTER B, 1992, P NATL ACAD SCI USA, V89, P9986, DOI 10.1073/pnas.89.21.9986; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Trent J M, 1989, Carcinog Compr Surv, V11, P165; TRENT JM, 1991, CANCER METAST REV, V10, P103, DOI 10.1007/BF00049408; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WELCH DR, 1983, INVAS METAST, V3, P65; WELCH DR, 1989, INT J CANCER, V43, P449, DOI 10.1002/ijc.2910430318; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105	63	153	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					255	262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302587				2022-12-17	WOS:A1994MW24700031
J	REISSMANN, PT; KOGA, H; TAKAHASHI, R; FIGLIN, RA; HOLMES, EC; PIANTADOSI, S; CORDONCARDO, C; SLAMON, DJ				REISSMANN, PT; KOGA, H; TAKAHASHI, R; FIGLIN, RA; HOLMES, EC; PIANTADOSI, S; CORDONCARDO, C; SLAMON, DJ			INACTIVATION OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE IN NON-SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							RAS ONCOGENE ACTIVATION; GROWTH-FACTOR RECEPTORS; OSTEO-SARCOMA; RB GENE; ALTERED EXPRESSION; DNA-SEQUENCE; HUMAN-BREAST; SHORT ARM; EGF-R; CARCINOMA	Mutations that prevent the normal expression of the retinoblastoma susceptibility gene (RB) have been linked to the pathogenesis of several human malignancies. Mutational inactivation of this tumor-suppressor gene appears to initiate the development of retinoblastoma, and may also contribute to the pathogenesis of osteosarcomas, soft-tissue sarcomas, small-cell lung cancer and other malignancies. In cooperation with the Lung Cancer Study Group, we studied the structure and expression of the RB gene in a cohort of 219 primary non-small-cell lung cancers (NSCLCs). RB gene structure was studied at the DNA level by Southern blot and chromosome 13 restriction fragment length polymorphism analyses. Expression of the RB gene was evaluated by Northern analysis of the transcript and immunohistochemical analysis of the protein (p105RB). Immunohistochemistry of the RB protein proved to be the most sensitive method for the detection of Rb gene inactivation. Absent or abnormal RB protein staining was detected in 53/163 (32%) evaluable cases studied, while Northern analysis showed 22/219 cases to have an altered or absent RB transcript. Southern analysis revealed only two cases of structural alteration of the gene, but loss of heterozygosity from chromosome 13 was common in tumors that failed to express the protein. Analysis of the clinical outcomes of the patients whose tumors were studied did not show any correlation of RB inactivation with time to relapse or death. The data from this study indicate that the RB gene is inactivated in a significant number of NSCLCs. The role that these mutations may play in the development of NSCLC remains to be defined.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; BAYLOR UNIV, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA; JOHNS HOPKINS UNIV, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, LOS ANGELES, CA 90024 USA; MEM SLOAN KETTERING CANC CTR, DEPT PATHOL, NEW YORK, NY 10021 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Baylor College of Medicine; Baylor University; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 55827] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ABRAMSON DH, 1976, T AM ACAD OPHTHALMOL, V81, pP454; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CHIBA I, 1990, ONCOGENE, V5, P1603; COX DR, 1972, J R STAT SOC B, V34, P187; DAZZI H, 1989, BRIT J CANCER, V59, P746, DOI 10.1038/bjc.1989.156; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; HENSEL CH, 1990, CANCER RES, V50, P3067; HOVIG E, 1987, CANCER GENET CYTOGEN, V24, P327, DOI 10.1016/0165-4608(87)90115-4; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAGIMOTO M, 1985, INT J CANCER, V35, P809, DOI 10.1002/ijc.2910350618; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KITCHIN FD, 1974, J MED GENET, V11, P244, DOI 10.1136/jmg.11.3.244; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOGA H, UNPUB; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MANIATIS T, 1982, MOL CLONING LABORATO, P282; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MIYAKI M, 1985, JPN J CANCER RES, V76, P260; MORI N, 1990, ONCOGENE, V5, P1713; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; REISSMANN PT, 1989, ONCOGENE, V4, P839; RODENHUIS S, 1988, CANCER RES, V48, P5738; RYGAARD K, 1990, CANCER RES, V50, P5312; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASANO H, 1990, CANCER, V66, P2150, DOI 10.1002/1097-0142(19901115)66:10<2150::AID-CNCR2820661018>3.0.CO;2-7; SHERWIN SA, 1981, CANCER RES, V41, P3538; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; VOGEL F, 1979, HUM GENET, V52, P1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOTA J, 1988, ONCOGENE, V2, P607	67	153	157	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1913	1919						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390038				2022-12-17	WOS:A1993LG68200024
J	SIMON, D; KNOWLES, BB; WEITH, A				SIMON, D; KNOWLES, BB; WEITH, A			ABNORMALITIES OF CHROMOSOME-1 AND LOSS OF HETEROZYGOSITY ON 1P IN PRIMARY HEPATOMAS	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; HEPATITIS-B VIRUS; CELL-LINE; HUMAN NEUROBLASTOMAS; C-MYC; GENE; INTEGRATION; LIVER; HETEROCHROMATIN; EXPRESSION	Cytogenetic analysis of eight human hepatoma-derived cell lines and one primary hepatocellular carcinoma biopsy revealed multiple chromosome abnormalities; however, only chromosome 1 was consistently affected by rearrangements. Pseudopolysomy 1 as well as chromosome 1 deletions and/or translocations that resulted in loss of the distal 1p region from at least one copy of chromosome 1 were observed in all but one of the cell lines analysed. Molecular analyses of tumor-derived and normal genomic DNA from six cases of hepatocellular carcinoma and from two of hepatoblastoma, using a panel of chromosome 1p-specific DNA probes indicated allelic loss in the distal 1p region in five of the six hepatocellular carcinomas but not in either hepatoblastoma. These results suggest the location of a gene in the distal 1p region whose functional loss may be involved in hepatocellular carcinogenesis.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	The Wistar Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	KNOWLES, BB (corresponding author), WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.			Knowles, Barbara B./0000-0002-2597-5619	NCI NIH HHS [CA10815, CA37725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BEASLEY RP, 1981, LANCET, V2, P1129; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHATTERJEE B, 1989, MUTAT RES, V210, P49, DOI 10.1016/0027-5107(89)90043-2; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; HUH N, 1981, GANN, V72, P178; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; KEICHLESCHWARTZ M, 1990, GENE CHROMOSOME CANC, V1, P312; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; OBRIEN SJ, 1990, GENETIC MAPS; PINTO MR, 1985, CANCER GENET CYTOGEN, V18, P11, DOI 10.1016/0165-4608(85)90033-0; ROBINSON WS, 1989, CANCER DETECT PREV, V14, P245; ROGLER CE, 1985, SCIENCE, V230, P219; ROONEY DE, 1971, HUMAN CYTOGENETICS P, V2, P971; SEABRIGH.M, 1971, LANCET, V2, P971; SIMON D, 1986, LAB INVEST, V55, P657; SIMON D, 1982, INT J CANCER, V30, P27, DOI 10.1002/ijc.2910300106; SIMON D, 1985, CYTOGENET CELL GENET, V39, P116, DOI 10.1159/000132118; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; Simon D.R., UNPUB; SMUZNESS W, 1978, PROG MED VIROL, V24, P40; STEVENSON D, 1987, HEPATOLOGY, V7, P1291, DOI 10.1002/hep.1840070619; SUMNER AT, 1972, EXP CELL RES, V75, P304, DOI 10.1016/0014-4827(72)90558-7; TADA M, 1990, CANCER RES, V40, P1122; TAKADA S, 1989, ONCOGENE, V4, P189; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TWIST EM, 1981, J VIROL, V37, P239, DOI 10.1128/JVI.37.1.239-243.1981; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WUU KD, 1987, CANCER GENET CYTOGEN, V26, P279, DOI 10.1016/0165-4608(87)90062-8; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	42	153	156	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					765	770						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646986				2022-12-17	WOS:A1991GT82500012
J	SOMERS, KD; CARTWRIGHT, SL; SCHECHTER, GL				SOMERS, KD; CARTWRIGHT, SL; SCHECHTER, GL			AMPLIFICATION OF THE INT-2 GENE IN HUMAN HEAD AND NECK SQUAMOUS-CELL CARCINOMAS	ONCOGENE			English	Article									EASTERN VIRGINIA MED SCH, DEPT OTOLARYNGOL HEAD & NECK SURG, NORFOLK, VA 23501 USA; EASTERN VIRGINIA MED SCH, HEAD & NECK TUMOR BIOL PROGRAM, NORFOLK, VA 23501 USA	Eastern Virginia Medical School	SOMERS, KD (corresponding author), EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, POB 1980, NORFOLK, VA 23501 USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1989, ONCOGENE, V4, P89; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BROOKES S, 1989, ONCOGENE, V4, P429; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; EISBRUCH A, 1987, CANCER RES, V47, P3603; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD JK, 1986, ANTICANCER RES, V6, P595; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KING CR, 1989, CANCER RES, V49, P4185; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; NGUYEN C, 1988, ONCOGENE, V3, P703; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1985, ANTICANCER RES, V5, P221; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TADOKORO K, 1989, ONCOGENE, V4, P499; TAGGART RT, 1985, P NATL ACAD SCI USA, V82, P6240, DOI 10.1073/pnas.82.18.6240; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VARLEY JM, 1988, ONCOGENE, V3, P87; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILLIAMS BP, 1988, ONCOGENE, V3, P345; WILLMAN CL, 1987, HUM PATHOL, V18, P895, DOI 10.1016/S0046-8177(87)80266-6; WRIGHT C, 1989, CANCER RES, V49, P2087; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279	53	153	159	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1990	5	6					915	920						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2193294				2022-12-17	WOS:A1990DP55300019
J	Feng, J; Yang, H; Zhang, Y; Wei, H; Zhu, Z; Zhu, B; Yang, M; Cao, W; Wang, L; Wu, Z				Feng, J.; Yang, H.; Zhang, Y.; Wei, H.; Zhu, Z.; Zhu, B.; Yang, M.; Cao, W.; Wang, L.; Wu, Z.			Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells	ONCOGENE			English	Article							IMMUNE CHECKPOINT BLOCKADE; AEROBIC GLYCOLYSIS; RECEPTOR; PROTEIN; MECHANISM; SURVIVAL; PATHWAY	The clinical success of immunotherapy that inhibits the negative immune regulatory pathway programmed cell death protein 1/PD-1 ligand (PD-1/PD-L1) has initiated a new era in the treatment of metastatic cancer. PD-L1 expression is upregulated in many solid tumors including lung cancer and functions predominantly in lactate-enriched tumor microenvironments. Here, we provided evidence for PD-L1 induction in response to lactate stimulation in lung cancer cells. Lactate-induced PD-L1 induction was mediated by its receptor GPR81. The silencing of GPR81 signaling in lung cancer cells resulted in a decrease in PD-L1 protein levels and functional inactivation of PD-L1 promoter activity. In addition, GPR81-mediated upregulation of PD-L1 in glucose-stimulated lung cancer cells that recapitulates the enhanced glycolysis in vivo was dependent on lactate dehydrogenase A (LDHA). We also demonstrated that activation of GPR81 decreases intracellular cAMP levels and inhibits protein kinase A (PKA) activity, leading to activation of the transcriptional coactivator TAZ. Interaction of TAZ with the transcription factor TEAD was essential for TAZ activation of PD-L1 and induction of its expression. Furthermore, we found that lactate-induced activation of PD-L1 in tumor cells led to reduced production of interferon-gamma and induction of apoptosis of cocultured Jurkat T-cell leukemia cells. Our findings reveal an unexpected role of lactate in contributing to tumor cell protection from cytotoxic T-cell targeting and establishes a direct connection between tumor cell metabolic reprograming and tumor evasion from the immune response.	[Feng, J.; Wang, L.] Wannan Med Coll, Affiliated Hosp 1, Med Oncol, Wuhu, Peoples R China; [Yang, H.] Tianjin Med Univ Gen Hosp, Tianjin Lung Canc Ctr & Inst, Tianjin Key Lab Lung Canc Metastasis & Tumor Micr, Tianjin, Peoples R China; [Zhang, Y.; Wu, Z.] Wannan Med Coll, Anhui Prov Key Lab Act Biol Macromol Res, Wuhu, Peoples R China; [Wei, H.] Wannan Med Coll, Dept Cent Lab, Wuhu, Peoples R China; [Zhu, Z.] Wannan Med Coll, Sch Pharm, Wuhu, Peoples R China; [Zhu, Z.] Wannan Med Coll, Sch Forens Med, Wuhu, Peoples R China; [Yang, M.; Cao, W.] Wannan Med Coll, Sch Anesthesiol, Wuhu, Peoples R China; [Wang, L.; Wu, Z.] Wannan Med Coll, Sch Preclin Med, 22 Wenchang West Rd, Wuhu 241001, Peoples R China	Wannan Medical College; Tianjin Medical University; Wannan Medical College; Wannan Medical College; Wannan Medical College; Wannan Medical College; Wannan Medical College; Wannan Medical College	Wang, L; Wu, Z (corresponding author), Wannan Med Coll, Sch Preclin Med, 22 Wenchang West Rd, Wuhu 241001, Peoples R China.	lucyyjs@163.com; zwu2ster@163.com		Yang, Hui/0000-0002-3938-9530	National Natural Science Foundation of China [81272359]; Wannan Medical College	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wannan Medical College	We thank Dr Hen Wu (Tianjin Lung Cancer Center and Institute, Tianjin Medical University General Hospital) for helping with the correlation analysis in a data set obtained from GEO, and Sean Hackett (Johns Hopkins University) for critical reading and revising of this manuscript. This work was supported by the National Natural Science Foundation of China (81272359 to ZW) and introduction of high-level scientific research start-up fund by Wannan Medical College (to ZW).	Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Kuei C, 2011, MOL PHARMACOL, V80, P848, DOI 10.1124/mol.111.074500; Li XB, 2015, THORAC CANCER, V6, P17, DOI 10.1111/1759-7714.12148; Lipson EJ, 2015, SEMIN ONCOL, V42, P587, DOI 10.1053/j.seminoncol.2015.05.013; Liu CL, 2009, J BIOL CHEM, V284, P2811, DOI 10.1074/jbc.M806409200; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Palucka AK, 2016, CELL, V164, P1233, DOI 10.1016/j.cell.2016.01.049; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Shimomura T, 2014, BIOCHEM BIOPH RES CO, V443, P917, DOI 10.1016/j.bbrc.2013.12.100; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711; Yu FX, 2013, GENE DEV, V27, P1223, DOI 10.1101/gad.219402.113; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	26	152	158	10	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5829	5839		10.1038/onc.2017.188	http://dx.doi.org/10.1038/onc.2017.188			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604752				2022-12-17	WOS:000413292900005
J	Guo, L; Chen, C; Shi, M; Wang, F; Chen, X; Diao, D; Hu, M; Yu, M; Qian, L; Guo, N				Guo, L.; Chen, C.; Shi, M.; Wang, F.; Chen, X.; Diao, D.; Hu, M.; Yu, M.; Qian, L.; Guo, N.			Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition	ONCOGENE			English	Article						OSM; EMT; Stat3; let-7; miR-200	DOUBLE-EDGED-SWORD; NF-KAPPA-B; SELF-RENEWAL; FEEDBACK LOOP; CELL MOTILITY; TGF-BETA; CANCER; INFLAMMATION; EXPRESSION; EMT	Inflammation can act as a crucial mediator of epithelial-to-mesenchymal transition (EMT). In this study, we show that oncostatin M (OSM) is expressed in an autocrine/paracrine fashion in invasive breast carcinoma. OSM stimulation promotes spontaneous lung metastasis of MCF-7 xenografts in nude mice. A conspicuous epigenetic transition was induced by OSM stimulation not only in breast cancer cell lines but also in MCF-7 xenografts in nude mice. The expression of miR-200 and let-7 family members in response to OSM stimulation was downregulated in a signal transducer and activator of transcription factor 3 (Stat3)-dependent manner, resulting in comprehensive alterations of the transcription factors and oncoproteins targeted by these microRNAs. Inhibition of Stat3 activation or the ectopic expression of let-7 and miR-200 effectively reversed the mesenchymal phenotype of breast cancer cells. Stat3 promotes the transcription of Lin-28 by directly binding to the Lin-28 promoter, resulting in the repression of let-7 expression and concomitant upregulation of the let-7 target, high-mobility group A protein 2 (HMGA2). Knock down of HMGA2 significantly impairs OSM-driven EMT. Our data indicate that downregulation of let-7 and miR-200 levels initiates and maintains OSM-induced EMT phenotypes, and HMGA2 acts as a master switch of OSM-induced EMT. These findings highlight the importance of Stat3-coordinated Lin-28B-let-7-HMGA2 and miR-200-ZEB1 circuits in the cytokine-mediated phenotypic reprogramming of breast cancer cells.	[Guo, L.; Chen, C.; Shi, M.; Diao, D.; Hu, M.; Yu, M.; Qian, L.; Guo, N.] Beijing Inst Basic Med Sci, Dept Mol Immunol, Beijing, Peoples R China; [Wang, F.] Inst Basic Med Sci, Dept Brain Protect & Plast Res, Beijing 100850, Peoples R China; [Chen, X.] 307 Hosp, Beijing, Peoples R China; [Diao, D.] Henan Univ, Lab Cellular & Mol Immunol, Sch Med, Kaifeng, Peoples R China	Academy of Military Medical Sciences - China; Fifth Medical Center of Chinese PLA General Hospital; Henan University	Qian, L (corresponding author), Inst Basic Med Sci, Dept Mol Immunol, Beijing 100850, Peoples R China.	qianlubj@sohu.com; ningguo@nic.bmi.ac.cn		, Liang/0000-0002-8748-5770	National Basic Research Program of China (973 Program) [2010CB911904]; National Natural Science Foundation of China [30972690, 31271440, 81272232]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful to Dr Xuemin Zhang (National Center of Biomedical Analysis, Beijing) for kindly providing us the plasmids pRc/CMV-Stat3C-Flag and luciferase reporter vectors containing the binding sequences for Stat3, NF-kappa B, AP-1 and Smad. We also thank Dr Xiaofei Zheng (Beijing Institute of Radiation Medicine, Beijing) for the gift of the modified pGL3-control plasmid. This work is supported by National Basic Research Program of China (973 Program, No. 2010CB911904) and National Natural Science Foundation of China (Nos. 30972690, 31271440 and 81272232).	Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06; Bhaumik D, 2009, CELL CYCLE, V8, P1822; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Chiappetta G, 1996, ONCOGENE, V13, P2439; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Gomez-Lechon MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024-3205(99)00296-9; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Jun C, 2007, PROG BIOCHEM BIOPHYS, V34, P389; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Nightingale J, 2004, J AM SOC NEPHROL, V15, P21, DOI 10.1097/01.ASN.0000102479.92582.43; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Pfannkuche K, 2009, STEM CELL REV REP, V5, P224, DOI 10.1007/s12015-009-9078-9; Pollack V, 2007, AM J PHYSIOL-RENAL, V293, pF1714, DOI 10.1152/ajprenal.00130.2007; Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008-5472.CAN-05-1734; Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Shi M, 2011, BREAST CANCER RES TR, V125, P351, DOI 10.1007/s10549-010-0822-2; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Tan EJ, 2012, J BIOL CHEM, V287, P7134, DOI 10.1074/jbc.M111.291385; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Winder DM, 2011, J PATHOL, V225, P448, DOI 10.1002/path.2968; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yang L, 2010, CANCER METAST REV, V29, P263, DOI 10.1007/s10555-010-9226-3; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123	53	152	158	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5272	5282		10.1038/onc.2012.573	http://dx.doi.org/10.1038/onc.2012.573			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23318420	hybrid			2022-12-17	WOS:000326922100003
J	Vervoort, SJ; van Boxtel, R; Coffer, PJ				Vervoort, S. J.; van Boxtel, R.; Coffer, P. J.			The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe?	ONCOGENE			English	Review						SOX4; cancer; metastasis	GENE-EXPRESSION PATTERNS; GLIOMA-INITIATING CELLS; DIFFERENTIAL EXPRESSION; PROGNOSTIC-SIGNIFICANCE; POSITIVE REGULATOR; BLADDER-CARCINOMA; MINOR-GROOVE; TGF-BETA; IDENTIFICATION; PROTEIN	Development and progression of cancer are mediated by alterations in transcriptional networks, resulting in a disturbed balance between the activity of oncogenes and tumor suppressor genes. Transcription factors have the capacity to regulate global transcriptional profiles, and are consequently often found to be deregulated in their expression and function during tumorigenesis. Sex-determining region Y-related high-mobility-group box transcription factor 4 (SOX4) is a member of the group C subfamily of the SOX transcription factors and has a critical role during embryogenesis, where its expression is widespread and controls the development of numerous tissues. SOX4 expression is elevated in a wide variety of tumors, including leukemia, colorectal cancer, lung cancer and breast cancer, suggesting a fundamental role in the development of these malignancies. In many cancers, deregulated expression of this developmental factor has been correlated with increased cancer cell proliferation, cell survival, inhibition of apoptosis and tumor progression through the induction of an epithelial-to-mesenchymal transition and metastasis. However, in a limited subset of tumors, SOX4 has also been reported to act as a tumor suppressor. These opposing roles suggest that the outcome of SOX4 activation depends on the cellular context and the tumor origin. Indeed, SOX4 expression, transcriptional activity and target gene specificity can be controlled by signaling pathways, including the transforming growth factor-beta and the WNT pathway, as well as at the post-translational level through regulation of protein stability and interaction with specific cofactors, such as TCF, syntenin-1 and p53. Here, we provide an overview of our current knowledge concerning the role of SOX4 in tumor development and progression.	[Vervoort, S. J.; van Boxtel, R.; Coffer, P. J.] Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; [Vervoort, S. J.; Coffer, P. J.] Wilhelmina Childrens Hosp, Div Pediat, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Vervoort, SJ (corresponding author), Univ Med Ctr Utrecht, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	P.J.Coffer@umcutrecht.nl	Vervoort, Stephin/AAP-7854-2020; Coffer, Paul/AAF-7970-2020	Vervoort, Stephin/0000-0001-7459-126X; van Boxtel, Ruben/0000-0003-1285-2836	'Center for Translational Molecular Medicine' (CTMM) grant	'Center for Translational Molecular Medicine' (CTMM) grant	Ruben van Boxtel is supported by a 'Center for Translational Molecular Medicine' (CTMM) grant.	Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; Ahn SG, 1999, BIOCHEM BIOPH RES CO, V260, P216, DOI 10.1006/bbrc.1999.0856; Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34; Andersen CL, 2009, BRIT J CANCER, V100, P511, DOI 10.1038/sj.bjc.6604884; Aue G, 2011, BLOOD, V118, P4674, DOI 10.1182/blood-2011-04-351528; Bangur CS, 2002, ONCOGENE, V21, P3814, DOI 10.1038/sj.onc.1205480; Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401; Beekman JM, 2009, BLOOD, V114, P3917, DOI 10.1182/blood-2009-03-208850; Beekman JM, 2011, ONCOGENE; Bergsland M, 2006, GENE DEV, V20, P3475, DOI 10.1101/gad.403406; Bernard P, 2010, INT J BIOCHEM CELL B, V42, P400, DOI 10.1016/j.biocel.2009.10.017; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Bies J, 2010, BLOOD, V116, P979, DOI 10.1182/blood-2009-08-238360; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Boyd KE, 2006, BLOOD, V107, P733, DOI 10.1182/blood-2003-05-1626; Boyer J, 2006, CANCER RES, V66, P2765, DOI 10.1158/0008-5472.CAN-05-2693; Bruch J, 2000, CANCER RES, V60, P4526; Cao DF, 2004, CANCER BIOL THER, V3, P1081, DOI 10.4161/cbt.3.11.1175; Castillo SD, 2012, CANCER RES, V72, P176, DOI 10.1158/0008-5472.CAN-11-3506; Chedotal A, 2005, CELL DEATH DIFFER, V12, P1044, DOI 10.1038/sj.cdd.4401707; Chetty C, 2012, CANCER LETT, V323, P188, DOI 10.1016/j.canlet.2012.04.014; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; Deneault E, 2009, CELL, V137, P369, DOI 10.1016/j.cell.2009.03.026; Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372; Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162; Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Fevre-Montange M, 2006, J NEUROPATH EXP NEUR, V65, P675, DOI 10.1097/01.jnen.0000225907.90052.e3; Fortier JM, 2010, LEUKEMIA, V24, P950, DOI 10.1038/leu.2010.61; Friedman RS, 2004, J IMMUNOL, V172, P3319, DOI 10.4049/jimmunol.172.5.3319; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goldsworthy M, 2008, DIABETES, V57, P2234, DOI 10.2337/db07-0337; Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295; Gunes S, 2011, PATHOL RES PRACT, V207, P423, DOI 10.1016/j.prp.2011.05.005; Haram KM, 2008, PROSTATE, V68, P1517, DOI 10.1002/pros.20803; Harley V, 2010, INT J BIOCHEM CELL B, V42, P376, DOI 10.1016/j.biocel.2009.12.004; Heidenblad M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-3; Herbst Roy S, 2004, J Natl Compr Canc Netw, V2 Suppl 2, pS41; Herman JG, 2007, INT J ONCOL, V30, P1231; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Hoser M, 2008, MOL CELL BIOL, V28, P4675, DOI 10.1128/MCB.00338-08; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Hur W, 2010, CARCINOGENESIS, V31, P1298, DOI 10.1093/carcin/bgq072; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Iqbal MS, 2010, INT J HEMATOL, V91, P267, DOI 10.1007/s12185-009-0474-3; Jafarnejad SM, 2010, AM J PATHOL, V177, P2741, DOI 10.2353/ajpath.2010.100377; Jafarnejad SM, 2012, ONCOGENE; Jauch R, 2012, BIOCHEM J, V443, P39, DOI 10.1042/BJ20111768; Jemtland R, 2011, J BONE MINER RES, V26, P1793, DOI 10.1002/jbmr.396; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim BE, 2004, EXP MOL MED, V36, P444, DOI 10.1038/emm.2004.56; Kim HD, 2011, MOL ENDOCRINOL, V25, P1184, DOI 10.1210/me.2010-0332; Kindla J, 2011, DRUG METAB DISPOS, V39, P1047, DOI 10.1124/dmd.110.037622; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Kvinlaug BT, 2011, CANCER RES, V71, P4117, DOI 10.1158/0008-5472.CAN-11-0176; Lai YH, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-50; Lee AK, 2011, ONCOL REP, V25, P559, DOI 10.3892/or.2010.1091; Lee CJ, 2002, J NEURO-ONCOL, V57, P201, DOI 10.1023/A:1015773818302; Li ZX, 2007, ANN NY ACAD SCI, V1106, P95, DOI 10.1196/annals.1392.003; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liber D, 2010, CELL STEM CELL, V7, P114, DOI 10.1016/j.stem.2010.05.020; Lin BY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010210; Lin L, 2011, DEV DYNAM, V240, P52, DOI 10.1002/dvdy.22489; Lioubinski O, 2003, DEV DYNAM, V227, P402, DOI 10.1002/dvdy.10311; Litovkin K. V., 2008, Experimental Oncology, V30, P106; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Liu SL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002751; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lund PK, 2009, SCAND J CLIN LAB INV, V69, P251, DOI 10.1080/00365510802499399; MARSHALL JC, 1986, NEW ENGL J MED, V315, P1459; Maschhoff KL, 2003, GENE, V320, P23, DOI 10.1016/j.gene.2003.07.002; Mavropoulos A, 2005, DEV BIOL, V285, P211, DOI 10.1016/j.ydbio.2005.06.024; McCracken S, 1997, ONCOGENE, V15, P2929, DOI 10.1038/sj.onc.1201474; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Molatore S, 2010, P NATL ACAD SCI USA, V107, P18493, DOI 10.1073/pnas.1003956107; Moreno CS, 2010, AM J PATHOL, V176, P518, DOI 10.2353/ajpath.2010.090657; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; Nissen-Meyer LSH, 2007, J CELL SCI, V120, P2785, DOI 10.1242/jcs.003855; Novershtern N, 2011, CELL, V144, P296, DOI 10.1016/j.cell.2011.01.004; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pan X, 2006, BIOCHEM BIOPH RES CO, V344, P727, DOI 10.1016/j.bbrc.2006.03.194; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566; Ragvin A, 2010, P NATL ACAD SCI USA, V107, P775, DOI 10.1073/pnas.0911591107; Reichling T, 2005, CANCER RES, V65, P166; Reppe S, 2000, J BONE MINER RES, V15, P2402, DOI 10.1359/jbmr.2000.15.12.2402; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Ritter AR, 2010, DEV DYNAM, V239, P2685, DOI 10.1002/dvdy.22407; Ruebel KH, 2008, ENDOCRINE, V33, P62, DOI 10.1007/s12020-008-9060-3; Saegusa M, 2012, LAB INVEST, V92, P511, DOI 10.1038/labinvest.2011.196; Sandoval S, 2012, BLOOD, V120, P155, DOI 10.1182/blood-2011-05-357418; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schilham MW, 1997, EUR J IMMUNOL, V27, P1292, DOI 10.1002/eji.1830270534; Serrero G, 2003, BIOCHEM BIOPH RES CO, V308, P409, DOI 10.1016/S0006-291X(03)01452-9; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406; Sock E, 2004, MOL CELL BIOL, V24, P6635, DOI 10.1128/mcb.24.15.6635-6644.2004; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanaka S, 2004, MOL CELL BIOL, V24, P8834, DOI 10.1128/MCB.24.20.8834-8846.2004; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Testa U, 2011, ANN HEMATOL, V90, P245, DOI 10.1007/s00277-010-1118-7; Thein DC, 2010, J NEUROCHEM, V115, P131, DOI 10.1111/j.1471-4159.2010.06910.x; Tian CX, 2011, DEVELOPMENT, V138, P1033, DOI 10.1242/dev.062240; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Turner DP, 2007, J CELL BIOCHEM, V102, P549, DOI 10.1002/jcb.21494; van Beest M, 2000, J BIOL CHEM, V275, P27266; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Vanaja DK, 2006, CLIN CANCER RES, V12, P1128, DOI 10.1158/1078-0432.CCR-05-2072; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; vanHoute LPA, 1995, J BIOL CHEM, V270, P30516, DOI 10.1074/jbc.270.51.30516; Wang CG, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-41; Watanabe T, 2010, EUR J CANCER, V46, P2119, DOI 10.1016/j.ejca.2010.04.019; Weiss MA, 2001, MOL ENDOCRINOL, V15, P353, DOI 10.1210/me.15.3.353; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Wilson ME, 2005, DIABETES, V54, P3402, DOI 10.2337/diabetes.54.12.3402; WOTTON D, 1995, J BIOL CHEM, V270, P7515, DOI 10.1074/jbc.270.13.7515; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yang LQ, 2012, FUTURE ONCOL, V8, P431, DOI [10.2217/FON.12.27, 10.2217/fon.12.27]; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045	147	152	155	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3397	3409		10.1038/onc.2012.506	http://dx.doi.org/10.1038/onc.2012.506			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	23246969				2022-12-17	WOS:000322014900001
J	Fang, X; Cai, Y; Liu, J; Wang, Z; Wu, Q; Zhang, Z; Yang, CJ; Yuan, L; Ouyang, G				Fang, X.; Cai, Y.; Liu, J.; Wang, Z.; Wu, Q.; Zhang, Z.; Yang, C. J.; Yuan, L.; Ouyang, G.			Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal	ONCOGENE			English	Article						Twist2; epithelial-mesenchymal transition; cancer stem cell; breast cancer; metastasis	UP-REGULATION; EMT; GROWTH; ACTIVATION; DERMO-1; PROTEIN; GENE; MORPHOGENESIS; METASTASIS; INVASION	The epithelial to mesenchymal transition (EMT) is a highly conserved cellular programme that has an important role in normal embryogenesis and in cancer invasion and metastasis. We report here that Twist2, a tissue-specific basic helix-loop-helix transcription factor, is overexpressed in human breast cancers and lymph node metastases. In mammary epithelial cells and breast cancer cells, ectopic overexpression of Twist2 results in morphological transformation, downregulation of epithelial markers and upregulation of mesenchymal markers. Moreover, Twist2 enhances the cell migration and colony-forming abilities of mammary epithelial cells and breast cancer cells in vitro and promotes tumour growth in vivo. Ectopic expression of Twist2 in mammary epithelial cells and breast cancer cells increases the size and number of their CD44(high)/CD24(low) stem-like cell sub-populations, promotes the expression of stem cell markers and enhances the self-renewal capabilities of stem-like cells. In addition, exogenous expression of Twist2 leads to constitutive activation of STAT3 (signal transducer and activator of transcription 3) and downregulation of E-cadherin. Thus, the overexpression of Twist2 may contribute to breast cancer progression by activating the EMT programme and enhancing the self-renewal of cancer stem-like cells. Oncogene (2011) 30, 4707-4720; doi:10.1038/onc.2011.181; published online 23 May 2011	[Fang, X.; Cai, Y.; Liu, J.; Wang, Z.; Yuan, L.; Ouyang, G.] Xiamen Univ, Sch Life Sci, State Key Lab Stress Cell Biol, Xiamen 361005, Peoples R China; [Wu, Q.; Zhang, Z.] Xiamen Univ, Affiliated Hosp 1, Dept Breast Surg, Xiamen 361005, Peoples R China; [Yang, C. J.] Xiamen Univ, Coll Chem & Chem Engn, Xiamen 361005, Peoples R China	Xiamen University; Xiamen University; Xiamen University	Ouyang, G (corresponding author), Xiamen Univ, Sch Life Sci, State Key Lab Stress Cell Biol, Xiamen 361005, Peoples R China.	oygldz@yahoo.com.cn	Fang, Xiaoguang/N-2313-2014; Yang, Chaoyong/Q-5734-2019; yang, chaoyong/F-9741-2010	Yang, Chaoyong/0000-0002-2374-5342; yang, chaoyong/0000-0002-2374-5342	National Nature Science Foundation of China [30871242, 31071302]; National Basic Research Program of China [2009CB941601, 2010CB732402]; Fundamental Research Funds for the Central Universities [2010121095]; Science Planning Program of Fujian Province [2009J1010]; Outstanding Young Science Foundation of Fujian Province [2010J06013]; Xiamen University [985]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Science Planning Program of Fujian Province; Outstanding Young Science Foundation of Fujian Province; Xiamen University(Xiamen University)	We thank Professor Kunxin Luo (Department of Molecular and Cell Biology, University of California, Berkeley), Professor Shideng Bao (Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic) and reviewers for critical comments. This work was supported by grants from the National Nature Science Foundation of China (no. 30871242, 31071302), National Basic Research Program of China (no. 2009CB941601, 2010CB732402), the Fundamental Research Funds for the Central Universities (no. 2010121095), the Science Planning Program of Fujian Province (2009J1010), the Outstanding Young Science Foundation of Fujian Province (no. 2010J06013) and the 985 Project grant from Xiamen University.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ansieau S, 2010, ONCOGENE, V29, P3173, DOI 10.1038/onc.2010.92; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Battula VL, 2010, STEM CELLS, V28, P1435, DOI 10.1002/stem.467; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dimri GP, 2002, CANCER RES, V62, P4736; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fernando RI, 2010, J CLIN INVEST, V120, P533, DOI 10.1172/JCI38379; Franco HL, 2011, NUCLEIC ACIDS RES, V39, P1177, DOI 10.1093/nar/gkq890; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lee MS, 2000, BONE, V27, P591, DOI 10.1016/S8756-3282(00)00380-X; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018-009-0013-7; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Song G, 2009, J CELL MOL MED, V13, P1706, DOI 10.1111/j.1582-4934.2008.00540.x; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang YN, 2006, CANCER RES, V66, P8617, DOI 10.1158/0008-5472.CAN-06-1308; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	57	152	162	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4707	4720		10.1038/onc.2011.181	http://dx.doi.org/10.1038/onc.2011.181			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602879				2022-12-17	WOS:000298033700003
J	Wendt, MK; Smith, JA; Schiemann, WP				Wendt, M. K.; Smith, J. A.; Schiemann, W. P.			Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression	ONCOGENE			English	Article						EGFR; TGF-beta; FAK; breast cancer; metastasis; invasion	FOCAL ADHESION KINASE; FACTOR RECEPTOR INHIBITION; MAMMARY-CARCINOMA CELLS; TGF-BETA; GENE-EXPRESSION; TUMOR; METASTASIS; ACTIVATION; LINES; PROLIFERATION	Transforming growth factor-beta (TGF-beta) and epidermal growth factor (EGF) have critical roles in regulating the metastasis of aggressive breast cancers, yet the impact of epithelial-mesenchymal transition (EMT) induced by TGF-beta in altering the response of breast cancer cells to EGF remains unknown. We show in this study that murine metastatic 4T1 breast cancer cells formed compact and dense spheroids when cultured under three-dimensional (3D) conditions, which was in sharp contrast to the branching phenotypes exhibited by their nonmetastatic counterparts. Using the human MCF10A series, we show that epithelial-type and nonmetastatic breast cancer cells were unable to invade to EGF, whereas their mesenchymal-type and metastatic counterparts readily invaded to EGF. Furthermore, EMT induced by TGF-beta was sufficient to manifest dense spheroid morphologies, a phenotype that increased primary tumor exit and invasion to EGF. Post-EMT invasion to EGF was dependent on increased activation of EGF receptor (EGFR) and p38 mitogen-activated protein kinase, all of which could be abrogated either by pharmacologic (PF-562271) or by genetic (shRNA) targeting of focal adhesion kinase (FAK). Mechanistically, EMT induced by TGF-beta increased cell-surface levels of EGFR and prevented its physical interaction with E-cadherin, leading instead to the formation of oncogenic signaling complexes with T beta R-II. Elevated EGFR expression was sufficient to transform normal mammary epithelial cells, and to progress their 3D morphology from that of hollow acini to branched structures characteristic of nonmetastatic breast cancer cells. Importantly, we show that TGF-beta stimulation of EMT enabled this EGFR-driven breast cancer model to abandon their inherent branching architecture and form large, undifferentiated masses that were hyperinvasive to EGF and showed increased pulmonary tumor growth upon tail vein injection. Finally, chemotherapeutic targeting of FAK was sufficient to revert the aggressive behaviors of these structures. Collectively, this investigation has identified a novel EMT-based approach to neutralize the oncogenic activities of EGF and TGF-beta in aggressive and invasive forms of breast cancer. Oncogene (2010) 29, 6485-6498; doi:10.1038/onc.2010.377; published online 30 August 2010	[Wendt, M. K.; Smith, J. A.; Schiemann, W. P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Schiemann, WP (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci Oncol, Wolstein Res Bldg,2103 Cornell Rd, Cleveland, OH 44106 USA.	william.schiemann@case.edu		Wendt, Mike/0000-0002-3665-7413	National Institutes of Health [CA129359]; Susan G Komen for the Cure Foundation [BCTR0706967]; Department of Defense [BC084561]; American Cancer Society [PF-09-120-01]; NATIONAL CANCER INSTITUTE [R01CA129359] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Pfizer for graciously providing the novel small molecule FAK inhibitor, PF-562271. We also thank Dr Alexander D Sorkin for providing the retroviral construct that encoded human EGFR. WPS was supported in part by grants from the National Institutes of Health (CA129359) and the Susan G Komen for the Cure Foundation (BCTR0706967) and the Department of Defense (BC084561), whereas MKW was supported by a fellowship from the American Cancer Society (PF-09-120-01).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Cicchini C, 2008, EXP CELL RES, V314, P143, DOI 10.1016/j.yexcr.2007.09.005; Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Ding Q, 2008, J BIOL CHEM, V283, P26839, DOI 10.1074/jbc.M803645200; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Joo CK, 2008, ONCOGENE, V27, P614, DOI 10.1038/sj.onc.1210649; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Thomson S, 2008, CLIN EXP METASTAS, V25, P843, DOI 10.1007/s10585-008-9200-4; Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wang SE, 2009, CANCER RES, V69, P475, DOI 10.1158/0008-5472.CAN-08-2649; Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751; Wendt MK, 2009, J BIOL CHEM, V284, P34145, DOI 10.1074/jbc.M109.023614; Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Wilding J, 1996, CANCER RES, V56, P5285; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	48	152	157	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6485	6498		10.1038/onc.2010.377	http://dx.doi.org/10.1038/onc.2010.377			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802523	Green Accepted			2022-12-17	WOS:000285138900008
J	Sato, T; Nakashima, A; Guo, L; Coffman, K; Tamanoi, F				Sato, T.; Nakashima, A.; Guo, L.; Coffman, K.; Tamanoi, F.			Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer	ONCOGENE			English	Article						mTORC1; rapamycin; cancer genome database; kinase activity	CDC25 PHOSPHATASES; SIGNALING NETWORK; PROTEIN; GROWTH; RAPAMYCIN; PATHWAY; TARGET	Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates a variety of cellular functions such as growth, proliferation and autophagy. In a variety of cancer cells, overactivation of mTOR has been reported. In addition, mTOR inhibitors, such as rapamycin and its derivatives, are being evaluated in clinical trials as anticancer drugs. However, no active mutants of mTOR have been identified in human cancer. Here, we report that two different point mutations, S2215Y and R2505P, identified in human cancer genome database confer constitutive activation of mTOR signaling even under nutrient starvation conditions. S2215Y was identified in large intestine adenocarcinoma whereas R2505P was identified in renal cell carcinoma. mTOR complex 1 prepared from cells expressing the mutant mTOR after nutrient starvation still retains the activity to phosphorylate 4E-BP1 in vitro. The cells expressing the mTOR mutant show increased percentage of S-phase cells and exhibit resistance to cell size decrease by amino-acid starvation. The activated mutants are still sensitive to rapamycin. However, they show increased resistance to 1-butanol. Our study points to the idea that mTOR activating mutations can be identified in a wide range of human cancer. Oncogene (2010) 29, 2746-2752; doi:10.1038/onc.2010.28; published online 1 March 2010	[Sato, T.; Nakashima, A.; Guo, L.; Coffman, K.; Tamanoi, F.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Jonsson Comprehens Canc Ctr, 1602 Mol Sci Bldg,609 Charles E Young Dr E, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu			National Institutes of Health [CA41996]; NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant CA41996.	Aressy B, 2008, ANTI-CANCER AGENT ME, V8, P818, DOI 10.2174/187152008786847756; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Edinger AL, 2004, ONCOGENE, V23, P5654, DOI 10.1038/sj.onc.1207738; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Kranenburg O, 2005, BBA-REV CANCER, V1756, P81, DOI 10.1016/j.bbcan.2005.10.001; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Ohne Y, 2008, J BIOL CHEM, V283, P31861, DOI 10.1074/jbc.M801546200; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Ray D, 2007, CELL CYCLE, V6, P3039, DOI 10.4161/cc.6.24.5104; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Robb VA, 2007, J UROLOGY, V177, P346, DOI 10.1016/j.juro.2006.08.076; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sato T, 2009, J BIOL CHEM, V284, P12783, DOI 10.1074/jbc.M809207200; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	23	152	161	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2746	2752		10.1038/onc.2010.28	http://dx.doi.org/10.1038/onc.2010.28			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190810	Green Accepted			2022-12-17	WOS:000277354600014
J	Hartman, TR; Nicolas, E; Klein-Szanto, A; Al-Saleem, T; Cash, TP; Simon, MC; Henske, EP				Hartman, T. R.; Nicolas, E.; Klein-Szanto, A.; Al-Saleem, T.; Cash, T. P.; Simon, M. C.; Henske, E. P.			The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis	ONCOGENE			English	Article						BHD; mTOR; folliculin; renal carcinoma; oncocytoma	TUBEROUS SCLEROSIS COMPLEX; RIBOSOMAL S6 KINASE; NIHON RAT MODEL; BHD GENE; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; TUBEROUS-SCLEROSIS-COMPLEX-2 TSC2; SPONTANEOUS PNEUMOTHORAX; EMBRYONIC LETHALITY; NATURAL-HISTORY; CELL CARCINOMA	Birt-Hogg-Dube (BHD) syndrome is a tumor-suppressor gene disorder characterized by skin tumors, cystic lung disease and renal cell carcinoma. Very little is known about the molecular pathogenesis of BHD. Clinical similarities between BHD and tuberous sclerosis complex (TSC) suggest that the BHD and TSC proteins may function within a common pathway. The TSC proteins inhibit the activity of the mammalian target of rapamycin complex 1 (TORC1), and in Schizosaccharomyces pombe, Bhd and Tsc1/Tsc2 have opposing roles in the regulation of amino-acid homeostasis. We report here that in mammalian cells, downregulation of BHD reduces the phosphorylation of ribosomal protein S6, an indicator of TORC1 activity. To determine whether folliculin, the product of the BHD gene, regulates mammalian target of rapamycin activity in vivo, we generated a mouse with targeted inactivation of the Bhd gene. The mice developed spontaneous oncocytic cysts and tumors composed of cells that resemble the renal cell carcinomas in BHD patients. The cysts and tumors had low levels of phospho-S6. Taken together, these data indicate that folliculin regulates the activity of TORC1, and suggest a new paradigm in which both inappropriately high and inappropriately low levels of TORC1 activity can be associated with renal tumorigenesis.	[Henske, E. P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Hartman, T. R.; Henske, E. P.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; [Nicolas, E.] Fox Chase Canc Ctr, Genom Core Facil, Philadelphia, PA 19111 USA; [Klein-Szanto, A.; Al-Saleem, T.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; [Cash, T. P.; Simon, M. C.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Simon, M. C.] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; [Simon, M. C.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Henske, EP (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, 1 Blackfan Circle, Boston, MA 02115 USA.	Ehenske@partners.org	Simon, Celeste/AAG-3941-2021; Klein-Szanto, A./E-6218-2010		NIH [RO1 (DK51052), F32 (DK076443-01)]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051052, R29DK051052, F32DK076443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Victoria Robb for critical reading of this paper. We also thank Dr Laura Schmidt for the FLCN mAb, Dr Samuel Litwin for statistical analysis and the Fox Chase Cancer Center Lab Animal Facility for technical assistance with the development and maintenance of the Bhd mutant mice. This work was supported by NIH RO1 (DK51052). Dr Hartman was supported by NIH F32 (DK076443-01).	Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; Babbitt JT, 2000, CARCINOGENESIS, V21, P1379, DOI 10.1093/carcin/21.7.1379; Ballif BA, 2005, P NATL ACAD SCI USA, V102, P667, DOI 10.1073/pnas.0409143102; BARBOUR G L, 1978, Urology, V12, P694, DOI 10.1016/0090-4295(78)90434-X; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chen JD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003581; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hasumi H, 2008, GENE, V415, P60, DOI 10.1016/j.gene.2008.02.022; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; Hino O, 2001, JPN J CANCER RES, V92, P1147, DOI 10.1111/j.1349-7006.2001.tb02133.x; HINO O, 1993, CANCER RES, V53, P5856; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Khoo SK, 2002, J MED GENET, V39, P906, DOI 10.1136/jmg.39.12.906; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kouchi M, 2006, VIRCHOWS ARCH, V448, P463, DOI 10.1007/s00428-005-0142-9; Leter EM, 2008, J INVEST DERMATOL, V128, P45, DOI 10.1038/sj.jid.5700959; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mohr U, 1996, PATHOBIOLOGY AGING M, V1; Murakami T, 2007, J PATHOL, V211, P524, DOI 10.1002/path.2139; Nagy A, 2004, INT J CANCER, V109, P472, DOI 10.1002/ijc.11694; NELLIST M, 1993, CELL, V75, P1305; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; O'Callaghan FJK, 1998, LANCET, V351, P1490, DOI 10.1016/S0140-6736(05)78872-3; Okimoto K, 2004, CURR MOL MED, V4, P887, DOI 10.2174/1566524043359737; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Painter JN, 2005, AM J HUM GENET, V76, P522, DOI 10.1086/428455; Pavlovich CP, 2005, J UROLOGY, V173, P1482, DOI 10.1097/01.ju.0000154629.45832.30; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Robb VA, 2007, J UROLOGY, V177, P346, DOI 10.1016/j.juro.2006.08.076; Rolfe M, 2005, BIOCHEM J, V388, P973, DOI 10.1042/BJ20041888; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stutman O, 1975, Adv Cancer Res, V22, P261; Takagi Y, 2008, ONCOGENE, V27, P5339, DOI 10.1038/onc.2008.261; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195; Urban T, 1999, MEDICINE, V78, P321, DOI 10.1097/00005792-199909000-00004; van Slegtenhorst M, 2007, J BIOL CHEM, V282, P24583, DOI 10.1074/jbc.M700857200; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Warren MB, 2004, MODERN PATHOL, V17, P998, DOI 10.1038/modpathol.3800152; Yang Y, 2008, CANCER GENET CYTOGEN, V180, P100, DOI 10.1016/j.cancergencyto.2007.10.010; Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	58	152	157	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1594	1604		10.1038/onc.2009.14	http://dx.doi.org/10.1038/onc.2009.14			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234517	Green Accepted			2022-12-17	WOS:000264780500004
J	Wallez, Y; Cand, F; Cruzalegui, F; Wernstedt, C; Souchelnytskyi, S; Vilgrain, I; Huber, P				Wallez, Y.; Cand, F.; Cruzalegui, F.; Wernstedt, C.; Souchelnytskyi, S.; Vilgrain, I.; Huber, P.			Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site	ONCOGENE			English	Article						angiogenesis; adherens junctions; VE-cadherin; tyrosine kinases	FOCAL ADHESION KINASE; VE-CADHERIN; C-SRC; INDUCED ANGIOGENESIS; BETA-CATENIN; CELL; PROTEIN; BINDING; ASSOCIATION; FAMILY	Src-family tyrosine kinases are regulatory proteins that play a pivotal role in the disorganization of cadherin-dependent cell-cell contacts. We previously showed that Src was associated with vascular endothelial (VE)cadherin and that tyrosine phosphorylation level of VE-cadherin was dramatically increased in angiogenic tissues as compared to quiescent tissues. Here, we examined whether VE-cadherin was a direct substrate for Src in vascular endothelial growth factor ( VEGF)induced VE-cadherin phosphorylation, and we identified the target tyrosine sites. Co-transfections of Chinese hamster ovary cells (CHO) cells with VE-cadherin and constitutively active Src (Y530F) resulted in a robust tyrosine phosphorylation of VE-cadherin that was not detected with kinase-dead Src (K298M). In an in vitro Src assay, the VE-cadherin cytoplasmic domain is directly phosphorylated by purified Src as well as the tyrosine residue 685 (Tyr)685-containing peptide RPSLY(685)AQVQ. VE-cadherin peptide mapping from human umbilical vein endothelial cells stimulated by VEGF and VE-cadherin-CHO cells transfected with active Src revealed that Y685 was the unique phosphorylated site. The presence of Phospho Y685 was confirmed by its ability to bind to C-terminal Src kinase-SH2 domain in a pull-down assay. Finally, we found that in a VEGF-induced wound-healing assay, cadherin adhesive activity was impaired by Src kinase inhibitors. These data identify that VEGF-induced-VE- cadherin tyrosine phosphorylation is mediated by Src on Y685, a process that appears to be critical for VEGF-induced endothelial cell migration.	Univ Grenoble 1, ISERE, CEA Grenoble,INSERM,Dept Rech & Dynam Cellulaires, EMI 0219,Lab Dev & Viellissement Endothelium, F-38054 Grenoble 9, France; SERVIER, Inst Rech, Croissy, Croissy Sur Seine, France; Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Servier; Ludwig Institute for Cancer Research	Vilgrain, I (corresponding author), Univ Grenoble 1, ISERE, CEA Grenoble,INSERM,Dept Rech & Dynam Cellulaires, EMI 0219,Lab Dev & Viellissement Endothelium, 17 Rue Martyrs, F-38054 Grenoble 9, France.	ivilgrain@cea.fr	Wallez, Yann/H-1033-2013; Souchelnytskyi, Serhiy/J-9446-2014; Souchelnytskyi, Serhiy/G-6491-2011; Huber, Philippe/C-7971-2019	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Huber, Philippe/0000-0002-4153-7694; Wallez, Yann/0000-0001-9654-6187; VILGRAIN, Isabelle/0000-0002-5511-5871				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Calcerrada MC, 2002, NEUROCHEM RES, V27, P313, DOI 10.1023/A:1014911329489; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Esser S, 1998, J CELL SCI, V111, P1853; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Hudry-Clergeon H, 2005, FASEB J, V19, P512, DOI 10.1096/fj.04-2202com; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lampugnani MG, 1999, METH MOL B, V96, P177; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Shasby DM, 2002, AM J PHYSIOL-LUNG C, V282, pL1330, DOI 10.1152/ajplung.00329.2001; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Su WH, 2002, BLOOD, V100, P3597, DOI 10.1182/blood-2002-01-0303; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; van Oijen MGCT, 1998, J ORAL PATHOL MED, V27, P147; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008; Zhao Y, 1998, J CELL PHYSIOL, V174, P370, DOI 10.1002/(SICI)1097-4652(199803)174:3<370::AID-JCP11>3.0.CO;2-D	42	152	157	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1067	1077		10.1038/sj.onc.1209855	http://dx.doi.org/10.1038/sj.onc.1209855			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909109				2022-12-17	WOS:000244245400013
J	Ehtesham, M; Winston, JA; Kabos, P; Thompson, RC				Ehtesham, M; Winston, JA; Kabos, P; Thompson, RC			CXCR4 expression mediates glioma cell invasiveness	ONCOGENE			English	Article						chemokine; CXCR4; invasion; glioma; brain tumor	BREAST-CANCER METASTASIS; NF-KAPPA-B; TUMOR-GROWTH; CHEMOKINE RECEPTOR; MALIGNANT GLIOMA; INVASION; MIGRATION; BRAIN; METALLOPROTEINASE; ANGIOGENESIS	Glioblastoma multiforme is a highly invasive tumor bearing a dismal prognosis. Experimental strategies that focus on the specific biological cues governing the invasive capacity of these tumors may hold significant therapeutic promise. In this context, we describe the in vitro and in vivo association of the cell surface chemokine receptor, CXCR4, with the development of an invasive phenotype in malignant glioblastoma. We demonstrate that invasive populations of glioma cells overexpress CXCR4 at the message and protein levels, and that this expression ranges from 25- to 89-fold higher than that found in noninvasive tumor cells. Furthermore, neutralization of CXCR4 significantly impairs the in vitro invasive capacity of malignant glial cells. In addition, glioma cells secrete CXCL12 and demonstrate robust invasive capacity toward a CXCL12 gradient in vitro. These findings underscore the importance of CXCR4 as a potential therapeutic target for the treatment of invasive glioblastoma.	Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ So Calif, Dept Med, Los Angeles, CA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Southern California	Ehtesham, M (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, T-4224 Med Ctr N, Nashville, TN 37232 USA.	moneeb.ehtesham@vanderbilt.edu			NINDS NIH HHS [NS051557] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051557] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbero S, 2003, CANCER RES, V63, P1969; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Belperio JA, 2004, CHEST, V125, p156S, DOI 10.1378/chest.125.5_suppl.156S; COLEMAN MT, 1980, CANCER LETT, V8, P255, DOI 10.1016/0304-3835(80)90011-7; Ehtesham M, 2003, J IMMUNOTHER, V26, P107, DOI 10.1097/00002371-200303000-00003; Ehtesham M, 2002, CANCER GENE THER, V9, P925, DOI 10.1038/sj.cgt.7700516; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Liang ZX, 2005, CANCER RES, V65, P967; Mori T, 2004, MOL CANCER THER, V3, P29; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Woo JH, 2003, CANCER RES, V63, P3430; Yu JS, 2001, CANCER RES, V61, P842; Zeelenberg IS, 2003, CANCER RES, V63, P3833; ZHANG J, 2005, CARCINOGENESIS; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	26	152	163	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2801	2806		10.1038/sj.onc.1209302	http://dx.doi.org/10.1038/sj.onc.1209302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407848				2022-12-17	WOS:000237272900011
J	O'Donnell, RK; Kupferman, M; Wei, SJ; Singhal, S; Weber, R; O'Malley, B; Cheng, Y; Putt, M; Feldman, M; Ziober, B; Muschel, RJ				O'Donnell, RK; Kupferman, M; Wei, SJ; Singhal, S; Weber, R; O'Malley, B; Cheng, Y; Putt, M; Feldman, M; Ziober, B; Muschel, RJ			Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity	ONCOGENE			English	Article						lymphatic metastasis; squamous cell carcinoma; microarray; gene expression pattern	MOLECULAR CLASSIFICATION; NODE METASTASIS; CHEMOKINE RECEPTORS; CDNA MICROARRAYS; DNA MICROARRAYS; BREAST-CANCER; IDENTIFICATION; HEAD; PROFILES; VALIDATION	Metastasis via the lymphatics is a major risk factor in squamous cell carcinoma of the oral cavity (OSCC). We sought to determine whether the presence of metastasis in the regional lymph node could be predicted by a gene expression signature of the primary tumor. A total of 18 OSCCs were characterized for gene expression by hybridizing RNA to Affymetrix U133A gene chips. Genes with differential expression were identified using a permutation technique and verified by quantitative RT-PCR and immunohistochemistry. A predictive rule was built using a support vector machine, and the accuracy of the rule was evaluated using crossvalidation on the original data set and prediction of an independent set of four patients. Metastatic primary tumors could be differentiated from nonmetastatic primary tumors by a signature gene set of 116 genes. This signature gene set correctly predicted the four independent patients as well as associating five lymph node metastases from the original patient set with the metastatic primary tumor group. We concluded that lymph node metastasis could be predicted by gene expression profiles of primary oral cavity squamous cell carcinomas. The presence of a gene expression signature for lymph node metastasis indicates that clinical testing to assess risk for lymph node metastasis should be possible.	Hosp Univ Penn, Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD USA; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; University of Pennsylvania	Muschel, RJ (corresponding author), Hosp Univ Penn, Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA.	muschel@xrt.upenn.edu		O'Donnell, Rebekah/0000-0001-5878-7510				Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Bei R, 2001, J PATHOL, V195, P343, DOI 10.1002/path.965; Belbin TJ, 2002, CANCER RES, V62, P1184; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Chen BS, 2000, INT J CANCER, V88, P862, DOI 10.1002/1097-0215(20001215)88:6<862::AID-IJC4>3.0.CO;2-L; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Clare Amanda, 2002, In Silico Biology, V2, P511; Datta S, 2003, BIOINFORMATICS, V19, P459, DOI 10.1093/bioinformatics/btg025; Delilbasi CB, 2004, ORAL ONCOL, V40, P154, DOI 10.1016/S1368-8375(03)00144-1; Depondt J, 1999, EUR J ORAL SCI, V107, P442, DOI 10.1046/j.0909-8836.1999.eos107605.x; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Greenberg JS, 2003, CANCER, V97, P1464, DOI 10.1002/cncr.11202; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hong WKWR, 1995, HEAD NECK CANC BASIC; Hwang D, 2003, ORAL ONCOL, V39, P259, DOI 10.1016/S1368-8375(02)00108-2; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Kato M, 2003, BREAST CANCER RES, V5, pR144, DOI 10.1186/bcr627; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kim Hyoun Chull, 1993, Kurume Medical Journal, V40, P183; Leethanakul C, 2003, ORAL ONCOL, V39, P248, DOI 10.1016/S1368-8375(02)00107-0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loriot A, 2003, INT J CANCER, V105, P371, DOI 10.1002/ijc.11104; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Myers LL, 1998, LARYNGOSCOPE, V108, P232, DOI 10.1097/00005537-199802000-00014; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7; Ohta T, 1996, BRIT J CANCER, V73, P1511, DOI 10.1038/bjc.1996.285; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Roth C, 2000, GENOMICS, V63, P384, DOI 10.1006/geno.1999.6084; Schmalbach CE, 2004, ARCH OTOLARYNGOL, V130, P295, DOI 10.1001/archotol.130.3.295; Scimone ML, 2004, J EXP MED, V199, P1113, DOI 10.1084/jem.20031645; Stringer BK, 2001, CANCER RES, V61, P582; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van Kempen LCLT, 2003, EUR J CELL BIOL, V82, P539, DOI 10.1078/0171-9335-00346; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Warner GC, 2004, INT J CANCER, V110, P857, DOI 10.1002/ijc.20197; Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	51	152	162	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1244	1251		10.1038/sj.onc.1208285	http://dx.doi.org/10.1038/sj.onc.1208285			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558013				2022-12-17	WOS:000226898700011
J	Arnott, CH; Scott, KA; Moore, RJ; Robinson, SC; Thompson, RG; Balkwill, FR				Arnott, CH; Scott, KA; Moore, RJ; Robinson, SC; Thompson, RG; Balkwill, FR			Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development	ONCOGENE			English	Article						TNFR1; TNFR2; keratinocyte; GM-CSF; MMP-9; c-jun	NECROSIS-FACTOR RECEPTOR; DEFICIENT LIVER-REGENERATION; FACTOR-KAPPA-B; MOUSE SKIN; C-JUN; TRANSGENIC MICE; CARCINOGENESIS; CELLS; LIGAND; P55	Keratinocyte-derived TNF-alpha acts as an endogenous tumour promoter and can also regulate AP-1 activity in mouse epidermis. To gain further insight into TNF-alpha signalling during skin tumour formation, mice deficient in TNFR1 (TNFR1(-/-) mice) or TNFR2 (TNFR2(-/-) mice) were subjected to chemical carcinogenesis. Tumour multiplicity was significantly reduced in TNFR1(-/-) and TNFR2(-/-) mice compared to wild-type (wt) mice, suggesting that both receptors have protumour activity. However, TNFR1(-/-) mice were markedly more resistant to tumour development than TNFR2(-/-) mice indicating that TNFR1 is the major mediator of TNF-alpha-induced tumour formation. TNFR1 and TNFR2 were both expressed in wt epidermis during tumour promotion and by primary keratinocytes in vitro. TPA-induced c-Jun expression was transient in TNFR1(-/-) and TNFR2(-/-) compared to wt epidermis and this was reflected by reduced induction of the AP-1-responsive genes granulocyte/macrophage-colony stimulating factor, matrix metalloproteinase-9 and matrix metalloproteinase-3. The se genes were differentially regulated in TNFR1(-/-) compared to TNFR2(-/-) epidermis, suggesting that the TNF-alpha receptors act independently via different AP-1 complexes to transduce TNF-alpha signals during tumour promotion. In addition, TNFR2 cooperated with TNFR1 to optimise TNFR1-mediated TNF-alpha bioactivity on keratinocytes in vitro. Our data provide further insight into TNF-alpha signalling in malignancy and provide some rationale for the use of TNF-alpha antagonists in the treatment of cancer.	Barts & London Queen Marys Sch Med & Dent, John Vane Sci Ctr, Canc Res UK Translat Oncol Lab, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London	Scott, KA (corresponding author), Barts & London Queen Marys Sch Med & Dent, John Vane Sci Ctr, Canc Res UK Translat Oncol Lab, Charterhouse Sq, London EC1M 6BQ, England.	kate.scott@cancer.org.uk		Balkwill, Frances/0000-0002-5587-9759				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arnott CH, 2002, ONCOGENE, V21, P4728, DOI 10.1038/sj.onc.1205588; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; Hulboy DL, 2001, MOL CELL BIOL, V21, P5478, DOI 10.1128/MCB.21.16.5478-5487.2001; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kitakata H, 2002, CANCER RES, V62, P6682; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Littlejohn AF, 2003, BIOCHEM PHARMACOL, V65, P91, DOI 10.1016/S0006-2952(02)01443-0; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mann A, 2001, CANCER RES, V61, P2311; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mori R, 2002, FASEB J, V16, P963, DOI 10.1096/fj.01-0776com; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Papathoma AS, 2001, MOL CARCINOGEN, V31, P74, DOI 10.1002/mc.1042; Peschon JJ, 1998, J IMMUNOL, V160, P943; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Rutberg SE, 1996, ONCOGENE, V13, P167; Scott KA, 2003, MOL CANCER THER, V2, P445; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Suganuma M, 1999, CANCER RES, V59, P4516; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yamada Y, 1998, AM J PATHOL, V152, P1577; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhong SP, 2001, CANCER RES, V61, P4084; Zhuang LH, 1999, J IMMUNOL, V162, P1440	43	152	157	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1902	1910		10.1038/sj.onc.1207317	http://dx.doi.org/10.1038/sj.onc.1207317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14661063				2022-12-17	WOS:000220129500012
J	Waki, T; Tamura, G; Sato, M; Motoyama, T				Waki, T; Tamura, G; Sato, M; Motoyama, T			Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples	ONCOGENE			English	Article						age-related methylation; tumor suppressor gene; autopsy	ABERRANT PROMOTER METHYLATION; CPG-ISLAND METHYLATION; E-CADHERIN GENE; DNA METHYLATION; GASTRIC-CANCER; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; MULTIPLE GENES; HYPERMETHYLATION; P16	Age-related methylation may have the potential to behave as a mutator process. To clarify the physiological consequence of age-related methylation of tumor suppressor and tumor-related genes, we studied promoter methylation status in non-neoplastic cells of various organs obtained at autopsy by methylation-specific PCR. Promoter methylation status of APC, DAP-kinase, E-cadherin, GSTP1, hMLH1, p16, RASSF1A and RUNX3 genes, which are frequently silenced in certain human malignancies, was studied in non-neoplastic cells of the esophagus, stomach, small and large intestines, liver, pancreas, kidney and lung obtained from 38 Japanese autopsies. The tumor suppressor and tumor-related genes, except APC and RASSF1A, were generally unmethylated in samples obtained from people who were less than 32 years old (n = 11). Methylated promoters were present at variable frequencies in a tissue-specific manner in samples obtained from people who were greater than 42 years old (n = 27), although GSTP1 and hMLH1 methylation was absent or infrequent and lacked tissue specificity. In the majority of organs, the incidence of age-related methylation paralleled the reported methylation incidence in malignant counterparts. Thus, age-related methylation of a different set of genes is thought to constitute a field defect in different organs.	Yamagata Univ, Sch Med, Dept Pathol, Yamagata 9909585, Japan	Yamagata University	Tamura, G (corresponding author), Yamagata Univ, Sch Med, Dept Pathol, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; Belinsky SA, 2002, CANCER RES, V62, P2370; Byun DS, 2001, CANCER RES, V61, P7034; Chan AOO, 2003, GUT, V52, P502, DOI 10.1136/gut.52.4.502; Esteller M, 2001, CANCER RES, V61, P3225; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kang GH, 2001, CANCER RES, V61, P2847; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Nakagawa H, 2001, CANCER RES, V61, P6991; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Paz MF, 2002, CANCER RES, V62, P4519; Satoh A, 2002, BRIT J CANCER, V86, P1817, DOI 10.1038/sj.bjc.6600319; To KF, 2002, INT J CANCER, V102, P623, DOI 10.1002/ijc.10783; Tokugawa T, 2002, CANCER RES, V62, P4938; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Ueki T, 2000, CANCER RES, V60, P1835; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waki T, 2002, AM J PATHOL, V161, P399, DOI 10.1016/S0002-9440(10)64195-8; Yanagawa N, 2002, JPN J CANCER RES, V93, P1107, DOI 10.1111/j.1349-7006.2002.tb01212.x; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	25	152	170	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4128	4133		10.1038/sj.onc.1206651	http://dx.doi.org/10.1038/sj.onc.1206651			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821947				2022-12-17	WOS:000183707600016
J	Ahonen, M; Poukkula, M; Baker, AH; Kashiwagi, M; Nagase, H; Eriksson, JE; Kahari, VM				Ahonen, M; Poukkula, M; Baker, AH; Kashiwagi, M; Nagase, H; Eriksson, JE; Kahari, VM			Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors	ONCOGENE			English	Article						TIMP-3; death receptor; apoptosis; caspase; melanoma	FAS-LIGAND EXPRESSION; MATRIX-METALLOPROTEINASE; TNF RECEPTOR; IN-VITRO; TIMP-3; GENE; INVASION; PROTEASE; CANCER; DOMAIN	Tissue inhibitors of metalloproteinases (TIMPs) are important regulators of matrix metalloproteinase (MMP) and adamalysin (ADAM) activity. We have previously shown that adenovirally expressed tissue inhibitor of metalloproteinases-3 (TIMP-3) induces apoptosis in melanoma cells and inhibits growth of human melanoma xenografts. Here, we have studied the role of death receptors in apoptosis of melanoma cells induced by TIMP-3. Our results show, that the exposure of three metastatic melanoma cell lines (A2058, SK-Mel-5, and WM-266-4) to recombinant TIMP-3, N-terminal MMP inhibitory domain of TIMP-3, as well as to adenovirally expressed TIMP-3 results in stabilization of tumor necrosis factor receptor-1 (TNF-RI), FAS, and TNF-related apoptosis inducing ligand receptor-1 (TRAIL-RI) on melanoma cell surface and sensitizes these cells to apoptosis induced by TNF-alpha, anti-Fas-antibody and TRAIL. Stabilization of death receptors by TIMP-3 results in activation of caspase-8 and caspase-3, and subsequent apoptosis is blocked by specific caspase-8 inhibitor (Z-IETD-FMK) and by pan-caspase inhibitor (Z-DEVD-FMK). Adenovirus-mediated expression of TIMP-3 in human melanoma xenografts in vivo resulted in increased immunostaining for TNF-RI, FAS, and cleaved caspase-3, and in apoptosis of melanoma cells. Taken together, these results show that TIMP-3 promotes apoptosis in melanoma cells through stabilization of three distinct death receptors and activation of their apoptotic signaling cascade through caspase-8.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Dept Biol, FIN-20014 Turku, Finland; Univ Glasgow, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Turku; University of Glasgow; Imperial College London; University of Oxford	Kahari, VM (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Baker, Andy/AAO-5250-2021; Kahari, Veli-Matti/E-5144-2011	Baker, Andy/0000-0003-1441-5576; Kahari, Veli-Matti/0000-0003-2421-9368; Poukkula, Minna Karoliina/0000-0003-4192-2899	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bachman KE, 1999, CANCER RES, V59, P798; Baker AH, 1996, MATRIX BIOL, V15, P383, DOI 10.1016/S0945-053X(96)90158-4; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHIRIVI RGS, 1994, INT J CANCER, V58, P460, DOI 10.1002/ijc.2910580326; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Ekmekcioglu S, 1999, MELANOMA RES, V9, P261, DOI 10.1097/00008390-199906000-00008; Fariss RN, 1997, AM J PATHOL, V150, P323; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI200113171; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Killar L, 1999, ANN NY ACAD SCI, V878, P442, DOI 10.1111/j.1749-6632.1999.tb07701.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Mitsiades N, 2001, CANCER RES, V61, P577; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Schlondorff J, 1999, J CELL SCI, V112, P3603; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Solomon KA, 1999, J IMMUNOL, V163, P4105; Soubrane C, 2000, BRIT J DERMATOL, V143, P307, DOI 10.1046/j.1365-2133.2000.03655.x; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Terheyden P, 1999, J INVEST DERMATOL, V112, P899, DOI 10.1046/j.1523-1747.1999.00607.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ueki T, 2000, CANCER RES, V60, P1835; UGUREL S, 2001, CLIN CANCER RES, V7, P1108; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	54	152	168	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2121	2134		10.1038/sj.onc.1206292	http://dx.doi.org/10.1038/sj.onc.1206292			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687014				2022-12-17	WOS:000182066900006
J	Zhou, A; Scoggin, S; Gaynor, RB; Williams, NS				Zhou, A; Scoggin, S; Gaynor, RB; Williams, NS			Identification of NF-kappa B-regulated genes induced by TNF alpha utilizing expression profiling and RNA interference	ONCOGENE			English	Article						TNF alpha; NF-kappa B; cDNA microarrays; RNA interference; gene expression profiles; apoptosis	TUMOR-NECROSIS-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CULTURED-MAMMALIAN-CELLS; PROSTAGLANDIN-E SYNTHASE; ZINC FINGER PROTEIN; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL REGULATION; INDUCIBLE EXPRESSION; ENDOTHELIAL-CELLS; EGR-1 PROMOTER	Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine with important roles in regulating inflammatory responses as well as cell cycle proliferation and apoptosis. Although TNFalpha stimulates apoptosis, it also activates the transcription factor NF-kappaB, and studies have shown that inhibition of NF-kappaB potentiates the cytotoxicity of TNFalpha. Since several chemotherapy agents act like TNFalpha to both promote apoptosis and activate NF-kappaB, understanding the role of NF-kappaB in suppressing apoptosis may have significant clinical applications. To understand the effects of stimulation with TNFalpha and the role of NF-kappaB in regulating this response, a 23k human cDNA microarray was used to screen TNFalpha-inducible genes in HeLa cells. Real-time PCR verified expression changes in 16 of these genes and revealed three distinct temporal patterns of expression after TNFalpha stimulation. Using RNA interference to disrupt expression of the p65 subunit of NF-kappaB, all but two of the genes were shown to depend on this transcription factor for their expression, which correlated well with the existence of NF-kappaB binding sites in most of their promoters. Inflammatory, proapoptotic, and antiapoptotic genes were all shown to be regulated by NF-kappaB, demonstrating the wide variety of targets activated by NF-kappaB signaling and the necessity of differentiating among these genes for therapeutic purposes.	Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med,Harold Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, NS (corresponding author), Univ Texas, SW Med Ctr, Div Hematol Oncol, Dept Med,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Scoggin, Shane/0000-0003-2510-2823	NCI NIH HHS [CA74128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AntrasFerry J, 1997, FEBS LETT, V403, P100, DOI 10.1016/S0014-5793(97)00033-1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Berman KS, 2002, CLIN CANCER RES, V8, P354; Brown RT, 1995, J BIOL CHEM, V270, P31129, DOI 10.1074/jbc.270.52.31129; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chaudhary LR, 1996, MOL CELL BIOCHEM, V156, P69; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; COFFER P, 1995, ONCOGENE, V10, P985; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dong G, 1999, CANCER RES, V59, P3495; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Finch JS, 2001, GENE, V267, P135, DOI 10.1016/S0378-1119(01)00398-5; Forsberg L, 2000, FEBS LETT, V471, P78, DOI 10.1016/S0014-5793(00)01367-3; Grimbacher B, 1998, RHEUMATOL INT, V17, P185, DOI 10.1007/s002960050032; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Harborth J, 2001, J CELL SCI, V114, P4557; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; KAKIZAKI Y, 1995, KIDNEY INT, V48, P1866, DOI 10.1038/ki.1995.485; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; Maehara K, 2001, FASEB J, V15, P2025, DOI 10.1096/fj.00-0909fje; Manos EJ, 2001, CANCER RES, V61, P433; Murakami T, 2000, J Atheroscler Thromb, V7, P39; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SARMA V, 1992, J IMMUNOL, V148, P3302; Schageman JJ, 2002, BIOTECHNIQUES, V32, P338, DOI 10.2144/02322st07; STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tsai JC, 2000, FASEB J, V14, P1870; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; VAN AD, 1996, SCIENCE, V274, P787; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	59	152	165	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2054	2064		10.1038/sj.onc.1206262	http://dx.doi.org/10.1038/sj.onc.1206262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673210				2022-12-17	WOS:000181967700015
J	Tarsounas, M; Davies, D; West, SC				Tarsounas, M; Davies, D; West, SC			BRCA2-dependent and independent formation of RAD51 nuclear foci	ONCOGENE			English	Article						recombination; DNA repair; genome stability; breast cancer	DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; CANCER SUSCEPTIBILITY; CELL-CYCLE; BRCA2; PROTEIN; REPAIR; GENE; ASSOCIATION; DEFICIENCY	The formation of RAD51 foci in response to ionizing radiation (IR) represents an important step in the repair of DNA double-strand breaks. RAD51 foci also appear during S phase and are thought to be required for the restart of stalled or broken replication forks. The RAD51 recombinase interacts directly with the breast cancer-associated tumour suppressor BRCA2, an interaction that is required for normal recombination proficiency, radiation resistance and genome stability. In CAPAN-1 cells, which express a truncated form of BRCA2 that is cytoplasmic because of loss of the nuclear localization signal, the formation of IR-induced RAD51 foci is impaired. In this work, we show that S-phase RAD51 foci form normally in CAPAN-1 cells expressing truncated BRCA2. Moreover, we find that RAD51 specifically associates with chromatin at S phase in a reaction that is BRCA2-independent. The observed BRCA2-dependent and independent formation of RAD51 foci shows that intact BRCA2 is not required for RAD51 focus formation per se, leading us to suggest that S phase and IR-induced RAD51 foci assemble by distinct pathways with defined protein requirements.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		Davies, Derek/0000-0002-6977-4181; West, Stephen/0000-0001-8848-9418				Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Darzynkiewicz Z, 1999, EXP CELL RES, V249, P1, DOI 10.1006/excr.1999.4477; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Goggins M, 1996, CANCER RES, V56, P5360; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tashiro S, 1996, ONCOGENE, V12, P2165; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.biochem.54.1.425; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547	44	152	163	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1115	1123		10.1038/sj.onc.1206263	http://dx.doi.org/10.1038/sj.onc.1206263			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606939				2022-12-17	WOS:000181249700001
J	Zermati, Y; De Sepulveda, P; Feger, F; Letard, S; Kersual, J; Casteran, N; Gorochov, G; Dy, M; Dumas, AR; Dorgham, K; Parizot, C; Bieche, Y; Vidaud, M; Lortholary, O; Arock, M; Hermine, O; Dubreuil, P				Zermati, Y; De Sepulveda, P; Feger, F; Letard, S; Kersual, J; Casteran, N; Gorochov, G; Dy, M; Dumas, AR; Dorgham, K; Parizot, C; Bieche, Y; Vidaud, M; Lortholary, O; Arock, M; Hermine, O; Dubreuil, P			Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms	ONCOGENE			English	Article						mastocytosis; c-kit; STI571; kinase inhibitor	GASTROINTESTINAL STROMAL TUMOR; ACTIVATING MUTATION; MYELOID-LEUKEMIA; CATALYTIC DOMAIN; ABL PROTEIN; BONE-MARROW; LINE UT-7; MASTOCYTOSIS; DIFFERENTIATION; ERYTHROPOIETIN	Systemic mastocytosis (SM) is a rare disease caused by an abnormal mast cell accumulation in various tissues. Two classes of constitutive activating e-kit mutations are found in SM. The most frequent class occurs in the catalytic pocket coding region with substitutions at codon 816 and the other in the intracellular juxtamembrane coding region. Therefore, kinase inhibitors that block mutated c-kit activity might be used as therapeutic agents in SM. Here, we show that STI571 inhibits both wild-type and juxtamembrane mutant c-kit kinase activity, but has no effect an the activity of the D816 V mutant. Accordingly, STI571 selectively decreases the survival of normal mast cell and of mast cell lines either with juxtamembrane c-kit mutations, but not that of tumoral mast cell from patient with SM or of mast cell lines with the D816 V mutation. Therefore, STI571 is not a good candidate to treat SM and specific kinase inhibitors should be designed to inhibit constitutive activating mutations at codon 816.	Hop Necker Enfants Malad, Dept Adult Hematol, F-75743 Paris 15, France; Univ Paris 05, Hop Necker Enfants Malad, CNRS UMR 8603, Paris, France; INSERM, U119, F-13258 Marseille, France; GHPS, Inserm U584, Lab Immunol Cellulaire & Tissulaire, Paris, France; Univ Paris 05, Fac Pharm, UPRES JE 2195, Genet Mol Lab, Paris, France; Hop Avicenne, Dept Internal Med & Infect Dis, F-93009 Bobigny, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13	Dubreuil, P (corresponding author), Hop Necker Enfants Malad, Dept Adult Hematol, 149-161 Rue Sevres, F-75743 Paris 15, France.		Vidaud, Michel/O-7346-2017; Hermine, Olivier/Q-7072-2018; dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019; De sepulveda, paulo/K-6043-2015; Dorgham, karim/A-2241-2016; Gorochov, Guy/P-2911-2017	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; De sepulveda, paulo/0000-0001-8295-5414; Dorgham, karim/0000-0001-9539-3203; Hermine, Olivier/0000-0003-2574-3874; PARIZOT, Christophe/0000-0001-5723-4471; LETARD, Sebastien/0000-0002-6508-7376; Gorochov, Guy/0000-0003-2097-9677				Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hashimoto K, 1996, AM J PATHOL, V148, P189; HERMINE O, 1992, BLOOD, V80, P3060; Hongyo T, 2000, CANCER RES, V60, P2345; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; KITAMURA Y, 1978, BLOOD, V52, P447; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Longley BJ, 2000, HEMATOL ONCOL CLIN N, V14, P697, DOI 10.1016/S0889-8588(05)70303-8; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; LONGLEY J, 1995, J AM ACAD DERMATOL, V32, P545, DOI 10.1016/0190-9622(95)90336-4; Marone G, 2001, LEUKEMIA RES, V25, P583, DOI 10.1016/S0145-2126(01)00039-X; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Tsujimura T, 1996, BLOOD, V87, P273; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; VALENT P, 1992, BLOOD, V80, P2237; Worobec AS, 2000, HEMATOL ONCOL CLIN N, V14, P659, DOI 10.1016/S0889-8588(05)70301-4; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Zermati Y, 2000, EXP HEMATOL, V28, P256, DOI 10.1016/S0301-472X(99)00155-1	25	152	162	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					660	664		10.1038/sj.onc.1206120	http://dx.doi.org/10.1038/sj.onc.1206120			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569358				2022-12-17	WOS:000180642100003
J	Baldi, A; De Luca, A; Morini, M; Battista, T; Felsani, A; Baldi, F; Catricala, C; Amantea, A; Noonan, DM; Albini, A; Natali, PG; Lombardi, D; Paggi, MG				Baldi, A; De Luca, A; Morini, M; Battista, T; Felsani, A; Baldi, F; Catricala, C; Amantea, A; Noonan, DM; Albini, A; Natali, PG; Lombardi, D; Paggi, MG			The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells	ONCOGENE			English	Article						melanoma; tumor progression; PRSS11; HtrA1; serine protease	MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; GENE-PRODUCT; EXPRESSION; MAC25; SUPPRESSOR; ASSAY	Differential gene expression of cell lines derived from a malignant melanoma or its autologous lymph node metastasis using cDNA arrays indicated down-regulation of PRSS11, a gene encoding the serine protease HtrA1, a homolog of the Escherichia coli protease HtrA, in the metastatic line. Stable PRSS11 overexpression in the metastatic cell line strongly inhibited proliferation, chemoinvasion and Nm23-H1 protein expression in vitro, as well as cell growth in vivo in nu/nu mice. A polyclonal anti-HtrA1 serum demonstrated a significantly higher expression in primary melanomas when compared to unrelated metastatic lesions in a human melanoma tissue array, and down-modulation of HtrA1 expression in autologous lymph node melanoma metastases in seven out of 11 cases examined. These results suggest that down-regulation of PRSS11 and HtrA1 expression may represent an indicator of melanoma progression.	Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C,CRS, I-00158 Rome, Italy; Natl Inst Canc Res, Genoa, Italy; CNR, Ist Neurobiol & Med Mol, Rome, Italy; Univ Naples 2, Sect Pathol, Dept Biochem & Biophys F Cedrangolo, Naples, Italy; San Gallicano Dermatol Inst, Rome, Italy; Regina Elena Inst Canc Res, CRS, Immunol Lab, Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila	Paggi, MG (corresponding author), Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C,CRS, Via Messi Oro 156, I-00158 Rome, Italy.	paggi@ifo.it	Paggi, Marco G./K-3494-2018; Noonan, Douglas M/A-8620-2010; Felsani, Armando/D-1784-2010; De Luca, Antonio/AAD-9562-2020; Baldi, Alfonso/ABG-2397-2021	Noonan, Douglas M/0000-0001-8058-0719; Felsani, Armando/0000-0001-8851-6295; De Luca, Antonio/0000-0002-3905-6154; Albini, Adriana/0000-0002-9624-5103; Baldi, Alfonso/0000-0002-8693-3842				ALBINI A, 1987, CANCER RES, V47, P3239; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Berwick Marianne, 1997, Current Opinion in Oncology, V9, P178; Bishop JAN, 1997, CANCER METAST REV, V16, P141, DOI 10.1023/A:1005752510012; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Guldberg P, 1997, CANCER RES, V57, P3660; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Indsto JO, 1998, CANCER GENET CYTOGEN, V100, P68, DOI 10.1016/S0165-4608(97)00016-2; Kato MV, 1996, ONCOGENE, V12, P1361; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Ponting CP, 1997, PROTEIN SCI, V6, P464; Robertson GP, 1999, CANCER RES, V59, P3596; Shridhar V, 2002, CANCER RES, V62, P262; Slominski A, 2001, ARCH PATHOL LAB MED, V125, P1295; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Zumbrunn J, 1997, GENOMICS, V45, P461, DOI 10.1006/geno.1997.4953; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	30	152	167	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6684	6688		10.1038/sj.onc.1205911	http://dx.doi.org/10.1038/sj.onc.1205911			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242667				2022-12-17	WOS:000178202300015
J	Zhang, YW; Wang, LM; Jove, R; Vande Woude, GF				Zhang, YW; Wang, LM; Jove, R; Vande Woude, GF			Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis	ONCOGENE			English	Article						HGF/SF; Met; Stat3; Stat3 beta; anchorage independent growth; tumorigenesis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; ANCHORAGE-INDEPENDENT GROWTH; RECEPTOR TYROSINE KINASE; FACTOR/SCATTER FACTOR; SOMATIC MUTATIONS; CELLULAR-TRANSFORMATION; EPITHELIAL-CELLS; SPLICE VARIANT; IN-VIVO	Hepatocyte Growth Factor/Scatter Factor (HGF/SF) mediates a wide variety of cellular responses by acting through the Met tyrosine kinase receptor. Inappropriate expression of HGF/SF and/or Met has been found in most types of solid tumors and is often associated with poor prognosis. Importantly, constitutional and sporadic activating mutations in Met have been discovered in human papillary renal carcinomas and other cancers, while autocrine and paracrine signaling of this receptor/ligand pair has been shown to contribute to tumorigenesis and metastasis. Numerous downstream signaling molecules have been implicated in HGF/SF-Met mediated tumorigenesis and metastasis. Stat3 is a downstream signaling molecule activated by HGF/SF-Met signaling, and is reported to contribute to cell transformation induced by a diverse set of oncoproteins. Stat3 is constitutively activated in many primary tumors and tumor cell lines, suggesting that signaling by this molecule may be important for cell transformation. To address whether Stat3 is required for HGF/SF-Met mediated tumorigenesis and metastasis, we introduced a dominant-negative form of Stat3, Stat3 beta into the human leiomyosarcoma cell line SK-LMS-1. We found that Stat3 beta has no effect on the transformed morphology, proliferation, invasion or branching morphogenesis in vitro. By contrast, expression of Stat3 beta affected HGF/SF-Met mediated anchorage-independent colony formation and prevented tumorigenic growth in athymic nu/nu mice. Thus, Met signaling through Stat3 provides an essential function for tumorigenic growth, which is manifested in vitro by loss of anchorage-independent growth.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	Van Andel Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.							Besser D, 1999, MOL CELL BIOL, V19, P1401; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CORTNER J, 1995, MET HGF SF AUTOCRINE; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Faletto D L, 1993, EXS, V65, P107; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koochekpour S, 1997, CANCER RES, V57, P5391; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Matsumoto K, 1993, EXS, V65, P225; Niu GL, 1999, CANCER RES, V59, P5059; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Park WS, 1999, CANCER RES, V59, P307; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT A, 1995, DEVELOPMENT, V121, P813; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	58	152	156	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					217	226		10.1038/sj/onc/1205004	http://dx.doi.org/10.1038/sj/onc/1205004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803465				2022-12-17	WOS:000173026200006
J	Lafarge, S; Sylvain, V; Ferrara, M; Bignon, YJ				Lafarge, S; Sylvain, V; Ferrara, M; Bignon, YJ			Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway	ONCOGENE			English	Article						BRCA1; microtubule-interfering agents; JNK; ribozyme	DNA-DAMAGE RESPONSE; CELL-CYCLE; TUMOR-SUPPRESSOR; CANCER-CELLS; SELF-CLEAVAGE; RNA; EXPRESSION; APOPTOSIS; PROTEIN; PHOSPHORYLATION	We have developed ribozymes (Rz) that inhibit BRCA1 expression in order to study the role of this gene in chemosensitivity. Two Rz, targeting positions 358 or 5282 of the BRCA1 mRNA, were cloned into the retroviral vector LXSN and lipofected into the breast cancer cell-line HBL100. We obtained 79-99% inhibition of BRCA1 expression, as determined by real-time quantitative PCR and by Western blotting. Decreased expression of BRCA1 led to sensitivity to the DNA damaging agents cisplatin and etoposide, resistance to the microtubule-interfering agents (MIA) taxol and vincristine. The molecular mechanism of resistance to MIA was investigated further by determining the status of the JNK pathway. We found that JNK1 expression was elevated, while JNK2 expression was decreased in Rz-expressing clones compared to controls. We have quantified the mRNA levels of BRCA1, JNK1, 2, MEK-4, -7 and c-jun after treatment with MIA. Vincristine treatment of control cells resulted in transcriptional repression of BRCA1, while the JNK1, 2, MEK-4, -7 and c-jun genes were induced. In Rz-treated cells, only JNK1 and MEK-4 were expressed and none was induced after MIA treatment. We then studied the phosphorylation of c-jun, a downstream effector of the JNK pathway. We observed a strong increase in phosphorylated c-jun after MIA treatment of the control cells but not in BRCA1-Rz treated cells, suggesting inhibition of the JNK pathway. These results show that the BRCA1-JNK pathway is involved in the cytotoxic response to MIA treatment, and inhibition of BRCA1 leads to transcriptional modifications of the JNK pathway.	Ctr Jean Perrin, Oncol Mol Lab, F-63011 Clermont Ferrand 1, France; INRA, UNCM, F-63122 St Genes Champanelle, France	UNICANCER; Centre Jean Perrin; INRAE	Bignon, YJ (corresponding author), Ctr Jean Perrin, Oncol Mol Lab, BP 392, F-63011 Clermont Ferrand 1, France.	Yves-Jean.Bignon@cjp.u-clermont1.fr	, bignon/Y-3243-2019					Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 2000, CANCER RES, V60, P5037; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; Fromes Y, 1996, J PROTEIN CHEM, V15, P377, DOI 10.1007/BF01886864; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Husain A, 1998, CANCER RES, V58, P1120; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rao VN, 1996, ONCOGENE, V12, P523; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Tomlinson GE, 1998, CANCER RES, V58, P3237; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; Vaish NK, 1998, NUCLEIC ACIDS RES, V26, P5237, DOI 10.1093/nar/26.23.5237; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang CC, 1999, CANCER RES, V59, P3663; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	47	152	163	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6597	6606		10.1038/sj.onc.1204812	http://dx.doi.org/10.1038/sj.onc.1204812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641785				2022-12-17	WOS:000171404200013
J	Nam, SW; Clair, T; Campo, CK; Lee, HY; Liotta, LA; Stracke, ML				Nam, SW; Clair, T; Campo, CK; Lee, HY; Liotta, LA; Stracke, ML			Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells	ONCOGENE			English	Article						autotaxin; invasion; metastasis; motility; ras	MOTILITY-STIMULATING PROTEIN; SURFACE-ANTIGENS; EXPRESSION; CLONING; GROWTH; BRAIN; SITE	Autotaxin (ATX), an exo-nucleotide pyrophosphatase and phosphodiesterase, was originally isolated as a potent stimulator of tumor cell motility. In order to study whether ATX expression affects motility-dependent processes such as invasion and metastasis, we stably transfected full-length ATX cDNA into two nonexpressing cell lines, parental and ras-transformed NIH3T3 (clone7) cells. The effect of ATX secretion on in vitro cell motility was variable, The ras-transformed, ATX-secreting subclones had enhanced motility to ATX as chemoattractant, but there was little difference in the motility responses of NIH3T3 cells transfected with atx, an inactive mutant gene, or empty vector, In MatrigelTM invasion assays, all subclones, which secreted enzymatically active ATX, demonstrated greater spontaneous and ATX-stimulated invasion than appropriate controls. This difference in invasiveness was not caused by differences in gelatinase production, which was constant within each group of transfectants, In vivo studies with athymic nude mice demonstrated that injection of atx-transfected NIH3T3 cells resulted in a weak tumorigenic capacity with few experimental metastases. Combination of ATX expression with ras transformation produced cells with greatly amplified tumorigenesis and metastatic potential compared to ras-transformed controls, Thus, ATX appears to augment cellular characteristics necessary for tumor aggressiveness.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nam, SW (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Room 2A33, Bethesda, MD 20892 USA.			Alewine, Christine/0000-0003-1661-0957				Aznavoorian S, 1996, J BIOL CHEM, V271, P3247, DOI 10.1074/jbc.271.6.3247; Bachner D, 1998, DEV DYNAM, V213, P398; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Deissler H, 1999, FASEB J, V13, P657, DOI 10.1096/fasebj.13.6.657; Deterre P, 1996, J IMMUNOL, V157, P1381; Fuss B, 1997, J NEUROSCI, V17, P9095; Huang RP, 1998, INT J CANCER, V77, P880, DOI 10.1002/(SICI)1097-0215(19980911)77:6<880::AID-IJC14>3.0.CO;2-5; JU WD, 1991, NEW BIOL, V3, P380; Kawagoe H, 1997, CANCER RES, V57, P2516; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; Mulvaney PT, 1998, INT J CANCER, V78, P46, DOI 10.1002/(SICI)1097-0215(19980925)78:1<46::AID-IJC9>3.0.CO;2-X; MURATA J, 1994, J BIOL CHEM, V269, P30479; Stefan C, 1999, BBA-MOL CELL RES, V1450, P45, DOI 10.1016/S0167-4889(99)00031-2; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAHASHI T, 1970, J EXP MED, V132, P1181, DOI 10.1084/jem.132.6.1181; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	23	152	155	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					241	247		10.1038/sj.onc.1203263	http://dx.doi.org/10.1038/sj.onc.1203263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645002				2022-12-17	WOS:000084844400009
J	Singh, KK; Russell, J; Sigala, B; Zhang, YG; Williams, J; Keshav, KF				Singh, KK; Russell, J; Sigala, B; Zhang, YG; Williams, J; Keshav, KF			Mitochondrial DNA determines the cellular response to cancer therapeutic agents	ONCOGENE			English	Article						mitochondria; mitochondrial DNA; cell death; adriamycin	PHOTODYNAMIC THERAPY; CELLS; DOXORUBICIN; APOPTOSIS; AMPLIFICATION; BIOENERGETICS; EXPRESSION; PORPHYRIN; FAILURE; REPAIR	Mutations in the mitochondrial genome leading to mitochondrial dysfunction have been reported in a variety of cancers. However, the potential implication of these findings in the cellular response to cancer therapeutic agents is unclear. To examine the importance of mitochondrial DNA (mitDNA) encoded functions in cancer therapeutic response, we determined the clonogenic survival of HSL2 (Rho(+), HeLa subline), and its derivative cell line lacking mitDNA (Rho(o)) after exposure to different anticancer agents. We found that isogenic Rho(o) cells lacking mitDNA were extremely resistant to adriamycin and photodynamic therapy (PDT) induced cell death, whereas the Rho(+) cell line was sensitive. However, there was no measurable difference in the responses of these cell lines to either alkylating agent or gamma-radiation. We show that the development of resistance to adriamycin was not due to changes in apoptotic cell death, cell cycle response or to the uptake of adriamycin in isogenic Rho(o) cells. We also demonstrate that exposure of HeLa cells to adriamycin leads to mutations in mitDNA. These studies provide direct evidence that mitDNA plays an important role in cellular sensitivity to cancer therapeutic agents.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA; Drexel Univ, Dept Biosci & Biotechnol, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; Drexel University	Singh, KK (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, 600 N Wolfe St,Room 2-121, Baltimore, MD 21287 USA.				NCI NIH HHS [CA/ES 66204] Funding Source: Medline; NIEHS NIH HHS [ES 09714-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boultwood J, 1996, BRIT J HAEMATOL, V95, P426, DOI 10.1046/j.1365-2141.1996.d01-1922.x; CHEVILLARD S, 1990, J CANCER RES CLIN, V116, P633, DOI 10.1007/BF01637086; Eguchi Y, 1997, CANCER RES, V57, P1835; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; Fisher AMR, 1999, CANCER RES, V59, P331; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; HILF R, 1987, PHOTOCHEM PHOTOBIOL, V46, P806; Isaacs JS, 1997, ONCOGENE, V14, P1669, DOI 10.1038/sj.onc.1201001; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; KESHAV KF, 1998, MITOCHONDRIAL DNA MU; Kiberstis PA, 1999, SCIENCE, V283, P1475; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KULE C, 1994, MOL PHARMACOL, V46, P1234; Liang BC, 1996, MUTAT RES-FUND MOL M, V354, P27, DOI 10.1016/0027-5107(96)00004-8; Liang BC, 1998, CELL DEATH DIFFER, V5, P694, DOI 10.1038/sj.cdd.4400401; Marchetti P, 1996, CANCER RES, V56, P2033; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; MORAIS R, 1994, CANCER RES, V54, P3889; Munday AD, 1996, BBA-MOL CELL RES, V1311, P1, DOI 10.1016/0167-4889(96)00008-0; NASS MMK, 1972, EXP CELL RES, V72, P211, DOI 10.1016/0014-4827(72)90583-6; Palmeira CM, 1997, BBA-BIOENERGETICS, V1321, P101, DOI 10.1016/S0005-2728(97)00055-8; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 1997, J BIOENERG BIOMEMBR, V29, P301, DOI 10.1023/A:1022417911796; PETIT PX, 1998, MITOCHONDRIAL DNA MU; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rempel A, 1996, CANCER RES, V56, P2468; RICHTER C, 1988, FEBS LETT, V241, P1, DOI 10.1016/0014-5793(88)81018-4; SCHATZ G, 1995, BBA-MOL BASIS DIS, V1271, P123, DOI 10.1016/0925-4439(95)00018-Y; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; SHARKEY SM, 1993, CANCER RES, V53, P4994; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; Singal PK, 1997, FASEB J, V11, P931, DOI 10.1096/fasebj.11.12.9337145; SINGH KK, 1998, MITOCHONDRIAL DNA MU; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; TALLINI G, 1997, VIRCHOWS ARCH, V433, P5; Tanaka M, 1996, Methods Enzymol, V264, P407, DOI 10.1016/S0076-6879(96)64037-3; Toffoli G, 1996, EUR J CANCER, V32A, P1591, DOI 10.1016/0959-8049(96)00113-X; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; Wallace KB, 1997, FUND APPL TOXICOL, V38, P23, DOI 10.1006/faat.1997.2320; WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112; WOODBURN KW, 1992, PHOTOCHEM PHOTOBIOL, V55, P697	43	152	162	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6641	6646		10.1038/sj.onc.1203056	http://dx.doi.org/10.1038/sj.onc.1203056			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597269				2022-12-17	WOS:000083792000003
J	Pantoja, C; Serrano, M				Pantoja, C; Serrano, M			Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras	ONCOGENE			English	Article						p21; cell cycle; senescence; ras; transformation	CELL-CYCLE ARREST; MAMMARY EPITHELIAL-CELLS; ARF TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; GROWTH-CHARACTERISTICS; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; BINDING PROTEIN-3; DEPENDENT KINASES; DNA-SYNTHESIS	The cell-cycle inhibitor p21 is upregulated during senescence and upon induction of senescence-like arrest by oncogenic Pas, We have used primary fibroblasts derived from p21-null mice to evaluate the role of p21 in these processes. We find that primary p21(-/-) cells enter senescence and have a lifespan similar to wild-ta pe cells. Upon immortalization, most wild-type and p21(-/-) cultures acquire alterations in either p53 or p16(INK4a), further indicating that p21-deficiency is not sufficient by itself to allow immortalization. Primary p21(-/-) cells, like wild-type cells, respond to oncogenic Pas by accumulating p53 and p16(INK4a), and by decreasing their proliferation rate. In agreement with this, p21(-/-) cells are refractory to neoplasic transformation by oncogenic Ras when compared to p53(-/-) cells. We conclude that, in murine fibroblasts, p21 is not essential neither for senescence nor for preventing neoplasic transformation by oncogenic Ras.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Serrano, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.		Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; Pantoja, Cristina/0000-0003-0180-5823				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carman TA, 1998, EXP CELL RES, V244, P33, DOI 10.1006/excr.1998.4207; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gallimore PH, 1997, J VIROL, V71, P6629, DOI 10.1128/JVI.71.9.6629-6640.1997; Garkavtsev I, 1998, EXP GERONTOL, V33, P81, DOI 10.1016/S0531-5565(97)00086-7; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2357; HARVEY M, 1993, ONCOGENE, V8, P2457; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mazars GR, 1997, P NATL ACAD SCI USA, V94, P151, DOI 10.1073/pnas.94.1.151; Medcalf ASC, 1996, CANCER RES, V56, P4582; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Reznikoff CA, 1996, CANCER RES, V56, P2886; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; RITTLING SR, 1992, ONCOGENE, V7, P935; Rittling SR, 1996, EXP CELL RES, V229, P7, DOI 10.1006/excr.1996.0337; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAHARA H, 1995, ONCOGENE, V10, P835; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKADA T, 1993, ONCOGENE, V8, P3313; VOTJA PJ, 1995, BIOCHIM BIOPHYS ACTA, V1242, P29; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Yan Y, 1996, MOL BIOL CELL, V7, P975, DOI 10.1091/mbc.7.6.975; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	83	152	157	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4974	4982		10.1038/sj.onc.1202880	http://dx.doi.org/10.1038/sj.onc.1202880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490832				2022-12-17	WOS:000082321700010
J	Terradillos, O; Pollicino, T; Lecoeur, H; Tripodi, M; Gougeon, ML; Tiollais, P; Buendia, MA				Terradillos, O; Pollicino, T; Lecoeur, H; Tripodi, M; Gougeon, ML; Tiollais, P; Buendia, MA			p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro	ONCOGENE			English	Article						hepatitis B virus; apoptosis; X protein; liver; p53	WILD-TYPE P53; MYC-MEDIATED APOPTOSIS; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; LIVER-CANCER; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; CELL-DEATH; HELA-CELLS	The hepatitis B virus protein HBx is a promiscuous transactivator implicated in both cell growth and death and in the development of hepatocellular carcinoma. We recently reported that HBx can potentiate c-myc-induced liver oncogenesis in a transgenic model where low level expression of HBx induces no pathology, To assess if HBx could affect the hepatocyte turnover, we investigated the HBx-elicited apoptotic responses in transgenic livers and in primary hepatocyte cultures. Here we show that transgenic expression of HBx is associated with a twofold increase of spontaneous cell death in the mouse liver, The finding that apoptosis was enhanced to similar extents in HBx mice carrying homozygous p53 null mutations implied that functionally intact p53 was not required to transduce the death signal, A direct, dose-dependent apoptotic function of HBx was demonstrated in transient transfections of liver-derived cell lines. We further show that stable expression of HBx at low, presumably physiological levels in primary hepatocytes, induced cellular susceptibility to diverse apoptotic insults, including growth factor deprivation, treatment with anti-Fas antibodies or doxorubicine and oxidative stress, HBx expression, but not p53 status profoundly affected the commitment of cells to die upon apoptotic stimuli, These data strengthen the notion that HEX may contribute to HBV pathogenesis by enhancing apoptotic death in the chronically infected liver.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France; Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France; Univ Roma La Sapienza, Sez Genet Mol, Dipartimento Biotechnol Cellulari, Fdn Inst Pasteur Cenci Bolognetti, Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Sapienza University Rome	Buendia, MA (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75724 Paris, France.		Pollicino, Teresa/K-5790-2016; Pollicino, Teresa/HDN-3708-2022; Tripodi, Marco/F-1143-2011; Tripodi, Marco/ABO-1160-2022	Pollicino, Teresa/0000-0001-6602-3035; Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X				Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BALSANO C, 1993, ARCH VIROL, P63; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISCHER M, 1995, VIRUS GENES, V10, P99, DOI 10.1007/BF01724303; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HOOPER ML, 1994, J CELL SCI, P13; HSU B, 1995, ONCOGENE, V11, P175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lecoeur H, 1997, J IMMUNOL METHODS, V209, P111, DOI 10.1016/S0022-1759(97)00138-5; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, CANCER RES, V57, P5137; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Peterhans E, 1997, J NUTR, V127, pS962, DOI 10.1093/jn/127.5.962S; Petersen J, 1997, J VIROL, V71, P5455, DOI 10.1128/JVI.71.7.5455-5463.1997; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; TEODORO JG, 1995, ONCOGENE, V11, P467; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	65	152	158	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	1998	17	16					2115	2123		10.1038/sj.onc.1202432	http://dx.doi.org/10.1038/sj.onc.1202432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798683				2022-12-17	WOS:000076540900011
J	West, MJ; Stoneley, M; Willis, AE				West, MJ; Stoneley, M; Willis, AE			Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway	ONCOGENE			English	Article						c-myc; eIF-4G; rapamycin; S6 kinase; TOR; translation	EPSTEIN-BARR-VIRUS; INITIATION-FACTOR 4E; 5' UNTRANSLATED REGION; MESSENGER-RNA; PROTEIN-KINASE; GROWTH-FACTOR; S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ORNITHINE DECARBOXYLASE; DEPENDENT TRANSLATION	Previous studies on the regulation of c-myc have focused on the transcriptional control of this proto-oncogene. We have investigated the signalling pathways involved under circumstances in which there is a translational upregulation in the levels of c-myc protein. We have demonstrated an up to tenfold serum-dependent increase of c-myc protein levels in Epstein-Barr virus immortalized B-cell lines 2-4 h after disruption of cellular aggregates, which is not accompanied by an equivalent increase in mRNA. Overall protein synthesis rates only increased threefold suggesting that the c-myc message was being selectively translated. We observed increases in the phosphorylation of p70 and p85 S6 kinases and of initiation factor eIF-4E binding protein 1 (4E-BP1) 1-2 h after stimulation, suggesting activation of the FRAP/TOR signalling pathway. The increased phosphorylation of 4E-BP1 led to a decrease in its association with eIF-4E and an increase in its association with the eIF-4G component of the eIF-4F initiation complex. The signalling; inhibitors rapamycin and wortmannin blocked the phosphorylation of 4E-BP1 and abolished the translational component of the c-myc response. Our data suggest that dissociation of eIF-4E from 4E-BP1, leading to an increase in the formation of the eIF-4F initiation complex, relieves the translation repression imposed ion the c-myc mRNA by its structured 5'UTR.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England.			West, Michelle/0000-0002-9497-9365; Willis, Anne/0000-0002-1470-8531				ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; AMAN P, 1986, CURR TOP MICROBIOL, V132, P266; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEAN M, 1986, J BIOL CHEM, V261, P9161; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Flynn A, 1996, EUR J BIOCHEM, V236, P40, DOI 10.1111/j.1432-1033.1996.00040.x; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JONES N, 1996, IMMUNOLOGY, V89, P26; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LAZARUS P, 1992, ONCOGENE, V7, P1037; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LYONS RT, 1980, J BIOL CHEM, V255, P6330; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MAO XH, 1992, J BIOL CHEM, V267, P20444; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marshall CJ, 1996, FASEB J, V10, P7; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; NEPVEU A, 1987, ONCOGENE, V1, P243; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PROUD CG, 1994, NATURE, V371, P747, DOI 10.1038/371747a0; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; Rosenwald IB, 1995, CANCER LETT, V98, P77, DOI 10.1016/0304-3835(95)90206-6; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WATERS CM, 1991, ONCOGENE, V6, P797; West MJ, 1995, ONCOGENE, V11, P2515; Young L S, 1992, Semin Cancer Biol, V3, P273	67	152	159	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					769	780		10.1038/sj.onc.1201990	http://dx.doi.org/10.1038/sj.onc.1201990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715279				2022-12-17	WOS:000075337200012
J	Kondo, T; Minamino, N; NagamuraInoue, T; Matsumoto, M; Taniguchi, T; Tanaka, N				Kondo, T; Minamino, N; NagamuraInoue, T; Matsumoto, M; Taniguchi, T; Tanaka, N			Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity	ONCOGENE			English	Article						IRF-1; NPM; tumor suppressor; human cancers	REGULATORY FACTOR-I; IFN-BETA-GENE; NUCLEAR FACTOR; DNA-DAMAGE; EXPRESSION; PROTEINS; LEUKEMIA; GROWTH; P53; TRANSFORMATION	Interferon regulatory factor-1 (IRF-1) acts as a transcriptional activator in the interferon system and as a tumor suppressor. The loss of functional IRF-1 has been observed in a significant number of patients with myelodysplastic syndrome (MDS) and leukemia, suggesting a potentially critical role of IRF-1 in human oncostasis. Here we report an alternative mechanism by which IRF-1 may be inactivated. We purified an IRF-1 association molecule which was revealed to be identical to a nuclear factor nucleophosmin (NPM)/B23/numatrin. Functional analysis showed that NPM inhibited the DNA-binding and transcriptional activity of IRF-1. Moreover, NPM was overexpressed in several clinical leukemia samples and human-derived leukemia cell lines. Finally, overexpression of NPM in NIH3T3 cells resulted in malignant transformation. These results suggest the possible involvement of NPM in inactivating IRF-1-dependent anti-oncogenic surveillance in human cancer development.	UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN	University of Tokyo; National Cerebral & Cardiovascular Center - Japan			Kondo, Takeshi/G-2103-2012	Kondo, Takeshi/0000-0001-7455-5824; Tanaka, Nobuyuki/0000-0002-6373-2220				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BENETT JM, 1985, ANN INTERN MED, V103, P626; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; LEBEAU MM, 1989, CANCER CEL, V7, P53; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIEBEL F, 1969, J CELL PHYSIOL, V74, P191, DOI 10.1002/jcp.1040740211; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	152	159	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1275	1281		10.1038/sj.onc.1201286	http://dx.doi.org/10.1038/sj.onc.1201286			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315094				2022-12-17	WOS:A1997XV84500004
J	Chin, K; Kurashima, Y; Ogura, T; Tajiri, H; Yoshida, S; Esumi, H				Chin, K; Kurashima, Y; Ogura, T; Tajiri, H; Yoshida, S; Esumi, H			Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells	ONCOGENE			English	Article						vascular endothelial growth factor; nitric oxide; gene expression	HUMAN ERYTHROPOIETIN GENE; FACTOR EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PERMEABILITY FACTOR; HYPOXIC INDUCTION; IN-VIVO; ENHANCER; ANGIOGENESIS; SIMILARITIES; PROMOTER	We evaluated the effect of nitric oxide (NO) on vascular endothelial growth factor (VEGF) gene expression in human A-172 glioblastoma cells and human HepG2 hepatocellular carcinoma cells, The mRNA level of VEGF increased in response to S-Nitroso-N-acetyl-D,L-penicillamine (SNAP) in both cell lines, and increased in mRNA level well coincided with VEGF protein production in A-172 cells. SNAP at 0.5 mM induced maximal stimulation of 4.4 and 3.7 kb VEGF mRNA expression after 6 h about 11 and 8 fold increase, respectively above control level. Similar VEGF mRNA accumulation was observed also with NOR3, another chemical NO generator. To evaluate the effect of SNAP on VEGF mRNA stability, half-lives of VEGF mRNA were measured in A-172 cells cultured with or without 0.5 mM SNAP and treated with actinomycin D (25 mu g/ml). Half-life for VEGF mRNA was found to be prolonged about 2.4 fold by SNAP, VEGF expression induced by SNAP was inhibited by guanylate cyclase inhibitors, methylene blue (10 mu M) and LY-83583 (1 mu M), and by the protein synthesis inhibitor, cycloheximide (25 mu g/ml). These results suggest that induction of VEGF gene expression by NO is mediated through guanylate cyclase activity and requires on-going protein synthesis.	NATL CANC CTR, RES INST E, INVEST TREATMENT DIV, KASHIWA, CHIBA, JAPAN; NATL CANC CTR HOSP E, DIV INTERNAL MED, KASHIWA, CHIBA, JAPAN	National Cancer Center - Japan; National Cancer Center - Japan								ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KONTUREK SJ, 1993, EUR J PHARMACOL, V239, P215, DOI 10.1016/0014-2999(93)90997-V; KRANTZ SB, 1991, BLOOD, V77, P419; KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, LAB INVEST, V71, P374; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OHIGASHI T, 1993, J CLIN INVEST, V92, P1587, DOI 10.1172/JCI116740; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; POHL U, 1989, AM J PHYSIOL, V256, pH1595, DOI 10.1152/ajpheart.1989.256.6.H1595; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	36	152	168	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					437	442		10.1038/sj.onc.1201201	http://dx.doi.org/10.1038/sj.onc.1201201			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242380				2022-12-17	WOS:A1997XM23800008
J	ZAUBERMAN, A; LUPO, A; OREN, M				ZAUBERMAN, A; LUPO, A; OREN, M			IDENTIFICATION OF P53 TARGET GENES THROUGH IMMUNE SELECTION OF GENOMIC DNA - THE CYCLIN-G GENE CONTAINS 2 DISTINCT P53 BINDING-SITES	ONCOGENE			English	Article						P53 TARGETS; CYCLINS; CELL CYCLE; TUMOR SUPPRESSOR; DNA BINDING	WILD-TYPE P53; PROTEIN; EXPRESSION; TRANSACTIVATION; P53-PROTEIN; INHIBITOR; KINASES; ELEMENT; MUTANT; P21	An immune-selection procedure was employed in order to isolate p53-binding sites from rat genomic DNA. One such site was found to reside within the first intron of the cyclin G gene. Cyclin G mRNA levels are strongly elevated upon induction of wild type p53 activity in cells carrying a temperature sensitive p53 mutant. The cyclin G gene also carries a second p53-binding motif upstream to its transcriptional start site. The presence of two high affinity p53-binding sites may confer upon the cyclin G gene the potential to be activated very efficiently by p53. These data raise the possibility that cyclin G may be a downstream mediator of at least some of the biological effects of p53.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science					NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GANNON JV, 1991, NATURE, V349, P802; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; OTTO A, 1993, ONCOGENE, V8, P2591; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAMURA K, 1993, ONCOGENE, V8, P2113; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	33	152	155	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2361	2366						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784084				2022-12-17	WOS:A1995RE54300011
J	LESSNICK, SL; BRAUN, BS; DENNY, CT; MAY, WA				LESSNICK, SL; BRAUN, BS; DENNY, CT; MAY, WA			MULTIPLE DOMAINS MEDIATE TRANSFORMATION BY THE EWINGS-SARCOMA EWS/FLI-1 FUSION GENE	ONCOGENE			English	Article						EWINGS SARCOMA; EWS/FLI-1; ETS PROTEINS; CHIMERIC TRANSCRIPTION FACTOR	CHIMERIC TRANSCRIPTION FACTOR; DNA-BINDING DOMAIN; TRANSACTIVATION DOMAIN; PRE-B; ACTIVATION; TRANSLOCATION; PROTEINS; FAMILY; FLI-1; LIPOSARCOMA	The (11;22) chromosomal translocation found in Ewing's sarcoma and related tumors fuses the amino terminus of the EWS protein to the DNA-binding domain of the FLI-1 transcription factor. In contrast to normal FLI-1, the EWS/FLI-1 fusion transforms NIH3T3 cells and this activity requires both EWS and FLI-1 sequences. Reporter gene assays showed that the portion of EWS fused to FLI-1 encodes a strong transcriptional activation domain. To determine whether this function is necessary for transformation by EWS/FLI-1, deletion analysis of EWS was performed. We found that the EWS domain could be functionally subdivided into two regions: (i) an amino terminal domain (domain A) which transforms efficiently when fused to FLI-1 but has little transactivation activity in a model system and (ii) a distal region (domain B) which transactivates efficiently but transforms less efficiently when fused to FLI-1. Replacement of the EWS domain with known heterologous transcriptional activation domains yielded chimeric FLI-1 fusions that in some instances could transform NM3T3 cells. Finally we demonstrate that EWS/FLI-1 and related FLI-1 chimeras are able to cooperate,vith another transcription factor to activate a model reporter gene. These results further demonstrate that EWS/FLI-1 is an aberrant transcription factor and suggest that the EWS domain mediates important protein-protein interactions with other factors resulting in the transcriptional modulation of target genes.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,GWYNNE HAZEN CHERRY MEM LABS,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA50443, CA12800] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA012800, R01CA050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS J, 1992, BLOOD, V80, P2953; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NYE JA, 1992, GENE DEV, V67, P975; OHNO T, 1993, CANCER RES, V53, P5859; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1993, ONCOGENE, V8, P2167; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WU YL, 1990, NUCLEIC ACIDS RES, V18, P1919, DOI 10.1093/nar/18.7.1919; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	152	161	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					423	431						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845667				2022-12-17	WOS:A1995QF64800002
J	SAMESHIMA, Y; MATSUNO, Y; HIROHASHI, S; SHIMOSATO, Y; MIZOGUCHI, H; SUGIMURA, T; TERADA, M; YOKOTA, J				SAMESHIMA, Y; MATSUNO, Y; HIROHASHI, S; SHIMOSATO, Y; MIZOGUCHI, H; SUGIMURA, T; TERADA, M; YOKOTA, J			ALTERATIONS OF THE P53 GENE ARE COMMON AND CRITICAL EVENTS FOR THE MAINTENANCE OF MALIGNANT PHENOTYPES IN SMALL-CELL LUNG-CARCINOMA	ONCOGENE			English	Article							CHROMOSOME-17; HETEROZYGOSITY; MUTATIONS; CANCER; EXPRESSION; PROTEIN	To clarify the incidence, timing and pathogenetic significance of p53 gene alterations in the progression of small-cell lung carcinoma (SCLC), 17 primary tumors, 13 metastases and nine cell lines from 27 patients were analysed by a polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. Allelic losses and mutations of the p53 gene were detected in 24 out of 25 informative cases (96%) and 23 out of 27 cases (85%) respectively. Simultaneous losses and mutations were detected in all 16 stage III-IV tumors, while these alterations were detected only in 3 of 6 stage I-II tumors. When allelic losses and/or mutations were detected in the primary tumors, the same alterations were always maintained in the process of metastasis. In three cases, identical p53 alterations were detected among different organ metastases. The mutations detected in five cell lines were also detected in the corresponding original tumors. These results suggest that the alterations of the p53 gene are common and early events, but probably not the first events, in the development of SCLC, and that these alterations are essential for the maintenance of malignant phenotypes in the progression of SCLC.	TOKYO WOMENS MED COLL,DEPT MED,SHINJUKU KU,TOKYO 162,JAPAN; NATL CANC CTR,CHUO KU,TOKYO 104,JAPAN	Tokyo Women's Medical University; National Cancer Center - Japan	SAMESHIMA, Y (corresponding author), NATL CANC CTR,RES INST,STUDIES METASTASIS SECT,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN.							BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; ECCLES DM, 1990, ONCOGENE, V5, P1599; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LEONE A, 1991, CANCER RES, V51, P2490; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MORI N, 1990, ONCOGENE, V5, P1713; MORI N, 1989, CANCER RES, V49, P5130; MURAKAMI Y, 1991, CANCER RES, V51, P3356; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO A, 1991, CANCER RES, V51, P5632; OKAMOTO A, 1991, CANCER RES, V51, P5171; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; 1981, INT HISTOLOGICAL TYP; 1987, TNM CLASSIFICATION M	24	152	155	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					451	457						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312700				2022-12-17	WOS:A1992HK00500008
J	Schenk, B; Fulda, S				Schenk, B.; Fulda, S.			Reactive oxygen species regulate Smac mimetic/TNF alpha-induced necroptotic signaling and cell death	ONCOGENE			English	Article							MIXED LINEAGE KINASE; DOMAIN-LIKE; PROGRAMMED NECROSIS; COMPLEX I; APOPTOSIS; DOWNSTREAM; ACTIVATION; RESISTANCE; RIP3; FADD	Necroptosis represents a key programmed cell death pathway involved in various physiological and pathophysiological conditions. However, the role of reactive oxygen species (ROS) in necroptotic signaling has remained unclear. In the present study, we identify ROS as critical regulators of BV6/tumor necrosis factor-alpha (TNF alpha)-induced necroptotic signaling and cell death. We show that BV6/TNF alpha-induced cell death depends on ROS production, as several ROS scavengers such as butylated hydroxyanisole, N-acetylcysteine, alpha-tocopherol and ethyl pyruvate significantly rescue cell death. Before cell death, BV6/TNF alpha-stimulated ROS generation promotes stabilization of the receptor-interacting protein kinase 1 (RIP1)/RIP3 necrosome complex via a potential positive feedback loop, as on the one hand radical scavengers attenuate RIP1/RIP3 necrosome assembly and phosphorylation of mixed lineage kinase domain like (MLKL), but on the other hand silencing of RIP1 or RIP3 reduces ROS production. Although MLKL knockdown effectively decreases BV6/TNF alpha-induced cell death, it does not affect RIP1/RIP3 interaction and only partly reduces ROS generation. Moreover, the deubiquitinase cylindromatosis (CYLD) promotes BV6/TNF alpha-induced ROS generation and necrosome assembly even in the presence of BV6, as CYLD silencing attenuates these events. Genetic silencing of phosphoglycerate mutase 5 or dynamin-related protein 1 (Drp1) fails to protect against BV6/TNF alpha-induced cell death. By demonstrating that ROS are involved in regulating BV6/TNF alpha-induced necroptotic signaling, our study provides new insights into redox regulation of necroptosis.	[Schenk, B.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60054 Frankfurt, Germany; [Fulda, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Fulda, S.] German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60054 Frankfurt, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft [SFB815]; BMBF	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF))	We thank D Vucic (Genentech Inc., South San Francisco, CA, USA) for providing Smac mimetic, X Wang (Beijing, China) for providing anti-RIP3 and anti-PGAM5 antibodies and C Hugenberg for expert secretarial assistance. This work has been partially supported by the Deutsche Forschungsgemeinschaft (SFB815) and the BMBF.	Arslan SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026069; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chen TY, 2009, FREE RADICAL BIO MED, V46, P643, DOI 10.1016/j.freeradbiomed.2008.11.022; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Coupienne I, 2011, PHOTOCH PHOTOBIO SCI, V10, P1868, DOI 10.1039/c1pp05213f; Davis CW, 2010, FREE RADICAL BIO MED, V48, P306, DOI 10.1016/j.freeradbiomed.2009.11.001; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Han D, 2009, ANTIOXID REDOX SIGN, V11, P2245, DOI [10.1089/ars.2009.2611, 10.1089/ARS.2009.2611]; He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Held JM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.R111.013037; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149; Irrinki KM, 2011, MOL CELL BIOL, V31, P3745, DOI 10.1128/MCB.05303-11; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kikuchi M, 2012, J BIOL CHEM, V287, P41165, DOI 10.1074/jbc.M112.419747; Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021; Kulathu Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2567; Laukens B, 2011, NEOPLASIA, V13, P971, DOI 10.1593/neo.11610; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Luedde M, 2014, CARDIOVASC RES, V103, P206, DOI 10.1093/cvr/cvu146; Moquin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076841; Morgan MJ, 2010, MOL CELLS, V30, P1, DOI 10.1007/s10059-010-0105-0; Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018; Remijsen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.531; Roca FJ, 2013, CELL, V153, P521, DOI 10.1016/j.cell.2013.03.022; Shindo R, 2015, BIOCHEM BIOPH RES CO, V436, P212; Shulga N, 2014, J CELL SCI, V127, P896, DOI 10.1242/jcs.140764; Shulga N, 2012, J CELL SCI, V125, P2995, DOI 10.1242/jcs.103093; Song KJ, 2011, PARASITE IMMUNOL, V33, P390, DOI 10.1111/j.1365-3024.2011.01297.x; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tait SWG, 2013, CELL REP, V5, P878, DOI 10.1016/j.celrep.2013.10.034; Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Vanlangenakker N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.111; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vernon PJ, 2013, ANTIOXID REDOX SIGN, V18, P677, DOI 10.1089/ars.2012.4810; Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Ye YC, 2012, INT IMMUNOPHARMACOL, V14, P674, DOI 10.1016/j.intimp.2012.08.003; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	53	151	159	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5796	5806		10.1038/onc.2015.35	http://dx.doi.org/10.1038/onc.2015.35			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25867066				2022-12-17	WOS:000365035200003
J	Park, J; Schwarzbauer, JE				Park, J.; Schwarzbauer, J. E.			Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition	ONCOGENE			English	Article						fibronectin; EMT; MCF-10A cells; breast cancer; TGF beta	HUMAN BREAST-CANCER; EXTRACELLULAR-MATRIX COMPONENTS; FOCAL ADHESION KINASE; TGF-BETA; BASEMENT-MEMBRANE; GLAND DEVELOPMENT; UP-REGULATION; E-CADHERIN; EXPRESSION; BINDING	In the mammary gland, the stromal extracellular matrix (ECM) undergoes dramatic changes during development and in tumorigenesis. For example, normal adult breast tissue is largely devoid of the ECM protein fibronectin (FN) whereas high FN levels have been detected in the stroma of breast tumors. FN is an established marker for epithelial-mesenchymal transition (EMT), which occurs during development and has been linked to cancer. During EMT, epithelial cell adhesion switches from cell-cell contacts to mainly cell-ECM interactions, raising the possibility that FN may have a role in promoting this transition. Using MCF-10A mammary epithelial cells, we show that exposure to exogenous FN induces an EMT response including upregulation of the EMT markers FN, Snail, N-cadherin, vimentin, the matrix metalloprotease MMP2, alpha-smooth muscle actin and phospho-Smad2, as well as acquisition of cell migratory behavior. FN-induced EMT depends on Src kinase and extracellular signal-regulated kinase/mitogen-activated protein (ERK/MAP) kinase signaling but not on the immediate early gene EGR-1. FN initiates EMT under serum-free conditions; this response is partially reversed by a transforming growth factor (TGF)beta-neutralizing antibody, suggesting that FN enhances the effect of endogenous TGF beta. EMT marker expression is upregulated in cells on a fragment of FN containing the integrin-binding domain but not other domains. Differences in gene expression between FN and Matrigel are maintained with addition of a subthreshold level of TGF beta 1. Together, these results show that cells interacting with FN are primed to respond to TGF beta. The ability of FN to induce EMT shows an active role for the stromal ECM in this process and supports the notion that the increased levels of FN observed in breast tumors facilitate tumorigenesis.	[Park, J.; Schwarzbauer, J. E.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	jschwarz@princeton.edu		Schwarzbauer, Jean/0000-0003-1012-7593	NIH [R01 GM059383, R01 CA160611]; Ruth L Kirschstein National Research Service Award [T32 CA 009528]; NATIONAL CANCER INSTITUTE [R01CA160611, T32CA009528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007388, R01GM059383] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Jina Hong for assistance with some experiments. We thank Dr Keith Johnson (University of Nebraska Medical Center) for generously providing N-cadherin antibody. This work was supported by grants from the NIH (R01 GM059383 and R01 CA160611 to JES). JP received support from a Ruth L Kirschstein National Research Service Award (T32 CA 009528).	BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHRISTENSEN L, 1992, APMIS, V100, P1; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Duband JL, 2009, DEV GROWTH DIFFER, V51, P25, DOI 10.1111/j.1440-169X.2009.01076.x; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Neira RE, 2012, INT J BIOCHEM CELL B, V44, P2194, DOI 10.1016/j.biocel.2012.08.018; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Geiger B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005033; Ghajar CM, 2008, HISTOCHEM CELL BIOL, V130, P1105, DOI 10.1007/s00418-008-0537-1; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Goyal A, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-56; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Kadar A, 2002, SEMIN CANCER BIOL, V12, P243, DOI 10.1016/S1044-579X(02)00027-5; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; Kim ES, 2004, INT J ONCOL, V25, P1375; Klinowska TCM, 1999, DEV BIOL, V215, P13, DOI 10.1006/dbio.1999.9435; Komiya E, 2012, CANCER SCI, V103, P691, DOI 10.1111/j.1349-7006.2012.02203.x; KOUKOULIS GK, 1993, J SUBMICR CYTOL PATH, V25, P285; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Mao Y, 2005, J CELL SCI, V118, P4427, DOI 10.1242/jcs.02566; Martinez-Orozco R, 2010, EUR J CELL BIOL, V89, P476, DOI 10.1016/j.ejcb.2009.12.005; Martino MM, 2010, FASEB J, V24, P4711, DOI 10.1096/fj.09-151282; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; RUELLAND A, 1988, CLIN CHIM ACTA, V178, P283, DOI 10.1016/0009-8981(88)90236-7; Sandal T, 2007, AM J PATHOL, V170, P1739, DOI 10.2353/ajpath.2007.060922; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Slade MJ, 1999, EXP CELL RES, V247, P267, DOI 10.1006/excr.1998.4340; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Williams CM, 2008, CANCER RES, V68, P3185, DOI 10.1158/0008-5472.CAN-07-2673; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Xu QS, 2012, J BIOL CHEM, V287, P16563, DOI 10.1074/jbc.M111.262154; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	48	151	156	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1649	1657		10.1038/onc.2013.118	http://dx.doi.org/10.1038/onc.2013.118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23624917	Green Accepted			2022-12-17	WOS:000334344700005
J	Pagliuca, A; Valvo, C; Fabrizi, E; di Martino, S; Biffoni, M; Runci, D; Forte, S; De Maria, R; Ricci-Vitiani, L				Pagliuca, A.; Valvo, C.; Fabrizi, E.; di Martino, S.; Biffoni, M.; Runci, D.; Forte, S.; De Maria, R.; Ricci-Vitiani, L.			Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression	ONCOGENE			English	Article						RAS/MAPK; signaling pathway; miRNA; microarray; colorectal cancer	MESSENGER-RNAS; MICRORNA-143; EXPRESSION; TARGETS; SYSTEM; KRAS; CLUSTER; GROWTH	MicroRNAs (miRNAs) from the gene cluster miR-143-145 are diminished in cells of colorectal tumor origin when compared with normal colon epithelia. Until now, no report has addressed the coordinate action of these miRNAs in colorectal cancer (CRC). In this study, we performed a comprehensive molecular and functional analysis of the miRNA cluster regulatory network. First, we evaluated proliferation, migration, anchorage-independent growth and chemoresistance in the colon tumor cell lines after miR-143 and miR-145 restoration. Then, we assessed the contribution of single genes targeted by miR-143 and miR-145 by reinforcing their expression and checking functional recovery. Restoring miR-143 and miR-145 in colon cancer cells decreases proliferation, migration and chemoresistance. We identified cluster of differentiation 44 (CD44), Kruppel-like factor 5 (KLF5), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as proteins targeted by miR-143 and miR145. Their re-expression can partially revert a decrease in transformation properties caused by the overexpression of miR-143 and miR145. In addition, we determined a set of mRNAs that are diminished after reinforcing miR-143 and miR-145 expression. The whole transcriptome analysis ascertained that downregulated transcripts are enriched in predicted target genes in a statistically significant manner. A number of additional genes, whose expression decreases as a direct or indirect consequence of miR-143 and miR-145, reveals a complex regulatory network that affects cell signaling pathways involved in transformation. In conclusion, we identified a coordinated program of gene repression by miR-143 and miR-145, in CRC, where either of the two miRNAs share a target transcript, or where the target transcripts share a common signaling pathway. Major mediators of the oncosuppression by miR-143 and miR-145 are genes belonging to the growth factor receptor-mitogen-activated protein kinase network and to the p53 signaling pathway.	[Pagliuca, A.; Fabrizi, E.; di Martino, S.; Biffoni, M.; Runci, D.; Ricci-Vitiani, L.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Valvo, C.; De Maria, R.] Italian Natl Canc Inst Regina Elena, Rome, Italy; [Forte, S.] IOM Ric Srl, Viagrande, CT, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto Officina dei Materiali (IOM-CNR)	Pagliuca, A (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	alfredo.pagliuca@iss.it; lriccivitiani@yahoo.it	Pagliuca, Alfredo/AAI-3689-2020; Biffoni, Mauro/J-8318-2016; di Martino, Simona SdM/K-9304-2016; Ricci Vitiani, Lucia/J-8320-2016; De Maria, Ruggero/S-6385-2019; Forte, Stefano/D-3645-2013	Biffoni, Mauro/0000-0002-1304-9060; di Martino, Simona SdM/0000-0003-4533-3776; Ricci Vitiani, Lucia/0000-0001-7336-5615; De Maria, Ruggero/0000-0003-2255-0583; Forte, Stefano/0000-0001-5746-7451; pagliuca, alfredo/0000-0002-8703-2077	Associazione Italiana per la Ricerca sul Cancro, AIRC [6326]	Associazione Italiana per la Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grant from Associazione Italiana per la Ricerca sul Cancro, AIRC (Start-up 6326 to LR-V and Regional Fellowship to CV). We thank Tania Merlino for contribution in editing the manuscript.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Batliner J, 2012, LEUKEMIA RES, V36, P237, DOI 10.1016/j.leukres.2011.10.006; Bockmeyer CL, 2011, BREAST CANCER RES TR, V130, P735, DOI 10.1007/s10549-010-1303-3; Brest P, 2011, NAT GENET, V43, P242, DOI 10.1038/ng.762; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao W, 2010, BIOMED PHARMACOTHER, V64, P399, DOI 10.1016/j.biopha.2010.01.018; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hsu JBK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-300; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kent OA, 2013, ONCOGENE, V32, P2576, DOI 10.1038/onc.2012.266; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195; Nonne N, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1100; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Ricci-Vitiani L, 2010, FASEB J, V24, P4291, DOI 10.1096/fj.10-159970; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Villadsen SB, 2012, BRIT J CANCER, V106, P366, DOI 10.1038/bjc.2011.520; Zhu HY, 2011, MOL CANCER RES, V9, P960, DOI 10.1158/1541-7786.MCR-10-0531	35	151	159	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4806	4813		10.1038/onc.2012.495	http://dx.doi.org/10.1038/onc.2012.495			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23128394				2022-12-17	WOS:000325274700009
J	Gong, J; Zhang, JP; Li, B; Zeng, C; You, K; Chen, MX; Yuan, Y; Zhuang, SM				Gong, J.; Zhang, J-P; Li, B.; Zeng, C.; You, K.; Chen, M-X; Yuan, Y.; Zhuang, S-M			MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R	ONCOGENE			English	Article						miR-125b; apoptosis; Mcl-1; Bcl-w; IL-6R; hepatocellular carcinoma	HEPATOCELLULAR-CARCINOMA; MIR-125B; CANCER; SUPPRESSES; PROLIFERATION; DEREGULATION; TARGET; GROWTH; CELLS; GENE	The microRNA miR-125b is multi-faceted, with the ability to function as a tumor suppressor or an oncogene, depending on the cellular context. To date, the pro-apoptotic role of miR-125b and its underlying mechanisms are unexplored. In this study, both gain-and loss-of-function experiments revealed that miR-125b expression not only induced spontaneous apoptosis in various cell lines derived from the liver, lung and colorectal cancers, but also sensitized cancer cells to diverse apoptotic stimuli, including nutrient starvation and chemotherapeutic treatment. Furthermore, downregulation of miR-125b was a frequent event in hepatocellular carcinoma (HCC) tissues, and the miR-125b level was positively associated with the rate of apoptosis in HCC tissues. Subsequent investigations identified Mcl-1, Bcl-w and interleukin (IL)-6R as direct targets of miR-125b. Restoration of miR-125b expression not only diminished the expression of Mcl-1 and Bcl-w directly but also indirectly reduced the Mcl-1 and Bcl-xL levels by attenuating IL-6/signal transducer and activator of transcription 3 signaling. Consistent with these findings, introduction of miR-125b reduced the mitochondrial membrane potential and promoted the cleavage of pro-caspase-3. These data indicate that miR-125b may promote apoptosis by suppressing the anti-apoptotic molecules of the Bcl-2 family and miR-125b downregulation may facilitate tumor development by conferring upon cells the capability to survive under conditions of nutrient deprivation and chemotherapeutic treatment. Our findings highlight the importance of miR-125b in the regulation of apoptosis and suggest miR-125b as an attractive target for anti-cancer therapy.	[Gong, J.; Zhang, J-P; Zeng, C.; You, K.; Zhuang, S-M] Sch Life Sci, Dept Biochem, State Key Lab Biocontrol, Key Lab Gene Engn,Minist Educ, Guangzhou, Guangdong, Peoples R China; [Li, B.; Chen, M-X; Yuan, Y.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Dept Hepatobiliary Oncol, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Yuan, Y (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Hepatobiliary Oncol, Dongfengdong Rd 651, Guangzhou 510060, Guangdong, Peoples R China.	yuanyf@mail.sysu.edu.cn; zhuangshimei@163.com	ZHANG, JINGPING/AAT-8229-2021; zhang, jingping/AAM-2751-2021	zhang, jingping/0000-0003-0090-6710; , Gong/0000-0003-3767-1636; Yuan, Yunfei/0000-0003-2467-3683; Li, Binkui/0000-0003-3201-2914; Zhuang, Shi-Mei/0000-0002-2512-3942	Ministry of Science and Technology of China [2010CB912803, 2011CB811305]; Ministry of Health of China [2012ZX10002-011]; National Natural Science Foundation of China [30925036]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Health of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the Ministry of Science and Technology of China (2010CB912803 and 2011CB811305), the Ministry of Health of China (2012ZX10002-011) and the National Natural Science Foundation of China (30925036).	Alpini G, 2011, J HEPATOL, V55, P1339, DOI 10.1016/j.jhep.2011.04.015; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Bousquet M, 2008, J EXP MED, V205, P2499, DOI 10.1084/jem.20080285; Bousquet M, 2010, P NATL ACAD SCI USA, V107, P21558, DOI 10.1073/pnas.1016611107; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Glud M, 2011, MELANOMA RES, V21, P253, DOI 10.1097/CMR.0b013e328345333b; Guan Y, 2011, INT J CANCER, V128, P2274, DOI 10.1002/ijc.25575; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hofmann MH, 2009, MOL CANCER RES, V7, P1635, DOI 10.1158/1541-7786.MCR-09-0043; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee HW, 2003, CANCER RES, V63, P1093; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Li WX, 2008, INT J CANCER, V123, P1616, DOI 10.1002/ijc.23693; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pogue AI, 2010, NEUROSCI LETT, V476, P18, DOI 10.1016/j.neulet.2010.03.054; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Sieghart W, 2006, J HEPATOL, V44, P151, DOI 10.1016/j.jhep.2005.09.010; Soresi M, 2006, WORLD J GASTROENTERO, V12, P2563, DOI 10.3748/wjg.v12.i16.2563; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Surdziel E, 2011, BLOOD, V117, P4338, DOI 10.1182/blood-2010-06-289058; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435	35	151	158	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3071	3079		10.1038/onc.2012.318	http://dx.doi.org/10.1038/onc.2012.318			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824797				2022-12-17	WOS:000320705700007
J	Jalava, SE; Urbanucci, A; Latonen, L; Waltering, KK; Sahu, B; Janne, OA; Seppala, J; Lahdesmaki, H; Tammela, TLJ; Visakorpi, T				Jalava, S. E.; Urbanucci, A.; Latonen, L.; Waltering, K. K.; Sahu, B.; Janne, O. A.; Seppala, J.; Lahdesmaki, H.; Tammela, T. L. J.; Visakorpi, T.			Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer	ONCOGENE			English	Article						neoplasia; prostatic; miR-32; BTG2; hormone refractory; androgen independent	MICRORNA EXPRESSION; RECEPTOR GENE; MESSENGER-RNAS; PROTEIN; CELLS; AMPLIFICATION; PROGNOSIS; MIR-148A; REGIONS; BINDING	The androgen receptor (AR) signaling pathway is involved in the emergence of castration-resistant prostate cancer (CRPC). Here, we identified several androgen-regulated microRNAs (miRNAs) that may contribute to the development of CRPC. Seven miRNAs, miR-21, miR-32, miR-99a, miR-99b, miR-148a, miR-221 and miR-590-5p, were found to be differentially expressed in CRPC compared with benign prostate hyperplasia (BPH) according to microarray analyses. Significant growth advantage for LNCaP cells transfected with pre-miR-32 and pre-miR-148a was found. miR-32 was demonstrated to reduce apoptosis, whereas miR-148a enhanced proliferation. Androgen regulation of miR-32 and miR-148a was confirmed by androgen stimulation of the LNCaP cells followed by expression analyses. The AR-binding sites in proximity of these miRNAs were demonstrated with chromatin immunoprecipitation (ChIP). To identify target genes for the miRNAs, mRNA microarray analyses were performed with LNCaP cells transfected with pre-miR-32 and pre-miR-148a. Expression of BTG2 and PIK3IP1 was reduced in the cells transfected with pre-miR-32 and pre-miR-148a, respectively. Also, the protein expression was reduced according to western blot analysis. BTG2 and PIK3IP1 were confirmed to be targets by 3'UTR-luciferase assays. Finally, immunostainings showed a statistically significant (P<0.0001) reduction of BTG2 protein in CRPCs compared with untreated prostate cancer (PC). The lack of BTG2 staining was also associated (P<0.01) with a short progression-free time in patients who underwent prostatectomy. In conclusion, androgen-regulated miR-32 is overexpressed in CRPC, leading to reduced expression of BTG2. Thus, miR-32 is a potential marker for aggressive disease and is a putative drug target in PC. Oncogene (2012) 31, 4460-4471; doi: 10.1038/onc.2011.624; published online 23 January 2012	[Jalava, S. E.; Urbanucci, A.; Latonen, L.; Waltering, K. K.; Visakorpi, T.] Tampere Univ, Inst Biomed Technol, FIN-33014 Tampere, Finland; [Sahu, B.; Janne, O. A.] Univ Helsinki, Inst Biomed Physiol, Helsinki, Finland; [Seppala, J.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Lahdesmaki, H.] Aalto Univ, Sch Sci, Dept Informat & Comp Sci, Helsinki, Finland; [Tammela, T. L. J.] Univ Tampere, Dept Urol, FIN-33101 Tampere, Finland; [Tammela, T. L. J.] Tampere Univ Hosp, Tampere, Finland	Tampere University; University of Helsinki; Tampere University; Aalto University; Tampere University; Tampere University; Tampere University Hospital	Visakorpi, T (corresponding author), Tampere Univ, Inst Biomed Technol, FIN-33014 Tampere, Finland.	tapio.visakorpi@uta.fi	Jackson, Benjamin L/C-4297-2012; Latonen, Leena/C-8787-2016; Urbanucci, Alfonso/S-4450-2019; Sahu, Biswajyoti/U-6724-2017	Latonen, Leena/0000-0003-4502-2193; Urbanucci, Alfonso/0000-0003-2931-3652; Sahu, Biswajyoti/0000-0001-6576-5440; Visakorpi, Tapio/0000-0002-5004-0364	European Community [HEALTH-F2-2007-201438]; Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; Medical Research Fund of Tampere University Hospital	European Community(European Commission); Academy of Finland(Academy of Finland); Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Medical Research Fund of Tampere University Hospital	We thank Ms Mariitta Vakkuri, Ms Paivi Martikainen and Mr Rolle Rahikainen for skillful technical assistance. The research leading to these results was funded by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. HEALTH-F2-2007-201438. In addition, grant support has been received from the Academy of Finland, the Cancer Society of Finland, the Reino Lahtikari Foundation, the Sigrid Juselius Foundation and the Medical Research Fund of Tampere University Hospital.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Di Leva G, 2010, TRENDS MOL MED, V16, P257, DOI 10.1016/j.molmed.2010.04.001; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hong JW, 2005, J BIOL CHEM, V280, P21256, DOI 10.1074/jbc.M500318200; Hu XD, 2011, BIOCHEM BIOPH RES CO, V404, P903, DOI 10.1016/j.bbrc.2010.12.064; Jalava SE, 2009, INT J CANCER, V124, P95, DOI 10.1002/ijc.23916; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Leinonen KA, 2010, CLIN CANCER RES, V16, P2845, DOI 10.1158/1078-0432.CCR-09-2505; Linja MJ, 2001, CANCER RES, V61, P3550; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078-0432.CCR-10-2815; Mollerstrom E, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-296; Murata T, 2010, PROSTATE CANCER P D, V13, P356, DOI 10.1038/pcan.2010.32; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Saramaki OR, 2008, CLIN CANCER RES, V14, P3395, DOI 10.1158/1078-0432.CCR-07-2051; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thompson J, 2006, EMBO J, V25, P2757, DOI 10.1038/sj.emboj.7601161; Tomlins SA, 2009, EUR UROL, V56, P275, DOI 10.1016/j.eururo.2009.04.036; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu ZQ, 2007, BIOCHEM BIOPH RES CO, V358, P66, DOI 10.1016/j.bbrc.2007.04.096	47	151	165	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4460	4471		10.1038/onc.2011.624	http://dx.doi.org/10.1038/onc.2011.624			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266859				2022-12-17	WOS:000309704500004
J	Zhuang, D; Mannava, S; Grachtchouk, V; Tang, WH; Patil, S; Wawrzyniak, JA; Berman, AE; Giordano, TJ; Prochownik, EV; Soengas, MS; Nikiforov, MA				Zhuang, D.; Mannava, S.; Grachtchouk, V.; Tang, W-H; Patil, S.; Wawrzyniak, J. A.; Berman, A. E.; Giordano, T. J.; Prochownik, E. V.; Soengas, M. S.; Nikiforov, M. A.			C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells	ONCOGENE			English	Article						C-MYC; melanoma; senescence	MALIGNANT-MELANOMA; CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; BRAF MUTATIONS; P53; ONCOPROTEIN; CANCER; CYCLE; NEVI; TRANSFORMATION	Malignant melanomas often harbor activating mutations in BRAF (V600E) or, less frequently, in NRAS (Q61R). Intriguingly, the same mutations have been detected at higher incidences in benign nevi, which are largely composed of senescent melanocytes. Overexpression of BRAF(V600E) or NRAS(Q61R) in human melanocytes in vitro has been shown to induce senescence, although via different mechanisms. How oncogene-induced senescence is overcome during melanoma progression remains unclear. Here, we report that in the majority of analysed BRAF(V600E)- or NRAS(Q61R)-expressing melanoma cells, C-MYC depletion induced different yet overlapping sets of senescence phenotypes that are characteristic of normal melanocytes undergoing senescence due to overexpression of BRAF(V600E) or NRAS(Q61R), respectively. These senescence phenotypes were p16(INK4A)- or p53-independent, however, several of them were suppressed by genetic or pharmacological inhibition of BRAF(V600E) or phosphoinositide 3-kinase pathways, including rapamycin-mediated inhibition of mTOR-raptor in NRAS(Q61R)-expressing melanoma cells. Reciprocally, overexpression of C-MYC in normal melanocytes suppressed BRAF(V600E)-induced senescence more efficiently than NRAS(Q61R)-induced senescence, which agrees with the generally higher rates of activating mutations in BRAF than NRAS gene in human cutaneous melanomas. Our data suggest that one of the major functions of C-MYC overexpression in melanoma progression is to continuous suppress BRAF(V600E)- or NRAS(Q61R)-dependent senescence programs.	[Zhuang, D.; Mannava, S.; Grachtchouk, V.; Wawrzyniak, J. A.; Nikiforov, M. A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Zhuang, D.; Mannava, S.; Grachtchouk, V.; Tang, W-H; Patil, S.; Soengas, M. S.; Nikiforov, M. A.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Zhuang, D.; Mannava, S.; Grachtchouk, V.; Tang, W-H; Patil, S.; Giordano, T. J.; Soengas, M. S.; Nikiforov, M. A.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Berman, A. E.] RAMS, Inst Biomed Chem, Moscow, Russia; [Giordano, T. J.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Prochownik, E. V.] Childrens Hosp Pittsburgh, Rangos Res Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA	Roswell Park Cancer Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, Elm & Carlton St,L3-317, Buffalo, NY 14263 USA.	mikhail.nikiforov@roswellpark.org	EBerman, Albert/F-5042-2017; Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Giordano, Thomas/0000-0003-0641-8873	NIH [R01 CA120244, CA107237]; University of Michigan's Cancer Center [NIH 5 P30 CA46592]; Melanoma Research Foundation Scholar; NATIONAL CANCER INSTITUTE [R01CA120244, R01CA107237, P30CA046592] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan's Cancer Center(University of Michigan System); Melanoma Research Foundation Scholar; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Michelle Vinco for assistance with the human tissue work. This work was supported by Grants NIH R01 CA120244 (MAN), CA107237 (MSS), and, in part, by the University of Michigan's Cancer Center Support Grant (NIH 5 P30 CA46592). MAN is a Melanoma Research Foundation Scholar.	Arvanitis C, 2006, SEMIN CANCER BIOL, V16, P313, DOI 10.1016/j.semcancer.2006.07.012; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Biroccio A, 2003, J BIOL CHEM, V278, P35693, DOI 10.1074/jbc.M304597200; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goding C R, 2000, Forum (Genova), V10, P176; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Greulich KM, 2000, CANCER, V89, P97, DOI 10.1002/1097-0142(20000701)89:1<97::AID-CNCR14>3.0.CO;2-0; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Haluska F, 2007, SEMIN ONCOL, V34, P546, DOI 10.1053/j.seminoncol.2007.09.011; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Kastan MB, 2007, CELL, V128, P837, DOI 10.1016/j.cell.2007.02.022; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Meier F, 2005, FRONT BIOSCI-LANDMRK, V10, P2986, DOI 10.2741/1755; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Ross DA, 1998, BRIT J SURG, V85, P46; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Takaoka M, 2004, ONCOGENE, V23, P6760, DOI 10.1038/sj.onc.1207923; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64	50	151	158	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6623	6634		10.1038/onc.2008.258	http://dx.doi.org/10.1038/onc.2008.258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18679422	Green Accepted			2022-12-17	WOS:000260638800001
J	Averous, J; Proud, CG				Averous, J.; Proud, C. G.			When translation meets transformation: the mTOR story	ONCOGENE			English	Review						apoptosis; mRNA translation; protein kinase; initiation; elongation; rapamycin	INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASE; CAP-BINDING PROTEIN; MESSENGER-RNA TRANSPORT; AMINO-ACIDS; S6 KINASE; CYCLIN D1; ELONGATION-FACTOR-2 KINASE; MAMMALIAN TARGET; FACTOR EIF4E	There is currently a high level of interest in signalling through the mammalian target of rapamycin ( mTOR). This reflects both its key role in many cell functions and its involvement in disease states such as cancers. The best understood targets for mTOR signalling are proteins involved in controlling the translational machinery, including the ribosomal protein S6 kinases and proteins that regulate the initiation and elongation phases of translation. Indeed, there is compelling evidence that at least one of these targets of mTOR ( eukaryotic initiation factor eIF4E) plays a key role in tumorigenesis. It is regulated through the mTOR-dependent phosphorylation of inhibitory proteins such as eIF4E-binding protein 1. Thus, targeting mTOR signalling may be an effective anticancer strategy, in at least a significant subset of tumours. Not all effects of mTOR are sensitive to the classical anti-mTOR drug rapamycin, and this compound also interferes with other processes besides eIF4E function. Developing new approaches to targeting mTOR for cancer therapy requires more detailed knowledge of signalling downstream of mTOR. Such advances are likely to come from further work to understand the regulation of mTOR targets such as components of the translational apparatus.	Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; INRA, Unite Nutr Humaine, St Genes Champanelle, France	University of British Columbia; INRAE	Proud, CG (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	cgpr@interchange.ubc.ca		Proud, Christopher/0000-0003-0704-6442				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Ali SM, 2005, J BIOL CHEM, V280, P19445, DOI 10.1074/jbc.C500125200; Arora S, 2003, CANCER RES, V63, P6894; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BAGAGLIO DM, 1994, CELL GROWTH DIFFER, V5, P1403; BAGAGLIO DM, 1993, CANCER RES, V53, P2260; Barlund M, 2000, CANCER RES, V60, P5340; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Bradley CA, 2002, J BIOL CHEM, V277, P12559, DOI 10.1074/jbc.M111134200; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Byrd MP, 2005, J BIOL CHEM, V280, P18610, DOI 10.1074/jbc.M414014200; Calastretti A, 2001, EUR J CANCER, V37, P2121, DOI 10.1016/S0959-8049(01)00256-8; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CHENG EHC, 1995, CELL GROWTH DIFFER, V6, P615; Choo AY, 2006, CANCER CELL, V9, P77, DOI 10.1016/j.ccr.2006.01.021; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; DSARBASSOV D, 2006, MOL CELL, V22, P159; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Fang P, 2006, EXP CELL RES, V312, P1229, DOI 10.1016/j.yexcr.2005.12.011; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Ferguson G, 2003, J BIOL CHEM, V278, P47459, DOI 10.1074/jbc.M307949200; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; GRESSNER AM, 1974, BIOCHEM BIOPH RES CO, V60, P1482, DOI 10.1016/0006-291X(74)90365-9; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Hui AS, 2006, FASEB J, V20, P466, DOI 10.1096/fj.05-5086com; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kentsis A, 2001, J MOL BIOL, V312, P609, DOI 10.1006/jmbi.2001.5003; Kimball SR, 2006, J NUTR, V136, p227S, DOI 10.1093/jn/136.1.227S; Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491; Kleijn M, 2002, FEBS LETT, V532, P319, DOI 10.1016/S0014-5793(02)03694-3; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Loghlen A, 2004, EXP CELL RES, V299, P343, DOI 10.1016/j.yexcr.2004.06.006; Parmer TG, 1999, BRIT J CANCER, V79, P59, DOI 10.1038/sj.bjc.6690012; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; Parra JL, 2005, J BIOL CHEM, V280, P37623, DOI 10.1074/jbc.M508356200; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Shuda M, 2000, ANTICANCER RES, V20, P2489; Slepenkov SV, 2006, J BIOL CHEM, V281, P14927, DOI 10.1074/jbc.M601653200; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Surace EI, 2004, ANN NEUROL, V56, P295, DOI 10.1002/ana.20201; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tomoo K, 2005, BBA-PROTEINS PROTEOM, V1753, P191, DOI 10.1016/j.bbapap.2005.07.023; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Tuhackova Z, 1999, INT J CANCER, V81, P963, DOI 10.1002/(SICI)1097-0215(19990611)81:6<963::AID-IJC20>3.0.CO;2-C; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhou HY, 2006, ENDOCRINOLOGY, V147, P2557, DOI 10.1210/en.2005-1404; Zuberek J, 2004, BIOCHEMISTRY-US, V43, P5370, DOI 10.1021/bi030266t; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403	134	151	160	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6423	6435		10.1038/sj.onc.1209887	http://dx.doi.org/10.1038/sj.onc.1209887			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041627				2022-12-17	WOS:000241380700008
J	Ahmed, M; Rahman, N				Ahmed, M.; Rahman, N.			ATM and breast cancer susceptibility	ONCOGENE			English	Review						ATM; breast cancer susceptibility; ataxia-telangiectasia; breast cancer genes	ATAXIA-TELANGIECTASIA GENE; DNA-DAMAGE; EARLY-ONSET; MISSENSE MUTATIONS; FUNCTIONAL CONSEQUENCES; FAMILIAL BREAST; RISK; VARIANTS; HETEROZYGOTES; FREQUENCY	ATM was originally identified by positional cloning as the gene that underlies the autosomal recessive condition ataxia-telangiectasia. The encoded protein plays a central role in the complex processes that repair DNA double-strand breaks. Nearly 20 years ago, epidemiological surveys of relatives of ataxia-telangiectasia cases suggested that female relatives were at modestly increased risk of breast cancer. Subsequently, many studies have tried to clarify the role of ATM in breast cancer susceptibility, but have produced inconclusive and/or inconsistent results. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK	Rahman, N (corresponding author), Inst Canc Res, Sect Canc Genet, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	nazneen.rahman@icr.ac.uk	Rahman, Nazneen/B-8890-2012; Rahman, Nazneen/D-2802-2013	Rahman, Nazneen/0000-0003-4376-0440				Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Allinen M, 2002, J MED GENET, V39, P192, DOI 10.1136/jmg.39.3.192; Angele S, 2003, CANCER RES, V63, P8717; Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bay JO, 1998, INT J ONCOL, V12, P1385; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Bretsky P, 2003, CANCER EPIDEM BIOMAR, V12, P733; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; Buchholz TA, 2004, CANCER, V100, P1345, DOI 10.1002/cncr.20133; Chen JD, 1998, CANCER RES, V58, P1376; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Domchek SM, 2006, ONCOGENE, V25, P5825, DOI 10.1038/sj.onc.1209881; Dork T, 2001, CANCER RES, V61, P7608; Drumea KC, 2000, BREAST CANCER RES TR, V61, P79, DOI 10.1023/A:1006463730337; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Geoffroy-Perez B, 2001, INT J CANCER, V93, P288, DOI 10.1002/ijc.1329; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Gutierrez-Enriquez S, 2004, GENE CHROMOSOME CANC, V40, P109, DOI 10.1002/gcc.20025; Iannuzzi CM, 2002, INT J RADIAT ONCOL, V52, P606, DOI 10.1016/S0360-3016(01)02684-0; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; JEGGO PA, 2006, IN PRESS DNA REPAIR; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Laake K, 2000, BRIT J CANCER, V83, P1650, DOI 10.1054/bjoc.2000.1519; Lavin MF, 2004, DNA REPAIR, V3, P1197, DOI 10.1016/j.dnarep.2004.03.011; Lee KM, 2005, CANCER EPIDEM BIOMAR, V14, P821, DOI 10.1158/1055-9965.EPI-04-0330; Lindeman GJ, 2004, BREAST CANCER RES, V6, pR401, DOI 10.1186/bcr806; Maillet P, 2002, J MED GENET, V39, P751, DOI 10.1136/jmg.39.10.751; Meyer A, 2004, RADIOTHER ONCOL, V72, P319, DOI 10.1016/j.radonc.2004.07.010; MORRELL D, 1986, J NATL CANCER I, V77, P89; Neubauer S, 2002, RADIAT RES, V157, P312, DOI 10.1667/0033-7587(2002)157[0312:ROATAN]2.0.CO;2; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Offit K, 2002, CLIN CANCER RES, V8, P3813; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; OLSON JH, 2005, BRIT J CANCER, V93, P260; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; RENWICK A, 2006, IN PRESS NAT GENET; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman TD, 2000, GENE CHROMOSOME CANC, V27, P124, DOI 10.1002/(SICI)1098-2264(200002)27:2<124::AID-GCC2>3.0.CO;2-M; Shayeghl M, 1998, BRIT J CANCER, V78, P922, DOI 10.1038/bjc.1998.602; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Sommer SS, 2003, CANCER GENET CYTOGEN, V145, P115, DOI 10.1016/S0165-4608(03)00119-5; Sommer SS, 2002, CANCER GENET CYTOGEN, V134, P25, DOI 10.1016/S0165-4608(01)00594-5; Speit G, 2000, CYTOGENET CELL GENET, V91, P261, DOI 10.1159/000056855; Spurdle AB, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr534; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stewart GS, 2001, J BIOL CHEM, V276, P30133, DOI 10.1074/jbc.M103160200; SWIFT M, 1976, CANCER RES, V36, P209; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Szabo CI, 2004, CANCER RES, V64, P840, DOI 10.1158/0008-5472.CAN-03-2678; Tamimi RM, 2004, BREAST CANCER RES, V6, pR416, DOI 10.1186/bcr809; Taylor AMR, 2005, J CLIN PATHOL, V58, P1009, DOI 10.1136/jcp.2005.026062; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Thompson Deborah, 2005, Hum Mutat, V25, P594, DOI 10.1002/humu.9344; Thorstenson YR, 2003, CANCER RES, V63, P3325; Vorechovsky I, 1996, CANCER RES, V56, P4130	66	151	154	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5906	5911		10.1038/sj.onc.1209873	http://dx.doi.org/10.1038/sj.onc.1209873			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998505				2022-12-17	WOS:000240765900011
J	Nowis, D; Legat, M; Grzela, T; Niderla, J; Wilczek, E; Wilczynski, GM; Glodkowska, E; Mrowka, P; Issat, T; Dulak, J; Jozkowicz, A; Was, H; Adamek, M; Wrzosek, A; Nazarewski, S; Makowski, M; Stoklosa, T; Jakobisiak, M; Golab, J				Nowis, D.; Legat, M.; Grzela, T.; Niderla, J.; Wilczek, E.; Wilczynski, G. M.; Glodkowska, E.; Mrowka, P.; Issat, T.; Dulak, J.; Jozkowicz, A.; Was, H.; Adamek, M.; Wrzosek, A.; Nazarewski, S.; Makowski, M.; Stoklosa, T.; Jakobisiak, M.; Golab, J.			Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity	ONCOGENE			English	Article						photodynamic therapy; Photofrin; heme oxygenase; cancer	MANGANESE SUPEROXIDE-DISMUTASE; UP-REGULATION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; GENE-EXPRESSION; CARBON-MONOXIDE; SINGLET OXYGEN; NITRIC-OXIDE; CANCER CELLS; APOPTOSIS	Photodynamic therapy is a promising antitumor treatment modality approved for the management of both early and advanced tumors. The mechanisms of its antitumor action include generation of singlet oxygen and reactive oxygen species that directly damage tumor cells and tumor vasculature. A number of mechanisms seem to be involved in the protective responses to PDT that include activation of transcription factors, heat shock proteins, antioxidant enzymes and antiapoptotic pathways. Elucidation of these mechanisms might result in the design of more effective combination strategies to improve the antitumor efficacy of PDT. Using DNA microarray analysis to identify stress-related genes induced by Photofrin-mediated PDT in colon adenocarcinoma C-26 cells, we observed a marked induction of heme oxygenase-1 (HO-1). Induction of HO-1 with hemin or stable transfection of C-26 with a plasmid vector encoding HO-1 increased resistance of tumor cells to PDT-mediated cytotoxicity. On the other hand, zinc (II) protoporphyrin IX, an HO-1 inhibitor, markedly augmented PDT-mediated cytotoxicity towards C-26 and human ovarian carcinoma MDAH2774 cells. Neither bilirubin, biliverdin nor carbon monoxide, direct products of HO-1 catalysed heme degradation, was responsible for cytoprotection. Importantly, desferrioxamine, a potent iron chelator significantly potentiated cytotoxic effects of PDT. Altogether our results indicate that HO-1 is involved in an important protective mechanism against PDT-mediated phototoxicity and administration of HO-1 inhibitors might be an effective way to potentiate antitumor effectiveness of PDT.	Warsaw Univ, Ctr Biostruct Res, Dept Immunol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Histol & Embryol, PL-02097 Warsaw, Poland; Warsaw Univ, Ctr Biostruct Res, Dept Pathol, PL-02097 Warsaw, Poland; Warsaw Univ, Dept Gen & Vasc Surg & Transplantat, PL-02097 Warsaw, Poland; Jagiellonian Univ, Fac Biotechnol, Dept Med Biotechnol, Krakow, Poland; Silesian Univ, Ctr Laser Diagnost & Therapy, Chair & Clin Internal Dis & Phys Med, Bytom, Poland; M Nencki Inst Expt Biol, Dept Muscle Biochem, PL-02093 Warsaw, Poland	University of Warsaw; University of Warsaw; University of Warsaw; University of Warsaw; Jagiellonian University; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Golab, J (corresponding author), Warsaw Univ, Ctr Biostruct Res, Dept Immunol, 1A Banacha Str,F Bldg, PL-02097 Warsaw, Poland.	jgolab@ib.amwaw.edu.pl	Glodkowska-Mrowka, Eliza/AAC-7294-2020; Wolinska, Ewa/AAE-4628-2021; Nazarewski, Sławomir D./T-3998-2018; Glodkowska-Mrowka, Eliza/AAR-8503-2021; Issat, Tadeusz/AAE-4176-2019; Nowis, Dominika/P-1213-2017; Nowis, Dominika/P-6866-2019; Wrzosek, Antoni/AAE-8070-2021; Golab, Jakub/K-6974-2013	Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Nazarewski, Sławomir D./0000-0003-1195-9252; Glodkowska-Mrowka, Eliza/0000-0002-5865-8425; Issat, Tadeusz/0000-0002-3647-3550; Nowis, Dominika/0000-0003-2748-9523; Nowis, Dominika/0000-0003-2748-9523; Golab, Jakub/0000-0002-2830-5100; Wrzosek, Antoni/0000-0001-6376-8816; Stoklosa, Tomasz/0000-0001-6918-5056; Wolinska, Ewa/0000-0001-9592-1301; Wilczynski, Grzegorz/0000-0001-6667-0291; Was, Halina/0000-0003-2743-0337				Abels C, 2004, PHOTOCH PHOTOBIO SCI, V3, P765, DOI 10.1039/b314241h; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; BACHOWSKI GJ, 1994, LIPIDS, V29, P449, DOI 10.1007/BF02578241; BALLA G, 1992, J BIOL CHEM, V267, P18148; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; BRESSOUD D, 1992, J PHOTOCH PHOTOBIO B, V14, P311, DOI 10.1016/1011-1344(92)85110-G; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Cisowski J, 2005, BIOCHEM BIOPH RES CO, V326, P670, DOI 10.1016/j.bbrc.2004.11.083; Deshane J, 2005, ACTA BIOCHIM POL, V52, P273; Dolgachev V, 2005, BIOCHEM BIOPH RES CO, V332, P411, DOI 10.1016/j.bbrc.2005.04.141; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dulak J, 2002, ANTIOXID REDOX SIGN, V4, P229, DOI 10.1089/152308602753666280; Dulak J, 2003, ACTA BIOCHIM POL, V50, P31; Fang J, 2004, INT J CANCER, V109, P1, DOI 10.1002/ijc.11644; Ferrario A, 2000, CANCER RES, V60, P4066; Ferrario A, 2002, CANCER RES, V62, P3956; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Golab J, 2000, BRIT J CANCER, V82, P1485; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Golab J, 2002, CLIN CANCER RES, V8, P1265; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x; Granville DJ, 2000, BLOOD, V95, P256; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Grune T, 2001, FREE RADICAL BIO MED, V30, P1243, DOI 10.1016/S0891-5849(01)00515-9; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Jalili A, 2004, CLIN CANCER RES, V10, P4498, DOI 10.1158/1078-0432.CCR-04-0367; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Kliukiene R, 1997, BIOCHEM MOL BIOL INT, V41, P707; Koukourakis MI, 2001, CANCER RES, V61, P1830; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lin FB, 1996, CANCER RES, V56, P4636; LUNA MC, 1994, CANCER RES, V54, P1374; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Mcbride G, 2002, J NATL CANCER I, V94, P1740; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613; Nowis D, 2005, ACTA BIOCHIM POL, V52, P339; Oberdanner CB, 2005, PHOTOCHEM PHOTOBIOL, V81, P609, DOI 10.1562/2004-08-23-RN-284.1; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Rasch MH, 1997, PHOTOCHEM PHOTOBIOL, V66, P209, DOI 10.1111/j.1751-1097.1997.tb08645.x; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Sahoo SK, 2002, BIOCONJUGATE CHEM, V13, P1031, DOI 10.1021/bc020010k; Sharman WM, 2000, METHOD ENZYMOL, V319, P376; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Shiraishi F, 2001, ANAL BIOCHEM, V289, P303, DOI 10.1006/abio.2000.4965; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Tanaka S, 2003, BRIT J CANCER, V88, P902, DOI 10.1038/sj.bjc.6600830; Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005; Verwanger T, 2002, INT J ONCOL, V21, P1353; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Woods JA, 2004, PHOTOCHEM PHOTOBIOL, V79, P105, DOI 10.1111/j.1751-1097.2004.tb09864.x; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zhuang SG, 2003, PHOTOCHEM PHOTOBIOL, V78, P361, DOI 10.1562/0031-8655(2003)078<0361:SOAOPK>2.0.CO;2	61	151	154	2	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3365	3374		10.1038/sj.onc.1209378	http://dx.doi.org/10.1038/sj.onc.1209378			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16462769	Green Accepted			2022-12-17	WOS:000238448100002
J	Astrinidis, A; Henske, EP				Astrinidis, A; Henske, EP			Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease	ONCOGENE			English	Article						tuberous sclerosis complex; lymphangiomyomatosis; mammalian target of Rapamycin; Rheb; AKT/ PKB	TUMOR-SUPPRESSOR GENE; S6 KINASE ACTIVATION; TSC2 GAP ACTIVITY; B-RAF KINASE; CELL-GROWTH; MAMMALIAN TARGET; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; MUTATIONAL ANALYSIS; RENAL ANGIOMYOLIPOMAS; 3-KINASE/AKT PATHWAY	The most exciting advances in the tuberous sclerosis complex (TSC) field occurred in 1993 and 1997 with the cloning of the TSC2 and TSC1 genes, respectively, and in 2003 with the identification of Rheb as the target of tuberin's ( TSC2) GTPase activating protein ( GAP) domain. Rheb has a dual role: it activates mTOR and inactivates B-Raf. Activation of mTOR leads to increased protein synthesis through phosphorylation of p70S6K and 4E-BP1. Upon insulin or growth factor stimulation, tuberin is phosphorylated by several kinases, including AKT/PKB, thereby suppressing its GAP activity and activating mTOR. Phosphorylation of hamartin (TSC1) by CDK1 also negatively regulates the activity of the hamartin/tuberin complex. Despite these biochemical advances, exactly how mutations in TSC1 or TSC2 lead to the clinical manifestations of TSC is far from being understood. Two of the most unusual phenotypes in TSC are the apparent metastasis of benign cells carrying TSC1 and TSC2 mutations, resulting in pulmonary lymphangio-myomatosis, and the ability of cells with TSC1 or TSC2 mutations to differentiate into the separate components of renal angiomyolipomas (vessels, smooth muscle and fat). We will discuss how the TSC signaling pathways are affected by mutations in TSC1 or TSC2, focusing on how these mutations may lead to the renal and pulmonary manifestations of TSC.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Henske, EP (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Elizabeth.Henske@fccc.edu	Astreinidis, Aristotelis/ABA-6715-2021; Astrinidis, Aristotelis/A-1396-2010; Astreinidis, Aristotelis/AAK-5137-2020	Astrinidis, Aristotelis/0000-0001-7098-1391				Astrinidis A, 2003, J BIOL CHEM, V278, P51372, DOI 10.1074/jbc.M303956200; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; El-Hashemite N, 2003, CANCER RES, V63, P5173; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Finlay GA, 2004, J BIOL CHEM, V279, P23114, DOI 10.1074/jbc.M401912200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova E, 2004, J CELL BIOL, V167, P1171, DOI 10.1083/jcb.200405130; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Govindarajan B, 2003, CLIN CANCER RES, V9, P3469; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Haddad LA, 2002, J BIOL CHEM, V277, P44180, DOI 10.1074/jbc.M207211200; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Han S, 2004, CANCER RES, V64, P812, DOI 10.1158/0008-5472.CAN-03-3277; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Henske EP, 1996, AM J HUM GENET, V59, P400; Henske EP, 2004, CURR MOL MED, V4, P825, DOI 10.2174/1566524043359610; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HOWE SR, 1995, ENDOCRINOLOGY, V136, P4996, DOI 10.1210/en.136.11.4996; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Karbowniczek M, 2003, AM J RESP CRIT CARE, V167, P976, DOI 10.1164/rccm.200208-969OC; Karbowniczek M, 2003, AM J PATHOL, V162, P491, DOI 10.1016/S0002-9440(10)63843-6; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kenerson HL, 2002, CANCER RES, V62, P5645; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kinoshita Masaharu, 1995, Kurume Medical Journal, V42, P141; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kwiatkowska J, 1998, ANN HUM GENET, V62, P277, DOI 10.1046/j.1469-1809.1998.6240277.x; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Liu MY, 2003, CANCER RES, V63, P2675; Logginidou H, 2000, CHEST, V117, P25, DOI 10.1378/chest.117.1.25; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Mak BC, 2005, AM J PATHOL, V167, P107, DOI 10.1016/S0002-9440(10)62958-6; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nellist M, 2005, BIOCHEM BIOPH RES CO, V333, P818, DOI 10.1016/j.bbrc.2005.05.175; Nellist M, 2005, EUR J HUM GENET, V13, P59, DOI 10.1038/sj.ejhg.5201276; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Noonan DJ, 2002, ARCH BIOCHEM BIOPHYS, V398, P132, DOI 10.1006/abbi.2001.2682; Plank TL, 1999, MODERN PATHOL, V12, P539; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Ramesh V, 2003, BIOCHEM SOC T, V31, P579, DOI 10.1042/bst0310579; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sancak O, 2005, EUR J HUM GENET, V13, P731, DOI 10.1038/sj.ejhg.5201402; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sato T, 2002, J HUM GENET, V47, P20, DOI 10.1007/s10038-002-8651-8; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; van Slegtenhorst M, 1999, J MED GENET, V36, P285; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wienecke R, 1996, ONCOGENE, V13, P913; York B, 2005, FASEB J, V19, P1202, DOI 10.1096/fj.04-3142fje; Yu J, 2004, AM J PHYSIOL-LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	86	151	157	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7475	7481		10.1038/sj.onc.1209090	http://dx.doi.org/10.1038/sj.onc.1209090			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288294	Bronze			2022-12-17	WOS:000233201900010
J	McManus, DC; Lefebvre, CA; Cherton-Horvat, G; St-Jean, M; Kandimalla, ER; Agrawal, S; Morris, SJ; Durkin, JP; LaCasse, EC				McManus, DC; Lefebvre, CA; Cherton-Horvat, G; St-Jean, M; Kandimalla, ER; Agrawal, S; Morris, SJ; Durkin, JP; LaCasse, EC			Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics	ONCOGENE			English	Article						XIAP; RNAi; antisense; apoptosis; IAPs	X-LINKED INHIBITOR; LIGAND-INDUCED APOPTOSIS; STRUCTURAL BASIS; SERINE-PROTEASE; DOWN-REGULATION; CYTOCHROME-C; IN-VITRO; CASPASE INHIBITION; GENE-TRANSFER; BCL-2 GENE	Stable expression of short-hairpin RNAs (shRNAs) directed against the X-linked inhibitor of apoptosis (XIAP) resulted in the generation of three MDA-MB-231 cell lines (XIAP shRNA cells) with reductions in XIAP mRNA and protein levels >85% relative to MDA-MB-231 cells stably transfected with the U6 RNA polymerase III promoter alone (U6 cells). This RNA interference (RNAi) approach dramatically sensitized these cells to killing by the (t) under bar umor necrosis factor-(r) under bar elated (a) under bar poptosis-(i) under bar nducing (l) under bar igand (TRAIL). Importantly, loss of XIAP also sensitized the cells to killing by taxanes but had no additional effects on killing by carboplatin and doxorubicin. The increased sensitivity of the XIAP shRNA cells to killing by TRAIL and taxanes correlated with enhanced caspase cleavage and activation, including caspase-8, and robust processing of poly(ADP-ribose) polymerase and BID compared to U6 cells. Additionally, increasing XIAP levels by adenovirus-mediated expression protected both XIAP shRNA and U6 cells from TRAIL killing in a dose-dependent manner. The effects observed by stable RNAi with respect to TRAIL sensitization were also achieved following downregulation of XIAP in Panc-1 cells treated with a second-generation, mixed-backbone antisense oligonucleotide, AEG 35156/GEM640. These data indicate that reducing XIAP protein expression by either RNAi or antisense approaches increases cancer cell susceptibility to functionally diverse chemotherapeutic agents and supports the notion that downregulation of XIAP in vivo may synergize with disease-relevant chemotherapeutic regimes, including TRAIL and taxanes, to increase the effectiveness of antineoplastic agents.	Univ Ottawa, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; Hybridon Inc, Cambridge, MA 02139 USA; Aegera Therapeut Inc, Verdun, PQ H3E 1A8, Canada	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	LaCasse, EC (corresponding author), Univ Ottawa, Aegera Oncol Inc, Rm 306,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	eric.lacasse@aegera.com		Agrawal, Sudhir/0000-0003-4275-2510				Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Carter BZ, 2003, BLOOD, V102, P4179, DOI 10.1182/blood-2003-03-0960; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; CHAWLASARKAR M, 2004, CELL DEATH DIFFER, V30, P1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cummings BS, 2004, J PHARMACOL EXP THER, V310, P126, DOI 10.1124/jpet.104.065862; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Giodini A, 2002, CANCER RES, V62, P2462; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(02)02075-5; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1997, APOPTOSIS, V2, P423, DOI 10.1023/A:1026465926478; Lo YMD, 1999, CANCER RES, V59, P3899; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sasaki H, 2000, CANCER RES, V60, P5659; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi J, 2003, CURR MOL MED, V3, P727, DOI 10.2174/1566524033479401; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tillman DM, 2003, CANCER RES, V63, P5118; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vilenchik M, 2002, CANCER RES, V62, P2175; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang L, 2003, CANCER RES, V63, P6815; Zhang XD, 2001, CANCER RES, V61, P7339	58	151	162	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8105	8117		10.1038/sj.onc.1207967	http://dx.doi.org/10.1038/sj.onc.1207967			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378029				2022-12-17	WOS:000224692500008
J	Kluza, J; Marchetti, P; Gallego, MA; Lancel, S; Fournier, C; Loyens, A; Beauvillain, JC; Bailly, C				Kluza, J; Marchetti, P; Gallego, MA; Lancel, S; Fournier, C; Loyens, A; Beauvillain, JC; Bailly, C			Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells	ONCOGENE			English	Article						doxorubicin; mitoxantrone; apoptosis; mitochondrial proliferation; cardiotoxicity	ADENOCARCINOMA MTLN3 CELLS; RAT MAMMARY ADENOCARCINOMA; CARDIOMYOCYTE APOPTOSIS; DIFFERENTIAL REGULATION; OXIDATIVE STRESS; DYSFUNCTION; DNA; ANTHRACYCLINES; CARDIOTOXICITY; INCREASE	Doxorubicin is one of the most largely prescribed antitumor drug for the treatment of breast, liver and colon cancers as well as leukemia, but the cardiotoxicity of this anthracycline derivative limits its clinical use. Although doxorubicin is toxic to both cancer and cardiac cells, there are evidences suggesting that the mechanism of cell death is different for the two cell types. To investigate further this issue, we have compared the proapoptotic effects of doxorubicin and the functionally related anthracenedione compound mitoxantrone, which is also used in the clinic for the treatment of cancer. After evaluating the toxicity of the two drugs to mammary adenocarcinoma MTLn3 cells and H9C2 cardiomyocytes, we dissected the drug-induced apoptotic machinery by measuring the effects on the cell cycle progression, DNA condensation and fragmentation, production of endogenous peroxides and caspase activation. Both doxorubicin and mitoxantrone are potent inducers of apoptosis in H9C2 cardiomyocytes and MTLn3 breast cancer cells, but there are significant differences between the two cell types in terms of kinetics and order of the events. In particular, flow cytometry measurements of drug-induced changes in mitochondrial transmembrane potential and mitochondrial mass with different fluorescent probes suggested that the two drugs induced a progressive increase in mitochondrial mass in the cancer cells but not in the cardiac cells. The hypothesis was validated by means of electron microscopy, which revealed a significant increase in the number of mitochondria in drug-treated MTLn3 but not in H9C2 cells. The mitochondrial proliferation precedes the nuclear apoptosis in doxorubicin-treated MTLn3 cells. The changes in the architecture and number of mitochondria are linked to the drug-induced perturbation of the cell cycle progression and apoptosis. The proliferation of mitochondria could explain the higher toxicity of doxorubicin to cancer cells compared to cardiac cells and this suggests novel therapeutic opportunities to better control the cardiotoxicity of anthracyclines.	IRCL, INSERM, U524, F-59045 Lille, France; IRCL, Ctr Oscar Lambret, Lab Pharmacol Antitumorale, F-59045 Lille, France; Fac Med Lille, INSERM, U459, F-59045 Lille, France; Fac Med Lille, EA2689, F-59045 Lille, France; Ctr Oscar Lambret, Dept Biostat, F-59020 Lille, France; Univ Lille 2, INSERM, U422, F-59045 Lille, France; Univ Lille 2, Serv Imagerie, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Oscar Lambret; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; UNICANCER; Centre Oscar Lambret; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Bailly, C (corresponding author), IRCL, INSERM, U524, Pl Verdun, F-59045 Lille, France.	bailly@lille.inserm.fr	, Lancel/H-9047-2019; BAILLY, Christian/AAK-2799-2021; Lancel, Steve/C-4387-2012; Kluza, Jérome/B-6312-2012	, Lancel/0000-0002-3292-5433; BAILLY, Christian/0000-0002-2973-9357; Kluza, Jérome/0000-0002-7346-1305; MARCHETTI, Philippe/0000-0002-4663-6800				ALDERTON PM, 1992, CANCER RES, V52, P194; Arola OJ, 2000, CANCER RES, V60, P1789; Bellarosa D, 2001, J PHARMACOL EXP THER, V296, P276; Bonavita F, 2003, FEBS LETT, V536, P85, DOI 10.1016/S0014-5793(03)00029-2; Bossy-Wetzel E, 2003, CELL DEATH DIFFER, V10, P757, DOI 10.1038/sj.cdd.4401244; Camilleri-Broet S, 1998, EXP CELL RES, V239, P277, DOI 10.1006/excr.1997.3899; Childs AC, 2002, CANCER RES, V62, P4592; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eliseev RA, 2003, EXP CELL RES, V289, P275, DOI 10.1016/S0014-4827(03)00278-7; EVANS DP, 1986, CANCER CHEMOTH PHARM, V18, P137; Favory R, 2004, CRIT CARE MED, V32, P495, DOI 10.1097/01.CCM.0000109452.36271.FA; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Green PS, 2002, BBA-MOL BASIS DIS, V1588, P94, DOI 10.1016/S0925-4439(02)00144-8; Herman EH, 1997, J MOL CELL CARDIOL, V29, P2415, DOI 10.1006/jmcc.1997.0477; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Huigsloot M, 2001, BIOCHEM PHARMACOL, V62, P1087, DOI 10.1016/S0006-2952(01)00755-9; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karbowski M, 2001, J CELL SCI, V114, P281; Kluza J, 2002, BIOCHEM PHARMACOL, V63, P1443, DOI 10.1016/S0006-2952(02)00899-7; Kluza J, 2000, CANCER RES, V60, P4077; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1159/000064724; Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425; LeVea CM, 2000, BREAST CANCER RES TR, V64, P221, DOI 10.1023/A:1006410509740; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Marchetti P, 1999, CANCER RES, V59, P6257; Marchetti P, 1996, CANCER RES, V56, P2033; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Neuss M, 2001, J BIOL CHEM, V276, P33915, DOI 10.1074/jbc.M104080200; PAGLIACCI MC, 1993, EUR J CANCER, V29A, P1573, DOI 10.1016/0959-8049(93)90297-S; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Rebbaa A, 2001, CANCER CHEMOTH PHARM, V48, P423, DOI 10.1007/s002800100375; REIPERT S, 1995, EXP CELL RES, V221, P281, DOI 10.1006/excr.1995.1376; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Solary E, 2003, LEUKEMIA LYMPHOMA, V44, P563, DOI 10.1080/1042819021000038001; Solem LE, 1996, J MOL CELL CARDIOL, V28, P1023, DOI 10.1006/jmcc.1996.0095; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; Toyota N, 1998, INT J CANCER, V76, P499; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou SY, 2001, CANCER RES, V61, P771; Zucchi Riccardo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P151, DOI 10.2174/1568011033353434	49	151	157	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7018	7030		10.1038/sj.onc.1207936	http://dx.doi.org/10.1038/sj.onc.1207936			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273722				2022-12-17	WOS:000223885100003
J	Daniotti, M; Oggionni, M; Ranzani, T; Vallacchi, V; Carnpi, V; Di Stasi, D; Della Torre, G; Perrone, F; Luoni, C; Suardi, S; Frattini, M; Pilotti, S; Anichini, A; Tragni, G; Parmiani, G; Pierotti, MA; Rodolfo, M				Daniotti, M; Oggionni, M; Ranzani, T; Vallacchi, V; Carnpi, V; Di Stasi, D; Della Torre, G; Perrone, F; Luoni, C; Suardi, S; Frattini, M; Pilotti, S; Anichini, A; Tragni, G; Parmiani, G; Pierotti, MA; Rodolfo, M			BRAF alterations are associated with complex mutational profiles in malignant melanoma	ONCOGENE			English	Article						melanoma; BRAF; NRAS; PTEN; TP53; CDKN2A	N-RAS MUTATIONS; TUMOR-SUPPRESSOR GENE; CUTANEOUS MELANOMA; CELL LINES; P53 MUTATIONS; METASTATIC MELANOMA; HUMAN CANCER; PTEN; SUSCEPTIBILITY; PATHWAYS	To evaluate the mutational profiles associated with BRAF mutations in human melanoma, we have studied BRAF, RAS, PTEN, TP53, CDKN2A and CDK4 genes and their expression in melanoma lesions. Owing to the lack of sufficient material from fresh specimens, we employed short-term cell lines obtained from melanoma biopsies. In all, 41 melanoma obtained from eight primary lesions, 20 nodal, 11 cutaneous and two visceral metastases from patients with sporadic (n=31), familial (n=4) and multiple melanoma (n=2) were analysed. The results revealed novel missense mutations in the BRAF, PTEN, CDKN2A and CDK4 genes. Overall, activating mutations of BRAF and loss of functional p16 and ARF were detected in the majority of melanomas (29/41, 36/41 and 29/41, respectively), while PTEN alterations/loss, NRAS and TP53 mutations occurred less frequently (6/41, 6/41 and 10/41, respectively). In the resulting 12 mutational profiles, p16/ARF loss associated with mutated BRAF(V599E) was the most represented (n=15). In addition, TP53 and PTEN mutations were always accompanied with BRAF alterations, while PTEN loss was found in association with CDKN2A or TP53 mutations in the absence of BRAF activation. The p16/ARFDelta+BRAF/RAS profile was significantly associated with a longer survival, while complex mutational profiles were detected in highly aggressive disease and poor survival. These data support the existence of several molecularly defined melanoma groups which likely reflect different clinical/biological behaviour, thus suggesting that a more extensive molecular classification of melanoma would significantly impact its clinical management.	Ist Nazl Studio & Cura Tumori, Unit Melanoma Genet, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Mol Mech Tumour Growth & Progress, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Human Tumour Immunobiol, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Unit Immunotherapy Human Tumours, I-20133 Milan, Italy; FIRC Inst Mol Oncol, IFOM, I-20139 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Rodolfo, M (corresponding author), Ist Nazl Studio & Cura Tumori, Unit Melanoma Genet, Via Venezian 1, I-20133 Milan, Italy.	monica.rodolfo@istitutotumori.mi.it	Pierotti, Marco Alessandro/AAC-4728-2022; rodolfo, monica/H-2671-2012; Perrone, Federica/S-6171-2016; Anichini, Andrea/K-1434-2016; Vallacchi, Viviana/K-5709-2016	Pierotti, Marco Alessandro/0000-0002-7431-8332; rodolfo, monica/0000-0002-9196-0298; Perrone, Federica/0000-0003-4406-8245; Anichini, Andrea/0000-0001-5096-5538; Vallacchi, Viviana/0000-0002-2819-0630				ALBINO AP, 1989, ONCOGENE, V4, P1363; Bertram CG, 2002, J INVEST DERMATOL, V119, P961, DOI 10.1046/j.1523-1747.2002.01825.x; Brose MS, 2002, CANCER RES, V62, P6997; Cascinelli N, 2001, LANCET, V358, P866, DOI 10.1016/S0140-6736(01)06068-8; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Castellano M, 1997, CANCER RES, V57, P4868; Ceha HM, 1998, BIOCHEM BIOPH RES CO, V249, P550, DOI 10.1006/bbrc.1998.9183; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deichmann M, 2002, BRIT J CANCER, V87, P1431, DOI 10.1038/sj.bjc.6600653; Dong JL, 2003, CANCER RES, V63, P3883; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; Eskandarpour M, 2003, J NATL CANCER I, V95, P790, DOI 10.1093/jnci/95.11.790; Esteller M, 2000, CANCER RES, V60, P129; EYCHENE A, 1995, ONCOGENE, V10, P1159; Fargnoli MC, 1998, J INVEST DERMATOL, V111, P1202, DOI 10.1046/j.1523-1747.1998.00412.x; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Gorden A, 2003, CANCER RES, V63, P3955; Guldberg P, 1997, CANCER RES, V57, P3660; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; Hashemi J, 2002, CANCER LETT, V180, P211, DOI 10.1016/S0304-3835(02)00027-7; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Hayward NK, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P207; Hussein MR, 2003, EUR J CANCER PREV, V12, P93, DOI 10.1097/00008469-200304000-00002; Ku JL, 1999, LARYNGOSCOPE, V109, P976, DOI 10.1097/00005537-199906000-00025; Kumar R, 2003, ONCOGENE, V22, P9217, DOI 10.1038/sj.onc.1206909; Kumar R, 2003, CLIN CANCER RES, V9, P3362; LUPETTI R, 1994, MELANOMA RES, V4, P11, DOI 10.1097/00008390-199402000-00003; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ragnarsson-Olding BK, 2002, MELANOMA RES, V12, P453, DOI 10.1097/00008390-200209000-00007; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Satyamoorthy K, 2003, CANCER RES, V63, P756; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2000, CANCER RES, V60, P1800; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zerp SF, 1999, BRIT J CANCER, V79, P921, DOI 10.1038/sj.bjc.6690147; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	44	151	164	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5968	5977		10.1038/sj.onc.1207780	http://dx.doi.org/10.1038/sj.onc.1207780			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15195137				2022-12-17	WOS:000222941100011
J	Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE			CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells	ONCOGENE			English	Article						anoikis; pancreatic cancer; adenocarcinoma; CEACAM6; RNA interference; metastasis	CARCINOEMBRYONIC ANTIGEN FAMILY; INTEGRIN-LINKED KINASE; GPI-ANCHORED PROTEINS; COLON-CANCER CELLS; DUCTAL ADENOCARCINOMA; BILIARY GLYCOPROTEIN; MELANOMA-CELLS; TUMOR-GROWTH; CEA FAMILY; N-DOMAINS	Anoikis is the apoptotic response induced in normal cells by inadequate or inappropriate adhesion to substrate. It is postulated that resistance to anoikis facilitates tumorigenesis and metastasis. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is an immunoglobulin superfamily member overexpressed in a number of human cancers and implicated in anoikis resistance. We tested the effect of CEACAM6 gene silencing on anoikis in pancreatic adenocarcinoma cell lines. Anoikis was induced in PANC1, Capan2, MiaPaCa2 and Mia(AR) (a MiaPaCa2-derived anoikis-resistant subline) by culture in poly-2-hydroxyethylmethacrylate-coated wells. Anoikis was quantified by YO-PRO-1/propidium iodide staining and flow cytometry. The role of caspase activation was determined using fluorometric profiling and the caspase inhibitor Z-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk). CEACAM6 expression was suppressed by RNA interference. Using a nude mouse orthotopic xenograft model, we assessed the effect of this treatment on in vivo metastatic ability. Anoikis resistance was associated with increased CEACAM6 expression. CEACAM6-specific short interfering ribonucleic acid (siRNA), but not control siRNA, increased susceptibility to caspase-mediated anoikis, an effect abrogated by Z-VAD-fmk, and decreased Akt phosphorylation (Ser-473) under anchorage-independent conditions. CEACAM6 gene silencing reversed the acquired anoikis resistance of Mia(AR) and inhibited its in vivo metastatic ability. CEACAM6 warrants further investigation as a novel therapeutic target for the treatment of pancreatic adenocarcinoma.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Beauchemin N, 1999, EXP CELL RES, V252, P243; Bouvet M, 2002, CANCER RES, V62, P1534; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; COURNOYER D, 1988, CANCER RES, V48, P3153; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Farrell TJ, 1997, ANN SURG, V226, P66, DOI 10.1097/00000658-199707000-00009; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; GORELIK E, 1993, CLIN EXP METASTAS, V11, P439, DOI 10.1007/BF00054935; HASEGAWA T, 1993, BRIT J CANCER, V67, P58, DOI 10.1038/bjc.1993.9; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HRC, 1999, CANCER RES, V59, P4148; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Kunath T, 1995, ONCOGENE, V11, P2375; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; MAYNE KM, 1993, BRIT J HAEMATOL, V83, P30, DOI 10.1111/j.1365-2141.1993.tb04627.x; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; Ordonez C, 2000, CANCER RES, V60, P3419; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Qiao L, 1996, CANCER LETT, V107, P83, DOI 10.1016/0304-3835(96)04346-7; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAZ A, 1983, SCIENCE, V221, P1307, DOI 10.1126/science.6612347; ROBINSON P, 1994, BRAZ J MED BIOL RES, V27, P263; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; Semba S, 2003, PANCREAS, V26, P250, DOI 10.1097/00006676-200304000-00008; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Skubitz KM, 2001, J PEPT RES, V58, P515, DOI 10.1034/j.1399-3011.2001.00931.x; Soeth E, 2001, CLIN CANCER RES, V7, P2022; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; TAN MH, 1985, TUMOUR BIOL, V6, P89; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Wang WX, 2001, ANTICANCER RES, V21, P1789; Wirth T, 2002, CLIN EXP METASTAS, V19, P155, DOI 10.1023/A:1014566127493; Yao Z, 2002, PANCREAS, V24, P42, DOI 10.1097/00006676-200201000-00006; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zhu ZY, 2001, CANCER RES, V61, P1707	50	151	168	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					465	473		10.1038/sj.onc.1207036	http://dx.doi.org/10.1038/sj.onc.1207036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724575				2022-12-17	WOS:000188098300017
J	Bernardi, R; Pandolfi, PP				Bernardi, R; Pandolfi, PP			Role of PML and the PML-nuclear body in the control of programmed cell death	ONCOGENE			English	Article						apoptosis; PML-nuclear body; tumor suppression; transcription; transcription factors; cancer; APL	ACUTE PROMYELOCYTIC LEUKEMIA; INTERACTING PROTEIN KINASE-2; DNA-DAMAGE; TELOMERE MAINTENANCE; INDUCED APOPTOSIS; PREMATURE SENESCENCE; TRANSGENIC MICE; ONCOGENIC RAS; MRE11 COMPLEX; P53	PML is a tumor suppressor implicated in leukemia and cancer pathogenesis. PML epitomizes a multiprotein nuclear structure, the PML-nuclear body (PML-NB), whose proper formation and function depends on PML. Studies in knockout (KO) mic e and cells unraveled an essential pleiotropic role for PML in multiple p53-dependent and -independent apoptotic pathways. As a result, Pml(-/-) mice and cells are protected from apoptosis triggered by a number of stimuli such as ionizing radiation, interferon, ceramide, Fas and TNF. It is becoming apparent that PML and the PML-NB act as molecular hubs for the induction and/or reinforcement of programmed cell death through a selective and dynamic regulation of proapoptotic transcriptional events. In addition, recent observations propose a role for PML in checkpoint responses upon DNA damage. Moreover, PML and the PML-NB have also been implicated in the control of genomic stability and DNA repair. Here, we will discuss the molecular mechanisms by which PML regulates these processes and the implication of these findings for cancer pathogenesis and therapy.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Pathol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, 1275 York Ave, New York, NY 10021 USA.	p-pandol.@ski.mskcc.org	bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Changou AC, 2001, BLOOD, V98, p99A; Chehab NH, 2000, GENE DEV, V14, P278; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LAVAU C, 1995, ONCOGENE, V11, P871; Le S, 1999, GENETICS, V152, P143; LEBEAU MM, 2003, BLOOD           0410; Lendvay TS, 1996, GENETICS, V144, P1399; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lombard DB, 2000, CANCER RES, V60, P2331; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pandolfi PP, 2001, ONCOGENE, V20, P5726, DOI 10.1038/sj.onc.1204600; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Stadler M, 1995, ONCOGENE, V11, P2565; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wiesmeijer K, 2002, J STRUCT BIOL, V140, P180, DOI 10.1016/S1047-8477(02)00529-4; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, J BIOL CHEM, V277, P31734, DOI 10.1074/jbc.M201648200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yeager TR, 1999, CANCER RES, V59, P4175; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	69	151	160	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9048	9057		10.1038/sj.onc.1207106	http://dx.doi.org/10.1038/sj.onc.1207106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663483				2022-12-17	WOS:000187043600008
J	Landowski, TH; Olashaw, NE; Agrawal, D; Dalton, WS				Landowski, TH; Olashaw, NE; Agrawal, D; Dalton, WS			Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells	ONCOGENE			English	Article						myeloma; drug resistance; adhesion; NF-kappa B; microarray	INDUCED APOPTOSIS; CONFERS RESISTANCE; EXPRESSION; INHIBITOR; FIBRONECTIN; INDUCTION; DEATH; BCL-2; TRANSCRIPTION; FIBROBLASTS	The microenvironment has been shown to influence tumor cell phenotype with respect to growth, metastasis, and response to chemotherapy. We have utilized oligonucleotide microarray analysis to identify signal transduction pathways and gene products altered by the interaction of myeloma tumor cells with the extracellular matrix component fibronectin that may contribute to the antiapoptotic phenotype conferred by the microenvironment. Genes with altered expression associated with fibronectin cell adhesion, either induced or repressed, were numerically ranked by fold change. FN adhesion repressed the expression of 469 gene products, while 53 genes with known coding sequences were induced by twofold or more. Of these 53 genes with two fold, or greater increase in expression, 11 have been reported to be regulated by the nuclear factor-kappa B (NF-kappaB) family of transcription factors. EMSA analysis demonstrated NF-kappaB binding activity significantly increased in cells adhered to fibronectin compared to cells in suspension. This DNA binding activity consisted primarily of RelB-p50 heterodimers, which was distinct from the NF-kappaB activation of TNFalpha. These data demonstrate the selectivity of signal transduction from the microenvironment that may contribute to tumor cell resistance to programmed cell death.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cell Biol, Tampa, FL 33612 USA; Univ Arizona, Arizona Canc Ctr, Dept Med, Tucson, AZ 85724 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Arizona Center Cancer Care; University of Arizona	Dalton, WS (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA.							Bearz A, 1998, BIOCHEM BIOPH RES CO, V243, P732, DOI 10.1006/bbrc.1997.8017; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Do RKG, 2002, CYTOKINE GROWTH F R, V13, P19, DOI 10.1016/S1359-6101(01)00025-9; Feinman R, 1999, BLOOD, V93, P3044; Green SK, 1999, ANTI-CANCER DRUG DES, V14, P153; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kudoh K, 2000, CANCER RES, V60, P4161; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Rosales C, 1996, CANCER RES, V56, P2302; Scupoli MT, 2000, J CELL SCI, V113, P169; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Shain KH, 1999, J CELL BIOCHEM, V73, P237, DOI 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H; StCroix B, 1996, NAT MED, V2, P1204; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	33	151	154	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2417	2421		10.1038/sj.onc.1206315	http://dx.doi.org/10.1038/sj.onc.1206315			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717418				2022-12-17	WOS:000182383500004
J	Fan, FY; Jin, SQ; Amundson, SA; Tong, T; Fan, WH; Zhao, HC; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Fornace, AJ; Rajasekaran, B; Zhan, QM				Fan, FY; Jin, SQ; Amundson, SA; Tong, T; Fan, WH; Zhao, HC; Zhu, XC; Mazzacurati, L; Li, XX; Petrik, KL; Fornace, AJ; Rajasekaran, B; Zhan, QM			ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth	ONCOGENE			English	Article						ATF3; p53; DNA damage; gene regulation	TRANSCRIPTION FACTOR; MOLECULAR-BIOLOGY; C-FOS; P53; GADD45; GENE; CYCLE; ACTIVATION; INHIBITOR; STRESS	Mammalian cells have a remarkable diverse repertoire of response to genotoxic stress that damage DNA. Cellular responses to DNA damaging agents will initially exhibit gene induction, which is regulated by complex mechanism(s) and probably involves multiple signaling pathways. In this paper, we demonstrate that induction of ATF3 protein, a member of the ATF/CREB family of transcription factors, by ionizing radiation (IR) requires normal cellular p53 function. In contrast, induction of ATF3 after UV radiation (UV) or Methyl methanesulphonate (MMS) is independent of p53 status. Induction of ATF3 by DNA damage is rapid, transient, and through a transcriptional mechanism. The ATF3 promoter is induced by UV and MMS, but not by IR. In addition, ATF3 promoter can be activated by MEKK1, an upstream activator of the ERK and JNK kinase pathway, but not induced following p53 expression. Those results indicate that regulation of ATF3 induction after DNA damage utilizes both the p53-dependent and independent pathways, and may also involve MAP kinase signaling pathways. Using the tetracycline-inducible system (tet-off), we have found that overexpression of ATF3 protein moderately suppresses cell growth. Interestingly, over-expression of ATF3 protein is able to slow down progression of cells from G1 to S phase, indicating that ATF3 protein might play a negative role in the control of cell cycle progression.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; NCI, Lab Basic Sci, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.	qzhan+@pitt.edu	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; mazzacurati, lucia/0000-0002-8336-8032				Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Holbrook N J, 1996, EXS, V77, P273; HOLLANDER MC, 1989, CANCER RES, V49, P1687; Ishiguro T, 2000, ONCOL RES, V12, P343, DOI 10.3727/096504001108747792; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kumari SR, 2000, CANCER INVEST, V18, P715, DOI 10.3109/07357900009012203; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; MIYASHITA T, 1995, CELL, V80, P293; Rajanbabu R, 1999, CRIT REV ONCOGENESIS, V10, P275; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Schmutte C, 1999, ANTICANCER RES, V19, P4665; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhao HC, 2000, CANCER RES, V60, P6276	50	151	159	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7488	7496		10.1038/sj.onc.1205896	http://dx.doi.org/10.1038/sj.onc.1205896			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386811				2022-12-17	WOS:000178618200004
J	Tarapore, P; Fukasawa, K				Tarapore, P; Fukasawa, K			Loss of p53 and centrosome hyperamplification	ONCOGENE			English	Review						centrosome hyperamplification; cancer; p53; p21	P53-DEFICIENT MICE; CELL-CYCLE; GENOMIC INSTABILITY; MAMMALIAN-CELLS; CDK INHIBITORS; HUMAN CANCER; DUPLICATION; MUTATIONS; PROMOTES; PROGRESSION	Loss or mutational inactivation of p53 has been shown to lead to abnormal amplification of centrosomes through deregulation of the centrosome duplication cycle and failure to undergo cytokinesis. In mouse cells, most cases of centrosome hyperamplification are attributed to deregulation of centrosome duplication. The presence of excess copies of centrosomes increases the frequency of mitotic defects, leading to unbalanced chromosome transmission to daughter cells. p53 controls centrosome duplication via transactivation-dependent and transactivation-independent mechanisms. In its transactivation-dependent control, p21(Waf1/Cip1) acts as a major effector, likely guarding against untimely activation of CDK2/cyclin E kinase, hence ensuring the coordinated initiation of centrosome and DNA duplication. p53 appears to exert its transactivation-independent control through direct physical binding to the centrosomes.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661	NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NCI NIH HHS [CA90522] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Brown A, 2000, ONCOGENE, V19, P3032, DOI 10.1038/sj.onc.1203619; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Bunz F, 2002, CANCER RES, V62, P1129; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Hainaut P, 2000, ADV CANCER RES, V77, P81; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; MORO F, 1995, CARCINOGENESIS, V16, P2435, DOI 10.1093/carcin/16.10.2435; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mowat MRA, 1998, ADV CANCER RES, V74, P25, DOI 10.1016/S0065-230X(08)60764-2; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; PURDIE CA, 1994, ONCOGENE, V9, P603; Reed SI, 1997, CANCER SURV, V29, P7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang LHV, 1998, IEEE ENG MED BIOL, V17, P45, DOI 10.1109/51.664029; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	59	151	159	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6234	6240		10.1038/sj.onc.1205707	http://dx.doi.org/10.1038/sj.onc.1205707			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214254				2022-12-17	WOS:000177840500013
J	Crepieux, P; Marion, S; Martinat, N; Fafeur, V; Le Vern, Y; Kerboeuf, D; Guillou, F; Reiter, E				Crepieux, P; Marion, S; Martinat, N; Fafeur, V; Le Vern, Y; Kerboeuf, D; Guillou, F; Reiter, E			The ERK-dependent signalling is stage-specifically modulated by FSH, during primary Sertoli cell maturation	ONCOGENE			English	Article						ERK MAP kinases; cAMP/PKA; FSH; cell proliferation; cell differentiation	ACTIVATED PROTEIN-KINASE; FOLLICLE-STIMULATING-HORMONE; CYCLIN D1 EXPRESSION; OVARIAN GRANULOSA-CELLS; MAP KINASE; SIGNALING PATHWAY; COUPLED RECEPTORS; TRANSFERRIN GENE; CAMP; PHOSPHORYLATION	Primary cultures of Sertoli cells provide an interesting model to study how signalling pathways induced by a single hormone in a single cell type evolve, depending. on the developmental stage. In vivo, follicle-stimulating hormone (FSH) induces proliferation of Sertoli cells in neonate and controls the subsequent differentiation of the entire population. Molecular mechanisms underlying Sertoli cell pleiotropic responses to FSH have long been investigated. But to date, only cAMP-dependent kinase (PKA) activation has been reported to account for most FSH biological activities in male. Here, we demonstrate that FSH activates the ERK MAP kinase pathway following dual coupling of the FSH-R both to Gs and to Gi heterotrimeric proteins, in a PKA- and also Src-dependent manner. This activation is required for FSH-induced proliferation of Sertoli cells isolated 5 days after birth. Consistently, we show that the ERK-mediated FSH mitogenic effect triggers upregulation of cyclin D1. In sharp contrast, at 19 days after birth, as cells proceed through their differentiation program, the ERK pathway is dramatically inhibited by FSH treatment. Taken together, these results show that FSH can exert opposite effects on the ERK signalling cascade during the maturation process of Sertoli cells. Thus, signalling modules triggered by the FSH-R evolve dynamically throughout development of FSH natural target cells.	Univ Tours, Lab Physiol Reprod & Comportements, Inst Natl Rech Agron, CNRS,UMR 6073, Nouzilly, France; Ctr Rech Tours, Lab Pathol Aviaire & Parasitol, F-37380 Tours, France; CNRS, FRE 2353, Inst Biol Lille, Inst Pasteur Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; INRAE; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Crepieux, P (corresponding author), Univ Tours, Lab Physiol Reprod & Comportements, Inst Natl Rech Agron, CNRS,UMR 6073, Nouzilly, France.	crepieux@tours.inra.fr	Crepieux, Pascale/X-3217-2019; Fafeur, Veronique/L-9072-2018	Marion, Sebastien/0000-0002-3302-3845				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cameron MR, 1996, BIOL REPROD, V55, P111, DOI 10.1095/biolreprod55.1.111; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; COFFER P, 1994, ONCOGENE, V9, P911; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Fuller PJ, 1998, J CLIN ENDOCR METAB, V83, P274, DOI 10.1210/jc.83.1.274; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; GUILLOU F, 1986, BIOCHIM BIOPHYS ACTA, V887, P196, DOI 10.1016/0167-4889(86)90055-8; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANSSON V, 2000, J STEROID BIOCHEM, V72, P81; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; MONN E, 1972, ENDOCRINOLOGY, V91, P716, DOI 10.1210/endo-91-3-716; NIKULA H, 1990, MOL CELL ENDOCRINOL, V70, P247, DOI 10.1016/0303-7207(90)90215-T; ORTH JM, 1984, ENDOCRINOLOGY, V115, P1248, DOI 10.1210/endo-115-4-1248; PAULSSEN RH, 1991, BIOL REPROD, V45, P566, DOI 10.1095/biolreprod45.4.566; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; PURUSHOTHAM KR, 1994, BIOCHEM BIOPH RES CO, V202, P743, DOI 10.1006/bbrc.1994.1993; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SAEZ JM, 1991, HORM RES, V36, P104, DOI 10.1159/000182142; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SPITERIGRECH J, 1993, J REPROD FERTIL, V98, P1; Stanislaus D, 1998, MOL CELL ENDOCRINOL, V144, P1, DOI 10.1016/S0303-7207(98)00126-9; Suire S, 1997, MOL REPROD DEV, V48, P168, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;168::AID-MRD4&gt;3.0.CO;2-Q; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Troispoux C, 1998, MOL CELL ENDOCRINOL, V142, P75, DOI 10.1016/S0303-7207(98)00115-4; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	51	151	161	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4696	4709		10.1038/sj.onc.1204632	http://dx.doi.org/10.1038/sj.onc.1204632			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498792				2022-12-17	WOS:000170208600010
J	Chen, WX; Tang, QB; Gonzales, MS; Bowden, GT				Chen, WX; Tang, QB; Gonzales, MS; Bowden, GT			Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes	ONCOGENE			English	Article						UVB; p38; ERK; COX-2; PGE(2)	ACTIVATED PROTEIN-KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); COLON-CANCER CELLS; SKIN-CANCER; MULTISTAGE CARCINOGENESIS; COX-2 EXPRESSION; REGULATED KINASE; MOUSE SKIN; INHIBITION; INDUCTION	The roles of p38 MAP kinases and ERK in UVB induced cox-2 gene expression were studied in a human keratinocyte cell line, HaCaT, UVB significantly increased cox-2 gene expression at both protein and mRNA levels. As we reported previously, p38 and ERK were significantly activated after UVB irradiation in HaCaT cells. In addition, treating the cells with p38 inhibitor SB202190 or MEK inhibitor PD98059 specifically inhibited UVB induced p38 or ERK activation, respectively. In this study, we further examined the roles of p38 and ERK in UVB induced cox-2 gene expression in HaCaT cells. We found that SB202190 strongly inhibited UVB induced COX-2 protein expression at different time points and various UVB doses. Furthermore, SB202190 markedly inhibited UVB induced cox-2 mRNA. Our data indicated that ERK did not play a role in UVB induced cox-2 gene expression in human keratinocytes since suppression of ERK did not significantly alter UVB induced increase of COX-2 protein and mRNA. These results suggested, for the first time, that activation of p38 is required for UVB induced cox-2 gene expression in human keratinocytes, Since cox-2 expression plays an important role in UV carcinogenesis, p38 could be a potential molecular target for chemoprevention of skin cancer.	Univ Arizona, Coll Med, Dept Radiat Oncol, Arizona Canc Ctr, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Dept Radiat Oncol, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA27502, CA23074] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; Barthelman M, 1998, CANCER RES, V58, P711; BENNETT A, 1982, BRIT J CANCER, V46, P888, DOI 10.1038/bjc.1982.298; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 1997, NUTR CANCER, V29, P205, DOI 10.1080/01635589709514625; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 2000, MOL CARCINOGEN, V28, P196, DOI 10.1002/1098-2744(200008)28:4<196::AID-MC2>3.0.CO;2-C; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chulada P. C., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P195; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEGRUIJL FR, 1995, BIOESSAYS, V17, P651, DOI 10.1002/bies.950170711; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FURSTENBERGER G, 1990, EICOSANOIDS SKIN, P108; Geijsen N, 2000, FEBS LETT, V471, P83, DOI 10.1016/S0014-5793(00)01373-9; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Higashi Y, 2000, INT J CANCER, V86, P667, DOI 10.1002/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.3.CO;2-P; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, P396; Marks F, 2000, EUR J CANCER, V36, P314, DOI 10.1016/S0959-8049(99)00318-4; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sheng HM, 1998, CANCER RES, V58, P362; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199	43	151	156	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3921	3926		10.1038/sj.onc.1204530	http://dx.doi.org/10.1038/sj.onc.1204530			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439356				2022-12-17	WOS:000169494700018
J	Urnov, FD; Wolffe, AP				Urnov, FD; Wolffe, AP			Chromatin remodeling and transcriptional activation: the cast (in order of appearance)	ONCOGENE			English	Review						chromatin; transcription; histone deacetylase; histone acetyltransferase; chromatin remodeling	THYROID-HORMONE RECEPTOR; YEAST SWI/SNF COMPLEX; IFN-BETA ENHANCEOSOME; CORE HISTONE ACETYLATION; IN-VIVO; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; NUCLEOSOMAL DNA; SWI-SNF	The number of chromatin modifying and remodeling complexes implicated in genome control is growing faster than our understanding of the functional roles they play. We discuss recent in vitro experiments with biochemically defined chromatin templates that illuminate new aspects of action by histone acetyltransferases and ATP-dependent chromatin remodeling engines in facilitating transcription. We review a number of studies that present an 'ordered recruitment' view of transcriptional activation, according to which various complexes enter and exit their target promoter in a set sequence, and at specific times, such that action by one complex sets the stage for the arrival of the next one. A consensus emerging from all these experiments is that the joint action by several types of chromatin remodeling machines can lead to a more profound alteration of the infrastructure of chromatin over a target promoter than could be obtained by these enzymes acting independently. In addition, it appears that in specific cases one type of chromatin structure alteration (e.g., histone hyperacetylation) is contingent upon prior alterations of a different sort (i.e., ATP-dependent remodeling of histone-DNA contacts), The striking differences between the precise sequence of action by various cofactors observed in these studies may be - at least in part - due to differences between the specific promoters studied, and distinct requirements exhibited by specific loci for chromatin remodeling based on their pre-existing nucleoprotein architecture.	Sangamo Biosci, Pt Richmond Tech Ctr, Richmond, CA 94804 USA	Sangamo Therapeutics, Inc.	Urnov, FD (corresponding author), Sangamo Biosci, Pt Richmond Tech Ctr, 501 Canal Blvd,Suite A100, Richmond, CA 94804 USA.	furnov@sangamo.com						Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1989, STEROID THYROID HORM, P221; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRIZUELA BJ, 1994, GENETICS, V137, P803; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Bultman S, 2000, MAMM GENOME, V11, P251, DOI 10.1007/s003350010049; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Collins RT, 2000, GENE DEV, V14, P3140, DOI 10.1101/gad.854300; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Di Croce L, 1999, Nucleic Acids Res, V27, pe11, DOI 10.1093/nar/27.16.e11; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; Fletcher TM, 2000, MOL CELL BIOL, V20, P6466, DOI 10.1128/MCB.20.17.6466-6475.2000; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Goodman RH, 2000, GENE DEV, V14, P1553; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Guschin D, 2000, J BIOL CHEM, V275, P35248, DOI 10.1074/jbc.M006041200; Hager GL, 2001, PROG NUCLEIC ACID RE, V66, P279; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HERSKOWITZ I, 1992, TRANSCRIPTIONAL REGU, V2, P949; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Jiang W, 2000, J BIOL CHEM, V275, P39819, DOI 10.1074/jbc.C000713200; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Kung AL, 2000, GENE DEV, V14, P272; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, V2, P1193; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; Pile LA, 2000, J BIOL CHEM, V275, P1398, DOI 10.1074/jbc.275.2.1398; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; RUBINSTEIN JH, 1990, AM J MED GENET, P3; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SAMUELS HH, 1982, RECENT PROG HORM RES, V38, P557; Sawa H, 2000, MOL CELL, V6, P617, DOI 10.1016/S1097-2765(00)00060-5; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schubeler D, 2000, GENE DEV, V14, P940; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Sewack GF, 2001, MOL CELL BIOL, V21, P1404, DOI 10.1128/MCB.21.4.1404-1415.2001; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Tumbar T, 1999, J CELL BIOL, V145, P1341, DOI 10.1083/jcb.145.7.1341; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Vazquez M, 1999, DEVELOPMENT, V126, P733; Verreault A, 2000, GENE DEV, V14, P1430; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; WEISENBERGER D, 1995, J CELL BIOL, V129, P561, DOI 10.1083/jcb.129.3.561; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	150	151	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					2991	3006		10.1038/sj.onc.1204323	http://dx.doi.org/10.1038/sj.onc.1204323			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420714				2022-12-17	WOS:000169308500002
J	Chang, BD; Broude, EV; Fang, J; Kalinichenko, TV; Abdryashitov, R; Poole, JC; Roninson, IB				Chang, BD; Broude, EV; Fang, J; Kalinichenko, TV; Abdryashitov, R; Poole, JC; Roninson, IB			p21(Waf1/Cip1/Sdi1)-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells	ONCOGENE			English	Article						p21; mitosis; endoreduplication; spindle checkpoint control; senescence	TERMINAL PROLIFERATION ARREST; CYCLIN-DEPENDENT KINASES; NORMAL HUMAN FIBROBLASTS; HUMAN TUMOR-CELLS; REPLICATIVE SENESCENCE; MAMMALIAN-CELLS; INHIBITOR P21; DNA-DAMAGE; EXPRESSION; CHECKPOINT	Induction of a cyclin-dependent kinase inhibitor p21(Wafl/) (Cip1/Sdi1) is an integral part of cell growth arrest associated with senescence and damage response, p21 overexpression from an inducible promoter resulted in senescence-like growth arrest in a human fibrosarcoma cell line. After release from p21-induced growth arrest, cells reentered the cell cycle but displayed growth retardation, cell death and decreased clonogenicity. The failure to form colonies was associated with abnormal mitosis and endoreduplication in the recovering cells and was correlated with the induced level of p21 and the duration of p21 induction. p21 induction was found to inhibit the expression of multiple proteins involved in the execution and control of mitosis, p21-induced depletion of the cellular pools of mitosis-control proteins nas followed by asynchronous resynthesis of such proteins after release from p21, which explains the observed mitotic abnormalities. Genetic destabilization in cells recovering from p21-induced growth arrest may conceivably play a role in carcinogenesis and tumor progression.	Univ Illinois, Dept Mol Genet MC 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Univ Illinois, Dept Mol Genet MC 669, 900 S Ashland Ave, Chicago, IL 60607 USA.		Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NATIONAL CANCER INSTITUTE [R01CA062099, R37CA040333] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA40333, R01CA62099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHANG BD, 1999, CANCER RES, V18, P4808; CHANG BP, 2000, IN PRESS P NATL ACAD; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; GARTEL AL, 1998, INHIBITORS CELL GROW, V20, P43; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hixon ML, 1998, MOL CELL BIOL, V18, P6224, DOI 10.1128/MCB.18.11.6224; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Jordan MA, 1996, CANCER RES, V56, P816; Kalitsis P, 1998, GENOMICS, V47, P108, DOI 10.1006/geno.1997.5109; Kikuchi J, 1997, BLOOD, V89, P3980, DOI 10.1182/blood.V89.11.3980; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139	41	151	159	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2165	2170		10.1038/sj.onc.1203573	http://dx.doi.org/10.1038/sj.onc.1203573			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815808				2022-12-17	WOS:000086728000010
J	Dougher, M; Terman, BI				Dougher, M; Terman, BI			Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization	ONCOGENE			English	Article						VEGF; KDR receptor; autophosphorylation; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CELLS; IDENTIFICATION; EXPRESSION; SITES; PHOSPHORYLATION	We have previously reported the identification of four autophosphorylation sites on the KDR VEGF receptor. Two of these sites (tyrosines 951 and 996) are located in the receptor's kinase insert domain, and two (tyrosines 1054 and 1059) are located in the catalytic domain. In order to clarify the functional significance of these sites, we made DNA constructs in which tyrosine codons were replaced with those for phenylalanine, and expressed the DNA constructs in 293 cells. VEGF binding to cells expressing the native receptor led to a rapid increase in receptor and PLC gamma phosphorylation, and a slower increase in the phosphorylation of p(125)FAK and paxillin. VEGF binding to KDR(Y951F) and KDR(Y996F) expressing cells resulted in phosphorylation of all cellular substrates tested, although the level of PLC gamma phosphorylation was decreased for KDR(Y996F). The decreased level of PLC gamma phosphorylation was not because PLC gamma-containing SH2 domains bind to the Y996 autophosphorylation site. We conclude that there exists receptor autophosphorylation sites not previously identified which allow for signaling via PLC gamma, as well as p(125)FAK and paxillin. VEGF binding to cells expressing KDR mutated at both tyrosine's 1054 and 1059 activated receptor autophosphorylation but at a level which was only 10% of that seen for cells expressing native receptor. Tyrosine phosphorylation of cell signaling proteins was not observed in KDR(Y1054,1059) expressing cells. Utilizing an in vitro assay which directly measures receptor catalytic activity allowed us to determine that the tyrosine kinase activity of the native receptor was significantly greater than that for the double mutant. We conclude from this result that VEGF-induced autophosphorylation at tyrosines 1054 and 1059 is a required step for allowing maximal KDR kinase activity. Maximal rates of receptor kinase activity is required for VEGF-induced receptor internalization, as internalization was delayed in the KDR(Y1054,1059F) expressing cells when compared to cells expressing native receptor.	Wyeth Ayerst Oncol Res, Pearl River, NY 10965 USA	Pfizer	Terman, BI (corresponding author), Wyeth Ayerst Oncol Res, Bldg 200-4623, Pearl River, NY 10965 USA.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BROWN LF, 1993, AM J PATHOL, V143, P1255; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; CUNNINGHAM SA, 1997, BIOCHEM BIOPH RES CO, V240, P35; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARNER A, 1994, DYNAMIC APPROACH, P1625; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LONGATI P, 1994, ONCOGENE, V9, P3457; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WILEY HS, 1991, J BIOL CHEM, V266, P11083	45	151	166	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1619	1627		10.1038/sj.onc.1202478	http://dx.doi.org/10.1038/sj.onc.1202478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102632				2022-12-17	WOS:000078770700012
J	Tahara, H; Yasui, W; Tahara, E; Fujimoto, J; Ito, K; Tamai, K; Nakayama, J; Ishikawa, F; Tahara, E; Ide, T				Tahara, H; Yasui, W; Tahara, E; Fujimoto, J; Ito, K; Tamai, K; Nakayama, J; Ishikawa, F; Tahara, E; Ide, T			Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections	ONCOGENE			English	Article						telomerase; in situ detection; hTERT; immuno-histochemistry; colorectal carcinoma	MAMMALIAN TELOMERASE; SUBUNIT GENE; CELLS; PROTEIN; CANCER; RNA; EXPRESSION; STOMACH	Human telomerase is expressed in germ tissues and in the majority of primary tumors. Cell renewal tissues and some pre-cancerous tissues also have weak telomerase activity, Yet, neither the exact location and frequency of telomerase-positive cells nor the changes in telomerase expression during differentiation or carcinogenesis of individual cells are known. This paper reports on the expression of hTERT (telomerase reverse transcriptase) protein in tumor and non-tumor colorectal tissues by Western blotting and tissue sections by immunohistochemistry using antibodies raised against partial peptides of hTERT, Though telomerase activity and hTERT expression at both mRNA and protein levels were generally higher in tumor part than in non-tumor part, these two were not always correlated: expression of hTERT did not always give rise to high telomerase activity. Colonic carcinoma cell nuclei were stained with anti-hTERT antibodies but not with antigen-preabsorbed antibodies. In normal mucosa, hTERT protein was expressed, though weaker than in carcinoma, in all colonic crypt epithelial cells except those at the tip; the expressing-cell distribution was much wider than that of Ki-67 positive cells which were located at the bottom of the crypt, Isolated crypt contained a significant level of hTERT protein revealed by Western blotting, while having very weak telomerase activity. Telomerase activity was detected in epithelial cells only at the bottom half of the crypt, Specific hTERT-staining was positive in tissue lymphocytes but negative in almost all other stromal cells. It is of interest to see whether a significant level of hTERT expression with low telomerase activity is characteristic of physiologically regenerating tissues containing stem cells, In situ detection of the hTERT protein mill permit further analysis of cancer diagnosis and stem cell differentiation.	Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Pathol 1, Hiroshima 734, Japan; Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 226, Japan; Med & Biol Labs Co Ltd, Nagano, Japan	Hiroshima University; Hiroshima University; Tokyo Institute of Technology	Ide, T (corresponding author), Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Kasumi 1-2-3, Hiroshima 734, Japan.		Nakayama, Jun-ichi/C-6003-2011; Tamai, Katsuyuki/F-4743-2013; Ishikawa, Fuyuki/AAU-4056-2021	Nakayama, Jun-ichi/0000-0002-5597-8239; Tamai, Katsuyuki/0000-0003-4094-3911; Ishikawa, Fuyuki/0000-0002-5580-2305				Avilion AA, 1996, CANCER RES, V56, P645; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Ohyashiki K, 1997, CANCER RES, V57, P2100; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Yasui W, 1996, J PATHOL, V180, P122, DOI 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C	20	151	170	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1561	1567		10.1038/sj.onc.1202458	http://dx.doi.org/10.1038/sj.onc.1202458			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102626				2022-12-17	WOS:000078770700006
J	Medema, RH; Klompmaker, R; Smits, VAJ; Rijksen, G				Medema, RH; Klompmaker, R; Smits, VAJ; Rijksen, G			p21(waf1) can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases	ONCOGENE			English	Article						p21; cyclin B; PCNA; growth inhibition; tetracycline	WILD-TYPE P53; DEPENDENT KINASES; TERMINAL DIFFERENTIATION; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; GENE AMPLIFICATION; CDK INHIBITORS; P21; EXPRESSION; ARREST	p21(waf1) has been shown to mediate the p53-dependent growth arrest induced by DNA-damaging agents, Several functions have been ascribed to p21(waf1) that could be involved in this growth arrest, For one, p21(waf1) is an efficient inhibitor of cyclin-dependent kinases (CDKs). Also, p21(waf1) can interact with proliferating cell nuclear antigen (PCNA), and as such inhibit in vitro DNA-replication. Finally, p21(waf1) has been reported to inhibit stress-activated protein kinases (SAPKs). In order to study these multiple functions of p21(waf1) we have established U2OS-derived cell lines, in which the expression of p21(waf1) can be regulated by the concentration of tetracycline in the culture medium, We observed a virtually complete, but reversible inhibition of cell growth upon induction of p21(waf1)-expression. Both [H-3]thymidine-incorporation and CDK2-activity were strongly inhibited by p21(waf1). Upon induction of p21(waf1) cells accumulated with a 2N or 4N DNA content suggesting events in G1 and G2 can be inhibited by p21(waf1). Indeed, kinase activity associated with cyclin B was reduced dramatically upon induction of p21(waf1), although cyclin B continues to be expressed, In contrast, p21(waf1) does not seem to inhibit the function of PCNA in ongoing DNA replication, since cells expressing high levels of p21(waf1) apparently progressed normally through S-phase. Also, the activity of SAPKs was not substantially affected by the high levels of p21(waf1). We conclude that, at least in these U2OS-derived cells, p21(waf1) functions as an inhibitor of CDK-activity in G1 and G2, but not as an inhibitor of PCNA or SAPKs.	Univ Utrecht Hosp, Dept Haematol, Jordan Lab, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Utrecht Hosp, Dept Haematol, Jordan Lab, POB 85500, NL-3508 GA Utrecht, Netherlands.		Medema, Rene H/E-2981-2013; Smits, Veronique A.J./R-2302-2019; Medema, Rene H/G-5415-2011	Smits, Veronique A.J./0000-0002-9160-4525; Medema, Rene/0000-0002-6754-0381	NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NCI NIH HHS [CA39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Savio M, 1996, ONCOGENE, V13, P1591; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wyllie FS, 1996, ONCOGENE, V12, P1077; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	57	151	154	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					431	441		10.1038/sj.onc.1201558	http://dx.doi.org/10.1038/sj.onc.1201558			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484832				2022-12-17	WOS:000071739400001
J	Sudo, T; Nishikawa, S; Ogawa, M; Kataoka, H; Ohno, N; Izawa, A; Hayashi, SI; Nishikawa, SI				Sudo, T; Nishikawa, S; Ogawa, M; Kataoka, H; Ohno, N; Izawa, A; Hayashi, SI; Nishikawa, SI			Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M	ONCOGENE			English	Article						c-kit; c-fms; hematopoiesis M-CSF; mAb	COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PROGENITOR CELLS; FACTOR CSF-1; EXPRESSION; RECEPTOR; DIFFERENTIATION; MOUSE; HEMATOPOIESIS	Whereas the molecular natures of M-CSF/CSF-1 and its receptor c-fms are well characterized, its actual role in the intramarrow hematopoiesis remains obscure, This is because disruption of this signaling pathway results in the osteopetrosis mouse that lacks the bone cavity for hematopoiesis. To elucidate the role of c-fms in intramarrow hematopoiesis, we produced an antagonistic monoclonal antibody to murine c-fms and investigated its expression and function in the normal bone marrow, c-fms(+) cells were detected both in mature and immature hematopoietic cells, Morphologically, c-kit(+)c-fms(-), c-kit(+)c-fms(+) and c-kit(-)c-fms(+) cells were medium sized blasts, large promyelocytes with azurophilic granules and mature monocytes respectively, CFU-M was 10-fold more enriched in the c-kit(+)c-fms(-) than c-kit(+)c-fms(+) fraction, Moreover, injection of the anti c-fms antibody had no effect on the production of CFU-M in the bone marrow, while anti-c-kit mAb could deplete them, hs ckit(+)c-fms(+) cells were readily generated in the culture of c-kit(+)c-fms(-) cells, most of the CFU-M in the bone marrow are, in fact, c-fms(-) cells that differentiate into c-fms(+) upon culture, These observations indicate a clear functional hierarchy of c-kit and c-fms in the bone marrow, Namely, c-kit plays the primary role in the production and maintenance of CFU-M, while c-fms, though it co-expressed with c-kit and functions as the growth receptor for M-CSF in the culture, has only a minimum role in the proliferation of c-fms(+) cells in the bone marrow.	KYOTO UNIV,FAC MED,DEPT MOLEC GENET,SAKYO KU,KYOTO 60601,JAPAN; TORAY INDUSTRIES LTD,BASIC RES LABS,KAMAKURA,KANAGAWA 248,JAPAN	Kyoto University; Toray Industries, Inc.								ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BICKNELL DC, 1988, EXP HEMATOL, V16, P88; BOEGEL F, 1985, EXP HEMATOL, V13, P912; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; COFFMAN RL, 1986, IMMUNOL REV, V69, P5; ERA T, 1994, IMMUNOL REV, V137, P35, DOI 10.1111/j.1600-065X.1994.tb00658.x; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GREENBERGER J, 1992, EXP HEMATOL, V20, P92; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NAITO M, 1991, AM J PATHOL, V139, P657; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NISHIKAWA S, 1994, IMMUNOL LETT, V40, P163, DOI 10.1016/0165-2478(94)90188-0; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PANTERNE B, 1993, J CELL PHYSIOL, V155, P282, DOI 10.1002/jcp.1041550209; RALPH P, 1977, CANCER RES, V37, P546; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SHADDUCK RK, 1993, EXP HEMATOL, V21, P515; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPANGRUDE GJ, 1991, CURR OPIN IMMUNOL, V3, P171, DOI 10.1016/0952-7915(91)90046-4; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YASUNAGA Y, 1995, J EXP MED, V182, P315; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	37	151	159	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2469	2476						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545103				2022-12-17	WOS:A1995TP18800002
J	AHMED, NN; FRANKE, TF; BELLACOSA, A; DATTA, K; GONZALEZPORTAL, ME; TAGUCHI, T; TESTA, JR; TSICHLIS, PN				AHMED, NN; FRANKE, TF; BELLACOSA, A; DATTA, K; GONZALEZPORTAL, ME; TAGUCHI, T; TESTA, JR; TSICHLIS, PN			THE PROTEINS ENCODED BY C-AKT AND V-AKT DIFFER IN POSTTRANSLATIONAL MODIFICATION, SUBCELLULAR-LOCALIZATION AND ONCOGENIC POTENTIAL	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; MURINE LEUKEMIA-VIRUS; MYRISTIC ACID; CELLS; GENE; TRANSFORMATION; MYRISTYLATION; EXPRESSION; BINDING; VECTORS	The acute retrovirus AKT8, isolated from an AKR mouse T-cell lymphoma, transforms mink lung cells in culture and is oncogenic when inoculated into newborn mice. The oncogene carried by this virus, v-akt, arose by recombination between Gag and the 5' untranslated region of the cellular gene c-akt. v-akt encodes a 105 kilodalton (kd) Gag-Akt fusion protein which is phosphorylated on serine and threonine residues. c-akt encodes a 55 kd serine-threonine protein-kinase, which is related to members of the protein kinase C (PKC) family and contains an SH2-like domain. The SH2-like and catalytic domains of Akt were expressed in E. coli as fusions to the carboxy-terminus of the Maltose binding protein (MBP). Antibodies against these proteins were raised in rabbits and they were used to determine the potential myristylation and subcellular localization of the v-akt and c-akt protein products. Immunoprecipitation of v-akt and c-akt from lysates of [S-35]methionine and [H-3]myristic acid labeled AKT8 transformed mink lung cells revealed that only v-akt was myristylated. Fractionation of Dounce-homogenized cellular extracts from uninfected and v-akt-transformed mink lung and PA317 cells and from uninfected PC12 cells by differential centrifugation showed that while the c-akt protein was localized primarily in the cytosol (90%), the v-akt protein was dispersed among the cellular compartments with approximately 40% on the plasma membranes, approximately 30% in the nucleus and approximately 30% in the cytosol. To determine whether the differences in post-translational modification and subcellular distribution between c-akt and v-akt translated into oncogenicity differences between the two proteins, we used retrovirus based constructs to express them both in the nontumorigenic rat T cell lymphoma line 5675. Intraperitoneal (IP) inoculation of the parental and c-akt expressing 5675 cells in nude Balb/c mice revealed that neither was oncogenic. In sharp contrast to these results, v-akt expressing 5675 cells inoculated in nude Balb/c mice were found to be highly oncogenic.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Gonzalez, Maria Eugenia/B-5146-2008	Gonzalez, Maria Eugenia/0000-0003-0355-5469	NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BELLACOSA A, 1992, IN PRESS ONCOGENE; BIGBEE WL, 1983, MOL IMMUNOL, V20, P1353, DOI 10.1016/0161-5890(83)90166-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSTOS JG, 1990, BIOCHIM BIOPHYS ACTA, V1071, P83; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY AJ, 1974, VIROLOGY, V60, P398, DOI 10.1016/0042-6822(74)90335-3; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HOMSEY VS, 1986, IMMUNOL METH, V93, P83; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KELJO DJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P500, DOI 10.1016/0005-2736(78)90095-0; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHULTZ AM, 1989, J VIROL, V63, P2370, DOI 10.1128/JVI.63.5.2370-2373.1989; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; WILLINGHAM MC, 1990, FOCUS, V12, P62; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992	33	151	151	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1957	1963						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510938				2022-12-17	WOS:A1993LG68200028
J	PORTIER, M; MOLES, JP; MAZARS, GR; JEANTEUR, P; BATAILLE, R; KLEIN, B; THEILLET, C				PORTIER, M; MOLES, JP; MAZARS, GR; JEANTEUR, P; BATAILLE, R; KLEIN, B; THEILLET, C			P53 AND RAS GENE-MUTATIONS IN MULTIPLE-MYELOMA	ONCOGENE			English	Note							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN LYMPHOID MALIGNANCIES; TUMOR SUPPRESSOR GENE; C-MYC; N-RAS; ONCOGENE MUTATIONS; POINT MUTATION; CELL-LINES; EXPRESSION	We analysed genomic DNA from 30 patients with multiple myeloma (MM), searching for alterations in the p53 and RAS genes by a combination of polymerase chain reaction and single-strand conformation polymorphism techniques. Mutations in the p53 gene were observed in 20% (6 out of 30) of the patients, and were located in conserved sequence blocks within exons 5 and 7. These were single-nucleotide substitutions and consisted predominantly (4/6) of G:C to A:T transitions. Of the six patients with a mutated p53 gene, four were in the terminal phase of the disease. RAS gene mutations were found more frequently since they occurred in 47% (14 out of 30) of the patients. Mutations consisted of single-nucleotide substitutions, located in codons 12, 13 and 61 of either K- or N-RAS, to the exclusion of H-RAS. Moreover, one patient bore two simultaneous mutations, affecting simultaneously the K- and the N-RAS genes. RAS gene mutations were more frequently observed in patients with fulminating disease (10/15, 67%) than in patients with less aggressive forms of the disease (4/15, 26%). We also analysed genomic DNAs from 10 human myeloma cell lines, of which two bore mutations affecting codon 12 of the K-RAS gene, and one codon 12 of the N-RAS gene. The first two cell lines were obtained from freshly explanted tumor cells in which we observed identical mutations. Results presented here show that activating mutations in the RAS genes are, in MM, more frequent than those affecting the p53 gene and suggest that both events are related to terminal phases of the disease.	UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,URA 1191,PL EUGENE BATAILLON,F-34095 MONTPELLIER,FRANCE; INSERM,U IMMUNOPATHOL MALADIES TUMORALES & AUTOIMMUNES 291,F-34090 MONTPELLIER,FRANCE; HOP ST ELOI,CTR GUI DE CHAULIAC,F-34059 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier			Molès, Jean-Pierre/M-2286-2017; Theillet, Charles/O-7634-2018	Molès, Jean-Pierre/0000-0002-6863-6350; Theillet, Charles/0000-0001-5555-2759				BAKKUS MHC, 1990, ONCOGENE, V5, P1359; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; ERNST TJ, 1988, BLOOD, V72, P1163; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GREIL R, 1991, BLOOD, V78, P180; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KLEIN B, 1989, BLOOD, V73, P517; LEMAISTRE A, 1989, BLOOD, V73, P889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T, 1989, DECONTAMINATION DILU; MAZARS GR, 1992, ONCOGENE, V7, P1015; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; PALUMBO AP, 1989, CANCER RES, V49, P4701; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; PETTERSSON M, 1992, BLOOD, V79, P495; RADICH JP, 1990, BLOOD, V76, P801; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAWADA M, 1989, NUCLEIC ACIDS RES, V17, P8867, DOI 10.1093/nar/17.21.8867; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SLINGERLAND JM, 1991, BLOOD, V77, P1500; WRIGHT PA, 1991, ONCOGENE, V6, P1693	28	151	154	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2539	2543						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461658				2022-12-17	WOS:A1992KA85600022
J	Borsig, L; Wolf, MJ; Roblek, M; Lorentzen, A; Heikenwalder, M				Borsig, L.; Wolf, M. J.; Roblek, M.; Lorentzen, A.; Heikenwalder, M.			Inflammatory chemokines and metastasis-tracing the accessory	ONCOGENE			English	Review						tumor cell extravasation; inflammatory chemokines; CCL2; CCL5; metastasis	MONOCYTE CHEMOATTRACTANT PROTEIN-1; PROSTATE-CANCER GROWTH; BREAST-CANCER; TUMOR-GROWTH; ENDOTHELIAL-CELLS; LUNG METASTASIS; EXPRESSION; CCL2; MACROPHAGE; MCP-1	The tumor microenvironment consists of stromal cells and leukocytes that contribute to cancer progression. Cross-talk between tumor cells and their microenvironment is facilitated by a variety of soluble factors, including growth factors and cytokines such as chemokines. Due to a wide expression of chemokine receptors on cells in the tumor microenvironment, including tumor cells, chemokines affect various processes such as leukocyte recruitment, angiogenesis, tumor cell survival, tumor cell adhesion, proliferation, vascular permeability, immune suppression, invasion and metastasis. Inflammatory chemokines are instrumental players in cancer-related inflammation and significantly contribute to numerous steps during metastasis. Recruitment of myeloid-derived cells to metastatic sites is mainly mediated by the inflammatory chemokines CCL2 and CCL5. Tumor cell homing and extravasation from the circulation to distant organs are also regulated by inflammatory chemokines. Recent experimental evidence demonstrated that besides leukocyte recruitment, tumor cell-derived CCL2 directly activated endothelial cells and together with monocytes facilitated tumor cell extravasation, in a CCL2- and CCL5-dependent manner. Furthermore, CX3CL1 expression in the bone facilitated metastasis of CX3CR1 expressing tumor cells to this site. Current findings in preclinical models strongly suggest that inflammatory chemokines have an important role during metastasis and targeting of the chemokine axis might have a therapeutic potential.	[Borsig, L.; Roblek, M.] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Borsig, L.; Roblek, M.] Zurich Ctr Integrat Human Physiol, CH-8057 Zurich, Switzerland; [Wolf, M. J.] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Lorentzen, A.; Heikenwalder, M.] Tech Univ Munich, Helmholtz Zentrum Munich, Inst Virol, D-80290 Munich, Germany	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Borsig, L (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	lborsig@access.uzh.ch	Heikenwalder, Mathias/AAA-2269-2020	Lorentzen, Anna/0000-0002-4405-935X; Borsig, Lubor/0000-0003-2263-9545	Swiss National Foundation [31003A-133025]; EuroNanoMed2; project NANODIATER; Helmholtz foundation; Starting ERC grant; Helmholtz alliance PCCC; Hofschneider foundation;  [SFB transregio 36]	Swiss National Foundation(Swiss National Science Foundation (SNSF)); EuroNanoMed2; project NANODIATER; Helmholtz foundation(Helmholtz Association); Starting ERC grant; Helmholtz alliance PCCC; Hofschneider foundation; 	LB was supported by Swiss National Foundation (31003A-133025) and by EuroNanoMed2 2nd call; project NANODIATER. MH was supported by the Helmholtz foundation, a Starting ERC grant, the SFB transregio 36, the Helmholtz alliance PCCC and the Hofschneider foundation.	Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Allavena P, 2011, EXP CELL RES, V317, P664, DOI 10.1016/j.yexcr.2010.11.013; Andre F, 2006, ANN ONCOL, V17, P945, DOI 10.1093/annonc/mdl053; Azenshtein E, 2002, CANCER RES, V62, P1093; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Buonamici S, 2009, NATURE, V459, P1000, DOI 10.1038/nature08020; Chiu HY, 2012, CYTOKINE, V59, P423, DOI 10.1016/j.cyto.2012.04.017; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; de Vasconcellos JF, 2011, PEDIATR BLOOD CANCER, V56, P568, DOI 10.1002/pbc.22941; Eisenkraft A, 2006, LEUKEMIA RES, V30, P1259, DOI 10.1016/j.leukres.2006.01.017; Fang WB, 2012, J BIOL CHEM, V287, P36593, DOI 10.1074/jbc.M112.365999; Feil C, 1998, BIOCHEM BIOPH RES CO, V247, P38, DOI 10.1006/bbrc.1998.8499; Forst B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010374; Fridlender ZG, 2011, AM J RESP CELL MOL, V44, P230, DOI 10.1165/rcmb.2010-0080OC; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Garin A, 2011, EXP CELL RES, V317, P602, DOI 10.1016/j.yexcr.2010.12.021; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Gu L, 2010, ENDOCR-RELAT CANCER, V17, P481, DOI 10.1677/ERC-09-0328; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hembruff SL, 2010, NEOPLASIA, V12, P425, DOI 10.1593/neo.10200; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Janowska-Wieczorek A, 2005, INT J CANCER, V113, P752, DOI 10.1002/ijc.20657; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Keeley EC, 2011, EXP CELL RES, V317, P685, DOI 10.1016/j.yexcr.2010.10.020; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Krumbholz M, 2007, J NEUROIMMUNOL, V190, P72, DOI 10.1016/j.jneuroim.2007.07.024; Laubli H, 2009, BLOOD, V114, P4583, DOI 10.1182/blood-2008-10-186585; Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792; Li X, 2009, CANCER RES, V69, P1685, DOI 10.1158/0008-5472.CAN-08-2164; Liu YL, 2010, AM J PATHOL, V176, P2490, DOI 10.2353/ajpath.2010.090777; Loberg RD, 2006, NEOPLASIA, V8, P578, DOI 10.1593/neo.06280; Low-Marchelli JM, 2013, CANCER RES, V73, P662, DOI 10.1158/0008-5472.CAN-12-0653; Lu X, 2009, J BIOL CHEM, V284, P29087, DOI 10.1074/jbc.M109.035899; Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464; Lu Y, 2009, CLIN EXP METASTAS, V26, P161, DOI 10.1007/s10585-008-9226-7; Lukanidin E, 2012, SEMIN CANCER BIOL, V22, P216, DOI 10.1016/j.semcancer.2012.02.006; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Mao YL, 2011, INT J COLORECTAL DIS, V26, P29, DOI 10.1007/s00384-010-1090-7; Marchesi F, 2008, CANCER RES, V68, P9060, DOI 10.1158/0008-5472.CAN-08-1810; Marchesi F, 2010, CYTOKINE GROWTH F R, V21, P77, DOI 10.1016/j.cytogfr.2009.11.001; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Mishra P, 2011, J LEUKOCYTE BIOL, V89, P31, DOI 10.1189/jlb.0310182; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; Molloy AP, 2009, INT J CANCER, V124, P326, DOI 10.1002/ijc.23939; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nakasone Y, 2012, AM J PATHOL, V180, P365, DOI 10.1016/j.ajpath.2011.09.005; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Pan JD, 2006, J IMMUNOL, V176, P1456, DOI 10.4049/jimmunol.176.3.1456; Park SI, 2012, CANCER RES, V72, P2522, DOI 10.1158/0008-5472.CAN-11-2928; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Reed JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045877; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Robinson SC, 2003, CANCER RES, V63, P8360; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; Rollins BJ, 2006, EUR J CANCER, V42, P760, DOI 10.1016/j.ejca.2006.01.002; Said N, 2012, J CLIN INVEST, V122, P1503, DOI 10.1172/JCI61392; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; SCHEIBENBOGEN C, 1995, MELANOMA RES, V5, P179, DOI 10.1097/00008390-199506000-00006; Shulby SA, 2004, CANCER RES, V64, P4693, DOI 10.1158/0008-5472.CAN-03-3437; Soria G, 2008, CYTOKINE, V44, P191, DOI 10.1016/j.cyto.2008.08.002; Stormes KA, 2005, BREAST CANCER RES TR, V89, P209, DOI 10.1007/s10549-004-5328-3; Takahashi M, 2009, CLIN EXP METASTAS, V26, P817, DOI 10.1007/s10585-009-9281-8; Tremblay PL, 2006, ONCOGENE, V25, P6563, DOI 10.1038/sj.onc.1209664; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Ueno T, 2000, CLIN CANCER RES, V6, P3282; Varney ML, 2006, AM J CLIN PATHOL, V125, P209, DOI 10.1309/VPL5R.JR7F1D6V03; Velasco-Velazquez M, 2012, CANCER RES, V72, P3839, DOI 10.1158/0008-5472.CAN-11-3917; Weber KSC, 1999, ARTERIOSCL THROM VAS, V19, P2085, DOI 10.1161/01.ATV.19.9.2085; Wendel C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030046; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Wolf MJ, 2010, ONCOGENE, V29, P5006, DOI 10.1038/onc.2010.260; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Wu S, 2012, CANCER MED-US, V1, P306, DOI 10.1002/cam4.28; Yaal-Hahoshen N, 2006, CLIN CANCER RES, V12, P4474, DOI 10.1158/1078-0432.CCR-06-0074; Yang C., 2011, CLIN DEV IMMUNOL, V2011, P842; Yoshidome H, 2009, INT J ONCOL, V34, P923, DOI 10.3892/ijo_00000218; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhao L, 2013, HEPATOLOGY, V57, P829, DOI 10.1002/hep.26094; Zijlmans HJMAA, 2006, J PATHOL, V208, P507, DOI 10.1002/path.1918; Zlotnik A, 2011, NAT REV IMMUNOL, V11, P597, DOI 10.1038/nri3049	91	150	152	1	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3217	3224		10.1038/onc.2013.272	http://dx.doi.org/10.1038/onc.2013.272			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23851506	Green Accepted			2022-12-17	WOS:000338443400001
J	Algire, C; Amrein, L; Bazile, M; David, S; Zakikhani, M; Pollak, M				Algire, C.; Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.; Pollak, M.			Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo	ONCOGENE			English	Article						metformin; insulin; cancer; LKB1	HIGH-ENERGY DIET; BREAST-CANCER; DIABETES-MELLITUS; LKB1-AMPK PATHWAY; GLUCOSE-UPTAKE; RISK; GROWTH; KINASE; ACTIVATION; INSULIN	Hypothesis-generating epidemiological research has suggested that cancer burden is reduced in diabetics treated with metformin and experimental work has raised questions regarding the role of direct adenosine monophosphate-activated protein kinase (AMPK)-mediated antineoplastic effects of metformin as compared with indirect effects attributable to reductions in circulating insulin levels in the host. We treated both tumor LKB1 expression and host diet as variables, and observed that metformin inhibited tumor growth and reduced insulin receptor activation in tumors of mice with diet-induced hyperinsulinemia, independent of tumor LKB1 expression. In the absence of hyperinsulinemia, metformin inhibited only the growth of tumors transfected with short hairpin RNA against LKB1, a finding attributable neither to an effect on host insulin level nor to activation of AMPK within the tumor. Further investigation in vitro showed that cells with reduced LKB1 expression are more sensitive to metformin-induced adenosine triphosphate depletion owing to impaired ability to activate LKB1-AMPK-dependent energy-conservation mechanisms. Thus, loss of function of LKB1 can accelerate proliferation in contexts where it functions as a tumor suppressor, but can also sensitize cells to metformin. These findings predict that any clinical utility of metformin or similar compounds in oncology will be restricted to subpopulations defined by host insulin levels and/or loss of function of LKB1. Oncogene (2011) 30, 1174-1182; doi:10.1038/onc.2010.483; published online 22 November 2010	[Algire, C.; Pollak, M.] McGill Univ, Segal Canc Ctr E423, Jewish Gen Hosp, Dept Expt Med, Montreal, PQ H3T 1E2, Canada; [Algire, C.; Pollak, M.] McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Amrein, L.; Bazile, M.; David, S.; Zakikhani, M.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University; Lady Davis Institute; McGill University	Pollak, M (corresponding author), McGill Univ, Segal Canc Ctr E423, Jewish Gen Hosp, Dept Expt Med, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	michael.pollak@mcgill.ca	Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604	Terry Fox Research Institute; Montreal Centre for Experimental Therapeutics in Cancer; Canadian Institute of Health Research Canada	Terry Fox Research Institute; Montreal Centre for Experimental Therapeutics in Cancer; Canadian Institute of Health Research Canada(Canadian Institutes of Health Research (CIHR))	We thank Dr Andre Veillette for his advice and technical expertise, Dr Pnina Brodt for the MC38 cells, Drs Lawrence Panasci and Ernesto Schiffrin for sharing laboratory resources, and Dr Nahum Sonenberg and Dr Russell Jones for reviewing the manuscript prior to submission. This work was supported by a grant from the Terry Fox Research Institute. Ms Algire is supported through the Montreal Centre for Experimental Therapeutics in Cancer student fellowship and the Canadian Institute of Health Research Canada Graduate Fellowship.	Algire C, 2008, ENDOCR-RELAT CANCER, V15, P833, DOI 10.1677/ERC-08-0038; Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252; BLAKE DA, 1989, ANAL BIOCHEM, V177, P156, DOI 10.1016/0003-2697(89)90031-6; Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6; DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Dykens JA, 2008, TOXICOL APPL PHARM, V233, P203, DOI 10.1016/j.taap.2008.08.013; El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223; Engelman JA, 2010, CANCER PREV RES, V3, P1049, DOI 10.1158/1940-6207.CAPR-10-0178; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2006, GASTROENTEROLOGY, V131, P973, DOI 10.1053/j.gastro.2006.07.032; HOSONO K, 2007, CAN PREV RES, V3, P1077; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Larsson SC, 2005, JNCI-J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375; Larsson SC, 2007, INT J CANCER, V121, P856, DOI 10.1002/ijc.22717; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814; Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175; Pollak M, 2009, CELL METAB, V9, P401, DOI 10.1016/j.cmet.2009.04.006; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x; van Lier MGF, 2010, AM J GASTROENTEROL, V105, P1258, DOI 10.1038/ajg.2009.725; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Vigneri P, 2009, ENDOCR-RELAT CANCER, V16, P1103, DOI 10.1677/ERC-09-0087; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081	48	150	158	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1174	1182		10.1038/onc.2010.483	http://dx.doi.org/10.1038/onc.2010.483			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21102522				2022-12-17	WOS:000288202400004
J	Liu, X; Wang, X; Zhang, J; Lam, EKY; Shin, VY; Cheng, ASL; Yu, J; Chan, FKL; Sung, JJY; Jin, HC				Liu, X.; Wang, X.; Zhang, J.; Lam, E. K. Y.; Shin, V. Y.; Cheng, A. S. L.; Yu, J.; Chan, F. K. L.; Sung, J. J. Y.; Jin, H. C.			Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis	ONCOGENE			English	Article						methylation; gastric cancer; glucose metabolism; ras	NF-KAPPA-B; PYRUVATE-KINASE; GLUCOSE-METABOLISM; II HEXOKINASE; CANCER; RAS; P53; TRANSFORMATION; TRANSCRIPTION; REPRESSION	In cancer cells, glucose is often converted into lactic acid, which is known as the 'Warburg effect'. The reason that cancer cells have a higher rate of aerobic glycolysis, but not oxidative phosphorylation, remains largely unclear. Herein, we proposed an epigenetic mechanism of the Warburg effect. Fructose-1,6-bisphosphatase-1 (FBP1), which functions to antagonize glycolysis was downregulated through NF-kappaB pathway in Ras-transformed NIH3T3 cells. Restoration of FBP1 expression suppressed anchorage-independent growth, indicating the relevance of FBP1 downregulation in carcinogenesis. Indeed, FBP1 was downregulated in gastric carcinomas (P < 0.01, n = 22) and gastric cancer cell lines (57%, 4/7). Restoration of FBP1 expression reduced growth and glycolysis in gastric cancer cells. Moreover, FBP1 downregulation was reversed by pharmacological demethylation. Its promoter was hypermethylated in gastric cancer cell lines (57%, 4/7) and gastric carcinomas (33%, 33/101). Inhibition of NF-kappaB restored FBP1 expression, partially through demethylation of FBP1 promoter. Notably, Cox regression analysis revealed FBP1 promoter methylation as an independent prognosis predicator for gastric cancer (hazard ratio: 3.60, P = 0.010). In summary, we found that NF-kappaB functions downstream of Ras to promote epigenetic downregulation of FBP1. Promoter methylation of FBP1 can be used as a new biomarker for prognosis prediction of gastric cancer. Such an important epigenetic link between glycolysis and carcinogenesis partly explains the Warburg effect. Oncogene (2010) 29, 442-450; doi:10.1038/onc.2009.332; published online 2 November 2009	[Jin, H. C.] Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Runrun Shaw Hosp,Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Liu, X.; Zhang, J.; Lam, E. K. Y.; Shin, V. Y.; Cheng, A. S. L.; Jin, H. C.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Chan, F. K. L.; Sung, J. J. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Zhejiang Univ, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Zhejiang University	Jin, HC (corresponding author), Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Runrun Shaw Hosp,Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.	jinhc@srrsh.com	Cheng, Alfred SL/C-3327-2014; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Jin, Hongchuan/C-3686-2009; Chan, Francis K. L./F-4851-2010	Cheng, Alfred SL/0000-0003-2345-6951; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436; Shin, Vivian Yvonne/0000-0003-1282-7593; Jin, Hongchuan/0000-0002-6697-3097; Wang, Xian/0000-0003-0041-7589	RGC-GRF [465808]; Institute of Digestive Disease, the Chinese University of Hong Kong	RGC-GRF(Hong Kong Research Grants Council); Institute of Digestive Disease, the Chinese University of Hong Kong(Chinese University of Hong Kong)	The project was supported by RGC-GRF ( Project No. 465808) granted to HJ, and Research Funding from the Institute of Digestive Disease, the Chinese University of Hong Kong.	Aarenstrup L, 2008, J INVEST DERMATOL, V128, P1095, DOI 10.1038/sj.jid.5701146; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhat KP, 2008, FEBS LETT, V582, P3193, DOI 10.1016/j.febslet.2008.08.010; Cheng YY, 2008, BRIT J CANCER, V99, P2083, DOI 10.1038/sj.bjc.6604760; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Ferguson EC, 2008, TRENDS BIOCHEM SCI, V33, P359, DOI 10.1016/j.tibs.2008.05.006; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kondoh H, 2005, CANCER RES, V65, P177; KOSHIBA M, 1993, JPN J CANCER RES, V84, P163, DOI 10.1111/j.1349-7006.1993.tb02850.x; Lee MG, 2003, J BIOL CHEM, V278, P41047, DOI 10.1074/jbc.M307031200; Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Peng SY, 2008, ONCOL REP, V19, P1045; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; TANNOCK IF, 1968, BRIT J CANCER, V22, P258, DOI 10.1038/bjc.1968.34; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUPEL P, 1989, CANCER RES, V49, P6449; Wang LJ, 2009, BIOCHEM BIOPH RES CO, V379, P959, DOI 10.1016/j.bbrc.2008.12.180; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	36	150	162	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					442	450		10.1038/onc.2009.332	http://dx.doi.org/10.1038/onc.2009.332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19881551				2022-12-17	WOS:000273793200013
J	Stewart, TJ; Abrams, SI				Stewart, T. J.; Abrams, S. I.			How tumours escape mass destruction	ONCOGENE			English	Review						tumour immunity; tumour escape; tumour microenvironment; immunosuppression; immunosurveillance	REGULATORY T-CELLS; MYELOID SUPPRESSOR-CELLS; FAS-MEDIATED APOPTOSIS; COLON-CARCINOMA CELLS; GROWTH-FACTOR-BETA; ANTIGEN-PROCESSING MACHINERY; IMMUNE-RESPONSES; PERIPHERAL-BLOOD; CANCER-IMMUNOTHERAPY; BREAST-CANCER	It is now well established that the immune system can control neoplastic development and growth in a process termed immunosurveillance. A link between host immunosurveillance and neoplastic progression is revealed in cases where the immune response becomes compromised due to genetic or other pathological conditions, resulting in a substantially increased incidence and rate of spontaneous tumour formation in both preclinical animal models and patients. It has also been demonstrated in tumour-bearing hosts that the tumorigenic process itself can promote a state of immunosuppression that, in turn, facilitates neoplastic progression. The ability of neoplastic populations to induce a hostile microenvironment through both cell contact-dependent and -independent immunosuppressive networks is a significant barrier to effective cellmediated immunity and immunotherapy. Thus, a competent immune system is integral for the control of neoplastic disease, and dissecting the plethora of tumour escape mechanisms that disrupt this essential host defense capability is integral for the development of effective immunotherapeutic paradigms.	[Stewart, T. J.; Abrams, S. I.] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Abrams, SI (corresponding author), Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.	scott.abrams@roswellpark.org	Stewart, Trina/F-5967-2012	Stewart, Trina/0000-0003-3220-9231	Intramural Research Program of the NIH; National Cancer Institute; Center for Cancer Research	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Abrams SI, 2004, CURR OPIN MOL THER, V6, P71; Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Bosque A, 2005, EUR J IMMUNOL, V35, P1812, DOI 10.1002/eji.200526046; Bron LP, 2004, PATHOLOGY, V36, P561, DOI 10.1080/00313020400011268; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Chang CC, 2007, CANCER IMMUNOL IMMUN, V56, P227, DOI 10.1007/s00262-006-0183-1; Cuenca A, 2003, CANCER RES, V63, P9007; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202; Demaria S, 2005, CLIN CANCER RES, V11, P728; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Ercolini AM, 2005, J EXP MED, V201, P1591, DOI 10.1084/jem.20042167; Espana L, 2004, BREAST CANCER RES TR, V87, P33, DOI 10.1023/B:BREA.0000041579.51902.89; Ferris RL, 2006, CLIN CANCER RES, V12, P3890, DOI 10.1158/1078-0432.CCR-05-2750; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Flies DB, 2007, J IMMUNOTHER, V30, P251, DOI 10.1097/CJI.0b013e31802e085a; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fricke I, 2007, CLIN CANCER RES, V13, P4840, DOI 10.1158/1078-0432.CCR-07-0409; Gallimore A, 2002, IMMUNOLOGY, V107, P5, DOI 10.1046/j.1365-2567.2002.01471.x; Giovarelli M, 1999, J IMMUNOL, V163, P4886; Gordon N, 2005, J PEDIAT HEMATOL ONC, V27, P611, DOI 10.1097/01.mph.0000188112.42576.df; Greeneltch KM, 2007, CANCER RES, V67, P10406, DOI 10.1158/0008-5472.CAN-07-1228; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harizi H, 2001, CELL IMMUNOL, V209, P19, DOI 10.1006/cimm.2001.1785; Hirano F, 2005, CANCER RES, V65, P1089; Hoffmann TK, 2002, CLIN CANCER RES, V8, P2553; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ichihara F, 2003, CLIN CANCER RES, V9, P4404; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Jung YJ, 2004, INT J MOL MED, V13, P99; Keane MM, 1996, CANCER RES, V56, P4791; Kim R, 2004, CANCER-AM CANCER SOC, V100, P2281, DOI 10.1002/cncr.20270; Koneru M, 2005, J IMMUNOL, V174, P1830, DOI 10.4049/jimmunol.174.4.1830; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Krambeck AE, 2006, P NATL ACAD SCI USA, V103, P10391, DOI 10.1073/pnas.0600937103; Krammer PH, 1998, ADV CANCER RES, V75, P251, DOI 10.1016/S0065-230X(08)60744-7; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kusmartsev S, 2006, CANCER IMMUNOL IMMUN, V55, P237, DOI 10.1007/s00262-005-0048-z; Kuss I, 2004, CLIN CANCER RES, V10, P3755, DOI 10.1158/1078-0432.CCR-04-0054; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Litzinger MT, 2007, BLOOD, V110, P3192, DOI 10.1182/blood-2007-06-094615; Liu KB, 2005, CANCER RES, V65, P4376, DOI 10.1158/0008-5472.CAN-04-4269; Liu KB, 2005, CANCER RES, V65, P1045; Liu KB, 2003, J IMMUNOL, V171, P4164, DOI 10.4049/jimmunol.171.8.4164; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; Liu KB, 2003, J IMMUNOL, V170, P5973, DOI 10.4049/jimmunol.170.12.5973; Liu KB, 2006, J IMMUNOL, V176, P3374, DOI 10.4049/jimmunol.176.6.3374; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lopez-Albaitero A, 2006, J IMMUNOL, V176, P3402, DOI 10.4049/jimmunol.176.6.3402; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Nagaraj S, 2007, ADV EXP MED BIOL, V601, P213; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Ormandy LA, 2005, CANCER RES, V65, P2457, DOI 10.1158/0008-5472.CAN-04-3232; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; Owen-Schaub L, 2000, INT J ONCOL, V17, P5; Pardoll D, 2003, ANNU REV IMMUNOL, V21, P807, DOI 10.1146/annurev.immunol.21.120601.141135; Pawelec Graham, 2002, Trends in Immunology, V23, P330, DOI 10.1016/S1471-4906(02)02255-X; Penn I, 1999, TRANSPLANT P, V31, P1260, DOI 10.1016/S0041-1345(98)01987-3; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Reckamp KL, 2006, CLIN CANCER RES, V12, P3381, DOI 10.1158/1078-0432.CCR-06-0112; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Sadun RE, 2007, CLIN CANCER RES, V13, P4016, DOI 10.1158/1078-0432.CCR-07-0016; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Schmielau J, 2001, CANCER RES, V61, P4756; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Sica GL, 2003, IMMUNITY, V18, P849, DOI 10.1016/S1074-7613(03)00152-3; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Stewart Trina J., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000233; Street SEA, 2007, CANCER RES, V67, P5454, DOI 10.1158/0008-5472.CAN-06-4084; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Terabe M, 2003, J EXP MED, V198, P1741, DOI 10.1084/jem.20022227; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; von Reyher U, 1998, CANCER RES, V58, P526; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Whiteside TL, 2006, SEMIN CANCER BIOL, V16, P3, DOI 10.1016/j.semcancer.2005.07.008; Willimsky G, 2005, NATURE, V437, P141, DOI 10.1038/nature03954; Woo EY, 2001, CANCER RES, V61, P4766; Worth LL, 2002, ONCOL REP, V9, P823; Yang DF, 2007, CANCER RES, V67, P3301, DOI 10.1158/0008-5472.CAN-06-4068; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zamanakou M, 2007, IMMUNOL LETT, V111, P69, DOI 10.1016/j.imlet.2007.06.001; Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505; Zhou G, 2006, BLOOD, V107, P628, DOI 10.1182/blood-2005-07-2737	109	150	159	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 6	2008	27	45					5894	5903		10.1038/onc.2008.268	http://dx.doi.org/10.1038/onc.2008.268			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QE	18836470	Bronze			2022-12-17	WOS:000259722600004
J	Goldin, N; Arzoine, L; Heyfets, A; Israelson, A; Zaslavsky, Z; Bravman, T; Bronner, V; Notcovich, A; Shoshan-Barmatz, V; Flescher, E				Goldin, N.; Arzoine, L.; Heyfets, A.; Israelson, A.; Zaslavsky, Z.; Bravman, T.; Bronner, V.; Notcovich, A.; Shoshan-Barmatz, V.; Flescher, E.			Methyl jasmonate binds to and detaches mitochondria-bound hexokinase	ONCOGENE			English	Article						jasmonate; target; hexokinase; VDAC; mitochondria	DEPENDENT ANION CHANNEL; PERMEABILITY TRANSITION; ENERGY-METABOLISM; ANTICANCER AGENTS; BRAIN HEXOKINASE; CELL-DEATH; RAT-BRAIN; CANCER; APOPTOSIS; GLYCOLYSIS	Cellular bio-energetic metabolism and mitochondria are recognized as potential targets for anticancer agents, due to the numerous relevant peculiarities cancer cells exhibit. Jasmonates are anticancer agents that interact directly with mitochondria. The aim of this study was to identify mitochondrial molecular targets of jasmonates. We report that jasmonates bind to hexokinase and detach it from the mitochondria and its mitochondrial anchor-the voltage-dependent anion channel (VDAC), as judged by hexokinase immunochemical and activity determinations, surface plasmon resonance analysis and planar lipid bilayer VDAC- activity analysis. Furthermore, the susceptibility of cancer cells and mitochondria to jasmonates is dependent on the expression of hexokinase, evaluated using hexokinase-overexpressing transfect ants and its mitochondrial association. Many types of cancer cells exhibit overexpression of the key glycolytic enzyme, hexokinase, and its excessive binding to mitochondria. These characteristics are considered to play a pivotal role in cancer cell growth rate and survival. Thus, our findings provide an explanation for the selective effects of jasmonates on cancer cells. Most importantly, this is the first demonstration of a cytotoxic mechanism based on direct interaction between an anticancer agent and hexokinase. The proposed mechanism can serve to guide development of a new selective approach for cancer therapy.	[Goldin, N.; Heyfets, A.; Flescher, E.] Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; [Arzoine, L.; Israelson, A.; Shoshan-Barmatz, V.] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; [Zaslavsky, Z.] Tel Aviv Univ, Sackler Fac Med, Interdept Core Facil, IL-69978 Tel Aviv, Israel; [Bravman, T.; Bronner, V.; Notcovich, A.] Bio Rad Haifa, Haifa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Tel Aviv University; Sackler Faculty of Medicine	Flescher, E (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.	flascher@post.tau.ac.il		Israelson, Adrian/0000-0002-8289-7653				Al jamal JA, 2005, PROTEIN J, V24, P1, DOI 10.1007/s10930-004-0600-2; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Boozer C, 2006, CURR OPIN BIOTECH, V17, P400, DOI 10.1016/j.copbio.2006.06.012; Brawer Michael K, 2005, Rev Urol, V7 Suppl 7, pS21; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Chini A, 2007, NATURE, V448, P666, DOI 10.1038/nature06006; Cuezva JM, 2002, CANCER RES, V62, P6674; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Ehsani-Zonouz A, 2001, MOL CELL BIOCHEM, V223, P81, DOI 10.1023/A:1017952827675; Fingrut O, 2005, BRIT J PHARMACOL, V146, P800, DOI 10.1038/sj.bjp.0706394; Fingrut O, 2002, LEUKEMIA, V16, P608, DOI 10.1038/sj.leu.2402419; Flescher E, 2005, ANTI-CANCER DRUG, V16, P911, DOI 10.1097/01.cad.0000176501.63680.80; Flescher E, 2007, CANCER LETT, V245, P1, DOI 10.1016/j.canlet.2006.03.001; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goldin N, 2007, J BIOENERG BIOMEMBR, V39, P51, DOI 10.1007/s10863-006-9061-y; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hamilton MD, 2007, NUCLEIC ACIDS RES, V35, P143, DOI 10.1093/nar/gkl1015; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Heyfets A, 2007, CANCER LETT, V250, P300, DOI 10.1016/j.canlet.2006.10.013; Ishii Y, 2004, LEUKEMIA, V18, P1413, DOI 10.1038/sj.leu.2403421; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; KEISARI Y, 1992, J IMMUNOL METHODS, V146, P155, DOI 10.1016/0022-1759(92)90224-H; Kroemer G, 2006, ONCOGENE, V25, P4630, DOI 10.1038/sj.onc.1209589; Kroemer G, 2003, CURR MED CHEM, V10, P1469, DOI 10.2174/0929867033457232; Lampidis TJ, 2006, CANCER CHEMOTH PHARM, V58, P725, DOI 10.1007/s00280-006-0207-8; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Machida K, 2006, J BIOL CHEM, V281, P14314, DOI 10.1074/jbc.M513297200; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Miccoli L, 1998, CANCER RES, V58, P5777; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; OUDARD S, 1995, INT J CANCER, V62, P216, DOI 10.1002/ijc.2910620218; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5; PEDERSEN PL, 2002, BIOCHIM BIOPHYS ACTA, V1355, P14; Penso J, 2003, MOL GENET METAB, V78, P74, DOI 10.1016/S1096-7192(02)00203-2; Reischer D, 2007, BRIT J PHARMACOL, V150, P738, DOI 10.1038/sj.bjp.0707146; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Robey R.B., 2005, DRUG DISCOV TODAY DI, V2, P239, DOI [10.1016/j.ddmec.2005.05.021, DOI 10.1016/J.DDMEC.2005.05.021, DOI 10.1016/j.ddmec.2005.05.021]; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Shoshan-Barmatz V, 2005, J MEMBRANE BIOL, V204, P57, DOI 10.1007/s00232-005-0749-4; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; Varbiro G, 2001, FREE RADICAL BIO MED, V31, P548, DOI 10.1016/S0891-5849(01)00616-5; Warburg O.H., 1930, METABOLISM TUMOURS I; WILSON JE, 1989, PREP BIOCHEM, V19, P13, DOI 10.1080/10826068908544893; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WILSON JE, 1968, J BIOL CHEM, V243, P3640; WILSON JE, 1989, ARCH BIOCHEM BIOPHYS, V269, P517, DOI 10.1016/0003-9861(89)90135-5; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599	55	150	159	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4636	4643		10.1038/onc.2008.108	http://dx.doi.org/10.1038/onc.2008.108			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408762				2022-12-17	WOS:000258236300002
J	McCabe, NP; De, S; Vasanji, A; Brainard, J; Byzova, TV				McCabe, N. P.; De, S.; Vasanji, A.; Brainard, J.; Byzova, T. V.			Prostate cancer specific integrin alpha v beta 3 modulates bone metastatic growth and tissue remodeling	ONCOGENE			English	Article						prostate cancer; metastasis; bone; integrins	BREAST-CANCER; TUMOR-GROWTH; INTEGRIN; ACTIVATION; EXPRESSION; MUTATION; PLATELET; DOMAIN; IIIA	The management of pain and morbidity due to the spreading and growth of cancer within bone remains to be a paramount problem in clinical care. Cancer cells actively transform bone, however, the molecular requirements and mechanisms of this process remain unclear. This study shows that functional modulation of the alpha v beta 3 integrin receptor in prostate cancer cells is required for progression within bone and determines tumor-induced bone tissue transformation. Using histology and quantitative microCT analysis, we show that avb3 integrin is required not only for tumor growth within the bone but for tumor-induced bone gain, a response resembling bone lesions in prostate cancer patients. Expression of normal, fully functional avb3 enabled tumor growth in bone ( incidence: 4/4), whereas avb3 (-), inactive or constitutively active mutants of alpha v beta 3 did not ( incidence: 0/4, 0/6 and 1/7, respectively) within a 35-day-period. This response appeared to be bone-specific in comparison to the subcutis where tumor incidence was greater than 60% for all groups. Interestingly, bone residing prostate cancer cells expressing normal or dis-regulated alpha v beta 3 ( either inactive of constitutively active), but not those lacking beta 3 promoted bone gain or afforded protection from bone loss in the presence or absence of histologically detectable tumor 35 days following implantation. As bone is replete with ligands for beta 3 integrin, we next demonstrated that avb3 integrin activation on tumor cells is essential for the recognition of key bone-specific matrix proteins. As a result, prostate cancer cells expressing fully functional but not dis-regulated avb3 integrin are able to control their own adherence and migration to bone matrix, functions that facilitate tumor growth and control bone lesion development.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Cleveland, OH 44195 USA; Cleveland Clin Educ Fdn, Dept Biomed Engn, Cleveland, OH USA; Cleveland Clin Educ Fdn, Dept Anat & Pathol, Cleveland, OH USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org		Byzova, Tatiana/0000-0002-2615-875X	NCI NIH HHS [R01 CA126847-06, CA1172462, R01 CA126847, R01 CA126847-05A1] Funding Source: Medline; NIAMS NIH HHS [P30 AR050953, 1P30 AR-050953] Funding Source: Medline; NIDDK NIH HHS [R01 DK060933-04, DK060933, R01 DK060933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA126847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090-4295(83)90147-4; Kanamori M, 2004, CANCER RES, V64, P2751, DOI 10.1158/0008-5472.CAN-03-3354; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Latson L, 2003, P ANN INT IEEE EMBS, V25, P1058, DOI 10.1109/IEMBS.2003.1279427; Li W, 2005, P NATL ACAD SCI USA, V102, P1424, DOI 10.1073/pnas.0409334102; Nemeth JA, 2003, CLIN EXP METASTAS, V20, P413, DOI 10.1023/A:1025461507027; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Ruiz C, 2001, BLOOD, V98, P2432, DOI 10.1182/blood.V98.8.2432; Saad F, 2006, EUR UROL, V49, P429, DOI 10.1016/j.eururo.2005.12.045; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398; Stewart Delisha A, 2004, Reprod Biol Endocrinol, V2, P2, DOI 10.1186/1477-7827-2-2; Takayama S, 2005, ANTICANCER RES, V25, P79	23	150	154	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6238	6243		10.1038/sj.onc.1210429	http://dx.doi.org/10.1038/sj.onc.1210429			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17369840	Green Accepted			2022-12-17	WOS:000249401300015
J	Nevanlinna, H; Bartek, J				Nevanlinna, H.; Bartek, J.			The CHEK2 gene and inherited breast cancer susceptibility	ONCOGENE			English	Review						CHEK2; Chk2; DNA damage checkpoints; breast cancer; familial; cancer susceptibility	LI-FRAUMENI-SYNDROME; HEREDITARY PROSTATE-CANCER; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; COLORECTAL-CANCER; 1100DELC MUTATION; TUMOR-SUPPRESSOR; CHK2 GENE; CHEK2-ASTERISK-1100DELC VARIANT; GERMLINE MUTATIONS	Checkpoint kinase 2 (CHEK2, Chk2) emerges as an important signal transducer of cellular responses to DNA damage and a candidate tumor suppressor whose defects contribute to molecular pathogenesis of diverse types of human malignancies, both sporadic and hereditary. Here, we briefly outline the molecular properties, regulation and physiological role of CHEK2, and review in more detail its defects that predispose to tumors, with particular emphasis on familial breast cancer. The frequency, penetrance and epidemiological as well as clinical significance of the two most studied breast cancer-predisposing variants of the CHEK2 gene, 1100delC and I157T, are highlighted in more depth, and additional CHEK2 mutations and their cancer relevance are discussed as well. These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression. Finally, the potential value of information about the CHEK2 status in family counseling and optimizition of individualized cancer treatment is discussed.	Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Biomed Helsinki, FIN-00029 Helsinki, Finland; Inst Canc Biol, Copenhagen, Denmark; Danish Canc Soc, Ctr Genotoxic Stress Res, Copenhagen, Denmark	University of Helsinki; Helsinki University Central Hospital; Danish Cancer Society	Nevanlinna, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Biomed Helsinki, POB 700, FIN-00029 Helsinki, Finland.	heli.nevanlinna@hus.fi	Bartek, Jiri/G-5870-2014	Nevanlinna, Heli/0000-0002-0916-2976				Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Bachinski LL, 2005, CANCER RES, V65, P427; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartkova J, 2004, ONCOGENE, V23, P8545, DOI 10.1038/sj.onc.1207878; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baysal BE, 2004, GYNECOL ONCOL, V95, P62, DOI 10.1016/j.ygyno.2004.07.015; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bernstein JL, 2006, CANCER EPIDEM BIOMAR, V15, P348, DOI 10.1158/1055-9965.EPI-05-0557; Bogdanova N, 2005, INT J CANCER, V116, P263, DOI 10.1002/ijc.21022; Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253; Broeks A, 2004, BREAST CANCER RES TR, V83, P91, DOI 10.1023/B:BREA.0000010697.49896.03; Caligo MA, 2004, HUM MUTAT, V24, P100, DOI 10.1002/humu.20051; Cybulski C, 2004, AM J HUM GENET, V75, P1131, DOI 10.1086/426403; Cybulski C, 2004, CANCER RES, V64, P2677, DOI 10.1158/0008-5472.CAN-04-0341; de Bock GH, 2004, J MED GENET, V41, P731, DOI 10.1136/jmg.2004.019737; de Jong MM, 2005, GENE CHROMOSOME CANC, V43, P377, DOI 10.1002/gcc.20195; de Jong MM, 2005, EUR J CANCER, V41, P1819, DOI 10.1016/j.ejca.2005.04.035; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Dufault MR, 2004, INT J CANCER, V110, P320, DOI 10.1002/ijc.20073; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Einarsdottir K, 2006, PLOS MED, V3, P895, DOI 10.1371/journal.pmed.0030168; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Friedrichsen DM, 2004, BREAST CANCER RES, V6, pR629, DOI 10.1186/bcr933; Goode EL, 2002, CANCER RES, V62, P3052; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Huzarski T, 2005, BREAST CANCER RES TR, V90, P187, DOI 10.1007/s10549-004-3778-2; Ingvarsson S, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr435; Isinger A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-64; Johnson N, 2005, LANCET, V366, P1554, DOI 10.1016/S0140-6736(05)67627-1; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kato N, 2004, CELL DEATH DIFFER, V11, pS153, DOI 10.1038/sj.cdd.4401461; Kilpivaara O, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e110; Kilpivaara O, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.038331; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Kilpivaara O, 2004, INT J CANCER, V111, P543, DOI 10.1002/ijc.20299; Kleibl Z, 2005, BREAST CANCER RES TR, V90, P165, DOI 10.1007/s10549-004-4023-8; Kuschel B, 2003, CANCER EPIDEM BIOMAR, V12, P809; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Lee SB, 2001, CANCER RES, V61, P8062; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Lipton L, 2003, CANCER LETT, V200, P149, DOI 10.1016/S0304-3835(03)00391-4; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2001, CANCER RES, V61, P4990; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meijers-Heijboer H, 2003, AM J HUM GENET, V72, P1308, DOI 10.1086/375121; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Neuhausen S, 2004, INT J CANCER, V108, P477, DOI 10.1002/ijc.11385; Offit Kenneth, 2003, BMC Med Genet, V4, P1, DOI 10.1186/1471-2350-4-1; Oldenburg RA, 2003, CANCER RES, V63, P8153; Osorio A, 2004, INT J CANCER, V108, P54, DOI 10.1002/ijc.11414; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Schutte M, 2003, AM J HUM GENET, V72, P1023, DOI 10.1086/373965; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shaag A, 2005, HUM MOL GENET, V14, P555, DOI 10.1093/hmg/ddi052; Siddiqui R, 2005, FAM CANCER, V4, P177, DOI 10.1007/s10689-004-1946-5; Sodha N, 2002, HUM MUTAT, V20, P460, DOI 10.1002/humu.10136; Sodha N, 2004, CANCER LETT, V215, P187, DOI 10.1016/j.canlet.2004.07.002; Sodha N, 2000, Science, V289, P359; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Syrjakoski K, 2004, INT J CANCER, V108, P475, DOI 10.1002/ijc.11384; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; van Puijenbroek M, 2005, J PATHOL, V206, P198, DOI 10.1002/path.1764; Wagenius M, 2006, SCAND J UROL NEPHROL, V40, P23, DOI 10.1080/00365590500368518; Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379; ZHOU BBS, 2004, NAT REV CANCER, V4, P1, DOI DOI 10.1038/NRC1296	77	150	154	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2006	25	43					5912	5919		10.1038/sj.onc.1209877	http://dx.doi.org/10.1038/sj.onc.1209877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998506				2022-12-17	WOS:000240765900012
J	Nagaraja, GM; Othman, M; Fox, BP; Alsaber, R; Pellegrino, CM; Zeng, Y; Khanna, R; Tamburini, P; Swaroop, A; Kandpal, RP				Nagaraja, GM; Othman, M; Fox, BP; Alsaber, R; Pellegrino, CM; Zeng, Y; Khanna, R; Tamburini, P; Swaroop, A; Kandpal, RP			Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics	ONCOGENE			English	Article						representational difference analysis; microarrays; proteomics; breast carcinoma; biomarkers; copper homeostasis	CARCINOMA CELLS; LYSYL OXIDASE; PROTEINS; DISEASE; IDENTIFICATION; ADHESION; TUMORS; FAMILY; GROWTH; PROGRESSION	We have characterized comprehensive transcript and proteomic profiles of cell lines corresponding to normal breast (MCF10A), noninvasive breast cancer (MCF7) and invasive breast cancer (MDA-MB-231). The transcript profiles were first analysed by a modified protocol for representational difference analysis (RDA) of cDNAs between MCF7 and MDA-MB-231 cells. The majority of genes identified by RDA showed nearly complete concordance with microarray results, and also led to the identification of some differentially expressed genes such as lysyl oxidase, copper transporter ATP7A, EphB6, RUNX2 and a variant of RUNX2. The altered transcripts identified by microarray analysis were involved in cell-cell or cell-matrix interaction, Rho signaling, calcium homeostasis and copper-binding/sensitive activities. A set of nine genes that included GPCR11, cadherin 11, annexin A1, vimentin, lactate dehydrogenase B (upregulated in MDA-MB-231) and GREB1, S100A8, amyloid beta precursor protein, claudin 3 and cadherin 1 (downregulated in MDA-MB-231) were sufficient to distinguish MDA-MB-231 from MCF7 cells. The downregulation of a set of transcripts for proteins involved in cell-cell interaction indicated these transcripts as potential markers for invasiveness that can be detected by methylation-specific PCR. The proteomic profiles indicated altered abundance of fewer proteins as compared to transcript profiles. Antisense knockdown of selected transcripts led to inhibition of cell proliferation that was accompanied by altered proteomic profiles. The proteomic profiles of antisense transfectants suggest the involvement of peptidylprolyl isomerase, Raf kinase inhibitor and 80 kDa protein kinase C substrate in mediating the inhibition of cell proliferation.	Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA; Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA; Bayer Corp, West Haven, CT USA	Fordham University; University of Michigan System; University of Michigan; Bayer AG	Kandpal, RP (corresponding author), Fordham Univ, Dept Biol Sci, Larkin Hall,Room 250,441 E Fordham Rd, Bronx, NY 10458 USA.	kandpal@fordham.edu		Swaroop, Anand/0000-0002-1975-1141				Akiri G, 2003, CANCER RES, V63, P1657; Alpan RS, 1996, MOL MED, V2, P469, DOI 10.1007/BF03401906; Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; Becker M, 2005, MOL CANCER THER, V4, P151; Berger M, 2005, MOL CELL BIOL, V25, P5380, DOI 10.1128/MCB.25.13.5380-5388.2005; BIECHE I, 1995, CLIN CANCER RES, V1, P123; CAMPBELL FC, 1983, BRIT J SURG, V70, P202, DOI 10.1002/bjs.1800700405; CEROSALETTI KM, 1995, GENOMICS, V25, P226, DOI 10.1016/0888-7543(95)80130-E; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Dan S, 2002, CANCER RES, V62, P1139; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Hall J, 2005, CANCER LETT, V227, P105, DOI 10.1016/j.canlet.2004.12.001; Jacob ANK, 1997, SOMAT CELL MOLEC GEN, V23, P83, DOI 10.1007/BF02679968; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; Jones CE, 2004, J BIOL CHEM, V279, P32018, DOI 10.1074/jbc.M403467200; Katoh M, 2003, INT J MOL MED, V12, P3; Keller ET, 2004, CANCER LETT, V207, P131, DOI 10.1016/j.canlet.2004.02.006; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kousidou OC, 2004, ANTICANCER RES, V24, P4025; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mantovani F, 2004, CELL CYCLE, V3, P905; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Moller LB, 2005, HUM MUTAT, V26, P84, DOI 10.1002/humu.20190; Nagaraja GM, 2004, BIOCHEM BIOPH RES CO, V313, P654, DOI 10.1016/j.bbrc.2003.12.001; Pase L, 2004, BIOCHEM J, V378, P1031, DOI 10.1042/BJ20031181; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pratap J, 2003, CANCER RES, V63, P5357; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008-5472.CAN-04-2367; SIEGEL RC, 1976, J BIOL CHEM, V251, P5786; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Warner SL, 2003, MOL CANCER THER, V2, P589; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wiseman A, 2005, MED HYPOTHESES, V65, P32, DOI 10.1016/j.mehy.2005.01.041; Yoshida S, 2004, HUM MOL GENET, V13, P1487, DOI 10.1093/hmg/ddh160; Yu YX, 2001, INT J ONCOL, V18, P905	45	150	199	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2328	2338		10.1038/sj.onc.1209265	http://dx.doi.org/10.1038/sj.onc.1209265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16314837				2022-12-17	WOS:000236764300005
J	Herrant, M; Jacquel, A; Marchetti, S; Belhacene, N; Colosetti, P; Luciano, F; Auberger, P				Herrant, M; Jacquel, A; Marchetti, S; Belhacene, N; Colosetti, P; Luciano, F; Auberger, P			Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis	ONCOGENE			English	Article						Mcl-1; Bim; caspases; cleavage; mitochondria	HUMAN MYELOMA CELLS; FAS-MEDIATED APOPTOSIS; PROTEIN-KINASE-C; BCL-2 FAMILY; INTERFERON-ALPHA; T-LYMPHOCYTES; GENE-PRODUCT; EXPRESSION; SURVIVAL; DEATH	Mcl-1 is an antiapoptotic member of the Bcl-2 family that can promote cell viability. We report here that Mcl-1 is a new substrate for caspases during induction of apoptosis. Mcl-1 cleavage occurs after Asp127 and Asp157 and generates four fragments of 24, 19, 17 and 12 kDa in both intact cells and in vitro, an effect prevented by selective caspase inhibitors. As a consequence, the resulting protein that lacks the first 127 or 157 amino acids contains only the BH1-BH3 domains of Bcl-2 family members. Mutation of Asp127 and Asp157 abolishes the generation of the 24 and 12 kDa fragments and that of the 19 and 17 kDa fragments, respectively. Interestingly, when expressed in HeLa cells Mcl-1 wt and Mcl-1 Delta127 showed a markedly different intracellular distribution. Mcl-1 wt colocalized with a-Tubulin near the internal face of the plasma membrane, while Mcl-1 Delta127 coassociated with Bim-EL at the mitochondrial level. Coinamunoprecipitation experiments also demonstrated that Mcl1 Delta127 exhibited increased binding to Bim when compared to Mcl-1 wt. Finally, Mcl-1 wt unlike Mcl-1 Delta127 inhibited Bim-EL-induced caspase activation. Altogether, our findings demonstrate that cleavage of Mcl-1 by caspases modifies its subcellular localization, increases its association with Bim and inhibits its antiapoptotic function.	Fac Med Nice, INSERM, U526, Equipe Labellisee Ligue Natl Canc,IFR50, F-06107 Nice 2, France; Burnham Inst, La Jolla, CA 92037 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Sanford Burnham Prebys Medical Discovery Institute	Auberger, P (corresponding author), Fac Med Nice, INSERM, U526, Equipe Labellisee Ligue Natl Canc,IFR50, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Jacquel, Arnaud/O-1928-2017; Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; AUBERGER, Patrick/G-1491-2013; Marchetti, Sandrine/P-6479-2016; luciano, frederic/P-6264-2016	Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; Marchetti, Sandrine/0000-0001-8326-5730; luciano, frederic/0000-0001-9253-4998				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; HAN J, 2004, J BIOL CHEM, V10, P10; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; JACQUEL A, 2003, FASEB J, V4, P4; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Luciano F, 2003, FASEB J, V17, P711, DOI 10.1096/fj.02-0716fje; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rinkenberger JL, 2000, GENE DEV, V14, P23; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; ZHU Y, 2004, P NATL ACAD SCI USA, V10, P10; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	150	151	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7863	7873		10.1038/sj.onc.1208069	http://dx.doi.org/10.1038/sj.onc.1208069			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15378010				2022-12-17	WOS:000224331600012
J	Komuro, A; Imamura, T; Saitoh, M; Yoshida, Y; Yamori, T; Miyazono, K; Miyazawa, K				Komuro, A; Imamura, T; Saitoh, M; Yoshida, Y; Yamori, T; Miyazono, K; Miyazawa, K			Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1)	ONCOGENE			English	Article						WWP1; Smurfs; ubiquitin-proteasome pathway; Smad7; TGF-beta	UBIQUITIN LIGASE; SMAD7; RECEPTOR; TARGETS; SMURF1; INHIBITION; EXPRESSION; CANCER; DEGRADATION; ACTIVATION	Smad7 negatively regulates transforming growth factor (TGF)-beta superfamily signaling by binding to activated type I receptors, thereby preventing the phosphorylation of receptor-regulated Smads (R-Smads), as well as by recruiting HECT-type E3 ubiquitin ligases to degrade type I receptors through a ubiquitin-dependent mechanism. To elucidate the regulatory mechanisms of TGF-beta signaling, we searched for novel members of proteins that interact with Smad7 using a yeast two-hybrid system. One of the proteins identified was the WW domain-containing protein 1 (WWP1) that is structurally related to Smad ubiquitin regulatory factors (Smurfs), E3 ubiquitin ligases for Smads and TGF-beta superfamily receptors. Using a TGF-beta-responsive reporter in mammalian cells, we found that WWP1 inhibited transcriptional activities induced by TGF-beta. Similar to Smurfs, WWP1 associated with Smad7 and induced its nuclear export, and enhanced binding of Smad7 to TGF-beta type I receptor to cause ubiquitination and degradation of the receptor. Consistent with these results, WWP1 inhibited phosphorylation of Smad2 induced by TGF-beta. WWP1 thus negatively regulates TGF-beta signaling in cooperation with Smad7. However, unlike Smurfs, WWP1 failed to ubiquitinate R-Smads and SnoN. Importantly, WWP1 and Smurfs were expressed in distinct patterns in human tissues and carcinoma cell lines, suggesting unique pathophysiological roles of WWP1 and Smurfs.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Inst Technol, Grad Sch Biosci Biotechnol, Dept Biol Sci, Yokohama, Kanagawa 2268501, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Japanese Fdn Canc Res, Inst Canc, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Tokyo Institute of Technology; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Miyazawa, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	keiji-miyazawa@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014; 高, 雨莉/HGU-8187-2022					ARTEAGA CL, 1988, CANCER RES, V48, P3898; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; Dan S, 2002, CANCER RES, V62, P1139; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 1999, J CELL SCI, V112, P3519; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Fukuchi M, 2002, CANCER RES, V62, P7162; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	36	150	170	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6914	6923		10.1038/sj.onc.1207885	http://dx.doi.org/10.1038/sj.onc.1207885			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15221015	Bronze			2022-12-17	WOS:000223750700008
J	Stiller, CA				Stiller, CA			Epidemiology and genetics of childhood cancer	ONCOGENE			English	Review						childhood cancer; incidence; familial syndromes; genetic associations; risk factors	ACUTE LYMPHOBLASTIC-LEUKEMIA; EPSTEIN-BARR-VIRUS; IN-VITRO FERTILIZATION; BECKWITH-WIEDEMANN-SYNDROME; POPULATION-BASED COHORT; NEONATAL RISK-FACTORS; WILMS-TUMOR; GERM-LINE; HEREDITARY RETINOBLASTOMA; CHROMOSOME-ABNORMALITIES	Childhood cancer is rare everywhere in the world, with age-standardized annual incidence usually between 70 and 160 per million at age 0-14 years. Greater variation is seen between populations for some specific tumour types. Some of the largest variations are geographical and are attributable to environmental factors, whereas variation mainly on ethnic lines seems likely to be a marker of genetic predisposition. A wide range of familial and genetic syndromes is associated with an increased risk of childhood cancer. Virtually all the excess risk of cancer among first-degree relatives of children with cancer can be accounted for by known hereditary syndromes. Studies of weak predisposition and gene-environment interaction have so far shown limited consistency. There are very few established environmental or exogenous risk factors and most of these are infective agents. Many putative risk factors can hardly ever be investigated epidemiologically except by interview or questionnaire studies. Some recent examples illustrate the continuing problems of participation bias and recall bias.	Univ Oxford, Dept Paediat, Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Stiller, CA (corresponding author), Univ Oxford, Dept Paediat, Childhood Canc Res Grp, 57 Woodstock Rd, Oxford OX2 6HJ, England.	charles.stiller@ccrg.ox.ac.uk		Stiller, Charles/0000-0002-3006-7869				Ajiki W, 1998, CANCER CAUSE CONTROL, V9, P631, DOI 10.1023/A:1008897123707; Alves S, 2002, LEUKEMIA, V16, P1565, DOI 10.1038/sj.leu.2402543; Barbujani G, 1997, P NATL ACAD SCI USA, V94, P4516, DOI 10.1073/pnas.94.9.4516; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Becroft DMO, 1999, PATHOLOGY, V31, P83, DOI 10.1080/003130299105232; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Biegel JA, 1999, CANCER RES, V59, P74; Blatt J, 1997, J PEDIATR-US, V131, P666, DOI 10.1016/S0022-3476(97)70090-8; Breslow NE, 1996, MED PEDIATR ONCOL, V27, P398; Bruinsma F, 2000, HUM REPROD, V15, P604, DOI 10.1093/humrep/15.3.604; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; Chen CL, 1997, BLOOD, V89, P1701, DOI 10.1182/blood.V89.5.1701.1701_1701_1707; CNATTINGIUS S, 1995, J NATL CANCER I, V87, P908, DOI 10.1093/jnci/87.12.908; CNATTINGIUS S, 1995, CANCER EPIDEM BIOMAR, V4, P441; Cope JU, 2000, MED PEDIATR ONCOL, V34, P195, DOI 10.1002/(SICI)1096-911X(200003)34:3<195::AID-MPO6>3.0.CO;2-B; COPPES MJ, 1994, NEW ENGL J MED, V331, P586; Cowan R, 1997, BRIT J CANCER, V76, P141, DOI 10.1038/bjc.1997.354; Crawford DH, 2001, PHILOS T R SOC B, V356, P461, DOI 10.1098/rstb.2000.0783; Davies SM, 2000, CANCER EPIDEM BIOMAR, V9, P563; Davies SM, 2002, BLOOD, V100, P67, DOI 10.1182/blood.V100.1.67; Dearden SP, 1996, BRIT J CANCER, V73, P603, DOI 10.1038/bjc.1996.104; DeBaun MR, 1998, J PEDIATR-US, V132, P398, DOI 10.1016/S0022-3476(98)70008-3; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; Dockerty JD, 2001, INT J EPIDEMIOL, V30, P1428, DOI 10.1093/ije/30.6.1428; Dorak MT, 1999, BLOOD, V94, P694, DOI 10.1182/blood.V94.2.694.414k07_694_700; Dorak MT, 2002, LEUKEMIA RES, V26, P651, DOI 10.1016/S0145-2126(01)00189-8; Doyle P, 1998, LANCET, V352, P452, DOI 10.1016/S0140-6736(05)79186-8; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRAPER GJ, 1977, J MED GENET, V14, P81, DOI 10.1136/jmg.14.2.81; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; Dror Y, 2002, BRIT J HAEMATOL, V118, P701, DOI 10.1046/j.1365-2141.2002.03585.x; DRUT R, 1988, Pediatric Pathology, V8, P331; Evans DGR, 1999, ARCH DIS CHILD, V81, P496, DOI 10.1136/adc.81.6.496; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; Franco RF, 2001, BRIT J HAEMATOL, V115, P616, DOI 10.1046/j.1365-2141.2001.03140.x; GARBER JE, 1988, J NATL CANCER I, V80, P1626, DOI 10.1093/jnci/80.20.1626; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GIUSTI RM, 1995, ANN INTERN MED, V122, P778, DOI 10.7326/0003-4819-122-10-199505150-00008; Glaser SL, 1997, INT J CANCER, V70, P375, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;375::AID-IJC1&gt;3.0.CO;2-T; Glazer ER, 1999, CANCER, V86, P1070, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1070::AID-CNCR25>3.3.CO;2-0; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; GREAVES MF, 1993, LEUKEMIA, V7, P27; Gripp KW, 2002, AM J MED GENET, V108, P80, DOI 10.1002/ajmg.10241; GUTIERREZ MI, 1992, BLOOD, V79, P3261; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; Hasle H, 2001, LANCET ONCOL, V2, P429, DOI 10.1016/S1470-2045(00)00435-6; Hemminki K, 1999, EPIDEMIOLOGY, V10, P271, DOI 10.1097/00001648-199905000-00014; Henneveld HT, 1999, AM J MED GENET, V86, P439, DOI 10.1002/(SICI)1096-8628(19991029)86:5<439::AID-AJMG9>3.3.CO;2-W; Hermon C, 2001, ANN HUM GENET, V65, P167, DOI 10.1017/S0003480001008508; HERSH JH, 1992, J PEDIATR-US, V120, P572, DOI 10.1016/S0022-3476(10)80004-6; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOLLY EA, 1992, AM J EPIDEMIOL, V135, P122, DOI 10.1093/oxfordjournals.aje.a116265; Hooper ML, 1999, BRIT J CANCER, V79, P1273, DOI 10.1038/sj.bjc.6690204; Hoyme HE, 1998, AM J MED GENET, V79, P274, DOI 10.1002/(SICI)1096-8628(19981002)79:4<274::AID-AJMG8>3.0.CO;2-M; Hrusak O, 2002, LEUKEMIA, V16, P720, DOI 10.1038/sj/leu/2402422; Infante-Rivard C, 2002, EPIDEMIOLOGY, V13, P277, DOI 10.1097/00001648-200205000-00007; Infante-Rivard C, 2002, ENVIRON HEALTH PERSP, V110, P591, DOI 10.1289/ehp.02110591; Infante-Rivard C, 1999, EPIDEMIOLOGY, V10, P481, DOI 10.1097/00001648-199909000-00004; Infante-Rivard C, 2000, CANCER CAUSE CONTROL, V11, P547, DOI 10.1023/A:1008976116512; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Iscovich J, 1997, INT J CANCER, V70, P649, DOI 10.1002/(SICI)1097-0215(19970317)70:6<649::AID-IJC4>3.3.CO;2-L; Jemal A, 2000, BRIT J CANCER, V82, P1875, DOI 10.1054/bjoc.2000.1215; Kleinerman RA, 2000, JNCI-J NATL CANCER I, V92, P2037, DOI 10.1093/jnci/92.24.2037; Klip H, 2001, HUM REPROD, V16, P2451, DOI 10.1093/humrep/16.11.2451; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Krajinovic M, 2002, INT J CANCER, V97, P230, DOI 10.1002/ijc.1589; Krajinovic M, 2000, CANCER EPIDEM BIOMAR, V9, P557; Krajinovic M, 1999, BLOOD, V93, P1496, DOI 10.1182/blood.V93.5.1496.405a36_1496_1501; Kramarova E, 1996, INT J CANCER, V68, P759; Law GR, 2002, BRIT J CANCER, V86, P350, DOI 10.1038/sj/bjc/6600092; Lerner-Geva L, 2000, CANCER, V88, P2845, DOI 10.1002/1097-0142(20000615)88:12<2845::AID-CNCR26>3.0.CO;2-E; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1988, PEDIATRICS, V81, P147; LIN HJ, 1994, PHARMACOGENETICS, V4, P125, DOI 10.1097/00008571-199406000-00003; Lindor NM, 1998, JNCI-J NATL CANCER I, V90, P1039, DOI 10.1093/jnci/90.14.1039; Lindsay S, 1997, J MED GENET, V34, P480, DOI 10.1136/jmg.34.6.480; LINET MS, 1991, BRIT J CANCER, V63, P424, DOI 10.1038/bjc.1991.98; Lipton JM, 2001, J PEDIAT HEMATOL ONC, V23, P39, DOI 10.1097/00043426-200101000-00009; McGaughran JM, 1999, J MED GENET, V36, P197; McNally RJQ, 2001, CANCER-AM CANCER SOC, V92, P1967, DOI 10.1002/1097-0142(20011001)92:7<1967::AID-CNCR1716>3.0.CO;2-#; MORRELL D, 1986, J NATL CANCER I, V77, P89; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4; NAROD SA, 1991, BRIT J CANCER, V63, P993, DOI 10.1038/bjc.1991.216; Narod SA, 1997, AM J HUM GENET, V60, P474; Newton R, 2001, INT J CANCER, V92, P622, DOI 10.1002/1097-0215(20010601)92:5&lt;622::AID-IJC1256&gt;3.0.CO;2-K; OLSEN JH, 1995, NEW ENGL J MED, V333, P1594, DOI 10.1056/NEJM199512143332403; OLSON JM, 1995, MED PEDIATR ONCOL, V24, P305, DOI 10.1002/mpo.2950240507; Opitz JM, 1998, AM J MED GENET, V79, P294, DOI 10.1002/(SICI)1096-8628(19981002)79:4<294::AID-AJMG12>3.0.CO;2-M; Paraf F, 1997, J CLIN ONCOL, V15, P2744, DOI 10.1200/JCO.1997.15.7.2744; Parkin DM, 1999, CANCER SURV, V33, P5; Perri P, 2002, ANN NY ACAD SCI, V963, P74; Powell JE, 1998, LANCET, V352, P682, DOI 10.1016/S0140-6736(97)11239-9; POWELL JE, 1995, BRIT J CANCER, V72, P1563, DOI 10.1038/bjc.1995.549; RAJALEKSHMY KR, 1994, LEUKEMIA RES, V18, P183, DOI 10.1016/0145-2126(94)90113-9; Rasmussen SA, 2001, AM J HUM GENET, V68, P1110, DOI 10.1086/320121; Reynolds P, 2002, AM J EPIDEMIOL, V155, P603, DOI 10.1093/aje/155.7.603; Ricciardone MD, 1999, CANCER RES, V59, P290; Roman E, 2002, BRIT J CANCER, V86, P63, DOI 10.1038/sj.bjc.6600007; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; Sandrini R, 1997, J CLIN ENDOCR METAB, V82, P2027, DOI 10.1210/jc.82.7.2027; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schuz J, 1999, INT J EPIDEMIOL, V28, P631, DOI 10.1093/ije/28.4.631; Shibata Y, 2001, LANCET, V358, P1965, DOI 10.1016/S0140-6736(01)06971-9; SHIRAMIZU B, 1991, BLOOD, V77, P1516; Smith MA, 1998, J NATL CANCER I, V90, P1269, DOI 10.1093/jnci/90.17.1269; SOTELOAVILA C, 1980, J PEDIATR-US, V96, P47, DOI 10.1016/S0022-3476(80)80322-2; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; Swerdlow AJ, 2001, ANN HUM GENET, V65, P177, DOI 10.1017/S0003480001008569; Taylor GM, 2002, HUM MOL GENET, V11, P1585; Taylor GM, 1998, BRIT J CANCER, V78, P561, DOI 10.1038/bjc.1998.540; TAYLOR GM, 1995, LEUKEMIA, V9, P440; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Thompson JR, 2001, LANCET, V358, P1935, DOI 10.1016/S0140-6736(01)06959-8; Varley JM, 1999, AM J HUM GENET, V65, P995, DOI 10.1086/302575; Vasen HFA, 2001, J CLIN ONCOL, V19, P4074, DOI 10.1200/JCO.2001.19.20.4074; Wabinga HR, 2000, BRIT J CANCER, V82, P1585, DOI 10.1054/bjoc.1999.1071; Wang LL, 2001, AM J MED GENET, V102, P11, DOI 10.1002/1096-8628(20010722)102:1<11::AID-AJMG1413>3.0.CO;2-A; Wang Q, 1999, CANCER RES, V59, P294; Webb DW, 1996, DEV MED CHILD NEUROL, V38, P146; WEINBERG AG, 1976, J PEDIATR-US, V88, P434, DOI 10.1016/S0022-3476(76)80259-4; Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939; Whiteside D, 2002, CANCER RES, V62, P359; Wiemels JL, 2001, P NATL ACAD SCI USA, V98, P4004, DOI 10.1073/pnas.061408298; Wilkinson JD, 2001, CANCER, V91, P1402, DOI 10.1002/1097-0142(20010401)91:7<1402::AID-CNCR1145>3.0.CO;2-6; WINN DM, 1992, CANCER EPIDEM BIOMAR, V1, P525; Winther JF, 2001, LANCET, V358, P711, DOI 10.1016/S0140-6736(01)05838-X; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387; WU TC, 1987, HEPATOLOGY, V7, P46, DOI 10.1002/hep.1840070111; Ziegler JL, 1996, INT J CANCER, V65, P200, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;200::AID-IJC12&gt;3.0.CO;2-H	136	150	155	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2004	23	38					6429	6444		10.1038/sj.onc.1207717	http://dx.doi.org/10.1038/sj.onc.1207717			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322515				2022-12-17	WOS:000223468800009
J	Zheng, YH; Shi, Y; Tian, CH; Jiang, CS; Jin, HJ; Chen, JJ; Almasan, A; Tang, H; Chen, Q				Zheng, YH; Shi, Y; Tian, CH; Jiang, CS; Jin, HJ; Chen, JJ; Almasan, A; Tang, H; Chen, Q			Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide	ONCOGENE			English	Article						apoptosis; arsenic trioxide; Bcl-2 proteins; cytochrome c; VDAC	ACUTE PROMYELOCYTIC LEUKEMIA; BCL-2 FAMILY; CASPASE ACTIVATION; CELL APOPTOSIS; BAX; MODULATION; MEMBRANE; PROTEIN; MEGACHANNEL; YEAST	The precise molecular mechanism underlying arsenic trioxide (As2O3)-induced apoptosis is a subject of extensive study. Here, we show that clinically relevant doses of As2O3 can induce typical apoptosis in IM-9, a multiple myeloma cell line, in a Bcl-2 inhibitable manner. We confirmed that As2O3 directly induced cytochrome c (cyto c) release from isolated mouse liver mitochondria via the mitochondrial permeability transition pore, and we further identified the voltage-dependent anion channel (VDAC) as a biological target of As2O3 responsible for eliciting cyto c release in apoptosis. First, pretreatment of the isolated mitochondria with an anti-VDAC antibody specifically prevented As2O3-induced cyto c release. Second, in proteoliposome experiments, VDAC by itself was sufficient to mediate As2O3-induced cyto c release, which could be specifically inhibited by Bcl-X-L. Third, As2O3 induced mitochondria membrane potential (DeltaPsim) reduction and cyto c release only in the VDAC-expressing, but not in the VDAC-deficient yeast strain. Finally, we found that As2O3 induced the increased expression and homodimerization of VDAC in IM-9 cells, but not in Bcl-2 overexpressing cells, suggesting that VDAC homodimerization could potentially determine its gating capacity to cyto c, and Bcl-2 blockage of VDAC homodimerization represents a novel mechanism for its inhibition of apoptosis.	Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, State Key lab Biomembrane & Membrane Biotechnol, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing 100080, Peoples R China; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; Institute of Microbiology, CAS; Cleveland Clinic Foundation	Chen, Q (corresponding author), Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, State Key lab Biomembrane & Membrane Biotechnol, Beijing 100080, Peoples R China.	chenq@panda.ioz.ac.cn	Tian, Changhai/AAD-4856-2019; yang, zheng/HGC-7753-2022; Almasan, Alex/C-2715-2008	Almasan, Alex/0000-0002-8916-6650; Chen, Quan/0000-0001-7539-8728	NCI NIH HHS [CA81504, R01 CA082858, R01 CA081504-05, CA82858, R01 CA081504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; BERNARDI P, 1984, BIOCHIM BIOPHYS ACTA, V766, P277, DOI 10.1016/0005-2728(84)90242-1; Chen GQ, 1996, BLOOD, V88, P1052; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KRAUSE J, 1986, BIOCHIM BIOPHYS ACTA, V860, P690, DOI 10.1016/0005-2736(86)90568-7; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mannella CA, 1998, J STRUCT BIOL, V121, P207, DOI 10.1006/jsbi.1997.3954; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Matsuyama S, 1999, CURR OPIN MICROBIOL, V2, P618, DOI 10.1016/S1369-5274(99)00031-4; Miller WH, 2002, CANCER RES, V62, P3893; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Rousselot P, 1999, CANCER RES, V59, P1041; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shi Y, 2003, BIOCHEM BIOPH RES CO, V303, P475, DOI 10.1016/S0006-291X(03)00359-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Takagi-Morishita Y, 2003, BIOL REPROD, V68, P1178, DOI 10.1095/biolreprod.102.007997; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang XD, 2001, GENE DEV, V15, P2922; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Xia T, 2002, CHINESE SCI BULL, V47, P553, DOI 10.1360/02tb9127; Xia T, 2002, FEBS LETT, V510, P62, DOI 10.1016/S0014-5793(01)03228-8; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762	69	150	163	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1239	1247		10.1038/sj.onc.1207205	http://dx.doi.org/10.1038/sj.onc.1207205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647451	Green Accepted			2022-12-17	WOS:000188892200008
J	Meuwissen, R; Linn, SC; van der Valk, M; Mooi, WJ; Berns, A				Meuwissen, R; Linn, SC; van der Valk, M; Mooi, WJ; Berns, A			Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene	ONCOGENE			English	Article						somatic activation; Cre-lox; conditional K-Ras allele; lung epithelial tissue; lung tumors; non-small cell lung cancer	TRANSCRIPTION FACTOR-I; SURFACTANT PROTEIN-B; TRANSGENIC MICE; PULMONARY ADENOCARCINOMA; CLINICAL-SIGNIFICANCE; PROGNOSTIC MARKER; CELL CARCINOMAS; GENE-TRANSFER; CANCER; EXPRESSION	The onset of human lung cancer occurs through sequential mutations in oncogenes and tumor suppressor genes. Mutations in K-Ras play a prominent role in human non-small cell lung cancer. We have developed a mouse lung tumor model in which K-Ras can be sporadically activated through Cre-lox mediated somatic recombination. Adenoviral mediated delivery of Cre recombinase in lung epithelial cells gave rise to rapid onset of tumorigenesis, yielding pulmonary adenocarcinomas with 100% incidence after a short latency. The lung tumor lesions shared many features with human non-small cell lung cancer. Our data show that sporadic expression of the K-Ras oncogene is sufficient to elicit lung tumorigenesis. Therefore this model has many advantages over conventional transgenic models used thus far.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Diagnost Oncol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	tberns@nki.nl						Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; BOHINSKI RJ, 1993, J BIOL CHEM, V268, P11160; BOS JL, 1989, CANCER RES, V49, P4682; CAREY FA, 1992, THORAX, V47, P1041, DOI 10.1136/thx.47.12.1041; CHAN GL, 1992, THER DRUG MONIT, V14, P42, DOI 10.1097/00007691-199202000-00007; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Cooper CA, 1997, J PATHOL, V181, P401, DOI 10.1002/(SICI)1096-9896(199704)181:4<401::AID-PATH799>3.0.CO;2-Y; EDWARDS CW, 1987, J CLIN PATHOL, V40, P125, DOI 10.1136/jcp.40.2.125; FIJNEMAN RJA, 1995, IMMUNOGENETICS, V41, P106, DOI 10.1007/BF00182320; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Howell JM, 1998, HUM GENE THER, V9, P629, DOI 10.1089/hum.1998.9.5-629; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kaufmann O, 2000, HISTOPATHOLOGY, V36, P8; KHOOR A, 1994, J HISTOCHEM CYTOCHEM, V42, P1187, DOI 10.1177/42.9.8064126; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLS NE, 1995, CANCER RES, V55, P1444; Omer CA, 2000, CANCER RES, V60, P2680; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; Ordonez NG, 2000, ADV ANAT PATHOL, V7, P123, DOI 10.1097/00125480-200007020-00007; Otake K, 1998, HUM GENE THER, V9, P2207, DOI 10.1089/hum.1998.9.15-2207; OUDEJANS JJ, 1991, INT J CANCER, V49, P875, DOI 10.1002/ijc.2910490613; Park JY, 2000, LUNG CANCER-J IASLC, V30, P83, DOI 10.1016/S0169-5002(00)00189-6; PELLEGATA NS, 1994, CANCER RES, V54, P1556; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rom WN, 2000, AM J RESP CRIT CARE, V161, P1355, DOI 10.1164/ajrccm.161.4.9908012; SAITOH A, 1990, ONCOGENE, V5, P1195; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SOZZI G, 1995, CANCER RES, V55, P135; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TenHaveOpbroek AAW, 1997, HISTOL HISTOPATHOL, V12, P319; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; WHITSETT JA, 1995, PHYSIOL REV, V75, P749, DOI 10.1152/physrev.1995.75.4.749; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; World Health Organization, 1981, HIST TYP LUNG TUM; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	52	150	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6551	6558		10.1038/sj.onc.1204837	http://dx.doi.org/10.1038/sj.onc.1204837			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641780				2022-12-17	WOS:000171404200008
J	Tagami, S; Eguchi, Y; Kinoshita, M; Takeda, M; Tsujimoto, Y				Tagami, S; Eguchi, Y; Kinoshita, M; Takeda, M; Tsujimoto, Y			A novel protein, RTN-x(S), interacts with both Bcl-x(L) and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity	ONCOGENE			English	Article						RTN-x(S); Bcl-x(L); Bcl-2; endoplasmic reticulum; apoptosis	CYTOCHROME-C; FAMILY PROTEINS; X-L; SUBCELLULAR-LOCALIZATION; BCL-2-BINDING PROTEIN; MITOCHONDRIAL CONTROL; CELL-DEATH; RELEASE; CLONING; APAF-1	Bcl-2 and Bcl-x(L) serve as critical inhibitors of apoptosis triggered by a broad range of stimuli, mainly acting on the mitochondria, We identified two members of the reticulon (RTN) family as Bcl-x(L) binding proteins, i.e,, NSP-C (RTNt-C) and a new family member, RTN-x(S), both of which did not belong to the Bcl-2 family and were predominantly localized on the endoplasmic reticulum (ER). RTN-x(S) interacted with both Bcl-x(L) and Bcl-2, increased the localization of Bcl-xL and Bcl-2 on the ER, and reduced the anti-apoptotic activity of Bcl-xL and Bcl-2. On the other hand, NSP-C interacted only with Bcl-x(L), affected the localization of Bcl-x(L), and reduced Bcl-xL activity, but had no effect on Bcl-2, These results suggest that RTN family proteins can modulate the anti-apoptotic activity of Bcl-x(L) and Bcl-2 by binding with them and can change their localization to the ER.	Osaka Univ, Grad Sch Med, Dept Med Genet, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neuropsychiat, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Med Genet, Biomed Res Ctr, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Kinoshita, Manabu/0000-0001-7923-6902				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; Jia L, 1999, BLOOD, V93, P2353, DOI 10.1182/blood.V93.7.2353.407k20_2353_2359; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	47	150	160	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5736	5746		10.1038/sj.onc.1203948	http://dx.doi.org/10.1038/sj.onc.1203948			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126360				2022-12-17	WOS:000165477700005
J	Baek, JH; Jang, JE; Kang, CM; Chung, HY; Kim, ND; Kim, KW				Baek, JH; Jang, JE; Kang, CM; Chung, HY; Kim, ND; Kim, KW			Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis	ONCOGENE			English	Article						hypoxia; apoptosis; VEGF; bax; bcl-2; MAPK/ERK	ENDOTHELIAL GROWTH-FACTOR; HUMAN HEPATOCELLULAR-CARCINOMA; ACID-INDUCED APOPTOSIS; CYTOCHROME-C; CELL-DEATH; TRANSCRIPTIONAL REGULATION; GENE-TRANSCRIPTION; EXPRESSION; ACTIVATION; RELEASE	Low oxygen and nutrient depletion play critical roles in tumorigenesis, but little is known about how they interact to produce tumor survival and tumor malignancy. In the present study, we investigated the mechanism underlying hypoxia-modulated apoptosis of serum-deprived HepG2 cells, Our results showed that hypoxia blocked the apoptosis, which was accompanied with decreased Bax/ Bcl-2 ratio, inhibited cytochrome c release, and reduced caspase-3 activity. More importantly, increased expressions of VEGF and its receptor-2 (KDR) under hypoxic/ serum-deprived condition suggest that VEGF may act as a survival factor in a self-promoting manner. Data were further supported by results that recombinant human VEGF (rhVEGF) suppressed the serum deprivation-induced apoptosis, and anti-VEGF neutralizing antibody block anti-apoptotic activity of hypoxia, In addition, inhibitors of receptor tyrosine kinase blocked anti-apoptosis of hypoxia, Our study further showed that rhVEGF or hypoxia induced ERK phosphorylation in serum-deprived cells, and that a specific inhibitor of MAPK/ERK, PD98059 eliminated the anti-apoptotic activity of rhVEGF or hypoxia by increasing Bax/Bcl-2 ratio and caspase-3 activity. Our data led us to conclude that induction of ERK phosphorylation and decrease of Bax/Bcl-2 ratio by rhVEGF implies that hypoxia-induced VEGF prevents apoptosis of serum-deprived cells by activating the MAPK/ERK pathway. Taken together, we propose that hypoxia enhances survival of nutrient-depleted tumor cells by reducing susceptibility to apoptosis, which consequently leads to tumor malignancy.	Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Seoul Natl Univ, WHO, Collaborat Ctr Phys Culture & Aging Res Hlth Prom, Seoul 110799, South Korea; Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea	Pusan National University; Seoul National University (SNU); World Health Organization; Pusan National University	Kim, KW (corresponding author), Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea.							ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Bae SK, 1998, CANCER LETT, V126, P97, DOI 10.1016/S0304-3835(97)00538-7; Baek JH, 1996, J BIOCHEM MOL BIOL, V29, P68; Baek JH, 1997, INT J CANCER, V73, P725, DOI 10.1002/(SICI)1097-0215(19971127)73:5<725::AID-IJC19>3.3.CO;2-T; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; DOLBEARE F, 1994, METHOD CELL BIOL, V41, P297; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gotz ME, 1999, J NEUROSCI RES, V56, P420; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hockel M, 1996, CANCER RES, V56, P4509; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Jinno H, 1999, CARCINOGENESIS, V20, P229, DOI 10.1093/carcin/20.2.229; Kim KW, 1998, CANCER RES, V58, P348; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; KWO P, 1995, AM J PHYSIOL-GASTR L, V268, pG613, DOI 10.1152/ajpgi.1995.268.4.G613; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Piossek C, 1999, J BIOL CHEM, V274, P5612, DOI 10.1074/jbc.274.9.5612; Rempel A, 1996, CANCER RES, V56, P2468; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Satoh T, 1996, BRAIN RES, V733, P9, DOI 10.1016/0006-8993(96)00527-6; SCHUSTER SJ, 1989, BLOOD, V73, P13; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; WANG TTY, 1995, CANCER RES, V55, P2487; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Younes M, 1996, CANCER RES, V56, P1164	48	150	167	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4621	4631		10.1038/sj.onc.1203814	http://dx.doi.org/10.1038/sj.onc.1203814			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030151				2022-12-17	WOS:000089438200008
J	Liu, Y; Corcoran, M; Rasool, O; Ivanova, G; Ibbotson, R; Grander, D; Iyengar, A; Baranova, A; Kashuba, V; Merup, M; Wu, XS; Gardiner, A; Mullenbach, R; Poltaraus, A; Hultstrom, AL; Juliusson, G; Chapman, R; Tiller, M; Cotter, F; Gahrton, G; Yankovsky, N; Zabarovsky, E; Einhorn, S; Oscier, D				Liu, Y; Corcoran, M; Rasool, O; Ivanova, G; Ibbotson, R; Grander, D; Iyengar, A; Baranova, A; Kashuba, V; Merup, M; Wu, XS; Gardiner, A; Mullenbach, R; Poltaraus, A; Hultstrom, AL; Juliusson, G; Chapman, R; Tiller, M; Cotter, F; Gahrton, G; Yankovsky, N; Zabarovsky, E; Einhorn, S; Oscier, D			Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia	ONCOGENE			English	Article						chronic lymphocytic leukemia; 13q14; tumor suppressor gene	RETINOBLASTOMA GENE; LOCUS; DELETIONS; CELLS; PRODUCT; TRANSLOCATION; HYBRIDIZATION; BREAKPOINT; PROTEINS; TOOL	Previous studies have indicated the presence of a putative tumor suppressor gene on chromosome 13q14, commonly deleted in patients with B-cell chronic lymphocytic leukemia (B-CLL), We have previously defined a minimally deleted region of 130 kb centromeric to the marker D13S272, and constructed a PAC and cosmid contig encompassing this area, In the present study we have made a detailed restriction and transcriptional map of the region of interest, Using these tools we have screened a panel of 206 primary CLL clones and three cell lines. In five CLL cases we found limited deletions defining the region of interest to an area of no more than 10 kb, Two adjacent genes, termed Leu1 and Leu2 (leukemia-associated gene 1 and 2), mere mapped to the minimally deleted region, with several patients showing deletion borders within these genes, The Leu1 and Lead genes show little homology to previously published genes at the nucleotide and expected translated amino acid sequence level, Mutational analysis of the Leu1 and 2 genes in 170 CLL samples revealed no small intragenic mutations or point mutations, However, in all cases of 13q14 loss examined, the first exon of both genes, which are only 300 bp apart, were deleted, We conclude that the Leu1 and Lead genes are strong candidates as tumor suppressor gene(s) involved in B-CLL leukemogenesis.	KAROLINSKA HOSP,RADIUMHEMMET,S-17176 STOCKHOLM,SWEDEN; ROYAL BOURNEMOUTH HOSP,MOL BIOL LAB,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND; RUSSIAN ACAD SCI,INST GEN GENET,GENOME ANAL LAB,MOSCOW 117809,RUSSIA; KAROLINSKA INST,MOL & TUMOR BIOL CTR,S-17177 STOCKHOLM,SWEDEN; HUDDINGE HOSP,DEPT HEMATOL,S-14186 HUDDINGE,SWEDEN; HUDDINGE HOSP,DEPT MED,S-14186 HUDDINGE,SWEDEN; ICRF,MOL ONCOL UNIT,INST CHILD HLTH,LONDON,ENGLAND; RUSSIAN ACAD SCI,VA ENGELHARDT MOL BIOL INST,DEPT SEQUENCING & MAPPING HUMAN GENOME,MOSCOW 117984,RUSSIA; LINKOPING UNIV HOSP,DEPT HEMATOL,S-58185 LINKOPING,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Karolinska Institutet; University of London; University College London; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Linkoping University			Liu, Yie/AAO-2092-2020; Baranova, Anna/HGB-3721-2022; , Ancha/B-4608-2012; Kashuba, Vladimir I/N-3732-2017; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir/AAO-7742-2020; Yankovsky, Nick/AAU-9657-2021	, Ancha/0000-0001-6810-5982; Kashuba, Vladimir I/0000-0001-9416-8282; Liebe, Roman/0000-0002-3199-5595; Yankovsky, Nikolay/0000-0002-2467-2683				ALLIKMETS RL, 1994, GENOMICS, V19, P303, DOI 10.1006/geno.1994.1062; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Batova A, 1997, CANCER RES, V57, P832; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CORCORAN MM, 1997, IN PRESS BLOOD; DIGWEED M, 1995, MOL CELL BIOL, V15, P305, DOI 10.1128/MCB.15.1.305; FISHER SG, 1994, GENOMICS, V21, P525; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8898; FU TB, 1994, CANCER RES, V54, P6297; GarciaMarco JA, 1996, BLOOD, V88, P1568; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; HAIDAR MA, 1995, BLOOD, V86, P311, DOI 10.1182/blood.V86.1.311.bloodjournal861311; HAWTHORN LA, 1993, ONCOGENE, V8, P1415; HEISKANEN M, 1994, BIOTECHNIQUES, V17, P928; HEISKANEN M, 1994, BIOTECHNIQUES, V17, P932; Heyman M, 1996, LEUKEMIA LYMPHOMA, V23, P235, DOI 10.3109/10428199609054826; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; IMREH S, 1997, IN PRESS GENES CHROM; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kapanadze BI, 1996, GENETIKA+, V32, P331; KISHIDA T, 1995, CANCER RES, V55, P4544; LIU Y, 1992, GENE CHROMOSOME CANC, V4, P250, DOI 10.1002/gcc.2870040310; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LIU Y, 1993, P NATL ACAD SCI USA, V90, P8697, DOI 10.1073/pnas.90.18.8697; MEEKER TC, 1989, BLOOD, V74, P1801; MERUP M, 1997, IN PRESS LEUKAEMIA; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; OSCIER DG, 1994, BLOOD REV, V8, P88, DOI 10.1016/S0268-960X(05)80013-X; Panayiotidis P, 1997, BRIT J HAEMATOL, V97, P844, DOI 10.1046/j.1365-2141.1997.1322949.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUELLE DE, 1995, CELL, V83, P993; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SOULIER J, 1994, ONCOGENE, V9, P3565; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WASMUTH JJ, 1991, HUMAN GENEMAPPING, V11, P261; WENDELHANSEN V, 1994, LEUKEMIA, V8, P476; WU X, 1997, IN PRESS GENES CHROM	39	150	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2463	2473		10.1038/sj.onc.1201643	http://dx.doi.org/10.1038/sj.onc.1201643			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395242				2022-12-17	WOS:A1997YE96300008
J	Barrett, MT; Sanchez, CA; Galipeau, PC; Neshat, K; Emond, M; Reid, BJ				Barrett, MT; Sanchez, CA; Galipeau, PC; Neshat, K; Emond, M; Reid, BJ			Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus	ONCOGENE			English	Article						9p21; CDKN2/p16; Barrett's esophagus	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; HOMOZYGOUS DELETIONS; LUNG-CANCER; P16 GENE; ADENOCARCINOMA; MELANOMA; CHROMOSOME-9; P16/CDKN2	High frequency allelic loss of chromosome 9p21 has been reported in a number of human cancers, including those of the esophagus, The CDKN2 gene on chromosome 9p21 that encodes the p16 inhibitor of cyclinD/Cdk4 complexes is a target of allelic loss and inactivation in a variety of human cancers and cell lines, However, the roles of 9p21 allelic losses and CDKN2 mutations in human neoplastic progression in vivo remain controversial, We determined the prevalence of allelic loss at 9p21 and mutations in CDKN2 in esophageal adenocarcinomas and investigated the order in which they occurred relative to the development of aneuploidy and cancer during neoplastic progression, Aneuploid cell populations from 32 patients with Barrett's esophagus who had premalignant epithelium, cancer, or both, were purified by DNA content flow cytometric cell sorting and evaluated by polymerase chain reaction, Twenty-four of 32 informative patients (75%) had allelic loss at 9p21 in aneuploid cell populations, Premalignant epithelium was available for seven of the patients who had 9p21 allelic losses in cancer; allelic loss of 9p21 was detected before cancer in all seven (100%), Allelic loss of 9p21 preceded the development of aneuploidy in 13 of 15 patients (87%) who had aneuploid cell populations detected in premalignant epithelium, and the two events were detected simultaneously in the remaining two patients, Five of 22 aneuploid populations (23%) with 9p21 loss had somatic mutations in the remaining CDKN2 allele, The same mutations and 9p21 allelic losses were also found in the corresponding diploid cells from premalignant epithelium in all three cases that were evaluable, However, there was no evidence for mutation or homozygous deletion of p16 in the other 17 patients with 9p21 allelic loss, Our results indicate that 9p21 allelic losses and CDKN2 mutations develop as early lesions in diploid cells before aneuploidy and cancer during neoplastic progression in Barrett's esophagus.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NCI NIH HHS [R01CA61202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett MT, 1996, ONCOGENE, V12, P1873; BARRETT MT, 1995, NUC ACIDS RES, V23, P3368; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DREYLING MH, 1995, CANCER RES, V55, P984; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; MERLO A, 1994, CANCER RES, V54, P640; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NESHAT K, 1994, COLD SPRING HARB SYM, V59, P577, DOI 10.1101/SQB.1994.059.01.065; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; REID BI, 1992, GASTROENTEROLOGY, V102, P1211; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; TARMIN L, 1994, CANCER RES, V54, P6094; VANDERRIET P, 1994, CANCER RES, V54, P1156; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WICK ST, 1995, XU L, V11, P2013; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; ZHANG SY, 1994, CANCER RES, V54, P5050; Zhou P, 1996, CANCER RES, V56, P36	42	150	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1867	1873						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934532				2022-12-17	WOS:A1996VR79500005
J	Rickert, P; Seghezzi, W; Shanahan, F; Cho, H; Lees, E				Rickert, P; Seghezzi, W; Shanahan, F; Cho, H; Lees, E			Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II	ONCOGENE			English	Article						cyclin C; CDK8; RNA polymerase II; cell cycle	CARBOXYL-TERMINAL-DOMAIN; HUMAN CELL-CYCLE; PROTEIN-KINASE; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; YEAST; PHOSPHORYLATION; PHASE; G(1)	A number of cyclin/kinase complexes have been identified in mammalian cells that are essential for controlled cell proliferation. Cyclin C was isolated by virtue of its ability to rescue the triple CLN mutation in yeast; however, until now its function has remained unclear. Cyclin C associates with a novel cyclin dependent kinase, CDK8, and we demonstrate that this complex is associated with kinase activity towards the carboxy-terminal domain (CTD) of RNA polymerase II. We have identified at least two distinct cyclin C/CDK8 containing complexes within the cell, a larger complex over 500 kD in size, that also contains the largest subunit of RNA polymerase II, and a smaller 170 kD species. Both of these cyclin C complexes retain potent CTD kinase activity. We further demonstrate that the cyclin C/CDK8 complex associates with the large subunit of RNA polymerase II in vivo, implicating a potential role for cyclin C/CDK8 in regulating its activities.	DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center								BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BATES S, 1994, ONCOGENE, V9, P71; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANA X, 1995, ONCOGENE, V11, P211; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUCHIN A, 1995, P NATL ACAD SCI USA, V92, P4006; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALDONADO E, 1996, IN PRESS NATURE; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; NEVINS JR, 1992, SCIENCE, V258, P424; NONET ML, 1989, GENETICS, V123, P715; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; TAMURA K, 1993, ONCOGENE, V8, P2113; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1989, J BIOL CHEM, V264, P1151; TSAI LH, 1993, ONCOGENE, V8, P1593; WU LT, 1994, ONCOGENE, V9, P2089; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013	72	150	157	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2631	2640						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700522				2022-12-17	WOS:A1996UW48700017
J	PARK, DJ; NAKAMURA, H; CHUMAKOV, AM; SAID, JW; MILLER, CW; CHEN, DL; KOEFFLER, HP				PARK, DJ; NAKAMURA, H; CHUMAKOV, AM; SAID, JW; MILLER, CW; CHEN, DL; KOEFFLER, HP			TRANSACTIVATIONAL AND DNA-BINDING ABILITIES OF ENDOGENOUS P53 IN P53 MUTANT-CELL LINES	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENE; WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; MUTATIONS; EXPRESSION; ANTIGEN; CARCINOMAS	Cells with divergent mutant alleles of the p53 gene have different biological and biochemical properties in vitro. Increasing evidence indicates that p53 is a transcriptional activator, and recently, high affinity DNA binding sites for p53 have been identified. The purpose of this study was to determine in vivo, the effect that various mutant p53 proteins have on their ability to mediate transactivation and to bind specifically to DNA. Either a p53 responsive or control reporter gene was transfected into 18 human carcinoma cell lines, having various p53 mutations, either with or without a wild-type p53 expression vector, The CAT activity and DNA gel retardation were studied to measure transactivation and DNA binding by these endogenous p53s. As expected, the endogenously produced wild-type p53 binds to DNA binding sequences and can transactivate a reporter construct containing a p53 high affinity DNA binding site. Four of five cell lines with homozygous p53 mutations at codon 273 (273(His)), contained p53 which had the ability to bind to p53 DNA binding sequences and transactivate. In contrast, all the homozygous, non-codon 273 mutant p53s (156(Pro), 175(His), 223(Leu), 248(Gln), 248(Trp), 280(Lys)) present in the other cell lines had no transactivating ability. These findings suggest that the biology of cancers with mutations at codon 273 may be different than those with p53 mutations at other sites. The p53 from WRO, a thyroid carcinoma cell line with p53 mutation at codon 223 (223(Leu)), was able to bind p53 DNA recognition sequences, but was unable to transactivate. Interestingly, in a vulvar carcinoma cell line (A431) with a p53 mutation at codon 273 (273(His)), the p53 was unable to transactivate and gave an aberrant band on gel retardation. Both CEM and SK-UT-1, which have compound heterozygous mutations at codons 175/248 (175(His)/248(His)), produced p53 which can complex with DNA, as well as transactivate. In contrast, the p53 in cell lines with either homozygous 175(His) or 248(His) p53 mutations, were unable either to transactivate or bind to the p53 response element. A cell line (NPA) heterozygous for 266(Glu) p53 mutation, was able to efficiently transactivate a reporter containing a p53 DNA binding site, therefore showing no evidence of a dominant negative effect of the endogenous p53 mutant allele. In summary, this in vivo study further supports the idea that different p53 mutant alleles have various properties which may affect their function.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	PARK, DJ (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV HEMATOL ONCOL,8700 BEVERLY BLVD,B-210,LOS ANGELES,CA 90048, USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NCI NIH HHS [CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042710, P01CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN JY, 1993, ONCOGENE, V8, P2159; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDEIRY WS, 1992, NAT GENET, V1, P44; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEVINE AJ, 1992, CANCER SURV, V12, P59; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MILLER CW, 1993, ONCOGENE, V8, P1815; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SAID JW, 1992, AM J PATHOL, V141, P1343; SAKASHITA A, 1992, BLOOD, V79, P477; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P636; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SLINGERLAND JM, 1991, BLOOD, V77, P1500; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRATTON MR, 1990, ONCOGENE, V5, P1297; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	70	150	152	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1899	1906						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208536				2022-12-17	WOS:A1994NR68500013
J	PIERCE, JH; ARNSTEIN, P; DIMARCO, E; ARTRIP, J; KRAUS, MH; LONARDO, F; DIFIORE, PP; AARONSON, SA				PIERCE, JH; ARNSTEIN, P; DIMARCO, E; ARTRIP, J; KRAUS, MH; LONARDO, F; DIFIORE, PP; AARONSON, SA			ONCOGENIC POTENTIAL OF ERBB-2 IN HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							NEU ONCOGENE; EGF RECEPTOR; AMPLIFICATION; LINES; GENE; TRANSFORMATION; OVEREXPRESSION; ADENOCARCINOMA; PROTOONCOGENE; CARCINOMAS	Introduction of the normal erbB-2 gene into immortalized human mammary epithelial cells (184B5) by transfection conferred a growth advantage to these cells both in vitro and in vivo. The 184B5 cells overexpressing erbB-2 formed colonies in semi-solid medium, frequently induced transient nodules in athymic mice and produced progressive tumors in vivo at a low frequency. Those tumors which did arise from erbB-2-transfected cells displayed substantially higher levels of normal gp185erb-2 protein when compared to the original transfectants, consistent with their selection for increased erbB-2 expression. Introduction of genes encoding genetically altered erbB-2 molecules into 184B5 cells increased their colony-forming efficiency and converted the cells to a tumorigenic phenotype at a high frequency. When the biological and biochemical properties of human mammary carcinoma cell lines known to overexpress erbB-2 were compared to the transfected 184B5 lines, they behaved most like those overexpressing the normal erbB-2 protein. Results indicate that overexpression of normal erbB-2 may directly contribute to the transformation of human mammary epithelium if sufficient levels of erbB-2 protein are expressed or if the erbB-2 gene is genetically altered.	CALIF DEPT HLTH SERV,BERKELEY,CA 94704; IST NAZL RIC,I-16132 GENOA,ITALY; UNIV ROCHESTER,SCH MED,DEPT PATHOL,ROCHESTER,NY 14627	California Department of Health Care Services; University of Rochester	PIERCE, JH (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Di Marco, Eddi/AAB-5162-2021; Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CLARK R, 1988, CANCER RES, V48, P4689; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KOZBOR D, 1984, CANCER RES, V44, P438; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEGATTO O, 1988, MOL CELL BIOL, V8, P5510; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019	23	150	152	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1189	1194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1713661				2022-12-17	WOS:A1991GV26000014
J	Zerdes, I; Matikas, A; Bergh, J; Rassidakis, GZ; Foukakis, T				Zerdes, Ioannis; Matikas, Alexios; Bergh, Jonas; Rassidakis, George Z.; Foukakis, Theodoros			Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations	ONCOGENE			English	Review							CELL LUNG-CANCER; NF-KAPPA-B; TUMOR-INFILTRATING LYMPHOCYTES; INDUCED B7-H1 EXPRESSION; EBV-DRIVEN LMP1; PD-L1 EXPRESSION; SQUAMOUS-CELL; BREAST-CANCER; POOR-PROGNOSIS; OPEN-LABEL	The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies that are approved for routine clinical use. The regulation of PD-L1 expression is complex, varies between different tumor types and occurs at the genetic, transcriptional and post-transcriptional levels. Copy number alterations of PD-L1 locus have been reported with varying frequency in several tumor types. At the transcriptional level, a number of transcriptional factors seem to regulate PD-L1 expression including HIF-1, STAT3, NF-kappa B, and AP-1. Activation of common oncogenic pathways such as JAK/STAT, RAS/ERK, or PI3K/AKT/MTOR, as well as treatment with cytotoxic agents have also been shown to affect tumoral PD-L1 expression. Correlative studies of clinical trials with PD-1/PD-L1 inhibitors have so far shown markedly discordant results regarding the value of PD-L1 expression as a marker of response to treatment. As the indications for immune checkpoint inhibition broaden, understanding the regulation of PD-L1 in cancer will be of utmost importance for defining its role as predictive marker but also for optimizing strategies for cancer immunotherapy. Here, we review the current knowledge of PD-L1 regulation, and its use as biomarker and as therapeutic target in cancer.	[Zerdes, Ioannis; Matikas, Alexios; Bergh, Jonas; Rassidakis, George Z.; Foukakis, Theodoros] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden; [Matikas, Alexios; Bergh, Jonas; Foukakis, Theodoros] Karolinska Univ Hosp, Dept Oncol, Radiumhemmet, Stockholm, Sweden; [Rassidakis, George Z.] Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Foukakis, T (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden.; Foukakis, T (corresponding author), Karolinska Univ Hosp, Dept Oncol, Radiumhemmet, Stockholm, Sweden.	Theodoros.Foukakis@ki.se	Zerdes, Ioannis/AAJ-3258-2020; Rassidakis, George/V-9553-2019	Bergh, Jonas/0000-0001-5526-1847; Foukakis, Theodoros/0000-0001-8952-9987; Zerdes, Ioannis/0000-0002-8304-2462; Matikas, Alexios/0000-0002-4122-9624	Swedish Cancer Society [CAN 2015/713]; Cancer Society in Stockholm [154132]; Swedish Breast Cancer Association; European Society for Medical Oncology Georges Mathe Translational Research Fellowship; Hellenic Society of Medical Oncology	Swedish Cancer Society(Swedish Cancer Society); Cancer Society in Stockholm; Swedish Breast Cancer Association; European Society for Medical Oncology Georges Mathe Translational Research Fellowship; Hellenic Society of Medical Oncology	This study was supported by the Swedish Cancer Society (CAN 2015/713 to TF); the Cancer Society in Stockholm (154132 to TF); The Swedish Breast Cancer Association (IZ, TF); European Society for Medical Oncology Georges Mathe Translational Research Fellowship (AM); and Hellenic Society of Medical Oncology (AM).	Abbas M, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0770-8; Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Atsaves V, 2017, LEUKEMIA, V31, P1633, DOI 10.1038/leu.2017.103; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Balan M, 2015, J BIOL CHEM, V290, P8110, DOI 10.1074/jbc.M114.612689; Barrett MT, 2015, ONCOTARGET, V6, P26483, DOI 10.18632/oncotarget.4494; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Belldegrun AS, 2008, CANCER-AM CANCER SOC, V113, P2457, DOI 10.1002/cncr.23851; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bellucci R, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008824; Bi XW, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0341-7; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Budczies J, 2016, GENE CHROMOSOME CANC, V55, P626, DOI 10.1002/gcc.22365; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Casadevall D, 2017, CLIN LUNG CANCER, V18, P682, DOI 10.1016/j.cllc.2017.04.014; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chang YL, 2017, ONCOTARGET, V8, P18021, DOI 10.18632/oncotarget.14935; Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Chen S, 2017, INT J CANCER, V140, P1384, DOI 10.1002/ijc.30552; Cheung JC, 2007, METHODS, V41, P451, DOI 10.1016/j.ymeth.2006.10.002; Chikuma S, 2016, INT J CLIN ONCOL, V21, P448, DOI 10.1007/s10147-016-0958-0; Chong LC, 2016, BLOOD, V128, P1206, DOI 10.1182/blood-2015-11-683003; Choueiri TK, 2014, ANN ONCOL, V25, P2178, DOI 10.1093/annonc/mdu445; Clave S, 2018, HISTOPATHOLOGY, V72, P259, DOI 10.1111/his.13339; Coelho M, 2014, 10 NCRI CANC C LIV U; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Coppin C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001425.pub2; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Dai C, 2017, ONCOTARGETS THER, V10, P3625, DOI 10.2147/OTT.S138044; Danilova L, 2016, P NATL ACAD SCI USA, V113, pE7769, DOI 10.1073/pnas.1607836113; Darb-Esfahani S, 2016, ONCOTARGET, V7, P1486, DOI 10.18632/oncotarget.6429; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Diana A, 2016, ONCOTARGET, V7, P40992, DOI 10.18632/oncotarget.10038; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dorand RD, 2016, SCIENCE, V353, P399, DOI 10.1126/science.aae0477; Erlmeier F, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0926-1; Escudier B, 2017, ANN ONCOL, V28; Escudier B, 2017, EUR UROL, V72, P368, DOI 10.1016/j.eururo.2017.03.037; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Fan YW, 2016, ONCOTARGETS THER, V9, P6075, DOI 10.2147/OTT.S115054; Fan YH, 2013, PROTEIN CELL, V4, P176, DOI 10.1007/s13238-013-2084-3; Fang WF, 2014, ONCOTARGET, V5, P12189, DOI 10.18632/oncotarget.2608; Fang X, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006398; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Fujita Y, 2015, MOL THER, V23, P717, DOI 10.1038/mt.2015.10; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gallagher SJ, 2014, PIGM CELL MELANOMA R, V27, P1126, DOI 10.1111/pcmr.12282; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Gandara D, 2017, AM SOC CLIN ONC ANN; Gandini S, 2016, CRIT REV ONCOL HEMAT, V100, P88, DOI 10.1016/j.critrevonc.2016.02.001; Gangadhar T, 2016, EUR SOC MED ONC ANN; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; George J, 2017, CLIN CANCER RES, V23, P1220, DOI 10.1158/1078-0432.CCR-16-1069; Georgiou K, 2016, BLOOD, V127, P3026, DOI 10.1182/blood-2015-12-686550; Gevensleben H, 2016, CLIN CANCER RES, V22, P1969, DOI 10.1158/1078-0432.CCR-15-2042; Ghebeh H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2605; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Goldmann T, 2016, ANN ONCOL, V27, P206, DOI 10.1093/annonc/mdv510; Gong AY, 2009, J IMMUNOL, V182, P1325, DOI 10.4049/jimmunol.182.3.1325; Gong WR, 2011, J CHEMOTHERAPY, V23, P295, DOI 10.1179/joc.2011.23.5.295; Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168; Gotwals P, 2017, NAT REV CANCER, V17, P286, DOI 10.1038/nrc.2017.17; Gowrishankar K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123410; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Grinberg-Bleyer Y, 2016, CANCER CELL, V30, P829, DOI 10.1016/j.ccell.2016.11.013; Gu LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182692; Gu XB, 2016, ONCOTARGETS THER, V9, P4805, DOI 10.2147/OTT.S110713; Guo L, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2513-x; Han WL, 2003, GENOMICS, V81, P609, DOI 10.1016/S0888-7543(03)00095-8; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Horita H, 2017, NEOPLASIA, V19, P346, DOI 10.1016/j.neo.2017.02.006; Horvat TZ, 2015, J CLIN ONCOL, V33, P3193, DOI 10.1200/JCO.2015.60.8448; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Huang SY, 2016, ONCOTARGET, V7, P62490, DOI 10.18632/oncotarget.11519; Huang YD, 2015, ONCOL REP, V33, P3075, DOI 10.3892/or.2015.3933; Igawa S, 2017, ONCOLOGY-BASEL, V92, P283, DOI 10.1159/000458412; Ikeda S, 2016, J THORAC ONCOL, V11, P62, DOI 10.1016/j.jtho.2015.09.010; Ingram JR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00799-8; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jesinghaus M, 2017, ONCOTARGET, V8, P46756, DOI 10.18632/oncotarget.18606; Jiang XF, 2013, CLIN CANCER RES, V19, P598, DOI 10.1158/1078-0432.CCR-12-2731; Jung HI, 2017, CANCER RES TREAT, V49, P246, DOI 10.4143/crt.2016.066; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Khunger M, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.16.00030; Kim HR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36956; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Kogashiwa Y, 2017, ANTICANCER RES, V37, P1417, DOI 10.21873/anticanres.11465; Koh J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1108514; Koh YW, 2017, ANN HEMATOL, V96, P1883, DOI 10.1007/s00277-017-3115-6; Koromilas Antonis E, 2013, JAKSTAT, V2, pe23353, DOI 10.4161/jkst.23353; La-Beck NM, 2015, PHARMACOTHERAPY, V35, P963, DOI 10.1002/phar.1643; Labiano S, 2015, SEMIN ONCOL, V42, P378, DOI 10.1053/j.seminoncol.2015.02.009; Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee CK, 2018, JAMA ONCOL, V4, P210, DOI 10.1001/jamaoncol.2017.4427; Lee KS, 2017, CANCER IMMUNOL IMMUN, V66, P927, DOI 10.1007/s00262-017-1999-6; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Leite KRM, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0414-x; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Li XX, 2016, AM J CLIN PATHOL, V146, P496, DOI [10.1093/AJCP/AQW134, 10.1093/ajcp/aqw134]; Li X, 2016, TARGET ONCOL, V11, P753, DOI 10.1007/s11523-016-0451-8; Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x; Lienlaf M, 2016, MOL ONCOL, V10, P735, DOI 10.1016/j.molonc.2015.12.012; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Lin YK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137890; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Liu YX, 2016, ONCOTARGETS THER, V9, P2649, DOI 10.2147/OTT.S102616; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Long GV, 2017, JAMA ONCOL, V3, P1511, DOI 10.1001/jamaoncol.2017.1588; Luo M, 2016, ONCOTARGET, V7, P29794, DOI 10.18632/oncotarget.7631; Ma K, 2017, ONCOL LETT, V14, P250, DOI 10.3892/ol.2017.6105; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Meissl K, 2017, CYTOKINE, V89, P12, DOI 10.1016/j.cyto.2015.11.011; Messai Y, 2016, EUR UROL, V70, P623, DOI 10.1016/j.eururo.2015.11.029; Micke P, 2005, AM SOC CLIN ONC ANN; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Motoshima T, 2017, BMC UROL, V17, DOI 10.1186/s12894-016-0195-x; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Muenst S, 2014, BREAST CANCER RES TR, V146, P15, DOI 10.1007/s10549-014-2988-5; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Nakanishi J, 2007, CANCER IMMUNOL IMMUN, V56, P1173, DOI 10.1007/s00262-006-0266-z; Nanda R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.506; Ness N, 2017, ONCOTARGET, V8, P26789, DOI 10.18632/oncotarget.15817; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Obeid JM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1235107; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Okita R, 2017, CANCER IMMUNOL IMMUN, V66, P865, DOI 10.1007/s00262-017-1986-y; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Palazon A, 2017, CANCER CELL, V32, P669, DOI 10.1016/j.ccell.2017.10.003; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Pawlus MR, 2014, ONCOGENE, V33, P1670, DOI 10.1038/onc.2013.115; Paydas S, 2015, ANN HEMATOL, V94, P1545, DOI 10.1007/s00277-015-2403-2; Perez R, 2017, AM SOC CLIN ONC ANN; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Pyo JS, 2017, INT J BIOL MARKER, V32, pE68, DOI 10.5301/jbm.5000225; Qian YG, 2008, CANCER INVEST, V26, P816, DOI 10.1080/07357900801941852; Qin X., 2010, CELL MOL BIOL, V56; Que Y, 2017, J CANCER, V8, P2018, DOI 10.7150/jca.18683; Rakhra K, 2010, CANCER CELL, V18, P485, DOI 10.1016/j.ccr.2010.10.002; Rech AJ, 2013, CANCER DISCOV, V3, P1330, DOI 10.1158/2159-8290.CD-13-0775; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roemer MGM, 2016, J CLIN ONCOL, V34, P2690, DOI 10.1200/JCO.2016.66.4482; Ruf M, 2016, INT J CANCER, V139, P396, DOI 10.1002/ijc.30077; Rugo HS, 2017, 2017 SAN ANT BREAST; Sabatier R, 2015, ONCOTARGET, V6, P5449, DOI 10.18632/oncotarget.3216; Sanchez-Pulido L, 2002, TRENDS BIOCHEM SCI, V27, P599, DOI 10.1016/S0968-0004(02)02229-6; Sato H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01883-9; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schlierf A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13166; Schmidt LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136023; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shin SJ, 2016, ANN SURG ONCOL, V23, P694, DOI 10.1245/s10434-015-4903-7; Spranger S, 2016, CELL RES, V26, P639, DOI 10.1038/cr.2016.50; Straub M, 2016, ONCOTARGET, V7, P12024, DOI 10.18632/oncotarget.7593; Sumimoto H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166626; Takada K, 2017, LUNG CANCER, V104, P7, DOI 10.1016/j.lungcan.2016.12.006; Tartari F, 2016, CANCER TREAT REV, V48, P20, DOI 10.1016/j.ctrv.2016.06.002; Tsang JYS, 2017, BREAST CANCER RES TR, V162, P19, DOI 10.1007/s10549-016-4095-2; Tsao MS, 2017, ANN ONCOL, V28, P882, DOI 10.1093/annonc/mdx003; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Twa DDW, 2014, BLOOD, V123, P2062, DOI 10.1182/blood-2013-10-535443; Uhercik M, 2017, ANTICANCER RES, V37, P4249, DOI 10.21873/anticanres.11817; Utreras Elias, 2009, Drug Discov Today Ther Strateg, V6, P105, DOI 10.1016/j.ddstr.2009.04.004; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; VISAN I, 2017, NAT IMMUNOL, V18, P1067; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HB, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1327494; Wang L, 2015, ONCOTARGET, V6, P41228, DOI 10.18632/oncotarget.5682; Wang QQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006369; Wang WP, 2013, HUM GENET, V132, P641, DOI 10.1007/s00439-013-1275-6; Wang WP, 2012, HUM MUTAT, V33, P480, DOI 10.1002/humu.22014; Wang X, 2015, CELL SIGNAL, V27, P443, DOI 10.1016/j.cellsig.2014.12.003; Webb JR, 2016, GYNECOL ONCOL, V141, P293, DOI 10.1016/j.ygyno.2016.03.008; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Woan KV, 2015, MOL ONCOL, V9, P1447, DOI 10.1016/j.molonc.2015.04.002; Woan KV, 2012, IMMUNOL CELL BIOL, V90, P55, DOI 10.1038/icb.2011.96; Xia HF, 2017, CLIN CHIM ACTA, V469, P191, DOI 10.1016/j.cca.2017.02.005; Xia Y, 2016, BBA-REV CANCER, V1865, P58, DOI 10.1016/j.bbcan.2015.09.002; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yoon KW, 2015, SCIENCE, V349, DOI 10.1126/science.1261669; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zaritskaya L, 2010, EXPERT REV VACCINES, V9, P601, DOI [10.1586/erv.10.49, 10.1586/ERV.10.49]; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zhang MH, 2017, ONCOTARGET, V8, P31347, DOI 10.18632/oncotarget.15532; Zhang N, 2016, INT J ONCOL, V49, P1360, DOI 10.3892/ijo.2016.3632; Zhang P, 2008, MOL IMMUNOL, V45, P1470, DOI 10.1016/j.molimm.2007.08.013; Zhang YX, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000515; Zhao L, 2016, ONCOTARGET, V7, P45370, DOI 10.18632/oncotarget.9659; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032; Zhu JJ, 2014, HUM IMMUNOL, V75, P348, DOI 10.1016/j.humimm.2014.01.006	229	149	158	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4639	4661		10.1038/s41388-018-0303-3	http://dx.doi.org/10.1038/s41388-018-0303-3			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29765155	Green Published, hybrid			2022-12-17	WOS:000442514400002
J	Buchert, M; Burns, CJ; Ernst, M				Buchert, M.; Burns, C. J.; Ernst, M.			Targeting JAK kinase in solid tumors: emerging opportunities and challenges	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN HEPATOCELLULAR-CARCINOMA; MULTIPLE SIGNALING PATHWAYS; CLONOGENIC STEM-CELLS; HUMAN PROSTATE-CANCER; BREAST-CANCER; STAT3 ACTIVATION; CONSTITUTIVE ACTIVATION; COLORECTAL-CANCER; GROWTH-FACTOR	Various human malignancies are characterized by excessive activation of the Janus family of cytoplasmic tyrosine kinases (JAK) and their associated transcription factors STAT3 and STAT5. In the majority of solid tumors, this occurs in response to increased abundance of inflammatory cytokines in the tumor microenvironment prominently produced by infiltrating innate immune cells. Many of these cytokines share common receptor subunits and belong to the interleukin (IL)-6/IL-11, IL-10/IL-22 and IL-12/IL-23 families. Therapeutic inhibition of the JAK/STAT3 pathway potentially offers considerable benefit owing to the capacity of JAK/STAT3 signaling to promote cancer hallmarks in the tumor and its environment, including proliferation, survival, angiogenesis, tumor metabolism while suppressing antitumor immunity. This is further emphasized by the current successful clinical applications of JAK-specific small molecule inhibitors for the treatment of inflammatory disorders and hematopoietic malignancies. Here we review current preclinical applications for JAK inhibitors for the treatment of solid cancers in mice, with a focus on the most common malignancies emanating from oncogenic transformation of the epithelial mucosa in the stomach and colon. Emerging data with small molecule JAK-specific adenosine triphosphate-binding analogs corroborate genetic findings and suggest that interference with the JAK/STAT3 pathway may suppress the growth of the most common forms of sporadic colon cancers that arise from mutations of the APC tumor suppressor gene. Likewise inhibition of cytokine-dependent activation of the JAK/STAT3 pathway may also afford orthogonal treatment opportunities for other oncogene-addicted cancer cells that have gained drug resistance.	[Buchert, M.; Burns, C. J.; Ernst, M.] Univ Melbourne, Walter & Eliza Hall Inst, Dept Med Biol, Melbourne, Vic, Australia; [Buchert, M.; Ernst, M.] La Trobe Univ, Austin Hlth, Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia; [Buchert, M.; Ernst, M.] La Trobe Univ, Austin Hlth, Sch Canc Med, Heidelberg, Vic, Australia	University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University; Olivia Newton-John Cancer Research Institute; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University	Buchert, M; Ernst, M (corresponding author), ONJCRI, Austin Hlth, 145 Studley Rd, Heidelberg, Vic 3084, Australia.	Michael.Buchert@onjcri.org.au; Matthias.Ernst@onjcri.org.au	Ernst, Matthias/D-5111-2012	Ernst, Matthias/0000-0002-6399-1177; Buchert, Michael/0000-0003-2672-0148; Burns, Christopher/0000-0002-4463-4916	Cancer Council Victoria; National Health and Medical Research Council, Australia [1064987, 1079257]; Ludwig Cancer Research; Operational Infrastructure Support Program by the Victorian Government, Australia	Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Ludwig Cancer Research; Operational Infrastructure Support Program by the Victorian Government, Australia	The work in the authors' laboratories is supported by the Cancer Council Victoria, grants (#1064987 and #1079257) from the National Health and Medical Research Council, Australia, by Ludwig Cancer Research and by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia.	Andraos R, 2012, CANCER DISCOV, V2, P512, DOI 10.1158/2159-8290.CD-11-0324; Baltgalvis KA, 2008, AM J PHYSIOL-REG I, V294, pR393, DOI 10.1152/ajpregu.00716.2007; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Beebe K, 2010, DEV BIOL, V338, P28, DOI 10.1016/j.ydbio.2009.10.045; Behnsen J, 2014, IMMUNITY, V40, P262, DOI 10.1016/j.immuni.2014.01.003; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biteau B, 2011, DEVELOPMENT, V138, P1045, DOI 10.1242/dev.056671; Blaas L, 2010, HEPATOLOGY, V51, P1319, DOI 10.1002/hep.23469; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Chang HC, 2009, BLOOD, V113, P5887, DOI 10.1182/blood-2008-09-179820; Chang Q, 2014, SEMIN IMMUNOL, V26, P48, DOI 10.1016/j.smim.2014.01.007; Chen PL, 2005, J BIOL CHEM, V280, P5361, DOI 10.1074/jbc.M411974200; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choong ML, 2013, J CELL MOL MED, V17, P1397, DOI 10.1111/jcmm.12156; Chueh FY, 2010, BIOCHEM BIOPH RES CO, V402, P778, DOI 10.1016/j.bbrc.2010.10.112; Cirillo D, 2008, J CELL BIOCHEM, V105, P956, DOI 10.1002/jcb.21911; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Cordero JB, 2012, DEVELOPMENT, V139, P4524, DOI 10.1242/dev.078261; da Rocha LF, 2012, J RHEUMATOL, V39, P1320, DOI 10.3899/jrheum.111027; Dagvadorj A, 2008, CLIN CANCER RES, V14, P1317, DOI 10.1158/1078-0432.CCR-07-2024; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Derenzini E, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.46; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DU XX, 1994, BLOOD, V83, P33; DU XX, 1994, BLOOD, V83, P2023; Duarte CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029653; DUMMER W, 1995, MELANOMA RES, V5, P67, DOI 10.1097/00008390-199502000-00008; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Durmus S, 2013, PHARMACOL RES, V76, P9, DOI 10.1016/j.phrs.2013.06.009; Emmerich J, 2012, CANCER RES, V72, P3570, DOI 10.1158/0008-5472.CAN-12-0721; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Evrot E, 2013, CLIN CANCER RES, V19, P6230, DOI 10.1158/1078-0432.CCR-13-0905; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Fiskus W, 2013, MOL CANCER THER, V12, P577, DOI 10.1158/1535-7163.MCT-12-0862; Fiskus W, 2011, CLIN CANCER RES, V17, P7347, DOI 10.1158/1078-0432.CCR-11-1541; Fujitake S, 2004, J GASTROENTEROL, V39, P120, DOI 10.1007/s00535-003-1262-0; Fuke H, 2007, BIOCHEM BIOPH RES CO, V363, P738, DOI 10.1016/j.bbrc.2007.09.049; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Gajewski TF, 2010, CANCER J, V16, P399, DOI 10.1097/PPO.0b013e3181eacbd8; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600-065X.2008.00754.x; GOLDSTEIN D, 1988, CA-CANCER J CLIN, V38, P258, DOI 10.3322/canjclin.38.5.258; Gough DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083395; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Greenwood C, 2012, J PROTEOMICS, V75, P3031, DOI 10.1016/j.jprot.2011.11.033; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harir N, 2007, BLOOD, V109, P1678, DOI 10.1182/blood-2006-01-029918; Hauschild A, 2008, CANCER-AM CANCER SOC, V112, P982, DOI 10.1002/cncr.23251; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hosui A, 2009, J EXP MED, V206, P819, DOI 10.1084/jem.20080003; HUANG M, 1995, CANCER RES, V55, P3847; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Inagaki-Ohara Kyoko, 2013, JAKSTAT, V2, pe24053, DOI 10.4161/jkst.24053; Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14; Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Jones AV, 2005, BLOOD, V106, P2162, DOI 10.1182/blood-2005-03-1320; Joung YH, 2014, INT J ONCOL, V44, P883, DOI 10.3892/ijo.2014.2250; Judd LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095993; Justa S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093279; Kamiya S, 2011, IMMUNOL LETT, V138, P47, DOI 10.1016/j.imlet.2011.02.022; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karpowicz P, 2010, DEVELOPMENT, V137, P4135, DOI 10.1242/dev.060483; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kershaw NJ, 2013, NAT STRUCT MOL BIOL, V20, P469, DOI 10.1038/nsmb.2519; KIM J, 1995, J IMMUNOL, V155, P2240; Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308; Komazaki T, 2004, JPN J CLIN ONCOL, V34, P191, DOI 10.1093/jjco/hyh035; Koppikar P, 2012, NATURE, V489, P155, DOI 10.1038/nature11303; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lederle W, 2011, INT J CANCER, V128, P2803, DOI 10.1002/ijc.25621; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee SK, 2005, J DERMATOL SCI, V40, P95, DOI 10.1016/j.jdermsci.2005.06.008; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Leibowitz MS, 2013, CLIN CANCER RES, V19, P798, DOI 10.1158/1078-0432.CCR-12-1517; Leipe J, 2011, ANN RHEUM DIS, V70, P1453, DOI 10.1136/ard.2011.152074; Letellier E, 2014, BRIT J CANCER, V111, P726, DOI 10.1038/bjc.2014.377; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li HZ, 2004, CANCER RES, V64, P4774, DOI 10.1158/0008-5472.CAN-03-3499; Li Y, 2012, CARCINOGENESIS, V33, P1889, DOI 10.1093/carcin/bgs214; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Lindemann C, 2011, ACTA NEUROPATHOL, V122, P241, DOI 10.1007/s00401-011-0832-0; Liu SH, 2008, PIGM CELL MELANOMA R, V21, P545, DOI 10.1111/j.1755-148X.2008.00484.x; Lucet IS, 2006, BLOOD, V107, P176, DOI 10.1182/blood-2005-06-2413; Mao YL, 2011, PATHOL ONCOL RES, V17, P333, DOI 10.1007/s12253-010-9321-3; Marini A, 2006, J INVEST DERMATOL, V126, P422, DOI 10.1038/sj.jid.5700073; Marit MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043437; Martini M, 2008, INT J CANCER, V123, P2955, DOI 10.1002/ijc.23805; Masuda M, 2002, CANCER RES, V62, P3351; Mcgee HM, 2013, J INVEST DERMATOL, V133, P1321, DOI 10.1038/jid.2012.463; Melzner I, 2006, INT J CANCER, V118, P1941, DOI 10.1002/ijc.21485; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Mencalha AL, 2010, CANCER CHEMOTH PHARM, V65, P1039, DOI 10.1007/s00280-009-1109-3; Messina NL, 2013, IMMUNOL CELL BIOL, V91, P556, DOI 10.1038/icb.2013.41; Miteva LD, 2014, TUMOR BIOL, V35, P12655, DOI 10.1007/s13277-014-2589-2; Mohan CD, 2014, J BIOL CHEM, V289, P34296, DOI 10.1074/jbc.M114.601104; Monaghan KA, 2011, LEUKEMIA, V25, P1891, DOI 10.1038/leu.2011.175; Mori T, 2006, CANCER RES, V66, P6692, DOI 10.1158/0008-5472.CAN-06-0801; Mumm JB, 2011, CANCER CELL, V20, P781, DOI 10.1016/j.ccr.2011.11.003; Murray PJ, 2006, CURR OPIN PHARMACOL, V6, P379, DOI 10.1016/j.coph.2006.01.010; Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nagai H, 2002, CANCER LETT, V186, P59, DOI 10.1016/S0304-3835(02)00244-6; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; Nagakawa H, 2004, SCAND J IMMUNOL, V60, P449, DOI 10.1111/j.0300-9475.2004.01504.x; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Norman P, 2014, EXPERT OPIN INV DRUG, V23, P1067, DOI 10.1517/13543784.2014.918604; Novotny-Diermayr V, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.14; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Okochi O, 2003, CLIN CANCER RES, V9, P5295; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Onnis B, 2013, J CLIN INVEST, V123, P1615, DOI 10.1172/JCI59623; Orazi A, 1996, LAB INVEST, V75, P33; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Pardanani A, 2013, LEUKEMIA, V27, P1322, DOI 10.1038/leu.2013.71; Pecquet C, 2010, BLOOD, V115, P1037, DOI 10.1182/blood-2008-10-183558; Phesse TJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005411; Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683; Pierconti F, 2011, PROSTATE, V71, P318, DOI 10.1002/pros.21245; Pilati C, 2011, J EXP MED, V208, P1359, DOI 10.1084/jem.20110283; PISA P, 1992, P NATL ACAD SCI USA, V89, P7708, DOI 10.1073/pnas.89.16.7708; Plimack ER, 2013, ONCOLOGIST, V18, P819, DOI 10.1634/theoncologist.2013-0198; Potten CS, 1996, STEM CELLS, V14, P452, DOI 10.1002/stem.140452; POTTEN CS, 1995, INT J CANCER, V62, P356, DOI 10.1002/ijc.2910620321; Poussin K, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27090; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Qiu J, 2013, IMMUNITY, V39, P386, DOI 10.1016/j.immuni.2013.08.002; Qiu XY, 2013, MOL CELL BIOCHEM, V378, P99, DOI 10.1007/s11010-013-1599-5; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sasi Walid, 2014, Mol Biol Int, V2014, P630797, DOI 10.1155/2014/630797; Sato T, 1996, CLIN CANCER RES, V2, P1383; Schafer ZT, 2007, J CLIN INVEST, V117, P3660, DOI 10.1172/JCI34237; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schneller D, 2011, HEPATOLOGY, V54, P164, DOI 10.1002/hep.24329; Seavey MM, 2012, MOL CANCER THER, V11, P984, DOI 10.1158/1535-7163.MCT-11-0951; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Silver JS, 2010, J LEUKOCYTE BIOL, V88, P1145, DOI 10.1189/jlb.0410217; Simpson JAD, 2010, GUT, V59, P926, DOI 10.1136/gut.2009.194472; Sobti RC, 2011, CELL ONCOL, V34, P533, DOI 10.1007/s13402-011-0056-2; Sonnenberg GF, 2012, SCIENCE, V336, P1321, DOI 10.1126/science.1222551; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; Steensma DP, 2005, BLOOD, V106, P1207, DOI 10.1182/blood-2005-03-1183; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Stuart E, 2014, MOL CANCER THER, V13, P468, DOI 10.1158/1535-7163.MCT-13-0583-T; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Tan SH, 2008, ENDOCR-RELAT CANCER, V15, P367, DOI 10.1677/ERC-08-0013; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Taylor P, 2014, ANN RHEUM DIS, V73, pA31, DOI 10.1136/annrheumdis-2013-205124.71; Thoma G, 2014, BIOORG MED CHEM LETT, V24, P4617, DOI 10.1016/j.bmcl.2014.08.046; Thompson JE, 2002, BIOORG MED CHEM LETT, V12, P1219, DOI 10.1016/S0960-894X(02)00106-3; Tischoff I, 2007, GUT, V56, P1047, DOI 10.1136/gut.2006.111633; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Ueda M, 2003, BRIT J HAEMATOL, V123, P288, DOI 10.1046/j.1365-2141.2003.04601.x; Upadhyay V, 2012, NAT IMMUNOL, V13, P947, DOI 10.1038/ni.2403; Vafaizadeh V, 2010, STEM CELLS, V28, P928, DOI 10.1002/stem.407; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; van Vollenhoven RF, 2012, NEW ENGL J MED, V367, P508, DOI 10.1056/NEJMoa1112072; Venetsanakos E, 1997, BRIT J CANCER, V75, P1826, DOI 10.1038/bjc.1997.311; Walter M, 2009, ONCOGENE, V28, P2745, DOI 10.1038/onc.2009.130; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wang SJ, 2015, ONCOTARGET, V6, P243, DOI 10.18632/oncotarget.2801; Wang YC, 2009, BLOOD, V114, P5024, DOI 10.1182/blood-2009-05-222133; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Will B, 2010, BLOOD, V115, P2901, DOI 10.1182/blood-2009-03-209544; Wolfle SJ, 2011, EUR J IMMUNOL, V41, P413, DOI 10.1002/eji.201040979; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Xi SC, 2003, CANCER RES, V63, P6763; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Xiong H, 2009, LAB INVEST, V89, P717, DOI 10.1038/labinvest.2009.11; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yang J, 2005, CANCER RES, V65, P939; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yeh YT, 2012, WORLD J SURG, V36, P1128, DOI 10.1007/s00268-012-1505-4; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zenewicz LA, 2013, J IMMUNOL, V190, P5306, DOI 10.4049/jimmunol.1300016; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zhang L, 2014, HEPATOLOGY, V59, P178, DOI 10.1002/hep.26628; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	228	149	157	2	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					939	951		10.1038/onc.2015.150	http://dx.doi.org/10.1038/onc.2015.150			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25982279				2022-12-17	WOS:000370823300001
J	Tsang, WP; Kwok, TT				Tsang, W. P.; Kwok, T. T.			Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells	ONCOGENE			English	Article						H19; MDR1; drug resistance; P-glycoprotein; DNA methylation	PROMOTER REGION; MDR1 GENE; NONCODING RNA; CANCER-CELLS; OVEREXPRESSION; METHYLATION; EXPRESSION	Acquisition of drug resistance is one of the main obstacles encountered in cancer chemotherapy. Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicinresistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. In addition, Northern-blot analysis revealed an eight fold upregulation of the imprinted H19 mRNA in R-HepG2 cells. H19 knockdown bytrans fection with antisense H19 oligonucleotides suppressed the MDR1/P-glycoprotein expression, increased the cellular doxorubicin accumulation level and sensitized doxorubicin toxicityin both HepG2 parent cells and R-HepG2 cells. Results from methylation-specific polymerase chain reaction analysis indicated that the MDR1 gene promoter was hypomethylated in R-HepG2 cells. Antisense H19 oligonucleotides transfection induced a marked increase in the percentage of MDR1 promoter methylation and decrease in MDR1 expression in R- HepG2 cells. Thus, the H19 gene is believed to induce P- glycoprotein expression and MDR1-associated drug resistance at least in liver cancer cells through regulation of MDR1 promoter methylation.	Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Kwok, TT (corresponding author), Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China.	kwok2020@cuhk.edu.hk						Baylin SB, 1998, ADV CANCER RES, V72, P141; Doyle LA, 1996, CANCER RES, V56, P2904; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P1766, DOI 10.1210/jc.82.6.1766; Lottin S, 2002, ONCOGENE, V21, P1625, DOI 10.1038/sj.onc.1205233; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; Tada Y, 2000, CLIN CANCER RES, V6, P4618; Vernucci M, 2004, HUM MOL GENET, V13, P353, DOI 10.1093/hmg/ddh028	14	149	158	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4877	4881		10.1038/sj.onc.1210266	http://dx.doi.org/10.1038/sj.onc.1210266			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297456				2022-12-17	WOS:000248170400013
J	Sun, HL; Liu, YN; Huang, YT; Pan, SL; Huang, DY; Guh, JH; Lee, FY; Kuo, SC; Teng, CM				Sun, H-L; Liu, Y-N; Huang, Y-T; Pan, S-L; Huang, D-Y; Guh, J-H; Lee, F-Y; Kuo, S-C; Teng, C-M			YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappa B signaling to HIF-1 alpha accumulation during hypoxia	ONCOGENE			English	Article						YC-1; HIF-1; Akt; NF-kappa B; prostate cancer	INDUCIBLE FACTOR 1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; RIBOSOME ENTRY SITE; NUCLEAR-LOCALIZATION; GENE-EXPRESSION; TRANSCRIPTION FACTORS; DOWN-REGULATION; TUMOR HYPOXIA; UP-REGULATION; FACTOR-1-ALPHA	Hypoxia-inducible factor 1 ( HIF-1), a transcription factor that is critical for tumor adaptation to microenvironmental stimuli, represents an attractive chemotherapeutic target. YC-1 is a novel antitumor agent that inhibits HIF-1 through previously unexplained mechanisms. In the present study, YC-1 was found to prevent HIF-1 alpha and HIF-1 beta accumulation in response to hypoxia or mitogen treatment in PC-3 prostate cancer cells. Neither HIF-1 alpha protein half-life nor mRNA level was affected by YC-1. However, YC-1 was found to suppress the PI3K/Akt/mTOR/4E-BP pathway, which serves to regulate HIF-1 alpha expression at the translational step. We demonstrated that YC-1 also inhibited hypoxia-induced activation of nuclear factor ( NF)-kappa B, a downstream target of Akt. Two modulators of the Akt/NF-kappa B pathway, caffeic acid phenethyl ester and evodiamine, were observed to decrease HIF-1 alpha expression. Additionally, overexpression of NF-kappa B partly reversed the ability of wortmannin to inhibit HIF-1 alpha-dependent transcriptional activity, suggesting that NF-kappa B contributes to Akt-mediated HIF-1 alpha accumulation during hypoxia. Overall, we identify a potential molecular mechanism whereby YC-1 serves to reduce HIF-1 expression.	Natl Taiwan Univ, Inst Pharmacol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ, Sch Pharm, Coll Med, Taipei 100, Taiwan; Yung Shin Pharmaceut Ind Co Ltd, China Med Coll, Taichung, Taiwan; China Med Coll, Grad Inst Pharmaceut Chem, Taichung, Taiwan	National Taiwan University; National Taiwan University; China Medical University Taiwan; China Medical University Taiwan	Teng, CM (corresponding author), Natl Taiwan Univ, Inst Pharmacol, Coll Med, 1 Jen Ai Rd,Sect 1, Taipei 100, Taiwan.	cmteng@ntumc.org	Pan, Shiow-Lin/C-1372-2010	Huang, Yao-Ting/0000-0001-5912-8090; GUH, JIH-HWA/0000-0002-6738-6054; TENG, CHE-MING/0000-0002-9719-7334				Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen EY, 2001, CANCER RES, V61, P2429; Chiang PC, 2005, J HEPATOL, V43, P679, DOI 10.1016/j.jhep.2005.02.049; Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0; Domingo-Domenech J, 2005, BRIT J CANCER, V93, P1285, DOI 10.1038/sj.bjc.6602851; Figueroa YG, 2002, EXP HEMATOL, V30, P1419, DOI 10.1016/S0301-472X(02)00934-7; Fradet V, 2004, CLIN CANCER RES, V10, P8460, DOI 10.1158/1078-0432.CCR-04-0764; Funasaka T, 2005, FASEB J, V19, P1422, DOI 10.1096/fj.05-3699com; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang DM, 2005, J UROLOGY, V173, P256, DOI 10.1097/01.ju.0000141587.72429.e3; Huang YT, 2005, MOL CANCER THER, V4, P1628, DOI 10.1158/1535-7163.MCT-05-0090; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kim I, 2004, EXP CELL RES, V298, P229, DOI 10.1016/j.yexcr.2004.04.017; KO FN, 1994, BLOOD, V84, P4226, DOI 10.1182/blood.V84.12.4226.bloodjournal84124226; KOONG AC, 1994, CANCER RES, V54, P1425; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Lessard L, 2003, BJU INT, V91, P417, DOI 10.1046/j.1464-410X.2003.04104.x; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; McEleny K, 2004, BJU INT, V94, P402, DOI 10.1111/j.1464-410X.2004.04936.x; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406; Pan SL, 2005, J PHARMACOL EXP THER, V314, P35, DOI 10.1124/jpet.105.085126; Powis G, 2004, MOL CANCER THER, V3, P647; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200; Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009; Zhong H, 2001, BIOCHEM BIOPH RES CO, V284, P352, DOI 10.1006/bbrc.2001.4981; Zhong H, 2000, CANCER RES, V60, P1541; Zhou J, 2004, CANCER RES, V64, P9041, DOI 10.1158/0008-5472.CAN-04-1437; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598; Zundel W, 2000, GENE DEV, V14, P391	53	149	155	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3941	3951		10.1038/sj.onc.1210169	http://dx.doi.org/10.1038/sj.onc.1210169			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213816				2022-12-17	WOS:000247144500004
J	Bindels, S; Mestdagt, M; Vandewalle, C; Jacobs, N; Volders, L; Noel, A; van Roy, F; Berx, G; Foidart, JM; Gilles, C				Bindels, S.; Mestdagt, M.; Vandewalle, C.; Jacobs, N.; Volders, L.; Noel, A.; van Roy, F.; Berx, G.; Foidart, J-M; Gilles, C.			Regulation of vimentin by SIP1 in human epithelial breast tumor cells	ONCOGENE			English	Article						vimentin; SIP1; cell migration	SMAD-INTERACTING PROTEIN-1; REPRESSES E-CADHERIN; INTERMEDIATE-FILAMENTS; BETA-CATENIN; MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTORS; SNAIL; EXPRESSION; GENE; INVASION	The expression of Smad interacting protein-1 (SIP1; ZEB2) and the de novo expression of vimentin are frequently involved in epithelial-to-mesenchymal transitions (EMTs) under both normal and pathological conditions. In the present study, we investigated the potential role of SIP1 in the regulation of vimentin during the EMT associated with breast tumor cell migration and invasion. Examining several breast tumor cell lines displaying various degrees of invasiveness, we found SIP1 and vimentin expression only in invasive cell lines. Also, using a model of cell migration with human mammary MCF10A cells, we showed that SIP1 is induced specifically in vimentin-positive migratory cells. Furthermore, transfection of SIP1 cDNA in MCF10A cells increased their vimentin expression both at the mRNA and protein levels and enhanced their migratory abilities in Boyden Chamber assays. Inversely, inhibition of SIP1 expression by RNAi strategies in BT-549 cells and MCF10A cells decreased vimentin expression. We also showed that SIP1 transfection did not activate the TOP-FLASH reporter system, suggesting that the beta-catenin/TCF pathway is not implicated in the regulation of vimentin by SIP1. Our results therefore implicate SIP1 in the regulation of vimentin observed in the EMT associated with breast tumor cell migration, a pathway that may contribute to the metastatic progression of breast cancer.	Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, Ctr Biomed Integrated Genoproteom, B-4000 Liege, Belgium; Univ Ghent VIB, Dept Mol Biomed Res, B-9000 Ghent, Belgium; Univ Liege, CHU Sart Tilman, Lab Anatomopathol, Ctr Biomed Integrated Genoproteom, B-4000 Liege, Belgium	University of Liege; Flanders Institute for Biotechnology (VIB); Ghent University; University of Liege	Gilles, C (corresponding author), Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, Ctr Biomed Integrated Genoproteom, Tour Pathol B23, B-4000 Liege, Belgium.	cgilles@ulg.ac.be	van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039; Noel, Agnes/0000-0002-7670-6179; Jacobs, Nathalie/0000-0002-9895-8465; Berx, Geert/0000-0001-5770-2458				Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Duband JL, 1995, ACTA ANAT, V154, P63; Eckes B, 1998, J CELL SCI, V111, P1897; Eckes B, 2000, J CELL SCI, V113, P2455; Eisaki A, 2000, BIOCHEM BIOPH RES CO, V271, P151, DOI 10.1006/bbrc.2000.2545; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 2003, CANCER RES, V63, P2658; Gilles C, 1996, BREAST JOURNAL, VOL 2, NO 1, JANUARY/FEBRUARY 1996, P83; GILLES C, 2004, RISE FALL EPITHELIAL, pCH2; Goldman RD, 1999, FASEB J, V13, pS261, DOI 10.1096/fasebj.13.9002.S261; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; GUARINO M, 1995, HISTOL HISTOPATHOL, V10, P171; Hajra KM, 2002, CANCER RES, V62, P1613; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Helfand BT, 2004, J CELL SCI, V117, P133, DOI 10.1242/jcs.00936; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Homan SM, 1998, J CELL SCI, V111, P2717; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kreis S, 2005, EXP CELL RES, V305, P110, DOI 10.1016/j.yexcr.2004.12.023; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Million K, 2001, AM J RESP CELL MOL, V25, P744, DOI 10.1165/ajrcmb.25.6.4549; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; NAWROCKI RB, 2001, INT J CANCER, V93, P644; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Singh S, 2003, CANCER RES, V63, P2306; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P173, DOI 10.1016/S1357-2725(03)00243-7; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; van Grunsven LA, 2000, MECH DEVELOP, V94, P189, DOI 10.1016/S0925-4773(00)00318-X; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Yokoyama K, 2003, INT J ONCOL, V22, P891	61	149	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4975	4985		10.1038/sj.onc.1209511	http://dx.doi.org/10.1038/sj.onc.1209511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568083	Green Submitted			2022-12-17	WOS:000239921300003
J	Munoz-Najar, UM; Neurath, KM; Vumbaca, F; Claffey, KP				Munoz-Najar, UM; Neurath, KM; Vumbaca, F; Claffey, KP			Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation	ONCOGENE			English	Article						breast cancer; hypoxia; invasion; MT1-MMP; RhoA	TYPE-1 MATRIX-METALLOPROTEINASE; MESSENGER-RNA EXPRESSION; EXTRACELLULAR-MATRIX; 1-MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; UP-REGULATION; GELATINASE-A; SURFACE; CANCER; TRAFFICKING	The process of cancer cell invasion involves degradation of the extracellular matrix (ECM) by proteases, integrin adhesion and cell motility. The role of ECM degrading proteases on the hypoxia-induced invasion of breast carcinoma cells was investigated. Hypoxia markedly increased the invasion capacity of MDA-MB-231and MDA-MB-435 breast carcinoma cell lines. Matrix metalloproteinase (MMP) inhibitors blocked the hypoxia-induced invasion, whereas other protease inhibitors had no effect. Antibodies or siRNAs blocking either membrane type-1MMP (MT1-MMP) or MMP-2 were effective in reducing the hypoxia-induced invasion. Serum-free reconstitution experiments confirmed the involvement of the MT1-MMP/ MMP-2/tissue inhibitor of metalloproteinase-2 complex in this hypoxia-induced response. Overexpression of MT1-MMP in a poorly invasive breast cancer cell line, T47-D, promoted hypoxia-induced invasion and MMP-2 activation. Cell surface accumulation and activation of MT1-MMP without apparent regulation at the mRNA or protein levels indicated a post-translational adaptive response to hypoxia. Inhibition of the small GTPase RhoA eliminated the hypoxia-induced invasion and blocked the localization of MT1-MMP to the plasma membrane. Zymographic and molecular analysis of human breast tumors showed a strong correlation between hypoxic microenvironments and MMP-2 activation without changes in MT1-MMP expression. Our studies suggest that hypoxic tumor microenvironments promote breast cancer invasion through an MT1-MMP-dependent mechanism.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA	University of Connecticut	Claffey, KP (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, EM028,263 Farmington Ave, Farmington, CT 06030 USA.	claffey@nso2.uchc.edu			NCI NIH HHS [CA64436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064436, R29CA064436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Bailly K, 2004, CIRC RES, V94, P1383, DOI 10.1161/01.RES.0000128405.83582.2e; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Ben-Yosef Y, 2002, CIRC RES, V90, P784, DOI 10.1161/01.RES.0000015588.70132.DC; Brat DJ, 2004, CANCER RES, V64, P920, DOI 10.1158/0008-5472.CAN-03-2073; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002-9440(10)63483-9; Canning MT, 2001, EXP CELL RES, V267, P88, DOI 10.1006/excr.2001.5243; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Claffey KP, 1996, CANCER RES, V56, P172; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2; Deschamps AM, 2005, CIRCULATION, V111, P1166, DOI 10.1161/01.CIR.0000157149.71297.3A; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fahling M, 2004, COMP BIOCHEM PHYS C, V139, P119, DOI 10.1016/j.cca.2004.09.013; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Giannelli G, 2002, INT J CANCER, V97, P425, DOI 10.1002/ijc.1635; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; HOFMANN UB, 2005, ARCH DERMATOL RES, V4, P1; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Kinoshita T, 1996, CANCER RES, V56, P2535; Krishnamachary B, 2003, CANCER RES, V63, P1138; Lambert E, 2004, CRIT REV ONCOL HEMAT, V49, P187, DOI 10.1016/j.critrevonc.2003.09.008; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Leufgen H, 2005, J CELL PHYSIOL, V204, P146, DOI 10.1002/jcp.20289; Liu WH, 2002, BIOCHEM BIOPH RES CO, V294, P347, DOI 10.1016/S0006-291X(02)00478-3; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; Mimori K, 2001, ONCOL REP, V8, P401; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Ottino P, 2004, MOL VIS, V10, P341; Oxford G, 2003, CANCER LETT, V189, P117, DOI 10.1016/S0304-3835(02)00510-4; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Ridgway PF, 2005, J SURG RES, V124, P180, DOI 10.1016/j.jss.2004.10.020; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Saad S, 2002, CANCER RES, V62, P283; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato Y, 2003, ENDOTHELIUM-J ENDOTH, V10, P287, DOI 10.1080/10623320390272334; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; SLOANE JP, 1981, CANCER, V47, P1786, DOI 10.1002/1097-0142(19810401)47:7<1786::AID-CNCR2820470711>3.0.CO;2-8; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5; Takino T, 2003, BIOCHEM BIOPH RES CO, V304, P160, DOI 10.1016/S0006-291X(03)00544-8; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Turcotte S, 2004, AM J PHYSIOL-RENAL, V286, pF338, DOI 10.1152/ajprenal.00254.2003; Udayakumar TS, 2003, CANCER RES, V63, P2292; Ueno H, 1997, CANCER RES, V57, P2055; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Yamanaka M, 2000, J DERMATOL SCI, V24, P99, DOI 10.1016/S0923-1811(00)00086-4; Yoon SO, 2003, J BIOCHEM MOL BIOL, V36, P128; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Yu M, 1997, CANCER RES, V57, P5028; Zhai YL, 2005, CANCER RES, V65, P6543, DOI 10.1158/0008-5472.CAN-05-0231; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	75	149	165	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2379	2392		10.1038/sj.onc.1209273	http://dx.doi.org/10.1038/sj.onc.1209273			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16369494				2022-12-17	WOS:000236764300010
J	Ruggero, D; Sonenberg, N				Ruggero, D; Sonenberg, N			The Akt of translational control	ONCOGENE			English	Review						Akt; ribosome biogenesis; eIF4E; translation control; cancer	MESSENGER-RNA TRANSLATION; CAP-DEPENDENT TRANSLATION; PROTEIN-KINASE-B; EIF4E GENE AMPLIFICATION; INITIATION-FACTOR EIF-4E; FACTOR 4E GENE; P70 S6 KINASE; EUKARYOTIC TRANSLATION; CELL-GROWTH; MAMMALIAN TARGET	The oncogene AKT (also called protein kinase B (PKB)) signals to the translational machinery, and activation of protein synthesis by Akt is associated with cancer formation. Akt directly stimulates the activity of translation initiation factors and upregulates ribosome biogenesis. Activation of protein synthesis by Akt is phylogenetically conserved from Drosophila to humans, and is important for regulating cell growth, proliferation and cell survival. Consequently, translation defects due to aberrant Akt activation may be a crucial mechanism leading to tumorigenesis. However, few in vivo studies have established a causative role for aberrant protein synthesis control in cancer. A major challenge in the future will be to identify the specific mRNAs regulated at the level of translation control directly relevant for cellular transformation. In this review, we highlight and discuss the emerging molecular and genetic evidence that support a model by which deregulation of specific or global protein synthesis contributes to cancer.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	Fox Chase Cancer Center; McGill University; McGill University	Ruggero, D (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	davide.ruggero@fccc.edu; nahum.sonenberg@mcgill.ca						Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Baserga Renato, 2004, VVolume 42, P235; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; Dmitriev SE, 2003, MOL CELL BIOL, V23, P8925, DOI 10.1128/MCB.23.24.8925-8933.2003; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Filonenko VV, 2004, EXP ONCOL, V26, P294; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hornstein E, 2001, COLD SPRING HARB SYM, V66, P477, DOI 10.1101/sqb.2001.66.477; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito T, 1996, MOL CELL BIOL, V16, P943; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; James MJ, 2004, J BIOL CHEM, V279, P8911, DOI 10.1074/jbc.M307735200; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Loreni F, 2000, EUR J BIOCHEM, V267, P6594, DOI 10.1046/j.1432-1327.2000.01753.x; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; MADER S, 1995, MOL CELL BIOL, V15, P4990; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Mende I, 2001, ONCOGENE, V20, P4419, DOI 10.1038/sj.onc.1204486; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Montagne Jacques, 2004, VVolume 42, P265; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; NIELSEN PJ, 1981, EUR J BIOCHEM, V120, P523, DOI 10.1111/j.1432-1033.1981.tb05731.x; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rathmell JC, 2003, EUR J IMMUNOL, V33, P2223, DOI 10.1002/eji.200324048; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Rousseau D, 1996, ONCOGENE, V13, P2415; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Savinska LO, 2004, EXP ONCOL, V26, P24; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shuda M, 2000, ANTICANCER RES, V20, P2489; Sonenberg N, 2000, TRANSLATION CONTROL; Sonenberg Nahum, 1993, Gene Expression, V3, P317; Sorrells DL, 1999, J SURG RES, V85, P37, DOI 10.1006/jsre.1999.5653; Sorrells DL, 1999, HEAD NECK-J SCI SPEC, V21, P60, DOI 10.1002/(SICI)1097-0347(199901)21:1<60::AID-HED8>3.0.CO;2-J; Sorrells DL, 1998, ANN SURG ONCOL, V5, P232, DOI 10.1007/BF02303778; Sorrells DL, 1999, J ORAL MAXIL SURG, V57, P294, DOI 10.1016/S0278-2391(99)90676-6; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Surace EI, 2004, ANN NEUROL, V56, P295, DOI 10.1002/ana.20201; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yuan XJ, 2005, MOL CELL, V19, P77, DOI 10.1016/j.molcel.2005.05.023; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	132	149	159	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7426	7434		10.1038/sj.onc.1209098	http://dx.doi.org/10.1038/sj.onc.1209098			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288289	Green Published			2022-12-17	WOS:000233201900005
J	Takeda, DY; Dutta, A				Takeda, DY; Dutta, A			DNA replication and progression through S phase	ONCOGENE			English	Review						cell cycle; S phase; DNA replication	ORIGIN RECOGNITION COMPLEX; XENOPUS EGG EXTRACTS; MINICHROMOSOME MAINTENANCE PROTEINS; CYCLIN-DEPENDENT KINASES; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; BUDDING YEAST; POLYMERASE-EPSILON; CHROMATIN-BINDING	Initiation and completion of DNA replication defines the beginning and ending of S phase of the cell cycle. Successful progression through S phase requires that replication be properly regulated and monitored to ensure that the entire genome is duplicated exactly once, without errors, in a timely fashion. Given the immense size and complexity of eukaryotic genomes, this presents a significant challenge for the cell. As a result, DNA replication has evolved into a tightly regulated process involving the coordinated action of numerous factors that function in all phases of the cell cycle. We will review our current understanding of these processes from the formation of prereplicative complexes in preparation for S phase to the series of events that culminate in the loading of DNA polymerases during S phase. We will incorporate structural data from archaeal and bacterial replication proteins and discuss their implications for understanding the mechanism of action of their corresponding eukaryotic homologues. We will also describe the concept of replication licensing which protects against genomic instability by limiting initiation events to once per cell cycle. Lastly, we will review our knowledge of checkpoint pathways that maintain the integrity of stalled forks and relay defects in replication to the rest of the cell cycle.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Virginia	Dutta, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Takeda, David/0000-0002-5986-1169	NATIONAL CANCER INSTITUTE [R01CA089406, R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60499, CA89406] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Alexandrow MG, 2004, MOL CELL BIOL, V24, P1614, DOI 10.1128/MCB.24.4.1614-1627.2004; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Biermann E, 2002, EUR J BIOCHEM, V269, P1040, DOI 10.1046/j.0014-2956.2001.02746.x; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Brown EJ, 2000, GENE DEV, V14, P397; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cheng LA, 1999, MOL CELL BIOL, V19, P4270; Chesnokov IN, 2003, P NATL ACAD SCI USA, V100, P9150, DOI 10.1073/pnas.1633580100; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Cobb JA, 2004, CURR OPIN GENET DEV, V14, P292, DOI 10.1016/j.gde.2004.04.001; Cobb JA, 2003, EMBO J, V22, P4325, DOI 10.1093/emboj/cdg391; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; Coverley D, 2000, J CELL SCI, V113, P1929; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; Danis E, 2004, NAT CELL BIOL, V6, P721, DOI 10.1038/ncb1149; Davey MJ, 2002, NAT REV MOL CELL BIO, V3, P826, DOI 10.1038/nrm949; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Delmolino LM, 2001, J BIOL CHEM, V276, P26947, DOI 10.1074/jbc.M101870200; DePamphilis ML, 2003, GENE, V310, P1, DOI 10.1016/S0378-1119(03)00546-8; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; Ferreira MG, 2000, MOL CELL BIOL, V20, P242; Fien K, 2004, J BIOL CHEM, V279, P16144, DOI 10.1074/jbc.M400142200; Findeisen M, 1999, EUR J BIOCHEM, V264, P415, DOI 10.1046/j.1432-1327.1999.00613.x; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedman KL, 1996, GENE DEV, V10, P1595, DOI 10.1101/gad.10.13.1595; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Fukui T, 2004, GENES CELLS, V9, P179, DOI 10.1111/j.1356-9597.2004.00716.x; Geraghty DS, 2000, J BIOL CHEM, V275, P18011, DOI 10.1074/jbc.M909787199; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Gregan J, 2003, MOL BIOL CELL, V14, P3876, DOI 10.1091/mbc.E03-02-0090; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Harvey KJ, 2003, J BIOL CHEM, V278, P48524, DOI 10.1074/jbc.M307661200; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Homesley L, 2000, GENE DEV, V14, P913; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jares P, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-5; Jares P, 2000, GENE DEV, V14, P1528; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kawasaki Y, 2001, MOL CELLS, V12, P277; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Krude T, 1996, J CELL SCI, V109, P309; Kubota Y, 2003, GENE DEV, V17, P1141, DOI 10.1101/gad.1070003; Kukimoto I, 1999, EUR J BIOCHEM, V265, P936, DOI 10.1046/j.1432-1327.1999.00791.x; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lee JK, 2003, P NATL ACAD SCI USA, V100, P2334, DOI 10.1073/pnas.0237384100; Lei M, 2001, J CELL SCI, V114, P1447; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Li A, 2004, NAT CELL BIOL, V6, P260, DOI 10.1038/ncb1100; Li CJ, 2004, MOL CELL BIOL, V24, P5875, DOI 10.1128/MCB.24.13.5875-5886.2004; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Li F, 2001, J CELL BIOL, V154, P283, DOI 10.1083/jcb.200104043; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Liu QH, 2000, GENE DEV, V14, P1448; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Lucas I, 2000, J MOL BIOL, V296, P769, DOI 10.1006/jmbi.2000.3500; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; Maiorano D, 2004, EXP CELL RES, V295, P138, DOI 10.1016/j.yexcr.2003.11.018; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masuda T, 2003, GENES CELLS, V8, P145, DOI 10.1046/j.1365-2443.2003.00621.x; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; Masumoto H, 2002, NATURE, V415, P651, DOI 10.1038/nature713; McFarlane RJ, 1997, MOL GEN GENET, V255, P332, DOI 10.1007/s004380050504; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; McNairn AJ, 2003, BIOESSAYS, V25, P647, DOI 10.1002/bies.10305; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Messer W, 2001, BIOCHIMIE, V83, P5, DOI 10.1016/S0300-9084(00)01216-5; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Mimura S, 2000, GENES CELLS, V5, P439, DOI 10.1046/j.1365-2443.2000.00340.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Mizushima T, 2000, GENE DEV, V14, P1631; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Nakajima R, 2002, MOL BIOL CELL, V13, P1462, DOI 10.1091/mbc.02-01-0006; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Noguchi E, 2002, CURR BIOL, V12, P599, DOI 10.1016/S0960-9822(02)00739-X; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Okuno Y, 1999, MOL CELL BIOL, V19, P6699; Okuno Y, 2001, EMBO J, V20, P4263, DOI 10.1093/emboj/20.15.4263; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Oshiro G, 1999, MOL CELL BIOL, V19, P4888; Pavlov YI, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-11; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pospiech H, 1999, NUCLEIC ACIDS RES, V27, P3799, DOI 10.1093/nar/27.19.3799; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Prokhorova TA, 2000, J BIOL CHEM, V275, P2491, DOI 10.1074/jbc.275.4.2491; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Rowles A, 1999, J CELL SCI, V112, P2011; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Santocanale C, 1999, GENE DEV, V13, P2360, DOI 10.1101/gad.13.18.2360; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Sasaki T, 1999, MOL CELL BIOL, V19, P547; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; Sawyer SL, 2004, J MOL BIOL, V340, P195, DOI 10.1016/j.jmb.2004.04.066; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; Schaarschmidt D, 2004, EMBO J, V23, P191, DOI 10.1038/sj.emboj.7600029; Schepers A, 2001, EMBO J, V20, P4588, DOI 10.1093/emboj/20.16.4588; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Segurado M, 2003, EMBO REP, V4, P1048, DOI 10.1038/sj.embor.7400008; Shcherbakova PV, 1996, GENETICS, V142, P717; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Shreeram S, 2003, Prog Cell Cycle Res, V5, P287; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stevenson JB, 1999, GENE DEV, V13, P146, DOI 10.1101/gad.13.2.146; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Sun WH, 2002, EMBO J, V21, P1437, DOI 10.1093/emboj/21.6.1437; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Uchiyama M, 2001, J BIOL CHEM, V276, P26189, DOI 10.1074/jbc.M100007200; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Vujcic M, 1999, MOL CELL BIOL, V19, P6098; Waga S, 2001, P NATL ACAD SCI USA, V98, P4978, DOI 10.1073/pnas.081088798; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Wilmes GM, 2004, GENE DEV, V18, P981, DOI 10.1101/gad.1202304; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wu JR, 1998, EMBO J, V17, P1810, DOI 10.1093/emboj/17.6.1810; Wu JR, 1997, MOL CELL BIOL, V17, P4312, DOI 10.1128/MCB.17.8.4312; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5; Yamamoto RR, 2000, GENETICS, V156, P711; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Zappulla DC, 2002, CURR BIOL, V12, P869, DOI 10.1016/S0960-9822(02)00871-0; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601; Zhao H, 2003, MOL CELL BIOL, V23, P8395, DOI 10.1128/MCB.23.22.8395-8403.2003; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	261	149	152	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2827	2843		10.1038/sj.onc.1208616	http://dx.doi.org/10.1038/sj.onc.1208616			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838518				2022-12-17	WOS:000228465800008
J	Yang, YL; Li, CCH; Weissman, AM				Yang, YL; Li, CCH; Weissman, AM			Regulating the p53 system through ubiquitination	ONCOGENE			English	Review						p53; Mdm2; ubiquitination; molecular targeting; apoptosis	EARLY EMBRYONIC LETHALITY; PROLYL ISOMERASE PIN1; ARF TUMOR-SUPPRESSOR; STABILIZES P53; MUTANT P53; PROTEIN LIGASE; MDM2-DEFICIENT MICE; MDM2 DEGRADATION; DOWN-REGULATION; C-ABL	The tumor suppressor p53 is tightly controlled at low levels in cells by constant ubiquitination and proteasomal degradation. In response to stresses, ubiquitination of p53 is inhibited through diverse pathways, depending on the nature of the stimulus and cell type. This leads to the accumulation and activation of p53, which induces cell cycle arrest and/or apoptosis to prevent cells from transformation. Many studies have indicated that defects of the p53 system are present in most, if not all, human tumor cells. Meanwhile, significant progress has been made in understanding the molecular mechanisms of p53 ubiquitination and the regulation of the p53 system. Therefore, it is possible now to consider targeting ubiquitination as a means to regulate and reactivate p53 in tumors. Emerging evidence suggests that inhibiting the E3 activity of Mdm2, blocking the interaction of p53 and Mdm2, and restoring the function of mutated p53 are potential effective strategies to kill certain tumor cells selectively. It is conceivable that new chemotherapeutic agents based on these studies will be generated in the not-so-distant future.	NCI, Regulat Prot Funct Lab, Ctr Canc Res, Frederick, MD 21702 USA; NCI, Lab Canc Prevent, SAIC Frederick, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Yang, YL (corresponding author), NCI, Regulat Prot Funct Lab, Ctr Canc Res, 1050 Boyles St,560-22-64, Frederick, MD 21702 USA.	yangyili@ncifcrf.gov			NCI NIH HHS [N01-CA-12400] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC010029] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chene P, 2002, FEBS LETT, V529, P293, DOI 10.1016/S0014-5793(02)03362-8; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Duncan SJ, 2001, J AM CHEM SOC, V123, P554, DOI 10.1021/ja002940p; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garcia-Echeverria C, 2000, J MED CHEM, V43, P3205, DOI 10.1021/jm990966p; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo ML, 2003, CANCER RES, V63, P1046; Lai ZH, 2002, P NATL ACAD SCI USA, V99, P14734, DOI 10.1073/pnas.212428599; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Leung KM, 2002, CANCER RES, V62, P4890; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liefer KM, 2000, CANCER RES, V60, P4016; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luu Y, 2002, EXP CELL RES, V276, P214, DOI 10.1006/excr.2002.5526; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Ruland J, 2001, P NATL ACAD SCI USA, V98, P1859, DOI 10.1073/pnas.98.4.1859; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yarbrough WG, 2002, CANCER RES, V62, P1171; Yu XD, 2002, J NATL CANCER I, V94, P504; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhao JH, 2002, CANCER LETT, V183, P69, DOI 10.1016/S0304-3835(02)00084-8; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	129	149	162	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2004	23	11					2096	2106		10.1038/sj.onc.1207411	http://dx.doi.org/10.1038/sj.onc.1207411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	803EC	15021897				2022-12-17	WOS:000220213400014
J	von Haefen, C; Wieder, T; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT				von Haefen, C; Wieder, T; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop	ONCOGENE			English	Article						chemotherapy; apoptosis; mitochondria; amplification loop; BJAB cells; caspase-3; caspase-8; cytochrome c; Bcl-x(L); taxol; paclitaxel	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CANCER CELLS; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; OCCURS DOWNSTREAM; CARCINOMA-CELLS; PATHWAYS; BCL-2; RADIATION	Caspase-8 is a key effector of death-receptor-triggered apoptosis. In a previous study, we demonstrated, however, that caspase-8 can also be activated in a death receptor-independent manner via the mitochondrial apoptosis pathway, downstream of caspase-3. Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol). In contrast, Smac release from mitochondria followed a different pattern, and therefore seems to be regulated independently from cytochrome c release. Taxol-induced cell death was inhibited by the use of synthetic, cell-permeable caspase-3- (zDEVD-fmk) or caspase-8-specific (zIETD-fmk) inhibitors. Apoptosis signaling was not affected by a dominant-negative FADD mutant (FADD-DN), thereby excluding a role of death receptor signaling in the amplification loop and drug-induced apoptosis. The inhibitor experiments were corroborated by the use of BJAB cells overexpressing the natural serpin protease inhibitor, cytokine response modifier A. These data demonstrate that the complete activation of mitochondria, release of cytochrome c, and execution of drug-induced apoptosis require a mitochondrial amplification loop that depends on caspases-3 and -8 activation. In addition, this is the first report to demonstrate death receptor-independent caspase-8 autoprocessing in vivo.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.		Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Biswas RS, 2001, MOL CELL BIOCHEM, V225, P7, DOI 10.1023/A:1012203110027; Bricker K.S., 1978, Kasetsart University Fisheries Research Bulletin, V10, P1; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Das GC, 2001, CANCER LETT, V165, P147, DOI 10.1016/S0304-3835(01)00404-9; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LAMBERT IH, 1989, J MEMBRANE BIOL, V111, P113, DOI 10.1007/BF01871776; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Perkins CL, 2000, CANCER RES, V60, P1645; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	52	149	153	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2236	2247		10.1038/sj.onc.1206280	http://dx.doi.org/10.1038/sj.onc.1206280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700660				2022-12-17	WOS:000182231500003
J	Ehrlich, M; Jiang, GC; Fiala, E; Dome, JS; Yu, MC; Long, TI; Youn, B; Sohn, OS; Widschwendter, M; Tomlinson, GE; Chintagumpala, M; Champagne, M; Parham, D; Liang, GN; Malik, K; Laird, PW				Ehrlich, M; Jiang, GC; Fiala, E; Dome, JS; Yu, MC; Long, TI; Youn, B; Sohn, OS; Widschwendter, M; Tomlinson, GE; Chintagumpala, M; Champagne, M; Parham, D; Liang, GN; Malik, K; Laird, PW			Hypomethylation and hypermethylation of DNA in Wilms tumors	ONCOGENE			English	Article						DNA hypomethylation; DNA hypermethylation; Wilms tumors	PROMOTER METHYLATION; PERICENTROMERIC DNA; COLORECTAL TUMORS; CARCINOMA-CELLS; CPG ISLANDS; GENE; EXPRESSION; CANCERS; BREAST; 5-METHYLCYTOSINE	We quantitatively analysed hypermethylation at CpG islands in the 5' ends of 12 genes and one non-CpG island 5' region (MTHFR) in 31 Wilms tumors. We also determined their global genomic 5-methylcytosine content. Compared with various normal postnatal tissues, similar to40-90% of these pediatric kidney cancers were hypermethylated in four of the genes, MCJ, RASSF1A, TNFRSF12 and CALCA as determined by a quantitative bisulfite-based assay (MethyLight). Interestingly, the non-CpG island 5' region of MTHFR was less methylated in most tumors relative to the normal tissues. By chromatographic analysis of DNA digested to deoxynucleosides, about 60% of the Wilms tumors were found to be deficient in their overall levels of DNA methylation. We also analysed expression of the three known functional DNA methyltransferase genes. No relationship was observed between global genomic 5-methylcytosine levels and relative amounts of RNA for DNA methyltransferases DNMT1, DNMT3A, and DNMT3B. Importantly, no association was seen between CpG island hypermethylation and global DNA hypomethylation in these cancers. Therefore, the overall genomic hypomethylation frequently observed in cancers is probably not just a response or a prelude to hypermethylation elsewhere in the genome. This suggests that the DNA hypomethylation contributes independently to oncogenesis or tumor progression.	Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Human Genet Program, New Orleans, LA 70112 USA; Amer Hlth Fdn, Dept Biochem Pharmacol, Valhalla, NY 10595 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Hop St Justine, Serv Hematol Oncol, Montreal, PQ H3T 1C5, Canada; Arkansas Childrens Hosp, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Univ Bristol, Sch Med Sci, Dept Pathol, Canc & Leukaemia Childhood Unit, Bristol BS8 1TD, Avon, England	Tulane University; Tulane University; American Health Foundation; St Jude Children's Research Hospital; University of Southern California; University of Southern California; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; Texas Children's Cancer Center; Universite de Montreal; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; University of Bristol	Ehrlich, M (corresponding author), Tulane Univ, Sch Med, Human Genet Program SL31, 1430 Tulane Ave, New Orleans, LA 70112 USA.	ehrlich@tulane.edu	Laird, Peter W/G-8683-2012; Parham, David M./AAN-1059-2020; Tomlinson, Gail/AAR-9776-2020; Dome, Jeffrey/AAH-7825-2019	Laird, Peter W/0000-0001-9117-3641; Parham, David M./0000-0002-6912-9748; Widschwendter, Martin/0000-0002-7778-8380; Liang, Gangning/0000-0001-8664-922X	NATIONAL CANCER INSTITUTE [P01CA070972, P01CA046589, R01CA075090] Funding Source: NIH RePORTER; NCI NIH HHS [CA1506, R01 CA075090, CA 75090, P01 CA 70972, P01 CA 46589] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 1998, CANCER RES, V58, P5489; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; BUSSON P, 1992, INT J CANCER, V50, P863, DOI 10.1002/ijc.2910500605; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; EHRLICH M, 2002, IN PRESS CANC GENET; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gaughan DJ, 2000, GENE, V257, P279, DOI 10.1016/S0378-1119(00)00392-9; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Hollander M., 1973, NONPARAMETRIC STAT, P68; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Malik K, 2000, CANCER RES, V60, P2356; Mares J, 2001, CANCER LETT, V166, P165, DOI 10.1016/S0304-3835(01)00402-5; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Shridhar V, 2001, CANCER RES, V61, P4258; Strichman-Almashanu LZ, 2002, GENOME RES, V12, P543, DOI 10.1101/gr.224102; Toyota M, 2000, CANCER RES, V60, P4044; Tuckwell KD, 2000, AUSTRALAS I MIN MET, V2000, P121; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Wang ECY, 2001, IMMUNOGENETICS, V53, P59, DOI 10.1007/s002510000290; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; YOUNG R, 2001, J GERONTOL A-BIOL, V56, pR268; ZHANG XY, 1987, NUCLEIC ACIDS RES, V15, P9429, DOI 10.1093/nar/15.22.9429	39	149	165	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6694	6702		10.1038/sj.onc.1205890	http://dx.doi.org/10.1038/sj.onc.1205890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242669				2022-12-17	WOS:000178202300017
J	Brodie, SG; Xu, XL; Qiao, WH; Li, WM; Cao, L; Deng, CX				Brodie, SG; Xu, XL; Qiao, WH; Li, WM; Cao, L; Deng, CX			Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice	ONCOGENE			English	Article						Brca1; p53; ErbB2; cyclin D1; c-Myc; tumorigenesis	CANCER-SUSCEPTIBILITY GENES; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; BREAST-CANCER; CELL-CYCLE; TRANSGENIC MICE; TUMOR-FORMATION; MEIOTIC CELLS; 5 REGIONS; C-MYC	Germline mutations in the tumor suppressor gene BRCA1 predispose women to breast cancer, however somatic mutations in the gene are rarely detected in sporadic cancers. To understand this phenomenon, we examined mouse models carrying conditional disruption of Brca1 in mammary epithelium in either p53 wild type (wt) or heterozygous backgrounds. Although a p53(+/-) mutation significantly accelerated tumorigenesis, both strains developed mammary tumors in a stochastic fashion, suggesting that multiple factors, in addition to p53 mutations, may be involved in Brca1 related tumorigenesis. A unique feature of Brca1 mammary tumors is their highly diverse histopathology accompanied by severe chromosome abnormalities. The tumors also display extensive genetic/molecular alterations, including overexpression of ErbB2, c-Myc, p27 and Cyclin D1 in the majority of tumors, while they were virtually ER alpha and p16 negative. Translocations involving p53 were also identified which lead to abnormal RNA and protein products. In addition, we generated cell lines from mammary tumors and found that the cells retained many of the genetic changes found in the primary tumors, suggesting that these genes may be players in Brca1-associated tumorigenesis. Despite their distinct morphology, all cultured tumor cells were Tamoxifen resistant but highly sensitive to Doxorubicin or irradiation, suggesting that these methods would be effective in treatment of this disease.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Barbareschi M, 2000, INT J CANCER, V89, P236, DOI 10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.3.CO;2-Q; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bonsing BA, 2000, GENE CHROMOSOME CANC, V28, P173, DOI 10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO;2-1; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GATEI M, 2001, J BIOL CHEM, V13, P13; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mueller A, 1997, CANCER RES, V57, P5542; O'Brien KA, 1999, BIOCHEM BIOPH RES CO, V260, P658, DOI 10.1006/bbrc.1999.0892; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Osborne RJ, 2000, CANCER RES, V60, P3706; Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530; Robson M, 1998, CANCER RES, V58, P1839; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Walker RA, 1999, J PATHOL, V188, P229, DOI 10.1002/(SICI)1096-9896(199907)188:3<229::AID-PATH341>3.0.CO;2-F; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	63	149	153	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7514	7523		10.1038/sj.onc.1204929	http://dx.doi.org/10.1038/sj.onc.1204929			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709723				2022-12-17	WOS:000171976900008
J	Xirodimas, D; Saville, MK; Edling, C; Lane, DP; Lain, S				Xirodimas, D; Saville, MK; Edling, C; Lane, DP; Lain, S			Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo	ONCOGENE			English	Article						p53; p14ARF; Mdm2; ubiquitin; proteasome inhibition	RING-FINGER DOMAIN; TUMOR-SUPPRESSOR P53; IN-VIVO; NUCLEOLAR-LOCALIZATION; NUCLEAR EXPORT; STABILIZES P53; DEGRADATION; PROMOTES; P19(ARF); PROTEIN	Mdm2 has been shown to promote its own ubiquitination and the ubiquitination of the p53 tumour suppressor by virtue of its E3 ubiquitin ligase activity. This modification targets Mdm2 and p53 for degradation by the proteasome. The p14ARF tumour suppressor has been shown to inhibit degradation of p53 mediated by Mdm2. Several models have been proposed to explain this effect of p14ARF. Here we have compared the effects of p14ARF overexpression on the in vivo ubiquitination of p53 and Mdm2. We report that the inhibition of the Mdm2-mediated degradation of p53 by p14ARF is associated with a decrease in the proportion of ubiquitinated p53. The levels of polyubiquitinated p53 decreased preferentially compared to monoubiquitinated species. p14ARF overexpression increased the levels of Mdm2 but it did not reduce the overall levels of ubiquitinated Mdm2 in vivo. This is unexpected because p14ARF has been reported to inhibit the ubiquitination of Mdm2 in vitro. In addition we show that like p14ARF, the proteasome inhibitor MG132 can promote the accumulation of Mdm2 in the nucleolus and that this can occur in the absence of p14ARF expression. We also show that the mutation of the nucleolar localization signal of Mdm2 does not impair the overall ubiquitination of Mdm2 but is necessary for the effective polyubiquitination of p53. These studies reveal important differences in the regulation of the stability of p53 and of Mdm2.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Lain, S (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	s.lain@dundee.ac.uk	Lain, Sonia/B-6980-2014; Lane, David P/C-4920-2008	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545; Xirodimas, Dimitris/0000-0001-9275-1140				An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	37	149	154	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					4972	4983		10.1038/sj.onc.1204656	http://dx.doi.org/10.1038/sj.onc.1204656			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526482				2022-12-17	WOS:000170439800007
J	Reinstein, E; Scheffner, M; Oren, M; Ciechanover, A; Schwartz, A				Reinstein, E; Scheffner, M; Oren, M; Ciechanover, A; Schwartz, A			Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue	ONCOGENE			English	Article						human papilloma-virus (HPV); E7; ubiquitin; proteolysis; N-terminus	TRANSGENIC MICE; END RULE; TYPE-16; PROTEIN; EXPRESSION; GENE; E6; TRANSFORMATION; CONJUGATION; CELLS	The E7 oncoprotein of the high risk human papillomavirus type 16 (HPV-16), which is etiologically associated with uterine cervical cancer, is a potent immortalizing and transforming agent, It probably exerts its oncogenic functions by interacting and altering the normal activity of cell cycle control proteins such as p21(WAF1), p27(KIP1) pRb, transcriptional activators such as TBP and AP-1, and metabolic regulators such as M2-pyruvate kinase (M2-PK), Here we show that E7 is a short-lived protein and its degradation both in vitro and in vivo is mediated by the ubiquitin-proteasome pathway. interestingly; ubiquitin does not attach to any of the two internal Lysine residues of E7, Substitution of these residues with Arg does not affect the ability of the protein to be conjugated and degraded; in contrast, addition of a MSc tag to the N-terminal but not to the C-terminal residue, stabilizes the protein. Also, deletion of the first If amino acid residues stabilizes the protein in cells, Taken together, these findings strongly suggest that, like MyoD and the Epstein Barr Virus (EBV) transforming Latent Membrane Protein 1 (LMP1), the first ubiquitin moiety is attached linearly to the free N-terminal residue of E7, Additional ubiquitin moieties are then attached to an internal Lys residue of the previously conjugated molecule, The involvement of E7 in many diverse and apparently unrelated processes requires tight regulation of its function and cellular level, which is controlled in this case by ubiquitin-mediated proteolysis.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-30196 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-30196 Haifa, Israel; Univ Cologne, Fak Med, Inst Biochem, D-50931 Cologne, Germany; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Cologne; Weizmann Institute of Science; Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, POB 9649,Efron St, IL-30196 Haifa, Israel.		高, 雨莉/HGU-8187-2022; Ciechanover, Aaron J/C-9166-2017; Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128; Oren, Moshe/0000-0003-4311-7172				Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; Boyer SN, 1996, CANCER RES, V56, P4620; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CHEN LP, 1993, P NATL ACAD SCI USA, V90, P6523, DOI 10.1073/pnas.90.14.6523; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HU TH, 1995, INT J ONCOL, V6, P167; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; KANDA T, 1988, J VIROL, V62, P610, DOI 10.1128/JVI.62.2.610-613.1988; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; MUNGER K, 1989, J VIROL, V63, P4417; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291	39	149	157	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2000	19	51					5944	5950		10.1038/sj.onc.1203989	http://dx.doi.org/10.1038/sj.onc.1203989			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127826				2022-12-17	WOS:000165563100014
J	Scanga, SE; Ruel, L; Binari, RC; Snow, B; Stambolic, V; Bouchard, D; Peters, M; Calvieri, B; Mak, TW; Woodgett, JR; Manoukian, AS				Scanga, SE; Ruel, L; Binari, RC; Snow, B; Stambolic, V; Bouchard, D; Peters, M; Calvieri, B; Mak, TW; Woodgett, JR; Manoukian, AS			The conserved PI3 ' K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila	ONCOGENE			English	Article						Drosophila; PKB; PI3K; PTEN; cell size; cell survival	PROTEIN-KINASE B/AKT; B C-AKT; PHOSPHOINOSITIDE 3-KINASE; GROWTH; TRANSFORMATION; ACTIVATION; APOPTOSIS; DEATH	Akt (or PKB) is an oncogene involved in the regulation of cell survival. Akt is regulated by phosphatidylinositol 3-OH kinase (P13'K) signaling and has shown to be hyperactivated through the loss of the PTEN tumor suppressor. In Drosophila, insulin signaling as studied using the Drosophila IRS-4 homolog (Chico) has been shown to be a crucial regulator of cell size. We have studied Drosophila Akt (Dakt1) and have shown that it is also involved in the regulation of cell size. Furthermore me have performed genetic epistasis tests to demonstrate that in Drosophila, PI3'K, PTEN and Akt comprise a signaling cassette that is utilized during multiple stages of development. In addition, we show that this signaling cassette is also involved in the regulation of cell survival during embryogenesis. This study therefore establishes the evolutionary conservation of this signaling pathway in Drosophila.	Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Cell & Mol Biol,Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Expt Therapeut,Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Electron Microscopy Unit, Toronto, ON M5S 1A8, Canada; Amgen Res Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Manoukian, AS (corresponding author), Univ Toronto, Princess Margaret Hosp, Univ Hlth Network,Dept Med Biophys, Div Cell & Mol Biol,Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797; Stambolic, Vuk/0000-0001-8853-3239				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ANJELKOVIC M, 1996, P NATL ACAD SCI USA, V93, P5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Coffer PJ, 1998, BIOCHEM J, V335, P1; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CULLEN CF, 1991, TISSUE CELL, V23, P29, DOI 10.1016/0040-8166(91)90064-Z; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Huang H, 1999, DEVELOPMENT, V126, P5365; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lehner CF, 1999, NAT CELL BIOL, V1, pE129, DOI 10.1038/12961; MANOUKIAN AS, 1997, MRNA FORMATION FUNCT, P361; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	29	149	153	10	22	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3971	3977		10.1038/sj.onc.1203739	http://dx.doi.org/10.1038/sj.onc.1203739			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962553				2022-12-17	WOS:000088825300002
J	Loukinova, E; Dong, G; Enamorado-Ayalya, I; Thomas, GR; Chen, Z; Schreiber, H; Van Waes, C				Loukinova, E; Dong, G; Enamorado-Ayalya, I; Thomas, GR; Chen, Z; Schreiber, H; Van Waes, C			Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism	ONCOGENE			English	Article						GRO-alpha; KC; CXCR2; chemokines; squamous cell carcinoma	PROINFLAMMATORY CYTOKINE EXPRESSION; COLONY-STIMULATING FACTOR; FACTOR-KAPPA-B; CONSTITUTIVE ACTIVATION; ENVIRONMENT PROMOTES; CANCER-CELLS; NECK-CANCER; HUMAN HEAD; IN-VIVO; LINES	Growth Regulated Oncogene-alpha (GRO-alpha) is an autocrine growth factor in melanoma and is a member of the C-X-C family of chemokines which promote chemotaxis of granulocytes and endothelia through binding to CXC Receptor 2, We found previously that variants of murine squamous cell carcinoma PAM 212 which grow and metastasize more rapidly in vivo constitutively express increased levels of murine GRO-alpha, designated mGRO-alpha, or KC, We have examined the possible role of mGRO-alpha. expression in malignant progression of squamous cell carcinoma PAM 212 in homologous BALB/c and BALB CXC Receptor-2 deficient mice, Transfection of the PAM 212 cell line which exhibits low expression of GRO-alpha and malignant potential with a pActin-KC vector encoding mGRO-alpha enabled isolation of PAM-KC expressing cell lines, These PAM-KC transfectants displayed an increased rate of growth and metastasis in BALB/c mice, similar to the highly malignant phenotype observed in spontaneously occurring metastatic variants. Furthermore, the PAM-KC tumors showed an increase in infiltration of host leukocytes and CD31+ blood vessels, consistent with increased CXC chemokine activity. The increased growth of PAM-KC cells was attenuated in CXCR-2 deficient mice, indicating that the increased growth was dependent in part upon host cells responsive to the CXC chemokine, Together, these results show that a CXC chemokine such as GRO-alpha can promote malignant growth of murine squamous cell carcinoma by a host CXCR-2 dependent pathway.	Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Comm Immunol, Dept Pathol, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Chicago	Van Waes, C (corresponding author), Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bldg 10,Rm 5D55,MSC-1419, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R37CA022677, R01CA022677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000016, ZIADC000016] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22677] Funding Source: Medline; NIDCD NIH HHS [Z01-DC-00016] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BALENTIEN E, 1991, ONCOGENE, V6, P1115; BOZIC CR, 1995, J IMMUNOL, V154, P6048; Chen Z, 1998, CANCER RES, V58, P3668; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; COHEN RF, 1995, ARCH OTOLARYNGOL, V121, P202; Dong G, 1999, CANCER RES, V59, P3495; Dong G, 1997, J CELL BIOCHEM, P90; Duffey DC, 1999, CANCER RES, V59, P3468; GASPARINI G, 1993, INT J CANCER, V55, P739, DOI 10.1002/ijc.2910550507; GUTMAN M, 1994, CANCER BIOTHERAPY, V9, P163, DOI 10.1089/cbr.1994.9.163; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PAK AS, 1995, CLIN CANCER RES, V1, P95; PEKAREK LA, 1995, J EXP MED, V181, P435, DOI 10.1084/jem.181.1.435; Schrieber H, 1999, INFLAMMATION BASIC P, P1117; SEUNG LP, 1995, CANCER RES, V55, P5094; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Strieter RM, 1996, CHEMOKINES DIS, P195; VANWAES C, 2000, IN PRESS NEW FRONTIE; Weidner Noel, 1996, P167; Young MRI, 1997, INT J CANCER, V74, P69, DOI 10.1002/(SICI)1097-0215(19970220)74:1<69::AID-IJC12>3.0.CO;2-D; YUSPA SH, 1980, CANCER RES, V40, P4694	25	149	157	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3477	3486		10.1038/sj.onc.1203687	http://dx.doi.org/10.1038/sj.onc.1203687			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918606				2022-12-17	WOS:000088346500004
J	Takada, S; Shirakata, Y; Kaneniwa, N; Koike, K				Takada, S; Shirakata, Y; Kaneniwa, N; Koike, K			Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death	ONCOGENE			English	Article						HBV X protein; cytoplasmic location; mitochondrial aggregation; p53 protein; cell death	GENE-PRODUCT; TRANSACTIVATOR PX; SERINE-PROTEASE; DNA; TRANSFORMATION; ACTIVATION; INHIBITOR; PROMOTER; RAS	Hepatitis B virus (HBV) X protein activates many viral and cellular genes in trans and functional disruption of the p53 tumor suppressor gene product occurs when X protein is transiently expressed in the cytoplasm of cultured cells. We have carried out investigations to determine the exact location of X protein in X gene transfected cells by using a fluorescent staining technique as well as by biochemical analyses. Aggregation of mitochondrial structures became evident at the periphery of nucleus in the cytoplasm of X transfected cells. X protein was found associated with the aggregated mitochondrial structures. Furthermore, transiently expressed p53 protein co-localized with X protein in X transfected cells, However, the appearance of aggregated mitochondrial structures at the nuclear periphery was independent of the presence of p53 protein in X transfected cells. X protein expression also caused an appearance of TUNEL positive nucleus, cytochrome c release from mitochondrial, the decrease of mitochondrial membrane potential and the membrane blebbing of X transfected cells, which are characteristic of cell death. Our data suggest that X protein causes an abnormal aggregation of mitochondrial structures in the cell, which may be eventually connected with cell death.	Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research	Koike, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Gene Res, Toshima Ku, Tokyo 1708455, Japan.							ARII M, 1992, ONCOGENE, V7, P397; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2837; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Sambrook J, 1989, MOL CLONING LAB MANU; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; TAKADA S, 1994, ONCOGENE, V9, P341; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TANAKA S, 1978, BIOCHEM BIOPH RES CO, V81, P791, DOI 10.1016/0006-291X(78)91421-3; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493	30	149	157	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6965	6973		10.1038/sj.onc.1203188	http://dx.doi.org/10.1038/sj.onc.1203188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597295				2022-12-17	WOS:000083901900001
J	Zamzami, N; Marzo, I; Susin, SA; Brenner, C; Larochette, N; Marchetti, P; Reed, J; Kofler, R; Kroemer, G				Zamzami, N; Marzo, I; Susin, SA; Brenner, C; Larochette, N; Marchetti, P; Reed, J; Kofler, R; Kroemer, G			The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition	ONCOGENE			English	Article						cytochrome c; mitochondrial transmembrane potential; permeability transition; programmed cell death	PROGRAMMED CELL-DEATH; POLYCYSTIC KIDNEY; GLUTATHIONE; PORE; OXIDATION; REDUCTION; OXYGEN; PHOSPHORYLATION; INACTIVATION; GENERATION	In several different cell lines, Bcl-2 prevents the induction of apoptosis (DNA fragmentation, PARP cleavage, phosphatidylserine exposure) by the pro-oxidant terbutylhydroperoxide (t-BHP) but has no cytoprotective effect when apoptosis is induced by the thiol crosslinking agent diazenedicarboxylic acid bis 5,N-dimethylamide (diamide), Both t-BHP and diamide cause a disruption of the mitochondrial transmembrane potential Delta Psi(m), that is not inhibited by the broad spectrum caspase inhibitor z-VAD.fmk, although z-VAD.fmk does prevent nuclear DNA fragmentation and poly(ADP-ribose) polymerase cleavage in these models, Bcl-2 stabilizes the Delta Psi(m) of t-BHP-treated cells but has no inhibitory effect on the Delta Psi(m) collapse induced by diamide, As compared to normal controls, isolated mitochondria from Bcl-2 overexpressing cells are relatively resistant to the induction of Delta Psi(m) disruption by t-BHP in vitro, Such Bcl-2 overexpressing mitochondria also fail to release apoptosis-inducing factor (AIF) and cytochrome c from the intermembrane space, whereas control mitochondria not overexpressing Bcl-2 do liberate AIF and cytochrome c in response to t-BHP. In contrast, Bcl-2 does not confer protection against diamide-triggered Delta Psi(m) collapse and the release of AIF and cytochrome c, This indicates that Bcl-2 suppresses the permeability transition (PT) and the associated release of intermembrane proteins induced by t-BHP but not by diamide, To further investigate the mode of action of Bcl-2, semi-purified PT pore complexes were reconstituted in liposomes in a cell-free, organelle-free system, Recombinant Bcl-2 or Bcl-X, proteins augment the resistance of reconstituted PT pore complexes to pore opening induced by t-BHP, In contrast, mutated Bcl-2 proteins which have lost their cytoprotective potential also lose their PT-modulatory capacity, Again, Bcl-2 fails to confer protection against diamide in this experimental system, The reconstituted PT pore complex itself cannot release cytochrome c encapsulated into liposomes, Altogether these data suggest that pro-oxidants, thiol-reactive agents, and Bcl-2 can regulate the PT pore complex in a direct fashion, independently from their effects on cytochrome c, Furthermore, our results suggest a strategy for inducing apoptosis in cells overexpressing apoptosis-inhibitory Bcl-2 analogs.	CNRS, Unite Propre Rech 420, F-94801 Villejuif, France; Burnham Inst, La Jolla, CA 92037 USA; Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	Centre National de la Recherche Scientifique (CNRS); Sanford Burnham Prebys Medical Discovery Institute; University of Innsbruck	Kroemer, G (corresponding author), CNRS, Unite Propre Rech 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.		brenner, catherine/AAE-8632-2020; Marzo, Isabel/E-6918-2016; Susin, Santos A/Q-6754-2017; LAROCHETTE, Nathanael/R-4298-2017; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	Marzo, Isabel/0000-0002-2315-9079; Susin, Santos A/0000-0002-3366-1628; LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405; MARCHETTI, Philippe/0000-0002-4663-6800				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DROGE W, 1994, FASEB J, V8, P1131; Ellerby HM, 1997, J NEUROSCI, V17, P6165; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMADA S, 1995, CANCER RES, V55, P354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353; Kinnally KW, 1996, J BIOENERG BIOMEMBR, V28, P115, DOI 10.1007/BF02110641; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer Guido, 1997, P1111; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Macho A, 1997, J IMMUNOL, V158, P4612; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARZO I, 1998, IN PRESS J EXP MED; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REED DJ, 1995, BBA-MOL BASIS DIS, V1271, P43, DOI 10.1016/0925-4439(95)00008-R; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SATO N, 1995, J IMMUNOL, V154, P3194; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YING XM, 1994, NATURE, V369, P321; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	59	149	170	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1055	1063		10.1038/sj.onc.1201864	http://dx.doi.org/10.1038/sj.onc.1201864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519879				2022-12-17	WOS:000072335900011
J	Hurlin, PJ; Foley, KP; Ayer, DE; Eisenman, RN; Hanahan, D; Arbeit, JM				Hurlin, PJ; Foley, KP; Ayer, DE; Eisenman, RN; Hanahan, D; Arbeit, JM			Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis	ONCOGENE			English	Article						Myc-Mad network; epithelial differentiation; HPV; neoplastic progression; keratinocytes	C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; HUMAN KERATINOCYTES; NEOPLASTIC-CELLS; GENE-EXPRESSION; PROTEIN; PROLIFERATION; DISTINCT	c-Myc and Mad each form heterodimers with Max that bind the same E-box related DNA sequences, Whereas Myc:Max complexes activate transcription and promote cell proliferation and transformation, Mad:Max complexes repress transcription and block c-Myc-mediated cell transformation. Here we examine these antagonistic transcription factors during epithelial differentiation and neoplastic progression, During differentiation of primary human keratinocytes, Mad is rapidly induced and c-Myc is downregulated, resulting in a switch from c-Myc:Max to Mad:Max heterodimers, In normal epidermis and colonic mucosa c-myc expression is proliferating cell layers, while mad restricted to differentiating cell layers, Using HPV18 transformed keratinocytes that vary in their ability to differentiate in organotypic cultures, we find that Mad induction occurs only in those cells that retain a differentiation response, In the epidermis of transgenic mice in which expression of the HPV16 E6 and E7 oncogenes are targeted to basal keratinocytes, neoplastic progression occurs and is marked by an expansion of c-myc expressing basal-like cells. Expression of mad is found only in growth-arrested differentiating cells on the outer edges of preneoplastic lesions, The squamous cell carcinomas that arise evidence a variable number of sites within the tumor masses where mad expression and morphological differentiation coincide; increasing malignancy correlates with loss of both mad and capability to differentiate, These results indicate that c-Myc and Mad expression are tightly coupled to the transition from proliferation to differentiation of epithelial cells and that restriction of Mad expression may be associated with loss of normal differentiation capability and with tumorigenesis.	FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA	Fred Hutchinson Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arbeit, Jeffrey/K-6920-2019; Foley, Kevin/ABC-1041-2020	Ayer, Donald/0000-0002-5595-3269	NATIONAL CANCER INSTITUTE [R01CA057138, R01CA047632] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47632-07A1, R01CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ASSELINEAU D, 1986, J INVEST DERMATOL, V86, P181, DOI 10.1111/1523-1747.ep12284237; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1995, GENE DEV, V80, P767; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Broders AC, 1932, NYJ MED, V32, P667; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1993, J CELL SCI, P197; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; HURLING PJ, 1995, IN PRESS EMBO J; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; Maniatis T., 1982, MOL CLONING; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERRICK DT, 1992, AM J PATHOL, V140, P167; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; OKUN MR, 1988, GROSS MICROSCOPIC PA, V2, P806; PIENTENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAKASAKI Y, 1981, J EXP MED, V154, P1899, DOI 10.1084/jem.154.6.1899; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WILLE JJ, 1985, CARCINOGENESIS, V6, P1181, DOI 10.1093/carcin/6.8.1181; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZURHAUSEN H, 1990, VIROLOGY, V184, P9	63	149	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2487	2501						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545105				2022-12-17	WOS:A1995TP18800004
J	HIGASHINO, F; YOSHIDA, K; NOUMI, T; SEIKI, M; FUJINAGA, K				HIGASHINO, F; YOSHIDA, K; NOUMI, T; SEIKI, M; FUJINAGA, K			ETS-RELATED PROTEIN E1A-F CAN ACTIVATE 3 DIFFERENT MATRIX METALLOPROTEINASE GENE PROMOTERS	ONCOGENE			English	Note						ETS; MMP; INVASION; TRANSCRIPTION	COLLAGENASE GENE; MAMMALIAN-CELLS; ONCOGENE FAMILY; BINDING-SITES; EXPRESSION; PEA3; FOS; AP-1; TRANSCRIPTION; ELEMENTS	An Ets-related E1A-F has been characterized as an enhancer-binding protein for the adenovirus E1A gene, Here we show, in transient expression assays, that E1A-F can activate three different subclasses of the matrix metalloproteinase gene promoters, Expressions of the chloramphenicol acetyltransferase (CAT) reporter gene under the control of stromelysin, type I collagenase and 92 kD type IV collagenase promoters were increased approximately 10- to 20-fold by co-transfection with the E1A-F expression vector. Activation levels were as much high as those obtained by exogenous expression of AP-1 transcription factor. These results suggest that EIA-F positively regulates transcriptions from matrix metalloproteinase genes that are associated with invasion and metastasis of tumor cells.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOL MOLEC, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; OKAYAMA UNIV, FAC ENGN SCI, DEPT BIOTECHNOL, OKAYAMA 700, JAPAN; KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN	Sapporo Medical University; Okayama University; Kanazawa University			Higashino, Fumihiro/F-8510-2012; Seiki, Motoharu/K-9443-2015					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1989, NATURE, V284, P67; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NERLOV C, 1991, ONCOGENE, V6, P1583; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POWELL WC, 1993, CANCER RES, V53, P417; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SATO H, 1993, ONCOGENE, V8, P395; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YOSHIDA K, 1989, NUCLEIC ACIDS RES, V17, P10015, DOI 10.1093/nar/17.23.10015	29	149	153	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1461	1463						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731700				2022-12-17	WOS:A1995QR65100027
J	MITCHELL, PJ; BARKER, KT; MARTINDALE, JE; KAMALATI, T; LOWE, PN; PAGE, MJ; GUSTERSON, BA; CROMPTON, MR				MITCHELL, PJ; BARKER, KT; MARTINDALE, JE; KAMALATI, T; LOWE, PN; PAGE, MJ; GUSTERSON, BA; CROMPTON, MR			CLONING AND CHARACTERIZATION OF CDNAS ENCODING A NOVEL NONRECEPTOR TYROSINE KINASE, BRK, EXPRESSED IN HUMAN BREAST-TUMORS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; SH3 DOMAINS; PROTEIN OVEREXPRESSION; SIGNAL TRANSDUCTION; PROGNOSTIC VALUE; RNA ISOLATION; CANCER; ONCOGENE; GENE; AMPLIFICATION	Using a polymerase chain reaction based differential screening approach, we have isolated and characterised a cDNA from a human metastatic breast tumour representing a novel protein tyrosine kinase (brk). Sequencing of brk cDNAs isolated from T-47D and MCF-7 human breast tumour cell lines indicate that they encode a protein with the features of a novel nonreceptor tyrosine kinase, including amino terminal SH3 and SH2 domains. When synthesised in recombinant baculovirus and bacterial expression systems, brk protein products are capable of autophosphorylation on tyrosine residues. Initial expression studies have detected low levels of brk transcripts in some human breast tumours and breast tumour cell lines, but not in normal breast tissue.	INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories			gusterson, barry a/D-3752-2009; Mitchell, Philip J/F-6393-2013					ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P4107, DOI 10.1093/nar/20.15.4107; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRIMAUX M, 1989, BREAST CANCER RES TR, V14, P77, DOI 10.1007/BF01805978; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HENNIPMAN A, 1989, CANCER RES, V49, P516; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE ST, 1993, ONCOGENE, V8, P3403; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NICOLSON S, 1991, BRIT J CANCER, V63, P146; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATERSON MC, 1991, CANCER RES, V51, P556; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAINSBURY JRC, 1987, LANCET, V1, P1398; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; 1989, BREAST SCREENING PUB	49	149	158	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2383	2390						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036022				2022-12-17	WOS:A1994NX62900033
J	ROSELL, R; LI, SR; SKACEL, Z; MATE, JL; MAESTRE, J; CANELA, M; TOLOSA, E; ARMENGOL, P; BARNADAS, A; ARIZA, A				ROSELL, R; LI, SR; SKACEL, Z; MATE, JL; MAESTRE, J; CANELA, M; TOLOSA, E; ARMENGOL, P; BARNADAS, A; ARIZA, A			PROGNOSTIC IMPACT OF MUTATED K-RAS GENE IN SURGICALLY RESECTED NONSMALL CELL LUNG-CANCER PATIENTS	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; ONCOGENE ACTIVATION; ENZYMATIC AMPLIFICATION; POINT MUTATION; ADENOCARCINOMA; MARKER; DNA	Mutated K-ras oncogenes have been detected in a third of lung adenocarcinomas, located usually in codon 12, its presence correlating negatively with survival. To further define the role of K-ras point mutations in non-small cell lung cancer, we studied the presence of mutated K-ras genes in surgical specimens from 66 patients. Polymerase chain reaction was performed from sections of formalin-fixed paraffin-embedded tissue. We screened for point mutations in codons 12, 13 and 61 of the K-ras gene by dot blot hybridization analysis with mutation-specific oligonucleotide probes. Ras gene mutations were present in 13 of 66 carcinomas (20%), nine in codon 12 and four in codon 61. Three squamous cell carcinomas harbored two different point mutations in K-ras codon 12. Mutated K-ras genes were found more frequently in squamous cell carcinomas (eight of 38) than in adenocarcinoma (three of 22). Analysis of nucleotide sequence disclosed a multifarious mutation pattern of K-ras codon 12, where the most common conversion was from glycine (GGT) to valine (GTT). K-ras point mutation positive subset had poorer survival, nine of the 13 patients died during the follow-up period as compared with 22 of 53 patients with no mutation in the K-ras gene (P=0.01). The difference was also strikingly significant when stratified according to node status.	UNIV BADALONA, HOSP GERMANS & PUJOL, DEPT IMMUNOL, E-08916 BADALONA, SPAIN; UNIV BADALONA, HOSP GERMANS TRIAS & PUJA, DEPT THORAC SURG, E-08916 BADALONA, SPAIN		ROSELL, R (corresponding author), UNIV BADALONA, HOSP GERMAN TRIAS & PUJOL, DEPT MED ONCOL, E-08916 BADALONA, SPAIN.			MATE SANZ, JOSE LUIS/0000-0002-4829-3426				[Anonymous], 1982, Am J Clin Pathol, V77, P123; ANWAR K, 1992, CANCER RES, V52, P5991; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; DIXON WJ, 1983, BMDP STATISTICAL SOF, P555; ENOMOTO T, 1991, CANCER RES, V51, P5308; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; KOBAYASHI T, 1990, CANCER, V66, P289, DOI 10.1002/1097-0142(19900715)66:2<289::AID-CNCR2820660216>3.0.CO;2-6; KRAEGEL SA, 1992, CANCER RES, V52, P4724; LEVI S, 1991, CANCER RES, V51, P3497; MARIYAMA M, 1989, JPN J CANCER RES, V80, P622, DOI 10.1111/j.1349-7006.1989.tb01687.x; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SLEBOS RJC, 1992, J NATL CANCER I MONO, V13, P23; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUGIO K, 1992, CANCER RES, V52, P2903; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TADA M, 1990, CANCER-AM CANCER SOC, V66, P930, DOI 10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VRIES MV, 1986, GENE, V50, P313	31	149	151	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2407	2412						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395679				2022-12-17	WOS:A1993LT36800011
J	HIRAI, H; FUJISAWA, J; SUZUKI, T; UEDA, K; MURAMATSU, M; TSUBOI, A; ARAI, N; YOSHIDA, M				HIRAI, H; FUJISAWA, J; SUZUKI, T; UEDA, K; MURAMATSU, M; TSUBOI, A; ARAI, N; YOSHIDA, M			TRANSCRIPTIONAL ACTIVATOR TAX OF HTLV-1 BINDS TO THE NF-KAPPA-B PRECURSOR P105	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; LONG TERMINAL REPEATS; NECROSIS-FACTOR-ALPHA; DNA-BINDING; TRANS-ACTIVATION; NUCLEAR PROTEINS; GENE-EXPRESSION; REL ONCOGENE	Human T-cell leukemia virus type 1 (HTLV-1) induces adult T-cell leukemia and also a neurological disease, tropical spastic paraparesis. Tax protein (p40tax) of HTLV-1 activates in trans its own transcriptional enhancer in the long terminal repeat and also those in some cellular genes such as interleukin 2 receptor-alpha, granulocyte-macrophage colony-stimulating factor, Fos, Jun and MHC class I. Thus, Tax has been proposed to play a critical role in the pathogenesis induced by HTLV-1 infection. Here, we report formation of a complex of Tax protein with the precursor protein p105 of the NF-kappa-B p50 subunit. p105 was co-immunoprecipitated with Tax protein from cells infected with HTLV-1 from cells transfected with the Tax expression plasmid, but not from cells transfected with inactive mutants of Tax. Furthermore, a GST-p105 fusion protein produced in Escherichia coli bound to Tax protein. These results strongly suggest that the trans-activator Tax protein forms a complex with precursor NF-kappa-B p105 and plays a role in trans-activation of transcriptional initiation.	UNIV TOKYO,INST MED SCI,DEPT CELLULAR & MOLEC BIOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,TOKYO 108,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA	University of Tokyo; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Tsuboi, Akio/0000-0002-4790-4512				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GESSAIN A, 1985, LANCET, V2, P407; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3635; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KIYOKAWA T, 1984, GANN, V75, P747; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RODGERSJOHNSON P, 1985, LANCET, V2, P1247; SAWADA M, 1990, J VIROL, V64, P4002, DOI 10.1128/JVI.64.8.4002-4006.1990; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V226, P177; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	45	149	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1737	1742						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501885				2022-12-17	WOS:A1992JJ37600009
J	GREEN, AR; LINTS, T; VISVADER, J; HARVEY, R; BEGLEY, CG				GREEN, AR; LINTS, T; VISVADER, J; HARVEY, R; BEGLEY, CG			SCL IS COEXPRESSED WITH GATA-1 IN HEMATOPOIETIC-CELLS BUT IS ALSO EXPRESSED IN DEVELOPING BRAIN	ONCOGENE			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; ERYTHROID TRANSCRIPTION FACTOR; DNA-BINDING PROTEIN; C-MYC GENES; INDUCED-DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; GLOBIN GENE; GM-CSF; LEUKEMIA; LINE	The SCL gene encodes a putative transcription factor with a basic helix-loop-helix (B-HLH) motif and is known to be predominantly expressed in erythroid cells. Here we also demonstrate expression of SCL mRNA in normal mast cells, mast cell lines and megakaryocytic cell lines. SCL is therefore expressed in the same three lineages as GATA-1, a well-recognized hemopoietic transcription factor. SCL and GATA-1 mRNA were also co-expressed in interleukin 3-dependent primitive myeloid lines. In murine erythroleukemia (MEL) cells SCL and GATA-1 underwent coordinated biphasic modulation during hexamethylene bisacetamide (HMBA)-induced erythroid differentiation. The kinetics of SCL and GATA-1 mRNA expression was inversely correlated with changes in ID, a negative regulator of B-HLH proteins, and was distinct from changes in MYC, MYB and erythropoietin receptor transcripts. During myeloid differentiation of K562 celts, SCL and GATA-1 mRNA levels also underwent biphasic modulation. Thus SCL and GATA-1 are coordinately expressed in multiple hemopoietic lineages and coordinately regulated during induced erythroid and myeloid differentiation. In non-hemopoietic tissues SCL was only detected in adult and developing brain where GATA-1 is reportedly not expressed. In day 14.5 embryos analysed by in situ hybridization, SCL transcripts were detected in post-mitotic neurons in the metencephalon and roof of the mesencephalon. This suggests a previously unexpected role for SCL in neural differentation.	DEPT HAEMATOL, MRC BLDG, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND; ROYAL MELBOURNE HOSP, DEPT DIAGNOST HAEMATOL, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute			Lints, Thierry/K-4408-2012	Harvey, Richard/0000-0002-9950-9792; Green, Anthony/0000-0002-9795-0218				BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1991, IN PRESS P NATL ACAD; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COOPER PC, 1982, LEUKEMIA RES, V6, P313, DOI 10.1016/0145-2126(82)90093-5; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; DUNN TB, 1957, J NATL CANCER I, V18, P587; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1991, IN PRESS EMBO J; GREENBERG SM, 1988, BLOOD, V72, P1968; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HARA K, 1988, EXP HEMATOL, V16, P256; HARVEY RP, 1991, IN PRESS P NATL ACAD; HASTHORPE S, 1981, CANCER RES, V41, P3985; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARKS PA, 1989, ENVIRON HEALTH PERSP, V80, P181, DOI 10.2307/3430743; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MCCARTHY JH, 1980, EXP HEMATOL, V8, P562; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OGURA M, 1985, BLOOD, V66, P1384; OGURA M, 1988, BLOOD, V72, P49; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SERFLING E, 1989, TRENDS GENET, V5, P131, DOI 10.1016/0168-9525(89)90049-8; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P187; VONMELCHNER H, 1981, BLOOD, V57, P906; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668	59	149	149	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					653	660						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565464				2022-12-17	WOS:A1992HQ68200006
J	LASSAM, N; BICKFORD, S				LASSAM, N; BICKFORD, S			LOSS OF C-KIT EXPRESSION IN CULTURED MELANOMA-CELLS	ONCOGENE			English	Article							TYROSINE KINASE RECEPTOR; W-MUTANT MICE; PROTO-ONCOGENE; SI-LOCUS; MOUSE; MELANOCYTES; LIGAND; MUTATIONS; GROWTH; KL	The proto-oncogene c-kit encodes a receptor tyrosine kinase which has been shown to play a key role in melanocyte development. In this report we asked whether the c-kit gene product is also involved in promoting the growth of transformed melanocytes. We found that, while c-Kit protein was readily observed in normal human neonatal and adult melanocytes, the majority of cell lines established from human melanoma samples did not express detectable levels of c-kit mRNA or protein. A similar pattern of differential expression was also observed in normal and transformed murine melanocytes. Our findings raise the possibility that a marked reduction in c-kit gene expression either promotes or is a consequence of transformation in melanocytes.	UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; TORONTO BAYVIEW REG CANC CTR,TORONTO M4N 3M5,ONTARIO,CANADA; SUNNYBROOK MED CTR,TORONTO M4N 3M5,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	LASSAM, N (corresponding author), UNIV TORONTO,DIV MED ONCOL,TORONTO M5S 1A1,ONTARIO,CANADA.							BEAN MA, 1975, CANCER RES, V35, P2902; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAJAL SRY, 1991, AM J PATHOL, V138, P349; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; FEINBERG AP, 1963, ANAL BIOCHEM, V132, P6; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FITZPATRICK TB, 1987, DERMATOLOGY GENERAL; FLANAGAN JG, 1990, CELL, V63, P85; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HERLYN M, 1985, CANCER RES, V45, P5670; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; MAYER TC, 1970, DEV BIOL, V23, P297, DOI 10.1016/0012-1606(70)90100-4; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, P NATL ACAD SCI USA, V88, P2341; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sambrook J., 1989, MOL CLONING LAB MANU; Silvers W.K., 1979, COAT COLORS MICE, P206; SILVERS WILLYS KENT, 1956, J MORPH, V99, P41, DOI 10.1002/jmor.1050990103; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; ULRICH A, 1990, CELL, V61, P23; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	37	149	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					51	56						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371338				2022-12-17	WOS:A1992HC22700007
J	FRISCH, SM; REICH, R; COLLIER, IE; GENRICH, LT; MARTIN, G; GOLDBERG, GI				FRISCH, SM; REICH, R; COLLIER, IE; GENRICH, LT; MARTIN, G; GOLDBERG, GI			ADENOVIRUS E1A REPRESSES PROTEASE GENE-EXPRESSION AND INHIBITS METASTASIS OF HUMAN TUMOR-CELLS	ONCOGENE			English	Article									NIDR, DEV BIOL & ANOMALIES LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	FRISCH, SM (corresponding author), WASHINGTON UNIV, SCH MED, DIV DERMATOL, ST LOUIS, MO 63110 USA.				NIADDK NIH HHS [TO-AM07284] Funding Source: Medline; NIAMS NIH HHS [AR 12129, AR 39472] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [T32AM007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR012129, R01AR012129, R01AR039472] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINI A, 1987, CANCER RES, V47, P3239; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1987, MOL CELL BIOL, V7, P256; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CALZONE FJ, 1988, GUIDE MOL CLONING TE, P611; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DYNAN W, 1986, TRENDS GENET     AUG, P196; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FRISCH SM, 1985, MOL CELL BIOL, V5, P253, DOI 10.1128/MCB.5.1.253; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GARBISA S, 1987, CANCER RES, V47, P1523; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; LAMPH W, 1988, NATURE, V34, P629; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARUYAMA K, 1987, ONCOGENE, V1, P361; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MISKIN R, 1981, ANAL BIOCHEM, V118, P252, DOI 10.1016/0003-2697(81)90187-1; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REICH R, 1988, CANCER RES, V48, P3307; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1984, CANCER CELLS, V2; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; SUEMORI H, 1988, MOL CELL BIOL, V8, P3553, DOI 10.1128/MCB.8.8.3553; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	47	149	152	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					75	83						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157183				2022-12-17	WOS:A1990CM62000011
J	Shang, Y; Zhang, Z; Liu, Z; Feng, B; Ren, G; Li, K; Zhou, L; Sun, Y; Li, M; Zhou, J; An, Y; Wu, K; Nie, Y; Fan, D				Shang, Y.; Zhang, Z.; Liu, Z.; Feng, B.; Ren, G.; Li, K.; Zhou, L.; Sun, Y.; Li, M.; Zhou, J.; An, Y.; Wu, K.; Nie, Y.; Fan, D.			miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1	ONCOGENE			English	Article						miR-508-5p; gastric cancer; drug resistance; ABCB1; ZNRD1	P-GLYCOPROTEIN; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; CELLS; EXPRESSION; MICRORNAS; CISPLATIN; GLYCOSYLATION; MECHANISM; CHEMORESISTANCE	Multidrug resistance (MDR) is usually correlated with the poor prognosis of gastric cancer. In this study, we revealed a total of 11 microRNAs (miRNA) that regulated MDR of gastric cancer via high-throughput functional screening, and miR-508-5p reversed MDR most efficiently among these candidate miRNAs. The overexpression of miR-508-5p was sufficient to reverse cancer cell resistance to multiple chemotherapeutics in vitro and sensitize tumours to chemotherapy in vivo. Further studies showed that miR-508-5p could directly target the 3'-untranslated regions of ABCB1 and Zinc ribbon domain-containing 1 (ZNRD1), and suppress their expression at the mRNA and protein levels. Meanwhile, the suppression of ZNRD1 led to a decrease in ABCB1. These findings suggest that a miR-508-5p/ZNRD1/ABCB1 regulatory loop has a critical role in MDR in gastric cancer. In addition, miR-508-5p could be used as a prognostic factor for overall survival in gastric cancer. These data reveal an important role for miR-508-5p in the regulation of MDR in gastric cancer, and suggest the potential application of miR-508-5p in drug resistance prediction and treatment.	[Shang, Y.; Zhang, Z.; Liu, Z.; Feng, B.; Ren, G.; Li, K.; Zhou, L.; Sun, Y.; Li, M.; Zhou, J.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Shang, Y.; Zhang, Z.; Liu, Z.; Feng, B.; Ren, G.; Li, K.; Zhou, L.; Sun, Y.; Li, M.; Zhou, J.; Wu, K.; Nie, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp, Xijing Hosp Digest Dis, Xian 710032, Peoples R China; [An, Y.] Jinan Mil Command, Gen Hosp, Dept Gen Surg, Jinan, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Nie, Y (corresponding author), Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, West Changle Rd, Xian 710032, Peoples R China.	yongznie@fmmu.edu.cn; daimingfan@fmmu.edu.cn	meng, li/GVT-2063-2022		 [81030044];  [2010CB529300];  [2010CB529305];  [2010CB529306];  [2010CB529302];  [NSFC-81120108005];  [81172096];  [863-2012AA02A203];  [8632012AA02A504]	; ; ; ; ; ; ; ; 	This work was supported by grants 81030044, 2010CB529300, 2010CB529305, 06, 02, NSFC-81120108005, 81172096, 863-2012AA02A203 and 8632012AA02A504. We would like to thank Zheng Chen and Jianhua Dou from the Fourth Military Medical University for providing excellent technical assistance.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Catuogno S, 2012, ONCOGENE, V27, P1; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Feng DD, 2011, J CELL MOL MED, V15, P2164, DOI 10.1111/j.1582-4934.2010.01213.x; Fodale V, 2011, CANCER J, V17, P89, DOI 10.1097/PPO.0b013e318212dd3d; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gribar JJ, 2000, J MEMBRANE BIOL, V173, P203, DOI 10.1007/s002320001020; Guo W, 2008, TUMOR BIOL, V29, P188, DOI 10.1159/000146864; Han JY, 2003, MED ONCOL, V20, P355, DOI 10.1385/MO:20:4:355; Hendrikx JJMA, 2013, INT J CANCER, V132, P2439, DOI 10.1002/ijc.27912; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Hong L, 2004, BRIT J BIOMED SCI, V61, P206, DOI 10.1080/09674845.2004.11732673; Hong L, 2006, BIOCHEM CELL BIOL, V84, P199, DOI 10.1139/O05-173; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Huang DY, 2009, ENVIRON SCI TECHNOL, V43, P7803, DOI 10.1021/es901189c; Hwang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010630; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kim CH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-79; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; KRAMER R, 1995, BRIT J CANCER, V71, P670, DOI 10.1038/bjc.1995.133; Ma KL, 2012, J BIOL CHEM, V287, P5639, DOI 10.1074/jbc.M111.291229; Michaud WA, 2009, CLIN CANCER RES, V15, P1645, DOI 10.1158/1078-0432.CCR-08-2581; Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Seres M, 2011, INT J MOL SCI, V12, P7772, DOI 10.3390/ijms12117772; Shi YQ, 2004, CANCER BIOL THER, V3, P377, DOI 10.4161/cbt.3.4.724; Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009; Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tsuji K, 2012, HEMATOL REP, V4, P56, DOI 10.4081/hr.2012.e18; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Zhang HW, 2010, DIGEST DIS SCI, V55, P2545, DOI 10.1007/s10620-009-1051-6; Zhao L, 2009, J BIOL CHEM, V284, P26273, DOI 10.1074/jbc.M109.028068; Zhao XH, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-55; Zhu HR, 2012, EUR J PHARMACOL, V696, P43, DOI 10.1016/j.ejphar.2012.09.046; Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3; Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4; Zhu W, 2010, INT J CANCER, V127, P2520, DOI 10.1002/ijc.25260; Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071	45	148	152	0	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3267	3276		10.1038/onc.2013.297	http://dx.doi.org/10.1038/onc.2013.297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23893241				2022-12-17	WOS:000338443400006
J	Cao, L; Shao, M; Schilder, J; Guise, T; Mohammad, KS; Matei, D				Cao, L.; Shao, M.; Schilder, J.; Guise, T.; Mohammad, K. S.; Matei, D.			Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer	ONCOGENE			English	Article						TG2; TGF-beta; ovarian cancer; cancer stem cells; epithelial to mesenchymal transition; metastasis	GROWTH-FACTOR-BETA; METASTATIC BREAST-CANCER; E-CADHERIN; SANDWICH DOMAIN; GENE-EXPRESSION; UP-REGULATION; KAPPA-B; CARCINOMA; ACTIVATION; PATHWAY	Tissue transglutaminase (TG2), an enzyme involved in cell proliferation, differentiation and apoptosis is over-expressed in ovarian carcinomas, where it modulates epithelial-to-mesenchymal transition (EMT) and promotes metastasis. Its regulation in ovarian cancer (OC) remains unexplored. Here, we show that transforming growth factor (TGF)-beta, a cytokine involved in tumor dissemination is abundantly secreted in the OC microenvironment and induces TG2 expression and enzymatic activity. This is mediated at transcriptional level by SMADs and by TGF-beta-activated kinase 1-mediated activation of the nuclear factor-kappa B complex. TGF-beta-stimulated OC cells aggregate as spheroids, which enable peritoneal dissemination. We show that TGF-beta-induced TG2 regulates EMT, formation of spheroids and OC metastasis. TG2 knock-down in OC cells decreases the number of cells harboring a cancer stem cell phenotype (CD44+ /CD117+). Furthermore, CD44+ /CD117+ cells isolated from human ovarian tumors express high levels of TG2. In summary, TGF-beta-induced TG2 enhances ovarian tumor metastasis by inducing EMT and a cancer stem cell phenotype. Oncogene (2012) 31, 2521-2534; doi:10.1038/onc.2011.429; published online 3 October 2011	[Cao, L.; Shao, M.; Guise, T.; Mohammad, K. S.; Matei, D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA; [Cao, L.; Matei, D.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; [Schilder, J.; Matei, D.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN USA; [Schilder, J.; Guise, T.; Mohammad, K. S.; Matei, D.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA; [Matei, D.] Indiana Univ Sch Med, VA Roudebush Hosp, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Matei, D (corresponding author), Indiana Univ, Dept Med, Simon Canc Ctr, 535 Barnhill Dr,RT 473, Indianapolis, IN 46202 USA.	dmatei@iupui.edu	Mohammad, Khalid/AAE-9569-2022; Mohammad, Khalid/AFE-4205-2022	Matei, Daniela/0000-0003-2169-5035	US Department of Veterans Affairs; American Cancer Society; NATIONAL CANCER INSTITUTE [U01CA143057] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs J Tucholski, H Nakshatri, Y Xu, A Belkin and R Bigsby for reagents and Dr A Belkin for useful discussion. This work was supported by the US Department of Veterans Affairs through a VA Merit Award and by the American Cancer Society through a Research Scholar grant to DM.	Abendstein B, 2000, CYTOKINE, V12, P1115, DOI 10.1006/cyto.1999.0632; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Baldwin RL, 2003, CANCER RES, V63, P1413; Bartlett JM, 1997, EUR J CANCER, V33, P2397, DOI 10.1016/S0959-8049(97)00304-3; Bristow RE, 1999, CANCER, V85, P658, DOI 10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M; Cao LY, 2008, CARCINOGENESIS, V29, P1893, DOI 10.1093/carcin/bgn158; Cardillo MR, 1997, J EXP CLIN CANC RES, V16, P49; Chen T, 2001, CANCER RES, V61, P4679; Chou CY, 2011, J BIOL CHEM, V286, P27825, DOI 10.1074/jbc.M111.226340; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Gillan L, 2002, CANCER RES, V62, P5358; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; Hocevar BA, 2005, J BIOL CHEM, V280, P25920, DOI 10.1074/jbc.M501150200; Hu W, 2000, ANTICANCER RES, V20, P729; Hurteau JA, 2001, GYNECOL ONCOL, V83, P292, DOI 10.1006/gyno.2001.6376; KOPP A, 1995, CANCER RES, V55, P4512; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Lynch MA, 1998, CANCER RES, V58, P4227; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mann AP, 2006, CANCER RES, V66, P8788, DOI 10.1158/0008-5472.CAN-06-1457; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nilsson E, 2001, MOL CELL ENDOCRINOL, V182, P145, DOI 10.1016/S0303-7207(01)00584-6; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PINCUS JH, 1968, ARCH BIOCHEM BIOPHYS, V126, P44, DOI 10.1016/0003-9861(68)90557-2; Qiao B, 2005, J BIOL CHEM, V280, P17562, DOI 10.1074/jbc.M500646200; Rodriguez GC, 2001, GYNECOL ONCOL, V80, P245, DOI 10.1006/gyno.2000.6042; Satpathy M, 2009, J BIOL CHEM, V284, P15390, DOI 10.1074/jbc.M808331200; Satpathy N, 2007, CANCER RES, V67, P7194, DOI 10.1158/0008-5472.CAN-07-0307; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wakahara K, 2004, J CELL BIOCHEM, V93, P437, DOI 10.1002/jcb.20160; Yamada SD, 1999, GYNECOL ONCOL, V75, P72, DOI 10.1006/gyno.1999.5535; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	55	148	158	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2521	2534		10.1038/onc.2011.429	http://dx.doi.org/10.1038/onc.2011.429			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21963846				2022-12-17	WOS:000304191800003
J	Lo, PK; Kanojia, D; Liu, X; Singh, UP; Berger, FG; Wang, Q; Chen, H				Lo, P-K; Kanojia, D.; Liu, X.; Singh, U. P.; Berger, F. G.; Wang, Q.; Chen, H.			CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGF beta signaling	ONCOGENE			English	Article						tumor-initiating cells; Her2/neu; mammary tumor; CD49f; CD61; ESA	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; STEM-CELLS; II RECEPTOR; EXPRESSION; MOUSE; GLAND; TUMORIGENESIS; POPULATION; TGF-BETA-1	Human epidermal growth factor receptor 2 (HER2)/Neu is overexpressed in 20-30% of breast cancers and associated with aggressive phenotypes and poor prognosis. For deciphering the role of HER2/Neu in breast cancer, mouse mammary tumor virus (MMTV)-Her2/neu transgenic mice that develop mammary tumors resembling human HER2-subtype breast cancer have been established. Several recent studies have revealed that HER2/Neu is overexpressed in and regulates self renewal of breast tumor-initiating cells (TICs). However, in the MMTV-Her2/neu transgenic mouse model, the identity of TICs remains elusive, despite previous studies showing supportive evidence for existence of TICs in Her2/neu-induced mammary tumors. Through systematic screening and characterization, we identified that surface markers CD49f, CD61 and ESA were aberrantly overexpressed in Her2-overexpressing mammary tumor cells. Analysis of these markers and CD24 detected anomalous expansion of the luminal progenitor population in preneoplastic mammary glands of Her2/neu transgenic mice, indicating that aberrant luminal progenitors originated in Her2-induced mammary tumors. The combined markers, CD49f and CD61, further delineated the CD49f(high)CD61(high)-sorted fraction as a TIC-enriched population, which displayed increased tumorsphere formation ability, enhanced tumorigenicity both in vitro and in vivo and drug resistance to pacitaxel and doxorubicin. Moreover, the TIC-enriched population manifested increased transforming growth factor-beta (TGF beta) signaling and exhibited gene expression signatures of stemness, TGF beta signaling and epithelial-to-mesenchymal transition. Our findings that self-renewal and clonogenicity of TICs were suppressed by pharmacologically inhibiting the TGF beta signaling further indicate that the TGF beta pathway is vital for maintenance of the TIC population. Finally, we showed that the integrin-beta 3 (CD61) signaling pathway was required for sustaining active TGF beta signaling and self-renewal of TICs. We for the first time developed a technique to highly enrich TICs from mammary tumors of Her2/neu transgenic mice, unraveled their properties and identified the cooperative integrin-beta 3-TGF beta signaling axis as a potential therapeutic target for HER2-induced TICs. Oncogene (2012) 31, 2614-2626; doi:10.1038/onc.2011.439; published online 26 September 2011	[Lo, P-K; Kanojia, D.; Berger, F. G.; Chen, H.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Lo, P-K; Kanojia, D.; Berger, F. G.; Wang, Q.; Chen, H.] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA; [Liu, X.] Univ S Carolina, Dept Math, Columbia, SC 29208 USA; [Singh, U. P.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Wang, Q.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chen, H (corresponding author), Univ S Carolina, Dept Biol Sci, 715 Sumter St,PSC621, Columbia, SC 29208 USA.	hchen@biol.sc.edu	chen, hexin/F-1714-2011; Kanojia, Deepak/G-5120-2014	Kanojia, Deepak/0000-0003-4295-4972; Wang, Qian/0000-0002-2149-384X; Singh, Udai/0000-0002-7048-4325	Elsa U Pardee Cancer Foundation [B94AFFAA]; American Cancer Society [RSG-10-067-01-TBE]; NIH [3P20RR017698-08]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017698] Funding Source: NIH RePORTER	Elsa U Pardee Cancer Foundation; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Marai M Pena, Celestia Davis, Sara Johnson and Andrea Daamen for experimental assistance. This work was supported by the Elsa U Pardee Cancer Foundation grant (B94AFFAA), the American Cancer Society Research Award (RSG-10-067-01-TBE) to HC and NIH grant (3P20RR017698-08) to HC and QW.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078-0432.CCR-06-0952; Chen H, 2011, J BIOTECH RES, V3, P7; Chen HX, 2010, PROTEOMICS, V10, P3800, DOI 10.1002/pmic.201000297; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanker L, 2010, BREAST CANCER RES TR, V122, P765, DOI 10.1007/s10549-009-0608-6; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; Ishikawa Toshihisa, 2009, J Exp Ther Oncol, V8, P5; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kveiborg M., 2001, Journal of Endocrinology, V169, P549, DOI 10.1677/joe.0.1690549; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Scaffidi AK, 2004, J BIOL CHEM, V279, P37726, DOI 10.1074/jbc.M403010200; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yang C, 2007, EXP CELL RES, V313, P1240, DOI 10.1016/j.yexcr.2007.01.011	38	148	154	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2614	2626		10.1038/onc.2011.439	http://dx.doi.org/10.1038/onc.2011.439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	22525271	Green Accepted			2022-12-17	WOS:000304523500002
J	Gustafson, WC; Weiss, WA				Gustafson, W. C.; Weiss, W. A.			Myc proteins as therapeutic targets	ONCOGENE			English	Review						myc; mycn; neuroblastoma; N-myc; mTor; PI3K	ANAPLASTIC LYMPHOMA KINASE; INITIAL TESTING STAGE-1; ARF TUMOR-SUPPRESSOR; C-MYC; N-MYC; GENE-EXPRESSION; DNA-BINDING; CELL-LINES; TRANSCRIPTIONAL CONTROL; MALIGNANT PROGRESSION	Myc proteins (c-myc, Mycn and Mycl) target proliferative and apoptotic pathways vital for progression in cancer. Amplification of the MYCN gene has emerged as one of the clearest indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the most common extracranial solid tumor of childhood. Phosphorylation and ubiquitin-mediated modulation of Myc protein influence stability and represent potential targets for therapeutic intervention. Phosphorylation of Myc proteins is controlled in-part by the receptor tyrosine kinase/phosphatidylinositol 3-kinase/Akt/mTOR signaling, with additional contributions from Aurora A kinase. Myc proteins regulate apoptosis in part through interactions with the p53/Mdm2/Arf signaling pathway. Mutation in p53 is commonly observed in patients with relapsed neuroblastoma, contributing to both biology and therapeutic resistance. This review examines Myc function and regulation in neuroblastoma, and discusses emerging therapies that target Mycn. Oncogene (2010) 29, 1249-1259; doi:10.1038/onc.2009.512; published online 25 January 2010	[Gustafson, W. C.; Weiss, W. A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA; [Gustafson, W. C.] Univ Calif San Francisco, Div Pediat Hematol Oncol, San Francisco, CA 94143 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gustafson, WC (corresponding author), Univ Calif San Francisco, Dept Pediat, Helen Diller Family Canc Res Bldg,1450 3rd St, San Francisco, CA 94158 USA.	GustafsonC@peds.ucsf.edu		Weiss, William/0000-0003-2230-9132	NIH [CA133091, NS055750, CA102321, CA097257, CA128583]; Burroughs Wellcome Fund; American Brain Tumor Association; Brain Tumor Society; Accelerate Brain Cancer Cure; Alex's Lemonade Stand Foundation; Children's National Brain Tumor Foundation; Wallace H. Coulter Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Samuel G Waxman Foundation; V Foundation; NATIONAL CANCER INSTITUTE [R01CA102321, R01CA148699, P01CA081403, P50CA097257, R01CA133091, T32CA128583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055750] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Brain Tumor Association; Brain Tumor Society; Accelerate Brain Cancer Cure; Alex's Lemonade Stand Foundation; Children's National Brain Tumor Foundation; Wallace H. Coulter Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Samuel G Waxman Foundation; V Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Chris Hackett and Theo Nicolaides for critical review. We acknowledge support from NIH grants CA133091, NS055750, CA102321, CA097257, CA128583; Burroughs Wellcome Fund, American Brain Tumor Association, The Brain Tumor Society, Accelerate Brain Cancer Cure; Alex's Lemonade Stand, Children's National Brain Tumor, Wallace H. Coulter, Katie Dougherty, Pediatric Brain Tumor, Samuel G Waxman and V Foundations.	Alaminos M, 2003, CANCER RES, V63, P4538; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amente S, 2007, FEBS LETT, V581, P821, DOI 10.1016/j.febslet.2007.01.062; ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; ASKEW DS, 1991, ONCOGENE, V6, P1915; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Bell E, 2007, CELL CYCLE, V6, P1249, DOI 10.4161/cc.6.10.4222; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Berg T, 2008, CURR OPIN CHEM BIOL, V12, P464, DOI 10.1016/j.cbpa.2008.07.023; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brooks TA, 2009, NAT REV CANCER, V9, P849, DOI 10.1038/nrc2733; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Chan HSL, 1997, CLIN CANCER RES, V3, P1699; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Cheng AJ, 2007, EUR J CANCER, V43, P1467, DOI 10.1016/j.ejca.2007.03.008; Chesler L, 2008, NEOPLASIA, V10, P1268, DOI 10.1593/neo.08778; Chesler L, 2007, CANCER RES, V67, P9435, DOI 10.1158/0008-5472.CAN-07-1316; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; CLAUSEN N, 1989, ACTA PAEDIATR SCAND, V78, P736, DOI 10.1111/j.1651-2227.1989.tb11135.x; Cobbold LC, 2008, MOL CELL BIOL, V28, P40, DOI 10.1128/MCB.01298-07; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Cotterman R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005799; Coutts AS, 2009, DNA REPAIR, V8, P483, DOI 10.1016/j.dnarep.2009.01.008; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2009, CURR CANCER DRUG TAR, V9, P729, DOI 10.2174/156800909789271521; Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Gingras AC, 2001, GENE DEV, V15, P2852; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Hackett CS, 2003, CANCER RES, V63, P5266; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Ho R, 2002, CANCER RES, V62, P6462; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hossain MS, 2008, ONCOGENE, V27, P6075, DOI 10.1038/onc.2008.200; Houghton PJ, 2008, PEDIATR BLOOD CANCER, V50, P799, DOI 10.1002/pbc.21296; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Ikegaki N, 2007, CLIN CANCER RES, V13, P6001, DOI 10.1158/1078-0432.CCR-07-0071; Inge TH, 2002, SURGERY, V132, P232, DOI 10.1067/msy.2002.125387; Jacobs JFM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-239; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kanemaru KK, 2008, PEDIATR BLOOD CANCER, V50, P806, DOI 10.1002/pbc.21273; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Keshelava N, 1998, CANCER RES, V58, P5396; Keshelava N, 1997, EUR J CANCER, V33, P2002, DOI 10.1016/S0959-8049(97)00213-X; Keshelava N, 2000, MED PEDIATR ONCOL, V35, P563, DOI 10.1002/1096-911X(20001201)35:6<563::AID-MPO15>3.0.CO;2-J; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koppen A, 2007, CANCER LETT, V256, P218, DOI 10.1016/j.canlet.2007.06.011; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Li RS, 2008, MED RES REV, V28, P372, DOI 10.1002/med.20109; Li ZL, 2009, CELL CYCLE, V8, P2703, DOI 10.4161/cc.8.17.9418; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu T, 2009, EUR J CANCER, V45, P1846, DOI 10.1016/j.ejca.2009.03.002; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Manohar CF, 2004, ONCOGENE, V23, P753, DOI 10.1038/sj.onc.1207151; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Maris JM, 2008, PEDIATR BLOOD CANCER, V51, P42, DOI 10.1002/pbc.21535; Maris JM, 2008, NEW ENGL J MED, V358, P2585, DOI 10.1056/NEJMoa0708698; Maris JM, 2009, CANCER CELL, V15, P5, DOI 10.1016/j.ccr.2008.12.008; Marques M, 2008, MOL CELL BIOL, V28, P2803, DOI 10.1128/MCB.01786-07; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Martins RAP, 2008, GENE DEV, V22, P179, DOI 10.1101/gad.1608008; Marzec M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mill P, 2005, DEV CELL, V9, P293, DOI 10.1016/j.devcel.2005.05.009; Moore HC, 2008, J CLIN PATHOL, V61, P1098, DOI 10.1136/jcp.2007.054627; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2009, CLIN CANCER RES, V15, P5609, DOI 10.1158/1078-0432.CCR-08-2762; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Norris MD, 2000, MED PEDIATR ONCOL, V35, P585, DOI 10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.0.CO;2-P; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Ota S, 2007, DEVELOPMENT, V134, P1583, DOI 10.1242/dev.000703; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Paffhausen T, 2007, CANCER LETT, V250, P17, DOI 10.1016/j.canlet.2006.09.010; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PULVERER BJ, 1994, ONCOGENE, V9, P59; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; Rohrer T, 2002, PEDIATR PULM, V33, P71, DOI 10.1002/ppul.10031; Ruggero D, 2009, CANCER RES, V69, P8839, DOI 10.1158/0008-5472.CAN-09-1970; SAKSELA K, 1992, ONCOGENE, V7, P347; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; Schramm A, 2009, CANCER LETT, V282, P55, DOI 10.1016/j.canlet.2009.02.052; Schulte JH, 2009, CANCER LETT, V274, P10, DOI 10.1016/j.canlet.2008.06.010; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shang XY, 2009, MOL CANCER THER, V8, P2461, DOI 10.1158/1535-7163.MCT-08-0857; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Slack A, 2005, CANCER LETT, V228, P21, DOI 10.1016/j.canlet.2005.01.050; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Trochet D, 2005, AM J HUM GENET, V76, P421, DOI 10.1086/428366; Tweddle DA, 2001, CANCER RES, V61, P8; Ushmorov A, 2008, ONCOGENE, V27, P3424, DOI 10.1038/sj.onc.1211017; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Van Maerken T, 2009, CELL DEATH DIFFER, V16, P1563, DOI 10.1038/cdd.2009.138; Van Maerken T, 2009, JNCI-J NATL CANCER I, V101, P1562, DOI 10.1093/jnci/djp355; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VOGAN K, 1993, CANCER RES, V53, P5269; Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094; Walkley CR, 2005, NAT CELL BIOL, V7, P172, DOI 10.1038/ncb1214; Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weiss WA, 2000, CANCER RES, V60, P2483; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Witt O, 2009, CURR PHARM DESIGN, V15, P436, DOI 10.2174/138161209787315774; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Zask A, 2009, J MED CHEM, V52, P5013, DOI 10.1021/jm900851f; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	199	148	154	1	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1249	1259		10.1038/onc.2009.512	http://dx.doi.org/10.1038/onc.2009.512			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	20101214	Green Accepted			2022-12-17	WOS:000275170600001
J	O'Connell, MP; Fiori, JL; Xu, M; Carter, AD; Frank, BP; Camilli, TC; French, AD; Dissanayake, SK; Indig, FE; Bernier, M; Taub, DD; Hewitt, SM; Weeraratna, AT				O'Connell, M. P.; Fiori, J. L.; Xu, M.; Carter, A. D.; Frank, B. P.; Camilli, T. C.; French, A. D.; Dissanayake, S. K.; Indig, F. E.; Bernier, M.; Taub, D. D.; Hewitt, S. M.; Weeraratna, A. T.			The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma	ONCOGENE			English	Article						Ror2; Wnt5A; melanoma; metastasis; endosome; clathrin	RECESSIVE ROBINOW-SYNDROME; BREAST-CANCER METASTASIS; BRACHYDACTYLY TYPE-B; GENE-EXPRESSION; PROSTATE-CANCER; CELL-MIGRATION; PATHWAY; INHIBITION; ACTIVATION; MOTILITY	Tyrosine kinase receptors represent targets of great interest for cancer therapy. Here we show, for the first time, the importance of the orphan tyrosine kinase receptor, ROR2, in melanoma progression. Using melanoma tissue microarrays, we show that ROR2 is expressed predominantly in metastatic melanoma. As ROR2 has been shown to specifically interact with the non-canonical Wnt ligand, Wnt5A, this corroborates our earlier data implicating Wnt5A as a mediator of melanoma metastasis. We show here that increases in Wnt5A cause increases in ROR2 expression, as well as the PKC-dependent, clathrin-mediated internalization of ROR2. WNT5A knockdown by siRNA decreases ROR2 expression, but silencing of ROR2 has no effect on WNT5A levels. ROR2 knockdown does, however, result in a decrease in signaling downstream of Wnt5A. Using in vitro and in vivo metastasis assays, we show that ROR2 is necessary for the Wnt5A-mediated metastasis of melanoma cells. These data imply that ROR2 may represent a novel target for melanoma therapy.	[Weeraratna, A. T.] NIA, Immunol Lab, NIH, Biomed Res Ctr, Baltimore, MD 21224 USA; [Fiori, J. L.; Bernier, M.] NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA; [Indig, F. E.] NIA, Confocal Imaging Unit, Res Resources Branch, NIH, Baltimore, MD 21224 USA; [Hewitt, S. M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Weeraratna, AT (corresponding author), NIA, Immunol Lab, NIH, Biomed Res Ctr, 251 Bayview Blvd,Suite 100,Rm 08C226, Baltimore, MD 21224 USA.	prubinstein@nybloodcenter.org	O'Connell, Michael/F-9236-2017; Bernier, Michel/Y-7139-2019; Bernier, Michel/AAO-3983-2021	Bernier, Michel/0000-0002-5948-368X; O'Connell, Michael/0000-0002-8615-7660; Hewitt, Stephen/0000-0001-8283-1788	National Institute on Aging, Baltimore, USA [MD 21224]; NATIONAL CANCER INSTITUTE [ZICBC010923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000450, ZICAG000615, ZIAAG000442, ZIAAG000764] Funding Source: NIH RePORTER	National Institute on Aging, Baltimore, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Ms Ana Lustig for assistance with animal experiments. This work was supported by the Intramural Research Program of the National Institute on Aging, Baltimore, MD 21224, USA.	Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; Akbarzadeh S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001873; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28; Da Forno PD, 2008, CLIN CANCER RES, V14, P5825, DOI 10.1158/1078-0432.CCR-07-5104; Desmet CJ, 2006, CELL MOL LIFE SCI, V63, P755, DOI 10.1007/s00018-005-5490-8; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Dissanayake SK, 2008, CANCER RES, V68, P10205, DOI 10.1158/0008-5472.CAN-08-2149; He FL, 2008, DEVELOPMENT, V135, P3871, DOI 10.1242/dev.025767; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Jonsson M, 1998, BRIT J CANCER, V78, P430, DOI 10.1038/bjc.1998.511; Katoh M, 2005, ONCOL REP, V14, P1583; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Liang ZX, 2005, CANCER RES, V65, P967; Liu Y, 2008, J CELL BIOCHEM, V105, P497, DOI 10.1002/jcb.21848; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; *NAT RES COUNC, 1985, GUID CAR USE LAB AN; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; O'Connell MP, 2009, J BIOL CHEM, V284, P28704, DOI 10.1074/jbc.M109.028498; O'Connell MP, 2009, J INVEST DERMATOL, V129, P1782, DOI 10.1038/jid.2008.433; O'Connell Michael P., 2008, V468, P243, DOI 10.1007/978-1-59745-249-6_19; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Pfeiffer S, 2002, CURR BIOL, V12, P957, DOI 10.1016/S0960-9822(02)00867-9; Romanowska M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005354; Safholm A, 2006, J BIOL CHEM, V281, P2740, DOI 10.1074/jbc.M508386200; Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711; Saldanha J, 1998, PROTEIN SCI, V7, P1632, DOI 10.1002/pro.5560070718; Sen M, 2001, ARTHRITIS RHEUM, V44, P772, DOI 10.1002/1529-0131(200104)44:4<772::AID-ANR133>3.0.CO;2-L; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Yamamoto H, 2007, GENES CELLS, V12, P1215, DOI 10.1111/j.1365-2443.2007.01128.x	36	148	154	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					34	44		10.1038/onc.2009.305	http://dx.doi.org/10.1038/onc.2009.305			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802008	Green Accepted			2022-12-17	WOS:000273373500004
J	Mathew, CG				Mathew, C. G.			Fanconi anaemia genes and susceptibility to cancer	ONCOGENE			English	Review						Fanconi anaemia; chromosomal instability; leukaemia, squamous cell carcinoma	DNA-REPAIR DEFECT; BREAST-CANCER; COMPLEMENTATION GROUP; PANCREATIC-CANCER; MUTATION ANALYSIS; HELICASE BRIP1; BRCA PATHWAY; PROTEIN; BACH1; FAMILIES	Fanconi anaemia (FA) is a rare recessive disorder associated with chromosomal fragility, aplastic anaemia, congenital abnormalities and a high risk of cancer, including acute myeloid leukaemia and squamous cell carcinomas. The identification of 11 different FA genes has revealed a complex web of interacting proteins that are involved in the recognition or repair of DNA interstrand crosslinks and perhaps other forms of DNA damage. Bi- allelic mutations in BRCA2 are associated with a rare and highly cancer-prone form of FA, and the DNA helicase BRIP1 (formerly BACH1) is mutated in FA group J. There is little convincing evidence that FA heterozygotes are at increased risk of cancer, but larger studies are needed to address the possibility of modest risk effects. Somatic inactivation of the FA pathway by mutation or epigenetic silencing has been observed in several different types of sporadic cancer, and this may have important implications for targeted chemotherapy. Inhibition of this pathway represents a possible route to sensitization of tumours to DNA crosslinking drugs such as cisplatin.	Kings Coll London, Sch Med, Div Med & Mol Genet, Guys Hosp, London SE5 9PJ, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Mathew, CG (corresponding author), Guys Hosp, Dept Med & Mol Genet, 8th Floor Guys Tower, London SE1 9RT, England.	christopher.mathew@genetics.kcl.ac.uk	Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838				Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; Alter BP, 2005, ARCH OTOLARYNGOL, V131, P635, DOI 10.1001/archotol.131.7.635; Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; Barber LM, 2003, BRIT J HAEMATOL, V121, P57, DOI 10.1046/j.1365-2141.2003.04234.x; BARROSO E, 2006, IN PRESS CARCIN 0505; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Callen E, 2005, BLOOD, V105, P1946, DOI 10.1182/blood-2004-07-2588; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carreau M, 2004, BLOOD, V103, P2430, DOI 10.1182/blood-2003-11-3946; Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood-2004-11-4286; Chirnomas D, 2006, MOL CANCER THER, V5, P952, DOI 10.1158/1535-7163.MCT-05-0493; Condie A, 2002, LEUKEMIA LYMPHOMA, V43, P1849, DOI 10.1080/1042819021000009274; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couch FJ, 2005, CANCER RES, V65, P383; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Djuzenova CS, 2001, LAB INVEST, V81, P185, DOI 10.1038/labinvest.3780226; Fagerlie S, 2001, EXP HEMATOL, V29, P1371, DOI 10.1016/S0301-472X(01)00755-X; Faivre L, 2000, BLOOD, V96, P4064; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ferrer M, 2004, CANCER GENE THER, V11, P539, DOI 10.1038/sj.cgt.7700734; Friedman LS, 1998, CANCER RES, V58, P1338; Futaki M, 2000, BLOOD, V95, P1493, DOI 10.1182/blood.V95.4.1493.004k35_1493_1498; Garcia-Closas M, 2006, HUM GENET, V119, P376, DOI 10.1007/s00439-006-0135-z; Gillio AP, 1997, BLOOD, V90, P105; Hirsch B, 2004, BLOOD, V103, P2554, DOI 10.1182/blood-2003-06-1970; HODGSON SV, 2004, AM SOC HUM GEN M TOR; HOUGHTALING S, 2003, GENE DEV, V17, P1933; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2006, DNA REPAIR, V5, P629, DOI 10.1016/j.dnarep.2006.02.007; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Karppinen SM, 2003, EUR J CANCER, V39, P366, DOI 10.1016/S0959-8049(02)00498-7; Kutler DI, 2003, J NATL CANCER I, V95, P1718, DOI 10.1093/jnci/djg091; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Lewis AG, 2005, BREAST CANCER RES, V7, pR1005, DOI 10.1186/bcr1336; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo LP, 2002, INT J CANCER, V98, P638, DOI 10.1002/ijc.10214; Lyakhovich A, 2006, CANCER LETT, V232, P99, DOI 10.1016/j.canlet.2005.07.038; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Meyer S, 2006, BRIT J HAEMATOL, V133, P284, DOI 10.1111/j.1365-2141.2006.05985.x; Morgan NV, 2005, BLOOD, V105, P3542, DOI 10.1182/blood-2004-10-3968; Mosedale G, 2005, NAT STRUCT MOL BIOL, V12, P763, DOI 10.1038/nsmb981; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Pearson T, 2001, CANCER GENET CYTOGEN, V126, P52, DOI 10.1016/S0165-4608(00)00388-5; POTTER NU, 1983, CANCER GENET CYTOGEN, V9, P61, DOI 10.1016/0165-4608(83)90025-0; Reid S, 2005, J MED GENET, V42, P147, DOI 10.1136/jmg.2004.022673; Reuter TY, 2003, EXP CELL RES, V289, P211, DOI 10.1016/S0014-4827(03)00261-1; Rogers CD, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.024851; Rogers CD, 2004, CANCER BIOL THER, V3, P167, DOI 10.4161/cbt.3.2.609; Rosenberg PS, 2003, BLOOD, V101, P822, DOI 10.1182/blood-2002-05-1498; Rosenberg PS, 2005, BLOOD, V105, P67, DOI 10.1182/blood-2004-04-1652; ROSENDORFF J, 1987, AM J MED GENET, V27, P793, DOI 10.1002/ajmg.1320270408; Rutter JL, 2003, HUM MUTAT, V22, P121, DOI 10.1002/humu.10238; SCHROEDER TM, 1964, HUMANGENETIK, V1, P194, DOI 10.1007/BF00389636; Seal S, 2003, CANCER RES, V63, P8596; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sigurdson AJ, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-9; Surralles Jordi, 2004, Genes Dev, V18, P1359, DOI 10.1101/gad.1216304; SWIFT M, 1980, J NATL CANCER I, V65, P863; SWIFT M, 1971, NATURE, V230, P370, DOI 10.1038/230370a0; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; THOMPSON D, 2004, GENETIC PREDISPOSITI, P256; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; Tipping AJ, 2001, P NATL ACAD SCI USA, V98, P5734, DOI 10.1073/pnas.091402398; Tischkowitz M, 2004, BRIT J HAEMATOL, V126, P176, DOI 10.1111/j.1365-2141.2004.05023.x; Tischkowitz M, 2003, BRIT J HAEMATOL, V123, P469, DOI 10.1046/j.1365-2141.2003.04640.x; Tischkowitz MD, 2004, LEUKEMIA, V18, P420, DOI 10.1038/sj.leu.2403280; Vahteristo P, 2005, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-19; Van der Heijden MS, 2004, AM J PATHOL, V165, P651, DOI 10.1016/S0002-9440(10)63329-9; van der Heijden MS, 2003, CANCER RES, V63, P2585; van Zeeburg HJT, 2004, JNCI-J NATL CANCER I, V96, P968, DOI 10.1093/jnci/djh178; VERLANDER PC, 1994, AM J HUM GENET, V54, P595; VERLANDER PC, 1995, BLOOD, V86, P4034, DOI 10.1182/blood.V86.11.4034.bloodjournal86114034; Wagner JE, 2004, BLOOD, V103, P3226, DOI 10.1182/blood-2003-09-3138; Waisfisz Q, 1999, NAT GENET, V22, P379, DOI 10.1038/11956; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; WHITNEY MA, 1993, NAT GENET, V4, P202, DOI 10.1038/ng0693-202; Xie Y, 2000, BRIT J HAEMATOL, V111, P1057, DOI 10.1111/j.1365-2141.2000.02450.x; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yamashita T, 1996, BLOOD, V87, P4424, DOI 10.1182/blood.V87.10.4424.bloodjournal87104424	92	148	155	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5875	5884		10.1038/sj.onc.1209878	http://dx.doi.org/10.1038/sj.onc.1209878			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998502				2022-12-17	WOS:000240765900008
J	Fukui, T; Kondo, M; Ito, G; Maeda, O; Sato, N; Yoshioka, H; Yokoi, K; Ueda, Y; Shimokata, K; Sekido, Y				Fukui, T; Kondo, M; Ito, G; Maeda, O; Sato, N; Yoshioka, H; Yokoi, K; Ueda, Y; Shimokata, K; Sekido, Y			Transcriptional silencing of secreted frizzled related protein 1 (SFRP1) by promoter hypermethylation in non-small-cell lung cancer	ONCOGENE			English	Article						chromosome 8p; hypermethylation; non small-cell lung cancer; SFRP1; tumor suppressor gene	WNT ANTAGONIST SFRP1; COLORECTAL-CANCER; BREAST-CANCER; GENE; INACTIVATION; EXPRESSION; CATENIN; ADENOCARCINOMAS; HETEROZYGOSITY; MESOTHELIOMA	Secreted frizzled related protein 1 (SFRP1) is an antagonist of the transmembrane frizzled receptor, a component of the Wnt signaling pathway, and has been suggested to be a candidate tumor suppressor in several human malignancies. Since SFRP1 is located at chromosome 8p11, where lung cancers also exhibit frequent allelic loss, we hypothesized that the inactivation of SFRP1 is also involved in lung carcinogenesis. To substantiate this, we performed mutational analysis of SFRP1 for 29 nonsmall-cell lung cancer (NSCLC) and 25 small-cell lung cancer (SCLC) cell lines, and expression analysis for the same cell lines. Although somatic mutations were not detected in the coding sequence, downregulation of SFRP1 was observed in 14 (48%) NSCLC and nine (36%) SCLC cell lines. We analysed epigenetic alteration of the SFRP1 promoter region and detected hypermethylation in 15 (52%) of 29 NSCLC cell lines, two (8%) of 25 SCLC cell lines, and 44 (55%) of 80 primary lung tumors. By comparing the methylation status with SFRP1 expression, we found a significant correlation between them. We also performed loss of heterozygosity (LOH) analysis and found that 15 (38%) of 40 informative surgical specimens had LOH in the SFRP1 gene locus. Furthermore, we performed colony formation assay of two NSCLC cell lines (NCI-H460 and NCI-H2009) and found the reduction of colony formation with SFRP1 transfection. In addition, we also detected that SFRP1 inhibits the transcriptional activity of beta-catenin, which is thought to be a downstream molecule of SFRP1, with luciferase reporter assay. Our current studies demonstrated that the SFRP1 gene is frequently downregulated by promoter hypermethylation and suppresses tumor growth activity of lung cancer cells, which suggests that SFRP1 is a candidate tumor suppressor gene for lung cancer.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Resp Med, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ysekido@aichi-cc.jp	Kondo, Masashi/I-7378-2014; Yokoi, Kohei/I-7261-2014; Fukui, Takayuki/AAR-2292-2021; Sekido, Yoshitaka/P-9756-2015; FUKUI, Takayuki/I-7443-2014	Sekido, Yoshitaka/0000-0002-2428-3848				Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; EMI M, 1992, CANCER RES, V52, P5368; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Girard L, 2000, CANCER RES, V60, P4894; HORII A, 1992, CANCER RES, V52, P6696; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041; Klopocki E, 2004, INT J ONCOL, V25, P641; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Minna JD, 2002, CANCER J, V8, pS41; Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164; Morin Patrice J, 2003, Cancer Treat Res, V115, P169; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Polakis P, 2000, GENE DEV, V14, P1837; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sekido Y, 2002, CANCER GENET CYTOGEN, V137, P33, DOI 10.1016/S0165-4608(02)00536-8; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Toyooka S, 2002, CLIN CANCER RES, V8, P2292; Uchiyama M, 2003, INT J CANCER, V107, P962, DOI 10.1002/ijc.11493; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Wistuba II, 1999, CANCER RES, V59, P1973; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291	30	148	153	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6323	6327		10.1038/sj.onc.1208777	http://dx.doi.org/10.1038/sj.onc.1208777			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007200				2022-12-17	WOS:000231877100013
J	Mo, YY; Yu, YN; Theodosiou, E; Ee, PLR; Beck, WT				Mo, YY; Yu, YN; Theodosiou, E; Ee, PLR; Beck, WT			A role for Ubc9 in tumorigenesis	ONCOGENE			English	Article						Ubc9; sumoylation; SUMO; Bcl-2; apoptosis	UBIQUITIN-CONJUGATING ENZYME; BREAST-CANCER CELLS; BCL-2 EXPRESSION; PROTEIN SUMO-1; RECEPTOR; P53; SUMOYLATION; ACTIVATION; INTERACTS; FAMILY	The post-translational modi. cations ubiquitination and sumoylation have been implicated in regulating many critical cellular pathways. Like ubiquitination, sumoylation is a multistep process involving maturation, activation, conjugation and deconjugation. Ubc9 is a sole E2-conjugating enzyme essential for sumoylation. We have previously shown that alterations of Ubc9 expression affect tumor drug responsiveness. However, it is not clear whether there is any link between sumoylation and tumorigenesis, even though alterations of the ubiquitination pathway can lead to the development of cancer. In this study, we found that Ubc9 expression levels were elevated in ovarian tumors compared to the matched normal ovarian specimens, suggesting that Ubc9 may play a role in tumorigenesis. To test this, we overexpressed a dominant-negative mutant of Ubc9 ( Ubc9-DN) and wildtype Ubc9 ( Ubc9-WT) in the MCF-7 human breast tumor cells. Inoculating these cells as xenografts in mice revealed that tumors expressing Ubc9-WT grew better than the vector control, while tumors expressing Ubc9-DN exhibited reduced growth. This pattern was also seen in these cells when grown in culture. To better understand the mechanism behind this observation, we pro. led gene expressions in these cells by microarray analysis and found alterations in expression of the pro-oncogene bcl-2 in these Ubc9-DN- and Ubc9-WT-expressing cells. Consistent with the bcl-2 results, subsequent studies revealed a higher rate of apoptosis and poor survival for the MCF-7 cells expressing Ubc9-DN, which are associated with downregulation of bcl-2. Together, these results suggest a role for Ubc9 in tumorigenesis at least partially through regulation of bcl-2 expression.	Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA; Univ Illinois, Core Lab Mol Pharmacol, Gynecol Oncol Grp, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 911 N Rutledge,Room 1300A, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/R-8255-2019; EE, P.L. Rachel/C-7538-2014; 高, 雨莉/HGU-8187-2022; Mo, Yin-Yuan/B-6141-2011	Ee, Pui Lai Rachel/0000-0002-7277-6233	NATIONAL CANCER INSTITUTE [R01CA040570, U10CA027469, R01CA030103, R01CA102630] Funding Source: NIH RePORTER; NCI NIH HHS [CA27469, R01 CA102630, CA102630, CA30103, CA40570] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALDERSON LM, 1995, CANCER RES, V55, P999; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541; Martinez-Arribas F, 2003, ANTICANCER RES, V23, P565; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Zhang GJ, 1998, ONCOL REP, V5, P1211; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	33	148	157	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2677	2683		10.1038/sj.onc.1208210	http://dx.doi.org/10.1038/sj.onc.1208210			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735760				2022-12-17	WOS:000228356700009
J	Agarwal, A; Das, K; Lerner, N; Sathe, S; Cicek, M; Casey, G; Sizemore, N				Agarwal, A; Das, K; Lerner, N; Sathe, S; Cicek, M; Casey, G; Sizemore, N			The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin	ONCOGENE			English	Article						AKT; PTEN; I kappa B kinase; nuclear factor-kappa B; beta-catenin; colorectal cancer	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; SEVERE LIVER DEGENERATION; GAMMA-DEFICIENT MICE; IKK-BETA; SUPPRESSOR PTEN; NEMO/IKK-GAMMA; COLON-CANCER; P65 SUBUNIT; TRANSCRIPTIONAL ACTIVATION	Our laboratory has delineated that the phosphatidylinositol 30 kinase (PI3K)/AKT/IkappaB kinase (IKK) pathway positively regulates NFkappaB and beta-catenin, both important transcriptional regulators in colorectal cancer (CRC). Therefore, we investigated the effect of inhibiting the PI3K/AKT/IKKalpha pathway in regulating the inappropriate constitutive activation of NFkappaB and beta-catenin in CRC cell lines. SW480 and RKO CRC cell lines demonstrate constitutive activation of AKT as well as both NFkappaB- and beta-catenin-dependent transcription. The constitutive activation of NFkappaB- and beta-catenin-dependent transcription is inhibited by transiently transfecting either kinase dead (KD) IKKalpha, which blocks IKKalpha kinase activity, KD AKT, which blocks AKT activity, or wildtype (WT) PTEN, which inhibits PI3K and AKT activity. The ability of KD IKKalpha, KD AKT or WT PTEN to decrease beta-catenin-dependent transcription is independent of their effects on NFkappaB. Inducible expression of either KD IKKalpha or WT PTEN strongly inhibits both the constitutive NFkappaB- and beta-catenin-dependent promoter and endogenous gene activation. Targeted array-based gene expression analysis of this inducible system reveals that many of the genes downregulated upon inhibition of this pathway are involved in tumor angiogenesis and metastasis. The activation of this pathway and the expression of the three most repressed genes was further analysed in samples of CRC. These results indicate a role of this pathway in controlling gene expression important in tumor progression and metastasis.	Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sizemore, N (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	sizemon@ccf.org			NCI NIH HHS [R01 CA100748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 2003, CR BIOL, V326, P1041, DOI 10.1016/j.crvi.2003.09.007; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Clauss M, 2000, CIRC RES, V86, P251, DOI 10.1161/01.RES.86.3.251; Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006; Easwaran V, 2003, CANCER RES, V63, P3145; Furudoi A, 2002, ONCOLOGY-BASEL, V62, P157, DOI 10.1159/000048262; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Haefner B, 2002, DRUG DISCOV TODAY, V7, P653, DOI 10.1016/S1359-6446(02)02309-7; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Hanrahan V, 2003, J PATHOL, V200, P183, DOI 10.1002/path.1339; Haraguchi M, 2002, ONCOL REP, V9, P159; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Polakis P, 2000, GENE DEV, V14, P1837; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROTHWARF DM, 1999, SCI STKE, P5; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wigmore SJ, 2001, INT J ONCOL, V18, P467; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	67	148	156	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1021	1031		10.1038/sj.onc.1208296	http://dx.doi.org/10.1038/sj.onc.1208296			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592509				2022-12-17	WOS:000226749200008
J	Rose-Hellekant, TA; Arendt, LM; Schroeder, MD; Gilchrist, K; Sandgren, EP; Schuler, LA				Rose-Hellekant, TA; Arendt, LM; Schroeder, MD; Gilchrist, K; Sandgren, EP; Schuler, LA			Prolactin induces ER alpha-positive and ER alpha-negative mammary cancer in transgenic mice	ONCOGENE			English	Article						mammary cancer; prolactin; ER alpha; transgenic mice	ESTROGEN-RECEPTOR-ALPHA; GLAND DEVELOPMENT; GROWTH-HORMONE; PROGESTERONE-RECEPTOR; CELL-PROLIFERATION; BREAST-CANCER; EPITHELIAL-CELLS; EXPRESSION; TUMORS; DISRUPTION	The role of prolactin in human breast cancer has been controversial. However, it is now apparent that human mammary epithelial cells can synthesize prolactin endogenously, permitting autocrine/paracrine actions within the mammary gland that are independent of pituitary prolactin. To model this local mammary production of prolactin (PRL), we have generated mice that overexpress prolactin within mammary epithelial cells under the control of a hormonally nonresponsive promoter, neurelated lipocalin (NRL). In each of the two examined NRL-PRL transgenic mouse lineages, female virgin mice display mammary developmental abnormalities, mammary intraepithelial neoplasias, and invasive neoplasms. Prolactin increases proliferation in morphologically normal alveoli and ducts, as well as in lesions. The tumors are of varied histotype, but papillary adenocarcinomas and adenosquamous neoplasms predominate. Neoplasms can be separated into two populations: one is estrogen receptor alpha (ERalpha) positive (greater than 15% of the cells stain for ERalpha), and the other is ERalpha- ( < 3%). ER alpha expression does not correlate with tumor histotype, or proliferative or apoptotic indices. These studies provide a mouse model of hormonally dependent breast cancer, and, perhaps most strikingly, a model in which some neoplasms retain ERa, as occurs in the human disease.	Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu		Arendt, Lisa/0000-0002-7954-3635	NATIONAL CANCER INSTITUTE [R01CA064843, R01CA078312] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000265] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA078312, R01-CA64843, R01 CA78312] Funding Source: Medline; NCRR NIH HHS [K01 RR00145] Funding Source: Medline; NIA NIH HHS [T32 AG000265, T32-AG00265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Beck MT, 2002, ONCOGENE, V21, P5047, DOI 10.1038/sj.onc.1205637; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/edrv-17-6-639; BERA TK, 1994, MOL CELL BIOCHEM, V132, P145, DOI 10.1007/BF00926923; BOOT LM, 1962, GEN COMP ENDOCR, V2, P601; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Camarillo IG, 2001, J ENDOCRINOL, V171, P85, DOI 10.1677/joe.0.1710085; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; Christov KT, 1996, CARCINOGENESIS, V17, P1741, DOI 10.1093/carcin/17.8.1741; Clarke RB, 1997, CANCER RES, V57, P4987; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; DEOME KB, 1959, CANCER RES, V19, P515; EDERY M, 1985, ENDOCRINOLOGY, V116, P105, DOI 10.1210/endo-116-1-105; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; GOUT PW, 1980, CANCER RES, V40, P2433; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Grippo PJ, 2000, AM J PATHOL, V157, P805, DOI 10.1016/S0002-9440(10)64594-4; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Hu ZZ, 2001, J BIOL CHEM, V276, P41086, DOI 10.1074/jbc.M102109200; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; HUSEBY RA, 1985, ENDOCRINOLOGY, V116, P1440, DOI 10.1210/endo-116-4-1440; Imagawa W, 2002, J STEROID BIOCHEM, V80, P213, DOI 10.1016/S0960-0760(01)00188-1; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7; Mertani HC, 1998, INT J CANCER, V79, P202; MULDOON TG, 1987, ENDOCRINOLOGY, V121, P141, DOI 10.1210/endo-121-1-141; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; Qin W, 1999, J VIROL, V73, P368, DOI 10.1128/JVI.73.1.368-376.1999; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rose-Hellekant TA, 2002, AM J PATHOL, V161, P1439, DOI 10.1016/S0002-9440(10)64419-7; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Schroeder MD, 2001, MOL CELL ENDOCRINOL, V175, P173, DOI 10.1016/S0303-7207(01)00385-9; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SHAFIE S, 1977, CANCER RES, V37, P792; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Shyamala G, 2002, J STEROID BIOCHEM, V80, P137, DOI 10.1016/S0960-0760(01)00182-0; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Stoesz SP, 1995, ONCOGENE, V11, P2233; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; WELSCH CW, 1977, CANCER RES, V37, P951; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Yarus S, 1996, Genet Eng (N Y), V18, P57; Yoshidome K, 2000, CANCER RES, V60, P6901; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x	66	148	148	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4664	4674		10.1038/sj.onc.1206619	http://dx.doi.org/10.1038/sj.onc.1206619			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879011	Green Accepted			2022-12-17	WOS:000184157000007
J	Wikman, H; Kettunen, E; Seppanen, JK; Karjalainen, A; Hollmen, J; Anttila, S; Knuutila, S				Wikman, H; Kettunen, E; Seppanen, JK; Karjalainen, A; Hollmen, J; Anttila, S; Knuutila, S			Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array	ONCOGENE			English	Article						cDNA array; RT-PCR; adenocarcinoma; lung cancer	CELL LUNG-CANCER; POLO-LIKE KINASE; TUMOR-SUPPRESSOR GENE; K-RAS MUTATIONS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; MALIGNANT MESOTHELIOMA; HYDROCARBON RECEPTOR; ENDOTHELIAL-CELLS; TISSUE INHIBITOR	No clear patterns in molecular changes underlying the malignant processes in lung cancer of different histological types have been found so far. To identify critical genes in lung cancer progression we compared the expression profile of cancer related genes in 14 pulmonary adenocarcinoma patients with normal lung tissue by using the cDNA array technique. Principal component analyses (PCA) and permutation test were used to detect the differentially expressed genes. The expression profiles of 10 genes were confirmed by semiquantitative real-time RT-PCR. In tumour samples, as compared to normal lung tissue, the up-regulated genes included such known tumour markers as CCNB1, PLK, tenascin, KRT8, KRT19 and TOP2A. The down-regulated genes included caveolin 1 and 2, and TIMP3. We also describe, for the first time, down-regulation of the interesting SOCS2 and 3, DOC2 and gravin. We show that silencing of SOCS2 is not caused by methylation of exon 1 of the gene. In conclusion, by using the cDNA array technique we were able to reveal marked differences in the gene expression level between normal lung and tumour tissue and find possible new tumour markers for pulmonary adenocarcinoma.	Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Helsinki Univ Technol, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Finnish Inst Occupat Hlth, Dept Occupat Med, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Aalto University; Finnish Institute of Occupational Health	Knuutila, S (corresponding author), Haartman Inst, Dept Med Genet, POB 21, FIN-00014 Helsinki, Finland.			Wikman, Harriet/0000-0001-6862-0888				Aalto Y, 2001, LEUKEMIA, V15, P1721, DOI 10.1038/sj.leu.2402282; Anbazhagan R, 1999, CANCER RES, V59, P5119; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bjorkqvist AM, 1998, BRIT J CANCER, V77, P260, DOI 10.1038/bjc.1998.42; Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; CALIGO MA, 1995, INT J CANCER, V60, P837, DOI 10.1002/ijc.2910600619; Chen JJW, 2001, CANCER RES, V61, P5223; CHU W, 1995, J BIOL CHEM, V270, P10236, DOI 10.1074/jbc.270.17.10236; Cilley RE, 2000, J PEDIATR SURG, V35, P113, DOI 10.1016/S0022-3468(00)80026-3; Diviani D, 2001, J CELL SCI, V114, P1431; Dohmoto K, 2000, LUNG CANCER-J IASLC, V30, P55, DOI 10.1016/S0169-5002(00)00125-2; Dohr O, 1997, MOL PHARMACOL, V51, P703, DOI 10.1124/mol.51.5.703; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; EVERETT AD, 2001, J BIOL CHEM, V31, P31; Fassina G, 2000, CLIN EXP METASTAS, V18, P111, DOI 10.1023/A:1006797522521; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Fong KM, 1996, CLIN CANCER RES, V2, P1369; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Hand D. J., 2001, ADAPTIVE COMPUTATION; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hefferan TE, 2000, J CELL BIOCHEM, V78, P380, DOI 10.1002/1097-4644(20000901)78:3<380::AID-JCB4>3.0.CO;2-L; Hellmann GM, 2001, TOXICOL SCI, V61, P154, DOI 10.1093/toxsci/61.1.154; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Huang Y, 2001, LAB INVEST, V81, P863, DOI 10.1038/labinvest.3780295; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Kang SH, 2000, INT J CANCER, V86, P632, DOI 10.1002/(SICI)1097-0215(20000601)86:5<632::AID-IJC5>3.0.CO;2-5; Karameris A, 1997, AM J RESP CRIT CARE, V156, P1930, DOI 10.1164/ajrccm.156.6.9612046; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; Kellner U, 2000, ONKOLOGIE, V23, P424, DOI 10.1159/000027205; Keohavong P, 1996, CLIN CANCER RES, V2, P411; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kishimoto T, 2001, NAT GENET, V28, P4, DOI 10.1038/88244; Kojima S, 2000, BLOOD, V95, P1309; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kusagawa H, 1998, BRIT J CANCER, V77, P98, DOI 10.1038/bjc.1998.15; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Lee IH, 1997, MOL CELLS, V7, P589; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; Nhung N V, 1999, Cesk Patol, V35, P80; Nishihira J, 1998, INT J MOL MED, V2, P17; PENDLETON N, 1994, EUR J CANCER, V1, P93; PINES J, 1992, CIBA F SYMP, V170, P187; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; RAZANI B, 2001, AM J PHYSIOL-CELL PH, V281, pC1241; Reeves R, 1995, Prog Cell Cycle Res, V1, P339; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Smith MM, 1991, CURR OPIN CELL BIOL, V3, P429, DOI 10.1016/0955-0674(91)90070-F; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Soria JC, 2000, CANCER RES, V60, P4000; Suzuki H, 2000, ELECTROPHORESIS, V21, P904, DOI 10.1002/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.3.CO;2-W; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; Thomas P, 2000, J PATHOL, V190, P150; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tuder RM, 2001, EUR RESPIR J, V17, P1065, DOI 10.1183/09031936.01.00202701; Ueki T, 2000, CANCER RES, V60, P1835; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wilson MJ, 2000, IMMUNOL RES, V22, P21, DOI 10.1385/IR:22:1:21; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wolf M, 2000, CANCER GENET CYTOGEN, V123, P128, DOI 10.1016/S0165-4608(00)00319-8; Xia W, 2001, CANCER RES, V61, P5644; Xiao S, 1997, AM J PATHOL, V150, P901; Ylisirnio S, 2001, CLIN CANCER RES, V7, P1633; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	84	148	164	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5804	5813		10.1038/sj.onc.1205726	http://dx.doi.org/10.1038/sj.onc.1205726			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173052				2022-12-17	WOS:000177463400017
J	Pandolfi, PP				Pandolfi, PP			Transcription therapy for cancer	ONCOGENE			English	Review						transcription factors; transcription therapy; HDAC inhibitors; differentiation; cancer; APL; polyamides	ACUTE PROMYELOCYTIC LEUKEMIA; SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; TRANSFORMED-CELL DIFFERENTIATION; PLZF-RAR-ALPHA; RETINOIC ACID; IN-VITRO; ARSENIC TRIOXIDE; GENE-EXPRESSION	In the post genome era it will soon be possible to associate a specific tumor type with a specific gene expression profile and to define each molecular lesion characteristic of any given cancer. It is intuitive that a successful therapeutic strategy for cancer should aim at blocking the aberrant biochemical activity triggered by the oncogene or the lack of tumor suppressor gene activity that ultimately leads to full-blown neoplastic transformation. However, an attractive alternative approach entails the blockade of the transcriptional consequences of such oncogenic activities irrespective of their original biochemical nature, thus antagonizing the key transcriptional events underlying cancer pathogenesis in any specific neoplastic cellular population. This approach is now rendered possible by major advances along several lines of investigation: (i) the possibility of analysing gene expression through high throughput methods; (ii) a more detailed knowledge of the regulatory regions and of the transcription factors that control gene expression also facilitated in the future by a comprehensive whole genome comparative analysis of these regulatory sequences; (iii) the ability of modulating gene expression at the single gene level through various approaches both pharmacological and biochemical; (iv) the opportunity of directly antagonizing the aberrant activities of oncogenic transcription factors through a detailed knowledge of their abnormal transcriptional function; (v) the possibility of validating, in vivo, in animal models the relevance for neoplastic transformation of specific transcriptional events as well as of testing the efficacy of 'transcription therapy' in faithful animal models of human cancer. Here, we will review the facts, the existing applications and the hypothesis underlying such therapeutic modality for cancer therapy.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.							Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Aman P, 1999, SEMIN CANCER BIOL, V9, P303, DOI 10.1006/scbi.1999.0130; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Baylin SB, 1998, ADV CANCER RES, V72, P141; Butler LM, 2000, CANCER RES, V60, P5165; Byrd JC, 1999, BLOOD, V94, P1401, DOI 10.1182/blood.V94.4.1401.416k30_1401_1408; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Coffey DC, 2000, MED PEDIATR ONCOL, V35, P577, DOI 10.1002/1096-911X(20001201)35:6<577::AID-MPO18>3.0.CO;2-3; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Dervan PB, 1999, CURR OPIN CHEM BIOL, V3, P688, DOI 10.1016/S1367-5931(99)00027-7; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, BLOOD, V92, p510A; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Janssen S, 2000, MOL CELL, V6, P999, DOI 10.1016/S1097-2765(00)00099-X; Jurcic JG, 2000, CLIN CANCER RES, V6, P372; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; Kushner D M, 2000, Curr Oncol Rep, V2, P23, DOI 10.1007/s11912-000-0007-y; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU PQ, 2001, IN PRESS J BIOL CHEM; LO CF, 1994, BLOOD, V83, P1757; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; MAGRATH I, 1990, NONHODGKINS LYMPHOMA, P29; Mapp AK, 2000, P NATL ACAD SCI USA, V97, P3930, DOI 10.1073/pnas.97.8.3930; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Reich S, 2000, BLOOD, V96, P3357, DOI 10.1182/blood.V96.10.3357.h8003357_3357_3363; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Trauger JW, 1998, J AM CHEM SOC, V120, P3534, DOI 10.1021/ja9800378; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; White S, 1998, NATURE, V391, P468, DOI 10.1038/35106; WOLFFE AP, 2001, IN PRESS ONCOGENE; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	58	148	158	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3116	3127		10.1038/sj.onc.1204299	http://dx.doi.org/10.1038/sj.onc.1204299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420728				2022-12-17	WOS:000169308500016
J	Eymin, B; Karayan, L; Seite, P; Brambilla, C; Brambilla, E; Larsen, CJ; Gazzeri, S				Eymin, B; Karayan, L; Seite, P; Brambilla, C; Brambilla, E; Larsen, CJ; Gazzeri, S			Human ARF binds E2F1 and inhibits its transcriptional activity	ONCOGENE			English	Article						ARF; E2F1; mdm2; tumour suppressor; transcription regulation	P19(ARF) TUMOR-SUPPRESSOR; CELL LUNG-CANCER; P53-DEPENDENT APOPTOSIS; RETINOBLASTOMA PROTEIN; NUCLEOLAR LOCALIZATION; BETA-TRANSCRIPT; STABILIZES P53; DNA-SYNTHESIS; GENE-PRODUCT; MDM2	The INK4a/ARF locus which is frequently inactivated in human tumours encodes two different tumour suppressive proteins, p16(INK4a) and ARF, p16(INK4a) is a major component of the RE pathway. ARF is part of an ARF-mdm2-p53 network that exerts a negative control on hyperproliferative signals emanating from oncogenic stimuli. Among these is the transcription factor E2F1, a final effector of the RE pathway, that induces ARF expression. Recent data suggest that ARF function is not restricted to the p53 pathway. However, ARF target(s) implicated in this p53-independent function remains to be identified. We show that ARF is able to inhibit the proliferation of human cell lines independently of their p53 status. In this context, we demonstrate that ARF interacts physically with E2F1 and inhibits its transcriptional activity. Moreover, we show that mdm2 is required for the modulation of E2F1 activity by ARF, Beside the well-known p53 and mdm2 partners, these results identify E2F1 as a new ARF target. Thus, ARF can be viewed as a dual-acting tumour suppressor protein in both the p53 and RE pathways, further emphasizing its role in tumour surveillance.	Inst Albert Bonniot, INSERM EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France; CHU La Miletrie, CNRS ESA 6031, Lab Immunol & Biochim Prot, F-86021 Poitiers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CHU Poitiers; Universite de Poitiers	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France.		Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019	gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; Seite, Paule/0000-0002-7809-7610				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EYMIN B, 2001, IN PRESS ONCOGENE; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Gazzeri S, 1998, CANCER RES, V58, P3926; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTIN F, 1995, NATURE, V373, P691; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; NEVINS JR, 1992, SCIENCE, V258, P424; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	37	148	154	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1033	1041		10.1038/sj.onc.1204220	http://dx.doi.org/10.1038/sj.onc.1204220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314038	Green Submitted, Bronze			2022-12-17	WOS:000167232100003
J	Grotzer, MA; Eggert, A; Zuzak, TJ; Janss, AJ; Marwaha, S; Wiewrodt, BR; Ikegaki, N; Brodeur, GM; Phillips, PC				Grotzer, MA; Eggert, A; Zuzak, TJ; Janss, AJ; Marwaha, S; Wiewrodt, BR; Ikegaki, N; Brodeur, GM; Phillips, PC			Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression	ONCOGENE			English	Article						TRAIL; PNET; medulloblastoma; apoptosis	DRUG-INDUCED APOPTOSIS; LIGAND TRAIL; LEUKEMIA-CELLS; MELANOMA-CELLS; DEATH DOMAIN; APO2 LIGAND; RECEPTOR; FAMILY; GENE; IDENTIFICATION	TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in adult malignant glioma and various other human solid tumor models but not in normal tissues. To characterize the TRAIL death pathway in childhood primitive neuroectodermal brain tumor (PNET), 8 human PNET cell lines were tested for TRAIL-induced apoptosis, TRAIL-sensitivity of the PNET cell lines was correlated with mRNA expression levels of TRAIL, its agonistic (TRAIL-R1, TRAIL-R2) and antagonistic (TRAIL-R3, TRAIL-R4) receptors, cellular FLICE-like inhibitory protein (cFLIP), caspase-3 and caspase-8, Three of 8 PNET cell lines tested were susceptible to TRAIL-induced apoptosis, Sensitivity to TRAIL-induced apoptosis did not correlate with mRNA expression of TRAIL receptors or cFLIP, However, all TRAIL-sensitive PNET cell lines expressed caspase-8 mRNA and protein, while none of the five TRAIL-resistant PNET cell lines expressed caspase-8 protein. Treatment with the methyltransferase inhibitor 5-aza-2'-deoxycytidine restored mRNA expression of caspase-8 and TRAIL-sensitivity in formerly TRAIL-resistant PNET cells, suggesting that gene methylation inhibits caspase-8 transcription in these cells. We conclude, that loss of caspase-8 mRNA is an important mechanism of TRAIL-resistance in PNET cells. Treatment with recombinant soluble TRAIL, possibly in combination with methyltransferase inhibitors, represents a promising therapeutic approach for PNET that deserves further investigation.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Grotzer, MA (corresponding author), Univ Zurich, Childrens Hosp, Steinwiesstr 75, CH-8032 Zurich, Switzerland.		Eggert, Angelika/AAE-6907-2022	Eggert, Angelika/0000-0003-3476-8184; Grotzer, Michael/0000-0002-1154-2732				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; Faderl S, 1999, CLIN CANCER RES, V5, P4041; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P3823; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Griffith TS, 1998, J IMMUNOL, V161, P2833; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1999, RECENT PROG HORM RES, V54, P225; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakamura M, 2000, ACTA NEUROPATHOL, V99, P1, DOI 10.1007/PL00007399; PACKER RJ, 1994, J NEUROSURG, V81, P690, DOI 10.3171/jns.1994.81.5.0690; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Phillips TA, 1999, J IMMUNOL, V162, P6053; POLLACK IF, 1994, NEW ENGL J MED, V331, P1500, DOI 10.1056/NEJM199412013312207; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Tang XX, 1999, CLIN CANCER RES, V5, P1491; Thomas WD, 1998, J IMMUNOL, V161, P2195; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Weller M, 1998, CANCER LETT, V128, P121, DOI 10.1016/S0304-3835(98)00019-6; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang XD, 1999, CANCER RES, V59, P2747	40	148	154	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4604	4610		10.1038/sj.onc.1203816	http://dx.doi.org/10.1038/sj.onc.1203816			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030149				2022-12-17	WOS:000089438200006
J	Kristensen, VN; Harada, N; Yoshimura, N; Haraldsen, E; Lonning, P; Erikstein, B; Karesen, R; Kristensen, T; Borresen-Dale, AL				Kristensen, VN; Harada, N; Yoshimura, N; Haraldsen, E; Lonning, P; Erikstein, B; Karesen, R; Kristensen, T; Borresen-Dale, AL			Genetic variants of CYP19 (aromatase) and breast cancer risk	ONCOGENE			English	Article						CYP19 (aromatase); estrogen metabolism; polymorphism; breast cancer risk	CYTOCHROME-P450 GENE; EXPRESSION; PROMOTERS; TISSUE; CELLS; WOMEN	The effect of a SNP in exon 10 of CYP19 on tumor mRNA levels and splice variants were studied and correlated with clinical parameters and risk of breast cancer. In the vast majority of breast cancers, the estrogen levels modulate the tumor growth and depend on the activity of CYP19, Patients (n=481) and controls (n=236) were genotyped by T-tracks in a single sequencing reaction (SSR), The frequency of TT genotypes was significantly higher in patients versus controls (P=0.007) particularly among those with stage III and IV disease (P=0.004) and with tumors larger than 5 cm (P=0.001), A significant association between presence of the T allele and the level of aromatase mRNA in the tumors was observed (P=0.018), as well as with a switch from adipose promoter to ovary promoter (P=0.004). Previously, we reported a rare polymorphic allele of CYP19 (repeat (TTTA)(12)) to be significantly more frequent in breast cancer patients than in controls, Here we describe another polymorphism, a C-T substitution in exon 10 of the CYP19 gene which is in strong linkage disequilibrium with the (TTTA)n polymorphism but with higher frequency of the variant allele, Our data suggest that the T-allele of the CYP19 gene is associated with a 'high activity' phenotype.	Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway; Fujita Hlth Univ, Sch Med, Dept Biochem, Toyoake, Aichi 47011, Japan; Norwegian Radium Hosp, Inst Canc Res, Dept Oncol, N-0310 Oslo, Norway; Univ Bergen, Haukeland Hosp, Dept Oncol, N-5020 Bergen, Norway; Univ Oslo, Ullevaal Hosp, Dept Oncol, N-0407 Oslo, Norway; Univ Oslo, Dept Biochem, N-0316 Oslo, Norway	University of Oslo; Fujita Health University; University of Oslo; University of Bergen; Haukeland University Hospital; University of Oslo; University of Oslo	Borresen-Dale, AL (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.		Kristensen, Tom/C-5873-2019	Kristensen, Tom/0000-0002-2131-4469; Lonning, Per Eystein/0000-0002-8890-6303				Burak WE, 1997, BREAST CANCER RES TR, V44, P57, DOI 10.1023/A:1005782311558; DURGAM VR, 1995, BBA-GENE STRUCT EXPR, V1263, P89, DOI 10.1016/0167-4781(95)00093-V; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1992, AM J HUM GENET, V51, P666; HARADA N, 1995, PHARMACOGENETICS, V5, P59; Kristensen T, 1998, BIOTECHNIQUES, V24, P832, DOI 10.2144/98245dt04; Kristensen VN, 1998, PHARMACOGENETICS, V8, P43, DOI 10.1097/00008571-199802000-00006; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MEANS GD, 1989, J BIOL CHEM, V264, P19386; Michael MD, 1997, MOL CELL ENDOCRINOL, V134, P147, DOI 10.1016/S0303-7207(97)00178-0; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Simpson E R, 1994, Int J Fertil Menopausal Stud, V39 Suppl 2, P75; SOURDAINE P, 1994, J MOL ENDOCRINOL, V13, P331, DOI 10.1677/jme.0.0130331; Thomas HV, 1997, BRIT J CANCER, V75, P1075, DOI 10.1038/bjc.1997.183; TODA K, 1989, FEBS LETT, V247, P371, DOI 10.1016/0014-5793(89)81373-0; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; Zhao Y, 1997, J STEROID BIOCHEM, V61, P203, DOI 10.1016/S0960-0760(97)80013-1	19	148	155	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 2	2000	19	10					1329	1333		10.1038/sj.onc.1203425	http://dx.doi.org/10.1038/sj.onc.1203425			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	291NW	10713674				2022-12-17	WOS:000085743800009
J	Carter, S; Auer, KL; Reardon, DB; Birrer, M; Fisher, PB; Valerie, K; Schmidt-Ullrich, R; Mikkelsen, R; Dent, P				Carter, S; Auer, KL; Reardon, DB; Birrer, M; Fisher, PB; Valerie, K; Schmidt-Ullrich, R; Mikkelsen, R; Dent, P			Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells	ONCOGENE			English	Article						MAP kinase; p21(Cip-1); ionizing radiation; cell death	CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR RECEPTOR; P53-INDEPENDENT PATHWAY; INDUCED APOPTOSIS; EGF RECEPTOR; DNA-DAMAGE; C-JUN; DIFFERENTIATION; STRESS; P21	The molecular mechanism(s) by which tumor cells survive after exposure to ionizing radiation are not fully understood. Exposure of A431 cells to low doses of radiation (1Gy) caused prolonged activations of the mitogen activated protein (MAP) kinase and stress activated protein (SAP) kinase pathways, and induced p21(Cip-1/WAF1) via a MAP kinase dependent mechanism. In contrast, higher doses of radiation (6 Gy) caused a much weaker activation of the MAP kinase cascade, but a similar degree of SAP kinase cascade activation. In the presence of MAP kinase blockade by the specific MEK1 inhibitor (PD98059) the basal activity of the SAP kinase pathway was enhanced twofold, and the ability of a 1 Gy radiation exposure to activate the SAP kinase pathway was increased similar to sixfold 60 min after irradiation, In the presence of MAP kinase blockade by PD98059 the ability of a single 1Gy exposure to cause double stranded DNA breaks (TUNEL assay) was enhanced at least threefold over the following 24-48h. The increase in DNA damage within 48 h was also mirrored by a similar decrease in A431 cell growth as judged by MTT assays over the next 4-8 days following radiation exposure. This report demonstrates that the MAP kinase cascade is a key cytoprotective pathway in A431 human squamous carcinoma cells which is activated in response to clinically used doses of ionizng radiation, Inhibition of this pathway potentiates the ability of low dose radiation exposure to induce cell death im vitro.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Immunol & Microbiol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; NIH, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Columbia University; National Institutes of Health (NIH) - USA	Dent, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [R01CA065896] Funding Source: NIH RePORTER; NCI NIH HHS [CA65896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 1997, CANCER RES, V57, P1495; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; BOYLE W, 1990, CELL, V64, P573; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARMICHAEL J, 1987, CANCER RES, V47, P943; Chmura SJ, 1997, CANCER RES, V57, P1270; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Freemerman AJ, 1997, LEUKEMIA, V11, P504, DOI 10.1038/sj.leu.2400625; JARVIS DW, 1996, J BIOL CHEM, V271, P8275; JARVIS WD, 1997, IN PRESS MOL PHARM; JARVIS WD, 1997, FEBS LETT, V112, P9; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Liu Y, 1996, CANCER RES, V56, P31; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOTHERSILL C, 1995, RADIAT RES, V142, P181, DOI 10.2307/3579027; Muschel RJ, 1997, VITAM HORM, V53, P1, DOI 10.1016/S0083-6729(08)60702-5; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; TOMBES RM, 1998, IN PRESS BIOCH J; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TSAI LH, 1993, ONCOGENE, V8, P1593; VALERIE K, 1995, MUTAT RES-DNA REPAIR, V336, P91, DOI 10.1016/0921-8777(94)00046-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	53	148	149	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2787	2796		10.1038/sj.onc.1201802	http://dx.doi.org/10.1038/sj.onc.1201802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652746				2022-12-17	WOS:000073812200011
J	Madden, SL; Galella, EA; Zhu, JS; Bertelsen, AH; Beaudry, GA				Madden, SL; Galella, EA; Zhu, JS; Bertelsen, AH; Beaudry, GA			SAGE transcript profiles for p53-dependent growth regulation	ONCOGENE			English	Article						SAGE; p53; transcription	MESSENGER-RNA; DIFFERENTIAL DISPLAY; GENE-EXPRESSION; P53 MUTANTS; CELL-CYCLE; APOPTOSIS; IDENTIFICATION; PROTEIN; OSTEOPONTIN; ACTIVATION	Serial analysis of gene expression (SAGE) allows for a quantitative, representative, and comprehensive profile of gene expression, We have utilized SAGE technology to contrast the differential gene expression profile in rat embryo fibroblast cells producing temperature-sensitive p53 tumor suppressor protein at permissive or nonpermissive temperatures, Analysis of similar to 15 000 genes revealed that the expression of 14 genes (P<0.001, greater than or equal to 0.03% abundance) was dependent on functional p53 protein, whereas the expression of three genes was significantly higher in cells producing non-functional p53 protein, Those genes whose expression was increased by functional p53 include RAS, U6 snRNA, cyclin G, EGR-1, and several novel genes, The expression of actin, tubulin, and HSP70 genes was elevated at the nonpermissive temperature for p53 function, Interestingly, the expression of several genes was dependent on a non-temperature-sensitive mutant p53 suggesting altered transcription profiles dependent on specific p53 mutant proteins. These results demonstrate the utility of SAGE for rapidly and reproducibly evaluating global transcriptional responses within different cell populations.			Madden, SL (corresponding author), PHARMAGEN INC,DEPT CELLULAR & MOL BIOL,4 PEARL COURT,ALLENDALE,NJ 07401, USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AMBARTSUMIAN N, 1995, GENE, V159, P125, DOI 10.1016/0378-1119(94)00778-Q; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Arai T, 1996, INT J RADIAT BIOL, V69, P547, DOI 10.1080/095530096145553; Bains W, 1996, NAT BIOTECHNOL, V14, P711, DOI 10.1038/nbt0696-711; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BERTIOLI DJ, 1995, NUCLEIC ACIDS RES, V23, P4520, DOI 10.1093/nar/23.21.4520; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAMBERS AF, 1995, ANN NY ACAD SCI, V760, P101, DOI 10.1111/j.1749-6632.1995.tb44623.x; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HARPER JW, 1993, CELL, V75, P805; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Madden SL, 1996, CANCER RES, V56, P5384; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Oates AJ, 1996, ONCOGENE, V13, P97; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wright PS, 1996, EXP CELL RES, V222, P54, DOI 10.1006/excr.1996.0007; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	37	148	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1079	1085		10.1038/sj.onc.1201091	http://dx.doi.org/10.1038/sj.onc.1201091			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285562				2022-12-17	WOS:A1997XT16100009
J	Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Treon, S; Urashima, M; Kharbanda, S; Anderson, KC				Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Treon, S; Urashima, M; Kharbanda, S; Anderson, KC			Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism	ONCOGENE			English	Article						multiple myeloma; irradiation; dexamethasone; apoptosis	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH FACTOR; JUN; DNA; EXPRESSION; PHOSPHORYLATION; INTERLEUKIN-6	The stress-activated protein kinases (SAPKs), also known as c-Jun amino-terminal kinases (JNKs), are activated in response to diverse stimuli including DNA damage, heat shock, interleukin-1, tumor necrosis factor-alpha and Fas, Although all these inducers cause apoptosis, whether SAPK/JNK activation is required for apoptosis is controversial, In this study, we demonstrate that ionizing radiation (IR) and dexamethasone (Dex) induce apoptosis in multiple myeloma (MM) derived cell lines, as well as in patient cells, IR-induced apoptosis is associated with activation of SAPK/JNK and p38 kinase, in contrast to Dex-induced apoptosis, which is not associated with activation of stress kinases, Moreover, Dex-induced apoptosis is associated with a significant decrease in the activities of mitogen activated protein kinase (MAPK) and p70(S6K), whereas IR-treatment does not alter the activity of these kinases. Both IR and Dex induce poly (ADP ribose) polymerase (PARP) cleavage, a signature event of apoptosis. Finally, interleukin-6 (IL-6) inhibits Dex-induced apoptosis, downregulation of MAP and p70(S6K) growth kinases and PARP cleavage; in contrast, IL-6 does not inhibit IR-induced apoptosis, activation of SAPK/JNK, and PARP cleavage, Taken together, our findings suggest that SAPK/JNK activation is not required for apoptosis in MM cells, and that there are at least two distinct apoptotic signaling pathways: (i) SAPK/JNK-associated, which is induced by IR and unaffected by IL-6; and (ii) SAPK/JNK-independent, which is induced by Dex, associated with downregulation of MAPK and p70(S6K) and inhibited by IL-6.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Ogata, Atsushi/0000-0003-3944-3442				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; DUKE RC, 1992, CURRENT PROTOCOLS IM, V1; FRANK R, 1992, NUCLEIC ACIDS RES, V20, P5243; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P128; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATA H, 1995, BLOOD, V86, P1939, DOI 10.1182/blood.V86.5.1939.bloodjournal8651939; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LIMOLI CL, 1993, RADIAT RES, V134, P160, DOI 10.2307/3578455; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTENDORF JJ, 1995, BLOOD, V85, P3566, DOI 10.1182/blood.V85.12.3566.bloodjournal85123566; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZIA Z, 1995, SCIENCE, V270, P1326	45	148	155	3	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					837	843		10.1038/sj.onc.1201253	http://dx.doi.org/10.1038/sj.onc.1201253			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266970				2022-12-17	WOS:A1997XQ11700010
J	Waridel, F; Estreicher, A; Bron, L; Flaman, JM; Fontolliet, C; Monnier, P; Frebourg, T; Iggo, R				Waridel, F; Estreicher, A; Bron, L; Flaman, JM; Fontolliet, C; Monnier, P; Frebourg, T; Iggo, R			Field cancerisation and polyclonal p53 mutation in the upper aerodigestive tract	ONCOGENE			English	Article						p53 functional assay; head and neck cancer; preneoplastic lesions	SQUAMOUS-CELL CARCINOMA; GENE-MUTATIONS; FUNCTIONAL ASSAY; NECK-CANCER; HEAD; DIAGNOSIS; TUMORS	Field cancerisation of the aerodigestive tract is caused by chronic exposure to alcohol and tobacco, but the nature of the genetic alterations preceding overt malignancy is unknown. To identify potential field changes we have used a functional assay which tests the transcriptional competence of human p53 expressed in yeast, To increase the sensitivity and reliability of the technique for samples containing under 20% mutant p53, the 5' and 3'-ends of the p53 cDNA were examined separately. With this split form of the assay the tissue p53 mRNA acts as its own control for RNA quality. Mutations were detected in 87% (46/53) of tumours, reflecting the high sensitivity of the technique, Multiple biopsies of histologically normal tissue from the upper aero-digestive tract were tested and clonal p53 mutations were identified in 76% (38/50) of biopsies from patients presenting with multiple tumours compared with 32% (38/117) of biopsies from patients presenting with single tumours (P<0.000001). AU patients (16/16) presenting with multiple tumours had at least one positive biopsy, compared with only 53% (19/36) of patients presenting with single tumours (P<0.001), This defines expansion of multiple clones of mutant p53-containing cells as an important biological mechanism of field cancerisation, and provides a means to identify patients likely to benefit from intensive screening for the development of new head and neck tumours.	SWISS INST EXPT CANC RES,ONCOGENE GRP,ISREC,CH-1066 EPALINGES,SWITZERLAND; CHU VAUDOIS,UNIV HOSP,SERV OTORHINOLARYNGOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,UNIV HOSP,PATHOL SERV,CH-1011 LAUSANNE,SWITZERLAND; CHU ROUEN,MOL GENET UNIT,F-76031 ROUEN,FRANCE	Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Rouen			Flaman, Jean-Michel/K-8415-2018; Frebourg, Thierry/AAK-8390-2020; Iggo, Richard/G-3546-2014	Flaman, Jean-Michel/0000-0003-3544-0199; Estreicher, Anne/0000-0001-6828-2508				BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; CHUNG KY, 1993, CANCER RES, V53, P1676; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; Flaman JM, 1996, ONCOGENE, V12, P813; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; MAO L, 1994, CANCER RES, V54, P1634; NEES M, 1993, CANCER RES, V53, P4189; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; SAVARY M, 1991, ADV OTO-RHINO-LARYNG, V46, P165; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306	18	148	150	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					163	169		10.1038/sj.onc.1200812	http://dx.doi.org/10.1038/sj.onc.1200812			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010218				2022-12-17	WOS:A1997WC81800004
J	LAI, C; GORE, M; LEMKE, G				LAI, C; GORE, M; LEMKE, G			STRUCTURE, EXPRESSION, AND ACTIVITY OF TYRO-3, A NEURAL ADHESION-RELATED RECEPTOR TYROSINE KINASE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; NERVOUS-SYSTEM; HIPPOCAMPAL-NEURONS; SIGNAL-TRANSDUCTION; SH3 DOMAINS; PROTEIN; BINDING; BRAIN; ENCODES	We have isolated mouse cDNA clones encoding Tyro 3, a receptor protein-tyrosine kinase (PTK) of the mammalin central nervous system (CNS). Expression of the Tyro 3 gene is strongly up-regulated in neurons of the mouse neocortex, cerebellum, and hippocampus after the day of birth, during periods of active synaptogenesis, and high expression is maintained in the adult CNS. The sequence of Tyro 3 cDNAs predicts a glycoprotein receptor with similarity to neural cell recognition and adhesion molecules - the extracellular (ligand binding) region of this receptor is composed of two immunoglobulin-related domains followed by two fibronectin type III repeats. Immunoblot and immunoprecipitation analyses with anti-Tyro 3 antibodies indicate that the 125 kD Tyro 3 protein is abundantly expressed in CNS synaptosomes, and immunohistochemical analysis of cultured hippocampal cells demonstrates that Tyro 3 is a product of neurons. Rat-2 fibroblasts stably transfected with a Tyro 3 expression construct acquire the ability to grow in soft agar, suggesting that Tyro 3 is potentially oncogenic.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Salk Institute; Scripps Research Institute; University of California System; University of California San Diego								AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BASLER K, 1988, CELL, V54, P299; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAI W, 1994, ONCOGENE, V9, P975; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HUNTER T, 1990, N HORIZ TH, P119; HUNTER T, 1993, FRONTIERS BIOL PROTE; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JIA R, 1992, VIROLOGY, V66, P5975; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOODY SA, 1989, J COMP NEUROL, V279, P567, DOI 10.1002/cne.902790406; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; O'Leary D D, 1992, Curr Opin Neurobiol, V2, P70, DOI 10.1016/0959-4388(92)90165-H; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; RESCIGNO J, 1991, ONCOGENE, V6, P1909; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; WILKIE T M, 1991, Methods (Orlando), V2, P32, DOI 10.1016/S1046-2023(05)80123-9; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	148	166	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2567	2578						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058320				2022-12-17	WOS:A1994PC05400016
J	ULLRICH, SJ; MERCER, WE; APPELLA, E				ULLRICH, SJ; MERCER, WE; APPELLA, E			HUMAN WILD-TYPE P53 ADOPTS A UNIQUE CONFORMATIONAL AND PHOSPHORYLATION STATE INVIVO DURING GROWTH ARREST OF GLIOBLASTOMA CELLS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; LARGE-T-ANTIGEN; MUTANT P53; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; SUPPRESSOR PROTEIN; TRANSFORMED-CELLS; CYCLE CONTROL; EXPRESSION; GENE	The wild-type (wt) human tumor-suppressor gene product, p53, and its mutant form have been analysed in an in vivo system in which the inducible expression of wt p53 results in growth arrest in the G1 phase of the cell cycle. Two major pools of p53 are detected after wt p53 expression by their differential reactivity with the p53 monoclonal antibodies PAb 421 and 1801 as well as the mutant and wt-specific monoclonal antibodies PAb 240 and 1620; one pool contains wt and mutant p53 and is characterized as having a mutant conformation, whereas the other pool contains only wt p53 with a wt conformation. As G1 arrest is entered, the amount of wt p53 associated with the mutant pool decreases, such that by 12 h free wt and mutant p53 are the - major pools. Two-dimensional gel analysis of the p53 pools revealed that free wt p53 is phosphorylated to a greater degree than mutant p53, which correlated with the loss of the PAb 421 epitope on wt p53. In summary, the ability of wt p53 to exert an antiproliferative effect correlates with the presence of a unique conformational state of wt p53 characterized by increased phosphorylation and the loss of both the PAb 421 epitope and association with mutant p53 pool, whereas mutant p53 is unable to assume this conformational state.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University	ULLRICH, SJ (corresponding author), NCI,CELL BIOL LAB,BLDG 37,RM 1B03,BETHESDA,MD 20892, USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINDLAY CA, 1989, CELL, V57, P1083; GANNON JV, 1990, EMBO J, V9, P1591; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, ONCOGENE, V6, P131; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1989, ONCOGENE, V4, P643; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PRASOLOV V S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1371; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHOHAT O, 1987, ONCOGENE, V1, P277; VANROY F, 1990, ONCOGENE, V5, P207; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	52	148	153	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1635	1643						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630823				2022-12-17	WOS:A1992JE81300021
J	JHIANG, SM; CARUSO, DR; GILMORE, E; ISHIZAKA, Y; TAHIRA, T; NAGAO, M; CHIU, IM; MAZZAFERRI, EL				JHIANG, SM; CARUSO, DR; GILMORE, E; ISHIZAKA, Y; TAHIRA, T; NAGAO, M; CHIU, IM; MAZZAFERRI, EL			DETECTION OF THE PTC RETTPC ONCOGENE IN HUMAN THYROID CANCERS	ONCOGENE			English	Article								We have investigated the PTC/ret(TPC) oncogene, an activated form of ret proto-oncogene with a specific rearrangement, in thyroid malignancies. Southern analysis was used to screen 36 thyroid papillary carcinomas (PC), 22 normal thyroid tissues from glands with PC elsewhere, three follicular carcinomas, eight follicular adenomas and 30 other non-malignant thyroids. Rearrangements were detected in four PCs (11%) using probes derived from the ret proto-oncogene. Genomic breakpoints from a PC and a PC cell line (TPC-1) were cloned and sequenced. The rearrangement points of ret proto-oncogene were found in the intron between the exon for the transmembrane domain and the first exon for the tyrosine kinase domain. Furthermore, the PTC/ret(TPC) chimeric transcripts were detected in two PCs with the rearrangement by reverse transcription polymerase chain reaction. Distant metastases were present in 50% (2/4) of PCs with the rearrangement, but in only two out of 32 PCs without a detectable rearrangement (P = 0.05, Fisher exact test). Our study suggests that the rearrangement of the ret proto-oncogene may be involved in the development of distant metastases in patients with papillary thyroid carcinomas. However, a larger clinical study will be required to verify this observation.	OHIO STATE UNIV, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; NATL CANC CTR, RES INST, DIV CARCINOGENESIS, CHUO KU, TOKYO 104, JAPAN; NATL CANC CTR, CTR COMPREHENS CANC, TOKYO 104, JAPAN	University System of Ohio; Ohio State University; National Cancer Center - Japan; National Cancer Center - Japan			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [CA01369, CA45611] Funding Source: Medline; NCRR NIH HHS [GCRC-RR-34] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BONGARZONE I, 1989, ONCOGENE, V4, P1457; Cox D.R., 1984, ANAL SURVIVAL DATA; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEITZ P, 1976, CANCER, V37, P2329, DOI 10.1002/1097-0142(197605)37:5<2329::AID-CNCR2820370523>3.0.CO;2-7; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; MAZZAFERRI EL, 1991, MAYO CLIN PROC, V66, P105, DOI 10.1016/S0025-6196(12)61179-3; MAZZAFERRI EL, 1987, SEMIN ONCOL, V14, P315; MAZZAFERRI EL, 1983, CLIN SURGERY INT, V6, P18; MAZZAFERRI EL, 1992, WERNER INGBARS THYRO, P1138; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; VENKATESH YSS, 1990, CANCER-AM CANCER SOC, V66, P321, DOI 10.1002/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A	25	148	152	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1331	1337						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620547				2022-12-17	WOS:A1992HZ97100011
J	BANKS, L; EDMONDS, C; VOUSDEN, KH				BANKS, L; EDMONDS, C; VOUSDEN, KH			ABILITY OF THE HPV16 E7 PROTEIN TO BIND RB AND INDUCE DNA-SYNTHESIS IS NOT SUFFICIENT FOR EFFICIENT TRANSFORMING ACTIVITY IN NIH3T3 CELLS	ONCOGENE			English	Article									ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND; INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY	Imperial College London; Ludwig Institute for Cancer Research; International Center for Genetic Engineering & Biotechnology (ICGEB)								ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2640; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1987, CANCER CELL, V5, P195; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SATO H, 1989, VIROLOGY, V170, P311, DOI 10.1016/0042-6822(89)90386-3; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TSUNOKAWA Y, 1986, P NATL ACAD SCI USA, V83, P2200, DOI 10.1073/pnas.83.7.2200; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; [No title captured]	37	148	154	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1383	1389						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216461				2022-12-17	WOS:A1990EC24100016
J	ALI, IU; MERLO, G; CALLAHAN, R; LIDEREAU, R				ALI, IU; MERLO, G; CALLAHAN, R; LIDEREAU, R			THE AMPLIFICATION UNIT ON CHROMOSOME-11Q13 IN AGGRESSIVE PRIMARY HUMAN-BREAST TUMORS ENTAILS THE BCL-1, INT-2 AND HST LOCI	ONCOGENE			English	Article									CTR RENE HUGUENIN,F-92211 ST CLOUD,FRANCE	Rene Huguenin Hospital	ALI, IU (corresponding author), NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892, USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1988, ONCOGENE RES, V3, P139; ALI IU, 1988, IN PRESS MOL DIAGNOS; ALI IU, 1988, BREAST CANCER CELLUL, P25; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BIGNER SH, 1987, CANCER GENET CYTOGEN, V29, P165, DOI 10.1016/0165-4608(87)90045-8; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRESLOW JL, 1982, P NATL ACAD SCI-BIOL, V79, P6861, DOI 10.1073/pnas.79.22.6861; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COLLINS SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4813, DOI 10.1073/pnas.80.15.4813; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; DALLAFAVERA R, 1982, NATURE, V299, P61; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON C, 1987, NATURE, V326, P823; EMANUEL BS, 1985, P NATL ACAD SCI USA, V82, P3736, DOI 10.1073/pnas.82.11.3736; GAZDAR AF, 1985, CANCER RES, V45, P2924; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; KARATHANASIS SK, 1983, NATURE, V304, P371, DOI 10.1038/304371a0; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KOZBOR D, 1984, CANCER RES, V44, P438; LAW ML, 1987, P NATL ACAD SCI USA, V84, P2877, DOI 10.1073/pnas.84.9.2877; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LIDEREAU R, 1986, J NATL CAN I, V77, P687; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RABBITTS PH, 1988, ONCOGENE, V3, P99; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHELDON JR, 1983, P NATL ACAD SCI USA, V80, P7289; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDENELSEN P, 1984, NATURE, V312, P413, DOI 10.1038/312413a0; WILLIAMS B, 1987, HUMAN GENE MAPPING, V9, pA731; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305	44	148	148	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					89	92						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915903				2022-12-17	WOS:A1989U567400013
J	Pennington, KL; Chan, TY; Torres, MP; Andersen, JL				Pennington, K. L.; Chan, T. Y.; Torres, M. P.; Andersen, J. L.			The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions	ONCOGENE			English	Review							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CAMKII-MEDIATED PHOSPHORYLATION; SMALL-MOLECULE MODULATORS; DNA-DAMAGE CHECKPOINT; CANCER-CELL-SURVIVAL; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; LUNG-CANCER; IN-VIVO; STRUCTURAL-ANALYSIS	14-3-3 proteins are a family of structurally similar phospho-binding proteins that regulate essentially every major cellular function. Decades of research on 14-3-3s have revealed a remarkable network of interacting proteins that demonstrate how 14-3-3s integrate and control multiple signaling pathways. In particular, these interactions place 14-3-3 at the center of the signaling hub that governs critical processes in cancer, including apoptosis, cell cycle progression, autophagy, glucose metabolism, and cell motility. Historically, the majority of 14-3-3 interactions have been identified and studied under nutrient-replete cell culture conditions, which has revealed important nutrient driven interactions. However, this underestimates the reach of 14-3-3s. Indeed, the loss of nutrients, growth factors, or changes in other environmental conditions (e.g., genotoxic stress) will not only lead to the loss of homeostatic 14-3-3 interactions, but also trigger new interactions, many of which are likely stress adaptive. This dynamic nature of the 14-3-3 interactome is beginning to come into focus as advancements in mass spectrometry are helping to probe deeper and identify context-dependent 14-3-3 interactions-providing a window into adaptive phosphorylation-driven cellular mechanisms that orchestrate the tumor cell's response to a variety of environmental conditions including hypoxia and chemotherapy. In this review, we discuss emerging 14-3-3 regulatory mechanisms with a focus on post-translational regulation of 14-3-3 and dynamic protein-protein interactions that illustrate 14-3-3's role as a stress-adaptive signaling hub in cancer.	[Pennington, K. L.; Chan, T. Y.; Andersen, J. L.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; [Torres, M. P.] Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA	Brigham Young University; University System of Georgia; Georgia Institute of Technology	Andersen, JL (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.	jandersen@chem.byu.edu	Chan, Tsz Yin/ABG-4045-2021	Pennington, Katie/0000-0003-2883-0025; Torres, Matthew/0000-0001-7296-4536	National Institutes of Health [R15CA202619, R01GM117400]; Fritz B. Burns Foundation; Elsa U. Pardee Foundation; NATIONAL CANCER INSTITUTE [R15CA202618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM117400] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fritz B. Burns Foundation; Elsa U. Pardee Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grants to JLA (R15CA202619) and MPT (R01GM117400), as well as research support from the Fritz B. Burns Foundation and Elsa U. Pardee Foundation to JLA.	Acevedo SF, 2007, GENETICS, V177, P239, DOI 10.1534/genetics.107.072280; Aeluri M, 2014, CHEM REV, V114, P4640, DOI 10.1021/cr4004049; Aghazadeh Y, 2016, DRUG DISCOV TODAY, V21, P278, DOI 10.1016/j.drudis.2015.09.012; Aghazadeh Y, 2014, J BIOL CHEM, V289, P26542, DOI 10.1074/jbc.M114.569079; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; Aitken A, 2011, SEMIN CELL DEV BIOL, V22, P673, DOI 10.1016/j.semcdb.2011.08.003; An SS, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-8; Andersen JL, 2011, MOL CELL, V43, P834, DOI 10.1016/j.molcel.2011.07.028; Andersen SD, 2012, DNA REPAIR, V11, P267, DOI 10.1016/j.dnarep.2011.11.007; Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894; Banks CJ, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00354-17; Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Cao WD, 2010, APOPTOSIS, V15, P230, DOI 10.1007/s10495-009-0437-4; Chatterjee D, 2004, INT J ONCOL, V25, P503; Chen CM, 2017, METHODS MOL BIOL, V1558, P3, DOI 10.1007/978-1-4939-6783-4_1; Chen QL, 2017, DIABETOLOGIA, V60, P336, DOI 10.1007/s00125-016-4151-9; Chen QL, 2014, CELL SIGNAL, V26, P1636, DOI 10.1016/j.cellsig.2014.04.012; Chen S, 2011, TRENDS ENDOCRIN MET, V22, P429, DOI 10.1016/j.tem.2011.07.005; Chen XQ, 2015, J BIOL CHEM, V290, P12300, DOI 10.1074/jbc.M115.644005; Chen YJ, 2015, NUCLEIC ACIDS RES, V43, pD503, DOI 10.1093/nar/gku1176; Cheruiyot A, 2015, DNA REPAIR, V35, P106, DOI 10.1016/j.dnarep.2015.09.021; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chuthapisith S, 2007, INT J ONCOL, V30, P1545; Cockrell LM, 2010, ONCOGENE, V29, P822, DOI 10.1038/onc.2009.382; Collins BC, 2013, NAT METHODS, V10, P1246, DOI [10.1038/NMETH.2703, 10.1038/nmeth.2703]; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Corradi V, 2011, BIOORG MED CHEM LETT, V21, P6867, DOI 10.1016/j.bmcl.2011.09.011; Corradi V, 2010, BIOORG MED CHEM LETT, V20, P6133, DOI 10.1016/j.bmcl.2010.08.019; Dalal SN, 2004, CELL CYCLE, V3, P672; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dewhurst HM, 2015, MOL CELL PROTEOMICS, V14, P2285, DOI 10.1074/mcp.M115.051177; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Dikiy A, 2007, BIOCHEMISTRY-US, V46, P6871, DOI 10.1021/bi602462q; Dong S, 2008, LEUKEMIA, V22, P572, DOI 10.1038/sj.leu.2405064; Du YH, 2006, J BIOMOL SCREEN, V11, P269, DOI 10.1177/1087057105284862; Dubois F, 2009, MOL CELL PROTEOMICS, V8, P2487, DOI 10.1074/mcp.M800544-MCP200; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Eischen CM, 2017, J MOL CELL BIOL, V9, P69, DOI 10.1093/jmcb/mjw052; Ellis JJ, 2003, MOL CELL BIOCHEM, V242, P153, DOI 10.1023/A:1021158216582; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Favier FB, 2010, AM J PHYSIOL-REG I, V298, pR1659, DOI 10.1152/ajpregu.00550.2009; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007; Gardino AK, 2011, SEMIN CELL DEV BIOL, V22, P688, DOI 10.1016/j.semcdb.2011.09.008; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Gill JG, 2016, COLD SH Q B, V81, P163, DOI 10.1101/sqb.2016.81.030791; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Gu Y, 2018, LEUKEMIA, V32, P744, DOI 10.1038/leu.2017.288; Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hartman AM, 2017, EUR J MED CHEM, V136, P573, DOI 10.1016/j.ejmech.2017.04.058; He GF, 2014, MOL CELL BIOL, V34, P148, DOI 10.1128/MCB.00670-13; Holman GD, 2008, CELL METAB, V8, P344, DOI 10.1016/j.cmet.2008.10.006; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Jeon YH, 2016, BBA-MOL CELL RES, V1863, P10, DOI 10.1016/j.bbamcr.2015.10.006; Jeon YH, 2013, BBA-MOL CELL RES, V1833, P2135, DOI 10.1016/j.bbamcr.2013.05.005; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; Johnson C, 2010, BIOCHEM J, V427, P69, DOI 10.1042/BJ20091834; Joshi S, 2017, AM J CANCER RES, V7, P1654; Kanno T, 2011, J CELL PHYSIOL, V226, P2329, DOI 10.1002/jcp.22571; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Knetsch MLW, 1997, BBA-MOL CELL RES, V1357, P243, DOI 10.1016/S0167-4889(97)00060-8; Kobayashi H, 2011, J BIOL CHEM, V286, P39259, DOI 10.1074/jbc.M111.255489; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lalle M, 2006, J BIOL CHEM, V281, P5137, DOI 10.1074/jbc.M509673200; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Lee JH, 2012, J BIOL CHEM, V287, P20898, DOI 10.1074/jbc.M111.336875; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Li C, 2017, J BIOL CHEM, V292, P16746, DOI 10.1074/jbc.M117.803338; Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Lienhard GE, 2008, TRENDS BIOCHEM SCI, V33, P351, DOI 10.1016/j.tibs.2008.05.004; Lin MT, 2009, INT J CANCER, V125, P603, DOI 10.1002/ijc.24346; Liou JY, 2007, CANCER RES, V67, P3185, DOI 10.1158/0008-5472.CAN-06-3431; Litzenburger BC, 2011, CLIN CANCER RES, V17, P2314, DOI 10.1158/1078-0432.CCR-10-1903; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Logsdon CD, 2003, CANCER RES, V63, P2649; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Ma YF, 2005, J BIOL CHEM, V280, P26011, DOI 10.1074/jbc.M409081200; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Margolis SS, 2006, MOL BIOL CELL, V17, P1779, DOI 10.1091/mbc.E05-08-0751; Margolis SS, 2003, EMBO J, V22, P5734, DOI 10.1093/emboj/cdg545; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Matta A, 2012, EXPERT OPIN THER TAR, V16, P515, DOI 10.1517/14728222.2012.668185; Maxwell SA, 2009, J BIOL CHEM, V284, P22379, DOI 10.1074/jbc.M109.022418; Merkel O, 2017, MUTAT RES-REV MUTAT, V773, P1, DOI 10.1016/j.mrrev.2017.02.003; Milton AH, 2006, EMBO J, V25, P1046, DOI 10.1038/sj.emboj.7600999; Molzan M, 2012, J MOL BIOL, V423, P486, DOI 10.1016/j.jmb.2012.08.009; Mori M, 2014, CHEMMEDCHEM, V9, P973, DOI 10.1002/cmdc.201400044; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Mortenson JB, 2015, J BIOL CHEM, V290, P12487, DOI 10.1074/jbc.M114.607580; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Neal CL, 2012, ONCOGENE, V31, P897, DOI 10.1038/onc.2011.284; Neal CL, 2010, EXPERT OPIN THER TAR, V14, P1343, DOI 10.1517/14728222.2010.531011; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Neukamm SS, 2013, J BIOL CHEM, V288, P16403, DOI 10.1074/jbc.M113.474593; Neupane D, 2008, CLIN CANCER RES, V14, P7614, DOI 10.1158/1078-0432.CCR-08-1366; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Noguchi T, 2005, J BIOL CHEM, V280, P37033, DOI 10.1074/jbc.M506771200; Nutt LK, 2009, DEV CELL, V16, P856, DOI 10.1016/j.devcel.2009.04.005; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Ottmann C, 2007, MOL CELL, V25, P427, DOI 10.1016/j.molcel.2006.12.017; Ottmann C, 2007, EMBO J, V26, P902, DOI 10.1038/sj.emboj.7601530; Ottmann C, 2013, BIOORGAN MED CHEM, V21, P4058, DOI 10.1016/j.bmc.2012.11.028; Papa L, 2014, J BIOL CHEM, V289, P5412, DOI 10.1074/jbc.C113.526475; Paul AL, 2005, MOL BIOL CELL, V16, P1735, DOI 10.1091/mbc.E04-09-0839; Pehmoller C, 2009, AM J PHYSIOL-ENDOC M, V297, pE665, DOI 10.1152/ajpendo.00115.2009; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pereg Y, 2006, MOL CELL BIOL, V26, P6819, DOI 10.1128/MCB.00562-06; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Petrvalska O, 2016, J BIOL CHEM, V291, P20753, DOI 10.1074/jbc.M116.724310; Pieri BLS, 2014, HORM METAB RES, V46, P621, DOI 10.1055/s-0034-1371824; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Puckett MC, 2013, MOL CELL BIOL, V33, P2252, DOI 10.1128/MCB.00047-13; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Rehman SK, 2014, CANCER RES, V74, P363, DOI 10.1158/0008-5472.CAN-13-2016; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schoenwaelder SM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12862; Seong HA, 2010, J BIOL CHEM, V285, P2397, DOI 10.1074/jbc.M109.064295; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Slone SR, 2015, NEUROBIOL DIS, V79, P1, DOI 10.1016/j.nbd.2015.02.032; Sluchanko NN, 2008, ARCH BIOCHEM BIOPHYS, V477, P305, DOI 10.1016/j.abb.2008.05.020; Sluchanko NN, 2017, STRUCTURE, V25, P305, DOI 10.1016/j.str.2016.12.005; Sluchanko NN, 2012, BIOCHEMISTRY-US, V51, P6127, DOI 10.1021/bi300674e; Sluchanko NN, 2011, ARCH BIOCHEM BIOPHYS, V506, P24, DOI 10.1016/j.abb.2010.11.003; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Suzuki H, 2000, CANCER RES, V60, P4353; Takeda K, 2013, GENES CELLS, V18, P369, DOI 10.1111/gtc.12043; Tang SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055268; Tang YF, 2016, ONCOTARGET, V7, P15854, DOI 10.18632/oncotarget.7493; Tang YF, 2015, INT J CLIN EXP PATHO, V8, P15845; Tarrado-Castellarnau M, 2016, ONCOTARGET, V7, P62726, DOI 10.18632/oncotarget.10911; Teo Z, 2017, ONCOGENE, V36, P6408, DOI 10.1038/onc.2017.244; Testerink C, 1999, PLANT PHYSIOL, V121, P81, DOI 10.1104/pp.121.1.81; Thiel P, 2013, CHEM COMMUN, V49, P8468, DOI 10.1039/c3cc44612c; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Torres MP, 2016, MOL CELL PROTEOMICS, V15, P3513, DOI 10.1074/mcp.M116.062331; Truong AB, 2002, PROTEINS, V49, P321, DOI 10.1002/prot.10210; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Tzivion G, 2000, J BIOL CHEM, V275, P29772, DOI 10.1074/jbc.M001207200; van Hemert MJ, 2004, J CELL SCI, V117, P1411, DOI 10.1242/jcs.00990; Vega-Rubin-de-Celis S, 2010, BIOCHEMISTRY-US, V49, P2491, DOI 10.1021/bi902135e; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weerasekara VK, 2014, MOL CELL BIOL, V34, P4379, DOI 10.1128/MCB.00740-14; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Woodcock JM, 2010, CELL SIGNAL, V22, P1291, DOI 10.1016/j.cellsig.2010.04.004; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yan YM, 2012, BIOORG MED CHEM LETT, V22, P4179, DOI 10.1016/j.bmcl.2012.04.027; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yang X, 2012, CANCER GENE THER, V19, P153, DOI 10.1038/cgt.2011.85; Yang XL, 2011, NEUROSURGERY, V68, P932, DOI 10.1227/NEU.0b013e3182098c30; Yip MF, 2008, CELL METAB, V8, P384, DOI 10.1016/j.cmet.2008.09.011; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhao J, 2011, SEMIN CELL DEV BIOL, V22, P705, DOI 10.1016/j.semcdb.2011.09.012; Zhao J, 2011, P NATL ACAD SCI USA, V108, P16212, DOI 10.1073/pnas.1100012108; Zhao T, 2014, SCI REP-UK, V4, DOI 10.1038/srep03793; Zhou JB, 2009, MOL CELL BIOL, V29, P4167, DOI 10.1128/MCB.01067-08; Zhou X, 2017, J MOL CELL BIOL, V9, P62, DOI 10.1093/jmcb/mjx001; Zuo SA, 2010, J PROTEOME RES, V9, P3465, DOI 10.1021/pr9011377	197	147	148	5	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5587	5604		10.1038/s41388-018-0348-3	http://dx.doi.org/10.1038/s41388-018-0348-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29915393	hybrid, Green Published			2022-12-17	WOS:000447619100001
J	Chau, WK; Ip, CK; Mak, ASC; Lai, HC; Wong, AST				Chau, W. K.; Ip, C. K.; Mak, A. S. C.; Lai, H-C; Wong, A. S. T.			c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling	ONCOGENE			English	Article						c-Kit; ovarian cancer; chemoresistance; beta-catenin; ABCG2	BETA-CATENIN; EPITHELIAL OVARIAN; IMATINIB MESYLATE; CLINICOPATHOLOGICAL FEATURES; GENE-EXPRESSION; STEM-CELLS; CARCINOMA; RESISTANCE; RECURRENT; BIOLOGY	Cisplatin and paclitaxel are standard chemotherapy for metastatic ovarian cancer, but with limited efficacy. Cancer stem/progenitor cells (or tumor-initiating cells, TICs) are hypothesized to be chemoresistant, and the existence of TICs in ovarian cancer has been previously demonstrated. However, the key signals and molecular events regulating the formation and expansion of ovarian tumor-initiating cells (OTICs) remain elusive. Here, we show that c-Kit is not just a marker of OTICs, but also a critical mediator of the phenotype that can be a viable target for the treatment of ovarian cancer. In contrast to non-OICs, c-Kit was overexpressed in OTICs. Moreover, the use of small interfering RNA to inhibit c-Kit expression markedly attenuated the number and size of OTIC subpopulations, inhibited the expression of stem cell markers and decreased the tumorigenic capabilities of OTICs. Imatinib (Gleevec), a clinical drug that blocks c-Kit kinase activity, also demonstrated its inhibition potency on OTICs. In addition, cisplatin/paclitaxel, which killed non-OTICs, with c-Kit knockdown or imatinib revealed that this was critically required for intervening ovarian cancer progression and recurrence in vitro and in xenograft tumors in vivo. Similar results were obtained with OTICs derived from ovarian carcinoma patients. Studies into the mechanisms suggest an important role for the activation of Wnt/beta-catenin and ATP-binding cassette G2 downstream of c-Kit. The tumor-promoting microenvironment, such as hypoxia, could promote OTICs via upregulation of c-Kit expression. These results unravel an integral role for c-Kit in ovarian neoplastic processes and shed light on its mechanisms of action.	[Chau, W. K.; Ip, C. K.; Mak, A. S. C.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Lai, H-C] Natl Def Med Ctr, Triserv Gen Hosp, Dept Obstet & Gynecol, Taipei, Taiwan	University of Hong Kong; National Defense Medical Center; Tri-Service General Hospital	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475; Ip, Carman K.M./0000-0002-6672-5982	National Health Research Institute of Taiwan [NHRI-EX100-9717NC]; HKU Strategic Research Theme Fund on Cancer, CRCG [201109176078, CUHK8/CRF/11R]; Croucher Senior Research Fellowship	National Health Research Institute of Taiwan(National Health Research Institutes - Taiwan); HKU Strategic Research Theme Fund on Cancer, CRCG; Croucher Senior Research Fellowship	This study was supported by the National Health Research Institute of Taiwan (NHRI-EX100-9717NC) to H-C Lai, and by HKU Strategic Research Theme Fund on Cancer, CRCG (201109176078), CUHK8/CRF/11R, and Croucher Senior Research Fellowship to AST Wong.	Alberts DS, 2007, INT J GYNECOL CANCER, V17, P784, DOI 10.1111/j.1525-1438.2007.00882.x; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Birner P, 2001, CLIN CANCER RES, V7, P1661; BROUDY VC, 1994, BLOOD, V83, P2145; Brustmann H, 2005, GYNECOL ONCOL, V98, P396, DOI 10.1016/j.ygyno.2005.04.035; Cheon S, 2005, LAB INVEST, V85, P416, DOI 10.1038/labinvest.3700237; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Coleman RL, 2006, GYNECOL ONCOL, V101, P126, DOI 10.1016/j.ygyno.2005.09.041; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; HEINRICH MC, 1993, BLOOD, V82, P771, DOI 10.1182/blood.V82.3.771.bloodjournal823771; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Johnson SW, 1997, CANCER RES, V57, P850; Karlsson MO, 1999, DRUG METAB DISPOS, V27, P1220; Kildal W, 2005, EUR J CANCER, V41, P1127, DOI 10.1016/j.ejca.2005.01.022; Lee CM, 2003, GYNECOL ONCOL, V88, P363, DOI 10.1016/S0090-8258(02)00015-X; Luo LJ, 2011, EXP MOL PATHOL, V91, P596, DOI 10.1016/j.yexmp.2011.06.005; Matei D, 2008, CANCER-AM CANCER SOC, V113, P723, DOI 10.1002/cncr.23605; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Mundhenke C, 2008, J CANCER RES CLIN, V134, P1397, DOI 10.1007/s00432-008-0408-0; MUTCH DG, 1994, CLIN OBSTET GYNECOL, V37, P406, DOI 10.1097/00003081-199406000-00017; Nakayama K, 2002, CANCER LETT, V176, P215, DOI 10.1016/S0304-3835(01)00762-5; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; Pon YL, 2006, MOL ENDOCRINOL, V20, P3336, DOI 10.1210/me.2006-0125; Posadas EM, 2007, CANCER-AM CANCER SOC, V110, P309, DOI 10.1002/cncr.22757; Raspollini AR, 2004, ANN ONCOL, V15, P594, DOI 10.1093/annonc/mdh139; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roberts KG, 2007, MOL CANCER THER, V6, P1159, DOI 10.1158/1535-7163.MCT-06-0641; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Schilder RJ, 2008, J CLIN ONCOL, V26, P3418, DOI 10.1200/JCO.2007.14.3420; Schmandt RE, 2003, CANCER-AM CANCER SOC, V98, P758, DOI 10.1002/cncr.11561; Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950; Shaw TJ, 2007, GYNECOL ONCOL, V105, P122, DOI 10.1016/j.ygyno.2006.10.052; Shield K, 2009, GYNECOL ONCOL, V113, P143, DOI 10.1016/j.ygyno.2008.11.032; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG GL, 1993, BLOOD, V82, P3610; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Zajchowski DA, 2012, MOL CANCER THER, V11, P492, DOI 10.1158/1535-7163.MCT-11-0746; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	50	147	150	1	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2767	2781		10.1038/onc.2012.290	http://dx.doi.org/10.1038/onc.2012.290			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797058				2022-12-17	WOS:000319808000008
J	Long, JS; Ryan, KM				Long, J. S.; Ryan, K. M.			New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy	ONCOGENE			English	Review						cancer; apoptosis; necroptosis; autophagy; therapy	RECEPTOR-INTERACTING PROTEIN; NF-KAPPA-B; CASPASE-MEDIATED CLEAVAGE; BCL-2 FAMILY PROTEINS; C-MYC; PROGRAMMED NECROSIS; CD95 APO-1/FAS; SUPPRESSES TUMORIGENESIS; FRAMESHIFT MUTATIONS; REGULATES AUTOPHAGY	Cancer is a multifaceted disease comprising a combination of genetic, metabolic and signalling aberrations, which severely disrupt the normal homeostasis of cell growth and death. Many oncogenic events while promoting tumour development also increase the sensitivity of cells to cell death stimuli including chemotherapeutic drugs. As a result, tumour cells often acquire the ability to evade death by inactivating cell death pathways that normally function to eliminate damaged and harmful cells. The impairment of cell death function is also often the reason for the development of chemotherapeutic resistance encountered during treatment. It is therefore necessary to achieve a comprehensive understanding of existing cell death pathways and the relevant regulatory components involved, with the intention of identifying new strategies to kill cancer cells. This review provides an insightful overview of the common forms of cell death signalling pathways, the interactions between these pathways and the ways in which these pathways are deregulated in cancer. We also discuss the emerging therapies targeted at activating or restoring cell death pathways to induce tumour cell death, which are currently being tested in clinical trials. Oncogene (2012) 31, 5045-5060; doi: 10.1038/onc.2012.7; published online 6 February 2012	[Long, J. S.; Ryan, K. M.] Beatson Inst Canc Res, Tumour Cell Death Lab, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Ryan, KM (corresponding author), Beatson Inst Canc Res, Tumour Cell Death Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.ryan@beatson.gla.ac.uk		Ryan, Kevin M./0000-0002-1059-9681	Cancer Research UK; Association for International Cancer Research; Cancer Research UK [15816] Funding Source: researchfish; Worldwide Cancer Research [09-0170] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	We apologise to researchers whose studies we were unable to cite due to the length of this review. We thank the members of the Tumour Cell Death Laboratory for critical reading of the manuscript. Work in the Tumour Cell Death Laboratory is supported by Cancer Research UK and the Association for International Cancer Research.	Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Artal-Sanz M, 2006, J CELL BIOL, V173, P231, DOI 10.1083/jcb.200511103; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bianchi K, 2009, MOL CELL, V36, P736, DOI 10.1016/j.molcel.2009.11.029; Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310; Briceno E, 2007, SURG NEUROL, V67, P388, DOI 10.1016/j.surneu.2006.08.080; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Ch'en IL, 2011, J EXP MED, V208, P633, DOI 10.1084/jem.20110251; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chen DJ, 2009, ANTI-CANCER DRUG, V20, P646, DOI 10.1097/CAD.0b013e32832ced78; Cheung WC, 2004, J CLIN INVEST, V113, P1763, DOI 10.1172/JCI200420369; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Cho DH, 2009, CANCER LETT, V274, P95, DOI 10.1016/j.canlet.2008.09.004; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432; DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eguchi Y, 1997, CANCER RES, V57, P1835; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fecker LF, 2006, J INVEST DERMATOL, V126, P1366, DOI 10.1038/sj.jid.5700192; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gdynia G, 2007, MOL CANCER RES, V5, P1232, DOI 10.1158/1541-7786.MCR-07-0343; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greenhalgh DG, 1998, INT J BIOCHEM CELL B, V30, P1019, DOI 10.1016/S1357-2725(98)00058-2; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x; Helgason GV, 2011, BLOOD, V118, P2035, DOI 10.1182/blood-2011-01-330621; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetschko H, 2008, FEBS J, V275, P1925, DOI 10.1111/j.1742-4658.2008.06351.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020; Koneri K, 2007, ANTICANCER RES, V27, P1453; Koschny R, 2007, CLIN CANCER RES, V13, P3403, DOI 10.1158/1078-0432.CCR-07-0251; Kosta A, 2004, J BIOL CHEM, V279, P48404, DOI 10.1074/jbc.M408924200; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li G, 1998, BRIT J DERMATOL, V139, P3; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V270, pF700, DOI 10.1152/ajprenal.1996.270.4.F700; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Mayer B, 2003, NEWS PHYSIOL SCI, V18, P89, DOI 10.1152/nips.01433.2002; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; McKenzie S, 2006, J CELL BIOCHEM, V97, P18, DOI 10.1002/jcb.20634; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miracco C, 2007, INT J ONCOL, V30, P429; Miura M, 2011, DEV GROWTH DIFFER, V53, P125, DOI 10.1111/j.1440-169X.2010.01228.x; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NOVIKOFF AB, 1964, FED PROC, V23, P1010; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Odonkor Charles Amoatey, 2008, Open Biochem J, V2, P121, DOI 10.2174/1874091X00802010121; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pavet V, 2011, ONCOGENE, V30, P1, DOI 10.1038/onc.2010.460; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031; Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, DEV CELL, V2, P256, DOI 10.1016/S1534-5807(02)00137-5; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 1999, J PATHOL, V187, P127; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X; Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shiraishi H, 2010, BBA-GEN SUBJECTS, V1800, P405, DOI 10.1016/j.bbagen.2009.11.008; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Solary E, 1996, EUR RESPIR J, V9, P1293, DOI 10.1183/09031936.96.09061293; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Thornborrow EC, 2002, ONCOGENE, V21, P990, DOI 10.1038/sj.onc.1205069; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Wu YT, 2011, CELL DEATH DIFFER, V18, P26, DOI 10.1038/cdd.2010.72; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang YH, 2005, BIOCHEM BIOPH RES CO, V332, P181, DOI 10.1016/j.bbrc.2005.04.114; Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng H, 2010, CANCER BIOTHER RADIO, V25, P705, DOI 10.1089/cbr.2010.0786; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	176	147	151	0	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5045	5060		10.1038/onc.2012.7	http://dx.doi.org/10.1038/onc.2012.7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22310284				2022-12-17	WOS:000312000900001
J	Luker, KE; Lewin, SA; Mihalko, LA; Schmidt, BT; Winkler, JS; Coggins, NL; Thomas, DG; Luker, GD				Luker, K. E.; Lewin, S. A.; Mihalko, L. A.; Schmidt, B. T.; Winkler, J. S.; Coggins, N. L.; Thomas, D. G.; Luker, G. D.			Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells	ONCOGENE			English	Article						chemokines; luciferase; bioluminescence; breast cancer; chemokine receptor	CHEMOKINE RECEPTOR CXCR4; IN-VIVO; ENDOTHELIAL-CELLS; DENDRITIC CELLS; PROSTATE-CANCER; EXPRESSION; MIGRATION; LUCIFERASE; FACTOR-1-ALPHA; INVOLVEMENT	Chemokine CXCL12 and receptor CXCR4 control multiple steps in primary tumor growth and metastasis in breast cancer and more than 20 other human malignancies. Mechanisms that regulate availability of CXCL12 in tumor microenvironments will substantially impact cancer progression and ongoing efforts to target the CXCL12-CXCR4 pathway for cancer chemotherapy. We used dual luciferase imaging to investigate CXCR7-dependent scavenging of CXCL12 in breast tumors in vivo and quantify effects of CXCR7 on tumor growth and metastasis of a separate population of CXCR4+ breast cancer cells. In a mouse xenograft model of human breast cancer, in vivo imaging showed that malignant cells expressing CXCR7 reduced bioluminescent CXCL12 secreted in the primary tumor microenvironment. Capitalizing on sensitive detection of bioluminescent CXCL12, we also demonstrated that CXCR7+ cells reduced amounts of chemokine released from orthotopic tumors into the circulation. Immunofluorescence staining of human primary breast cancers showed expression of CXCR4 and CXCR7 on malignant cells in approximate to 30% of cases. In most cases, CXCR4 and CXCR7 predominantly were expressed on separate populations of malignant cells in a tumor. We modeled these cases of human breast cancer by co-implanting tumor xenografts with CXCR4+ breast cancer cells, human mammary fibroblasts secreting CXCL12, and CXCR7+ or control breast cancer cells. Bioluminescence imaging showed that CXCR7+ breast cancer cells enhanced proliferation of CXCR4+ breast cancer cells in orthotopic tumors and spontaneous metastases. Treatment with a small-molecule inhibitor of CXCR7 chemokine limited the growth of CXCR4+ breast cancer cells in tumors that also contained malignant CXCR7+ cells. These studies establish a new in vivo imaging method to quantify chemokine scavenging by CXCR7 in the tumor microenvironment and identify that CXCR7+ cells promote growth and metastasis of CXCR4+ breast cancer cells.	[Luker, K. E.; Lewin, S. A.; Mihalko, L. A.; Schmidt, B. T.; Winkler, J. S.; Coggins, N. L.; Luker, G. D.] Univ Michigan, Sch Med, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA; [Thomas, D. G.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Luker, G. D.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Sch Med, Ctr Mol Imaging, Dept Radiol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu		luker, gary/0000-0001-6832-2581; Schmidt, Bradley/0000-0002-4011-4630	NIH [R01CA136553, R01CA136829, P50CA093990, R24CA083099]; Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE [R01CA136829, R24CA083099, P50CA093990, R01CA136553] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research was supported by NIH grantsR01CA136553, R01CA136829, P50CA093990 and R24CA083099. Support also was provided by Fashion Footwear Association of New York (FFANY)/QVC presents Shoes on Sale. We thank ChemoCentryx for small-molecule inhibitors of CXCR7 and antibody 11G8.	Akashi T, 2008, CANCER SCI, V99, P539, DOI 10.1111/j.1349-7006.2007.00712.x; Albright CF, 2005, MOL CANCER THER, V4, P751, DOI 10.1158/1535-7163.MCT-05-0006; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; Chu QYD, 2010, J SURG RES, V159, P689, DOI 10.1016/j.jss.2008.09.020; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Hattermann K, 2010, CANCER RES, V70, P3299, DOI 10.1158/0008-5472.CAN-09-3642; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Konoplev S, 2011, CANCER-AM CANCER SOC, V117, P4689, DOI 10.1002/cncr.26113; Lee BC, 2004, MOL CANCER RES, V2, P327; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luker KE, 2010, ONCOGENE, V29, P4599, DOI 10.1038/onc.2010.212; Luker KE, 2009, BIOTECHNIQUES, V47, P625, DOI 10.2144/000113126; Luker KE, 2009, FASEB J, V23, P823, DOI 10.1096/fj.08-116749; Meng H, 2011, CLIN CANCER RES, V17, P2426, DOI 10.1158/1078-0432.CCR-10-2385; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756; Takano S, 2010, J ONCOL, V2010, DOI 10.1155/2010/351908; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Torisawa YS, 2010, INTEGR BIOL-UK, V2, P680, DOI 10.1039/c0ib00041h; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Wang YL, 2011, NEURON, V69, P61, DOI 10.1016/j.neuron.2010.12.005; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI 10.1038/NMETH.1177; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	38	147	153	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4750	4758		10.1038/onc.2011.633	http://dx.doi.org/10.1038/onc.2011.633			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266857	Green Accepted			2022-12-17	WOS:000311033000003
J	Weigelt, B; Warne, PH; Downward, J				Weigelt, B.; Warne, P. H.; Downward, J.			PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs	ONCOGENE			English	Article						PIK3CA; PTEN; mTOR; everolimus; PP242; breast cancer	DUAL PI3K/MTOR INHIBITOR; MAMMALIAN PROTEIN; HIGH-FREQUENCY; PHASE-II; PATHWAY; PI3K; GENE; KINASE; GROWTH; TEMSIROLIMUS	The phosphatidylinositol 3-kinase (PI3K) pathway is commonly activated in breast cancers due to frequent mutations in PIK3CA, loss of expression of PTEN or over-expression of receptor tyrosine kinases. PI3K pathway activation leads to stimulation of the key growth and proliferation regulatory kinase mammalian target of rapamycin (mTOR), which can be inhibited by rapamycin analogues and by kinase inhibitors; the effectiveness of these drugs in breast cancer treatment is currently being tested in clinical trials. To identify the molecular determinants of response to inhibitors that target mTOR via different mechanisms in breast cancer cells, we investigated the effects of pharmacological inhibition of mTOR using the allosteric mTORC1 inhibitor everolimus and the active-site mTORC1/mTORC2 kinase inhibitor PP242 on a panel of 31 breast cancer cell lines. We demonstrate here that breast cancer cells harbouring PIK3CA mutations are selectively sensitive to mTOR allosteric and kinase inhibitors. However, cells with PTEN loss of function are not sensitive to these drugs, suggesting that the functional consequences of these two mechanisms of activation of the mTOR pathway are quite distinct. In addition, a subset of HER2-amplified cell lines showed increased sensitivity to PP242, but not to everolimus, irrespective of the PIK3CA/PTEN status. These selective sensitivities were confirmed in more physiologically relevant three-dimensional cell culture models. Our findings provide a rationale to guide selection of breast cancer patients who may benefit from mTOR inhibitor therapy and highlight the importance of accurately assessing the expression of PTEN protein and not just its mutational status. Oncogene (2011) 30, 3222-3233; doi:10.1038/onc.2011.42; published online 28 February 2011	[Weigelt, B.; Warne, P. H.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	julian.downward@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Miriam Molina Arcas, Ralph Fritsch, Elza de Bruin, Charles Swanton (CRUK London Research Institute) and Maryou Lambros and Jorge Reis-Filho (Breakthrough Breast Cancer Centre, London, UK) for helpful discussions, technical advice or critical reading of the manuscript, members of the LRI Equipment Park for sequencing and of the LRI FACS facility for cell-cycle analysis. We thank Morri Feldman and Kevan Shokat (UCSF) for providing PP242. This work was funded by Cancer Research UK.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Atkins MB, 2009, NAT REV DRUG DISCOV, V8, P535, DOI 10.1038/nrd2924; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130; Cobleigh MA, 2003, SEMIN ONCOL, V30, P117, DOI 10.1053/j.seminoncol.2003.08.013; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dan S, 2010, CANCER RES, V70, P4982, DOI 10.1158/0008-5472.CAN-09-4172; Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21; Del Bufalo D, 2006, CANCER RES, V66, P5549, DOI 10.1158/0008-5472.CAN-05-2825; Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; FORBES SA, 2008, CURR PROTOC HUM GE S, V57; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hu XL, 2009, MOL CANCER RES, V7, P511, DOI 10.1158/1541-7786.MCR-08-0107; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Janku F, 2011, MOL CANCER THER, V10, P558, DOI 10.1158/1535-7163.MCT-10-0994; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Loi S, 2010, P NATL ACAD SCI USA, V107, P10208, DOI 10.1073/pnas.0907011107; Masters JRW, 2010, NAT REV CANCER, V10, P441, DOI 10.1038/nrc2852; Pallares J, 2005, MODERN PATHOL, V18, P719, DOI 10.1038/modpathol.3800347; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Roidl A, 2010, ONCOGENE, V29, P1543, DOI 10.1038/onc.2009.432; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Serebriiskii I, 2008, MATRIX BIOL, V27, P573, DOI 10.1016/j.matbio.2008.02.008; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tomlinson GE, 1998, CANCER RES, V58, P3237; Torbett NE, 2008, BIOCHEM J, V415, P97, DOI 10.1042/BJ20080639; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Wang X, 2008, ONCOGENE, V27, P5454, DOI 10.1038/onc.2008.242; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhang SY, 2010, CLIN CANCER RES, V16, P4325, DOI 10.1158/1078-0432.CCR-09-2990	63	147	153	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3222	3233		10.1038/onc.2011.42	http://dx.doi.org/10.1038/onc.2011.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21358673				2022-12-17	WOS:000293006800002
J	Melillo, RM; Guarino, V; Avilla, E; Galdiero, MR; Liotti, F; Prevete, N; Rossi, FW; Basolo, F; Ugolini, C; de Paulis, A; Santoro, M; Marone, G				Melillo, R. M.; Guarino, V.; Avilla, E.; Galdiero, M. R.; Liotti, F.; Prevete, N.; Rossi, F. W.; Basolo, F.; Ugolini, C.; de Paulis, A.; Santoro, M.; Marone, G.			Mast cells have a protumorigenic role in human thyroid cancer	ONCOGENE			English	Article						chemokine; mast cell; thyroid cancer	ENDOTHELIAL GROWTH-FACTOR; PAPILLARY CARCINOMA; FOLLICULAR CELLS; TUMOR-GROWTH; INFLAMMATION; EXPRESSION; LINES; BRAF; ANGIOGENESIS; ACTIVATION	In different human carcinoma types, mast cell infiltrate increases with respect to normal tissue and mast cell density correlates with a bad prognosis. To assess the role of mast cells in human thyroid cancer, we compared the density of tryptase-positive mast cells in 96 papillary thyroid carcinomas (PTCs) versus normal thyroid tissue from 14 healthy individuals. Mast cell density was higher in 95% of PTCs (n - 91) than in control tissue. Mast cell infiltrate correlated with extrathyroidal extension (P = 0.0005) of PTCs. We show that thyroid cancer cell-line-derived soluble factors induce mast cell activation and chemoattraction in vitro. Different mast cell lines (HMC-1 and LAD2) and primary human lung mast cells induced thyroid cancer cell invasive ability, survival and DNA synthesis in vitro. The latter effect was mainly mediated by three mast-cell-derived mediators: histamine, and chemokines CXCL1/GRO alpha and CXCL10/IP10. We show that xenografts of thyroid carcinoma cells (8505-C) could recruit mast cells injected into the tail vein of mice. Co-injection of human mast cells accelerated the growth of thyroid cancer cell (8505-C) xenografts in athymic mice. This effect was mediated by increased tumor vascularization and proliferation, and was reverted by treating mice with sodium cromoglycate (Cromolyn), a specific mast cell inhibitor. In conclusion, our study data suggest that mast cells are recruited into thyroid carcinomas and promote proliferation, survival and invasive ability of cancer cells, thereby contributing to thyroid carcinoma growth and invasiveness. Oncogene (2010) 29, 6203-6215; doi:10.1038/onc.2010.348; published online 23 August 2010	[Melillo, R. M.; Guarino, V.; Avilla, E.; Liotti, F.; Santoro, M.] Univ Naples Federico 2, DBPCM, IEOS, CNR, I-80131 Naples, Italy; [Galdiero, M. R.; Prevete, N.; Rossi, F. W.; de Paulis, A.; Marone, G.] Univ Naples Federico 2, Div Immunol Clin & Allergol, Ctr Interdipartimentale Ric Sci Immunol Base & Cl, I-80131 Naples, Italy; [Melillo, R. M.] Fac Sci Biotecnol, Naples, Italy; [Basolo, F.; Ugolini, C.] Univ Pisa, Dipartimento Chirurg, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; University of Pisa	Melillo, RM (corresponding author), Univ Naples Federico 2, DBPCM, IEOS, CNR, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it	UGOLINI, Clara/AAG-1760-2019; Basolo, Fulvio/AAC-2727-2019; melillo, rosa marina/O-5255-2015; GALDIERO, MARIA ROSARIA/J-6869-2018; Liotti, Federica/AAC-1614-2019; UGOLINI, CLARA/AAI-6489-2021	UGOLINI, Clara/0000-0002-3489-8280; Basolo, Fulvio/0000-0003-1657-5020; GALDIERO, MARIA ROSARIA/0000-0002-8086-9130; Liotti, Federica/0000-0002-0145-988X; MELILLO, Rosa Marina/0000-0002-9233-5275; de Paulis, Amato/0000-0003-0347-2540	Associazione Italiana per la Ricerca sul Cancro (AIRC); Istituto Superiore di Oncologia (ISO); Project 'Applicazioni Biotecnologiche dalle molecole all'uomo' (MoMa); EC [03695]; Project 'Sviluppo di nuovi farmaci capaci alterare il microambiente tumorale e ripristinare la risposta immune anti-tumorale' (ACC); Project 'Molecular diagnostic and prognostic markers of thyroid neoplasis' [RF-CAM-353005]	Associazione Italiana per la Ricerca sul Cancro (AIRC); Istituto Superiore di Oncologia (ISO); Project 'Applicazioni Biotecnologiche dalle molecole all'uomo' (MoMa); EC(European CommissionEuropean Commission Joint Research Centre); Project 'Sviluppo di nuovi farmaci capaci alterare il microambiente tumorale e ripristinare la risposta immune anti-tumorale' (ACC); Project 'Molecular diagnostic and prognostic markers of thyroid neoplasis'	We would like to dedicate this paper to the memory of Professor Gaetano Salvatore, who continues to inspire our work. We are indebted to AS Kirshenbaum and JH Butterfield for the LAD2 and HMC-1 cell lines, respectively and to F Curcio for the P5 primary thyroid culture. We thank Mario Galgani and Salvatore De Simone for PBMC purification and 8505-C GFP-expressing cell sorting. We also thank Jean Ann Gilder for text editing. This study was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC), the Istituto Superiore di Oncologia (ISO), the Project 'Applicazioni Biotecnologiche dalle molecole all'uomo' (MoMa), the EC Contract 03695 (GenRisk-T), the Project 'Sviluppo di nuovi farmaci capaci alterare il microambiente tumorale e ripristinare la risposta immune anti-tumorale' (ACC) and the Project 'Molecular diagnostic and prognostic markers of thyroid neoplasis' RF-CAM-353005 of the Health Ministry. VG was a fellow of the Fondazione Italiana per la Ricerca sul Cancro (FIRC).	Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Borrello MG, 2008, CANCER LETT, V267, P262, DOI 10.1016/j.canlet.2008.03.060; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Castellone MD, 2004, ONCOGENE, V23, P5958, DOI 10.1038/sj.onc.1207790; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; de la Torre NG, 2006, ENDOCR-RELAT CANCER, V13, P931, DOI 10.1677/erc.1.01210; de Paulis A, 2006, J IMMUNOL, V177, P7322, DOI 10.4049/jimmunol.177.10.7322; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Di Pasquale M, 2001, HUM PATHOL, V32, P24, DOI 10.1053/hupa.2001.21138; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Jo YS, 2006, J CLIN ENDOCR METAB, V91, P3667, DOI 10.1210/jc.2005-2836; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Klein M, 2001, J CLIN ENDOCR METAB, V86, P656, DOI 10.1210/jc.86.2.656; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marone G, 2005, ADV IMMUNOL, V88, P97, DOI 10.1016/S0065-2776(05)88004-6; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; Parsons ME, 2006, BRIT J PHARMACOL, V147, pS127, DOI 10.1038/sj.bjp.0706440; Pufnock JS, 2009, J IMMUNOL, V182, P5498, DOI 10.4049/jimmunol.0801284; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Rhoden KJ, 2006, J CLIN ENDOCR METAB, V91, P2414, DOI 10.1210/jc.2006-0240; Rivera ES, 2000, SEMIN CANCER BIOL, V10, P15, DOI 10.1006/scbi.2000.0303; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Salvatore G, 2006, CLIN CANCER RES, V12, P1623, DOI 10.1158/1078-0432.CCR-05-2378; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Welsh TJ, 2005, J CLIN ONCOL, V23, P8959, DOI 10.1200/JCO.2005.01.4910; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041	39	147	152	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	47					6203	6215		10.1038/onc.2010.348	http://dx.doi.org/10.1038/onc.2010.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729915				2022-12-17	WOS:000284601700002
J	Kupferman, ME; Jiffar, T; El-Naggar, A; Yilmaz, T; Zhou, G; Xie, T; Feng, L; Wang, J; Holsinger, FC; Yu, D; Myers, JN				Kupferman, M. E.; Jiffar, T.; El-Naggar, A.; Yilmaz, T.; Zhou, G.; Xie, T.; Feng, L.; Wang, J.; Holsinger, F. C.; Yu, D.; Myers, J. N.			TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma	ONCOGENE			English	Article						TrkB; squamous cell carcinoma; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; NEUROTROPHIC FACTOR ACTIVATION; PROTECTS NEUROBLASTOMA-CELLS; ORAL-CAVITY; CANCER STATISTICS; TUMOR PROGRESSION; RECEPTOR TRKA; IN-VITRO; EXPRESSION; METASTASIS	Head and neck squamous cell carcinoma (HNSCC) remains a significant public health problem, accounting for over 5% of all cancer-related deaths, and these deaths primarily result from metastatic disease. The molecular processes involved in HNSCC pathogenesis and progression are poorly understood, and here we present experimental evidence for a direct role of the cell surface receptor tyrosine kinase, TrkB, in HNSCC tumor progression. Using immunohistochemical analysis and transcriptional profiling of archival HNSCC tumor specimens, we found that TrkB and its secreted ligand, brain-derived neurotrophic factor (BDNF), are expresses in greater than 50% of human HNSCC tumors, but not in normal upper aerodigestive tract (UADT) epithelia. Studies with HNSCC cell lines reveal that in vitro stimulation with BDNF, the ligand for TrkB, upregulates the migration and invasion of HNSCC cells, and both transient and stable suppressions of TrkB result in significant abrogation of constitutive and ligand-mediated migration and invasion. Furthermore, enforced overexpression of TrkB results in altered expression of molecular mediators of epithelial-to-mesenchymal transition (EMT), including downregulation of E-cadherin and upregulation of Twist. Using an in vivo mouse model of HNSCC, we were able to show that downregulation of TrkB suppresses tumor growth. These results directly implicate TrkB in EMT and the invasive behavior of HNSCC, and correlate with the in vivo overexpression of TrkB in human HNSCC. Taken together, these data suggest that the TrkB receptor may be a critical component in the multi-step tumor progression of HNSCC, and may be an attractive target for much needed new therapies for this disease. Oncogene (2010) 29, 2047-2059; doi: 10.1038/onc.2009.486; published online 18 January 2010	[Kupferman, M. E.; Jiffar, T.; Yilmaz, T.; Zhou, G.; Xie, T.; Holsinger, F. C.; Myers, J. N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [El-Naggar, A.] Dept Pathol, Houston, TX USA; [Feng, L.] Dept Biostat, Houston, TX USA; [Wang, J.] Dept Bioinformat, Houston, TX USA; [Yu, D.] Dept Mol & Cellular Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Kupferman, ME (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1400 Pressler St Unit 1445, Houston, TX 77030 USA.	mekupfer@mdanderson.org		Wang, Jennifer Rui/0000-0002-0807-3832; Yu, Dihua/0000-0001-6231-9381	American Head and Neck Society; Young Investigator Award (MEK); MDACC (MEK); NIH [CA16672]; NIDCR (MEK) [K08 DE019185]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K08DE019185] Funding Source: NIH RePORTER	American Head and Neck Society; Young Investigator Award (MEK); MDACC (MEK); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDCR (MEK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank S Jasser, MS, for technical assistance, T Astin for administrative assistance and X Wu, PhD, for critical review of the paper. This study was supported by the following funding sources: American Head and Neck Society; Young Investigator Award (MEK); Head and Neck SPORE ProgramCareer Development Award, MDACC (MEK); and the MD Anderson Cancer Center Physician-Scientist Program (MEK). NIH Cancer Center Support Grant CA16672 (MDACC) and Grant K08 DE019185 from the NIDCR (MEK).	Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Armistead PM, 2007, CANCER, V110, P2293, DOI 10.1002/cncr.23038; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Chao MV, 2004, J ALZHEIMERS DIS, V6, pS7; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Ho R, 2002, CANCER RES, V62, P6462; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jaboin J, 2002, CANCER RES, V62, P6756; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Karamouzis MV, 2007, JAMA-J AM MED ASSOC, V298, P70, DOI 10.1001/jama.298.1.70; Ketterer K, 2003, CLIN CANCER RES, V9, P5127; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; Kupferman ME, 2006, OTOLARYNG CLIN N AM, V39, P229, DOI 10.1016/j.otc.2005.11.003; Kupferman Michael E, 2009, J Exp Ther Oncol, V8, P117; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Luikart BW, 2008, J NEUROSCI, V28, P7006, DOI 10.1523/JNEUROSCI.0195-08.2008; Martens LK, 2007, J BIOL CHEM, V282, P14379, DOI 10.1074/jbc.M609857200; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Nakashima T, 2000, BBA-GENE STRUCT EXPR, V1492, P441, DOI 10.1016/S0167-4781(00)00100-7; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pearse RN, 2005, BLOOD, V105, P4429, DOI 10.1182/blood-2004-08-3096; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yang MH, 2007, ONCOGENE, V26, P1459, DOI 10.1038/sj.onc.1209929; Yigitbasi OG, 2004, CANCER RES, V64, P7977, DOI 10.1158/0008-5472.CAN-04-1477; Zhou G, 2008, ONCOGENE, V27, P3527, DOI 10.1038/sj.onc.1211015	41	147	150	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2047	2059		10.1038/onc.2009.486	http://dx.doi.org/10.1038/onc.2009.486			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101235	Green Accepted			2022-12-17	WOS:000276402800004
J	Saito, Y; Suzuki, H; Tsugawa, H; Nakagawa, I; Matsuzaki, J; Kanai, Y; Hibi, T				Saito, Y.; Suzuki, H.; Tsugawa, H.; Nakagawa, I.; Matsuzaki, J.; Kanai, Y.; Hibi, T.			Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells	ONCOGENE			English	Article						miRNA; DNA methylation; histone modification; epigenetic treatment; Alu repeats; gastric cancer	MESSENGER-RNA; METHYLATION; THERAPY; TARGET; FUTURE	Epigenetic therapy using DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors has clinical promise for the treatment of human malignancies. To investigate roles of microRNAs (miRNAs) on epigenetic therapy of gastric cancer, the miRNA expression profile was analysed in human gastric cancer cells treated with 5-aza-2'-deoxycytidine (5-Aza-CdR) and 4-phenylbutyric acid (PBA). miRNA microarray analysis shows that most of miRNAs activated by 5-Aza-CdR and PBA in gastric cancer cells are located at Alu repeats on chromosome 19. Analyses of chromatin modification show that DNA demethylation and HDAC inhibition at Alu repeats activates silenced miR-512-5p by RNA polymerase II. In addition, activation of miR-512-5p by epigenetic treatment induces suppression of Mcl-1, resulting in apoptosis of gastric cancer cells. These results suggest that chromatin remodeling at Alu repeats plays critical roles in the regulation of miRNA expression and that epigenetic activation of silenced Alu-associated miRNAs could be a novel therapeutic approach for gastric cancer. Oncogene (2009) 28, 2738-2744; doi:10.1038/onc.2009.140; published online 8 June 2009	[Saito, Y.; Suzuki, H.; Tsugawa, H.; Nakagawa, I.; Matsuzaki, J.; Hibi, T.] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Shinjuku Ku, Tokyo 1608582, Japan; [Kanai, Y.] Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 104, Japan	Keio University; National Cancer Center - Japan	Suzuki, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hsuzuki@sc.itc.keio.ac.jp	Suzuki, Hidekazu/J-4396-2013; Kanai, Yae/AAE-6987-2019; Tsugawa, Hitoshi/V-9589-2019; Tsugawa, Hitoshi/J-4941-2013; Matsuzaki, Juntaro/S-4107-2019; SUZUKI, HIDEKAZU/S-9376-2019	Tsugawa, Hitoshi/0000-0002-4344-4475; Tsugawa, Hitoshi/0000-0002-4344-4475; Matsuzaki, Juntaro/0000-0002-3204-5049; 	Japan Society for the Promotion of Science (JSPS) [19599024, 19659057]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors are grateful to Dr Robert Roeder at Rockefeller University for providing antibody to Pol III. This work was supported by a Grant-in-Aid for Scientific Research C from the Japan Society for the Promotion of Science (JSPS) ( 19599024, to Y.S.) and a Grant-in-Aid for Exploratory Research from JSPS ( 19659057, to HS).	Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816; Kondo Y, 2003, J BIOL CHEM, V278, P27658, DOI 10.1074/jbc.M304072200; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V149, P1449; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; Maeta Yoshihiko, 2004, Gastric Cancer, V7, P78; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; Oei SL, 2004, GENOMICS, V83, P873, DOI 10.1016/j.ygeno.2003.11.001; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; Suzuki H, 1998, AM J PHYSIOL-GASTR L, V275, pG712, DOI 10.1152/ajpgi.1998.275.4.G712; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Wacheck V, 2006, CANCER BIOL THER, V5, P1348, DOI 10.4161/cbt.5.10.3224; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zangemeister-Wittke U, 2006, CANCER BIOL THER, V5, P1355, DOI 10.4161/cbt.5.10.3488; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	26	147	161	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2738	2744		10.1038/onc.2009.140	http://dx.doi.org/10.1038/onc.2009.140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19503096				2022-12-17	WOS:000268452900004
J	Lau, LMS; Nugent, JK; Zhao, X; Irwin, MS				Lau, L. M. S.; Nugent, J. K.; Zhao, X.; Irwin, M. S.			HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function	ONCOGENE			English	Article						Nutlin; p73; HDM2; apoptosis; p53	MOLECULE MDM2 ANTAGONISTS; SQUAMOUS-CELL CARCINOMA; CENTRAL DOMAIN; P53 PATHWAY; MUTANT P53; IN-VIVO; APOPTOSIS; FAMILY; SITE; P63	Nutlin-3, a small molecule inhibitor, activates p53 by disrupting p53-HDM2 association. In this study, we found that Nutlin-3 suppressed cell growth and induced apoptosis in the absence of wild-type p53, suggesting a p53-independent mechanism for Nutlin-3-induced cell death. Like p53, its homolog p73 transactivates proapoptotic genes and induces cell death. Since HDM2, a key negative regulator of p53, also binds to and inhibits p73, we asked whether p73 could mediate Nutlin-3-induced apoptosis. We demonstrate that Nutlin-3 inhibits endogenous binding between the proapoptotic p73 isoform TAp73 alpha and HDM2 in p53-null cells. Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with up regulation of p73 target genes noxa, puma and p21,as well as enhanced apoptosis. p73 knockdown by siRNA results in rescue of Nutlin-3-treated cells, indicating that Nutlin-3-induced apoptosis is, at least in part, p73 dependent. In addition, Nutlin-3 treatment increases TAp73 alpha protein levels with prolongation of p73 half-life. These results provide the first evidence that Nutlin-3 disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73 and thus, provides a rationale for the use of Nutlin-3 in the large number of human tumors in which p53 is inactivated.	[Lau, L. M. S.; Zhao, X.; Irwin, M. S.] Univ Toronto, Div Hematol Oncol, Dept Paediat, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Lau, L. M. S.; Nugent, J. K.; Irwin, M. S.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Irwin, MS (corresponding author), Univ Toronto, Div Hematol Oncol, Dept Paediat, Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970				Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Ma JH, 2006, BIOCHEMISTRY-US, V45, P9238, DOI 10.1021/bi060661u; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; VanderBorght A, 2006, ONCOGENE, V25, P6672, DOI 10.1038/sj.onc.1209667; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	30	147	153	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					997	1003		10.1038/sj.onc.1210707	http://dx.doi.org/10.1038/sj.onc.1210707			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700533				2022-12-17	WOS:000252946300011
J	Ang, XLL; Harper, JW				Ang, XLL; Harper, JW			SCF-mediated protein degradation and cell cycle control	ONCOGENE			English	Review						proteolysis; ubiquitin; SCF; APC; E3 ubiquitin-ligase; phosphodegron	ANAPHASE-PROMOTING COMPLEX; F-BOX PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; KINASE INHIBITOR P27; LIGASE SUBUNIT SKP2; POLO-LIKE KINASE; S-PHASE ENTRY; C-MYC PROTEIN; BETA-TRCP; MULTISITE PHOSPHORYLATION	The regulatory step in ubiquitin ( Ub)- mediated protein degradation involves recognition and selection of the target substrate by an E3 Ub- ligase. E3 Ub- ligases evoke sophisticated mechanisms to regulate their activity temporally and spatially, including multiple post- translational modi. cations, combinatorial E3 Ub- ligase pathways, and subcellular localization. The phosphodegrons of many substrates incorporate the activities of multiple kinases, and ubiquitination only occurs when all necessary phosphorylation signals have been incorporated. In this manner, the precise timing of degradation can be controlled. Another way that the Ub pathway tightly controls the timing of proteolysis is with multiple E3 Ub-ligases acting upon a single target. Lastly, subcellular localization can either promote or prevent degradation by regulating the accessibility of kinases and E3 Ub- ligases. This review highlights recent findings that exemplify these emerging themes in the regulation of E3 Ub- ligase substrate recognition.	Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Harper, JW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Program Biol & Biomed Sci, Boston, MA 02115 USA.	wade_harper@hms.harvard.edu	Cambronne, Xiaolu Ang/GRY-7149-2022	Cambronne, Xiaolu Ang/0000-0002-3547-448X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS054507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG11085] Funding Source: Medline; NIGMS NIH HHS [GM54137] Funding Source: Medline; NINDS NIH HHS [F31 NS054507-01, F31 NS054507] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANG XL, 2004, SCI STKE, V13, pPE31; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Barral Y, 1999, GENE DEV, V13, P176, DOI 10.1101/gad.13.2.176; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Guardavaccaro D, 2004, ONCOGENE, V23, P2037, DOI 10.1038/sj.onc.1207413; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Moshe Y, 2004, P NATL ACAD SCI USA, V101, P7937, DOI 10.1073/pnas.0402442101; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; PULVERER BJ, 1994, ONCOGENE, V9, P59; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Reed SI, 2002, CELL CYCLE, V1, P389, DOI 10.4161/cc.1.6.261; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sakchaisri K, 2004, P NATL ACAD SCI USA, V101, P4124, DOI 10.1073/pnas.0400641101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; Sia RAL, 1998, EMBO J, V17, P6678, DOI 10.1093/emboj/17.22.6678; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sreenivasan A, 1999, MOL CELL BIOL, V19, P7983; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang W, 2004, ONCOGENE, V23, P1064, DOI 10.1038/sj.onc.1207204; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang G, 2002, CLIN CANCER RES, V8, P3419; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Yokoi S, 2002, AM J PATHOL, V161, P207, DOI 10.1016/S0002-9440(10)64172-7; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	112	147	149	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2860	2870		10.1038/sj.onc.1208614	http://dx.doi.org/10.1038/sj.onc.1208614			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838520				2022-12-17	WOS:000228465800010
J	Portis, T; Longnecker, R				Portis, T; Longnecker, R			Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway	ONCOGENE			English	Article						EBV; LMP2A; ras; PI3K; akt; apoptosis	MEMBRANE-PROTEIN 2A; REED-STERNBERG CELLS; GENE-TRANSCRIPTION; DEVELOPMENTAL PROGRESSION; IN-VIVO; KINASE; APOPTOSIS; EXPRESSION; 3-KINASE; SIGNALS	Epstein-Barr virus (EBV) establishes a lifelong latent infection in host B cells and is associated with the development of a variety of malignancies. The viral LMP2A protein mediates viral latency by mimicking a constitutively activated B-cell receptor (BCR). In vivo LMP2A provides developmental and survival signals to BCR-negative B cells, allowing them to survive in peripheral lymphoid organs. In this study, we have demonstrated that Ras is constitutively active in peripheral, BCR-negative B cells from LMP2A transgenic mice. Furthermore, increased expression of activated Ras correlated with elevated levels of Bcl-xL expression and a slower migrating, band-shifted form of Bcl-2. B cells from LMP2A transgenic mice were sensitive to apoptosis induction in the presence of specific inhibitors of Ras, phosphatidylinositol 3-kinase (PI3K), and Akt, indicating that LMP2A activates the Ras/PI3K/Akt pathway to mediate B-cell survival. Increased B-cell apoptosis correlated with reduced expression of Bcl-xL, suggesting that this Bcl-2 family member may be involved in apoptosis inhibition mediated by LMP2A. The ability of LMP2A to activate constitutively the Ras pathway, a common event during tumorigenesis, suggests that this viral protein plays an active role in the development of EBV-associated malignancies.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Longnecker, R (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Ward 6-231,303 E Chicago Ave, Chicago, IL 60611 USA.	r-longnecker@northwestern.edu			NCI NIH HHS [CA93444, CA62234, CA73507] Funding Source: Medline; NIDCR NIH HHS [DE13127] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073507, R01CA062234, R01CA093444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013127] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bairey O, 1999, CLIN CANCER RES, V5, P2860; Blank N, 2002, CYTOMETRY, V48, P179, DOI 10.1002/cyto.10127; Brinkmann MM, 2003, J VIROL, V77, P9346, DOI 10.1128/JVI.77.17.9346-9358.2003; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Fang W, 1996, IMMUNITY, V4, P291, DOI 10.1016/S1074-7613(00)80437-9; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fuentes-Panana EM, 2004, IMMUNOL REV, V197, P26, DOI 10.1111/j.0105-2896.2004.0105.x; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kuppers R, 2002, ANN ONCOL, V13, P11, DOI 10.1093/annonc/13.S1.11; Longnecker R, 1998, HUMAN TUMOR VIRUSES, P133; Merchant M, 2000, J VIROL, V74, P9115, DOI 10.1128/JVI.74.19.9115-9124.2000; Merchant M, 2001, VIROLOGY, V291, P46, DOI 10.1006/viro.2001.1187; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; Milne CD, 2004, IMMUNOL REV, V197, P75, DOI 10.1111/j.0105-2896.2004.0103.x; Nagaoka H, 2000, J EXP MED, V192, P171, DOI 10.1084/jem.192.2.171; Niedobitek G, 1997, BLOOD, V90, P1664, DOI 10.1182/blood.V90.4.1664.1664_1664_1672; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Portis T, 2003, BLOOD, V102, P4166, DOI 10.1182/blood-2003-04-1018; Portis T, 2003, J VIROL, V77, P105, DOI 10.1128/JVI.77.1.105-114.2003; Portis T, 2002, FRONT BIOSCI-LANDMRK, V7, pD414, DOI 10.2741/portis; QU LR, 1992, J VIROL, V66, P3715, DOI 10.1128/JVI.66.6.3715-3724.1992; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schlaifer D, 1996, AM J PATHOL, V149, P177; SCHLAIFER D, 1995, BLOOD, V85, P2671, DOI 10.1182/blood.V85.10.2671.bloodjournal85102671; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shaw AC, 1999, P NATL ACAD SCI USA, V96, P2239, DOI 10.1073/pnas.96.5.2239; Shaw AC, 1999, J EXP MED, V189, P123, DOI 10.1084/jem.189.1.123; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556	56	147	154	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8619	8628		10.1038/sj.onc.1207905	http://dx.doi.org/10.1038/sj.onc.1207905			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15361852				2022-12-17	WOS:000224988800008
J	Sauvageau, G; Iscove, NN; Humphries, RK				Sauvageau, G; Iscove, NN; Humphries, RK			In vitro and in vivo expansion of hematopoietic stem cells	ONCOGENE			English	Review						hematopoietic stem cells; self-renewal; expansion; Hoxb4	SELF-RENEWAL DIVISIONS; BLOOD CD34(+) CELLS; WNT GENE FAMILY; HOMEOBOX GENES; DIFFERENTIAL EXPRESSION; REPOPULATING ACTIVITY; SELECTIVE EXPANSION; EMBRYONIC ORIGINS; HOXB4 EXPRESSION; OVEREXPRESSION	The capacity for sustained self-renewal-the generation of daughter cells having the same regenerative properties as the parent cell-is the defining feature of hematopoietic stem cells (HSCs). Strong evidence exists that self-renewal of HSC is under extrinsic biological control in vivo. A variety of cytokines, morphogenic ligands and associated signaling components influence self-renewal in culture and in vivo. Specific homeobox transcription factors act as powerful intrinsic agonists of HSC self-renewal in vitro and in vivo when supplied either as transduced cDNAs or as externally delivered proteins. These findings provide tools for deepening our knowledge of mechanism and for achievement of clinically useful levels of HSC expansion.	Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 4E3, Canada	Universite de Montreal; Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; British Columbia Cancer Agency; University of British Columbia	Sauvageau, G (corresponding author), Univ Montreal, IRIC Inst Res Immunol & Canc, Lab Mol Genet Hemopoiet Stem Cells, CP 6128,Downtown Stn, Montreal, PQ H3C 3J7, Canada.	guy.sauvageau@umontreal.ca; khumphri@bccrc.ca		Sauvageau, Guy/0000-0002-4333-7266; Humphries, Richard/0000-0003-0540-7005				Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Audet J, 2001, P NATL ACAD SCI USA, V98, P1757, DOI 10.1073/pnas.98.4.1757; Audet J, 2002, BIOTECHNOL BIOENG, V80, P393, DOI 10.1002/bit.10399; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Baron MH, 2003, EXP HEMATOL, V31, P1160, DOI 10.1016/j.exphem.2003.08.019; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; BESLU N, 2004, IN PRESS BLOOD  0629; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bhatia M, 1997, J EXP MED, V186, P619, DOI 10.1084/jem.186.4.619; Brun ACM, 2003, MOL THER, V8, P618, DOI 10.1016/S1525-0016(03)00237-5; Bryder D, 2000, BLOOD, V96, P1748, DOI 10.1182/blood.V96.5.1748.h8001748_1748_1755; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cashman JD, 1999, BLOOD, V93, P481, DOI 10.1182/blood.V93.2.481.402k20_481_487; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; de Haan G, 2003, DEV CELL, V4, P241, DOI 10.1016/S1534-5807(03)00018-2; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Domen J, 2000, J EXP MED, V192, P1707, DOI 10.1084/jem.192.12.1707; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; Faloon P, 2000, DEVELOPMENT, V127, P1931; Fox N, 2002, J CLIN INVEST, V110, P389, DOI 10.1172/JCI200215430; FRASER CC, 1990, BLOOD, V76, P1071; FRASER CC, 1992, P NATL ACAD SCI USA, V89, P1968, DOI 10.1073/pnas.89.5.1968; Gammaitoni L, 2003, EXP HEMATOL, V31, P261, DOI 10.1016/S0301-472X(02)01077-9; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GIAMPAOLO A, 1995, STEM CELLS, V13, P90; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; Glimm H, 1999, BLOOD, V94, P2161, DOI 10.1182/blood.V94.7.2161.419k32_2161_2168; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; HARRISON DE, 1991, BLOOD, V78, P1237; Helgason CD, 2003, BLOOD, V102, P3541, DOI 10.1182/blood-2002-12-3939; Hisa T, 2004, EMBO J, V23, P450, DOI 10.1038/sj.emboj.7600038; Hoffman R, 1999, Curr Opin Hematol, V6, P184, DOI 10.1097/00062752-199905000-00010; Iscove NN, 1997, CURR BIOL, V7, P805, DOI 10.1016/S0960-9822(06)00341-1; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kirito K, 2003, BLOOD, V102, P3172, DOI 10.1182/blood-2003-03-0944; Kojika S, 2001, EXP HEMATOL, V29, P1041, DOI 10.1016/S0301-472X(01)00676-2; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Krosl J, 2003, IMMUNITY, V18, P561, DOI 10.1016/S1074-7613(03)00090-6; Marshall CJ, 2001, BRIT J HAEMATOL, V112, P838, DOI 10.1046/j.1365-2141.2001.02537.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; MORETTI P, 1994, GENE, V144, P213, DOI 10.1016/0378-1119(94)90380-8; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Nakauchi H, 2001, ANN NY ACAD SCI, V938, P18; Nicolini FE, 2004, LEUKEMIA, V18, P341, DOI 10.1038/sj.leu.2403222; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Petzer AL, 1997, BLOOD, V90, P64; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Schiedlmeier B, 2003, BLOOD, V101, P1759, DOI 10.1182/blood-2002-03-0767; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; Ueda T, 2000, J CLIN INVEST, V105, P1013, DOI 10.1172/JCI8583; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Varnum-Finney B, 2003, BLOOD, V101, P1784, DOI 10.1182/blood-2002-06-1862; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yonemura Y, 1996, P NATL ACAD SCI USA, V93, P4040, DOI 10.1073/pnas.93.9.4040; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhu J, 2003, BLOOD, V102, P2420, DOI 10.1182/blood-2003-01-0251	75	147	158	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7223	7232		10.1038/sj.onc.1207942	http://dx.doi.org/10.1038/sj.onc.1207942			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378082				2022-12-17	WOS:000223998800008
J	Cao, C; Mu, Y; Hallahan, DE; Lu, B				Cao, C; Mu, Y; Hallahan, DE; Lu, B			XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer	ONCOGENE			English	Article						XIAP; survivin; lung cancer; radio therapy	X-LINKED INHIBITOR; ENDOTHELIAL-CELLS; IAP PROTEINS; APOPTOSIS; EXPRESSION; MARKER; GENE; ANGIOPOIETIN-1; ANGIOGENESIS; SUPPRESSION	Survivin and XIAP are members of inhibitors of apoptosis (IAPs) family. They are upregulated in various malignancies. Inactivation of these molecules has resulted in chemosensitization. The purpose of this study was to determine whether inhibition of survivin, XIAP, or both enhances radiotherapy in a lung cancer model. Transient transfection of H460 cells with antisense oligonucleotides (ASOs) against either molecule has specifically reduced their expression, by Western analysis. Results from 3-(4,5-methylthiazol- 2-yl)-2,5-diphenyl-tetrazolium bromide and clonogenic assays suggest that inhibition of survivin or XIAP greatly decreased cell survival following irradiation. A significantly increased number of apoptotic cells were detected when H460 cells were treated with either antisurvivin, anti-XIAP or both ASOs ( P = 0.03, 0.0003 and 0.01, respectively) plus irradiation. H460 xenografts that were treated with ASOs plus radiotherapy demonstrated growth delay beyond 15 days. Growth delay in the groups of combined treatment was greater than that in other groups. However, treatment with ASOs alone did not affect tumor growth delay in mice, but decreased the survival of H460 cells in culture. Antisense treatment did not cause any mortality or weight loss during the 32 days of study. These data suggest that inhibition of survivin or XIAP radiosensitizes H460 lung cancer cells by upregulating apoptosis and downregulating cell survival. Combination of radiotherapy and inhibition of survivin and XIAP through the antisense approach results in improved tumor control by radiotherapy in a mouse model of lung cancer.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Radiat Oncol,Vanderbilt Clin B902, Nashville, TN 37232 USA	Vanderbilt University	Lu, B (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Radiat Oncol,Vanderbilt Clin B902, 1301 22nd Ave S, Nashville, TN 37232 USA.	bo.lu@vanderbilt.edu	lu, bo/G-4573-2010		NCI NIH HHS [R01-CA89674, R01-CA88076, R01-CA58508, P50-CA90949] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090949, R01CA058508, R01CA088076, R01CA089674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Bao RD, 2002, J NATL CANCER I, V94, P522; Blanc-Brude OP, 2003, CLIN CANCER RES, V9, P2683; Edwards E, 2002, CANCER RES, V62, P4671; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Geng L, 2001, CANCER RES, V61, P2413; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ikehara M, 2002, ONCOL REP, V9, P835; Jansen B, 2002, LANCET ONCOL, V3, P672, DOI 10.1016/S1470-2045(02)00903-8; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Lu B, 2004, CANCER RES, V64, P2840, DOI 10.1158/0008-5472.CAN-03-3547; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Olie RA, 2000, CANCER RES, V60, P2805; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Rodel C, 2003, INT J RADIAT ONCOL, V55, P1341, DOI 10.1016/S0360-3016(02)04618-7; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7	28	147	160	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7047	7052		10.1038/sj.onc.1207929	http://dx.doi.org/10.1038/sj.onc.1207929			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258565				2022-12-17	WOS:000223885100005
J	Durst, KL; Hiebert, SW				Durst, KL; Hiebert, SW			Role of RUNX family members in transcriptional repression and gene silencing	ONCOGENE			English	Article						RUNX; AML; repression; transcription; silencing; histone deacetylases	ACUTE MYELOID-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; CORE-BINDING FACTOR; MYOSIN HEAVY-CHAIN; FUSION PROTEIN; FUNCTIONAL COOPERATION; HISTONE H3; DOMAIN PROTEINS; C/EBP-ALPHA; DNA-BINDING	RUNX family members are DNA-binding transcription factors that regulate the expression of genes involved in cellular differentiation and cell cycle progression. The RUNX family includes three mammalian RUNX proteins (RUNX1, - 2, - 3) and two homologues in Drosophila. Experiments in Drosophila and mouse indicate that the RUNX proteins are required for gene silencing of engrailed and CD4, respectively. RUNX-mediated repression involves recruitment of corepressors such as mSin3A and Groucho as well as histone deacetylases. Furthermore, RUNX1 and RUNX3 associate with SUV39H1, a histone methyltransferase involved in gene silencing. RUNX1 is frequently targeted in human leukemia by chromosomal translocations that fuse the DNA-binding domain of RUNX1 to other transcription factors and corepressor molecules. The resulting leukemogenic fusion proteins are transcriptional repressors that form stable complexes with corepressors, histone deacetylases and histone methyltransferases. Thus, transcriptional repression and gene silencing through RUNX1 contribute to the mechanisms of leukemogenesis of the fusion proteins. Therapies directed at the associated cofactors may be beneficial for treatment of these leukemias.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, PRB 512,23rd & Pierce, Nashville, TN 37232 USA.	scott.hiebert@mcmail.vanderbilt.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Canon J, 2000, SEMIN CELL DEV BIOL, V11, P327, DOI 10.1006/scdb.2000.0185; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; ERICKSON P, 1992, BLOOD, V80, P1825; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Guidez F, 2000, BLOOD, V96, P2557; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Javed A, 2000, J CELL SCI, V113, P2221; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Wheeler JC, 2002, NAT GENET, V32, P206, DOI 10.1038/ng942; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	48	147	151	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4220	4224		10.1038/sj.onc.1207122	http://dx.doi.org/10.1038/sj.onc.1207122			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156176				2022-12-17	WOS:000221586000005
J	Liu, ZM; Chen, GG; Ng, EKW; Leung, WK; Sung, JJY; Chung, SCS				Liu, ZM; Chen, GG; Ng, EKW; Leung, WK; Sung, JJY; Chung, SCS			Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells	ONCOGENE			English	Article						gastric cancer; heme oxygenase-1; p21; p53; apoptosis	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INHIBITS APOPTOSIS; GENE-EXPRESSION; TNF-ALPHA; CARCINOMA; PATHWAY; DEATH; HEAT-SHOCK-PROTEIN-70; OVEREXPRESSION	Both heme oxygenase-1 (HO-1) and p21(WAF1/Cip1) (p21) are involved in the pathogenesis of human cancer and their functions are closely associated with apoptosis. However, how these two molecules regulate apoptosis in human gastric cancer is unknown. In this study, we studied how HO-1 and p21 were regulated in two gastric cancer cell lines, MKN-45 with wild p53 and MKN-28 with mutant p53. The cells were treated with hemin and cadmium to induce HO-1. The result showed that HO-1 protein was significantly induced by hemin and cadmium in both cells tested. Following the HO-1 expression, p21 level was also markedly induced. The cells with increased HO-1 and p21 showed obviously resistantance to apoptotic stimuli. The levels of HO-1 and p21 induced were significantly inhibited by p38 mitogen-activated protein kinase (p38 MAPK) inhibitor (SB203580) and extracellular-regulated kinase (ERK) inhibitor (PD098059). Parallel to decreased HO-1 and p21 expression, the kinase inhibitors also significantly attenuated the resistance of the cells to apoptosis. The elevated HO-1 and p21 was further found to be associated with increase activity of the nuclear NF-kappaB and the inhibition of NF-kappaB led to the block of their induction. The elevated HO-1 and p21 were also demonstrated to be related to increased cellular inhibitor of caspase inbitory protein-2 (c-IAP2) and decreased caspapse-3 activity. It was noted that the above changes observed were not different between MKN-45 and MKN-28 cells, suggesting the functions of HO-1 and p21 were irrespective of the status of p53. In conclusion, we demonstrate that the resistance to apoptosis in gastric cancer cells with elevated HO-1 and p21 is independent of p53 status in a p38 MAPK- and ERK-mediated pathway with elevated c-IAP2 and decreased caspase-3 activity and that this pathway is sensitive to the inhibition of NF-kappaB.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; Sichuan Univ, W China Hosp, Inst Gasterointestinal Surg, Chengdu 610041, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Sichuan University	Chen, GG (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.	gchen@cuhk.edu.hk	Leung, Wai Keung/B-8140-2011; Chen, George Gong/I-2757-2016; Sung, Joseph J. Y./R-3203-2018; Lin, Hualiang/E-6622-2010; Ng, Enders Kwok-wai/E-8276-2016	Leung, Wai Keung/0000-0002-5993-1059; Sung, Joseph J. Y./0000-0003-3125-5199; Lin, Hualiang/0000-0002-2462-5158; Ng, Enders Kwok-wai/0000-0001-7219-5810				Baas IO, 1998, J CLIN PATHOL, V51, P662, DOI 10.1136/jcp.51.9.662; Baldus SE, 2001, SCAND J GASTROENTERO, V36, P975, DOI 10.1080/003655201750305512; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; Chen GG, 2002, LIFE SCI, V70, P2631, DOI 10.1016/S0024-3205(02)01510-2; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Craanen ME, 1999, J PATHOL, V189, P481, DOI 10.1002/(SICI)1096-9896(199912)189:4<481::AID-PATH482>3.0.CO;2-U; Davis JN, 2001, FREE RADICAL BIO MED, V30, P1293, DOI 10.1016/S0891-5849(01)00535-4; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; ELLEDGE RM, 1994, CANCER RES, V54, P3752; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54; Helt CE, 2001, TOXICOL SCI, V63, P214, DOI 10.1093/toxsci/63.2.214; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Inguaggiato P, 2001, KIDNEY INT, V60, P2181, DOI 10.1046/j.1523-1755.2001.00046.x; Jobin C, 1998, J IMMUNOL, V160, P410; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maines MD, 1999, J PHARMACOL EXP THER, V291, P911; Maines MD, 1996, UROLOGY, V47, P727, DOI 10.1016/S0090-4295(96)00010-6; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MURPHY BJ, 1993, CANCER RES, V53, P2700; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; TAKAHASHI S, 1994, AM J CLIN PATHOL, V101, P519; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Wakana Y, 2002, ONCOL REP, V9, P1213; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	43	147	158	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					503	513		10.1038/sj.onc.1207173	http://dx.doi.org/10.1038/sj.onc.1207173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647439				2022-12-17	WOS:000188098300021
J	Rebbaa, A; Zheng, X; Chou, PM; Mirkin, BL				Rebbaa, A; Zheng, X; Chou, PM; Mirkin, BL			Caspase inhibition switches doxorubicin-induced apoptosis to senescence	ONCOGENE			English	Article						apoptosis; senescence; P21/WAF1; drug resistance	CYTOCHROME-C RELEASE; PROTEIN EXPRESSION; CANCER CELLS; DEATH; P53; RESISTANCE; SURVIVAL; PATHWAY; P21; CYTOTOXICITY	The inhibition of apoptosis is generally believed to be a major determinant of resistance to chemotherapy. However, recent findings have shown that caspase inhibitors do not protect cancer cells from death by cytotoxic agents, but may switch drug-induced apoptosis to an alternative 'default death'. The primary goals of this study were to determine the major characteristics of the 'default death' and the mechanism by which this switch is activated. For this purpose, we first investigated putative cell death modes induced by doxorubicin. Molecular markers associated with these death modes were utilized to identify the default death resulting from the inhibition of apoptosis. Our findings demonstrated that doxorubicin induced at least three distinct types of cell death, senescence, apoptosis and a type of necrosis, which were concentration dependent. Specific molecular markers such as p21/WAF1, activated caspase-3 and activated Akt were associated with these death modes. The pan-caspase inhibitor (Q-VD-OPH) greatly reduced doxorubicin-induced caspase-3 activation but did not protect cells against drug toxicity. The combination of doxorubicin and Q-VD-OPH caused an increased expression of p21/WAF1 and senescence -associated -beta-galactosidase activity, but did not alter Akt activation. Collectively, these findings suggest that the inhibition of apoptosis may lead to an increased expression of cell cycle inhibitors and cellular senescence.	Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pathol, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Rebbaa, A (corresponding author), Childrens Mem Hosp, Childrens Mem Inst Educ & Res, Dept Pediat, M-C 224,2300 Childrens Plaza, Chicago, IL 60614 USA.	arebbaa@childrensmemorial.org						Ahrendt SA, 2000, SURGERY, V128, P520, DOI 10.1067/msy.2000.108052; Borst P, 2001, DRUG RESIST UPDATE, V4, P129, DOI 10.1054/drup.2001.0187; Brognard J, 2001, CANCER RES, V61, P3986; Brown JM, 1999, CANCER RES, V59, P1391; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Emran MA, 2002, CANCER LETT, V182, P53, DOI 10.1016/S0304-3835(02)00062-9; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kapranos N, 2001, ANTICANCER RES, V21, P521; Kim SO, 2001, J ENDOTOXIN RES, V7, P292, DOI 10.1179/096805101101532873; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Martinsson P, 2001, ANTI-CANCER DRUG, V12, P699, DOI 10.1097/00001813-200109000-00009; Nakashima S, 2000, ANTICANCER RES, V20, P1933; Rebbaa A, 2001, CANCER CHEMOTH PHARM, V48, P423, DOI 10.1007/s002800100375; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; RONINSON IB, 2002, DRUG RESIST UPDATE, V252, P1; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; te Poele RH, 2002, CANCER RES, V62, P1876; Yaginuma H, 2001, MOL CELL NEUROSCI, V18, P168, DOI 10.1006/mcne.2001.1009; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zunino F, 1997, PHARMACOL THERAPEUT, V76, P177, DOI 10.1016/S0163-7258(97)00086-7	33	147	160	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2003	22	18					2805	2811		10.1038/sj.onc.1206366	http://dx.doi.org/10.1038/sj.onc.1206366			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743603				2022-12-17	WOS:000182569300011
J	Spankuch-Schmitt, B; Wolf, G; Solbach, C; Loibl, S; Knecht, R; Stegmuller, M; von Minckwitz, G; Kaufmann, M; Strebhardt, K				Spankuch-Schmitt, B; Wolf, G; Solbach, C; Loibl, S; Knecht, R; Stegmuller, M; von Minckwitz, G; Kaufmann, M; Strebhardt, K			Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells	ONCOGENE			English	Article						polo-like kinase; antisense; anticancer activity; xenograft	PROTEIN-KINASE; PHASE-I; SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE KINASE; PROGNOSTIC-SIGNIFICANCE; PLK EXPRESSION; C-ALPHA; CYCLE; DROSOPHILA; OLIGODEOXYNUCLEOTIDE	A central role for polo-like kinases (PLK) in regulating several stages of mitotic progression has been born out in several species. Overexpression of PLK1 is observed in the majority of hitherto analysed human tumors. PLK1 overexpression is a negative prognostic factor in patients suffering from non-small cell lung cancer, head and neck tumors, esophageal carcinomas and melanomas. In order to define the role of PLK1 for mitotic progression of human cells and for neoplastic cell growth, phosphorothioate antisense oligonucleotides (ASOs) were tested to selectively downregulate PLK1 expression in MDA-MB-435 (breast cancer), HeLa S3 (cervical carcinoma) and A549 (non-small cell lung cancer) cells. ASOs were identified which suppress PLK1 mRNA and protein in a dose-dependent and sequence-specific manner. This approach also led to reduced PLK1 serine/threonine kinase activity. Downregulation of cellular PLK1 levels in cancer cells altered cell cycle progression moderately with an elevated percentage (20-30%) of cells in G(2)/M. Furthermore, cells with reduced PLK1 protein gained a rounded phenotype with multiple centrosomes. Moreover, ASO treatment resulted in potent antiproliferative effects in cell culture. Considerable antitumor activity was observed in vivo against A549 cells. This study suggests that antisense inhibitors targeted against PLK1 at well tolerated doses may be considered as a cancer therapeutic agent.	Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Sch Med, Dept Otorhinolaryngol, D-60596 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.	Stebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Agrawal S, 1996, TRENDS BIOTECHNOL, V14, P376, DOI 10.1016/0167-7799(96)10053-6; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crooke ST, 1998, ANTISENSE NUCLEIC A, V8, pVII, DOI 10.1089/oli.1.1998.8.vii; Crooke ST, 2000, ONCOGENE, V19, P6651, DOI 10.1038/sj.onc.1204093; CROOKE ST, 1994, CLIN PHARMACOL THER, V56, P641, DOI 10.1038/clpt.1994.189; Cunningham CC, 2000, CLIN CANCER RES, V6, P1626; DIRKSEN ML, 1981, J BIOL CHEM, V256, P1569; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HARTWELL LH, 1973, GENETICS, V74, P267; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Knecht R, 1999, CANCER RES, V59, P2794; Kuss B, 1999, ANN ONCOL, V10, P495, DOI 10.1023/A:1026416314887; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; SHARON G, 1990, GENETICS, V125, P475; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; SUNKEL CE, 1988, J CELL SCI, V89, P25; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yuan JP, 1997, AM J PATHOL, V150, P1165; Yuen AR, 1999, CLIN CANCER RES, V5, P3357; ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3	39	147	158	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3162	3171		10.1038/sj.onc.1205412	http://dx.doi.org/10.1038/sj.onc.1205412			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082631				2022-12-17	WOS:000175373600007
J	Song, JZ; Stirzaker, C; Harrison, J; Melki, JR; Clark, SJ				Song, JZ; Stirzaker, C; Harrison, J; Melki, JR; Clark, SJ			Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells	ONCOGENE			English	Article						DNA methylation; CpG islands; bisulphite genomic sequencing; GSTP1; prostate cancer	DE-NOVO METHYLATION; CPG ISLAND; PROMOTER HYPERMETHYLATION; DNA HYPERMETHYLATION; P1 GENE; EXPRESSION; TRANSCRIPTION; SP1; METHYLTRANSFERASES; DIFFERENTIATION	Understanding what triggers hypermethylation of tumour suppressor genes in cancer cells is critical if we are to discern the role of methylation in the oncogenic process. CpG sites in CpG island promoters, that span most tumour suppressor genes, remain unmethylated in the normal cell, despite the fact that CpG sites are the prime target for de novo methylation by the DNA methyltransferases. The CpG island-associated with the GSTP1 gene is an intriguing example of a CpG rich region which is susceptible to hypermethylation in the majority of prostate tumours and yet is unmethylated in the normal prostate cell. In this study we evaluate a number of factors purported to be involved in hypermethylation to test their role in triggering hypermethylation of GSTP1 in prostate cancer DU145 and LNCaP cells. We find that hypermethylation is not associated with (1) elevated expression of the DNA methyltranferases, or (2) removal of Sp1 transcription factor binding sites in the CpG island or (3) removal of CpG island boundary elements or (4) prior gene silencing. Instead our results support a model that requires a combination of prior gene silencing and random 'seeds' of methylation to trigger hypermethylation of the GSTP1 gene in the prostate cancer cell. We propose that the GSTP1 gene is initially silenced in the prostate cancer and random sites of methylation accumulate that result in subsequent hypermethylation and chromatin remodelling.	Royal Prince Alfred Hosp, Kanematsu Labs, Sydney Canc Ctr, Camperdown, NSW 2050, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; CSIRO, Sydney Lab, N Ryde, NSW 1670, Australia	University of Sydney; University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Clark, SJ (corresponding author), Royal Prince Alfred Hosp, Kanematsu Labs, Sydney Canc Ctr, Camperdown, NSW 2050, Australia.		Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008	Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030; Stirzaker, Clare/0000-0001-5601-3140				Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARK SJ, 1995, DNA NUCLEOPROTEIN ST, P123; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; Eads CA, 1999, CANCER RES, V59, P5860; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Hsieh CL, 1999, MOL CELL BIOL, V19, P8211; Huschtscha LI, 1998, CANCER RES, V58, P3508; Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jost JP, 1997, NUCLEIC ACIDS RES, V25, P4545, DOI 10.1093/nar/25.22.4545; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kuzmin I, 1999, ONCOGENE, V18, P5672, DOI 10.1038/sj.onc.1202959; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Melki JR, 2000, BLOOD, V95, P3208; Melki JR, 1999, CANCER RES, V59, P3730; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Tchou JC, 2000, INT J ONCOL, V16, P663; Thalmann GN, 1996, J NATL CANCER I, V88, P794, DOI 10.1093/jnci/88.12.794; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WARNECKE P, 1998, THESIS U SYDNEY SYDN; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; Wong DJ, 1997, CANCER RES, V57, P2619	40	147	152	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1048	1061		10.1038/sj.onc.1205153	http://dx.doi.org/10.1038/sj.onc.1205153			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850822				2022-12-17	WOS:000173580100008
J	Stallcup, MR				Stallcup, MR			Role of protein methylation in chromatin remodeling and transcriptional regulation	ONCOGENE			English	Review						protein methylation; coactivators; histones; transcriptional regulation; chromatin	YEAST ARGININE METHYLTRANSFERASE; STEROID-RECEPTOR COACTIVATOR-1; HISTONE H3; IN-VITRO; SUBCELLULAR-LOCALIZATION; N-METHYLTRANSFERASE; CRYSTAL-STRUCTURE; ACETYLATION; CELLS; ACETYLTRANSFERASE	Recent findings suggest that lysine and arginine-specific methylation of histones may cooperate with other types of post-translational histone modification to regulate chromatin structure and gene transcription. Proteins that methylate histones on arginine residues can collaborate with other coactivators to enhance the activity of specific transcriptional activators such as nuclear receptors, Lysine methylation of histones is associated with transcriptionally active nuclei, regulates other types of histone modifications, and is necessary for proper mitotic cell divisions. The fact that some transcription factors and proteins involved in RNA processing can also be methylated suggests that protein methylation may also contribute in other ways to regulation of transcription and post-transcriptional steps in gene regulation. In future work, it will be important to develop methods for evaluating the precise roles of protein methylation in the regulation of native genes in physiological settings, e.g. by using chromatin immunoprecipitation assays, differentiating cell culture systems, and genetically altered cells and animals. It will also be important to isolate additional protein methyltransferases by molecular cloning and to characterize new methyltransferase substrates, the regulation of methyltransferase activities, and the roles of new methyltransferases and substrates.	Univ So Calif, Dept Pathol, HMR 301, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301, 2011 Zonal Ave, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK055274, R01DK055274] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55274] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Glass CK, 2000, GENE DEV, V14, P121; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEE YW, 2001, UNPUB; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Ma H, 1999, MOL CELL BIOL, V19, P6164; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAIK WK, 1974, ARCH BIOCHEM BIOPHYS, V165, P369, DOI 10.1016/0003-9861(74)90175-1; PAIK WK, 1973, BIOCHEM BIOPH RES CO, V51, P781, DOI 10.1016/0006-291X(73)91383-1; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VANHOLDE KE, 1989, CHROMATIN, P111; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Westin S, 2000, ADV PHARMACOL, V47, P89; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	64	147	152	1	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3014	3020		10.1038/sj.onc.1204325	http://dx.doi.org/10.1038/sj.onc.1204325			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420716				2022-12-17	WOS:000169308500004
J	Fachinger, G; Deutsch, U; Risau, W				Fachinger, G; Deutsch, U; Risau, W			Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2	ONCOGENE			English	Article						receptor-type tyrosine phosphatase; vascular endothelium; Tie-2; interaction	GROWTH-FACTOR; EMBRYONIC ANGIOGENESIS; KINASE TIE2; IN-VITRO; EXPRESSION; CELLS; VASCULOGENESIS; GENE; LETHALITY; LIGANDS	During development of the vertebrate vascular system essential signals are transduced via protein-tyrosine phosphorylation. Null-mutations of receptor-tyrosine kinase (RTK) genes expressed in endothelial (ECs) display early lethal vascular phenotypes, we aimed to identify endothelial protein-tyrosine phosphatases (PTPs), which should have similar importance in EC-biology. A murine receptor-type PTP was identified by a degenerated PCR cloning approach from endothelial cells (VE-PTP). By in situ hybridization this phosphatase was found to be specifically expressed in vascular ECs throughout mouse development. In experiments using GST-fusion proteins, as well as in transient transfections, trapping mutants of VE-PTP co-precipitated with the Angiopoietin receptor Tie-2, but not with the Vascular Endothelial Growth Factor receptor 2 (VEGFR-2/Flk-1). In addition, VE-PTP dephosphorylates Tie-2 but not VEGFR-2. We conclude that VE-PTP is a Tie-2 specific phosphatase expressed in ECs, and VE-PTP phosphatase activity serves to specifically modulate Angiopoietin/Tie-2 function. Based on its potential role as a regulator of blood vessel morphogenesis and maintenance, VE-PTP is a candidate gene for inherited vascular malformations similar to the Tie-2 gene.	Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	Max Planck Society	Deutsch, U (corresponding author), Max Planck Inst Physiol & Clin Res, WG Kerckhoff Inst, Dept Mol Cell Biol, Pk Str 1, D-61231 Bad Nauheim, Germany.			Deutsch, Urban/0000-0003-4265-6262				Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; SCHLAEGER TM, 1998, THESIS PHILIPPS U MA; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514	38	147	172	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5948	5953		10.1038/sj.onc.1202992	http://dx.doi.org/10.1038/sj.onc.1202992			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557082				2022-12-17	WOS:000083270700012
J	Shtil, AA; Mandlekar, S; Yu, R; Walter, RJ; Hagen, K; Tan, TH; Roninson, IB; Kong, ANT				Shtil, AA; Mandlekar, S; Yu, R; Walter, RJ; Hagen, K; Tan, TH; Roninson, IB; Kong, ANT			Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells	ONCOGENE			English	Article						taxol; colchicine; MAP kinases; microtubules; breast cancer	N-TERMINAL KINASE-1; EPIDERMAL GROWTH-FACTOR; C-JUN; KAPPA-B; INDUCED APOPTOSIS; GENE-EXPRESSION; UV IRRADIATION; JNK ACTIVATION; LEUKEMIA-CELLS; STRESS	Drug design targeted at microtubules has led to the advent of some potent anti-cancer drugs. In the present study, we demonstrated that microtubule-binding agents (MBAs) taxol and colchicine induced immediate early gene (c-jun and A TF3) expression, cell cycle arrest, and apoptosis in the human breast cancer cell line MCF-7. To elucidate the signal transduction pathways that mediate such biological activities of MBAs, we studied the involvement of mitogen-activated protein (MAP) kinases, Treatment,vith tah;ol, colchicine, or other MBAs (vincristine, podophyllotoxin, nocodazole) stimulated the activity of c-jun N-terminal kinase 1 (JNK1) in MCF-7 cells. In contrast, p38 was activated only by taxol and none of the MBAs changed the activity of extracellular signal-regulated protein kinase 2 (ERK2), Activation of JNK1 or p38 by MBAs occurred subsequent to the morphological changes in the microtubule cytoskeleton induced by these compounds. furthermore, baccatine III and beta-lumicolchicine, inactive analogs of taxol and colchicine, respectively, did not activate JNK1 or p38, These results suggest that interactions between microtubules and MBAs are essential for the activation of these kinases, Pretreatment with the antioxidants N-acetyl-L-cysteine (NAC), ascorbic acid or vitamin E, blocked H2O2- or doxorubicin-induced JNK1 activity, but had no effect on JNK1 activation by MBAs, excluding a role for oxidative stress. However, BAPTA/AM, a specific intracellular Ca2+ chelator, attenuated JNK1 activation by taxol but not by colchicine, and had no effect on microtubule changes induced by taxol. Thus, stabilization or depolymerization of microtubules may regulate JNK1 activity via distinct downstream signaling pathways. The differential activation of MAP kinases opens up a new avenue for addressing the mechanism of action of anti-microtubule drugs.	Univ Illinois, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, Coll Pharm, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Cook Cty Hosp, Dept Surg, Chicago, IL 60612 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; Baylor College of Medicine	Kong, ANT (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol, Dept Pharmaceut & Pharmacodynam, Coll Pharm, Chicago, IL 60607 USA.		Tan, Tse-Hua/E-3983-2010; Shtil, Alexander A./K-1568-2017; Kong, Ah-Ng Tony/AAX-2828-2020; Roninson, Igor/K-1310-2017; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Shtil, Alexander A./0000-0001-6469-0221; Roninson, Igor/0000-0002-9211-1327; Tan, Tse-Hua/0000-0003-4969-3170	NCI NIH HHS [R37CA40333] Funding Source: Medline; NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIEHS NIH HHS [R01-ES06887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; BHALLA K, 1993, LEUKEMIA, V7, P563; BUCKLER AJ, 1988, MOL CELL BIOL, V8, P1371, DOI 10.1128/MCB.8.3.1371; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dustin P., 1984, MICROTUBULES; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JORDAN MA, 1991, CANCER RES, V51, P2212; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Komarov PG, 1996, INT J CANCER, V68, P245, DOI 10.1002/(SICI)1097-0215(19961009)68:2<245::AID-IJC18>3.0.CO;2-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANIE S, 1993, J BIOL CHEM, V268, P13675; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; SYMPSON CJ, 1990, EXP CELL RES, V189, P28, DOI 10.1016/0014-4827(90)90252-6; UNEMORI EN, 1986, J CELL BIOL, V103, P1021, DOI 10.1083/jcb.103.3.1021; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	42	147	156	1	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					377	384		10.1038/sj.onc.1202305	http://dx.doi.org/10.1038/sj.onc.1202305			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927194				2022-12-17	WOS:000078166500010
J	Kharbanda, S; Yuan, ZM; Weichselbaum, R; Kufe, D				Kharbanda, S; Yuan, ZM; Weichselbaum, R; Kufe, D			Determination of cell fate by c-Abl activation in the response to DNA damage	ONCOGENE			English	Review						c-Abl; DNA damage; growth arrest; recombination; apoptosis	PROTEIN-KINASE-C; RADIATION-INDUCED APOPTOSIS; ATAXIA-TELANGIECTASIA GENE; NUCLEAR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DROSOPHILA-ABL; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; IONIZING-RADIATION; CATALYTIC SUBUNIT	The cellular response to DNA damage includes growth arrest and activation of DNA repair, Certain insights into how DNA damage is converted into intracellular signals that control the genotoxic stress response have been derived from the finding that the c-Abl protein tyrosine kinase is activated by ionizing radiation and other DNA-damaging agents. c-Abl associates with the DNA-dependent protein kinase (DNA-PK) and is activated by DNA-PK-dependent phosphorylation, The ataxia telangiectasia mutated (ATM) gene product also contributes to c-Abl activation, The demonstration that c-Abl binds to p53, induces the transactivation function of p53 and activates p21 expression has supported involvement of c-Abl in regulation of the p53-dependent G1 arrest response, Interaction between c-Abl and the Rad51 protein has also provided support for involvement of c-Abl in recombinational repair of DNA strand breaks, Defects in G1 arrest and repair predispose to replication of damaged templates and, in the event of irreparable DNA lesions, induction of apoptosis, The available evidence indicates that c-Abl effects proapoptotic function by a mechanism largely independent of p53, c-Abl also functions as an upstream effector of the proapoptotic JNK/SAPK and p38 MAPK pathways. In addition, c-Abl-dependent inhibition of PI 3-kinase contributes to the induction of apoptosis, The findings thus suggest that, in response to genotoxic stress, c-Abl functions in determining cell fate, that is growth arrest and repair or induction of apoptosis, The physiologic function of c-Abl may reside in control of the cellular response to DNA strand breaks that occur during DNA replication, genetic recombination and gene rearrangements.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431, CA 55241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; Agami R, 1998, ONCOGENE, V16, P1779, DOI 10.1038/sj.onc.1201708; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN PC, 1975, NATURE, V258, P427; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dorsch M, 1996, P NATL ACAD SCI USA, V93, P13131, DOI 10.1073/pnas.93.23.13131; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Game J., 1983, YEAST GENETICS FUNDA, P109; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hardin JD, 1996, ONCOGENE, V12, P2669; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HIRANO Y, 1995, ONCOGENE, V10, P1879; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; ISHII T, 1995, BIOCHEM BIOPH RES CO, V216, P970, DOI 10.1006/bbrc.1995.2715; ISHII T, 1993, J BIOL CHEM, V268, P18633; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; MATTIONI T, 1995, ONCOGENE, V10, P1325; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Milner LA, 1996, P NATL ACAD SCI USA, V93, P13014, DOI 10.1073/pnas.93.23.13014; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PATERSON MC, 1979, CANCER RES, V39, P3725; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RESNICK M A, 1987, P157; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VANETTEN RA, 1995, ONCOGENE, V10, P1977; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; YUAN ZM, 1999, IN PRESS J BIOL CHEM; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	176	147	154	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3309	3318		10.1038/sj.onc.1202571	http://dx.doi.org/10.1038/sj.onc.1202571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916993	Bronze			2022-12-17	WOS:000078048200012
J	Crook, T; Brooks, LA; Crossland, S; Osin, P; Barker, KT; Waller, J; Philp, E; Smith, PD; Yulug, I; Peto, J; Parker, G; Allday, MJ; Crompton, MR; Gusterson, BA				Crook, T; Brooks, LA; Crossland, S; Osin, P; Barker, KT; Waller, J; Philp, E; Smith, PD; Yulug, I; Peto, J; Parker, G; Allday, MJ; Crompton, MR; Gusterson, BA			p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours	ONCOGENE			English	Article						BRCA1; BRCA2; p53; mutation(s); breast; tumour; familial	WILD-TYPE CHROMOSOME; OVARIAN-CANCER; FAMILIAL BREAST; MICROSATELLITE INSTABILITY; GERMLINE MUTATIONS; POINT MUTATION; CELL-LINES; GENE; CARCINOMA; TUMORS	The status of p53 was investigated in breast tumours arising in germ-line carriers of mutant alleles of BRCA1 and BRCA2 and in a control series of sporadic breast tumours, p53 expression was detected in 20/26 (77%) BRCA1-, 10/22 (45%) BRCA2-associated and 25/72 (35%) grade-matched sporadic tumours, Analysis of p53 sequence revealed that the gene was mutant in 33/50 (66%) BRCA-associated tumours, whereas 7/20 (35%) sporadic grade-matched tumours contained p53 mutation (P<0.05), A number of the mutations detected in the BRCA-associated tumours have not been previously described in human cancer databases, whilst others occur extremely rarely. Analysis of additional genes, p16(INK4), Ki-ras and beta-globin revealed absence or very low incidence of mutations, suggesting that the higher frequency of p53 mutation in the BRCA-associated tumours does not reflect a generalized increase in susceptibility to the acquisition of somatic mutation. Furthermore, absence of frameshift mutations in the polypurine tracts present in the coding sequence of the TGF beta type II receptor (TGF beta IIR) and Bax implies that loss of function of BRCA1 or BRCA2 does not confer a mutator phenotype such as that found in tumours with microsatellite instability (MST), p21(Waf1) was expressed in BRCA-associated tumours regardless of p53 status and, furthermore, some tumours expressing wild-type p53 did not express detectable p21(Waf1). These data do not support, therefore, the simple model based on studies of BRCA-/- embryos, in which mutation of p53 in BRCA-associated tumours results in loss of p21(Waf1) expression and deregulated proliferation, Rather, they imply that proliferation of such tumours will be subject to multiple mechanisms of growth regulation.	Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; London Sch Hyg & Trop Med, Div Clin Sci, London W1, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England	University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London	Crook, T (corresponding author), Inst Canc Res, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.		gusterson, barry a/D-3752-2009	Yulug, Isik/0000-0002-7577-2502	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BOS JL, 1989, CANCER RES, V49, P4682; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Chung YJ, 1997, ONCOGENE, V15, P1719, DOI 10.1038/sj.onc.1201343; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Eisinger F, 1996, CANCER RES, V56, P471; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GLEBOV OK, 1994, CANCER RES, V54, P3703; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kelsell DP, 1996, LANCET, V347, P1554, DOI 10.1016/S0140-6736(96)90707-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Lakhani SR, 1997, LANCET, V349, P1505; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; QUESNEL B, 1995, BRIT J CANCER, V72, P351, DOI 10.1038/bjc.1995.337; REID TM, 1993, P NATL ACAD SCI USA, V90, P3904, DOI 10.1073/pnas.90.9.3904; ROCHLITZ CF, 1989, CANCER RES, V49, P357; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Visscher DW, 1996, DIAGN MOL PATHOL, V5, P187, DOI 10.1097/00019606-199609000-00007; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; XU L, 1994, CANCER RES, V54, P5262; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; ZHANG SY, 1994, CANCER RES, V54, P5050	44	147	150	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	1998	17	13					1681	1689		10.1038/sj.onc.1202106	http://dx.doi.org/10.1038/sj.onc.1202106			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796697	Green Published			2022-12-17	WOS:000076200100006
J	Lim, CP; Jain, N; Cao, XM				Lim, CP; Jain, N; Cao, XM			Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1	ONCOGENE			English	Article						egr-1; stress; MAP kinases; p38/JNK1	SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; MAP KINASE KINASE; C-FOS PROMOTER; PROTEIN-KINASE; TERNARY COMPLEX; SODIUM ARSENITE; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; PLASMA-MEMBRANE	The Ras/Raf/MAP kinase (ERK) pathway is a major signaling pathway induced by growth factors in mammalian cells. Two other types of mammalian MAP kinases, JNK (SAPK) and p38 (RK, CSBP), are induced by environmental stress. Although the immediate-early gene, egr-1, is induced by growth factors, cytokines, differentiation signals and DNA damaging agents, less is known about its induction by environmental stress and the mechanism involved. Here we report that in NIH3T3 cells, egr-1 is induced by various stress treatments such as heat shock, sodium arsenite, ultraviolet (U.V.) radiation, and anisomycin. p38 and JNK1, but not ERK2, were activated by these stress treatments. Induction of egr-1 by anisomycin is inhibited by a specific inhibitor of p38, SE 203580. We also show that p38 and JNK1 activated by their upstream kinases induce egr-1 promoter activity through activation of the ternary complex factor, Elk-l. The stress treatments also lead to an increase in Egr-1 protein phosphorylation and its DNA binding activity. Together, our data suggest that induction of egr-1 gene by growth factors and stress are mediated through different subgroups of MAP kinases which may also differentially affect egr-1 function on its target genes.	Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Cao, XM (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Signal Transduct Lab, Singapore 117609, Singapore.							Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P1345; CAO XM, 1992, J BIOL CHEM, V267, P12991; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG RN, 1995, ENVIRON MOL MUTAGEN, V25, P188, DOI 10.1002/em.2850250304; HUANG RP, 1995, ONCOGENE, V10, P467; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JOHNSTON D, 1980, J BIOL CHEM, V255, P6975; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KHARBANDA S, 1993, BIOCHEMISTRY-US, V32, P9137, DOI 10.1021/bi00086a019; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; van Wijk R, 1985, Int J Hyperthermia, V1, P147, DOI 10.3109/02656738509029281; VANWIJK R, 1993, J CELL PHYSIOL, V155, P265, DOI 10.1002/jcp.1041550207; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	61	147	151	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2915	2926		10.1038/sj.onc.1201834	http://dx.doi.org/10.1038/sj.onc.1201834			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671412				2022-12-17	WOS:000073988200010
J	Kondo, Y; Kondo, S; Tanaka, Y; Haqqi, T; Barna, BP; Cowell, JK				Kondo, Y; Kondo, S; Tanaka, Y; Haqqi, T; Barna, BP; Cowell, JK			Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis	ONCOGENE			English	Article						telomerase; apoptosis; cisplatin; glioma	COMBINATION THERAPY; ANTICANCER AGENTS; GLIOMA-CELLS; P53; RESISTANCE; CANCER; CIS-DIAMMINEDICHLOROPLATINUM(II); INDUCTION; IDENTIFICATION; ACCUMULATION	Malignant glioblastomas grow very rapidly and are generally resistant to either DNA-damaging drugs or gamma-irradiation, If tumor cells could be made more susceptible to cell death with treatments, this would clearly represent a significant improvement in the success of treatment. Recently, telomerase has become a focus of interest among oncologists as a target for treating cancer cells. Telomerase elongates telomeric DNA repeats (TTAGGG)(n) and is important in protecting and replicating DNA, The vast majority of tumor cells, indeed, express telomerase activity whereas normal somatic cells, except for a few cells, do not, Since telomerase is essential for protecting DNA, we may be able to make tumors more sensitive to treatments with DNA-damaging drugs by inhibiting telomerase activity, In this study, we used cis-diamminedichloroplatinum (cisplatin)-sensitive U87-MG cells and cisplatin-resistant U251-MG of human malignant glioblastoma cell lines, U87-MG cells did not express telomerase activity, whereas telomerase was highly detected in U251-MG cells. Interestingly, inhibition of telomerase with an antisense telomerase expression vector not only decreased telomerase activity but also increased susceptibility to cisplatin-induced apoptotic cell death in U251-MG cells. These findings suggest that treatment with antisense telomerase may represent a new chemosensitisation for tumors resistant to anticancer drugs.	Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosurg, Cleveland, OH 44195 USA; Tokyo Metropolitan Inst Med Sci, Dept Microbiol, Tokyo 113, Japan; Metrohlth Med Ctr, Rammel Kamp Ctr Educ & Res, Cleveland, OH 44109 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Tokyo Metropolitan Institute of Medical Science; MetroHealth System	Kondo, S (corresponding author), Cleveland Clin Fdn, Brain Tumor Neurooncol Ctr, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Cowell, John/0000-0002-2079-5950				ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; DeMasters BKK, 1997, AM J CLIN PATHOL, V107, P548; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hiyama E, 1997, CANCER RES, V57, P326; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; IKEDA H, 1987, CANCER RES, V47, P231; KATO H, 1997, P JAPAN CANC ASS, V56, P701; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONDO S, 1995, J NEUROSURG, V82, P469, DOI 10.3171/jns.1995.82.3.0469; KONDO S, 1995, CANCER RES, V55, P6166; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; Kondo S, 1996, ONCOGENE, V13, P1279; KONDO S, 1995, ONCOGENE, V10, P2001; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; ONODA JM, 1989, CANCER RES, V49, P2844; OZOLS RF, 1987, J CLIN ONCOL, V5, P641, DOI 10.1200/JCO.1987.5.4.641; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Sallinen P, 1997, AM J PATHOL, V150, P1159; Strahl C, 1996, MOL CELL BIOL, V16, P53; TIMMERBOSSCHA H, 1989, J NATL CANCER I, V81, P1069, DOI 10.1093/jnci/81.14.1069; VAN MEIR EG, 1994, CANCER RES, V54, P649	38	147	169	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2243	2248		10.1038/sj.onc.1201754	http://dx.doi.org/10.1038/sj.onc.1201754			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619833				2022-12-17	WOS:000073298000009
J	Sato, S; Roberts, K; Gambino, G; Cook, A; Kouzarides, T; Goding, CR				Sato, S; Roberts, K; Gambino, G; Cook, A; Kouzarides, T; Goding, CR			CBP/p300 as a co-factor for the Microphthalmia transcription factor	ONCOGENE			English	Article						microphthalmia; transcription activation; E1A; CBP; melanocytes	MELANOCYTE-SPECIFIC TRANSCRIPTION; NUCLEAR-PROTEIN CBP; ACTIVATION DOMAINS; TYROSINASE GENE; E1A; DIFFERENTIATION; MUTATIONS; P300; EXPRESSION; MYOBLASTS	The Microphthalmia basic-Helix-loop-Helix-Leucine Zipper (bHLH-LZ) transcription factor (Mi) plays a crucial role in the genesis of melanocytes; mice deficient for a functional (Microphthalmia) gene product lack all pigment cells, We show here that the Mi activation domain resides N-terminal to the DNA-binding domain and that as little as 18 amino acids are sufficient to mediate transcription activation, The minimal activation region of Mi is highly conserved in the related transcription factor TFE3 and is predicted to adopt an amphipathic alphahelical conformation, This region of Mi is also highly conserved with a region of E1A known to be essential for binding the CBP/p300 transcription cofactor, Consistent with these observations, the Mi activation domain can interact in vitro with CBP specifically through a region of CBP required for complex formation with E1A, P/CAF and c-Fos, and anti p300 antibodies can co-immunoprecipitate Mi from both melanocyte and melanoma cell lines, In addition, co-transfection of a vector expressing CBP2 (aas 1621-1891) fused to the VP16 activation domain potentiated the ability of Mi to activate transcription, confirming the significance of the CBP-Mi interaction observed in vitro. These data suggest that transcription activation by Mi is achieved at least in part by recruitment of CBP, The parallels between transcription regulation by Microphthalmia in melanocytes and MyoD in muscle cells are discussed.	MARIE CURIE RES INST,EUKARYOT TRANSCRIPT LAB,OXTED RH8 0TL,SURREY,ENGLAND; CRC,WELLCOME INST,CAMBRIDGE CB2 1QR,ENGLAND	Wellcome Trust Sanger Institute			Sato, Shigeru/ABE-2090-2020	Goding, Colin/0000-0002-1614-3909; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BANERJEE AC, 1994, ONCOGENE, V9, P1733; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BATTACHARYA S, 1996, NATURE, V383, P344; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FITZPATRICK TB, 1979, BIOL MELANIN PIGMENT; GANSS R, 1994, J BIOL CHEM, V269, P29808; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Janknecht R, 1996, ONCOGENE, V12, P1961; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; OELGESCHLAGER M, 1996, EMBO J, V15, P1227; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; PERKINS ND, 1997, SCIENCE, V275, P451; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STEEL KP, 1989, DEVELOPMENT, V107, P453; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; YACUIK P, 1991, MOL CELL BIOL, V11, P5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	57	147	151	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3083	3092		10.1038/sj.onc.1201298	http://dx.doi.org/10.1038/sj.onc.1201298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223672				2022-12-17	WOS:A1997XG10000011
J	NATOLI, G; IANNI, A; COSTANZO, A; DEPETRILLO, G; ILARI, I; CHIRILLO, P; BALSANO, C; LEVRERO, M				NATOLI, G; IANNI, A; COSTANZO, A; DEPETRILLO, G; ILARI, I; CHIRILLO, P; BALSANO, C; LEVRERO, M			RESISTANCE TO FAS-MEDIATED APOPTOSIS IN HUMAN HEPATOMA-CELLS	ONCOGENE			English	Article						FAS; SOLUBLE FAS; ALTERNATIVE SPLICING; APOPTOSIS; PROTEIN SYNTHESIS INHIBITORS	TUMOR-NECROSIS-FACTOR; FACTOR RECEPTOR SUPERFAMILY; MOLECULAR-CLONING; SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; PROTEIN; DNA; EXPRESSION; INDUCTION; MEMBER	CTLs- and lymphokine-induced apoptosis of infected hepatocytes during the course of chronic viral hepatitis is thought to be important for both disease termination and prevention of hepatocellular transformation, We therefore studied apoptosis induced by Pas (APO-1 or CD95) - a widely expressed cell surface receptor whose ligand is involved in lymphocyte cytotoxicity - in a set of human hepatoma cell lines. As normal hepatocytes, all of the human hepatoma cell lines tested do express detectable amounts of Fas on their surface. Nevertheless, only PLC/PRF/5 cells undergo apoptosis following treatment with anti-Fas. Systematic cloning and sequence analysis of the Pas cDNA did not show mutations in the Pas gene in any of the cells lines tested, However, due to alternative splicing, 5 to 10% of the Fas cDNAs are deleted of 63 internal nucleotides corresponding to the transmembrane domain, thus encoding for a soluble and secreted form of Fas (Fas Delta TM), potentially able to neutralize anti-Fas or Fas-Ligand. Although we could not demonstrate a direct correlation between resistance of different hepatoma cell lines to Pas mediated death and endogenous expression of this transcript, we show that PLC/PRF 5 stable transfectants overexpressing Fas Delta TM are less sensitive to anti-Pas than control cells, Tn three different cell lines, resistance to anti-Pas was overcome by treatment with the protein synthesis inhibitor cyclohexymide, Although this could suggest the existence of short-lived repressors of the Fas-activated apoptotic signalling pathway(s), we show that translational inhibition is not required for the synergistic effect of cycloheximide to take place, and that resistant hepatoma cells can be sensitized to anti-Pas by subinhibitory concentrations of this protein synthesis inhibitor. Since cycloheximide is able to activate intracellular signalling independently on its effects on protein sysnthesis, we suggest that it might provide a costimulatory signal that cooperates with Fas in the induction of cell death and that, at least in the cells we tested, resistance to Fas is not an active process involving gene transciption and translation but only the consequence of an inadequate apoptotic stimulation.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,IST CLIN MED 1,I-00161 ROME,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,LAQUILA,ITALY; UNIV CAGLIARI,IST MED INTERNA,CAGLIARI,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of Cagliari	NATOLI, G (corresponding author), UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Costanzo, Antonio/D-3896-2012; Natoli, gioacchino/J-2100-2018; Costanzo, Antonio/GZG-2433-2022; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Levrero, Massimo/0000-0002-4978-0875				ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALEXANDER JJ, 1976, S AFR MED J, V50, P2124; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CRISPE IN, 1994, IMMUNITY, V1, P347; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1979, LANCET, V2, P827; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; MORIMOTO H, 1993, CANCER RES, V53, P2591; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OSAWA H, 1986, EUR J IMMUNOL, V16, P467, DOI 10.1002/eji.1830160426; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Popper H., 1988, LIVER BIOL PATHOBIOL, P1087; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHALL TJ, 1990, CELL, V61, P361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WALLACH D, 1984, J IMMUNOL, V132, P2464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	38	147	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1157	1164						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566976				2022-12-17	WOS:A1995RX18000019
J	COFFER, PJ; BURGERING, BMT; PEPPELENBOSCH, MP; BOS, JL; KRUIJER, W				COFFER, PJ; BURGERING, BMT; PEPPELENBOSCH, MP; BOS, JL; KRUIJER, W			UV ACTIVATION OF RECEPTOR TYROSINE KINASE-ACTIVITY	ONCOGENE			English	Article						UV; GROWTH FACTOR; RECEPTORS; EGF; INSULIN; SIGNAL TRANSDUCTION	ARACHIDONIC-ACID; EGF RECEPTOR; DNA-BINDING; NF-KAPPA; PROTEIN; INSULIN; CELLS; PHOSPHORYLATION; EXPRESSION; SIGNAL	The exposure of mammalian cells to ultraviolet radiation (UV) may lead to DNA damage resulting in mutation and thus possibly cancer, while irradiation can further act as a potent tumour promoter. In addition UV induces p21ras-mediated signalling leading to activation of transcription factors such as AP-1 and NF-kappa B, as well as activation of the Src tyrosine kinase. This 'UV-response' has been well studied in mammalian cells and furthermore is conserved in yeast, however the most upstream components of this signal transduction pathway have remained elusive. Here we show that UV rapidly activates both the EGF receptor and insulin receptor, as shown by tyrosine phosphorylation of these receptors. We demonstrate that this activation is due to autophosphorylation as it only occurs in cells containing receptors with a functional kinase domain. We have further analysed the propagation of the UV-induced signal to downstream events such as, IRS-1 and Shc tyrosine phosphorylation, phosphatidylinositol 3-kinase activation, leukotriene synthesis, MAP kinase activation and gene induction all of which are activated by UV irradiation. Importantly, we demonstrate that in cells expressing a 'kinase-dead' receptor mutant the UV-response is inhibited, blocking leukotriene synthesis, MAP kinase activation and transcriptional induction. Furthermore, prior-stimulation of cells with UV appears to reduce further responsiveness to addition of growth factor suggesting a common signaling pathway. These data demonstrate a critical role for receptor-mediated events in regulating the response of mammalian cells to UV exposure.	UNIV UTRECHT,3508 TA UTRECHT,NETHERLANDS; UNIV GRONINGEN,CTR BIOL,DEPT GENET,9750 AA HAREN,NETHERLANDS	Utrecht University; University of Groningen	COFFER, PJ (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020	Peppelenbosch, Maikel/0000-0001-9112-6028				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1985, DNA REPAIR; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, BIOCHEM SOC T, V21, P888, DOI 10.1042/bst0210888; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALDENHOVEN E, 1994, J BIOL CHE3M, V269, P22146; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; COFFER P, 1994, ONCOGENE, V9, P911; COHEN D, 1993, PHOTOCHEM PHOTOBIOL, V57, P383, DOI 10.1111/j.1751-1097.1993.tb02306.x; DEEG HJ, 1989, BLOOD, V73, P369; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FISHER SM, 1989, PROGR CLIN BIOL RES, V298, P249; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fursin G. I., 1990, Engineering Information in Data Bases and Knowledge Based Systems. Techno-Data '90. Proceedings of the International Conference Techno-Data '90, P107; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HAWK JLM, 1983, J INVEST DERMATOL, V80, P496, DOI 10.1111/1523-1747.ep12535038; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HURZA LL, 1993, J INVEST DERMATOL, V100, P35; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KRAMER M, 1993, J BIOL CHEM, V257, P13193; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVINE L, 1981, ADV CANCER RES, V35, P49, DOI 10.1016/S0065-230X(08)60908-2; MAHER VM, 1988, DNA REPLICATION MUTA, P465; MATSUI MS, 1989, J INVEST DERMATOL, V93, P617; MATSUI MS, 1991, CANCER CELLS, V31, P8; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKADATE T, 1990, EICOSANOIDS SKIN, P185; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Romerdahl C A, 1989, Cancer Commun, V1, P209; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WARMUTH I, 1994, CANCER RES, V54, P374; WHITMAN M, 1990, BIOCHEM J, V247, P165; YAMAMOTO S, 1992, CANCER CHEMOPREVENTION, P141; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	147	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					561	569						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543196				2022-12-17	WOS:A1995RN53000017
J	BERNARD, O; LECOINTE, N; JONVEAUX, P; SOUYRI, M; MAUCHAUFFE, M; BERGER, R; LARSEN, CJ; MATHIEUMAHUL, D				BERNARD, O; LECOINTE, N; JONVEAUX, P; SOUYRI, M; MAUCHAUFFE, M; BERGER, R; LARSEN, CJ; MATHIEUMAHUL, D			2 SITE-SPECIFIC DELETIONS AND T(1,14) TRANSLOCATION RESTRICTED TO HUMAN T-CELL ACUTE LEUKEMIAS DISRUPT THE 5' PART OF THE TAL-1 GENE	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; LEUCINE ZIPPER; SCL GENE; COMMON; LINE; ENCODES; RECOMBINATION	Analysis of several cases of t(1:14)(p32;q11) translocation present in 3% of T-cell acute leukemias (T-ALL) has revealed the tal-1 gene. This gene encodes a helix-loop-helix protein. It has been found to be expressed in normal bone marrow and in leukemic T-cell and erythroleukemia cell lines, but not in normal T cells. Recently, a site-specific deletion, tal(d), renamed tal(d1) in this paper, has been detected in a high proportion of pediatric T-ALL, which arose by a site-specific DNA recombination between tal-1 and a new locus termed SIL. In this study we searched for structural rearrangements within tal-1 in a panel of 134 non-selected leukemic patients (including 66 with T-ALL). Only 6% of patients with T-ALL harbored the tal(d1) deletion. A second specific deletion termed tal(d2) was observed in another 6% of T-ALL patients; it involves another site within tal-1 plus the same site as tal(d1) in the SIL locus. Similarly to tal(d1) deletion, tal dl junctions harbor structural characteristics that are reminiscent of aberrant recombinase activity. Moreover, we report a detailed analysis of the tal-1 gene structure. Transcription analysis and in vitro translation data are consistent with the differential expression of several TAL-1 protein species containing the HLH motif but differing in their amino terminus. Taken together, our data indicate that t(1;14) translocations and both tal(d) deletions disrupt the 5' part of the tal-1 gene, placing its entire coding sequences under the control of the regulatory elements of the TCR-delta-gene or the SIL gene, both of which are normally expressed in T-cell lineage.	INST GENET MOLEC,INSERM,U301,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE; HOP COCHIN,INSERM,U148,F-75674 PARIS 14,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Bernard, Olivier A./E-5721-2016; Souyri, Michele/L-5845-2017; Mathieu, Daniele/G-6092-2012	Bernard, Olivier/0000-0002-0463-9747				APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1989, NUCLEIC ACIDS RES, V17, P6427, DOI 10.1093/nar/17.15.6427; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CROCE CM, 1987, ADV VIRAL ONCOL, V7, P35; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HERSHFIELD MS, 1984, P NATL ACAD SCI-BIOL, V81, P253, DOI 10.1073/pnas.81.1.253; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KURTZBERG J, 1985, J EXP MED, V162, P1561, DOI 10.1084/jem.162.5.1561; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATHIEUMAHUL D, 1986, CR ACAD SCI III-VIE, V302, P525; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; SAIKI RK, 1988, SCIENCE, V239, P488	34	147	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1477	1488						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886719				2022-12-17	WOS:A1991GX27200027
J	Santini, R; Pietrobono, S; Pandolfi, S; Montagnani, V; D'Amico, M; Penachioni, JY; Vinci, MC; Borgognoni, L; Stecca, B				Santini, R.; Pietrobono, S.; Pandolfi, S.; Montagnani, V.; D'Amico, M.; Penachioni, J. Y.; Vinci, M. C.; Borgognoni, L.; Stecca, B.			SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX2; NEURAL STEM-CELL; SONIC HEDGEHOG; IN-VITRO; PROGENITOR; EXPRESSION; PROLIFERATION; SURVIVAL; LUNG; GLI1	Melanoma is one of the most aggressive types of human cancer, characterized by enhanced heterogeneity and resistance to conventional therapy at advanced stages. We and others have previously shown that HEDGEHOG-GLI (HH-GLI) signaling is required for melanoma growth and for survival and expansion of melanoma-initiating cells (MICs). Recent reports indicate that HH-GLI signaling regulates a set of genes typically expressed in embryonic stem cells, including SOX2 (sex-determining region Y (SRY)-Box2). Here we address the function of SOX2 in human melanomas and MICs and its interaction with HH-GLI signaling. We find that SOX2 is highly expressed in melanoma stem cells. Knockdown of SOX2 sharply decreases self-renewal in melanoma spheres and in putative melanoma stem cells with high aldehyde dehydrogenase activity (ALDH(high)). Conversely, ectopic expression of SOX2 in melanoma cells enhances their self-renewal in vitro. SOX2 silencing also inhibits cell growth and induces apoptosis in melanoma cells. In addition, depletion of SOX2 progressively abrogates tumor growth and leads to a significant decrease in tumor-initiating capability of ALDH(high) MICs upon xenotransplantation, suggesting that SOX2 is required for tumor initiation and for continuous tumor growth. We show that SOX2 is regulated by HH signaling and that the transcription factors GLI1 and GLI2, the downstream effectors of HH-GLI signaling, bind to the proximal promoter region of SOX2 in primary melanoma cells. In functional studies, we find that SOX2 function is required for HH-induced melanoma cell growth and MIC self-renewal in vitro. Thus SOX2 is a critical factor for self-renewal and tumorigenicity of MICs and an important mediator of HH-GLI signaling in melanoma. These findings could provide the basis for novel therapeutic strategies based on the inhibition of SOX2 for the treatment of a subset of human melanomas.	[Santini, R.; Pietrobono, S.; Pandolfi, S.; Montagnani, V.; Penachioni, J. Y.; Vinci, M. C.; Stecca, B.] Ist Toscano Tumori, Corp Res Lab, Tumor Cell Biol Lab, I-50139 Florence, Italy; [D'Amico, M.] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Borgognoni, L.] Ist Toscano Tumori, Reg Melanoma Referral Ctr, SM Annunziata Hosp, Plast Surg Unit, I-50139 Florence, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Stecca, B (corresponding author), Ist Toscano Tumori, Corp Res Lab, Tumor Cell Biol Lab, Viale Pieraccini 6, I-50139 Florence, Italy.	barbara.stecca@ittumori.it	Stecca, Barbara/J-7209-2016; Borgognoni, Lorenzo/X-1981-2019; Vinci, Maria Cristina/E-7401-2016; Pietrobono, Silvia S/K-3932-2016	Borgognoni, Lorenzo/0000-0002-3571-0366; Vinci, Maria Cristina/0000-0001-6323-147X; Pietrobono, Silvia S/0000-0002-5544-7286; Stecca, Barbara/0000-0003-1197-1622	AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG-9566]; Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze (FiorGen Foundation) [2011.1072]; AIRC fellowship	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze (FiorGen Foundation)(Fondazione Cassa Risparmio Firenze); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Gianni Gerlini (S Maria Annunziata Hospital, Florence, Italy), Nicola Pimpinelli (Department of Dermatology, University of Florence, Florence, Italy) and Riccardo Gattai (Department of Medical-Surgical Critical Area, General and Oncological Surgery, University of Florence, Florence, Italy) for providing samples. We also thank Alessio Zippo (INGM, Milan, Italy) and Lucio Luzzatto (Istituto Toscano Tumori, Florence, Italy) for helpful comments on the paper and Elisabetta Rovida and Eugenio Torre (Department of Biomedical and Clinical Sciences, University of Florence, Italy) for assistance with confocal microscopy and histology. This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro, IG-9566), Regional Health Research Program 2009 and Fondazione Cassa di Risparmio di Firenze (2011.1072, FiorGen Foundation) to BS. SP was supported by an AIRC fellowship.	Adameyko I, 2012, DEVELOPMENT, V139, P397, DOI 10.1242/dev.065581; Ahlfeld J, 2013, CANCER RES, V73, P3796, DOI 10.1158/0008-5472.CAN-13-0238; Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baltus GA, 2009, STEM CELLS, V27, P2175, DOI 10.1002/stem.168; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Boonyaratanakornkit JB, 2010, J INVEST DERMATOL, V130, P2799, DOI 10.1038/jid.2010.237; Brownell I, 2011, CELL STEM CELL, V8, P552, DOI 10.1016/j.stem.2011.02.021; Calloni GW, 2007, P NATL ACAD SCI USA, V104, P19879, DOI 10.1073/pnas.0708806104; Chartrain M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036762; Chen PL, 2013, MODERN PATHOL, V26, P44, DOI 10.1038/modpathol.2012.132; Chou YT, 2013, STEM CELLS, V31, P2607, DOI 10.1002/stem.1518; Civenni G, 2011, CANCER RES, V71, P3098, DOI 10.1158/0008-5472.CAN-10-3997; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Favaro R, 2009, NAT NEUROSCI, V12, P1248, DOI 10.1038/nn.2397; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Freier K, 2010, GENE CHROMOSOME CANC, V49, P9, DOI 10.1002/gcc.20714; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Girouard SD, 2012, LAB INVEST, V92, P362, DOI 10.1038/labinvest.2011.188; Girouard SD, 2011, LAB INVEST, V91, P647, DOI 10.1038/labinvest.2011.50; Gopinath S, 2013, CARCINOGENESIS, V34, P550, DOI 10.1093/carcin/bgs375; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hu YP, 2012, AM J CANCER RES, V2, P340; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hutz K, 2014, CARCINOGENESIS, V35, P942, DOI 10.1093/carcin/bgt410; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Jalili A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069064; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Laga AC, 2011, EXP DERMATOL, V20, P339, DOI 10.1111/j.1600-0625.2011.01247.x; Laga AC, 2010, AM J PATHOL, V176, P903, DOI 10.2353/ajpath.2010.090495; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lee J, 1997, DEVELOPMENT, V124, P2537; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Miyagi S, 2006, J BIOL CHEM, V281, P13374, DOI 10.1074/jbc.M512669200; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Murphy GF, 2014, MOL ASPECTS MED, V39, P33, DOI 10.1016/j.mam.2013.10.003; Nakatsugawa M, 2011, LAB INVEST, V91, P1796, DOI 10.1038/labinvest.2011.140; Narasimhan K, 2011, ACS CHEM BIOL, V6, P573, DOI 10.1021/cb100432x; O'Reilly KE, 2013, PHARMACEUTICALS, V6, P1429, DOI 10.3390/ph6111429; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Pinc A, 2012, MOL THER, V20, P1056, DOI 10.1038/mt.2012.27; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Ramgolam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018784; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Rybak AP, 2013, CELL SIGNAL, V25, P2734, DOI 10.1016/j.cellsig.2013.08.041; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schlaak M, 2012, ONCOTARGET, V3, P22; Schmidt P, 2011, P NATL ACAD SCI USA, V108, P2474, DOI 10.1073/pnas.1009069108; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takanaga H, 2009, STEM CELLS, V27, P165, DOI 10.1634/stemcells.2008-0580; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137	74	146	152	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4697	4708		10.1038/onc.2014.71	http://dx.doi.org/10.1038/onc.2014.71			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24681955	hybrid, Green Published			2022-12-17	WOS:000342007200008
J	Huang, WH; Chang, MC; Tsai, KS; Hung, MC; Chen, HL; Hung, SC				Huang, W-H; Chang, M-C; Tsai, K-S; Hung, M-C; Chen, H-L; Hung, S-C			Mesenchymal stem cells promote growth and angiogenesis of tumors in mice	ONCOGENE			English	Article						mesenchymal stem cells; cancer cells; endothelial cells; IL-6; endothelian-1; angiogenesis	STROMAL FIBROBLASTS; EXPANSION; RELEASE; PATHWAY	Though the early integration of mesenchymal stem cells (MSCs) into tumor-associated stroma of cancer has been demonstrated, the functional contributions and underlying mechanisms of these cells to tumor growth and angiogenesis remain to be clarified. Using a xenograft model, human colorectal cancer cells, MSCs, and their cell mixture were introduced to a subcutaneous site of immunodeficient mice. The tumor growth rate and angiogenesis of each transplantation was then compared. We demonstrate that a variety of colorectal cancer cells, when mixed with otherwise non-tumorigenic MSCs, increase the tumor growth rate and angiogenesis more than that when mixed with carcinoma-associated fibroblasts or normal colonic fibroblasts. The secretion of interleukin-6 (IL-6) from MSCs increases the secretion of endothelin-1 (ET-1) in cancer cells, which induces the activation of Akt and ERK in endothelial cells, thereby enhancing their capacities for recruitment and angiogenesis to tumor. The IL-6/ET-1/Akt or ERK pathway of tumor-stroma interaction can be targeted by an antibody against IL-6 or Lentiviral-mediated RNAi against IL-6 in MSCs, by inhibition or knockdown of ET-1 in cancer cells, or by inhibition of ERK and Akt in host endothelial cells. These demonstrate that attempts to interrupt the interaction of MSCs and cancer cells help to abrogate angiogenesis and inhibit tumor growth in tumors formed by cancer cells admixed with MSCs. These data demonstrate that the tumor microenvironment, namely, MSCs-secreted IL-6, may enrich the proangiognic factors secreted by cancer cells to increase angiogenesis and tumor growth and that targeting this interaction may lead to novel therapeutic and preventive strategies.	[Huang, W-H; Chen, H-L] Natl Yang Ming Univ, Inst Oral Biol, Dept Dent, Taipei 112, Taiwan; [Chang, M-C; Tsai, K-S] Natl Yang Ming Univ, Inst Anat & Cell Biol, Dept Dent, Taipei 112, Taiwan; [Chang, M-C; Hung, S-C] Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei, Taiwan; [Tsai, K-S; Hung, S-C] Taipei Vet Gen Hosp, Dept Med Res & Educ, Stem Cell Lab, Taipei, Taiwan; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Coll Med, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, S-C] Natl Yang Ming Univ, Inst Clin Med, Dept Dent, Taipei 112, Taiwan; [Hung, S-C] Natl Yang Ming Univ, Inst Pharmacol, Dept Dent, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chen, HL (corresponding author), Natl Yang Ming Univ, Inst Oral Biol, Dept Dent, 155,Sect 2,Li Ron St, Taipei 112, Taiwan.	hlchen2@ym.edu.tw; hungsc@vghtpe.gov.tw	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	National Science Council [99-3111-B-010-005-, 100-2321-B-010-022-]; Taipei Veterans General Hospital [V99E1-011]; National Yang-Ming University, Ministry of Education	National Science Council(Ministry of Science and Technology, Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital); National Yang-Ming University, Ministry of Education	National Science Council (99-3111-B-010-005-; 100-2321-B-010-022-), Taipei Veterans General Hospital (V99E1-011) and National Yang-Ming University, Ministry of Education. The study sponsors do not have a role in the study design, collection, analysis and interpretation of date.	Basile JR, 2007, J BIOL CHEM, V282, P6899, DOI 10.1074/jbc.M609570200; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Eldesoky A, 2011, SAUDI J GASTROENTERO, V17, P170, DOI 10.4103/1319-3767.80378; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; FOLKMAN J, 1973, J EXP MED, V138, P745, DOI 10.1084/jem.138.4.745; Hung SC, 2005, CLIN CANCER RES, V11, P7749, DOI 10.1158/1078-0432.CCR-05-0876; Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006-0686; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Lis R, 2011, INT J CANCER, V128, P715, DOI 10.1002/ijc.25619; Liu Y, 2011, J BIOL CHEM, V286, P25007, DOI 10.1074/jbc.M110.213108; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143; Piperi C, 2011, CYTOKINE, V55, P387, DOI 10.1016/j.cyto.2011.05.012; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Shinagawa K, 2010, INT J CANCER, V127, P2323, DOI 10.1002/ijc.25440; Shojaei F, 2008, CANCER RES, V68, P5501, DOI 10.1158/0008-5472.CAN-08-0925; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Stagg J, 2008, STEM CELL REV, V4, P119, DOI 10.1007/s12015-008-9030-4; Tsai KS, 2011, GASTROENTEROLOGY, V141, P1046, DOI 10.1053/j.gastro.2011.05.045; Yamanashi T, 2009, ONCOLOGY-BASEL, V77, P53, DOI 10.1159/000226112	29	146	151	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4343	4354		10.1038/onc.2012.458	http://dx.doi.org/10.1038/onc.2012.458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085755				2022-12-17	WOS:000324404200003
J	Floor, S; van Staveren, WCG; Larsimont, D; Dumont, JE; Maenhaut, C				Floor, S.; van Staveren, W. C. G.; Larsimont, D.; Dumont, J. E.; Maenhaut, C.			Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations	ONCOGENE			English	Review						cancer stem cells; epithelial mesenchymal transition metastasis; tumor propagating cell	HIGH ALDEHYDE DEHYDROGENASE; BREAST-CANCER; INITIATING CELLS; GROWTH-FACTOR; PANCREATIC-CANCER; PROSTATE-CANCER; OVARIAN-CANCER; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTORS; GENOMIC INSTABILITY	Cell populations of solid cancers and their distant models, the cancer cell lines, have been categorized in sub-populations: cancer stem-tumor-propagating cells (CSC-TPC) versus derived cells, epithelial-versus mesenchymal-type cells, dormant versus actively proliferating cells and so on. CSC-TPC are minimally defined by their operational properties: immortality and the ability to regenerate in vivo or in vitro the whole panel of cancer cells. The epithelial-to-mesenchymal transition (EMT), mostly observed in vitro, generates mesenchymal-type from epithelial-type cells. The converse transition is mesenchymal-to-epithelial transition. In vitro work suggests that CSC-TPC and EMT cell phenotypes overlap. An analysis of the properties of these sub-populations, as studied in vitro, shows that indeed these two phenotypes may be linked to some extent. However, the in vivo counterpart of this relation in human tumors has barely been investigated. A model in which among the EMT cells released from the tumor only the most competent CSC-TPC will succeed to metastasize is proposed. It is suggested that in the Darwinian evolution of cancer cells, many phenotypes reflecting the expression of various programs, reversible to irreversible, exclusive, overlapping or linked coexist and compete with each other. Oncogene (2011) 30, 4609-4621; doi:10.1038/onc.2011.184; published online 6 June 2011	[Floor, S.; van Staveren, W. C. G.; Dumont, J. E.; Maenhaut, C.] Univ Brussels, Fac Med, Inst Interdisciplinary Res IRIBHM, B-1070 Brussels, Belgium; [Larsimont, D.] Univ Brussels, Inst Bordet, Fac Med, B-1070 Brussels, Belgium; [Maenhaut, C.] Univ Brussels, Fac Med, WELBIO, B-1070 Brussels, Belgium	Institut Jules Bordet; Universite Libre de Bruxelles; Vrije Universiteit Brussel; WELBIO	Dumont, JE (corresponding author), Univ Brussels, Fac Med, Inst Interdisciplinary Res IRIBHM, Campus Erasme,CP 602,Route Lennik 808, B-1070 Brussels, Belgium.	jedumont@ulb.ac.be						Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Alexander S, 2008, HISTOCHEM CELL BIOL, V130, P1147, DOI 10.1007/s00418-008-0529-1; Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; Alison MR, 2010, J CELL SCI, V123, P2357, DOI 10.1242/jcs.054296; Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Atsumi N, 2008, BIOCHEM BIOPH RES CO, V373, P36, DOI 10.1016/j.bbrc.2008.05.163; Aulmann S, 2010, HUM PATHOL, V41, P574, DOI 10.1016/j.humpath.2009.08.023; Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365; BAPTIST M, 1993, J CELL SCI, V105, P69; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bortolomai I, 2010, CELL CYCLE, V9, P1194, DOI 10.4161/cc.9.6.11108; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737; Carmeliet P, 2009, NAT REV CLIN ONCOL, V6, P315, DOI 10.1038/nrclinonc.2009.64; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clement V, 2010, NAT METHODS, V7, P224, DOI [10.1038/nmeth.1430, 10.1038/NMETH.1430]; COCLET J, 1991, MOL CELL ENDOCRINOL, V76, P135, DOI 10.1016/0303-7207(91)90268-W; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Cremers N, 2010, CELL MOL LIFE SCI, V67, P2311, DOI 10.1007/s00018-010-0342-6; Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Daly AC, 2010, J BIOL CHEM, V285, P6489, DOI 10.1074/jbc.M109.043877; Davidson EH, 2010, NATURE, V468, P911, DOI 10.1038/nature09645; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Dirks P, 2010, NATURE, V466, P40, DOI 10.1038/466040a; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; Eberth S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-517; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gosselin K, 2009, CANCER RES, V69, P7917, DOI 10.1158/0008-5472.CAN-08-2510; Goswami S, 2004, CANCER RES, V64, P7664, DOI 10.1158/0008-5472.CAN-04-2027; GREENBURG G, 1988, DEVELOPMENT, V102, P605; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gunaratne PH, 2009, CURR STEM CELL RES T, V4, P168, DOI 10.2174/157488809789057400; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harless WW, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-1; He XB, 2009, STEM CELLS, V27, P1487, DOI 10.1002/stem.92; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Horst D, 2009, J PATHOL, V219, P427, DOI 10.1002/path.2597; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Janes KA, 2010, NAT METHODS, V7, P311, DOI [10.1038/NMETH.1442, 10.1038/nmeth.1442]; Jiao XM, 2010, J BIOL CHEM, V285, P8218, DOI 10.1074/jbc.M110.100792; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Lander Arthur D., 2009, Journal of Biology (London), V8, P70, DOI 10.1186/jbiol177; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lehn S, 2010, AM J PATHOL, V177, P2886, DOI 10.2353/ajpath.2010.100303; LEROY A, 1994, INVAS METAST, V14, P177; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Liang Y, 2010, J BIOL CHEM, V285, P4931, DOI 10.1074/jbc.M109.048397; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lingala S, 2010, EXP MOL PATHOL, V89, P27, DOI 10.1016/j.yexmp.2010.05.005; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lopez-Garcia C, 2010, SCIENCE, V330, P822, DOI 10.1126/science.1196236; Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773; Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013; Maenhaut C, 2010, CARCINOGENESIS, V31, P149, DOI 10.1093/carcin/bgp259; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Masugi Y, 2010, HUM PATHOL, V41, P1061, DOI 10.1016/j.humpath.2010.01.016; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Merlo LMF, 2010, J CLIN INVEST, V120, P401, DOI 10.1172/JCI42088; Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619; Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mun GI, 2010, AM J PHYSIOL-HEART C, V298, pH2102, DOI 10.1152/ajpheart.00835.2009; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; NEVE P, 1970, Z ZELLFORSCH MIK ANA, V103, P61, DOI 10.1007/BF00335401; Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008-5472.CAN-09-3880; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Pantel K, 2010, TRENDS MOL MED, V16, P398, DOI 10.1016/j.molmed.2010.07.001; Pera MF, 2010, NATURE, V465, P713, DOI 10.1038/nature09228; Perez-Losada M, 2005, MOL BIOL EVOL, V22, P1887, DOI 10.1093/molbev/msi184; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pusch A, 2010, BBA-MOL CELL RES, V1803, P261, DOI 10.1016/j.bbamcr.2009.12.003; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Refaeli Y, 2009, EMBO REP, V10, P965, DOI 10.1038/embor.2009.184; Reiman JM, 2010, CANCER RES, V70, P3005, DOI 10.1158/0008-5472.CAN-09-4041; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Richardson L, 2006, MECH DEVELOP, V123, P288, DOI 10.1016/j.mod.2006.01.004; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Robson EJD, 2006, DIFFERENTIATION, V74, P254, DOI 10.1111/j.1432-0436.2006.00075.x; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sell S, 2006, CURR GENE THER, V6, P579, DOI 10.2174/156652306778520674; Shackleton M, 2010, SEMIN CANCER BIOL, V20, P85, DOI 10.1016/j.semcancer.2010.04.002; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shervington A, 2009, MOL CELL BIOCHEM, V331, P153, DOI 10.1007/s11010-009-0153-y; Shi Ke-hua, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P785; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Stahlberg A, 2010, METHODS, V50, P282, DOI 10.1016/j.ymeth.2010.01.002; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van Zijl F, 2009, ONCOGENE, V28, P4022, DOI 10.1038/onc.2009.253; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Weinberg R, 2007, BIOL CANC GARLAND SC; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xu XL, 2010, CARCINOGENESIS, V31, P167, DOI 10.1093/carcin/bgp232; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Zalzman M, 2010, NATURE, V464, P858, DOI 10.1038/nature08882	146	146	153	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	46					4609	4621		10.1038/onc.2011.184	http://dx.doi.org/10.1038/onc.2011.184			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21643013				2022-12-17	WOS:000297252100001
J	Yamazaki, D; Kurisu, S; Takenawa, T				Yamazaki, D.; Kurisu, S.; Takenawa, T.			Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates	ONCOGENE			English	Article						cancer; invasion; migration; mesenchymal; amoeboid; Rac	ACTIN-RELATED PROTEIN-2; PERICELLULAR PROTEOLYSIS; INVASION; MIGRATION; GTPASES; WAVE2; MODES; MECHANISMS; PLASTICITY; MEMBRANE	The motility of cancer cells in 3D matrices is of two types: mesenchymal motility, in which the cells are elongated and amoeboid motility, in which the cells are round. Amoeboid motility is driven by an actomyosin-based contractile force, which is regulated by the Rho/ROCK pathway. However, the molecular mechanisms underlying the motility of elongated cells remain unknown. Here, we show that the motility of elongated cells is regulated by Rac signaling through the WAVE2/Arp2/3-dependent formation of elongated pseudopodia and cell-substrate adhesion in 3D substrates. The involvement of Rac signaling in cell motility was different in cell lines that displayed an elongated morphology in 3D substrates. In U87MG glioblastoma cells, most of which exhibit mesenchymal motility, inhibition of Rac signaling blocked the invasion of these cells in 3D substrates. In HT1080 fibrosarcoma cells, which display mixed cell motility involving both elongated and rounded cells, inhibition of Rac1 signaling not only blocked mesenchymal motility but also caused a mesenchymal-amoeboid transition. Additionally, Rac1 and RhoA signaling regulated the mesenchymal and amoeboid motility in these cells, respectively, and the inhibition of both pathways dramatically decreased cell invasion. Hence, we could conclude that Rac1 and RhoA signaling simultaneously regulate cell invasion in 3D matrices.	[Takenawa, T.] Kobe Univ, Grad Sch Med, Lab Lipid Biochem, Dept Biochem & Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Yamazaki, D.] Kobe Univ, Grad Sch Med, Div Membrane Biol, Dept Biochem & Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Kurisu, S.] RIKEN, Brain Sci Inst, Lab Dev Gene Regulat, Brain Sci Inst,Inst Phys Chem Res, Saitama, Japan	Kobe University; Kobe University; RIKEN	Takenawa, T (corresponding author), Kobe Univ, Grad Sch Med, Lab Lipid Biochem, Dept Biochem & Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	takenawa@med.kobe-u.ac.jp	Kurisu, Shusaku/AAB-1799-2022	Kurisu, Shusaku/0000-0002-4876-4419				Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Furutani M, 2006, J BIOCHEM, V139, P663, DOI 10.1093/jb/mvj076; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Goldberg L, 2006, CANCER RES, V66, P11709, DOI 10.1158/0008-5472.CAN-06-1878; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Iwaya K, 2007, CANCER SCI, V98, P992, DOI 10.1111/j.1349-7006.2007.00488.x; Iwaya K, 2007, MODERN PATHOL, V20, P339, DOI 10.1038/modpathol.3800741; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Ohta Y, 2006, NAT CELL BIOL, V8, P803, DOI 10.1038/ncb1437; Paluch E, 2006, TRENDS CELL BIOL, V16, P5, DOI 10.1016/j.tcb.2005.11.003; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Semba S, 2006, CLIN CANCER RES, V12, P2449, DOI 10.1158/1078-0432.CCR-05-2566; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Torka R, 2006, EXP CELL RES, V312, P3857, DOI 10.1016/j.yexcr.2006.08.025; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298	41	146	151	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1570	1583		10.1038/onc.2009.2	http://dx.doi.org/10.1038/onc.2009.2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234490				2022-12-17	WOS:000264780500002
J	Altieri, DC				Altieri, D. C.			New wirings in the survivin networks	ONCOGENE			English	Review						surviving; mitosis; IAP; cancer gene; signaling network; apoptosis	CHROMOSOMAL PASSENGER COMPLEX; CANCER STEM-CELLS; MEDIATES RADIATION-RESISTANCE; NEGATIVE BREAST-CANCER; IN-VIVO; INHIBITS APOPTOSIS; PROGENITOR CELLS; DRUG DISCOVERY; SELF-RENEWAL; TUMOR-GROWTH	A little over 10 years after its discovery in 1997, the small inhibitor of apoptosis (IAP) protein, survivin, continues to generate intense interest and keen attention from disparate segments of basic and disease-related research. Part of this interest reflects the intricate biology of this multifunctional protein that intersects fundamental networks of cellular homeostasis. Part is because of the role of survivin as a cancer gene, which touches nearly every aspect of the disease, from onset to outcome. And part is due to the potential value of survivin for novel cancer diagnostics and therapeutics, which have already reached the clinic, and with some promise. Grappling with emerging new signaling circuits in survivin biology, and their implications in cancer, will further our understanding of this nodal protein, and open fresh opportunities for translational oncology research.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu			NIH [CA78810, CA90917, HL54131]; NATIONAL CANCER INSTITUTE [R01CA090917, R01CA078810] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	I apologize to all the colleagues whose work could not be cited for reasons of space. This work was supported by NIH Grants CA78810, CA90917 and HL54131.	Adida C, 1998, AM J PATHOL, V152, P43; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2006, CURR OPIN CELL BIOL, V18, P609, DOI 10.1016/j.ceb.2006.08.015; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Ceballos-Cancino G, 2007, ONCOGENE, V26, P7569, DOI 10.1038/sj.onc.1210560; Chen MS, 2007, J CELL SCI, V120, P468, DOI 10.1242/jcs.03348; Connell CM, 2008, J BIOL CHEM, V283, P3289, DOI 10.1074/jbc.M704461200; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Delacour-Larose M, 2007, CELL CYCLE, V6, P1878, DOI 10.4161/cc.6.15.4482; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004; Duhl DM, 2005, CURR OPIN DRUG DISC, V8, P431; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Engelsma D, 2007, TRAFFIC, V8, P1495, DOI 10.1111/j.1600-0854.2007.00629.x; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Fortugno P, 2002, J CELL SCI, V115, P575; Fortugno P, 2003, P NATL ACAD SCI USA, V100, P13791, DOI 10.1073/pnas.2434345100; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Fukuda S, 2002, CELL CYCLE, V1, P322, DOI 10.4161/cc.1.5.149; Ghosh JC, 2008, J BIOL CHEM, V283, P5188, DOI 10.1074/jbc.M705904200; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gu LB, 2007, EXP HEMATOL, V35, P957, DOI 10.1016/j.exphem.2007.03.007; Guo Y, 2008, STEM CELLS, V26, P30, DOI 10.1634/stemcells.2007-0401; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hetzer M, 2002, NAT CELL BIOL, V4, pE177, DOI 10.1038/ncb0702-e177; Hopfer O, 2007, EXP HEMATOL, V35, P712, DOI 10.1016/j.exphem.2007.01.054; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Jiang YY, 2005, J NEUROSCI, V25, P6962, DOI 10.1523/JNEUROSCI.1446-05.2005; Jones G, 2000, J BIOL CHEM, V275, P22157, DOI 10.1074/jbc.M000369200; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kang BH, 2006, J BIOL CHEM, V281, P24721, DOI 10.1074/jbc.M603175200; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Klein UR, 2006, MOL BIOL CELL, V17, P2547, DOI 10.1091/mbc.E05-12-1133; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kotwaliwale C, 2006, CELL, V127, P1105, DOI 10.1016/j.cell.2006.11.032; Krause DS, 2007, TRENDS MOL MED, V13, P470, DOI 10.1016/j.molmed.2007.09.003; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lee CW, 2008, CANCER RES, V68, P5273, DOI 10.1158/0008-5472.CAN-07-6673; Lens SMA, 2006, CURR OPIN CELL BIOL, V18, P616, DOI 10.1016/j.ceb.2006.08.016; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Li FZ, 2006, AM J PATHOL, V169, P1, DOI 10.2353/ajpath.2006.060121; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Liu WH, 2007, EMBO J, V26, P1660, DOI 10.1038/sj.emboj.7601611; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Marconi A, 2007, STEM CELLS, V25, P149, DOI 10.1634/stemcells.2006-0165; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Oh SH, 2008, CLIN CANCER RES, V14, P1581, DOI 10.1158/1078-0432.CCR-07-0952; Okada H, 2004, J EXP MED, V199, P399, DOI 10.1084/jem.20032092; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pennartz S, 2004, MOL CELL NEUROSCI, V25, P692, DOI 10.1016/j.mcn.2003.12.011; Pohl C, 2008, CELL, V132, P832, DOI 10.1016/j.cell.2008.01.012; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rajalingam K, 2006, PLOS PATHOG, V2, P1013, DOI 10.1371/journal.ppat.0020114; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sampath Janardhan, 2007, Curr Drug Discov Technol, V4, P174, DOI 10.2174/157016307782109652; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Sandall S, 2006, CELL, V127, P1179, DOI 10.1016/j.cell.2006.09.049; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Skokowa J, 2007, ANN NY ACAD SCI, V1106, P143, DOI 10.1196/annals.1392.012; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sun CH, 2005, BIOCHEMISTRY-US, V44, P11, DOI 10.1021/bi0485171; Taubert H, 2007, ONCOGENE, V26, P7170, DOI 10.1038/sj.onc.1210530; TOLCHER AW, 2006, ASCO ANN M, P3014; Tulu US, 2006, CURR BIOL, V16, P536, DOI 10.1016/j.cub.2006.01.060; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; Vaira V, 2007, ONCOGENE, V26, P2678, DOI 10.1038/sj.onc.1210094; van der Greef J, 2005, NAT REV DRUG DISCOV, V4, P961, DOI 10.1038/nrd1904; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Walter D, 2006, J CELL SCI, V119, P1843, DOI 10.1242/jcs.02902; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wheatley SP, 2007, CELL CYCLE, V6, P1220, DOI 10.4161/cc.6.10.4179; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Xia F, 2006, CANCER RES, V66, P3392, DOI 10.1158/0008-5472.CAN-05-4537; Xia F, 2008, CANCER RES, V68, P1826, DOI 10.1158/0008-5472.CAN-07-5279; Xing Z, 2004, J EXP MED, V199, P69, DOI 10.1084/jem.20031588; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhang T, 2001, CANCER RES, V61, P8664; Zhao J, 2000, J CELL SCI, V113, P4363	119	146	161	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	48					6276	6284		10.1038/onc.2008.303	http://dx.doi.org/10.1038/onc.2008.303			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931693	Green Accepted			2022-12-17	WOS:000260162800008
J	Baker, SP; Grant, PA				Baker, S. P.; Grant, P. A.			The SAGA continues: expanding the cellular role of a transcriptional co-activator complex	ONCOGENE			English	Review						SAGA; histone; modification; acetyl transferase; chromatin; transcription	MESSENGER-RNA EXPORT; TATA-BINDING PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEX; NUCLEOTIDE EXCISION-REPAIR; HUMAN STAGA COMPLEX; IN-VIVO; SACCHAROMYCES-CEREVISIAE; NUCLEOSOME ACETYLATION; POLYMERASE-II; DNA-DAMAGE	Throughout the last decade, great advances have been made in our understanding of how DNA-templated cellular processes occur in the native chromatin environment. Proteins that regulate transcription, replication, DNA repair, mitosis and other processes must be targeted to specific regions of the genome and granted access to DNA, which is normally tightly packaged in the higher-order chromatin structure of eukaryotic nuclei. Massive multiprotein complexes have been discovered, which facilitate access to DNA and recruitment of downstream effectors through three distinct mechanisms: chemical modi. cation of histone amino-acid residues, ATP-dependent chromatin remodeling and histone exchange. The yeast Spt-Ada-Gcn5-Acetyl transferase ( SAGA) transcriptional co-activator complex regulates numerous cellular processes through coordination of multiple histone post-translational modi. cations. SAGA is known to generate and interact with a number of histone modi. cations, including acetylation, methylation, ubiquitylation and phosphorylation. Although best characterized for its role in regulating transcriptional activation, SAGA is also required for optimal transcription elongation, mRNA export and perhaps nucleotide excision repair. Here, we discuss findings from recent years that have elucidated the function of this 1.8-MDa complex in multiple cellular processes, and how misregulation of the homologous complexes in humans may ultimately play a role in development of disease.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Grant, PA (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	pag9n@virginia.edu			NCI NIH HHS [T32 CA009109, 5 T32 CA009109-30] Funding Source: Medline; NINDS NIH HHS [R01 NS049065, R01 NS049065-02, NS049065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altaf M, 2007, MUTAT RES-FUND MOL M, V618, P81, DOI 10.1016/j.mrfmmm.2006.09.009; Baker SP, 2005, CELL, V123, P361, DOI 10.1016/j.cell.2005.10.013; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Bu P, 2007, MOL CELL BIOL, V27, P3405, DOI 10.1128/MCB.00066-07; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Cabal GG, 2006, NATURE, V441, P770, DOI 10.1038/nature04752; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; Daniel JA, 2005, CELL CYCLE, V4, P919, DOI 10.4161/cc.4.7.1824; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; EISENMANN DM, 1994, GENETICS, V137, P647; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Ferreiro JA, 2006, NUCLEIC ACIDS RES, V34, P976, DOI 10.1093/nar/gkj501; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; GANSHEROFF LJ, 1995, GENETICS, V139, P523; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Govind CK, 2007, MOL CELL, V25, P31, DOI 10.1016/j.molcel.2006.11.020; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Ingvarsdottir K, 2005, MOL CELL BIOL, V25, P1162, DOI 10.1128/MCB.25.3.1162-1172.2005; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; Kinyamu HK, 2005, J MOL ENDOCRINOL, V34, P281, DOI 10.1677/jme.1.01680; Kohler A, 2006, MOL BIOL CELL, V17, P4228, DOI 10.1091/mbc.E06-02-0098; Kulesza CA, 2002, ONCOGENE, V21, P1411, DOI 10.1038/sj.onc.1205201; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Lee KK, 2005, MOL CELL BIOL, V25, P1173, DOI 10.1128/MCB.25.3.1173-1182.2005; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; Lo WS, 2005, EMBO J, V24, P997, DOI 10.1038/sj.emboj.7600577; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARCUS GA, 1996, MOL CELL BIOL, V3197, P16; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; McMahon SJ, 2005, P NATL ACAD SCI USA, V102, P8478, DOI 10.1073/pnas.0503493102; Mitra D, 2006, MOL CELL BIOL, V26, P4095, DOI 10.1128/MCB.01849-05; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Okuda M, 2007, J MOL BIOL, V365, P1047, DOI 10.1016/j.jmb.2006.10.039; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Powell DW, 2004, MOL CELL BIOL, V24, P7249, DOI 10.1128/MCB.24.16.7249-7259.2004; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Reeves WM, 2005, MOL CELL BIOL, V25, P9092, DOI 10.1128/MCB.25.20.9092-9102.2005; Ricci AR, 2002, MOL CELL BIOL, V22, P4033, DOI 10.1128/MCB.22.12.4033-4042.2002; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Shukla A, 2006, MOL CELL BIOL, V26, P3339, DOI 10.1128/MCB.26.9.3339-3352.2006; Shukla A, 2006, NUCLEIC ACIDS RES, V34, P6225, DOI 10.1093/nar/gkl844; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yu YC, 2005, P NATL ACAD SCI USA, V102, P8650, DOI 10.1073/pnas.0501458102	99	146	151	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5329	5340		10.1038/sj.onc.1210603	http://dx.doi.org/10.1038/sj.onc.1210603			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694076	Green Accepted, Bronze			2022-12-17	WOS:000248674300003
J	Bangham, CRM; Osame, M				Bangham, CRM; Osame, M			Cellular immune response to HTLV-1	ONCOGENE			English	Article						cytotoxic T lymphocyte; HTLV-1; genetics; microarray; virological synapse; lymphocyte dynamics; HAM/TSP; host defence	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; CYTOTOXIC T-LYMPHOCYTES; BLOOD MONONUCLEAR-CELLS; CENTRAL-NERVOUS-SYSTEM; TYPE-1 PROVIRAL LOAD; NEUROLOGICAL-DISEASE; PERIPHERAL-BLOOD; ASYMPTOMATIC CARRIERS; CEREBROSPINAL-FLUID	There is strong evidence at the individual level and the population level that an efficient cytotoxic T lymphocyte (CTL) response to HTLV-1 limits the proviral load and the risk of associated in. ammatory diseases such as HAM/TSP. This evidence comes from host population genetics, viral genetics, DNA expression microarrays and assays of lymphocyte function. However, until now there has been no satisfactory and rigorous means to de. ne or to measure the efficiency of an antiviral CTL response. Recently, methods have been developed to quantify lymphocyte turnover rates in vivo and the efficiency of anti-HTLV-1 CTLs ex vivo. Data from these new techniques appear to substantiate the conclusion that variation between individual hosts in the rate at which a single CTL kills HTLV-1-infected lymphocytes is an important determinant, perhaps the decisive determinant, of the proviral load and the risk of HAM/TSP. With these experimental data, it is becoming possible to re. ne, parameterize and test mathematical models of the immune control of HTLV-1, which are a necessary part of an understanding of this complex dynamic system.	Univ London Imperial Coll Sci & Technol, Dept Immunol, London W2 1PG, England; Kagoshima Univ, Fac Med, Dept Internal Med 3, Univ Hosp, Kagoshima 8908520, Japan	Imperial College London; Kagoshima University	Bangham, CRM (corresponding author), Univ London Imperial Coll Sci & Technol, Dept Immunol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	c.bangham@imperial.ac.uk		Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnulf B, 2004, LEUKEMIA, V18, P126, DOI 10.1038/sj.leu.2403176; Asquith B, 2003, P ROY SOC B-BIOL SCI, V270, P1651, DOI 10.1098/rspb.2003.2386; Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2; Asquith B, 2005, J GEN VIROL, V86, P1515, DOI 10.1099/vir.0.80766-0; Asquith B, 2000, PHILOS T ROY SOC B, V355, P1013, DOI 10.1098/rstb.2000.0638; Bangham CRM, 1996, SEMIN VIROL, V7, P41, DOI 10.1006/smvy.1996.0006; Bangham CRM, 2003, J GEN VIROL, V84, P3177, DOI 10.1099/vir.0.19334-0; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borducchi DM, 2003, BRIT J HAEMATOL, V123, P954, DOI 10.1046/j.1365-2141.2003.04711.x; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Cavrois M, 1996, ONCOGENE, V12, P2419; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; DAENKE S, 1990, J VIROL, V64, P1278, DOI 10.1128/JVI.64.3.1278-1282.1990; DAENKE S, 1994, CLIN EXP IMMUNOL, V96, P179; Eiraku N, 1998, J IMMUNOL, V161, P6674; ELOVAARA I, 1993, J EXP MED, V177, P1567, DOI 10.1084/jem.177.6.1567; Etoh K, 1997, CANCER RES, V57, P4862; FUJIHARA K, 1991, J NEUROL SCI, V105, P99, DOI 10.1016/0022-510X(91)90125-Q; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Furukawa Y, 2000, J INFECT DIS, V182, P1343, DOI 10.1086/315897; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GESSAIN A, 1991, J VIROL, V65, P1628, DOI 10.1128/JVI.65.3.1628-1633.1991; Goon PKC, 2004, J INFECT DIS, V189, P2294, DOI 10.1086/420832; Goon PKC, 2004, J IMMUNOL, V172, P1735, DOI 10.4049/jimmunol.172.3.1735; Goon PKC, 2003, J VIROL, V77, P9716, DOI 10.1128/JVI.77.17.9716-9722.2003; Goon PKC, 2002, BLOOD, V99, P3335, DOI 10.1182/blood.V99.9.3335; Greten TF, 1998, P NATL ACAD SCI USA, V95, P7568, DOI 10.1073/pnas.95.13.7568; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Harashima N, 2004, CANCER RES, V64, P391, DOI 10.1158/0008-5472.CAN-03-1452; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; Higuchi I, 1996, ACTA NEUROPATHOL, V92, P358, DOI 10.1007/s004010050530; Hisada M, 2004, J INFECT DIS, V190, P1605, DOI 10.1086/424598; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; IJICHI S, 1993, MED HYPOTHESES, V41, P542, DOI 10.1016/0306-9877(93)90111-3; ISHIHARA S, 1994, J ACQ IMMUN DEF SYND, V7, P199; IWASAKI Y, 1992, AM J PATHOL, V140, P1003; IWASAKI Y, 1993, BRAIN PATHOL, V3, P1, DOI 10.1111/j.1750-3639.1993.tb00719.x; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508; JACOBSON S, 1986, CONCEPTS VIRAL PATHO, V2, P187; Jeffery KJM, 1999, P NATL ACAD SCI USA, V96, P3848, DOI 10.1073/pnas.96.7.3848; Jeffery KJM, 2000, J IMMUNOL, V165, P7278, DOI 10.4049/jimmunol.165.12.7278; KANNAGI M, 1984, J IMMUNOL, V133, P1037; KANNAGI M, 1991, INT IMMUNOL, V3, P761, DOI 10.1093/intimm/3.8.761; KANNAGI M, 1983, J IMMUNOL, V130, P2942; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; KINOSHITA T, 1991, INT J CANCER, V47, P491, DOI 10.1002/ijc.2910470403; KIRA J, 1992, J NEUROL SCI, V107, P98, DOI 10.1016/0022-510X(92)90215-7; Kitze B, 1998, CLIN EXP IMMUNOL, V111, P278; Kodama D, 2004, J NEUROIMMUNOL, V156, P188, DOI 10.1016/j.jneuroim.2004.07.007; KOMURIAN F, 1991, J VIROL, V65, P3770, DOI 10.1128/JVI.65.7.3770-3778.1991; Kubota R, 2000, AIDS RES HUM RETROV, V16, P1705, DOI 10.1089/08892220050193182; Kubota R, 2000, J NEUROIMMUNOL, V102, P208, DOI 10.1016/S0165-5728(99)00175-7; LEHKY TJ, 1995, ANN NEUROL, V37, P167, DOI 10.1002/ana.410370206; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509; Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; Matsuoka E, 1998, ACTA NEUROPATHOL, V96, P340, DOI 10.1007/s004010050903; McGinn TM, 2004, AIDS RES HUM RETROV, V20, P443, DOI 10.1089/088922204323048195; Moritoyo T, 1999, J NEUROVIROL, V5, P241, DOI 10.3109/13550289909015810; Nagai M, 1998, J NEUROVIROL, V4, P586, DOI 10.3109/13550289809114225; NAGASATO K, 1991, J NEUROL SCI, V103, P203, DOI 10.1016/0022-510X(91)90165-4; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; NIEWIESK S, 1995, J VIROL, V69, P2649, DOI 10.1128/JVI.69.4.2649-2653.1995; Niewiesk S, 1996, J MOL EVOL, V42, P452, DOI 10.1007/BF02498639; NIEWIESK S, 1994, J VIROL, V68, P6778, DOI 10.1128/JVI.68.10.6778-6781.1994; NISHIMURA Y, 1991, TISSUE ANTIGENS, V37, P230, DOI 10.1111/j.1399-0039.1991.tb01877.x; Nomura M, 2004, J VIROL, V78, P3827, DOI 10.1128/JVI.78.8.3827-3836.2004; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Overbaugh J, 2001, SCIENCE, V292, P1106, DOI 10.1126/science.1059128; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; PARKER CE, 1994, J VIROL, V68, P2860, DOI 10.1128/JVI.68.5.2860-2868.1994; Pende D, 2001, EUR J IMMUNOL, V31, P1076, DOI 10.1002/1521-4141(200104)31:4<1076::AID-IMMU1076>3.0.CO;2-Y; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; Plancoulaine S, 2000, J INFECT DIS, V182, P405, DOI 10.1086/315741; Rafatpanah H, 2004, HUM IMMUNOL, V65, P839, DOI 10.1016/j.humimm.2004.05.006; Sabouri AH, 2005, J GEN VIROL, V86, P773, DOI 10.1099/vir.0.80509-0; Sabouri AH, 2004, J INFECT DIS, V190, P1279, DOI 10.1086/423942; Saito M, 2003, BLOOD, V102, P577, DOI 10.1182/blood-2002-09-2855; Slattery JP, 1999, GENOME RES, V9, P525; Smith MJ, 2001, J VIROL, V75, P2301, DOI 10.1128/JVI.75.5.2301-2313.2001; Sonoda S, 1996, J ACQ IMMUN DEF SYND, V13, pS119, DOI 10.1097/00042560-199600001-00020; Sutherland CL, 2002, J IMMUNOL, V168, P671, DOI 10.4049/jimmunol.168.2.671; USUKU K, 1990, EUR J IMMUNOL, V20, P1603, DOI 10.1002/eji.1830200729; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; Vine AM, 2004, J IMMUNOL, V173, P5121, DOI 10.4049/jimmunol.173.8.5121; Vine AM, 2002, J INFECT DIS, V186, P932, DOI 10.1086/342953; Wodarz D, 2001, P ROY SOC B-BIOL SCI, V268, P1215, DOI 10.1098/rspb.2001.1608; Wodarz D, 2000, J MOL EVOL, V50, P448, DOI 10.1007/s002390010047; YU F, 1991, J NEUROIMMUNOL, V33, P121, DOI 10.1016/0165-5728(91)90056-D	94	146	155	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2005	24	39					6035	6046		10.1038/sj.onc.1208970	http://dx.doi.org/10.1038/sj.onc.1208970			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155610				2022-12-17	WOS:000231623400013
J	Sciamanna, E; Landriscina, M; Pittoggi, C; Quirino, M; Mearelli, C; Beraldi, R; Mattei, E; Serafino, A; Cassano, A; Sinibaldi-Vallebona, P; Garaci, E; Barone, C; Spadafora, C				Sciamanna, E; Landriscina, M; Pittoggi, C; Quirino, M; Mearelli, C; Beraldi, R; Mattei, E; Serafino, A; Cassano, A; Sinibaldi-Vallebona, P; Garaci, E; Barone, C; Spadafora, C			Inhibition of endogenous reverse transcriptase antagonizes human tumor growth	ONCOGENE			English	Article						endogenous reverse transcriptase; proliferation; differentiation; tumor growth; RNAi; anticancer therapy	EMBRYONAL CARCINOMA-CELLS; CUTANEOUS MELANOMA; LINE-1 RNA; MOUSE; EXPRESSION; CANCER; RETROTRANSPOSITION; DIFFERENTIATION; PROLIFERATION; EPIGENETICS	Undifferentiated cells and embryos express high levels of endogenous non-telomerase reverse transcriptase (RT) of retroposon/retroviral origin. We previously found that RT inhibitors modulate cell growth and differentiation in several cell lines. We have now sought to establish whether high levels of RT activity are directly linked to cell transformation. To address this possibility, we have employed two different approaches to inhibit RT activity in melanoma and prostate carcinoma cell fines: pharmacological inhibition by two characterized RT inhibitors, nevirapine and efavirenz, and downregulation of expression of RT-encoding LINE-1 elements by RNA interference (RNAi). Both treatments reduced proliferation, induced morphological differentiation and reprogrammed gene expression. These features are reversible upon discontinuation of the anti-RT treatment, suggesting that RT contributes to an epigenetic level of control. Most importantly, inhibition of RT activity in vivo antagonized tumor growth in animal experiments. Moreover, pretreatment with RT inhibitors attenuated the tumorigenic phenotype of prostate carcinoma cells inoculated in nude mice. Based on these data, the endogenous RT can be regarded as an epigenetic regulator of cell differentiation and proliferation and may represent a novel target in cancer therapy.	Ist Super Sanita, I-00161 Rome, Italy; Univ Sacred Heart, Med Oncol Unit, I-00168 Rome, Italy; Univ Siena, Dept Pediat Obstet & Reprod Med, I-53100 Siena, Italy; CNR, Inst Mol Biol & Pathol, Rome, Italy; CNR, Inst Neurobiol & Mol Med, Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy	Istituto Superiore di Sanita (ISS); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Siena; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata	Spadafora, C (corresponding author), Ist Super Sanita, Viale Regina Elena 299,Via Castro Laurenziano 25, I-00161 Rome, Italy.	cspadaf@tin.it	Landriscina, Matteo/K-1092-2016; Serafino, Annalucia/AAC-1719-2019	Serafino, Annalucia/0000-0002-1142-4752; SINIBALDI VALLEBONA, PAOLA/0000-0002-8186-9861; Spadafora, Corrado/0000-0002-5743-3224; Landriscina, Matteo/0000-0003-0591-9799; Spadafora, Corrado/0000-0001-9647-1410; Sciamanna, Ilaria/0000-0002-5629-6184				Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Crone TM, 1999, HEPATOLOGY, V29, P1114, DOI 10.1002/hep.510290449; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Deininger PL, 2003, CURR OPIN GENET DEV, V13, P651, DOI 10.1016/j.gde.2003.10.013; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Friedlander A, 1999, CRIT REV ONCOGENESIS, V10, P129; Giordano R, 2000, J CELL BIOL, V148, P1107, DOI 10.1083/jcb.148.6.1107; Hagan Christy R, 2002, Am J Pharmacogenomics, V2, P25, DOI 10.2165/00129785-200202010-00003; Hagan CR, 2003, NAT GENET, V35, P219, DOI 10.1038/ng1259; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Khan AS, 2001, VIRUS RES, V79, P39, DOI 10.1016/S0168-1702(01)00280-5; KIESSLING AA, 1989, P NATL ACAD SCI USA, V86, P5109, DOI 10.1073/pnas.86.13.5109; Kuo KW, 1998, BIOCHEM BIOPH RES CO, V253, P566, DOI 10.1006/bbrc.1998.9811; Li L, 2003, CANCER RES, V63, P2733; Li TH, 2001, GENE, V276, P135, DOI 10.1016/S0378-1119(01)00637-0; Lilja H, 2003, UROLOGY, V62, P27, DOI 10.1016/S0090-4295(03)00775-1; Linja MJ, 2001, CANCER RES, V61, P3550; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; Mangiacasale R, 2003, ONCOGENE, V22, P2750, DOI 10.1038/sj.onc.1206354; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Melino G, 1993, CLIN CHEM ENZYM COMM, V6, P105; MWENDA JM, 1993, CELL MOL BIOL, V39, P317; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PACKER AI, 1993, DEV BIOL, V157, P281, DOI 10.1006/dbio.1993.1133; Pittoggi C, 2003, MOL REPROD DEV, V66, P225, DOI 10.1002/mrd.10349; Portsmouth S, 2003, AIDS, V17, pF17, DOI 10.1097/00002030-200307250-00001; POZNANSKI AA, 1991, DEV BIOL, V143, P271, DOI 10.1016/0012-1606(91)90077-G; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sauter ER, 2002, CANCER RES, V62, P3200; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Tirelli U, 2001, EUR J CANCER, V37, P1320, DOI 10.1016/S0959-8049(01)00106-X; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; Utikal J, 2002, CANCER INVEST, V20, P914, DOI 10.1081/CNV-120005904; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	40	146	162	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3923	3931		10.1038/sj.onc.1208562	http://dx.doi.org/10.1038/sj.onc.1208562			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15806170				2022-12-17	WOS:000229435300008
J	Wittenberg, C; Reed, SI				Wittenberg, C; Reed, SI			Cell cycle-dependent transcription in yeast: promoters, transcription factors, and transcriptomes	ONCOGENE			English	Review						transcription; cell cycle; cyclin-dependent protein kinase	START-SPECIFIC TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; POSITIVE FEEDBACK; GENE-EXPRESSION; PROTEIN-KINASE; BUDDING YEAST; G1 CYCLINS; REGULATORY NETWORKS; CLN3-CDC28 KINASE; CLN3	In the budding yeast, Saccharomyces cerevisiae, a significant fraction of genes (> 10%) are transcribed with cell cycle periodicity. These genes encode critical cell cycle regulators as well as proteins with no direct connection to cell cycle functions. Cell cycle- regulated genes can be organized into ` clusters' exhibiting similar patterns of regulation. In most cases periodic transcription is achieved via both repressive and activating mechanisms. Fine tuning appears to have evolved by the juxtaposition of regulatory motifs characteristic of more than one cluster within the same promoter. Recent reports have provided significant new insight into the role of the cyclin- dependent kinase Cdk1 ( Cdc28) in coordination of transcription with cell cycle events. In early G1, the transcription factor complex known as SBF is maintained in a repressed state by association of the Whi5 protein. Phosphorylation of Whi5 by Cdk1 in late G1 leads to dissociation from SBF and transcriptional derepression. G2/ M- specific transcription is achieved by converting the repressor Fkh2 into an activator. Fkh2 serves as a repressor during most of the cell cycle. However, phosphorylation of a cofactor, Ndd1, by Cdk1 late in the cell cycle promotes binding to Fkh2 and conversion into a transcriptional activator. Such insights derived from analysis of specifc genes when combined with genome- wide analysis provide a more detailed and integrated view of cell cycle- dependent transcription.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	sreed@scripps.edu						AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Amon A, 2002, METHOD ENZYMOL, V351, P457; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Breitkreutz A, 2003, GENETICS, V165, P997; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; de Bruin RAM, 2004, CELL, V117, P887, DOI 10.1016/j.cell.2004.05.025; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Doolin MT, 2001, MOL MICROBIOL, V40, P422, DOI 10.1046/j.1365-2958.2001.02388.x; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgington NP, 2001, J CELL SCI, V114, P4599; EPSTEIN CB, 1994, MOL CELL BIOL, V14, P2041, DOI 10.1128/MCB.14.3.2041; Futcher B, 2002, CURR OPIN CELL BIOL, V14, P676, DOI 10.1016/S0955-0674(02)00391-5; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gari E, 2001, GENE DEV, V15, P2803; Geymonat M, 2004, MOL CELL BIOL, V24, P2277, DOI 10.1128/MCB.24.6.2277-2285.2004; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Haase SB, 1999, NATURE, V401, P394, DOI 10.1038/43930; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Hollenhorst PC, 2001, GENE DEV, V15, P2445, DOI 10.1101/gad.906201; Horak Christine E, 2002, Funct Integr Genomics, V2, P171; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kato M, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r56; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Kumar R, 2000, CURR BIOL, V10, P896, DOI 10.1016/S0960-9822(00)00618-7; Kusari AB, 2004, J CELL BIOL, V164, P267, DOI 10.1083/jcb.200310021; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Loy CJ, 1999, MOL CELL BIOL, V19, P3312; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MacKay VL, 2001, MOL CELL BIOL, V21, P4140, DOI 10.1128/MCB.21.13.4140-4148.2001; MARINI NJ, 1992, GENE DEV, V6, P557, DOI 10.1101/gad.6.4.557; McBride HJ, 1999, J BIOL CHEM, V274, P21029, DOI 10.1074/jbc.274.30.21029; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Miller ME, 2000, MOL CELL BIOL, V20, P542, DOI 10.1128/MCB.20.2.542-555.2000; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; Morillon A, 2003, SCIENCE, V300, P492, DOI 10.1126/science.1081379; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; Partridge JF, 1997, J BIOL CHEM, V272, P9071; Parviz F, 1998, J BACTERIOL, V180, P4508, DOI 10.1128/JB.180.17.4508-4515.1998; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Pramila T, 2002, GENE DEV, V16, P3034, DOI 10.1101/gad.1034302; Queralt E, 2003, MOL CELL BIOL, V23, P3126, DOI 10.1128/MCB.23.9.3126-3140.2003; Reynolds D, 2003, GENE DEV, V17, P1789, DOI 10.1101/gad.1074103; Rustici G, 2004, NAT GENET, V36, P809, DOI 10.1038/ng1377; SHERWOOD PW, 1993, MOL CELL BIOL, V13, P28, DOI 10.1128/MCB.13.1.28; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Siegmund RF, 1996, MOL CELL BIOL, V16, P2647; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; van Drogen F, 2001, NAT CELL BIOL, V3, P1051, DOI 10.1038/ncb1201-1051; Wang HY, 2004, EMBO J, V23, P180, DOI 10.1038/sj.emboj.7600022; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Whitaker M, 1997, Prog Cell Cycle Res, V3, P261; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wijnen H, 2002, MOL CELL BIOL, V22, P4402, DOI 10.1128/MCB.22.12.4402-4418.2002; Wijnen H, 1999, GENETICS, V153, P1131; Withee JL, 1998, GENETICS, V149, P865; WITTENBERG C, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P189; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	92	146	149	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2746	2755		10.1038/sj.onc.1208606	http://dx.doi.org/10.1038/sj.onc.1208606			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838511				2022-12-17	WOS:000228465800001
J	White, RJ				White, RJ			RNA polymerase III transcription and cancer	ONCOGENE			English	Review						cancer; c-Myc; p53; RB; RNA polymerase III transcription; TFIIIB	TATA-BINDING PROTEIN; CASEIN KINASE-II; VIRUS-X PROTEIN; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; CELL-CYCLE; RIBOSOMAL-RNA; FACTOR UBF; MALIGNANT-TRANSFORMATION; RDNA TRANSCRIPTION	RNA polymerase (pol) III synthesizes a range of essential products, including tRNA, 5S rRNA and 7SL RNA, which are required for protein synthesis and trafficking. High rates of pol III transcription are necessary for cells to sustain growth. A wide range of transformed and tumour cell types have been shown to express elevated levels of pol III products. This review will summarize what is known about the mechanisms responsible for this deregulation. Some transforming agents have been shown to stimulate expression of the pol III-specific transcription factors TFIIIB or TFIIIC2. In addition, TFIIIB is bound and activated by several oncogenic proteins, including c-Myc. Conversely, TFIIIB interacts in healthy cells with the tumour suppressors RB and p53. Indeed, the ability to limit pol III transcription through TFIIIB may contribute to their growth-suppression capacities. The function of p53 and/or RB is compromised in most if not all transformed cells; the resultant derepression of TFIIIB may provide an almost universal route to deregulate pol III transcription in cancers. In addition to effects on protein synthesis and growth, there is a precedent for a pol III product having oncogenic activity.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	rwhite@udcf.gla.ac.uk						AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ALTMANN GG, 1982, J CELL SCI, V56, P83; ARRAND JR, 1982, J VIROL, V41, P376, DOI 10.1128/JVI.41.2.376-389.1982; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Busch H, 1970, NUCLEOLUS, P448; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; CLEMENS M, 1992, NATURE, V360, P210, DOI 10.1038/360210a0; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; DALY NL, UNPUB ONCOGENE; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; Derenzini M., 1994, MOL BIOL HISTOPATHOL, P231; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elia A, 1996, NUCLEIC ACIDS RES, V24, P4471, DOI 10.1093/nar/24.22.4471; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Felton-Edkins ZA, 2003, CELL CYCLE, V2, P181, DOI 10.4161/cc.2.3.375; FRANCIS MA, 1990, MOL CELL BIOL, V10, P4486, DOI 10.1128/MCB.10.9.4486; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; Harbour JW, 1998, OPHTHALMOLOGY, V105, P1442, DOI 10.1016/S0161-6420(98)98025-3; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIRAMA T, 1995, BLOOD, V86, P841; Hirsch HA, 2000, MOL CELL BIOL, V20, P9182, DOI 10.1128/MCB.20.24.9182-9191.2000; Hockman DJ, 1996, MOL CELL BIOL, V16, P892; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON LF, 1974, CELL, V1, P95, DOI 10.1016/0092-8674(74)90068-3; Johnson SAS, 2000, MOL CELL BIOL, V20, P5000, DOI 10.1128/MCB.20.14.5000-5009.2000; Johnson SAS, 2003, MOL CELL BIOL, V23, P3043, DOI 10.1128/MCB.23.9.3043-3051.2003; Johnston IM, 2002, MOL CELL BIOL, V22, P3757, DOI 10.1128/MCB.22.11.3757-3768.2002; KING RJB, 1996, CANC BIOL, P27; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KRATZKE RA, 1994, ONCOGENE, V9, P1321; KURATA SI, 1978, CHROMOSOMA, V68, P313, DOI 10.1007/BF00327166; LAING KG, 1995, BIOCHEM SOC T, V23, pS311, DOI 10.1042/bst023311s; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIEBHABER SA, 1978, CELL, V13, P121, DOI 10.1016/0092-8674(78)90143-5; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MAUCK JC, 1974, CELL, V3, P171, DOI 10.1016/0092-8674(74)90122-6; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Notterman DA, 2001, CANCER RES, V61, P3124; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Pianese G., 1896, BEITR PATHOL ANAT AL, V142, P1; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5889; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Stein T, 2002, ONCOGENE, V21, P5540, DOI 10.1038/sj.onc.1205739; Stein T, 2002, ONCOGENE, V21, P2961, DOI 10.1038/sj.onc.1205372; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; SUTCLIFFE JE, 2000, THESIS U GLASGOW; THIMMAPPAYA B, 1982, CELL, V31, P543, DOI 10.1016/0092-8674(82)90310-5; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WANG HD, 1995, MOL CELL BIOL, V15, P6720; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; Wang HD, 1998, MOL CELL BIOL, V18, P7086, DOI 10.1128/MCB.18.12.7086; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; WHITE RJ, 2002, LANDES BIOSCIENCE; WHTIE RJ, 2004, CELL GROWTH CONTROL; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Ying CW, 1996, MOL CELL ENDOCRINOL, V118, P207, DOI 10.1016/0303-7207(96)03786-0; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; Zhai WG, 1999, MOL CELL BIOL, V19, P2791; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	130	146	148	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3208	3216		10.1038/sj.onc.1207547	http://dx.doi.org/10.1038/sj.onc.1207547			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094770				2022-12-17	WOS:000220879700009
J	Mehta, PB; Jenkins, BL; McCarthy, L; Thilak, L; Robson, CN; Neal, DE; Leung, HY				Mehta, PB; Jenkins, BL; McCarthy, L; Thilak, L; Robson, CN; Neal, DE; Leung, HY			MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion	ONCOGENE			English	Article						MAPK; MEK5; ERK5; prostate cancer; metastasis	NF-KAPPA-B; BONE MORPHOGENETIC PROTEIN-6; SIGNAL-REGULATED KINASE; BREAST-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; MATRIX METALLOPROTEINASES; TIMP-2 EXPRESSION; GENE-EXPRESSION; CARCINOMA-CELLS; GROWTH-FACTOR	The novel mitogen/extracellular-signal-regulated kinase kinase 5/extracellular signal-regulated kinase-5 (MEK5/ERK5) pathway has been implicated in the regulation of cellular proliferation. MEK5 expression has been detected in prostate cancer cells, although the significance of the MEK5/ERK5 pathway in human prostate cancer has not been tested. We examined MEK5 expression in 127 cases of prostate cancer and 20 cases of benign prostatic hypertrophy (BPH) by immunohistochemistry and compared the results to clinical parameters. We demonstrated that MEK5 expression is increased in prostate cancer as compared to benign prostatic tissue. Strong MEK5 expression correlates with the presence of bony metastases and less favourable disease-specific survival. Furthermore, among the patients with high Gleason score of 8-10, MEK5 overexpression has an additional prognostic value in survival. MEK5 transfection experiments confirm its ability to induce proliferation (P<0.0001), motility (P=0.0001) and invasion in prostate cancer cells (P=0.0001). MEK5 expression drastically increased MMP-9, but not MMP-2 mRNA expression. Luciferase report assays suggest that the -670/MMP-9 promoter is upregulated by MEK5 and electromobility shift assay further suggests the involvement of activator protein-I (AP-1), but not the NF-kappaB, binding site in the MMP-9 promoter. Using an AP-1 luciferase construct, activation of MEK5 was confirmed to enhance AP-1 activities up to twofold. Taken together, our results establish MEK5 as a key signalling molecule associated with prostate carcinogenesis. As the MEK5/ERK5 interaction is highly specific, it represents a potential target of therapy.	Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Surg, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; Dong Z, 2001, INT J CANCER, V93, P507, DOI 10.1002/ijc.1358; EASTHAM JA, 1995, LAB INVEST, V73, P628; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30; Hamdy FC, 1997, CANCER RES, V57, P4427; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Jenkins BL, 2001, BRIT J CANCER, V85, P22; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOSTENUIK PJ, 1992, CLIN EXP METASTAS, V10, P411, DOI 10.1007/BF00133470; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Okamoto M, 1997, CANCER RES, V57, P141; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SATO H, 1993, ONCOGENE, V8, P395; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sehgal G, 1998, AM J PATHOL, V152, P591; Stack MS, 1998, INT J ONCOL, V12, P569; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; STEARNS ME, 1993, CANCER RES, V53, P878; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	38	146	154	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1381	1389		10.1038/sj.onc.1206154	http://dx.doi.org/10.1038/sj.onc.1206154			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618764	Bronze			2022-12-17	WOS:000181360900013
J	Schroeder, JA; Adriance, MC; Thompson, MC; Camenisch, TD; Gendler, SJ				Schroeder, JA; Adriance, MC; Thompson, MC; Camenisch, TD; Gendler, SJ			MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion	ONCOGENE			English	Article						MUC 1; beta-catenin; C-src; erbB; breast cancer; invasion	GROWTH-FACTOR RECEPTOR; CARCINOMA-ASSOCIATED ANTIGEN; ACTIN-BUNDLING PROTEIN; BREAST-CANCER; EPISIALIN MUC1; MAMMARY-GLAND; E-CADHERIN; TYROSINE PHOSPHORYLATION; TRANSGENIC MICE; C-SRC	MUC1 is aberrantly expressed in greater than 90% of all breast carcinomas, yet its function as a tumor antigen is not fully understood. Recently, studies have shown that MUC1 interacts with beta-catenin, erbB receptors, src, GSK-3beta and protein kinase Cdelta, possibly in a complex that promotes the disassembly of adherens junctions and the invasion of cells. Here we show that the deletion of Muc1 expression from MMTV-Wnt-1 transgenic mice results in a significant increase in the time to mammary gland tumor onset. Analysis of MMTV-Wnt-1 tumors on a wild-type Muc1 background shows a tumor-specific complex formation between Muc1 and beta-catenin that can be observed in both the membrane and the cytoplasm of transformed epithelium. Analysis of primary human adenocarcinomas revealed that this MUC1/beta-catenin interaction occurs in both primary and metastatic tumors, but is dramatically increased in metastatic lesions. Addition of MUC1-cytoplasmic domain peptides to the invasive MDA-MB-468 and MDA-MB-231 cell lines increases their invasive capability, and these peptides colocalize with both beta-catenin and the focal adhesion protein vinculin, primarily at sites of membrane invasion into a collagen matrix. These data indicate a potential mechanism for MUC1 promotion of invasive tumorigenesis in the breast through the modulation of beta-catenin localization and subsequent cytoskeletal dynamics.	Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu		Camenisch, Todd/0000-0002-7797-9822; schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA90204, F32 CA081703-03, F32 CA081703, CA64389, CA81703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA081703, F31CA090204, R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Kondo K, 1998, CANCER RES, V58, P2014; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2002, J BIOL CHEM, V277, P22692, DOI 10.1074/jbc.M201975200; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Walsh MD, 1999, BREAST CANCER RES TR, V58, P255; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; ZOTTER S, 1988, CANCER RES, V111, P55; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	32	146	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1324	1332		10.1038/sj.onc.1206291	http://dx.doi.org/10.1038/sj.onc.1206291			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618757				2022-12-17	WOS:000181360900006
J	Jaumot, M; Hancock, JF				Jaumot, M; Hancock, JF			Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions	ONCOGENE			English	Article						Ras; Raf; 14-3-3; phophatases; plasma membrane	CYSTEINE-RICH DOMAIN; RECEPTOR TYROSINE KINASE; DISTINCT BINDING DOMAINS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; B-RAF; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC RAS; ZINC-FINGER; PHOSPHORYLATION	Raf-1 activation is a complex process which involves plasma membrane recruitment, phosphorylation, protein-protein and lipid-protein interactions, We now show that PP1 and PP2A serine-threonine phosphatases also have a positive role in Ras dependent Raf-1 activation, General serine-threonine phosphatase inhibitors such sodium fluoride, or beta-glycerophosphate and sodium pyrophosphate, or specific PP1 and PP2A inhibitors including microcystin-LR, protein phosphatase 2A inhibitor I-1 or protein phosphatase inhibitor 2 all abrogate H-Ras and K-Ras dependent Raf-1 activation in vitro. A critical Raf-1 target residue for PP1 and PP2A is S259. Serine phosphatase inhibitors block the dephosphorylation of S259, which accompanies Raf-1 activation, and Ras dependent activation of mutant Raf259A is relatively resistant to serine phosphatase inhibitors. Sucrose gradient analysis demonstrates that serine phosphatase inhibition increases the total amount of 14-3-3 and Raf-1 associated with the plasma membrane and significantly alters the distribution of 14-3-3 and Raf-1 across different plasma membrane microdomains, These observations suggest that dephosphorylation of S259 is a critical early step in Ras dependent Raf-1 activation which facilitates 14-3-3 displacement. Inhibition of PP1 and PP2A therefore causes plasma membrane accumulation of Raf-1/14-3-3 complexes which cannot be activated.	Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Brisbane, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Expt Oncol Lab, Herston Rd, Brisbane, Qld 4006, Australia.		Jaumot, Montserrat/F-2640-2016	Hancock, John/0000-0003-0542-4710; Jaumot, Montserrat/0000-0003-2864-357X				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cissel DS, 2000, J BIOL CHEM, V275, P7066, DOI 10.1074/jbc.275.10.7066; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Okada T, 1999, MOL CELL BIOL, V19, P6057; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pol A, 2000, J BIOL CHEM, V275, P30566, DOI 10.1074/jbc.M001131200; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; Sieburth DS, 1999, GENE DEV, V13, P2562, DOI 10.1101/gad.13.19.2562; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	146	148	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3949	3958		10.1038/sj.onc.1204526	http://dx.doi.org/10.1038/sj.onc.1204526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494123				2022-12-17	WOS:000169681500003
J	Swinnen, JV; Heemers, H; Deboel, L; Foufelle, F; Heyns, W; Verhoeven, G				Swinnen, JV; Heemers, H; Deboel, L; Foufelle, F; Heyns, W; Verhoeven, G			Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway	ONCOGENE			English	Article						epidermal growth factor; prostate cancer; LNCaP; lipogenesis	ONCOGENIC ANTIGEN-519 OA-519; LIPOGENIC GENE-EXPRESSION; PROSTATE-CANCER CELLS; ANDROGEN RECEPTOR; BREAST-CANCER; TRANSGENIC MICE; KINASE PATHWAY; CULTURED-CELLS; MAP KINASE; LINE LNCAP	Increased expression of fatty acid synthase (FAS) is observed in a clinically aggressive subset of various common cancers and interference with FAS offers promising opportunities for selective chemotherapeutic intervention, The mechanisms by which FAS expression is (up)-regulated in these tumors remain, however, largely unknown. Recently we demonstrated that in LNCaP prostate cancer cells FAS expression is markedly elevated by androgens via an indirect pathway involving sterol regulatory element-binding proteins (SREBPs), Here, we also show that growth factors such as EGF are able to stimulate FAS mRNA, protein and activity. Several observations also indicate that the effects of EGF on FAS expression are ultimately mediated by SREBPs, EGF stimulates SREBP-1c mRNA expression and induces an increase in mature nuclear SREBP-1. Moreover, in transient transfection studies EGF stimulates the transcriptional activity of a 178 bp FAS promoter fragment harboring a complex SREBP-binding site. Deletion or mutation of this binding site abolishes these effects and ectopic expression of dominant negative SREBP-1 inhibits FAS expression and induction in intact LNCaP cells, Given the frequent dysregulation of growth factor signaling in cancer and the key role of SREBP-1 in lipid homeostasis, growth factor-induced activation of the SREBP pathway is proposed as one of the mechanisms responsible for upregulation of lipogenic gene expression in a subset of cancer cells.	Katholieke Univ Leuven, Fac Med Onderwijs & Navorsing, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Univ Paris 06, INSERM, U465, Ctr Rech Biomed Cordeliers, Paris, France	KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Swinnen, JV (corresponding author), Katholieke Univ Leuven, Fac Med Onderwijs & Navorsing, Lab Expt Med & Endocrinol, Herestr 49, B-3000 Louvain, Belgium.		Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077; FOUFELLE, Fabienne/0000-0002-0752-622X; DEBOEL, LUDO/0000-0002-2303-513X				Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1995, EUR UROL, V27, P45; CULIG Z, 1995, WORLD J UROL, V13, P285; CULIG Z, 1996, PROSTATE, V28, P329; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/0264-6021:3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fukazawa H, 2000, CANCER RES, V60, P2104; FURUYA Y, 1997, ANTICANCER RES, V17, P4583; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Hardman W., 1995, Modern Pathology, V8, p90A; Hobisch A, 1998, CANCER RES, V58, P4640; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; JENSEN V, 1995, J PATHOL, V176, P343, DOI 10.1002/path.1711760405; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Krontiras H, 1999, HEAD NECK-J SCI SPEC, V21, P325, DOI 10.1002/(SICI)1097-0347(199907)21:4<325::AID-HED6>3.3.CO;2-G; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Pizer ES, 1996, CANCER RES, V56, P745; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Putz T, 1999, CANCER RES, V59, P227; Rashid A, 1997, AM J PATHOL, V150, P201; SCHUURMANS ALG, 1988, PROSTATE, V12, P55, DOI 10.1002/pros.2990120108; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SHURBAJI MS, 1992, AM J CLIN PATHOL, V97, P686, DOI 10.1093/ajcp/97.5.686; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Swinnen JV, 1998, J STEROID BIOCHEM, V65, P191, DOI 10.1016/S0960-0760(97)00187-8; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Swinnen JV, 1997, CANCER RES, V57, P1086; VERHOEVEN G, 1995, INT J ANDROL, V18, P23, DOI 10.1111/j.1365-2605.1995.tb00931.x; Visca P, 1999, CLIN CANCER RES, V5, P4111; Vlad L. D., 1999, Modern Pathology, V12, p70A; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/0092-8674(93)90690-R	52	146	158	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5173	5181		10.1038/sj.onc.1203889	http://dx.doi.org/10.1038/sj.onc.1203889			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064454				2022-12-17	WOS:000090124100006
J	Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB				Chainy, GBN; Manna, SK; Chaturvedi, MM; Aggarwal, BB			Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappa B, AP-1, JNK, MAPKK and apoptosis	ONCOGENE			English	Article						anethole; TNF; NF-kappa B; AP-1; JNK; apoptosis	LIPID-PEROXIDATION; TRANSCRIPTION FACTOR; POTENT INHIBITOR; TERMINAL KINASE; COLON-CANCER; ACTIVATION; EUGENOL; CELLS; CHEMOPREVENTION; OVEREXPRESSION	Anethole, a chief constituent of anise, camphor, and fennel, has been shown to block both inflammation and carcinogenesis, but just how these effects are mediated is not known, One possibility is TNF-mediated signaling, which has also been associated with both inflammation and carcinogenesis. In the present report we show that anethole is a potent inhibitor of TNF-induced NF-kappa B activation (an early response) as monitored by electrophoretic mobility shift assay I kappa B alpha phosphorylation and degradation, and NF-kappa B reporter gene expression. Suppresaon of I kappa B alpha phosphorylation and NF-kappa B reporter gene expression induced by TRAF2 and NIK, suggests that anethole acts on I kappa B alpha kinase, Anethole also blocked the NF-kappa B activation induced by a variety of other inflammatory agents. Besides NF-kappa B, anethole also suppressed TNF-induced activation of the transcription factor AP-1, c-jun N-terminal kinase and MAPK-kinase, In addition, anethole abrogated TNF-induced apoptosis as measured by both caspase activation and cell viability. The anethole analogues eugenol and isoeugenol also blocked TNF signaling. Anethole suppressed TNF-induced both lipid peroxidation and ROI generation. Overall, our results demonstrate that anethole inhibits TNF-induced cellular responses,,which mag explain its role in suppression of inflammation and carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013; Chainy, Gagan B.N./G-7020-2012	Chainy, Gagan/0000-0002-6418-0480				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ALHARBI MM, 1995, EUR J CANCER PREV, V4, P307, DOI 10.1097/00008469-199508000-00006; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Bouthillier L, 1996, TOXICOL APPL PHARM, V139, P177, DOI 10.1006/taap.1996.0156; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Budavari S., 1996, MERCK INDEX, P108; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Drukarch B, 1997, EUR J PHARMACOL, V329, P259, DOI 10.1016/S0014-2999(97)89187-X; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khanna S, 1998, BIOCHEM PHARMACOL, V56, P61, DOI 10.1016/S0006-2952(98)00113-0; KO FN, 1995, BBA-LIPID LIPID MET, V1258, P145; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LUBET RA, 1997, INT J CANCER, P7295; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V163, P6800; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; MANSUY D, 1986, BIOCHEM BIOPH RES CO, V135, P1015, DOI 10.1016/0006-291X(86)91029-6; NAGABABU E, 1994, FREE RADICAL RES, V20, P253, DOI 10.3109/10715769409147521; NAIDU KA, 1995, PROSTAG LEUKOTR ESS, V53, P381, DOI 10.1016/0952-3278(95)90060-8; RAJAKUMAR DV, 1993, BIOCHEM PHARMACOL, V46, P2067, DOI 10.1016/0006-2952(93)90649-H; Reddy BS, 1996, PREV MED, V25, P48, DOI 10.1006/pmed.1996.0017; Reddy BS, 1997, ADV EXP MED BIOL, V400, P931; REDDY BS, 1993, CANCER RES, V53, P3493; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; ROMPELBERG CJM, 1993, FOOD CHEM TOXICOL, V31, P637, DOI 10.1016/0278-6915(93)90046-2; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; SHARMA JN, 1994, PHARMACOLOGY, V49, P314, DOI 10.1159/000139248; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; STOHS SJ, 1986, MECH AGEING DEV, V37, P137, DOI 10.1016/0047-6374(86)90071-0; Suganuma M, 1996, CANCER RES, V56, P3711; TAIRA J, 1992, FREE RADICAL RES COM, V16, P197, DOI 10.3109/10715769209049172; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	40	146	150	0	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2943	2950		10.1038/sj.onc.1203614	http://dx.doi.org/10.1038/sj.onc.1203614			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871845				2022-12-17	WOS:000087544500008
J	Esteller, M; Avizienyte, E; Corn, PG; Lothe, RA; Baylin, SB; Aaltonen, LA; Herman, JG				Esteller, M; Avizienyte, E; Corn, PG; Lothe, RA; Baylin, SB; Aaltonen, LA; Herman, JG			Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome	ONCOGENE			English	Article						LKB1; hypermethylation; Peutz-Jeghers; human cancer	PROMOTER HYPERMETHYLATION; SOMATIC MUTATIONS; COLON-CANCER; CELL-LINES; METHYLATION; GENE; NEOPLASIA; KINASE; HMLH1	Germ-Line mutations of the LKB1 gene cause Peutz-Jeghers syndrome (PJS) characterized by mucocutaneous pigmentation, predisposition to benign hamartomas of the gastrointestinal tract and also to several types of tumors. However, somatic mutations of this gene are, very rare. To examine inactivation of LKB1 by epigenetic mechanisms,,ve investigated a series of primary tumors and canter cell lines, for hg permethylation affecting the CpG island located in the 5' region of the LKB1 gene using Methylation-specific PCR (MSP). First, we screened 51 cancer cell lines. Only three colorectal and one cervical carcinoma cell lines were methylated at LKB1, and loss of the LKB1 transcript was demonstrated. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored LKB1 expression, To address the incidence of LKB1 epigenetic inactivation in primary tumors, we analysed colorectal, breast, gastric, pancreatic, thyroid, bladder and testicular carcinomas (n = 195), Normal tissues from the mentioned organs were unmethylated in this region. Among the described tumors, only one colorectal carcinoma and three testicular tumors displayed LKB1 promoter hypermethylation. Further study of those histological types more commonly associated with PJS, demonstrated that LKB1 promoter hypermethylation was present in five of 11 (45%) papillary breast carcinomas, Finally, in three patients with a strong family story suggestive of PJS disease, abnormal LKB1 methylation was found in four of 22 (18%) hamartomatous polyps lesions. Our findings provide an alternative pathway for inactivation of the LKB1 tumor suppressor gene involving promoter hypermethylation.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; University of Oslo	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, 424 N Bond St, Baltimore, MD 21231 USA.		Esteller, Manel/L-5956-2014; Aaltonen, Lauri/A-5375-2010	Esteller, Manel/0000-0003-4490-6093; Aaltonen, Lauri/0000-0001-6839-4286; Lothe, Ragnhild A./0000-0002-1693-1032				Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bignell GR, 1998, CANCER RES, V58, P1384; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; Dong SM, 1998, CANCER RES, V58, P3787; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 1999, AM J CLIN PATHOL, V111, P336; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; JONES HW, 1971, OBSTET GYNECOL, V38, P945; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kane MF, 1997, CANCER RES, V57, P808; Lee JY, 1998, CANCER RES, V58, P1140; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Resta N, 1998, CANCER RES, V58, P4799; RILEY E, 1980, CANCER, V46, P815, DOI 10.1002/1097-0142(19800815)46:4<815::AID-CNCR2820460428>3.0.CO;2-V; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101; Vermeulen SJ, 1998, CANCER GENET CYTOGEN, V107, P76, DOI 10.1016/S0165-4608(98)00081-8; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45	29	146	152	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					164	168		10.1038/sj.onc.1203227	http://dx.doi.org/10.1038/sj.onc.1203227			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644993				2022-12-17	WOS:000084844300020
J	Moskaluk, CA; Tian, Q; Marshall, CR; Rumpel, CA; Franquemont, DW; Frierson, HF				Moskaluk, CA; Tian, Q; Marshall, CR; Rumpel, CA; Franquemont, DW; Frierson, HF			Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors	ONCOGENE			English	Article						c-kit; oncogene; gene mutation; sarcoma; gastrointestinal tract	RECEPTOR TYROSINE KINASE; CELL GROWTH-FACTOR; INTERSTITIAL-CELLS; ELECTRICAL RHYTHMICITY; TISSUES; CAJAL; EXPRESSION; PROTEIN; LIGAND; INTESTINE	The c-kit gene encodes a transmembrane receptor kinase (KIT) which is expressed in the majority of human gastrointestinal stromal tumors (GISTs), a subtype of gastrointestinal mesenchymal neoplasms. A previous study identified mutations in the juxtamembrane (JR I) domain of c-X-it in five of six GISTs (Science 279: 577, 1998), To better define the frequency and spectrum of c-kit gene mutations in mesenchymal neoplasms of the GI tract that had been characterized for KIT protein expression, we examined archived tissue samples for mutations in the JM domain by PCR amplification and DNA sequencing. c-kit JM domain mutations were found in nine of 56 mesenchymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusively in GISTs (21%), Seven of the nine mutations consisted of intragenic deletions of one to 19 codons, There was one insertion mutation that added 12 codons and one missense mutation (Val560Asp), None of the mutations disrupted the downstream reading frame of the gene, The single missense mutation (Val560Asp) is very similar to the only other missense mutation reported in GISTs (Val599Asp). Of the 46 GISTs, 43,were strongly positive for KIT protein expression and negative for diffuse expression of desmin, Neither KIT expression nor gene mutations,were found in gastrointestinal leiomyomas or leiomyosarcomas. We conclude that mutation of the c-kit JM domain does not occur in gastrointestinal mesenchymal neoplasms,vith well developed-smooth muscle differentiation, and is restricted to GISTs, However, since these mutations are only found in a minority of GISTs, further investigation into the mechanisms of c-kit gene activation in this group of neoplasms is warranted.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Penrose Hosp, Dept Pathol, Colorado Springs, CO 80907 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [K08CA074431] Funding Source: NIH RePORTER; NCI NIH HHS [5K08CA74431-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber DA, 1998, HUM PATHOL, V29, P498, DOI 10.1016/S0046-8177(98)90066-1; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; FRANQUEMONT DW, 1992, AM J SURG PATHOL, V16, P947, DOI 10.1097/00000478-199210000-00004; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HJERMSTAD BM, 1987, AM J SURG PATHOL, V11, P383, DOI 10.1097/00000478-198705000-00007; HORIE K, 1993, HUM REPROD, V8, P1955, DOI 10.1093/oxfordjournals.humrep.a137967; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Isozaki K, 1997, AM J GASTROENTEROL, V92, P332; Kenny SE, 1998, J PEDIATR SURG, V33, P130, DOI 10.1016/S0022-3468(98)90379-7; Kindblom LG, 1998, AM J PATHOL, V152, P1259; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kluppel M, 1998, DEV DYNAM, V211, P60; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MATSUDA R, 1993, AM J PATHOL, V142, P339; MIETTINEN M, 1995, AM J SURG PATHOL, V19, P207, DOI 10.1097/00000478-199502000-00009; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216; SARLOMORIKALA M, 1998, IN PRESS MOD PATHOL; SAUL SH, 1987, AM J SURG PATHOL, V11, P464, DOI 10.1097/00000478-198706000-00007; Torihashi S, 1997, GASTROENTEROLOGY, V112, P144, DOI 10.1016/S0016-5085(97)70229-4; Tsujimura T, 1996, BLOOD, V87, P273; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P279, DOI 10.1053/gast.1996.v111.pm8690192; Vliagoftis H, 1997, J ALLERGY CLIN IMMUN, V100, P435, DOI 10.1016/S0091-6749(97)70131-3; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	30	146	159	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1897	1902		10.1038/sj.onc.1202496	http://dx.doi.org/10.1038/sj.onc.1202496			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086344				2022-12-17	WOS:000079090000013
J	Muller, D; Bouchard, C; Rudolph, B; Steiner, P; Stuckmann, I; Saffrich, R; Ansorge, W; Huttner, W; Eilers, M				Muller, D; Bouchard, C; Rudolph, B; Steiner, P; Stuckmann, I; Saffrich, R; Ansorge, W; Huttner, W; Eilers, M			Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes	ONCOGENE			English	Article						Myc; p27; cyclin E; cdk2	UBIQUITIN-PROTEASOME PATHWAY; C-MYC; DEPENDENT KINASES; CELL-CYCLE; TRANSCRIPTIONAL REPRESSOR; ACTIVATES TRANSCRIPTION; IN-VIVO; MAX; GENE; PROTEINS	Activation of Myc triggers a rapid induction of cyclin El cdk2 kinase activity and degradation of p27. Overt degradation of p27 is preceded by a specific dissociation of p27 from cyclin E/cdk2, but not from cyclin D/cdk4 complexes. We now show that cyclin E/cdk2 phosphorylates p27 at a carboxy-terminal threonine residue (T187) in vitro; mutation of this residue to valine stabilises cyclin E/cdk2 complexes. This reaction is not significantly inhibited by high concentrations of p27, suggesting that cdk2 bound to p27 is catalytically active. In vivo, p27 bound to cyclins E and A, but not to D-type cyclins is phosphorylated. Myc-induced release of p27 from cdk2 requires cdk2 kinase activity and is delayed in a T187V mutant of p27. After induction of MSc, p27 phosphorylated at threonine 187 transiently accumulates in a non cdk2 bound form. Our data suggest a mechanism in which p27 is released from cyclin E/cdk2 upon phosphorylation; in Myc-transformed cells, release is efficient as phosphorylated p27 is transiently bound in a non-cdk2 containing complex and subsequently degraded.	ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, DEPT NEUROBIOL, D-69120 HEIDELBERG, GERMANY; EUROPEAN MOL BIOL LAB, BIOCHEM INSTRUMENTAT PROGRAMME, D-69117 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)			Ansorge, Wilhelm/AAN-8780-2020	Eilers, Martin/0000-0002-0376-6533; Saffrich, Rainer/0000-0002-0547-4550				ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; An SK, 1996, FEBS LETT, V386, P115, DOI 10.1016/0014-5793(96)00427-9; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BERNS K, 1997, IN PRESS ONCOGENE; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Celis JE, 1995, ELECTROPHORESIS, V16, P2177, DOI 10.1002/elps.11501601355; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAAS K, 1997, IN PRESS ONCOGENE; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEREIRA MEF, 1994, J NEUROCHEM, V63, P1578; PEREZROGER I, 1997, IN PRESS ONCOGENE; PEUKERT K, 1997, IN PRESS EMBO J; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PUSCH O, 1997, IN PRESS ONCOGENE; Rao G, 1996, ONCOGENE, V12, P1165; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilmut I., 1990, TRENDS BIOTECHNOLOGY; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	64	146	149	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	1997	15	21					2561	2576		10.1038/sj.onc.1201440	http://dx.doi.org/10.1038/sj.onc.1201440			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399644				2022-12-17	WOS:A1997YG73200006
J	Knippschild, U; Milne, DM; Campbell, LE; DeMaggio, AJ; Christenson, E; Hoekstra, MF; Meek, DW				Knippschild, U; Milne, DM; Campbell, LE; DeMaggio, AJ; Christenson, E; Hoekstra, MF; Meek, DW			p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs	ONCOGENE			English	Article						CK1 delta; CK1 epsilon; DNA damage; p53; phosphorylation; protein kinase	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CELLS; CHECKPOINT; EXPRESSION; GENE; IRRADIATION; APOPTOSIS; MUTATION	The p53 tumour suppressor protein plays a key role in the integration of stress signals, Multi-site phosphorylation of p53 may play an integral part in the transmission of these signals and is catalysed by many different protein kinases including an unidentified p53-N-terminus-targeted protein kinase (p53NK) which phosphorylates a group of sites at the N-terminus of the protein. In this paper, we present evidence that the delta and epsilon isoforms of casein kinase 1 (CK1 delta and CK1 epsilon) show identical features to p53NK and can phosphorylate p53 both in vitro and in vivo. Recombinant, purified glutathione S-transferase (GST)-CK1 delta and GST-CK1 epsilon fusion proteins each phosphorylate p53 in vitro at serines 4, 6 and 9, the sites recognised by p53NK. Furthermore, p53NK (i) co-purifies with CK1 delta/epsilon, (ii) shares identical kinetic properties to CK1 delta/epsilon, and (iii) is inhibited by a CK1 delta/epsilon-specific inhibitor (IC261). In addition, CK1 delta is also present in purified preparations of p53NK as judged by immunoanalysis using a CK1 delta-specific monoclonal antibody. Treatment of murine SV3T3 cells with IC261 specifically blocked phosphorylation in vivo of the CK1 delta/epsilon phosphorylation sites in p53, indicating that p53 interacts physiologically with CK1 delta and/or CK1 epsilon. Similarly, over-expression of a green fluorescent protein (GFP)-CK1 delta fusion protein led to hyper-phosphorylation of p53 at its N-terminus. Treatment of MethAp53ts cells with the topoisomerase-directed drugs etoposide or camptothecin led to increases in both CK1 delta-mRNA and -protein levels in a manner dependent on the integrity of p53, These data suggest that p53 is phosphorylated by CK1 delta and CK1 epsilon and additionally that there may be a regulatory feedback loop involving p53 and CK1 delta.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND; ICOS CORP, BOTHELL, WA 98021 USA	University of Dundee; Icos Corporation								ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; Christenson E, 1997, Recent Results Cancer Res, V143, P263; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; FISCELLA M, 1993, ONCOGENE, V8, P1519; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Hall PA, 1996, J PATHOL, V180, P1; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lohrum M, 1996, ONCOGENE, V13, P2527; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; OTTO A, 1993, ONCOGENE, V8, P2591; PAULES RS, 1995, CANCER RES, V55, P1763; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Santos JA, 1996, J CELL SCI, V109, P1847; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	146	146	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1727	1736		10.1038/sj.onc.1201541	http://dx.doi.org/10.1038/sj.onc.1201541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349507				2022-12-17	WOS:A1997XY63100013
J	Benz, CC; OHagan, RC; Richter, B; Scott, GK; Chang, CH; Xiong, XH; Chew, K; Ljung, BM; Edgerton, S; Thor, A; Hassell, JA				Benz, CC; OHagan, RC; Richter, B; Scott, GK; Chang, CH; Xiong, XH; Chew, K; Ljung, BM; Edgerton, S; Thor, A; Hassell, JA			HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer	ONCOGENE			English	Article						breast cancer; HER2/Neu; PEA3; Ets transcription factor	EWINGS-SARCOMA TRANSLOCATION; MESSENGER-RNA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; C-ERBB-2 EXPRESSION; MAMMARY-CARCINOMA; MOLECULAR-CLONING; PHORBOL-ESTER; GENE FAMILY; EWS GENE	HER2/Neu is overexpressed in 25-30% of all human breast cancers as a result of both gene amplification and enhanced transcription. Transcriptional upregulation of HER2/neu leads to a 6-8-fold increased abundance of its mRNA per gene copy and likely results from the elevated activity of transcription factors acting on the HER2/neu promoter, Here we report that transcripts of PEA3, an ETS transcription factor implicated in oncogenesis, were increased in 93% of HER2/Neu-overexpressing human breast tumor samples, Analyses to uncover the molecular basis for elevated PEA3 transcripts in HER2/Neu-positive breast tumors revealed that the HER2/Neu receptor tyrosine kinase initiated an intracellular signaling cascade resulting in increased PEA3 transcriptional activity; transcriptionally-activated PEA3 stimulated HER2/neu and PEA3 gene transcription by binding to sites in the promoters of these genes, PEA3 also activates transcription of genes encoding matrix-degrading proteinases, enzymes required for tumor cell migration and invasion, These findings implicate PEA3 in the initiation and progression of HER2/Neu positive breast cancer, and suggest that PEA3 and signaling proteins affecting its regulation are appropriate therapeutic targets.	MCMASTER UNIV, INST MOL BIOL & BIOTECHNOL, CANC RES GRP, HAMILTON, ON L8S 4K1, CANADA; UNIV CALIF SAN FRANCISCO, CANC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV MOL CYTOMETRY, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV VERMONT, DEPT PATHOL, BURLINGTON, VT 05405 USA	McMaster University					NATIONAL CANCER INSTITUTE [R01CA036773, P50CA058207, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [CA58207, CA44768, CA36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; DANKORT DL, 1996, MAMMARY TUMOR CELL C, P71; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGLEHART JD, 1990, CANCER RES, V50, P6701; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KING CR, 1989, CANCER RES, V49, P4185; KOHN EC, 1995, CANCER RES, V55, P1856; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIU E, 1992, ONCOGENE, V7, P1027; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; MONTE D, 1994, ONCOGENE, V9, P1397; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHagan RC, 1996, ONCOGENE, V13, P1323; PARKES HC, 1990, BRIT J CANCER, V61, P39, DOI 10.1038/bjc.1990.9; PASLEAU F, 1993, ONCOGENE, V8, P849; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SINGLETON TP, 1992, PATHOL ANNU, V27, P165; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; TRIPATHY D, 1994, HEMATOL ONCOL CLIN N, V8, P29, DOI 10.1016/S0889-8588(18)30186-2; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	146	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1513	1525		10.1038/sj.onc.1201331	http://dx.doi.org/10.1038/sj.onc.1201331			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380403				2022-12-17	WOS:A1997XX36900002
J	Chen, J; Carey, K; Godowski, PJ				Chen, J; Carey, K; Godowski, PJ			Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation	ONCOGENE			English	Article						Gas6; Mer; Rse/Tyro3; Axl	DEPENDENT PROTEIN-S; HORMONE-BINDING GLOBULIN; ARREST-SPECIFIC GENE-6; EXPRESSION; AXL; PROTOONCOGENE; HOMOLOGY; DOMAINS; CLONING; FAMILY	Mer/Nyk/Eyk is an orphan receptor tyrosine kinase expressed at high levels in monocytes and cells derived from epithelial and reproductive tissues. Overexpression of Mer has been associated with lymphoid malignancies. Here we identify Gas6, the product of a growth arrest specific gene, as a ligand for Mer. Gas6 has previously been shown to activate both Axl and Rse/Tyro3, two other receptor tyrosine kinases in the same family as Mer. The apparent relative association and dissociation rate constants of Gas6 for soluble Axl, Rse/Tyro3 and Mer were compared using surface plasmon resonance. Gas6 was shown to induce rapid phosphorylation of Mer expressed in several different types of cells. We also observed a transient activation of p42 MAP kinase following activation of Mer by Gas6. Thus, Gas6 exerts its biological effects through multiple receptor tyrosine kinases.	GENENTECH INC,DEPT MOL BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BIESECKER LG, 1995, ONCOGENE, V10, P2239; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAI W, 1994, ONCOGENE, V9, P975; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GERSHAGEN S, 1987, FEBS LETT, V220, P129, DOI 10.1016/0014-5793(87)80890-6; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HAMMOND GL, 1987, FEBS LETT, V215, P101; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; LAI C, 1994, ONCOGENE, V9, P2567; Li RH, 1996, J NEUROSCI, V16, P2012; LING L, 1995, MOL CELL BIOL, V15, P6582; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; OHASHI K, 1994, ONCOGENE, V9, P669; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Rutishauser U, 1993, Curr Opin Neurobiol, V3, P709, DOI 10.1016/0959-4388(93)90142-L; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	37	146	159	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2033	2039		10.1038/sj.onc.1201039	http://dx.doi.org/10.1038/sj.onc.1201039			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160883				2022-12-17	WOS:A1997WW80900005
J	OHagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA				OHagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA			The activity of the ets transcription factor PEA3 is regulated by two distinct MAPK cascades	ONCOGENE			English	Article						PEA3; Ets; MAPK; Ras; transcription	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; COMPLEX FACTOR ELK-1; DNA-BINDING MOTIF; C-JUN; RAS TRANSFORMATION; MAMMALIAN-CELLS; DOMAIN PROTEIN; PHOSPHORYLATION; GENE	PEA3, a member of the Ets family of transcriptional regulatory proteins, binds to the PEA3 promoter element and stimulates transcription through this site, The activity of the PEA3 element is regulated by mitogens, activated receptor tyrosine kinases, members Ras signal However, not clear whether transcriptional regulation by these agents because a number of different Ets proteins can functionally interact with the PEA3 element. To specifically learn whether the activity of PEA3 is regulated, we investigated the ability of constitutively-activated Ras (Ha-RasV12) and signaling proteins downstream of Ras to alter PEA3-dependent reporter gene expression in COS cells, Ha-RasV12 and activated proteins in both the extra-cellular regulated kinase (ERK) and the stress-activated protein kinase (SAPK) or Jun N-terminal kinase (JNK) cascades independently stimulated PEA3-mediated gene expression. Ha-RasV12 stimulation of PEA3 activity was reduced by dominant-negative mutants in each of these protein kinase cascades, suggesting that Ras activates PEA3 through both pathways. Furthermore, the ability of unique activators of each kinase cascade to stimulate PEA3-dependent gene expression was selectively reduced by dominant-negative mutants within the homologous but not the heterologous pathway. Hence two distinct mitogen-activated protein kinase (MAPK) cascades regulate PEA3 activity, PEA3 was phosphorylated in vivo at serine residues consistent with the possibility that it may be a direct target of MAPKs.	MCMASTER UNIV, CANC RES GRP, INST MOL BIOL & BIOTECHNOL, HAMILTON, ON L8S 4K1, CANADA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	McMaster University								BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FISHER RJ, 1991, ONCOGENE, V6, P2249; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KYRIAKIS JM, 1994, PROTEIN KINASES FRON, P85; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAN MH, 1994, NATURE, V372, P798; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	57	146	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1323	1333						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808707				2022-12-17	WOS:A1996VJ20200024
J	Weber, RG; Sabel, M; Reifenberger, J; Sommer, C; Oberstrass, J; Reifenberger, G; Kiessling, M; Cremer, T				Weber, RG; Sabel, M; Reifenberger, J; Sommer, C; Oberstrass, J; Reifenberger, G; Kiessling, M; Cremer, T			Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization	ONCOGENE			English	Article						CGH; glioma; mutation; p53; progression	HUMAN-MALIGNANT GLIOMAS; HUMAN BRAIN-TUMORS; MOLECULAR CYTOGENETIC ANALYSIS; LOW-GRADE ASTROCYTOMA; CELL-CYCLE CONTROL; WILD-TYPE P53; GLIOBLASTOMA-MULTIFORME; GENE AMPLIFICATION; PROSTATE-CANCER; OLIGODENDROGLIAL TUMORS	Genomic alterations associated with glioma progression were determined by comparative genomic hybridization (CGH) 30 tumors from 15 patients with primary gliomas of World Health Organization (WHO) grade II that on recurrence showed progression to malignant gliomas of WHO grades III or IV (five cases of astrocytoma grade II (A II) to grade III (AA III), five cases of A II to glioblastoma multiforme grade IV (GEM) and five cases of oligodendroglioma grade II (O II) to grade III (AO III)). All tumors were additionally screened for p53 mutations by single strand conformational polymorphism and heteroduplex analysis of exons 5-8, followed by direct sequencing. Mutations of p53 were found in the primary and recurrent tumors of all cases of A II progressing to GEM and three of five cases of A II recurring as AA III. Alterations identified by CGH in more than one primary A II included losses on Xp (3/10) and 5p (2/10), gains on 8q and 19p (2/10 each), and gain/amplification on 12p (2/10). Common progression associated changes found in AA III or GEM were losses on 4q, 9p, 10q, 11p, 13q (4/10 each) and gains on 1q, 6p, 20q (2/10 each). The most frequent amplification site was located on 12p13 (1/10 A II, 3/5 AA III, 1/5 GEM). Other amplified chromosomal regions were 13q32-q34 (1/10 AII, 2/5 GBM), 7q31-qter (1/5 AA III, 1/5 GEM), 12q22-qter and 18p (1/5 AA III), In contrast to the astrocytic gliomas, only one of five oligodendroglial cases showed a p53 mutation. Genetic abnormalities identified by CGH to occur more than once were restricted to four chromosomes (1, 4, 9 and 19). Our results provide a comprehensive overview of the genomic alterations associated with the progression of individual gliomas and substantiate the hypothesis that glioma progression is associated with a cumulative acquisition of multiple genetic changes.	UNIV HEIDELBERG,INST HUMAN GENET,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST NEUROPATHOL,D-69120 HEIDELBERG,GERMANY; UNIV DUSSELDORF,DEPT NEUROPATHOL,D-40225 DUSSELDORF,GERMANY; UNIV DUSSELDORF,CTR BIOL & MED RES,D-40225 DUSSELDORF,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf			Weber, Ruthild/E-2906-2015; Reifenberger, Guido/AAE-3599-2019	Weber, Ruthild/0000-0001-6610-1080; Cremer, Thomas/0000-0001-7135-7216				BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P33; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; DUMANOIR S, 1995, CYTOMETRY, V19, P27, DOI 10.1002/cyto.990190105; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULLER GN, 1992, MUTAT RES, V276, P299, DOI 10.1016/0165-1110(92)90016-3; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; GRANA X, 1995, ONCOGENE, V11, P211; GREEN AJ, 1994, NAT GENET, V6, P192; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; JOOS S, 1995, GENE CHROMOSOME CANC, V14, P267, DOI 10.1002/gcc.2870140405; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KLEIHUES P, 1993, HIST TYPING TUMORS C; Kondo M, 1996, ONCOGENE, V12, P1365; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LAWS ER, 1984, J NEUROSURG, V61, P665, DOI 10.3171/jns.1984.61.4.0665; LEACH FS, 1993, CANCER RES, V53, P1986; LEENSTRA S, 1994, BRIT J CANCER, V70, P684, DOI 10.1038/bjc.1994.373; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; LICHTER P, 1995, HUMAN CHROMOSOMES FL, P192; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCCORMACK BM, 1992, NEUROSURGERY, V31, P636; Mitelman F., 1995, ISCN INT SYSTEM HUMA; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOULTON T, 1995, AM J PATHOL, V146, P613; MULERIS M, 1994, ONCOGENE, V9, P2717; MULLER W, 1977, ACTA NEUROCHIR, V37, P75, DOI 10.1007/BF01401927; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; Oberstrass J, 1996, J PATHOL, V179, P151, DOI 10.1002/(SICI)1096-9896(199606)179:2<151::AID-PATH556>3.0.CO;2-0; OHGAKI H, 1991, CANCER RES, V51, P6202; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; PIZON V, 1988, ONCOGENE, V3, P201; RASHEED BKA, 1994, CANCER RES, V54, P1324; RECHT LD, 1992, ANN NEUROL, V31, P431, DOI 10.1002/ana.410310413; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Reifenberger G, 1996, BRAIN TUMOR, P187; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RIED T, 1994, CANCER RES, V54, P1801; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; ROUSSEAUMERCK MF, 1990, CYTOGENET CELL GENET, V53, P2, DOI 10.1159/000132883; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHROCK E, 1994, AM J PATHOL, V144, P1203; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, CANCER RES, V55, P2166; SPEICHER MR, 1995, CANCER RES, V55, P1010; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Ueki K, 1996, CANCER RES, V56, P150; VENTER DJ, 1991, ONCOGENE, V6, P445; VERTOSICK FT, 1991, NEUROSURGERY, V28, P496, DOI 10.1227/00006123-199104000-00002; VISAKORPI T, 1995, CANCER RES, V55, P342; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; VONDEIMLING A, 1994, CANCER RES, V54, P1397; VONDEIMLING A, 1992, CANCER RES, V52, P2987; VOORTER C, 1995, AM J PATHOL, V146, P1341; WALKER DG, 1995, CANCER RES, V55, P20; Weber RG, 1996, LAB INVEST, V74, P108; WINGER MJ, 1989, J NEUROSURG, V71, P487, DOI 10.3171/jns.1989.71.4.0487; WONG AJ, 1994, SEMIN ONCOL, V21, P139; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	86	146	147	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					983	994						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806688				2022-12-17	WOS:A1996VG76600012
J	Tashiro, S; Kotomura, N; Shinohara, A; Tanaka, K; Ueda, K; Kamada, N				Tashiro, S; Kotomura, N; Shinohara, A; Tanaka, K; Ueda, K; Kamada, N			S phase specific formation of the human Rad51 protein nuclear foci in lymphocytes	ONCOGENE			English	Article						human Rad51 protein; lymphocyte; S phase	RECOMBINATION; GENES; YEAST; RECA	The Rad51 protein, which is a homologue of the bacterial RecA protein, is involved in mitotic and meiotic recombination and in repair of double-strand breaks of DNA in yeast, The Rad51 homologue is conserved from yeast to human, In this study, the Rad51 protein was shown to be induced in peripheral blood lymphocytes (PBLs) 36 h after phytohemagglutinin (PHA) stimulation, Immunofluorescence study revealed that the distribution of the Rad51 protein in the nucleus was not uniform and focus-like staining was observed, Formation of the Rad51 foci was induced at 36 h after treatment of the cells with PHA. Twenty five percent of the cells had the foci at this time and the number of cells with foci declined thereafter, Cell cycle study using laser microscope by double staining method suggested that the appearance of the Rad51 nuclear foci was S phase specific, Furthermore, double staining study for the Rad51 protein and incorporated BrdU confirmed S phase specific appearance of the Rad51 nuclear foci, Formation of the Rad51 nuclear foci in PHA-stimulated lymphocytes might be involved in DNA recombination or DNA repair in S phase, The roles of RAD51 foci in S-phase will be discussed.	HIROSHIMA UNIV,RES INST RADIAT BIOL & MED,DIV MOLEC BIOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 734,JAPAN; OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	Hiroshima University; Hiroshima University; Osaka University								BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; FAED MJW, 1978, MUTAT RES, V49, P437, DOI 10.1016/0027-5107(78)90115-X; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HOZAK P, 1994, J CELL SCI, V107, P219; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KOGOMA T, 1994, MOL GEN GENET, V244, P557, DOI 10.1007/BF00583907; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Ogawa H, 1990, Adv Biophys, V26, P33, DOI 10.1016/0065-227X(90)90006-F; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WITKIN EM, 1969, ANNU REV MICROBIOL, V23, P487, DOI 10.1146/annurev.mi.23.100169.002415; WOLFF S, 1974, MUTAT RES, V25, P73, DOI 10.1016/0165-1218(74)90082-2	17	146	146	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2165	2170						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668342				2022-12-17	WOS:A1996UP28300015
J	Clark, J; Benjamin, H; Gill, S; Sidhar, S; Goodwin, G; Crew, J; Gusterson, BA; Shipley, J; Cooper, CS				Clark, J; Benjamin, H; Gill, S; Sidhar, S; Goodwin, G; Crew, J; Gusterson, BA; Shipley, J; Cooper, CS			Fusion of the EWS gene to CHN, a member of the steroid thyroid receptor gene superfamily, in a human myxoid chondrosarcoma	ONCOGENE			English	Article						CHN oncogene; chondrosarcoma; steroid thyroid receptor	ACUTE PROMYELOCYTIC LEUKEMIA; ALPHA LOCUS; DNA-BINDING; TRANSLOCATION; BREAKPOINT; REGION; TUMORS; FAMILY	The specific chromosomal translocation t(9;22)(q22-31;q11-12) has been observed in the myxoid variant of human chondrosarcoma. In agreement with this observation we report that the EWS gene located at chromosome band 22q12 becomes fused to CHN, a member of the steroid/thyroid receptor gene superfamily located at 9q22-31, in a skeletal myxoid chondrosarcoma. CHN appears to be the human homologue of the rat gene NOR1, which was recently identified as a sequence overexpressed in rat brain cells undergoing apoptosis. Our results also indicate that the chimaeric EWS-CHN gene encodes a EWS-CHN fusion protein in which the C-terminal RNA-binding domain of EWS is replaced by the entire CHN protein, comprising a long N-terminal domain, a central DNA binding domain and a C-terminal ligand-binding/dimerisation domain.	INST CANC RES,HADDOW LABS,SECT MOLEC CARCINOGENESIS,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,HADDOW LABS,SECT CELL BIOL & EXPTL PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; CHESTER BEATTY LABS,SECT CELL & MOLEC BIOL,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK			gusterson, barry a/D-3752-2009	Shipley, Janet/0000-0001-6748-8678				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEGOS L, 1992, Current Opinion in Oncology, V4, P45, DOI 10.1097/00001622-199202000-00007; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GILL S, 1995, CANCER, V12, P307; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HINRICHS SH, 1985, CANCER GENET CYTOGEN, V14, P219, DOI 10.1016/0165-4608(85)90187-6; JEON IS, 1995, ONCOGENE, V10, P1229; LADANYI M, 1994, CANCER RES, V54, P2837; MAGES HW, 1994, MOL ENDOCRINOL, V8, P1583, DOI 10.1210/me.8.11.1583; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; ORNDAL C, 1991, CYTOPATHOLOGY, V2, P261, DOI 10.1111/j.1365-2303.1991.tb00497.x; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAINATI L, 1993, CANCER GENET CYTOGEN, V71, P144, DOI 10.1016/0165-4608(93)90020-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TARKKANEN M, 1994, GENE CHROMOSOME CANC, V9, P136, DOI 10.1002/gcc.2870090210; TSAI MJ, 1994, ANN REV BIOCH, V63, P431; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1297; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	146	149	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570200				2022-12-17	WOS:A1996TR53800002
J	XIAO, S; LI, DZ; VIJG, J; SUGARBAKER, DJ; CORSON, JM; FLETCHER, JA				XIAO, S; LI, DZ; VIJG, J; SUGARBAKER, DJ; CORSON, JM; FLETCHER, JA			CODELETION OF P15 AND P16 IN PRIMARY MALIGNANT MESOTHELIOMA	ONCOGENE			English	Article						MESOTHELIOMA; IN SITU HYBRIDIZATION; CYCLINS; CYCLIN-DEPENDENT KINASES	DELETIONS; 9P	The p15 and p16 CDK4 inhibitor genes map within the chromosome band 9p21 region deleted frequently in malignant mesothelioma and other cancers, p16 has been implicated recently as a potential target of 9p21 deletions in mesothelioma, but the role of this gene is uncertain because deletions have been detected more often in established cell lines than in primary tumor specimens. We determined p15 and p16 copy number by fluorescence in situ hybridization with a P1 contig in 50 primary mesotheliomas. Codeletion of p15 and p16 was found in 72% of mesotheliomas, including all cases with spindle-cell components (n = 21) and total deletion of p15 and p16 was found in several mesotheliomas that lacked cytogenetic deletion of the chromosome 9 short arm. Point mutations were not found, however, in exon 2 of retained p15 and p16 alleles from seven mesotheliomas. These findings demonstrate that p15, p16 and/or a closely neighboring gene, are the targets of frequent chromosome 9p deletion in primary malignant mesothelioma.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DIV GERONTOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NCI NIH HHS [1K11CA01498-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CARINS P, 1994, SCIENCE, V265, P415; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; CHENG JQ, 1994, CANCER RES, V54, P5547; CHENG JQ, 1993, CANCER RES, V53, P4761; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FUSCO V, 1993, ANTICANCER RES, V13, P683; GRANADOS R, 1994, ACTA CYTOL, V38, P711; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MEAD LJ, 1994, CANCER RES, V54, P2307; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OELS HC, 1971, CHEST, V60, P564, DOI 10.1378/chest.60.6.564; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; POPESCU NC, 1988, CANCER RES, V48, P142; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAGUCHI T, 1993, CANCER RES, V53, P4349; WALKER DG, 1995, CANCER RES, V55, P20; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	27	146	148	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					511	515						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630635				2022-12-17	WOS:A1995RN53000011
J	TAMURA, K; KANAOKA, Y; JINNO, S; NAGATA, A; OGISO, Y; SHIMIZU, K; HAYAKAWA, T; NOJIMA, H; OKAYAMA, H				TAMURA, K; KANAOKA, Y; JINNO, S; NAGATA, A; OGISO, Y; SHIMIZU, K; HAYAKAWA, T; NOJIMA, H; OKAYAMA, H			CYCLIN-G - A NEW MAMMALIAN CYCLIN WITH HOMOLOGY TO FISSION YEAST CIG1	ONCOGENE			English	Article							CELL-CYCLE; DNA-REPLICATION; IDENTIFICATION; EUKARYOTES; ACTIVATION; PROTEINS; FAMILY; PHASE; SWI4	A new gene encoding a cyclin-like protein has been isolated from a rat fibroblast cDNA library by cross-hybridization with a mixutre of c-src family proto-oncogene kinase domains as a probe. This putative cyclin, called cyclin G, contains a typical cyclin box at the N-terminus but no apparent 'destruction box' or 'PEST' sequence. Interestingly, in its C-terminus region, it has a sequence homologous with a tyrosine phosphorylation site of the epidermal growth factor receptor. Although this cyclin is phylogenetically related to HCS26 of Saccharomyces cerevisiae, it most resembles Cig1, a B-type cyclin, of Schizosaccharomyces pombe, which has been suggested to act at the G1/S phase of the cell cycle. Cyclin G mRNA is induced within 3h after growth stimulation and remains elevated with no apparent cell cycle dependency, indicating its close association with growth stimuli but not with the cell cycle.	OSAKA UNIV, DEPT MOLEC GENET, MICROBIAL DIS RES INST, SUITA, OSAKA 565, JAPAN; RES DEV CORP JAPAN, OKAYAMA CELL SWITCHING PROJECT, KYOTO 606, JAPAN; OSAKA UNIV, DEPT NEUROSURG, OSAKA 553, JAPAN	Osaka University; Japan Science & Technology Agency (JST); Osaka University								BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINSHULL J, 1989, J CELL SCI, P77; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STUDIER JA, 1988, MOL BIOL EVOL, V5, P729; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	28	146	159	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2113	2118						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336937				2022-12-17	WOS:A1993LP17100011
J	He, WM; Liang, BS; Wang, CL; Li, SW; Zhao, Y; Huang, Q; Liu, ZX; Yao, ZQ; Wu, QJ; Liao, WJ; Zhang, SY; Liu, YJ; Xiang, Y; Liu, J; Shi, M				He, Wanming; Liang, Bishan; Wang, Chunlin; Li, Shaowei; Zhao, Yang; Huang, Qiong; Liu, Zexian; Yao, Zhiqi; Wu, Qijing; Liao, Wangjun; Zhang, Shuyi; Liu, Yajing; Xiang, Yi; Liu, Jia; Shi, Min			MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer	ONCOGENE			English	Article							TGF-BETA; DRUG-RESISTANCE; CELLS; MECHANISMS; CHEMOTHERAPY; METASTASIS; METABOLISM; SURVIVAL	Chemotherapy is the preferred treatment for advanced stage gastric cancer (GC) patients and chemotherapy resistance is the major obstacle to effective cancer therapy. Increasing evidence suggests that mesenchymal stem cells (MSCs) make important contributions to development of drug resistance. However, the underlying mechanism remains elusive. In this study, we discovered that abundant MSCs in tumor tissues predicted a poor prognosis in GC patients. MSCs promoted stemness and chemoresistance in GC cells through fatty acid oxidation (FAO) in vitro and in vivo. Mechanically, transforming growth factor beta 1 (TGF-beta 1) secretion by MSCs activated SMAD2/3 through TGF-beta receptors and induced long non-coding RNA (lncRNA) MACC1-AS1 expression in GC cells, which promoted FAO-dependent stemness and chemoresistance through antagonizing miR-145-5p. Moreover, pharmacologic inhibition of FAO with etomoxir (ETX) attenuated MSC-induced FOLFOX regiment resistance in vivo. These results suggest that FAO plays an important role in MSC-mediated stemness and chemotherapy resistance in GC and FAO inhibitors in combination with chemotherapeutic drugs present as a promising strategy to overcome chemoresistance.	[He, Wanming; Liang, Bishan; Wang, Chunlin; Li, Shaowei; Zhao, Yang; Huang, Qiong; Yao, Zhiqi; Wu, Qijing; Liao, Wangjun; Zhang, Shuyi; Liu, Yajing; Xiang, Yi; Liu, Jia; Shi, Min] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Liu, Zexian] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University	Shi, M (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China.	nfyyshimin@163.com	Liu, Zexian/D-1153-2011	Liu, Zexian/0000-0001-9698-0610	National Key R&D Program of China [2017YFC1105000]; National Natural Science Foundation of China [81702398]; Natural Science Foundation of Guangdong Province of China [2016A020215232]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province)	This study was supported by National Key R&D Program of China (grant number 2017YFC1105000), National Natural Science Foundation of China (grant number 81702398), and Natural Science Foundation of Guangdong Province of China (grant number 2016A020215232).	Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Chen CT, 2010, BBA-GEN SUBJECTS, V1800, P257, DOI 10.1016/j.bbagen.2009.09.001; Davidson M, 2015, CLIN COLORECTAL CANC, V14, P239, DOI 10.1016/j.clcc.2015.05.013; Di Francesco AM, 2016, J CELL PHYSIOL, V231, P2081, DOI 10.1002/jcp.25318; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Digklia A, 2016, WORLD J GASTROENTERO, V22, P2403, DOI 10.3748/wjg.v22.i8.2403; Graversen M, 2017, CLIN EXP METASTAS, V34, P309, DOI 10.1007/s10585-017-9849-7; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hao SH, 2017, NEOPLASIA, V19, P1022, DOI 10.1016/j.neo.2017.10.005; Houthuijzen J, 2012, BRIT J CANCER, V106, P1901, DOI 10.1038/bjc.2012.201; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hung SP, 2013, CELL TRANSPLANT, V22, P1869, DOI 10.3727/096368912X657954; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Kastaniotis AJ, 2017, BBA-MOL CELL BIOL L, V1862, P39, DOI 10.1016/j.bbalip.2016.08.011; Kim HM, 2012, ANN SURG ONCOL, V19, pS539, DOI 10.1245/s10434-011-2040-5; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Lin YY, 2014, MOL CELL BIOL, V34, P2339, DOI 10.1128/MCB.00042-14; Liu B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0706-7; Liu RL, 2015, TUMOR BIOL, V36, P5011, DOI 10.1007/s13277-015-3152-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Novikova IV, 2013, J MOL BIOL, V425, P3731, DOI 10.1016/j.jmb.2013.02.030; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Ricci-Vitiani L, 2009, J MOL MED, V87, P1097, DOI 10.1007/s00109-009-0518-4; Roberto M, 2016, EXPERT REV ANTICANC, V16, P717, DOI 10.1080/14737140.2016.1184979; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shitara K, 2017, GASTRIC CANCER, V20, pS102, DOI 10.1007/s10120-016-0648-7; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011; Wang H, 2017, J CELL PHYSIOL, V232, P1030, DOI 10.1002/jcp.25499; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang TY, 2018, CELL METAB, V27, P136, DOI 10.1016/j.cmet.2017.11.001; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Xu Z, 2016, NEURO-ONCOLOGY, V18, P830, DOI 10.1093/neuonc/nov298; Ye HM, 2012, CANCER INVEST, V30, P513, DOI 10.3109/07357907.2012.692171; Yuan SX, 2016, HEPATOLOGY, V63, P499, DOI 10.1002/hep.27893; Zhan M, 2016, TUMOR BIOL, V37, P10553, DOI 10.1007/s13277-016-4957-6; Zhao Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0820-2; Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1	49	145	150	4	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4637	4654		10.1038/s41388-019-0747-0	http://dx.doi.org/10.1038/s41388-019-0747-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742067	hybrid, Green Published			2022-12-17	WOS:000470240300014
J	Sun, ZQ; Ou, CL; Liu, JB; Chen, C; Zhou, QB; Yang, SX; Li, GY; Wang, GX; Song, JM; Li, Z; Zhang, ZY; Yuan, WT; Li, XY				Sun, Zhenqiang; Ou, Chunlin; Liu, Jinbo; Chen, Chen; Zhou, Quanbo; Yang, Shuaixi; Li, Guiyuan; Wang, Guixian; Song, Junmin; Li, Zhen; Zhang, Zhiyong; Yuan, Weitang; Li, Xiayu			YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer	ONCOGENE			English	Article							LONG NONCODING RNA; OSTEOSARCOMA DEVELOPMENT; EXPRESSION PROFILES; CELL-PROLIFERATION; POOR-PROGNOSIS; TUMOR-GROWTH; YAP1; METASTASIS; ONCOGENE; PROGRESSION	Yes-associated protein 1 (YAP1) exerts significant effects in various malignancies. However, the oncogenic role of YAP1 remains controversial, and the mechanism by which YAP1 regulates non-coding RNAs is still largely unknown. The present study aimed to assess the effect of YAP1 on the malignant behaviors of colorectal carcinoma (CRC) and explore the underlying regulatory mechanism of the YAP1-MALAT1-miR-126-5p axis. YAP1 was highly expressed in CRC tissues as assessed by GSE20916 and its expression was negatively correlated with overall survival in 83 CRC cases. Meanwhile, YAP1 promoted proliferation, invasion, and migration in colon cancer cells, in vitro and in vivo. MALAT1 was obviously expressed, with differential expression of 11 lncRNAs in HCT116 cells after transfection with siYAP1 or si-Ctl. Based on bioinformatics prediction, immunoprecipitation (IP), and chromatin immunoprecipitation (ChIP), the interaction of YAP1 with TCF4/beta-catenin was regulated by MALAT1. Bioinformatics prediction, dual luciferase assay, RNA-IP, and RNA pulldown assay demonstrated that YAP1-induced MALAT1 promoted the expression of metastasis-associated molecules such as VEGFA, SLUG, and TWIST, by sponging miR-126-5p in CRC. These findings indicated that the YAP1-MALAT1-miR126-5p axis could control angiogenesis and epithelial-mesenchymal transition in CRC, providing potential biomarkers and therapeutic targets for CRC.	[Sun, Zhenqiang; Liu, Jinbo; Chen, Chen; Zhou, Quanbo; Yang, Shuaixi; Wang, Guixian; Song, Junmin; Li, Zhen; Zhang, Zhiyong; Yuan, Weitang] Zhengzhou Univ, Dept Anorectal Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China; [Sun, Zhenqiang; Ou, Chunlin; Li, Guiyuan] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Sun, Zhenqiang; Ou, Chunlin; Li, Guiyuan] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Ou, Chunlin; Li, Xiayu] Cent S Univ, Xiangya Hosp 3, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha 410013, Hunan, Peoples R China; [Li, Xiayu] Cent S Univ, Dept Gastroenterol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Zhengzhou University; Central South University; Central South University; Central South University; Central South University	Sun, ZQ; Yuan, WT (corresponding author), Zhengzhou Univ, Dept Anorectal Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.; Sun, ZQ (corresponding author), Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.; Sun, ZQ (corresponding author), Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Li, XY (corresponding author), Cent S Univ, Xiangya Hosp 3, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha 410013, Hunan, Peoples R China.; Li, XY (corresponding author), Cent S Univ, Dept Gastroenterol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.	zqsun82@csu.edu.cn; yuanweitang@zzu.edu.cn; lixiayu002@sina.com		Ou, Chunlin/0000-0003-2313-4186	National Natural Science Foundation of China [81560385]; Natural Science Foundation of Xinjiang Uygur Autonomous Region [2015211C136]; Medical Scientific and Technological Research Project of Henan Province [201702027]; China Postdoctoral Science Foundation [2017M610462]; Youth Innovation Fund Project of The First Affiliated Hospital of Zhengzhou University [YNQN2017035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Xinjiang Uygur Autonomous Region; Medical Scientific and Technological Research Project of Henan Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Youth Innovation Fund Project of The First Affiliated Hospital of Zhengzhou University	This work was supported by the National Natural Science Foundation of China (81560385), the Natural Science Foundation of Xinjiang Uygur Autonomous Region (2015211C136), the Medical Scientific and Technological Research Project of Henan Province (201702027), China Postdoctoral Science Foundation (2017M610462), and the Youth Innovation Fund Project of The First Affiliated Hospital of Zhengzhou University (YNQN2017035).	Ai FY, 2015, ONCOTARGET, V6, P5412, DOI 10.18632/oncotarget.3027; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Bottomley A, 2002, LANCET, V359, P1537, DOI 10.1016/S0140-6736(02)08526-4; Chan LH, 2014, ONCOGENE, V33, P4857, DOI 10.1038/onc.2013.433; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Di Cecilia S, 2016, CANCER RES, V76, P5615, DOI 10.1158/0008-5472.CAN-15-1824; Ebrahimi F, 2015, EXP CELL RES, V339, P333, DOI 10.1016/j.yexcr.2015.10.004; Fiala O, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317709283; Ghosh A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.123; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Hu Y, 2015, CLIN GASTROENTEROL H, V75, P6890; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Lee KW, 2015, CLIN CANCER RES, V21, P357, DOI 10.1158/1078-0432.CCR-14-1374; Lee NK, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2988-4; Li C, 2017, ONCOTARGET, V8, P28683, DOI 10.18632/oncotarget.15640; Li HL, 2018, BIOCHEM BIOPH RES CO, V495, P2350, DOI 10.1016/j.bbrc.2017.12.114; Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591; Li QL, 2016, CANCER LETT, V383, P28, DOI 10.1016/j.canlet.2016.09.019; Li S, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2015.06.003; Li W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0612-3; Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Liu K, 2017, CELL CYCLE, V16, P578, DOI 10.1080/15384101.2017.1288324; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu TT, 2018, CANCER LETT, V423, P36, DOI 10.1016/j.canlet.2018.02.015; Ma XY, 2017, J BIOL CHEM, V292, P17046, DOI 10.1074/jbc.M117.805655; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Matsumura K, 2017, ONCOGENE, V36, P1191, DOI 10.1038/onc.2016.282; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagy ZB, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-016-0305-3; de Almeida ALNR, 2016, ACTA CIR BRAS, V31, P13, DOI 10.1590/S0102-86502016001300004; Okazaki S, 2012, INT J ONCOL, V40, P209, DOI [10.3892/ijo.2011.1201, 10.3892/ijo.2011.120]; Ou CL, 2017, CANCER LETT, V399, P53, DOI 10.1016/j.canlet.2017.04.011; Ou CL, 2015, ONCOL REP, V33, P2779, DOI 10.3892/or.2015.3913; Park J, 2015, ONCOTARGET, V6, P34658, DOI 10.18632/oncotarget.5778; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Ren WG, 2016, ARCH MED RES, V47, P214, DOI 10.1016/j.arcmed.2016.07.001; Ross J, 2009, NUCLEIC ACIDS RES, V37, P5295, DOI 10.1093/nar/gkp545; Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Seton-Rogers S, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3791; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Sun M, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0445-8; Sun ZQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135119; Tan DSW, 2017, NAT MED, V23, P1167, DOI 10.1038/nm.4401; Tan XY, 2017, J CELL BIOCHEM, V118, P3643, DOI 10.1002/jcb.25862; Tsai KW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0821-1; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wang Z, 2017, CANCER RES, V77, P2413, DOI 10.1158/0008-5472.CAN-16-3229; Watanabe T, 2011, CLIN TRANSL ONCOL, V13, P419, DOI 10.1007/s12094-011-0676-z; Xiong W, 2008, BLOOD, V112, P4235, DOI 10.1182/blood-2007-10-119123; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zeng ZY, 2007, HUM PATHOL, V38, P120, DOI 10.1016/j.humpath.2006.06.023; Zeng ZY, 2016, TUMOR BIOL, V37, P729, DOI 10.1007/s13277-015-3860-x; Zhang XM, 2015, INT J CANCER, V137, P2803, DOI 10.1002/ijc.29671; Zheng HT, 2014, INT J CLIN EXP PATHO, V7, P3174; Zhou Y., 2017, J CELLULAR PHYSL, V233, P5805, DOI 10. 1002/jcp. 26357; Zhou Y, 2013, INT J SYST DYN APPL, V2, P1, DOI 10.4018/ijsda.2013040101	67	145	148	5	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2627	2644		10.1038/s41388-018-0628-y	http://dx.doi.org/10.1038/s41388-018-0628-y			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531836	hybrid, Green Published			2022-12-17	WOS:000463335200013
J	Miess, H; Dankworth, B; Gouw, AM; Rosenfeldt, M; Schmitz, W; Jiang, M; Saunders, B; Howell, M; Downward, J; Felsher, DW; Peck, B; Schulze, A				Miess, Heike; Dankworth, Beatrice; Gouw, Arvin M.; Rosenfeldt, Mathias; Schmitz, Werner; Jiang, Ming; Saunders, Becky; Howell, Michael; Downward, Julian; Felsher, Dean W.; Peck, Barrie; Schulze, Almut			The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma	ONCOGENE			English	Article							GLUTAMINE-METABOLISM; TUMOR SUPPRESSION; OXIDATIVE STRESS; C-MYC; CANCER; HYPOXIA; DEATH; PROLIFERATION; PROGRESSION; EXPRESSION	Metabolic reprogramming is a prominent feature of clear cell renal cell carcinoma (ccRCC). Here we investigated metabolic dependencies in a panel of ccRCC cell lines using nutrient depletion, functional RNAi screening and inhibitor treatment. We found that ccRCC cells are highly sensitive to the depletion of glutamine or cystine, two amino acids required for glutathione (GSH) synthesis. Moreover, silencing of enzymes of the GSH biosynthesis pathway or glutathione peroxidases, which depend on GSH for the removal of cellular hydroperoxides, selectively reduced viability of ccRCC cells but did not affect the growth of non-malignant renal epithelial cells. Inhibition of GSH synthesis triggered ferroptosis, an iron-dependent form of cell death associated with enhanced lipid peroxidation. VHL is a major tumour suppressor in ccRCC and loss of VHL leads to stabilisation of hypoxia inducible factors HIF-1 alpha and HIF-2 alpha. Restoration of functional VHL via exogenous expression of pVHL reverted ccRCC cells to an oxidative metabolism and rendered them insensitive to the induction of ferroptosis. VHL reconstituted cells also exhibited reduced lipid storage and higher expression of genes associated with oxidiative phosphorylation and fatty acid metabolism. Importantly, inhibition of beta-oxidation or mitochondrial ATP-synthesis restored ferroptosis sensitivity in VHL reconstituted cells. We also found that inhibition of GSH synthesis blocked tumour growth in a MYC-dependent mouse model of renal cancer. Together, our data suggest that reduced fatty acid metabolism due to inhibition of beta-oxidation renders renal cancer cells highly dependent on the GSH/GPX pathway to prevent lipid peroxidation and ferroptotic cell death.	[Miess, Heike; Peck, Barrie; Schulze, Almut] Canc Res UK London Res Inst, Gene Express Anal Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England; [Miess, Heike] Francis Crick Inst, Oncogene Biol Lab, 1 Midland Rd London, London NW1 1AT, England; [Dankworth, Beatrice; Schmitz, Werner; Schulze, Almut] Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany; [Gouw, Arvin M.; Felsher, Dean W.] Stanford Univ, Div Med Oncol, Sch Med, Stanford, CA 94305 USA; [Rosenfeldt, Mathias] Univ Hosp Wurzburg, Inst Pathol, D-97080 Wurzburg, Germany; [Jiang, Ming; Saunders, Becky; Howell, Michael] Francis Crick Inst, High Throughput Screening, 1 Midland Rd London, London NW1 1AT, England; [Downward, Julian; Peck, Barrie] Inst Canc Res, Div Canc Biol, 237 Fulham Rd, London SW7 3RP, England; [Schulze, Almut] Comprehens Canc Ctr Mainfranken, Josef Schneider Str 6, D-97080 Wurzburg, Germany	Cancer Research UK; Francis Crick Institute; University of Wurzburg; Stanford University; University of Wurzburg; Francis Crick Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Wurzburg	Schulze, A (corresponding author), Canc Res UK London Res Inst, Gene Express Anal Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.; Schulze, A (corresponding author), Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Germany.; Schulze, A (corresponding author), Comprehens Canc Ctr Mainfranken, Josef Schneider Str 6, D-97080 Wurzburg, Germany.	almut.schulze@uni-wuerzburg.de	Schulze, Almut/AAX-8257-2020; Rosenfeldt, Mathias/ABE-4736-2022	Schulze, Almut/0000-0002-8199-6422; Rosenfeldt, Mathias/0000-0001-7650-8458; Gouw, Arvin/0000-0002-9552-635X; Downward, Julian/0000-0002-2331-4729; Howell, Michael/0000-0003-0912-0079; Peck, Barrie/0000-0002-6687-8495	Cancer Research UK; German Research Foundation [FOR2314]; German Cancer Aid [111917]; NATIONAL CANCER INSTITUTE [T32CA196585] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); German Research Foundation(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the LRI research services for technical support. We also thank Prof. William Kaelin (Dana Faber Cancer Institute, Boston) for providing isogenic renal cancer cell lines. This study was funded by Cancer Research UK, the German Research Foundation (FOR2314) and the German Cancer Aid (111917).	AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Bierl C, 2004, J BIOL CHEM, V279, P26839, DOI 10.1074/jbc.M401907200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brigelius-Flohe R, 2009, BBA-GEN SUBJECTS, V1790, P1555, DOI 10.1016/j.bbagen.2009.03.006; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Carroll PA, 2015, CANCER CELL, V27, P271, DOI 10.1016/j.ccell.2014.11.024; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalleau S, 2013, CELL DEATH DIFFER, V20, P1615, DOI 10.1038/cdd.2013.138; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Drabkin HA, 2012, CURR OPIN PHARMACOL, V12, P742, DOI 10.1016/j.coph.2012.08.002; Faronato M, 2007, HISTOL HISTOPATHOL, V22, P1109, DOI 10.14670/HH-22.1109; Gatto F, 2015, SCI REP-UK, V5, DOI 10.1038/srep10738; Gatto F, 2014, P NATL ACAD SCI USA, V111, pE866, DOI 10.1073/pnas.1319196111; GEBHARD RL, 1987, J LIPID RES, V28, P1177; Gerlinger M, 2012, J PATHOL, V227, P146, DOI 10.1002/path.4006; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Malo N, 2006, NAT BIOTECHNOL, V24, P167, DOI 10.1038/nbt1186; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Perroud B, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-64; Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507; Radmark O, 2015, BBA-MOL CELL BIOL L, V1851, P331, DOI 10.1016/j.bbalip.2014.08.012; Saito K, 2016, SCI REP-UK, V6, DOI 10.1038/srep28932; Semenza GL, 2007, J BIOENERG BIOMEMBR, V39, P231, DOI 10.1007/s10863-007-9081-2; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Singer EA, 2013, CURR OPIN ONCOL, V25, P273, DOI 10.1097/CCO.0b013e32835fc857; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Tang SW, 2009, CANCER LETT, V273, P35, DOI 10.1016/j.canlet.2008.07.038; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Warner GJ, 2000, J BIOL CHEM, V275, P28110; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152	56	145	151	5	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5435	5450		10.1038/s41388-018-0315-z	http://dx.doi.org/10.1038/s41388-018-0315-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29872221	Green Accepted, Green Submitted			2022-12-17	WOS:000446312900005
J	Dong, C; Wu, Y; Wang, Y; Wang, C; Kang, T; Rychahou, PG; Chi, YI; Evers, BM; Zhou, BP				Dong, C.; Wu, Y.; Wang, Y.; Wang, C.; Kang, T.; Rychahou, P. G.; Chi, Y-I; Evers, B. M.; Zhou, B. P.			Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer	ONCOGENE			English	Article						metastasis; EMT; chromatin modifications; transcription; Snail	EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; HISTONE H3; DNA METHYLATION; GENE-EXPRESSION; G9A; METHYLTRANSFERASES; DOMAIN; INFLAMMATION; SUPERFAMILY	Expression of E-cadherin, a hallmark of epithelial-mesenchymal transition (EMT), is often lost due to promoter DNA methylation in basal-like breast cancer (BLBC), which contributes to the metastatic advantage of this disease; however, the underlying mechanism remains unclear. Here, we identified that Snail interacted with Suv39H1 (suppressor of variegation 3-9 homolog 1), a major methyltransferase responsible for H3K9me3 that intimately links to DNA methylation. We demonstrated that the SNAG domain of Snail and the SET domain of Suv39H1 were required for their mutual interactions. We found that H3K9me3 and DNA methylation on the E-cadherin promoter were higher in BLBC cell lines. We showed that Snail interacted with Suv39H1 and recruited it to the E-cadherin promoter for transcriptional repression. Knockdown of Suv39H1 restored E-cadherin expression by blocking H3K9me3 and DNA methylation and resulted in the inhibition of cell migration, invasion and metastasis of BLBC. Our study not only reveals a critical mechanism underlying the epigenetic regulation of EMT, but also paves a way for the development of new treatment strategies against this disease. Oncogene (2013) 32, 1351-1362; doi:10.1038/onc.2012.169; published online 7 May 2012	[Dong, C.; Wang, Y.; Chi, Y-I; Evers, B. M.; Zhou, B. P.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40506 USA; [Dong, C.; Wu, Y.; Wang, Y.; Wang, C.; Rychahou, P. G.; Evers, B. M.; Zhou, B. P.] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA; [Wu, Y.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA; [Wang, C.] Univ Kentucky, Coll Med, Dept Biostat, Lexington, KY 40506 USA; [Kang, T.] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Rychahou, P. G.; Evers, B. M.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; State Key Lab Oncology South China; University of Kentucky	Zhou, BP (corresponding author), Univ Kentucky, Coll Med, Markey Canc Ctr, Dept Mol & Cellular Biochem, BBSRB Room B336,741 South Limestone, Lexington, KY 40506 USA.	peter.zhou@uky.edu		Rychahou, Piotr/0000-0001-7352-9122	NIH [RO1CA125454]; Susan G Komen Foundation [KG081310]; Mary Kay Ash Foundation; NATIONAL CANCER INSTITUTE [R01CA125454] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Mary Kay Ash Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nathan L Vanderford for critical reading and editing of this manuscript. This work was supported by grants from NIH (RO1CA125454), Susan G Komen Foundation (KG081310), and Mary Kay Ash Foundation (to BP Zhou).	Barrallo-Gimeno A, 2009, TRENDS GENET, V25, P248, DOI 10.1016/j.tig.2009.04.001; Bergamaschi A, 2009, MOL ONCOL, V3, P469, DOI 10.1016/j.molonc.2009.07.003; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227; Dodge JE, 2004, MOL CELL BIOL, V24, P2478, DOI 10.1128/MCB.24.6.2478-2486.2004; Eissenberg JC, 2010, DEV BIOL, V339, P240, DOI 10.1016/j.ydbio.2009.08.017; Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpbi.3, 10.1002/0471250953.bi0506s15, 10.1002/cpps.20]; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003; Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mullins M, 2007, CLIN CHEM, V53, P1273, DOI 10.1373/clinchem.2006.083725; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rudolph T, 2007, MOL CELL, V26, P103, DOI 10.1016/j.molcel.2007.02.025; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wang Yifan, 2011, Chin J Cancer, V30, P603, DOI 10.5732/cjc.011.10226; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wu H, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008570, 10.1371/journal.pone.0013316]; Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	65	145	153	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1351	1362		10.1038/onc.2012.169	http://dx.doi.org/10.1038/onc.2012.169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562246	Green Accepted, Green Submitted			2022-12-17	WOS:000316455600002
J	Muller, PAJ; Trinidad, AG; Timpson, P; Morton, JP; Zanivan, S; van den Berghe, PVE; Nixon, C; Karim, SA; Caswell, PT; Noll, JE; Coffill, CR; Lane, DP; Sansom, OJ; Neilsen, PM; Norman, JC; Vousden, KH				Muller, P. A. J.; Trinidad, A. G.; Timpson, P.; Morton, J. P.; Zanivan, S.; van den Berghe, P. V. E.; Nixon, C.; Karim, S. A.; Caswell, P. T.; Noll, J. E.; Coffill, C. R.; Lane, D. P.; Sansom, O. J.; Neilsen, P. M.; Norman, J. C.; Vousden, K. H.			Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion	ONCOGENE			English	Article						mutant p53; MET; recycling	HEPATOCYTE GROWTH-FACTOR; WILD-TYPE P53; RECEPTOR TYROSINE KINASES; LI-FRAUMENI-SYNDROME; C-MET; BREAST-CANCER; MALIGNANT MESOTHELIOMA; TUMOR-SUPPRESSOR; GENE CONTRIBUTES; CARCINOMA CELLS	Tumour-derived mutant p53 proteins promote invasion, in part, by enhancing Rab coupling protein (RCP)-dependent receptor recycling. Here we identified MET as an RCP-binding protein and showed that mutant p53 promoted MET recycling. Mutant p53-expressing cells were more sensitive to hepatocyte growth factor, the ligand for MET, leading to enhanced MET signalling, invasion and cell scattering that was dependent on both MET and RCP. In cells expressing the p53 family member TAp63, inhibition of TAp63 also lead to cell scattering and MET-dependent invasion. However, in cells that express very low levels of TAp63, the ability of mutant p53 to promote MET-dependent cell scattering was independent of TAp63. Taken together, our data show that mutant p53 can enhance MET signalling to promote cell scattering and invasion through both TAp63-dependent and -independent mechanisms. MET has a predominant role in metastatic progression and the identification of mechanisms through which mutations in p53 can drive MET signalling may help to identify and direct therapy. Oncogene (2013) 32, 1252-1265; doi:10.1038/onc.2012.148; published online 14 May 2012	[Muller, P. A. J.; Trinidad, A. G.; Timpson, P.; Morton, J. P.; Zanivan, S.; van den Berghe, P. V. E.; Nixon, C.; Karim, S. A.; Sansom, O. J.; Norman, J. C.; Vousden, K. H.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Caswell, P. T.] Univ Manchester, Welcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England; [Noll, J. E.; Neilsen, P. M.] Univ Adelaide, Canc Therapeut Labs, Adelaide, SA, Australia; [Coffill, C. R.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Lane, D. P.] ASTAR, Lab P53, Singapore, Singapore	Beatson Institute; University of Manchester; University of Adelaide; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR)	Vousden, KH (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	j.norman@beatson.gla.ac.uk; k.vousden@beatson.gla.ac.uk	Morton, Jennifer/AAJ-5113-2021; Muller, Patricia AJ/AAH-1888-2019; Caswell, Patrick/N-3063-2015; Zanivan, Sara/GOV-5505-2022; Timpson, Paul/A-9429-2016; Morton, Jennifer P/E-1633-2011	Morton, Jennifer/0000-0001-5766-9141; Muller, Patricia AJ/0000-0002-0926-1499; Caswell, Patrick/0000-0002-2633-2324; Morton, Jennifer P/0000-0001-5766-9141; Sansom, Owen J./0000-0001-9540-3010; Zanivan, Sara/0000-0002-9880-9099; Noll, Jacqueline/0000-0001-7375-635X; Neilsen, Paul/0000-0001-7937-3675; Coffill, Cynthia/0000-0003-2914-4481; NORMAN, Jim/0000-0002-0098-3014; Lane, David/0000-0003-0551-3545; Timpson, Paul/0000-0002-5514-7080	Cancer Research UK; AICR; Rubicon Fellowship from the Netherlands Organisation for Scientific Research; Cancer Research UK [12481, 12935] Funding Source: researchfish; Worldwide Cancer Research [11-0626] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); AICR; Rubicon Fellowship from the Netherlands Organisation for Scientific Research; Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	We thank Cancer Research UK and the AICR for funding of work in KHV and JCN's laboratories. PAJM is a recipient of a Rubicon Fellowship from the Netherlands Organisation for Scientific Research. We thank Julin Wong from DPL's lab for the MET construct, Bert Vogelstein for the HCT116 p53 null and HCT116 248W cells, Karen Oien for help with quantifying the staining in the pancreatic tumours and Christine Gundry for help with optimizing the recycling assays.	Accornero P, 2010, J MOL ENDOCRINOL, V44, P115, DOI 10.1677/JME-09-0035; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brevet M, 2011, J THORAC ONCOL, V6, P864, DOI 10.1097/JTO.0b013e318215a07d; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cirit M, 2010, J BIOL CHEM, V285, P36736, DOI 10.1074/jbc.M110.148759; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DOGAN A, 1995, J CLIN PATHOL, V48, P143, DOI 10.1136/jcp.48.2.143; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; FUKUYAMA R, 1991, JPN J CANCER RES, V82, P8, DOI 10.1111/j.1349-7006.1991.tb01737.x; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Herrera R, 1998, J CELL SCI, V111, P1039; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leonard MK, 2011, CELL DEATH DIFFER, V18, P1924, DOI 10.1038/cdd.2011.73; Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335; Liu J, 2012, DNA REPAIR, V11, P167, DOI 10.1016/j.dnarep.2011.10.016; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; NALDINI L, 1991, ONCOGENE, V6, P501; Noll JE, 2011, ONCOGENE; O'Farrell TJ, 2004, CANCER RES, V64, P8199, DOI 10.1158/0008-5472.CAN-03-3639; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Sigal A, 2000, CANCER RES, V60, P6788; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; STOKER M, 1985, J CELL SCI, V77, P209; Stolarov J, 2001, P NATL ACAD SCI USA, V98, P13043, DOI 10.1073/pnas.221450598; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Wong MYW, 2011, INT J ONCOL, V38, P1189, DOI 10.3892/ijo.2011.970; Xu H, 2011, CLIN CANCER RES, V17, P4425, DOI 10.1158/1078-0432.CCR-10-3339; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622; Zhang YH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.214585	65	145	147	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1252	1265		10.1038/onc.2012.148	http://dx.doi.org/10.1038/onc.2012.148			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22580601	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000316454500006
J	Bonnomet, A; Syne, L; Brysse, A; Feyereisen, E; Thompson, EW; Noel, A; Foidart, JM; Birembaut, P; Polette, M; Gilles, C				Bonnomet, A.; Syne, L.; Brysse, A.; Feyereisen, E.; Thompson, E. W.; Noel, A.; Foidart, J-M; Birembaut, P.; Polette, M.; Gilles, C.			A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer	ONCOGENE			English	Article						EMT; circulating tumor cells; metastases; vimentin; MDA-MB-468	GROWTH-FACTOR RECEPTOR-2; GENE-EXPRESSION; STEM-CELL; CARCINOMA CELLS; E-CADHERIN; BASAL; SNAIL; PHENOTYPE; INVASION; SUBTYPE	Epithelial-to-mesenchymal transition (EMT) processes endow epithelial cells with enhanced migratory/invasive properties and are therefore likely to contribute to tumor invasion and metastatic spread. Because of the difficulty in following EMT processes in human tumors, we have developed and characterized an animal model with transplantable human breast tumor cells (MDA-MB-468) uniquely showing spontaneous EMT events to occur. Using vimentin as a marker of EMT, heterogeneity was revealed in the primary MDA-MB-468 xenografts with vimentin-negative and vimentin-positive areas, as also observed on clinical human invasive breast tumor specimens. Reverse transcriptase-PCR after microdissection of these populations from the xenografts revealed EMT traits in the vimentin-positive zones characterized by enhanced 'mesenchymal gene' expression (Snail, Slug and fibroblast-specific protein-1) and diminished expression of epithelial molecules (E-cadherin, ZO-3 and JAM-A). Circulating tumor cells (CTCs) were detected in the blood as soon as 8 days after s.c. injection, and lung metastases developed in all animals injected as examined by in vivo imaging analyses and histology. High levels of vimentin RNA were detected in CTCs by reverse transcriptase-quantitative PCR as well as, to a lesser extent, Snail and Slug RNA. Von Willebrand Factor/vimentin double immunostainings further showed that tumor cells in vascular tumoral emboli all expressed vimentin. Tumoral emboli in the lungs also expressed vimentin whereas macrometastases displayed heterogenous vimentin expression, as seen in the primary xenografts. In conclusion, our data uniquely demonstrate in an in vivo context that EMT occurs in the primary tumors, and associates with an enhanced ability to intravasate and generate CTCs. They further suggest that mesenchymal-to-epithelial phenomena occur in secondary organs, facilitating the metastatic growth. Oncogene (2012) 31, 3741-3753; doi:10.1038/onc.2011.540; published online 28 November 2011	[Bonnomet, A.; Syne, L.; Brysse, A.; Feyereisen, E.; Noel, A.; Foidart, J-M; Gilles, C.] Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; [Thompson, E. W.] St Vincents Inst, Melbourne, Vic, Australia; [Thompson, E. W.] Univ Melbourne, St Vincents Hosp, Dept Surg, Melbourne, Vic, Australia; [Bonnomet, A.; Birembaut, P.; Polette, M.] INSERM, Unite U903, Lab Pol Bouin, Reims, France	University of Liege; St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gilles, C (corresponding author), Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.	cgilles@ulg.ac.be	POLETTE, Myriam/P-5147-2016; Thompson, Erik W/A-1425-2009; Thompson, Erik/GPK-2067-2022; BIREMBAUT, Philippe/P-5210-2016	Thompson, Erik W/0000-0002-9723-4924; Thompson, Erik/0000-0002-9723-4924; POLETTE, Myriam/0000-0001-8173-3246; Noel, Agnes/0000-0002-7670-6179; BONNOMET, Arnaud/0000-0002-4933-3338	Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium); Foundation against Cancer (foundation of public interest, Belgium); C.G.R.I.-F.N.R.S.-INSERM Cooperation; Fonds speciaux de la Recherche (University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege); Region Champagne-Ardenne; Ligue Contre le Cancer; Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante ACI INCa (Canceropole Grand-Est project); US. Army Medical Research and Materiel Command [BC0213201, BC084667]; Victorian Breast Cancer Research Consortium, Cancer Council Victoria [509295]; National Breast Cancer Foundation (Australia); National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Foundation against Cancer (foundation of public interest, Belgium); C.G.R.I.-F.N.R.S.-INSERM Cooperation(Fonds de la Recherche Scientifique - FNRS); Fonds speciaux de la Recherche (University of Liege)(University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege)(University of Liege); Region Champagne-Ardenne(Region Grand-Est); Ligue Contre le Cancer(Ligue nationale contre le cancer); Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante ACI INCa (Canceropole Grand-Est project)(Region Grand-Est); US. Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Victorian Breast Cancer Research Consortium, Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Breast Cancer Foundation (Australia); National Breast Cancer Foundation	The research effort associated with this article was funded in part by the Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium), the Foundation against Cancer (foundation of public interest, Belgium), the 'C.G.R.I.-F.N.R.S.-INSERM Cooperation', the Fonds speciaux de la Recherche (University of Liege), the Centre Anticancereux pres l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the 'Region Champagne-Ardenne', the 'Ligue Contre le Cancer', the Lions Club of Soissons, Un Euro contre le Cancer and the Fond National pour la Sante ACI 2004-2010 INCa (Canceropole Grand-Est project), the US. Army Medical Research and Materiel Command (BC0213201 and BC084667), the Victorian Breast Cancer Research Consortium, Cancer Council Victoria (#509295), the National Breast Cancer Foundation (Australia). CG is a Senior Research Associate from the F.R.S.-FNRS (Belgium). AB is supported by the 'Region Champagne-Ardenne'. We thank Nathalie Lefin and Benoit Brouwers for their technical assistance.	Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Bonnomet A, 2010, J MAMMARY GLAND BIOL, V15, P261, DOI 10.1007/s10911-010-9174-0; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Chen XD, 2008, J MOL HISTOL, V39, P283, DOI 10.1007/s10735-008-9164-3; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Mego M, 2011, INT J CANC; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Pantel K, 2010, TRENDS MOL MED, V16, P398, DOI 10.1016/j.molmed.2010.07.001; Paterlini-Brechot P, 2007, CANCER LETT, V253, P180, DOI 10.1016/j.canlet.2006.12.014; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Rakha EA, 2006, J PATHOL, V208, P495, DOI 10.1002/path.1916; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Xue CS, 2003, CANCER RES, V63, P3386; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhang A, 2008, ANTICANCER RES, V28, P621	40	145	151	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	33					3741	3753		10.1038/onc.2011.540	http://dx.doi.org/10.1038/onc.2011.540			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120722	Green Submitted			2022-12-17	WOS:000307924900001
J	Quintavalle, C; Garofalo, M; Zanca, C; Romano, G; Iaboni, M; De Caro, MD; Martinez-Montero, JC; Incoronato, M; Nuovo, G; Croce, CM; Condorelli, G				Quintavalle, C.; Garofalo, M.; Zanca, C.; Romano, G.; Iaboni, M.; De Caro, M. del Basso; Martinez-Montero, J. C.; Incoronato, M.; Nuovo, G.; Croce, C. M.; Condorelli, G.			miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu	ONCOGENE			English	Article						Glioma; microRNA; tumorigenesis; apoptosis	GLIOMA-CELL MIGRATION; MICRORNA SIGNATURES; TRAIL RESISTANCE; INVASION; RECEPTOR; CANCER; GENE	Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, survival of patients remains poor. In order to identify microRNAs (miRs) involved in glioma tumorigenesis, we evaluated, by a miRarray, differential expression of miRs in the tumorigenic glioma LN-18, LN-229 and U87MG cells compared with the non-tumorigenic T98G cells. Among different miRs we focused our attention on miR-221 and -222. We demonstrated the presence of a binding site for these two miRs in the 30 untranslated region of the protein tyrosine phosphatase l (PTP mu). Previous studies indicated that PTPl suppresses cell migration and is downregulated in glioblastoma. Significantly, we found that miR-221 and -222 overexpression induced a downregulation of PTPl as analyzed by both western blot and real-time PCR. Furthermore, miR-222 and -221 induced an increase in cell migration and growth in soft agar in glioma cells. Interestingly, the re-expression of PTPl gene was able to revert the miR-222 and -221 effects on cell migration. Furthermore, we found an inverse correlation between miR-221 and -222 and PTPl in human glioma cancer samples. In conclusion, our results suggest that miR-221 and -222 regulate glioma tumorigenesis at least in part through the control of PTPl protein expression. Oncogene (2012) 31, 858-868; doi: 10.1038/onc.2011.280;published online 11 July 2011	[Condorelli, G.] Univ Naples Federico II, Fac Sci Biotecnol, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, NA, Italy; [Garofalo, M.; Nuovo, G.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; [Romano, G.; Incoronato, M.] Fdn IRCCS SDN, Naples, Italy; [De Caro, M. del Basso] Sez Anat Patol & Fitopatol, Dipartimento Sci Biomorfol & Funzionali, Bologna, Italy; [Martinez-Montero, J. C.] Hosp Univ Gregorio Maranon, Inst Oftalm, Madrid, Spain; [Condorelli, G.] CNR, IEOS, I-80125 Naples, Italy	University of Naples Federico II; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); General University Gregorio Maranon Hospital; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Condorelli, G (corresponding author), Univ Naples Federico II, Fac Sci Biotecnol, Dipartimento Biol & Patol Cellulare & Mol, Ed 19 A,2 Floor,Via Pansini 5, I-80131 Naples, NA, Italy.	gecondor@unina.it	Quintavalle, Cristina/AHH-9379-2022; Young, Richard A/F-6495-2012; Incoronato, Mariarosaria/AAA-7541-2021; Condorelli, Gerolama/AAC-3472-2022; Incoronato, Mariarosaria/K-8727-2016	Young, Richard A/0000-0001-8855-8647; Incoronato, Mariarosaria/0000-0001-7019-0581; Condorelli, Gerolama/0000-0003-0177-8829; Incoronato, Mariarosaria/0000-0001-7019-0581; Del Basso De Caro, Marialaura/0000-0002-5055-5050	Associazione Italiana Ricerca sul Cancro, AIRC [10620]; MERIT [RBNE08E8CZ_002]; Federazione Italiana Ricerca sul Cancro (FIRC); American-Italian Cancer Foundation; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA129242] Funding Source: NIH RePORTER	Associazione Italiana Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro); MERIT; Federazione Italiana Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro); American-Italian Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by funds from Associazione Italiana Ricerca sul Cancro, AIRC to GC ( Grant n. ro 10620) and MERIT (RBNE08E8CZ_002) to GC. CQ is supported by a Federazione Italiana Ricerca sul Cancro (FIRC) Post-Doctoral Research Fellowship. CZ is supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship.	BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Burgoyne AM, 2009, NEURO-ONCOLOGY, V11, P767, DOI 10.1215/15228517-2009-019; Burgoyne AM, 2009, CANCER RES, V69, P6960, DOI 10.1158/0008-5472.CAN-09-0863; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cerchia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007971; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; DERIDDER LI, 1987, ACTA NEUROPATHOL, V72, P207, DOI 10.1007/BF00691091; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6; Garofalo M, 2010, CELL DEATH DIFFER, V17, P200, DOI 10.1038/cdd.2009.105; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Liang YX, 2002, J BIOL CHEM, V277, P20087, DOI 10.1074/jbc.M201766200; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nuovo GJ, 2009, BIOTECHNIQUES, V46, P115, DOI 10.2144/000113068; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Sredni ST, 2010, CHILD NERV SYST, V26, P279, DOI 10.1007/s00381-009-1028-y; Tran B, 2010, J CLIN NEUROSCI, V17, P417, DOI 10.1016/j.jocn.2009.09.004; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037	29	145	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					858	868		10.1038/onc.2011.280	http://dx.doi.org/10.1038/onc.2011.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743492	Green Accepted			2022-12-17	WOS:000300615800005
J	Lujambio, A; Portela, A; Liz, J; Melo, SA; Rossi, S; Spizzo, R; Croce, CM; Calin, GA; Esteller, M				Lujambio, A.; Portela, A.; Liz, J.; Melo, S. A.; Rossi, S.; Spizzo, R.; Croce, C. M.; Calin, G. A.; Esteller, M.			CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer	ONCOGENE			English	Article						DNA methylation; CpG island; non-coding RNA; epigenetics	MICRORNA; GENES; METHYLATION; EPIGENETICS; SITES; CONTRIBUTES; EPIGENOMICS; SIGNATURES; MUTATIONS; ELEMENTS	Although only 1.5% of the human genome appears to code for proteins, much effort in cancer research has been devoted to this minimal fraction of our DNA. However, the last few years have witnessed the realization that a large class of non-coding RNAs (ncRNAs), named microRNAs, contribute to cancer development and progression by acting as oncogenes or tumor suppressor genes. Recent studies have also shown that epigenetic silencing of microRNAs with tumor suppressor features by CpG island hypermethylation is a common hallmark of human tumors. Thus, we wondered whether there were other ncRNAs undergoing aberrant DNA methylation-associated silencing in transformed cells. We focused on the transcribed-ultraconserved regions (T-UCRs), a subset of DNA sequences that are absolutely conserved between orthologous regions of the human, rat and mouse genomes and that are located in both intra-and intergenic regions. We used a pharmacological and genomic approach to reveal the possible existence of an aberrant epigenetic silencing pattern of T-UCRs by treating cancer cells with a DNA-demethylating agent followed by hybridization to an expression microarray containing these sequences. We observed that DNA hypomethylation induces release of T-UCR silencing in cancer cells. Among the T-UCRs that were reactivated upon drug treatment, Uc.160+, Uc283+A and Uc.346+ were found to undergo specific CpG island hypermethylation-associated silencing in cancer cells compared with normal tissues. The analysis of a large set of primary human tumors (n = 283) demonstrated that hypermethylation of the described T-UCR CpG islands was a common event among the various tumor types. Our finding that, in addition to microRNAs, another class of ncRNAs (T-UCRs) undergoes DNA methylation-associated inactivation in transformed cells supports a model in which epigenetic and genetic alterations in coding and non-coding sequences cooperate in human tumorigenesis. Oncogene (2010) 29, 6390-6401; doi:10.1038/onc.2010.361; published online 30 August 2010	[Esteller, M.] Hosp Duran & Reynals, Bellvitge Inst Biomed Res IDI BELL, Canc Epigenet & Biol Program, Barcelona 08907, Catalonia, Spain; [Rossi, S.; Spizzo, R.; Calin, G. A.] Texas State Univ, MD Anderson Canc Ctr, Houston, TX USA; [Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Texas State University System; Texas State University San Marcos; University of Texas System; UTMD Anderson Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Inst Biomed Res IDI BELL, Canc Epigenet & Biol Program, 08907 Hosp,3rd Floor,Avda Gran Via 199-203, Barcelona 08907, Catalonia, Spain.	mesteller@iconcologia.net	Calin, George/E-9390-2011; MELO, SONIA/H-8972-2013; Esteller, Manel/L-5956-2014; Spizzo, Riccardo/V-1057-2019; Young, Richard A/F-6495-2012	MELO, SONIA/0000-0002-2291-4263; Esteller, Manel/0000-0003-4490-6093; Spizzo, Riccardo/0000-0001-7772-0960; Young, Richard A/0000-0001-8855-8647; Portela, Anna/0000-0003-2184-2584; Calin, George/0000-0001-6704-5615; Lujambio, Amaia/0000-0002-2798-1481	Consolider [CSD2006-49]; CANCERDIP [HEALTH-F2-2007-200620]; Dr Josef Steiner Cancer Research Foundation; FPU;  [SAF2007-00027-65134]; ICREA Funding Source: Custom	Consolider(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); CANCERDIP; Dr Josef Steiner Cancer Research Foundation; FPU(Spanish Government); ; ICREA(ICREA)	This work was supported by Grants SAF2007-00027-65134, Consolider CSD2006-49, CANCERDIP HEALTH-F2-2007-200620 and the Dr Josef Steiner Cancer Research Foundation. AL is supported by a FPU Fellowship. AP is a Sara Borell Postdoctoral Fellow. ME is an ICREA Research Professor.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bejerano G, 2006, NATURE, V441, P87, DOI 10.1038/nature04696; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen LL, 2009, MOL CELL, V35, P467, DOI 10.1016/j.molcel.2009.06.027; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Davalos V, 2010, CURR OPIN ONCOL, V22, P35, DOI 10.1097/CCO.0b013e328333dcbb; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Hammond SM, 2007, NAT GENET, V39, P582, DOI 10.1038/ng0507-582; Han L, 2007, CANCER BIOL THER, V6, P1284; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Henikoff S, 2008, NAT REV GENET, V9, P15, DOI 10.1038/nrg2206; Henikoff S, 2007, CANCER CELL, V12, P407, DOI 10.1016/j.ccr.2007.10.024; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Iwama H, 2007, FEBS LETT, V581, P1805, DOI 10.1016/j.febslet.2007.03.066; Jacinto FV, 2009, ONCOGENE, V28, P4212, DOI 10.1038/onc.2009.267; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katzman S, 2007, SCIENCE, V317, P915, DOI 10.1126/science.1142430; Lareau LF, 2007, NATURE, V446, P926, DOI 10.1038/nature05676; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CELL CYCLE, V6, P1455; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Nguyen CT, 2002, CANCER RES, V62, P6456; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Pennacchio LA, 2006, NATURE, V444, P499, DOI 10.1038/nature05295; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rossi S, 2008, MAMM GENOME, V19, P526, DOI 10.1007/s00335-008-9119-8; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040; Takai Daiya, 2003, In Silico Biology, V3, P235; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Velculescu VE, 2008, CARCINOGENESIS, V29, P1087, DOI 10.1093/carcin/bgn096; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	60	145	151	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6390	6401		10.1038/onc.2010.361	http://dx.doi.org/10.1038/onc.2010.361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20802525	Green Published, hybrid			2022-12-17	WOS:000284874700009
J	Giam, M; Huang, DCS; Bouillet, P				Giam, M.; Huang, D. C. S.; Bouillet, P.			BH3-only proteins and their roles in programmed cell death	ONCOGENE			English	Review						Bcl-2 family; BH3-only proteins; Bax/Bak activation; direct/indirect models; mitochondria; cytochrome c release	MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; BCL-2 FAMILY; CONFORMATIONAL-CHANGE; TRIGGER APOPTOSIS; INDUCE APOPTOSIS; DEFICIENT MICE; CYTOCHROME-C; BH3 DOMAINS; T-CELL; BAX	The Bcl-2 family of proteins controls the mitochondrial pathway to apoptosis. It consists of pro-survival and proapoptotic members, and their interactions decide whether apoptogenic factor confined to the mitochondrial intermembrane space can leak to the cytosol. Despite the intense efforts to understand the molecular mechanisms that lead to the permeabilization of the mitochondrial membrane, this particular issue remains a matter of intense controversy. It is well accepted that pro-apoptotic Bax and Bak are directly responsible for the damage to the mitochondria, but pro-survival family members prevent them from doing so. It is also accepted that stress signals activate selected Bcl-2 homology (BH) 3-only proteins. But do these BH3-only proteins bind and activate Bax and Bak directly, or do they inhibit the pro-survival family members? Oncogene (2009) 27, S128-S136; doi: 10.1038/onc.2009.50	[Giam, M.; Huang, D. C. S.; Bouillet, P.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; [Giam, M.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Bouillet, P (corresponding author), Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Parkville, Vic 3050, Australia.	bouillet@wehi.edu.au	Bouillet, Philippe/E-1241-2013; Huang, David C. S./C-7586-2013	Bouillet, Philippe/0000-0002-9012-6058; Huang, David C. S./0000-0002-3101-4873	NHMRC; Charles and Sylvia Viertel Charitable Foundation	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Charles and Sylvia Viertel Charitable Foundation	This work was supported by the NHMRC (Program Grant, Fellowship, Career Development Award and Project Grant) and the Charles and Sylvia Viertel Charitable Foundation. We are grateful to our colleagues at WEHI for stimulating discussions and insightful comments. We apologize to the authors whose contributions have not been cited owing to space limitations.	Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cai BB, 2008, APOPTOSIS, V13, P803, DOI 10.1007/s10495-008-0218-5; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Green DR, 2008, NATURE, V455, P1047, DOI 10.1038/4551047a; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Khoury CM, 2008, BBA-MOL CELL RES, V1783, P1449, DOI 10.1016/j.bbamcr.2007.12.013; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Oh KJ, 2006, J BIOL CHEM, V281, P36999, DOI 10.1074/jbc.M602341200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Rinkenberger JL, 2000, GENE DEV, V14, P23; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorilas A, 2001, GENOMICS, V72, P217, DOI 10.1006/geno.2000.6455; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Strasser A, 2008, IMMUNOL CELL BIOL, V86, P57, DOI 10.1038/sj.icb.7100141; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Theodorakis P, 2002, CANCER RES, V62, P3373; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Weber A, 2007, J CELL BIOL, V177, P625, DOI 10.1083/jcb.200610148; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	59	145	150	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S128	S136		10.1038/onc.2009.50	http://dx.doi.org/10.1038/onc.2009.50			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641498				2022-12-17	WOS:000268566800011
J	Stoletov, K; Klemke, R				Stoletov, K.; Klemke, R.			Catch of the day: zebrafish as a human cancer model	ONCOGENE			English	Review						zebrafish; cancer; metastasis; angiogenesis; xenotransplantant; transgenic	REGULATED TRANSGENIC ZEBRAFISH; DIFFERENT DEVELOPMENTAL-STAGES; ACUTE LYMPHOBLASTIC-LEUKEMIA; CAUSES GENOME INSTABILITY; T-CELL LEUKEMIA; DANIO-RERIO; IN-VIVO; VE-CADHERIN; EXPOSURE ROUTES; GENE-EXPRESSION	Zebrafish are making big waves in the field of cancer research. The effect has been widespread and continues to gain speed as more and more cancer researchers ride the wave of zebrafish biology. This has been largely due to the development of transgenic and xenograft models of cancer, which recapitulate many aspects of different human cancers including lymphoblastic T-cell leukemia, pancreatic cancer, melanoma and rhabdomyosarcoma. These models are already being utilized by academia and industry to search for genetic and chemical modifiers of cancer with success. The attention has been further stimulated by the amenability of zebrafish to pharmacological testing and the superior imaging properties of fish tissues that allow visualization of cancer progression and angiogenesis in live animals. This review summarizes the current zebrafish models of cancer and discusses their utility in human cancer research and future directions in the field.	[Stoletov, K.; Klemke, R.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Stoletov, K.; Klemke, R.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Klemke, R (corresponding author), Univ Calif San Diego, Dept Pathol, 9500 Gilman Dr,MC0612, La Jolla, CA 92093 USA.	rklemke@ucsd.edu		Stoletov, Konstantin/0000-0002-7384-2917	NCI NIH HHS [CA097022] Funding Source: Medline; NIGMS NIH HHS [GM068487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ablooglu AJ, 2007, DEV DYNAM, V236, P2268, DOI 10.1002/dvdy.21229; Amatruda JF, 2002, CANCER CELL, V1, P229, DOI 10.1016/S1535-6108(02)00052-1; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Beckwith LG, 2000, LAB INVEST, V80, P379, DOI 10.1038/labinvest.3780042; Beis D, 2006, TRENDS CELL BIOL, V16, P105, DOI 10.1016/j.tcb.2005.12.001; Berghmans S, 2005, BIOTECHNIQUES, V39, P227, DOI 10.2144/05392RV02; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chen J, 2007, LEUKEMIA, V21, P462, DOI 10.1038/sj.leu.2404546; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Feng H, 2007, BRIT J HAEMATOL, V138, P169, DOI 10.1111/j.1365-2141.2007.06625.x; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Goessling W, 2007, J CLIN ONCOL, V25, P2473, DOI 10.1200/JCO.2006.08.9821; Goessling W, 2007, NAT METHODS, V4, P551, DOI 10.1038/NMETH1059; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Haldi Maryann, 2006, Angiogenesis, V9, P139, DOI 10.1007/s10456-006-9040-2; Hall C, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-42; Haramis APG, 2006, EMBO REP, V7, P444, DOI 10.1038/sj.embor.7400638; Her GM, 2003, FEBS LETT, V538, P125, DOI 10.1016/S0014-5793(03)00157-1; Hong WY, 2004, CANCER RES, V64, P7256, DOI 10.1158/0008-5472.CAN-04-0931; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Kari G, 2007, CLIN PHARMACOL THER, V82, P70, DOI 10.1038/sj.clpt.6100223; Lam SH, 2006, NAT BIOTECHNOL, V24, P73, DOI 10.1038/nbt1169; Lam SH, 2006, CELL CYCLE, V5, P573, DOI 10.4161/cc.5.6.2550; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Langenau DM, 2005, BLOOD, V105, P3278, DOI 10.1182/blood-2004-08-3073; Langenau DM, 2005, P NATL ACAD SCI USA, V102, P6068, DOI 10.1073/pnas.0408708102; Langenau DM, 2004, P NATL ACAD SCI USA, V101, P7369, DOI 10.1073/pnas.0402248101; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Larson JD, 2004, DEV DYNAM, V231, P204, DOI 10.1002/dvdy.20102; Le XN, 2007, P NATL ACAD SCI USA, V104, P9410, DOI 10.1073/pnas.0611302104; Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471; Mathias JR, 2006, J LEUKOCYTE BIOL, V80, P1281, DOI 10.1189/jlb.0506346; Mizgireuv IV, 2006, CANCER RES, V66, P3120, DOI 10.1158/0008-5472.CAN-05-3800; Mizgireuv IV, 2004, TOXICOL PATHOL, V32, P514, DOI 10.1080/01926230490496311; Mould AP, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-24; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Nicoli S, 2007, CANCER RES, V67, P2927, DOI 10.1158/0008-5472.CAN-06-4268; Okihiro MS, 1999, CARCINOGENESIS, V20, P933, DOI 10.1093/carcin/20.6.933; Parng C, 2002, ASSAY DRUG DEV TECHN, V1, P41, DOI 10.1089/154065802761001293; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Sabaawy HE, 2006, P NATL ACAD SCI USA, V103, P15166, DOI 10.1073/pnas.0603349103; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Shepard JL, 2007, GENE DEV, V21, P55, DOI 10.1101/gad.1470407; Shepard JL, 2005, P NATL ACAD SCI USA, V102, P13194, DOI 10.1073/pnas.0506583102; Smolowitz R, 2002, BIOL BULL, V203, P265, DOI 10.2307/1543433; Spitsbergen J, 2007, NAT METHODS, V4, P548, DOI 10.1038/nmeth0707-548; Spitsbergen JM, 2000, TOXICOL PATHOL, V28, P705, DOI 10.1177/019262330002800511; Spitsbergen JM, 2000, TOXICOL PATHOL, V28, P716, DOI 10.1177/019262330002800512; Stern HM, 2005, NAT CHEM BIOL, V1, P366, DOI 10.1038/nchembio749; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Sun L, 2005, MATRIX BIOL, V24, P69, DOI 10.1016/j.matbio.2004.12.002; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Wakamatsu Y, 2001, P NATL ACAD SCI USA, V98, P10046, DOI 10.1073/pnas.181204298; Wallace KN, 2005, DEV CELL, V8, P717, DOI 10.1016/j.devcel.2005.02.015; Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008; Wan HY, 2006, EXP CELL RES, V312, P1526, DOI 10.1016/j.yexcr.2006.01.016; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Zijlstra A, 2002, CANCER RES, V62, P7083	64	145	150	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4509	4520		10.1038/onc.2008.95	http://dx.doi.org/10.1038/onc.2008.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18372910				2022-12-17	WOS:000258077300001
J	Kim, YH; Girard, L; Giacomini, CP; Wang, P; Hernandez-Boussard, T; Tibshirani, R; Minna, JD; Pollack, JR				Kim, YH; Girard, L; Giacomini, CP; Wang, P; Hernandez-Boussard, T; Tibshirani, R; Minna, JD; Pollack, JR			Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification	ONCOGENE			English	Article						small cell lung cancer; array CGH; expression profiling; DNA amplification; MYC	COMPARATIVE GENOMIC HYBRIDIZATION; DNA-BINDING; N-MYC; C-MYC; IDENTIFICATION; COMPLEX; PROTEIN; DEATH; MECHANISMS; DATABASE	DNA amplifications and deletions frequently contribute to the development and progression of lung cancer. To identify such novel alterations in small cell lung cancer (SCLC), we performed comparative genomic hybridization on a set of 24 SCLC cell lines, using cDNA microarrays representing similar to 22 000 human genes (providing an average mapping resolution of < 70 kb). We identified localized DNA amplifi. cations corresponding to oncogenes known to be amplified in SCLC, including MYC (8q24), MYCN (2p24) and MYCL1 (1p34). Additional highly localized DNA amplifi. cations suggested candidate oncogenes not previously identified as amplifified in SCLC, including the antiapoptotic genes TNFRSF4 (1p36), DAD1 (14q11), BCL2L1 (20q11) and BCL2L2 (14q11). Likewise, newly discovered PCR-validated homozygous deletions suggested candidate tumor-suppressor genes, including the proapoptotic genes MAPK10 (4q21) and TNFRSF6 (10q23). To characterize the effect of DNA amplifi. cation on gene expression patterns, we performed expression pro. ling using the same microarray platform. Among our findings, we identified sets of genes whose expression correlated with MYC, MYCN or MYCL1 amplification, with surprisingly little overlap among gene sets. While both MYC and MYCN ampli. cation were associated with increased and decreased expression of known MYC upregulated and downregulated targets, respectively, MYCL1 amplification was associated only with the latter. Our. findings support a role of altered apoptotic balance in the pathogenesis of SCLC, and suggest that MYC family genes might affect oncogenesis through distinct sets of targets, in particular implicating the importance of transcriptional repression.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University; Stanford University; Stanford University	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 269 Campus Dr,CCSR 3245A, Stanford, CA 94305 USA.	pollack1@stanford.edu		Wang, Pei/0000-0002-6890-6453	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayad NG, 2003, CELL, V113, P101, DOI 10.1016/S0092-8674(03)00232-0; Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bednarek AK, 2001, CANCER RES, V61, P8068; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARNEY DN, 1985, CANCER RES, V45, P2913; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cory S, 1999, CANCER RES, V59, p1685S; Curtin JF, 2003, CELL SIGNAL, V15, P983, DOI 10.1016/S0898-6568(03)00093-7; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Jensen LE, 2003, FEBS LETT, V545, P199, DOI 10.1016/S0014-5793(03)00533-7; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lucito R, 2000, GENOME RES, V10, P1726, DOI 10.1101/gr.138300; MA A, 1993, ONCOGENE, V8, P1093; Malynn BA, 2000, GENE DEV, V14, P1390; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; PERLAKY L, 1992, CANCER RES, V52, P428; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Raetz EA, 2003, CANCER, V98, P841, DOI 10.1002/cncr.11584; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang P, 2005, BIOSTATISTICS, V6, P45, DOI 10.1093/biostatistics/kxh017; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	46	145	151	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					130	138		10.1038/sj.onc.1208997	http://dx.doi.org/10.1038/sj.onc.1208997			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16116477				2022-12-17	WOS:000234406400014
J	Bandyopadhyay, S; Pai, SK; Hirota, S; Hosobe, S; Takano, Y; Saito, K; Piquemal, D; Commes, T; Watabe, M; Gross, SC; Wang, Y; Ran, S; Watabe, K				Bandyopadhyay, S; Pai, SK; Hirota, S; Hosobe, S; Takano, Y; Saito, K; Piquemal, D; Commes, T; Watabe, M; Gross, SC; Wang, Y; Ran, S; Watabe, K			Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression	ONCOGENE			English	Article						marker; metastasis; invasion; methylation	PROTEIN; DIFFERENTIATION; EXPRESSION; MOTILITY; GROWTH; CAP43	The differentiation-related gene-1 (Drg-1) was first identified as a gene strongly upregulated by induction of differentiation in colon carcinoma cells in vitro, and later the same gene was shown to suppress tumorigenicity of human bladder cancer cells in vivo. On the other hand, we and others have demonstrated that the Drg-1 gene suppresses prostate and colon cancer metastases in mouse models. In the context of such potential organ-specific differential function of the Drg-1 gene, the present study was designed to clarify the expression status, regulation and function of Drg-1 in the case of human breast cancer. We found that the expression of the Drg-1 protein was significantly reduced in breast tumor cells, particularly in patients with lymph node or bone metastasis as compared to those with localized breast cancer. Drg-1 expression also exhibited significant inverse correlation with the disease-free survival rate of patients and emerged as an independent prognostic factor. The downregulation of the Drg-1 gene appeared to be largely at the RNA level, and the DNA methylation inhibitor, 5-Azacytidine, significantly elevated the Drg-1 gene expression in various breast tumor cell lines. Furthermore, we found that overexpression of the Drg-1 gene suppresses the invasiveness of breast cancer cells in vitro, and this suppression was also achieved by treatment of cells with 5-Azacytidine. Together, our results strongly suggest functional involvement of the Drg-1 gene in suppressing the metastatic advancement of human breast cancer.	So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, Springfield, IL 62702 USA; Akita Red Cross Hosp, Akita, Japan; Univ Montpellier II, Montpellier, France	Southern Illinois University System; Southern Illinois University; Akita Red Cross Hospital; Universite de Montpellier	Watabe, K (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol & Immunol, 801 N Rutledge St, Springfield, IL 62702 USA.	kwatabe@siumed.edu		commes, therese/0000-0002-7918-0176; Piquemal, David/0000-0002-5870-4276	NATIONAL CANCER INSTITUTE [R01CA089438] Funding Source: NIH RePORTER; NCI NIH HHS [5R01CA89438] Funding Source: Medline; PHS HHS [1R15V50079473] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bandyopadhyay S, 2003, CANCER RES, V63, P1731; Davol PA, 2003, CANCER RES, V63, P6772; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Guang RJ, 2000, CANCER RES, V60, P749; Hartsough MT, 2001, CANCER RES, V61, P2320; Kim HL, 2001, CANCER RES, V61, P2833; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lin TM, 1997, P NATL ACAD SCI USA, V94, P4988, DOI 10.1073/pnas.94.10.4988; Masuda K, 2003, INT J CANCER, V105, P803, DOI 10.1002/ijc.11152; Okuda T, 1999, BIOCHEM BIOPH RES CO, V266, P208, DOI 10.1006/bbrc.1999.1780; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; vanBelzen N, 1997, LAB INVEST, V77, P85; Yamada SD, 2002, CANCER RES, V62, P6717; Zhou DJ, 1998, CANCER RES, V58, P2182	18	145	155	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5675	5681		10.1038/sj.onc.1207734	http://dx.doi.org/10.1038/sj.onc.1207734			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184886				2022-12-17	WOS:000222629500012
J	Lee, LF; Louie, MC; Desai, SJ; Yang, J; Chen, HW; Evans, CP; Kung, HJ				Lee, LF; Louie, MC; Desai, SJ; Yang, J; Chen, HW; Evans, CP; Kung, HJ			Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK	ONCOGENE			English	Article						interleukin-B; androgen-independence; migration; LNCAP; Src; focal adhesion kinase	PROSTATE-CANCER CELLS; FOCAL ADHESION KINASE; CARCINOMA-CELLS; RECEPTOR TRANSACTIVATION; CHEMOKINE RECEPTORS; GENE-EXPRESSION; OVARIAN-CANCER; IN-VITRO; ACTIVATION; PATHWAY	Interleukin- 8 ( IL- 8), a chemokine implicated in the metastasis and angiogenesis of a variety of cancers, has been reported to be overexpressed in prostate cancer. In this study, we ascribe a new role for IL- 8 in prostate cancer progression using LNCaP cells. We demonstrate that IL- 8 activates the androgen receptor and confers androgen- independent growth, while serving as a potent chemotactic factor. Our evaluation of the possible signal pathways involved in androgen- independence and cell migration shows that the tyrosine kinases Src and FAK ( focal adhesion kinase) are involved in IL- 8- induced signaling. Pharmacological and genetic inhibitors of Src and FAK interfere with IL- 8- induced cell migration, while only the Src inhibitor was able to repress androgen-independent growth. This suggests that both growth and migration depend on the activity of Src, whereas cell migration also requires the activation of FAK. Our evidence that IL- 8- induced androgen- independent growth is, at least in part, due to androgen receptor activation includes ( 1) an inhibitor of androgen receptor activity diminishes cell growth; ( 2) androgen receptor transactivation potential is augmented by IL- 8 and ( 3) androgen receptor is recruited to the promoter of prostate specific antigen ( PSA) upon IL- 8 treatment, based on chromatin immunoprecipitation experiments. Taken together, our data suggest that in addition to its role in metastasis and angiogenesis, IL- 8 may also serve as a facilitator for androgen- independent transition of prostate cancers. To our knowledge, this is the first report about the tyrosine kinase signals and androgen receptor activation induced by IL- 8 in prostate cancer cells. The observation that IL- 8 mediates its growth and chemotactic effects via Src and FAK suggests the potential use for tyrosine kinase inhibitors at early stage of prostate cancer development.	Univ Calif Davis, Dept Biol Chem, Sacramento, CA 95817 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA	University of California System; University of California Davis; Stanford University; University of California System; University of California Davis	Kung, HJ (corresponding author), Univ Calif Davis, Ctr Canc, Res III,UCDMC,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [R01CA057179, R01CA082073, R01CA039207, P30CA093373, R37CA039207, U01CA057179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060748] Funding Source: NIH RePORTER; NCI NIH HHS [CA82073, CA 57179, P30 CA93373, CA39207] Funding Source: Medline; NIDDK NIH HHS [DK52695, K08 DK60748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balbay MD, 1999, CLIN CANCER RES, V5, P783; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen TS, 2000, CANCER RES, V60, P2132; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dai J, 2002, CLIN CANCER RES, V8, P2399; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Debes JD, 2002, CANCER RES, V62, P5632; Feniger-Barish R, 2003, BIOCHEMISTRY-US, V42, P2874, DOI 10.1021/bi026783d; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Greene GF, 1997, AM J PATHOL, V150, P1571; Herrera CA, 2002, INT J ONCOL, V20, P5; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kanda N, 2001, J INVEST DERMATOL, V117, P274, DOI 10.1046/j.1523-1747.2001.01422.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee SO, 2003, CLIN CANCER RES, V9, P370; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Luttrell LM, 2002, J CELL SCI, V115, P455; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MOORE BB, 1999, AM J PATHOL, V162, P5511; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Reiland J, 1999, PROSTATE, V41, P78; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Torring N, 2000, ANTICANCER RES, V20, P91; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wen Y, 2000, CANCER RES, V60, P6841; Xia L, 2002, J BIOL CHEM, V277, P35422, DOI 10.1074/jbc.M203940200; Xiao DM, 2003, CELL SIGNAL, V15, P945, DOI 10.1016/S0898-6568(03)00059-7; Xu L, 1998, HUM GENE THER, V9, P2699, DOI 10.1089/hum.1998.9.18-2699; Yang L, 2003, BIOCHEM BIOPH RES CO, V305, P462, DOI 10.1016/S0006-291X(03)00792-7; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	52	145	156	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2197	2205		10.1038/sj.onc.1207344	http://dx.doi.org/10.1038/sj.onc.1207344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14767470				2022-12-17	WOS:000220280900009
J	Losa, JH; Cobo, CP; Viniegra, JG; Lobo, VJSA; Cajal, SRY; Sanchez-Prieto, R				Losa, JH; Cobo, CP; Viniegra, JG; Lobo, VJSA; Cajal, SRY; Sanchez-Prieto, R			Role of the p38 MAPK pathway in cisplatin-based therapy	ONCOGENE			English	Article						p38 MAPK; cisplatin; phosphorylation resistance; p38 MAPK gamma/ERK6; p38 MAPK delta/SAPK4	ACTIVATED PROTEIN-KINASE; SQUAMOUS-CELL CARCINOMAS; C-ABL ACTIVATION; INDUCED APOPTOSIS; CANCER-CELLS; UV-RADIATION; GENOTOXIC STRESS; TRANS ISOMER; CYCLE ARREST; CROSS-LINKS	p38 MAPK has been implicated in the response to cancer therapy. To determine whether the activation of p38 MAPK could be specific to cancer therapy, we investigated the activation of p38 MAPK in response to several chemotherapeutic agents, such as cisplatin, doxorubicin and taxol in several human cell lines. Activation of p38 MAPK was measured after exposure to several chemotherapeutic agents, using specific phosphoantibodies. Only cisplatin was able to activate p38 MAPK in all the cell lines tested. Furthermore, other platinum compounds such as transplatin and platinum (IV) chloride can induce activation of p38 MAPK. The kinetics of this activation is a key event in the biological role of p38 MAPK in response to cisplatin, as we conclude from the differences observed after treatment with transplatin and cisplatin. The p38 MAPK activation is independent of the origin or genetic alterations of the cell lines and seems to be mediated through both upstream activators MKK6 and MKK3. Although the isoforms alpha/beta are mainly activated, we also demonstrated that other members of the p38 MAPK family were susceptible to activation by cisplatin when they were overexpressed in 293 T. Finally, pretreatment with specific inhibitors (SB 203580 and SKF 86002) induces a resistant phenotype in response to cisplatin. Furthermore, low activation of this SAPK pathway correlates with a resistant phenotype as demonstrated in our experimental model of head and neck cancer. Therefore, we conclude that the p38 MAPK pathway is a specific target for cisplatin-based therapy with clinical implications.	Hosp Univ Puerta de Hierro, Unidad Patol Mol, Madrid 28035, Spain	Hospital Puerta de Hierro-Majadahonda	Sanchez-Prieto, R (corresponding author), Hosp Univ Puerta de Hierro, Unidad Patol Mol, C San Martin de Porres 4, Madrid 28035, Spain.		Prieto, Ricardo/AAZ-7221-2021; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Javier, Hernandez Losa/C-1173-2008; Sanchez-Prieto, Ricardo/AAY-4271-2021; Sanchez-Prieto, Ricardo/B-6877-2008; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019; Ramon y Cajal, Santiago/H-4955-2016	Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Javier, Hernandez Losa/0000-0003-1526-3201; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Ramon y Cajal, Santiago/0000-0002-3867-1390				Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; Asselin E, 2001, CANCER RES, V61, P1862; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BOUDVILLAIN M, 1995, NUCLEIC ACIDS RES, V23, P2381, DOI 10.1093/nar/23.13.2381; Brognard J, 2001, CANCER RES, V61, P3986; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.3.CO;2-4; CUMMINGS J, 1993, ANN ONCOL, V4, P533, DOI 10.1093/oxfordjournals.annonc.a058584; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Hayakawa J, 2000, CANCER RES, V60, P5988; Hortobagyi GN, 1999, SEMIN ONCOL, V26, P32; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 2001, J BIOL CHEM, V276, P16064, DOI 10.1074/jbc.M101224200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lippert B, 1996, MET IONS BIOL SYST, V33, P105; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NOMURA M, 2001, J BIOL CHEM, V11, P11; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Patel V, 1997, INT J CANCER, V73, P551, DOI 10.1002/(SICI)1097-0215(19971114)73:4<551::AID-IJC16>3.0.CO;2-C; Patel V, 1998, J CLIN INVEST, V102, P1674, DOI 10.1172/JCI3661; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sodhi A, 2000, CANCER RES, V60, P4873; Trimmer EE, 1999, ESSAYS BIOCHEM, V34, P191, DOI 10.1042/bse0340191; Verheij M, 1998, RADIOTHER ONCOL, V47, P225, DOI 10.1016/S0167-8140(98)00007-3; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yu ZP, 2000, TOXICOL APPL PHARM, V168, P200, DOI 10.1006/taap.2000.9033; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	54	145	151	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					3998	4006		10.1038/sj.onc.1206608	http://dx.doi.org/10.1038/sj.onc.1206608			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821934				2022-12-17	WOS:000183707600003
J	Ferber, MJ; Montoya, DP; Yu, C; Aderca, I; McGee, A; Thorland, EC; Nagorney, DM; Gostout, BS; Burgart, LJ; Boix, L; Bruix, J; McMahon, BJ; Cheung, TH; Chung, TKH; Wong, YF; Smith, DI; Roberts, LR				Ferber, MJ; Montoya, DP; Yu, C; Aderca, I; McGee, A; Thorland, EC; Nagorney, DM; Gostout, BS; Burgart, LJ; Boix, L; Bruix, J; McMahon, BJ; Cheung, TH; Chung, TKH; Wong, YF; Smith, DI; Roberts, LR			Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers	ONCOGENE			English	Article						hepatitis B virus; human papillomavirus; telomerase reverse transcriptase; hepatocellular carcinoma; cervical cancer; viral integration	RESTRICTION-SITE PCR; COMMON FRAGILE SITES; HEPATOCELLULAR-CARCINOMA; DNA INTEGRATION; CELL-LINES; MYC GENES; ACTIVATION; TYPE-16; SEQUENCE; REGION	Chronic infections with the hepatitis B virus (HBV) and high-risk human papillomaviruses (HPVs) are important risk factors for hepatocellular carcinoma (HCC) and cervical cancer (CC), respectively. HBV and HPV are DNA viruses that almost invariably integrate into the host genome in invasive tumors. The viral integration sites occur throughout the genome, leading to the presumption that there are no preferred sites of integration. A number of viral integrations have been shown to occur within the vicinity of important cancer-related genes. In studies of HBV-induced HCC and HPV-induced CC, we have identified two HBV and three HPV integrations into the human telomerase reverse transcriptase (hTERT) gene. Detailed characterization of the integrations revealed that four integrations occurred within the hTERT promoter and upstream region and the fifth integration occurred in intron 3 of the hTERT gene. None of the integrations altered the hTERT coding sequence and all resulted in juxtaposition of viral enhancers near hTERT, with potential activation of hTERT expression. Our work supports the hypothesis that the sites of oncogenic viral integration are nonrandom and that genes at the sites of viral integration may play important roles in carcinogenesis.	Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin, Div Gastroenterol & Gen Surg, Rochester, MN 55905 USA; Mayo Clin, Dept Obstet & Gynaecol, Rochester, MN 55905 USA; Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA; Univ Barcelona, IMD Hosp Clin, BCLC Grp Liver Unit, Barcelona 08036, Spain; Alaska Native Med Ctr, Anchorage, AK 99508 USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Barcelona; Alaska Native Medical Center; Chinese University of Hong Kong; Prince of Wales Hospital	Roberts, LR (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA.			CHUNG, Tony/0000-0002-6362-8546; Bruix, Jordi/0000-0002-9826-0753; Roberts, Lewis/0000-0001-7885-8574	NATIONAL CANCER INSTITUTE [R01CA048031, K08CA082862] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031, CA82862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; Berasain C, 1998, ONCOGENE, V16, P1277, DOI 10.1038/sj.onc.1201893; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Buendia M A, 1992, Semin Cancer Biol, V3, P309; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; CHOO KB, 1995, CANCER LETT, V93, P249, DOI 10.1016/0304-3835(95)03817-G; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DEJEAN A, 1990, MOL BIOL MED, V7, P213; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Horikawa I, 1999, CANCER RES, V59, P826; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kalantari M, 1998, INT J GYNECOL PATHOL, V17, P146, DOI 10.1097/00004347-199804000-00009; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kozuka T, 2000, JPN J CANCER RES, V91, P271, DOI 10.1111/j.1349-7006.2000.tb00941.x; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Sarkar G, 1993, PCR Methods Appl, V2, P318; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; Shera KA, 2001, J VIROL, V75, P12339, DOI 10.1128/JVI.75.24.12339-12346.2001; Smola-Hess S, 2001, J GEN VIROL, V82, P2335, DOI 10.1099/0022-1317-82-10-2335; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Waris G, 2002, J VIROL, V76, P2721, DOI 10.1128/JVI.76.6.2721-2729.2002; Weber KL, 1998, BIOTECHNIQUES, V25, P415, DOI 10.2144/98253st02; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187	34	145	167	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3813	3820		10.1038/sj.onc.1206528	http://dx.doi.org/10.1038/sj.onc.1206528			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802289				2022-12-17	WOS:000183551000016
J	Licht, JD				Licht, JD			AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML	ONCOGENE			English	Review						AML1; RUNX; transcription ETO; leukemia; translocation	ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; POLYMERASE-CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; ACUTE PROMYELOCYTIC LEUKEMIA; BONE-MARROW TRANSPLANTATION; STIMULATING FACTOR-RECEPTOR; LONG-TERM REMISSION; BINDING-FACTOR-BETA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS		CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Licht, Jonathan/AAL-9184-2020; Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; 	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Andrieu V, 1996, BRIT J HAEMATOL, V92, P855, DOI 10.1046/j.1365-2141.1996.415954.x; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; ASOU H, 1991, BLOOD, V77, P2031; Austin GE, 1998, LEUKEMIA RES, V22, P1037, DOI 10.1016/S0145-2126(98)00105-2; BAE SC, 1993, ONCOGENE, V8, P809; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Berardi MJ, 1999, STRUCT FOLD DES, V7, P1247, DOI 10.1016/S0969-2126(00)80058-1; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; BritosBray M, 1996, LEUKEMIA, V10, P984; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen LF, 1998, MOL CELL BIOL, V18, P4165, DOI 10.1128/MCB.18.7.4165; Corsetti MT, 1997, BLOOD, V89, P2359, DOI 10.1182/blood.V89.7.2359; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; DEGREEF GE, 1995, LEUKEMIA, V9, P282; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DOWNING JR, 1993, BLOOD, V81, P2860; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ERA T, 1995, GENE CHROMOSOME CANC, V13, P25, DOI 10.1002/gcc.2870130105; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fracchiolla NS, 1998, BLOOD, V92, P3481, DOI 10.1182/blood.V92.9.3481.splL6_3481_3484; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; Fujii M, 1998, ONCOGENE, V17, P1813, DOI 10.1038/sj.onc.1202087; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Goger M, 1999, NAT STRUCT BIOL, V6, P620; GOLEMIS EA, 1990, J VIROL, V64, P534, DOI 10.1128/JVI.64.2.534-542.1990; Golling G, 1996, MOL CELL BIOL, V16, P932; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; GUERRASIO A, 1995, BRIT J HAEMATOL, V90, P364, DOI 10.1111/j.1365-2141.1995.tb05160.x; Guidez F, 2000, BLOOD, V96, P2557; Harada H, 1999, MOL CELL BIOL, V19, P3808; Hayashi K, 2000, J IMMUNOL, V165, P6816, DOI 10.4049/jimmunol.165.12.6816; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; Higuchi M, 2000, BLOOD, V96, p222A; HILDEBRAND D, 2001, J BIOL CHEM, V9, P9; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang XM, 1999, NAT STRUCT BIOL, V6, P624; Hwang ES, 1999, FEBS LETT, V446, P86, DOI 10.1016/S0014-5793(99)00190-8; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kim JH, 1999, INT J BIOCHEM CELL B, V31, P933, DOI 10.1016/S1357-2725(99)00048-5; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kondo M, 2000, LEUKEMIA RES, V24, P951, DOI 10.1016/S0145-2126(00)00071-0; KOZU T, 1993, BLOOD, V82, P1270; Krauter J, 1999, BRIT J HAEMATOL, V107, P80, DOI 10.1046/j.1365-2141.1999.01674.x; Kurokawa M, 1996, ONCOGENE, V12, P883; KUSEC R, 1994, LEUKEMIA, V8, P735; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Langabeer SE, 1997, BRIT J HAEMATOL, V99, P925, DOI 10.1046/j.1365-2141.1997.4663270.x; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levanon D, 2001, GENE, V262, P23, DOI 10.1016/S0378-1119(00)00532-1; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU J, 1995, MOL CELL BIOL, V15, P1651; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Marcucci G, 1998, LEUKEMIA, V12, P1482, DOI 10.1038/sj.leu.2401128; MARUYAMA F, 1994, LEUKEMIA, V8, P40; MATOZAKI S, 1995, BRIT J HAEMATOL, V89, P805; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.0.CO;2-B; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Miyamoto T, 1996, BLOOD, V87, P4789, DOI 10.1182/blood.V87.11.4789.bloodjournal87114789; MIYAMOTO T, 1995, BRIT J HAEMATOL, V91, P132, DOI 10.1111/j.1365-2141.1995.tb05258.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Miyoshi H, 1997, LEUKEMIA RES, V21, P45, DOI 10.1016/S0145-2126(96)00089-6; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morii E, 1999, BIOCHEM BIOPH RES CO, V261, P53, DOI 10.1006/bbrc.1999.0996; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Morschhauser F, 2000, J CLIN ONCOL, V18, P788, DOI 10.1200/JCO.2000.18.4.788; Mukouyama Y, 2000, DEV BIOL, V220, P27, DOI 10.1006/dbio.2000.9617; Muto A, 1996, BRIT J HAEMATOL, V95, P85, DOI 10.1046/j.1365-2141.1996.d01-1877.x; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Niitsu N, 1997, CELL GROWTH DIFFER, V8, P319; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NIWAKAWAKITA M, 1995, GENOMICS, V29, P755, DOI 10.1006/geno.1995.9941; North T, 1999, DEVELOPMENT, V126, P2563; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P883; NUCIFORA G, 1994, LEUKEMIA, V8, P1533; NUCIFORA G, 1993, BLOOD, V82, P712; NUCIFORA G, 1995, BLOOD, V86, P1; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Preudhomme C, 1996, LEUKEMIA, V10, P186; Puig-Kroger A, 2000, J BIOL CHEM, V275, P28507, DOI 10.1074/jbc.M004323200; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Sacchi N, 1996, ONCOGENE, V12, P437; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sakata N, 1997, LEUKEMIA LYMPHOMA, V26, P141, DOI 10.3109/10428199709109169; Salomon-Nguyen F, 2000, LEUKEMIA, V14, P1704, DOI 10.1038/sj.leu.2401885; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SATAKE N, 1995, BRIT J HAEMATOL, V91, P892, DOI 10.1111/j.1365-2141.1995.tb05406.x; Saunders, 1999, Expert Opin Investig Drugs, V8, P1611, DOI 10.1517/13543784.8.10.1611; Saunders MJ, 1997, BRIT J HAEMATOL, V99, P921, DOI 10.1046/j.1365-2141.1997.4673271.x; Saunders MJ, 1996, LEUKEMIA, V10, P1139; SAUNDERS MJ, 1994, LEUKEMIA RES, V18, P891, DOI 10.1016/0145-2126(94)90100-7; Sherr CJ, 2000, CANCER RES, V60, P3689; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shikami M, 1999, LEUKEMIA, V13, P358, DOI 10.1038/sj.leu.2401343; Shimada H, 2000, BLOOD, V96, P655; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; Sugimoto T, 2000, AM J HEMATOL, V64, P101, DOI 10.1002/(SICI)1096-8652(200006)64:2<101::AID-AJH5>3.0.CO;2-X; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(02)02053-6; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; TIGHE JE, 1993, BLOOD, V81, P592; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; TIGHE JE, 1995, CLIN SCI, V89, P215, DOI 10.1042/cs0890215; Tobal K, 1996, BLOOD, V88, P3704, DOI 10.1182/blood.V88.10.3704.bloodjournal88103704; Tobal K, 2000, BLOOD, V95, P815, DOI 10.1182/blood.V95.3.815.003k30_815_819; Uchida H, 1997, J IMMUNOL, V158, P2251; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Wang JX, 1997, CANCER RES, V57, P2951; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Wolford JK, 1998, BIOCHEM BIOPH RES CO, V246, P624, DOI 10.1006/bbrc.1998.8683; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Wong IHN, 2000, BLOOD, V95, P1942, DOI 10.1182/blood.V95.6.1942; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; Zhang HT, 2000, CHEM J CHINESE U, V21, P156; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	211	145	159	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2001	20	40					5660	5679		10.1038/sj.onc.1204593	http://dx.doi.org/10.1038/sj.onc.1204593			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	470TP	11607817				2022-12-17	WOS:000170887500008
J	Michaelson, JS; Leder, P				Michaelson, JS; Leder, P			beta-catenin is a downstream effector of Wnt-mediated tumorigenesis in the mammary gland	ONCOGENE			English	Article						beta-catenin; breast cancer; mammary gland; Wnt; adenocarcinoma; MMTV	POLYPOSIS-COLI PROTEIN; CYCLIN D1 GENE; EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; FEMALE MICE; IN-VIVO; C-MYC; EXPRESSION; APC; TRANSFORMATION	The Wnt signal transduction pathway has been implicated in mammary tumorigenesis in the mouse. beta -catenin, a key downstream effector of this pathway interacts with and thus activates the Tcf/Lef family of transcription factors. Elevated levels of beta -catenin have been found in many human tumors, notably colon carcinomas. Recently, elevated levels of beta -catenin have been associated with poor prognosis in human adenocarcinoma of the breast. In order to assess the possible role of beta -catenin in mammary carcinoma, we have created transgenic mice bearing the MMTV-LTR driving an activated form of beta -catenin. These mice develop mammary gland hyperplasia and mammary adenocarcinoma, a phenotype very similar to that of transgenic mice expressing an MMTV-driven Writ gene. Indeed, the histopathology of the mammary tumors in Wnt-mediated adenocarcinoma is identical to that observed in our beta -catenin-mediated disease model. Furthermore, putative beta -catenin transcriptional targets, cyclin D1 and c-myc, are elevated in beta -catenin-mediated mammary tumors and cell lines. These observations support the notion that the oncogenic Wnt pathway operates via beta -catenin and its targets in the context of mammary hyperplasia and carcinoma.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.							Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xu LF, 2000, GENE DEV, V14, P585; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	31	145	169	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5093	5099		10.1038/sj.onc.1204586	http://dx.doi.org/10.1038/sj.onc.1204586			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526497				2022-12-17	WOS:000170464000002
J	Krueger, JS; Keshamouni, VG; Atanaskova, N; Reddy, KB				Krueger, JS; Keshamouni, VG; Atanaskova, N; Reddy, KB			Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion	ONCOGENE			English	Article						MAPK; MEK; cell motility; breast cancer; cell signaling	HUMAN BREAST-CANCER; EPIDERMAL GROWTH-FACTOR; FACTOR SCATTER FACTOR; TYROSINE KINASE; EGF RECEPTOR; SIGNAL-TRANSDUCTION; MIGRATION; EXPRESSION; LINES; RAS	We have shown that ER-negative and invasive human breast cancer cell lines MDA-MB-468 and MDA-MB-231 have constitutively higher mitogen activated protein kinase (ERK1&2/MAPK) when compared to the ER-positive and non-invasive MCF-7 human breast cancer cells. In MCF-7 cells, TGF alpha stimulation induced only transient MAPK activation, leading to a transient increase in cell migration. However, MDA 231 and MDA 468 cells, TCF alpha stimulation induced sustained MAPK activation, which correlated with enhanced cell motility and in vitro invasion, Serum stimulation activates ERK/MAPK activity persistently ire both ER-positive and ER-negative breast cancer cells, leading to enhanced and sustained cell migration. Inhibition of MAPK activation by anti-sense MEK expression in MDA-MB-468 cells significantly inhibits cell migration and in vitro invasion. In contrast, MCF-7 cells expressing constitutively activated MEK show a significant increase in MAPK activity and cell migration, but this failed to enhance in vitro invasion. The kinetic profiles of MAPK activation and inhibition show a relationship between the duration and magnitude of MAPK activation and cell migration in both ER-positive and ER-negative human breast cancer cells. These studies show that cell motility is modulated by the magnitude and the duration of MAPK activation; but increased activation of MAPK may not be sufficient to allow in vitro invasion in noninvasive MCF-7 breast cancer cells.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.			Keshamouni, Venkateshwar/0000-0003-1947-791X	NCI NIH HHS [CA 64248, CA 83964] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083964, R29CA064248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Fan W H, 1998, Cell Res, V8, P63; FRIEDL P, 1995, CANCER RES, V55, P4557; Gilhooly EM, 1999, INT J ONCOL, V15, P267; Gopalakrishna R, 1999, CANCER LETT, V136, P143, DOI 10.1016/S0304-3835(98)00315-2; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kondapaka SB, 1997, INT J CANCER, V70, P722, DOI 10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.3.CO;2-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSKE M, 1994, INT REV CYTOL, V155, P49, DOI 10.1016/S0074-7696(08)62096-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MISHRA S, 1993, BIOCHEM BIOPH RES CO, V191, P1066, DOI 10.1006/bbrc.1993.1325; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Prasad KSS, 1997, J BIOL CHEM, V272, P11457; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Reddy KB, 1999, INT J ONCOL, V15, P301; Rigot V, 1998, J CELL SCI, V111, P3119; SATO C, 1995, J INVEST DERMATOL, V104, P958, DOI 10.1111/1523-1747.ep12606221; SEGER R, 1995, J BIOL CHEM, V270, P28325; Shao ZM, 1998, ANTICANCER RES, V18, P1435; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slack JK, 1999, J BIOL CHEM, V274, P27177, DOI 10.1074/jbc.274.38.27177; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Xie H, 1998, J CELL SCI, V111, P615; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	41	145	161	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4209	4218		10.1038/sj.onc.1204541	http://dx.doi.org/10.1038/sj.onc.1204541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464287				2022-12-17	WOS:000169857200011
J	Kusano, H; Shimizu, S; Koya, RC; Fujita, H; Kamada, S; Kuzumaki, N; Tsujimoto, Y				Kusano, H; Shimizu, S; Koya, RC; Fujita, H; Kamada, S; Kuzumaki, N; Tsujimoto, Y			Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC	ONCOGENE			English	Article						gelsolin; VDAC; apoptosis	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; REGULATORY PROTEIN; BAX; MEMBRANE; FAMILY; PLASMA; GENE	Gelsolin is a Ca2+-dependent actin-regulatory protein that modulates actin assembly and disassembly, and is believed to regulate cell motility through modulation of the actin network. Gelsolin was also recently suggested to be involved in the regulation of apoptosis: human gelsolin (hGsn) has anti-apoptotic activity, whereas mouse gelsolin (mGsn) exerts either proapoptotic or anti-apoptotic activity depending on different cell types. Here, we studied the basis of anti-apoptotic activity of hGsn, We showed that both endogenous and overexpressed hGsn has anti-apoptotic activity, that depends on its C-terminal half. We also found that hGsn and its C-terminal half but not mGsn could prevent apoptotic mitochondrial changes such as Delta psi loss and cytochrome c release in isolated mitochondria to a similar extent as Bcl-x(L), indicating that hGsn targets the mitochondria to prevent apoptosis via its C-terminal half. In the same way as anti-apoptotic Bcl-xL, which we recently found to prevent apoptotic mitochondrial changes by binding and closing the voltage-dependent anion channel (VDAC), hGsn and its C-terminal half inhibited the activity of VDAC on liposomes through direct binding in a Ca2+-dependent manner. These results suggest that hGsn inhibits apoptosis by blocking mitochondrial VDAC activity.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Suita, Osaka 5650871, Japan; JST, CREST, Suita, Osaka, Japan; Hokkaido Univ, Inst Med Genet, Div Canc Gene Regulat, Kita Ku, Sapporo, Hokkaido, Japan	Osaka University; Japan Science & Technology Agency (JST); Hokkaido University	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Azuma T, 2000, J BIOL CHEM, V275, P3761, DOI 10.1074/jbc.275.6.3761; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Endres M, 1999, J CLIN INVEST, V103, P347, DOI 10.1172/JCI4953; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fujita H, 1997, EUR J BIOCHEM, V248, P834, DOI 10.1111/j.1432-1033.1997.00834.x; FUJITA H, 1995, EUR J BIOCHEM, V229, P615, DOI 10.1111/j.1432-1033.1995.tb20505.x; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Rappaport L, 1998, MOL CELL BIOCHEM, V184, P101, DOI 10.1023/A:1006843113166; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	34	145	148	1	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4807	4814		10.1038/sj.onc.1203868	http://dx.doi.org/10.1038/sj.onc.1203868			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039896				2022-12-17	WOS:000089757800001
J	Yeh, JJ; Lunetta, KL; van Orsouw, NJ; Moore, FD; Mutter, GL; Vijg, J; Dahia, PLM; Eng, C				Yeh, JJ; Lunetta, KL; van Orsouw, NJ; Moore, FD; Mutter, GL; Vijg, J; Dahia, PLM; Eng, C			Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours	ONCOGENE			English	Article						mitochondria; thyroid tumours; sequence variants; mutations	TUMORS; APOPTOSIS; CANCER	Somatic mutations in mtDNA have recently been identified in colorectal tumours, Studies of oncocytic tumours have led to hypotheses which propose that defects in oxidative phosphorylation may result in a compensatory increase in mitochondrial replication and/or gene expression. Mutational analysis of mtDNA in thyroid neoplasia, which is characterised by increased numbers of mitochondria and is also one of the most common sites of oncocytic tumours, has been limited to date. Using the recently developed technique of two-dimensional gene scanning, me have successfully examined 21 cases of thyroid tumours, six cases of nonneoplastic thyroid pathology, 30 population controls, nine foetal thyroid tissues and nine foetal tissues of nonthyroid origin, either kidney or liver. We have identified three different somatic mutations (23%) in papillary thyroid carcinomas. In addition, we have found significant differential distributions of mtDNA sequence variants between thyroid carcinomas and controls. Interestingly, these variants appear to be more frequent in the genes which encode complex I of the mitochondrial electron transport chain compared to normal population controls, These findings suggest first, that somatic mtDNA mutations may be involved in thyroid tumorigenesis and second, that the accumulation of certain non-somatic variants may be related to tumour progression in the thyroid.	Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet & Human Canc Genet Program, Med Res Facil 690C, Columbus, OH 43210 USA; Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA; San Antonio Canc Inst, Inst Drug Dev, San Antonio, TX USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Surg, Boston, MA 02114 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston University	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet & Human Canc Genet Program, Med Res Facil 690C, 420 W 12th Ave, Columbus, OH 43210 USA.		Mutter, George L/C-5819-2009	Lunetta, Kathryn/0000-0002-9268-810X; Eng, Charis/0000-0002-3693-5145	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA16058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BIANCHI MS, 1995, CYTOGENET CELL GENET, V71, P99, DOI 10.1159/000134072; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Cavalli LR, 1998, MUTAT RES-FUND MOL M, V398, P19, DOI 10.1016/S0027-5107(97)00223-6; Dhanda RK, 1998, BIOTECHNIQUES, V25, P664, DOI 10.2144/98254dt06; EBNER D, 1991, VIRCHOWS ARCH B, V60, P139, DOI 10.1007/BF02899539; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; JOHNSON D, 1996, AM J PATHOL, V149, P1786; Muller-Hocker J, 1998, ULTRASTRUCT PATHOL, V22, P91; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; SIGEL S, 1998, NONPARAMETRIC STAT B; Simon DK, 1999, ANNU REV MED, V50, P111; Stefaneanu L, 1979, Endocrinologie, V17, P233; TALLINI G, 1994, CYTOGENET CELL GENET, V66, P253, DOI 10.1159/000133706; van Orsouw NJ, 1998, GENOMICS, V52, P27, DOI 10.1006/geno.1998.5410; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112	22	145	162	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					2060	2066		10.1038/sj.onc.1203537	http://dx.doi.org/10.1038/sj.onc.1203537			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803467				2022-12-17	WOS:000086613200010
J	Bates, S; Ryan, KM; Phillips, AC; Vousden, KH				Bates, S; Ryan, KM; Phillips, AC; Vousden, KH			Cell cycle arrest and DNA endoreduplication following p21(Waf1/Cip1) expression	ONCOGENE			English	Article						p21(Waf1/Cip1); cell cycle arrest; cyclin dependent kinase; endoreduplication; senescence	DEPENDENT-KINASE INHIBITOR; P53-MEDIATED G(1) ARREST; HUMAN CANCER-CELLS; WILD-TYPE P53; S-PHASE; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; CDK INHIBITORS; GROWTH ARREST; IN-VIVO	p21(Waf1/Cip1) is a major transcriptional target of p53 and has been shown to be one of the principal mediators of the p53 induced G1 cell cycle arrest. We show that in addition to the G1 block, p21(Waf1/Cip1) can also contribute to a delay in G2 and expression of p21(Waf1/Cip1) gives rise to cell cycle profiles essentially indistinguishable from those obtained following p53 expression. Arrest of cells in G2 likely reflects an inability to induce cyclin B1/cdc2 kinase activity in the presence of p21(Waf1/Cip1), although the inefficient association of p21(Waf1/cip1) and cyclin B1 suggests that the mechanism of inhibition is indirect. Cells released from an S-phase block were not retarded in their ability to progress through S-phase by the presence of p21(Waf1/Cip1), despite efficient inhibition of cyclin E, A and B1 dependent kinase activity, suggesting that p2l(Waf1/Cip1) is inefficient at inhibiting replicative DNA synthesis in vivo. Interestingly, significant numbers of cells released from the p21(Waf1/Cip1) activated G2 block undergo endoreduplication, passing through another S-phase before undergoing mitosis, This supports a function of the mitotic kinases in both entry into mitosis, and also in preventing re-replication of DNA following S-phase and suggests a role for p21(Waf1/Cip1) in coupling DNA synthesis and mitosis, Unlike p53, which induces apoptosis in these cells, extended expression of p21(Waf1/Cip1) resulted in the expression of a senescent-like phenotype in these p53 null, pRB null tumor cells.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.			Ryan, Kevin M./0000-0002-1059-9681				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BOND JA, 1995, CANCER RES, V55, P2404; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; McDonald E, 1996, CANCER RES, V56, P2250; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Stern B, 1996, TRENDS GENET, V12, P345; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P504; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	62	145	149	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1691	1703		10.1038/sj.onc.1202104	http://dx.doi.org/10.1038/sj.onc.1202104			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796698				2022-12-17	WOS:000076200100007
J	Brimmell, M; Mendiola, R; Mangion, J; Packham, G				Brimmell, M; Mendiola, R; Mangion, J; Packham, G			BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability	ONCOGENE			English	Article						BAX; MSH2; microsatellite instability; apoptosis; leukaemia; lymphoma	NONPOLYPOSIS COLORECTAL-CANCER; MUTATOR PHENOTYPE; MISMATCH REPAIR; DEFICIENT MICE; GENE BAX; B-CELLS; DEATH; BCL-2; EXPRESSION; MSH2	Bax suppresses tumorigenesis in a mouse model system and Bax-deficient mice exhibit lymphoid hyperplasia suggesting that BAX functions as a tumour suppressor in human haemopoietic cells. We examined BAX expression in 20 cell lines derived from human haemopoietic malignancies and consistent with a potential tumour suppressor function, identified two cell lines, DG75 (a Burkitt lymphoma cell line) and Jurkat (a T-cell leukaemia line), which lacked detectable BAX expression. Apoptosis of DG75 cells induced by low serum or ionomycin was significantly delayed relative to similar Burkitt lymphoma cell lines with normal BAX levels, Although DG75 and Jurkat cells expressed several BAX RNA species including the prototypical BAX alpha RNA, the absence of BAX protein was due to single base deletions and additions in a polyguanine tract within the BAX open reading frame. These frameshift mutations result in premature termination of translation and have recently also been identified in some colon cancers with microsatellite instability, Although mismatch repair defects are not considered a common feature of haemopoietic malignancies, DG75 and Jurkat cells had widespread microsatellite instability and did not express detectable levels of MSH2. In Jurkat cells, lack of MSH2 expression was due to a point mutation in exon 13 of MSH2 resulting in premature termination of translation. Our results suggest that a pathway linking mismatch repair defects, BAX tumour suppressor frameshift mutations and resistance to apoptosis may be a key feature of some lymphomas and leukaemias.	Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Ludwig Inst Canc Res, London W2 1PG, England; Inst Canc Res, Haddow Labs, Mol Carcinogenesis Sect, Sutton SM2 5NG, Surrey, England; Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Dept Med Microbiol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK; Imperial College London	Packham, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med St Marys, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.							APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; ASKEW DS, 1991, ONCOGENE, V6, P1815; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BenYehuda D, 1996, BLOOD, V88, P4296; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GALA JL, 1994, ANN HEMATOL, V69, P17, DOI 10.1007/BF01757343; Gartenhaus R, 1996, BLOOD, V87, P38; GAZDAR AF, 1980, BLOOD, V55, P409; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Larson RS, 1996, CANCER RES, V56, P4378; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1994, CANCER RES, V54, P4590; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; MEIJERINK JPP, 1995, LEUKEMIA, V9, P1828; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Randerson J, 1996, BRIT J HAEMATOL, V93, P160, DOI 10.1046/j.1365-2141.1996.456994.x; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROBLEDO M, 1995, LEUKEMIA, V9, P960; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; VOLPE G, 1996, ANN HEMATOL, V72, P62; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	39	145	147	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1803	1812		10.1038/sj.onc.1201704	http://dx.doi.org/10.1038/sj.onc.1201704			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583678				2022-12-17	WOS:000072994600004
J	FRANZA, BR; SAMBUCETTI, LC; COHEN, DR; CURRAN, T				FRANZA, BR; SAMBUCETTI, LC; COHEN, DR; CURRAN, T			ANALYSIS OF FOS PROTEIN COMPLEXES AND FOS-RELATED ANTIGENS BY HIGH-RESOLUTION TWO-DIMENSIONAL GEL-ELECTROPHORESIS	ONCOGENE			English	Article									COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL,NUTLEY,NJ 07110	Cold Spring Harbor Laboratory; Roche Holding			Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Cohen, Donna/0000-0002-0419-9542				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CAMPISI J, 1984, CELL, V36, P242; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1984, CELL, V36, P259; CURRAN T, 1987, IN PRESS ONCOGENE HD; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Franza BR, 1984, CANC CELLS, V1, P137; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; JONES NC, 1986, ADENOVIRUS DNA, P161; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; SAMBUCETTI LC, 1986, GENE, V43, P69, DOI 10.1016/0378-1119(86)90009-0; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	38	145	146	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					213	221						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3325882				2022-12-17	WOS:A1987J635200014
J	Dorayappan, KDP; Wanner, R; Wallbillich, JJ; Saini, U; Zingarelli, R; Suarez, AA; Cohn, DE; Selvendiran, K				Dorayappan, Kalpana Deepa Priya; Wanner, Ross; Wallbillich, John J.; Saini, Uksha; Zingarelli, Roman; Suarez, Adrian A.; Cohn, David E.; Selvendiran, Karuppaiyah			Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins	ONCOGENE			English	Article							INTERCELLULAR-COMMUNICATION; CARCINOMA CELLS; STEM-CELLS; METASTASIS; TRAFFICKING; PROGRESSION; EXPRESSION; CISPLATIN; PATHWAY; NICHE	Hypoxia-mediated tumor progression, metastasis, and drug resistance are major clinical challenges in ovarian cancer. Exosomes released in the hypoxic tumor microenvironment may contribute to these challenges by transferring signaling proteins between cancer cells and normal cells. We observed that ovarian cancer cells exposed to hypoxia significantly increased their exosome release by upregulating Rab27a, downregulating Rab7, LAMP1/2, NEU-1, and also by promoting a more secretory lysosomal phenotype. STAT3 knockdown in ovarian cancer cells reduced exosome release by altering the Rab family proteins Rab7 and Rab27a under hypoxic conditions. We also found that exosomes from patient-derived ascites ovarian cancer cell lines cultured under hypoxic conditions carried more potent oncogenic proteins-STAT3 and FAS that are capable of significantly increasing cell migration/invasion and chemo-resistance in vitro and tumor progression/metastasis in vivo. Hypoxic ovarian cancer cells derived exosomes (HEx) are proficient in re-programming the immortalized fallopian tube secretory epithelial cells (FT) to become pro-tumorigenic in mouse fallopian tubes. In addition, cisplatin efflux via exosomes was significantly increased in ovarian cancer cells under hypoxic conditions. Co-culture of HEx with tumor cells led to significantly decreased dsDNA damage and increased cell survival in response to cisplatin treatment. Blocking exosome release by known inhibitor Amiloride or STAT3 inhibitor and treating with cisplatin resulted in a significant increase in apoptosis, decreased colony formation, and proliferation. Our results demonstrate that HEx are more potent in augmenting metastasis/chemotherapy resistance in ovarian cancer and may serve as a novel mechanism for tumor metastasis, chemo-resistance, and a point of intervention for improving clinical outcomes.	[Dorayappan, Kalpana Deepa Priya; Wanner, Ross; Saini, Uksha; Zingarelli, Roman; Cohn, David E.; Selvendiran, Karuppaiyah] Ohio State Univ, Ctr Comprehens Canc, Wexner Med Ctr, Div Gynecol Oncol, Columbus, OH 43210 USA; [Wallbillich, John J.] Augusta Univ, Div Gynecol Oncol, Dept OB GYN, Georgia Canc Ctr, Augusta, GA USA; [Suarez, Adrian A.] Ohio State Univ, Ctr Comprehens Canc, Wexner Med Ctr, Dept Pathol,Gynecol Oncol, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Georgia; Augusta University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Selvendiran, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Wexner Med Ctr, Div Gynecol Oncol, Columbus, OH 43210 USA.	selvendiran.karuppaiyah@osumc.edu		Wallbillich, John/0000-0001-5913-8088	NIH [S10 OD018056]; National Cancer Institute, Bethesda, MD [P30 CA016058]; Ovarian Cancer Research Fund (OCRF); NCI [RO1-CA176078]; KOH ovarian cancer foundation; NATIONAL CANCER INSTITUTE [R01CA176078, P30CA016058] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD018056] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Bethesda, MD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund (OCRF); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); KOH ovarian cancer foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Zhang Liwen, PhD for proteomic analysis using Fusion Orbitrap instrument at OSU supported by NIH Award Number Grant S10 OD018056; Dr. Xiaokui Mo, Ph.D for analysis of Bioinformatics data; and Dr. Min Gao, Ph.D, Kent University for TEM analysis. Confocal images presented in this manuscript were generated using the services of the Campus Microscopy and Imaging Facility at OSU supported in part by grant P30 CA016058, National Cancer Institute, Bethesda, MD. We also thank Dr. John Olesik, Trace Element Research laboratory at OSU who helped us to quantify the Cisplatin concentration in exosomes by ICP-Mass Spectrometry; Dr. John Hays for his willingness to pre-review this manuscript and provide valuable comments and suggestions; Dr. Matthew Ringel, MD and his laboratory member Dr. Moto Saji for their invaluable help in exosome isolation protocols; and Brentley Smith, GYN/ONC fellow at OSU, Graduate students Dongju Park and Christopher Koivisto, Medical student Rashmi Madhukar, and Undergraduate student Maria Riley, for the IHC, cell culture, and basic assay help. This work was funded by Ovarian Cancer Research Fund (OCRF), NCI RO1-CA176078 grant (to KS and DEC) and KOH ovarian cancer foundation grant to KDPD.	[Anonymous], 2015, SEER STAT FACT SHEET; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Beach A, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-14; Chacko SM, 2010, AM J PHYSIOL-CELL PH, V299, pC1562, DOI 10.1152/ajpcell.00221.2010; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Dorayappan KDP, 2016, GYNECOL ONCOL, V141, P66; ElNaggar AC, 2016, CANCER BIOL THER, V17, P1107, DOI 10.1080/15384047.2016.1210733; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Gao M, 2014, MICROSC RES TECHNIQ, V77, P754, DOI 10.1002/jemt.22397; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Graves LE, 2004, CANCER RES, V64, P7045, DOI 10.1158/0008-5472.CAN-04-1800; Gupta S, 2007, AM J PHYSIOL-HEART C, V292, pH3052, DOI 10.1152/ajpheart.01355.2006; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Kanlikilicer P, 2016, CANCER RES, V76, P7194, DOI 10.1158/0008-5472.CAN-16-0714; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Kreuzaler PA, 2011, NAT CELL BIOL, V13, P303, DOI 10.1038/ncb2171; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734; Liang B, 2013, J PROTEOMICS, V80, P171, DOI 10.1016/j.jprot.2012.12.029; Lobb RJ, 2017, SEMIN CELL DEV BIOL, V67, P3, DOI 10.1016/j.semcdb.2017.01.004; McCann Georgia A, 2014, Oncoscience, V1, P216; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Rath KS, 2014, CANCER RES, V74, P2316, DOI 10.1158/0008-5472.CAN-13-2433; Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102; Safaei R, 2005, CLIN CANCER RES, V11, P756; Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197; Savina A, 2002, J CELL SCI, V115, P2505; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shender VO, 2014, MOL CELL PROTEOMICS, V13, P3558, DOI 10.1074/mcp.M114.041194; Su SA, 2017, ONCOTARGET, V8, P25700, DOI 10.18632/oncotarget.14878; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Vaksman O, 2014, CARCINOGENESIS, V35, P2113, DOI 10.1093/carcin/bgu130; Vanlandingham PA, 2009, J BIOL CHEM, V284, P12110, DOI 10.1074/jbc.M809277200; Wang T, 2014, P NATL ACAD SCI USA, V111, pE3234, DOI 10.1073/pnas.1410041111; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Yogalingam G, 2008, DEV CELL, V15, P74, DOI 10.1016/j.devcel.2008.05.005; Zhang HG, 2014, AM J PATHOL, V184, P28, DOI 10.1016/j.ajpath.2013.09.027; Zhang W, 2016, TUMOR BIOL, V37, P4213, DOI 10.1007/s13277-015-4105-8	46	144	152	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3806	3821		10.1038/s41388-018-0189-0	http://dx.doi.org/10.1038/s41388-018-0189-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29636548	Green Accepted			2022-12-17	WOS:000438465600004
J	Lu, MH; Tang, B; Zeng, S; Hu, CJ; Xie, R; Wu, YY; Wang, SM; He, FT; Yang, SM				Lu, M-H; Tang, B.; Zeng, S.; Hu, C-J; Xie, R.; Wu, Y-Y; Wang, S-M; He, F-T; Yang, S-M			Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer	ONCOGENE			English	Article							TELOMERASE ACTIVITY; CATALYTIC SUBUNIT; GENE-EXPRESSION; CELLS; MICRORNAS; DIFFERENTIATION; EVOLUTION; INVASION; GROWTH	Long noncoding RNAs (lncRNAs) are emerging as new players in gene regulation and are associated with the development of cancers. To investigate the important role and mechanism of lncRNAs in the progression of gastric cancer, we screened lncRNAs in gastric cancer tissues and corresponding adjacent tissues, and assessed the effects on gastric cancer. Here, we report that BC032469, a novel lncRNA, expressed highly in gastric cancer tissues, and the upregulation was clinically associated with larger tumor size, poor differentiation and shorter survival of gastric cancer patients. Downregulation of BC032469 resulted in a significant inhibition of proliferation in vitro and in vivo. Mechanistically, BC032469 could directly bind to miR-1207-5p and effectively functioned as a sponge for miR-1207-5p to modulate the derepression of hTERT. Thus, BC032469 may function as a ceRNA to impair miR-1207-5p-dependent hTERT downregulation, suggesting that it may be clinically valuable as a poor prognostic biomarker of gastric cancer.	[Lu, M-H; Tang, B.; Zeng, S.; Hu, C-J; Xie, R.; Wu, Y-Y; Wang, S-M; Yang, S-M] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Xinqiao St, Chongqing 400037, Peoples R China; [Lu, M-H] Luzhou Med Coll, Affiliated Hosp, Dept Gastroenterol, Luzhou, Peoples R China; [He, F-T] Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing, Peoples R China	Army Medical University; Southwest Medical University; Army Medical University	Yang, SM (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Xinqiao St, Chongqing 400037, Peoples R China.	shimingyang@yahoo.com			National Natural Science Foundation of China [81201950]; Luzhou Medical University [2014ZD-001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Luzhou Medical University	This study was supported by the National Natural Science Foundation of China (No. 81201950) and Luzhou Medical University Funding (No. 2014ZD-001). We thank Professor Xia Zhang for suggestions on the manuscript.	Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Berghoff EG, 2013, DEVELOPMENT, V140, P4407, DOI 10.1242/dev.099390; Boreiri M, 2013, ARCH IRAN MED, V16, P343, DOI 013166/AIM.007; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Cazalla D, 2010, SCIENCE, V328, P1563, DOI 10.1126/science.1187197; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.553; Didiano D, 2006, NAT STRUCT MOL BIOL, V13, P849, DOI 10.1038/nsmb1138; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Franco-Zorrilla JM, 2007, NAT GENET, V39, P1033, DOI 10.1038/ng2079; Hammell M, 2010, SEMIN CELL DEV BIOL, V21, P738, DOI 10.1016/j.semcdb.2010.01.004; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608; Lee DY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013599; Lu MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068972; Lu MH, 2012, EXP THER MED, V3, P728, DOI 10.3892/etm.2012.471; Lu SF, 2009, NUCLEIC ACIDS RES, V37, P1878, DOI 10.1093/nar/gkp031; Ma HR, 2014, INT J MOL MED, V33, P1627, DOI 10.3892/ijmm.2014.1722; Padberg I, 2013, INT J MED MICROBIOL, V303, P463, DOI 10.1016/j.ijmm.2013.06.001; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Ramachandran V, 2008, SCIENCE, V321, P1490, DOI 10.1126/science.1163728; Saldanha SN, 2003, ANAL BIOCHEM, V315, P1, DOI 10.1016/S0003-2697(02)00663-2; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Seitz H, 2009, CURR BIOL, V19, P870, DOI 10.1016/j.cub.2009.03.059; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Yadetie F, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-12; Yamaguchi A, 2012, J PLANT RES, V125, P693, DOI 10.1007/s10265-012-0513-7; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yang G, 2007, CARCINOGENESIS, V28, P174, DOI 10.1093/carcin/bgl115; Yu ST, 2012, CANCER-AM CANCER SOC, V118, P1884, DOI 10.1002/cncr.26476; Yu ST, 2009, INT J ONCOL, V35, P329, DOI 10.3892/ijo_00000344; Zhang S, 2013, BIOTECH HISTOCHEM, V88, P281, DOI 10.3109/10520295.2013.769633; Zhang Z, 2013, CELL DEATH DIFFER, V20, P1558, DOI 10.1038/cdd.2013.110	38	144	149	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3524	3534		10.1038/onc.2015.413	http://dx.doi.org/10.1038/onc.2015.413			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549025				2022-12-17	WOS:000379621500005
J	Morris, MR; Ricketts, CJ; Gentle, D; McRonald, F; Carli, N; Khalili, H; Brown, M; Kishida, T; Yao, M; Banks, RE; Clarke, N; Latif, F; Maher, ER				Morris, M. R.; Ricketts, C. J.; Gentle, D.; McRonald, F.; Carli, N.; Khalili, H.; Brown, M.; Kishida, T.; Yao, M.; Banks, R. E.; Clarke, N.; Latif, F.; Maher, E. R.			Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; methylation; epigenetics	CLEAR-CELL; PROMOTER HYPERMETHYLATION; DNA METHYLATION; ABERRANT METHYLATION; GLUTAMINYL CYCLASE; TARGETED THERAPIES; KIDNEY CANCER; EXPRESSION; DISEASE; ESOPHAGEAL	The detection of promoter region hypermethylation and transcriptional silencing has facilitated the identification of candidate renal cell carcinoma (RCC) tumour suppressor genes (TSGs). We have used a genome-wide strategy (methylated DNA immunoprecipitation (MeDIP) and whole-genome array analysis in combination with high-density expression array analysis) to identify genes that are frequently methylated and silenced in RCC. MeDIP analysis on 9 RCC tumours and 3 non-malignant normal kidney tissue samples was performed, and an initial short-list of 56 candidate genes that were methylated by array analysis was further investigated; 9 genes were confirmed to show frequent promoter region methylation in primary RCC tumour samples (KLHL35 (39%), QPCT (19%), SCUBE3 (19%), ZSCAN18 (32%), CCDC8 (35%), FBN2 (34%), ATP5G2 (36%), PCDH8 (58%) and CORO6 (22%)). RNAi knockdown for KLHL35, QPCT, SCUBE3, ZSCAN18, CCDC8 and FBN2 resulted in an anchorage-independent growth advantage. Tumour methylation of SCUBE3 was associated with a significantly increased risk of cancer death or relapse (P = 0.0046). The identification of candidate epigenetically inactivated RCC TSGs provides new insights into renal tumourigenesis. Oncogene (2011) 30, 1390-1401; doi:10.1038/onc.2010.525; published online 6 December 2010	[Maher, E. R.] Univ Birmingham, Inst Biomed Res W, Dept Med & Mol Genet, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Morris, M. R.; Ricketts, C. J.; Gentle, D.; McRonald, F.; Latif, F.; Maher, E. R.] Univ Birmingham, Canc Res UK Renal Mol Oncol Grp, Birmingham B15 2TT, W Midlands, England; [Morris, M. R.; Ricketts, C. J.; Gentle, D.; Latif, F.; Maher, E. R.] Univ Birmingham, Ctr Rare Dis & Personalised Med, Birmingham B15 2TT, W Midlands, England; [Brown, M.; Clarke, N.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England; [Kishida, T.; Yao, M.] Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan; [Banks, R. E.] St James Univ Hosp, Leeds Inst Mol Med, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England; [Maher, E. R.] Birmingham Womens Hosp, W Midlands Region Genet Serv, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; Paterson Institute for Cancer Research; University of Manchester; Yokohama City University; Cancer Research UK; Saint James's University Hospital; University of Leeds; Birmingham Women's Hospital	Maher, ER (corresponding author), Univ Birmingham, Inst Biomed Res W, Dept Med & Mol Genet, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	Ricketts, Christopher/AAV-9580-2020; Morris, Mark/C-6413-2008; Brown, Mick D/N-6521-2015; MAHER, EAMONN R/A-9507-2008; Brown, Mick/A-1308-2012	Brown, Mick D/0000-0003-1322-4671; MAHER, EAMONN R/0000-0002-6226-6918; Clarke, Noel/0000-0001-7776-8059; McRonald, Fiona/0000-0001-7226-9461; Banks, Rosamonde/0000-0002-0042-8715; Morris, Mark/0000-0002-0700-355X	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Cancer Research UK for financial support.	Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Battagli C, 2003, CANCER RES, V63, P8695; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Breault JE, 2005, CLIN CANCER RES, V11, P557; Chaudhry SS, 2007, J CELL BIOL, V176, P355, DOI 10.1083/jcb.200608167; Chen H, 2005, LUNG CANCER, V50, P43, DOI 10.1016/j.lungcan.2005.04.013; Chowdhury S, 2008, EUR J CANCER, V44, P2152, DOI 10.1016/j.ejca.2008.06.028; Christoph F, 2006, CLIN CANCER RES, V12, P5040, DOI 10.1158/1078-0432.CCR-06-0144; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Costa LJ, 2007, ONCOLOGIST, V12, P1404, DOI 10.1634/theoncologist.12-12-1404; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; DYER MR, 1993, BIOCHEM J, V293, P51, DOI 10.1042/bj2930051; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Grimmond S, 2000, GENOMICS, V70, P74, DOI 10.1006/geno.2000.6370; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hogg RP, 2002, EUR J CANCER, V38, P1585, DOI 10.1016/S0959-8049(01)00422-1; Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265; Huttemann M, 2008, J BIOENERG BIOMEMBR, V40, P445, DOI 10.1007/s10863-008-9169-3; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McRonald FE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-31; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Morrissey C, 2001, CANCER RES, V61, P7277; Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Pflug BR, 2007, CANCER LETT, V246, P139, DOI 10.1016/j.canlet.2006.02.007; POHL T, 1991, P NATL ACAD SCI USA, V88, P10059, DOI 10.1073/pnas.88.22.10059; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Roadcap David W., 2008, V48, P124, DOI 10.1007/978-0-387-09595-0_12; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; Sato N, 2003, CANCER RES, V63, P3735; Thouennon E, 2007, J CLIN ENDOCR METAB, V92, P4865, DOI 10.1210/jc.2007-1253; Tsunoda S, 2009, ONCOL REP, V21, P1067, DOI 10.3892/or_00000325; Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Yamada D, 2006, INT J CANCER, V118, P916, DOI 10.1002/ijc.21450; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	51	144	155	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	12					1390	1401		10.1038/onc.2010.525	http://dx.doi.org/10.1038/onc.2010.525			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21132003	Green Published			2022-12-17	WOS:000288743800002
J	Imam, JS; Buddavarapu, K; Lee-Chang, JS; Ganapathy, S; Camosy, C; Chen, Y; Rao, MK				Imam, J. S.; Buddavarapu, K.; Lee-Chang, J. S.; Ganapathy, S.; Camosy, C.; Chen, Y.; Rao, M. K.			MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers	ONCOGENE			English	Article						Cancer; Six1; microRNA; miR-185; tumor suppressor	HOMEOPROTEIN SIX1; GENE-EXPRESSION; OVEREXPRESSION; APOPTOSIS; RESISTANCE; MECHANISM; CARCINOMA; TRAIL; EZRIN	Homeobox genes encode transcription factors that are essential for normal development and are often dysregulated in cancers. The molecular mechanisms that cause their misregulation in cancers are largely unknown. In this study, we investigate the mechanism by which the Six1 homeobox protein, which has a crucial role during development, is frequently deregulated in several poor outcome, aggressive, metastatic adult human cancers, including breast cancer, ovarian cancer, hepatocellular carcinoma and pediatric malignancies such as rhabdomyosarcoma and Wilms' tumor. Our results reveal that miRNA-185 translationally represses Six1 by binding to its 3'-untranslated region. Analyses of ovarian cancers, pediatric renal tumors and multiple breast cancer cell lines showed decreased miR-185 expression, paralleling an increase in Six1 levels. Further investigation revealed that miR-185 impedes anchorage-independent growth and cell migration, in addition to suppressing tumor growth in vivo, implicating it to be a potent tumor suppressor. Our results indicate that miR-185 mediates its tumor suppressor function by regulating cell-cycle proteins and Six1 transcriptional targets c-myc and cyclin A1. Furthermore, we show that miR-185 sensitizes Six1-overexpressing resistant cancer cells to apoptosis in general and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in particular. Together, our findings suggest that the altered expression of the novel tumor suppressor miR-185 may be one of the central events that leads to dysregulation of oncogenic protein Six1 in human cancers. Oncogene (2010) 29, 4971-4979; doi: 10.1038/onc.2010.233; published online 5 July 2010	[Rao, M. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Ganapathy, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, San Antonio, TX 78229 USA; [Chen, Y.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Rao, MK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, Greehey Childrens Canc Res Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	RaoM@uthscsa.edu	Ganapathy, Suthakar/C-1266-2013	Ganapathy, Suthakar/0000-0003-3828-5382; Imam, J Saadi/0000-0003-3463-838X	San Antonio Area Foundation; GCCRI	San Antonio Area Foundation; GCCRI	We thank Jennifer Rebeles and Tiffany Jones for their assistance in flow cytometry and data analysis; Dr Yao-Fu-Chang for his suggestions in the preparation of this paper; Drs James Garbe and Martha Stampfer of Lawrence Berkeley National Laboratory for kindly providing us normal HMEC RNA samples; the Children's Oncology Group for providing Wilms' tumor and matched control kidney tissues; Dr Russell Broaddus and Ovarian Cancer Translational Research Tumor Bank, MD Anderson Cancer Center for normal and ovarian cancer tissues; and Dr Padmanabhan Swami, UT Health Science Center, San Antonio for recombinant human TRAIL. Financial support: This work was supported by San Antonio Area Foundation Grant (JSI and MKR) and GCCRI startup fund (MKR).	Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Grifone R, 2005, DEVELOPMENT, V132, P2235, DOI 10.1242/dev.01773; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Ozaki H, 2004, DEVELOPMENT, V131, P551, DOI 10.1242/dev.00943; Radisky DC, 2009, J CLIN INVEST, V119, P2528, DOI 10.1172/JCI40555; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75; Shen C, 2008, BIOLOGICALS, V36, P263, DOI 10.1016/j.biologicals.2008.02.002; Shin MS, 2001, CANCER RES, V61, P4942; Vasilatou D, 2010, EUR J HAEMATOL, V84, P1, DOI 10.1111/j.1600-0609.2009.01348.x; Wan F, 2008, INT J CANCER, V123, P32, DOI 10.1002/ijc.23463; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zheng WM, 2003, DEVELOPMENT, V130, P3989, DOI 10.1242/dev.00628	25	144	158	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4971	4979		10.1038/onc.2010.233	http://dx.doi.org/10.1038/onc.2010.233			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20603620				2022-12-17	WOS:000281578700011
J	Pommier, AJC; Alves, G; Viennois, E; Bernard, S; Communal, Y; Sion, B; Marceau, G; Damon, C; Mouzat, K; Caira, F; Baron, S; Lobaccaro, JMA				Pommier, A. J. C.; Alves, G.; Viennois, E.; Bernard, S.; Communal, Y.; Sion, B.; Marceau, G.; Damon, C.; Mouzat, K.; Caira, F.; Baron, S.; Lobaccaro, J. M. A.			Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells	ONCOGENE			English	Article						LXRs; cholesterol; lipid rafts; apoptosis; prostate	FATTY-ACID SYNTHASE; AKT/PROTEIN KINASE-B; TUMOR-GROWTH; NUCLEAR RECEPTORS; PLASMA-MEMBRANE; ATHYMIC MICE; CHOLESTEROL; INHIBITION; PROLIFERATION; EXPRESSION	Cholesterol is a structural component of lipid rafts within the plasma membrane. These domains, used as platforms for various signaling molecules, regulate cellular processes including cell survival. Cholesterol contents are tightly correlated with the structure and function of lipid rafts. Liver X receptors (LXRs) have a central role in the regulation of cholesterol homeostasis within the cell. Therefore, we investigated whether these nuclear receptors could modulate lipid raft signaling and consequently alter prostate cancer (PCa) cell survival. Treatment with the synthetic LXR agonist T0901317 downregulated the AKT survival pathway and thus induced apoptosis of LNCaP PCa cells in both xenografted nude mice and cell culture. The decrease in tumor cholesterol content resulted from the upregulation of ABCG1 and the subsequent increase in reverse cholesterol transport. RNA interference experiments showed that these effects were mediated by LXRs. Atomic force microscopy scanning of the inner plasma membrane sheet showed smaller and thinner lipid rafts after LXR stimulation, associated with the downregulation of AKT phosphorylation in these lipid rafts. Replenishment of cell membranes with exogenous cholesterol antagonized these effects, showing that cholesterol is a key modulator in this process. Altogether, pharmacological modulation of LXR activity could thus reduce prostate tumor growth by enhancing apoptosis in a lipid raft-dependent manner. Oncogene (2010) 29, 2712-2723; doi:10.1038/onc.2010.30; published online 1 March 2010	[Lobaccaro, J. M. A.] Clermont Univ, CNRS, GReD, UMR 6247, F-63177 Aubiere, France; [Pommier, A. J. C.; Alves, G.; Viennois, E.; Damon, C.; Caira, F.; Baron, S.; Lobaccaro, J. M. A.] Univ Clermont Ferrand, Clermont Univ, Clermont Ferrand, France; [Pommier, A. J. C.; Alves, G.; Viennois, E.; Caira, F.; Baron, S.; Lobaccaro, J. M. A.] Ctr Rech Nutr Humaine Auvergne, Clermont Ferrand, France; [Bernard, S.] Univ Paris 05, CNRS, UPR 2228, Paris, France; [Communal, Y.] Ctr Jean Perrin, Dept Oncogenet, Clermont Ferrand, France; [Sion, B.] Univ Auvergne, Equipe Accueil EA975, Clermont Ferrand, France; [Marceau, G.] Univ Auvergne, Clermont Univ, Clermont Ferrand, France; [Marceau, G.] Ctr Hosp Univ, Serv Biochim, Clermont Ferrand, France; [Mouzat, K.] Ctr Hosp Univ, Serv Biochim, Nimes, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); Universite Clermont Auvergne (UCA); CHU Clermont Ferrand; Universite de Montpellier; CHU de Nimes	Lobaccaro, JMA (corresponding author), Clermont Univ, CNRS, GReD, UMR 6247, Campus Cezeaux,24 Ave Landais, F-63177 Aubiere, France.	j-marc.lobaccaro@univ-bpclermont.fr	Sion, Benoit/K-2268-2015; LOBACCARO, Jean-Marc/L-6151-2015; Lobaccaro, Jean-Marc/Q-3926-2019	Lobaccaro, Jean-Marc/0000-0001-9890-2392; Viennois, Emilie/0000-0002-3104-620X; MARCEAU, GEOFFROY/0000-0003-4713-7162	Association de Recherche sur les Tumeurs Prostatiques; Ligue Allier contre le Cancer; FRM; Fondation BNP-Paribas; MNERT and Region Auvergne; Region Auvergne	Association de Recherche sur les Tumeurs Prostatiques; Ligue Allier contre le Cancer; FRM(Fondation pour la Recherche Medicale); Fondation BNP-Paribas; MNERT and Region Auvergne(Region Auvergne-Rhone-Alpes); Region Auvergne(Region Auvergne-Rhone-Alpes)	This study was supported by Association de Recherche sur les Tumeurs Prostatiques, Ligue Allier contre le Cancer, FRM and Fondation BNP-Paribas research grants. A Pommier and E Viennois are funded by MNERT and Region Auvergne grants, respectively, and G Alves is funded by Region Auvergne program. We are grateful to ICCF-Imagerie Confocale Clermont-Ferrand-for the help in confocal analyses. We thank JP Saru and A De Haze for molecular biology technical assistance, and C Puchol and S Plantade for animal facilities. We also thank Dr P Val, Dr A Martinez, Dr L Morel and Dr C White for their help in the editing of the paper and for fruitful scientific discussions.	Adam RM, 2007, CANCER RES, V67, P6238, DOI 10.1158/0008-5472.CAN-07-0288; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Beckers A, 2007, CANCER RES, V67, P8180, DOI 10.1158/0008-5472.CAN-07-0389; Bravi F, 2006, ANN ONCOL, V17, P1014, DOI 10.1093/annonc/mdl080; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Brusselmans K, 2007, J BIOL CHEM, V282, P18777, DOI 10.1074/jbc.M611763200; Carson JP, 1999, CANCER RES, V59, P1449; Choe SS, 2007, DIABETES, V56, P1534, DOI 10.2337/db06-1059; Chuu CP, 2006, CANCER RES, V66, P6482, DOI 10.1158/0008-5472.CAN-06-0632; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; Dwyer JR, 2007, J BIOL CHEM, V282, P8959, DOI 10.1074/jbc.M611741200; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Frankel DJ, 2006, BIOPHYS J, V90, P2404, DOI 10.1529/biophysj.105.073692; Freeman MR, 2004, J CELL BIOCHEM, V91, P54, DOI 10.1002/jcb.10724; Fukuchi J, 2004, CANCER RES, V64, P7682, DOI 10.1158/0008-5472.CAN-04-2647; Fukuchi J, 2004, CANCER RES, V64, P7686, DOI 10.1158/0008-5472.CAN-04-2332; Grizard G, 2000, J CHROMATOGR B, V740, P101, DOI 10.1016/S0378-4347(00)00039-6; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; Kim HJ, 2009, P NATL ACAD SCI USA, V106, P558, DOI 10.1073/pnas.0811295106; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Lawrence JC, 2003, BIOPHYS J, V84, P1827, DOI 10.1016/S0006-3495(03)74990-X; Li YC, 2006, AM J PATHOL, V168, P1107, DOI 10.2353/ajpath.2006.050959; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Magura L, 2008, CANCER CAUSE CONTROL, V19, P1259, DOI 10.1007/s10552-008-9197-7; Meng ZX, 2009, DIABETOLOGIA, V52, P125, DOI 10.1007/s00125-008-1174-x; Mo HB, 2004, EXP BIOL MED, V229, P567, DOI 10.1177/153537020422900701; Mouzat K, 2009, ENDOCRINOLOGY, V150, P3369, DOI 10.1210/en.2008-1519; Murtola TJ, 2008, NAT CLIN PRACT UROL, V5, P376, DOI 10.1038/ncpuro1146; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Rossi S, 2003, MOL CANCER RES, V1, P707; Rusinol AE, 2004, J BIOL CHEM, V279, P1392, DOI 10.1074/jbc.M308619200; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sekine Y, 2008, BIOCHEM BIOPH RES CO, V372, P356, DOI 10.1016/j.bbrc.2008.05.043; Shannon J, 2005, AM J EPIDEMIOL, V162, P318, DOI 10.1093/aje/kwi203; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Swyer GIM, 1942, CANCER RES, V2, P372; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; Volle DH, 2007, MOL CELL ENDOCRINOL, V265, P183, DOI 10.1016/j.mce.2006.12.018; Walczak R, 2004, J BIOL CHEM, V279, P9905, DOI 10.1074/jbc.M310587200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; White CP, 1909, J PATHOL BACTERIOL, V13, P3, DOI 10.1002/path.1700130103; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang L, 2000, BIOCHEM BIOPH RES CO, V278, P557, DOI 10.1006/bbrc.2000.3855; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zhuang LY, 2005, J CLIN INVEST, V115, P959	52	144	153	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2712	2723		10.1038/onc.2010.30	http://dx.doi.org/10.1038/onc.2010.30			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190811				2022-12-17	WOS:000277354600011
J	Piccirillo, SGM; Combi, R; Cajola, L; Patrizi, A; Redaelli, S; Bentivegna, A; Baronchelli, S; Maira, G; Pollo, B; Mangiola, A; DiMeco, F; Dalpra, L; Vescovi, AL				Piccirillo, S. G. M.; Combi, R.; Cajola, L.; Patrizi, A.; Redaelli, S.; Bentivegna, A.; Baronchelli, S.; Maira, G.; Pollo, B.; Mangiola, A.; DiMeco, F.; Dalpra, L.; Vescovi, A. L.			Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution	ONCOGENE			English	Article						brain tumours; cancer stem-like cells; tumorigenicity	IDENTIFICATION	Glioblastomas (GBMs) contain transformed, self-maintaining, multipotent, tumour-initiating cancer stem cells, whose identification has radically changed our perspective on the physiology of these tumours. Currently, it is unknown whether multiple types of transformed precursors, which display alternative sets of the complement of properties of true cancer stem cells, can be found in a GBM. If different subsets of such cancer stem-like cells (CSCs) do exist, they might represent distinct cell targets, with a differential therapeutic importance, also depending on their characteristics and lineage relationship. Here, we report the presence of two types of CSCs within different regions of the same human GBM. Cytogenetic and molecular analysis shows that the two types of CSCs bear quite diverse tumorigenic potential and distinct genetic anomalies, and, yet, derive from common ancestor cells. This provides critical information to unravel the development of CSCs and the key molecular/genetic components underpinning tumorigenicity in human GBMs.	[Patrizi, A.; Redaelli, S.; Bentivegna, A.; Baronchelli, S.; Dalpra, L.] Univ Milano Bicocca, Dept Neurosci & Biomed Technol, I-20052 Monza, Mi, Italy; [Piccirillo, S. G. M.; Combi, R.; Vescovi, A. L.] Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; [Piccirillo, S. G. M.; Cajola, L.; Vescovi, A. L.] Univ Milano Bicocca, Unit Canc Stem Cell Biol, I-20126 Milan, Italy; [Maira, G.; Mangiola, A.] Univ Cattolica Sacro Cuore, Dept Neurol Sci, Inst Neurosurg, I-00168 Rome, Italy; [Pollo, B.; DiMeco, F.] Natl Neurol Inst C Besta, Dept Neurosurg, Milan, Italy; [Pollo, B.; DiMeco, F.] Johns Hopkins Med Sch, Dept Neurol Surg, Baltimore, MD USA	University of Milano-Bicocca; University of Milano-Bicocca; University of Milano-Bicocca; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Istituto Neurologico Besta; Johns Hopkins University; Johns Hopkins Medicine	Dalpra, L (corresponding author), Univ Milano Bicocca, Dept Neurosci & Biomed Technol, I-20052 Monza, Mi, Italy.	leda.dalpra@unimib.it; vescovi@tin.it	Combi, Romina/AAC-2944-2020; DiMeco, Francesco/Z-5431-2019; Bentivegna, Angela/J-3478-2018; Vescovi, Angelo Luigi/A-4919-2015; Baronchelli, Simona/G-6771-2016; Pollo, Bianca/K-5347-2018; DiMeco, Francesco/Q-3785-2016	Combi, Romina/0000-0003-1742-6078; Bentivegna, Angela/0000-0001-7535-846X; Vescovi, Angelo Luigi/0000-0002-1742-4112; Baronchelli, Simona/0000-0002-1857-1472; Pollo, Bianca/0000-0002-5523-4256; DiMeco, Francesco/0000-0001-6213-5793; Piccirillo, Sara Grazia Maria/0000-0003-4109-1992	'Associazione Italiana per la Ricerca Sul Cancro' AIRC, Italy; Brain Tumor Funders Collaborative Initiative, USA	'Associazione Italiana per la Ricerca Sul Cancro' AIRC, Italy(Fondazione AIRC per la ricerca sul cancro); Brain Tumor Funders Collaborative Initiative, USA	This work was supported by grants of the 'Associazione Italiana per la Ricerca Sul Cancro' AIRC, Italy and the Brain Tumor Funders Collaborative Initiative, USA.	Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Piccirillo SGM, 2007, EXPERT OPIN BIOL TH, V7, P1129, DOI 10.1517/14712598.7.8.1129; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Trent S, 2002, J NEURO-ONCOL, V57, P247, DOI 10.1023/A:1015788814667; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130	14	144	150	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1807	1811		10.1038/onc.2009.27	http://dx.doi.org/10.1038/onc.2009.27			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19287454	Bronze			2022-12-17	WOS:000265640400007
J	Hui, L; Zheng, Y; Yan, Y; Bargonetti, J; Foster, DA				Hui, L.; Zheng, Y.; Yan, Y.; Bargonetti, J.; Foster, D. A.			Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D	ONCOGENE			English	Article						phospholipase D; p53; survival signals; apoptosis; breast cancer	GAIN-OF-FUNCTION; TUMOR-SUPPRESSOR GENE; WILD-TYPE; FUNCTION MUTATIONS; EXPRESSION; BINDING; MDM2; TRANSFORMATION; ACTIVATION; RESISTANCE	p53 is the most commonly mutated gene in human cancer. Although the loss of tumor suppressor functions for p53 in tumorigenesis is well characterized, gain-of-function p53 mutations observed in most cancers are not as widely appreciated. The human breast cancer cell line MDA-MB-231, which has high levels of a mutant p53, has high levels of phospholipase D (PLD) activity, which provides a survival signal in these cells when deprived of serum growth factors. We report here that the mutant p53 in MDA-MB-231 cells is stabilized by the elevated PLD activity in these cells. Surprisingly, the survival of MDA-MB-231 cells deprived of serum was dependent on the mutant p53. These data indicate that a mutant p53, stabilized by elevated PLD activity, can contribute to the suppression of apoptosis in a human breast cancer cell line and suggest a rationale for the selection of p53 mutations early in tumorigenesis to suppress apoptosis in an emerging tumor.	CUNY, Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY, Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu		Bargonetti, Jill/0000-0003-2692-0991	NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asher G, 2003, P NATL ACAD SCI USA, V100, P15065, DOI 10.1073/pnas.2436329100; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; FOSTER DA, 2006, IN PRESS CURR SIGNAL, V1; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HSIAO M, 1994, AM J PATHOL, V145, P702; Hui L, 2005, J BIOL CHEM, V280, P35829, DOI 10.1074/jbc.M504192200; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Irwin MS, 2004, CELL CYCLE, V3, P319; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Katayose D, 1995, CLIN CANCER RES, V1, P889; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Moll UM, 2003, MOL CANCER RES, V1, P1001; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Strano S, 2003, CELL CYCLE, V2, P348, DOI 10.4161/cc.2.4.426; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	44	144	148	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7305	7310		10.1038/sj.onc.1209735	http://dx.doi.org/10.1038/sj.onc.1209735			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16785993				2022-12-17	WOS:000242244700009
J	Hein, DW				Hein, DW			N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk	ONCOGENE			English	Review						N-acetyltransferase 2; urinary bladder cancer; aromatic amines; NAT2 acetylator genotype; singlenucleotide polymorphisms; NAT2 haplotypes	ARYLAMINE N-ACETYLTRANSFERASE; GLUTATHIONE-S-TRANSFERASE; SLOW ACETYLATOR PHENOTYPE; METABOLIC-ACTIVATION; AROMATIC-AMINES; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-GENETICS; HUMAN LIVER; CHROMOSOMAL LOCALIZATION; KINETIC CHARACTERIZATION	A role for the N-acetyltransferase 2 (NAT2) genetic polymorphism in cancer risk has been the subject of numerous studies. Although comprehensive reviews of the NAT2 acetylation polymorphism have been published elsewhere, the objective of this paper is to briefly highlight some important features of the NAT2 acetylation polymorphism that are not universally accepted to better understand the role of NAT2 polymorphism in carcinogenic risk assessment. NAT2 slow acetylator phenotype(s) infer a consistent and robust increase in urinary bladder cancer risk following exposures to aromatic amine carcinogens. However, identification of specific carcinogens is important as the effect of NAT2 polymorphism on urinary bladder cancer differs dramatically between monoarylamines and diarylamines. Misclassifications of carcinogen exposure and NAT2 genotype/phenotype confound evidence for a real biological effect. Functional understanding of the effects of NAT2 genetic polymorphisms on metabolism and genotoxicity, tissue-specific expression and the elucidation of the molecular mechanisms responsible are critical for the interpretation of previous and future human molecular epidemiology investigations into the role of NAT2 polymorphism on cancer risk. Although associations have been reported for various cancers, this paper focuses on urinary bladder cancer, a cancer in which a role for NAT2 polymorphism was first proposed and for which evidence is accumulating that the effect is biologically significant with important public health implications.	Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, James Graham Brown Canc Ctr, Louisville, KY 40292 USA	University of Louisville; University of Louisville	Hein, DW (corresponding author), Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA.	d.hein@louisville.edu	Garcia-Closas, Montserrat/AAZ-6930-2021; Hein, David W/A-9707-2008	Garcia-Closas, Montserrat/0000-0003-1033-2650; Hein, David/0000-0003-3261-9775	NATIONAL CANCER INSTITUTE [R01CA034627] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA34627, R01 CA034627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1993, BIOCHEM BIOPH RES CO, V191, P811, DOI 10.1006/bbrc.1993.1289; Agundez JAG, 1996, PHARMACOGENETICS, V6, P465; Airoldi L, 2002, CARCINOGENESIS, V23, P861, DOI 10.1093/carcin/23.5.861; Anitha A, 2003, INT J MOL MED, V11, P125; BADAWI AF, 1995, CANCER RES, V55, P5230; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; BLUM M, 1989, P NATL ACAD SCI USA, V86, P9554, DOI 10.1073/pnas.86.23.9554; Bolt HM, 2005, ARCH TOXICOL, V79, P196, DOI 10.1007/s00204-004-0622-8; Boukouvala S, 2005, BASIC CLIN PHARMACOL, V96, P343, DOI 10.1111/j.1742-7843.2005.pto_02.x; Brockmoller J, 1996, CANCER RES, V56, P3915; Carreon T, 2006, INT J CANCER, V118, P161, DOI 10.1002/ijc.21308; CARTWRIGHT RA, 1982, LANCET, V2, P842; Cascorbi I, 1999, PHARMACOGENETICS, V9, P123, DOI 10.1097/00008571-199902000-00016; Cascorbi I, 1999, DRUG METAB REV, V31, P489, DOI 10.1081/DMR-100101932; CASCORBI I, 1995, AM J HUM GENET, V57, P581; Cascorbi I, 1996, PHARMACOGENETICS, V6, P257, DOI 10.1097/00008571-199606000-00009; CHAPRON DJ, 1980, CLIN PHARMACOL THER, V27, P104, DOI 10.1038/clpt.1980.16; CHUNG JG, 1993, DRUG METAB DISPOS, V21, P1057; CRIBB AE, 1994, PHARMACOGENETICS, V4, P166, DOI 10.1097/00008571-199406000-00009; DEGUCHI T, 1990, J BIOL CHEM, V265, P12757; DEGUCHI T, 1992, J BIOL CHEM, V267, P18140; Deitz AC, 2004, CANCER EPIDEM BIOMAR, V13, P1543; Deitz AC, 2000, CANCER EPIDEM BIOMAR, V9, P905; Delomenie C, 1996, PHARMACOGENETICS, V6, P177, DOI 10.1097/00008571-199604000-00004; Dewan A., 1995, Indian Journal of Cancer, V32, P15; DOLL MA, 1995, PHARMACOGENETICS, V5, P247, DOI 10.1097/00008571-199508000-00009; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; Dupret JM, 2005, CURR MED CHEM, V12, P311, DOI 10.2174/0929867053363289; EBISAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P1252, DOI 10.1016/0006-291X(91)90676-X; El Desoky ES, 2005, THER DRUG MONIT, V27, P297, DOI 10.1097/01.ftd.0000164197.95494.aa; FERGUSON RJ, 1994, DRUG METAB DISPOS, V22, P371; Ferguson RJ, 1996, PHARMACOGENETICS, V6, P55, DOI 10.1097/00008571-199602000-00004; Filiadis IF, 1999, J UROLOGY, V161, P1672, DOI 10.1016/S0022-5347(05)69002-7; FREDERICKSON SM, 1992, CARCINOGENESIS, V13, P955, DOI 10.1093/carcin/13.6.955; FREDERICKSON SM, 1994, CANCER EPIDEM BIOMAR, V3, P25; Fretland AJ, 2001, PHARMACOGENETICS, V11, P511, DOI 10.1097/00008571-200108000-00006; Gago-Dominguez M, 2003, CARCINOGENESIS, V24, P483, DOI 10.1093/carcin/24.3.483; Garcia-Closas M, 2005, LANCET, V366, P649, DOI 10.1016/S0140-6736(05)67137-1; Giannakopoulos X, 2002, ANTICANCER RES, V22, P3801; Golka K, 2002, TOXICOL LETT, V128, P229, DOI 10.1016/S0378-4274(01)00544-6; GRANT DM, 1990, J CLIN INVEST, V85, P968, DOI 10.1172/JCI114527; Grant DM, 2004, BRIT J CLIN PHARMACO, V58, pS788, DOI 10.1111/j.1365-2125.2004.02297.x; Grant DM, 1997, MUTAT RES-FUND MOL M, V376, P61, DOI 10.1016/S0027-5107(97)00026-2; Green J, 2000, BRIT J CANCER, V83, P412, DOI 10.1054/bjoc.2000.1265; Gross M, 1999, CANCER EPIDEM BIOMAR, V8, P683; Gu J, 2005, MUTAT RES-GEN TOX EN, V581, P97, DOI 10.1016/j.mrgentox.2004.11.012; HANSSEN HP, 1985, EUR UROL, V11, P263; Hao Gang-yue, 2004, Zhonghua Zhongliu Zazhi, V26, P283; HAYES RB, 1993, CARCINOGENESIS, V14, P675, DOI 10.1093/carcin/14.4.675; HEARSE DJ, 1973, BIOCHEM J, V132, P519, DOI 10.1042/bj1320519; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; HEIN DW, 1994, HUM MOL GENET, V3, P729; HEIN DW, 1995, CANCER RES, V55, P3531; HEIN DW, 1993, CARCINOGENESIS, V14, P1633, DOI 10.1093/carcin/14.8.1633; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; HEIN DW, 1991, J PHARMACOL EXP THER, V259, P699; HEIN DW, 1991, DRUG METAB DISPOS, V19, P933; Hein DW, 1997, MUTAT RES-FUND MOL M, V376, P101, DOI 10.1016/S0027-5107(97)00031-6; HEIN DW, 1993, CANCER RES, V53, P509; Hein DW, 2003, PHARMACOGENETICS, V13, P159, DOI 10.1097/00008571-200303000-00005; HEIN DW, 1988, DRUG METAB DISPOS, V16, P341; HEIN DW, 1988, BIOCHIM BIOPHYS ACTA, V948, P37, DOI 10.1016/0304-419X(88)90004-2; HEIN DW, 1985, J PHARMACOL EXP THER, V234, P358; HEIN DW, 1994, TOXICOL APPL PHARM, V124, P16, DOI 10.1006/taap.1994.1003; HEIN DW, 2006, IN PRESS MOL CARCINO; HICKMAN D, 1995, BIOCHEM PHARMACOL, V50, P697, DOI 10.1016/0006-2952(95)00182-Y; HICKMAN D, 1994, BIOCHEM J, V297, P441, DOI 10.1042/bj2970441; Hickman D, 1998, GUT, V42, P402, DOI 10.1136/gut.42.3.402; HORAI Y, 1989, EUR J CLIN PHARMACOL, V37, P581; Hsieh FI, 1999, BRIT J CANCER, V81, P537, DOI 10.1038/sj.bjc.6690727; HUGHES HB, 1954, AM REV TUBERC PULM, V70, P266; Hung RJ, 2004, INT J CANCER, V110, P598, DOI 10.1002/ijc.20157; ILETT KF, 1991, CARCINOGENESIS, V12, P1465, DOI 10.1093/carcin/12.8.1465; ILETT KF, 1994, BIOCHEM PHARMACOL, V47, P914, DOI 10.1016/0006-2952(94)90493-6; Ishizu S, 1995, JPN J CANCER RES, V86, P1179, DOI 10.1111/j.1349-7006.1995.tb03312.x; Jaskula-Sztul Renata, 2001, Journal of Applied Genetics, V42, P223; JENNE JW, 1965, J CLIN INVEST, V44, P1992, DOI 10.1172/JCI105306; KAISARY A, 1987, CANCER RES, V47, P5488; KARAKAYA AE, 1986, HUM TOXICOL, V5, P333, DOI 10.1177/096032718600500507; Kim WJ, 2000, J UROLOGY, V164, P209, DOI 10.1016/S0022-5347(05)67496-4; KIRLIN WG, 1991, CANCER RES, V51, P549; KIRLIN WG, 1989, CANCER RES, V49, P2448; LADERO JM, 1985, ANN CLIN RES, V17, P96; Lan Q, 2003, CANCER EPIDEM BIOMAR, V12, P384; LEE EJD, 1982, BRIT J CLIN PHARMACO, V13, P375, DOI 10.1111/j.1365-2125.1982.tb01388.x; Lee SY, 2002, CLIN CHEM, V48, P775; Leff MA, 1999, J BIOL CHEM, V274, P34519, DOI 10.1074/jbc.274.49.34519; Loktionov A, 2002, CANCER DETECT PREV, V26, P15, DOI 10.1016/S0361-090X(02)00010-7; LORENZO B, 1989, BRIT J CLIN PHARMACO, V28, P207, DOI 10.1111/j.1365-2125.1989.tb05420.x; LOWER GM, 1979, ENVIRON HEALTH PERSP, V29, P71, DOI 10.2307/3429048; LUCERI F, 1993, TOXICOL IND HEALTH, V9, P405, DOI 10.1177/074823379300900302; Ma QW, 2004, BIOMED ENVIRON SCI, V17, P291; MARTELL KJ, 1991, MOL PHARMACOL, V40, P218; Matas N, 1997, CYTOGENET CELL GENET, V77, P290, DOI 10.1159/000134601; MILLER ME, 1983, J UROLOGY, V130, P65, DOI 10.1016/S0022-5347(17)50956-8; MINCHIN RF, 1992, BIOCHEM BIOPH RES CO, V185, P839, DOI 10.1016/0006-291X(92)91703-S; Mittal Rama D., 2004, Int. braz j urol., V30, P279, DOI 10.1590/S1677-55382004000400003; MITTAL RD, 2004, INT BRAZ J UROL, V30, P285, DOI DOI 10.1590/S1677-55382004000400003; MOMMSEN S, 1985, SCAND J UROL NEPHROL, V19, P203, DOI 10.3109/00365598509180254; NAGATA K, 1994, PHARMACOGENETICS, V4, P91, DOI 10.1097/00008571-199404000-00006; O'Neil WM, 2000, PHARMACOGENETICS, V10, P171, DOI 10.1097/00008571-200003000-00009; Okkels H, 1997, CANCER EPIDEM BIOMAR, V6, P225; OZAWA S, 1990, CARCINOGENESIS, V11, P2137, DOI 10.1093/carcin/11.12.2137; PACIFICI GM, 1986, PHARMACOLOGY, V32, P283; Palmiotto G, 2001, CHEMOSPHERE, V43, P355, DOI 10.1016/S0045-6535(00)00109-0; Parkin DP, 1997, AM J RESP CRIT CARE, V155, P1717, DOI 10.1164/ajrccm.155.5.9154882; Peluso M, 1998, CANCER EPIDEM BIOMAR, V7, P341; PINK JC, 1992, DRUG METAB DISPOS, V20, P559; Probst-Hensch NM, 2000, CANCER EPIDEM BIOMAR, V9, P619; Reilly TP, 2000, J INVEST DERMATOL, V114, P1164, DOI 10.1046/j.1523-1747.2000.00985.x; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V291, P116, DOI 10.1006/bbrc.2002.6414; Rodrigues-Lima F, 2001, BIOCHEM J, V356, P327, DOI 10.1042/0264-6021:3560327; ROTHMAN N, 1993, CANCER EPIDEM BIOMAR, V2, P299; Rothman N, 1996, P NATL ACAD SCI USA, V93, P5084, DOI 10.1073/pnas.93.10.5084; Sandy J, 2002, J MOL BIOL, V318, P1071, DOI 10.1016/S0022-2836(02)00141-9; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Smith CAD, 1997, J MED GENET, V34, P758, DOI 10.1136/jmg.34.9.758; SMITH TJ, 1986, CARCINOGENESIS, V7, P697, DOI 10.1093/carcin/7.5.697; Stabbert R, 2003, RAPID COMMUN MASS SP, V17, P2125, DOI 10.1002/rcm.1161; Stanley LA, 1997, PHARMACOGENETICS, V7, P121, DOI 10.1097/00008571-199704000-00005; Su HJ, 1998, PHARMACOGENETICS, V8, P187, DOI 10.1097/00008571-199804000-00011; Sugamori KS, 2003, MOL PHARMACOL, V64, P170, DOI 10.1124/mol.64.1.170; Svensson CK, 2005, METHOD PHARMACOL TOX, P173; Taylor JA, 1998, CANCER RES, V58, P3603; TRINIDAD A, 1989, DRUG METAB DISPOS, V17, P238; Tsukino H, 2004, EUR J CANCER PREV, V13, P509, DOI 10.1097/00008469-200412000-00008; TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839; van der Hel OL, 2003, PHARMACOGENETICS, V13, P399, DOI 10.1097/00008571-200307000-00005; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; Vineis P, 2004, INT J CANCER, V108, P2, DOI 10.1002/ijc.11467; Vineis P, 2001, CANCER EPIDEM BIOMAR, V10, P1249; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WEBER WW, 1985, PHARMACOL REV, V37, P25; Windmill KF, 2000, TOXICOL SCI, V54, P19, DOI 10.1093/toxsci/54.1.19; WOODHOUSE KW, 1982, HUM TOXICOL, V1, P443, DOI 10.1177/096032718200100411; YEROKUN T, 1989, DRUG METAB DISPOS, V17, P231; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712; Zang Y, 2004, PHARMACOGENETICS, V14, P717, DOI 10.1097/00008571-200411000-00002; ZANG Y, 2005, P AM ASS CANC RES, V46; ZHANG X, 2006, IN PRESS J PHARM EXP, V316	143	144	148	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1649	1658		10.1038/sj.onc.1209374	http://dx.doi.org/10.1038/sj.onc.1209374			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550165	Green Accepted			2022-12-17	WOS:000235904700007
J	Ren, B; Yu, G; Tseng, GC; Cieply, K; Gavel, T; Michalopoulos, G; Yu, YP; Luo, JH				Ren, B; Yu, G; Tseng, GC; Cieply, K; Gavel, T; Michalopoulos, G; Yu, YP; Luo, JH			MCM7 amplification and overexpression are associated with prostate cancer progression	ONCOGENE			English	Article						MCM7; metastasis; prostate cancer; amplification	COMPARATIVE GENOMIC HYBRIDIZATION; MINICHROMOSOME-MAINTENANCE PROTEIN-7; DNA-REPLICATION; TUMOR-GROWTH; S-PHASE; COMPLEX; EXPRESSION; IDENTIFICATION; LOCALIZATION; MICROARRAYS	The genomic DNA profiles of prostate cancers with aggressive features were compared to the profiles of matched normal DNA to identify genes that are selectively amplified in the cancer cells. One of the identified genes, MCM7, which is a component of the DNA replication licensing complex, has been studied extensively both at the DNA and protein levels in human prostate tissues. Approximately half of the prostate cancer specimens studied showed MCM7 gene amplification, and 60% of the aggressive prostate cancer specimens had increased MCM7 protein expression. Amplification or overexpression of MCM7 was significantly associated with relapse, local invasion and a worse tumor grade. Constitutive expression of MCM7 in a human prostate cancer cell line, DU145, resulted in markedly increased DNA synthesis and cell proliferation compared to vector-only controls, and an increased cell invasion in vitro. Indeed, MCM7 overexpression produced primary tumors 12 times larger than vector-only controls and resulted in a rapid demise of mice bearing those tumors. These studies implicate MCM7, and the DNA replication licensing gene family, in prostate cancer progression, growth and invasion.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Luo, JH (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Scaife Hall A-725,3550 Terrace St, Pittsburgh, PA 15261 USA.	luoj@msx.upmc.edu	Yu, Yan/GYV-4514-2022		NCI NIH HHS [1 UO1CA88110-01, R01 CA098249] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088110, R01CA098249] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brake T, 2003, CANCER RES, V63, P8173; Clark J, 2003, ONCOGENE, V22, P1247, DOI 10.1038/sj.onc.1206247; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Laitinen S, 2002, GENE CHROMOSOME CANC, V35, P66, DOI 10.1002/gcc.10097; Lu ZH, 1999, MOL BIOL CELL, V10, P4091, DOI 10.1091/mbc.10.12.4091; LUO JH, 2003, EXPERT REV MOL MED, P1; Pacek M, 2004, EMBO J, V23, P3667, DOI 10.1038/sj.emboj.7600369; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; Wolter H, 2002, EUR UROL, V41, P328, DOI 10.1016/S0302-2838(02)00035-0; Xue WC, 2003, HISTOPATHOLOGY, V43, P485, DOI 10.1046/j.1365-2559.2003.01728.x; Yoshida K, 2003, FEBS LETT, V553, P213, DOI 10.1016/S0014-5793(03)01018-4	25	144	157	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1090	1098		10.1038/sj.onc.1209134	http://dx.doi.org/10.1038/sj.onc.1209134			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247466				2022-12-17	WOS:000235361000013
J	Oliveira, AM; Perez-Atayde, AR; Dal Cin, P; Gebhardt, MC; Chen, CJ; Neff, JR; Demetri, GD; Rosenberg, AE; Bridge, JA; Fletcher, JA				Oliveira, AM; Perez-Atayde, AR; Dal Cin, P; Gebhardt, MC; Chen, CJ; Neff, JR; Demetri, GD; Rosenberg, AE; Bridge, JA; Fletcher, JA			Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes	ONCOGENE			English	Article						aneurysmal bone cyst; USP6; translocation	MOLECULAR-CLONING; FUSION ONCOGENES; PROTEIN; 17P13; CELL; IDENTIFICATION; ABERRATIONS; CHERUBISM; MUTATIONS; CADHERIN	Aneurysmal bone cysts (ABC) are locally aggressive bone tumors that often feature chromosome 17p13 rearrangements. One of the ABC 17p13 rearrangements-t(16; 17)(q22; p13)-was recently shown to create a CDH11-USP6 fusion in which the USP6/TRE17 oncogene is overexpressed through juxtaposition with the CDH11 promoter. Herein, we characterize four different ABC translocations involving 17p13, and we show that each is associated with a novel USP6 fusion oncogene. Specifically, we demonstrate that t(1;17), t(3;17), t(9;17), and t(17;17) result in USP6 fusions with TRAP150 (thyroid receptor-associated protein 150), ZNF9 ((Z) under bari (N) under barc (F) under bar inger (9) under bar), Osteomodulin, and COL1A1 (Collagen 1A1), respectively. The oncogenic mechanism in these fusion genes is akin to CDH11-USP6, with the USP6 coding sequences juxtaposed to the promoter regions in each of the four novel translocation partners. The novel fusion partners appear well suited to drive USP6 transcription in the bone/mesenchymal context: osteomodulin is expressed strongly in osteoblastic lineages, and the COL1A1 promoter has an oncogenic role in the mesenchymal cancer dermatofibrosarcoma protuberans. In summary, these studies show that USP6 oncogenic activation results from heterogeneous genomic mechanisms involving USP6 transcriptional upregulation by juxtaposition with ectopic promoters.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Orthoped Surg, Boston, MA 02215 USA; Childrens Hosp, Med Ctr, Dept Orthoped Surg, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Dept Orthopaed Surg, Omaha, NE USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Mayo Clinic; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; University of Nebraska System; University of Nebraska Medical Center; Harvard University; Dana-Farber Cancer Institute	Oliveira, AM (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	oliveira.andre@mayo.edu; jfletcher@partners.org						Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090; Argani P, 1998, MODERN PATHOL, V11, P65; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; BYERS PH, 2004, METABOLIC BASIS MOL, P5241; Dal Cin P, 2000, GENE CHROMOSOME CANC, V28, P233, DOI 10.1002/(SICI)1098-2264(200006)28:2<233::AID-GCC13>3.0.CO;2-H; DEDIOS AMV, 1992, CANCER, V69, P2921, DOI 10.1002/1097-0142(19920615)69:12<2921::AID-CNCR2820691210>3.0.CO;2-E; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Hibbard MK, 2000, CANCER RES, V60, P4869; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Kurahashi H, 2000, HUM MOL GENET, V9, P1665, DOI 10.1093/hmg/9.11.1665; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; Miah SMS, 2004, GENES CELLS, V9, P993, DOI 10.1111/j.1365-2443.2004.00784.x; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; O'Brien KP, 1998, GENE CHROMOSOME CANC, V23, P187, DOI 10.1002/(SICI)1098-2264(199810)23:2<187::AID-GCC13>3.0.CO;2-L; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#; Paulding CA, 2003, P NATL ACAD SCI USA, V100, P2507, DOI 10.1073/pnas.0437015100; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; Rosenberg AENGP, 2002, WHO CLASSIFICATION T; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; Sinnett D, 1998, BIOTECHNIQUES, V24, P752, DOI 10.2144/98245bm12; Spiteri E, 2003, HUM MOL GENET, V12, P1823, DOI 10.1093/hmg/ddg203; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Winnepenninckx W, 2001, VIRCHOWS ARCH, V439, P636, DOI 10.1007/s004280100449; Wyatt-Ashmead J, 2001, PEDIATR DEVEL PATHOL, V4, P418, DOI 10.1007/s10024-001-0035-0	32	144	148	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3419	3426		10.1038/sj.onc.1208506	http://dx.doi.org/10.1038/sj.onc.1208506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735689				2022-12-17	WOS:000229038800004
J	Petrella, BL; Lohi, J; Brinckerhoff, CE				Petrella, BL; Lohi, J; Brinckerhoff, CE			Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma	ONCOGENE			English	Article						von Hippel-Lindau; MT1-MMP; HIF-2 alpha; renal cell carcinoma	PAS DOMAIN PROTEIN-1; TUMOR-SUPPRESSOR; ENDOTHELIAL-CELLS; MESSENGER-RNAS; GROWTH; INVASION; EXPRESSION; CANCER; GENE; TRANSCRIPTION	Metastatic renal cell carcinoma (RCC) resulting from the hereditary loss of the von Hippel - Lindau (VHL) tumor suppressor gene is the leading cause of death in VHL patients due to the deleterious effects of the metastatic tumor(s). VHL functions in the destruction of the alpha subunits of the heterodimeric transcription factor, hypoxia-inducible factor (HIF-1alpha and HIF-2alpha), in normoxic conditions. When VHL function is lost, HIF-alpha protein is stabilized, and target hypoxia-inducible genes are transcribed. The process of tumor invasion and metastasis involves the destruction of the extracellular matrix, which is accomplished primarily by the matrix metalloproteinase (MMP) family of enzymes. Here, we describe a connection between the loss of VHL tumor suppressor function and the upregulation of membrane type-1 MMP (MT1-MMP) gene expression and protein. Specifically, MT1-MMP is upregulated in VHL -/- RCC cells through an increase in gene transcription, which is mediated by the cooperative effects of the transcription factors, HIF-2 and Sp1. Further, we identify a functional HIF-binding site in the proximal promoter of MT1-MMP. To our knowledge, this is the first report to show direct regulation of MT1-MMP by HIF-2 and to provide a direct link between the loss of VHL tumor suppressor function and an increase in MMP gene and protein expression.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Biochem, Lebanon, NH 03756 USA; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Brinckerhoff, CE (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Med, 1 Med Ctr Dr,Rubin Bldg,HB 7936, Lebanon, NH 03756 USA.	constance.e.brinckerhoff@dartmouth.edu			NCI NIH HHS [CA-77267, R01 CA077267] Funding Source: Medline; NIAID NIH HHS [T32 AI007363] Funding Source: Medline; NIAMS NIH HHS [AR-26599, R01 AR026599, R37 AR026599] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337; Barry RE, 2004, TRENDS MOL MED, V10, P466, DOI 10.1016/j.molmed.2004.07.008; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hes FJ, 2001, NETH J MED, V59, P225, DOI 10.1016/S0300-2977(01)00165-6; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kitagawa Y, 1999, J UROLOGY, V162, P905, DOI 10.1097/00005392-199909010-00088; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maquoi E, 2004, CLIN CANCER RES, V10, P4038, DOI 10.1158/1078-0432.CCR-04-0125; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Miki N, 2004, J BIOL CHEM, V279, P15025, DOI 10.1074/jbc.M313186200; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Ottino P, 2004, MOL VIS, V10, P341; Richards FM, 1998, J INTERN MED, V243, P527; Sanchez-Elsner T, 2004, J MOL BIOL, V336, P9, DOI 10.1016/j.jmb.2003.12.023; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Singh AD, 2001, SURV OPHTHALMOL, V46, P117, DOI 10.1016/S0039-6257(01)00245-4; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Zimmer M, 2004, MOL CANCER RES, V2, P89	46	144	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2005	24	6					1043	1052		10.1038/sj.onc.1208305	http://dx.doi.org/10.1038/sj.onc.1208305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592504	Green Accepted			2022-12-17	WOS:000226749200010
J	Houlston, RS; Peto, J				Houlston, RS; Peto, J			The search for low-penetrance cancer susceptibility alleles	ONCOGENE			English	Article						low-penetrance genes; cancer; risk	COMPLEX HUMAN-DISEASES; BREAST-CANCER; LINKAGE DISEQUILIBRIUM; LUNG-CANCER; BRCA2 MUTATIONS; RISK; ASSOCIATION; POLYMORPHISMS; GENE; LOCALIZATION	Much of the familial aggregation of common cancer results from inherited susceptibility, but highly penetrant mutations in known genes cannot account for most of the excess. Some of the unexplained familial risk is presumably due to high-penetrance mutations in as yet unidentified genes, but polygenic mechanisms are likely to account for a greater proportion, particularly in breast cancer. This inference, coupled with technological developments, has led to a renaissance in association studies. Most such studies have evaluated small numbers of single-nucleotide polymorphisms (SNPs) in a few candidate genes, but reliable high-density oligonucleotide arrays and other novel techniques will allow genome-wide allelic association studies to be conducted. High-density genome-wide SNP analysis will include targets identified by structural considerations, as well as the growing list of candidate genes. In the longer term, high-throughput resequencing will be required to identify the rare pathogenic variants that may constitute the majority of low-penetrance alleles. The detection of low-penetrance cancer susceptibility genes will then be restricted mainly by the availability of large numbers of well-characterized cases and controls. Cancer patients with affected relatives are considerably more informative than unselected cases for such studies.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Inst Canc Res, Canc Res UK Epidemiol & Genet Unit, Sutton SMZ 5NG, Surrey, England	University of London; Institute of Cancer Research - UK; University of London; London School of Hygiene & Tropical Medicine; University of London; Institute of Cancer Research - UK	Houlston, RS (corresponding author), Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.	richard.houlston@icr.ac.uk; julian.peto@lshtm.ac.uk		Houlston, Richard/0000-0002-5268-0242				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; Antoniou AC, 2003, GENET EPIDEMIOL, V25, P190, DOI 10.1002/gepi.10261; Benhamou S, 2002, CARCINOGENESIS, V23, P1343, DOI 10.1093/carcin/23.8.1343; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Collins A, 2001, HUM MUTAT, V17, P255, DOI 10.1002/humu.21; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DeMille MMC, 2002, HUM GENET, V111, P521, DOI 10.1007/s00439-002-0809-0; Dunning AM, 2000, AM J HUM GENET, V67, P1544, DOI 10.1086/316906; Dunning AM, 1999, CANCER EPIDEM BIOMAR, V8, P843; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Feyler A, 2002, CANCER EPIDEM BIOMAR, V11, P1550; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Heijmans BT, 2003, CANCER RES, V63, P1249; Houlston RS, 2001, GASTROENTEROLOGY, V121, P282, DOI 10.1053/gast.2001.26265; Houlston RS, 2003, HUM GENET, V112, P434, DOI 10.1007/s00439-002-0902-4; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Morton NE, 2001, P NATL ACAD SCI USA, V98, P5217, DOI 10.1073/pnas.091062198; NTAIS C, 2003, CANCER EPIDEM BIOMAR, V12, P20; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; Peto J, 2002, CANCER CELL, V1, P411, DOI 10.1016/S1535-6108(02)00079-X; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Peto J, 1996, INT J CANCER, V65, P275, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;275::AID-IJC1&gt;3.0.CO;2-X; PETO J, 1980, BANBURY REPORT, V4, P203; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rostami-Hodjegan A, 1998, PHARMACOGENETICS, V8, P227, DOI 10.1097/00008571-199806000-00005; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	42	144	146	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2004	23	38					6471	6476		10.1038/sj.onc.1207951	http://dx.doi.org/10.1038/sj.onc.1207951			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322517				2022-12-17	WOS:000223468800011
J	Pavey, S; Johansson, P; Packer, L; Taylor, J; Stark, M; Pollock, PM; Walker, GJ; Boyle, GM; Harper, U; Cozzi, SJ; Hansen, K; Yudt, L; Schmidt, C; Hersey, P; Ellem, KAO; O'Rourke, MGE; Parsons, PG; Meltzer, P; Ringner, M; Hayward, NK				Pavey, S; Johansson, P; Packer, L; Taylor, J; Stark, M; Pollock, PM; Walker, GJ; Boyle, GM; Harper, U; Cozzi, SJ; Hansen, K; Yudt, L; Schmidt, C; Hersey, P; Ellem, KAO; O'Rourke, MGE; Parsons, PG; Meltzer, P; Ringner, M; Hayward, NK			Microarray expression profiling in melanoma reveals a BRAF mutation signature	ONCOGENE			English	Article						BRAF; melanoma; microarray; mitogenactivated protein kinase; mutation	PROTEIN-TYROSINE-PHOSPHATASE; N-RAS; DIFFERENTIAL DISPLAY; ONCOGENIC PATHWAYS; KINASE ACTIVATION; GENE; CANCER; CLASSIFICATION; PROGRESSION; ADHESION	We have used microarray gene expression pro. ling and machine learning to predict the presence of BRAF mutations in a panel of 61 melanoma cell lines. The BRAF gene was found to be mutated in 42 samples (69%) and intragenic mutations of the NRAS gene were detected in seven samples (11%). No cell line carried mutations of both genes. Using support vector machines, we have built a classifier that differentiates between melanoma cell lines based on BRAF mutation status. As few as 83 genes are able to discriminate between BRAF mutant and BRAF wild-type samples with clear separation observed using hierarchical clustering. Multidimensional scaling was used to visualize the relationship between a BRAF mutation signature and that of a generalized mitogen-activated protein kinase ( MAPK) activation ( either BRAF or NRAS mutation) in the context of the discriminating gene list. We observed that samples carrying NRAS mutations lie somewhere between those with or without BRAF mutations. These observations suggest that there are gene-specific mutation signals in addition to a common MAPK activation that result from the pleiotropic effects of either BRAF or NRAS on other signaling pathways, leading to measurably different transcriptional changes.	Queensland Inst Med Res, Herston, Qld 4006, Australia; Lund Univ, Dept Theoret Phys, Complex Syst Div, SE-22362 Lund, Sweden; Pk Ctr Mental Hlth, Queensland Ctr Schizophrenia Res, Wacol, Qld 4076, Australia; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Newcastle, Newcastle, NSW 2300, Australia; Mater Misericordiae Univ Hosp, Brisbane, Qld 4101, Australia	QIMR Berghofer Medical Research Institute; Lund University; Queensland Centre for Mental Health Research; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Newcastle; University College Dublin	Hayward, NK (corresponding author), Queensland Inst Med Res, 300 Herston Rd, Herston, Qld 4006, Australia.	nickH@qimr.edu.au	Ringnér, Markus/G-3641-2011; hayward, nick/AAV-8802-2020; Taylor, Jennifer M/A-1686-2010; Boyle, Glen/G-1347-2013; Stark, Mitchell/K-6794-2019; hayward, nicholas k/C-1367-2015; Parsons, Peter G/H-8163-2015; Johansson, Peter A/K-1053-2014; Walker, Graeme J/C-2548-2012; Schmidt, Christopher W/A-4353-2009; Pavey, Sandra/B-3662-2011; Stark, Mitchell S/E-3542-2010; Stark, Mitchell/K-3874-2019	Ringnér, Markus/0000-0001-5469-8940; Taylor, Jennifer M/0000-0003-4231-0181; Boyle, Glen/0000-0002-1385-529X; Stark, Mitchell/0000-0002-4510-2161; hayward, nicholas k/0000-0003-4760-1033; Parsons, Peter G/0000-0002-0473-3346; Johansson, Peter A/0000-0001-7015-5452; Walker, Graeme J/0000-0002-9392-8769; Schmidt, Christopher W/0000-0002-3955-5076; Pavey, Sandra/0000-0003-4519-5932; Stark, Mitchell S/0000-0002-4510-2161; Pollock, Pamela/0000-0001-8420-1026	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bastian BC, 1997, CELL MOL LIFE SCI, V53, P554, DOI 10.1007/s000180050071; Brose MS, 2002, CANCER RES, V62, P6997; Castellano M, 1997, CANCER RES, V57, P4868; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cristianini N., 2000, INTRO SUPPORT VECTOR; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Francia G, 1996, CANCER RES, V56, P3855; Fukushima T, 2003, ONCOGENE, V22, P6455, DOI 10.1038/sj.onc.1206739; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gorden A, 2003, CANCER RES, V63, P3955; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Johnson JP, 1997, INT J CANCER, V73, P769; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kimura ET, 2003, CANCER RES, V63, P1454; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; MUSTELIN T, 2002, SCI STKE, V115, pPE3; Naoki K, 2002, CANCER RES, V62, P7001; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Prathapam T, 2002, NUCLEIC ACIDS RES, V30, P5261, DOI 10.1093/nar/gkf658; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schleger C, 2000, MOL CARCINOGEN, V28, P31, DOI 10.1002/(SICI)1098-2744(200005)28:1<31::AID-MC5>3.0.CO;2-F; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Shih IM, 1997, CANCER RES, V57, P3835; Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Troyanskaya OG, 2002, BIOINFORMATICS, V18, P1454, DOI 10.1093/bioinformatics/18.11.1454; vanElsas A, 1996, AM J PATHOL, V149, P883; Xie SH, 1997, CANCER RES, V57, P2295; Yuen ST, 2002, CANCER RES, V62, P6451; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	144	154	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4060	4067		10.1038/sj.onc.1207563	http://dx.doi.org/10.1038/sj.onc.1207563			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048078				2022-12-17	WOS:000221520200003
J	Weissenberger, J; Loeffler, S; Kappeler, A; Kopf, M; Lukes, A; Afanasieva, TA; Aguzzi, A; Weis, J				Weissenberger, J; Loeffler, S; Kappeler, A; Kopf, M; Lukes, A; Afanasieva, TA; Aguzzi, A; Weis, J			IL-6 is required for glioma development in a mouse model	ONCOGENE			English	Article						gliomas; mouse model; IL-6 knockout; STAT3 signalling	GROWTH-FACTOR; CELL-GROWTH; STAT3; ACTIVATION; GLIOBLASTOMA; ASTROCYTES; EXPRESSION; DIFFERENTIATION; OVEREXPRESSION; PROLIFERATION	The pleiotropic cytokine interleukin- 6 (IL-6) contributes to malignant progression and apoptosis resistance of various cancer types. Although IL-6 is elevated in malignant gliomas, and glioma cells respond to IL-6, its functional role in gliomagenesis is unclear. We have investigated this role of IL-6 in a mouse model of spontaneous astrocytoma by crossbreeding glial fibrillary acidic protein (GFAP)-viral src oncogene transgenic mice with IL-6-deficient mice. We show here that ablation of IL-6 prevents tumour formation in these predisposed animals, but did not affect preneoplastic astrogliosis. Moreover, we demonstrate phosphorylation and nuclear translocation of the transcription factor signal transducer and activator of transcription (STAT) 3, a prerequisite for IL-6 signalling, in 51 human gliomas WHO grade II-IV and all experimental mouse tumours investigated. Together with the observation that STAT3 activation increases with malignancy, these findings indicate an important role for IL-6 in the development and malignant progression of astrocytomas.	Univ Bern, Inst Pathol, Div Neuropathol, CH-3010 Bern, Switzerland; Swiss Fed Inst Technol, Dept Environm Sci, CH-8952 Zurich, Switzerland; Univ Bern, Inselspital, Dept Neurosurg, CH-3010 Bern, Switzerland; Univ Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland; Rhein Westfal TH Aachen, Univ Hosp, Inst Neuropathol, D-52074 Aachen, Germany	University of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Bern; University Hospital of Bern; University of Zurich; RWTH Aachen University; RWTH Aachen University Hospital	Weissenberger, J (corresponding author), Univ Bern, Inst Pathol, Div Neuropathol, Murtenstr 31, CH-3010 Bern, Switzerland.	weissenb@patho.unibe.ch	Aguzzi, Adriano/A-3351-2008; Kopf, Manfred/B-6907-2009; Weis, Joachim/G-1984-2014	Kopf, Manfred/0000-0002-0628-7140; Weis, Joachim/0000-0003-3280-6773; Aguzzi, Adriano/0000-0002-0344-6708; Adams, Tatiana/0000-0002-8656-7096				Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunello AG, 2000, AM J PATHOL, V157, P1485, DOI 10.1016/S0002-9440(10)64787-6; Buettner R, 2002, CLIN CANCER RES, V8, P945; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Candi E, 1997, J NEURO-ONCOL, V31, P115, DOI 10.1023/A:1005706019048; Cardenas H, 2003, BRAIN RES, V985, P89, DOI 10.1016/S0006-8993(03)03172-X; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Goswami S, 1998, J NEUROCHEM, V71, P1837; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kleihues, 2000, WHO CLASSIFICATION T; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kossakowska AE, 1999, BLOOD, V94, P2080, DOI 10.1182/blood.V94.6.2080.418k30_2080_2089; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nagashima G, 2002, CLIN NEUROL NEUROSUR, V104, P125, DOI 10.1016/S0303-8467(01)00197-4; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rolhion C, 2001, J NEUROSURG, V94, P97, DOI 10.3171/jns.2001.94.1.0097; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SEHGAL PB, 2002, J BIOL CHEM, V28, P28; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Senger DL, 2002, CANCER RES, V62, P2131; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Takizawa T, 2001, CYTOKINE, V13, P272, DOI 10.1006/cyto.2000.0831; Tchirkov A, 2001, BRIT J CANCER, V85, P518, DOI 10.1054/bjoc.2001.1942; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; VAN MEIR E, 1990, CANCER RES, V50, P6683; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	144	159	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3308	3316		10.1038/sj.onc.1207455	http://dx.doi.org/10.1038/sj.onc.1207455			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064729				2022-12-17	WOS:000220975000005
J	Sharpless, NE; Ramsey, MR; Balasubramanian, P; Castrillon, DH; DePinho, RA				Sharpless, NE; Ramsey, MR; Balasubramanian, P; Castrillon, DH; DePinho, RA			The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis	ONCOGENE			English	Article						Rb; p14(ARF); p53; cdkn2a	MAMMARY EPITHELIAL-CELLS; HUMAN-DIPLOID FIBROBLASTS; TUMOR SUPPRESSION; INDUCED SENESCENCE; KERATINOCYTE SENESCENCE; GERMLINE MUTATION; FAMILIAL MELANOMA; INK4A LOCUS; IN-VIVO; INACTIVATION	Mounting genetic evidence suggests that each product of the Ink4/Arf locus, p16(INK4a) and p19(ARF), possesses tumor-suppressor activity (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001a). We report the generation and characterization of a p19(ARF)-specific knockout allele (p19(ARF)-/-) and direct comparison with mice and derivative cells deficient for p16(INK4a), both p16(INK4a) and p19(ARF), and p53. Like Ink4/Arf-/- murine embryo fibroblasts (MEFs), p19(ARF)-/- MEFs were highly susceptible to oncogenic transformation, exhibited enhanced subcloning efficiency at low density, and resisted both RAS- and culture-induced growth arrest. In contrast, the biological profile of p16(INK4a)-/- MEFs in these assays more closely resembled that of wild-type cells. In vivo, however, both p19(ARF)-/- and p16(INK4a)-/- animals were significantly more tumor prone than wild-type animals, but each less so than p53-/- or Ink4/Arf-/- animals, and with differing tumor spectra. These data confirm the predominant role of p19(ARF) over p16(INK4a) in cell culture-based assays of MEFs, yet also underscore the importance of the analysis of tumor suppressors across many cell types within the organism. The cancer-prone conditions of mice singly deficient for either p16(INK4a) or p19(ARF) agree with data derived from human cancer genetics, and reinforce the view that both gene products play significant and nonredundant roles in suppressing malignant transformation in vivo.	Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sharpless, NE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, CB 7295, Chapel Hill, NC 27599 USA.	NES@med.unc.edu		Ramsey, Matthew/0000-0003-2402-8502; DePinho, Ronald/0000-0002-5625-577X; Sharpless, Norman/0000-0001-7078-9455				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Eischen CM, 2002, CANCER RES, V62, P2184; Festing M, 1998, MOUSE GENOME INFORMA; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Huschtscha LI, 1998, CANCER RES, V58, P3508; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAO L, 1995, CANCER RES, V55, P2995; Munro J, 1999, CANCER RES, V59, P2516; OLSON DC, 1993, ONCOGENE, V8, P2353; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; SHARPLESS NE, 2003, IN PRESS ONCOGENE; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2001, CELL, V106, P531, DOI 10.1016/S0092-8674(01)00486-X; STONE S, 1995, CANCER RES, V55, P2988; Sviderskaya EV, 2003, J NATL CANCER I, V95, P723, DOI 10.1093/jnci/95.10.723; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	46	144	156	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					379	385		10.1038/sj.onc.1207074	http://dx.doi.org/10.1038/sj.onc.1207074			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724566				2022-12-17	WOS:000188098300007
J	Mossink, MH; van Zon, A; Scheper, RJ; Sonneveld, P; Wiemer, EAC				Mossink, MH; van Zon, A; Scheper, RJ; Sonneveld, P; Wiemer, EAC			Vaults: a ribonucleoprotein particle involved in drug resistance?	ONCOGENE			English	Review						vault complex; multidrug resistance; LRP; MVP	ACUTE MYELOID-LEUKEMIA; LEVEL DOXORUBICIN RESISTANCE; PROTEIN MESSENGER-RNA; SHORT-TERM EXPOSURE; P-GLYCOPROTEIN PGP; MULTIDRUG-RESISTANCE; POLY(ADP-RIBOSE) POLYMERASE; INCREASED EXPRESSION; BREAST-CANCER; TELOMERASE ACTIVITY	Vaults are ribonucleoprotein particles found in the cytoplasm of eucaryotic cells. The 13 MDa particles are composed of multiple copies of three proteins: an M-r 100 000 major vault protein (MVP) and two minor vault proteins of M-r 193 000 (vault poly-(ADP-ribose) polymerase) and M-r 240 000 (telomerase-associated protein 1), as well as small untranslated RNA molecules of approximately 100 bases. Although the existence of vaults was first reported in the mid-1980s no function has yet been attributed to this organelle. The notion that vaults might play a role in drug resistance was suggested by the molecular identification of the lung resistance-related (LRP) protein as the human MVP. MVP/LRP was found to be overexpressed in many chemoresistant cancer cell lines and primary tumor samples of different histogenetic origin. Several, but not all, clinico-pathological studies showed that MVP expression at diagnosis was an independent adverse prognostic factor for response to chemotherapy. The hollow barrel-shaped structure of the vault complex and its subcellular localization indicate a function in intracellular transport. It was therefore postulated that vaults contributed to drug resistance by transporting drugs away from their intracellular targets and/or the sequestration of drugs. Here, we review the current knowledge on the vault complex and critically discuss the evidence that links vaults to drug resistance.	Erasmus MC, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam	Wiemer, EAC (corresponding author), Erasmus MC, Dept Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	e.wiemer@erasmusmc.nl		Wiemer, Erik/0000-0002-0673-7236				Abbondanza C, 1998, J CELL BIOL, V141, P1301, DOI 10.1083/jcb.141.6.1301; Arts HJG, 1999, CLIN CANCER RES, V5, P2798; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Berger W, 2000, INT J CANCER, V88, P293, DOI 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S; Borg AG, 1998, BRIT J HAEMATOL, V103, P1083, DOI 10.1046/j.1365-2141.1998.01111.x; Cheng SH, 2000, TOXICOL APPL PHARM, V164, P134, DOI 10.1006/taap.2000.8903; CHUGANI DC, 1993, J CELL SCI, V106, P23; Damiani D, 1998, HAEMATOLOGICA, V83, P290; Den Boer ML, 1999, LEUKEMIA, V13, P2023, DOI 10.1038/sj.leu.2401576; den Boer ML, 1998, BLOOD, V91, P2092, DOI 10.1182/blood.V91.6.2092.2092_2092_2098; Dingemans AMC, 1996, ANN ONCOL, V7, P625; Filipits M, 1999, CLIN CANCER RES, V5, P2426; Filipits M, 1998, BLOOD, V91, P1508, DOI 10.1182/blood.V91.5.1508.1508_1508_1513; Filipits M, 2000, LEUKEMIA, V14, P68, DOI 10.1038/sj.leu.2401634; Goasguen JE, 1996, LEUKEMIA LYMPHOMA, V23, P567, DOI 10.3109/10428199609054866; Hamill DR, 1997, DEV BIOL, V190, P117, DOI 10.1006/dbio.1997.8676; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hart SM, 1997, EXP HEMATOL, V25, P1227; Herrmann C, 1999, J CELL BIOL, V144, P1163, DOI 10.1083/jcb.144.6.1163; Hu Y, 2002, INT J CANCER, V97, P149, DOI 10.1002/ijc.1590; Izquierdo MA, 1996, AM J PATHOL, V148, P877; Izquierdo MA, 1996, INT J CANCER, V65, P230; IZQUIERDO MA, 1995, JNCI-J NATL CANCER I, V87, P1230; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Kakihara T, 1999, PEDIATR INT, V41, P641, DOI 10.1046/j.1442-200X.1999.t01-1-01144.x; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1990, MOL BIOL REP, V14, P121, DOI 10.1007/BF00360441; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1996, TRENDS CELL BIOL, V6, P174, DOI 10.1016/0962-8924(96)10014-3; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157; Kitazono M, 2001, INT J CANCER, V91, P126, DOI 10.1002/1097-0215(20010101)91:1<126::AID-IJC1018>3.0.CO;2-8; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Komarov PG, 1998, ONCOL RES, V10, P185; Kong LB, 2000, RNA, V6, P890, DOI 10.1017/S1355838200000157; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Laurencot CM, 1997, INT J CANCER, V72, P1021; Legrand O, 1998, LEUKEMIA, V12, P1367, DOI 10.1038/sj.leu.2401117; Leith CP, 1999, BLOOD, V94, P1086; Li JY, 1999, NEUROSCIENCE, V91, P1055, DOI 10.1016/S0306-4522(98)00622-8; Linn SC, 1997, INT J CANCER, V71, P787, DOI 10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.3.CO;2-3; List AF, 1996, BLOOD, V87, P2464, DOI 10.1182/blood.V87.6.2464.bloodjournal8762464; Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178-8184.2000; Ma Q, 2001, BIOCHEM BIOPH RES CO, V289, P499, DOI 10.1006/bbrc.2001.5987; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; Michieli M, 1997, BRIT J HAEMATOL, V96, P356, DOI 10.1046/j.1365-2141.1997.d01-2020.x; Michieli M, 1999, BRIT J HAEMATOL, V104, P328, DOI 10.1046/j.1365-2141.1999.01172.x; Moran E, 1997, EUR J CANCER, V33, P652, DOI 10.1016/S0959-8049(96)00501-1; Mossink MH, 2002, CANCER RES, V62, P7298; Mossink MH, 2002, GENE, V294, P225, DOI 10.1016/S0378-1119(02)00789-8; Ogretmen B, 2000, J PEDIAT HEMATOL ONC, V22, P45, DOI 10.1097/00043426-200001000-00009; Ohno N, 2001, BLOOD, V98, P1160, DOI 10.1182/blood.V98.4.1160; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Pallis M, 1999, BRIT J HAEMATOL, V104, P307, DOI 10.1046/j.1365-2141.1999.01157.x; Pohl G, 1999, ANTICANCER RES, V19, P5051; Raaijmakers HGP, 1998, BLOOD, V91, P1029, DOI 10.1182/blood.V91.3.1029.1029_1029_1036; RAMANI P, 1995, J PATHOL, V175, P13, DOI 10.1002/path.1711750104; Rimsza LM, 1999, LEUKEMIA LYMPHOMA, V34, P315, DOI 10.3109/10428199909050956; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; SCHADENDORF D, 1995, AM J PATHOL, V147, P1545; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCHEPER RJ, 1993, CANCER RES, V53, P1475; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schroeijers AB, 2000, CANCER RES, V60, P1104; Schroeijers AB, 2002, J IMMUNOL, V168, P1572, DOI 10.4049/jimmunol.168.4.1572; Shall Sydney, 2002, Bioessays, V24, P197, DOI 10.1002/bies.10012; Siva AC, 2001, INT J CANCER, V92, P195, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Stephen AG, 2001, J BIOL CHEM, V276, P23217, DOI 10.1074/jbc.C100226200; Stoffler D, 1999, J MOL BIOL, V287, P741, DOI 10.1006/jmbi.1999.2637; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; van Zon A, 2002, BIOCHEM BIOPH RES CO, V291, P535, DOI 10.1006/bbrc.2002.6472; van Zon A, 2001, J BIOL CHEM, V276, P37715, DOI 10.1074/jbc.M106055200; vanderPol JP, 1997, INVEST OPHTH VIS SCI, V38, P2523; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VASU SK, 1993, J BIOL CHEM, V268, P15356; Verovski VN, 1996, BRIT J CANCER, V73, P596, DOI 10.1038/bjc.1996.103; VERSANTVOORT CHM, 1995, INT J CANCER, V61, P375, DOI 10.1002/ijc.2910610317; Volm M, 1997, ANTI-CANCER DRUG, V8, P662, DOI 10.1097/00001813-199708000-00003; Volm M, 1997, ANTI-CANCER DRUG, V8, P931, DOI 10.1097/00001813-199711000-00003; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wyler B, 1997, BRIT J HAEMATOL, V97, P65, DOI 10.1046/j.1365-2141.1997.52649.x; Xu DW, 1999, BRIT J HAEMATOL, V106, P627, DOI 10.1046/j.1365-2141.1999.01611.x; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200	93	144	146	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7458	7467		10.1038/sj.onc.1206947	http://dx.doi.org/10.1038/sj.onc.1206947			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576851				2022-12-17	WOS:000186112500016
J	Tomar, RS; Matta, H; Chaudhary, PM				Tomar, RS; Matta, H; Chaudhary, PM			Use of adeno-associated viral vector for delivery of small interfering RNA	ONCOGENE			English	Article						AAV; siRNA; RNAi; RNA interference	GENE-EXPRESSION; STABLE SUPPRESSION	Post-transcriptional gene silencing by small interfering RNAs (siRNAs) is rapidly becoming a powerful tool for genetic analysis of mammalian cells. Delivery of siRNA into mammalian cells is usually achieved via the transfection of double-stranded oligonucleotides or plasmids encoding RNA polymerase III promoter-driven small hairpin RNA. Recently, retroviral vectors have been used for siRNA delivery, which overcome the problem of poor transfection efficiency seen with the plasmid-based systems. However, retroviral vectors have several limitations, such as the need for active cell division for gene transduction, oncogenic potential, low titers and gene silencing. In this report, we have adapted a commercially available adenoassociated virus (AAV) vector for siRNA delivery into mammalian cells. We demonstrate the ability of this modified vector to deliver efficiently siRNA into HeLa S3 cells and downregulate p53 and caspase 8 expression. Our results suggest that AAV-based vectors are efficient vectors for the delivery of siRNA into mammalian cells. Based on the known ability of these vectors to infect both dividing and nondividing cells, their use as a therapeutic tool for the delivery of siRNA deserves further study.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	preet.chaudhary@utsouthwestern.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stilwell JL, 2003, BIOTECHNIQUES, V34, P148, DOI 10.2144/03341dd01; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599	17	144	192	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5712	5715		10.1038/sj.onc.1206733	http://dx.doi.org/10.1038/sj.onc.1206733			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944921				2022-12-17	WOS:000184865900022
J	Matsuoka, M				Matsuoka, M			Human T-cell leukemia virus type I and adult T-cell leukemia	ONCOGENE			English	Article						ATL; HTLV-I; tax; cytotoxic T cell; leukemogenesis; retrovirus	NF-KAPPA-B; HORMONE-RELATED PROTEIN; BLOOD MONONUCLEAR-CELLS; NON-HODGKIN-LYMPHOMA; HTLV-I; TAX PROTEIN; INFECTED CELLS; NUCLEAR-FACTOR; OSTEOPROTEGERIN LIGAND; RECEPTOR ACTIVATOR	Human T-cell leukemia virus type I (HTLV-I) causes adult T-cell leukemia (ATL) in about 5% of carriers after a long latent period. After its infection, HTLV-I promotes the clonal proliferation of HTLV-I infected cells in vivo by actions of encoded viral proteins, including Tax. However, leukemic cells frequently lack the expression of Tax by the genetic and epigenetic changes of HTLV-I provirus, suggesting that Tax is not always necessary after transformation. Alternatively, ATL cells without Tax protein could escape from the host immune system since Tax is the major target of cytotoxic lymphocytes. During the latent period, alterations of host genome accumulate, finally leading to onset of ATL.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University	Matsuoka, M (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.			Matsuoka, Masao/0000-0002-0473-754X				AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; Arisawa K, 2002, CANCER CAUSE CONTROL, V13, P657, DOI 10.1023/A:1019511224501; Arisawa K, 2000, INT J CANCER, V85, P319, DOI 10.1002/(SICI)1097-0215(20000201)85:3<319::AID-IJC4>3.0.CO;2-B; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Azimi N, 1998, P NATL ACAD SCI USA, V95, P2452, DOI 10.1073/pnas.95.5.2452; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BLATTNER WA, 1994, ADULT TCELL LEUKEMIA, P4; Borg A, 1996, BRIT J HAEMATOL, V94, P713, DOI 10.1046/j.1365-2141.1996.02338.x; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; CESARMAN E, 1992, BLOOD, V80, P3205; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Ding W, 2001, J VIROL, V75, P7672, DOI 10.1128/JVI.75.16.7672-7682.2001; Etoh K, 1999, INT J CANCER, V81, P859, DOI 10.1002/(SICI)1097-0215(19990611)81:6<859::AID-IJC4>3.0.CO;2-K; Etoh K, 1997, CANCER RES, V57, P4862; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; GIBBS WN, 1987, ANN INTERN MED, V106, P361, DOI 10.7326/0003-4819-106-3-361; GREENBERG SJ, 1990, BLOOD, V76, P911; Hanabuchi S, 2001, J NATL CANCER I, V93, P1775, DOI 10.1093/jnci/93.23.1775; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; Hanon E, 2000, BLOOD, V95, P1386, DOI 10.1182/blood.V95.4.1386.004k22_1386_1392; Hasegawa H, 2000, BLOOD, V95, P30; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HIMES SR, 1993, ONCOGENE, V8, P3189; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561; Hoshida Y, 2001, INT J CANCER, V91, P869, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1125>3.0.CO;2-N; Iga M, 2002, J INFECT DIS, V185, P691, DOI 10.1086/339002; Imura A, 1996, J EXP MED, V183, P2185, DOI 10.1084/jem.183.5.2185; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KANNAGI M, 1991, INT IMMUNOL, V3, P761, DOI 10.1093/intimm/3.8.761; KATSUKI T, 1987, JPN J CANCER RES, V78, P639; Kibler KV, 1999, JNCI-J NATL CANCER I, V91, P903, DOI 10.1093/jnci/91.11.903; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KIYOKAWA T, 1987, CANCER, V59, P1187, DOI 10.1002/1097-0142(19870315)59:6<1187::AID-CNCR2820590626>3.0.CO;2-8; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; MATSUOKA M, 2002, LEUKEMIA, P705; Matsuzaki K, 1999, ENDOCRINOLOGY, V140, P925, DOI 10.1210/en.140.2.925; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; Mori N, 1999, BLOOD, V93, P2360; MURAOKA O, 1993, IMMUNOL LETT, V37, P159, DOI 10.1016/0165-2478(93)90026-X; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; NIITSU Y, 1988, BLOOD, V71, P263; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Nosaka K, 2000, CANCER RES, V60, P1043; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rogers PR, 2001, IMMUNITY, V15, P445, DOI 10.1016/S1074-7613(01)00191-1; Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1557::AID-CNCR5>3.3.CO;2-K; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; SAKASHITA A, 1992, BLOOD, V79, P477; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1994, ADULT T CELL LEUKEMI, P22; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAJIMA K, 1994, ADULT TCELL LEUKEMIA, P9; Takaori-Kondo A, 1998, BLOOD, V91, P4747, DOI 10.1182/blood.V91.12.4747.412k41_4747_4751; Takatsuki T., 1977, 16 INT C HEM AMST, P73; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Tamiya S, 1998, BLOOD, V91, P3935; TOBINAI K, 1991, LEUKEMIA RES, V15, P837, DOI 10.1016/0145-2126(91)90468-9; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Tsukasaki K, 2001, CANCER RES, V61, P3770; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; VILLIGER PM, 1991, J IMMUNOL, V146, P550; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WELLES SL, 1994, INT J CANCER, V56, P337, DOI 10.1002/ijc.2910560307; Wodarz D, 2001, P ROY SOC B-BIOL SCI, V268, P1215, DOI 10.1098/rspb.2001.1608; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046/j.1365-2141.2001.02737.x; YAMAGUCHI K, 1994, LEUKEMIA, V8, P1708; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	96	144	148	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2003	22	33					5131	5140		10.1038/sj.onc.1206551	http://dx.doi.org/10.1038/sj.onc.1206551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910250				2022-12-17	WOS:000184615100004
J	Tauchi, H; Matsuura, S; Kobayashi, J; Sakamoto, S; Komatsu, K				Tauchi, H; Matsuura, S; Kobayashi, J; Sakamoto, S; Komatsu, K			Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability	ONCOGENE			English	Review						Nijmegen breakage syndrome; NBS1; Mre11; histone H2AX; double-strand break; two-step binding model	DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA GENE; VERTEBRATE CELLS; MRE11 COMPLEX; NO EVIDENCE; S-PHASE; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL INSTABILITY; V(D)J RECOMBINATION	DNA double-strand breaks represent the most potentially serious damage to a genome and hence, at least two pathways of DNA repair have evolved; namely, homologous recombination repair and non-homologous end joining. Defects in both rejoining processes result in genomic instability including chromosome rearrangements, LOH and gene mutations, which may lead to development of malignancies. Nijmegen breakage syndrome is a recessive genetic disorder, characterized by elevated sensitivity to ionizing radiation that induces double-strand breaks, and high frequency of malignancies. NBS1, the product of the gene underlying the disease, forms a multimeric complex with hMRE11/ hRAD50 nuclease and recruits them to the vicinity of sites of DNA damage by direct binding to phosphorylated histone H2AX. The combination of the highly-conserved NBS1 forkhead associated domain and BRCA1 C-terminus domain has a crucial role for recognition of damaged sites. Thereafter, the NBS1-complex proceeds to rejoin double-strand breaks predominantly by homologous recombination repair in vertebrates. This process collaborates with cell-cycle checkpoints at S and G2 phase to facilitate DNA repair. NBS1 is also associated with telomere maintenance and DNA replication. Based on recent knowledge regarding NBS1, we propose here a two-step binding mechanism for damage recognition by repair proteins, and describe the molecular links to factors for genome stability.	Kyoto Univ, Ctr Radiat Biol, Kyoto 6068501, Japan; Ibaraki Univ, Dept Environm Sci, Mito, Ibaraki 3108512, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima 7348553, Japan; Hiroshima Univ, Dept Oral & Maxillo Facial Radiol, Hiroshima 7348553, Japan	Kyoto University; Ibaraki University; Hiroshima University; Hiroshima University	Komatsu, K (corresponding author), Kyoto Univ, Ctr Radiat Biol, Kyoto 6068501, Japan.	komatsu@house.rbc.kyoto-u.ac.jp	Matsuura, Shinya/U-4182-2017; Kobayashi, Junya/AAX-6390-2021	Matsuura, Shinya/0000-0001-5294-081X; Kobayashi, Junya/0000-0003-4645-7500; Sakamoto, Shuichi/0000-0001-9396-9475				Antoccia A, 1999, INT J RADIAT BIOL, V75, P583; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Bullrich F, 1999, CANCER RES, V59, P24; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Carlomagno F, 1999, GENE CHROMOSOME CANC, V25, P393, DOI 10.1002/(SICI)1098-2264(199908)25:4<393::AID-GCC12>3.0.CO;2-8; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cerosaletti KM, 1998, AM J HUM GENET, V63, P125, DOI 10.1086/301927; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; Daoudal-Cotterell S, 2002, FEBS LETT, V516, P164, DOI 10.1016/S0014-5793(02)02536-X; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Jager M, 2001, NUCLEIC ACIDS RES, V29, P1317, DOI 10.1093/nar/29.6.1317; De Lange T, 2000, COLD SPRING HARB SYM, V65, P265, DOI 10.1101/sqb.2000.65.265; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hall E.J, 1978, RADIOBIOLOGY RADIOLO, V1st; Hama S, 2000, ANTICANCER RES, V20, P1897; Harfst E, 2000, MOL IMMUNOL, V37, P915, DOI 10.1016/S0161-5890(01)00008-6; HERNANDEZ D, 1993, J MED GENET, V30, P135, DOI 10.1136/jmg.30.2.135; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Hopfner KP, 2000, J BACTERIOL, V182, P6036, DOI 10.1128/JB.182.21.6036-6041.2000; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P716, DOI 10.1006/bbrc.1999.1737; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KIM J, 2002, IN PRESS J BIOL CHEM; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Klein C, 1996, MOVEMENT DISORD, V11, P217, DOI 10.1002/mds.870110217; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; KOMATSU K, 1995, CANCER RES, V55, P1774; KOMATSU K, 1989, INT J RADIAT BIOL, V56, P863, DOI 10.1080/09553008914552331; Komatsu K, 1996, AM J HUM GENET, V58, P885; KOMATSU K, 1993, INT J RADIAT BIOL, V63, P725, DOI 10.1080/09553009314552121; Kraakman-van der Zwet M, 2001, MUTAT RES-DNA REPAIR, V485, P177, DOI 10.1016/S0921-8777(00)00078-1; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Lo AWI, 2002, MOL CELL BIOL, V22, P4836, DOI 10.1128/MCB.22.13.4836-4850.2002; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Manis JP, 2002, IMMUNITY, V16, P607, DOI 10.1016/S1074-7613(02)00306-0; Maraschio P, 2001, J MED GENET, V38, P113, DOI 10.1136/jmg.38.2.113; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Matsuura S, 1997, AM J HUM GENET, V60, P1487, DOI 10.1086/515461; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Neubauer S, 2002, RADIAT RES, V157, P312, DOI 10.1667/0033-7587(2002)157[0312:ROATAN]2.0.CO;2; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Resnick IB, 2002, J PEDIATR-US, V140, P355, DOI 10.1067/mpd.2002.122724; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saar K, 1997, AM J HUM GENET, V60, P605; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SEEMANOVA E, 1990, MUTAT RES, V238, P321, DOI 10.1016/0165-1110(90)90024-6; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stanulla M, 2000, BRIT J HAEMATOL, V109, P117, DOI 10.1046/j.1365-2141.2000.01973.x; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Stumm P, 2001, CANCER GENET CYTOGEN, V126, P60, DOI 10.1016/S0165-4608(00)00390-3; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Tauchi H, 2002, NATURE, V420, P93, DOI 10.1038/nature01125; Tauchi H, 2001, J BIOL CHEM, V276, P12, DOI 10.1074/jbc.C000578200; Tauchi H, 1999, GENOMICS, V55, P242, DOI 10.1006/geno.1998.5657; van Engelen BGM, 2001, HUM IMMUNOL, V62, P1324, DOI 10.1016/S0198-8859(01)00345-7; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Varon R, 2000, EUR J HUM GENET, V8, P900, DOI 10.1038/sj.ejhg.5200554; Varon R, 2001, CANCER RES, V61, P3570; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wilda M, 2000, HUM MOL GENET, V9, P1739, DOI 10.1093/hmg/9.12.1739; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yamazaki V, 1998, CANCER RES, V58, P2316; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	116	144	154	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8967	8980		10.1038/sj.onc.1206136	http://dx.doi.org/10.1038/sj.onc.1206136			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483513				2022-12-17	WOS:000179889500008
J	Koniaras, K; Cuddihy, AR; Christopoulos, H; Hogg, A; O'Connell, MJ				Koniaras, K; Cuddihy, AR; Christopoulos, H; Hogg, A; O'Connell, MJ			Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells	ONCOGENE			English	Article						checkpoint; Chk1; p53; Cds1; DNA damage	CHK1 PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; IONIZING-RADIATION; CYCLE CHECKPOINTS; CDK INHIBITORS; HUMAN MYT1; CDC2; ATR; ACTIVATION; EXTRACTS	Cell cycle checkpoints are surveillance mechanisms that monitor and coordinate the order and fidelity of cell cycle events. When defects in the division program of a cell are detected, checkpoints prevent the pursuant cell cycle transition through regulation of the relevant cyclin-cdk complex(es). Checkpoints that respond to DNA damage have been described for the G1, S and G2 phases of the cell cycle. The p53 tumour suppressor is a key regulator of G1/S checkpoints, and can promote cell cycle delay or apoptosis in response to DNA damage. The importance of these events to cellular physiology is highlighted by the fact that tumours, in which p53 is frequently mutated, have widespread defects in the G1/S DNA damage checkpoints and a heightened level of genomic instability. G2/M DNA damage checkpoints have been defined by yeast genetics, though the genes in this response are conserved in mammals. We show here using biochemical and physiological assays that p53 is dispensable for a DNA damage checkpoint activated in the G2 phase of the cell cycle. Moreover, upregulation of p53 through serine 20 phosphorylation, does not occur in G2. Conversely, we show that the Chk1 protein kinase is essential for the human G2 DNA damage checkpoint. Importantly, inhibition of Chk1 in p53 deficient cells greatly sensitizes them to radiation, validating the hypothesis of targeting Chk1 in rational drug design and development for anti-cancer therapies.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; University of Melbourne	O'Connell, MJ (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, St Andrews Pl, Melbourne, Vic 3002, Australia.			Cuddihy, Andrew/0000-0002-9898-0443				Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown EJ, 2000, GENE DEV, V14, P397; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fattaey A, 1997, Prog Cell Cycle Res, V3, P233; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson JR, 2000, CANCER RES, V60, P566; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KASTAN MB, 1991, CANCER RES, V51, P6304; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KRAKER AJ, 2000, P AM ASSOC CANC RES, V41, P468; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leu JY, 1999, MOL CELL, V4, P805, DOI 10.1016/S1097-2765(00)80390-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Masui Y, 1998, BIOL CELL, V90, P537, DOI 10.1016/S0248-4900(99)80011-2; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Raleigh JM, 2000, J CELL SCI, V113, P1727; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Roberge M, 1998, CANCER RES, V58, P5701; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schmidt-Kastner PK, 1998, ONCOGENE, V16, P3003, DOI 10.1038/sj.onc.1201835; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shieh SY, 2000, GENE DEV, V14, P289; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	55	144	152	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7453	7463		10.1038/sj.onc.1204942	http://dx.doi.org/10.1038/sj.onc.1204942			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709716				2022-12-17	WOS:000171976900001
J	Gross, M; Liu, B; Tan, JA; French, FS; Carey, M; Shuai, K				Gross, M; Liu, B; Tan, JA; French, FS; Carey, M; Shuai, K			Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen signaling; protein inhibitor of activated STAT	NUCLEAR-RECEPTOR; DEPENDENT TRANSCRIPTION; COACTIVATORS; BINDING; DETERMINANTS; SPECIFICITY; COREGULATOR; INHIBITION; REQUIRES; COMPLEX	Androgen signaling influences the development and growth of prostate carcinoma. The transcriptional activity of androgen receptor (AR) is regulated by positive or negative transcriptional cofactors, We report here that PIAS1, PIAS3, and PIASy of the protein inhibitor of activated STAT (PIAS) family, which are expressed in human prostate, display distinct effects on AR-mediated gene activation in prostate cancer cells. While PIAS1 and PIAS3 enhance the transcriptional activity of AR, PIASy acts as a potent inhibitor of AR in prostate cancer cells, The effects of PIAS proteins on AR are competitive. PIASy binds to AR but does not affect the DNA binding activity of AR. An NH2-terminal LXXLL signature motif of PIASy, although not required for PIASy-AR interaction, is essential for the transrepression activity of PIASy, Our results identify PIASy as a transcriptional corepressor of AR and suggest that different PIAS proteins have distinct effects on AR signaling in prostate cancer cells.	Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ N Carolina, Sch Med, Dept Pediat, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of California System; University of California Los Angeles	Shuai, K (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, 11-934 Factor Bldg,1083 LeConte Ave, Los Angeles, CA 90095 USA.			Gross, Mitchell/0000-0002-1691-921X; Carey, Michael/0000-0003-3899-6280	NIAID NIH HHS [AI43438] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043438, R01AI043438] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Bentel JM, 1996, J ENDOCRINOL, V151, P1, DOI 10.1677/joe.0.1510001; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Kokontis JM, 1999, VITAM HORM, V55, P219; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; McDonald S, 2000, CANCER RES, V60, P2317; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050	30	144	153	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3880	3887		10.1038/sj.onc.1204489	http://dx.doi.org/10.1038/sj.onc.1204489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439351				2022-12-17	WOS:000169494700013
J	Kojima, M; Morisaki, T; Izuhara, K; Uchiyama, A; Matsunari, Y; Katano, M; Tanaka, M				Kojima, M; Morisaki, T; Izuhara, K; Uchiyama, A; Matsunari, Y; Katano, M; Tanaka, M			Lipopolysaccharide increases cyclo-oxygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation	ONCOGENE			English	Article						colon carcinoma; LPS; PGE2; COX-2; NF-kappa B	CYCLOOXYGENASE-2 GENE-EXPRESSION; EPITHELIAL-CELLS; INDUCIBLE CYCLOOXYGENASE; GASTRIC-CARCINOMA; MESSENGER-RNA; UP-REGULATION; CANCER CELLS; MACROPHAGES; PROTEIN; INDUCTION	Both nonneoplastic colon epithelium and colon carcinoma cells in situ are continuously exposed to lipopolysaccharide (LPS), Few reports have addressed possible direct effects of LPS in promotion of colon carcinoma and underlying mechanisms. We found evidence that LPS directly stimulated growth of the human colon carcinoma cell line CE-1 through an increase in the production of prostaglandin E-2 (PGE(2)) as a result of cyclo-oxygenase-2 (COX-2) expression. LPS induced significant increases in PGE(2) production in CE-1 cells, which were found to express a high-affinity LPS receptor, CD14, Positive correlations were found between PGE(2) production and activation of nuclear factor (NF)-kappa B as well as expression of both COX-2 mRNA and protein in LPS-stimnlated CE-I cells. When CE-1 cells were exposed to exogenous PGE(2), DNA synthesis increased. These results indicate that LPS may stimulate DNA synthesis in certain colon carcinoma cells as a result of PGE(2) production involving increased COX-2 expression that might result in turn from activation of NF-kappa B by LPS, Further investigation of the pathways mediating LPS-induced stimulation of colon carcinoma cells may provide insights into LPS effects in in vivo tumor biology.	Kyushu Univ, Grad Sch Med Sci, Fac Med, Dept Clin Chem & Lab Med,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Surg 1, Div Clin Immunol,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Morisaki, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Fac Med, Dept Clin Chem & Lab Med,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bellezzo JM, 1998, J LAB CLIN MED, V131, P36, DOI 10.1016/S0022-2143(98)90075-0; Brophy VH, 1998, IMMUNOGENETICS, V47, P196; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; DuBois RN, 1996, CANCER RES, V56, P733; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GustafsonSvard C, 1996, GUT, V38, P79, DOI 10.1136/gut.38.1.79; Hida T, 1998, CANCER RES, V58, P3761; Huang M, 1998, CANCER RES, V58, P1208; Huang M, 1996, J IMMUNOL, V157, P5512; Ikebe T, 1998, INT J CANCER, V77, P578; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kirkevold M, 1997, SCAND J CARING SCI, V11, P65, DOI 10.1111/j.1471-6712.1997.tb00434.x; Kucharzik T, 1997, CLIN EXP IMMUNOL, V110, P296; LEE SH, 1992, J BIOL CHEM, V267, P25934; MASTINO A, 1993, CELL IMMUNOL, V152, P120, DOI 10.1006/cimm.1993.1272; MAXWELL WJ, 1990, DIGESTION, V47, P160, DOI 10.1159/000200492; Mayeux PR, 1997, J TOXICOL ENV HEALTH, V51, P415, DOI 10.1080/00984109708984034; MORISAKI T, 1992, CANCER RES, V52, P6059; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; Reddy BS, 1996, CANCER RES, V56, P4566; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Ristimaki A, 1997, CANCER RES, V57, P1276; SANO H, 1995, CANCER RES, V55, P3785; SATO H, 1993, ONCOGENE, V8, P395; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Suh N, 1998, CANCER RES, V58, P717; Tanaka C, 1997, BIOCHEM BIOPH RES CO, V232, P568, DOI 10.1006/bbrc.1997.6264; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wolff H, 1998, CANCER RES, V58, P4997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	52	144	156	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1225	1231		10.1038/sj.onc.1203427	http://dx.doi.org/10.1038/sj.onc.1203427			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713711				2022-12-17	WOS:000085567800013
J	Steegenga, WT; Riteco, N; Jochemsen, AG; Fallaux, FJ; Bos, JL				Steegenga, WT; Riteco, N; Jochemsen, AG; Fallaux, FJ; Bos, JL			The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells	ONCOGENE			English	Article						p53; adenovirus; E1A; large E1B; E4orf6	HUMAN PAPILLOMAVIRUS TYPE-16; TRANSFORMED-CELLS; EARLY REGION-4; TUMOR-ANTIGEN; E6 ONCOPROTEIN; CELLULAR P53; WILD-TYPE; TRANSCRIPTIONAL REPRESSION; BINDING PROTEIN; EXPRESSION	It has recently been shown that an adenovirus mutant lacking expression of the large E1B protein (Delta E1B) selectively replicates in p53 deficient cells. However, apart from the large E1B protein the adenovirus early region encodes the E1A and E4orf6 proteins which also have been reported to affect p53 expression as well as its functioning. After infection with wild-type adenovirus we observed a dramatic decrease in wild-type p53 expression while no down-regulation of p53 could be detected after infection with the Delta E1B virus. The different effects of the wild-type and Delta E1B adenovirus on p53 expression were not only found in cells expressing wild-type p53 but mere also observed when tumor cells expressing highly stabilized mutant p53 were infected with these two viruses. Infection with different adenovirus mutants indicated the importance of a direct interaction between p53 and the large E1B protein for reduced p53 expression after infection. Moreover, coexpression of the E4orf6 protein was found to be required for this phenomenon, while expression of E1A is dispensable. Tn addition, we provide evidence that p53 is actively degraded in wild-type adenovirus-infected cells but not in Delta E1B-infected cells.	Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands; Leiden Univ, Sylvius Labs, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands	Utrecht University; Leiden University; Leiden University - Excl LUMC	Steegenga, WT (corresponding author), Univ Utrecht, Physiol Chem Lab, POB 80042, NL-3508 TA Utrecht, Netherlands.							Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAHAM FL, 1991, GENE TRANSFER EXPRES; GRAND RJA, 1995, VIROLOGY, V210, P323, DOI 10.1006/viro.1995.1349; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grand RJA, 1996, VIROLOGY, V218, P23, DOI 10.1006/viro.1996.0162; GRAND RJA, 1993, VIROLOGY, V193, P579, DOI 10.1006/viro.1993.1166; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Marcellus RC, 1996, J VIROL, V70, P6207, DOI 10.1128/JVI.70.9.6207-6215.1996; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; STEEGENGA WT, 1995, ONCOGENE, V11, P49; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STRATFORDPERRIC.LD, 1991, HUMAN GENE TRANSFER; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; VOJTESEK B, 1993, J CELL SCI, V105, P607; WEINBERG DH, 1983, P NATL ACAD SCI-BIOL, V80, P5383, DOI 10.1073/pnas.80.17.5383; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	144	150	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					349	357		10.1038/sj.onc.1201540	http://dx.doi.org/10.1038/sj.onc.1201540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467960				2022-12-17	WOS:000071582100007
J	Cacace, AM; Ueffing, M; Philipp, A; Han, EKH; Kolch, W; Weinstein, IB				Cacace, AM; Ueffing, M; Philipp, A; Han, EKH; Kolch, W; Weinstein, IB			PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase	ONCOGENE			English	Article						PKC epsilon; Raf; oncogene	MITOGENIC SIGNAL-TRANSDUCTION; PROTEIN-KINASE; MAP KINASE; IN-VITRO; C FAMILY; TYROSINE PHOSPHORYLATION; 3T3 CELLS; GROWTH; FIBROBLASTS; PATHWAY	Previous studies have indicated that PKC epsilon behaves as an oncogene when overproduced in rodent fibroblasts (Cacace ef al., 1993; Mishak et al., 1993), In the present study, Western blot analysis revealed that the hyperphosphorylated form of Raf kinase was present at a high level in PKC epsilon overproducing R6 rat fibroblasts but not in R6 fibroblasts overproducing PKC alpha or beta 1. Extracts from the PKC epsilon overproducing cells also exhibited a marked increase in Raf-l kinase and MAP-kinase activity, To investigate the significance of these findings, dominant negative mutants of ras (N17) or raf (301-1) were stably expressed in early passage control and PKC epsilon-transformed R6 fibroblasts, by transduction using retrovirus-derived constructs, Dominant negative mf expressing clones exhibited a flat morphology, a decreased saturation density, and decreased growth in soft agar, In addition, these reverted clones exhibited decreased Raf kinase activity, In contrast, dominant negative ras expressing clones remained highly transformed, In addition, PKC epsilon was detected in Raf-l immunoprecipitates indicating that PKC epsilon forms a complex with Raf-l in vivo, Taken together, these results suggest that PKC epsilon functions as an oncogene in R6 cells by enhancing activation of the Raf-l kinase.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; GSF MUNICH,INST KLIN MOL BIOL & TUMORGENET,HAMATOLOGIKUM,D-81377 MUNICH,GERMANY	Columbia University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Kolch, Walter/0000-0001-5777-5016	NCI NIH HHS [CA 02656] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEE KS, 1993, MCB, V13, P3167; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LU X, 1993, CELL, V73, P571; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; RAPP UR, 1991, ONCOGENE, V6, P495; SOZERI O, 1992, ONCOGENE, V7, P2259; SZEBERENYI J, 1990, MOL CELL BIOL, V12, P5329; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARNER LC, 1993, ONCOGENE, V8, P3249; WEINSTEIN IB, 1990, ORIGINS HUMAN CANC C, P113; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	54	144	145	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2517	2526						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000126				2022-12-17	WOS:A1996VZ65400002
J	Smith, ML; Kontny, HU; Zhan, QM; Sreenath, A; OConnor, PM; Fornace, AJ				Smith, ML; Kontny, HU; Zhan, QM; Sreenath, A; OConnor, PM; Fornace, AJ			Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to uv-irradiation or cisplatin	ONCOGENE			English	Article						p53; GADD45; repair	NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL DOMAIN; NUCLEAR ANTIGEN; GROWTH ARREST; G1 CHECKPOINT; P53; DAMAGE; PROTEIN; INHIBITION; REPLICATION	Loss of p53 function in cancer cells commonly results in a condition of genomic instability. This is believed to emanate from a loss of the G(1) checkpoint response to DNA damage. While the role of p53 in the induction of a G(1) arrest is well-accepted, additional p53 functions are being discovered. Cell cycle checkpoints presumably function to allow additional time for DNA repair after damage is incurred, however, genetic studies in yeast suggest that components of the checkpoint pathway may also be involved in DNA lesion processing (Lydall and Weinert, 1995). Recent evidence suggests that this may also be the case for p53, as suggested by numerous reports linking p53 function to DNA repair. Thus, loss of p53 function might contribute to genomic instability independent of G(1)-arrest. In the present study, we explored the effect of p53 disruption and consequences of antisense GADD45 expression on the DNA repair capacity of human colon carcinoma RKO cells. DNA repair was assayed using host-cell reactivation of u.v.-damaged reporter plasmids and unscheduled DNA synthesis experiments in transiently-transfected cells. We show that a number of transfected genes that suppress p53 function reduce the ability of cells to repair u.v.-induced DNA damage. Moreover, cells in which expression of the p53-regulated gene GADD45 was blocked by antisense vectors, also showed altered levels of DNA repair. Blocking Gadd45 expression by constitutive antisense expression sensitized cells to killing by u.v.-radiation or by cis-platinum (II) diamine-dichloride (CDDP, or cisplatin), a cancer chemotherapy drug which produces DNA cross-links. These findings suggest the involvement of downstream effecters of the p53 pathway in the coordination of cell cycle arrest and DNA repair.			Smith, ML (corresponding author), NCI,DIV CANC TREATMENT,MOL PHARMACOL LAB,DEV THERAPEUT PROGRAM,NIH,BLDG 37,ROOM 5C09,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bae I, 1996, CANCER RES, V56, P840; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BURK PG, 1971, J LAB CLIN MED, V77, P759; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN IT, 1995, ONCOGENE, V11, P1931; COFFER PJ, 1995, ONCOGENE, V11, P561; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FAN SJ, 1995, CANCER RES, V55, P1649; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDBERG EC, 1995, DNA REPAIR; HALL PA, 1995, ONCOGENE, V10, P2427; HAVRE PA, 1995, CANCER RES, V55, P4420; Hawkins DS, 1996, CANCER RES, V56, P892; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KLOCKER H, 1985, European Journal of Cell Biology, V39, P346; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Li G, 1996, AM J PATHOL, V148, P1113; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; McDonald E, 1996, CANCER RES, V56, P2250; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; Smith ML, 1996, AM J PATHOL, V148, P1019; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vairapandi M, 1996, ONCOGENE, V12, P2579; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1995, INT J ONCOL, V6, P937	44	144	153	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2255	2263						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950993				2022-12-17	WOS:A1996VV14500023
J	Boulakia, CA; Chen, G; Ng, FWH; Teodoro, JG; Branton, PE; Nicholson, DW; Poirier, GG; Shore, GC				Boulakia, CA; Chen, G; Ng, FWH; Teodoro, JG; Branton, PE; Nicholson, DW; Poirier, GG; Shore, GC			Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase	ONCOGENE			English	Article						apoptosia; E1A; PARP; CPP32; Bcl-2; E1B 19K	PROGRAMMED CELL-DEATH; C-ELEGANS; GENE CED-3; APOPTOSIS; TRANSFORMATION; POLYPEPTIDES; ASSOCIATION; INDUCTION; ENZYME	The E1A oncoproteins of adenovirus type 5 are potent inducers of apoptotic cell death. To manifest growth promoting and transforming properties, therefore, E1A requires the co-expression of a suppressor of apoptosis. During normal viral infection, this function is provided by the E1B 19 kDa protein. However, the cellular suppressor Bcl-2 can substitute for 19K during infection, and both proteins can effectively cooperate with E1A to facilitate transformation of primary cells in culture. How E1A induces apoptosis and at what point(s) on this pathway Bcl-2 and E1B 19K act are not presently known. Here, we demonstrate that E1A-induced apoptosis is accompanied by specific endo-proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), an event that is linked to the Ced-3/ICE apoptotic pathway in other systems. PARP cleavage was also observed in p53-null cells infected with 19K(-) virus expressing 13S EIA. In addition to PARP cleavage, expression of E1A caused processing of the zymogen form of CPP32, a Ced-3/ICE protease that cleaves PARP and is required for apoptosis in mammalian cells. These events were prevented when EIA was co-expressed with E1B 19K or BCL-2, which places these suppressors of apoptosis either at or upstream of processing of pro-CPP32.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; CHU LAVAL,RES CTR,DEPT MOLEC ENDOCRINOL,POLY ADP RIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA	McGill University; Merck & Company; Laval University			Teodoro, Joe/AFT-2440-2022	Teodoro, Joe/0000-0002-3713-6839; Poirier, Guy/0000-0002-4869-1424				BARBEAU D, 1994, ONCOGENE, V9, P359; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BURKLE A, 1992, EXP CLIN IMMUNOGENET, V9, P230; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; EGAN C, 1988, MOL CELL BIOL, V8, P869; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARVEY DM, 1991, GENE DEV, V5, P2365; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TEODORO JG, 1995, ONCOGENE, V11, P467; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	52	144	149	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					529	535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637709				2022-12-17	WOS:A1996TV59700009
J	SALGIA, R; BRUNKHORST, B; PISICK, E; LI, JL; LO, SH; CHEN, LB; GRIFFIN, JD				SALGIA, R; BRUNKHORST, B; PISICK, E; LI, JL; LO, SH; CHEN, LB; GRIFFIN, JD			INCREASED TYROSINE PHOSPHORYLATION OF FOCAL ADHESION PROTEINS IN MYELOID CELL-LINES EXPRESSING P210(BCR/ABL)	ONCOGENE			English	Article						P210(BCR/AB1); ACTIN; TYROSINE PHOSPHORYLATION; CYTOSKELETAL PROTEINS	CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; KINASE; PAXILLIN; BINDING; ABL; BCR; TRANSFORMATION; FIBROBLASTS; FIBRONECTIN	The BCR/ABL oncogene causes chronic myelogenous leukemia (CML) in humans and induces growth factor independence of hematopoietic cell lines in tissue culture. p210(BCR/ABL) is localized at least in part to the cytoskeleton, and has been shown to interact directly with actin filaments through an actin binding domain located in the C-terminus of ABL. CML cells have reduced adhesion to some extracellular matrix components but the mechanism of this phenomenon is unknown. In this study we examined tyrosine phosphorylation of focal adhesion proteins in cells expressing p210(BCR/ABL) An interleukin-3 (IL-3)-dependent cell line, 32Dc13, was transformed with a BCR/ABL cDNA, and the patterns of localization, expression, and tyrosine phosphorylation of focal adhesion proteins were compared among untransformed 32Dc13 cells with and without IL-3 stimulation and BCR/ABL-transformed 32Dc13 cells. Of the focal adhesion proteins examined, only paxillin exhibited tyrosine phosphorylation in response to IL-3; while in cells transformed by p210(BCR/ABL), paxillin, vinculin, p125(FAK), talin and tensin were constitutively tyrosine phosphorylated. IL-3 induced a transient association between paxillin and vinculin, while in BCR/ABL-transformed cells, several proteins coimmunoprecipitated with paxillin, including vinculin, p125(FAK), talin and tensin. Pseudopodia enriched in focal adhesion proteins were transiently detected in 32Dc13 cells in response to IL-3, but constitutively detected in cells expressing p210(BCR/ABL). P210(BCR/ABL) protein was also found concentrated in punctate structures adjacent to the cell membrane in myeloid cell lines, which often contained vinculin and paxillin. Since the focal adhesion is where the interaction between integrins and actin filaments is believed to occur, the observed effect of p210(BCR/ABL) on food adhesion protein interactions in myeloid cell lines could contribute to the adhesion defects in CML cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X; Lo, Su Hao/0000-0002-2675-9387				AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DRUKER B, 1992, BLOOD, V79, P2215; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	35	144	147	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	1995	11	6					1149	1155						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566975				2022-12-17	WOS:A1995RX18000018
J	RAMQVIST, T; MAGNUSSON, KP; WANG, YS; SZEKELY, L; KLEIN, G; WIMAN, KG				RAMQVIST, T; MAGNUSSON, KP; WANG, YS; SZEKELY, L; KLEIN, G; WIMAN, KG			WILD-TYPE P53 INDUCED APOPTOSIS IN A BURKITT-LYMPHOMA (BL) LINE THAT CARRIES MUTANT P53	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; PROGRAMMED CELL-DEATH; TUMOR-ANTIGEN; PROTEIN; GROWTH; TRANSLOCATION; LOCALIZATION; ASSOCIATION; MUTATIONS; INDUCTION	All Burkitt lymphoma (BL) biopsies and cell lines carry a c-myc/Ig translocation. The resulting constitutive activation of c-myc is regarded as an essential factor for the progressive growth of the tumor cells. At least 60% of BL cell lines carry a mutated p53 gene as well. It has been shown that the growth of mutant p53 carrying tumor cells could be inhibited by the introduction of wild-type p53. In order to examine whether this also applies to the presumably 'myc-driven' BL cell, we have transfected the Epstein-Barr virus (EBV) negative BL41 cell line with a temperature sensitive p53 mutant (p53-Val135) that expresses p53 with a largely mutant conformation at 37.5-degrees-C and mostly wild-type conformation at 32-degrees-C. At 37.5-degrees-C, the p53-Val135 transfected cells behaved like the parental or neo transfected control cells. However, expression of exogenous wild-type p53 at 32-degrees-C resulted in a rapid reduction of the number of viable cells white the parental and neo control cells remained unaffected. Cell death was due to apoptosis as shown by chromatin and nuclear condensation and specific DNA fragmentation. The first signs of apoptosis were evident after 10 h at 32-degrees-C and after 3 days 90-100% of the cells had undergone apoptosis. These findings indicate an incompatibility between expression of wild-type p53 and progressive growth of BL cells if their neoplastic development has included a p53 mutation. The question whether apoptosis was induced in by the wild-type protein per se or by the contradictory signals of a constitutively activated c-myc and wild-type p53 needs further investigation.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Wiman, Klas/AAB-8399-2021; Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Szekely, Laszlo/B-1268-2009	Wiman, Klas/0000-0002-7113-524X; Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; 	NCI NIH HHS [5R01 CA14054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P553; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CASEY G, 1991, ONCOGENE, V6, P1791; CHENG J, 1992, CANCER RES, V52, P222; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; ISAACS WB, 1991, CANCER RES, V51, P4716; LANE DP, 1979, NATURE, V351, P453; LENIOR GM, 1985, IARC SCI PUBL, V60, P309; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHALUSKY G, 1991, P NATL ACAD SCI USA, V88, P8982; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; TORSTEINSDOTTIR S, 1989, INT J CANCER, V43, P273, DOI 10.1002/ijc.2910430219; VOSS H, 1992, Methods in Molecular and Cellular Biology, V3, P30; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIMAN KG, 1991, ONCOGENE, V6, P1633; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	144	146	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1495	1500						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502475				2022-12-17	WOS:A1993LE06400012
J	ZASTAWNY, RL; SALVINO, R; CHEN, JM; BENCHIMOL, S; LING, V				ZASTAWNY, RL; SALVINO, R; CHEN, JM; BENCHIMOL, S; LING, V			THE CORE PROMOTER REGION OF THE P-GLYCOPROTEIN GENE IS SUFFICIENT TO CONFER DIFFERENTIAL RESPONSIVENESS TO WILD-TYPE AND MUTANT P53	ONCOGENE			English	Article							MULTIDRUG-RESISTANCE GENE; MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; EXPRESSION; CELLS; DNA; TISSUES; SUPPRESSOR; SEQUENCE; PRODUCT	The overexpression of P-glycoprotein is thought to be responsible for resistance to chemotherapy in some non-responsive cancers. The mechanism by which P-glycoprotein is overexpressed in human tumors is poorly understood. However, several lines of evidence suggest that the major regulatory mechanism of P-glycoprotein overexpression in human tumors is at the transcriptional level. During tumor progression one of the most commonly observed alterations is mutation of the p53 tumor-suppressor gene. It has been shown that the p53 protein plays a role in transcriptional regulation. To gain insight into the effect p53 protein may have on P-glycoprotein promoter activity, we transiently co-transfected plasmids containing the hamster pgp1 or human mdr1 promoter linked to the chloramphenicol acetyltransferase (CAT) reporter gene with plasmids encoding either wild-type or mutant p53 protein into Chinese hamster ovary (CHO) cells. In this report, we show that wild-type p53 protein represses P-glycoprotein promoter activity, while mutant forms of p53 protein enhance P-glycoprotein promoter activity. Furthermore, we present data which indicate that the transcriptional regulatory effects of p53 are mediated through interactions with pgp1/mdr1 core promoter sequences. These findings have implications for our understanding of the molecular mechanism(s) by which p53 protein functions as a transcriptional regulator of gene expression. In addition, our results suggest a mechanism by which P-glycoprotein may be overexpressed in human cancers that also express mutant forms of p53 protein.	UNIV TORONTO,ONTARIO CANC INST,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X	NCI NIH HHS [CA37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL DR, 1985, J CLIN ONCOL, V3, P311, DOI 10.1200/JCO.1985.3.3.311; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEUCHARS KL, 1987, MOL CELL BIOL, V7, P718, DOI 10.1128/MCB.7.2.718; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMADA H, 1988, CANCER RES, V48, P4926; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HIRT B, 1967, J MOL BIOL, V26, P363; JARRELL KA, 1991, P NATL ACAD SCI USA, V88, P102, DOI 10.1073/pnas.88.1.102; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MA DDF, 1987, LANCET, V1, P135; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	40	144	147	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1529	1535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502478				2022-12-17	WOS:A1993LE06400016
J	FIELD, JK; SPANDIDOS, DA; STELL, PM; VAUGHAN, ED; EVAN, GI; MOORE, JP				FIELD, JK; SPANDIDOS, DA; STELL, PM; VAUGHAN, ED; EVAN, GI; MOORE, JP			ELEVATED EXPRESSION OF THE C-MYC ONCOPROTEIN CORRELATES WITH POOR PROGNOSIS IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA	ONCOGENE			English	Article									UNIV LIVERPOOL, DEPT OTORHINOLARYNGOL, LIVERPOOL L69 3BX, ENGLAND; NATL HELLENIC RES FDN, BIOL RES CTR, GR-11635 ATHENS, GREECE; ST BARTHOLOMEWS HOSP, IMPERIAL CANC RES FUND, LONDON EC1A 7BE, ENGLAND; INST CANC RES, CHESTER BEATTY RES INST, SUTTON SM2 5PX, SURREY, ENGLAND; BEATSON INST CANC RES, GLASGOW G61 1BD, SCOTLAND; WALTON HOSP, DEPT MAXILLOFACIAL SURG, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND	University of Liverpool; National Hellenic Research Foundation; Cancer Research UK; University of London; Queen Mary University London; University of London; Institute of Cancer Research - UK; Beatson Institute; Walton Centre	FIELD, JK (corresponding author), UNIV LIVERPOOL, DEPT CLIN DENT SCI, POB 147, LIVERPOOL L69 3BX, ENGLAND.		Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365; Spandidos, Demetrios/0000-0002-1146-931X				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1987, CANCER RES, V47, P4248; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DAVIS RK, 1985, OTOLARYNG CLIN N AM, V18, P411; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; EISENMAN RN, 1986, CANCER SURV, V5, P309; ERISMAN MD, 1988, CANCER RES, V48, P1350; ERISMAN MD, 1988, ONCOGENE, V2, P367; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1988, CURR TOP MICROBIOL, V141, P189; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; FIELD JK, 1986, ANTICANCER RES, V6, P595; HARMER MN, 1978, UNION INT CANCER TNM; HOLM LE, 1983, LARYNGOSCOPE, V93, P792; JOHANSSON A, 1986, J IMMUNOL METHODS, V87, P7, DOI 10.1016/0022-1759(86)90337-6; JOHNSON BE, 1988, CANCER RES, V48, P5163; KALNINS IK, 1977, AM J SURG, V134, P450, DOI 10.1016/0002-9610(77)90376-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ AE, 1983, LARYNGOSCOPE, V93, P445; KOZBOR D, 1984, CANCER RES, V44, P438; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOORE JP, 1987, ONCOGENE RES, V2, P65; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RIOU G, 1987, LANCET, V1, P761; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEEGER RC, 1987, P AM ASSOC CANC RES, V28, P23; SELF CH, 1985, J IMMUNOL METHODS, V76, P389, DOI 10.1016/0022-1759(85)90316-3; Siegel S, 1956, NONPARAMETRIC STATIS; SIKORA K, 1985, BRIT J CANCER, V52, P171, DOI 10.1038/bjc.1985.174; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPANDIDOS DA, 1985, ANTICANCER RES, V5, P221; STANLEY CJ, 1985, J IMMUNOL METHODS, V83, P89, DOI 10.1016/0022-1759(85)90061-4; STELL PM, 1989, IN PRESS CLIN OTOL; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; VARLEY JM, 1987, ONCOGENE, V1, P423; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; 1978, MANUAL STAGING CANCE	45	144	146	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1463	1468						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687767				2022-12-17	WOS:A1989CB65900007
J	Papa, S; Choy, PM; Bubici, C				Papa, Salvatore; Choy, Pui Man; Bubici, Concetta			The ERK and JNK pathways in the regulation of metabolic reprogramming	ONCOGENE			English	Review							PYRUVATE-KINASE M2; AEROBIC GLYCOLYSIS; CELL-METABOLISM; GLUCOSE-METABOLISM; BRAF INHIBITION; DENDRITIC CELL; PROTEIN-KINASE; TUMOR-GROWTH; STEM-CELLS; CANCER	Most tumor cells reprogram their glucose metabolism as a result of mutations in oncogenes and tumor suppressors, leading to the constitutive activation of signaling pathways involved in cell growth. This metabolic reprogramming, known as aerobic glycolysis or the Warburg effect, allows tumor cells to sustain their fast proliferation and evade apoptosis. Interfering with oncogenic signaling pathways that regulate the Warburg effect in cancer cells has therefore become an attractive anticancer strategy. However, evidence for the occurrence of the Warburg effect in physiological processes has also been documented. As such, close consideration of which signaling pathways are beneficial targets and the effect of their inhibition on physiological processes are essential. The MAPK/ERK and MAPK/JNK pathways, crucial for normal cellular responses to extracellular stimuli, have recently emerged as key regulators of the Warburg effect during tumorigenesis and normal cellular functions. In this review, we summarize our current understanding of the roles of the ERK and JNK pathways in controlling the Warburg effect in cancer and discuss their implication in controlling this metabolic reprogramming in physiological processes and opportunities for targeting their downstream effectors for therapeutic purposes.	[Papa, Salvatore; Choy, Pui Man] Univ Leeds, St James Univ Hosp, Fac Med & Hlth, Cell Signaling & Canc Lab,Leeds Inst Canc & Patho, Leeds, W Yorkshire, England; [Choy, Pui Man] hVIVO PLC, Dept Res & Dev, Biopk,Broadwater Rd, Welwyn Garden City, Herts, England; [Bubici, Concetta] Brunel Univ London, Div Biosci, Inst Environm Hlth & Soc, Coll Hlth & Life Sci,Dept Life Sci, Uxbridge, Middx, England; [Bubici, Concetta] Imperial Coll London, Fac Med, Dept Med, London, England	Saint James's University Hospital; University of Leeds; Brunel University; Imperial College London	Papa, S (corresponding author), Univ Leeds, St James Univ Hosp, Fac Med & Hlth, Cell Signaling & Canc Lab,Leeds Inst Canc & Patho, Leeds, W Yorkshire, England.; Bubici, C (corresponding author), Brunel Univ London, Div Biosci, Inst Environm Hlth & Soc, Coll Hlth & Life Sci,Dept Life Sci, Uxbridge, Middx, England.; Bubici, C (corresponding author), Imperial Coll London, Fac Med, Dept Med, London, England.	s.papa@leeds.ac.uk; concetta.bubici@brunel.ac.uk	Papa, Salvatore/J-9413-2012	Papa, Salvatore/0000-0002-8369-6538; Bubici, Concetta/0000-0002-8074-4661	Brunel Research Initiative & Enterprise Fund, Brunel University of London; Kay Kendall Leukemia Fund [KKL443]; 250 Great Minds Fellowship, University of Leeds; AMMF Cholangiocarcinoma Charity; Bloodwise [17014]	Brunel Research Initiative & Enterprise Fund, Brunel University of London; Kay Kendall Leukemia Fund; 250 Great Minds Fellowship, University of Leeds; AMMF Cholangiocarcinoma Charity; Bloodwise	The authors acknowledge the research funding from Brunel Research Initiative & Enterprise Fund, Brunel University of London (to CB), Kay Kendall Leukemia Fund (KKL443) (to CB), 250 Great Minds Fellowship, University of Leeds (to SP), AMMF Cholangiocarcinoma Charity (to SP and PMC), and Bloodwise (17014) (to SP and CB).	Agathocleous M, 2012, NAT CELL BIOL, V14, P859, DOI 10.1038/ncb2531; Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Anbalagan M, 2012, INT J CANCER, V130, P1967, DOI 10.1002/ijc.26207; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Barbarulo A, 2013, ONCOGENE, V32, P4231, DOI 10.1038/onc.2012.448; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016; Biswas SK, 2012, IMMUNOL RES, V53, P11, DOI 10.1007/s12026-012-8291-9; Biswas SK, 2012, CELL METAB, V15, P432, DOI 10.1016/j.cmet.2011.11.013; Blaxter K, 1989, ENERGY METABOLISM AN; Board RE, 2009, BRIT J CANCER, V101, P1724, DOI 10.1038/sj.bjc.6605371; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Canto C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Cellurale C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012469; Chang CH, 2016, NAT IMMUNOL, V17, P364, DOI 10.1038/ni.3415; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chen NY, 2001, CANCER RES, V61, P3908; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Chung S, 2010, J MOL CELL CARDIOL, V48, P725, DOI 10.1016/j.yjmcc.2009.12.014; Cortes-Cros M, 2013, P NATL ACAD SCI USA, V110, P489, DOI 10.1073/pnas.1212780110; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Dayton TL, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0179-2; Dayton TL, 2016, GENE DEV, V30, P1020, DOI 10.1101/gad.278549.116; Deng HB, 2008, J BIOL CHEM, V283, P20754, DOI 10.1074/jbc.M800024200; Dixit D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.179; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Edmunds LR, 2014, J BIOL CHEM, V289, P25382, DOI 10.1074/jbc.M114.580662; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Everts B, 2012, BLOOD, V120, P1422, DOI 10.1182/blood-2012-03-419747; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Folmes CDL, 2013, J CARDIOVASC TRANSL, V6, P10, DOI 10.1007/s12265-012-9431-2; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Fritz HL, 1999, HISTOCHEM CELL BIOL, V112, P359, DOI 10.1007/s004180050417; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghesquiere B, 2014, NATURE, V511, P167, DOI 10.1038/nature13312; Goetzman ES, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00129; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Goyal MS, 2014, CELL METAB, V19, P49, DOI 10.1016/j.cmet.2013.11.020; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; Graves JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037699; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hall A, 2013, ONCOTARGET, V4, P584, DOI 10.18632/oncotarget.965; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hardeman KN, 2017, SCI REP-UK, V7, DOI 10.1038/srep42604; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hardie DG, 2015, CLIN CANCER RES, V21, P3836, DOI 10.1158/1078-0432.CCR-14-3300; Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77; HEDESKOV CJ, 1968, BIOCHEM J, V110, P373, DOI 10.1042/bj1100373; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Ho PC, 2015, CELL, V162, P1217, DOI 10.1016/j.cell.2015.08.012; Hom JR, 2011, DEV CELL, V21, P469, DOI 10.1016/j.devcel.2011.08.008; Hosios AM, 2018, J BIOL CHEM, V293, P7490, DOI 10.1074/jbc.TM117.000239; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; John S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017674; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kawashima I, 2015, EXP HEMATOL, V43, P524, DOI 10.1016/j.exphem.2015.03.005; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Khamari R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0340-4; Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017; Kondoh H, 2007, ANTIOXID REDOX SIGN, V9, P293, DOI 10.1089/ars.2006.1467; Kosteli A, 2010, J CLIN INVEST, V120, P3466, DOI 10.1172/JCI42845; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Lee MH, 2011, J CLIN ENDOCR METAB, V96, pE19, DOI 10.1210/jc.2010-1071; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Lehninger A., 1993, PRINCIPLES BIOCH; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li WL, 2018, ONCOGENE, V37, P6383, DOI 10.1038/s41388-018-0402-1; Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lim SO, 2016, CANCER RES, V76, P1284, DOI 10.1158/0008-5472.CAN-15-2478; Locasale JW, 2011, CELL METAB, V14, P443, DOI 10.1016/j.cmet.2011.07.014; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Lunt SY, 2015, MOL CELL, V57, P95, DOI 10.1016/j.molcel.2014.10.027; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Lusk G, 1909, ELEMENTS SCI NUTR; Marko AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015425; Martin OJ, 2014, CIRC RES, V114, P626, DOI 10.1161/CIRCRESAHA.114.302562; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Miniotis MF, 2013, CANCER RES, V73, P4039, DOI 10.1158/0008-5472.CAN-12-1969; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; MUNYON WH, 1959, EXP CELL RES, V17, P490, DOI 10.1016/0014-4827(59)90069-2; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI [10.1016/j.cmet.2015.01.017, 10.1016/j.cmet.2014.12.005]; Panopoulos AD, 2012, CELL RES, V22, P168, DOI 10.1038/cr.2011.177; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Papa S, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1103398; Parmenter TJ, 2014, CANCER DISCOV, V4, P423, DOI 10.1158/2159-8290.CD-13-0440; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; POUYSSEGUR J, 1980, NATURE, V287, P445, DOI 10.1038/287445a0; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635; Senyilmaz Deniz, 2015, F1000Prime Rep, V7, P41, DOI 10.12703/P7-41; Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Solinas G, 2017, MOL METAB, V6, DOI 10.1016/j.molmet.2016.12.001; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; Taha C, 1999, J BIOL CHEM, V274, P33085, DOI 10.1074/jbc.274.46.33085; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; Tech K, 2017, CANCER RES, V77, P3217, DOI 10.1158/0008-5472.CAN-16-3304; Traves PG, 2012, J IMMUNOL, V188, P1402, DOI 10.4049/jimmunol.1101781; Van den Bossche J, 2016, CELL REP, V17, P684, DOI 10.1016/j.celrep.2016.09.008; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914; Vernia S, 2014, CELL METAB, V20, P512, DOI 10.1016/j.cmet.2014.06.010; Wang RN, 2012, NAT IMMUNOL, V13, P907, DOI 10.1038/ni.2386; Wang YH, 2014, CELL, V158, P1309, DOI 10.1016/j.cell.2014.07.048; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006783; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593; Wiese EK, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00079; Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035; Yang R, 2007, J BIOL CHEM, V282, P22765, DOI 10.1074/jbc.M700790200; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zheng X, 2016, ELIFE, V5, DOI [10.7554/eLife.18638, 10.7554/eLife.13374]; Zhou Q, 2008, J NEUROCHEM, V104, P325, DOI 10.1111/j.1471-4159.2007.04957.x; Zhou WY, 2012, EMBO J, V31, P2103, DOI 10.1038/emboj.2012.71	153	143	147	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2223	2240		10.1038/s41388-018-0582-8	http://dx.doi.org/10.1038/s41388-018-0582-8			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30487597	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000462588000001
J	Sherman, MY; Gabai, VL				Sherman, M. Y.; Gabai, V. L.			Hsp70 in cancer: back to the future	ONCOGENE			English	Review							HEAT-SHOCK-PROTEIN; ONCOGENE-INDUCED SENESCENCE; SMALL-MOLECULE INHIBITOR; HEAT-SHOCK-PROTEIN-70 HSP70; BAG3 PROTEIN; HEPATOCELLULAR-CARCINOMA; PROGNOSTIC-SIGNIFICANCE; EXPRESSION PATTERNS; SELECTIVE AUTOPHAGY; PANCREATIC-CANCER	Mechanistic studies from cell culture and animal models have revealed critical roles for the heat shock protein Hsp70 in cancer initiation and progression. Surprisingly, many effects of Hsp70 on cancer have not been related to its chaperone activity, but rather to its role(s) in regulating cell signaling. A major factor that directs Hsp70 signaling activity appears to be the co-chaperone Bag3. Here, we review these recent breakthroughs, and how these discoveries drive drug development efforts.	[Sherman, M. Y.; Gabai, V. L.] Boston Univ Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Sherman, MY (corresponding author), Boston Univ Sch Med, Dept Biochem, 715 Albany St,K323, Boston, MA 02118 USA.	sherma1@bu.edu; gabai@bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718	NATIONAL CANCER INSTITUTE [R01CA081244, R01CA176326] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA176326, R01 CA081244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092041; Afanasyeva EA, 2007, INT J CANCER, V121, P2615, DOI 10.1002/ijc.22974; Alaiya AA, 2001, CELL MOL LIFE SCI, V58, P307, DOI 10.1007/PL00000858; Assimon VA, 2013, CURR PHARM DESIGN, V19, P404; Balaburski GM, 2013, MOL CANCER RES, V11, P219, DOI 10.1158/1541-7786.MCR-12-0547-T; Bauer K, 2012, CELL ONCOL, V35, P197, DOI 10.1007/s13402-012-0079-3; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bolhassani A, 2008, EXPERT REV VACCINES, V7, P1185, DOI 10.1586/14760584.7.8.1185; Boonjaraspinyo S, 2012, PATHOL ONCOL RES, V18, P227, DOI 10.1007/s12253-011-9432-5; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Braunstein MJ, 2011, J ONCOL, V2011, DOI 10.1155/2011/232037; Buchberger A, 2010, MOL CELL, V40, P238, DOI 10.1016/j.molcel.2010.10.001; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Cai MB, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-96; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Calderwood SK, 2005, EUR J IMMUNOL, V35, P2518, DOI 10.1002/eji.200535002; Calderwood SK, 2008, INT J HYPERTHER, V24, P31, DOI 10.1080/02656730701858305; Chang L, 2011, CHEM BIOL, V18, P210, DOI 10.1016/j.chembiol.2010.12.010; Chen D, 2005, BIOCHEM PHARMACOL, V69, P1421, DOI 10.1016/j.bcp.2005.02.022; Chen HQ, 2006, FEBS LETT, V580, P3145, DOI 10.1016/j.febslet.2006.04.066; Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679; Chuma M, 2014, CARCINOGENESIS, V35, P272, DOI 10.1093/carcin/bgt343; Chung J, 2008, P NATL ACAD SCI USA, V105, P1739, DOI 10.1073/pnas.0705799105; Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Colvin TA, 2014, CANCER RES, V74, P4731, DOI 10.1158/0008-5472.CAN-14-0747; Colvin TA, 2014, CELL CYCLE, V13, P2306, DOI 10.4161/cc.29296; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dodd K, 2015, ONCOGENE, V34, P1312, DOI 10.1038/onc.2014.63; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Falco A, 2013, AM J GASTROENTEROL, V108, P1178, DOI 10.1038/ajg.2013.128; Festa M, 2011, AM J PATHOL, V178, P2504, DOI 10.1016/j.ajpath.2011.02.002; Franceschelli S, 2008, J CELL PHYSIOL, V215, P575, DOI 10.1002/jcp.21397; Franco R, 2012, J INVEST DERMATOL, V132, P252, DOI 10.1038/jid.2011.257; GABAI VL, 1995, FEBS LETT, V375, P21, DOI 10.1016/0014-5793(95)01152-5; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gabai VL, 2009, MOL CELL BIOL, V29, P559, DOI 10.1128/MCB.01041-08; Gamerdinger M, 2011, J MOL MED, V89, P1175, DOI 10.1007/s00109-011-0795-6; Gamerdinger M, 2011, EMBO REP, V12, P149, DOI 10.1038/embor.2010.203; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Guerriero L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.143; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hellman K, 2004, BRIT J CANCER, V91, P319, DOI 10.1038/sj.bjc.6601944; Huryn DM, 2011, P NATL ACAD SCI USA, V108, P6757, DOI 10.1073/pnas.1015251108; Hwang TS, 2003, J GASTROEN HEPATOL, V18, P690, DOI 10.1046/j.1440-1746.2003.03011.x; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Iwasaki M, 2007, CANCER RES, V67, P10252, DOI 10.1158/0008-5472.CAN-07-0618; Jinwal UK, 2013, FASEB J, V27, P1450, DOI 10.1096/fj.12-220889; Joo M, 2005, J KOREAN MED SCI, V20, P829, DOI 10.3346/jkms.2005.20.5.829; Kabakov A. E., 1997, HEAT SHOCK PROTEINS; KABAKOV AE, 1995, J CELL PHYSIOL, V165, P1, DOI 10.1002/jcp.1041650102; Kassis JN, 2006, EXP CELL RES, V312, P2962, DOI 10.1016/j.yexcr.2006.05.023; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Koren J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035566; Koren J, 2010, J BIOL CHEM, V285, P2498, DOI 10.1074/jbc.M109.057208; Lee HW, 2013, VIRCHOWS ARCH, V463, P489, DOI 10.1007/s00428-013-1461-x; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Leznicki P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059590; Li D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.158; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Lopez-Lazaro M, 2002, J ENZYM INHIB MED CH, V17, P25, DOI 10.1080/14756360290011744; Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310; Luk JM, 2006, PROTEOMICS, V6, P1049, DOI 10.1002/pmic.200500306; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Malusecka E, 2008, ANTICANCER RES, V28, P501; Massey AJ, 2010, CANCER CHEMOTH PHARM, V66, P535, DOI 10.1007/s00280-009-1194-3; McCubrey JA, 2012, ONCOTARGET, V3, P954, DOI 10.18632/oncotarget.652; Meng L, 2011, ONCOGENE, V30, P2836, DOI 10.1038/onc.2011.5; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Miyata Y, 2013, ACS CHEM NEUROSCI, V4, P930, DOI 10.1021/cn300210g; Miyata Y, 2012, CHEM BIOL, V19, P1391, DOI 10.1016/j.chembiol.2012.07.026; Mo JS, 2014, TRENDS CELL BIOL, V22, P339; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Nakajima M, 2002, CANCER LETT, V178, P99, DOI 10.1016/S0304-3835(01)00825-4; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; O'Callaghan-Sunol C, 2007, CANCER RES, V67, P11779, DOI 10.1158/0008-5472.CAN-07-2441; Park CS, 1999, GYNECOL ONCOL, V74, P53, DOI 10.1006/gyno.1999.5429; Partida-Rodriguez O, 2010, INT J CANCER, V126, P1861, DOI 10.1002/ijc.24773; Patury S, 2009, CURR TOP MED CHEM, V9, P1337, DOI 10.2174/156802609789895674; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Phillips PA, 2011, CANCER LETT, V308, P181, DOI 10.1016/j.canlet.2011.05.002; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Powers MV, 2010, CELL CYCLE, V9, P1542, DOI 10.4161/cc.9.8.11204; Ramp U, 2007, HISTOL HISTOPATHOL, V22, P1099, DOI 10.14670/HH-22.1099; Raulet DH, 2009, NAT REV IMMUNOL, V9, P568, DOI 10.1038/nri2604; Ray S, 2004, J BIOL CHEM, V279, P35604, DOI 10.1074/jbc.M401851200; Rerole AL, 2011, CANCER RES, V71, P484, DOI 10.1158/0008-5472.CAN-10-1443; Ricaniadis N, 2001, EUR J SURG ONCOL, V27, P88, DOI 10.1053/ejso.1999.1018; Rodina A, 2013, CHEM BIOL, V20, P1469, DOI 10.1016/j.chembiol.2013.10.008; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Rosati A, 2012, AM J PATHOL, V181, P1524, DOI 10.1016/j.ajpath.2012.07.016; Rousaki A, 2011, J MOL BIOL, V411, P614, DOI 10.1016/j.jmb.2011.06.003; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Shin E, 2011, J HEPATO-BIL-PAN SCI, V18, P544, DOI 10.1007/s00534-010-0367-0; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Syrigos KN, 2003, UROLOGY, V61, P677, DOI 10.1016/S0090-4295(02)02289-6; Szondy K, 2012, CANCER INVEST, V30, P317, DOI 10.3109/07357907.2012.657815; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tanaka KI, 2007, J BIOL CHEM, V282, P23240, DOI 10.1074/jbc.M704081200; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017; Tao Y, 2009, CARCINOGENESIS, V30, P175, DOI 10.1093/carcin/bgn256; Tavassol F, 2011, HEAD NECK ONCOL, V3, DOI 10.1186/1758-3284-3-10; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Tsukahara F, 2010, BLOOD, V116, P3582, DOI 10.1182/blood-2009-10-249623; Ulbricht A, 2013, CURR BIOL, V23, P430, DOI 10.1016/j.cub.2013.01.064; Voellmy R, 1996, EXS, V77, P121; Vos MJ, 2008, BIOCHEMISTRY-US, V47, P7001, DOI 10.1021/bi800639z; Walerych D, 2009, ONCOGENE, V28, P4284, DOI 10.1038/onc.2009.281; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Wang AM, 2013, NAT CHEM BIOL, V9, P112, DOI [10.1038/nchembio.1140, 10.1038/NCHEMBIO.1140]; Wang XP, 2005, WORLD J GASTROENTERO, V11, P5561, DOI 10.3748/wjg.v11.i35.5561; Wang YZ, 2010, CLIN CHEM LAB MED, V48, P1657, DOI 10.1515/CCLM.2010.304; Weng DS, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3102; Wiech M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051426; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796; Yu HJ, 2013, HISTOPATHOLOGY, V62, P788, DOI 10.1111/his.12087; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	138	143	145	3	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4153	4161		10.1038/onc.2014.349	http://dx.doi.org/10.1038/onc.2014.349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347739	Green Accepted			2022-12-17	WOS:000359199800001
J	Trerotola, M; Cantanelli, P; Guerra, E; Tripaldi, R; Aloisi, AL; Bonasera, V; Lattanzio, R; de Lange, R; Weidle, UH; Piantelli, M; Alberti, S				Trerotola, M.; Cantanelli, P.; Guerra, E.; Tripaldi, R.; Aloisi, A. L.; Bonasera, V.; Lattanzio, R.; de Lange, R.; Weidle, U. H.; Piantelli, M.; Alberti, S.			Upregulation of Trop-2 quantitatively stimulates human cancer growth	ONCOGENE			English	Article						Trop-2; human tumours; cell growth; signalling; oncogene	CELL-SURFACE GLYCOPROTEIN; DNA METHYLATION PREVENTS; GENE-EXPRESSION; MAMMALIAN-CELLS; MONOCLONAL-ANTIBODIES; COLORECTAL-CANCER; HUMAN CARCINOMAS; TRANSGENIC MICE; FLOW-CYTOMETRY; BREAST-CANCER	Trop-2 is a calcium signal transducer that is associated with transformed cell growth in experimental systems. However, its role in human cancer remains essentially unknown. In this study, we profiled Trop-2 expression in normal human tissues at the mRNA and protein levels. We then systematically compared Trop-2 mRNA and protein levels in tumours with their tissues of origin. We find that Trop-2 expression is invariably upregulated in tumours, regardless of baseline expression in normal tissues, which suggests a corresponding selective advantage. Thus, we investigated the outcome of Trop-2 upregulation on tumour growth. Overexpression of wild-type Trop-2 was shown to be necessary and sufficient to drive cancer growth in a widely invariant manner across cell type and species. Upregulation of Trop-2 was shown to quantitatively stimulate tumour growth, as proportional to expression levels in vivo, and tumour cell growth was abrogated by somatic knockdown of Trop-2 expression. On the other hand, we found no evidence of tumour-associated TROP2 mutations, nor of TROP2 induction of oncogenic transformation per se. Our data support a model where above-baseline expression of wild-type Trop-2 is a key driver of human cancer growth. Oncogene (2013) 32, 222-233; doi:10.1038/onc.2012.36; published online 20 February 2012	[Trerotola, M.; Cantanelli, P.; Guerra, E.; Tripaldi, R.; Aloisi, A. L.; Bonasera, V.; Lattanzio, R.; Piantelli, M.; Alberti, S.] Fdn Univ G dAnnunzio, CeSI, Dept Oncol & Expt Med, Unit Canc Pathol, I-66100 Chieti, Italy; [de Lange, R.; Weidle, U. H.] Roche Diagnost GmbH, Pharma Res, Penzberg, Germany; [Alberti, S.] Univ G DAnnunzio, Dept Neurosci & Imaging, Chieti, Italy	G d'Annunzio University of Chieti-Pescara; Roche Holding; G d'Annunzio University of Chieti-Pescara	Alberti, S (corresponding author), Fdn Univ G dAnnunzio, CeSI, Dept Oncol & Expt Med, Unit Canc Pathol, Via Colle dell Ara, I-66100 Chieti, Italy.	s.alberti@unich.it	Trerotola, Marco/J-9015-2016; Lattanzio, Rossano/K-1927-2018; Alberti, Saverio/M-4511-2014	Trerotola, Marco/0000-0003-1855-7002; Lattanzio, Rossano/0000-0001-9803-4476; Alberti, Saverio/0000-0002-4647-6042; Guerra, Emanuela/0000-0002-7091-8621; Piantelli, Mauro/0000-0003-0154-482X	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation [CH01D0081]; Fondazione compagnia di San Paolo; Italian Ministry of Health [RicOncol RF-EMR-2006-361866]; Italian Foundation for Cancer Research (FIRC, Italy); Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Fondazione of the Cassa di Risparmio della Provincia di Chieti; ABO Foundation; Fondazione compagnia di San Paolo(Compagnia di San Paolo); Italian Ministry of Health(Ministry of Health, Italy); Italian Foundation for Cancer Research (FIRC, Italy)(Fondazione AIRC per la ricerca sul cancro); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Professor B Ponder and Dr S Martin for the generous supply of the genomic DNA of MEN-2A, pheochromocytoma and medullary thyroid carcinomas. We thank Dr A Mironov and GV Beznoussenko for help during the course of this work. This research was supported by the Fondazione of the Cassa di Risparmio della Provincia di Chieti, ABO Foundation (CH01D0081), Fondazione compagnia di San Paolo and Italian Ministry of Health (RicOncol RF-EMR-2006-361866). MT was a recipient of a scholarship from the Italian Foundation for Cancer Research (FIRC, Italy).	ALBERTI S, 1994, P NATL ACAD SCI USA, V91, P5833, DOI 10.1073/pnas.91.13.5833; ALBERTI S, 1988, P NATL ACAD SCI USA, V85, P8391, DOI 10.1073/pnas.85.22.8391; ALBERTI S, 1990, NUCLEIC ACIDS RES, V18, P351, DOI 10.1093/nar/18.2.351; ALBERTI S, 1987, CYTOMETRY, V8, P114, DOI 10.1002/cyto.990080203; ALBERTI S, 1991, J HISTOCHEM CYTOCHEM, V39, P701, DOI 10.1177/39.5.1901878; ALBERTI S, 1992, HYBRIDOMA, V11, P539, DOI 10.1089/hyb.1992.11.539; BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419; Bignotti E, 2010, EUR J CANCER, V46, P944, DOI 10.1016/j.ejca.2009.12.019; Bonasera V, 2007, BIOTECHNIQUES, V43, P173, DOI 10.2144/000112500; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carletti E, 2006, TRENDS BIOTECHNOL, V24, P443, DOI 10.1016/j.tibtech.2006.07.006; Chalk AM, 2004, BIOCHEM BIOPH RES CO, V319, P264, DOI 10.1016/j.bbrc.2004.04.181; CORDONCARDO C, 1984, J HISTOCHEM CYTOCHEM, V32, P1035, DOI 10.1177/32.10.6384360; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Cubas R, 2009, BBA-REV CANCER, V1796, P309, DOI 10.1016/j.bbcan.2009.08.001; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; El Sewedy T, 1998, INT J CANCER, V75, P324, DOI 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.3.CO;2-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ERBA E, 1989, BRIT J CANCER, V60, P45, DOI 10.1038/bjc.1989.217; Fang YJ, 2009, INT J COLORECTAL DIS, V24, P875, DOI 10.1007/s00384-009-0725-z; Fong D, 2008, BRIT J CANCER, V99, P1290, DOI 10.1038/sj.bjc.6604677; Fong D, 2008, MODERN PATHOL, V21, P186, DOI 10.1038/modpathol.3801001; FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; Goldstein AS, 2010, MOL ONCOL, V4, P385, DOI 10.1016/j.molonc.2010.06.009; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guerra E, 2008, CANCER RES, V68, P8113, DOI 10.1158/0008-5472.CAN-07-6135; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KLEIN CE, 1990, J INVEST DERMATOL, V95, P74, DOI 10.1111/1523-1747.ep12873988; KLEIN CE, 1987, J INVEST DERMATOL, V89, P500, DOI 10.1111/1523-1747.ep12460996; Lal A, 1999, CANCER RES, V59, P5403; LIPINSKI M, 1981, P NATL ACAD SCI-BIOL, V78, P5147, DOI 10.1073/pnas.78.8.5147; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Muhlmann G, 2009, J CLIN PATHOL, V62, P152, DOI 10.1136/jcp.2008.060590; Nakashima K, 2004, INT J CANCER, V112, P1029, DOI 10.1002/ijc.20517; NAQUET P, 1989, THYMUS, V13, P217; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Ohmachi T, 2006, CLIN CANCER RES, V12, P3057, DOI 10.1158/1078-0432.CCR-05-1961; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Querzoli P, 2006, CLIN CANCER RES, V12, P6696, DOI 10.1158/1078-0432.CCR-06-0569; Ripani E, 1998, INT J CANCER, V76, P671; Rossi C, 2008, EUR J CANCER, V44, P2696, DOI 10.1016/j.ejca.2008.08.021; Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Sukhthankar M, 2010, ANTICANCER RES, V30, P2497; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Trerotola M, 2010, AM J TRANSL RES, V2, P135; Trerotola M, 2010, BBA-REV CANCER, V1805, P119, DOI 10.1016/j.bbcan.2009.12.002; Varughese J, 2011, CANCER-AM CANCER SOC, V117, P3163, DOI 10.1002/cncr.25891; Wang JB, 2008, MOL CANCER THER, V7, P280, DOI 10.1158/1535-7163.MCT-07-2003; Wang JB, 2011, MOL CANCER RES, V9, P1686, DOI 10.1158/1541-7786.MCR-11-0241; Wolter S, 2002, J BIOL CHEM, V277, P3576, DOI 10.1074/jbc.M105800200; Zanna P, 2007, CANCER-AM CANCER SOC, V110, P452, DOI 10.1002/cncr.22785; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	59	143	157	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					222	233		10.1038/onc.2012.36	http://dx.doi.org/10.1038/onc.2012.36			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349828				2022-12-17	WOS:000314075500010
J	Ward, PS; Cross, JR; Lu, C; Weigert, O; Abel-Wahab, O; Levine, RL; Weinstock, DM; Sharp, KA; Thompson, CB				Ward, P. S.; Cross, J. R.; Lu, C.; Weigert, O.; Abel-Wahab, O.; Levine, R. L.; Weinstock, D. M.; Sharp, K. A.; Thompson, C. B.			Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production	ONCOGENE			English	Article						IDH1; IDH2; 2-hydroxyglutarate; oncometabolite; NADPH	ACUTE MYELOID-LEUKEMIA; HIGH-GRADE GLIOMAS; ISOCITRATE; MECHANISM; DISEASE	Mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or its mitochondrial homolog IDH2 can lead to R(-)-2-hydroxyglutarate (2HG) production. To date, mutations in three active site arginine residues, IDH1 R132, IDH2 R172 and IDH2 R140, have been shown to result in the neomorphic production of 2HG. Here we report on three additional 2HG-producing IDH1 mutations: IDH1 R100, which is affected in adult glioma, IDH1 G97, which is mutated in colon cancer cell lines and pediatric glioblastoma, and IDH1 Y139. All these new mutants stereospecifically produced 2HG's (R) enantiomer. In contrast, we find that the IDH1 SNPs V71I and V178I, as well as a number of other single-sample reports of IDH non-synonymous mutation, did not elevate cellular 2HG levels in cells and retained the wild-type ability for isocitrate-dependent NADPH production. Finally, we report the existence of additional rare, but recurring mutations found in lymphoma and thyroid cancer, which while failing to elevate 2HG nonetheless displayed loss of function, indicating a possible tumorigenic mechanism for a non-2HG-producing subset of IDH mutations in some malignancies. These data broaden our understanding of how IDH mutations may contribute to cancer through either neomorphic R(-)-2HG production or reduced wildtype enzymatic activity, and highlight the potential value of metabolite screening in identifying IDH-mutated tumors associated with elevated oncometabolite levels. Oncogene (2012) 31, 2491-2498; doi: 10.1038/onc.2011.416; published online 26 September 2011	[Ward, P. S.; Cross, J. R.; Lu, C.; Thompson, C. B.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Ward, P. S.; Lu, C.] Univ Penn, Abramson Canc Ctr, Dept Canc Biol, Philadelphia, PA 19104 USA; [Weigert, O.; Weinstock, D. M.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Abel-Wahab, O.; Levine, R. L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Abel-Wahab, O.; Levine, R. L.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10065 USA; [Sharp, K. A.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania	Thompson, CB (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Room M110, New York, NY 10065 USA.	thompsonc@mskcc.org	Lu, Chao/E-8047-2012; levine, ross/AAE-7658-2019; Ward, Patrick/H-2361-2014	Abdel-Wahab, Omar/0000-0002-3907-6171; Lu, Chao/0000-0003-0982-8122; Cross, Justin/0000-0002-6356-057X; Ward, Patrick/0000-0001-6437-8174	NCI; NIH; HHMI; Stand Up To Cancer Innovative Research Grant; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA092660, R01CA105463] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHMI(Howard Hughes Medical Institute); Stand Up To Cancer Innovative Research Grant; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grants from the NCI and NIH. RL Levine is a HHMI Early Career Award Recipient and Geoffrey Beene Junior Faculty Chair at MSKCC. DM Weinstock is supported by a Stand Up To Cancer Innovative Research Grant and American Cancer Society Research Scholar Grant.	Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; DeLano W., 2006, PYMOL MOL GRAPHICS S; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Hemerly JP, 2010, EUR J ENDOCRINOL, V163, P747, DOI 10.1530/EJE-10-0473; Ho PA, 2010, LEUKEMIA, V24, P909, DOI 10.1038/leu.2010.56; Jin GL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016812; KAMERLING JP, 1981, J CHROMATOGR, V222, P276, DOI 10.1016/S0378-4347(00)81061-0; Kranendijk M, 2010, SCIENCE, V330, P336, DOI 10.1126/science.1192632; Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Murugan AK, 2010, BIOCHEM BIOPH RES CO, V393, P555, DOI 10.1016/j.bbrc.2010.02.095; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; Pusch S, 2011, NEUROPATH APPL NEURO, V37, P428, DOI 10.1111/j.1365-2990.2010.01127.x; Rakheja D, 2011, PEDIATR BLOOD CANCER, V56, P379, DOI 10.1002/pbc.22697; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zou Y, 2010, BIOCHEM BIOPH RES CO, V402, P378, DOI 10.1016/j.bbrc.2010.10.038	27	143	149	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	19					2491	2498		10.1038/onc.2011.416	http://dx.doi.org/10.1038/onc.2011.416			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996744	Green Accepted			2022-12-17	WOS:000303985300011
J	Kim, K; Chadalapaka, G; Lee, SO; Yamada, D; Sastre-Garau, X; Defossez, PA; Park, YY; Lee, JS; Safe, S				Kim, K.; Chadalapaka, G.; Lee, S-O; Yamada, D.; Sastre-Garau, X.; Defossez, P-A; Park, Y-Y; Lee, J-S; Safe, S.			Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer	ONCOGENE			English	Article						ZBTB4; miR-17-92 cluster; breast cancer; prognostic; Sp transcription factors	MICRORNA EXPRESSION PROFILES; ZINC-FINGER PROTEINS; B-CELL LYMPHOMAS; REPRESSES TRANSCRIPTION; 5'-FLANKING REGION; GENE-EXPRESSION; METHYLATED DNA; MESSENGER-RNA; TUMOR-GROWTH; SP1	The human POK family members are transcription factors with a POZ domain and zinc-fingers that act primarily as transcriptional repressors. Several members of this family are involved in oncogenesis and this prompted us to assess whether expression levels of individual POK family members are associated with clinical outcomes in cancer. We have observed that ZBTB4 (zinc-finger and BTB domain containing 4) is downregulated in breast cancer patients, and that its expression is significantly correlated with relapse-free survival. Further integrative analysis of mRNA and microRNA (miR) expression data from the NCI-60 cell lines revealed an inverse correlation between ZBTB4 and oncogenic miRs derived from the miR-17-92 cluster and its paralogs. The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression. Overexpression of ZBTB4 or restoration of ZBTB4 by using an antagomir inhibit growth and invasion of breast cancer cells, and this effect is due, in part, to ZBTB4-dependent repression of the specificity protein 1 (Sp1), Sp3 and Sp4 genes, and subsequent downregulation of several Sp-dependent oncogenes, in part, through competition between ZBTB4 and Sp transcription factors for GC-rich promoter sequences. These results confirm that ZBTB4 functions as a novel tumor-suppressor gene with prognostic significance for breast cancer survival, and the oncogenic miR-17-92/ZBTB4/Sp axis may be a potential therapeutic target. Oncogene (2012) 31, 1034-1044; doi:10.1038/onc.2011.296; published online 18 July 2011	[Chadalapaka, G.; Safe, S.] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; [Kim, K.; Lee, S-O; Safe, S.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Yamada, D.; Defossez, P-A] Univ Paris 07, CNRS, UMR7216, Paris, France; [Sastre-Garau, X.] Inst Curie, Dept Tumor Biol, Paris, France; [Park, Y-Y; Lee, J-S] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Texas System; UTMD Anderson Cancer Center	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, Vet Res Bldg 410, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu		Defossez, Pierre-Antoine/0000-0002-6463-9263; Sastre-Garau, Xavier/0000-0001-5992-2083; Lee, Syng-Ook/0000-0002-8958-8634; Kim, Kyounghyun/0000-0002-7240-2768	National Institutes of Health [CA136571]; Association pour la Recherche sur le Cancer; Ligue contre le Cancer; Institut National du Cancer; NATIONAL CANCER INSTITUTE [R01CA136571] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the National Institutes of Health (CA136571) and is gratefully acknowledged. PAD is supported by Association pour la Recherche sur le Cancer, Ligue contre le Cancer and Institut National du Cancer. DY was supported by a postdoctoral fellowship from Association pour la Recherche sur le Cancer.	Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Abdelrahim M, 2007, CANCER RES, V67, P3286, DOI 10.1158/0008-5472.CAN-06-3831; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chadalapaka G, 2008, CANCER RES, V68, P5345, DOI 10.1158/0008-5472.CAN-07-6805; Chadalapaka G, 2010, MOL CANCER RES, V8, P739, DOI 10.1158/1541-7786.MCR-09-0493; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Costoya Jose A., 2007, Briefings in Functional Genomics & Proteomics, V6, P8, DOI 10.1093/bfgp/elm002; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Jeon BN, 2009, J BIOL CHEM, V284, P17935, DOI 10.1074/jbc.M809559200; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Jutooru I, 2010, MOL PHARMACOL, V78, P226, DOI 10.1124/mol.110.064451; Koh DI, 2009, J BIOL CHEM, V284, P19856, DOI 10.1074/jbc.M109.025817; Kojima S, 2001, DEVELOPMENT, V128, P57; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Sasai N, 2010, NUCLEIC ACIDS RES, V38, P5015, DOI 10.1093/nar/gkq280; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tapias A, 2008, BBA-GENE REGUL MECH, V1779, P318, DOI 10.1016/j.bbagrm.2008.02.006; Tillotson LG, 1999, J BIOL CHEM, V274, P8123, DOI 10.1074/jbc.274.12.8123; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weber A, 2008, EMBO J, V27, P1563, DOI 10.1038/emboj.2008.85; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107	47	143	149	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1034	1044		10.1038/onc.2011.296	http://dx.doi.org/10.1038/onc.2011.296			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765466	Green Accepted			2022-12-17	WOS:000300709700009
J	Ye, Y; Xiao, Y; Wang, W; Yearsley, K; Gao, JX; Shetuni, B; Barsky, SH				Ye, Y.; Xiao, Y.; Wang, W.; Yearsley, K.; Gao, J. X.; Shetuni, B.; Barsky, S. H.			ER alpha signaling through slug regulates E-cadherin and EMT	ONCOGENE			English	Article						ER alpha; slug; E-cadherin; EMT; ER alpha/N-CoR/HDAC1 corepressor complex	BREAST-CANCER CELLS; GLYCOGEN-SYNTHASE KINASE-3; ESTROGEN-RECEPTOR-ALPHA; EPITHELIAL-MESENCHYMAL TRANSITION; SEMIAUTOMATED IMAGING-SYSTEM; ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVITY; DOWN-REGULATION; BETA-CATENIN; EXPRESSION	The ER alpha signaling pathway is one of the most important and most studied pathways in human breast cancer, yet numerous questions still exist such as how hormonally responsive cancers progress to a more aggressive and hormonally independent phenotype. We have noted that human breast cancers exhibit a strong direct correlation between ER alpha and E-cadherin expression by immunohistochemistry, suggesting that ER alpha signaling might regulate E-cadherin and implying that this regulation might influence epithelial-mesenchymal transition (EMT) and tumor progression. To investigate this hypothesis and the mechanisms behind it, we studied the effects of ER alpha signaling in ER alpha-transfected ER alpha-negative breast carcinoma cell lines, the MDA-MB-468 and the MDA-MB-231 and the effects of ER alpha knockdown in naturally expressing ER alpha-positive lines, MCF-7 and T47D. When ER alpha was overexpressed in the ER alpha-negative lines, 17 beta-estradiol (E2) decreased slug and increased E-cadherin. Clones maximally exhibiting these changes grew more in clumps and became less invasive in Matrigel. When ER alpha was knocked down in the ER alpha-positive lines, slug increased, E-cadherin decreased, cells became spindly and exhibited increased Matrigel invasion. ER alpha signaling decreased slug expression by two different mechanisms: directly, by repression of slug transcription by the formation of a corepressor complex of ligand-activated ER alpha, HDAC inhibitor (HDAC1), and nuclear receptor corepressor (N-CoR) that bound the slug promoter in three half-site estrogen response elements (EREs); indirectly by phosphorylation and inactivation of GSK-3 beta through phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt). The GSK-3 beta inactivation, in turn, repressed slug expression and increased E-cadherin. In human breast cancer cases, there was a strong inverse correlation between slug and ER alpha and E-cadherin immunoreactivity. Our findings indicate that ER alpha signaling through slug regulates E-cadherin and EMT. Oncogene (2010) 29, 1451-1462; doi:10.1038/onc.2009.433; published online 18 January 2010	[Ye, Y.; Barsky, S. H.] Univ Nevada, Sch Med, Dept Pathol, Reno, NV 89557 USA; [Ye, Y.; Barsky, S. H.] Nevada Canc Inst, Dept Pathol, Las Vegas, NV USA; [Xiao, Y.; Wang, W.; Yearsley, K.; Gao, J. X.; Shetuni, B.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of California System; University of California San Diego; University System of Ohio; Ohio State University	Barsky, SH (corresponding author), Univ Nevada, Sch Med, Dept Pathol, 1 Manville Med Bldg, Reno, NV 89557 USA.	sbarsky@medicine.nevada.edu			Department of Defense Breast Cancer Research Program [W81XWH-06-1-0631]; Ohio State Strategic Initiative Grant Program; Donald A Senhauser Endowment	Department of Defense Breast Cancer Research Program(United States Department of Defense); Ohio State Strategic Initiative Grant Program; Donald A Senhauser Endowment	This study was supported by the Department of Defense Breast Cancer Research Program Grant W81XWH-06-1-0631, the Ohio State Strategic Initiative Grant Program and The Donald A Senhauser Endowment.	Alpaugh ML, 2002, AM J PATHOL, V161, P619, DOI 10.1016/S0002-9440(10)64217-4; Alpaugh ML, 2002, ONCOGENE, V21, P3631, DOI 10.1038/sj.onc.1205389; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barsky SH, 2003, EXP MOL PATHOL, V74, P113, DOI 10.1016/S0014-4800(03)00011-X; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Catalano A, 2004, J BIOL CHEM, V279, P46706, DOI 10.1074/jbc.M406696200; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; DEGROOT RP, 1993, ONCOGENE, V8, P841; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Grisouard J, 2007, MOL ENDOCRINOL, V21, P2427, DOI 10.1210/me.2007-0129; Hajra KM, 2002, CANCER RES, V62, P1613; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Hayashida Y, 2005, CANCER RES, V65, P8836, DOI 10.1158/0008-5472.CAN-05-0718; Hiraguri S, 1998, CANCER RES, V58, P1972; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Hyder SM, 1996, CANCER RES, V56, P3954; Joshi AS, 2007, CYTOM PART A, V71A, P273, DOI 10.1002/cyto.a.20374; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Mendez P, 2006, ENDOCRINOLOGY, V147, P3027, DOI 10.1210/en.2005-1224; Moggs JG, 2005, J MOL ENDOCRINOL, V34, P535, DOI 10.1677/jme.1.01677; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; Nam JS, 2006, CANCER RES, V66, P7176, DOI 10.1158/0008-5472.CAN-06-0825; Natsugoe S, 2007, ONCOL REP, V17, P517; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Oesterreich S, 2003, CANCER RES, V63, P5203; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15; Sasaki CY, 2000, CANCER RES, V60, P7057; Sharangpani GM, 2007, J MICROSC-OXFORD, V226, P244, DOI 10.1111/j.1365-2818.2007.01772.x; Tomlinson JS, 2001, CANCER RES, V61, P5231; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; Voss TC, 2005, MOL CELL ENDOCRINOL, V231, P33, DOI 10.1016/j.mce.2004.12.003; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yang S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-211; Ye Y, 2008, BIOCHEM J, V416, P179, DOI 10.1042/BJ20080328; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	54	143	155	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1451	1462		10.1038/onc.2009.433	http://dx.doi.org/10.1038/onc.2009.433			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20101232				2022-12-17	WOS:000275392400004
J	Jeong, JW; Lee, HS; Franco, HL; Broaddus, RR; Taketo, MM; Tsai, SY; Lydon, JP; DeMayo, FJ				Jeong, J-W; Lee, H. S.; Franco, H. L.; Broaddus, R. R.; Taketo, M. M.; Tsai, S. Y.; Lydon, J. P.; DeMayo, F. J.			beta-catenin mediates glandular formation and dysregulation of beta-catenin induces hyperplasia formation in the murine uterus	ONCOGENE			English	Article						beta-catenin; uterus; estrogen; hyperplasia	LEUKEMIA INHIBITORY FACTOR; FEMALE REPRODUCTIVE-TRACT; MOUSE UTERUS; ENDOMETRIAL CARCINOMAS; MICROSATELLITE INSTABILITY; TRANSCRIPTIONAL TARGET; NUCLEAR-LOCALIZATION; COLON-CARCINOMA; E-CADHERIN; CYCLIN D1	Endometrioid adenocarcinoma is the most frequent form of endometrial cancer, usually developing in pre- and perimenopausal women. beta-catenin abnormalities are common in endometrioid type endometrial carcinomas with squamous differentiation. To investigate the role of beta-catenin (Ctnnb1) in uterine development and tumorigenesis, mice were generated which expressed a dominant stabilized beta-catenin or had beta-catenin conditionally ablated in the uterus by crossing the PRCre mouse with the Ctnnb1(f(ex3)/+) mouse or Ctnnb1(f/f) mouse, respectively. Both of the beta-catenin mutant mice have fertility defects and the ability of the uterus to undergo a hormonally induced decidual reaction was lost. Expression of the dominant stabilized beta-catenin, PR(cre/+)Ctnnb1(f(ex3)/+), resulted in endometrial glandular hyperplasia, whereas ablation of b-catenin, PR(cre/+)Ctnnb1(f/f), induced squamous cell metaplasia in the murine uterus. Therefore, we have demonstrated that correct regulation of beta-catenin is important for uterine function as well as in the regulation of endometrial epithelial differentiation.	[Jeong, J-W; Franco, H. L.; Tsai, S. Y.; Lydon, J. P.; DeMayo, F. J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lee, H. S.] MizMedi Hosp, Infertil & Reprod Endocrinol Ctr, Dept Obstet & Gynecol, Seoul, South Korea; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Taketo, M. M.] Kyoto Univ, Dept Pharmacol, Grad Sch Med, Sakyo Ku, Kyoto, Japan	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Kyoto University	DeMayo, FJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	fdemayo@bcm.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	NICHD; NIH [R01HD042311, U54HD0077495, R01- CA77530, 1P50CA098258-01, R01HD057873]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD007495, R01HD057873, U54HD028934, R03HD077495, R01HD042311] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA098258, P50CA083639, R01CA077530] Funding Source: NIH RePORTER	NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jinghua Li and Bryan Ngo for technical assistance; Janet DeMayo, MS for manuscript preparation. This study was supported by the NICHD and, the NIH R01HD042311 and NIH U54HD0077495 (to FJD), NIH R01- CA77530 and the Susan G Komen Award BCTR0503763 (to JPL), NIH 1P50CA098258-01 (to RRB), NIH R01HD057873 and pilot grant from NIH 1P50CA098258-01 (to JWJ), and the NICHD U54HD28934 (to the Universityof Virginia Center for Research in Reproduction Ligand Assayand Analysis Core).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ANDERSON MC, 2002, ENDOMETRITIS METAPLA, P285; Arango NA, 2005, DEV BIOL, V288, P276, DOI 10.1016/j.ydbio.2005.09.045; Brault V, 2001, DEVELOPMENT, V128, P1253; Buchanan DL, 1999, ENDOCRINOLOGY, V140, P484, DOI 10.1210/en.140.1.484; Carta L, 2004, BIOL REPROD, V71, P444, DOI 10.1095/biolreprod.103.026534; Catasus L, 2004, HUM PATHOL, V35, P1360, DOI 10.1016/j.humpath.2004.07.019; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; Daikoku T, 2004, MOL ENDOCRINOL, V18, P1238, DOI 10.1210/me.2003-0403; DELIGDISCH L, 1987, CANCER DETECT PREV, V10, P237; Deutseher E, 2007, DEV BIOL, V307, P227, DOI 10.1016/j.ydbio.2007.04.036; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; FINN CA, 1964, J REPROD FERTIL, V8, P331; Fukuchi T, 1998, CANCER RES, V58, P3526; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herington JL, 2007, J HISTOCHEM CYTOCHEM, V55, P963, DOI 10.1369/jhc.7A7199.2007; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Hou XN, 2004, MOL ENDOCRINOL, V18, P3035, DOI 10.1210/me.2004-0259; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; Ikeda T, 2000, ONCOL REP, V7, P323; Irving JA, 2005, HUM PATHOL, V36, P605, DOI 10.1016/j.humpath.2005.03.005; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jha RK, 2006, FEBS LETT, V580, P5653, DOI 10.1016/j.febslet.2006.09.014; Kim YT, 2002, YONSEI MED J, V43, P701, DOI 10.3349/ymj.2002.43.6.701; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koster MI, 2007, CELL CYCLE, V6, P269, DOI 10.4161/cc.6.3.3792; Lee KY, 2007, TRENDS ENDOCRIN MET, V18, P234, DOI 10.1016/j.tem.2007.06.002; Lee KY, 2007, MOL CELL BIOL, V27, P5468, DOI 10.1128/MCB.00342-07; Li QX, 2007, J BIOL CHEM, V282, P31725, DOI 10.1074/jbc.M704723200; Lim HJ, 1999, MOL ENDOCRINOL, V13, P1005, DOI 10.1210/me.13.6.1005; Lin ZH, 2006, J CANCER RES CLIN, V132, P811, DOI 10.1007/s00432-006-0130-8; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; MARTIN L, 1973, J ENDOCRINOL, V56, P133, DOI 10.1677/joe.0.0560133; Mericskay M, 2004, DEVELOPMENT, V131, P2061, DOI 10.1242/dev.01090; Miller C, 1998, DEVELOPMENT, V125, P3201; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Mohamed OA, 2005, P NATL ACAD SCI USA, V102, P8579, DOI 10.1073/pnas.0500612102; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Parr BA, 1998, NATURE, V395, P707, DOI 10.1038/27221; PENTECOST BT, 1988, MOL ENDOCRINOL, V2, P1243, DOI 10.1210/mend-2-12-1243; Risinger JI, 1998, CLIN CANCER RES, V4, P3005; Risinger JI, 1997, CANCER RES, V57, P4736; Romano RA, 2007, J INVEST DERMATOL, V127, P1175, DOI 10.1038/sj.jid.5700652; Saegusa M, 2005, LAB INVEST, V85, P768, DOI 10.1038/labinvest.3700273; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Saegusa M, 2001, BRIT J CANCER, V84, P209, DOI 10.1054/bjoc.2000.1581; Samowitz WS, 1999, CANCER RES, V59, P1442; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Trink B, 2007, CELL CYCLE, V6, P240, DOI 10.4161/cc.6.3.3803; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Wappenschmidt B, 2004, HUM PATHOL, V35, P1260, DOI 10.1016/j.humpath.2004.06.007	64	143	151	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					31	40		10.1038/onc.2008.363	http://dx.doi.org/10.1038/onc.2008.363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806829	Green Accepted			2022-12-17	WOS:000262294100004
J	Horinaka, M; Yoshida, T; Shiraishi, T; Nakata, S; Wakada, M; Nakanishi, R; Nishino, H; Matsui, H; Sakai, T				Horinaka, M; Yoshida, T; Shiraishi, T; Nakata, S; Wakada, M; Nakanishi, R; Nishino, H; Matsui, H; Sakai, T			Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells	ONCOGENE			English	Article						luteolin; DR5; apoptosis; caspase	TRAIL-INDUCED APOPTOSIS; IN-VIVO; TUMORICIDAL ACTIVITY; KILLER/DR5 GENE; LIGAND; INHIBITION; EXPRESSION; MUTATION; CANCER; FAMILY	Luteolin, a naturally occurring flavonoid, induces apoptosis in various cancer cells. Little is known however concerning the underlying molecular mechanisms responsible for this activity. In this report, we reveal a novel mechanism by which luteolin-induced apoptosis occurs, and show for the first time that the apoptosis by luteolin is mediated through death receptor 5 (DR5) upregulation. Luteolin markedly induced the expression of DR5, along with Bcl-2-interacting domain cleavage and the activation of caspase-8, -10, -9 and -3. In addition, suppression of DR5 expression with siRNA efficiently reduced luteolin-induced caspase activation and apoptosis. Human recombinant DR5/Fc also inhibited luteolin-induced apoptosis. On the other hand, luteolin induced neither DR5 protein expression nor apoptosis in normal human peripheral blood mononuclear cells. These results suggest that DR5 induced by luteolin plays a role in luteolin-induced apoptosis, and raises the possibility that treatment with luteolin might be promising as a new therapy against cancer.	Kyoto Prefectural Univ Med, Grad Sch Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ, Dept Appl Biochem, Sakyo Ku, Kyoto 6068522, Japan; Kyoto Prefectural Univ Med, Dept Urol, Kamigyo Ku, Kyoto 6028566, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Biochem & Mol Biol, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	Sakai, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Sci, Dept Mol Targeting Canc Prevent, Kamigyo Ku, Kawaramachi Hirokoji, Kyoto 6028566, Japan.	tsakai@koto.kpu-m.ac.jp						Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Dechant MJ, 2004, INT J CANCER, V109, P661, DOI 10.1002/ijc.20008; ELANGOVAN V, 1994, CANCER LETT, V87, P107, DOI 10.1016/0304-3835(94)90416-2; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HUANG MT, 1983, CARCINOGENESIS, V4, P1631, DOI 10.1093/carcin/4.12.1631; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jeng YM, 2002, CANCER LETT, V181, P205, DOI 10.1016/S0304-3835(02)00051-4; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Ko WG, 2002, PHYTOTHER RES, V16, P295, DOI 10.1002/ptr.871; Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MAY E, 1991, ONCOGENE, V6, P1363; MERFORT I, 1994, PHARMAZIE, V49, P509; Miean KH, 2001, J AGR FOOD CHEM, V49, P3106, DOI 10.1021/jf000892m; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Pai SI, 1998, CANCER RES, V58, P3513; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Sheikh MS, 2004, CURR CANCER DRUG TAR, V4, P97, DOI 10.2174/1568009043481597; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimoi K, 1998, FEBS LETT, V438, P220, DOI 10.1016/S0014-5793(98)01304-0; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Ueda H, 2003, BIOL PHARM BULL, V26, P560, DOI 10.1248/bpb.26.560; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7	41	143	156	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7180	7189		10.1038/sj.onc.1208874	http://dx.doi.org/10.1038/sj.onc.1208874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16007131				2022-12-17	WOS:000232990100007
J	Hsieh, SY; Hsieh, PS; Chiu, CT; Chen, WY				Hsieh, SY; Hsieh, PS; Chiu, CT; Chen, WY			Dickkopf-3/REIC functions as a suppressor gene of tumor growth	ONCOGENE			English	Article						hepatoma; hepatocellular carcinoma; dickkopf; dkk-3; REIC; tumor suppressor gene	BETA-CATENIN; HEPATOCELLULAR CARCINOMAS; DOWN-REGULATION; CELL CARCINOMA; C-MYC; REIC/DKK-3; MUTATIONS; IDENTIFICATION; ANTAGONIST; EXPRESSION	To identify putative tumor suppressor genes in hepatocarcinogenesis, we combined the representational difference analysis and reverse northern blot identifying downregulated genes in human hepatoma tissues. One of them was Dkk-3/REIC. Dkk-3/REIC was downregulated in 11 out of the 20 human hepatoma tissues as compared to their counterparts of noncancerous liver tissues by northern blot analysis. It was also downregulated in 29 out of 48 human cancer samples including the kidney, urinary bladder, prostate, pancreas and lung cancers. Its gene product, Dkk-3/REIC, was found to be N-glycosylated and have two isoforms, the 55 kDa in the cytosol and 50 kDa secreted in the medium. Ectopic expression of Dkk-3/REIC in HeLa, Hep3B and Huh 7 cells led to suppression of cell growth, which was primarily attributable to induction of cell apoptosis. The suppression phenomenon was found to be cell-type related ( most prominent in HeLa and least in Hep3B cells) and cell-density dependent ( attenuated as the cell density increased). Transduction of Dkk-3/REIC into HeLa and Hep3B cells caused suppression on colony formation in vitro and reduced tumor growth rate in inoculated athymic nude mice. In conclusion, these data indicate that Dkk-3/REIC functions as a suppressor for human tumor growth.	Chang Gung Mem Hosp, Liver Res Ctr, Tao Yuan 333, Taiwan; Chang Gung Univ, Sch Med, Dept Microbiol & Immunol, Tao Yuan 333, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Hsieh, SY (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, No 5 Fu Hsin Rd, Tao Yuan 333, Taiwan.	siming@adm.cgmh.org.tw						Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; CARDIGAN KM, 1997, GENE DEV, V11, P3286; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Gao S, 2004, INT J CANCER, V109, P230, DOI 10.1002/ijc.11592; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsieh SY, 2003, BRIT J CANCER, V88, P210, DOI 10.1038/sj.bjc.6600695; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lin CH, 2001, CANCER RES, V61, P4238; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Micsenyi A, 2004, GASTROENTEROLOGY, V126, P1134, DOI 10.1053/j.gastro.2003.12.047; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sasaki T, 2003, CANCER RES, V63, P801; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Tsuji T, 2001, BIOCHEM BIOPH RES CO, V289, P257, DOI 10.1006/bbrc.2001.5972; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD	30	143	162	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9183	9189		10.1038/sj.onc.1208138	http://dx.doi.org/10.1038/sj.onc.1208138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516983				2022-12-17	WOS:000225638000003
J	Grabmaier, K; de Weijert, MCA; Verhaegh, GW; Schalken, JA; Oosterwijk, E				Grabmaier, K; de Weijert, MCA; Verhaegh, GW; Schalken, JA; Oosterwijk, E			Strict regulation of CAIX(G250/MN) by HIF-1 alpha in clear cell renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; G250/CAIX; gene regulation; hypoxia; von Hippel-Lindau	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CARBONIC-ANHYDRASE-IX; TRANSCRIPTIONAL REGULATION; NORMAL KIDNEY; DNA-BINDING; EXPRESSION; GENE; PROTEIN; CANCER; IDENTIFICATION	Renal cell carcinoma of the clear cell type (ccRCC) is associated with loss of functional von Hippel-Lindau (VHL) protein and high, homogeneous expression of the G250(MN) protein, an isoenzyme of the carbonic anhydrase family. High expression of G250(MN) is found in all ccRCCs, but not in most normal tissues, including normal human kidney. We specifically studied the mechanism of transcriptional regulation of the CAIX(G250) gene in RCC. Previous studies identified Sp1 and hypoxia-inducible factor (HIF) as main regulatory transcription factors of G250(MN) in various non-RCC backgrounds. However, G250(MN) regulation in RCC has not been studied and may be differently regulated in view of the HIF accumulation under normoxic conditions due to VHL mutations. Transient transfection of different G250(MN) promoter constructs revealed strong promoter activity in G250(MN) -positive RCC cell lines, but no activity in G250(MN) -negative cell lines. DNase-I footprint and handshift analysis demonstrated that Sp1 and HIF-1alpha proteins in nuclear extracts of RCC cells bind to the CAIX promoter and mutations in the most proximal Sp1 binding element or HIF binding element completely abolished CAIX promoter activity, indicating their critical importance for the activation of G250 expression in RCC. A close correlation between HIF-1alpha expression and G250(MN) expression was observed. In contrast, no relationship between HIF-2alpha expression and G250(MN) was seen. The participation of cofactor CBP/p300 in the regulation of G250 transcription was shown. In conclusion, HIF-1alpha and Sp1, in combination with CBP/p300, are crucial elements for G250(MN) expression in ccRCC, and CAIX(G250) can be regarded as a unique HIF-1alpha: target gene in ccRCC.	Catholic Univ Nijmegen, Med Ctr, Lab Expt Urol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Oosterwijk, E (corresponding author), Catholic Univ Nijmegen, Med Ctr, Lab Expt Urol, 190-RT NCMLS,POB 9101, NL-6500 HB Nijmegen, Netherlands.	e.oosterwijk@uro.umcn.nl	de Weijert, Mirjam/F-3192-2016; Schalken, Jack A/B-1277-2014; Oosterwijk, Egbert/P-5466-2014; Verhaegh, Gerald/L-4708-2015	Schalken, Jack A/0000-0001-8274-7797; Verhaegh, Gerald/0000-0003-0227-2280				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beasley NJP, 2001, CANCER RES, V61, P5262; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Bui MHT, 2003, CLIN CANCER RES, V9, P802; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; EBERT T, 1990, CANCER RES, V50, P5531; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Grabmaier K, 2000, INT J CANCER, V85, P865, DOI 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO;2-Q; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Kaanders JHAM, 2002, CANCER RES, V62, P7066; Kaluz S, 1999, J BIOL CHEM, V274, P32588, DOI 10.1074/jbc.274.46.32588; Kaluz S, 2003, CANCER RES, V63, P917; Kaluzova M, 2001, BIOCHEM J, V359, P669, DOI 10.1042/0264-6021:3590669; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Loncaster JA, 2001, CANCER RES, V61, P6394; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; OOSTERWIJK E, 1986, INT J CANCER, V38, P489, DOI 10.1002/ijc.2910380406; Opavsky R, 1996, GENOMICS, V33, P480, DOI 10.1006/geno.1996.0223; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Sambrook J, 2001, MOL CLONING LAB MANU; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Uemura H, 1999, BRIT J CANCER, V81, P741, DOI 10.1038/sj.bjc.6690757; Verhaegh GW, 2000, J BIOL CHEM, V275, P37496, DOI 10.1074/jbc.M006293200; Vet JAM, 1998, AM J CLIN PATHOL, V110, P647, DOI 10.1093/ajcp/110.5.647; Wiesener MS, 2001, CANCER RES, V61, P5215; Wykoff CC, 2000, CANCER RES, V60, P7075	36	143	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5624	5631		10.1038/sj.onc.1207764	http://dx.doi.org/10.1038/sj.onc.1207764			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184875				2022-12-17	WOS:000222629500007
J	Sarrio, D; Perez-Mies, B; Hardisson, D; Moreno-Bueno, G; Suarez, A; Cano, A; Martinez-Perez, J; Gamallo, C; Palacios, J				Sarrio, D; Perez-Mies, B; Hardisson, D; Moreno-Bueno, G; Suarez, A; Cano, A; Martinez-Perez, J; Gamallo, C; Palacios, J			Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions	ONCOGENE			English	Article						lobular breast cancer; p120ctn; E-cadherin; catenins	TYROSINE PHOSPHORYLATION; MESENCHYMAL TRANSITIONS; CATENIN EXPRESSION; BETA-CATENIN; IN-SITU; ADHESION; P120(CTN); PROTEIN; CANCER; SRC	Accumulating evidences indicate that p120 catenin, a member of the E-cadherin (E-CD)/catenin adhesion complex, plays a role in tumor invasion. To establish the expression pattern of p120 in breast cancer, we analysed 326 breast tissue biopsies by tissue microarray. Most of the lobular tumors (88%) showed exclusive cytoplasmic localization, and 6% of them also had p120 nuclear staining. Cytoplasmic p120 strongly associated with complete loss of E-CD and beta-catenin not only in lobular carcinoma and its metastases but also in atypical lobular hyperplasias. In the latter, loss of heterozygosity of E-CD gene was also observed. Complete loss of E-CD and cytoplasmic and nuclear p120 staining was also observed in primary lobular cancer cell cultures generated by us. In ductal tumors, by contrast, reduction of p120 and E-CD in membrane was very common (57 and 53%, respectively), whereas cytoplasmic p120 staining was rarely seen. This simultaneous reduction of membranous E-CD and p120 was not associated with increased Src kinase activity. To demonstrate that cytoplasmic p120 localization was a consequence of the absence of E-CD, the endogenous E-CD was re-expressed in MDA-231 cells by 5-Aza-2'-deoxycytidine (5Aza) treatment. After treatment, p120 shifted from the cytoplasm to the membrane, where it colocalized with endogenous E-CD. Additionally, suppressing E-CD expression in Madin-Darby canine kidney cells by stable transfection of the transcriptional repressors Snail, E47 or Slug, provokes p120 cytoplasmic localization and p120 isoform switching. In conclusion, abnormal cytoplasmic and nuclear localization of p120, which are mediated by the absence of E-CD, characteristically occur in the early stages of lobular breast cancer and are maintained during tumor progression to metastasis. Consequently, p120 may be an important mediator of the oncogenic effects derived from E-CD inactivation, including enhanced motility and invasion, in lobular breast cancer.	CNIO, Programa Patol Mol, Madrid, Spain; Hosp La Paz, Dept Pathol, Madrid, Spain; UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; La Princesa Hosp, Dept Pathol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario La Paz; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital de La Princesa	Palacios, J (corresponding author), CNIO, Programa Patol Mol, C Melchor Fernandez Almagro 3, Madrid, Spain.	jpalacios@cnio.es	Moreno-Bueno, Gema/K-9354-2016; Martin-Perez, Jorge/A-3522-2008; Hardisson, David/AAN-3833-2020; Hardisson, David/E-2832-2010; Palacios, Jose/AAV-3765-2020; Hardisson, David/A-6259-2011; SARRIO, DAVID/Y-8903-2019	Moreno-Bueno, Gema/0000-0002-5030-6687; Martin-Perez, Jorge/0000-0002-2292-0057; Hardisson, David/0000-0002-2183-3699; Sarrio, David/0000-0003-4886-8290; Perez Mies, Belen/0000-0001-5764-5182				Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Dillon DA, 1998, AM J PATHOL, V152, P75; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRAFF JR, 1995, CANCER RES, V55, P5195; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jawhari AU, 1999, J PATHOL, V189, P180, DOI 10.1002/(SICI)1096-9896(199910)189:2<180::AID-PATH414>3.0.CO;2-2; Jiang WG, 2000, SURG ONCOL, V9, P151, DOI 10.1016/S0960-7404(01)00010-X; KEISERBILCK A, 1998, GENOMICS, V50, P129; KOHY N, 2002, INT J CANCER, V104, P44; Lishman SC, 1999, HISTOPATHOLOGY, V35, P195; Lu YJ, 1998, CANCER RES, V58, P4721; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; Mo YY, 1996, CANCER RES, V56, P2633; Montonen O, 2001, J HISTOCHEM CYTOCHEM, V49, P1487, DOI 10.1177/002215540104901202; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x; Ozawa M, 2001, J CELL SCI, V114, P503; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Vara JAF, 2000, BIOCHEM J, V345, P17, DOI 10.1042/0264-6021:3450017	44	143	157	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3272	3283		10.1038/sj.onc.1207439	http://dx.doi.org/10.1038/sj.onc.1207439			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077190				2022-12-17	WOS:000220975000002
J	Schagdarsurengin, U; Wilkens, L; Steinemann, D; Flemming, P; Kreipe, HH; Pfeifer, GP; Schlegelberger, B; Dammann, R				Schagdarsurengin, U; Wilkens, L; Steinemann, D; Flemming, P; Kreipe, HH; Pfeifer, GP; Schlegelberger, B; Dammann, R			Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatocellular adenoma; methylation; RASSF1; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-CHROMOSOME 3P21.3; CPG ISLAND; DNA METHYLATION; LUNG-CANCER; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; BREAST CANCERS; CIRRHOSIS	Aberrant promoter methylation is a fundamental mechanism of inactivation of tumor suppressor genes in cancer. The Ras association domain family 1A gene (RASSF1A) is frequently epigenetically silenced in several types of human solid tumors. In this study, we have investigated the expression and methylation status of the RASSF1A gene in hepatocellular carcinoma (HCC). In two HCC cell tines (HepG2 and Hep3B) RASSF1A was inactivated and treatment of these cell lines with a DNA methylation inhibitor reactivated the transcription of RASSF1A. The methylation status of the RASSF1A promoter region was analysed in 26 primary liver tissues including HCC, hepatocellular adenoma (HCA), liver fibrosis, hepatocirrhosis. Out of 15, 14 (93%) HCC were methylated at the RASSF1A CpG island and hypermethylation was independent of hepatitis virus infection. RASSF1A was also methylated in two out of two fibrosis and in three (75%) out of four cirrhosis; the latter carries an increased risk of developing HCC. Additionally, we analysed the methylation status of p16(INK4A), and other cancer-related genes in the same liver tumors. Aberrant methylation in the HCC samples was detected in 71% of samples for p16, 25% for TIMP3, 17% for PTEN, 13% for CDH1, and 7% for RARbeta2. In conclusion, our results demonstrate that RASSF1A and p16(INK4a) inactivation by methylation are frequent events in hepatocellular carcinoma, but not in HCA, which is in contrast to HCC without cirrhosis, viral hepatitis, storage diseases, or genetic background. Therefore, this study gives additional evidence against a progression of adenoma to carcinoma in the liver. Thus, RASSF1A hypermethylation could be useful as a marker of malignancy and to distinguish between the distinct forms of highly differentiated liver neoplasm.	Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet Med Fak, D-06097 Halle Saale, Germany; Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany; Hannover Med Sch, Inst Zell & Mol Pathol, D-30625 Hannover, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	Martin Luther University Halle Wittenberg; Hannover Medical School; Hannover Medical School; City of Hope; Beckman Research Institute of City of Hope	Dammann, R (corresponding author), Univ Halle Wittenberg, Inst Human Genet & Med Biol, AG Tumorgenet Med Fak, Magdeburger Str 2, D-06097 Halle Saale, Germany.	reinhard.dammann@medizin.uni-halle.de	Schagdarsurengin, Undraga/AAH-4312-2020; Schagdarsurengin, Undraga/AAH-4346-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938; 	NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER; NCI NIH HHS [CA88873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Bachman KE, 1999, CANCER RES, V59, P798; Boige V, 1997, CANCER RES, V57, P1986; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Flemming P, 2001, PATHOLOGE, V22, P184, DOI 10.1007/s002920100456; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8; Lerman MI, 2000, CANCER RES, V60, P6116; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Roncalli M, 2000, HEPATOLOGY, V31, P846, DOI 10.1053/he.2000.5790; Roncalli M, 2002, HEPATOLOGY, V36, P427, DOI 10.1053/jhep.2002.34852; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyooka S, 2001, CANCER RES, V61, P5727; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wilkens L, 2001, J PATHOL, V193, P476, DOI 10.1002/path.825; Wistuba II, 2000, CANCER RES, V60, P1949; Wong IHN, 1999, CANCER RES, V59, P71; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zhong S, 2002, CLIN CANCER RES, V8, P1087	44	143	159	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1866	1871		10.1038/sj.onc.1206338	http://dx.doi.org/10.1038/sj.onc.1206338			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660822				2022-12-17	WOS:000181678200013
J	Okuda, M				Okuda, M			The role of nucleophosmin in centrosome duplication	ONCOGENE			English	Review						nucleophosmin; B23; centrosome; CDK2; cyclin E; duplication	NUCLEOLAR PROTEIN B23; TRANSCRIPTION FACTOR IRF-1; LEUKEMIA HL-60 CELLS; CYCLIN-A; LOCALIZATION SIGNALS; DOWN-REGULATION; KINASE; IDENTIFICATION; NUCLEAR; FUSION	In higher animal cells, duplication of centrosomes is triggered by CDK2/cyclin E-mediated phosphorylation. Nucleophosmin (NPM)/B23, a multifunctional protein, has recently been identified as one of the substrates of CDK2/cyclin E in centrosome duplication. Centrosome-bound NPM/B23 dissociates from centrosome upon phosphorylation by CDK2/cyclin E, which in turn triggers initiation of centriole duplication. Duplicated centrosomes remain free of NPM/B23 till mitosis. When the nuclear membrane breaks down during mitosis, NPM/B23 relocalizes to centrosomes. Upon cytokinesis, each daughter cell receives one centrosome bound by NPM/B23, which again dissociates from the centrosome upon exposure to CDK2/cyclin E at mid-late G1 phase of the next cell cycle. Thus, NPM/B23 would constitute one of the licensing systems for centrosome duplication, ensuring the coordination of centrosome and DNA duplication, which limiting duplication once per cell cycle.	Yamaguchi Univ, Fac Agr, Lab Vet Internal Med, Yamaguchi 7538515, Japan	Yamaguchi University	Okuda, M (corresponding author), Yamaguchi Univ, Fac Agr, Lab Vet Internal Med, Yoshida 1677-1, Yamaguchi 7538515, Japan.			Okuda, Masaru/0000-0003-4690-8244				ADACHI Y, 1993, J BIOL CHEM, V268, P13930; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hsu CY, 1998, ONCOGENE, V16, P915, DOI 10.1038/sj.onc.1201615; Huang WH, 2001, J BIOL CHEM, V276, P25166, DOI 10.1074/jbc.M010087200; KOFF A, 1992, ONCOGENE, V15, P1275; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Liu WH, 1998, ONCOGENE, V17, P3055, DOI 10.1038/sj.onc.1202234; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nigg E A, 1988, Int Rev Cytol, V110, P27; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANDRE DD, 1989, CENTROSOME CYCLE ANI, P39; WANG DR, 1994, J BIOL CHEM, V269, P30994; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; Zatsepina OV, 1999, J CELL SCI, V112, P455; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	55	143	157	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6170	6174		10.1038/sj.onc.1205708	http://dx.doi.org/10.1038/sj.onc.1205708			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214246				2022-12-17	WOS:000177840500005
J	Chesire, DR; Ewing, CM; Gage, WR; Isaacs, WB				Chesire, DR; Ewing, CM; Gage, WR; Isaacs, WB			In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis	ONCOGENE			English	Article						beta-catenin; prostate cancer; nuclear staining; T cell factor; androgen receptor	ANDROGEN RECEPTOR; CANCER-CELLS; TRANSCRIPTIONAL ACTIVITY; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CARCINOMA CELLS; MAMMARY-GLAND; UP-REGULATION; E-CADHERIN; MUTATIONS	Understanding the molecular etiology of prostate cancer (CaP) progression is paramount for broadening current diagnostic and therapeutic modalities. Current interest in the role of wnt pathway signaling in prostate tumorigenesis was generated with the finding of beta-catenin mutation and corresponding nuclear localization in primary lesions. The recent finding of beta-catenin-induced enhancement of androgen receptor (AR) function potentially ties beta-catenin to key regulatory steps of prostate cell growth, differentiation, and transformation. By immunohistological analysis of metastatic tumors, we detected nuclear beta-catenin in 20% of lethal CaP cases, suggesting a more common role for beta-catenin in advanced disease than would be predicted by its mutation rate. Interestingly, beta-catenin nuclear localization was found to occur concomitantly with androgen-induced regrowth of normal rat prostate. These in vivo observations likely implicate beta-catenin involvement in both normal and neoplastic prostate physiology, thus prompting our interest in further characterizing modes of beta-catenin signaling in prostate cells. Extending our previous findings, we demonstrate that transient beta-catenin over-expression stimulates T cell factor (TCF) signaling in most CaP cell lines. Further, this activity is not subject to cross- regulation by phosphoinositide-3-kinase (PI3-K)/Akt signaling, a stimulatory pathway often upregulated in CaP upon PTEN inactivation. Consistent with a previous report, we observed that transient beta-catenin overexpression enhances AR-mediated transcription off two natural target gene promoters. However, we were unable to recapitulate beta-catenin-induced stimulation of ectopically expressed AR in AR-negative cells, suggesting that other AR-associated factors are required for this activity. Although LNCaP cells are capable of this mode of AR co-stimulation, stable expression of mutant beta-catenin did not alter their proliferative response to androgen. In total, our characterization of beta-catenin signaling in CaP reveals the complex nature of its activity in prostate tissue, indicating that beta-catenin potentially contributes to multiple stimulatory inputs required for disease progression.	Johns Hopkins Med Inst, Brady Urol Inst Res Labs, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Isaacs, WB (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@mail.jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bubendorf L, 1999, CANCER RES, V59, P803; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1994, CANCER RES, V54, P5474; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Duval A, 2000, CANCER RES, V60, P3872; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hayes SA, 2001, CANCER RES, V61, P2112; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; Kinoshita H, 2000, CANCER RES, V60, P3623; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KYPRIANOU N, 1987, PROSTATE, V11, P41, DOI 10.1002/pros.2990110106; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; LUKE MC, 1994, J ANDROL, V15, P41; Luo J, 2001, CANCER RES, V61, P4683; McDonald S, 2000, CANCER RES, V60, P2317; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyazawa K, 2000, VIRCHOWS ARCH, V437, P508, DOI 10.1007/s004280000283; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park WS, 1999, CANCER RES, V59, P4257; Planz B, 1998, J UROLOGY, V160, P1850, DOI 10.1016/S0022-5347(01)62431-5; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANDFORD NL, 1984, PATHOLOGY, V16, P406, DOI 10.3109/00313028409084731; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shih IM, 2000, CANCER RES, V60, P1671; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Truica CI, 2000, CANCER RES, V60, P4709; UMBAS R, 1992, CANCER RES, V52, P5104; van Bokhoven A, 2001, CANCER RES, V61, P6340; Voeller HJ, 1998, CANCER RES, V58, P2520; Wen Y, 2000, CANCER RES, V60, P6841; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhu AJ, 1999, DEVELOPMENT, V126, P2285; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	73	143	148	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2679	2694		10.1038/sj.onc.1205352	http://dx.doi.org/10.1038/sj.onc.1205352			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965541				2022-12-17	WOS:000174996500008
J	Han, DC; Shen, TL; Guan, JL				Han, DC; Shen, TL; Guan, JL			The Grb7 family proteins: structure, interactions with other signaling molecules and potential cellular functions	ONCOGENE			English	Article						Grb7; protein interactions; cell migration; cell proliferation; signal transduction	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; FACTOR-I RECEPTOR; SH2 DOMAIN PROTEINS; INSULIN-RECEPTOR; ADAPTER PROTEIN; TYROSINE KINASE; ESOPHAGEAL-CARCINOMA; PLECKSTRIN HOMOLOGY; BINDING-PROTEIN	Grb7 family adaptor molecules consist of Grb7, Grb10 and Grb14, each of which has several splicing variants. Like other adaptor molecules, Grb7 family proteins function to mediate the coupling of multiple cell surface receptors to downstream signaling pathways in the regulation of various cellular functions. They share significant sequence homology with each other and a conserved molecular architecture including an aminoterminal proline-rich region, a central segment termed the GM region (for (G) under bar rb and (M) under bar ig) which includes a PH domain and shares sequence homology with the Caenorhabditis elegans protein, Mig-10, involved in embryonic migration, and a carboxyl-terminal SH2 domain. Grb7 family proteins are differentially expressed in a variety of tissues. They are phosphorylated on serine/threonine as well as tyrosine residues, although the kinases responsible have not been well characterized. Grb7 family proteins are mainly localized in the cytoplasm, but have been observed at the plasma membrane, focal contacts, or mitochondria under certain conditions. A large number of receptor tyrosine kinases and other signaling molecules can associate with Grb7 family proteins, mostly through the SH2 domains. Various isoforms of Grb1O have been shown to regulate cell proliferation and apoptosis, whereas Grb7 has been found to regulate cell migration and also implicated in tumor progression. Future studies of interests will include identification of potential downstream effectors of Grb7 family proteins as well as understanding of the mechanisms of specificity of the different family members in signal transduction.	Cornell Univ, Dept Mol Med, Canc Biol Lab, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Canc Biol Lab, Ithaca, NY 14853 USA.		Shen, Tang-Long/C-7460-2011	Shen, Tang-Long/0000-0001-6264-3608	NIGMS NIH HHS [GM48050] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dong LQ, 1998, J BIOL CHEM, V273, P17720, DOI 10.1074/jbc.273.28.17720; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kasus-Jacobi A, 2000, ONCOGENE, V19, P2052, DOI 10.1038/sj.onc.1203469; Keegan K, 1996, ONCOGENE, V12, P1537; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Leavey SF, 1998, AM J PHYSIOL-RENAL, V275, pF770, DOI 10.1152/ajprenal.1998.275.5.F770; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; Manser J, 1997, DEV BIOL, V184, P150, DOI 10.1006/dbio.1997.8516; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Morrione A, 1997, J BIOL CHEM, V272, P26382, DOI 10.1074/jbc.272.42.26382; Morrione A, 1996, CANCER RES, V56, P3165; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Moutoussamy S, 1998, J BIOL CHEM, V273, P15906, DOI 10.1074/jbc.273.26.15906; Nantel A, 1999, J BIOL CHEM, V274, P35719, DOI 10.1074/jbc.274.50.35719; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1621; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Reiske HR, 2000, FEBS LETT, V486, P275, DOI 10.1016/S0014-5793(00)02295-X; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wojcik J, 1999, BIOCHEM BIOPH RES CO, V259, P113, DOI 10.1006/bbrc.1999.0727; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942	52	143	147	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6315	6321		10.1038/sj.onc.1204775	http://dx.doi.org/10.1038/sj.onc.1204775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607834				2022-12-17	WOS:000171640600007
J	Trauzold, A; Wermann, H; Arlt, A; Schutze, S; Schafer, H; Oestern, S; Roder, C; Ungefroren, H; Lampe, E; Heinrich, M; Walczak, H; Kalthoff, H				Trauzold, A; Wermann, H; Arlt, A; Schutze, S; Schafer, H; Oestern, S; Roder, C; Ungefroren, H; Lampe, E; Heinrich, M; Walczak, H; Kalthoff, H			CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappa B contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells	ONCOGENE			English	Article						apoptosis; CD95; TRAIL; PKC; NF-kappa B; pancreatic adenocarcinoma	SIGNALING PATHWAYS; TNF-ALPHA; DEATH; FAMILY; LIGAND; INHIBITION; INDUCTION; MEMBER; FAS; MU	The molecular alterations in tumour cells leading to resistance towards apoptosis induced by CD95 and TRAIL-receptors are not fully understood. We report here that the stimulation of the CD95- and TRAIL-resistant human pancreatic adenocarcinoma cell line PancTuI with an agonistic anti-CDW antibody or TRAIL resulted in activation of protein kinase C and NF-kappaB, Inhibition of protein kinase C by Go6983 sensitized these cells to apoptotic challenges and strongly diminished activation of NF-kappaB by anti-CD95 and TRAIL. Similarly, inhibition of NF-kappaB by MG132 or by transient transfection with a dominant negative mutant of I kappaB alpha restored the responsiveness of PancTuI cells to both death ligands. In the CD95 and TRAIL-sensitive cell line Colo357 the induction of protein kinase C and NF-KB following activation of CD95 and TRAIL-R was very moderate compared with PancTuI cells. However, pre-incubation of these cells with PMA strongly reduced their apoptotic response to anti-CD95 and TRAIL. Taken together, we show that activation of protein kinase C operates directly in a death receptor-dependent manner in PancTuI cells and protect pancreatic tumour cells from anti-CD95 and TRAIL-mediated apoptosis by preventing the loss Delta Psim and Cytochrome c release as well as by induction of NF-kappaB.	Univ Kiel, Clin Gen Surg, D-24105 Kiel, Germany; Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany	University of Kiel; University of Kiel; University of Kiel; Helmholtz Association; German Cancer Research Center (DKFZ)	Kalthoff, H (corresponding author), Univ Kiel, Clin Gen Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Walczak, Henning/AAV-2214-2020; Kalthoff, Holger/B-1618-2010; Schütze, Stefan/C-8596-2011; Roeder, Christian/F-1068-2010; Arlt, Alexander/G-7308-2019; Trauzold, Anna/P-4398-2014	Walczak, Henning/0000-0002-6312-4591; Roeder, Christian/0000-0001-7881-9110; Arlt, Alexander/0000-0002-6160-1059; 				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kobayashi D, 1997, CHEMOTHERAPY, V43, P415, DOI 10.1159/000239600; Krammer P H, 1999, Adv Immunol, V71, P163; KUMUDA CD, 1997, J BIOL CHEM, V272, P14914; Leverkus M, 2000, CANCER RES, V60, P553; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Packham G, 1997, CELL DEATH DIFFER, V4, P130, DOI 10.1038/sj.cdd.4400217; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PETER ME, 1998, APOPTOSIS PROBLEMS D, P25; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Ravi R, 1998, CANCER RES, V58, P882; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Ungefroren H, 1998, CANCER RES, V58, P1741; von Reyher U, 1998, CANCER RES, V58, P526; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	40	143	144	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4258	4269		10.1038/sj.onc.1204559	http://dx.doi.org/10.1038/sj.onc.1204559			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464292				2022-12-17	WOS:000169857200016
J	Saavedra, HI; Knauf, JA; Shirokawa, JM; Wang, JW; Bin, OY; Elisei, R; Stambrook, PJ; Fagin, JA				Saavedra, HI; Knauf, JA; Shirokawa, JM; Wang, JW; Bin, OY; Elisei, R; Stambrook, PJ; Fagin, JA			The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway	ONCOGENE			English	Article						genomic instability; Ras; thyroid cancer; MAP kinase	SPINDLE ASSEMBLY CHECKPOINT; THYROTROPIN RECEPTOR GENE; TOPOISOMERASE II-ALPHA; XENOPUS EGG EXTRACTS; NIH 3T3 CELLS; PROTEIN-KINASE; PAPILLARY CARCINOMAS; CANCER-CELLS; METASTATIC ABILITY; MAMMALIAN-CELLS	Activating mutations of RAS are thought to be early events in the evolution of thyroid follicular neoplasms, We used a doxycycline-inducible expression system to explore the acute effects of H-RAS(V12) on genomic stability in thyroid PCCL3 cells, At 2-3 days (first or second cell cycle) there was a significant increase in the frequency of micronucleation, Treatment of cells with YVAD-CHO inhibited RAS-induced apoptosis, but had no effect on micronucleation, The effects of H-RAS(V12) were mediated by activation of MAPK, as treatment with PD98059 at concentrations verified to selectively inhibit MEK1 reduced the frequency of prevalence of cells with micronuclei. In addition, doxycycline-inducible expression of a constitutively active MEK1, but not of a mutant RAC1, mimicked the effects of H-RAS(V12). The effects of H-RAS(V12) on genome destabilization were apparent even though the sequence of p53 in PCCL3 cells was confirmed to be wild-type. Acute activation of H-RAS(V12) evoked a proportional increase in both CREST negative and CREST positive micronuclei, indicating that both clastogenic and aneugenic effects were involved. H-RAS(V12) and activated MEK1 also induced centrosome amplification, and chromosome misalignment, Evidence that acute expression of constitutively activated RAS destabilizes the genome of PCCL3 cells is consistent with a mode of tumor initiation in which this oncogene promotes phenotypic progression by predisposing to large scale genomic abnormalities.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Anat Cell Biol & Neurobiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.			Knauf, Jeffrey/0000-0003-4456-8792; ELISEI, ROSSELLA/0000-0002-5333-9257; Shirokawa, Jill/0000-0001-5669-1478	NATIONAL CANCER INSTITUTE [F32CA069711, R01CA050706, R29CA050706, R01CA072597] Funding Source: NIH RePORTER; NCI NIH HHS [CA72597, CA50706, F32CA69711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; ICHIKAWA T, 1990, CANCER RES, V50, P6349; ICHIKAWA T, 1991, PROSTATE, V18, P163, DOI 10.1002/pros.2990180209; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MILLER BM, 1993, MUTAGENESIS, V8, P35, DOI 10.1093/mutage/8.1.35; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nikiforov YE, 1997, CANCER RES, V57, P1690; NUSSE M, 1994, METHOD CELL BIOL, V42, P149; OLLER AR, 1989, MUTAT RES, V216, P149, DOI 10.1016/0165-1161(89)90001-0; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Porcellini A, 1997, J MOL MED-JMM, V75, P567, DOI 10.1007/s001090050141; Powell DJ, 1998, CANCER RES, V58, P5523; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; SHIROKAWA J, 1999, 81 ANN M END SOC JUN; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1988, ONCOGENE, V2, P403; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; THACKER J, 1985, MUTAT RES, V150, P431, DOI 10.1016/0027-5107(85)90140-X; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WANI MA, 1994, CANCER RES, V54, P2504; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; WOESSNER RD, 1990, CANCER RES, V50, P2901; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	54	143	149	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3948	3954		10.1038/sj.onc.1203723	http://dx.doi.org/10.1038/sj.onc.1203723			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951588				2022-12-17	WOS:000088614300014
J	Yakicier, MC; Irmak, MB; Romano, A; Kew, M; Ozturk, M				Yakicier, MC; Irmak, MB; Romano, A; Kew, M; Ozturk, M			Smad2 and Smad4 gene mutations in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; Smad2; Smad4; TGF beta; tumor suppressor genes; somatic mutation	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; SOMATIC MUTATIONS; DPC4 GENE; IN-VIVO; CANCERS; HEPATOCYTES; APOPTOSIS; 18Q21; LIVER	TGF-beta is a negative regulator of liver growth. Smad family of genes, as mediators of TGF-beta pathway, are candidate tumor suppressor genes in hepatocellular carcinoma (HCC). We studied 35 HCC and non-tumour liver tissues for possible mutations in Smad2 and Smad4 genes. Three tumours displayed somatic mutations; two in Smad4 (Asp332Gly and Cys401Arg) and one in Smad2 (Gln407Arg) genes. All three mutations were A:T --> G:C transitions suspected to result from oxidative stress as observed in mitochondrial DNA. These observation demonstrate that TGF-beta pathway is altered in hepatocellular carcinoma.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey; Univ Witwatersrand, Johannesburg, South Africa	Ihsan Dogramaci Bilkent University; University of Witwatersrand	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Ankara, Turkey.		ozturk, mehmet/G-3330-2014; OZTURK, MEHMET/AAS-7241-2021	OZTURK, MEHMET/0000-0002-6092-9706				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Gressner AM, 1997, J HEPATOL, V26, P1079, DOI 10.1016/S0168-8278(97)80117-1; GRISHAM JW, 1996, CARCINOGENESIS, V18, P59; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Kawate S, 1999, INT J ONCOL, V14, P127; Kim SK, 1996, CANCER RES, V56, P2519; MIYAMURA T, 1990, P NATL AAD SCI US, V87, P6971; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Ozturk Mehmet, 1995, P511; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Uchida K, 1996, CANCER RES, V56, P5583; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822	33	143	150	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4879	4883		10.1038/sj.onc.1202866	http://dx.doi.org/10.1038/sj.onc.1202866			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490821	Green Published			2022-12-17	WOS:000082184800012
J	Wang, WX; Abbruzzese, JL; Evans, DB; Chiao, PJ				Wang, WX; Abbruzzese, JL; Evans, DB; Chiao, PJ			Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA	ONCOGENE			English	Article						urokinase-type plasminogen activator; NF-kappa B; pancreatic adenocarcinoma	NF-KAPPA-B; HEPATOCYTE GROWTH-FACTOR; PHORBOL ESTER INDUCTION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; HA-RAS; CELLS; ALPHA; ONCOGENE	The Rel/NF-kappa-B transcription factors regulate the expression of many genes. The activity of RelA, a member of the Rel/NF-kappa B transcription factor family, is constitutively activated in the majority of pancreatic adenocarcinomas and cell lines. We report that the urokinase-type plasminogen activator (uPA), one of the critical proteases involved in tumor invasion and metastasis, is overexpressed in pancreatic tumor cells and its overexpression is induced by constitutive RelA activity. The uPA promoter contains an NF-kappa B binding site that directly mediates the induction of uPA expression by RelA. Expression of a dominant-negative I kappa B alpha mutant inhibits kappa B site-dependent transcriptional activation of a uPA promoter-CAT reporter gene. Treating the pancreatic tumor cell lints with the known NF-kappa B inhibitors, dexamethasone and n-tosylphenyalanine chloromethyl ketone (TPCK), abolishes constitutive RelA activity and uPA overexpression, These results show that uPA is one of the downstream target genes induced by constitutively activated RelA in human pancreatic tumor cells, and suggests that constitutive RelA activity may play a critical role in tumor invasion and metastasis. Inhibition of constitutive RelA in pancreatic tumor cells may reduce their invasive and metastatic potential.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol & Tumor Biol, Box 107,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R29CA073675] Funding Source: NIH RePORTER; NCI NIH HHS [CA71836-01, CA73675-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Besser D, 1995, ONCOGENE, V11, P2383; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BLASI F, 1990, SEMIN CANCER BIOL, V2, P117; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORDONCARDO C, 1994, CANCER RES, V51, P6372; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIGIUSEPPE JA, 1996, ADV ANAT PATHOL, V3, P139; DUFFY MJ, 1990, CANCER RES, V50, P6827; GHERSA P, 1992, J BIOL CHEM, V267, P19226; Gilmore TD, 1996, ONCOGENE, V13, P1367; Ginestra A, 1997, J BIOL CHEM, V272, P17216, DOI 10.1074/jbc.272.27.17216; Gogly B, 1998, ANAL BIOCHEM, V255, P211, DOI 10.1006/abio.1997.2318; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HARVEY SR, 1988, CLIN EXP METASTAS, V6, P431, DOI 10.1007/BF01784375; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Jankun J, 1997, CANCER RES, V57, P559; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lengye E, 1995, ONCOGENE, V11, P2639; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MARKSITZER R, 1995, J BIOL CHEM, V270, P21833, DOI 10.1074/jbc.270.37.21833; Mars WM, 1996, CANCER RES, V56, P2837; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; MURDOCH GH, 1982, NATURE, V300, P192, DOI 10.1038/300192a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; POLLANEN J, 1991, ADV CANCER RES, V57, P273; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rosewicz S, 1997, LANCET, V349, P485; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Sinicrope FA, 1996, CLIN CANCER RES, V2, P2015; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TESTA JE, 1989, INT J CANCER, V43, P816, DOI 10.1002/ijc.2910430513; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wang WX, 1999, CLIN CANCER RES, V5, P119; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; WEINEL RJ, 1995, GASTROENTEROLOGY, V108, P523, DOI 10.1016/0016-5085(95)90082-9; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	75	143	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4554	4563		10.1038/sj.onc.1202833	http://dx.doi.org/10.1038/sj.onc.1202833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467400				2022-12-17	WOS:000082018600005
J	Lilly, M; Sandholm, J; Cooper, JJ; Koskinen, PJ; Kraft, A				Lilly, M; Sandholm, J; Cooper, JJ; Koskinen, PJ; Kraft, A			The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway	ONCOGENE			English	Article						apoptosis; pim-1; bcl-2; mitochondria; IL-3; FDCP1	PROTEIN-KINASE; CELL-DEATH; HEMATOPOIETIC-CELLS; MYELOID CELLS; ANTIOXIDANT PATHWAY; SUPPRESS APOPTOSIS; BCL-2 EXPRESSION; TRANSGENIC MICE; CYTOCHROME-C; IN-VIVO	We have examined potential mechanisms by which the Pim-1 kinase acts as a hematopoietic cell survival factor. Enforced expression of the wild type 33 kd (FD/hpim33) and 44 kd (FD/mpim44) Pim-1 proteins in murine factor-dependent FDCP1 cells prolonged survival after withdrawal of IL-3, while expression of a dominant negative Pim-1 protein (FD/pimNT81) shortened survival, Following removal of IL-3 FDCP1 cells exhibited loss of mitochondrial transmembrane potential and production of reactive oxygen species, as determined by how cytometry analysis. The wild type Pim-1 proteins decreased these changes while the dominant negative protein enhanced mitochondrial dysfunction, The anti-apoptotic activity of the kinases could not be attributed to modulation of glutathione, catalase, or superoxide dismutase activities, Both the FD/hpim33 and FD/mpim44 cells maintained expression of bcl-2 mRNA following cytokine removal, while a substantial decrease was seen in FD/neo cells. To modulate Bcl-2 protein levels, a bcl-2 antisense RNA construct was coexpressed with the wild type pim-1 cDNAs, FD/hpim33 cells with low cellular Bcl-2 protein levels had shortened cytokine-independent survival compared with FD/hpim33 clones with high Bcl-2 expression. However survival of FD/mpim44 cells after IL-3 withdrawal was substantially independent of cellular Bcl-2 protein levels. The 33 kd protein delayed, and the 44 kd protein completely prevented enhanced cell death associated with enforced expression of human Bar protein however. Our results suggest that the 33 kd Pim-1 kinase may enhance cell survival through cooperation with and regulation of bcl-2, In addition the 44 kd kinase may regulate the expression or activity of other pro- and anti-apoptotic members of the bcl-2 family.	Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA; Vet Affairs Med Ctr, Seattle, WA USA; Univ Turku, Abo Akad Univ, Ctr Biotechnol, Turku, Finland; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Denver, CO 80262 USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Abo Akademi University; University of Turku; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Lilly, M (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Loma Linda, CA 92354 USA.		Koskinen, Päivi J/G-8939-2014		NATIONAL CANCER INSTITUTE [R01CA045672, R55CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER; NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Allen JD, 1996, SEMIN CANCER BIOL, V7, P299, DOI 10.1006/scbi.1996.0038; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BREUER M, 1991, CANCER RES, V51, P958; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DOMEN J, 1993, BLOOD, V82, P1445; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; HEDLEY D, 1994, METHOD CELL BIOL, V42, P31; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Oppenheim R W, 1997, Adv Neurol, V72, P69; Ou PM, 1996, J BIOCHEM BIOPH METH, V31, P59, DOI 10.1016/0165-022X(95)00039-T; Packham G, 1996, J IMMUNOL, V156, P2792; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wingett D, 1996, J IMMUNOL, V156, P549; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1996, J EXP MED, V183, P1293	51	143	151	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4022	4031		10.1038/sj.onc.1202741	http://dx.doi.org/10.1038/sj.onc.1202741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435626	Bronze			2022-12-17	WOS:000081327800013
J	Birch, JM; Blair, V; Kelsey, AM; Evans, DG; Harris, M; Tricker, KJ; Varley, JM				Birch, JM; Blair, V; Kelsey, AM; Evans, DG; Harris, M; Tricker, KJ; Varley, JM			Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome	ONCOGENE			English	Article						TP53; genotype; phenotype; Li-Fraumeni syndrome; familial cancer	GERMLINE P53 MUTATIONS; WILD-TYPE P53; BREAST-CANCER; MUTANT P53; PRONE FAMILIES; GENE; CHILDREN; PROTEINS; BINDING; TUMORS	The Li-Fraumeni cancer predisposition syndrome is associated with germline TP53 mutations in the majority of families. We have investigated cancer incidence in 34 Li-Fraumeni families, according to their constitutional TP53 mutation status. Families with germline missense mutations in the core DNA binding domain showed a more highly penetrant cancer phenotype than families with other TP53 mutations or no mutation. Cancer phenotype in families carrying such mutations was characterized by a higher cancer incidence and earlier ages at diagnosis, especially of breast cancer and brain tumours, compared with families carrying protein truncating or other inactivating mutations (P=0.03 for all cancers, P=0.006 for breast cancers, P=0.05 for brain tumours). Proband cancers showed significantly younger ages at diagnosis in those with missense mutations in the DNA binding domain than in those with protein inactivating mutations (P=0.031). In individuals with the former type of mutation, there was a significantly lower proportion of tumours which showed loss of the wild-type TP53 allele (P=0.004). These results are consistent with observations in experimental systems which demonstrate that certain mutations exhibit gain of function and/or dominant-negative properties. Our results support an enhanced oncogenic potential for such mutations in human populations.	Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England; Royal Manchester Childrens Hosp, Dept Histopathol, Manchester M27 1HA, Lancs, England; Christie Hosp, Dept Histopathol, Manchester, Lancs, England; Christie Hosp, CRC, Mol Genet Sect, Paterson Inst Canc Res, Manchester, Lancs, England	Royal Manchester Children's Hospital; Royal Manchester Children's Hospital; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Birch, JM (corresponding author), Royal Manchester Childrens Hosp, CRC, Paediat & Familial Canc Res Grp, Manchester M27 1HA, Lancs, England.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BIRCH JM, 1994, CANCER RES, V54, P1298; BIRCH JM, 1984, BRIT J CANCER, V49, P325, DOI 10.1038/bjc.1984.51; BIRCH JM, 1990, CANCER, V66, P2339; BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; BOYLE JM, 1998, IN PRESS BR J CANC; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORIO Y, 1994, ONCOGENE, V9, P1231; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Kawamura M, 1996, ONCOGENE, V12, P2361; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MILLER CW, 1993, ONCOGENE, V8, P1815; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; PURDIE CA, 1994, ONCOGENE, V9, P603; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STRONG LC, 1987, JNCI-J NATL CANCER I, V79, P1213; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Varley JM, 1997, CANCER RES, V57, P3245; VARLEY JM, 1995, J MED GENET, V32, P942, DOI 10.1136/jmg.32.12.942; Varley JM, 1996, ONCOGENE, V12, P2437; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707	44	143	148	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1061	1068		10.1038/sj.onc.1202033	http://dx.doi.org/10.1038/sj.onc.1202033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764816				2022-12-17	WOS:000075598400001
J	Yokomizo, A; Tindall, DJ; Drabkin, H; Gemmill, R; Franklin, W; Yang, P; Sugio, K; Smith, DI; Liu, WG				Yokomizo, A; Tindall, DJ; Drabkin, H; Gemmill, R; Franklin, W; Yang, P; Sugio, K; Smith, DI; Liu, WG			PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers	ONCOGENE			English	Article						PTEN/MMAC1; mutation; deletion; lung cancer; DHPLC	GENE; CHROMOSOME-10; HETEROZYGOSITY; PROGRESSION	A putative tumor suppressor, PTEN/MMAC1 gene at 10q23 was recently identified and found to be mutated in many different human tumors. To determine the role of the PTEN/MMAC1 gene in lung cancer, we screened 34 small cell lung cancer (SCLC) cell lines, 10 SCLC tumors, 13 non-small cell lung cancer (NSCLC) cell lines and 10 NSCLC tumors using Denaturing HPLC (DHPLC) and direct sequencing methods. In SCLC, six (18%) of the cell lines and one of the primary tumor samples (10%) showed alterations of the PTEN/ MMAC1 gene including point mutations, small fragment deletions, and homozygous deletions. All of the point mutations and small fragment deletions were observed in hemizygously deleted cell lines. In contrast to SCLC, none of the NSCLC tumors or cell lines had mutations in the PTEN/MMAC1 gene. These data indicate that PTEN/MMAC1 mutations contribute to the pathogenesis and neoplastic evolution in SCLC but not in NSCLC.	Mayo Clin & Mayo Fdn, Dept Pathol & Lab Med, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA; Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Kyushu Univ, Fac Med, Dept Surg 2, Fukuoka 81282, Japan	Mayo Clinic; Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kyushu University	Liu, WG (corresponding author), Mayo Clin & Mayo Fdn, Dept Expt Pathol & Med, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA58187, CA48031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048031, P50CA058187] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartsch D, 1996, CANCER LETT, V102, P73, DOI 10.1016/0304-3835(96)04167-5; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; JAMES CD, 1988, CANCER RES, V48, P5546; JOHNSON BE, 1995, LUNG CANCER-J IASLC, V12, pS5, DOI 10.1016/S0169-5002(10)80014-5; Kawamata N, 1996, PROSTATE, V29, P191, DOI 10.1002/1097-0045(199609)29:3<191::AID-PROS2990290305>3.0.CO;2-1; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; LEENSTRA S, 1994, BRIT J CANCER, V70, P684, DOI 10.1038/bjc.1994.373; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU W, 1998, IN PRESS NUCL ACIDS; Liu WG, 1997, CANCER RES, V57, P5254; Liu WG, 1996, HUM MOL GENET, V5, P1581, DOI 10.1093/hmg/5.10.1581; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; OPHOFF RA, 1996, CELL, V87, P1; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; Pennisi E, 1997, SCIENCE, V275, P1876, DOI 10.1126/science.275.5308.1876; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; RIED T, 1994, CANCER RES, V54, P1801; Risinger JI, 1997, CANCER RES, V57, P4736; RSAHEED BKA, 1997, CANCER RES, V57, P4187; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Underhill PA, 1996, P NATL ACAD SCI USA, V93, P196, DOI 10.1073/pnas.93.1.196; Wang SI, 1997, CANCER RES, V57, P4183	39	143	154	4	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					475	479		10.1038/sj.onc.1201956	http://dx.doi.org/10.1038/sj.onc.1201956			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696041				2022-12-17	WOS:000075043000010
J	Landgren, E; Schiller, P; Cao, YH; Claesson-Welsh, L				Landgren, E; Schiller, P; Cao, YH; Claesson-Welsh, L			Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1	ONCOGENE			English	Article						VEGF; PLGF; endothelial cells; migration; proliferation	TYROSINE KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; VASCULAR ENDOTHELIUM; RECEPTOR; VEGF; ANGIOGENESIS; BINDING; FLK-1; KDR	Vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) are structurally related growth factors for endothelial cells. VEGF binds to the related receptor tyrosine kinases Fit 1 and KDR/Flk 1 with high affinity, whereas PlGF binds only to Fit 1. Ligand-stimulated KDR is known to transduce signals for cellular activity such as proliferation and migration, whereas weak or no responses have been recorded for Fit 1. We examined VEGF and PIGF for their capacity to stimulate signal transduction in porcine aortic endothelial cells expressing Fit 1 or KDR. VEGF had essentially no effect on Fit 1 expressing cells, but induced DNA synthesis and migration of KDR expressing cells. PlGF on the other hand induced DNA synthesis but not migration of the Fit 1 cells. In agreement, MAP kinase, examined as a marker for DNA synthesis, was activated both by VEGF-stimulation of the KDR cells and by PlGF-stimulation of the Fit 1 cells. In contrast, phospholipase C-gamma (PLC-gamma), was tyrosine phosphorylated only in VEGF stimulated KDR cells, and not in the PlGF-stimulated Fit 1 cells, which is in agreement with a role for PLC-gamma in cellular migration. We furthermore examined induction of protein levels of plasminogen activator (PA), which was evident in the PlGF-stimulated Fit 1 cells, but not in the VEGF-stimulated KDR cells. These data show that Fit 1 is able to mediate an array-of biological signals when appropriately stimulated and that the pattern of responses of PlGF-stimulation of Fit 1 is distinct from the pattern of responses to VEGF-stimulation of KDR.	Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden; Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Karolinska Institutet	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med & Physiol Chem, Box 575, S-75123 Uppsala, Sweden.			Claesson-Welsh, Lena/0000-0003-4275-2000; Schiller, Petter/0000-0002-1790-3711				AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; Landgren E, 1996, EXP CELL RES, V223, P405, DOI 10.1006/excr.1996.0095; MAGLIONE D, 1993, ONCOGENE, V8, P925; Maniatis T., 1982, MOL CLONING LAB MANU; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; PARK JE, 1994, J BIOL CHEM, V269, P25646; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WENNSTROM S, 1994, ONCOGENE, V9, P651; WILKIE AOM, 1995, CURR BIOL, V5, P500	39	143	145	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					359	367		10.1038/sj.onc.1201545	http://dx.doi.org/10.1038/sj.onc.1201545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467961	Bronze			2022-12-17	WOS:000071582100008
J	ZHOU, XL; TARMIN, L; YIN, J; JIANG, HY; SUZUKI, H; RHYU, MG; ABRAHAM, JM; MELTZER, SJ				ZHOU, XL; TARMIN, L; YIN, J; JIANG, HY; SUZUKI, H; RHYU, MG; ABRAHAM, JM; MELTZER, SJ			THE MTS1 GENE IS FREQUENTLY MUTATED IN PRIMARY HUMAN ESOPHAGEAL TUMORS	ONCOGENE			English	Article							P53; CANCERS; HETEROZYGOSITY; MUTATIONS	Homozygous and heterozygous deletions involving chromosome 9p21 have been reported in a variety of primary human tumors in vivo, and point mutations have been reported in melanoma cell lines in vitro within a probable tumor suppressor gene, MTS1, located at chromosome 9p21. We describe six sequence alterations occurring among twenty-four primary esophageal squamous carcinomas and nineteen primary esophageal adenocarcinomas analyzed by DNA sequencing of MTS1 exon 2. Nucleotide substitutions were observed in five squamous cell carcinomas and in one adenocarcinoma. Two occurred in the germline, while four were somatic alterations. All six nucleotide changes resulted in marked alterations in amino acid sequence. Four were nonsense mutations leading to premature termination codons; nucleotide substitutions identical to two of these stop codons were previously reported in other tumor types. Loss of heterozygosity occurred in all five informative (constitutionally heterozygous) cases in which a sequence alteration was present. Esophageal cancer is one primary human tumor in which MTS1 constitutes an apparent target of heterozygous or homozygous deletions occurring at chromosome 9p21.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GI,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore					NIDDK NIH HHS [R01 DK47717] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT WP, 1991, ONCOGENE, V6, P1779; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BRISEBOIS JJ, 1993, MUTAT RES, V287, P191, DOI 10.1016/0027-5107(93)90012-5; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; HARRIS CC, 1991, ONCOGENE, V6, P1779; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUANG Y, 1993, CANCER RES, V53, P1889; HUANG Y, 1992, CANCER RES, V52, P6525; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MARX J, 1994, SCIENCE, V264, P344, DOI 10.1126/science.8153613; MEAD LJ, 1994, CANCER RES, V54, P2307; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2322; MERLO A, 1994, CANCER RES, V54, P640; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; ORLOW I, 1994, CANCER RES, V54, P2848; POWELL SM, 1994, IN PRESS GASTROENTER; RHYU MG, 1994, ONCOGENE, V9, P29; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	29	143	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3737	3741						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970734				2022-12-17	WOS:A1994PT39200040
J	MOGHUL, A; LIN, L; BEEDLE, A; KANBOURSHAKIR, A; DEFRANCES, MC; LIU, YH; ZARNEGAR, R				MOGHUL, A; LIN, L; BEEDLE, A; KANBOURSHAKIR, A; DEFRANCES, MC; LIU, YH; ZARNEGAR, R			MODULATION OF C-MET PROTOONCOGENE (HGF RECEPTOR) MESSENGER-RNA ABUNDANCE BY CYTOKINES AND HORMONES - EVIDENCE FOR RAPID DECAY OF THE 8 KB C-MET TRANSCRIPT	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; SCATTER FACTOR; EPITHELIAL-CELLS; TYROSINE KINASE; MOLECULAR-CLONING; HEPATOPOIETIN-A; CARCINOMA-CELLS; FACTOR-ALPHA; PROTOONCOGENE	The c-MET proto-oncogene product is a transmembrane tyrosine kinase receptor which was recently shown to transmit an array of important cellular responses induced by Hepatocyte Growth Factor (HGF). These biological effects include induction of mitogenesis, motogenesis, morphogenesis, metastogenesis and anti-tumor activity on a variety of epithelial cells, All of these processes are known to be associated with normal and abnormal tissue growth and development. The 190 kDa c-MET protein is encoded by a major transcript of 8 kilobases (Kb), which is reported to be expressed predominantly in epithelial tissues. The expression pattern of c-MET mRNA and protein are drastically modified in many tumor tissues and cell lines. Currently, no information is available on the molecular mechanisms that regulate c-MET mRNA level. In the present communication, we report for the first time that the inflammatory cytokines such as IL-1 alpha, IL-6 and TNF-alpha, as well as TGF-beta 1, EGF, HGF and the steroidal hormones (estrogen, progesterone, tamoxifen and dexamethasone) markedly influence the steady-state levels of the 8 kb c-MET mRNA in human carcinoma cell lines derived from human tissues such as ovary, breast and endometrium. We demonstrate that c-MET receptor protein is present at high levels in primary tumors of human ovaries (clear cell carcinomas). We present evidence that the 8 kb c-MET mRNA undergoes rapid degradation with a half-life of less than 30 min and that this decay can be quickly inhibited by cyclohex-imide. Our results suggests that the expression of the c-met proto-oncogene resembles that of an immediate early response gene.	UNIV PITTSBURGH,SCH MED,DEPT PATHOL,DIV CELLULAR & MOLEC PATHOL,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Liu, Youhua/0000-0002-4740-805X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES-06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPPUCCINI F, 1991, LYMPHOKINE CYTOK RES, V10, P225; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P38; ERROI A, 1989, INT J CANCER, V44, P795, DOI 10.1002/ijc.2910440508; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOMADA M, 1993, ONCOGENE, V8, P2381; LIU C, 1992, ONCOGENE, V7, P181; LIU YH, 1994, J BIOL CHEM, V269, P4152; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RODRIGUES GA, 1993, HEPATOCYTE GROWTH FA, P167; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SEOL DW, 1994, UNPUB; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHYU AB, 1989, GENE DEV, V3, P70; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WAY DL, 1983, IN VITRO CELL DEV B, V19, P147; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YANG XM, 1993, DEV BIOL, V157, P308, DOI 10.1006/dbio.1993.1137; YEE CJ, 1993, BIOCHEMISTRY-US, V32, P7922, DOI 10.1021/bi00082a013; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	44	143	144	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2045	2052						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208549				2022-12-17	WOS:A1994NR68500029
J	STERN, MH; SOULIER, J; ROSENZWAJG, M; NAKAHARA, K; CANKIKLAIN, N; AURIAS, A; SIGAUX, F; KIRSCH, IR				STERN, MH; SOULIER, J; ROSENZWAJG, M; NAKAHARA, K; CANKIKLAIN, N; AURIAS, A; SIGAUX, F; KIRSCH, IR			MTCP-1 - A NOVEL GENE ON THE HUMAN-CHROMOSOME XQ28 TRANSLOCATED TO THE T-CELL RECEPTOR ALPHA/DELTA LOCUS IN MATURE T-CELL PROLIFERATIONS	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; VARIABLE REGION GENES; ATAXIA-TELANGIECTASIA; MOLECULAR ANALYSIS; CHAIN LOCUS; BREAKPOINT; PATIENT; INVERSION; SEQUENCES; RECOMBINATION	T-cell lymphoproliferative diseases are often associated with recurrent chromosomal translocations involving T cell receptor genes (TCR) and genes that are thought to play a role in the pathogenesis of these diseases. Whereas numerous such genes have already been identified in acute T cell leukemias, no candidate gene has vet been identified to play a role in the heterogeneous group of T cell proliferations with a mature phenotype. We here report the molecular cloning of two examples of the rare but recurrent t(X;14) translocation. The first translocation was associated with a benign clonal proliferation in an ataxia telangiectasia patient and the second with a T cell prolymphocytic leukemia. Both translocations implicated the TCR alpha/delta locus and a common breakpoint region on chromosome Xq28. A previously unidentified gene, abnormally transcribed in both T cell proliferations, was characterized in the immediate proximity of the breakpoints. This Xq28 gene has no homology with known sequences, uses a complex alternative splicing pattern and demonstrates two short open reading frames. This gene, named MTCP-1 (Mature T Cell Proliferation-1) is the first candidate gene potentially involved in the leukemogenic process of mature T cell proliferations.	NATL CANC INST,NAVY MED ONCOL BRANCH,BETHESDA,MD 20889; SLUZBA ZA MED GENET,LJUBLJANA,SLOVENIA; INST CURIE,CNRS,URA620,F-75005 PARIS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	STERN, MH (corresponding author), HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS,FRANCE.		Rosenzwajg, Michelle/AAF-6276-2019; Stern, Marc-Henri/A-2728-2011	Rosenzwajg, Michelle/0000-0001-5312-6203; Stern, Marc-Henri/0000-0002-8100-2272				AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; Battey, 1986, BASIC METHODS MOL BI; BEATTY DW, 1986, S AFR MED J, V69, P115; BERTNESS VL, 1990, CANCER GENET CYTOGEN, V44, P47, DOI 10.1016/0165-4608(90)90196-H; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; KASAI M, 1992, MOL CELL BIOL, V12, P4751, DOI 10.1128/MCB.12.10.4751; KLEIN MH, 1987, P NATL ACAD SCI USA, V84, P6884, DOI 10.1073/pnas.84.19.6884; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE JB, 1988, CELL, V52, P51; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MCCAW BK, 1975, P NATL ACAD SCI USA, V72, P2071, DOI 10.1073/pnas.72.6.2071; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROMANROMAN S, 1991, EUR J IMMUNOL, V21, P927, DOI 10.1002/eji.1830210411; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; STERN MH, 1988, HUM GENET, V78, P33, DOI 10.1007/BF00291230; STERN MH, 1989, BLOOD, V74, P2076; STERN MH, 1989, BLOOD, V73, P1285; STERN MH, 1993, CAUSES CONSEQUENCES, P165; TAKIHARA Y, 1988, P NATL ACAD SCI USA, V85, P6097, DOI 10.1073/pnas.85.16.6097; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575	41	143	147	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2475	2483						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361760				2022-12-17	WOS:A1993LT36800019
J	SAITOH, A; KIMURA, M; TAKAHASHI, R; YOKOYAMA, M; NOMURA, T; IZAWA, M; SEKIYA, T; NISHIMURA, S; KATSUKI, M				SAITOH, A; KIMURA, M; TAKAHASHI, R; YOKOYAMA, M; NOMURA, T; IZAWA, M; SEKIYA, T; NISHIMURA, S; KATSUKI, M			MOST TUMORS IN TRANSGENIC MICE WITH HUMAN C-HA-RAS GENE CONTAINED SOMATICALLY ACTIVATED TRANSGENES	ONCOGENE			English	Article									TOKAI UNIV,SCH MED,DEPT DNA BIOL,ISEHARA,KANAGAWA 25911,JAPAN; CENT INST EXPTL ANIM,KAWASAKI,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN; NATL CANC CTR,RES INST,DIV ONCOL,TOKYO 104,JAPAN	Tokai University; National Cancer Center - Japan; National Cancer Center - Japan								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KATSUKI M, 1989, MOL BIOL MED, V6, P567; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MARIYAMA M, 1989, JPN J CANCER RES, V80, P622, DOI 10.1111/j.1349-7006.1989.tb01687.x; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEKIYA T, 1985, JPN J CANCER RES, V76, P851; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585	35	143	145	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1195	1200						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2202951				2022-12-17	WOS:A1990DX36100012
J	Patil, MD; Bhaumik, J; Babykutty, S; Banerjee, UC; Fukumura, D				Patil, M. D.; Bhaumik, J.; Babykutty, S.; Banerjee, U. C.; Fukumura, D.			Arginine dependence of tumor cells: targeting a chink in cancer's armor	ONCOGENE			English	Review							RECOMBINANT HUMAN ARGINASE; ADI-PEG 20; HUMAN HEPATOCELLULAR-CARCINOMA; APOPTOSIS-INDUCING FACTOR; NITRIC-OXIDE SYNTHASE; ARGININOSUCCINATE-SYNTHETASE; DEIMINASE ADI; GROWTH-INHIBITION; AMINO-ACIDS; IN-VITRO	Arginine, one among the 20 most common natural amino acids, has a pivotal role in cellular physiology as it is being involved in numerous cellular metabolic and signaling pathways. Dependence on arginine is diverse for both tumor and normal cells. Because of decreased expression of argininosuccinate synthetase and/or ornithine transcarbamoylase, several types of tumor are auxotrophic for arginine. Deprivation of arginine exploits a significant vulnerability of these tumor cells and leads to their rapid demise. Hence, enzyme-mediated arginine depletion is a potential strategy for the selective destruction of tumor cells. Arginase, arginine deiminase and arginine decarboxylase are potential enzymes that may be used for arginine deprivation therapy. These arginine catabolizing enzymes not only reduce tumor growth but also make them susceptible to concomitantly administered anti-cancer therapeutics. Most of these enzymes are currently under clinical investigations and if successful will potentially be advanced as anti-cancer modalities.	[Patil, M. D.; Bhaumik, J.; Banerjee, U. C.] Natl Inst Pharmaceut Educ & Res, Dept Pharmaceut Technol Biotechnol, Mohali, Punjab, India; [Babykutty, S.; Fukumura, D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs, 100 Blossom St, Boston, MA 02114 USA; [Babykutty, S.; Fukumura, D.] Harvard Med Sch, 100 Blossom St, Boston, MA 02114 USA	National Institute of Pharmaceutical Education & Research (NIPER); National Institute of Pharmaceutical Education & Research, S.A.S. Nagar (Mohali); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Fukumura, D (corresponding author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Labs, 100 Blossom St, Boston, MA 02114 USA.; Fukumura, D (corresponding author), Harvard Med Sch, 100 Blossom St, Boston, MA 02114 USA.	dai@steele.mgh.harvard.edu	BABYKUTTY, SUBOJ/R-3723-2017; Patil, Mahesh/AAF-8676-2019; Bhaumik, Jayeeta/AAR-4561-2021	Babykutty, Suboj/0000-0002-1376-6959; Banerjee, uttam Chand/0000-0002-7363-4042; Patil, Mahesh/0000-0002-5602-3442	National Institutes of Health [CA080124, CA096915, CA126642, CA197743]; NATIONAL CANCER INSTITUTE [R35CA197743, R01CA126642, R01CA096915, P01CA080124] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by National Institutes of Health (CA080124, CA096915, CA126642, CA197743).	Agrawal V, 2012, EXPERT OPIN BIOL TH, V12, P53, DOI 10.1517/14712598.2012.636349; Allen MD, 2014, CANCER RES, V74, P896, DOI 10.1158/0008-5472.CAN-13-1702; [Anonymous], [No title captured]; [Anonymous], [No title captured]; Appleton Jeremy, 2002, Altern Med Rev, V7, P512; Ascierto PA, 2005, J CLIN ONCOL, V23, P7660, DOI 10.1200/JCO.2005.02.0933; BACH S J, 1947, Enzymologia, V12, P198; BACH SJ, 1953, BIOCHIM BIOPHYS ACTA, V11, P69, DOI 10.1016/0006-3002(53)90009-2; Beauchamp EM, 2013, ONCOGENE, V32, P3923, DOI 10.1038/onc.2012.567; Beloussow K, 2002, CANCER LETT, V183, P155, DOI 10.1016/S0304-3835(01)00793-5; Bobak YP, 2010, CELL BIOL INT, V34, P1085, DOI 10.1042/CBI20100451; Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028; Bowles TL, 2008, INT J CANCER, V123, P1950, DOI 10.1002/ijc.23723; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Cantelmo AR, 2015, CANCER J, V21, P244, DOI 10.1097/PPO.0000000000000133; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Cao ZF, 2013, BBA-REV CANCER, V1836, P273, DOI 10.1016/j.bbcan.2013.08.001; Carreau A, 2011, EXP CELL RES, V317, P29, DOI 10.1016/j.yexcr.2010.08.011; Cetinbas N, 2015, ONCOGENE, V34, P4005, DOI 10.1038/onc.2014.316; Chamorro-Jorganes A, 2016, CIRC RES, V118, P38, DOI 10.1161/CIRCRESAHA.115.307408; Changou CA, 2014, P NATL ACAD SCI USA, V111, P14147, DOI 10.1073/pnas.1404171111; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Cheng PNM, 2007, CANCER RES, V67, P309, DOI 10.1158/0008-5472.CAN-06-1945; Choi YS, 1999, J BIOCHEM MOL BIOL, V32, P173; Chow AKM, 2012, CURR CANCER DRUG TAR, V12, P1233; Cui JZ, 2013, BBA-REV CANCER, V1836, P15, DOI 10.1016/j.bbcan.2013.02.003; CURRIE GA, 1978, NATURE, V273, P758, DOI 10.1038/273758a0; Daylami R, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0102-9; Delage B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.83; Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146; Dillon Brian J, 2002, Med Sci Monit, V8, pBR248; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Dodd KM, 2012, AM J PHYSIOL-ENDOC M, V302, pE1329, DOI 10.1152/ajpendo.00525.2011; Dudkowska M, 2003, BBA-GEN SUBJECTS, V1619, P159, DOI 10.1016/S0304-4165(02)00476-2; DURDEN DL, 1981, INT J CANCER, V27, P59, DOI 10.1002/ijc.2910270110; Eelen G, 2015, CIRC RES, V116, P1231, DOI 10.1161/CIRCRESAHA.116.302855; Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007; Elms S, 2013, AM J PHYSIOL-HEART C, V305, pH651, DOI 10.1152/ajpheart.00755.2012; Eng CH, 2011, ONCOGENE, V30, P4687, DOI 10.1038/onc.2011.220; Ensor CM, 2002, CANCER RES, V62, P5443; Ferraro E, 2007, ARCH BIOCHEM BIOPHYS, V462, P210, DOI 10.1016/j.abb.2007.02.006; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Feun L, 2008, CURR PHARM DESIGN, V14, P1049, DOI 10.2174/138161208784246199; Feun LG, 2010, J CLIN ONCOL, V28; Feun LG, 2012, BRIT J CANCER, V106, P1481, DOI 10.1038/bjc.2012.106; Feun Lynn, 2006, Expert Opin Investig Drugs, V15, P815, DOI 10.1517/13543784.15.7.815; Feun LG, 2015, CURR OPIN CLIN NUTR, V18, P78, DOI 10.1097/MCO.0000000000000122; Fimia GM, 2013, ONCOGENE, V32, P3311, DOI 10.1038/onc.2012.455; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fraisl P, 2013, EXP CELL RES, V319, P1331, DOI 10.1016/j.yexcr.2013.02.010; Fu YM, 2003, NUTR CANCER, V45, P60, DOI 10.1207/S15327914NC4501_8; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910; Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458; Garcia-Navas R, 2012, AUTOPHAGY, V8, P1557, DOI 10.4161/auto.21315; Gelb T, 2015, ONCOGENE, V34, P2711, DOI 10.1038/onc.2014.231; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; GILL P, 1970, CAN J MICROBIOL, V16, P415, DOI 10.1139/m70-071; Glazer ES, 2011, TRANSL ONCOL, V4, P138, DOI 10.1593/tlo.10265; Glazer ES, 2010, SURGERY, V148, P310, DOI 10.1016/j.surg.2010.03.022; Glazer ES, 2010, J CLIN ONCOL, V28, P2220, DOI 10.1200/JCO.2009.26.7765; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Gong H, 1999, BIOCHEM BIOPH RES CO, V261, P10, DOI 10.1006/bbrc.1999.1004; Gong H, 2000, LEUKEMIA, V14, P826, DOI 10.1038/sj.leu.2401763; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Graham ML, 2003, ADV DRUG DELIVER REV, V55, P1293, DOI 10.1016/S0169-409X(03)00110-8; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hernandez CP, 2010, BLOOD, V115, P5214, DOI 10.1182/blood-2009-12-258822; Holtsberg FW, 2002, J CONTROL RELEASE, V80, P259, DOI 10.1016/S0168-3659(02)00042-1; Hsueh EC, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-17; Huang CC, 2012, ORAL ONCOL, V48, P1227, DOI 10.1016/j.oraloncology.2012.06.004; Huang HY, 2013, CLIN CANCER RES, V19, P2861, DOI 10.1158/1078-0432.CCR-12-2641; HUANG MH, 1992, LIFE SCI, V51, P1725, DOI 10.1016/0024-3205(92)90301-5; Icard P, 2012, BBA-REV CANCER, V1826, P423, DOI 10.1016/j.bbcan.2012.07.001; Izzo F, 2004, J CLIN ONCOL, V22, P1815, DOI 10.1200/JCO.2004.11.120; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161; Jungbluth A, 2010, MODERN PATHOL, V23, p387A; Jurasz P, 2001, CANCER RES, V61, P376; Kalucka J, 2015, CELL CYCLE, V14, P3379, DOI 10.1080/15384101.2015.1090068; Kashiwagi S, 2005, J CLIN INVEST, V115, P1816, DOI 10.1172/JCI24015; Kashiwagi S, 2008, NAT MED, V14, P255, DOI 10.1038/nm1730; Kelly MP, 2012, BRIT J CANCER, V106, P324, DOI 10.1038/bjc.2011.524; Khoury O, 2015, J NEURO-ONCOL, V122, P75, DOI 10.1007/s11060-014-1698-5; Kilberg MS, 2012, ADV NUTR, V3, P295, DOI 10.3945/an.112.001891; Kim JH, 2007, ONCOL REP, V18, P1373; Kim JH, 2003, ELEC SOC S, V2003, P1; Kim RH, 2009, AUTOPHAGY, V5, P567, DOI 10.4161/auto.5.4.8252; Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157; Kobayashi E, 2010, MOL CANCER THER, V9, P535, DOI 10.1158/1535-7163.MCT-09-0774; Kohler ES, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-107; KOJI T, 1984, EXP CELL RES, V155, P359, DOI 10.1016/0014-4827(84)90196-4; Kung HJ, 2015, AUTOPHAGY, V11, P419, DOI 10.1080/15548627.2015.1009789; Lam TL, 2009, CANCER LETT, V277, P91, DOI 10.1016/j.canlet.2008.11.031; Lam TL, 2011, PIGM CELL MELANOMA R, V24, P366, DOI 10.1111/j.1755-148X.2010.00798.x; Lee MY, 2014, P NATL ACAD SCI USA, V111, P12865, DOI 10.1073/pnas.1408472111; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; Li LH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/423129; Li ZY, 2011, BIOCHEM BIOPH RES CO, V414, P5, DOI 10.1016/j.bbrc.2011.09.046; Lind DS, 2004, J NUTR, V134, p2837S, DOI 10.1093/jn/134.10.2837S; Liu JB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-686; Locasale JW, 2011, CELL METAB, V14, P443, DOI 10.1016/j.cmet.2011.07.014; Long Y, 2013, MOL CANCER THER, V12, P2581, DOI 10.1158/1535-7163.MCT-13-0302; Loreni F, 2014, ONCOGENE, V33, P2145, DOI 10.1038/onc.2013.153; Lorenzo HK, 2004, FEBS LETT, V557, P14, DOI 10.1016/S0014-5793(03)01464-9; Luo JQ, 2013, NUTRITION, V29, P284, DOI 10.1016/j.nut.2012.05.008; Macintosh RL, 2013, SEMIN CANCER BIOL, V23, P344, DOI 10.1016/j.semcancer.2013.05.006; Manca A, 2011, ONCOL REP, V25, P1495, DOI 10.3892/or.2011.1220; Mandal S, 2013, P NATL ACAD SCI USA, V110, P2169, DOI 10.1073/pnas.1219002110; Marino T, 2013, INORG CHEM, V52, P655, DOI 10.1021/ic301703t; Mayeur C, 2005, BBA-MOL CELL RES, V1745, P111, DOI 10.1016/j.bbamcr.2004.12.004; McAlpine JA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-621; MIYAZAKI K, 1990, CANCER RES, V50, P4522; Moens S, 2014, CYTOKINE GROWTH F R, V25, P473, DOI 10.1016/j.cytogfr.2014.07.009; Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001; Molderings GJ, 2012, PHARMACOL THERAPEUT, V133, P351, DOI 10.1016/j.pharmthera.2011.12.005; Morbidelli L, 2004, CANC TREAT, V117, P155; Morris SM, 2007, J NUTR, V137, p1602S, DOI 10.1093/jn/137.6.1602S; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Morrow K, 2013, LEUKEMIA, V27, P569, DOI 10.1038/leu.2012.247; Ni Y, 2008, CANCER LETT, V261, P1, DOI 10.1016/j.canlet.2007.11.038; Nicholson LJ, 2009, INT J CANCER, V125, P1454, DOI 10.1002/ijc.24546; Noh EJ, 2004, INT J CANCER, V112, P502, DOI 10.1002/ijc.20435; Noh EJ, 2002, MOL CELLS, V13, P137; Norberg E, 2010, BIOCHEM BIOPH RES CO, V396, P95, DOI 10.1016/j.bbrc.2010.02.163; Ohmura M, 2015, NITRIC OXIDE-BIOL CH, V46, P102, DOI 10.1016/j.niox.2014.11.005; Ott PA, 2013, INVEST NEW DRUG, V31, P425, DOI 10.1007/s10637-012-9862-2; Palii SS, 2009, AMINO ACIDS, V37, P79, DOI 10.1007/s00726-008-0199-2; Park IS, 2003, BRIT J CANCER, V89, P907, DOI 10.1038/sj.bjc.6601181; Peranzoni E, 2007, IMMUNOBIOLOGY, V212, P795, DOI 10.1016/j.imbio.2007.09.008; Perez E, 2015, ONCOGENE, V34, P3369, DOI 10.1038/onc.2014.285; Philip R, 2003, BRIT J CANCER, V88, P613, DOI 10.1038/sj.bjc.6600681; Phillips MM, 2013, CANCER RES TREAT, V45, P251, DOI 10.4143/crt.2013.45.4.251; Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002; Popovic PJ, 2007, J NUTR, V137, p1681S, DOI 10.1093/jn/137.6.1681S; Pradelli LA, 2010, CELL MOL LIFE SCI, V67, P1589, DOI 10.1007/s00018-010-0285-y; Proud CG, 2014, AM J CLIN NUTR, V99, p231S, DOI 10.3945/ajcn.113.066753; Qie S, 2012, CELL CYCLE, V11, P3679, DOI 10.4161/cc.21944; Qiu FM, 2015, CANCER LETT, V364, P1, DOI 10.1016/j.canlet.2015.04.020; Raber P, 2012, IMMUNOL INVEST, V41, P614, DOI 10.3109/08820139.2012.680634; Rabinovich S, 2015, NATURE, V527, P379, DOI 10.1038/nature15529; Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107; Regunathan S, 2000, J NEUROCHEM, V74, P2201, DOI 10.1046/j.1471-4159.2000.0742201.x; Roberts DD, 2007, CLIN CANCER RES, V13, P795, DOI 10.1158/1078-0432.CCR-06-1758; Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8; Satriano J, 1998, J BIOL CHEM, V273, P15313, DOI 10.1074/jbc.273.25.15313; Satriano J, 2004, AMINO ACIDS, V26, P321, DOI 10.1007/s00726-004-0078-4; Savaraj N, 2010, CURR MOL MED, V10, P405, DOI 10.2174/156652410791316995; Savaraj N, 2007, DRUG TARGET INSIGHT, V2, P119; Savaraj N, 2015, ONCOTARGET, V6, P6295, DOI 10.18632/oncotarget.3370; Scott L, 2000, BRIT J CANCER, V83, P800, DOI 10.1054/bjoc.2000.1353; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Shen LJ, 2006, CANCER LETT, V231, P30, DOI 10.1016/j.canlet.2005.01.007; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; Sikalidis AK, 2015, PATHOL ONCOL RES, V21, P9, DOI 10.1007/s12253-014-9860-0; Stapor P, 2014, J CELL SCI, V127, P4331, DOI 10.1242/jcs.153908; Stasyk OV, 2015, CELL BIOL INT, V39, P246, DOI 10.1002/cbin.10383; Stone EM, 2010, ACS CHEM BIOL, V5, P333, DOI 10.1021/cb900267j; SUGIMURA K, 1992, MELANOMA RES, V2, P191, DOI 10.1097/00008390-199209000-00007; Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556; Syed N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.197; Synakiewicz A, 2014, EXPERT OPIN INV DRUG, V23, P1517, DOI 10.1517/13543784.2014.934808; Szlosarek PW, 2006, CLIN CANCER RES, V12, P7126, DOI 10.1158/1078-0432.CCR-06-1101; Szlosarek PW, 2013, J CLIN ONCOL, V31, pE111, DOI 10.1200/JCO.2012.42.1784; TAKAKU H, 1993, JPN J CANCER RES, V84, P1195, DOI 10.1111/j.1349-7006.1993.tb02821.x; Takano N, 2014, MOL CANCER RES, V12, P1398, DOI 10.1158/1541-7786.MCR-14-0184; Tan B, 2010, AMINO ACIDS, V38, P1227, DOI 10.1007/s00726-009-0334-8; Tanios R, 2013, LEUKEMIA RES, V37, P1565, DOI 10.1016/j.leukres.2013.08.007; TERAYAMA H, 1982, BIOCHIM BIOPHYS ACTA, V720, P188, DOI 10.1016/0167-4889(82)90011-8; Thomas JB, 2002, BIOCHEM J, V363, P581, DOI 10.1042/0264-6021:3630581; Tomlinson B, 2013, J CLIN ONCOL, V31; Tomlinson BK, 2015, CLIN CANCER RES, V21, P2480, DOI 10.1158/1078-0432.CCR-14-2610; Tsai WB, 2012, CANCER RES, V72, P2622, DOI 10.1158/0008-5472.CAN-11-3605; Tsai WB, 2009, MOL CANCER THER, V8, P3223, DOI 10.1158/1535-7163.MCT-09-0794; Tsui SM, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-9; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Ulukaya E, 2011, CELL BIOCHEM FUNCT, V29, P468, DOI 10.1002/cbf.1774; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132; Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211; Wang Z, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.503; Wang ZY, 2014, APPL MICROBIOL BIOT, V98, P2485, DOI 10.1007/s00253-013-5118-0; Wangpaichitr M, 2014, ANTICANCER RES, V34, P6991; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Weiger TM, 2014, AMINO ACIDS, V46, P681, DOI 10.1007/s00726-013-1536-7; Wheatley Denys N., 2002, Pathology and Oncology Research, V8, P18; Wheatley DN, 2004, ANTI-CANCER DRUG, V15, P825, DOI 10.1097/00001813-200410000-00002; Wheatley DN, 2000, CELL PHYSIOL BIOCHEM, V10, P37, DOI 10.1159/000016333; Wheatley DN, 2003, BRIT J CANCER, V89, P573, DOI 10.1038/sj.bjc.6601134; Wheatley DN, 2003, MOL CELL BIOCHEM, V244, P177, DOI 10.1023/A:1022451705701; Wheatley DN, 2005, GENE THER MOL BIOL, V9, P33; Wu GY, 2009, AMINO ACIDS, V37, P153, DOI 10.1007/s00726-008-0210-y; Wu GY, 2013, AMINO ACIDS, V45, P407, DOI 10.1007/s00726-013-1500-6; Wu GY, 2013, AMINO ACIDS, V44, P1107, DOI 10.1007/s00726-012-1444-2; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480; Yan LJ, 2012, SEMIN CELL DEV BIOL, V23, P621, DOI 10.1016/j.semcdb.2012.02.001; Yang TS, 2010, BRIT J CANCER, V103, P954, DOI 10.1038/sj.bjc.6605856; Yau CC, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e13503; Yau T, 2013, INVEST NEW DRUG, V31, P99, DOI 10.1007/s10637-012-9807-9; Yoon JK, 2013, CLIN PHARMACOL-ADV A, V5, P11, DOI 10.2147/CPAA.S37350; You M, 2013, MOL CELL BIOCHEM, V374, P181, DOI 10.1007/s11010-012-1518-1; You M, 2010, BIOCHEM BIOPH RES CO, V394, P760, DOI 10.1016/j.bbrc.2010.03.066; Zecchin A, 2015, CURR OPIN BIOTECH, V34, P73, DOI 10.1016/j.copbio.2014.11.022; Zhang HQ, 2012, SEMIN CELL DEV BIOL, V23, P722, DOI 10.1016/j.semcdb.2012.03.017; Zhang L, 2015, CANCER LETT, V357, P346, DOI 10.1016/j.canlet.2014.11.042; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhu CL, 2007, J EXP MED, V204, P1741, DOI 10.1084/jem.20070193; Zhu MY, 2004, BBA-GEN SUBJECTS, V1670, P156, DOI 10.1016/j.bbagen.2003.11.006	214	142	143	1	51	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					4957	4972		10.1038/onc.2016.37	http://dx.doi.org/10.1038/onc.2016.37			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27109103	Green Submitted, Green Accepted			2022-12-17	WOS:000383965300001
J	Visciano, C; Liotti, F; Prevete, N; Cali, G; Franco, R; Collina, F; de Paulis, A; Marone, G; Santoro, M; Melillo, RM				Visciano, C.; Liotti, F.; Prevete, N.; Cali, G.; Franco, R.; Collina, F.; de Paulis, A.; Marone, G.; Santoro, M.; Melillo, R. M.			Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; EXPRESSION; CARCINOGENESIS; ANGIOGENESIS; PROGRESSION; MECHANISMS; IMMUNITY; ROLES	There is increasing evidence that mast cells (MCs) and their mediators are involved in the remodeling of the tumor microenvironment and promote tumor growth, angiogenesis and metastasis. We have found that an increased density of MCs in thyroid cancer (TC) correlates with enhanced invasiveness. However, the MC-derived factors responsible for this activity and the mechanisms by which they enhance TC invasiveness remain unidentified. Here, we report that MCs, when activated by TC cells, produce soluble factors that induce epithelial-to-mesenchymal transition (EMT) and stemness features of TC cells. We identified CXCL8/interleukin (IL)-8 as the main mediator contained in activated MC conditioned media (CM) capable of inducing both EMT and stemness of TC cells. Mechanistically, MC CM or exogenous IL-8 stimulated Akt phosphorylation and Slug expression in TC cells. The inhibition of the Akt pathway or depletion of the Slug transcription factor by RNA interference, reverted EMT and stemness responses. TC cells stably transfected with exogenous IL-8 underwent EMT, displayed increased stemness and enhanced tumorigenicity with respect to control cells. The analysis of TC surgical specimens by immunohistochemical analysis demonstrated a positive correlation between MC density (Tryptase(+) cells) and stemness features (OCT4 staining). Taken together, our data identify an MC-dependent IL-8-Akt-Slug pathway that sustains EMT/stemness of TC cells. The blockade of this circuit might be exploited for the therapy of advanced TC.	[Visciano, C.; Liotti, F.; Cali, G.; Santoro, M.; Melillo, R. M.] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, CNR G Salvato, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; [Prevete, N.; de Paulis, A.; Marone, G.] Univ Naples Federico II, Dipartimento Sci Med Traslaz, Ctr Interdipartimentale Ric Sci Immunol Base & Cl, I-80131 Naples, Italy; [Franco, R.; Collina, F.] Ist Nazl Fis Nucl, Struttura Complessa Anat Patol, Fdn G Pascale, I-80125 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; IRCCS Fondazione Pascale; Istituto Nazionale di Fisica Nucleare (INFN)	Melillo, RM (corresponding author), Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, CNR G Salvato, Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it	Liotti, Federica/AAC-1614-2019; Collina, Francesca/K-6763-2016; melillo, rosa marina/O-5255-2015	Liotti, Federica/0000-0002-0145-988X; Collina, Francesca/0000-0001-9862-3668; MELILLO, Rosa Marina/0000-0002-9233-5275; Franco, Renato/0000-0002-8340-3184; de Paulis, Amato/0000-0003-0347-2540	Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant 'Thyroid cancer and inflammation' [11827]; Italian Health Ministry grant 'Molecular diagnostic and prognostic markers of thyroid neoplasis' [RF-CAM-353005]; Istituto Superiore di Oncologia grant [MIUR PON01_02782/12]; Ministero della Salute; Regione Campania CISI-Lab Project; CREME Project; TIMING Project	Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant 'Thyroid cancer and inflammation'(Fondazione AIRC per la ricerca sul cancro); Italian Health Ministry grant 'Molecular diagnostic and prognostic markers of thyroid neoplasis'; Istituto Superiore di Oncologia grant; Ministero della Salute(Ministry of Health, Italy); Regione Campania CISI-Lab Project(Regione Campania); CREME Project; TIMING Project	We thank A Cerrato (IEOS, CNR, Naples) for helpful discussions and technical suggestions. We thank S Sequino for assistance in animal maintenance. We are grateful to PB Gupta (Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, MA, USA) for shSlug plasmids, to M Kajita (Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Atlanta) for the Slug myc plasmid and to BP Zhou (Department of Molecular and Cellular Oncology, Breast Cancer Basic Research Program, The University of Texas M. D. Anderson Cancer Center, Houston, Texas) for the FLAG Snail wt plasmid. Associazione Italiana per la Ricerca sul Cancro (AIRC) IG grant 11827 'Thyroid cancer and inflammation'; Italian Health Ministry grant RF-CAM-353005 'Molecular diagnostic and prognostic markers of thyroid neoplasis'; Istituto Superiore di Oncologia grant (MIUR PON01_02782/12); Ministero della Salute (Ricerca Finalizzata 2009-IZSM RF 2009), Regione Campania CISI-Lab Project, CREME Project and TIMING Project.	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Avilla E, 2011, CANCER RES, V71, P1792, DOI 10.1158/0008-5472.CAN-10-2186; Buehler D, 2013, MODERN PATHOL, V26, P54, DOI 10.1038/modpathol.2012.137; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Campbell LM, 2013, PHARMACEUTICALS, V6, P929, DOI 10.3390/ph6080929; Carling T, 2014, ANNU REV MED, V65, P125, DOI 10.1146/annurev-med-061512-105739; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Dalton DK, 2012, CANCER IMMUNOL IMMUN, V61, P1511, DOI 10.1007/s00262-012-1246-0; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Fang WY, 2014, CARCINOGENESIS, V35, P1780, DOI 10.1093/carcin/bgu060; French JD, 2012, J CLIN ENDOCR METAB, V97, pE934, DOI 10.1210/jc.2011-3428; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hardy RG, 2007, AM J PATHOL, V171, P1037, DOI 10.2353/ajpath.2007.061211; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kwon MJ, 2013, INT J MOL SCI, V14, P18148, DOI 10.3390/ijms140918148; Lengner CJ, 2008, CELL CYCLE, V7, P725, DOI 10.4161/cc.7.6.5573; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Nehs MA, 2012, ENDOCRINOLOGY, V153, P985, DOI 10.1210/en.2011-1519; Nowak EC, 2012, J EXP MED, V209, P2127, DOI 10.1084/jem.20120408; Palena C, 2012, FUTURE ONCOL, V8, P713, DOI [10.2217/FON.12.59, 10.2217/fon.12.59]; Phay JE, 2013, ENDOCR-RELAT CANCER, V20, pR307, DOI 10.1530/ERC-13-0187; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ryder M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054302; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Salerno P, 2011, J CLIN ENDOCR METAB, V96, pE772, DOI 10.1210/jc.2010-1182; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shaik S, 2012, J EXP MED, V209, P1289, DOI 10.1084/jem.20112446; Shi Q, 2001, J INTERF CYTOK RES, V21, P553, DOI 10.1089/10799900152547812; Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Wang YM, 2013, INT J CLIN EXP PATHO, V6, P326; Wasiuk A, 2012, CANCER IMMUNOL IMMUN, V61, P2273, DOI 10.1007/s00262-012-1276-7; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; Wei Q., 2012, THYROID, V22, P905	39	142	146	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5175	5186		10.1038/onc.2014.441	http://dx.doi.org/10.1038/onc.2014.441			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619830				2022-12-17	WOS:000362233400007
J	Bonora, M; Wieckowsk, MR; Chinopoulos, C; Kepp, O; Kroemer, G; Galluzzi, L; Pinton, P				Bonora, M.; Wieckowsk, M. R.; Chinopoulos, C.; Kepp, O.; Kroemer, G.; Galluzzi, L.; Pinton, P.			Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition (vol 34, pg 1475, 2015)	ONCOGENE			English	Correction													Kepp, Oliver/GPX-8627-2022; Pinton, Paolo/J-8025-2012; Galluzzi, Lorenzo/AAH-3286-2021; Galluzzi, Lorenzo/AAG-6432-2019; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAG-6294-2019; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/N-2763-2017	Pinton, Paolo/0000-0001-7108-6508; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Chinopoulos, Christos/0000-0003-0183-4149; Wieckowski, Mariusz/0000-0003-0789-4521	Telethon [GGP11139] Funding Source: Medline	Telethon(Fondazione Telethon)		Bonora M, 2015, ONCOGENE, V34, P1475, DOI 10.1038/onc.2014.96	1	142	151	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1608	1608		10.1038/onc.2014.462	http://dx.doi.org/10.1038/onc.2014.462			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	25790189	Bronze			2022-12-17	WOS:000351416800013
J	Xing, F; Persaud, Y; Pratilas, CA; Taylor, BS; Janakiraman, M; She, QB; Gallardo, H; Liu, C; Merghoub, T; Hefter, B; Dolgalev, I; Viale, A; Heguy, A; De Stanchina, E; Cobrinik, D; Bollag, G; Wolchok, J; Houghton, A; Solit, DB				Xing, F.; Persaud, Y.; Pratilas, C. A.; Taylor, B. S.; Janakiraman, M.; She, Q-B; Gallardo, H.; Liu, C.; Merghoub, T.; Hefter, B.; Dolgalev, I.; Viale, A.; Heguy, A.; De Stanchina, E.; Cobrinik, D.; Bollag, G.; Wolchok, J.; Houghton, A.; Solit, D. B.			Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF	ONCOGENE			English	Article						BRAF; PTEN; RB1; MEK inhibitor; BRAF inhibitor; CDKN2A	RETINOBLASTOMA GENE-PRODUCT; METASTATIC MELANOMA; HUMAN CANCER; AZD6244 ARRY-142886; INHIBITOR PLX4032; CELL LINES; BRAF; KINASE; MUTATIONS; PROTEIN	Identifying the spectrum of genetic alterations that cooperate with critical oncogenes to promote transformation provides a foundation for understanding the diversity of clinical phenotypes observed in human cancers. Here, we performed integrated analyses to identify genomic alterations that co-occur with oncogenic BRAF in melanoma and abrogate cellular dependence upon this oncogene. We identified concurrent mutational inactivation of the PTEN and RB1 tumor suppressors as a mechanism for loss of BRAF/MEK dependence in melanomas harboring (V600E)BRAF mutations. RB1 alterations were mutually exclusive with loss of p16(INK4A), suggesting that whereas p16(INK4A) and RB1 may have overlapping roles in preventing tumor formation, tumors with loss of RB1 exhibit diminished dependence upon BRAF signaling for cell proliferation. These findings provide a genetic basis for the heterogeneity of clinical outcomes in patients treated with targeted inhibitors of the mitogen-activated protein kinase pathway. Our results also suggest a need for comprehensive screening for RB1 and PTEN inactivation in patients treated with RAF and MEK-selective inhibitors to determine whether these alterations are associated with diminished clinical benefit in patients whose cancers harbor mutant BRAF. Oncogene (2012) 31, 446-457; doi: 10.1038/onc.2011.250; published online 4 July 2011	[Merghoub, T.; Wolchok, J.; Solit, D. B.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Xing, F.; Persaud, Y.; Janakiraman, M.; Dolgalev, I.; Heguy, A.; Solit, D. B.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Pratilas, C. A.; Cobrinik, D.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA; [Pratilas, C. A.; She, Q-B; Hefter, B.; De Stanchina, E.] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10065 USA; [Taylor, B. S.] Mem Sloan Kettering Canc Ctr, Dept Computat Biol, New York, NY 10065 USA; [Gallardo, H.; Liu, C.; Merghoub, T.; Wolchok, J.; Houghton, A.] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10065 USA; [Viale, A.] Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10065 USA; [Bollag, G.] Plexxikon Inc, Berkeley, CA USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Plexxikon	Solit, DB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.	solitd@mskcc.org	Dolgalev, Igor/AAY-6406-2020; Heguy, Adriana/GPP-3907-2022; Persaud, Yogindra/AAZ-7032-2021; Merghoub, Taha/ABD-8362-2021; Solit, David B./AAC-5309-2019	Dolgalev, Igor/0000-0003-4451-126X; Persaud, Yogindra/0000-0001-8266-9434; She, Qing-Bai/0000-0002-7207-0599; Janakiraman, Manickam/0000-0003-4423-6237	AstraZeneca; National Institutes of Health; Kimmel Foundation; Golfers-Against-Cancer; Melanoma Research Alliance; STARR Foundation; NATIONAL CANCER INSTITUTE [K08CA127350, P30CA008748, R01CA127240] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kimmel Foundation; Golfers-Against-Cancer; Melanoma Research Alliance; STARR Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	David Solit has received honoraria and research funding from AstraZeneca, and had an advisory role with Roche. Gideon Bollag is an employee of Plexxikon Inc.; We thank Drs Meenhard Herlyn and Kate Nathanson (University of Pennsylvania) and Dr Oystein Fodstad (Department of Tumor Biology of The Norwegian Radium Hospital, Norway) for kindly providing cell lines. This study was supported by grants from the National Institutes of Health (DBS), the Kimmel Foundation (DBS), Golfers-Against-Cancer (DBS), the Melanoma Research Alliance (DBS) and STARR Foundation (DBS). BST is the David H Koch Fellow in cancer genomics.	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; Dummer R, 2008, J CLIN ONCOL S, V2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hingorani SR, 2003, CANCER RES, V63, P5198; Janakiraman M, 2010, CANCER RES, V70, P5901, DOI 10.1158/0008-5472.CAN-10-0192; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NUSSE M, 1990, CYTOMETRY, V11, P813, DOI 10.1002/cyto.990110707; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; OHTA M, 1994, CANCER RES, V54, P5269; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Taylor BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003179; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Tsai J, 2006, AACR M ABSTR, V2006, p571a; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433	43	142	143	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					446	457		10.1038/onc.2011.250	http://dx.doi.org/10.1038/onc.2011.250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21725359	Green Accepted			2022-12-17	WOS:000300219300004
J	Li, XF; Yan, PJ; Shao, ZM				Li, X-F; Yan, P-J; Shao, Z-M			Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer	ONCOGENE			English	Article						microRNA; breast cancer; metastasis; uPA; mouse xenograft model	MICRORNA TARGETS; MESSENGER-RNA; CELL-MIGRATION; METASTASIS; CARCINOMA; PROGNOSIS; RECEPTOR; SYSTEM; GROWTH; DEMETHYLATION	Emerging evidence suggests the potential involvement of altered regulation of miRNAs in the pathogenesis of cancers, and these miRNAs are thought to be functional as tumor suppressors or oncogenes. Using miRNA arrays, we identified an miRNA differentially expressed between the MDA-MB-231 cell line and its highly metastatic variant. A bioinformatics search revealed a potential target site for miR-193b within the 3'UTR of uPA. Ectopic expression of miR-193b repressed the expression of sensor constructs harboring the 3'UTR of uPA in breast cancer cell lines. Anti-miR-193b treatment led to an increase of uPA protein and increased cell invasion in MDA-MB-231 cells. In contrast, overexpression of miR-193b significantly reduced uPA protein amounts and inhibited cell invasion in MDA-MB-231 and MDA-MB-435 cells. In an immunodeficient mouse model, miR-193b significantly inhibited the growth and dissemination of xenograft tumors. Immunohistochemical staining and real-time PCR assays showed that miR-193b was a negative regulator of the uPA gene in primary breast tumors. Our research reveals that miR-193b is closely associated with clinical metastasis and identifies miR-193b potentially targets uPA transcripts. Perturbation of the miRNA-mRNA pairing may have important roles in the initiation and development of breast cancer. Oncogene (2009) 28, 3937-3948; doi:10.1038/onc.2009.245; published online 24 August 2009	[Li, X-F; Yan, P-J; Shao, Z-M] Fudan Univ, Breast Canc Inst, Dept Breast Surg, Canc Hosp,Canc Inst,Shanghai Med Coll,Inst Biomed, Shanghai 200032, Peoples R China	Fudan University	Shao, ZM (corresponding author), Fudan Univ, Breast Canc Inst, Dept Breast Surg, Canc Hosp,Canc Inst,Shanghai Med Coll,Inst Biomed, 270 Dongan Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com			National Basic Research Program of China [2006CB910501]; National Natural Science Foundation of China [30371580, 30572109]; Shanghai Science and Technology Committee [03J14019, 06DJ14004, 06DZ19504]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	This research was supported in part by grants from the National Basic Research Program of China (2006CB910501), National Natural Science Foundation of China (30371580, 30572109) and Shanghai Science and Technology Committee (03J14019, 06DJ14004, 06DZ19504).	ACHBAROU A, 1994, CANCER RES, V54, P2372; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Biermann JC, 2008, INT J MOL MED, V21, P251; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Castello R, 2007, THROMB RES, V120, P753, DOI 10.1016/j.thromres.2006.12.016; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Foekens JA, 2000, CANCER RES, V60, P636; Frandsen TL, 2001, CANCER RES, V61, P532; Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li DQ, 2006, PROTEOMICS, V6, P3352, DOI 10.1002/pmic.200500617; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; McSherry EA, 2007, CELL MOL LIFE SCI, V64, P3201, DOI 10.1007/s00018-007-7388-0; Murchison EP, 2004, CURR OPIN CELL BIOL, V16, P223, DOI 10.1016/j.ceb.2004.04.003; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545; Pulukuri SMK, 2007, CANCER RES, V67, P6637, DOI 10.1158/0008-5472.CAN-07-0751; Rabbani SA, 1998, INT J ONCOL, V12, P911; Rabbani SA, 2007, CANCER METAST REV, V26, P663, DOI 10.1007/s10555-007-9085-8; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tetu B, 1998, HUM PATHOL, V29, P979, DOI 10.1016/S0046-8177(98)90204-0; Tetu B, 2001, CANCER, V92, P2957, DOI 10.1002/1097-0142(20011201)92:11<2957::AID-CNCR10112>3.0.CO;2-6; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488	42	142	152	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3937	3948		10.1038/onc.2009.245	http://dx.doi.org/10.1038/onc.2009.245			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19701247				2022-12-17	WOS:000271471900008
J	Frohlich, DA; McCabe, MT; Arnold, RS; Day, ML				Frohlich, D. A.; McCabe, M. T.; Arnold, R. S.; Day, M. L.			The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis	ONCOGENE			English	Article						tumorigenesis; Nrf2; oxidative stress; prostate cancer; DNA damage	GLUTATHIONE-S-TRANSFERASE; GENE-EXPRESSION; INTRAEPITHELIAL NEOPLASIA; OXIDATIVE STRESS; RESPONSE ELEMENT; ENZYME INDUCERS; CANCER; CARCINOGENESIS; MICE; REVEALS	The impact of oxidative stress in human cancer has been extensively studied. It is accepted that elevated reactive oxygen species (ROS) promote mutagenic DNA damage. Even with an extensive armament of cellular antioxidants and detoxification enzymes, alterations to DNA occur that initiate cellular transformation. Erythroid 2p45 (NFE2)-related factor 2 (Nrf2) is a basic-region leucine zipper transcription factor that mediates the expression of key protective enzymes through the antioxidant-response element (ARE). By analysing 10 human prostate cancer microarray data sets, we have determined that Nrf2 and members of the glutathione-S-transferase (GST) mu family are extensively decreased in human prostate cancer. Using the TRAMP transgene and Rb and Nrf2 knockout murine models, we demonstrated that the loss of Nrf2 initiates a detrimental cascade of reduced GST expression, elevated ROS levels and ultimately DNA damage associated with tumorigenesis. Based on overwhelming data from clinical samples and the current functional analysis, we propose that the disruption of the Nrf2-antioxidant axis leads to increased oxidative stress and DNA damage in the initiation of cellular transformation in the prostate gland.	[Frohlich, D. A.; Day, M. L.] Univ Michigan, UMCC, Dept Urol, Ann Arbor, MI 48109 USA; [McCabe, M. T.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA USA; [Arnold, R. S.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	University of Michigan System; University of Michigan; Emory University; Emory University	Day, ML (corresponding author), Univ Michigan, UMCC, Dept Urol, 6219 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NCI NIH HHS [5T32 CA009674] Funding Source: Medline; NIDDK NIH HHS [DK061488, 5T32 DK07758-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007758, R01DK061488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Baker AM, 1997, PROSTATE, V32, P229, DOI 10.1002/(SICI)1097-0045(19970901)32:4<229::AID-PROS1>3.0.CO;2-E; Bostwick DG, 2007, HUM PATHOL, V38, P1394, DOI 10.1016/j.humpath.2007.02.008; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Day KC, 2002, J BIOL CHEM, V277, P44475, DOI 10.1074/jbc.M205361200; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kwak MK, 2004, MUTAT RES-FUND MOL M, V555, P133, DOI 10.1016/j.mrfmmm.2004.06.041; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LaTulippe E, 2002, CANCER RES, V62, P4499; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, BBA-GENE STRUCT EXPR, V1629, P92, DOI 10.1016/j.bbaexp.2003.08.006; Luo J, 2001, CANCER RES, V61, P4683; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; Magee JA, 2001, CANCER RES, V61, P5692; McCabe MT, 2005, NEOPLASIA, V7, P141, DOI 10.1593/neo.04394; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Tam NNC, 2006, PROSTATE, V66, P57, DOI 10.1002/pros.20313; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Vanaja DK, 2006, CLIN CANCER RES, V12, P1128, DOI 10.1158/1078-0432.CCR-05-2072; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wang YH, 2000, CANCER RES, V60, P6008; Welsh JB, 2001, CANCER RES, V61, P5974; Yates MS, 2006, CANCER RES, V66, P2488, DOI 10.1158/0008-5472.CAN-05-3823; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944	51	142	151	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4353	4362		10.1038/onc.2008.79	http://dx.doi.org/10.1038/onc.2008.79			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372916	Bronze			2022-12-17	WOS:000257691100010
J	Fukata, M; Abreu, MT				Fukata, M.; Abreu, M. T.			Role of Toll-like receptors in gastrointestinal malignancies	ONCOGENE			English	Review						Toll-like receptor; cancer; stomach; intestine; colon; inflammation	INFLAMMATORY-BOWEL-DISEASE; INTESTINAL EPITHELIAL-CELLS; PROSTAGLANDIN E-2 SYNTHESIS; DEXTRAN SODIUM-SULFATE; HELICOBACTER-PYLORI; COLORECTAL-CANCER; CROHNS-DISEASE; COLON CARCINOGENESIS; ULCERATIVE-COLITIS; GERM-FREE	Mounting evidence supports the tenet that innate immune responses to luminal microbes participate in the development of gastrointestinal malignancies. The gastrointestinal tract is relatively unique in that it has evolved in the presence of diverse enteric micro. ora. Intestinal. ora is required to develop a normal adaptive immune response in the periphery. With the characterization of the innate immune system, we have begun to understand the adaptations the intestine has made to the microbiota. The interaction between the microbiota and the intestinal mucosa through Toll-like receptors (TLRs) is required to maintain intestinal homeostasis. In particular, intestinal epithelial cells and lamina propria mononuclear cells such as antigen-presenting cells and T cells must respond to breaches in the mucosal barrier by activating TLR-dependent pathways that result in increased epithelial proliferation, wound healing and recruitment of acute inflammatory cells. In the setting of chronic inflammation such as Helicobacter pylori (H. pylori) infection in the stomach or idiopathic inflammatory bowel disease, the process of repair may eventually result in carcinogenesis. The following review highlights human and animal data that support a role for innate immune responses and TLRs specifically in promoting gastrointestinal malignancies. Candidate pathways linking TLRs to gastrointestinal malignancies include activation of nuclear factor-kappa B and cyclooxygenase-2. Studying the link between innate immune signaling and gastrointestinal malignancies offers the possibility to identify novel ways to both prevent and treat gastrointestinal cancer.	[Fukata, M.; Abreu, M. T.] Mt Sinai Sch Med, Dept Med, Div Gastroenterol, Ctr Inflammatory Bowel Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Abreu, MT (corresponding author), Mt Sinai Sch Med, Dept Med, Div Gastroenterol, Ctr Inflammatory Bowel Dis, New York, NY 10029 USA.	Maria.Abreu@mssm.edu		Abreu, Maria T./0000-0002-7294-0574	NATIONAL CANCER INSTITUTE [R01CA137869] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522; Atherfold PA, 2006, BEST PRACT RES CL GA, V20, P813, DOI 10.1016/j.bpg.2006.04.003; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Baoprasertkul P, 2007, FISH SHELLFISH IMMUN, V22, P418, DOI 10.1016/j.fsi.2006.04.005; Bernstein CN, 2002, INFLAMM BOWEL DIS, V8, P356, DOI 10.1097/00054725-200209000-00007; Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355; Brand S, 2005, INFLAMM BOWEL DIS, V11, P645, DOI 10.1097/01.MIB.0000168372.94907.d2; Brittan M, 2002, J PATHOL, V197, P492, DOI 10.1002/path.1155; Brown SL, 2007, J CLIN INVEST, V117, P258, DOI 10.1172/JCI29159; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; Chang YJ, 2004, MOL PHARMACOL, V66, P1465, DOI 10.1124/mol.104.005199; CHOI PM, 1994, GUT, V35, P950, DOI 10.1136/gut.35.7.950; Chun KG, 2003, PHOTONIC NETW COMMUN, V6, P83, DOI 10.1023/A:1023642926131; Contasta I, 2006, CANCER BIOTHER RADIO, V21, P488, DOI 10.1089/cbr.2006.21.488; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2005, CANCER IMMUNOL IMMUN, V54, P1143, DOI 10.1007/s00262-005-0702-5; De Vita F, 2001, J INTERF CYTOK RES, V21, P45, DOI 10.1089/107999001459150; Derdak Z, 2006, CARCINOGENESIS, V27, P956, DOI 10.1093/carcin/bgi335; Dove WF, 1997, CANCER RES, V57, P812; Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; Engle SJ, 2002, CANCER RES, V62, P6362; Erdman SE, 2003, AM J PATHOL, V162, P691, DOI 10.1016/S0002-9440(10)63863-1; Farinha P, 2005, J CLIN ONCOL, V23, P6370, DOI 10.1200/JCO.2005.05.011; Fass R, 2001, GUT, V48, P310, DOI 10.1136/gut.48.3.310; Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x; Franchimont D, 2004, GUT, V53, P987, DOI 10.1136/gut.2003.030205; Frattini M, 2004, CLIN CANCER RES, V10, P4015, DOI 10.1158/1078-0432.CCR-04-0031; FUKATA M, 2005, AM J PHYSIOL-GASTR L, V288, pG105, DOI DOI 10.1152/AJPGI.00328.2004; FUKATA M, 2007, IN PRESS GASTROENTER; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Fukumoto S, 2003, WORLD J SURG, V27, P145, DOI 10.1007/s00268-002-6460-z; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gammon MD, 1997, J NATL CANCER I, V89, P1277, DOI 10.1093/jnci/89.17.1277; Garlanda C, 2007, CANCER RES, V67, P6017, DOI 10.1158/0008-5472.CAN-07-0560; Gazouli M, 2005, WORLD J GASTROENTERO, V11, P681, DOI 10.3748/wjg.v11.i5.681; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gunter MJ, 2006, CANCER EPIDEM BIOMAR, V15, P1126, DOI 10.1158/1055-9965.EPI-06-0042; Gupta RB, 2007, GASTROENTEROLOGY, V133, P1099, DOI 10.1053/j.gastro.2007.08.001; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; Haselkorn T, 2005, CANCER CAUSE CONTROL, V16, P781, DOI 10.1007/s10552-005-3635-6; Hausmann M, 2002, GASTROENTEROLOGY, V122, P1987, DOI 10.1053/gast.2002.33662; Helzlsouer KJ, 2006, EUR J CANCER, V42, P704, DOI 10.1016/j.ejca.2006.01.008; HILL MJ, 1971, LANCET, V1, P95; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Hope ME, 2005, FEMS MICROBIOL LETT, V244, P1, DOI 10.1016/j.femsle.2005.01.029; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; Huang B, 2005, CANCER RES, V65, P5009, DOI 10.1158/0008-5472.CAN-05-0784; Huang B, 2007, CANCER RES, V67, P4346, DOI 10.1158/0008-5472.CAN-06-4067; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Ishida I, 2002, J IMMUNOL, V169, P2069, DOI 10.4049/jimmunol.169.4.2069; Ishihara S, 2004, J IMMUNOL, V173, P1406, DOI 10.4049/jimmunol.173.2.1406; Itzkowitz SH, 2004, GASTROENTEROLOGY, V126, P1634, DOI 10.1053/j.gastro.2004.03.025; Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Jelavic TB, 2006, CLIN GENET, V70, P156, DOI 10.1111/j.1399-0004.2006.00651.x; Kado S, 2001, CANCER RES, V61, P2395; Kawahara T, 2001, INFECT IMMUN, V69, P4382, DOI 10.1128/IAI.69.7.4382-4389.2001; Kawahara Tsukasa, 2001, Journal of Medical Investigation, V48, P190; KELLY IMG, 1993, ABDOM IMAGING, V18, P366, DOI 10.1007/BF00201784; Kinoshita T, 1999, CANCER, V85, P2526, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LANGHOLZ E, 1992, GASTROENTEROLOGY, V103, P1444, DOI 10.1016/0016-5085(92)91163-X; LAQUEUR GL, 1981, J NATL CANCER I, V67, P1053; LEBLOND C. P., 1964, NAT CANCER INST MONOGR, V14, P119; Maggio-Price L, 2005, AM J PATHOL, V166, P1793, DOI 10.1016/S0002-9440(10)62489-3; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Manju V, 2006, EUR J CANCER PREV, V15, P377, DOI 10.1097/00008469-200610000-00001; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Naik S, 2001, J PEDIATR GASTR NUTR, V32, P449, DOI 10.1097/00005176-200104000-00011; NOWACKI MR, 1993, FOLIA HISTOCHEM CYTO, V31, P77; Ohara T, 2006, INT J MOL MED, V18, P59; Oostenbrug LE, 2005, INFLAMM BOWEL DIS, V11, P567, DOI 10.1097/01.MIB.0000161305.81198.0f; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; Ouburg S, 2005, GUT, V54, P439; Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; Paulsen JE, 2006, INT J CANCER, V118, P540, DOI 10.1002/ijc.21416; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peter S, 2007, DIGESTION, V75, P25, DOI 10.1159/000101564; Pierik M, 2006, INFLAMM BOWEL DIS, V12, P1, DOI 10.1097/01.MIB.0000195389.11645.ab; Pomorski T, 2001, J BIOL CHEM, V276, P804, DOI 10.1074/jbc.M003819200; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rad R, 2007, GASTROENTEROLOGY, V133, P150, DOI 10.1053/j.gastro.2007.04.071; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Rao CV, 2002, CANCER RES, V62, P165; REDDY BS, 1975, CANCER RES, V35, P287; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; Rumio C, 2004, AM J PATHOL, V165, P373, DOI 10.1016/S0002-9440(10)63304-4; Rumio C, 2006, J CELL PHYSIOL, V208, P47, DOI 10.1002/jcp.20632; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Sawaoka H, 1998, PROSTAG LEUKOTR ESS, V59, P313, DOI 10.1016/S0952-3278(98)90079-5; Schmausser B, 2005, INT J MED MICROBIOL, V295, P179, DOI 10.1016/j.ijmm.2005.02.009; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Schultz M, 1999, AM J PHYSIOL-GASTR L, V276, pG1461, DOI 10.1152/ajpgi.1999.276.6.G1461; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Sigel JE, 1999, AM J SURG PATHOL, V23, P651, DOI 10.1097/00000478-199906000-00003; Spechler SJ, 1999, GASTROENTEROLOGY, V117, P218, DOI 10.1016/S0016-5085(99)70571-8; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Suzuki M, 2003, INFECT IMMUN, V71, P3503, DOI 10.1128/IAI.71.6.3503-3511.2003; Suzuki R, 2006, CARCINOGENESIS, V27, P162, DOI 10.1093/carcin/bgi205; Suzuki R, 2005, HISTOL HISTOPATHOL, V20, P483, DOI 10.14670/HH-20.483; Swidsinski A, 1998, GASTROENTEROLOGY, V115, P281, DOI 10.1016/S0016-5085(98)70194-5; Tlaskalova-Hogenova H, 2004, IMMUNOL LETT, V93, P97, DOI 10.1016/j.imlet.2004.02.005; Torok HP, 2004, CLIN IMMUNOL, V112, P85, DOI 10.1016/j.clim.2004.03.002; Torok HP, 2004, GASTROENTEROLOGY, V127, P365, DOI 10.1053/j.gastro.2004.05.051; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wang XM, 2007, GASTROENTEROLOGY, V132, P551, DOI 10.1053/j.gastro.2006.11.040; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012	123	142	151	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					234	243		10.1038/sj.onc.1210908	http://dx.doi.org/10.1038/sj.onc.1210908			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176605	Green Accepted			2022-12-17	WOS:000252163600010
J	Winograd-Katz, SE; Levitzki, A				Winograd-Katz, S. E.; Levitzki, A.			Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor	ONCOGENE			English	Article						therapy; cisplatin; p38; EGPR; phosphorylation	GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; THREONINE PHOSPHORYLATION; INDEPENDENT MECHANISMS; PI3K/AKT PATHWAY; CELLS; P38; RESISTANCE; SIGNAL	Cisplatin is an effective DNA-damaging antitumor agent employed for the treatment of various human cancers. In this study, we report that Cisplatin activates PKB/Akt in several cancer cell lines and that this activation is mediated by EGFR, Src and PI3-kinase. Inhibition of PI3-kinase activity decreases the survival of the cells exposed to Cisplatin, suggesting that Cisplatin-induced PKB/Akt activation may lead to Cisplatin resistance. While investigating the EGFR-dependent PKB/Akt activation in MDA-MB-468 cells, we found that the EGFR receptor undergoes a gel mobility shift upon Cisplatin treatment, which is mediated by p38(MAPK). An EGFR, in which threonine 669 was mutated to alanine (A669), is phosphorylated by p38MAPK to a much lesser extent, suggesting that threonine 669 is a p38 phosphorylation site. We found that Cisplatin induces EGFR internalization, which is mediated by p38(MAPK-) dependent phosphorylation of the receptor on threonine 669. Our results identify the EGFR as a new substrate of p38 and identify threonine 669 as a new phosphorylation site that regulates EGFR internalization. Together, these results suggest that Cisplatin has side effects, which may alter the signaling pattern of cancer cells and modulate the desired effects of Cisplatin treatment.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il						Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hayakawa J, 2000, CANCER RES, V60, P5988; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LITMAN P, 2006, UNPUB; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	37	142	147	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7381	7390		10.1038/sj.onc.1209737	http://dx.doi.org/10.1038/sj.onc.1209737			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785992	Bronze			2022-12-17	WOS:000242419100007
J	Kang, DC; Gopalkrishnan, RV; Lin, L; Randolph, A; Valerie, K; Pestka, S; Fisher, PB				Kang, DC; Gopalkrishnan, RV; Lin, L; Randolph, A; Valerie, K; Pestka, S; Fisher, PB			Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene	ONCOGENE			English	Article						helicard; CARD; RNA helicase; terminal differentiation	HUMAN POLYNUCLEOTIDE PHOSPHORYLASE; TRANS-RETINOIC ACID; TERMINAL DIFFERENTIATION; PROTEIN FAMILY; ALPHA-INTERFERON; GAMMA-INTERFERON; GROWTH ARREST; CANCER CELLS; HYBRIDIZATION; IDENTIFICATION	Melanoma differentiation associated gene-5 (mda-5) was identified by subtraction hybridization as a novel upregulated gene in HO-1 human melanoma cells induced to terminally differentiate by treatment with IFN-beta + MEZ. Considering its unique structure, consisting of a caspase recruitment domain (CARD) and an RNA helicase domain, it was hypothesized that mda-5 contributes to apoptosis occurring during terminal differentiation. We have currently examined the expression pattern of mda-5 in normal tissues, during induction of terminal differentiation and after treatment with type I IFNs. In addition, we have defined its genomic structure and chromosomal location. IFN-beta, a type I IFN, induces mda-5 expression in a biphasic and dose-dependent manner. Based on its temporal kinetics of induction and lack of requirement for prior protein synthesis mda-5 is an early type I IFN-responsive gene. The level of mda-5 mRNA is in low abundance in normal tissues, whereas expression is induced in a spectrum of normal and cancer cells by IFN-beta. Expression of mda-5 by means of a replication incompetent adenovirus, Ad. mda-5, induces apoptosis in HO-1 cells as confirmed by morphologic, biochemical and molecular assays. Additionally, the combination of Ad.mda-5+MEZ further augments apoptosis as observed in Ad. null or uninfected HO-1 cells induced to terminally differentiate by treatment with IFN-beta+MEZ. The mda-5 gene is located on human chromosome 2q24 and consists of 16 exons, without pseudogenes, and is conserved in the mouse genome. Present data documents that mda-5 is a novel type I IFN-inducible gene, which may contribute to apoptosis induction during terminal differentiation and during IFN treatment. The conserved genomic and protein structure of mda-5 in human and mouse will permit analysis of the evolution and developmental aspects of this gene.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Virginia Commonwealth University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [R01CA098712, R01CA035675, R01CA097318] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA97318, CA98712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akesson E, 2002, GENES IMMUN, V3, P279, DOI 10.1038/sj.gene.6363866; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Chien G, 2001, CANCER GENET CYTOGEN, V126, P63, DOI 10.1016/S0165-4608(00)00392-7; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Du Plessis L, 1999, CANCER RES, V59, P1877; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Friesen H J, 1981, Methods Enzymol, V78, P430; Fusenig N E, 1995, Recent Results Cancer Res, V139, P1; Garattini Enrico, 2001, Current Opinion in Pharmacology, V1, P358, DOI 10.1016/S1471-4892(01)00062-5; Gopalkrishnan RV, 2000, ONCOGENE, V19, P4405, DOI 10.1038/sj.onc.1203767; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Jackson DP, 2003, MELANOMA RES, V13, P219, DOI 10.1097/00008390-200306000-00001; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Jia SF, 1999, J INTERF CYTOK RES, V19, P617, DOI 10.1089/107999099313758; JIANG H, 1994, MOL CELL DIFFER, V2, P22139; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kovacsovics M, 2002, CURR BIOL, V12, P838, DOI 10.1016/S0960-9822(02)00842-4; Kumon K, 2001, JPN J CANCER RES, V92, P854, DOI 10.1111/j.1349-7006.2001.tb01172.x; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Leszczyniecka M, 2003, GENE, V316, P143, DOI 10.1016/S0378-1119(03)00752-2; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; Lovat PE, 1997, EUR J CANCER, V33, P2075, DOI 10.1016/S0959-8049(97)00242-6; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; PACKER RJ, 1991, NEUROL CLIN, V9, P405, DOI 10.1016/S0733-8619(18)30293-7; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Peng Zhihai, 2002, Zhonghua Wai Ke Za Zhi, V40, P776; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; Pestka S, 2000, BIOPOLYMERS, V55, P254, DOI 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1; PESTKA S, 1997, SEMIN ONCOL, V24; Petersen OW, 1998, ADV CANCER RES, V75, P135, DOI 10.1016/S0065-230X(08)60741-1; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Scott RE, 1997, PHARMACOL THERAPEUT, V73, P51, DOI 10.1016/S0163-7258(96)00120-9; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tanabe T, 2000, J NEURO-ONCOL, V48, P225, DOI 10.1023/A:1006476408190; Tapper J, 1998, CANCER RES, V58, P2715; Toida M, 2001, CANCER GENET CYTOGEN, V127, P34, DOI 10.1016/S0165-4608(00)00410-6; Wang Q, 1998, GENE, V222, P83, DOI 10.1016/S0378-1119(98)00476-4; Wang Z Y, 2000, Lancet Oncol, V1, P101, DOI 10.1016/S1470-2045(00)00017-6; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246; Zhang JW, 2000, J BIOSCIENCES, V25, P275, DOI 10.1007/BF02703936; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	74	142	152	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1789	1800		10.1038/sj.onc.1207300	http://dx.doi.org/10.1038/sj.onc.1207300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14676839				2022-12-17	WOS:000220029300014
J	Ling, MT; Wang, XH; Ouyang, XS; Xu, KX; Tsao, SW; Wong, YC				Ling, MT; Wang, XH; Ouyang, XS; Xu, KX; Tsao, SW; Wong, YC			Id-1 expression promotes cell survival through activation of NF-kappa B signalling pathway in prostate cancer cells	ONCOGENE			English	Article						Id-1; prostate cancer; NF-kappa B; TNF alpha; apoptosis	LOOP-HELIX PROTEIN; CHEMOTHERAPY-INDUCED APOPTOSIS; SENESCENT HUMAN FIBROBLASTS; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; EPITHELIAL-CELLS; GROWTH; CARCINOMA; INDUCTION	The growth-promoting effect of Id-1 (inhibitor of differentiation/DNA binding) has been demonstrated in a number of human cancers. However, the mechanisms responsible for its action are not clear. In this study, we report that in prostate cancer cells, Id-1 promotes cell survival through activation of nuclear factor-kappaB (NF-kappaB) signalling pathway. After stable expression of Id-1 protein in LNCaP cells, we found that the Id-1 transfectants showed increased resistance to apoptosis induced by TNFalpha through inactivation of Bax and caspase 3. In addition, in the LNCaP cells expressing ectopic Id-1 protein, we also observed increased NF-kappaB transactivation activity and nuclear translocation of the p65 and p50 proteins, which was accompanied by upregulation of their downstream effectors Bcl-xL and ICAM-1. These results indicate that the Id-1-induced antiapoptotic effect may be via NF-kappaB signalling transduction pathway in these cells. In addition, inactivation of Id-1 by its antisense oligonucleotide and retroviral construct in DU145 cells resulted in the decrease of nuclear level of p65 and p50 proteins, which was associated with increased sensitivity to TNFalpha-induced apoptosis. Our results strongly suggest that Id-1 may be one of the upstream regulators of NF-kappaB and activation of NF-kappaB signalling pathway, may be essential for Id-1 induced cell proliferation through protection against apoptosis. Our findings also suggest a potential therapeutic strategy in which inactivation of Id-1 may lead to sensitization of prostate cancer cells to chemotherapeutic drug-induced apoptosis.	Univ Hong Kong, Canc Biol Grp, Dept Anat, Lab Block,Fac Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Cent Lab, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wong, YC (corresponding author), Univ Hong Kong, Canc Biol Grp, Dept Anat, Lab Block,Fac Med, 21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Tsao, George/C-4422-2009					Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Hara E, 1996, DEV GENET, V18, P161; HARA E, 1994, J BIOL CHEM, V269, P2139; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kim BY, 2002, ONCOGENE, V21, P4490, DOI 10.1038/sj.onc.1205547; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kleeff J, 1998, CANCER RES, V58, P3769; Langlands K, 2000, CANCER RES, V60, P5929; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Lin CQ, 2000, CANCER RES, V60, P1332; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ouyang XS, 2001, CARCINOGENESIS, V22, P965, DOI 10.1093/carcin/22.6.965; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Polsky D, 2001, CANCER RES, V61, P6008; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; Schindl M, 2001, CANCER RES, V61, P5703; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wilson JW, 2001, CANCER RES, V61, P8803; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	52	142	147	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4498	4508		10.1038/sj.onc.1206693	http://dx.doi.org/10.1038/sj.onc.1206693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881706				2022-12-17	WOS:000184054700005
J	Yang, HS; Knies, JL; Stark, C; Colburn, NH				Yang, HS; Knies, JL; Stark, C; Colburn, NH			Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation	ONCOGENE			English	Article						Pdcd4; AP-1; c-Jun; c-Fos; transformation	NF-KAPPA-B; C-JUN; TRANSCRIPTIONAL REGULATION; TRANSFORMATION SUPPRESSOR; CYCLE PROGRESSION; ANTISENSE RNA; EXPRESSION; GENES; PROMOTION; PROTEIN	Transformation suppressor Pdcd4 is downregulated in transformed (Tx) mouse epidermal JB6 RT101 cells relative to transformation-resistant (P-) and susceptible (P+) variants. Whether Pdcd4 downregulation is necessary not only to induce transformation but also to maintain tumor phenotypes has not been determined previously. In the present study, overexpression of Pdcd4 cDNA in stably transfected RT101 cells resulted in 40% fewer anchorage-independent colonies that were smaller in size than the vector control colonies, indicating that elevated Pdcd4 expression is sufficient to suppress tumor phenotype. Transient transfection of Pdcd4 expression plasmid and 4 x AP-1 reporter gene showed that activation of AP-1-dependent transcription was inhibited by Pdcd4 expression in a concentration-dependent manner. In contrast, Pdcd4 did not inhibit serum response element-dependent transcription, indicating specificity. In a Gal4 fusion assay, Pdcd4 specifically inhibited activation of c-Jun and c-Fos activation domains, but did not inhibit activation of JunB, JunD, Fra-1, or Fra-2. Gel mobility shift assay demonstrated that c-Jun is the major component detected in the AP-1 complex in RT101 cells. Previous studies suggested that AP-1 activity is required for maintaining the transformed phenotype in RT101 cells. Thus, Pdcd4 suppresses tumor phenotype by inhibiting AP-1-dependent transcription, possibly through inhibiting c-Jun and c-Fos activation.	Natl Canc Inst, Ctr Canc Res, Gene Regulat Sect, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yang, HS (corresponding author), Natl Canc Inst, Ctr Canc Res, Gene Regulat Sect, Gene Regulat Sect,Bldg 567,Rm 180, Frederick, MD 21702 USA.	hyang@ncifcrf.gov	Yang, Hsin-Sheng/AAF-6793-2020; Yang, Hsin-Sheng/A-6419-2008	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036	NATIONAL CANCER INSTITUTE [Z01BC010026, ZIABC010026] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Colburn N H, 1980, Carcinog Compr Surv, V5, P33; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Hsu TC, 2001, CANCER RES, V61, P4160; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; KAZUMI S, 2002, ONCOGENE, V21, P2181; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; RAPP UR, 1994, ONCOGENE, V9, P3493; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Svitkin YV, 2001, RNA, V7, P1743; TAKAHASHI K, 1986, CANCER RES, V46, P5923; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	42	142	156	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3712	3720		10.1038/sj.onc.1206433	http://dx.doi.org/10.1038/sj.onc.1206433			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802278				2022-12-17	WOS:000183551000005
J	Mirza, A; Wu, Q; Wang, LQ; McClanahan, T; Bishop, WR; Gheyas, F; Ding, W; Hutchins, B; Hockenberry, T; Kirschmeier, P; Greene, JR; Liu, SX				Mirza, A; Wu, Q; Wang, LQ; McClanahan, T; Bishop, WR; Gheyas, F; Ding, W; Hutchins, B; Hockenberry, T; Kirschmeier, P; Greene, JR; Liu, SX			Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression	ONCOGENE			English	Article						p53; transcription; microarray; chromatin immunoprecipitation; bioinformatics	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING; INHIBITS TRANSCRIPTION; PROMOTER; REPRESSION; ACTIVATION; EXPRESSION; ELEMENT; TRANSACTIVATION	The temporal gene expression profile during the entire process of apoptosis and cell cycle progression in response to p53 in human ovarian cancer cells was explored with cDNA microarrays representing 33 615 individual human genes. A total of 1501 genes (4.4%) were found to respond to p53 (approximately 80% of these were repressed by p53) using 2.5-fold change as a cutoff. It was anticipated that most of p53 responsive genes resulted from the secondary effect of p53 expression at late stage of apoptosis. To delineate potential p53 direct and indirect target genes during the process of apoptosis and cell cycle progression, microarray data were combined with global p53 DNA-binding site analysis. Here we showed that 361 out of 1501 p53 responsive genes contained p53 consensus DNA-binding sequence(s) in their regulatory region, approximately 80% of which were repressed by p53. This is the first time that a large number of p53-repressed genes have been identified to contain p53 consensus DNA-binding sequence(s) in their regulatory region. Hierarchical cluster analysis of these genes revealed distinct temporal expression patterns of transcriptional activation and repression by p53. More genes were activated at early time points, while more repressed genes were found after the onset of apoptosis. A small-scale quantitative chromatin immunoprecipitation analysis indicated that in vivo p53-DNA interaction was detected in eight out of 10 genes, most of which were repressed by p53 at the early onset of apoptosis, suggesting that a portion of p53 target genes in the human genome could be negatively regulated by p53 via sequence-specific DNA binding. The approaches and genes described here should aid the understanding of global gene regulatory network of p53.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Human Genom Res Dept, Kenilworth, NJ 07033 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Schering Plough Corp, Res Inst, Biostat Grp, Kenilworth, NJ 07033 USA; Canji Inc, San Diego, CA 92121 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Merck & Company; Schering Plough Corporation	Liu, SX (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, 2015 Galloping Hill Rd,K-15-4 4600, Kenilworth, NJ 07033 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaluzova M, 2000, BBA-GENE STRUCT EXPR, V1491, P20, DOI 10.1016/S0167-4781(00)00015-4; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P525, DOI 10.1146/annurev.physiol.60.1.525; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2000, CANCER GENE THER, V7, P1469, DOI 10.1038/sj.cgt.7700257; Wu Q, 2002, J BIOL CHEM, V277, P36329, DOI 10.1074/jbc.M204962200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhao RB, 2000, GENE DEV, V14, P981	40	142	143	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3645	3654		10.1038/sj.onc.1206477	http://dx.doi.org/10.1038/sj.onc.1206477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789273				2022-12-17	WOS:000183399200015
J	Thompson, HGR; Harris, JW; Wold, BJ; Lin, F; Brody, JP				Thompson, HGR; Harris, JW; Wold, BJ; Lin, F; Brody, JP			p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells	ONCOGENE			English	Article						breast cancer; P62; PDEF; promoter; proteasome inhibitor; SQSTM1	PHOSPHOTYROSINE-INDEPENDENT LIGAND; CHAIN BINDING-PROTEIN; KAPPA-B ACTIVATION; TRANSCRIPTION FACTOR; DNA-BINDING; SH2 DOMAIN; GENE; PEA3; PROTEASOME; EXPRESSION	p62 is a multifunctional cytoplasmic protein able to noncovalently bind ubiquitin and several signaling proteins, suggesting a regulatory role connected to the ubiquitin-proteasome pathway. No studies to date have linked p62 protein expression with pathological states. Here we demonstrate the overabundance of p62 protein in malignant breast tissue relative to normal breast tissue. The proteasome inhibitor PSI increased p62 mRNA and protein; however, PSI treatment of breast epithelial cells transfected with the p62 promoter did not affect promoter activity. High levels of prostate-derived Ets factor (PDEF) mRNA have been identified in breast cancer compared to normal breast. Only the PSA and maspin promoters have been identified as targets of this transcription factor. Here we show that PDEF stimulates the p62 promoter through at least two sites, and likely acts as a coactivator. PSI treatment abrogates the PDEF-stimulated increase of p62 promoter activity by 50%. Thus, multiple mechanisms for the induction of p62 exist. We conclude that (1) p62 protein is overexpressed in breast cancer; (2) p62 mRNA and protein increase in response to PSI, with no change of basal promoter activity; (3) PDEF upregulates p62 promoter activity through at least two sites; and (4) PSI downregulates PDEF-induced p62 promoter activation through one of these sites.	Univ Calif Irvine, Dept Biomed Engn, Rockwell Engn Ctr 204, Irvine, CA 92697 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA; Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92868 USA	University of California System; University of California Irvine; California Institute of Technology; University of California System; University of California Irvine	Brody, JP (corresponding author), Univ Calif Irvine, Dept Biomed Engn, Rockwell Engn Ctr 204, Irvine, CA 92697 USA.			Brody, James/0000-0002-7995-5197	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG000047] Funding Source: NIH RePORTER; NHGRI NIH HHS [1K22HG00047-01, K22 HG000047, K22 HG000047-01, K22 HG000047-03, K22 HG000047-02] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams J, 2001, SEMIN ONCOL, V28, P613, DOI 10.1053/sonc.2001.28609; Afrikanova I, 2002, ONCOGENE, V21, P1272, DOI 10.1038/sj.onc.1205183; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen H, 2002, CANCER RES, V62, P338; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Fan XM, 2001, INT J CANCER, V93, P481, DOI 10.1002/ijc.1373; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hiroumi H, 2001, INT J CANCER, V93, P786, DOI 10.1002/ijc.1410; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107; Lee YH, 1998, FEBS LETT, V438, P297, DOI 10.1016/S0014-5793(98)01323-4; Nagamura-Inoue T, 2001, Int Rev Immunol, V20, P83, DOI 10.3109/08830180109056724; Nozawa M, 2000, CANCER RES, V60, P1348; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Rachubinski RA, 1999, J BIOL CHEM, V274, P18278, DOI 10.1074/jbc.274.26.18278; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shin J, 1998, ARCH PHARM RES, V21, P629, DOI 10.1007/BF02976748; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Sudo T, 2000, BIOCHEM BIOPH RES CO, V269, P521, DOI 10.1006/bbrc.2000.2333; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Vadlamudi RK, 1998, FEBS LETT, V435, P138, DOI 10.1016/S0014-5793(98)01021-7; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300	44	142	148	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2322	2333		10.1038/sj.onc.1206325	http://dx.doi.org/10.1038/sj.onc.1206325			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700667				2022-12-17	WOS:000182231500010
J	Dong, QG; Sclabas, GM; Fujioka, S; Schmidt, C; Peng, BL; Wu, TA; Tsao, MS; Evans, DB; Abbruzzese, JL; McDonnell, TJ; Chiao, PJ				Dong, QG; Sclabas, GM; Fujioka, S; Schmidt, C; Peng, BL; Wu, TA; Tsao, MS; Evans, DB; Abbruzzese, JL; McDonnell, TJ; Chiao, PJ			The function of multiple I kappa B : NF-kappa B complexes in the resistance of cancer cells to Taxol-induced apoptosis	ONCOGENE			English	Article						apoptosis; gene expression; NF-kappa B; I kappa B; bcl-xl	PRECURSOR NF-KAPPA-B1; KINASE COMPLEX; MICE LACKING; ACTIVATION; ALPHA; PHOSPHORYLATION; INHIBITION; EXPRESSION; PROTEINS; PATHWAY	The Rel/NF-kappaB transcription factors play a key role in the regulation of apoptosis and in tumorigenesis by controlling the expressions of specific genes. To determine the role of the constitutive activity of RelA in tumorigenesis, we generated pancreatic tumor cell lines that express a dominant negative mutant Of IkappaBalpha (IkappaBalphaM). In this report, we show that the inhibition of constitutive NF-kappaB activity, either by ectopic expression Of IkappaBalphaM or by treating the cells with a proteasome inhibitor PS-341 which blocks intracellular degradation Of IBalpha proteins, downregulates the expression of bcl-xl. We identified two putative NF-kappaB binding sites (kappaB/A and B) in the bcl-xl promoter and found that these two sites interact with different NF-kappaB proteins. p65/p50 heterodimer interacts with kappaB/A site whereas p50/p50 homodimer interacts with kappaB/B. The bcl-xl promoter reporter gene assays reveal that NF-kappaB dependent transcriptional activation is mainly mediated by kappaB/A site, indicating that bcl-xl is one of the downstream target genes regulated by RelA/ p50. Both IkappaBalphaM and PS-341 completely abolish NF-kappaB DNA binding activity; however, PS-341, but not ectopic expression Of IkappaBalphaM, sensitized cells to apoptosis induced by Taxol. This is due to the Taxol-mediated reactivation of RelA through phosphorylation and degradation Of IkappaBbeta and the re-expression of NF-kappaB regulated bcl-xl gene in these cancer cells as ectopic expression of the bcl-xl gene confers resistance to Taxol-induced apoptosis in PS-341 sensitized cells. These results demonstrate the important function of various NF-kappaB/IkappaB complexes in regulating anti-apoptotic genes in response to apoptotic stimuli, and they raise the possibility that NF-kappaB:IkappaBalpha and NF-kappaB:IkappaBbeta complexes are regulated by different upstream activators, and that NF-kappaB plays a key role in pancreatic tumorigenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Bern, Inselspital, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bern; University Hospital of Bern; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405; Schmidt, Christian/0000-0002-1260-9732	NCI NIH HHS [CA73675, CA75517, CA78778] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075517, P01CA078778, R29CA073675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGIUSEPPE JA, 1996, ADV ANAT PATHOL, V3, P139; Gilmore TD, 1996, ONCOGENE, V13, P1367; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Ishikawa H, 1996, ONCOGENE, V13, P255; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Jordan MA, 1996, CANCER RES, V56, P816; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Sambrook J., 1989, MOL CLONING; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	41	142	151	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6510	6519		10.1038/sj.onc.1205848	http://dx.doi.org/10.1038/sj.onc.1205848			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226754				2022-12-17	WOS:000177925300011
J	Saeki, T; Mhashilkar, A; Swanson, X; Zou-Yang, XH; Sieger, K; Kawabe, S; Branch, CD; Zumstein, L; Meyn, RE; Roth, JA; Chada, S; Ramesh, R				Saeki, T; Mhashilkar, A; Swanson, X; Zou-Yang, XH; Sieger, K; Kawabe, S; Branch, CD; Zumstein, L; Meyn, RE; Roth, JA; Chada, S; Ramesh, R			Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo	ONCOGENE			English	Article						MDA-7; TRAIL; CD31; apoptosis; gene therapy; antiangiogenesis	DIFFERENTIATION-ASSOCIATED GENE; MELANOMA DIFFERENTIATION; TUMOR-GROWTH; APOPTOSIS; CELLS; VEGF	Overexpression of the melanoma differentiation associated gene-7 (mda-7) in vitro results in suppression of lung cancer cell proliferation. However, the ability of MDA-7 to suppress lung cancer in vivo has not been previously demonstrated. In this study, we investigated the possibility of inducing overexpression of the mda-7 gene in human non-small cell lung carcinoma cells in vivo and its effects on tumor growth. Adenovirus-mediated overexpression of MDA-7 in p53-wild-type A549 and p53-null H1299 subcutaneous tumors resulted in significant tumor growth inhibition through induction of apoptosis. In addition, decreased CD31/PECAM expression and upregulation of APO2/TRAIL were observed in tumors expressing MDA-7. In vivo studies correlated well with in vitro inhibition of lung tumor cell proliferation and endothelial cell differentiation mediated by Ad-mda7. These data demonstrate that Ad-mda7 functions as a multi-modality anti-cancer agent, possessing both, pro-apoptotic and anti-angiogenic properties. We demonstrate for the first time the potential therapeutic effects of Ad-mda7 in human lung cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ramesh, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, 1515 Holcombe Blvd,Box 45, Houston, TX 77030 USA.	rramesh@mdanderson.org			NCI NIH HHS [R43 CA86587, P01CA78778-01A1, P50-CA70907, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672, P50CA070907, R43CA086587] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; GEORGES RN, 1993, CANCER RES, V53, P1743; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kagawa S, 2001, CANCER RES, V61, P3330; Kundu N, 1998, INT J CANCER, V76, P713, DOI 10.1002/(SICI)1097-0215(19980529)76:5<713::AID-IJC17>3.0.CO;2-4; Madireddi MT, 2000, J CELL PHYSIOL, V185, P36, DOI 10.1002/1097-4652(200010)185:1<36::AID-JCP3>3.0.CO;2-V; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Nishizaki M, 1999, CLIN CANCER RES, V5, P1015; Orre M, 1999, INT J CANCER, V84, P101, DOI 10.1002/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; Rowe DH, 2000, J PEDIATR SURG, V35, P30, DOI 10.1016/S0022-3468(00)80008-1; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517	20	142	175	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4558	4566		10.1038/sj.onc.1205553	http://dx.doi.org/10.1038/sj.onc.1205553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085234				2022-12-17	WOS:000176476700010
J	Li, G; Schaider, H; Satyamoorthy, K; Hanakawa, Y; Hashimoto, K; Herlyn, M				Li, G; Schaider, H; Satyamoorthy, K; Hanakawa, Y; Hashimoto, K; Herlyn, M			Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development	ONCOGENE			English	Review						HGF; autocrine; E-cadherin; Desmoglein; melanoma	FACTOR SCATTER FACTOR; PEMPHIGUS-VULGARIS ANTIGEN; CELL-CELL ADHESION; EFFICIENT GENE ACTIVATION; C-MET; INTERMEDIATE FILAMENTS; MALIGNANT-MELANOMA; CATENIN COMPLEX; FACTOR-RECEPTOR; BETA-CATENIN	During melanoma development, transformed cells evade keratinocyte-mediated control by downregulating cell adhesion molecules. This study investigated the regulation of cell adhesion by hepatocyte growth factor (HGF) in melanoma. Melanocytes and two melanoma lines, WM164 and WM35, expressed normal level E-cadherin and Desmoglein 1, whereas most melanomas (18 out of 20) expressed no E-cadherin and significantly reduced Desmoglein 1. Overexpression of dominant negative E-cadherin and Desmoglein in melanocytes demonstrated that both molecules contribute to adhesion between melanocytes and keratinocytes. In contrast to melanocytes, most melanomas expressed HGF. All melanocytic cells expressed the HGF receptor c-Met, and autocrine HGF caused constitutive activation of c-Met, MAPK and PI3K. When autocrine activation was induced with HGF-expressing adenovirus, E-cadherin and Desmoglein I were decreased in melanocytes, WM164 and WM35. MAPK inhibitor PD98059 and PI3K inhibitor wortmannin partially blocked the downregulation, suggesting that both pathways are involved in this process. c-Met was coimmunoprecipitated with E-cadherin, Desmoglein I and Plakoglobin, suggesting that they form a complex (es) that acts to regulate intercellular adhesion. Together, the results indicate that autocrine HGF decouples melanomas from keratinocytes by downregulating E-cadherin and Desmoglein 1, therefore frees melanoma cells from the control by keratinocytes and allows dissemination of the tumor mass.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Program Cell & Mol Biol Biomed Grad Studies, Philadelphia, PA 19104 USA; Ehime Univ, Sch Med, Dept Dermatol, Matsuyama, Ehime 790, Japan	The Wistar Institute; University of Pennsylvania; Ehime University	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu	Satyamoorthy, Kapaettu/H-3254-2015	Schaider, Helmut/0000-0003-3195-2517; Satyamoorthy, Kapaettu/0000-0002-2368-5490	NATIONAL CANCER INSTITUTE [R01CA047159, R01CA080999, P30CA010815, P01CA025874, R01CA076674] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47159, CA-80999, CA-76674, CA-10815, CA-25874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERLE H, 1994, J CELL SCI, V107, P3655; ALBELDA SM, 1990, CANCER RES, V50, P6757; AMAGAI M, 1994, J INVEST DERMATOL, V102, P402, DOI 10.1111/1523-1747.ep12372164; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUTZ S, 1994, FEBS LETT, V355, P195, DOI 10.1016/0014-5793(94)01205-9; CONN IG, 1990, BRIT J UROL, V65, P176, DOI 10.1111/j.1464-410X.1990.tb14694.x; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Danen EHJ, 1996, MELANOMA RES, V6, P127, DOI 10.1097/00008390-199604000-00007; De Bruin A, 1999, CELL ADHES COMMUN, V7, P13; Depondt J, 1999, EUR J ORAL SCI, V107, P183, DOI 10.1046/j.0909-8836.1999.eos1070305.x; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Garrod D, 1996, CURR OPIN CELL BIOL, V8, P670, DOI 10.1016/S0955-0674(96)80108-6; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Halaban R, 1993, EXS, V65, P329; HALABAN R, 1992, ONCOGENE, V7, P2195; Hanakawa Y, 2000, J CELL SCI, V113, P1803; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hiscox S, 1999, ANTICANCER RES, V19, P509; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Imokawa G, 1998, BIOCHEM J, V330, P1235, DOI 10.1042/bj3301235; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Jouneau A, 2000, PIGM CELL RES, V13, P260, DOI 10.1034/j.1600-0749.2000.130408.x; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Krunic ALJ, 1996, ACTA DERM-VENEREOL, V76, P394; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2001, CANCER RES, V61, P3819; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Moriyama T, 1999, INT J MOL MED, V3, P531; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Noonan FP, 2000, CANCER RES, V60, P3738; North AJ, 1999, J CELL SCI, V112, P4325; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Otsuka T, 1998, CANCER RES, V58, P5157; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POSER I, 2001, J BIOL CHEM, V25, P25; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rickman L, 1999, HUM MOL GENET, V8, P971, DOI 10.1093/hmg/8.6.971; Ries LAG, 2000, CANCER-AM CANCER SOC, V88, P2398, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; ROH JY, 1995, J INVEST DERMATOL, V104, P720, DOI 10.1111/1523-1747.ep12606963; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rusciano D, 1998, TUMOR BIOL, V19, P335, DOI 10.1159/000030026; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Scott GA, 1998, J INVEST DERMATOL, V111, P243, DOI 10.1046/j.1523-1747.1998.00276.x; Shinohara M, 1998, J PATHOL, V184, P369, DOI 10.1002/(SICI)1096-9896(199804)184:4<369::AID-PATH1236>3.0.CO;2-L; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tada H, 2000, J CUTAN PATHOL, V27, P24, DOI 10.1034/j.1600-0560.2000.027001024.x; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TAKEICHI M, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P28; Tamatani T, 1999, CARCINOGENESIS, V20, P957, DOI 10.1093/carcin/20.6.957; TANG A, 1994, J CELL SCI, V107, P983; To CTT, 1998, ONCOL REP, V5, P1013; Troyanovsky S M, 1998, Subcell Biochem, V31, P263; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130	102	142	149	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8125	8135		10.1038/sj.onc.1205034	http://dx.doi.org/10.1038/sj.onc.1205034			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781826				2022-12-17	WOS:000172396800010
J	Rizos, H; Puig, S; Badenas, C; Malvehy, J; Darmanian, AP; Jimenez, L; Mila, M; Kefford, RF				Rizos, H; Puig, S; Badenas, C; Malvehy, J; Darmanian, AP; Jimenez, L; Mila, M; Kefford, RF			A melanoma-associated germline mutation in exon 1 beta inactivates p14ARF	ONCOGENE			English	Article						p14ARF; p16(INK4a); melanoma; germline mutation	CUTANEOUS MALIGNANT-MELANOMA; NUCLEOLAR LOCALIZATION; TUMOR SUPPRESSION; CDKN2A MUTATIONS; P53; MDM2; P19(ARF); GENE; LOCUS; P14(ARF)	The INK4a/ARF locus encodes the cyclin dependent kinase inhibitor, p16(INK4a) and the p53 activator, p14ARF. These two proteins have an independent first exon (exon 1 alpha and exon 1 beta, respectively) but share exons 2 and 3 and are translated in different reading frames. Germline mutations in this locus are associated with melanoma susceptibility in 20-40% of multiple case melanoma families. Although most of these mutations specifically inactivate p16(INK4a), more than 40% of the INK4a/ARF alterations located in exon 2, affect both p16(INK4a) and p14ARF. We now report a 16 base pair exon 1 beta germline insertion specifically altering p14ARF, but not p16(INK4a), in an individual with multiple primary melanomas. This mutant p14ARF, 60ins16, was restricted to the cytoplasm, did not stabilize p53 and was unable to arrest the growth of a p53 expressing melanoma cell line. This is the first example of an exon 1 beta mutation that inactivates p14ARF, and thus implicates a role for this tumour suppressor in melanoma predisposition.	Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; Univ Barcelona, IDIBAPS, Hosp Clin, E-08036 Barcelona, Spain	University of Sydney; Westmead Institute for Medical Research; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Rizos, H (corresponding author), Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.		Rizos, Helen/AAE-5010-2020; Puig, Susana/AAB-2091-2020; Badenas, Celia/ABH-5480-2020	Rizos, Helen/0000-0002-2094-9198; Puig, Susana/0000-0003-1337-9745; Badenas, Celia/0000-0002-0621-0477; Mila, Montserrat/0000-0002-7906-0916; malvehy, josep/0000-0002-6998-914X; Kefford, Richard/0000-0001-9251-9229				Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Dracopoli NC, 1996, CANCER SURV, V26, P115; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Flores JF, 1997, ONCOGENE, V15, P2999, DOI 10.1038/sj.onc.1201470; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Newcomb EW, 2000, HUM PATHOL, V31, P115, DOI 10.1016/S0046-8177(00)80207-5; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Pollock PM, 1998, HUM MUTAT, V11, P424, DOI 10.1002/(SICI)1098-1004(1998)11:6<424::AID-HUMU2>3.3.CO;2-U; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Puig S, 2000, MELANOMA RES, V10, P231, DOI 10.1097/00008390-200010030-00004; QUELLE DE, 1995, CELL, V83, P993; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 1997, ONCOGENE, V15, P515, DOI 10.1038/sj.onc.1201217; Rizos H, 1999, MELANOMA RES, V9, P10, DOI 10.1097/00008390-199902000-00003; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruiz A, 1998, INT J CANCER, V76, P312, DOI 10.1002/(SICI)1097-0215(19980504)76:3<312::AID-IJC4>3.3.CO;2-B; Ruiz A, 1999, J MED GENET, V36, P490; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	37	142	146	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5543	5547		10.1038/sj.onc.1204728	http://dx.doi.org/10.1038/sj.onc.1204728			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571653				2022-12-17	WOS:000170781100016
J	Chandel, NS; Vander Heiden, MG; Thompson, CB; Schumacker, PT				Chandel, NS; Vander Heiden, MG; Thompson, CB; Schumacker, PT			Redox regulation of p53 during hypoxia	ONCOGENE			English	Article						mitochondria; reactive oxygen species; hydrogen peroxide; apoptosis; cell cycle	INNER MEMBRANE; OXYGEN; MITOCHONDRIA; TUMOR; CARDIOMYOCYTES; PROLIFERATION; METABOLISM; APOPTOSIS; PROTEIN; DEATH	The transcription factor p53 can induce growth arrest or death in cells, Tumor cells that develop mutations in p53 demonstrate a diminished apoptotic potential, which may contribute to growth and tumor metastasis. Cellular levels of p53 are stabilized during hypoxia. The present study tested the hypothesis that reactive oxygen species (ROS) released from mitochondria regulate the cytosolic redox state and are required for the stabilization of p53 protein levels in response to hypoxia. Our results indicate that hypoxia (1.5% O-2) increases mitochondrial ROS generation and increases p53 protein levels in human breast carcinoma MCF-7 cells and in normal human diploid fibroblast IMR-90 cells. MCF-7 cells depleted of their mitochondrial DNA (rho degrees cells) failed to stabilize p53 protein levels during hypoxia. The antioxidant N-acetylcysteine and the Cu/Zn superoxide dismutase inhibitor diethyldithiocarbamic acid abolished the hypoxia-induced increases in ROS and p53 levels. Rotenone, an inhibitor of mitochondrial complex I, and 4,4'-diisothiocyanato-stilbene-2,2'-disulfonate, a mitochondrial anion channel inhibitor, also abolished the increase in ROS signal and p53 levels during hypoxia. The p53-dependent gene p21(WAF1/CIP1) was also induced by hypoxia in both MCF-7 and IMR-90 cells without affecting the growth rate of either cell line. In contrast, both cell lines exhibited increases in p21(WAF1/CIP1) expression and growth arrest after gamma irradiation. Primary chick cardiac myocytes and murine embryonic fibroblasts also showed an increase in p53 protein levels in response to hypoxia without cell death or growth arrest. These results indicate that mitochondria regulate p53 protein levels during hypoxia through a redox-dependent mechanism involving ROS, Despite p53-induction, hypoxia alone does not cause either growth arrest or cell death.	Northwestern Univ, Dept Med, Div Pulm & Crit Care, Chicago, IL 60611 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Gwen Knapp Ctr, Chicago, IL 60637 USA; Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	Northwestern University; University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Chandel, NS (corresponding author), Northwestern Univ, Dept Med, Div Pulm & Crit Care, Tarry Bldg 14-707,300 E Super St, Chicago, IL 60611 USA.		Rodríguez, Ferran A. A/H-4892-2011	Rodríguez, Ferran A. A/0000-0002-2280-8962; Schumacker, Paul T/0000-0001-9591-2034	NHLBI NIH HHS [HL35440, HL32646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ballarin C, 1996, J BIOENERG BIOMEMBR, V28, P125, DOI 10.1007/BF02110642; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; BASS DA, 1983, J IMMUNOL, V130, P1910; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Colombini M, 1996, Ion Channels, V4, P169; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; ELDEIRY WS, 1993, CELL, V75, P217; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; JONES DP, 1978, J BIOL CHEM, V253, P4874; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; MINERS JO, 1984, BIOCHEM PHARMACOL, V33, P2995, DOI 10.1016/0006-2952(84)90599-9; MISRA HP, 1979, J BIOL CHEM, V254, P1623; Ravi R, 2000, GENE DEV, V14, P34; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WILSON DF, 1979, ARCH BIOCHEM BIOPHYS, V195, P485, DOI 10.1016/0003-9861(79)90375-8	34	142	145	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3840	3848		10.1038/sj.onc.1203727	http://dx.doi.org/10.1038/sj.onc.1203727			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951577				2022-12-17	WOS:000088614300002
J	Li, Q; Ahuja, N; Burger, PC; Issa, JPJ				Li, Q; Ahuja, N; Burger, PC; Issa, JPJ			Methylation and silencing of the Thrombospondin-1 promoter in human cancer	ONCOGENE			English	Article						DNA methylation; glioblastoma multiforme; Thrombospondin-1 (THBS1); angiogenesis	ENDOTHELIAL GROWTH-FACTOR; NICKEL-TRANSFORMED CELLS; DNA METHYLATION; TUMOR ANGIOGENESIS; GENE-EXPRESSION; HUMAN BREAST; CPG ISLAND; INDUCTION; FIBROBLASTS; INHIBITION	Neovascularization is a common feature of many human cancers, but relatively few molecular defects have been demonstrated in genes regulating angiogenesis. Decreased expression of Thrombospondin-1 (THBS1), a P53 and Rb regulated angiogenesis inhibitor, has been observed in some human tumors, including glioblastoma multiforme (GBM). To study whether methylation-associated inactivation is involved in down-regulating THBS1 expression in cancer, we analysed the methylation status of THBS1 in several cell lines and primary tumors. Three cell lines (RKO, CEM and RAJI) were completely methylated at several CpG sites within the THBS1 5' CpG island, and had no detectable expression ba RT-PCR, THBS1 expression,vas readily reactivated using the methylation-inhibitor 5-deoxy-azacytidine in all three lines, Furthermore, THBS1 methylation was present in 33% (14/42) of primary GBMs, Thus, de novo methylation may serve as a potential way to inactivate THBS1 expression in human neoplasms.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Issa, JPJ (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21231 USA.		Ahuja, Nita/H-1064-2011	Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [5UO1CA64928] Funding Source: Medline; NIA NIH HHS [AG05146] Funding Source: Medline; NIDDK NIH HHS [1-T32-DK07713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA064928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja N, 1997, CANCER RES, V57, P3370; Baylin SB, 1998, ADV CANCER RES, V72, P141; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CANFIELD AE, 1995, J CELL SCI, V108, P797; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CLEZARDIN P, 1993, CANCER RES, V53, P1421; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DIPIETRO LA, 1994, J VASC RES, V31, P178, DOI 10.1159/000319585; Furnari FB, 1995, CANCER SURV, V25, P233; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Guo NH, 1997, CANCER RES, V57, P1735; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsu SC, 1996, CANCER RES, V56, P5684; Issa JPJ, 1997, LEUKEMIA, V11, pS7; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones PA, 1996, CANCER RES, V56, P2463; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; LEE YW, 1995, MOL CELL BIOL, V15, P2547; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; MEEHAN R, 1992, J CELL SCI, P9; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sadri R, 1996, NUCLEIC ACIDS RES, V24, P5058, DOI 10.1093/nar/24.24.5058; Salnikow K, 1997, CANCER RES, V57, P5060; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; Stirzaker C, 1997, CANCER RES, V57, P2229; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	37	142	153	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3284	3289		10.1038/sj.onc.1202663	http://dx.doi.org/10.1038/sj.onc.1202663			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359534				2022-12-17	WOS:000080523800011
J	Dobbelstein, M; Wienzek, S; Konig, C; Roth, J				Dobbelstein, M; Wienzek, S; Konig, C; Roth, J			Inactivation of the p53-homologue p73 by the mdm2-oncoprotein	ONCOGENE			English	Article						p53; p73; mdm2; transcription; protein stability	TUMOR-SUPPRESSOR; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53 BINDING; MDM2; PROTEIN; DOMAIN; TRANSACTIVATION; GROWTH; ACTIVATION	The p73 beta protein shares structural and functional similarities with the tumor suppressor gene product p53, Both proteins activate transcription from p53-responsive promoters. p53's activity is antagonized by the mdm2 protein (also termed hdma in human cells). Complex formation between p53 and mdm2 results in p53's transcriptional inactivation and destabilization, Here we show that overexpression of mdm2 reduces p73 beta's ability to activate transcription, too. The mdm2 protein forms a specific complex with p73 beta in vitro with an efficiency comparable to p53-binding. Further, both p73 beta and p53 relocalize a transport-defective mutant of mdm2 from the cytoplasm to the nucleus, arguing that complex formation occurs in vivo as well. Mutational analysis suggests that the interaction between p73 beta and mdm2 follows structural principles analogous to the p53-mdm2-complex, Whereas p53 is destabilized in the presence of mdm2, the amount of intracellular p73 beta was not detectably reduced by mdm2, The carboxyterminal RING finger domain of mdm2 was found to be required to reduce the intracellular abundance of p53, but it was dispensable for transcriptionally inactivating either p53 or p73 beta, Our results suggest that the autoregulatory feedback loop between p53 and mdm2 also controls p73's activity, but that mdm2-mediated protein degradation is unique to p53.	Univ Marburg, Fachbereich Med, Abt Gastroenterol & Stoffwechsel, Zentrum Innere Med, D-35045 Marburg, Germany; Univ Marburg, Zentrum Mikrobiol & Hyg, Inst Virol, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Roth, J (corresponding author), Univ Marburg, Fachbereich Med, Abt Gastroenterol & Stoffwechsel, Zentrum Innere Med, Baldingerstr, D-35045 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DOBBLESTEIN M, 1997, IN PRESS J GEN VIROL; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nomoto S, 1998, CANCER RES, V58, P1380; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	43	142	145	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2101	2106		10.1038/sj.onc.1202512	http://dx.doi.org/10.1038/sj.onc.1202512			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321734				2022-12-17	WOS:000079346200007
J	Garton, AJ; Burnham, MR; Bouton, AH; Tonks, NK				Garton, AJ; Burnham, MR; Bouton, AH; Tonks, NK			Association of PTP-PEST with the SH3 domain of p130(cas); a novel mechanism of protein tyrosine phosphatase substrate recognition	ONCOGENE			English	Article						p130(cas); SH3 domain; PTP-PEST; tyrosine phosphorylation; PTP	FOCAL ADHESION KINASE; SWISS 3T3 CELLS; V-CRK ONCOGENE; GROWTH-FACTOR; STRUCTURAL BASIS; RECEPTOR-BETA; CROSS-TALK; PHOSPHORYLATION; PHOSPHOTYROSINE; PAXILLIN	The protein tyrosine phosphatase PTP-PEST displays remarkable substrate specificity, in vitro and in vivo for p130(cas) a signalling intermediate implicated in mitogenic signalling, cell-adhesion induced signalling, and in transformation by a variety of oncogenes. We have identified a high affinity interaction between the SH3 domain of p130(cas) and a proline-rich sequence ((PPPKPPR)-P-335) within the C-terminal segment of PTP-PEST. Mutation of proline 337 within this sequence to alanine significantly impairs the ability of PTP-PEST to recognise tyrosine phosphorylated p130(cas) as a substrate, without qualitatively affecting the selectivity of the interaction. Thus the highly specific nature of the interaction between PTP-PEST and p130(cas) appears to result from a combination of two distinct substrate recognition mechanisms; the catalytic domain of PTP-PEST contributes specificity to the interaction with p130(cas), whereas the SH3 domain-mediated association of p130(cas) and PTP-PEST dramatically increases the efficiency of the interaction. Furthermore, our results indicate that one important function of the p130(cas) SH3 domain is to associate with PTP-PEST and thereby facilitate the dephosphorylation of p130(cas), resulting in the termination of tyrosine phosphorylation-dependent signalling events downstream of p130(cas).	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	Cold Spring Harbor Laboratory; University of Virginia; University of Virginia					NCI NIH HHS [CA 53840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Burnham MR, 1996, ONCOGENE, V12, P2467; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, J BIOL CHEM, V269, P704; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SCHNEIDER C, 1992, J BIOL CHEM, V267, P10766; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1993, J BIOL CHEM, V268, P17650; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	142	146	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	1997	15	8					877	885		10.1038/sj.onc.1201279	http://dx.doi.org/10.1038/sj.onc.1201279			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285683				2022-12-17	WOS:A1997XR76700001
J	Chen, RH; Juo, PCH; Curran, T; Blenis, J				Chen, RH; Juo, PCH; Curran, T; Blenis, J			Phosphorylation of c-Fos at the C-terminus enhances its transforming activity	ONCOGENE			English	Article						c-Fos; MAP kinase; pp90(RSK)	SERUM RESPONSE ELEMENT; ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; DNA-BINDING ACTIVITY; GROWTH-FACTOR; MAP KINASES; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; COMPLEX-FORMATION	c-Fos is phosphorylated by MAP kinase and the 90 kDa-ribosomal S6 kinase (RSK) in vitro at serines 362 and 374 (rat) which we demonstrate are major in vivo phosphorylation sites in early G1. We have constructed c-Fos mutants with these serines changed to aspartic acid residues (FosD) to mimic phosphorylation or to alanine residues (FosA) to prevent phosphorylation. Cells expressing FosD exhibited a more extensive transformed phenotype than those expressing either FosA or wild type c-Fos (FosWT). We also observed that FosA has a reduced half-life in comparison with FosD in G1. Furthermore, we observed enhanced AP-1 transactivation activity in cells expressing FosD. These results indicate that phosphorylation of c-Fos at its extreme carboxy-terminus, possibly by MAP kinase and RSK, supports the proliferative response by increasing c-Fos stability and/or by increasing its transactivation activity. Under conditions in which the MAP kinase pathway is constitutively activated, c-Fos phosphorylation probably contributes to cellular transformation. The highly conserved nature of these phosphorylation sites in other c-fos family members suggest that these may also be targets of MAP kinase and RSK.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA	Harvard University; Harvard Medical School; St Jude Children's Research Hospital			Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1984, CELL, V36, P259; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GRUDA MC, 1994, ONCOGENE, V9, P2537; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KONIG H, 1991, MOL CELL BIOL, V11, P2451; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; NEUBERG M, 1991, ONCOGENE, V6, P1325; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Sambrook J., 1989, MOL CLONING; SANGHERA JS, 1992, MOL BIOL CELL, V3, P775, DOI 10.1091/mbc.3.7.775; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	48	142	143	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1493	1502						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622865				2022-12-17	WOS:A1996UF07600013
J	KO, TC; SHENG, HM; REISMAN, D; THOMPSON, EA; BEAUCHAMP, RD				KO, TC; SHENG, HM; REISMAN, D; THOMPSON, EA; BEAUCHAMP, RD			TRANSFORMING GROWTH-FACTOR-BETA-1 INHIBITS CYCLIN D1 EXPRESSION IN INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article						TGF-BETA; CYCLIN; CELL CYCLE; EPITHELIAL CELL; CYCLIN-DEPENDENT KINASE; GENE EXPRESSION	SIGNAL-TRANSDUCTION PATHWAY; DEPENDENT KINASE CDK4; RAT SMALL-INTESTINE; FACTOR-BETA; TGF-BETA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; GENE-EXPRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS	Transforming growth factor-beta 1 (TGF-beta 1) inhibits most epithelial cell types by blocking cell cycle progression during the G(1) phase. D cyclins are normally expressed during G(1) and are regulators of G(1) progression. One of the crucial functions of D cyclins is their ability to bind to a cyclin-dependent kinase (Cdk4). In mink lung epithelial cells, TGF-beta 1 inhibits Cdk4 expression. We have measured cell cycle progression and D cyclins and Cdk4 expression in non-transformed rat intestinal epithelial cell lines (IEC-6 and RIE-1) after TGF-beta 1 treatment. In exponentially growing cultures, TGF-beta 1 blocked DNA synthesis and suppressed cyclin D1 mRNA and protein expression, whereas the levels of cyclins D2, D3 and Cdk4 remained relatively unchanged. TGF-beta 1 was also added to Go-synchronized IEC-6 cells after serum stimulation. TGF-beta 1 prevention of G(1) progression was associated with an inhibition of cyclin D1 protein expression. Cyclin D3 levels were not affected by TGF-beta 1 during G(1) traverse. Our results suggest that cyclin D/Cdk4 is a crucial target of TGF-beta 1 and that regulation of this kinase is mediated through cyclin D1 in intestinal epithelial cells.	UNIV TEXAS, MED BRANCH, DEPT SURG, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston				Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [R37CA024347, R01CA024347] Funding Source: NIH RePORTER; NCI NIH HHS [CA 24347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Babyatsky M. W., 1991, TXB GASTROENTEROLOGY, P475; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BLAY J, 1986, J CELL PHYSIOL, V129, P343, DOI 10.1002/jcp.1041290312; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRESLIN JS, 1993, AM J RESP CELL MOL, V9, P533, DOI 10.1165/ajrcmb/9.5.533; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAIRNIE AB, 1965, EXP CELL RES, V39, P528, DOI 10.1016/0014-4827(65)90055-8; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILMUS J, 1992, ONCOGENE, V7, P521; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GINTY DD, 1989, AM J PHYSIOL, V256, pG342, DOI 10.1152/ajpgi.1989.256.2.G342; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KO TC, 1993, SURGERY, V114, P147; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAEMMLI UK, 1983, NATURE, V303, P497; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1992, CANCER SURV, V12, P81; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGEE DW, 1991, CYTOKINE, V3, P543, DOI 10.1016/1043-4666(91)90480-2; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOLL T, 1993, PHILOS T ROY SOC B, V340, P351, DOI 10.1098/rstb.1993.0078; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; THOMPSON EA, 1980, J NATL CANCER I, V65, P477; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	73	142	146	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					177	184						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824270				2022-12-17	WOS:A1995QA98000020
J	ICHII, S; TAKEDA, S; HORII, A; NAKATSURU, S; MIYOSHI, Y; EMI, M; FUJIWARA, Y; KOYAMA, K; FURUYAMA, J; UTSUNOMIYA, J; NAKAMURA, Y				ICHII, S; TAKEDA, S; HORII, A; NAKATSURU, S; MIYOSHI, Y; EMI, M; FUJIWARA, Y; KOYAMA, K; FURUYAMA, J; UTSUNOMIYA, J; NAKAMURA, Y			DETAILED ANALYSIS OF GENETIC ALTERATIONS IN COLORECTAL TUMORS FROM PATIENTS WITH AND WITHOUT FAMILIAL ADENOMATOUS POLYPOSIS (FAP)	ONCOGENE			English	Article							GERM-LINE MUTATIONS; APC GENE; P53 GENE; SOMATIC MUTATIONS; CANCER; IDENTIFICATION; TUMORIGENESIS; CARCINOMA; OCCUR; LOCUS	To examine early genetic events during colorectal carcinogenesis, we searched for genetic alterations in 75 adenomas from seven patients with familial polyposis coli (FAP) and in 64 sporadic colorectal tumors (63 carcinomas and one adenoma). We investigated germ-line and somatic mutations in the APC gene, somatic mutations in the K-ras and p53 genes, and loss of heterozygosity (LOH) on chromosome 8p21-22. Thirty-two FAP adenomas carried detectable somatic mutations in the APC gene. The frequency of somatic APC mutations among adenomas was the same regardless of differences in size or histopathological classification. On the other hand, K-ras mutation was very rare in small adenomas where dysplasia was mild or moderate but frequent in large adenomas with severe dysplasia. Mutation of the p53 gene was observed in only two adenomas and LOH on 8p22 was detected in none. These results imply that a second 'hit' in the APC gene, but not necessarily mutation in K-ras or p53, is an important and critical event for formation of a colorectal adenoma.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN; HYOGO MED UNIV,DEPT GENET,NISHINOMIYA,HYOGO 663,JAPAN; HYOGO MED UNIV,DEPT PHARMACEUT,NISHINOMIYA,HYOGO 663,JAPAN	Japanese Foundation for Cancer Research; Hyogo College of Medicine; University of Hyogo; Hyogo College of Medicine; University of Hyogo			Horii, Akira/AAW-2839-2021	Horii, Akira/0000-0002-3967-3291				AMICO DD, 1992, CANCER RES, V52, P1996; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORII A, 1992, CANCER RES, V52, P6696; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KANEKO K, 1991, NUCLEIC ACIDS RES, V19, P6059, DOI 10.1093/nar/19.21.6059-a; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; LOPEZGALINDEZ C, 1988, P NATL ACAD SCI USA, V85, P3522, DOI 10.1073/pnas.85.10.3522; MIKI Y, 1992, GENE CHROMOSOME CANC, V4, P81, DOI 10.1002/gcc.2870040112; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1992, CANCER RES, V52, P4055; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SATO T, 1990, CANCER RES, V50, P7184; TAKEDA S, 1993, IN PRESS HUM MUT, V2; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	33	142	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2399	2405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395678				2022-12-17	WOS:A1993LT36800010
J	Zhang, CZ; Huang, SZ; Zhuang, HK; Ruan, SY; Zhou, ZX; Huang, KJ; Ji, F; Ma, ZY; Hou, BH; He, XS				Zhang, Chuanzhao; Huang, Shanzhou; Zhuang, Hongkai; Ruan, Shiye; Zhou, Zixuan; Huang, Kaijun; Ji, Fei; Ma, Zuyi; Hou, Baohua; He, Xiaoshun			YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation	ONCOGENE			English	Article							MICRORNAS	N-6-methyladenosine (m6A) RNA methylation contributes to the cancer stem cell (CSC) phenotype through regulating gene expression. YTHDF2, an m6A reader, was shown to be associated with hepatocellular carcinoma (HCC) patient prognosis. However, the effect of YTHDF2 on liver CSC and cancer metastasis and the molecular mechanism of this effect have not been documented. Here, we show that YTHDF2 expression is negatively correlated with HCC patient survival in both data from the Cancer Genome Atlas (TCGA) database and clinical data from our center. By detecting CD133(+) cells and carrying out sphere culture assays, we found that knockdown of YTHDF2 led to impaired stemness in Hep3B and Huh7 cells. In contrast, overexpression of YTHDF2 increased the CSC phenotype. Mechanistically, the knockdown and overexpression of YTHDF2 in liver cancer cells resulted in decreased and increased m6A levels in the 5 '-untranslated region (UTR) of OCT4 mRNA, respectively, leading to decreased and increased OCT4 protein expression, respectively. A luciferase activity assay showed that mutation of the corresponding m6A methylation sequence in the 5 '-UTR of OCT4 mRNA caused significantly decreased gene expression, suggesting a role for YTHDF2-dependent m6A methylation in protein translation. Polysome profiling results also indicated the knockdown and overexpression of YTHDF2 could decrease and increase OCT4 translation, respectively. In particular, overexpression of OCT4 rescued the impaired stemness caused by YTHDF2 depletion, which confirmed the effect of YTHDF2 on CSC phenotype is dependent on OCT4. In vivo, the loss of YTHDF2 reduced tumor burden and inhibited lung metastasis following orthotopic transplantation in nude mice. Last, we demonstrated that YTHDF2 expression is positively correlated with OCT4 expression and m6A levels in the 5 '-UTR of OCT4 mRNA in clinical HCC specimens. In conclusion, YTHDF2 promotes the CSC liver phenotype and cancer metastasis by modulating the m6A methylation of OCT4 mRNA.	[Zhang, Chuanzhao; Huang, Shanzhou; Zhuang, Hongkai; Ruan, Shiye; Zhou, Zixuan; Huang, Kaijun; Ji, Fei; Ma, Zuyi; Hou, Baohua] South China Univ Technol, Sch Med, Guangdong Acad Med Sci, Dept Gen Surg,Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China; [Zhuang, Hongkai; Ma, Zuyi] Shantou Univ Med Coll, Shantou 515000, Guangdong, Peoples R China; [He, Xiaoshun] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510080, Peoples R China	Guangdong Academy of Medical Sciences & Guangdong General Hospital; South China University of Technology; Sun Yat Sen University	Zhang, CZ; Hou, BH (corresponding author), South China Univ Technol, Sch Med, Guangdong Acad Med Sci, Dept Gen Surg,Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China.; He, XS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510080, Peoples R China.	641703837@qq.com; 15917919681@163.com; 13922171191@163.com	zhang, chuanzhao/K-8624-2019		National Natural Science Foundation of China [81702783, 81672475]; Natural Science Foundation of Guangdong Province [2017A030310574]; Guangdong Medical Science and Technology Research Fund [A2019494, A2019252]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Medical Science and Technology Research Fund	This study was supported by the National Natural Science Foundation of China (project Nos.: 81702783 and 81672475), the Natural Science Foundation of Guangdong Province (project No.: 2017A030310574), and Guangdong Medical Science and Technology Research Fund (A2019494 and A2019252).	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao GC, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160003; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen T, 2015, CELL STEM CELL, V16, P289, DOI 10.1016/j.stem.2015.01.016; Faye MD, 2014, JOVE-J VIS EXP, DOI 10.3791/52295; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Han DL, 2019, NATURE, V566, P270, DOI 10.1038/s41586-019-0916-x; Li MM, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1436-y; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Song YY, 2015, GASTROENTEROLOGY, V149, P1068, DOI 10.1053/j.gastro.2015.06.010; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Villanueva A, 2013, NAT REV GASTRO HEPAT, V10, P34, DOI 10.1038/nrgastro.2012.199; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015; Yang Z, 2017, J BIOL CHEM, V292, P3614, DOI 10.1074/jbc.M116.749689; Zhang CZ, 2016, ONCOTARGET, V7, P64527, DOI 10.18632/oncotarget.11743; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhao BS, 2018, RNA, V24, P268, DOI 10.1261/rna.064295.117; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhou J, 2015, NATURE, V526, P591, DOI 10.1038/nature15377; Zhu PP, 2015, J CLIN INVEST, V125, P3795, DOI 10.1172/JCI81979	24	141	148	13	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4507	4518		10.1038/s41388-020-1303-7	http://dx.doi.org/10.1038/s41388-020-1303-7		MAY 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32366907				2022-12-17	WOS:000530271400004
J	Liu, F; Yuan, JH; Huang, JF; Yang, F; Wang, TT; Ma, JZ; Zhang, L; Zhou, CC; Wang, F; Yu, J; Zhou, WP; Sun, SH				Liu, F.; Yuan, J-H; Huang, J-F; Yang, F.; Wang, T-T; Ma, J-Z; Zhang, L.; Zhou, C-C; Wang, F.; Yu, J.; Zhou, W-P; Sun, S-H			Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a	ONCOGENE			English	Article							INACTIVATION CENTER REGION; CHROMATIN-STRUCTURE; MIRNA PROMOTERS; LIVER-CANCER; SURVIVAL; DISEASE; EPIDEMIOLOGY; PROGRESSION; ACTIVATION; EXPRESSION	It has long been known that males are more susceptible than females to hepatocellular carcinoma (HCC), but the reason remains elusive. In this study, we investigated the expression and function of the long noncoding RNA FTX (lnc-FTX), an X-inactive-specific transcript (XIST) regulator transcribed from the X chromosome inactivation center, in both HCC and HCC gender disparity. lnc-FTX is expressed at higher levels in female livers than in male livers and is significantly downregulated in HCC tissues compared with normal liver tissues. Patients with higher lnc-FTX expression exhibited longer survival, suggesting that lnc-FTX is a useful prognostic factor for HCC patients. lnc-FTX inhibits HCC cell growth and metastasis both in vitro and in vivo. Mechanistically, lnc-FTX represses Wnt/beta-catenin signaling activity by competitively sponging miR-374a and inhibits HCC cell epithelial-mesenchymal transition and invasion. In addition, lnc-FTX binds to the DNA replication licensing factor MCM2, thereby impeding DNA replication and inhibiting proliferation in HCC cells. In conclusion, these findings suggest that lnc-FTX may act as a tumor suppressor in HCC through physically binding miR-374a and MCM2. It may also be one of the reasons for HCC gender disparity and may potentially contribute to HCC treatment.	[Liu, F.; Yuan, J-H; Huang, J-F; Yang, F.; Wang, T-T; Ma, J-Z; Zhang, L.; Zhou, C-C; Wang, F.; Sun, S-H] Second Mil Med Univ, Dept Med Genet, 800 Xiang Yin Rd, Shanghai 200433, Peoples R China; [Yu, J.; Zhou, W-P] Second Mil Med Univ, Eastern Hepatobiliary Hosp, Dept Hepat Surg 3, Shanghai, Peoples R China	Naval Medical University; Naval Medical University	Sun, SH (corresponding author), Second Mil Med Univ, Dept Med Genet, 800 Xiang Yin Rd, Shanghai 200433, Peoples R China.	shsun@vip.sina.com	Zhou, Weiping/AGI-5344-2022; Yang, Fu/L-8441-2019; Yang, Fu/C-3786-2008; Ma, Jinzhao/M-6520-2014; Yuan, Ji-hang/AAH-4918-2021	Yang, Fu/0000-0003-2459-3923; Ma, Jinzhao/0000-0002-9367-6602; , Jin-Feng/0000-0002-4757-3418	State Key Program of National Natural Science Foundation of China [81330037]; National Key Basic Research Program of China (973 Program) [2015CB554004]; National Natural Science Foundation of China [31201025, 81301831, 81301692, 81472691, 81402269]; National Natural Science Foundation of Shanghai [13ZR1448300]	State Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Shanghai	We thank Dr Le Qu and Mr Zhi-peng Xu from Department of Urology, Shanghai Changzheng Hospital and Dr Sheng-Xian Yuan and Dr Qi-Fei Tao from the Third Department of Hepatic Surgery, Eastern Hepatobiliary Hospital for technical assistance. This work was supported by grants from the State Key Program of National Natural Science Foundation of China (grant nos 81330037), the National Key Basic Research Program of China (973 Program) (grant nos 2015CB554004), the National Natural Science Foundation of China (grant nos 31201025, 81301831, 81301692, 81472691 and 81402269, and the National Natural Science Foundation of Shanghai (13ZR1448300).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Buch SC, 2008, HEPATOL INT, V2, P95, DOI 10.1007/s12072-007-9041-2; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Chureau C, 2002, GENOME RES, V12, P894, DOI 10.1101/gr.152902; Chureau C, 2011, HUM MOL GENET, V20, P705, DOI 10.1093/hmg/ddq516; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dohmen K, 2003, J GASTROEN HEPATOL, V18, P267, DOI 10.1046/j.1440-1746.2003.02936.x; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351; Giaginis C, 2009, DIGEST DIS SCI, V54, P282, DOI 10.1007/s10620-008-0305-z; Hartwell HJ, 2014, P NATL ACAD SCI USA, V111, P11455, DOI 10.1073/pnas.1404267111; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ma Y, 2015, GUT; Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Quaglia A, 2006, LIVER INT, V26, P424, DOI 10.1111/j.1478-3231.2006.01242.x; Reena RMZ, 2008, ANN DIAGN PATHOL, V12, P340, DOI 10.1016/j.anndiagpath.2008.04.001; Reiche K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106076; Remus D, 2009, CELL, V139, P719, DOI 10.1016/j.cell.2009.10.015; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shechter D, 2004, J BIOL CHEM, V279, P45586, DOI 10.1074/jbc.M407772200; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-93; Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295, DOI 10.3748/wjg.v13.i32.4295; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Sun Meiqian, 2010, Front Biosci (Elite Ed), V2, P829; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Xu D, 2013, HEPATOLOGY, V58, P739, DOI 10.1002/hep.26361; Yang DY, 2014, CANCER-AM CANCER SOC, V120, P3707, DOI 10.1002/cncr.28912; You XT, 2015, NAT NEUROSCI, V18, P603, DOI 10.1038/nn.3975; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011; Zinchuk V, 2007, ACTA HISTOCHEM CYTOC, V40, P101, DOI 10.1267/ahc.07002	39	141	144	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5422	5434		10.1038/onc.2016.80	http://dx.doi.org/10.1038/onc.2016.80			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27065331				2022-12-17	WOS:000386677800008
J	Josson, S; Gururajan, M; Sung, SY; Hu, P; Shao, C; Zhau, HE; Liu, C; Lichterman, J; Duan, P; Li, Q; Rogatko, A; Posadas, EM; Haga, CL; Chung, LWK				Josson, S.; Gururajan, M.; Sung, S. Y.; Hu, P.; Shao, C.; Zhau, H. E.; Liu, C.; Lichterman, J.; Duan, P.; Li, Q.; Rogatko, A.; Posadas, E. M.; Haga, C. L.; Chung, L. W. K.			Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis	ONCOGENE			English	Article							STEM-CELLS; CANCER PROGRESSION; METASTATIC-DISEASE; CHROMOSOME 12QF1; REACTIVE STROMA; BONE METASTASIS; LARGE ONCOSOMES; MICRORNA; GENE; ACTIVATION	Tumor-stromal interaction is a dynamic process that promotes tumor growth and metastasis via cell-cell interaction and extracellular vesicles. Recent studies demonstrate that stromal fibroblast-derived molecular signatures can be used to predict disease progression and drug resistance. To identify the epigenetic role of stromal noncoding RNAs in tumor-stromal interactions in the tumor microenvironment, we performed microRNA profiling of patient cancer-associated prostate stromal fibroblasts isolated by laser capture dissection microscopy and in bone-associated stromal models. We found specific upregulation of miR-409-3p and miR-409-5p located within the embryonically and developmentally regulated DLK1-DIO3 (delta-like 1 homolog-deiodinase, iodothyronine 3) cluster on human chromosome 14. The findings in cell lines were further validated in human prostate cancer tissues. Strikingly, ectopic expression of miR-409 in normal prostate fibroblasts conferred a cancer-associated stroma-like phenotype and led to the release of miR-409 via extracellular vesicles to promote tumor induction and epithelial-to-mesenchymal transition in vitro and in vivo. miR-409 promoted tumorigenesis through repression of tumor suppressor genes such as Ras suppressor 1 and stromal antigen 2. Thus, stromal fibroblasts derived miR-409-induced tumorigenesis, epithelial-to-mesenchymal transition and stemness of the epithelial cancer cells in vivo. Therefore, miR-409 appears to be an attractive therapeutic target to block the vicious cycle of tumor-stromal interactions that plagues prostate cancer patients.	[Josson, S.; Gururajan, M.; Hu, P.; Shao, C.; Zhau, H. E.; Liu, C.; Lichterman, J.; Duan, P.; Posadas, E. M.; Chung, L. W. K.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA; [Sung, S. Y.] Taipei Med Univ, Phd Program Translat Med, Taipei, Taiwan; [Li, Q.; Rogatko, A.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Biostat & Bioinformat, Los Angeles, CA 90048 USA; [Haga, C. L.] Scripps Res Inst, Jupiter, FL USA	Cedars Sinai Medical Center; Taipei Medical University; Cedars Sinai Medical Center; Scripps Research Institute	Josson, S (corresponding author), Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA.	Sajni.Josson@cshs.org; Murali.Gururajan@cshs.org; Leland.Chung@cshs.org	Li, Quanlin/H-2358-2015	Li, Quanlin/0000-0002-3876-0617; Lichterman, Jake/0000-0002-3428-1555	TSRI Stem Cell fellowship;  [P01-CA98912];  [DAMD-17-03-02-0033];  [RO1-CA122602];  [TMU102-AE-B01];  [NSC102-2320-B-039-058];  [MOHW103-TD-B-111-01]; NATIONAL CANCER INSTITUTE [R01CA122602, P01CA098912] Funding Source: NIH RePORTER	TSRI Stem Cell fellowship; ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by a grant from P01-CA98912, DAMD-17-03-02-0033, RO1-CA122602 (LWKC) and TMU102-AE-B01, NSC102-2320-B-039-058, and MOHW103-TD-B-111-01 (S-YS). Dr Haga is funded by the TSRI Stem Cell fellowship. We thank Dr Ladan Fazli for providing the Gleason score tissue array. We also thank Dror Berel for helping with the statistical analysis.	Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; Di Vizio D, 2012, AM J PATHOL, V181, P1573, DOI 10.1016/j.ajpath.2012.07.030; Di Vizio D, 2009, CANCER RES, V69, P5601, DOI 10.1158/0008-5472.CAN-08-3860; Dougherty GW, 2008, EUR J CELL BIOL, V87, P721, DOI 10.1016/j.ejcb.2008.02.011; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Freeman MR, 2013, CLIN CANCER RES, V19, P4905, DOI 10.1158/1078-0432.CCR-13-1694; Gonzalez-Nieves R, 2013, J CELL COMMUN SIGNAL, V7, P279, DOI 10.1007/s12079-013-0207-5; Gross M, 2007, CLIN CANCER RES, V13, P1979, DOI 10.1158/1078-0432.CCR-06-1156; Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761; Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352; Hu PZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028670; Josson S, 2008, PROSTATE, V68, P1599, DOI 10.1002/pros.20827; Josson S, 2011, CANCER RES, V71, P2600, DOI 10.1158/0008-5472.CAN-10-3382; Kim MS, 2012, NEOPLASMA, V59, P524, DOI 10.4149/neo_2012_067; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lempiainen H, 2013, TOXICOL SCI, V131, P375, DOI 10.1093/toxsci/kfs303; Lim L, 2014, HEPATOLOGY, V59, P202, DOI 10.1002/hep.26662; Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995; Luk JM, 2011, J BIOL CHEM, V286, P30706, DOI 10.1074/jbc.M111.229831; Morello M, 2013, CELL CYCLE, V12, P3526, DOI 10.4161/cc.26539; Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405; Nguyen HCN, 2013, PROSTATE, V73, P346, DOI 10.1002/pros.22572; Nomura T, 2006, CLIN CANCER RES, V12, P7294, DOI 10.1158/1078-0432.CCR-06-2060; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008-5472.CAN-08-2492; THALMANN GN, 1994, CANCER RES, V54, P2577; Wang JG, 2010, MAGNETIC FRINGE FIELDS AND INTERFERENCE IN HIGH INTENSITY ACCELERATORS, P1; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690; Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109	35	141	144	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2690	2699		10.1038/onc.2014.212	http://dx.doi.org/10.1038/onc.2014.212			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25065597				2022-12-17	WOS:000354979500002
J	Cai, LM; Lyu, XM; Luo, WR; Cui, XF; Ye, YF; Yuan, CC; Peng, QX; Wu, DH; Liu, TF; Wang, E; Marincola, FM; Yao, KT; Fang, WY; Cai, HB; Li, X				Cai, L-M; Lyu, X-M; Luo, W-R; Cui, X-F; Ye, Y-F; Yuan, C-C; Peng, Q-X; Wu, D-H; Liu, T-F; Wang, E.; Marincola, F-M; Yao, K-T; Fang, W-Y; Cai, H-B; Li, X.			EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; ENCODED MICRORNAS; TARGETING PTEN; LUNG-CANCER; E-CADHERIN; EXPRESSION; PROTEIN; INVASION	The epithelial-mesenchymal transition (EMT) is crucial to cancer progression and metastasis. Although multiple cellular miRNAs have been identified to regulate the EMT and metastasis in cancers, the role of viral miRNAs in cancer progression remains largely unknown. Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy typically characterized by its early metastasis. In the present study, we have discovered the involvement of a viral miRNA, EBV-miR-BART7-3p, in the EMT and metastasis of NPC cells. Initially, we observed that EBV-miR-BART7-3p was highly expressed in NPC and positively correlated with lymph node metastasis and clinical stage of NPC. Subsequently, we demonstrated that EBV-miR-BART7-3p enhanced cell migration/invasion in vitro, cancer metastasis in vivo, and particularly the EMT characterized by loss of epithelial markers and gain of mesenchymal features in NPC cells. Furthermore, mechanistic studies disclosed that EBV-miR-BART7-3p targeted a major human tumor suppressor PTEN, modulating PI3K/Akt/GSK-3 beta signaling and eventually leading to the high expression and nuclear accumulation of Snail and beta-catenin, which favor EMT. Knockdown of PTEN could phenocopy the effect of EBV-miR-BART7-3p, whereas re-expression of PTEN resulted in a phenotypic reversion. Moreover, these findings were supported by an observation of an EBV-positive cell model in which silencing of endogenous EBV-miR-BART7-3p partially attenuated cell migration/invasion and altered EMT protein expression pattern via reverting PI3K/Akt, Snail and beta-catenin expression. Thus, this study suggests a novel mechanism by which EBV-miR-BART7-3p modulates the EMT and metastasis of NPC cells, and a clinical implication of EBV-miR-BART7-3p as a potential biomarker or therapeutic target.	[Cai, L-M; Lyu, X-M; Luo, W-R; Ye, Y-F; Yuan, C-C; Yao, K-T; Fang, W-Y; Li, X.] Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China; [Lyu, X-M] Southern Med Univ, Dept Lab Med, Affiliated Hosp 3, Guangzhou 510515, Guangdong, Peoples R China; [Cui, X-F] 463 Hosp Chinese PLA, Dept ENT, Shenyang, Peoples R China; [Peng, Q-X; Cai, H-B] Southern Med Univ, Sch Chinese Tradit Med, Guangzhou 510515, Guangdong, Peoples R China; [Wu, D-H] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Liu, T-F] Southern Med Univ, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Wang, E.; Marincola, F-M] NIH, Infect Dis & Immunogenet Sect, DTM, Ctr Clin, Bethesda, MD 20892 USA	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Li, X (corresponding author), Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China.	fangweiyi1975@yahoo.com.cn; chbing2008@126.com; xinli268@gmail.com	Luo, Weiren/AAI-8364-2020; Lyu, Xiaoming/AAC-8564-2020	Luo, Weiren/0000-0002-2762-6332; Lyu, Xiaoming/0000-0002-6243-3536; Li, Xin/0000-0003-0958-1078	National Natural Science Foundation of China [81372895, 81172586]; Research Fund for the Doctoral Program of Higher Education of China [20134433110013]; Natural Science Foundation of Guangdong Province [S2011010004157]; Guangzhou Science and Technology research project [2014J4100149]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology research project	This study was financially supported by grants from National Natural Science Foundation of China (No. 81372895, 81172586), Research Fund for the Doctoral Program of Higher Education of China (No. 20134433110013), Natural Science Foundation of Guangdong Province (No. S2011010004157) and Guangzhou Science and Technology research project (No. 2014J4100149).	Barth S, 2008, NUCLEIC ACIDS RES, V36, P666, DOI 10.1093/nar/gkm1080; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Cai Xuezhong, 2006, PLoS Pathogens, V2, P236, DOI 10.1371/journal.ppat.0020023; Cao MR, 2012, INT J ONCOL, V41, P869, DOI 10.3892/ijo.2012.1535; Chan JYW, 2012, ANTICANCER RES, V32, P3201; Chen DY, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-50; Chen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056929; Chen SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012745; Choi H, 2013, J VIROL, V87, P8135, DOI 10.1128/JVI.03159-12; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998; Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Ho FCH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-98; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Hsu CY, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003974; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Iwakiri D, 2005, ONCOGENE, V24, P1767, DOI 10.1038/sj.onc.1208357; Johansson J, 2013, ONCOGENE, V32, P5614, DOI 10.1038/onc.2013.322; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Ke Y, 2013, BIOCHEM RES INT, V2013, DOI 10.1155/2013/506731; Kim DN, 2007, J VIROL, V81, P1033, DOI 10.1128/JVI.02271-06; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lei T, 2013, INT J CANCER, V133, P79, DOI 10.1002/ijc.28007; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu HO, 2012, CANCER SCI, V103, P2072, DOI 10.1111/cas.12017; Lo AKF, 2012, J PATHOL, V227, P392, DOI 10.1002/path.4025; Lo AKF, 2007, P NATL ACAD SCI USA, V104, P16164, DOI 10.1073/pnas.0702896104; Lung RWM, 2009, NEOPLASIA, V11, P1174, DOI 10.1593/neo.09888; Luo ZH, 2013, CARCINOGENESIS, V34, P415, DOI 10.1093/carcin/bgs329; Luo Zhaohui, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P604, DOI 10.3969/j.issn.1672-7347.2011.07.004; Lyu XM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-51; McLaughlin-Drubin ME, 2008, BBA-MOL BASIS DIS, V1782, P127, DOI 10.1016/j.bbadis.2007.12.005; MIN HQ, 1994, INT J RADIAT ONCOL, V30, P1037; Mishra Prajna, 2010, J Mol Signal, V5, P9, DOI 10.1186/1750-2187-5-9; Nachmani D, 2009, CELL HOST MICROBE, V5, P376, DOI 10.1016/j.chom.2009.03.003; Pagano JS, 1999, P ASSOC AM PHYSICIAN, V111, P573, DOI 10.1046/j.1525-1381.1999.t01-1-99220.x; Pan YR, 2008, CELL MICROBIOL, V10, P2447, DOI 10.1111/j.1462-5822.2008.01221.x; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Qiu J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002193; Qu CJ, 2012, CELL CYCLE, V11, P785, DOI 10.4161/cc.11.4.19228; Ramakrishnan R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027271; Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Talbot Lindsay J, 2012, Int J Biochem Mol Biol, V3, P117; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Villarejo A, 2014, J BIOL CHEM, V289, P930, DOI 10.1074/jbc.M113.528026; Wang X, 2008, ONCOGENE, V27, P5454, DOI 10.1038/onc.2008.242; Wong AMG, 2012, CANCER-AM CANCER SOC, V118, P698, DOI 10.1002/cncr.26309; Yang HJ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-314; Ye YF, 2013, BIOCHEM BIOPH RES CO, V436, P19, DOI 10.1016/j.bbrc.2013.05.008; Zhang GJ, 2014, DIGEST DIS SCI, V59, P98, DOI 10.1007/s10620-013-2858-8; Zhang J. P., 2013, ONCOGENE, V33, P4069; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6; Zhang LY, 2013, CARCINOGENESIS, V34, P454, DOI 10.1093/carcin/bgs346; Zheng HX, 2013, EUR J CANCER, V49, P2734, DOI 10.1016/j.ejca.2013.03.014	63	141	150	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2156	2166		10.1038/onc.2014.341	http://dx.doi.org/10.1038/onc.2014.341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	25347742				2022-12-17	WOS:000353473000002
J	Wang, F; Chan, CH; Chen, K; Guan, X; Lin, HK; Tong, Q				Wang, F.; Chan, C-H; Chen, K.; Guan, X.; Lin, H-K; Tong, Q.			Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation	ONCOGENE			English	Article						sirtuin; E3 ubiquitin ligase; Forkhead transcription factor; ubiquitination; acetylation; proteasomal degradation	TRANSCRIPTION FACTOR AFX; FORKHEAD TRANSCRIPTION; OXIDATIVE-STRESS; LIFE-SPAN; PROMOTES TUMORIGENESIS; NUCLEAR TRANSLOCATION; CELL-SURVIVAL; E3 LIGASE; CANCER; PHOSPHORYLATION	Sirtuin deacetylases and FOXO (Forkhead box, class O) transcription factors have important roles in many biological pathways, including cancer development. SIRT1 and SIRT2 deacetylate FOXO factors to regulate FOXO function. Because acetylation and ubiquitination both modify the epsilon-amino group of lysine residues, we investigated whether FOXO3 deacetylation by SIRT1 or SIRT2 facilitates FOXO3 ubiquitination and subsequent proteasomal degradation. We found that SIRT1 and SIRT2 promote FOXO3 poly-ubiquitination and degradation. Proteasome-inhibitor treatment prevented sirtuin-induced FOXO3 degradation, indicating that this process is proteasome dependent. In addition, we demonstrated that E3 ubiquitin ligase subunit Skp2 binds preferentially to deacetylated FOXO3. Overexpression of Skp2 caused poly-ubiquitination of FOXO3 and degradation, whereas knockdown of Skp2 increased the amount of FOXO3 protein. We also present evidence that SCF-Skp2 ubiquitinates FOXO3 directly in vitro. Furthermore, mutating four known acetylated lysine residues (K242, K259, K290 and K569) of FOXO3 into arginines to mimic deacetylated FOXO3 resulted in enhanced Skp2 binding but with inhibition of FOXO3 ubiquitination; this suggests that some or all of these four lysine residues are likely the sites for ubiquitination. In the livers of mice deficient in SIRT1, we detected increased expression of FOXO3, indicating SIRT1 regulates FOXO3 protein levels in vivo. Furthermore, we found that the elevation of SIRT1 and Skp2 expression in malignant PC3 and DU145 prostate cells is responsible for the downregulation of FOXO3 protein levels in these cells. Taken together, our data support the notion that deacetylation of FOXO3 by SIRT1 or SIRT2 facilitates Skp2-mediated FOXO3 poly-ubiquitination and proteasomal degradation. Oncogene (2012) 31, 1546-1557; doi:10.1038/onc.2011.347; published online 15 August 2011	[Wang, F.; Chen, K.; Guan, X.; Tong, Q.] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA; [Chan, C-H; Lin, H-K] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Tong, Q (corresponding author), Baylor Coll Med, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.	qtong@bcm.tmc.edu	高, 雨莉/HGU-8187-2022		Ellison Medical Foundation/American Federation for Aging Research; US Department of Agriculture [6250-51000-055]; NIH [DK075978]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075978] Funding Source: NIH RePORTER	Ellison Medical Foundation/American Federation for Aging Research(Lawrence Ellison Foundation); US Department of Agriculture(United States Department of Agriculture (USDA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Xinhua Feng for providing HA-ubiquitin expression plasmid and Dr Jianping Jin for providing HeLa cells stably transfected with His-Biotin-Ubiquitin. We thank Dr Steven I Reed for providing pcDNA-hSkp1, pcDNA-Cul1, pcDNA-Roc1 constructs, and Dr Anne Brunet for providing pECE-FOXO3-M2 wild-type and K242R, K259R, K290R, K569R individual mutants and 4KR mutants, Dr Tony Kouzarides for providing pcDNA-SIRT1, Dr Junjie Chen for providing pcDNA-SIRT1-H363Y plasmid and Dr Boudewijn MT Burgering for providing 6X DBE-Luc construct. We thank Dr Frederic Alt for providing SIRT1 knockout mice. FW was supported by the Ellison Medical Foundation/American Federation for Aging Research senior postdoctoral fellowship. This work was also supported by the US Department of Agriculture grant (6250-51000-055) and NIH (DK075978) to QT.	Arden KC, 2008, ONCOGENE, V27, P2345, DOI 10.1038/onc.2008.27; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Fukuoka M, 2003, INT J MOL MED, V12, P503; Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kaeberlein M, 2005, PLOS GENET, V1, P614, DOI 10.1371/journal.pgen.0010069; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lamming DW, 2005, SCIENCE, V309, P1861, DOI 10.1126/science.1113611; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Perrot V, 2005, MOL ENDOCRINOL, V19, P2283, DOI 10.1210/me.2004-0292; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ravid T, 2007, NAT CELL BIOL, V9, P422, DOI 10.1038/ncb1558; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Schwer B, 2008, CELL METAB, V7, P104, DOI 10.1016/j.cmet.2007.11.006; Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Sung JY, 2010, CANCER SCI, V101, P1738, DOI 10.1111/j.1349-7006.2010.01573.x; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Verdin E, 2007, MOL CELL, V28, P354, DOI 10.1016/j.molcel.2007.10.013; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang F, 2009, MOL BIOL CELL, V20, P801, DOI 10.1091/mbc.E08-06-0647; Wang JD, 2010, J BIOL CHEM, V285, P11458, DOI 10.1074/jbc.M109.087585; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	66	141	146	0	35	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1546	1557		10.1038/onc.2011.347	http://dx.doi.org/10.1038/onc.2011.347			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21841822				2022-12-17	WOS:000302132000007
J	Gery, S; Virk, RK; Chumakov, K; Yu, A; Koeffler, HP				Gery, S.; Virk, R. K.; Chumakov, K.; Yu, A.; Koeffler, H. P.			The clock gene Per2 links the circadian system to the estrogen receptor	ONCOGENE			English	Article						circadian rhythms; ER alpha; breast cancer; Per2; transcriptional activation; estrogen	EXPRESSION; CANCER; MOUSE	Circadian rhythms regulate diverse physiological processes including homeostatic functions of steroid hormones and their receptors. Estrogen receptor-alpha (ER alpha) is essential for normal mammary gland physiology and is a prognostic marker for the treatment of breast cancer. We report that Per2, a core clock gene, links the circadian cycle to the ER alpha signaling network. Binding of enhances ER alpha degradation, while suppression of Per2 levels leads to ER alpha stabilization. In turn, Per2 itself is estrogen inducible in these cells, suggesting a feedback mechanism to attenuate stimulation by estrogen. In addition, overexpression of Per2 in breast cancer cells leads to significant growth inhibition, loss of clonogenic ability and apoptosis. Taken together, these results further support a critical role for peripheral circadian regulation in tissue homeostasis and suggest a novel role for clock genes in estrogen receptor-positive breast cancer.	[Gery, S.; Virk, R. K.; Chumakov, K.; Yu, A.; Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, UCLA Sch Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gery, S (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Div Hematol Oncol, UCLA Sch Med, Davis Bldg 5066,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org						Chen ST, 2005, CARCINOGENESIS, V26, P1241, DOI 10.1093/carcin/bgi075; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106; Hansen J, 2001, JNCI-J NATL CANCER I, V93, P1513, DOI 10.1093/jnci/93.20.1513; Hua H, 2006, CANCER SCI, V97, P589, DOI 10.1111/j.1349-7006.2006.00225.x; Ishida N, 2007, NEUROSCI RES, V57, P483, DOI 10.1016/j.neures.2006.12.012; Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207; Lowrey PL, 2004, ANNU REV GENOM HUM G, V5, P407, DOI 10.1146/annurev.genom.5.061903.175925; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Metz RP, 2006, DEV DYNAM, V235, P263, DOI 10.1002/dvdy.20605; Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104; Nakamura TJ, 2005, J NEUROSCI RES, V82, P622, DOI 10.1002/jnr.20677; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Perrin JS, 2006, P NATL ACAD SCI USA, V103, P5591, DOI 10.1073/pnas.0601310103; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Romagnolo D, 1998, MOL CARCINOGEN, V22, P102, DOI 10.1002/(SICI)1098-2744(199806)22:2<102::AID-MC5>3.0.CO;2-O; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050	26	141	145	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7916	7920		10.1038/sj.onc.1210585	http://dx.doi.org/10.1038/sj.onc.1210585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599055				2022-12-17	WOS:000252163500010
J	Hornberg, JJ; Binder, B; Bruggeman, FJ; Schoeberl, B; Heinrich, R; Westerhoff, HV				Hornberg, JJ; Binder, B; Bruggeman, FJ; Schoeberl, B; Heinrich, R; Westerhoff, HV			Control of MAPK signalling: from complexity to what really matters	ONCOGENE			English	Article						MAPK signalling; control analysis; kinetic model; systems biology	EPIDERMAL-GROWTH-FACTOR; METABOLIC CONTROL ANALYSIS; PROTEIN-KINASE CASCADES; FACTOR RECEPTOR; MATHEMATICAL-MODELS; DNA-SYNTHESIS; HUMAN CANCER; ACTIVATION; PATHWAY; PHOSPHORYLATION	Oncogenesis results from changes in kinetics or in abundance of proteins in signal transduction networks. Recently, it was shown that control of signalling cannot reside in a single gene product, and might well be dispersed over many components. Which of the reactions in these complex networks are most important, and how can the existing molecular information be used to understand why particular genes are oncogenes whereas others are not? We implement a new method to help address such questions. We apply control analysis to a detailed kinetic model of the epidermal growth factor-induced mitogen-activated protein kinase network. We determine the control of each reaction with respect to three biologically relevant characteristics of the output of this network: the amplitude, duration and integrated output of the transient phosphorylation of extracellular signal-regulated kinase (ERK). We confirm that control is distributed, but far from randomly: a small proportion of reactions substantially control signalling. In particular, the activity of Raf is in control of all characteristics of the transient profile of ERK phosphorylation, which may clarify why Raf is an oncogene. Most reactions that really matter for one signalling characteristic are also important for the other characteristics. Our analysis also predicts the effects of mutations and changes in gene expression.	Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, Inst Mol Cell Biol, NL-1085 HV Amsterdam, Netherlands; Merrimack Pharmaceut, Cambridge, England; Humboldt Univ, Dept Theoret Biophys, Berlin, Germany; Univ Amsterdam, Swammerdan Inst Life Sci, NL-1012 WX Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Humboldt University of Berlin; University of Amsterdam	Westerhoff, HV (corresponding author), Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Mol Cell Physiol, Inst Mol Cell Biol, Boelelaan 1085, NL-1085 HV Amsterdam, Netherlands.	hw@bio.vu.nl	Bruggeman, Frank/C-4356-2015; Westerhoff, Hans V/I-5762-2012; Bruggeman, Frank/AAS-8371-2020; damiani, chiara/R-4256-2016	Bruggeman, Frank/0000-0002-0255-4766; Westerhoff, Hans V/0000-0002-0443-6114; Bruggeman, Frank/0000-0002-0255-4766; 	Biotechnology and Biological Sciences Research Council [BB/C008219/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Asthagiri AR, 2001, BIOTECHNOL PROGR, V17, P227, DOI 10.1021/bp010009k; Asthagiri AR, 2000, J CELL SCI, V113, P4499; Bakker BM, 1999, J BIOL CHEM, V274, P14551, DOI 10.1074/jbc.274.21.14551; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; BOS JL, 1989, CANCER RES, V49, P4682; Bruggeman FJ, 2000, BIOL CHEM, V381, P965, DOI 10.1515/BC.2000.119; Bruggeman FJ, 2002, J THEOR BIOL, V218, P507, DOI 10.1006/jtbi.2002.3096; BUDAY L, 1995, ONCOGENE, V11, P1327; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GROEN AK, 1982, J BIOL CHEM, V257, P2754; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Hornberg JJ, 2005, FEBS J, V272, P244, DOI 10.1111/j.1432-1033.2004.04404.x; Hornberg JJ, 2004, EUR J BIOCHEM, V271, P3905, DOI 10.1111/j.1432-1033.2004.04327.x; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kholodenko BN, 2000, TRENDS CELL BIOL, V10, P173, DOI 10.1016/S0962-8924(00)01741-4; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; KHOLODENKO BN, 1993, FEBS LETT, V320, P71, DOI 10.1016/0014-5793(93)81660-R; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Periwal V, 2002, NAT BIOTECHNOL, V20, P345, DOI 10.1038/nbt0402-345; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; SCHUSTER R, 1995, EUR J BIOCHEM, V229, P403, DOI 10.1111/j.1432-1033.1995.tb20481.x; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Snoep JL, 2004, CURR GENOMICS, V5, P687, DOI 10.2174/1389202043348553; Teusink B, 2000, EUR J BIOCHEM, V267, P5313, DOI 10.1046/j.1432-1327.2000.01527.x; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Tombes RM, 1998, BIOCHEM J, V330, P1451; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Westerhoff H., 1987, THERMODYNAMICS CONTR	54	141	140	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5533	5542		10.1038/sj.onc.1208817	http://dx.doi.org/10.1038/sj.onc.1208817			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007170				2022-12-17	WOS:000231296100001
J	Yang, Y; Yang, F; Xiong, ZY; Yan, Y; Wang, XM; Nishino, M; Mirkovic, D; Nguyen, J; Wang, H; Yang, XF				Yang, Y; Yang, F; Xiong, ZY; Yan, Y; Wang, XM; Nishino, M; Mirkovic, D; Nguyen, J; Wang, H; Yang, XF			An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity	ONCOGENE			English	Article						Bcl-xL; TCTP; apoptosis; protein interaction	HISTAMINE-RELEASING-FACTOR; BCL-2 FAMILY-MEMBERS; CELL-DEATH; IDENTIFICATION; APOPTOSIS; INHIBITION; EXPRESSION; INTERACTS; BCL-X(L); FORTILIN	Bcl-xL plays a critical role in maintaining cell survival. However, the relationship between the potential interaction of Bcl-xL with other cytosolic proteins and the regulation of cell survival remains incompletely defined. We have identified translationally controlled tumor protein (TCTP), a multifunctional protein, as a novel antiapoptotic Bcl-xL-interacting protein. TCTP interacted in vivo and in vitro with Bcl-xL, and their sites have been mapped to an N- terminal region of TCTP and the Bcl-2 homology domain 3 of Bcl-xL. Consistent with a role in maintaining T-cell survival during activation, TCTP was significantly upregulated in murine T cells activated by T-cell antigen receptor (TCR) ligation and CD28 costimulation, which was correlated with the upregulation of Bcl-xL in activated T cells. Moreover, downregulation of TCTP expression by antisense technology in T cells results in the increase of T-cell apoptosis. Furthermore, the N-terminal region of TCTP was required for its ability to inhibit apoptosis. In conclusion, this study has demonstrated that an N-terminal region of a cytosolic protein, TCTP, is required for its binding to Bcl-xL and for its antiapoptotic activity.	Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Lab Immunopathol,Biol Inflammat Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; Univ Houston, Dept Comp Sci, Houston, TX 77204 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Houston System; University of Houston	Yang, XF (corresponding author), Baylor Coll Med, Sect Immunol Allergy & Rheumatol, Dept Med, Lab Immunopathol,Biol Inflammat Ctr, 1 Baylor Plaza,BCM 285,Suite 672E, Houston, TX 77030 USA.	xyang1@bcm.tmc.edu		Nishino, Michiya/0000-0003-4692-4981	NCI NIH HHS [P20 CA103698] Funding Source: Medline; NIAID NIH HHS [AI054514, K08 AI054514] Funding Source: Medline; NIDDK NIH HHS [P30 DK56238, R01 DK056238] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA103698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI054514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056238] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; ADAMS PD, 2002, PROTEIN PROTEIN INTE, P59; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Bangrak P, 2004, J BIOTECHNOL, V108, P219, DOI 10.1016/j.jbiotec.2003.12.007; Basu A, 2003, FEBS LETT, V538, P41, DOI 10.1016/S0014-5793(03)00131-5; Baudet C, 1998, CELL DEATH DIFFER, V5, P116, DOI 10.1038/sj.cdd.4400327; Biswas RS, 2001, MOL CELL BIOCHEM, V225, P7, DOI 10.1023/A:1012203110027; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bommer UA, 2004, INT J BIOCHEM CELL B, V36, P379, DOI 10.1016/S1357-2725(03)00213-9; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Diaz JL, 1997, J BIOL CHEM, V272, P11350; EINARSON M, 2002, IDENTIFICATION PROTE; FANG W, 1994, J IMMUNOL, V153, P4388; Gachet Y, 1999, J CELL SCI, V112, P1257; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Graidist P, 2004, J BIOL CHEM, V279, P40868, DOI 10.1074/jbc.M401454200; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kang HS, 2001, J IMMUNOL, V166, P6545, DOI 10.4049/jimmunol.166.11.6545; Kim M, 2000, ARCH PHARM RES, V23, P633, DOI 10.1007/BF02975253; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; Marrack P, 2004, ANNU REV IMMUNOL, V22, P765, DOI 10.1146/annurev.immunol.22.012703.104554; Mihara K, 2000, BIOESSAYS, V22, P364, DOI 10.1002/(SICI)1521-1878(200004)22:4<364::AID-BIES6>3.0.CO;2-N; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Schwartz RH, 2003, ANNU REV IMMUNOL, V21, P305, DOI 10.1146/annurev.immunol.21.120601.141110; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Shim J, 2002, MOL CELLS, V14, P323; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Vonakis BM, 2003, J IMMUNOL, V171, P3742, DOI 10.4049/jimmunol.171.7.3742; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XF, 2002, MOL IMMUNOL, V39, P45, DOI 10.1016/S0161-5890(02)00049-4; Yang XF, 2001, P NATL ACAD SCI USA, V98, P7492, DOI 10.1073/pnas.131590998; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Ye QR, 2002, J EXP MED, V196, P87, DOI 10.1084/jem.20012084; Yoon T, 2000, ARCH BIOCHEM BIOPHYS, V384, P379, DOI 10.1006/abbi.2000.2108; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	55	141	153	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4778	4788		10.1038/sj.onc.1208666	http://dx.doi.org/10.1038/sj.onc.1208666			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870695	Green Accepted			2022-12-17	WOS:000230477900004
J	Tselepis, C; Perry, I; Dawson, C; Hardy, R; Darnton, SJ; McConkey, C; Stuart, RC; Wright, N; Harrison, R; Jankowski, JAZ				Tselepis, C; Perry, I; Dawson, C; Hardy, R; Darnton, SJ; McConkey, C; Stuart, RC; Wright, N; Harrison, R; Jankowski, JAZ			Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action	ONCOGENE			English	Article						tumour necrosis factor-alpha (TNF-alpha); Barrett's oesophagus; cancer; cadherins and catenins	GROWTH-FACTOR RECEPTOR; BETA-CATENIN; CANCER; ESOPHAGUS; CELLS; INFLAMMATION; EXPRESSION; ADENOCARCINOMA; ACTIVATION; REGULATORS	Barrett's metaplasia (BM) is an early lesion in the progression from oesophageal inflammation through dysplasia to the development of Barrett's adenocarcinoma (BA). Previous work indicates that BM and BA are associated with reduced E-cadherin expression and increased cytoplasmic/nuclear pools of its associated protein beta-catenin. beta-catenin participates in Wnt signalling and activates oncogene transcription by complexing with T-cells factors (TCF). One such oncogene is c-myc. We have previously shown that TNF-alpha can down-regulate E-cadherin expression. Here, we assess TNF-alpha expression in Barrett's metaplasia and examine if TNF-alpha can promote beta-catenin mediated transcription of oncogenes in a gastrointestinal model system. Employing immunohistochemistry and Western blot analysis of oesophageal tissue, epithelial expression of TNF-alpha increases with progression along the metaplasia-dysplasia-carcinoma sequence (P<0.001). beta-catenin mediated transcription was then assessed in TNF-alpha stimulated cell lines using the TOPFLASH reporter system whilst c-myc expression was assessed by real time PCR. In a columnar intestinal cell model, TNF-alpha induces c-myc expression which is induced via beta-catenin mediated transcription (P<0.05). This beta-catenin mediated transcription is independent of NF-kappaB activation. Thus, TNF-alpha is up-regulated in the progression of Barrett's oesophagus and beta-catenin mediated transcription of c-myc is a novel pathway whereby elevated levels of TNF-alpha may lead to oncogene transcription and altered biology in gastrointestinal epithelia and metaplasia.	Univ Birmingham, Queen Elizabeth Hosp, Epithelial Lab, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Queen Elizabeth Hosp, CRVK Lab, Birmingham B15 2TH, W Midlands, England; Birmingham Heartlands Hosp, Oesophageal Res Lab, Birmingham B9 SS, W Midlands, England; Univ Glasgow, Lister Dept Surg, Histopathol Unit, Glasgow G31 2ER, Lanark, Scotland; Imperial Canc Res Fund, London WC2A 3PN, England; Univ Leicester, Dept Med, Leicester LE1 5WW, Leics, England; Univ Leicester, Dept Oncol, Leicester LE1 5WW, Leics, England	University of Birmingham; University of Birmingham; Heart of England NHS Foundation Trust; University of Glasgow; Cancer Research UK; University of Leicester; University of Leicester	Jankowski, JAZ (corresponding author), Leicester Royal Infirm, Dept Med & Oncol, Mycosal Biol Lab, Leicester LE1 5WW, Leics, England.		Jankowski, Janusz/H-2706-2012	Jankowski, Janusz/0000-0003-2130-9181; Wright, Nicholas/0000-0002-5525-3457				Bailey T, 1998, AM J PATHOL, V152, P135; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; COTTAM DW, 1993, INT J ONCOL, V2, P861; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Dixon MF, 2001, GUT, V49, P359, DOI 10.1136/gut.49.3.359; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Eliopoulos AG, 1997, ONCOGENE, V14, P2899, DOI 10.1038/sj.onc.1201258; Frommel TO, 1999, MED HYPOTHESES, V52, P27, DOI 10.1054/mehy.1997.0621; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Jankowski JA, 2000, LANCET, V356, P2079, DOI 10.1016/S0140-6736(00)03411-5; Jankowski JA, 2002, GASTROENTEROLOGY, V122, P588, DOI 10.1053/gast.2002.31599; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MENKEPLUYMERS MBE, 1992, GUT, V33, P1454, DOI 10.1136/gut.33.11.1454; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; NATHKE I, 1999, MOL PATHOL, V52, P166; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160; Perry I, 1999, LAB INVEST, V79, P1489; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; Schmitz H, 1999, J CELL SCI, V112, P137; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMAS P, 1997, BRIT J SURG, V84, P110; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X	34	141	148	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6071	6081		10.1038/sj.onc.1205731	http://dx.doi.org/10.1038/sj.onc.1205731			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203119				2022-12-17	WOS:000177671300010
J	Kyo, S; Inoue, M				Kyo, S; Inoue, M			Complex regulatory mechanisms of telomerase activity in normal and cancer cells: How can we apply them for cancer therapy?	ONCOGENE			English	Article						telomerase; regulation; normal cells; cancers	REVERSE-TRANSCRIPTASE GENE; CATALYTIC SUBUNIT HTERT; HISTONE DEACETYLASE INHIBITOR; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; HUMAN TUMOR-CELLS; BREAST-CANCER; C-MYC; RNA COMPONENT; INTRAEPITHELIAL NEOPLASIA	Telomerase activation is observed in almost 90% of human cancers but not in normal tissues of somatic origin and thus is a critical step for multistep carcinogenesis. A more thorough understanding of telomerase regulation may provide not only a molecular basis of cancer progression but also as a way to manipulate telomerase activity as a potential therapeutic modality. Recent progress in studies on telomerase regulation has shown that telomerase activation is achieved at various steps, including transcriptional and post-transcriptional levels of the telomerase reverse transcriptase (hTERT) gene. Although a number of potentially important mechanisms of telomerase activation have been proposed, none of the current models can fully explain tumor-specific activation of telomerase, suggesting a need for further extensive analysis. This review includes a summary of recent works on telomerase regulation and a discussion of how we can overcome this situation.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan	Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan.							Akalin A, 2001, CANCER RES, V61, P4791; Aldous WK, 1999, CANCER, V85, P1523, DOI 10.1002/(SICI)1097-0142(19990401)85:7<1523::AID-CNCR13>3.3.CO;2-G; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Clark GM, 1997, J NATL CANCER I, V89, P1874, DOI 10.1093/jnci/89.24.1874; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Ducrest AL, 2001, CANCER RES, V61, P7594; Engelhardt M, 1997, BLOOD, V90, P182; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Gu J, 2000, CANCER RES, V60, P5359; Gunes C, 2000, CANCER RES, V60, P2116; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Horikawa I, 1999, CANCER RES, V59, P826; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinoshita T, 1997, VIROLOGY, V232, P53, DOI 10.1006/viro.1997.8536; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Koga S, 2000, HUM GENE THER, V11, P1397, DOI 10.1089/10430340050057477; Komata T, 2001, CANCER RES, V61, P5796; Kunimura C, 1998, ONCOGENE, V17, P187, DOI 10.1038/sj.onc.1201916; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1996, CLIN CANCER RES, V2, P2023; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1998, INT J CANCER, V79, P66, DOI 10.1002/(SICI)1097-0215(19980220)79:1<66::AID-IJC13>3.0.CO;2-F; Kyo S, 1999, CANCER RES, V59, P5917; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sawa H, 1999, J NEURO-ONCOL, V42, P45, DOI 10.1023/A:1006176708928; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Snijders PJF, 1998, CANCER RES, V58, P3812; Soda H, 2000, PROSTATE, V43, P161, DOI 10.1002/(SICI)1097-0045(20000515)43:3<161::AID-PROS1>3.0.CO;2-O; Sowa Y, 1999, CANCER RES, V59, P4266; Stein GS, 2000, CANCER RES, V60, P2067; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Takakura M, 1998, CANCER RES, V58, P1558; Tanaka M, 1998, AM J PATHOL, V153, P1985, DOI 10.1016/S0002-9440(10)65712-4; Ulaner GA, 1998, CANCER RES, V58, P4168; Ulaner GA, 2000, INT J CANCER, V85, P330, DOI 10.1002/(SICI)1097-0215(20000201)85:3<330::AID-IJC6>3.0.CO;2-U; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang Z, 2000, CANCER RES, V60, P5376; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yasumoto S, 1996, ONCOGENE, V13, P433; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Zhang WB, 1998, CANCER RES, V58, P619; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	93	141	157	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					688	697		10.1038/sj.onc.1205163	http://dx.doi.org/10.1038/sj.onc.1205163			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850797	Bronze			2022-12-17	WOS:000173390500024
J	Dammann, R; Takahashi, T; Pfeifer, GP				Dammann, R; Takahashi, T; Pfeifer, GP			The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas	ONCOGENE			English	Article						RASSF1; methylation; CpG island; tumor suppressor gene; small cell lung cancer; 3p21	HUMAN-CHROMOSOME 3P21.3; ONCOGENIC RAS; DNA HYPERMETHYLATION; HOMOZYGOUS DELETIONS; DENOVO METHYLATION; ALLELIC LOSS; CANCER; LINES; 3P; APOPTOSIS	Loss of heterozygosity at 3p21.3 occurs in more than 90% of small cell lung carcinomas (SCLCs). The Ras association domain family 1 (RASSF1) gene cloned from the lung tumor suppressor locus 3p21.3 consists of two major alternative transcripts, RASSF1A and RASSF1C. Epigenetic inactivation of isoform A (RASSF1A) was observed in 40% of primary non-small cell lung carcinomas and in several tumor cell lines. Transfection of RASSF1A suppressed the growth of lung cancer cells in vitro and in nude mice. Here we have analysed the methylation status of the CPG island promoters of RASSF1A and RASSF1C in primary SCLCs. In 22 of 28 SCLCs (=79%) the promoter of RASSF1A was highly methylated at all CpG sites analysed, None of the SCLCs showed evidence for methylation of the CpG island of RASSF1C. The results suggest that hypermethylation of the CpG island promoter of the RASSF1A gene is associated with SCLC pathogenesis.	City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Aichi Canc Ctr, Inst Res, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	City of Hope; Beckman Research Institute of City of Hope; Aichi Cancer Center	Pfeifer, GP (corresponding author), City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.		Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Girard L, 2000, CANCER RES, V60, P4894; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Palmisano WA, 2000, CANCER RES, V60, P5954; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; THIBERVILLE L, 1995, CANCER RES, V55, P5133; Todd S, 1997, CANCER RES, V57, P1344; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WAGNER SN, 1993, VIRCHOWS ARCH B, V63, P325, DOI 10.1007/BF02899279; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wu WG, 1999, CANCER RES, V59, P1846; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Yatabe Y, 2000, AM J PATHOL, V157, P985, DOI 10.1016/S0002-9440(10)64611-1; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	46	141	157	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3563	3567		10.1038/sj.onc.1204469	http://dx.doi.org/10.1038/sj.onc.1204469			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429703				2022-12-17	WOS:000169478300012
J	Bowers, G; Reardon, D; Hewitt, T; Dent, P; Mikkelsen, RB; Valerie, K; Lammering, G; Amir, C; Schmidt-Ullrich, RK				Bowers, G; Reardon, D; Hewitt, T; Dent, P; Mikkelsen, RB; Valerie, K; Lammering, G; Amir, C; Schmidt-Ullrich, RK			The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells	ONCOGENE			English	Review						radiation; ErbB; EGF; tyrphostins; mammary carcinoma cells	EPIDERMAL GROWTH-FACTOR; IONIZING-RADIATION; HYDROGEN-PEROXIDE; CANCER-CELLS; FACTOR-ALPHA; ACTIVATION; EXPRESSION; PHOSPHORYLATION; PATHWAY; HETERODIMERIZATION	Activation of the epidermal growth receptor (ErbB1) occurs within minutes of a radiation exposure. Immediate downstream consequences of this activation are currently indistinguishable from those obtained with growth factors (GF), e.g. stimulation of the pro-proliferative mitogen-activated protein kinase (MAPK). To identify potential differences, the effects of GFs and radiation on other members of the ErbB family have been compared in mammary carcinoma cell lines differing in their ErbB expression profiles. Treatment of cells with EGF (ErbB1-specific) or heregulin (ErbB4-specific) resulted in a hierarchic transactivations of ErbB2 and ErbB3 dependent on GF binding specificity. In contrast, radiation indiscriminately activated all ErbB species with the activation profile reflecting that cell's ErbB expression profile. Downstream consequences of these ErbB interactions were examined with MAPK after specifically inhibiting ErbB1 (or 4) with tyrphostin AG1478 or ErbB2 with tyrphostin AG825. MAPK activation by GFs or radiation was completely inhibited by AG1478 indicating total dependance on ErbB1 (or 4) depending on which ErbB is expressed. Inhibiting ErbB2 caused an enhanced MAPK response simulating an amplified ErbB1 (or 4) response. Thus ErbB2 is a modulator of ErbB1 (or 4) function leading to different MAPK response profiles to GF or radiation exposure.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA; Univ Louisiana, Dept Basic Pharmaceut Sci, Monroe, LA USA; Univ Dusseldorf, Dept Radiat Oncol, Duesseldorf, Germany	Virginia Commonwealth University; Emory University; University of Louisiana System; University of Louisiana Monroe; Heinrich Heine University Dusseldorf	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [R01 CA 65896, P01 CA 72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Chen BK, 2000, MOL PHARMACOL, V57, P153; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Frederick L, 2000, CANCER RES, V60, P1383; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gulliford TJ, 1997, ONCOGENE, V15, P2219, DOI 10.1038/sj.onc.1201595; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI NX, 1994, ONCOGENE, V9, P3457; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Park JS, 1999, MOL BIOL CELL, V10, P4231, DOI 10.1091/mbc.10.12.4231; Park JS, 2000, J BIOL CHEM, V275, P18, DOI 10.1074/jbc.275.1.18; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; Tsai CM, 1996, CANCER RES, V56, P1068; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443	44	141	148	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 15	2001	20	11					1388	1397		10.1038/sj.onc.1204255	http://dx.doi.org/10.1038/sj.onc.1204255			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313882				2022-12-17	WOS:000167495000012
J	Jerry, DJ; Kittrell, FS; Kuperwasser, C; Laucirica, R; Dickinson, ES; Bonilla, PJ; Butel, JS; Medina, D				Jerry, DJ; Kittrell, FS; Kuperwasser, C; Laucirica, R; Dickinson, ES; Bonilla, PJ; Butel, JS; Medina, D			A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development	ONCOGENE			English	Article						p53; knockout mice; DMBA; carcinogenesis; tumor incidence; hormonal stimulation	TRANSGENIC MICE; MOUSE MAMMARY; BREAST-CANCER; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; TUMORIGENESIS; MUTATIONS; APOPTOSIS; DEFICIENT; 7,12-DIMETHYLBENZ<A>ANTHRACENE	Although alterations in the p53 tumor suppressor gene are detected frequently in human breast cancers, mammary tumors are observed infrequently in p53(null) mice. This has led to the suggestion that absence of p53 alone is not sufficient for induction of mammary tumors. However, early death of p53(null) mice from thymic lymphomas may obscure tumor phenotypes that mould develop later. Therefore, p53(null) mammary epithelium was transplanted into cleared mammary fat pads of wild type p53 BALB/c hosts to allow long-term analysis of mammary tumor phenotypes. Five treatments were compared for their effects on tumor incidence in hosts bearing transplants of p53(null) and p53(wt) mammary epithelium, The treatment groups were: (1) untreated; (2) continuous hormone stimulation with pituitary isografts; (3) multiple pregnancies; (4) DMBA alone; and (5) DMBA + pituitary isografts, The tumor incidences in p53(null) vs p53(wt) mammary transplants for each treatment group were 62% vs 0%, 100% vs 0%, 68% vs 0%, 60% vs 4% and 91%, vs 14%, respectively. The mammary tumors that developed in the p53(null) mammary epithelium were all adenocarcinomas and were frequently aneuploid, These data demonstrate that the absence of p53 is sufficient to cause development of mammary tumors and that hormonal stimulation enhances the tumorigenicity of p53(null) mammary epithelium to a greater extent than DMBA exposure alone. This model provides an in situ approach to examine the molecular basis for the role of p53 in the regulation of mammary tumorigenesis.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	University of Massachusetts System; University of Massachusetts Amherst; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Jerry, DJ (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.			Butel, Janet/0000-0002-6876-3245	NATIONAL CANCER INSTITUTE [R01CA025215, R29CA066670] Funding Source: NIH RePORTER; NCI NIH HHS [CA66670, CA25215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; COLES C, 1992, CANCER RES, V52, P5291; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Kito K, 1996, MOL CARCINOGEN, V17, P78, DOI 10.1002/(SICI)1098-2744(199610)17:2<78::AID-MC4>3.0.CO;2-P; KUMAR R, 1990, ONCOGENE, V5, P1271; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maroulakou IG, 1997, MOL CARCINOGEN, V20, P168, DOI 10.1002/(SICI)1098-2744(199710)20:2<168::AID-MC3>3.0.CO;2-J; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; McKenzie KE, 1997, MOL CARCINOGEN, V20, P194, DOI 10.1002/(SICI)1098-2744(199710)20:2<194::AID-MC6>3.3.CO;2-7; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Medina D, 1999, J NATL CANCER I, V91, P967, DOI 10.1093/jnci/91.11.967; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; MEDINA D, 1973, METHOD CANCER RES, V7, P3; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PETO R, 1974, BRIT J CANCER, V29, P101, DOI 10.1038/bjc.1974.45; Qing WG, 1997, CARCINOGENESIS, V18, P553, DOI 10.1093/carcin/18.3.553; Ritland SR, 1997, CANCER RES, V57, P3520; Ross JA, 1999, MUTAT RES-FUND MOL M, V424, P155, DOI 10.1016/S0027-5107(99)00016-0; RUSSO J, 1990, LAB INVEST, V62, P244; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; WELLINGS SR, 1975, J NATL CANCER I, V55, P231	40	141	144	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1052	1058		10.1038/sj.onc.1203270	http://dx.doi.org/10.1038/sj.onc.1203270			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713689				2022-12-17	WOS:000085796400011
J	Legoix, P; Bluteau, O; Bayer, J; Perret, C; Balabaud, C; Belghiti, J; Franco, D; Thomas, G; Laurent-Puig, P; Zucman-Rossi, J				Legoix, P; Bluteau, O; Bayer, J; Perret, C; Balabaud, C; Belghiti, J; Franco, D; Thomas, G; Laurent-Puig, P; Zucman-Rossi, J			Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity	ONCOGENE			English	Article						hepatocellular carcinoma; beta-catenin; CNNTB1; allelic losses; APC; mutation; chromosome 4	GENE; ACTIVATION; PATHWAY; EXON-3; CANCER; TUMORS; MOUSE	To determine the frequency of Wnt/Wingless beta catenin pathway alteration in human hepatocellular carcinoma, a beta catenin and APC gene mutation screening was performed in a series of 119 tumors. An activating beta catenin mutation in exon 3 was found in 18% of the cases. Among tumors lacking beta catenin mutation, no APC mutation has been evidenced in a subset of 30 cases tested. The correlation between beta catenin mutation status and chromosome segment deletions was studied on a set of 48 hyperploid tumors. Chromosome 1p, 4q and 16p deletions were significantly associated with the absence of beta catenin mutation (P<0.05), Furthermore the Fractional Allelic Loss was significantly smaller in the beta catenin mutated tumors than in the non-mutated tumors (0.12 versus 022), Taken together, these results suggest, the existence of two carcinogenesis mechanisms, The first mechanism implies a beta catenin activating mutation associated with a low rate of loss of heterozygosity. The second mechanism, operating in a context of chromosomal instability, would involve tumor suppressor genes.	CEPH, Fdn Jean Dausset, Lab Genet Tumeurs, INSERM U434,Ctr Etud Polymorphisme Humain, F-75010 Paris, France; Commiss Energie Atom, DRR, DSV, Lab Cytometrie, F-92265 Fontenay Aux Roses, France; CHU Cochin Port Royal, INSERM U129, F-75014 Paris, France; Hop St Andre, F-33000 Bordeaux, France; Hop Beaujon, F-92110 Clichy, France; Hop Antoine Beclere, Serv Chirurg Digest, F-92140 Clamart, France	Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Zucman-Rossi, J (corresponding author), CEPH, Fdn Jean Dausset, Lab Genet Tumeurs, INSERM U434,Ctr Etud Polymorphisme Humain, 27 Rue Juliette Dodu, F-75010 Paris, France.		laurent-puig, pierre/B-2226-2013; j, zucman-rossi/AAV-3594-2021; bluteau, olivier/A-8844-2008; zucman-rossi, Jessica/B-5098-2009; Laurent-Puig, Pierre/K-3641-2019; Perret-Mayeux, Christine/L-3297-2017; Bluteau, Olivier/T-9907-2017	laurent-puig, pierre/0000-0001-8475-5459; j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; Laurent-Puig, Pierre/0000-0001-8475-5459; Bluteau, Olivier/0000-0002-6943-8858; perret, christine/0000-0003-4710-7051				BARDI G, 1992, CANCER GENET CYTOGEN, V58, P191, DOI 10.1016/0165-4608(92)90111-K; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; GRAEF E, 1994, ONCOGENE, V9, P81; Iwao K, 1998, CANCER RES, V58, P1021; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; Sparks AB, 1998, CANCER RES, V58, P1130; TADA M, 1990, CANCER RES, V50, P1121; Takahashi M, 1998, CANCER RES, V58, P42; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	20	141	145	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					4044	4046		10.1038/sj.onc.1202800	http://dx.doi.org/10.1038/sj.onc.1202800			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435629				2022-12-17	WOS:000081327800016
J	Levenberg, S; Yarden, A; Kam, Z; Geiger, B				Levenberg, S; Yarden, A; Kam, Z; Geiger, B			p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry	ONCOGENE			English	Article						cell adhesion; cadherin; cell growth; cell cycle; p27	DEPENDENT KINASE INHIBITOR; BETA-CATENIN; P27(KIP1); CYCLE; DROSOPHILA; ADHESION; PATHWAY; ARREST	In this study the direct involvement of cadherins in adhesion-mediated growth inhibition was investigated. It is shown here that overexpression of N-cadherin in CHO cells significantly suppresses their growth rate. Interaction of these cells and two additional fibroblastic lines with synthetic beads coated with N-cadherin ligands (recombinant N-cadherin ectodomain or specific antibodies) leads to growth arrest at the G1 phase of the cell cycle. The cadherin-reactive beads inhibit the entry into S phase and the reduction in the levels of cyclin-dependent kinase (cdk) inhibitors p21 and p27, following serum-stimulation of starved cells. In exponentially growing cells these beads induce G1 arrest accompanied by elevation in p27 only. We propose that cadherin-mediated signaling is involved in contact inhibition of growth by inducing cell cycle arrest at the G1 phase and elevation of p27 levels.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Geiger, B (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Levenberg, Shulamit/0000-0001-5471-7339				BECKER KF, 1994, CANCER RES, V54, P3845; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Deleu L, 1998, MOL CELL BIOL, V18, P409, DOI 10.1128/MCB.18.1.409; Dietrich C, 1997, ONCOGENE, V15, P2743, DOI 10.1038/sj.onc.1201439; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KAM Z, 1993, BIOIMAGING, V1, P71; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Levenberg S, 1998, J CELL SCI, V111, P347; LEVENBERG S, 1998, IN PRESS CELL ADHE C; MILLARD S, 1997, J BIOL CHEM, V272, P7039; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VOLK T, 1986, J CELL BIOL, V103, P1451, DOI 10.1083/jcb.103.4.1451; WEISER RJ, 1986, J CELL BIOL, V103, P361; WEISER RJ, 1985, EXP CELL RES, V158, P493	30	141	147	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					869	876		10.1038/sj.onc.1202396	http://dx.doi.org/10.1038/sj.onc.1202396			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023662				2022-12-17	WOS:000078510600003
J	Kumar, A; Dhawan, S; Aggarwal, BB				Kumar, A; Dhawan, S; Aggarwal, BB			Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappa B activation, I kappa B degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells	ONCOGENE			English	Article						emodin; TNF; NF-kappa B; adhesion; I kappa-B alpha; endothelial cells	TYROSINE KINASE INHIBITOR; CANCER CELLS; MOLECULE-1; PHOSPHORYLATION; GENE	Most inflammatory agents activate nuclear transcription factor-kappa B (NF-kappa B) which results in expression of genes for cytokines, adhesion molecules, and enzymes involved in amplification and perpetuation of inflammation. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) is an active component from the roots of Polygonum cuspidatum that has been reported to exhibit antiinflammatory properties but the mechanism is not known. In the present study we investigated the effects of emodin on the activation of NF-kappa B in human umbelical vein endothelial cells (EC), Treatment of EC with TNF activated NF-kappa B; preincubation with emodin inhibited this activation in a dose- and time-dependent manner. Emodin did not chemically modify NF-kappa B subunits but rather inhibited degradation of I kappa B, an inhibitory subunit of NF-kappa B. Since the promoter regions of ICAM-1, VCAM-1, and ELAM-1 contain NF-kappa B binding sites and these adhesion molecules are involved in the attachment of leukocytes to EC, the effect of emodin on the adhesion of monocytes to EC and the expression of these adhesion molecules was also studied. Treatment of EC with TNF for 6 h increased the adhesion of monocytes to EC, which correlated with increases in cell surface expression of ICAM-1, VCAM-1 and ELAM-1. Pretreatment of EC for Ih with emodin inhibited both monocyte-EC attachment and expression of ICAM-1, ELAM-1 and VCAM-1, These results indicate that emodin is a potent inhibitor of NF-kappa B activation and expression of adhesion molecules and thus could be useful in treating various inflammatory diseases.	Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA; US FDA, Lab Immunochem, Div Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; US Food & Drug Administration (FDA)	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Sect, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; CARLOS TM, 1994, BLOOD, V84, P2068; CHAN TCK, 1993, BIOCHEM BIOPH RES CO, V193, P1152, DOI 10.1006/bbrc.1993.1746; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; Dhawan S, 1997, BLOOD, V90, P1535; FREDENHAGEN A, 1995, J ANTIBIOT, V48, P1355, DOI 10.7164/antibiotics.48.1355; FREW T, 1994, ANTICANCER RES, V14, P2425; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUANG HC, 1992, EUR J PHARMACOL, V211, P359, DOI 10.1016/0014-2999(92)90393-I; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Lin CC, 1996, J ETHNOPHARMACOL, V52, P107, DOI 10.1016/0378-8741(96)01397-9; MCCARTY JM, 1995, FEBS LETT, V372, P194, DOI 10.1016/0014-5793(95)00976-G; Natarajan K, 1998, ARCH BIOCHEM BIOPHYS, V352, P59, DOI 10.1006/abbi.1998.0576; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; VORABERGER G, 1991, J IMMUNOL, V147, P2777; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhang LS, 1996, ONCOGENE, V12, P571	26	141	168	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					913	918		10.1038/sj.onc.1201998	http://dx.doi.org/10.1038/sj.onc.1201998			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780008				2022-12-17	WOS:000075448800013
J	Mok, SC; Chan, WY; Wong, KK; Cheung, KK; Lau, CC; Ng, SW; Baldini, A; Colitti, CV; Rock, CO; Berkowitz, RS				Mok, SC; Chan, WY; Wong, KK; Cheung, KK; Lau, CC; Ng, SW; Baldini, A; Colitti, CV; Rock, CO; Berkowitz, RS			DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer	ONCOGENE			English	Article						ovary; cancer; DOC-2; Dab; tumor suppressor	PROLINE-RICH PEPTIDES; SH3 DOMAINS; P53 GENE; BINDING; RAS; PHOSPHOTYROSINE; CARCINOMA; RNA; IDENTIFICATION; ACTIVATION	Using RNA fingerprinting (RAP) strategy and Northern blot analysis, we identified a differentially expressed sequence DOC-2 which is detectable in all normal human ovarian surface epithelial (HOSE) cell cultures but not in ovarian cancer cell lines and tissues. Subsequent cloning of DOC-2 from a cDNA library generated from the HOSE cells was carried out using the 3' and 5' RACE approach. A 3268 base pair full length cDNA of DOC-2 was isolated and sequenced. The predicted protein has a length of 770 amino acids. Homology search of all NCBI sequences indicated that the amino acid sequence of DOC-2 shares 93% homology with the mouse p96/mDab2 phosphoprotein and has a phosphotyrosine interacting domain (PID) and multiple SH3 binding motifs. Chromosomal localization by FISH showed that the DOC-2 gene is located on 5p13. Western blot analysis showed that the 105 kDa DOC-2 protein was down-regulated in all the carcinoma cell lines. In-situ immunohistochemistry performed on normal ovaries, and benign, borderline and invasive ovarian tumor tissues showed down regulation of DOC-2 protein particularly in serous ovarian tumor tissues. When DOC-2 was transfected into the ovarian carcinoma cell line SKOV3, the stable transfectants showed significantly reduced growth rate and ability to form tumors in nude mice. These data suggest that down-regulation of DOC-2 may play an important role in ovarian carcinogenesis.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA; Chinese Univ Hong Kong, Dept Anat, Shatin, Peoples R China; Pacific NW Lab, Richland, WA 99352 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38101 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong; United States Department of Energy (DOE); Pacific Northwest National Laboratory; Baylor College of Medicine; Baylor College of Medicine; St Jude Children's Research Hospital	Mok, SC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Biol, Div Gynecol Oncol,Lab Gynecol Oncol, Boston, MA 02115 USA.		Wong, K.-k./AAA-6589-2020; Chan, Wood Yee/R-6692-2018; genes, anthony/F-2541-2012; Baldini, Antonio/M-2355-2015	Wong, K.-k./0000-0002-0375-6669; Chan, Wood Yee/0000-0002-7114-1463; Cheung, Kwok Kuen/0000-0001-7367-9171; Baldini, Antonio/0000-0002-5330-0256	NATIONAL CANCER INSTITUTE [R01CA063381, R01CA069453, R01CA069291] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69453, R01CA63381, R01CA69291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ENOMOTO T, 1991, AM J PATHOL, V139, P777; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FILMUS JE, 1985, CANCER RES, V45, P4468; JACOBS IJ, 1992, J NATL CANCER I, V84, P1793, DOI 10.1093/jnci/84.23.1793; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARKS JR, 1991, CANCER RES, V51, P2979; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MOK SC, 1993, CANCER RES, V52, P5119; MOK SCH, 1993, CANCER RES, V53, P1489; OKAMOTO A, 1991, CANCER RES, V51, P5171; PIVER MS, 1992, GYNECOL ONCOL, P250; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; TSAO SW, 1991, ANTICANCER RES, V11, P1975; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VANTVEER LJ, 1988, ONCOGENE, V2, P157; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; WONG KK, 1993, INT J ONCOL, V3, P13; XU X, 1997, AM ASS CANC RES P, V38, P157; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	31	141	146	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	1998	16	18					2381	2387		10.1038/sj.onc.1201769	http://dx.doi.org/10.1038/sj.onc.1201769			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620555				2022-12-17	WOS:000073428000010
J	HernandezAlcoceba, R; Saniger, L; Campos, J; Nunez, MC; Khaless, F; Gallo, MA; Espinosa, A; Lacal, JC				HernandezAlcoceba, R; Saniger, L; Campos, J; Nunez, MC; Khaless, F; Gallo, MA; Espinosa, A; Lacal, JC			Choline kinase inhibitors as a novel approach for antiproliferative drug design	ONCOGENE			English	Article						oncogenes; choline kinase; antiproliferative drugs; growth factors; phosphorylcholine; ras; src; fos; hemicholinium-3	XENOPUS-LAEVIS OOCYTES; ETHANOLAMINE UPTAKE; LIPID-METABOLISM; GROWTH-FACTORS; RAS PROTEINS; IN-VITRO; ACTIVATION; CELLS; HEMICHOLINIUM-3; RAF-1	Recent progress in deciphering the molecular basis of carcinogenesis is of utmost importance to the development of new anticancer strategies, To this end, it is essential to understand the regulation of both normal cell proliferation and its alterations in cancer cells, We have previously demonstrated that in ras-transformed cells there is an increased level of phosphorylcholine (PCho) resulting from a constitutive activation on choiline kinase (ChoK), The importance of ChoK for the regulation of cell proliferation has also been proposed since an inhibitior for this enzyme, hemicholinium-3 (HC-3), drastically reduces entry into S phase after stimulation with growth factors, Here we report synthesis of several new compounds which are highly specific inhibitors for ChoK, with up to 1000-fold or 600-fold increased inhibitory activity, compared to HC-3 under ex vivo or in vitro conditions respectively, These novel compounds also drastically reduce entry into the S phase after stimulation with specific growth factors, A more profound inhibition of cell proliferation was observed in ras-, src- and mos-transformed cells in the presence of ChoK inhibitors, compared to their parental, untransformed NIH3T3 cells, By contrast, this effect was not observed in fos-transformed cells, While ras, src and mos transformation is associated with elevated levels of ChoK activity, fos-induced transformation does not affect ChoK activity, The inhibitory effect on proliferation of the new compounds correlates with their ability to inhibit the production of phosphorylcholine in whole cells, a proposed novel second messenger for cell proliferation. These results strongly support a critical role of choline kinase in the regulation of cell growth and makes this enzyme a novel target for the design of new antiproliferative and anticancer drugs.	CSIC,INST INVEST BIOMED,MADRID,SPAIN; UNIV GRANADA,DEPT QUIM ORGAN,FAC FARM,GRANADA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Granada			Lacal, Juan Carlos/AAL-2235-2020; Ubeda, Antonio Espinosa/L-8504-2014; del Carmen Nuñez-Carretero, M/L-7150-2014; Rosa, Joaquín/L-8436-2014; Lacal, Juan Carlos/N-9064-2015	Ubeda, Antonio Espinosa/0000-0001-9542-564X; Rosa, Joaquín/0000-0002-9035-8123; Lacal, Juan Carlos/0000-0002-1908-2777				BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Bhakoo KK, 1996, CANCER RES, V56, P4630; CANNON JG, 1990, J MED CHEM, V33, P577, DOI 10.1021/jm00164a017; CANNON JG, 1994, MED RES REV, V14, P505, DOI 10.1002/med.2610140503; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CUADRADO A, 1993, ONCOGENE, V8, P2959; delPeso L, 1997, BIOCHEM J, V322, P519; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DEVITA VT, 1993, CANCER PRINCIPLES PR; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUYENET P, 1973, MOL PHARMACOL, V9, P630; HAMZA M, 1983, BIOCHEM PHARMACOL, V32, P1893, DOI 10.1016/0006-2952(83)90055-2; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kerr DJ, 1994, NEW MOL TARGETS CANC; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MACARA I, 1989, MOL CELL BIOL, V10, P325; MACDONALD JS, 1995, MANUAL ONCOLOGIC THE; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; POLAK RL, 1977, J NEUROCHEM, V29, P477, DOI 10.1111/j.1471-4159.1977.tb10696.x; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; RONEN SM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P203, DOI 10.1016/0925-4439(92)90039-P; RONEN SM, 1991, BIOCHIM BIOPHYS ACTA, V1095, P5, DOI 10.1016/0167-4889(91)90038-Y; Rosa JC, 1996, J MED CHEM, V39, P4247, DOI 10.1021/jm950884a; TEEGARDEN D, 1990, J BIOL CHEM, V265, P16638; TUCEK S, 1985, J NEUROCHEM, V4, P12; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P204; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZLATKINE P, 1993, BIOCHIM BIOPHYS ACTA, V1153, P237, DOI 10.1016/0005-2736(93)90410-2	35	141	147	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2289	2301		10.1038/sj.onc.1201414	http://dx.doi.org/10.1038/sj.onc.1201414			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393874				2022-12-17	WOS:A1997YE15700004
J	Papadimitrakopoulou, V; Izzo, J; Lippman, SM; Lee, JS; Fan, YH; Clayman, G; Ro, JY; Hittelman, WN; Lotan, R; Hong, WK; Mao, L				Papadimitrakopoulou, V; Izzo, J; Lippman, SM; Lee, JS; Fan, YH; Clayman, G; Ro, JY; Hittelman, WN; Lotan, R; Hong, WK; Mao, L			Frequent inactivation of p16(INK4a) in oral premalignant lesions	ONCOGENE			English	Article						p16(INK4a); head and neck cancer; oral premalignant lesions; immunohistochemistry	CARCINOMA CELL-LINES; PRIMARY TUMORS; CYCLE ARREST; P16 MTS1; EXPRESSION; CANCERS; GENE; MUTATIONS; P16/CDKN2; HEAD	Head and neck carcinogenesis is believed to be a multistep process, whereby genetic events accumulate in the carcinogen-exposed field at risk, resulting in distinct phenotypic premalignant changes that eventually evolve into invasive cancer, Frequent loss of heterozygosity (LOH) at the chromosome 9p21 region and inactivation of p16(INK4a) by different mechanisms have been described in head and neck squamous cell carcinoma (HNSCC), Recently, we reported that loss of 9p21 is also frequent in oral premalignant lesions. To investigate potential inactivation of p16(INK4a) in these premalignant lesions, we analysed 74 biopsies from 36 patients by immunohistochemistry (MC) for expression of the p16 protein. Loss of p16 expression was found in 28 (38%) of the lesion biopsies from 17 patients (47%). LOH at the D9s171, a marker in the 9p21 region, was observed in 19 lesion biopsies from 12 cases and correlated with absence of p16 by IHC in 11 (92%) of the 12 comparable cases and 15 (79%) of 19 lesion biopsies, By direct sequencing of ten lesion biopsies from ten individuals with LOH at D9s171 for p16(INK4a) exon 2, one non-sense mutation at codon 88 (GGA-->TGA) was identified, Our data suggest that inactivation of p16(INK4a) may play an important role in early head and neck cancer development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC HEAD & NECK MED ONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN INVEST,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL & TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358	NCI NIH HHS [CA-52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Califano J, 1996, CANCER RES, V56, P2488; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; GERADTS J, 1995, CANCER RES, V55, P6006; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IZZO J, 1996, P AM ASSOC CANC RES, V37, P3687; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KUSHIMOTO Y, 1995, J NATL CANCER I, V87, P1224; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; LUKAS J, 1995, CANCER RES, V55, P4818; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NOBORI T, 1994, NATURE, V368, P735; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARKER SL, 1996, CA CANC J CLIN, V46, P8; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SILVERMAN S, 1984, CANCER, V53, P563; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; STONE S, 1995, CANCER RES, V55, P2988; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG SY, 1994, CANCER RES, V54, P5050	30	141	141	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1799	1803		10.1038/sj.onc.1201010	http://dx.doi.org/10.1038/sj.onc.1201010			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150385				2022-12-17	WOS:A1997WW16600005
J	FUKUDA, M; GOTOH, Y; TACHIBANA, T; DELL, K; HATTORI, S; YONEDA, Y; NISHIDA, E				FUKUDA, M; GOTOH, Y; TACHIBANA, T; DELL, K; HATTORI, S; YONEDA, Y; NISHIDA, E			INDUCTION OF NEURITE OUTGROWTH BY MAP KINASE IN PC12 CELLS	ONCOGENE			English	Article						PC12 CELL DIFFERENTIATION; THIOPHOSPHORYLATED MAP KINASE; CL100	NERVE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; XENOPUS-OOCYTES; PHOSPHORYLATION; CASCADE; ACTIVATION; INVITRO; PATHWAY	Treatment of PC12 cells with nerve growth factor (NGF) results in neural differentiation of the cells, inducing neurite outgrowth. Ras protein has been shown to play an essential role in this process. To examine whether or not the MAP kinase (MAPK) cascade mediates the NGF- and Pas-induced neural differentiation process, we injected PC12 cells with constitutive active forms of each components of the MAPK cascade. When a moderately active mutant of Xenopus MAPK kinase (S222E-MAPKK) in which Ser 222 was changed into glutamic acid was injected, the neurite outgrowth of PC12 cells occurred to some extent. Injection of an N-terminal truncated STE11 protein (Delta N-STE11), a constitutively active form of STE11 which is a yeast MAPKK kinase, induced neurite outgrowth in PC12 cells. Furthermore, injection of thiophosphorylated MAPK, but not purified active MAPK, into PC12 cells resulted in neurite outgrowth. Thiophosphorylated MAPK was resistant to protein phosphatase 2A treatment, while purified active MAPK was inactivated by this treatment. All these results have suggested that sustained activation of MAPK is sufficient for PC12 cell differentiation. In accord with this, the Delta N-STE11- or S222E- MAPKK-induced neurite outgrowth was inhibited by coinjection of CL-100 protein, a dual-specificity phosphatase that is capable of inactivating MAPK.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT & CELL BIOL,SUITA,OSAKA 565,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN	Kyoto University; University of Tokyo; Osaka University; National Center for Neurology & Psychiatry - Japan			Fukuda, Makoto/C-9745-2009	Fukuda, Makoto/0000-0003-0112-9925				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALLESSI DR, 1993, ONCOGENE, V8, P2015; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1994, TRENDS BIOCHEM SCI, V19, P1, DOI 10.1016/0968-0004(94)90163-5; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAMMUELS ML, 1993, MOL CELL BIOL, V13, P6241; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; ZHENG CF, 1993, J BIOL CHEM, V268, P644	53	141	143	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					239	244						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624141				2022-12-17	WOS:A1995RK95700004
J	TOMMASINO, M; ADAMCZEWSKI, JP; CARLOTTI, F; BARTH, CF; MANETTI, R; CONTORNI, M; CAVALIERI, F; HUNT, T; CRAWFORD, L				TOMMASINO, M; ADAMCZEWSKI, JP; CARLOTTI, F; BARTH, CF; MANETTI, R; CONTORNI, M; CAVALIERI, F; HUNT, T; CRAWFORD, L			HPV16 E7 PROTEIN ASSOCIATES WITH THE PROTEIN-KINASE P33CDK2 AND CYCLIN-A	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; RB PROTEIN; TRANSACTIVATION; MECHANISM; PHOSPHORYLATION; TRANSFORMATION; THIAMINE	E7 is the major transforming protein of human papillomavirus type 16 (HPV16). It has been found to associate with the retinoblastoma protein Rb1. We investigated whether HPV16 E7 protein was associated with other cellular proteins, in particular with those involved in cell cycle control. Immunoprecipitates from CaSki cell extracts with an anti E7 monoclonal antibody contained a histone H1 kinase. Recombinant E7, synthesized in yeast, when mixed with protein extracts from epithelial cells bound histone H1 kinase activity in vitro. The in vivo and the in vitro-formed E7-kinase complex had the same periodicity of activity during the cell cycle, being most active in S and G2/M. Immunoblotting of E7 immunoprecipitates with an antibody raised against the p33CDK2, revealed a 33 kDa protein band not detected by an anti-p34cdc2 antibody, suggesting that the E7-associated kinase activity is due to the p33CDK2. The interaction appears to be via cyclin A, since probing of similar immunoblots showed a 50 kDa band corresponding to cyclin A. The association of E7 with cyclin A appeared to be direct, not involving Rb1 or other proteins.	UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,VIRUS GRP,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; IRIS,I-53100 SIENA,ITALY; IMPERIAL CANC FUND,GROWTH CONTROL & DEV LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,POTTERS BAR EN6 3LD,HERTS,ENGLAND	University of Cambridge; Novartis								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANKS L, 1990, ONCOGENE, V5, P1383; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CRAWFORD LV, 1979, J VIROL, V29, P587, DOI 10.1128/JVI.29.2.587-596.1979; CROOK T, 1988, P NATL ACAD SCI USA, V85, P353; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TINDLE RW, 1990, J GEN VIROL, V71, P1347, DOI 10.1099/0022-1317-71-6-1347; TOMMASINO M, 1990, GENE, V93, P265, DOI 10.1016/0378-1119(90)90234-I; TOMMASINO M, 1991, CURR GENET, V20, P63, DOI 10.1007/BF00312766; TOMMASINO M, 1992, GENE, V111, P93, DOI 10.1016/0378-1119(92)90607-Q; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VOUSDEN KH, 1989, ONCOGENE, V4, P153; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	39	141	155	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					195	202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380917				2022-12-17	WOS:A1993KN00500024
J	Park, JE; Dutta, B; Tse, SW; Gupta, N; Tan, CF; Low, JK; Yeoh, KW; Kon, OL; Tam, JP; Sze, SK				Park, Jung Eun; Dutta, Bamaprasad; Tse, Shun Wilford; Gupta, Nikhil; Tan, Chee Fan; Low, Jee Keem; Yeoh, Kheng Wei; Kon, Oi Lian; Tam, James P.; Sze, Siu Kwan			Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift	ONCOGENE			English	Article							HEAVY-CHAIN FERRITIN; CANCER-CELLS; SUPPRESSOR-CELLS; IMMUNE-RESPONSES; DENDRITIC CELL; M2 MACROPHAGE; PROGRESSION; SECRETION; MIGRATION; RECEPTOR	Developing tumors rapidly outgrow their oxygen supply and are subject to hypoxia, which stimulates hypersecretion of tumor-derived exosomes that promote angiogenesis, metastasis, and immunosuppression, but the molecular mediators of these pathological effects remain poorly defined. Using quantitative proteomics, we identified that exosomes produced by hypoxic tumor cells are highly enriched in immunomodulatory proteins and chemokines including CSF-1, CCL2, FTH, FTL, and TGF beta. Modeling exosome effects on tumor-infiltrating immune cells, we observed a potent ability of these hypoxia-induced vesicles to influence macrophage recruitment and promote M2-like polarization both in vitro and in vivo. In addition, hypoxic, but not normoxic, tumor exosomes enhanced oxidative phosphorylation in bone marrow-derived macrophages via transfer of let-7a miRNA, resulting in suppression of the insulin-Akt-mTOR signaling pathway. Together, these data demonstrate that hypoxia promotes tumor secretion of biomolecule-loaded exosomes that can modify the immunometabolic profile of infiltrating monocyte-macrophages to better evade host immunity and enhance tumor progression.	[Park, Jung Eun; Dutta, Bamaprasad; Tse, Shun Wilford; Gupta, Nikhil; Tan, Chee Fan; Tam, James P.; Sze, Siu Kwan] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Low, Jee Keem] Tan Tock Seng Hosp, Dept Surg, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore; [Yeoh, Kheng Wei] Natl Canc Ctr Singapore, Dept Radiat Oncol, 11 Hosp Dr, Singapore 169610, Singapore; [Kon, Oi Lian] Natl Canc Ctr Singapore, Div Med Sci, 11 Hosp Dr, Singapore 169610, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Tan Tock Seng Hospital; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)	Park, JE; Sze, SK (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	jepark@ntu.edu.sg; sksze@ntu.edu.sg	Tam, James P/A-2176-2011; Dutta, Bamaprasad/AAH-4006-2020; Sze, Siu Kwan/AAO-3342-2020	Tam, James P/0000-0003-4433-198X; Dutta, Bamaprasad/0000-0002-2309-8771; Sze, Siu Kwan/0000-0002-5652-1687; Tan, Chee Fan/0000-0002-4109-8724	Singapore Ministry of Education [MOE2014-T2-2-043, MOE2016-T2-2-018, MOE2016-T3-1-003]; National Medical Research Council of Singapore [NMRC-OF-IRG-0003-2016]	Singapore Ministry of Education(Ministry of Education, Singapore); National Medical Research Council of Singapore(National Medical Research Council, Singapore)	This work is in part supported by grants from the Singapore Ministry of Education (MOE2014-T2-2-043, MOE2016-T2-2-018, and MOE2016-T3-1-003) and the National Medical Research Council of Singapore (NMRC-OF-IRG-0003-2016).	Alkhateeb AA, 2013, BBA-REV CANCER, V1836, P245, DOI 10.1016/j.bbcan.2013.07.002; Alkhateeb AA, 2013, BREAST CANCER RES TR, V137, P733, DOI 10.1007/s10549-012-2405-x; Balogh KN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197702; Bellomo C, 2016, BRIT J CANCER, V115, P761, DOI 10.1038/bjc.2016.255; Biswas SK, 2015, IMMUNITY, V43, P435, DOI 10.1016/j.immuni.2015.09.001; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bretz NP, 2013, J BIOL CHEM, V288, P36691, DOI 10.1074/jbc.M113.512806; Chen SC, 2012, J PATHOL, V228, P158, DOI 10.1002/path.3988; Chen X, 2004, CURR CANCER DRUG TAR, V4, P267, DOI 10.2174/1568009043333041; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Damuzzo V, 2015, CYTOM PART B-CLIN CY, V88, P77, DOI [10.1002/cyto.b.21206, 10.1002/cytob.21206]; De Toro J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00203; Dueck A, 2012, NUCLEIC ACIDS RES, V40, P9850, DOI 10.1093/nar/gks705; Elliott LA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00086; Espinoza JL, 2012, HAEMATOL-HEMATOL J, V97, P1295, DOI 10.3324/haematol.2011.058529; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Galvan-Pena S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00420; Geeraerts X, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00289; Genin M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1546-9; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Gilkes DM, 2013, MOL CANCER RES, V11, P456, DOI 10.1158/1541-7786.MCR-12-0629; Gray CP, 2003, CLIN CANCER RES, V9, P2551; Gray CP, 2002, BLOOD, V99, P3326, DOI 10.1182/blood.V99.9.3326; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Hoffman RM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3426; Hu JM, 2017, ONCOTARGET, V8, P21526, DOI 10.18632/oncotarget.15630; Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214; Jezequel P, 2012, INT J CANCER, V131, P426, DOI 10.1002/ijc.26397; Jia WZ, 2013, AM J PATHOL, V182, P1821, DOI 10.1016/j.ajpath.2013.01.017; KAO J, 1994, J BIOL CHEM, V269, P25106; Kikushige Y, 2008, J IMMUNOL, V180, P7358, DOI 10.4049/jimmunol.180.11.7358; Kindt N, 2016, ONCOL LETT, V12, P2247, DOI 10.3892/ol.2016.4929; Kore RA, 2018, BIOCHEM BIOPHYS REP, V14, P104, DOI 10.1016/j.bbrep.2018.03.008; Kucharzewska P, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20304; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; LEBRUN JJ, 2012, ISRN MOL BIOL, V2012, P28; Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734; Lee DD, 2016, AM J RESP CELL MOL, V55, P602, DOI 10.1165/rcmb.2016-0091OC; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25474; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Lobb RJ, 2017, SEMIN CELL DEV BIOL, V67, P3, DOI 10.1016/j.semcdb.2017.01.004; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Mogami T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080359; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Nielsen SR, 2017, MEDIAT INFLAMM, V2017, P11; O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570; Otero-Albiol D, 2016, CANC TRANSL MED, V2, P175, DOI DOI 10.3892/OL.2016.4316; Park JE, 2017, SCI REP-UK, V7, DOI 10.1038/srep40569; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qi HB, 2015, ONCOL LETT, V10, P1947, DOI 10.3892/ol.2015.3498; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Storm MP, 2016, JOVE-J VIS EXP, DOI 10.3791/53431; Sudan B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00253; Vo TTL, 2018, ANN NY ACAD SCI, V1431, P3, DOI 10.1111/nyas.13929; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Thompson A, 2003, ANAL CHEM, V75, P1895, DOI 10.1021/ac0262560; Torrisani J, 2007, CURR GENOMICS, V8, P229; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Viaud S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004942; Villarroya-Beltri C, 2014, SEMIN CANCER BIOL, V28, P3, DOI 10.1016/j.semcancer.2014.04.009; Wang DZ, 2018, GENET TEST MOL BIOMA, V22, P366, DOI 10.1089/gtmb.2018.0009; Wargo JA, 2016, CURR OPIN IMMUNOL, V41, P23, DOI 10.1016/j.coi.2016.05.006; Wenes M, 2016, CELL METAB, V24, P701, DOI 10.1016/j.cmet.2016.09.008; Whiteside TL, 2016, J CLIN INVEST, V126, P1216, DOI 10.1172/JCI81136; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Winter J, 2011, RNA BIOL, V8, P1149, DOI 10.4161/rna.8.6.17665; Wu LJ, 2016, TUMOR BIOL, V37, P12169, DOI 10.1007/s13277-016-5071-5; Wu TF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149361; Young L, 2010, NAT PROTOC, V5, P929, DOI 10.1038/nprot.2010.43; Zhou JB, 2016, ONCOTARGET, V7, P50698, DOI 10.18632/oncotarget.9333; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033; Zhu Q, 2015, NAT METHODS, V12, P211, DOI [10.1038/NMETH.3249, 10.1038/nmeth.3249]	80	140	146	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5158	5173		10.1038/s41388-019-0782-x	http://dx.doi.org/10.1038/s41388-019-0782-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30872795				2022-12-17	WOS:000473025300004
J	Bernardini, JP; Lazarou, M; Dewson, G				Bernardini, J. P.; Lazarou, M.; Dewson, G.			Parkin and mitophagy in cancer	ONCOGENE			English	Review							RECESSIVE JUVENILE PARKINSONISM; MITOCHONDRIAL COMPLEX-I; TUMOR-SUPPRESSOR GENE; EARLY-ONSET PARKINSONISM; HUMAN-MELANOMA CELLS; BCL-X-L; BREAST-CANCER; OXIDATIVE STRESS; OVARIAN-CANCER; PINK1-DEPENDENT PHOSPHORYLATION	Mitophagy, the selective engulfment and clearance of mitochondria, is essential for the homeostasis of a healthy network of functioning mitochondria and prevents excessive production of cytotoxic reactive oxygen species from damaged mitochondria. The mitochondrially targeted PTEN-induced kinase-1 ( PINK1) and the E3 ubiquitin ligase Parkin are well-established synergistic mediators of the mitophagy of dysfunctional mitochondria. This pathway relies on the ubiquitination of a number of mitochondrial outer membrane substrates and subsequent docking of autophagy receptor proteins to selectively clear mitochondria. There are also alternate Parkin-independent mitophagy pathways mediated by BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 and Nip-3 like protein X as well as other effectors. There is increasing evidence that ablation of mitophagy accelerates a number of pathologies. Familial Parkinsonism is associated with loss-of-function mutations in PINK1 and Parkin. A growing number of studies have observed a correlation between impaired Parkin activity and enhanced cancer development, leading to the emerging concept that Parkin activity, or mitophagy in general, is a tumour suppression mechanism. This review examines the molecular mechanisms of mitophagy and highlights the potential links between Parkin and the hallmarks of cancer that may influence tumour development and progression.	[Bernardini, J. P.; Dewson, G.] Walter & Eliza Hall Inst Med Res, Cell Signaling & Cell Death Div, Melbourne, Vic, Australia; [Bernardini, J. P.; Dewson, G.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Lazarou, M.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Melbourne, Vic, Australia	University of Melbourne; Monash University	Dewson, G (corresponding author), Walter & Eliza Hall Inst Med Res, Cell Signalling & Cell Death Div, 1G Royal Parade, Melbourne, Vic 3052, Australia.	dewson@wehi.edu.au	高, 雨莉/HGU-8187-2022; dewson, grant/C-7646-2013; Datta, Sayantan/D-1369-2010	dewson, grant/0000-0003-4251-8898; Lazarou, Michael/0000-0003-2150-5545; Bernardini, Jonathan/0000-0002-5767-7624	Australian Research Council Future Fellowship [FT100100791]; Victorian State Government; Australian Government NHMRC IRIISS	Australian Research Council Future Fellowship(Australian Research Council); Victorian State Government; Australian Government NHMRC IRIISS(National Health and Medical Research Council (NHMRC) of Australia)	The authors acknowledge Paul Ekert and Jamie Fletcher for advice and discussions in the preparation of the manuscript. GD is supported by an Australian Research Council Future Fellowship (#FT100100791). Supported through operational infrastructure grants through the Victorian State Government Operational Infrastructure Support and the Australian Government NHMRC IRIISS.	Alvero AB, 2011, MOL CANCER THER, V10, P1385, DOI 10.1158/1535-7163.MCT-11-0023; Balliet RM, 2011, CELL CYCLE, V10, P4065, DOI 10.4161/cc.10.23.18254; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bento CF, 2015, DNA CELL BIOL, V34, P228, DOI 10.1089/dna.2014.2745; Bingol B, 2014, NATURE, V510, P370, DOI 10.1038/nature13418; Birsa N, 2014, J BIOL CHEM, V289, P14569, DOI 10.1074/jbc.M114.563031; Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Carroll RG, 2014, CELL REP, V9, P1538, DOI 10.1016/j.celrep.2014.10.046; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048; Charan RA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.278; Chen D, 2010, J BIOL CHEM, V285, P38214, DOI 10.1074/jbc.M110.101469; Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034; Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031; Chiavarina B, 2010, CELL CYCLE, V9, P3534, DOI 10.4161/cc.9.17.12908; Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759; Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; CLEETER MWJ, 1992, J NEUROCHEM, V58, P786, DOI 10.1111/j.1471-4159.1992.tb09789.x; Cornelissen T, 2014, HUM MOL GENET, V23, P5227, DOI 10.1093/hmg/ddu244; Courjal F, 1996, INT J CANCER, V69, P247; Cunningham CN, 2015, NAT CELL BIOL, V17, P160, DOI 10.1038/ncb3097; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Dasgupta S, 2012, J CELL PHYSIOL, V227, P2451, DOI 10.1002/jcp.22980; Deas E, 2011, HUM MOL GENET, V20, P867, DOI 10.1093/hmg/ddq526; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; DEXTER DT, 1994, ANN NEUROL, V35, P38, DOI 10.1002/ana.410350107; Durcan TM, 2015, GENE DEV, V29, P989, DOI 10.1101/gad.262758.115; Durcan TM, 2014, EMBO J, V33, P2473, DOI 10.15252/embj.201489729; Foroud T, 2003, NEUROLOGY, V60, P796, DOI 10.1212/01.WNL.0000049470.00180.07; Fransson A, 2006, BIOCHEM BIOPH RES CO, V344, P500, DOI 10.1016/j.bbrc.2006.03.163; Fu M, 2013, MOL BIOL CELL, V24, P1153, DOI 10.1091/mbc.E12-08-0607; Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199; Gegg ME, 2010, HUM MOL GENET, V19, P4861, DOI 10.1093/hmg/ddq419; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; GILLETT C, 1994, CANCER RES, V54, P1812; Gong GH, 2015, SCIENCE, V350, DOI 10.1126/science.aad2459; Gong YX, 2014, NAT GENET, V46, P588, DOI 10.1038/ng.2981; Green DR, 2014, SCIENCE, V345, P1466, DOI 10.1126/science.1250256; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933; Hatano Y, 2004, NEUROLOGY, V63, P1482, DOI 10.1212/01.WNL.0000142258.29304.FE; Hatano Y, 2004, ANN NEUROL, V56, P424, DOI 10.1002/ana.20251; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hedrich K, 2006, ARCH NEUROL-CHICAGO, V63, P833, DOI 10.1001/archneur.63.6.833; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Heo JM, 2015, MOL CELL, V60, P7, DOI 10.1016/j.molcel.2015.08.016; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hollville E, 2014, MOL CELL, V55, P451, DOI 10.1016/j.molcel.2014.06.001; Hristova VA, 2009, J BIOL CHEM, V284, P14978, DOI 10.1074/jbc.M808700200; Hu HH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv340; Hung JY, 2009, J AGR FOOD CHEM, V57, P9809, DOI 10.1021/jf902315e; Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200; Inzelberg R, 2007, NEUROLOGY, V69, P1542, DOI 10.1212/01.wnl.0000277638.63767.b8; Itier JM, 2003, HUM MOL GENET, V12, P2277, DOI 10.1093/hmg/ddg239; Jin SM, 2013, AUTOPHAGY, V9, P1750, DOI 10.4161/auto.26122; Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084; Johnson BN, 2012, P NATL ACAD SCI USA, V109, P6283, DOI 10.1073/pnas.1113248109; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123; Kandala PK, 2012, ONCOTARGET, V3, P435; Kane LA, 2014, J CELL BIOL, V205, P143, DOI 10.1083/jcb.201402104; Kataoka T, 2001, J BIOL CHEM, V276, P19548, DOI 10.1074/jbc.M010520200; Kay DM, 2010, NEUROLOGY, V75, P1189, DOI 10.1212/WNL.0b013e3181f4d832; Kazlauskaite A, 2015, EMBO REP, V16, P939, DOI 10.15252/embr.201540352; Kazlauskaite A, 2014, BIOCHEM J, V460, P127, DOI 10.1042/BJ20140334; Kim KY, 2011, J CLIN INVEST, V121, P3701, DOI 10.1172/JCI44736; Kim SY, 2012, CLIN GENET, V82, P77, DOI 10.1111/j.1399-0004.2011.01693.x; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitada T, 2000, MAMM GENOME, V11, P417, DOI 10.1007/s003350010080; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Kondapalli C, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120080; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; Koyano F, 2014, NATURE, V510, P162, DOI 10.1038/nature13392; Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006; Lai J, 2003, BRIT J CANCER, V88, P270, DOI 10.1038/sj.bjc.6600674; Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696; Landes T, 2010, EMBO REP, V11, P459, DOI 10.1038/embor.2010.50; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893; Lazarou M, 2015, IMMUNOL CELL BIOL, V93, P3, DOI 10.1038/icb.2014.75; Lazarou M, 2012, DEV CELL, V22, P320, DOI 10.1016/j.devcel.2011.12.014; Lee KS, 2013, GENE DEV, V27, P2642, DOI 10.1101/gad.225169.113; Li Mark Xiang, 2015, F1000Prime Rep, V7, P42, DOI 10.12703/P7-42; Liang JR, 2015, EMBO REP, V16, P618, DOI 10.15252/embr.201439820; Lindqvist LM, 2014, P NATL ACAD SCI USA, V111, P8512, DOI 10.1073/pnas.1406425111; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Liu L, 2014, CELL RES, V24, P787, DOI 10.1038/cr.2014.75; Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422; Lo SC, 2006, J BIOL CHEM, V281, P37893, DOI 10.1074/jbc.M606539200; Lu W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147792; Lu W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5930; Lucking CB, 1998, LANCET, V352, P1355, DOI 10.1016/S0140-6736(05)60746-5; Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94; Maes H, 2014, MITOCHONDRION, V19, P58, DOI 10.1016/j.mito.2014.07.003; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Manzanillo PS, 2013, NATURE, V501, P512, DOI 10.1038/nature12566; Marino ML, 2012, J BIOL CHEM, V287, P30664, DOI 10.1074/jbc.M112.339127; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P4152, DOI 10.4161/cc.22226; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Meissner C, 2011, J NEUROCHEM, V117, P856, DOI 10.1111/j.1471-4159.2011.07253.x; MOLLER H, 1995, BRIT MED J, V310, P1500, DOI 10.1136/bmj.310.6993.1500; Moore DJ, 2005, HUM MOL GENET, V14, P71, DOI 10.1093/hmg/ddi007; Morris LGT, 2010, ONCOGENE, V29, P3453, DOI 10.1038/onc.2010.127; Mulholland PJ, 2006, CELL CYCLE, V5, P783, DOI 10.4161/cc.5.7.2631; Murakawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8527; Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018; Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Okatsu K, 2013, J BIOL CHEM, V288, P36372, DOI 10.1074/jbc.M113.509653; Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x; Olsen JH, 2005, BRIT J CANCER, V92, P201, DOI 10.1038/sj.bjc.6602279; Ordureau A, 2015, P NATL ACAD SCI USA, V112, P6637, DOI 10.1073/pnas.1506593112; Ordureau A, 2014, MOL CELL, V56, P360, DOI 10.1016/j.molcel.2014.09.007; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546; Otera H, 2011, J BIOCHEM, V149, P241, DOI 10.1093/jb/mvr002; Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perez FA, 2005, P NATL ACAD SCI USA, V102, P2174, DOI 10.1073/pnas.0409598102; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Pickrell AM, 2015, NEURON, V87, P371, DOI 10.1016/j.neuron.2015.06.034; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Plun-Favreau H, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001257; Poole AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010054; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Quinsay MN, 2010, J MOL CELL CARDIOL, V48, P1146, DOI 10.1016/j.yjmcc.2009.12.004; Radogna F, 2016, ONCOGENE, V35, P3839, DOI 10.1038/onc.2015.455; Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Remijsen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.531; Richter B, 2016, P NATL ACAD SCI USA, V113, P4039, DOI 10.1073/pnas.1523926113; Riley BE, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2982; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Saito S, 1996, CANCER RES, V56, P5586; Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264; Sarraf SA, 2013, NATURE, V496, P372, DOI 10.1038/nature12043; Scarffe LA, 2014, TRENDS NEUROSCI, V37, P315, DOI 10.1016/j.tins.2014.03.004; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; SERSHEN H, 1985, EUR J PHARMACOL, V113, P135, DOI 10.1016/0014-2999(85)90355-3; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; Tait SWG, 2013, CELL REP, V5, P878, DOI 10.1016/j.celrep.2013.10.034; Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thomas KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045319; Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004; Trempe JF, 2013, SCIENCE, V340, P1451, DOI 10.1126/science.1237908; Trempe JF, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00038; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Viotti J, 2014, ONCOGENE, V33, P1764, DOI 10.1038/onc.2013.124; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; WAGNER GC, 1985, NEUROPHARMACOLOGY, V24, P1261, DOI 10.1016/0028-3908(85)90164-9; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wang HX, 2011, J BIOL CHEM, V286, P11649, DOI 10.1074/jbc.M110.144238; Wang M, 2001, J NEUROCHEM, V77, P1561, DOI 10.1046/j.1471-4159.2001.00372.x; Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Watson RO, 2012, CELL, V150, P803, DOI 10.1016/j.cell.2012.06.040; West AB, 2004, J BIOL CHEM, V279, P28896, DOI 10.1074/jbc.M400126200; Whitworth AJ, 2008, DIS MODEL MECH, V1, P168, DOI 10.1242/dmm.000109; Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111; Wu H, 2014, AUTOPHAGY, V10, P1712, DOI 10.4161/auto.29568; Wu WX, 2014, EMBO REP, V15, P566, DOI 10.1002/embr.201438501; Xia M, 2014, ONCOTARGET, V5, P3907, DOI 10.18632/oncotarget.2028; Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; Xu L, 2014, J MOL MED, V92, P31, DOI 10.1007/s00109-013-1107-0; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yamano K, 2013, AUTOPHAGY, V9, P1758, DOI 10.4161/auto.24633; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Yun JN, 2014, ELIFE, V3, DOI 10.7554/eLife.01958; Zanchetta LM, 2011, INT J RADIAT BIOL, V87, P506, DOI 10.3109/09553002.2011.556175; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zhang CG, 2014, CURR BIOL, V24, P1854, DOI 10.1016/j.cub.2014.07.014; Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345; Ziviani E, 2010, P NATL ACAD SCI USA, V107, P5018, DOI 10.1073/pnas.0913485107	205	140	151	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1315	1327		10.1038/onc.2016.302	http://dx.doi.org/10.1038/onc.2016.302			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27593930				2022-12-17	WOS:000395862500001
J	Fernandez, S; Risolino, M; Mandia, N; Talotta, F; Soini, Y; Incoronato, M; Condorelli, G; Banfi, S; Verde, P				Fernandez, S.; Risolino, M.; Mandia, N.; Talotta, F.; Soini, Y.; Incoronato, M.; Condorelli, G.; Banfi, S.; Verde, P.			miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer	ONCOGENE			English	Article							MESSENGER-RNA; EXPRESSION; MICRORNA; MIR-222; MIRNA; OVEREXPRESSION; DEGRADATION; PROGRESSION; FAMILY; SKP2	MicroRNAs (miRNAs) control cell cycle progression by targeting the transcripts encoding for cyclins, CDKs and CDK inhibitors, such as p27(KIP1) (p27).p27 expression is controlled by multiple transcriptional and posttranscriptional mechanisms, including translational inhibition by miR-221/222 and posttranslational regulation by the SCFSKP2 complex. The oncosuppressor activity of miR-340 has been recently characterized in breast, colorectal and osteosarcoma tumor cells. However, the mechanisms underlying miR-340-induced cell growth arrest have not been elucidated. Here, we describe miR-340 as a novel tumor suppressor in non-small cell lung cancer (NSCLC). Starting from the observation that the growth-inhibitory and proapoptotic effects of miR-340 correlate with the accumulation of p27 in lung adenocarcinoma and glioblastoma cells, we have analyzed the functional relationship between miR-340 and p27 expression. miR-340 targets three key negative regulators of p27. The miR-340-mediated inhibition of both Pumilio family RNA-binding proteins (PUM1 and PUM2), required for the miR-221/222 interaction with the p27 3'-UTR, antagonizes the miRNA-dependent downregulation of p27. At the same time, miR-340 induces the stabilization of p27 by targeting SKP2, the key posttranslational regulator of p27. Therefore, miR-340 controls p27 at both translational and posttranslational levels. Accordingly, the inhibition of either PUM1 or SKP2 partially recapitulates the miR-340 effect on cell proliferation and apoptosis. In addition to the effect on tumor cell proliferation, miR-340 also inhibits intercellular adhesion and motility in lung cancer cells. These changes correlate with the miR-340-mediated inhibition of previously validated (MET and ROCK1) and potentially novel (RHOA and CDH1) miR-340 target transcripts. Finally, we show that in a small cohort of NSCLC patients (n = 23), representative of all four stages of lung cancer, miR-340 expression inversely correlates with clinical staging, thus suggesting that miR-340 downregulation contributes to the disease progression.	[Fernandez, S.; Risolino, M.; Mandia, N.; Talotta, F.; Verde, P.] CNR, Inst Genet & Biophys, I-80123 Naples, Italy; [Soini, Y.] Univ Eastern Finland, Canc Ctr Eastern Finland, Sch Med, Inst Clin Med Pathol & Forens Med, Kuopio, Finland; [Incoronato, M.] IRCCS SDN, Naples, Italy; [Condorelli, G.] Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, Naples, Italy; [Banfi, S.] Telethon Inst Genet & Med TIGEM, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Eastern Finland; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); University of Naples Federico II; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM)	Verde, P (corresponding author), CNR, Inst Genet & Biophys, Via P Castellino 111, I-80123 Naples, Italy.	pasquale.verde@igb.cnr.it	Incoronato, Mariarosaria/AAA-7541-2021; Incoronato, Mariarosaria/K-8727-2016; Banfi, Sandro/K-3963-2018; Condorelli, Gerolama/AAC-3472-2022	Incoronato, Mariarosaria/0000-0001-7019-0581; Incoronato, Mariarosaria/0000-0001-7019-0581; Banfi, Sandro/0000-0002-6541-8833; Condorelli, Gerolama/0000-0003-0177-8829	AIRC (Associazione Italiana per la Ricerca sul Cancro) [10489]; AICR (Association for International Cancer Research, UK) [08-182]; MERIT Grant (MIUR) [RBNE08YFN3]; AIRC [14046]; Fondazione Berlucchi; Fondazione Telethon Funding Source: Custom	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AICR (Association for International Cancer Research, UK); MERIT Grant (MIUR); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Berlucchi; Fondazione Telethon(Fondazione Telethon)	We thank Reuven Agami, Judy Lieberman and Vladimir Spiegelman for expression vectors. We also thank the IGB FACS and Microscopy facilities. This work was supported by the AIRC (Associazione Italiana per la Ricerca sul Cancro) Grant-10489, AICR (Association for International Cancer Research, UK) Grant-08-182 and MERIT Grant-RBNE08YFN3 (MIUR) to Pasquale Verde. Gerolama Condorelli was supported by grants from AIRC (Grant-14046) and Fondazione Berlucchi.	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Cai HQ, 2014, INT J MOL SCI, V15, P560, DOI 10.3390/ijms15010560; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Das S, 2013, ONCOGENE, V32, P2927, DOI 10.1038/onc.2012.311; Dong H, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-163; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Galgano A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003164; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Gennarino VA, 2012, GENOME RES, V22, P1163, DOI 10.1101/gr.130435.111; Goswami S, 2010, J BIOL CHEM, V285, P20532, DOI 10.1074/jbc.M110.109298; Hashimoto Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062589; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Huang YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019718; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; le Sage C, 2007, CELL CYCLE, V6, P2742, DOI 10.4161/cc.6.22.4900; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lin PY, 2010, BRIT J CANCER, V103, P1144, DOI 10.1038/sj.bjc.6605901; Medina R, 2008, CANCER RES, V68, P2773, DOI 10.1158/0008-5472.CAN-07-6754; Miles WO, 2012, GENE DEV, V26, P356, DOI 10.1101/gad.182568.111; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nassirpour R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062170; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Sun Y, 2012, ONCOL REP, V28, P1346, DOI 10.3892/or.2012.1958; Takanami I, 2005, ONCOL REP, V13, P727; Talotta F, 2010, ONCOGENE, V29, P4732, DOI 10.1038/onc.2010.211; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Zhang C, 2010, INT J ONCOL, V37, P1; Zhou X, 2013, BIOCHEM BIOPH RES CO, V437, P653, DOI 10.1016/j.bbrc.2013.07.033	41	140	147	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3240	3250		10.1038/onc.2014.267	http://dx.doi.org/10.1038/onc.2014.267			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151966	Green Accepted			2022-12-17	WOS:000356592300003
J	Tennakoon, JB; Shi, Y; Han, JJ; Tsouko, E; White, MA; Burns, AR; Zhang, A; Xia, X; Ilkayeva, OR; Xin, L; Ittmann, MM; Rick, FG; Schally, AV; Frigo, DE				Tennakoon, J. B.; Shi, Y.; Han, J. J.; Tsouko, E.; White, M. A.; Burns, A. R.; Zhang, A.; Xia, X.; Ilkayeva, O. R.; Xin, L.; Ittmann, M. M.; Rick, F. G.; Schally, A. V.; Frigo, D. E.			Androgens regulate prostate cancer cell growth via an AMPK-PGC-1 alpha-mediated metabolic switch	ONCOGENE			English	Article						androgen receptor; prostate cancer; AMP-activated protein kinase; peroxisome proliferator-activated receptor gamma coactivator 1 alpha; metabolism	FATTY-ACID OXIDATION; PROTEIN-KINASE AMPK; SKELETAL-MUSCLE; MOLECULAR-FEATURES; EXPRESSION; GLUCOSE; PROMOTES; PATHWAY; PHOSPHORYLATION; C-11-ACETATE	Prostate cancer is the most commonly diagnosed malignancy among men in industrialized countries, accounting for the second leading cause of cancer-related deaths. Although we now know that the androgen receptor (AR) is important for progression to the deadly advanced stages of the disease, it is poorly understood what AR-regulated processes drive this pathology. Here we demonstrate that AR regulates prostate cancer cell growth via the metabolic sensor 5'-AMP-activated protein kinase (AMPK), a kinase that classically regulates cellular energy homeostasis. In patients, activation of AMPK correlated with prostate cancer progression. Using a combination of radiolabeled assays and emerging metabolomic approaches, we also show that prostate cancer cells respond to androgen treatment by increasing not only rates of glycolysis, as is commonly seen in many cancers, but also glucose and fatty acid oxidation. Importantly, this effect was dependent on androgen-mediated AMPK activity. Our results further indicate that the AMPK-mediated metabolic changes increased intracellular ATP levels and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha)-mediated mitochondrial biogenesis, affording distinct growth advantages to the prostate cancer cells. Correspondingly, we used outlier analysis to determine that PGC-1 alpha is overexpressed in a subpopulation of clinical cancer samples. This was in contrast to what was observed in immortalized benign human prostate cells and a testosterone-induced rat model of benign prostatic hyperplasia. Taken together, our findings converge to demonstrate that androgens can co-opt the AMPK-PGC-1 alpha signaling cascade, a known homeostatic mechanism, to increase prostate cancer cell growth. The current study points to the potential utility of developing metabolic-targeted therapies directed toward the AMPK-PGC-1 alpha signaling axis for the treatment of prostate cancer.	[Tennakoon, J. B.; Shi, Y.; Han, J. J.; Tsouko, E.; White, M. A.; Frigo, D. E.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA; [Burns, A. R.] Univ Houston, Coll Optometry, Houston, TX 77204 USA; [Zhang, A.; Xia, X.; Frigo, D. E.] Houston Methodist Res Inst, Ctr Genom Med, Houston, TX USA; [Ilkayeva, O. R.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Xin, L.] Baylor Coll Med, Dept Mol Biol, Houston, TX 77030 USA; [Xin, L.] Baylor Coll Med, Dept Cellular Biol, Houston, TX 77030 USA; [Xin, L.; Ittmann, M. M.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Xin, L.; Ittmann, M. M.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; [Xin, L.; Ittmann, M. M.] Dan L Duncan Canc Ctr, Houston, TX USA; [Ittmann, M. M.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Rick, F. G.; Schally, A. V.] Vet Affairs Med Ctr, Miami, FL 33125 USA; [Rick, F. G.; Schally, A. V.] South Florida VA Fdn Res & Educ, Miami, FL 33125 USA; [Rick, F. G.] Florida Int Univ, Herbert Wertheim Coll Med, Dept Urol, Miami, FL 33199 USA; [Schally, A. V.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33136 USA; [Schally, A. V.] Univ Miami, Miller Sch Med, Div Hematol Oncol, Miami, FL 33136 USA; [Schally, A. V.] Univ Miami, Miller Sch Med, Dept Med, Div Endocrinol, Miami, FL USA	University of Houston System; University of Houston; University of Houston System; University of Houston; The Methodist Hospital System; The Methodist Hospital - Houston; Duke University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; Florida International University; University of Miami; University of Miami; University of Miami	Frigo, DE (corresponding author), Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, 3605 Cullen Blvd,Bldg 545, Houston, TX 77204 USA.	frigo@uh.edu		Schally, Andrew/0000-0003-1273-6747; Frigo, Daniel/0000-0002-0713-471X; Rick, Ferenc/0000-0001-6549-7597	NIH [K01DK084205, P30EY007551, R00CA125937, P30CA125123]; DoD/PCRP grant [W81XWH-12-1-0204]; CPRIT grant [RP110005]; Texas Emerging Technology Fund; Golfers Against Cancer; Urology Care Foundation Research Scholars Program; AUA Southeastern Section; NATIONAL CANCER INSTITUTE [P30CA125123, R00CA125937] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY007551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK084205] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD/PCRP grant; CPRIT grant; Texas Emerging Technology Fund; Golfers Against Cancer; Urology Care Foundation Research Scholars Program; AUA Southeastern Section; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of the Frigo Laboratory for technical advice, helpful suggestions and critical comments on this study and manuscript. We also thank Paul Landry for his assistance with Amira and mitochondrial volume measurements, the Duke University Department of Pathology's Electron Microscopy Core for help with transmission electron microscopy; Drs Dean Tang, Geoffrey Girnun and Thomas Westbrook for generously providing the LAPC9-derived tumors, shPGC-1 alpha constructs and pINDUCER22, respectively; Drs Timothy Koves and Pradip Saha for their advice on the CO<INF>2</INF> trap assays; Dr Christopher Newgard for help with the metabolomics; and Drs Sean McGuire and Kevin Phillips for critically reading this manuscript. This work was supported by NIH grants K01DK084205 (DEF), P30EY007551 (ARB), R00CA125937 (LX), P30CA125123 (Dan L Duncan Cancer Center Human Tissue Acquisition and Pathology Core), DoD/PCRP grant W81XWH-12-1-0204 (DEF), CPRIT grant RP110005 (LX) and grants from the Texas Emerging Technology Fund, the Golfers Against Cancer (DEF), the Urology Care Foundation Research Scholars Program and AUA Southeastern Section (FGR).	Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Arredouani MS, 2009, CLIN CANCER RES, V15, P5794, DOI 10.1158/1078-0432.CCR-09-0911; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bhalla K, 2011, CANCER RES, V71, P6888, DOI 10.1158/0008-5472.CAN-11-1011; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cormio A, 2009, BIOCHEM BIOPH RES CO, V390, P1182, DOI 10.1016/j.bbrc.2009.10.114; Costello LC, 2005, MITOCHONDRION, V5, P143, DOI 10.1016/j.mito.2005.02.001; Dakubo GD, 2006, J CLIN PATHOL, V59, P10, DOI 10.1136/jcp.2005.027664; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Ertel A, 2012, CELL CYCLE, V11, P253, DOI 10.4161/cc.11.2.19006; Frigo DE, 2011, CANCER RES, V71, P528, DOI 10.1158/0008-5472.CAN-10-2581; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodgson MC, 2011, CANCER RES, V71, P572, DOI 10.1158/0008-5472.CAN-10-2314; Hofer C, 1999, EUR UROL, V36, P31, DOI 10.1159/000019923; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Jung SN, 2009, EXP CELL RES, V315, P2433, DOI 10.1016/j.yexcr.2009.05.018; Karacosta LG, 2012, J BIOL CHEM, V287, P24832, DOI 10.1074/jbc.M112.370783; Klimcakova E, 2012, CANCER RES, V72, P1538, DOI 10.1158/0008-5472.CAN-11-2967; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Liu YY, 2010, ANTICANCER RES, V30, P369; Marin-Valencia I, 2012, CELL METAB, V15, P827, DOI 10.1016/j.cmet.2012.05.001; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Moon JS, 2011, BIOCHEM J, V433, P225, DOI 10.1042/BJ20101104; O'Mahony F, 2012, MOL ENDOCRINOL, V26, P2058, DOI 10.1210/me.2012-1191; Oyama N, 2003, J NUCL MED, V44, P549; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Pillarsetty NV, 2009, J NUCL MED, V50, P1709, DOI 10.2967/jnumed.109.064212; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rick FG, 2011, P NATL ACAD SCI USA, V108, P3755, DOI 10.1073/pnas.1018086108; Rick FG, 2011, PROSTATE, V71, P736, DOI 10.1002/pros.21289; Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787; Shiota M, 2010, MOL ENDOCRINOL, V24, P114, DOI 10.1210/me.2009-0302; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Stoss O, 2008, PROSTATE CANCER P D, V11, P166, DOI 10.1038/sj.pcan.4501001; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wang JH, 2011, CANCER RES, V71, P1325, DOI 10.1158/0008-5472.CAN-10-2210; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P4047, DOI 10.4161/cc.10.23.18151; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133; Xiao D, 2010, J BIOL CHEM, V285, P26558, DOI 10.1074/jbc.M109.063255; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yu EY, 2011, CLIN NUCL MED, V36, P192, DOI 10.1097/RLU.0b013e318208f140; Zha S, 2005, PROSTATE, V63, P316, DOI 10.1002/pros.20177; Zhang B, 2014, ONCOGENE, V33, P3099, DOI 10.1038/onc.2013.281	62	140	145	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5251	5261		10.1038/onc.2013.463	http://dx.doi.org/10.1038/onc.2013.463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186207	Green Accepted			2022-12-17	WOS:000345120400003
J	Sun, X; Jiao, X; Pestell, TG; Fan, C; Qin, S; Mirabelli, E; Ren, H; Pestell, RG				Sun, X.; Jiao, X.; Pestell, T. G.; Fan, C.; Qin, S.; Mirabelli, E.; Ren, H.; Pestell, R. G.			MicroRNAs and cancer stem cells: the sword and the shield	ONCOGENE			English	Review						miRNAs; anticancer treatment; cancer stem cells; targeted therapy; clinical therapeutics	EPITHELIAL-MESENCHYMAL TRANSITION; WNT SIGNALING PATHWAY; TUMOR-SUPPRESSOR; MULTIDRUG-RESISTANCE; OVARIAN-CANCER; SELF-RENEWAL; DOWN-REGULATION; FEEDBACK LOOP; EXPRESSION; TARGETS	Emerging chemotherapy drugs and targeted therapies have been widely applied in anticancer treatment and have given oncologists a promising future. Nevertheless, regeneration and recurrence are still huge obstacles on the way to cure cancer. Cancer stem cells (CSCs) are capable of self-renewal, tumor initiation, recurrence, metastasis, therapy resistance, and reside as a subset in many, if not all, cancers. Therefore, therapeutics specifically targeting and killing CSCs are being identified, and may be promising and effective strategies to eliminate cancer. MicroRNAs (miRNAs, miRs), small noncoding RNAs regulating gene expression in a post-transcriptional manner, are dysregulated in most malignancies and are identified as important regulators of CSCs. However, limited knowledge exists for biological and molecular mechanism by which miRNAs regulate CSCs. In this article, we review CSCs, miRNAs and the interactions between miRNA regulation and CSCs, with a specific focus on the molecular mechanisms and clinical applications. This review will help us to know in detail how CSCs are regulated by miRNAs networks and also help to develop more effective and secure miRNA-based clinical therapies.	[Sun, X.; Qin, S.; Ren, H.] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian 710061, Shaanxi Provinc, Peoples R China; [Sun, X.; Jiao, X.; Mirabelli, E.; Pestell, R. G.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Pestell, T. G.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Stem Cell Biol & Regenerat Med, Philadelphia, PA 19107 USA; [Fan, C.] Tianjin Med Univ, Affiliated Hosp 2, Cardiovasc Dept, Tianjin, Peoples R China; [Qin, S.] NYU Med Ctr, New York, NY 10016 USA	Xi'an Jiaotong University; Jefferson University; Jefferson University; Tianjin Medical University; New York University	Ren, H (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Dept Oncol, 277 Yanta West Rd, Xian 710061, Shaanxi Provinc, Peoples R China.	renhongs2000@aliyun.com; director@kimmelcancercenter.org	Sun, Xin/AAI-4648-2020		NIH [R01CA70896, R01CA75503, R01CA86072, R01CA137494, R01CA132115]; National Natural Science Foundation of China [81272418]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study is supported in part by NIH grants R01CA70896, R01CA75503, R01CA86072, R01CA137494 and R01CA132115 and National Natural Science Foundation of China 81272418. We are grateful to Elsa R Flores, Ph.D. (Department of Biochemistry and Molecular Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center) for her helpful advice and suggestions.	Bao B, 2011, CANCER LETT, V307, P26, DOI 10.1016/j.canlet.2011.03.012; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Beildeck ME, 2010, EXP CELL RES, V316, P1763, DOI 10.1016/j.yexcr.2010.02.001; Borel F, 2012, HEPATOLOGY, V55, P821, DOI 10.1002/hep.24682; Bourguignon LW, 2013, STEM CELLS CANC STEM, V9, P291; Boyerinas B, 2012, INT J CANCER, V130, P1787, DOI 10.1002/ijc.26190; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Cheng WW, 2012, FEBS J, V279, P2047, DOI 10.1111/j.1742-4658.2012.08589.x; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Debeb BG, 2009, J MAMMARY GLAND BIOL, V14, P11, DOI 10.1007/s10911-009-9114-z; DeSano JT, 2009, AAPS J, V11, P682, DOI 10.1208/s12248-009-9147-7; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Giovannetti E, 2012, CRIT REV ONCOL HEMAT, V81, P103, DOI 10.1016/j.critrevonc.2011.03.010; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Ha HT, 2013, AM J CLIN ONCOL-CANC, V36, P77, DOI 10.1097/COC.0b013e31823a4970; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019; Hu XW, 2013, MOL CANCER RES, V11, P240, DOI 10.1158/1541-7786.MCR-12-0432; Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Katoh M, 2006, INT J MOL MED, V17, P681; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Li M, 2009, WORLD J SURG, V33, P667, DOI 10.1007/s00268-008-9836-x; Li WQ, 2010, MED SCI MONITOR, V16, pHY27; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li YQ, 2012, CANCER RES, V72, P576, DOI 10.1158/0008-5472.CAN-11-3070; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Liep J, 2012, EPIGENETICS-US, V7, P315, DOI 10.4161/epi.19464; Liu B, 2010, CELL BIOL INT, V34, P21, DOI 10.1042/CBI20090129; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Lopez-Chavez A, 2009, CURR OPIN INVEST DR, V10, P1305; Mallick R, 2010, BIOL APPL DIAGNOSIS, V81, P410; Marcucci G, 2009, BEST PRACT RES CL HA, V22, P239, DOI 10.1016/j.beha.2009.05.003; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Mihatsch J, 2011, RADIOTHER ONCOL, V99, P300, DOI 10.1016/j.radonc.2011.06.003; Mishra PJ, 2009, PHARMACOGENOMICS, V10, P399, DOI 10.2217/14622416.10.3.399; Mohan M, 2010, GENE DEV, V24, P574, DOI 10.1101/gad.1898410; Murray MY, 2012, CELL SIGNAL, V24, P363, DOI 10.1016/j.cellsig.2011.09.021; Nguyen Giang Huong, 2011, Cancers (Basel), V3, P1232, DOI 10.3390/cancers3011232; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; O'Hara AJ, 2009, BLOOD, V113, P5938, DOI 10.1182/blood-2008-09-179168; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Peitzsch C, 2013, RADIOTHER ONCOL, V108, P378, DOI 10.1016/j.radonc.2013.06.003; Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pirollo KF, 2007, CANCER RES, V67, P2938, DOI 10.1158/0008-5472.CAN-06-4535; Plath K, 2012, CELL STEM CELL, V11, P607, DOI 10.1016/j.stem.2012.10.003; Plummer PN, 2013, CANCER RES, V73, P341, DOI 10.1158/0008-5472.CAN-12-0271; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Samantarrai D, 2013, MOL CANCER RES, V11, P315, DOI 10.1158/1541-7786.MCR-12-0649; Sandhu S, 2011, SEMIN ONCOL, V38, P781, DOI 10.1053/j.seminoncol.2011.08.007; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Schatton T, 2009, BIOESSAYS, V31, P1038, DOI 10.1002/bies.200900058; Schramedei K, 2011, ONCOGENE, V30, P2975, DOI 10.1038/onc.2011.15; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480; Shiiba M, 2013, BRIT J CANCER, V108, P1817, DOI 10.1038/bjc.2013.175; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Sindhu C, 2012, J BIOL CHEM, V287, P30922, DOI 10.1074/jbc.R111.319046; Sun X, 2013, MED HYPOTHESES, V81, P410, DOI 10.1016/j.mehy.2013.05.033; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Tamara Marie-Egyptienne D, 2012, CANC LETT; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; Turrini E, 2012, PHARMACOGENET GENOM, V22, P198, DOI 10.1097/FPC.0b013e328350012b; Vira D, 2012, CANCER METAST REV, V31, P733, DOI 10.1007/s10555-012-9382-8; Wang D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013067; Weng DS, 2013, J IMMUNOL, V191, P755, DOI 10.4049/jimmunol.1203286; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005; Wu KM, 2011, J BIOL CHEM, V286, P2132, DOI 10.1074/jbc.M110.148395; Xu K, 2012, BIOCHEM J, V446, P291, DOI 10.1042/BJ20120386; Yang YP, 2012, BIOMATERIALS, V33, P1462, DOI 10.1016/j.biomaterials.2011.10.071; Yao JC, 2013, CANCER RES, V73, P1449, DOI 10.1158/0008-5472.CAN-12-3923; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Yu Zuoren, 2012, Frontiers in Genetics, V3, P191, DOI 10.3389/fgene.2012.00191; Zhang R, 2012, CANCER LETT, V314, P155, DOI 10.1016/j.canlet.2011.09.027; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782; Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071; Zimmerman AL, 2011, CANCER LETT, V300, P10, DOI 10.1016/j.canlet.2010.09.019	107	140	147	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					4967	4977		10.1038/onc.2013.492	http://dx.doi.org/10.1038/onc.2013.492			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24240682	Bronze			2022-12-17	WOS:000343768000001
J	Pawlus, MR; Wang, L; Hu, CJ				Pawlus, M. R.; Wang, L.; Hu, C-J			STAT3 and HIF1 alpha cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells	ONCOGENE			English	Article						cotranscriptional activation; HIF; hypoxia; STAT3; transcription	HYPOXIA-INDUCIBLE FACTOR-1; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; REGULATES VEGF EXPRESSION; SMOOTH-MUSCLE-CELLS; SIGNAL TRANSDUCER; TRANSCRIPTION FACTOR; METABOLIC SWITCH; SRC KINASE; KAPPA-B	Solid tumors often exhibit simultaneously inflammatory and hypoxic microenvironments. The 'signal transducer and activator of transcription-3' (STAT3)-mediated inflammatory response and the hypoxia-inducible factor (HIF)-mediated hypoxia response have been independently shown to promote tumorigenesis through the activation of HIF or STAT3 target genes and to be indicative of a poor prognosis in a variety of tumors. We report here for the first time that STAT3 is involved in the HIF1, but not HIF2-mediated hypoxic transcriptional response. We show that inhibiting STAT3 activity in MDA-MB-231 and RCC4 cells by a STAT3 inhibitor or STAT3 small interfering RNA significantly reduces the levels of HIF1, but not HIF2 target genes in spite of normal levels of hypoxia-inducible transcription factor 1 alpha (HIF1 alpha) and HIF2 alpha protein. Mechanistically, STAT3 activates HIF1 target genes by binding to HIF1 target gene promoters, interacting with HIF1a protein and recruiting coactivators CREB binding protein (CBP) and p300, and RNA polymerase II (Pol II) to form enhanceosome complexes that contain HIF1 alpha, STAT3, CBP, p300 and RNA Pol II on HIF1 target gene promoters. Functionally, the effect of STAT3 knockdown on proliferation, motility and clonogenic survival of tumor cells in vitro is phenocopied by HIF1 alpha knockdown in hypoxic cells, whereas STAT3 knockdown in normoxic cells also reduces cell proliferation, motility and clonogenic survival. This indicates that STAT3 works with HIF1 to activate HIF1 target genes and to drive HIF1-depedent tumorigenesis under hypoxic conditions, but also has HIF-independent activity in normoxic and hypoxic cells. Identifying the role of STAT3 in the hypoxia response provides further data supporting the effectiveness of STAT3 inhibitors in solid tumor treatment owing to their usefulness in inhibiting both the STAT3 and HIF1 pro-tumorigenic signaling pathways in some cancer types.	[Pawlus, M. R.; Hu, C-J] Univ Colorado, Grad Sch, Mol Biol Grad Program, Aurora, CO 80045 USA; [Wang, L.; Hu, C-J] Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Hu, CJ (corresponding author), Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus, Aurora, CO 80045 USA.	Cheng-jun.hu@ucdenver.edu		Hu, Cheng-Jun/0000-0003-0985-1285; Pawlus, Matthew/0000-0001-6007-7198	National Cancer Institute [RO1CA134687]; Cancer Leagues of Colorado; NATIONAL CANCER INSTITUTE [R01CA134687, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008730] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Leagues of Colorado; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Cancer Institute (RO1CA134687, Hu) and Cancer Leagues of Colorado (Hu).	Adachi M, 2012, ORAL ONCOL, V48, P1220, DOI 10.1016/j.oraloncology.2012.06.006; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bai LF, 2012, INT J CANCER, V130, P2693, DOI 10.1002/ijc.26303; Bando H, 2003, BIOMED PHARMACOTHER, V57, P333, DOI 10.1016/S0753-3322(03)00098-2; Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Carraro F, 2007, J CELL PHYSIOL, V211, P439, DOI 10.1002/jcp.20951; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Gleadle JM, 1997, BLOOD, V89, P503, DOI 10.1182/blood.V89.2.503; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Horiguchi A, 2002, J UROLOGY, V168, P762, DOI 10.1016/S0022-5347(05)64741-6; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Indelicato M, 2010, J CELL PHYSIOL, V223, P359, DOI 10.1002/jcp.22041; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Jung JE, 2008, EXP MOL MED, V40, P479, DOI 10.3858/emm.2008.40.5.479; Kaelin WG, 2011, COLD SH Q B, V76, P335, DOI 10.1101/sqb.2011.76.010975; Kang SH, 2010, NEUROSURGERY, V67, P1386, DOI 10.1227/NEU.0b013e3181f1c0cd; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Lee MY, 2006, BREAST, V15, P187, DOI 10.1016/j.breast.2005.05.005; Liu T, 2012, INT J BIOCHEM CELL B, V44, P1337, DOI 10.1016/j.biocel.2012.04.017; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Noman MZ, 2009, J IMMUNOL, V182, P3510, DOI 10.4049/jimmunol.0800854; Oh MK, 2011, J BIOL CHEM, V286, P8857, DOI 10.1074/jbc.M110.150557; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pawlus MR, 2012, MOL CELL BIOL, V32, P4595, DOI 10.1128/MCB.00724-12; Pham NA, 2009, INT J CANCER, V124, P280, DOI 10.1002/ijc.23912; Piperi C, 2011, CYTOKINE, V55, P387, DOI 10.1016/j.cyto.2011.05.012; Rathinavelu A, 2012, J CELL MOL MED, V16, P1750, DOI 10.1111/j.1582-4934.2011.01472.x; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ruas JL, 2010, J BIOL CHEM, V285, P2601, DOI 10.1074/jbc.M109.021824; Santra M, 2008, J NEUROCHEM, V105, P324, DOI 10.1111/j.1471-4159.2007.05134.x; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Squarize CH, 2006, NEOPLASIA, V8, P733, DOI 10.1593/neo.06274; Wang HB, 2012, AM J PATHOL, V180, P1243, DOI 10.1016/j.ajpath.2011.11.031; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zia MK, 2007, INT J MOL MED, V20, P605	62	140	144	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1670	1679		10.1038/onc.2013.115	http://dx.doi.org/10.1038/onc.2013.115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604114	Green Accepted			2022-12-17	WOS:000334344700007
J	Li, Y; Hwang, TH; Oseth, LA; Hauge, A; Vessella, RL; Schmechel, SC; Hirsch, B; Beckman, KB; Silverstein, KA; Dehm, SM				Li, Y.; Hwang, T. H.; Oseth, L. A.; Hauge, A.; Vessella, R. L.; Schmechel, S. C.; Hirsch, B.; Beckman, K. B.; Silverstein, K. A.; Dehm, S. M.			AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression	ONCOGENE			English	Article						prostate cancer; androgen receptor variants; castration-resistant; intragenic rearrangement, AR alternative splicing	CIRCULATING TUMOR-CELLS; GENE AMPLIFICATION; PROTEIN EXPRESSION; COPY NUMBER; MUTATIONS; THERAPY; RESISTANCE; GROWTH; AXIS	Reactivation of the androgen receptor (AR) during androgen depletion therapy (ADT) underlies castration-resistant prostate cancer (CRPCa). Alternative splicing of the AR gene and synthesis of constitutively active COOH-terminally truncated AR variants lacking the AR ligand-binding domain has emerged as an important mechanism of ADT resistance in CRPCa. In a previous study, we demonstrated that altered AR splicing in CRPCa 22Rv1 cells was linked to a 35-kb intragenic tandem duplication of AR exon 3 and flanking sequences. In this study, we demonstrate that complex patterns of AR gene copy number imbalances occur in PCa cell lines, xenografts and clinical specimens. To investigate whether these copy number imbalances reflect AR gene rearrangements that could be linked to splicing disruptions, we carried out a detailed analysis of AR gene structure in the LuCaP 86.2 and CWR-R1 models of CRPCa. By deletion-spanning PCR, we discovered a 8579-bp deletion of AR exons 5, 6 and 7 in the LuCaP 86.2 xenograft, which provides a rational explanation for synthesis of the truncated AR v567es AR variant in this model. Similarly, targeted resequencing of the AR gene in CWR-R1 cells led to the discovery of a 48-kb deletion in AR intron 1. This intragenic deletion marked a specific CWR-R1 cell population with enhanced expression of the truncated AR-V7/AR3 variant, a high level of androgen-independent AR transcriptional activity and rapid androgen independent growth. Together, these data demonstrate that structural alterations in the AR gene are linked to stable gain-of-function splicing alterations in CRPCa.	[Hwang, T. H.; Silverstein, K. A.] Univ Minnesota, Masonic Canc Ctr, Biostat & Bioinformat Core, Minneapolis, MN 55455 USA; [Hauge, A.; Beckman, K. B.] Univ Minnesota, Biomed Genom Ctr, Minneapolis, MN 55455 USA; [Vessella, R. L.] Univ Washington, Med Ctr, Dept Urol, Seattle, WA 98195 USA; [Vessella, R. L.] Puget Sound VA Hlth Care Syst, Seattle, WA USA; [Schmechel, S. C.; Hirsch, B.; Dehm, S. M.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Hirsch, B.] Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; [Schmechel, S. C.] Univ Minnesota, BioNet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Dehm, SM (corresponding author), Univ Minnesota, Masonic Canc Ctr, Biostat & Bioinformat Core, Mayo Mail Code 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	dehm@umn.edu			comprehensive Masonic Cancer Center NIH [P30 CA077598]; Prostate Cancer Foundation; DOD [PC094384]; NCI [CA141011]; Institute of Human Genetics, University of Minnesota; NATIONAL CANCER INSTITUTE [R21CA141011, P30CA077598] Funding Source: NIH RePORTER	comprehensive Masonic Cancer Center NIH; Prostate Cancer Foundation; DOD(United States Department of Defense); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Institute of Human Genetics, University of Minnesota; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the Minnesota Supercomputing Institute and the Masonic Cancer Center Biostatistics and Bioinformatics Core for providing computing, bioinformatics, statistical, software and data storage support for this project. Cytogenetic analyses were performed in the Cytogenetics Shared Resource Laboratory at the University of Minnesota, with support from the comprehensive Masonic Cancer Center NIH Grant P30 CA077598. We thank Amanda Hemmingsen Jaeger for assistance with developing MLPA for AR gene structure analysis. SMD is a Masonic Scholar of the Masonic Cancer Center, University of Minnesota. This work was supported by a Young Investigator Award from the Prostate Cancer Foundation (SMD), DOD New Investigator Award PC094384 (SMD) NCI Grant CA141011 (SMD), and a seed grant from the Institute of Human Genetics, University of Minnesota.	Attard G, 2011, CLIN CANCER RES, V17, P1649, DOI 10.1158/1078-0432.CCR-10-0567; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; Dagvadorj A, 2008, CLIN CANCER RES, V14, P6062, DOI 10.1158/1078-0432.CCR-08-0979; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Ford OH, 2003, J UROLOGY, V170, P1817, DOI 10.1097/01.ju.0000091873.09677.f4; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Gregory CW, 2001, CANCER RES, V61, P2892; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Haapala K, 2001, LAB INVEST, V81, P1647, DOI 10.1038/labinvest.3780378; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hyytinen ER, 2002, LAB INVEST, V82, P1591, DOI 10.1097/01.LAB.0000038924.67707.75; Leversha MA, 2009, CLIN CANCER RES, V15, P2091, DOI 10.1158/1078-0432.CCR-08-2036; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Linja MJ, 2001, CANCER RES, V61, P3550; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Mohler JL, 2011, CANCER RES, V71, P1486, DOI 10.1158/0008-5472.CAN-10-1343; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Quinlan AR, 2010, GENOME RES, V20, P623, DOI 10.1101/gr.102970.109; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046-8177(03)00190-4; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Steinkamp MP, 2009, CANCER RES, V69, P4434, DOI 10.1158/0008-5472.CAN-08-3605; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tarailo-Graovac Maja, 2009, Curr Protoc Bioinformatics, VChapter 4, DOI 10.1002/0471250953.bi0410s25; Thompson J, 2003, LAB INVEST, V83, P1709, DOI 10.1097/01.LAB.0000107262.40402.44; TILLEY WD, 1990, CANCER RES, V50, P5382; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107	42	140	144	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4759	4767		10.1038/onc.2011.637	http://dx.doi.org/10.1038/onc.2011.637			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266865	Green Accepted			2022-12-17	WOS:000311033000004
J	Gonzalez, ME; Li, X; Toy, K; DuPrie, M; Ventura, AC; Banerjee, M; Ljungman, M; Merajver, SD; Kleer, CG				Gonzalez, M. E.; Li, X.; Toy, K.; DuPrie, M.; Ventura, A. C.; Banerjee, M.; Ljungman, M.; Merajver, S. D.; Kleer, C. G.			Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1	ONCOGENE			English	Article						EZH2; polycomb group protein; breast cancer; basal-cell phenotype; BRCA1; G(2)/M	GROUP PROTEIN EZH2; DNA-DAMAGE RESPONSE; CELL-CYCLE; CDC25C PHOSPHATASE; GENE-EXPRESSION; TARGET GENES; CANCER; POLYCOMB; PHOSPHORYLATION; PROLIFERATION	Increased levels of enhancer of zeste homolog 2 (EZH2), a critical regulator of cellular memory, are associated with negative estrogen receptor (ER) expression and disease progression in breast cancer. High levels of EZH2 signal the presence of metastasis and poor outcome in breast cancer patients. To test the hypothesis that deregulation of EZH2 contributes to ER-negative breast cancer progression, EZH2 expression was inhibited in ER-negative breast cancer cells MDA-MB-231 and CAL51 using a lentivirus system. EZH2 knockdown decreased proliferation and delayed the G(2)/M cell-cycle transition, although not affecting apoptosis. In vivo, EZH2 downregulation significantly decreased breast xenograft growth and improved survival. EZH2 knockdown upregulated BRCA1 protein. Of note, BRCA1 knockdown was sufficient to rescue the effects of EZH2 downregulation on proliferation, G(2)/M arrest, and on the levels of hyperphosphorylated mitotic Cdc25C and Cyclin B1 proteins, crucial for entry into mitosis. Invasive ER-negative breast carcinomas show significant overexpression of EZH2 and downregulation of BRCA1 proteins. Taken together, we show that EZH2 is important in ER-negative breast cancer growth in vivo and in vitro, and that BRCA1 is required for the proliferative effects of EZH2. Blockade of EZH2 may provide a prime target to prevent and/or halt ER-negative breast cancer progression.	[Gonzalez, M. E.; Li, X.; Toy, K.; DuPrie, M.; Kleer, C. G.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Ventura, A. C.; Merajver, S. D.] Univ Michigan, Sch Med, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA; [Ventura, A. C.; Banerjee, M.; Ljungman, M.; Merajver, S. D.; Kleer, C. G.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Banerjee, M.] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA; [Ljungman, M.] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kleer, CG (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 4217 Comprehens Canc Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kleer@umich.edu			NIH [CA090876, CA107469, CA77612]; Avon Foundation; Burroughs Wellcome Fund; Department of Defense Breast Cancer Research Program; NATIONAL CANCER INSTITUTE [R01CA077612, K08CA090876, R01CA107469] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Avon Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Department of Defense Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Arul Chinnaiyan for the EZH2 plasmid, and Tracey Filzen for technical support. We thank Robin Kunkel for assistance with artwork. We thank the University of Michigan Vector Core for virus generation. This work was supported by NIH grants CA090876 (CGK), CA107469 (CGK), CA77612 (SDM), a grant from the Avon Foundation (CGK), a grant from the Burroughs Wellcome Fund (SDM) and a grant from the Department of Defense Breast Cancer Research Program(ACV).	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bae I, 2005, CELL CYCLE, V4, P1641, DOI 10.4161/cc.4.11.2152; Bonnet J, 2008, BIOCHEM BIOPH RES CO, V370, P483, DOI 10.1016/j.bbrc.2008.03.117; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; ELLIS MJ, 2000, DIS BREAST, P749; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Fan MY, 2000, CANCER RES, V60, P6403; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4; Yuli C, 2007, ONCOGENE, V26, P6031, DOI 10.1038/sj.onc.1210420	44	140	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					843	853		10.1038/onc.2008.433	http://dx.doi.org/10.1038/onc.2008.433			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19079346	Green Accepted			2022-12-17	WOS:000263320000007
J	Bettayeb, K; Oumata, N; Echalier, A; Ferandin, Y; Endicott, JA; Galons, H; Meijer, L				Bettayeb, K.; Oumata, N.; Echalier, A.; Ferandin, Y.; Endicott, J. A.; Galons, H.; Meijer, L.			CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases	ONCOGENE			English	Article						cyclin-dependent kinase; kinase inhibitor; roscovitine; CR8; CDK9; cyclin	R-ROSCOVITINE; PROTEIN-KINASES; CELL-CYCLE; IN-VITRO; TARGETS; CYC202; CDC2; PHARMACOKINETICS; PHOSPHORYLATION; OLOMOUCINE	Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against non-small-cell lung and nasopharyngeal cancers. An extensive medicinal chemistry study, designed to generate more potent analogues of roscovitine, led to the identification of an optimal substitution at the N6 position (compound CR8). An extensive selectivity study (108 kinases) highlights the exquisite selectivity of CR8 for CDK1/2/3/5/7/9. CR8 was 2- to 4-fold more potent than (R)-roscovitine at inhibiting these kinases. Cocrystal structures of (R)-CR8 and (R)-roscovitine with pCDK2/cyclin A showed that both inhibitors adopt essentially identical positions. The cellular effects of CR8 and (R)-roscovitine were investigated in human neuroblastoma SH-SY5Y cells. CR8 inhibited the phosphorylation of CDK1 and 9 substrates, with a 25-50 times higher potency compared to (R)-roscovitine. CR8 was consistently more potent than (R)-roscovitine at inducing apoptotic cell death parameters: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reduction ( 40-fold), lactate dehydrogenase release (35-fold), caspases activation (68-fold) and poly-(ADP-ribose) polymerase cleavage (50-fold). This improved cell death-inducing activity of CR8 over (R)-roscovitine was observed in 25 different cell lines. Altogether these results show that second-generation analogues of (R)-roscovitine can be designed with improved antitumor potential.	[Oumata, N.; Galons, H.] Univ Paris 05, INSERM, U648, Lab Chim Organ 2, F-75270 Paris 06, France; [Bettayeb, K.; Ferandin, Y.; Meijer, L.] CNRS, Cell Cycle Grp, Biol Stn, Bretagne, France; [Echalier, A.; Endicott, J. A.] Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); University of Oxford	Galons, H (corresponding author), Univ Paris 05, INSERM, U648, Lab Chim Organ 2, 4 Ave Observ, F-75270 Paris 06, France.	herve.galons@univ-paris5.fr; meijer@sb-roscoff.fr		Endicott, Jane/0000-0003-4868-0116; , laurent/0000-0003-3511-4916	EEC [FP6-2002]; 'Canceropole Grand-Ouest'; 'Institut National du Cancer' (INCa 'Cancer Detection d'innovations 20060); 'Association France-Alzheimer Finistere'; 'Ligue Nationale contre le Cancer (Comite du Finistere)'; 'Ministere de la Recherche'; Association pour la Recherche sur le Cancer; Institut National du Cancer	EEC; 'Canceropole Grand-Ouest'; 'Institut National du Cancer' (INCa 'Cancer Detection d'innovations 20060)(Institut National du Cancer (INCA) France); 'Association France-Alzheimer Finistere'; 'Ligue Nationale contre le Cancer (Comite du Finistere)'; 'Ministere de la Recherche'(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut National du Cancer(Institut National du Cancer (INCA) France)	We are grateful to J Boix, C Guillouzo and J Mester for cell lines, G Ponzio for the human foreskin primary. broblasts, Dr Michael Kubbutat (ProQinase, Freiburg, Germany) and Sir Philip Cohen (Dundee, UK) for the selectivity panel assays and to the beamline scientists at the ESRF (ID14-EH-2 and ID14-EH-1) for providing excellent facilities for crystal data collection. This research was supported by grants from the EEC (FP6-2002-Life Sciences and Health, PRO-KINASE Research Project) (LM, JE), the 'Canceropole Grand-Ouest' grant (LM), the 'Institut National du Cancer' (INCa 'Cancer Detection d'innovations 20060) (LM), the 'Association France-Alzheimer Finistere' (LM) and the 'Ligue Nationale contre le Cancer (Comite du Finistere)' (LM). KB was supported by a fellowship from the 'Ministere de la Recherche' and from the 'Association pour la Recherche sur le Cancer'. NO benefited from a PhD fellowship from the 'Institut National du Cancer'. The structures of pCDK2/cyclin A/(R)-roscovitine, and pCDK2/cyclin A/(R)-CR8 have been deposited in the PDB with accession number codes 3DDQ and 3DDP, respectively.	Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Becker F, 2004, CHEM BIOL, V11, P211, DOI 10.1016/j.chembiol.2004.02.001; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Benson C, 2007, BRIT J CANCER, V96, P29, DOI 10.1038/sj.bjc.6603509; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; de la Motte S, 2004, INT J CLIN PHARM TH, V42, P232; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fischer PM, 2005, EXPERT OPIN INV DRUG, V14, P457, DOI 10.1517/13543784.14.4.457; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Guzi Timothy, 2004, Curr Opin Investig Drugs, V5, P1311; Haesslein Jean-Luc, 2002, Current Topics in Medicinal Chemistry, V2, P1037, DOI 10.2174/1568026023393291; Hallaert DYH, 2007, CELL DEATH DIFFER, V14, P1958, DOI 10.1038/sj.cdd.4402211; Havlicek L, 1997, J MED CHEM, V40, P408, DOI 10.1021/jm960666x; Kapasi AJ, 2008, J VIROL, V82, P394, DOI 10.1128/JVI.01681-07; Knippschild U, 2005, ONKOLOGIE, V28, P508, DOI 10.1159/000087137; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kostich M, 2002, GENOME BIOL, V3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Legraverend M, 2000, J MED CHEM, V43, P1282, DOI 10.1021/jm9911130; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; McClue SJ, 2008, DRUG METAB DISPOS, V36, P561, DOI 10.1124/dmd.107.019232; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Meijer L, 2006, MONOGRAPHS ENZYME IN, V2, P187; Misra RN, 2006, DRUG FUTURE, V31, P43, DOI 10.1358/dof.2006.031.01.953584; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Niedner RH, 2006, PROTEINS, V63, P78, DOI 10.1002/prot.20825; Nutley BP, 2005, MOL CANCER THER, V4, P125; OUMATA N, 2008, J MED CHEM IN PRESS; Payton M, 2006, CANCER RES, V66, P4299, DOI 10.1158/0008-5472.CAN-05-2507; Raynaud FI, 2005, CLIN CANCER RES, V11, P4875, DOI 10.1158/1078-0432.CCR-04-2264; Reinhardt J, 2007, PROTEIN EXPRES PURIF, V54, P101, DOI 10.1016/j.pep.2007.02.020; Ribas J, 2006, ONCOGENE, V25, P6304, DOI 10.1038/sj.onc.1209648; Ribas J, 2004, EXP CELL RES, V295, P9, DOI 10.1016/j.yexcr.2003.12.019; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; SMITH PJ, 2006, CDK INHIBITORS CYCLI, V2; Tang L, 2005, J BIOL CHEM, V280, P31220, DOI 10.1074/jbc.M500805200; Vandromme L, 2006, BIOORG MED CHEM LETT, V16, P3144, DOI 10.1016/j.bmcl.2006.03.060; Vita M, 2005, EUR J PHARM SCI, V25, P91, DOI 10.1016/j.ejps.2005.02.001	51	140	143	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5797	5807		10.1038/onc.2008.191	http://dx.doi.org/10.1038/onc.2008.191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18574471				2022-12-17	WOS:000259722400004
J	Averous, J; Fonseca, BD; Proud, CG				Averous, J.; Fonseca, B. D.; Proud, C. G.			Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1	ONCOGENE			English	Article						rapamycin; translation initiation; 4E-BP1; cell cycle; cancer	CAP-BINDING PROTEIN; MESSENGER-RNA; TRANSLATION INITIATION; MAMMALIAN TARGET; AMINO-ACIDS; C-MYC; RAPAMYCIN; PHOSPHORYLATION; MEDIATE; EIF-4E	There is currently substantial interest in the regulation of cell function by mammalian target of rapamycin ( mTOR), especially effects linked to the rapamycin-sensitive mTOR complex 1 ( mTORC1). Rapamycin induces G(1) arrest and blocks proliferation of many tumor cells, suggesting that the inhibition of mTORC1 signaling may be useful in cancer therapy. In MCF7 breast adenocarcinoma cells, rapamycin decreases levels of cyclin D1, without affecting cytoplasmic levels of its mRNA. In some cell - types, rapamycin does not affect cyclin D1 levels, whereas the starvation for leucine ( which impairs mTORC1 signaling more profoundly than rapamycin) does. This pattern correlates with the behavior of eukaryotic initiation factor 4E-binding protein 1 ( 4E-BP1, an mTORC1 target that regulates translation initiation). siRNA-mediated knockdown of 4E-BP1 abrogates the effect of rapamycin on cyclin D1 expression and increases the polysomal association of the cyclin D1 mRNA. Our data identify 4E-BP1 as a key regulator of cyclin D1 expression, indicate that this effect is not mediated through the changes in cytoplasmic levels of cyclin D1 mRNA and suggest that, in some cell types, interfering with the amino acid input to mTORC1, rather than using rapamycin, may inhibit proliferation.	[Averous, J.; Fonseca, B. D.; Proud, C. G.] Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Proud, CG (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	cgpr@interchange.ubc.ca		Proud, Christopher/0000-0003-0704-6442				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Averous J, 2005, FEBS LETT, V579, P2609, DOI 10.1016/j.febslet.2005.03.077; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 2001, GENE DEV, V15, P2852; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hizli AA, 2006, J BIOL CHEM, V281, P14596, DOI 10.1074/jbc.M601959200; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; Kimball SR, 2006, J NUTR, V136, p227S, DOI 10.1093/jn/136.1.227S; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	30	140	141	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1106	1113		10.1038/sj.onc.1210715	http://dx.doi.org/10.1038/sj.onc.1210715			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17724476				2022-12-17	WOS:000253136700010
J	Hu, B; Guo, P; Bar-Joseph, I; Imanishi, Y; Jarzynka, MJ; Bogler, O; Mikkelsen, T; Hirose, T; Nishikawa, R; Cheng, SY				Hu, B.; Guo, P.; Bar-Joseph, I.; Imanishi, Y.; Jarzynka, M. J.; Bogler, O.; Mikkelsen, T.; Hirose, T.; Nishikawa, R.; Cheng, S. Y.			Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway	ONCOGENE			English	Article						neuropilin-1; HGF/SF; c-Met; glioma	ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; CANCER CELLS; EXPRESSION; RECEPTORS; INDUCTION	Neuropilin-1 (NRP1) functions as a coreceptor through interaction with plexin A1 or vascular endothelial growth factor (VEGF) receptor during neuronal development and angiogenesis. NRP1 potentiates the signaling pathways stimulated by semaphorin 3A and VEGF-A in neuronal and endothelial cells, respectively. In this study, we investigate the role of tumor cell-expressed NRP1 in glioma progression. Analyses of human glioma specimens (WHO grade I-IV tumors) revealed a significant correlation of NRP1 expression with glioma progression. In tumor xenografts, overexpression of NRP1 by U87MG gliomas strongly promoted tumor growth and angiogenesis. Overexpression of NRP1 by U87MG cells stimulated cell survival through the enhancement of autocrine hepatocyte growth factor/scatter factor (HGF/SF)/c-Met signaling. NRP1 not only potentiated the activity of endogenous HGF/SF on glioma cell survival but also enhanced HGF/SF-promoted cell proliferation. Inhibition of HGF/SF, c-Met and NRP1 abrogated NRP1-potentiated autocrine HGF/SF stimulation. Furthermore, increased phosphorylation of c-Met correlated with glioma progression in human glioma biopsies in which NRP1 is upregulated and in U87MG NRP1-overexpressing tumors. Together, these data suggest that tumor cell-expressed NRP1 promotes glioma progression through potentiating the activity of the HGF/SF autocrine c-Met signaling pathway, in addition to enhancing angiogenesis, suggesting a novel mechanism of NRP1 in promoting human glioma progression.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Res Pavil Hillman Canc Ctr, Dept Pathol, Pittsburgh, PA USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Detroit, MI 48202 USA; Saitama Med Univ, Dept Pathol, Saitama, Japan; Saitama Med Univ, Dept Neurosurg, Saitama, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Henry Ford Health System; Henry Ford Hospital; Saitama Medical University; Saitama Medical University	Cheng, SY (corresponding author), Univ Pittsburgh, Inst Canc, Suite 2-26,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	hub@upmc.edu; chengs@upmc.edu	Imanishi, Yorihisa/AAL-3018-2021	Imanishi, Yorihisa/0000-0003-0047-7987; Bogler, Oliver/0000-0002-3700-0480	NATIONAL CANCER INSTITUTE [R24CA095809, R01CA130966, R01CA102011] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA130966-01A1, CA102011, R01 CA130966, R24 CA095809, R01 CA102011-04, R01 CA102011-02, R01 CA102011, CA095809, R01 CA102011-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abounader R, 2005, NEURO-ONCOLOGY, V7, P436, DOI 10.1215/S1152851705000050; Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Akagi M, 2003, BRIT J CANCER, V88, P796, DOI 10.1038/sj.bjc.6600811; Bachelder RE, 2003, CANCER RES, V63, P5230; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; Ding H, 2000, INT J CANCER, V88, P584, DOI 10.1002/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Guo P, 2001, CANCER RES, V61, P8569; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Laterra J, 1997, BIOCHEM BIOPH RES CO, V235, P743, DOI 10.1006/bbrc.1997.6853; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Rieger J, 2003, GLIA, V42, P379, DOI 10.1002/glia.10210; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663	17	140	145	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5577	5586		10.1038/sj.onc.1210348	http://dx.doi.org/10.1038/sj.onc.1210348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369861	Green Accepted			2022-12-17	WOS:000248801900003
J	Busa, R; Paronetto, MP; Farini, D; Pierantozzi, E; Botti, F; Angelini, DF; Attisani, F; Vespasiani, G; Sette, C				Busa, R.; Paronetto, M. P.; Farini, D.; Pierantozzi, E.; Botti, F.; Angelini, D. F.; Attisani, F.; Vespasiani, G.; Sette, C.			The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells	ONCOGENE			English	Article						prostate cancer; Sam68; cell proliferation; apoptosis; RNA metabolism	CYCLE PROGRESSION; TYROSINE KINASES; KH DOMAIN; SRC; RECEPTOR; ACTIVATION; PHOSPHORYLATION; INHIBITION; EXPRESSION; VARIANT	The tyrosine kinase Src is frequently activated in advanced human prostate carcinomas and its activation correlates with tyrosine phosphorylation of the RNA-binding protein Sam68. Herein, we have investigated the expression and function of Sam68 in human prostate cancer cells. Analysis of speci mens obtained from 20 patients revealed that Sam68 is upregulated at the protein level in 35% of the samples. Real-time polymerase chain reaction con. firmed the results at the mRNA level in most patients. Downregulation of Sam68 by RNAi in LNCaP prostate cancer cells delayed cell cycle progression and reduced the proliferation rate. Moreover, depletion of Sam68 sensitized cells to apoptosis induced by DNA-damaging agents. Similarly, stable cell lines expressing a truncated GFP-Sam68(GSG) protein displayed reduced growth rates and higher sensitivity to cisplatin-induced apoptosis. Microarray analyses revealed that a subset of genes involved in proliferation and apoptosis were altered when Sam68 was knocked down in LNCaP cells. Our results indicate that Sam68 expression supports prostate cancer cells proliferation and survival to cytotoxle agents.	Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Urol, Rome, Italy; IRCCS, Inst Neurosci, Fdn Santa Lucia, Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Santa Lucia	Sette, C (corresponding author), Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Via Montpellier 1, I-00133 Rome, Italy.	claudio.sette@uniroma2.it	Angelini, Daniela F/J-8001-2018; Paronetto, Maria Paola/A-9578-2012; Sette, Claudio/S-4307-2019	Angelini, Daniela F/0000-0003-4552-9226; Paronetto, Maria Paola/0000-0001-5324-0903; Sette, Claudio/0000-0003-2864-8266; PIERANTOZZI, Enrico/0000-0003-2925-7339; FARINI, DONATELLA/0000-0002-1991-3956				Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li HR, 2006, CANCER RES, V66, P4079, DOI 10.1158/0008-5472.CAN-05-4264; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Palapattu GS, 2005, CARCINOGENESIS, V26, P1170, DOI 10.1093/carcin/bgh317; Paronetto MP, 2006, MOL BIOL CELL, V17, P14, DOI 10.1091/mbc.e05-06-0548; Paronetto MP, 2004, AM J PATHOL, V164, P1243, DOI 10.1016/S0002-9440(10)63212-9; Paronetto MP, 2003, ONCOGENE, V22, P8707, DOI 10.1038/sj.onc.1207016; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Zhang CL, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-202; Zhou J, 2003, J BIOL CHEM, V278, P6936, DOI 10.1074/jbc.M210628200	29	140	145	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4372	4382		10.1038/sj.onc.1210224	http://dx.doi.org/10.1038/sj.onc.1210224			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17237817				2022-12-17	WOS:000247620000005
J	Guder, C; Philipp, I; Lengfeld, T; Watanabe, H; Hobmayer, B; Holstein, TW				Guder, C.; Philipp, I.; Lengfeld, T.; Watanabe, H.; Hobmayer, B.; Holstein, T. W.			The Wnt code: cnidarians signal the way	ONCOGENE			English	Review						Wnt signalling; regeneration; axis formation; Hydra; Nematostella; cnidaria	ANEMONE NEMATOSTELLA-VECTENSIS; SEA-ANEMONE; AXIS FORMATION; BETA-CATENIN; LARVAL DEVELOPMENT; SNAIL EXPRESSION; NANOS EXPRESSION; HEAD ORGANIZER; GENE FAMILY; STEM-CELLS	Cnidarians are the simplest metazoans with a nervous system. They are well known for their regeneration capacity, which is based on the restoration of a signalling centre (organizer). Recent work has identified the canonical Wnt pathway in the freshwater polyp Hydra, where it acts in organizer formation and regeneration. Wnt signalling is also essential for cnidarian embryogenesis. In the sea anemone Nematostella vectensis 11 of the 12 known wnt gene subfamilies were identified. Different wnt genes exhibit serial and overlapping expression domains along the oral-aboral axis of the embryo (the `wnt code'). This is reminiscent of the hox code (cluster) in bilaterian embryogenesis that is, however, absent in cnidarians. It is proposed that the common ancestor of cnidarians and bilaterians invented a set of wnt genes that patterned the ancient main body axis. Major antagonists of Wnt ligands (e.g. Dkk 1/2/4) that were previously known only from chordates, are also present in cnidarians and exhibit a similar conserved function. The unexpectedly high level of genetic complexity of wnt genes evolved in early multi-cellular animals about 650 Myr ago and suggests a radical expansion of the genetic repertoire, concurrent with the evolution of multi-cellularity and the diversification of eumetazoan body plans.	Heidelberg Univ, Dept Mol Evolut & Genom, D-69120 Heidelberg, Germany; Univ Innsbruck, Inst Zool, A-6020 Innsbruck, Austria; Univ Innsbruck, Ctr Mol Biosci, A-6020 Innsbruck, Austria	Ruprecht Karls University Heidelberg; University of Innsbruck; University of Innsbruck	Holstein, TW (corresponding author), Heidelberg Univ, Dept Mol Evolut & Genom, Neuenheimer Feld 230, D-69120 Heidelberg, Germany.	holstein@uni-hd.de	Guder, Corina/L-8413-2014; Watanabe, Hiroshi/GOP-0177-2022	Guder, Corina/0000-0002-8438-5168; Watanabe, Hiroshi/0000-0001-8887-5407; Holstein, Thomas/0000-0003-0480-4674				Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; [Anonymous], 2005, PLAUSIBILITY LIFE; Augustin R, 2006, DEV BIOL, V296, P62, DOI 10.1016/j.ydbio.2006.04.003; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Brooke NM, 2003, CURR OPIN GENET DEV, V13, P599, DOI 10.1016/j.gde.2003.09.002; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Broun M, 2005, DEVELOPMENT, V132, P2907, DOI 10.1242/dev.01848; Broun M, 2002, DEVELOPMENT, V129, P875; Browne EN, 1909, J EXP ZOOL, V7, P1, DOI 10.1002/jez.1400070102; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JY, 2002, DEV BIOL, V248, P182, DOI 10.1006/dbio.2002.0714; Chourrout D, 2006, NATURE, V442, P684, DOI 10.1038/nature04863; Darling JA, 2005, BIOESSAYS, V27, P211, DOI 10.1002/bies.20181; Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154; Extavour CG, 2005, EVOL DEV, V7, P201, DOI 10.1111/j.1525-142X.2005.05023.x; Fedders H, 2004, DEV GENES EVOL, V214, P72, DOI 10.1007/s00427-003-0378-9; Ferrier DEK, 2001, NAT REV GENET, V2, P33, DOI 10.1038/35047605; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Fritzenwanker JH, 2004, DEV BIOL, V275, P389, DOI 10.1016/j.ydbio.2004.08.014; Frobius AC, 2003, DEV GENES EVOL, V213, P445, DOI 10.1007/s00427-003-0344-6; Garcia-Fernandez J, 2005, NAT REV GENET, V6, P881, DOI 10.1038/nrg1723; Garcia-Fernandez J, 2005, HEREDITY, V94, P145, DOI 10.1038/sj.hdy.6800621; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Guder C, 2006, DEVELOPMENT, V133, P901, DOI 10.1242/dev.02265; HAND C, 1992, BIOL BULL, V182, P169, DOI 10.2307/1542110; HASSEL M, 1993, DEV BIOL, V156, P362, DOI 10.1006/dbio.1993.1083; Hayward DC, 2004, DEV GENES EVOL, V214, P257, DOI 10.1007/s00427-004-0398-0; He X, 2006, DEVELOPMENT, V133, P2597, DOI 10.1242/dev.02452; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Hobmayer E, 1996, GENE, V172, P155, DOI 10.1016/0378-1119(96)00162-X; Holland LZ, 2001, DEV BIOL, V232, P493, DOI 10.1006/dbio.2001.0160; Holland LZ, 2002, DEV BIOL, V241, P209, DOI 10.1006/dbio.2001.0503; Holland P, 2004, SCIENCE, V304, P1255, DOI 10.1126/science.1099829; Holstein TW, 2003, DEV DYNAM, V226, P257, DOI 10.1002/dvdy.10227; Jessen JR, 2005, CELL, V120, P736, DOI 10.1016/j.cell.2005.03.005; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Kamm K, 2006, CURR BIOL, V16, P920, DOI 10.1016/j.cub.2006.03.036; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Lee PN, 2006, SEMIN CELL DEV BIOL, V17, P157, DOI 10.1016/j.semcdb.2006.05.002; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Magie CR, 2005, DEV GENES EVOL, V215, P618, DOI 10.1007/s00427-005-0022-y; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Martindale MQ, 2004, DEVELOPMENT, V131, P2463, DOI 10.1242/dev.01119; Matus DQ, 2006, CURR BIOL, V16, P499, DOI 10.1016/j.cub.2006.01.052; Millar JBA, 2002, GENOME BIOL, V3; Miller DJ, 2005, TRENDS GENET, V21, P536, DOI 10.1016/j.tig.2005.08.002; Minobe S, 2000, DEV GENES EVOL, V210, P258, DOI 10.1007/s004270050312; Morris SC, 2000, P NATL ACAD SCI USA, V97, P4426, DOI 10.1073/pnas.97.9.4426; Muller WA, 2004, DEV BIOL, V275, P215, DOI 10.1016/j.ydbio.2004.08.006; Muller WA, 2004, INT J DEV BIOL, V48, P9, DOI 10.1387/ijdb.15005569; Onai T, 2004, DEV CELL, V7, P95, DOI 10.1016/j.devcel.2004.06.004; Plickert G, 2006, DEV BIOL, V298, P368, DOI 10.1016/j.ydbio.2006.06.043; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Prud'homme B, 2002, CURR BIOL, V12, P1395, DOI 10.1016/S0960-9822(02)01068-0; Rentzsch F, 2005, DEV BIOL, V278, P1, DOI 10.1016/j.ydbio.2004.10.007; Rentzsch F, 2006, DEV BIOL, V296, P375, DOI 10.1016/j.ydbio.2006.06.003; Scholz CB, 2003, DEV GENES EVOL, V212, P563, DOI 10.1007/s00427-002-0272-x; Spring J, 2002, DEV BIOL, V244, P372, DOI 10.1006/dbio.2002.0616; Spring J, 2000, DEV BIOL, V228, P363, DOI 10.1006/dbio.2000.9956; Steele RE, 2006, P NATL ACAD SCI USA, V103, P6415, DOI 10.1073/pnas.0601983103; Strutt H, 2006, CURR BIOL, V16, P1329, DOI 10.1016/j.cub.2006.04.041; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Technau U, 2000, P NATL ACAD SCI USA, V97, P12127, DOI 10.1073/pnas.97.22.12127; Technau U, 2005, TRENDS GENET, V21, P633, DOI 10.1016/j.tig.2005.09.007; Technau U, 2003, INT J DEV BIOL, V47, P531; Technau U, 1999, DEVELOPMENT, V126, P999; Teo R, 2006, DEV BIOL, V289, P91, DOI 10.1016/j.ydbio.2005.10.009; Torras R, 2005, INT J DEV BIOL, V49, P895, DOI 10.1387/ijdb.051980rt; Torras R, 2004, EVOL DEV, V6, P362, DOI 10.1111/j.1525-142X.2004.04044.x; Tree DRP, 2002, SEMIN CELL DEV BIOL, V13, P217, DOI 10.1016/S1084-9521(02)00042-3; VANLAUE CC, 2003, THESIS DARMSTADT U T, P97; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wikramanayake AH, 2003, NATURE, V426, P446, DOI 10.1038/nature02113; Wittlieb J, 2006, P NATL ACAD SCI USA, V103, P6208, DOI 10.1073/pnas.0510163103; Yang Yingzi, 2003, Birth Defects Research, V69, P305, DOI 10.1002/bdrc.10026	80	140	148	0	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7450	7460		10.1038/sj.onc.1210052	http://dx.doi.org/10.1038/sj.onc.1210052			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143289	Bronze			2022-12-17	WOS:000242514900003
J	Kuphal, S; Lodermeyer, S; Bataille, F; Schuierer, M; Hoang, BH; Bosserhoff, AK				Kuphal, S.; Lodermeyer, S.; Bataille, F.; Schuierer, M.; Hoang, B. H.; Bosserhoff, A. K.			Expression of Dickkopf genes is strongly reduced in malignant melanoma	ONCOGENE			English	Article						Dickkopf; tumor-suppressor gene; Wnt signaling; malignant melanoma; cancer	BETA-CATENIN; BREAST-CARCINOMA; REPRESSOR SNAIL; CELL-LINES; INVASION; TARGET; GROWTH; CANCER; HYPERMETHYLATION; DIFFERENTIATION	The Dickkopf (DKK) genes were originally identified as factors inducing head formation in Xenopus. The genes code for inhibitors that are involved in Wnt signaling. We speculate that loss of DKK expression plays a role in development or progression of malignant melanoma. Thus, we evaluated melanoma cell lines and tissue samples of malignant melanoma for loss of DKK, especially DKK-3 transcription. We found that DKK-1, -2 and -3 were downregulated or lost in all cell lines and in most of the tumor samples analysed. Reduced DKK-3 expression occurred as early as in primary tumors detected by both immunohistochemical and reverse transcription-polymerase chain reaction RT-PCR analysis. Functional assays with stable DKK-3 transfected cell lines revealed that DKK-3 expression increased cell-cell adhesion and decreased cell migration. Further, downregulation of bronectin, snail-1 and re-expression of E-cadherin was found in the DKK-3 expressing cell clones supporting a role of DKK-3 in tumor progression. Our studies thus indicate that loss of DKK-3 expression may contribute to melanoma progression.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Orthopaed Surg, Irvine, CA 92717 USA	University of Regensburg; University of California System; University of California Irvine	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022; Kuphal, Silke/AAW-2702-2020	Bosserhoff, Anja/0000-0001-8147-394X				Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Behrmann I, 2003, AM J PATHOL, V163, P683, DOI 10.1016/S0002-9440(10)63695-4; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 2003, CANCER RES, V63, P2658; Gilles C, 2001, J CELL SCI, V114, P2967; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Haass NK, 2004, J MOL HISTOL, V35, P309; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Laux H, 2004, LAB INVEST, V84, P1372, DOI 10.1038/labinvest.3700158; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Li G, 2004, EXP CELL RES, V297, P142, DOI 10.1016/j.yexcr.2004.03.012; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Tester AM, 2001, CLIN EXP METASTAS, V18, P553, DOI 10.1023/A:1011953118186; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; ZIEGLERHEITBROCK HWL, 1985, CANCER RES, V45, P1344	31	140	151	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5027	5036		10.1038/sj.onc.1209508	http://dx.doi.org/10.1038/sj.onc.1209508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568085				2022-12-17	WOS:000239921300008
J	Shishodia, S; Aggarwal, BB				Shishodia, S; Aggarwal, BB			Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression	ONCOGENE			English	Article						NF-kappa B; IKK; Akt; invasion; osteoclastogenesis; diosgenin	TRIGONELLA-FOENUM-GRAECUM; NECROSIS-FACTOR-ALPHA; CELL-CYCLE ARREST; FENUGREEK SEEDS; CARCINOMA-CELLS; CANCER-CELLS; HEL CELLS; APOPTOSIS; INDUCTION; CYCLOOXYGENASE-2	Diosgenin, a steroidal saponin present in fenugreek ( Trigonella foenum graecum) and other plants, has been shown to suppress inflammation, inhibit proliferation, and induce apoptosis in a variety of tumor cells, but through a mechanism that is poorly understood. In the present study, we report that diosgenin inhibits receptor-activated nuclear factor-kappaB ligand-induced osteoclastogenesis, suppresses tumor necrosis factor (TNF)-induced invasion, and blocks the proliferation of tumor cells, all activities known to be regulated by NF-kappa B. Diosgenin suppressed TNF-induced NF-kappa B activation as determined by DNA binding, activation of I kappa B alpha kinase, I kappa B alpha phosphorylation, I kappa B alpha degradation, p65 phosphorylation, and p65 nuclear translocation through inhibition of Akt activation. NF-kappa B-dependent reporter gene expression was also abrogated by diosgenin. TNF-induced expression of NF-kappa B-regulated gene products involved in cell proliferation (cyclin D1, COX-2, c-myc), antiapoptosis (IAP1, Bcl-2, Bcl-X-L, Bfl-1/A1, TRAF1 and cFLIP), and invasion (MMP-9) were also downregulated by the saponin. Diosgenin also potentiated the apoptosis induced by TNF and chemotherapeutic agents. Overall, our results suggest that diosgenin suppresses proliferation, inhibits invasion, and suppresses osteoclastogenesis through inhibition of NF-kappa B-regulated gene expression and enhances apoptosis induced by cytokines and chemotherapeutic agents.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Attiga FA, 2000, CANCER RES, V60, P4629; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bottero V, 2001, CANCER RES, V61, P7785; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Corbiere C, 2003, INT J ONCOL, V22, P899; DASGUPTA B, 1970, EXPERIENTIA, V26, P475, DOI 10.1007/BF01898450; DJERASSI C, 1992, SCIENCE, V258, P203, DOI 10.1126/science.1411515; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gupta A, 2001, J Assoc Physicians India, V49, P1057; HEBLE MR, 1968, SCIENCE, V161, P1145, DOI 10.1126/science.161.3846.1145; Hibasami H, 2003, INT J MOL MED, V11, P23; Higdon K, 2001, Biomed Sci Instrum, V37, P281; Leger DY, 2004, INT J ONCOL, V25, P555; Liagre B, 2004, ARTHRITIS RES THER, V6, pR373, DOI 10.1186/ar1199; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Liu MJ, 2005, CANCER CHEMOTH PHARM, V55, P79, DOI 10.1007/s00280-004-0849-3; MADAR Z, 1988, EUR J CLIN NUTR, V42, P51; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Moalic S, 2001, FEBS LETT, V506, P225, DOI 10.1016/S0014-5793(01)02924-6; NAPPEZ C, 1995, CANCER LETT, V96, P133, DOI 10.1016/0304-3835(95)03923-K; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ondeyka JG, 2005, MOL DIVERS, V9, P123, DOI 10.1007/s11030-005-1296-8; Ozes ON, 1999, NATURE, V401, P82; Pandian RS, 2002, J ETHNOPHARMACOL, V81, P393, DOI 10.1016/S0378-8741(02)00117-4; PURI HS, 1976, PLANTA MED, V30, P118, DOI 10.1055/s-0028-1097704; Raju J, 2004, CANCER EPIDEM BIOMAR, V13, P1392; SAUVAIRE Y, 1991, LIPIDS, V26, P191, DOI 10.1007/BF02543970; Scott A, 2001, Biomed Sci Instrum, V37, P13; SEGAL R, 1977, LLOYDIA, V40, P604; SHARMA RD, 1990, EUR J CLIN NUTR, V44, P301; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VALETTE G, 1984, ATHEROSCLEROSIS, V50, P105, DOI 10.1016/0021-9150(84)90012-1; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang SL, 2004, J ASIAN NAT PROD RES, V6, P115, DOI 10.1080/1028602031000147357; Yamada T, 1997, AM J PHYSIOL-GASTR L, V273, pG355, DOI 10.1152/ajpgi.1997.273.2.G355; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yin J, 2004, PLANTA MED, V70, P220, DOI 10.1055/s-2004-815538; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	48	140	149	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1463	1473		10.1038/sj.onc.1209194	http://dx.doi.org/10.1038/sj.onc.1209194			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16331273				2022-12-17	WOS:000235890400004
J	Corson, TW; Huang, A; Tsao, MS; Gallie, BL				Corson, TW; Huang, A; Tsao, MS; Gallie, BL			KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers	ONCOGENE			English	Article						retinoblastoma; breast cancer; lung cancer; medulloblastoma; kinesin; chromosome 1	KINESIN-RELATED PROTEIN; RETINOBLASTOMA; GENE; MOUSE; KLP38B; AMPLIFICATION; ORGANIZATION; ABERRATIONS; IMBALANCES; PARALLEL	Gain of chromosome 1q31-1q32 is seen in > 50% of retinoblastoma and is common in other tumors. To de. ne the minimal 1q region of gain, we determined genomic copy number by quantitative multiplex PCR of 14 sequence tagged sites (STSs) spanning 1q25.3-1q41. The most frequently gained STS at 1q32.1 (71%; 39 of 55 retinoblastoma) defined a 3.06Mbp minimal region of gain between flanking markers, containing 14 genes. Of these, only KIF14, a putative chromokinesin, was over-expressed in various cancers by real-time RT-PCR. KIF14 mRNA was expressed in 20/ 22 retinoblastoma samples 100-1000-fold higher than in retina (t-test P = 0.00002); cell lines (n = 10) had higher levels than tumors (n = 12) (P = 0.009). KIF14 protein was overexpressed in retinoblastoma tumors and breast cancer cell lines by immunoblot. KIF14 was expressed in 4/4 breast cancer cell lines 31-92-fold higher than in normal breast tissue, in 5/5 medulloblastoma cell lines 22-79-fold higher than in fetal brain, and in 10/22 primary lung tumors 3-34-fold higher than in normal lung. Patients with lung tumors that overexpress KIF14 showed a trend toward decreased survival. KIF14 may thus be important in oncogenesis, and has promise as a prognostic indicator and therapeutic target.	Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Canc Informat, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Canc Res Program, Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1LS, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto	Gallie, BL (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Canc Informat, Room 8-415,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	gallie@attglobal.net	Tsao, Ming Sound/AFQ-7332-2022; Corson, Timothy W./B-6851-2009; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Corson, Timothy W./0000-0002-1402-7875; Gallie, Brenda/0000-0002-9697-9211				Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; Bailey JA, 2001, GENOME RES, V11, P1005, DOI 10.1101/gr.GR-1871R; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Bertuzzi S, 1999, MECH DEVELOP, V81, P193, DOI 10.1016/S0925-4773(98)00233-0; Blackhall FH, 2004, LUNG CANCER, V46, P197, DOI 10.1016/j.lungcan.2004.04.002; Chen D, 2002, CANCER RES, V62, P967; Chen DN, 2001, CANCER GENET CYTOGEN, V129, P57, DOI 10.1016/S0165-4608(01)00427-7; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DeBonis S, 2004, MOL CANCER THER, V3, P1079; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5; Gallie BL, 1999, CANCER RES, V59, p1731S; GALLIE BL, 1999, HUMAN CELL CULTURE, V2, P361; Hackett CS, 2003, CANCER RES, V63, P5266; Herzog S, 2001, HUM GENET, V108, P98, DOI 10.1007/s004390000450; Hoglund M, 2002, CANCER RES, V62, P2675; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Leizerman I, 2004, CELL MOL LIFE SCI, V61, P2060, DOI 10.1007/s00018-004-4074-3; LEROY H, 1993, GENE CHROMOSOME CANC, V6, P156; Levesque AA, 2003, MOL BIOL CELL, V14, P3541, DOI 10.1091/mbc.E03-02-0082; Lillington DM, 2002, BRIT J CANCER, V87, P779, DOI 10.1038/sj.bjc.6600532; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Marchong MN, 2004, MOL CANCER RES, V2, P495; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Molina I, 1997, J CELL BIOL, V139, P1361, DOI 10.1083/jcb.139.6.1361; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Nomura N, 1994, DNA Res, V1, P251, DOI 10.1093/dnares/1.5.251; Ohkura H, 1997, J CELL SCI, V110, P945; OLIVEROS O, 1995, CANCER GENET CYTOGEN, V82, P155, DOI 10.1016/0165-4608(94)00212-T; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Retaux S, 1999, J NEUROSCI, V19, P783; Richter S, 2003, AM J HUM GENET, V72, P253, DOI 10.1086/345651; Ruden DM, 1997, DEV BIOL, V191, P284, DOI 10.1006/dbio.1997.8726; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sargent LM, 2002, CANCER RES, V62, P1152; Schreiner B, 2003, GENE CHROMOSOME CANC, V38, P240, DOI 10.1002/gcc.10285; Smith AN, 2002, GENE, V297, P169, DOI 10.1016/S0378-1119(02)00884-3; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; van der Wal JE, 2003, J CLIN PATHOL, V56, P26, DOI 10.1136/jcp.56.1.26; VANBERLO RJ, 1990, CANCER RES, V50, P3416; Yan RT, 1997, GENE, V189, P263, DOI 10.1016/S0378-1119(96)00860-8	44	140	146	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4741	4753		10.1038/sj.onc.1208641	http://dx.doi.org/10.1038/sj.onc.1208641			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897902				2022-12-17	WOS:000230477900001
J	Joyce, JA; Freeman, C; Meyer-Morse, N; Parish, CR; Hanahan, D				Joyce, JA; Freeman, C; Meyer-Morse, N; Parish, CR; Hanahan, D			A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer	ONCOGENE			English	Article						heparanase; heparan sulfate-binding proteins; invasion; angiogenesis; pancreatic neuroendocrine cancer; mouse model	FIBROBLAST GROWTH-FACTORS; MAMMALIAN HEPARANASE; CELL-SURFACE; ENDOTHELIAL-CELLS; GENE-EXPRESSION; BINDING; SEQUESTRATION; PROTEOGLYCANS; DEGRADATION; INVOLVEMENT	Heparan sulfate proteoglycans are integral components of the extracellular matrix that surrounds all mammalian cells. In addition to providing structural integrity, they act as a storage depot for a variety of heparan sulfate (HS)binding proteins, including growth factors and chemokines. Heparanase is a matrix-degrading enzyme that cleaves heparan sulfate side chains from the core proteoglycans, thus liberating such HS-binding proteins, as well as potentially contributing to extracellular matrix degradation. Here, we report that heparanase mRNA and protein expression are increased in the neoplastic stages progressively unfolding in a mouse model of multistage pancreatic islet carcinogenesis. Notably, heparanase is delivered to the neoplastic lesions in large part by infiltrating Gr1+/ Mac1+ innate immune cells. A sulfated oligosaccharide mimetic of heparan sulfate, PI-88, was used to inhibit simultaneously both heparanase activity and HS effector functions. PI-88 had significant effects at distinct stages of tumorigenesis, producing a reduction in the number of early progenitor lesions and an impairment of tumor growth at later stages. These responses were associated with decreased cell proliferation, increased apoptosis, impaired angiogenesis, and a substantive reduction in the number of invasive carcinomas. In addition, we show that the reduction in tumor angiogenesis is correlated with a reduced association of VEGF-A with its receptor VEGF-R2 on the tumor endothelium, implicating heparanase in the mobilization of matrix-associated VEGF. These data encourage clinical applications of inhibitors such as PI-88 for the many human cancers where heparanase expression is elevated or mobilization of HS-binding regulatory factors is implicated.	Univ Calif San Francisco, Dept Biochem & Biophys, Diabet & Comprehens Canc Ctr, San Francisco, CA 94143 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Canberra, ACT 2601, Australia	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Australian National University; John Curtin School of Medical Research	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 372, New York, NY 10021 USA.	joycej@mskcc.org; dh@biochem.ucsf.edu		Parish, Christopher/0000-0001-7740-0430				BARTLETT MR, 1995, J LEUKOCYTE BIOL, V57, P207, DOI 10.1002/jlb.57.2.207; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brekken RA, 1998, CANCER RES, V58, P1952; Cochran S, 2003, J MED CHEM, V46, P4601, DOI 10.1021/jm030180y; Compagni A, 2000, CANCER RES, V60, P7163; DAMORE MA, 1988, BIOCHEMISTRY-US, V27, P7131, DOI 10.1021/bi00418a070; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ferro V, 2001, CARBOHYD RES, V332, P183, DOI 10.1016/S0008-6215(01)00061-1; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Francis DJ, 2003, CIRC RES, V92, pE70, DOI 10.1161/01.RES.0000071345.76095.07; Freeman C, 1997, BIOCHEM J, V325, P229, DOI 10.1042/bj3250229; Freeman C, 1998, BIOCHEM J, V330, P1341, DOI 10.1042/bj3301341; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Haimov-Kochman R, 2002, MOL HUM REPROD, V8, P566, DOI 10.1093/molehr/8.6.566; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.0.CO;2-R; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kelly T, 2003, CANCER RES, V63, P8749; Khachigian LM, 2004, CARDIOVASC DRUG REV, V22, P1; Kim AW, 2002, J GASTROINTEST SURG, V6, P167, DOI 10.1016/S1091-255X(01)00087-7; Koliopanos A, 2001, CANCER RES, V61, P4655; Levidiotis V, 2004, J AM SOC NEPHROL, V15, P68, DOI 10.1097/01.ASN.0000103229.25389.40; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 2000, CANCER RES, V60, P4767; Maxhimer JB, 2002, SURGERY, V132, P326, DOI 10.1067/msy.2002.125719; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; PARANGI S, 1995, CANCER RES, V55, P6071; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BIOCHIM BIOPHYS ACTA, V1471, P99, DOI DOI 10.1016/S0304-419X(01)00017-8; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; Tang WH, 2002, MODERN PATHOL, V15, P593, DOI 10.1038/modpathol.3880571; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Uno F, 2001, CANCER RES, V61, P7855; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; Zcharia E, 2001, J MAMMARY GLAND BIOL, V6, P311, DOI 10.1023/A:1011375624902; Zetser A, 2003, CANCER RES, V63, P7733	56	140	155	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4037	4051		10.1038/sj.onc.1208602	http://dx.doi.org/10.1038/sj.onc.1208602			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806157				2022-12-17	WOS:000229680300004
J	Sumimoto, H; Miyagishi, M; Miyoshi, H; Yamagata, S; Shimizu, A; Taira, K; Kawakami, Y				Sumimoto, H; Miyagishi, M; Miyoshi, H; Yamagata, S; Shimizu, A; Taira, K; Kawakami, Y			Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference	ONCOGENE			English	Article						gene therapy; melanoma; lentiviral vector; BRAF; RNAi; MAPK	GENE-EXPRESSION; HAIRPIN RNAS; BETA-CATENIN; T-CELLS; INTEGRIN; SUPPRESSION; MODULATION; ACTIVATION; MUTATIONS; DELIVERY	Oncogenic mutations of molecules involved in the mitogen-activated protein kinase (MAPK) pathways provide signals mediating both tumor growth and invasion in various cancers including melanomas. BRAF somatic mutations, found in 66% of melanomas, have NIH3T3 transforming ability with the elevated kinase activity in vitro. We attempted to mediate RNA interference (RNAi) with HIV lentiviral vectors specific for either wild type or the most frequently mutated form of BRAF (V599E) in 10 melanoma cell lines, and found that RNAi inhibited the growth of most melanoma cell lines in vitro as well as in vivo, which was accompanied by decrease of both BRAF protein and ERK phosphorylation. Interestingly, the mutated BRAF (V599E)-specific siRNA inhibited the growth and MAPK activity of only melanoma cell lines with this mutation. Furthermore, BRAF RNAi inhibited matrigel invasion of melanoma cells accompanied with a decrease of matrix metalloproteinase activity and beta(1) integrin expression. These results clarify that the mutated BRAF (V599E) is essentially involved in malignant phenotype of melanoma cells through the MAPK activation and is an attractive molecular target for melanoma treatment. The lentivirus-mediated RNAi specific for oncogenic mutations may be a powerful technique for gene therapy of cancer.	Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; RIKEN, Tsukuba Inst, BioResource Ctr, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki 3050074, Japan	Keio University; University of Tokyo; RIKEN	Kawakami, Y (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	yutakawa@sc.itc.keio.ac.jp	Kawakami, Yutaka/E-7429-2013; Miyoshi, Hiroyuki/G-9808-2013; Miyagishi, Makoto/L-8174-2016; Sumimoto, Hidetoshi/AAE-6873-2020	Kawakami, Yutaka/0000-0003-4836-2855; Miyagishi, Makoto/0000-0001-7654-3616; 				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Genersch E, 2000, J CELL SCI, V113, P4319; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hingorani SR, 2003, CANCER RES, V63, P5198; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg158; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MIYAGISHI M, IN PRESS J GENE MED; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NATALI PG, 1993, INT J CANCER, V54, P68, DOI 10.1002/ijc.2910540112; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Petitclerc E, 1999, CANCER RES, V59, P2724; Puyraimond A, 1999, J CELL SCI, V112, P1283; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Satyamoorthy K, 2003, CANCER RES, V63, P756; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Vaisanen A, 1999, J PATHOL, V188, P56; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	40	140	158	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6031	6039		10.1038/sj.onc.1207812	http://dx.doi.org/10.1038/sj.onc.1207812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208655				2022-12-17	WOS:000223261000002
J	Hideshima, T; Chauhan, D; Hayashi, T; Akiyama, M; Mitsiades, N; Mitsiades, C; Podar, K; Munshi, NC; Richardson, PG; Anderson, KC				Hideshima, T; Chauhan, D; Hayashi, T; Akiyama, M; Mitsiades, N; Mitsiades, C; Podar, K; Munshi, NC; Richardson, PG; Anderson, KC			Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; proteasome inhibitor; IL-6; gp130; caspase	ACTIVATED PROTEIN-KINASE; MARROW STROMAL CELLS; DEXAMETHASONE-INDUCED APOPTOSIS; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; THERAPEUTIC APPLICATIONS; MOLECULAR-MECHANISMS; DRUG-RESISTANCE; UP-REGULATION; PLASMA-CELLS	Proteasome inhibitor PS-341 is one of the most promising novel agents against multiple myeloma (MM). We have previously shown that PS-341 inhibits IL-6 triggered phosphorylation of extracellular signal-regulated kinases (ERK) 1/2 (also known as p42/44 mitogen-activated protein kinases) in MM cells. In this study, we further examined whether clinically achievable concentrations of PS-341 could inhibit IL-6 triggered signaling cascades in MM. We found that PS-341 inhibited not only ERK, but also signal transducers and activators of transcription (STAT) 3 as well as Akt phosphorylation. Since gp130 (CD130) dimerizes and is phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be involved in PS-341-induced blockade of signaling cascades mediating MM cell growth, survival, and drug resistance in the bone marrow (BM) microenvironment. In this study, we first demonstrate that PS-341 induces downregulation of gp130 in a time- and dose-dependent manner in vitro, prior to MM cell death. Conversely, downregulation of gp130 is completely abrogated by the pan-caspase inhibitor Z-VAD-FMK, suggesting that downregulation of gp130 is mediated via caspase activation. Z-VAD-FMK also abrogates the inhibitory effect of PS-341 on IL-6-triggered signaling cascades. Importantly, we demonstrate that phosphorylation of ERK, STAT3, and Akt in MM.1S cells induced by either exogenous IL-6 or by binding of MM cells to BM stromal cells is abrogated by PS-341. These studies, therefore, define another novel mechanism whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu. Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Mayer 557,44 Binney St, Boston, MA 02115 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA 50947] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, MOL CANCER THER, V1, P539; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V90, P707, DOI 10.1111/j.1365-2141.1995.tb05605.x; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1989, BLOOD, V73, P517; Kurth I, 1999, J IMMUNOL, V162, P1480; LeBlanc R, 2002, CANCER RES, V62, P4996; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; Ogata A, 1997, J IMMUNOL, V159, P2212; Ogawa M, 2000, CANCER RES, V60, P4262; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Richardson PG, 2001, BLOOD, V98, p774A; Semenov I, 2002, LEUKEMIA RES, V26, P271, DOI 10.1016/S0145-2126(01)00103-5; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733	44	140	155	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8386	8393		10.1038/sj.onc.1207170	http://dx.doi.org/10.1038/sj.onc.1207170			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627979				2022-12-17	WOS:000186650300002
J	Ohtsuka, T; Buchsbaum, D; Oliver, P; Makhija, S; Kimberly, R; Zhou, T				Ohtsuka, T; Buchsbaum, D; Oliver, P; Makhija, S; Kimberly, R; Zhou, T			Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway	ONCOGENE			English	Article						apoptosis; TRAIL receptor; chemotherapy; JNK; mitochondria	TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; CYTOTOXIC LIGAND TRAIL; BLADDER-CANCER CELLS; N-TERMINAL KINASE; MEDIATED APOPTOSIS; DR5-MEDIATED APOPTOSIS; TUMORICIDAL ACTIVITY; ANTITUMOR-ACTIVITY; ANTICANCER AGENTS	Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.	Sankyo Co Ltd, Biomed Res Labs, Tokyo 1408710, Japan; Univ Alabama, Dept Med Radiobiol, Birmingham, AL 35294 USA; Univ Alabama, Div Gynecol Oncol, Birmingham, AL 35294 USA; Univ Alabama, Dept Math, Birmingham, AL 35294 USA	Daiichi Sankyo Company Limited; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhou, T (corresponding author), Univ Alabama, Dept Med, 465 LHRB,701 19th St S, Birmingham, AL 35249 USA.			Kimberly, Robert/0000-0002-5330-3086; Makhija, Sharmila/0000-0002-4078-9822; Buchsbaum, Donald/0000-0003-2797-5847	NCI NIH HHS [CA83591, CA89019] Funding Source: Medline; NIAMS NIH HHS [AR44982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083591, P50CA089019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Decaudin D, 1997, CANCER RES, V57, P62; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frese S, 2002, J THORAC CARDIOV SUR, V123, P168, DOI 10.1067/mtc.2002.119694; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gliniak B, 1999, CANCER RES, V59, P6153; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Lacour S, 2001, CANCER RES, V61, P1645; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Mizutani Y, 2001, J UROLOGY, V165, P263, DOI 10.1097/00005392-200101000-00076; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	48	140	165	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2034	2044		10.1038/sj.onc.1206290	http://dx.doi.org/10.1038/sj.onc.1206290			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673208				2022-12-17	WOS:000181967700013
J	Dhanalakshmi, S; Singh, RP; Agarwal, C; Agarwal, R				Dhanalakshmi, S; Singh, RP; Agarwal, C; Agarwal, R			Silibinin inhibits constitutive and TNF alpha-induced activation of NF-alpha B and sensitizes human prostate carcinoma DU145 cells to TNF alpha-induced apoptosis	ONCOGENE			English	Article						prostate cancer; NF-kappa B; apoptosis; silibinin	I-KAPPA-B; TUMOR-NECROSIS-FACTOR; FLAVONOID ANTIOXIDANT SILYMARIN; CANCER-CELLS; MEDIATED APOPTOSIS; CYCLOOXYGENASE 2; DNA-SYNTHESIS; KINASE; EXPRESSION; GROWTH	Prostate cancer (PCA) is one of the most common invasive malignancies of men in the US, however, there have been Limited successes so far in its therapy. Even most potent agents (e.g. TNFalpha) are ineffective in killing human PCA cells possibly due to constitutive activation of NF-kappaB that subsequently activates a large number of anti-apoptotic genes. In such a scenario, strong apoptotic agent TNFalpha, further induces NF-kappaB activation rather than inducing apoptosis. In several recent studies, we have demonstrated both cancer preventive and anti-cancer efficacy of silymarin and its constituent silibinin in a variety of experimental tumor models and cell culture systems. Here we examined whether silibinin is effective in inhibiting constitutive NF-kappaB activation in human PCA cells, which would help in overcoming TNFY-insensitivity. Our studies reveal that silibinin effectively inhibits constitutive activation of NF-kappaB in advanced human prostate carcinoma DU145 cells. Consistent with this, nuclear levels of p65 and p50 sub-units of NF-kappaB were also reduced. In the studies assessing molecular mechanism of this effect, silibinin treatment resulted in a significant increase in the level of IkappaBalpha with a concomitant decrease in phospho-IkappaBalpha. Kinase assays revealed that silibinin dose-dependently decreases IKKalpha kinase activity. The effect of silibinin on IKKalpha seemed to be direct as evidenced by the in vitro kinase assay, where immunoprecipitated IKKalpha was incubated with silibinin. This shows that silibinin does not necessarily need an upstream event to bring about its inhibitory effect on IKKalpha and downstream effectors. Additional studies showed that silibinin also inhibits TNFalpha-induced activation of NF-kappaB via IkappaBalpha pathway and subsequently sensitizes DU145 cells to TNFa-induced apoptosis. These results indicate that silibinin could be used to enhance the effectiveness of TNFalpha-based chemotherapy in advanced PCA.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@uchsc.edu		Singh, Rana Pratap/0000-0003-4261-7044	NCI NIH HHS [CA64514, CA83741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064514, R01CA064514, R01CA083741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; BACUERLE PA, 1996, CELL, V87, P13; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Davis JN, 1999, NUTR CANCER, V35, P167, DOI 10.1207/S15327914NC352_11; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong G, 1999, CANCER RES, V59, P3495; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; JONES S, 1997, WORKING PAPERS LIT, V1, P17; Lahiri-Chatterjee M, 1999, CANCER RES, V59, P622; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LETTERON P, 1990, BIOCHEM PHARMACOL, V39, P2027, DOI 10.1016/0006-2952(90)90625-U; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Manna SK, 1999, J IMMUNOL, V163, P6800; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NAKAJIMA Y, 1995, UROL RES, V23, P205, DOI 10.1007/BF00393299; Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Ripple MO, 1999, JNCI-J NATL CANCER I, V91, P1227, DOI 10.1093/jnci/91.14.1227; Rokhlin OW, 1997, CANCER RES, V57, P1758; Sharma Y, 2001, MOL CARCINOGEN, V30, P224, DOI 10.1002/mc.1032; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; SINHA BK, 1995, BBA-MOL BASIS DIS, V1270, P12, DOI 10.1016/0925-4439(94)00065-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; WAGNER H, 1974, ARZNEIMITTEL-FORSCH, V24, P466; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Yu R, 2000, CANCER RES, V60, P2384; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhao JF, 1999, MOL CARCINOGEN, V26, P321, DOI 10.1002/(SICI)1098-2744(199912)26:4<321::AID-MC11>3.3.CO;2-0; Zi XL, 2000, CANCER RES, V60, P5617; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	59	140	144	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1759	1767		10.1038/sj.onc.1205240	http://dx.doi.org/10.1038/sj.onc.1205240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896607				2022-12-17	WOS:000174214200014
J	Pandita, TK				Pandita, TK			ATM function and telomere stability	ONCOGENE			English	Article						ATM; telomeres; telomerase; hTERT; DNA damage; signal transduction	ABL TYROSINE KINASE; EXTENDED-LIFE-SPAN; ATAXIA-TELANGIECTASIA; C-ABL; PROTEIN-KINASE; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; RECOMBINATION NODULES; SYNAPTONEMAL COMPLEX	Accumulation of DNA damage has been associated with the onset of senescence and predisposition to cancer. The gene responsible for ataxia telangiectasia (A-T) is ATM (ataxia-telangiectasia mutant), a master controller of cellular pathways and networks, orchestrating the responses to a specific type of DNA damage: the double strand break. Based on the homology of the human ATM gene to the TEL1, MEC1 and rad3 genes of yeast, it has now been demonstrated that mutations in ATM lead to defective telomere maintenance in mammalian cells. While ATM has both nuclear and cytoplasmic functions, this review will focus on its roles in telomere metabolism and how ATM and telomeres serve as controllers of cellular responses to DNA damage.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Columbia University	Pandita, TK (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, VC11-213,630 W 168th St, New York, NY 10032 USA.	tkp1@columbia.edu	Pandita, Tej K/AAM-9188-2020		NINDS NIH HHS [NS34746] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Agami R, 1999, NATURE, V399, P809; ALBINI SM, 1984, EXP CELL RES, V155, P588, DOI 10.1016/0014-4827(84)90219-2; ANDEGEKO Y, 2001, IN PRESS J BIOL CHEM; ASHLEY T, 1994, HUM GENET, V94, P587, DOI 10.1007/BF00206950; Barlow C, 1998, DEVELOPMENT, V125, P4007; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan SWL, 2001, CURR BIOL, V11, P1240, DOI 10.1016/S0960-9822(01)00391-8; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; DERNBURG AF, 1995, SPRING HARBOR MONOGR, P295; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Fang Z. H., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P142; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; FUSSELL C P, 1987, P275; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilson Eric, 1993, Trends in Cell Biology, V3, P128, DOI 10.1016/0962-8924(93)90175-Z; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HITTELMAN WN, 1994, INT J RADIAT BIOL, V66, pS109; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Matsuura A, 1999, GENETICS, V152, P1501; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Pandita TK, 2001, RADIAT RES, V156, P642, DOI 10.1667/0033-7587(2001)156[0642:TROAIT]2.0.CO;2; Pandita TK, 2000, RADIAT RES, V154, P133; PANDITA TK, 2001, ADV CELL AGING GERON, V8, P61; PANDITA TK, 1992, RAD RAS, V130, P104; RASMUSSEN SW, 1980, HEREDITAS, V93, P187; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Rockmill B, 1998, GENE DEV, V12, P2574, DOI 10.1101/gad.12.16.2574; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Scherthan H, 2000, MOL CELL BIOL, V20, P7773, DOI 10.1128/MCB.20.20.7773-7783.2000; Scherthan H, 1997, CHROMOSOM T, V12, P217; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SVOBODA A, 1995, CHROMOSOMA, V104, P203, DOI 10.1007/s004120050109; THERMAN E, 1977, HUM GENET, V35, P137, DOI 10.1007/BF00393963; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615	80	140	149	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					611	618		10.1038/sj.onc.1205060	http://dx.doi.org/10.1038/sj.onc.1205060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850786				2022-12-17	WOS:000173390500013
J	Roth, W; Wild-Bode, C; Platten, M; Grimmel, C; Melkonyan, HS; Dichgans, J; Weller, M				Roth, W; Wild-Bode, C; Platten, M; Grimmel, C; Melkonyan, HS; Dichgans, J; Weller, M			Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells	ONCOGENE			English	Article						sFRP; Wnt signaling; migration; MMP-2; beta-catenin; malignant glioma	CADHERIN-CATENIN COMPLEX; CENTRAL-NERVOUS-SYSTEM; BETA-CATENIN; FACTOR RECEPTOR; IN-VITRO; TYROSINE-PHOSPHATASE; SPEMANN ORGANIZER; CARCINOMA-CELLS; CD95 LIGAND; MIGRATION	Cellular resistance to multiple proapoptotic stimuli and invasion of surrounding brain tissue by migrating tumor cells are main obstacles to an effective therapy for human malignant glioma. Here, we report that the Wnt family of embryonic differentiation genes modulate growth of malignant glioma cells in vitro and in ville and inhibit cellular migration in vitro. sFRPs (soluble Frizzled-related proteins) are soluble proteins that bind to Wnt and interfere with Wnt signaling. We find that sFRP-1 and sFRP-2 are produced by the majority of longterm and ex vivo malignant glioma cell lines. Glioma cells that ectopically express sFRPs exhibit increased clonogenicity and enhanced resistance to serum starvation. In contrast, sFRPs do not modulate glioma cell susceptibility to apoptosis induced by the cytotoxic cytokines, CD95 (Fas/APO-1) ligand (CD95L) or Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL), or various cytotoxic drugs. sFRP-2 strongly promotes the growth of intracranial glioma xenografts in nude mice. In contrast, enhanced expression of sFRPs inhibits the motility of glioma cells in vitro. sFRP-mediated effects on glioma cells are accompanied by decreased expression and activity of matrix metalloproteinase-2 (MMP-2) and decreased tyrosine phosphorylation of beta-catenin. Thus, sFRPs promote survival under non-supportive conditions and inhibit the migration of glioma cells. We suggest that the regulation of these cellular processes involves expression of MMP-2: and tyrosine phosphorylation of beta-catenin. These data support a function for Wnt signaling and its modulation by sFRPs in the biology of human gliomas.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; LXR Biotechnol Inc, Richmond, CA 94804 USA	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Platten, Michael/F-2902-2013	Platten, Michael/0000-0002-4746-887X; Weller, Michael/0000-0002-1748-174X				Amberger VR, 1998, CANCER RES, V58, P149; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; APODACA G, 1990, CANCER RES, V50, P2322; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dennis S, 1999, J CELL SCI, V112, P3815; Deryugina EI, 1997, J CELL SCI, V110, P2473; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Friedlander DR, 1996, CANCER RES, V56, P1939; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hueber A, 1998, FEBS LETT, V432, P155, DOI 10.1016/S0014-5793(98)00855-2; Jawhari AU, 1999, J PATHOL, V187, P155, DOI 10.1002/(SICI)1096-9896(199901)187:2<155::AID-PATH193>3.0.CO;2-E; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Liu D, 1997, LAB INVEST, V77, P557; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; MERZAK A, 1994, CANCER RES, V54, P3988; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Ogawa K, 1999, CANCER RES, V59, P1830; PAULUS W, 1994, J NEUROSURG, V80, P515, DOI 10.3171/jns.1994.80.3.0515; Platten M, 2000, BIOCHEM BIOPH RES CO, V268, P607, DOI 10.1006/bbrc.2000.2176; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Roth W, 2000, BRAIN PATHOL, V10, P223, DOI 10.1111/j.1750-3639.2000.tb00256.x; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WELLER M, 1995, CANCER RES, V55, P2936; Weller M, 1998, INT J CANCER, V79, P640; Wick W, 1998, FEBS LETT, V440, P419, DOI 10.1016/S0014-5793(98)01494-X; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yamamoto M, 1996, CANCER RES, V56, P384; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zurawel RH, 1998, CANCER RES, V58, P896	49	140	148	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4210	4220		10.1038/sj.onc.1203783	http://dx.doi.org/10.1038/sj.onc.1203783			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980594				2022-12-17	WOS:000089032900003
J	Fan, SJ; Ma, YX; Wang, JA; Yuan, RQ; Meng, QH; Cao, YJ; Laterra, JJ; Goldberg, ID; Rosen, EM				Fan, SJ; Ma, YX; Wang, JA; Yuan, RQ; Meng, QH; Cao, YJ; Laterra, JJ; Goldberg, ID; Rosen, EM			The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3 ' kinase	ONCOGENE			English	Article						scatter factor (SF); hepatocyte growth factor (HGF); HGF/SF; c-Met; breast cancer; adriamycin (doxorubicin)	C-MET RECEPTOR; SCATTER FACTOR; CELL-DEATH; TUMOR-SUPPRESSOR; EXPRESSION; SURVIVAL; BRCA1; AKT; PHOSPHORYLATION; ACTIVATION	Scatter factor (SF) [aka, hepatocyte growth factor (HGF)] (designated HGF/SF) is a multifunctional cytokine that stimulates tumor cell invasion and angiogenesis. We recently reported that HGF/SF protects epithelial and carcinoma cells against cytotoxicity from DNA-damaging agents and that HGF/SF-mediated cytoprotection was associated with up-regulation of the anti-apoptotic protein Bcl-X-L in cells exposed to adriamycin, We now; report that in addition to blocking apoptosis, HGF/SF markedly enhances the repair of DNA strand breaks caused by adriamycin or gamma radiation. Constitutive expression of Bcl-X-L in MDA-MB-453 breast cancer cells not only simulated the HGF/SF-mediated chemoradioresistance, but also enhanced the repair of DNA strand breaks, The ability of HGF/SF to induce both chemoresistance and DNA repair was inhibited by wortmannin, suggesting that these activities of HGF/SF are due, in part, to a phosphatidylinositol-3'-kinase (PI3K) dependent signaling pathway. Consistent with this finding, HGF/SF induced the phosphorylation of c-Akt (protein kinase-B), a PI3K substrate implicated in apoptosis inhibition; and an expression vector encoding a dominant negative kinase inactive Akt partially but significantly inhibited HGF/SF-mediated cell protection and DNA repair. These findings suggest that HGF/SF activates a cell survival and DNA repair pathway;ay that involves signaling through PI3K and c-Akt and stabilization of the expression of Bcl-X-L and they implicate Bcl-X-L in the DNA repair process.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY 11040 USA; Rockville Ctr, Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Mercy Med Ctr, New York, NY 11570 USA; Kennedy Krieger Res Inst, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Neurosci, Baltimore, MD 21205 USA; Kennedy Krieger Res Inst, Dept Oncol, Baltimore, MD 21205 USA	Northwell Health; Yeshiva University; Memorial Sloan Kettering Cancer Center; Kennedy Krieger Institute; Johns Hopkins University; Kennedy Krieger Institute; Kennedy Krieger Institute	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New York, NY 11040 USA.		Meng, Q./GSI-6185-2022		NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS CA32148] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032148] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Husain A, 1998, CANCER RES, V58, P1120; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KOLIK G, 1997, MOL CELL BIOL, V17, P1595; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Packham G, 1996, ONCOGENE, V13, P461; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rodriguez C, 1996, J CELL PHYSIOL, V166, P387, DOI 10.1002/(SICI)1097-4652(199602)166:2<387::AID-JCP17>3.0.CO;2-8; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; SATTLER MM, 1996, NATURE, V382, P335; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shao NS, 1996, ONCOGENE, V13, P1; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; STOKER M, 1987, NATURE, V327, P238; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao Y, 1996, AM J PATHOL, V149, P1707; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	47	140	157	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2212	2223		10.1038/sj.onc.1203566	http://dx.doi.org/10.1038/sj.onc.1203566			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822371				2022-12-17	WOS:000086974100006
J	Gual, P; Giordano, S; Williams, TA; Rocchi, S; Van Obberghen, E; Comoglio, PM				Gual, P; Giordano, S; Williams, TA; Rocchi, S; Van Obberghen, E; Comoglio, PM			Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis	ONCOGENE			English	Article						PLC-gamma; Gab1; HGF; tubulogenesis	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; KIDNEY-CELLS REQUIRES; GRB2 BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; EPITHELIAL-CELLS; DOCKING PROTEIN; SCATTER FACTOR; MET RECEPTOR	A distinctive property of Hepatocyte Growth Factor (HGF) is its ability to induce differentiation of tubular structures from epithelial and endothelial cells (branching tubulogenesis), The HGF receptor directly activates PI3 kinase, Ras and STAT signalling pathways and phosphorylates the adaptator GRB2 Associated Binder-1 (Gab1), Gab1 is also phosphorylated in response to Epidermal Growth Factor (EGF) but is unable to induce tubule formation. Comparison of P-32-peptide maps of Gab1 from EGF- versus HGF-treated cells, demonstrates that the same sites are phosphorylated in vivo. However, while both EGF and HGF induce rapid tyrosine phosphorylation of Gab1 with a peak at 15 min, the phosphorylation persists for over 1 h, only in response to HGF. Nine tyrosines are phosphorylated by both receptors, Three of them (Y307, Y373, Y407) bind phospholipase C-gamma (PLC-gamma), Interestingly, the overexpression of a Gab1 mutant unable to bind PLC-gamma (Gab1 Y307/373/407F) did not alter HGF-stimulated cell scattering, only partially reduced the growth stimulation but completely abolished HGF-mediated tubulogenesis, It is concluded that sustained recruitment of PLC gamma to Gab1 plays an important role in branching tubulogenesis.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Fac Med, INSERM, U145, F-06107 Nice 2, France	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Gual, P (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Comoglio, Paolo/G-6323-2011; Rocchi, Stephane/O-4152-2016; Gual, Philippe/M-8787-2017; Williams, Tracy/K-5604-2013; Giordano, Silvia/J-9858-2018; Gual, Philippe/P-9833-2019	Rocchi, Stephane/0000-0002-0943-1304; Gual, Philippe/0000-0001-7393-8356; Giordano, Silvia/0000-0003-1854-1086; Gual, Philippe/0000-0001-7393-8356; Williams, Tracy Ann/0000-0002-2388-6444; Comoglio, Paolo/0000-0002-7056-5328				AHARONOV A, 1978, J SUPRAMOL STR CELL, V9, P41, DOI 10.1002/jss.400090105; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HELIN K, 1991, J BIOL CHEM, V266, P8363; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kozu A, 1997, PHARMACEUT RES, V14, P1228, DOI 10.1023/A:1012167126364; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lipp P, 1996, PROG BIOPHYS MOL BIO, V65, P265, DOI 10.1016/S0079-6107(96)00014-4; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCINTYRE BS, 1995, CELL PROLIFERAT, V28, P45, DOI 10.1111/j.1365-2184.1995.tb00038.x; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; MIZUNO K, 1993, J BIOCHEM-TOKYO, V114, P96, DOI 10.1093/oxfordjournals.jbchem.a124147; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1993, FEBS LETT, V329, P147, DOI 10.1016/0014-5793(93)80212-D; NALDINI L, 1991, ONCOGENE, V6, P501; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P1; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TAKAISHI K, 1994, ONCOGENE, V9, P273; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WAHL M, 1991, BIOESSAYS, V13, P107, DOI 10.1002/bies.950130303; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	63	140	150	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1509	1518		10.1038/sj.onc.1203514	http://dx.doi.org/10.1038/sj.onc.1203514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734310				2022-12-17	WOS:000086108100003
J	Albrechtsen, N; Dornreiter, I; Grosse, F; Kim, E; Wiesmuller, L; Deppert, W				Albrechtsen, N; Dornreiter, I; Grosse, F; Kim, E; Wiesmuller, L; Deppert, W			Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53	ONCOGENE			English	Review						p53; DNA repair; DNA damage; DNA recombination; DNA replication; sequence-specific DNA binding	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; C-TERMINAL DOMAIN; DNA-BINDING FUNCTION; MISMATCH REPAIR DEFICIENCY; NUCLEOTIDE EXCISION-REPAIR; LI-FRAUMENI SYNDROME; CELL-CYCLE; HOMOLOGOUS RECOMBINATION; TUMOR-SUPPRESSOR	In this review we describe the multiple functions of p53 in response to DNA damage, with an emphasis on p53's role in DNA repair. We summarize data demonstrating that p53, through its various biochemical activities and via its ability to interact with components of the repair and recombination machinery, actively participates in various processes of DIVA repair and DNA recombination, An important aspect in evaluating p53 functions arises from the finding that the p53 core domain harbors two mutually exclusive biochemical activities, sequence-specific DNA binding, required for its transactivation function, and 3'->5' exonuclease activity, possibly involved in various aspects of DNA repair. As modifications of p53 that lead to activation of its sequence-specific DNA-binding activity result in inactivation of its 3'->5' exonuclease activity, we propose that p53 exerts its functions as a 'guardian of the genome' at various levels: in its non-induced state, p53 should not be regarded as a non-functional protein, but might be actively involved in prevention and repair of endogenous DNA damage, for example via its exonuclease activity. Upon induction through exogenous DNA damage, p53 will exert its well-documented functions as a superior response element in various types of cellular stress. The dual role model for p53 in maintaining genomic integrity significantly enhances p53's possibilities as a guardian of the genome.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.		Holst, Jens/AAA-8022-2022	Wewer Albrechtsen, Nicolai/0000-0003-4230-5753				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Adams PD, 1996, MOL CELL BIOL, V16, P6623; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1992, BIOCHEM SOC T, V20, P607, DOI 10.1042/bst0200607; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cheng RZ, 1997, EXP CELL RES, V234, P300, DOI 10.1006/excr.1997.3649; Cottu PH, 1996, ONCOGENE, V13, P2727; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1995, INT REV CYTOL A, V162, P486; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; DUDENHOFFER C, 1999, IN PRESS ONCOGENE; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDIERY WS, 1993, CELL, V75, P817; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRITSCHE M, 1993, ONCOGENE, V8, P307; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Goi K, 1997, CANCER RES, V57, P1895; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Haber JE, 1997, CELL, V89, P163, DOI 10.1016/S0092-8674(00)80194-4; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hall PA, 1996, J PATHOL, V180, P1; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HAVRE PA, 1995, CANCER RES, V55, P4420; Hecker D, 1996, ONCOGENE, V12, P953; HERMEKING H, 1909, MOL CELL, V1, P3; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Janus F, 1999, MOL CELL BIOL, V19, P2155; JASIN M, 1985, CELL, V43, P695, DOI 10.1016/0092-8674(85)90242-9; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MELENDY T, 1991, J BIOL CHEM, V266, P1942; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MODRICH P, 1987, ANNU REV BIOCHEM, V56, P435, DOI 10.1146/annurev.bi.56.070187.002251; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nickerson JA, 1998, J CELL BIOCHEM, V70, P172, DOI 10.1002/(SICI)1097-4644(19980801)70:2<172::AID-JCB3>3.0.CO;2-L; Oda N, 1996, J BIOL CHEM, V271, P13816, DOI 10.1074/jbc.271.23.13816; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; RADMAN M, 1993, NATURE, V366, P722, DOI 10.1038/366722a0; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SIEGEL J, 1995, ONCOGENE, V11, P1363; SMITH ML, 1995, ONCOGENE, V10, P1053; SNAPKA RM, 1991, NUCLEIC ACIDS RES, V19, P5065, DOI 10.1093/nar/19.18.5065; STEINMEYER K, 1988, ONCOGENE, V3, P501; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; Wang WF, 1996, J MOL EVOL, V43, P384; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wiesmuller L, 1996, J VIROL, V70, P737; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	151	140	148	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7706	7717		10.1038/sj.onc.1202952	http://dx.doi.org/10.1038/sj.onc.1202952			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618711				2022-12-17	WOS:000084634500010
J	Lam, CW; Xie, JW; To, KF; Ng, HK; Lee, KC; Yuen, NWF; Lim, PL; Chan, LYS; Tong, SF; McCormick, F				Lam, CW; Xie, JW; To, KF; Ng, HK; Lee, KC; Yuen, NWF; Lim, PL; Chan, LYS; Tong, SF; McCormick, F			A frequent activated smoothened mutation in sporadic basal cell carcinomas	ONCOGENE			English	Article						hedgehog; patched; smoothened; basal cell carcinoma; mutation	HUMAN HOMOLOG; RECEPTOR; GENE	Basal-cell carcinomas (BCCs) are the most common cancer in Caucasians, It has been reported that the patched gene is inactivated in 30-40% sporadic BCCs and 20% sporadic medulloblastomas via loss of heterozygosity and nonsense mutations. Recently, two activating smoothened mutations have been found in the sporadic basal cell carcinomas. One, at base pair 1604 (G-to-T transversion) of exon 9, changes codon 535 from tryptophan to leucine, and the other, at base pair 1685 (G-to-A transition) of exon 10, changes codon 562 from arginine to glutamine (Xie et al,, 1998), In our study, 1604G-->T was found in 20 out of 97 (20.6%) sporadic BCCs, The high prevalence indicates that 1604G is the mutation hot spot in our tumor samples. This mutation was detected in all three histological subtypes of BCCs, suggesting that smoothened mutation is an early event during the development of the tumor. Our finding of a high smoothened mutation rate, together with high frequent patched gene mutations reported recently, indicates that activation of the hedgehog signal transduction pathway is the most common and early event in the development of sporadic BCCs, Additionally, to determine whether smoothened, like patched, is also involved in the carcinogenesis of medulloblastomas, we screened medulloblastoma samples for these two mutations by restriction analysis. We have found the 1604G-->T mutation in 1 out of 21 medulloblastomas. This result confirmed smoothened gene involvement in the carcinogenesis of medulloblastoma.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Clin Immunol Unit, Hong Kong, Peoples R China; Princess Margaret Hosp, Dept Pathol, Hong Kong, Peoples R China; United Christian Hosp, Dept Pathol, Hong Kong, Peoples R China; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; United Christian Hospital; University of California System; University of California San Francisco	Lam, CW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China.		Ng, Ho Keung/I-3952-2015					BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; MAK ASY, 1995, SCAND J PLAST RECONS, V29, P149, DOI 10.3109/02844319509034331; Raffel C, 1997, CANCER RES, V57, P842; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Wicking C, 1997, AM J HUM GENET, V60, P21; Wong SS, 1998, J AM ACAD DERMATOL, V38, P179, DOI 10.1016/S0190-9622(98)70596-1; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	14	140	152	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					833	836		10.1038/sj.onc.1202360	http://dx.doi.org/10.1038/sj.onc.1202360			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989836				2022-12-17	WOS:000078394400031
J	Yanagisawa, K; Osada, H; Masuda, A; Kondo, M; Saito, T; Yatabe, Y; Takagi, K; Takahashi, T; Takahashi, T				Yanagisawa, K; Osada, H; Masuda, A; Kondo, M; Saito, T; Yatabe, Y; Takagi, K; Takahashi, T; Takahashi, T			Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells	ONCOGENE			English	Article						Smad; TGF-beta; apoptosis; down-regulation; lung	TRANSFORMING-GROWTH-FACTOR; MAD-RELATED PROTEIN; IN-VIVO ALTERATIONS; SIGNAL-TRANSDUCTION; RECEPTOR; 18Q21; GENES; SUPERFAMILY; CANCERS; DPC4	Small family members are essential intracellular signaling components of the transforming growth factor-beta (TGF-beta) superfamily involved in a range of biological activities, Two highly homologous molecules, Smad2 and Smad3, have so far been identified as receptor-activated Smads for TGF-beta signaling and have become the focus of intensive studies, However, no definite differences in regulation or function have been established between these TGF-beta signaling molecules. In the present study, we show that the expression of Smad3, but not its close relative, Smad2, is down-regulated by TGF-beta mediated signals themselves in human lung epithelial cells. This down-regulation of Smad3 by TGF-beta treatment did not appear to result from shortening of the half-life of Smad3 mRNA, Constitutive expression of Smad3 in the presence of TGF-beta induced apoptotic cell death, with an adverse effect on the cell growth of human lung epithelial cells, Apoptotic cell death could also be induced by forced expression of Smad2 in the presence of TGF-beta, but less efficiently than by that of Smad3. These findings clearly define the distinctions between Smad2 and Smad3 for the first time in that a qualitative difference was observed with regard to the regulation of their expression in response to TGF-beta, while Smad2 and Smad3 appeared to have quantitatively different capabilities regarding the induction of apoptotic cell death in human lung epithelial cells.	Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Pathophysiol Unit, Chikusa Ku, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Clin Labs, Chikusa Ku, Nagoya, Aichi 464, Japan; Nagoya Univ, Sch Med, Showa Ku, Nagoya, Aichi 466, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Lab Ultrastruct Res, Chikusa Ku, Nagoya, Aichi 464, Japan.		Yanagisawa, Kiyoshi/I-7263-2014; Osada, Hiroyuki/AAY-6254-2020; Kondo, Masashi/I-7378-2014; Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Masuda A, 1997, CANCER RES, V57, P4898; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; Nagatake M, 1996, CANCER RES, V56, P2718; Ookawa K, 1997, ONCOGENE, V14, P1389, DOI 10.1038/sj.onc.1200976; REDDEL RR, 1988, CANCER RES, V48, P1904; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Uchida K, 1996, CANCER RES, V56, P5583; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	26	140	150	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1743	1747		10.1038/sj.onc.1202052	http://dx.doi.org/10.1038/sj.onc.1202052			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796704				2022-12-17	WOS:000076200100013
J	Jarpe, MB; Widmann, C; Knall, C; Schlesinger, TK; Gibson, S; Yujiri, T; Fanger, GR; Gelfand, EW; Johnson, GL				Jarpe, MB; Widmann, C; Knall, C; Schlesinger, TK; Gibson, S; Yujiri, T; Fanger, GR; Gelfand, EW; Johnson, GL			Anti-apoptotic versus pro-apoptotic signal transduction: Checkpoints and stop signs along the road to death	ONCOGENE			English	Review						signal transduction; cell death	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PLECKSTRIN HOMOLOGY DOMAIN; ICE/CED-3 FAMILY PROTEASES; TUMOR-NECROSIS-FACTOR; ABL TYROSINE KINASE; NERVE GROWTH-FACTOR; FACTOR-I RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE	The activation of caspases is a final commitment step for apoptosis. It is now evident that signal transduction pathways involving specific protein kinases modulate the apoptotic response. Both pro-apoptotic and anti-apoptotic pathways integrate environmental cues that control the decision to undergo apoptosis. Pro- and anti-apoptotic signal pathways regulate the activation of the caspases. In this review we describe our current understanding of apoptotic signal transduction.	Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, Denver, CO 80206 USA.		Yujiri, Toshiaki/AAY-8150-2020; Widmann, Christian/N-9851-2013	Yujiri, Toshiaki/0000-0001-6838-3456; Widmann, Christian/0000-0002-6881-0363; Gibson, Spencer/0000-0003-0119-732X				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beckwith M, 1996, BLOOD, V88, P3502, DOI 10.1182/blood.V88.9.3502.bloodjournal8893502; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brown L, 1997, NATURE, V387, P450, DOI 10.1038/387450a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Musci MA, 1997, CLIN IMMUNOL IMMUNOP, V83, P205, DOI 10.1006/clin.1996.4315; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; PETTI RM, 1996, J BIOL CHEM, V271, P12687; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	79	140	143	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1475	1482		10.1038/sj.onc.1202183	http://dx.doi.org/10.1038/sj.onc.1202183			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779994				2022-12-17	WOS:000076161900015
J	Fujita, N; Nagahashi, A; Nagashima, K; Rokudai, S; Tsuruo, T				Fujita, N; Nagahashi, A; Nagashima, K; Rokudai, S; Tsuruo, T			Acceleration of apoptotic cell death after the cleavage of Bcl-X-L protein by caspase-3-like proteases	ONCOGENE			English	Article						Bcl-X-L; apoptosis; IL-2; caspase-3	CYTOCHROME-C; ICE/CED-3 PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; PROTOONCOGENE BCL-2; MAMMALIAN HOMOLOG; FAMILY PROTEASES; GENE CED-3; ELEGANS; BCL-X(L)	Interleukin-2 (IL-2)-dependent T cell clone CTLL-2 underwent apoptosis by deprivation of IL-2 from culture medium. The decrease in the anti-apoptotic Bcl-X-L protein level was observed during apoptosis after IL-2 withdrawal, We found that Bcl-X-L protein was cleaved to produce two 18 kDa fragments during CTLL-2 cell apoptosis. When the activation of caspases was suppressed by overexpressing human Bcl-2 protein or by the addition of caspase inhibitors, cleavage of Bcl-X-L protein was suppressed in vivo. Bcl-X-L protein cleavage by incubation with apoptosed CTLL-2 cell lysate was suppressed by the caspase-3/CPP32-specific tetrapeptide inhibitor in vitro. Therefore, caspase-3/CPP32-like proteases were activated and involved in the cleavage of Bcl-X-L protein during CTLL-2 cell apoptosis. We found that Bcl-X-L protein was cleaved by caspase-3/CPP32 at two sites in the loop domain (i.e., HLAD(61 down arrow)S and SSLD(76 down arrow)A), The transfection of the carboxy-terminal 18 kDa Bcl-X-L fragment increased the sensitivity to apoptosis. These results indicate that caspase-3/CPP32-like proteases cleaved anti-apoptotic Bcl-X-L protein and resulted in accelerated apoptotic cell death.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Rokudai, Susumu/O-6771-2018; Fujita, Naoya/A-7349-2010	Rokudai, Susumu/0000-0003-0300-0391; Fujita, Naoya/0000-0002-9631-9264				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boulakia CA, 1996, ONCOGENE, V12, P529; BROOME HE, 1995, J IMMUNOL, V155, P2311; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Frankel A, 1997, CANCER RES, V57, P2388; FUJITA N, 1993, CANCER RES, V53, P5022; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee SH, 1996, ONCOGENE, V13, P2131; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Naito M, 1997, CELL DEATH DIFFER, V4, P617, DOI 10.1038/sj.cdd.4400287; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Noguchi K, 1996, ONCOGENE, V13, P39; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Shimizu S, 1996, ONCOGENE, V12, P2251; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	54	140	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1295	1304		10.1038/sj.onc.1202065	http://dx.doi.org/10.1038/sj.onc.1202065			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771973				2022-12-17	WOS:000075803300012
J	Landesman-Bollag, E; Channavajhala, PL; Cardiff, RD; Seldin, DC				Landesman-Bollag, E; Channavajhala, PL; Cardiff, RD; Seldin, DC			p53 deficiency and misexpression of protein kinase CK2 alpha collaborate in the development of thymic lymphomas in mice	ONCOGENE			English	Article						casein kinase II; lymphoma; oncogene; protein kinase; p53; transgenic mice	TUMOR SUPPRESSOR PROTEIN; STRANDED-DNA ENDS; C-TERMINAL DOMAIN; T-CELL TUMORS; WILD-TYPE P53; TRANSGENIC MICE; CASEIN KINASE-2; PHOSPHORYLATION SITE; CONSENSUS SEQUENCES; P53-DEFICIENT MICE	Protein kinase CK2 (casein kinase II) is a serine-threonine protein kinase with many substrates, some of which are involved in cell cycle regulation. CK2 activity is elevated in human solid tumors and leukemia, and dysregulated expression of CK2 induces lymphoma in transgenic mice. Mice that are deficient in p53 also develop lymphomas, and p53 activity may be regulated by CK2 phosphorylation, Here we demonstrate that CK2 alpha transgenic mice partially or completely deficient in p53 develop thymic lymphomas at a markedly accelerated rate when compared to p53-deficient mice lacking the transgene, Lymphomas originating from CK2 alpha transgenic mice that are heterozygous for p53 generally Lose the wild type p53 allele, indicating that loss of p53 is an important step in tumor progression. Moreover, though lymphomas occur as early as 3 weeks of age in the transgenic mice that are nullizygous for p53, they are still monoclonal, indicating that additional stochastic mutations are required for their development. These lymphomas express high levels of myc mRNA and frequently ectopically express Lmo-2, a transcription factor involved in human T cell acute lymphocytic leukemia. The p53-null CK2 alpha transgenic lymphomas grow rapidly but are highly prone to apoptosis, suggesting that transformation occurs through synergistic dysregulation of cell cycle control induced by misexpression of CK2 and loss of function of p53.	Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Pathol, Boston, MA 02118 USA; Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA	Boston University; Boston University; Boston University; University of California System; University of California Davis	Seldin, DC (corresponding author), Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA.			Seldin, David C/0000-0003-0168-2333	NCI NIH HHS [CA71796] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLYTH K, 1995, ONCOGENE, V10, P1717; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BOUSSET K, 1993, ONCOGENE, V8, P3211; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Condorelli GL, 1996, CANCER RES, V56, P5113; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSON A, 1995, ONCOGENE, V11, P181; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Filhol O, 1996, BIOCHEM J, V316, P331, DOI 10.1042/bj3160331; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FRIEDRICH TD, 1989, BIOCHIM BIOPHYS ACTA, V992, P41, DOI 10.1016/0304-4165(89)90048-2; FUKASAWA K, 1996, SCIENCE, V271, P174; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; HSU B, 1995, ONCOGENE, V11, P175; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HWANG LY, 1995, CURR OPIN IMMUNOL, V7, P659, DOI 10.1016/0952-7915(95)80074-3; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; Matthews DE, 1996, USING UNDERSTANDING; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1991, FEBS LETT, V279, P307, DOI 10.1016/0014-5793(91)80174-2; MESTRES P, 1994, ACTA ANAT, V149, P13; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NEALE GAM, 1995, BLOOD, V86, P3060; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PURDIE CA, 1994, ONCOGENE, V9, P603; ROLIEY N, 1994, ONCOGENE, V9, P3067; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SELDIN DC, 1995, CURR OPIN IMMUNOL, V7, P665, DOI 10.1016/0952-7915(95)80075-1; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SIU G, 1984, CELL, V37, P393, DOI 10.1016/0092-8674(84)90369-6; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	78	140	143	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2965	2974		10.1038/sj.onc.1201854	http://dx.doi.org/10.1038/sj.onc.1201854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662328				2022-12-17	WOS:000074125300002
J	Buttice, G; DuterqueCoquillaud, M; Basuyaux, JP; Carrere, S; Kurkinen, M; Stehelin, D				Buttice, G; DuterqueCoquillaud, M; Basuyaux, JP; Carrere, S; Kurkinen, M; Stehelin, D			Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex	ONCOGENE			English	Article						extracellular matrix; metalloproteinases; oncogenes; gene regulation	SERUM RESPONSE ELEMENT; DNA-BINDING MOTIF; TRANSCRIPTION FACTORS; C-FOS; EXTRACELLULAR-MATRIX; DOMAIN PROTEINS; AP-1 SITE; ACTIVATION; ENHANCER; PROMOTER	Collagenase1 (MMP1) and stromelysin1 (MMP3) are extracellular proteolytic enzymes that degrade connective tissue macromolecules and basement membranes. Both genes are regulated by the Ets and Fos/Jun families of transcription factors/oncoproteins. Here, we show that two members of the Ets-family, Ets2 and Erg and their combinations differentially regulate collagenase1 and stromelysin1 promoter activity. In transiently transfected cells, Ets2 activates both promoters whereas Erg induces collagenase1 but not stromelysin1 promoter activity. Moreover, Erg completely inhibits stromelysin1 promoter activation by Ets2. In gel shift assays however, the Erg protein bound little or not to the collagenase1 promoter, whereas it bound to the stromelysin1 promoter. By site-specific mutagenesis, we identified one major site at -88 that abolished collagenase1 promoter activation by Erg. Surprisingly, mutation of the collagenase1 AP1 site at -73 also abolished the activation by Erg suggesting that Erg cooperates with Fos/Jun in collagenase1 promoter regulation. Indeed, gel shift and in vitro protein interaction studies showed that Erg binds to the Fos/Jun complex. Thus, Erg represents the first example of a transcription factor that can distinguish between the collagenase1 and stromelysin1 promoters in that when Erg is recruited by Fos/Jun at the promoter, it transcriptionally activates collagenase1 gene but not stromelysin1 expression.	WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, CTR MOL MED GENET, DETROIT, MI 48202 USA	Wayne State University; Wayne State University	Buttice, G (corresponding author), INST PASTEUR, CNRS URA 1160, MOL ONCOL LAB, 1 RUE CALMETTE, BP 245, F-59019 LILLE, FRANCE.			Buttice', Giovanna/0000-0001-6550-5585; Duterque-Coquillaud, Martine/0000-0003-3943-5629				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BUTTICE G, 1990, NUCLEIC ACIDS RES, V18, P3079, DOI 10.1093/nar/18.10.3079; BUTTICE G, 1994, CONTRIB NEPHROL, V107, P101; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NERLOV C, 1991, ONCOGENE, V6, P1583; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERB Z, 1994, PROTEINASES MATRIX D; WERNERT N, 1992, AM J PATHOL, V140, P119; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	57	140	141	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2297	2306						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957070				2022-12-17	WOS:A1996VX10800001
J	FORNEROD, M; BOER, J; VANBAAL, S; JAEGLE, M; VONLINDERN, M; MURTI, KG; DAVIS, D; BONTEN, J; BUIJS, A; GROSVELD, G				FORNEROD, M; BOER, J; VANBAAL, S; JAEGLE, M; VONLINDERN, M; MURTI, KG; DAVIS, D; BONTEN, J; BUIJS, A; GROSVELD, G			RELOCATION OF THE CARBOXYTERMINAL PART OF CAN FROM THE NUCLEAR-ENVELOPE TO THE NUCLEUS AS A RESULT OF LEUKEMIA-SPECIFIC CHROMOSOME REARRANGEMENTS	ONCOGENE			English	Article						LEUKEMIA; FUSION PROTEINS; NUCLEOPORINS; TRANSLOCATIONS; CAN PROTOONCOGENE	ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; MAMMALIAN-CELLS; TRANSLOCATION 6-9; CDNA CLONING; PORE COMPLEX; EXPRESSION; GENE; PROTEIN; FUSION	Fusion genes encoding the 3' part of the can gene are implicated in two types of leukemia, The dek-can fusion gene is present in t(6;9) acute myeloid leukemia and the set-can fusion gene is present in one case of acute undifferentiated leukemia. In order to obtain leads towards the molecular basis of these diseases, we have studied the cellular localization of the DEK-CAN and SET-CAN fusion proteins and their normal counterparts. DEK-CAN and SET-CAN were localized exclusively in the nucleus, and also DEK and SET were found to be nuclear proteins. However, CAN was mainly located at the nuclear and cytoplasmic face of the nuclear envelope. This observation is in accordance with the presence of an amino acid repeat in the C-terminal part of CAN, common to the family of nucleoporins. The C-terminal part also contains a nuclear location domain as shown by deletion analysis. This domain may be important for the presence of CAN at the nucleoplasmic side of the nuclear envelope. The relocation of the carboxyterminal part of CAN due to DEK-CAN and SET-CAN may reinforce a nuclear function of the CAN protein.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Erasmus University Rotterdam; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Boer, Judith/A-7546-2010; Fornerod, Maarten/A-7503-2010; von Lindern, Marieke/AAH-2350-2020	Fornerod, Maarten/0000-0002-6166-3030	NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ADRIAANSEN HJ, 1988, LEUKEMIA, V2, P136; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURT EC, 1989, J CELL SCI, P243; HURT EC, 1990, J CELL BIOL, V111, P2829, DOI 10.1083/jcb.111.6.2829; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MOGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068; MURTI KG, 1985, J ELECTRON MICR TECH, V2, P139, DOI 10.1002/jemt.1060020205; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; ROWLEY JD, 1976, BLOOD, V47, P705; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; SMITH GE, 1993, MOL CELL BIOL, V2, P2156; SOEKARMAN D, 1992, LEUKEMIA, V6, P489; SOEKARMAN D, 1992, BLOOD, V79, P2990; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WEBSTER RE, 1978, EXP CELL RES, V117, P47, DOI 10.1016/0014-4827(78)90426-3; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; YARMUSH ML, 1981, J IMMUNOL, V126, P2240; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P791	40	140	144	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1739	1748						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753551				2022-12-17	WOS:A1995QX46900007
J	SCHWARTZ, D; GOLDFINGER, N; ROTTER, V				SCHWARTZ, D; GOLDFINGER, N; ROTTER, V			EXPRESSION OF P53 PROTEIN IN SPERMATOGENESIS IS CONFINED TO THE TETRAPLOID PACHYTENE PRIMARY SPERMATOCYTES	ONCOGENE			English	Article							WILD-TYPE P53; T-ANTIGEN; CELL-DEVELOPMENT; DNA-REPLICATION; SV40 ORIGIN; MUTANT; ONCOGENE; TRANSFORMATION; LOCALIZATION; INVITRO	The various steps of differentiation and maturation in spermatogenesis are well characterized and offer a convenient system to explore the possibility that p53 plays a role in cell differentiation in vivo. In situ hybridization experiments indicate that the p53 gene is expressed in tetraploid primary spermatocytes at the meiotic pachytene stage of the first round of spermatogenesis in young mice. An analysis of spermatogenic cells treated with anti-p53 antibodies reveals that the p53 protein is expressed in a discrete tetraploid cell population, with size and cellular structure parameters characteristic of mid-pachytene spermatocytes. The specific kinetics of p53 expression in the first round of spermatogenesis and its localization in adult testicular sections, coupled with the fact that the protein is expressed in the largest cells with lower DNA density, suggest that p53 expression is confined to the tetraploid primary spermatocytes of the meiotic pachytene phase. These observations identify p53 protein as a potential member of the meiosis control protein family.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALCIVAR AA, 1992, BIOL REPROD, V46, P201, DOI 10.1095/biolreprod46.2.201; ALMON E, 1993, IN PRESS DEV BIOL; AUSTIN CR, 1982, GERM CELLS FERTILIZA; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN YM, 1991, ONCOGENE, V6, P1799; DILLER L, 1990, MOL CELL BIOL, V10, P5722; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOGEN B, 1986, MANIPULATING MOUSE E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JANCA FC, 1986, BIOL REPROD, V34, P613, DOI 10.1095/biolreprod34.4.613; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7492; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; NEVEL BR, 1961, SCIENCE, V143, P832; PROPST F, 1988, ONCOGENE, V2, P227; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISMAN D, 1993, IN PRESS CELL GROWTH; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; SAHW P, 1992, P NATL ACAD SCI USA, V89, P4495; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STURZBECHER HW, 1988, ONCOGENE, V3, P405; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WOLGEMUTH DJ, 1991, MAMM GENOME, V1, P283, DOI 10.1007/BF00352340; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	49	140	146	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1487	1494						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502474				2022-12-17	WOS:A1993LE06400011
J	GALLAND, F; KARAMYSHEVA, A; PEBUSQUE, MJ; BORG, JP; ROTTAPEL, R; DUBREUIL, P; ROSNET, O; BIRNBAUM, D				GALLAND, F; KARAMYSHEVA, A; PEBUSQUE, MJ; BORG, JP; ROTTAPEL, R; DUBREUIL, P; ROSNET, O; BIRNBAUM, D			THE FLT4 GENE ENCODES A TRANSMEMBRANE TYROSINE KINASE RELATED TO THE VASCULAR ENDOTHELIAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							LARGE CELL LYMPHOMA; PERMEABILITY FACTOR; FMS; MITOGEN; PROTEIN; T(2-5)(P23-Q35); TRANSLOCATION; LOCALIZATION; TRANSDUCTION; DOMAINS	Three receptor tyrosine kinases, FLT1, FLK1 and FLT4, contain seven immunoglobin-like domains in their extracellular region and are strongly related by sequence similarities to each other and, to a lesser degree, to the class III receptors CSF1R/FMS, PDGFR, SLFR/KIT and FLT3/FLK2. They constitute a family of receptors putatively involved in the growth regulation of endothelial cells. We describe here the structure and pattern of expression of the human FLT4 gene. Two FLT4 transcripts of 5.8 and 4.5 kb are expressed in the human placenta and several hematopoietic celt lines. In mouse, a 5.8-kb transcript is expressed in a variety of tissues. A translational product 1298 amino acids in length is predicted to be encoded by the largest open reading frame. The FLT4 protein, when transiently expressed in Cos-7 cells and immunoprecipitated with a FLT4-specific rabbit immune serum, has an apparent molecular weight of 170 kDa.	INSERM, U119, ONCOL MOLEC LAB, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE; CANC RES CTR, INST CARCINOGENESIS, MOSCOW 115478, RUSSIA; INSERM, U119, HEMATOL MOLEC LAB, F-13258 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019; Borg, Jean-Paul/AAX-8096-2020; Rosnet, Olivier/G-3536-2013	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; Rosnet, Olivier/0000-0002-3020-910X; Birnbaum, Daniel/0000-0001-7920-9883; Rottapel, Robert/0000-0002-6024-5558				ANDRE C, 1992, ONCOGENE, V7, P685; APRELIKOVA O, 1992, CANCER RES, V52, P746; BENZLEMOINE E, 1988, BLOOD, V72, P1045; BREIER G, 1992, DEVELOPMENT, V114, P521; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GALLAND F, 1990, BIOCHIMIE, V72, P759, DOI 10.1016/0300-9084(90)90161-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBEAU MM, 1989, LEUKEMIA, V3, P866; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAROC N, 1993, IN PRESS ONCOGENE; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; NOGUCHI T, 1991, Technique (Philadelphia), V3, P33; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; RIMOKH R, 1989, BRIT J HAEMATOL, V71, P31, DOI 10.1111/j.1365-2141.1989.tb06270.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; ROSNET O, 1993, ONCOGENE, V8, P173; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; WASMUTH JJ, 1991, CYTOGENET CELL GENET, V58, P261, DOI 10.1159/000133165; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	37	140	165	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1233	1240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386825				2022-12-17	WOS:A1993KY32800014
J	SHIBANUMA, M; KUROKI, T; NOSE, K				SHIBANUMA, M; KUROKI, T; NOSE, K			STIMULATION BY HYDROGEN-PEROXIDE OF DNA-SYNTHESIS, COMPETENCE FAMILY GENE-EXPRESSION AND PHOSPHORYLATION OF A SPECIFIC PROTEIN IN QUIESCENT BALB/3T3 CELLS	ONCOGENE			English	Article									UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; CHIDA K, 1986, CANCER RES, V46, P1055; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; ERNST V, 1978, P NATL ACAD SCI USA, V75, P4110, DOI 10.1073/pnas.75.9.4110; FISCHER SM, 1985, CANCER RES, V45, P3130; FOERDER CA, 1978, P NATL ACAD SCI USA, V75, P3183, DOI 10.1073/pnas.75.7.3183; FRIEDMAN J, 1983, CARCINOGENESIS, V4, P1425, DOI 10.1093/carcin/4.11.1425; GINDHART TD, 1985, CARCINOGENESIS, V6, P309, DOI 10.1093/carcin/6.2.309; HARRISON JR, 1986, CANCER RES, V46, P5571; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; KENSLER TW, 1983, SCIENCE, V221, P75, DOI 10.1126/science.6857269; KOHNO M, 1985, J BIOL CHEM, V260, P1771; LARSSON R, 1988, J BIOL CHEM, V263, P17452; MANIATIS T, 1982, LABORATORY MANUAL; MAY JM, 1979, J BIOL CHEM, V254, P9017; MUKHERJEE SP, 1978, BIOCHEM PHARMACOL, V27, P2589, DOI 10.1016/0006-2952(78)90332-5; NISHIZUKA Y, 1984, NATURE, V308, P673; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SHIBANUMA M, 1987, EUR J BIOCHEM, V164, P15, DOI 10.1111/j.1432-1033.1987.tb10985.x; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; SHIBANUMA M, 1987, BIOCHEM BIOPH RES CO, V144, P1317, DOI 10.1016/0006-291X(87)91454-9; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; YAMADA T, 1988, BIOCHEM BIOPH RES CO, V155, P569; ZAITSU K, 1980, ANAL BIOCHEM, V109, P109, DOI 10.1016/0003-2697(80)90017-2; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	37	140	142	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1025	1032						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115640				2022-12-17	WOS:A1990DP41500010
J	CHAN, AML; KING, HWS; DEAKIN, EA; TEMPEST, PR; HILKENS, J; KROEZEN, V; EDWARDS, DR; WILLS, AJ; BROOKES, P; COOPER, CS				CHAN, AML; KING, HWS; DEAKIN, EA; TEMPEST, PR; HILKENS, J; KROEZEN, V; EDWARDS, DR; WILLS, AJ; BROOKES, P; COOPER, CS			CHARACTERIZATION OF THE MOUSE MET PROTO-ONCOGENE	ONCOGENE			English	Article									NETHERLANDS CANC INST,ANTONI VANLEEUWENHOEK HUIS,DEPT TUMOUR BIOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Netherlands Cancer Institute; University of Oxford	CHAN, AML (corresponding author), INST CANC RES,CHESTER BEATTY LABS,CHEM CARCINOGENESIS SECT,FULHAM RD,LONDON SW3 6JB,ENGLAND.		Edwards, Dylan R/B-4734-2009; Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Edwards, Dylan R/0000-0002-3292-2064; Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464; Hilkens, John/0000-0002-0932-7793				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CACCIA N, 1984, CELL, V37, P1091, DOI 10.1016/0092-8674(84)90443-4; CHAN AML, 1987, ONCOGENE, V1, P229; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEAN M, 1985, NATURE, V311, P29; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HAYATA I, 1983, CANCER RES, V43, P367; HILKENS J, 1986, SOMAT CELL MOLEC GEN, V12, P81, DOI 10.1007/BF01560730; HOHN B, 1977, P NATL ACAD SCI USA, V74, P3259, DOI 10.1073/pnas.74.8.3259; HONEY NK, 1984, SOMAT CELL MOLEC GEN, V10, P377, DOI 10.1007/BF01535633; HONEY NK, 1984, SOMAT CELL MOLEC GEN, V10, P369, DOI 10.1007/BF01535632; HONEY NK, 1986, HUM GENET, V72, P27, DOI 10.1007/BF00278813; KIENY MP, 1983, GENE, V26, P91, DOI 10.1016/0378-1119(83)90039-2; LEBEAU MM, 1985, CELL, V41, P335, DOI 10.1016/0092-8674(85)90086-8; MANIATIS T, 1982, MOL CLONING LABORATO; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; SAKAGUCHI AY, 1984, P NATL ACAD SCI-BIOL, V81, P525, DOI 10.1073/pnas.81.2.525; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; 1988, J CELL BIOL, V106, P441	38	140	146	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					593	599						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838789				2022-12-17	WOS:A1988N841500010
J	ADELAIDE, J; MATTEI, MG; MARICS, I; RAYBAUD, F; PLANCHE, J; DELAPEYRIERE, O; BIRNBAUM, D				ADELAIDE, J; MATTEI, MG; MARICS, I; RAYBAUD, F; PLANCHE, J; DELAPEYRIERE, O; BIRNBAUM, D			CHROMOSOMAL LOCALIZATION OF THE HST ONCOGENE AND ITS CO-AMPLIFICATION WITH THE INT-2 ONCOGENE IN A HUMAN-MELANOMA	ONCOGENE			English	Article									INSERM,U119,27 BD LEI ROURE,F-13009 MARSEILLE,FRANCE; GRP HOSP TIMONE,HOP ENFANTS,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			ADELAIDE, José JA/O-4390-2017	ADELAIDE, José JA/0000-0003-4364-9857; Birnbaum, Daniel/0000-0001-7920-9883				ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BALABAN G, 1984, CANCER GENET CYTOGEN, V11, P429, DOI 10.1016/0165-4608(84)90024-4; BECHER R, 1983, CANCER RES, V43, P5010; BERGMAN EA, 1985, PHYS EARTH PLANET IN, V40, P1, DOI 10.1016/0031-9201(85)90002-0; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; NAKAGAMA H, 1987, JPN J CANCER RES, V78, P651; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NGUYEN C, 1986, J CELL BIOL, V102, P711, DOI 10.1083/jcb.102.3.711; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PIEROTTI M, 1987, CUTANEOUS MELANOMA, P339; RAYBAUD F, IN PRESS CANCER RES; ROBERTS AB, 1986, CANCER SURV, V5, P405; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS B, 1987, HUMAN GENE MAPPING, V9, pA731	29	140	141	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					413	416						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283658				2022-12-17	WOS:A1988M947200016
J	Chang, C; Lee, SO; Yeh, S; Chang, TM				Chang, C.; Lee, S. O.; Yeh, S.; Chang, T. M.			Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver	ONCOGENE			English	Review						androgen receptor; ARKO mice; cancers	UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; ACTIVATED-PROTEIN-KINASE; VIRUS X-PROTEIN; CANCER-CELLS; HEPATOCELLULAR-CARCINOMA; UROTHELIAL CARCINOMA; MALIGNANT-TRANSFORMATION; ONCOGENIC TRANSFORMATION; INTERMEDIATE CELLS	The androgen receptor (AR) is expressed in many cell types and the androgen/AR signaling has been found to have important roles in modulating tumorigenesis and metastasis in several cancers including prostate, bladder, kidney, lung, breast and liver. However, whether AR has differential roles in the individual cells within these tumors that contain a variety of cell types remains unclear. Generation of AR knockout (ARKO) mouse models with deletion of AR in selective cells within tumors indeed have uncovered many unique AR roles in the individual cell types during cancer development and progression. This review will discuss the results obtained from various ARKO mice and different human cell lines with special attention to the cell type- and tissue-specific ARKO models. The understanding of various results showing the AR indeed has distinct and contrasting roles in each cell type within many hormone-related tumors (as stimulator in bladder, kidney and lung metastases vs as suppressor in prostate and liver metastases) may eventually help us to develop better therapeutic approaches by targeting the AR or its downstream signaling in individual cell types to better battle these hormone-related tumors in different stages.	[Chang, C.; Lee, S. O.; Yeh, S.; Chang, T. M.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; [Chang, C.; Lee, S. O.; Yeh, S.; Chang, T. M.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@urmc.rochester.edu			NIH [CA127300, CA156700]; Taiwan Department of Health Clinical Trial and Research Center of Excellence (China Medical University, Taichung, Taiwan) [DOH99-TD-B-111-004]; NATIONAL CANCER INSTITUTE [R01CA127300, R01CA156700] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Department of Health Clinical Trial and Research Center of Excellence (China Medical University, Taichung, Taiwan)(China Medical University); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH Grants (CA127300 and CA156700), and Taiwan Department of Health Clinical Trial and Research Center of Excellence Grant DOH99-TD-B-111-004 (China Medical University, Taichung, Taiwan).	BERTRAM JS, 1972, EUR J CANCER, V8, P587, DOI 10.1016/0014-2964(72)90137-5; Boorjian S, 2004, UROLOGY, V64, P383, DOI 10.1016/j.urology.2004.03.025; Chao Y, 1996, CANCER, V77, P635, DOI 10.1002/(SICI)1097-0142(19960215)77:4<635::AID-CNCR8>3.3.CO;2-I; Chen CC, 2013, ONCOL REP, V30, P979, DOI 10.3892/or.2013.2506; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Colleoni M, 1995, TUMORI, V81, P351, DOI 10.1177/030089169508100509; Couto SS, 2009, DIFFERENTIATION, V77, P103, DOI 10.1016/j.diff.2008.09.010; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Gago-Dominguez M, 1999, CANCER EPIDEM BIOMAR, V8, P999; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GLEAVE M, 1991, CANCER RES, V51, P3753; Gonzalez-Montelongo MC, 2010, STEROIDS, V75, P533, DOI 10.1016/j.steroids.2009.09.012; Guo K, 2008, CANCER SCI, V99, P486, DOI 10.1111/j.1349-7006.2007.00702.x; Halin S, 2007, PROSTATE, V67, P370, DOI 10.1002/pros.20473; Hall MC, 1998, J UROLOGY, V160, P703, DOI 10.1016/S0022-5347(01)62763-0; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; HARTGE P, 1990, J NATL CANCER I, V82, P1636, DOI 10.1093/jnci/82.20.1636; HECHT SS, 1994, CARCINOGENESIS, V15, P2721, DOI 10.1093/carcin/15.12.2721; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heer R, 2007, J CELL PHYSIOL, V212, P572, DOI 10.1002/jcp.21154; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; HEINLEIN CA, 2002, ENDOCR REV, V23, P175, DOI DOI 10.1210/ER.23.2.175; Hickey TE, 2012, MOL ENDOCRINOL, V26, P1252, DOI 10.1210/me.2012-1107; Hsieh TF, 2013, ONCOL LETT, V5, P1325, DOI 10.3892/ol.2013.1140; Hsu JW, 2013, AM J PATHOL, V182, P1811, DOI 10.1016/j.ajpath.2013.01.018; Izumi K, 2013, MOL CARCINOGEN, V52, P94, DOI 10.1002/mc.21833; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jie X, 2007, ONCOGENE, V26, P5741, DOI 10.1038/sj.onc.1210362; Kalra M, 2008, WORLD J GASTROENTERO, V14, P5945, DOI 10.3748/wjg.14.5945; KEMP CJ, 1989, P NATL ACAD SCI USA, V86, P7505, DOI 10.1073/pnas.86.19.7505; Kinoshita H, 2000, CANCER RES, V60, P3623; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lai KP, 2013, AM J PATHOL, V182, P460, DOI 10.1016/j.ajpath.2012.10.029; Lai KP, 2012, EMBO MOL MED, V4, P791, DOI 10.1002/emmm.201101140; Lee SO, 2013, J MOL CELL BIOL, V5, P14, DOI 10.1093/jmcb/mjs042; Li CC, 2008, EUR UROL, V54, P1127, DOI 10.1016/j.eururo.2008.01.054; Li L, 2013, NEW THERAPY VI UNPUB; Li YR, 2008, J CELL MOL MED, V12, P2790, DOI 10.1111/j.1582-4934.2008.00279.x; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Llovet JM, 2005, J GASTROENTEROL, V40, P225, DOI 10.1007/s00535-005-1566-3; Lu HH, 2011 AACR ANN M 2011; Ma WL, 2012, HEPATOLOGY, V56, P176, DOI 10.1002/hep.25644; Ma WL, GASTROENTEROLOGY, V3, p55e1; Marques RB, 2005, INT J CANCER, V117, P221, DOI 10.1002/ijc.21201; Matsumoto T, 2000, LIVER, V20, P228, DOI 10.1034/j.1600-0676.2000.020003228.x; McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007; Mikkonen L, 2010, MOL CELL ENDOCRINOL, V317, P14, DOI 10.1016/j.mce.2009.12.022; Mirosevich J, 1999, J ENDOCRINOL, V162, P341, DOI 10.1677/joe.0.1620341; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Mo L, 2005, AM J PHYSIOL-RENAL, V289, pF562, DOI 10.1152/ajprenal.00368.2004; Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5; Munoz JJ, 2000, J UROLOGY, V164, P1523, DOI 10.1016/S0022-5347(05)67019-X; Nahleh Z, 2008, FUTURE ONCOL, V4, P15, DOI 10.2217/14796694.4.1.15; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Olapade-Alaopa EO, 1999, CLIN CANCER RES, V5, P569; Ozsahin M, 1999, EUR J CANCER, V35, P738, DOI 10.1016/S0959-8049(99)00012-X; Panet-Raymond V, 2000, MOL CELL ENDOCRINOL, V167, P139, DOI 10.1016/S0303-7207(00)00279-3; Papatsoris AG, 2008, TUMORI, V94, P75; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Peters KM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-132; Prickett TD, 2007, MOL CELL BIOL, V27, P4217, DOI 10.1128/MCB.00067-07; Remzi M, 2011, THER ADV UROL, V3, P69, DOI 10.1177/1756287211403349; Ricke EA, 2012, CARCINOGENESIS, V33, P1391, DOI 10.1093/carcin/bgs153; Ricke WA, 2006, INT J CANCER, V118, P2123, DOI 10.1002/ijc.21614; Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6; Rogers AB, 2007, CANCER RES, V67, P11536, DOI 10.1158/0008-5472.CAN-07-1479; Roupret M, 2011, EUR UROL, V59, P584, DOI 10.1016/j.eururo.2010.12.042; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Salmi S, 2001, J UROLOGY, V166, P674, DOI 10.1016/S0022-5347(05)66041-7; Shyr CR, 2013, ENDOCRINE, V43, P191, DOI 10.1007/s12020-012-9762-4; Simanainen U, 2012, HORM CANCER-US, V3, P113, DOI 10.1007/s12672-012-0107-9; Singh M, 2003, REV MED VIROL, V13, P243, DOI 10.1002/rmv.392; Sutton LM, 2012, AM J CLIN PATHOL, V138, P511, DOI 10.1309/AJCP8AVF8FDPTZLH; Tavian D, 2002, HISTOL HISTOPATHOL, V17, P1113, DOI 10.14670/HH-17.1113; Tian J, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395574; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; Trinchet JC, 2004, HEPATOLOGY, V40, P1361, DOI 10.1002/hep.20474; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; van Leenders G, 2002, PROSTATE, V51, P98, DOI 10.1002/pros.10073; van Leenders GJLH, 2001, J PATHOL, V195, P563, DOI 10.1002/path.993; VESSELINOVITCH SD, 1980, CANCER RES, V40, P1538; Walters KA, 2009, ENDOCRINOLOGY, V150, P3274, DOI 10.1210/en.2008-1750; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang XD, 2006, DEV BIOL, V290, P66, DOI 10.1016/j.ydbio.2005.11.009; Wilson CM, 1996, MOL CELL ENDOCRINOL, V120, P51, DOI 10.1016/0303-7207(96)03819-1; Wu CT, 2007, P NATL ACAD SCI USA, V104, P12679, DOI 10.1073/pnas.0704940104; Wu MH, 2010, SCI TRANSL MED; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang WJ, 2009, HEPATOLOGY, V49, P1515, DOI 10.1002/hep.22833; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Yeh SD, 2012 SIN S CLIN TRAN; Yeh SY, 2003, J EXP MED, V198, P1899, DOI 10.1084/jem.20031233; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang ZT, 1999, CANCER RES, V59, P3512; Zheng YY, 2007, VIROLOGY, V363, P454, DOI 10.1016/j.virol.2007.01.040; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	104	139	144	1	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3225	3234		10.1038/onc.2013.274	http://dx.doi.org/10.1038/onc.2013.274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23873027				2022-12-17	WOS:000338443400002
J	Kon, N; Kobayashi, Y; Li, M; Brooks, CL; Ludwig, T; Gu, W				Kon, N.; Kobayashi, Y.; Li, M.; Brooks, C. L.; Ludwig, T.; Gu, W.			Inactivation of HAUSP in vivo modulates p53 function	ONCOGENE			English	Article						hausp; p53; mdm2; deubiquitination; gene knockout; mouse	UBIQUITIN-SPECIFIC PROTEASE; EMBRYONIC LETHALITY; DEUBIQUITINATING ENZYMES; MDM2-DEFICIENT MICE; P53-MDM2 PATHWAY; CONTRIBUTES; USP7/HAUSP; REGULATOR; CARCINOMA; DOMAINS	Hausp is a deubiquitinase that has been shown to regulate the p53-Mdm2 pathway. Cotransfection of p53 and Hausp stabilizes p53 through the removal of ubiquitin moieties from polyubiquitinated p53. Interestingly, knockout or RNA interference-mediated knockdown of Hausp in human cells also resulted in the stabilization of p53 due to the destabilization of Mdm2, suggesting a dynamic role of Hausp in p53 activation. To understand the physiological functions of Hausp, we generated hausp knockout mice. Hausp knockout mice die during early embryonic development between embryonic days E6.5 and E7.5. The hausp knockout embryos showed p53 activation, but no apparent increase in apoptosis. Embryonic lethality was caused by a dramatic reduction in proliferation and termination in development, in part due to p53 activation and/or abrogation of p53-independent functions. Although deletion of p53 did not completely rescue the embryonic lethality of the hausp knockout, embryonic development was extended in both hausp and p53 double knockout embryos. These data show that Hausp has a critical role in regulating the p53-Mdm2 pathway. Oncogene (2010) 29, 1270-1279; doi:10.1038/onc.2009.427; published online 30 November 2009	[Gu, W.] Columbia Univ, Dept Pathol, Inst Canc Genet, New York, NY 10032 USA; [Ludwig, T.] Columbia Univ, Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Dept Pathol, Inst Canc Genet, 1130 St Nicholas Ave Rm 609A, New York, NY 10032 USA.	wg8@columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585	NIH; NIH/NCI; NATIONAL CANCER INSTITUTE [R01CA129627, P01CA097403] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Qiong Li and Xi Sun for their expert assistance with histology. We also thank Dr Chi-Ming Li for helpful suggestions. This study was supported in part by a post-doctoral fellowship from NIH to NK and grants from NIH/NCI to TL and WG.	Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Becker K, 2008, CELL CYCLE, V7, P1205, DOI 10.4161/cc.7.9.5756; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holowaty MN, 2003, J BIOL CHEM, V278, P47753, DOI 10.1074/jbc.M307200200; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; LUNA RMD, 1995, NATURE, V378, P203; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; PICKART CM, 2004, BIOCHIM BIOPHYS ACTA, V29, P55; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013; Wu XS, 2001, P NATL ACAD SCI USA, V98, P3191, DOI 10.1073/pnas.051631598	31	139	145	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1270	1279		10.1038/onc.2009.427	http://dx.doi.org/10.1038/onc.2009.427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946331	Green Accepted			2022-12-17	WOS:000275170600003
J	Villagra, A; Sotomayor, EM; Seto, E				Villagra, A.; Sotomayor, E. M.; Seto, E.			Histone deacetylases and the immunological network: implications in cancer and inflammation	ONCOGENE			English	Review						HDAC; inflammation; cytokine regulation	NF-KAPPA-B; MHC CLASS-I; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STEROID-RECEPTOR NUR77; GENE-EXPRESSION; MOLECULAR-MECHANISMS; DIFFERENTIAL EXPRESSION; TRANSCRIPTION REPRESSOR; REVERSIBLE ACETYLATION; TUMOR-SUPPRESSOR	The initiation, magnitude and duration of an immune response against antigens are a tightly regulated process involving a dynamic, orchestrated balance of pro- and anti-inflammatory pathways in immune cells. Such a delicate balance is critical for allowing efficient immune response against foreign antigens while preventing autoimmune attack against self-antigens. In recent years, much effort has been devoted to understanding immune evasion by cancer cells. Also, significant advances have been made in mechanistically understanding the role of pro- and anti-inflammatory cytokines in the regulation of immune responses against antigens, including those expressed by tumors. However, we still know very little about the regulation of inflammatory/anti-inflammatory genes in their natural setting, the chromatin substrate. Several mechanisms have been identified to influence chromatin flexibility and allow dynamic changes in gene expression. Among those, chromatin modi. cations induced by acetylation and deacetylation of histone tails have gained wide attention. In this study, we discuss the role of histone deacetylases in the transcriptional regulation of genes involved in the inflammatory response and how these enzymes coordinate the dynamic expression of these genes during an immune response. This emerging knowledge is opening new avenues to better understand epigenetic regulation of inflammatory responses and providing new molecular targets for either amplifying or ameliorating immune responses. Oncogene (2010) 29, 157-173; doi:10.1038/onc.2009.334; published online 26 October 2009	[Villagra, A.; Seto, E.] Univ S Florida, Dept Mol Oncol, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Villagra, A.; Sotomayor, E. M.] Univ S Florida, Dept Immunol, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Villagra, A.; Sotomayor, E. M.] Univ S Florida, Dept Malignant Hematol, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Villagra, A (corresponding author), Univ S Florida, Dept Mol Oncol, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	alejandro.villagra@moffitt.org; eduardo.sotomayor@moffitt.org; ed.seto@moffitt.org		Villagra, Alejandro/0000-0001-9346-8355	National Institutes of Health (NIH); American Heart Association; Kaul Foundation; NATIONAL CANCER INSTITUTE [R01CA169210, R01CA187040] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Kaul Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work in our laboratories was supported by grants to ES from the National Institutes of Health (NIH), the American Heart Association and the Kaul Foundation, and to EMS from the NIH.	Al-Janadi A, 2008, DRUGS R&D, V9, P369, DOI 10.2165/0126839-200809060-00003; Anderson LA, 2006, CANCER RES, V66, P4975, DOI 10.1158/0008-5472.CAN-05-4253; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Aptsiauri N, 2007, ADV EXP MED BIOL, V601, P123; Asirvatham AJ, 2009, CYTOKINE, V45, P58, DOI 10.1016/j.cyto.2008.11.010; Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019; Aune TM, 2009, IMMUNOLOGY, V126, P299, DOI 10.1111/j.1365-2567.2008.03026.x; Aung HT, 2006, FASEB J, V20, P1315, DOI 10.1096/fj.05-5360com; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barnes PJ, 2005, IMMUNOL ALLERGY CLIN, V25, P451, DOI 10.1016/j.iac.2005.05.003; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Bhat KP, 2008, FEBS LETT, V582, P3193, DOI 10.1016/j.febslet.2008.08.010; Bishton M, 2007, EXPERT REV ANTICANC, V7, P1439, DOI 10.1586/14737140.7.10.1439; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bonfils C, 2008, CLIN CANCER RES, V14, P3441, DOI 10.1158/1078-0432.CCR-07-4427; Bowen H, 2008, CLIN EXP ALLERGY, V38, P1422, DOI 10.1111/j.1365-2222.2008.03067.x; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Cabrera T, 2007, TISSUE ANTIGENS, V69, P264, DOI 10.1111/j.1399-0039.2006.00777.x; CALNAN BJ, 1995, IMMUNITY, V3, P273; Cavaillon JM, 2001, CELL MOL BIOL, V47, P695; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Chang SJ, 2008, J IMMUNOL, V181, P8372, DOI 10.4049/jimmunol.181.12.8372; Chen GY, 2006, P NATL ACAD SCI USA, V103, P16894, DOI 10.1073/pnas.0607926103; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Cohen MC, 1996, AM J CLIN PATHOL, V105, P589; CONNOR ME, 1993, INT J GYNECOL CANCER, V3, P103, DOI 10.1046/j.1525-1438.1993.03020103.x; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; de Visser KE, 2005, CANCER IMMUNOL IMMUN, V54, P1143, DOI 10.1007/s00262-005-0702-5; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Duenas-Gonzalez A, 2008, CANCER TREAT REV, V34, P206, DOI 10.1016/j.ctrv.2007.11.003; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ellis L, 2008, CLIN CANCER RES, V14, P4500, DOI 10.1158/1078-0432.CCR-07-4262; Emanuele S, 2008, INT J ONCOL, V33, P637, DOI 10.3892/ijo_00000049; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Enya K, 2008, J LEUKOCYTE BIOL, V83, P190, DOI 10.1189/jlb.0106008; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feng R, 2007, BRIT J HAEMATOL, V139, P385, DOI 10.1111/j.1365-2141.2007.06772.x; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381; Furumai R, 2002, CANCER RES, V62, P4916; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gesbert F, 1998, J CLIN IMMUNOL, V18, P307, DOI 10.1023/A:1023223614407; Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511; Gimsing P, 2008, EUR J HAEMATOL, V81, P170, DOI 10.1111/j.1600-0609.2008.01102.x; Gimsing P, 2009, EXPERT OPIN INV DRUG, V18, P501, DOI [10.1517/13543780902852560, 10.1517/13543780902852560 ]; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gopal YNV, 2006, CELL CYCLE, V5, P2738, DOI 10.4161/cc.5.23.3522; Gopal YNV, 2006, EMBO REP, V7, P291, DOI 10.1038/sj.embor.7400613; Guo Y, 2002, INT IMMUNOL, V14, P189, DOI 10.1093/intimm/14.2.189; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hallermalm K, 2001, BLOOD, V98, P1108, DOI 10.1182/blood.V98.4.1108; Hartlapp I, 2009, LEUKEMIA RES, V33, P929, DOI 10.1016/j.leukres.2008.12.013; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2001, FASEB J, V15, pA473; Jee YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/jbc.M503659200; Kametani Y, 2008, IMMUNOL LETT, V119, P97, DOI 10.1016/j.imlet.2008.05.006; Karpf AR, 2006, EPIGENETICS-US, V1, P116, DOI 10.4161/epi.1.3.2988; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Khan ANH, 2008, IMMUNOL RES, V40, P164, DOI 10.1007/s12026-007-0085-0; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kuendgen A, 2007, CANCER-AM CANCER SOC, V110, P943, DOI 10.1002/cncr.22891; Le Tourneau C, 2008, EXPERT OPIN INV DRUG, V17, P1247, DOI [10.1517/13543784.17.8.1247 , 10.1517/13543780802256896]; Lech-Maranda E, 2007, MINI-REV MED CHEM, V7, P1062, DOI 10.2174/138955707782110178; LEDER A, 1975, SCIENCE, V190, P893, DOI 10.1126/science.1059262; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Li H, 2006, BIOCHEM BIOPH RES CO, V349, P1315, DOI 10.1016/j.bbrc.2006.08.182; Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003; Lin Y, 2004, INT J CANCER, V109, P507, DOI 10.1002/ijc.11724; Ling H, 2004, BIOCHEM J, V380, P651, DOI 10.1042/BJ20040099; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lu J, 2005, CYTOKINE, V31, P46, DOI 10.1016/j.cyto.2005.03.001; Lucio-Eterovic AK, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-243; MA B, 2009, INVES NEW DRUG; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Mann BS, 2007, CLIN CANCER RES, V13, P2318, DOI 10.1158/1078-0432.CCR-06-2672; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Marquard L, 2009, HISTOPATHOLOGY, V54, P688, DOI 10.1111/j.1365-2559.2009.03290.x; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mishra N, 2001, P NATL ACAD SCI USA, V98, P2628, DOI 10.1073/pnas.051507098; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morinobu A, 2004, J BIOL CHEM, V279, P40640, DOI 10.1074/jbc.M407576200; Natoli G, 2009, CELL, V136, P19, DOI 10.1016/j.cell.2008.12.034; Nishioka C, 2008, LEUKEMIA, V22, P2159, DOI 10.1038/leu.2008.243; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; Osoata GO, 2009, BIOCHEM BIOPH RES CO, V384, P366, DOI 10.1016/j.bbrc.2009.04.128; Ouaissi M, 2008, ANN SURG ONCOL, V15, P2318, DOI 10.1245/s10434-008-9940-z; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pankaj B, 2008, J ALLERGY CLIN IMMUN, V121, P580; Parra M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Petersson M, 1998, J IMMUNOL, V161, P2099; Poulsen CB, 2005, EUR J HAEMATOL, V74, P453, DOI 10.1111/j.1600-0609.2005.00429.x; Rasheed W, 2008, EXPERT REV ANTICANC, V8, P413, DOI 10.1586/14737140.8.3.413; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Redner RL, 2002, LEUKEMIA, V16, P1927, DOI 10.1038/sj.leu.2402720; Rigas B, 2007, CURR OPIN GASTROEN, V23, P55, DOI 10.1097/MOG.0b013e32801145b0; Rosato RR, 2003, CANCER RES, V63, P3637; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Salminen A, 2008, BIOESSAYS, V30, P939, DOI 10.1002/bies.20799; SANDRA C, 2005, J NEUROIMMUNOL, V164, P10; Schmeck B, 2008, J IMMUNOL, V181, P940, DOI 10.4049/jimmunol.181.2.940; Scott FL, 2008, J BIOL CHEM, V283, P19499, DOI 10.1074/jbc.M800331200; Seliger B, 2006, INT J CANCER, V118, P129, DOI 10.1002/ijc.21312; Seliger B, 2008, CANCER IMMUNOL IMMUN, V57, P1719, DOI 10.1007/s00262-008-0515-4; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Skov S, 2005, CANCER RES, V65, P11136, DOI 10.1158/0008-5472.CAN-05-0599; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; Tao R, 2007, HEPATOB PANCREAT DIS, V6, P348; Togi S, 2009, BIOCHEM BIOPH RES CO, V379, P616, DOI 10.1016/j.bbrc.2008.12.132; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Valapour M, 2002, J ALLERGY CLIN IMMUN, V109, P238, DOI 10.1067/mai.2002.121145; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; van den Elsen PJ, 2003, CLIN IMMUNOL, V109, P46, DOI 10.1016/S1521-6616(03)00200-6; Villagra A, 2009, NAT IMMUNOL, V10, P92, DOI 10.1038/ni.1673; Wang J, 2009, INT IMMUNOL, V21, P227, DOI 10.1093/intimm/dxn143; WANG W, 2009, JPN J CANCER RES, V21, P1439; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Yao YX, 2005, J EXP MED, V201, P1899, DOI 10.1084/jem.20050324; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zeidler R, 1997, BLOOD, V90, P2390; Zhang C, 2009, CANCER IMMUNOL IMMUN, V58, P1275, DOI 10.1007/s00262-008-0645-8; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang X, 2006, J IMMUNOL, V177, P1282, DOI 10.4049/jimmunol.177.2.1282; Zhang YJ, 2008, J IMMUNOL, V180, P402, DOI 10.4049/jimmunol.180.1.402; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou W, 2009, CURR CANCER DRUG TAR, V9, P91, DOI 10.2174/156800909787314039; Zhou WS, 2004, P NATL ACAD SCI USA, V101, P2440, DOI 10.1073/pnas.0306002101; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	181	139	144	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					157	173		10.1038/onc.2009.334	http://dx.doi.org/10.1038/onc.2009.334			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19855430				2022-12-17	WOS:000273650000001
J	Anderton, E; Yee, J; Smith, P; Crook, T; White, RE; Allday, MJ				Anderton, E.; Yee, J.; Smith, P.; Crook, T.; White, R. E.; Allday, M. J.			Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma	ONCOGENE			English	Article						apoptosis; Bim; Burkitt's lymphoma; EBV; EBNA3A; EBNA3C; MYC	NUCLEAR ANTIGEN 3C; HUMAN B-CELLS; HOMOZYGOUS DELETIONS; HISTONE DEACETYLASE; BH3-ONLY PROTEIN; DOWN-REGULATION; C-MYC; APOPTOSIS; P53; CTBP	Epstein-Barr virus (EBV) contributes to the development of several human cancers including the endemic form of Burkitt's lymphoma (BL). In culture, EBV induces the continuous proliferation of primary B cells as lymphoblastoid cell lines (LCLs) and if EBV-negative BL-derived cells are infected with EBV, latency-associated viral factors confer resistance to various inducers of apoptosis. Nuclear proteins EBNA3A and EBNA3C (but not EBNA3B) are necessary to establish LCLs and their expression may be involved in the resistance of BL cells to cytotoxic agents. We have therefore created recombinant EBVs from which each of the EBNA3 genes has been independently deleted, and revertant viruses in which the genes have been re-introduced into the viral genome. Infection of EBV-negative BL cells with this panel of EBVs and challenge with various cytotoxic drugs showed that EBNA3A and EBNA3C cooperate as the main determinants of both drug resistance and the downregulation of the proapoptotic Bcl-2- family member Bcl-2-interacting mediator of cell death (Bim). The regulation of Bim is predominantly at the level of RNA, with little evidence of post-translational Bim stabilization by EBV. In the absence of Bim, EBNA3A and EBNA3C appear to provide no survival advantage. The level of Bim is a critical regulator of B cell survival and reduced expression is a major determinant of lymphoproliferative disease in mice and humans; moreover, Bim is uniquely important in the pathogenesis of BL. By targeting this tumour-suppressor for repression, EBV significantly increases the likelihood of B lymphomagenesis in general, and BL in particular. Our results may also explain the selection pressure that gives rise to a subset of BL that retain expression of the EBNA3 proteins.	[Anderton, E.; Yee, J.; White, R. E.; Allday, M. J.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; [Smith, P.; Crook, T.] Toby Robins Breast Canc Res Ctr, Inst Canc Res Breakthrough, London, England	Imperial College London; University of London; Institute of Cancer Research - UK	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England.	m.allday@imperial.ac.uk		White, Robert/0000-0002-5115-2173	Wellcome Trust Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Now		ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; Alvi AJ, 2005, BLOOD, V105, P4484, DOI 10.1182/blood-2004-07-2713; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bourillot PY, 1998, J GEN VIROL, V79, P363, DOI 10.1099/0022-1317-79-2-363; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cludts I, 1998, J VIROL, V72, P1862, DOI 10.1128/JVI.72.3.1862-1869.1998; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Dang CV, 2005, CANCER CELL, V8, P177, DOI 10.1016/j.ccr.2005.08.005; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Epeldegui M, 2007, MOL IMMUNOL, V44, P934, DOI 10.1016/j.molimm.2006.03.018; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hickabottom M, 2002, J BIOL CHEM, V277, P47197, DOI 10.1074/jbc.M208116200; Jimenez-Ramirez C, 2006, J VIROL, V80, P11200, DOI 10.1128/JVI.00897-06; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Kelly GL, 2006, P NATL ACAD SCI USA, V103, P14935, DOI 10.1073/pnas.0509988103; Kelly GL, 2005, J VIROL, V79, P10709, DOI 10.1128/JVI.79.16.10709-10717.2005; Knight JS, 2003, J VIROL, V77, P4261, DOI 10.1128/JVI.77.7.4261-4272.2003; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Leao M, 2007, J VIROL, V81, P248, DOI 10.1128/JVI.01096-06; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lindstrom MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; O'Nions F, 2004, ADV CANCER RES, V92, P119; O'Nions J, 2003, ONCOGENE, V22, P7181, DOI 10.1038/sj.onc.1206838; O'Nions J, 2006, J VIROL, V80, P12408, DOI 10.1128/JVI.01363-06; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; White RE, 2003, J GEN VIROL, V84, P3393, DOI 10.1099/vir.0.19387-0; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zimber-Strobl U, 2001, SEMIN CANCER BIOL, V11, P423, DOI 10.1006/scbi.2001.0409	46	139	142	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					421	433		10.1038/sj.onc.1210668	http://dx.doi.org/10.1038/sj.onc.1210668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653091				2022-12-17	WOS:000252426100002
J	Conroy, H; Marshall, NA; Mills, KHG				Conroy, H.; Marshall, N. A.; Mills, K. H. G.			TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours	ONCOGENE			English	Review						TLR ligand; regulatory T cell; dendritic cell; immunotherapeutic; cancer vaccine; antitumour immunity	REGULATORY T-CELLS; TOLL-LIKE RECEPTOR-2; THERAPEUTIC CANCER VACCINES; MEDIATED ANTITUMOR IMMUNITY; TRANSCRIPTION FACTOR FOXP3; GROWTH-FACTOR-BETA; DENDRITIC CELLS; TGF-BETA; METASTATIC MELANOMA; CUTTING EDGE	Toll-like receptor (TLR) agonists are potent activators of innate immune responses, activating dendritic cell (DC) maturation and inflammatory cytokine secretion by innate immune cells and as a consequence they promote adaptive immune response when coadministered with foreign antigens. There is also some evidence from mouse models that TLR ligands can help to break tolerance to self-antigens and promote immune responses to tumour antigens. Therefore, they have been exploited as adjuvants for tumour vaccines or as immunotherapeutics against cancer. Clinical evaluation of TLR agonists has resulted in a licensed immunotherapeutic for basal cell carcinoma, but there have also been disappointing results from clinical trials, with one pharmaceutical company recently halting its clinical programme. A major obstacle to the development of any active immunotherapeutic approach to cancer is the immunosuppressive environment of the growing tumour, including the induction of tolerogenic DCs and regulatory T (Treg) cells, which suppress the development of protective effector T-cell responses. This can be compounded by the use of TLR ligands as immunotherapeutics. A problem with TLR agonists that has not been fully appreciated is that they can generate suppressive as well as inflammatory responses in innate immune cells and can promote the induction of regulatory as well as effector T cells. This is part of a normal mechanism for limiting collateral damage during infection or sterile inflammation, but can constrain their ability to induce protective antitumour immunity, especially in the immune suppressed environment of the tumour. Alternatively, manipulating the TLR-activated innate immune responses to selectively blocking immunosuppressive arm, as well as that induced by the tumour, may hold the key to enhancing their efficacy as tumour immunotherapeutics and as adjuvants for cancer vaccines.	[Conroy, H.; Marshall, N. A.; Mills, K. H. G.] Trinity Coll Dublin, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin, Ireland	Trinity College Dublin	Mills, KHG (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin, Ireland.	kingston.mills@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222; Conroy, Helen/0000-0002-5857-2760				Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Alvaro T, 2005, CLIN CANCER RES, V11, P1467, DOI 10.1158/1078-0432.CCR-04-1869; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Baratelli F, 2005, J IMMUNOL, V175, P1483, DOI 10.4049/jimmunol.175.3.1483; Bellone G, 2006, J IMMUNOL, V177, P3448, DOI 10.4049/jimmunol.177.5.3448; Beutner KR, 1999, J AM ACAD DERMATOL, V41, P1002, DOI 10.1016/S0190-9622(99)70261-6; Boccaccio GL, 1999, INT IMMUNOL, V11, P289, DOI 10.1093/intimm/11.2.289; Bourquin C, 2006, INT J CANCER, V118, P2790, DOI 10.1002/ijc.21681; Boyd AP, 2005, J IMMUNOL, V175, P730, DOI 10.4049/jimmunol.175.2.730; Brandau S, 2007, BIOMED PHARMACOTHER, V61, P299, DOI 10.1016/j.biopha.2007.05.004; Braun D, 2005, BLOOD, V106, P2375, DOI 10.1182/blood-2005-03-0979; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218; Chakraborty NG, 2004, HUM IMMUNOL, V65, P794, DOI 10.1016/j.humimm.2004.05.012; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; den Haan JMM, 2007, J IMMUNOL, V178, P5429, DOI 10.4049/jimmunol.178.9.5429; Dercamp C, 2005, CANCER RES, V65, P8479, DOI 10.1158/0008-5472.CAN-05-1319; Espenschied J, 2003, J IMMUNOL, V170, P3401, DOI 10.4049/jimmunol.170.6.3401; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Foss F M, 2000, Clin Lymphoma, V1, P110, DOI 10.3816/CLM.2000.n.009; Frankel Arthur E, 2002, Cancer Chemother Biol Response Modif, V20, P301; Fricke I, 2006, IMMUNOL INVEST, V35, P459, DOI 10.1080/08820130600803429; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.102; FUJIMOTO S, 1975, IMMUNOL COMMUN, V4, P201, DOI 10.3109/08820137409055774; Gabrilovich DI, 1996, CELL IMMUNOL, V170, P101, DOI 10.1006/cimm.1996.0139; Garbi N, 2004, J IMMUNOL, V172, P5861, DOI 10.4049/jimmunol.172.10.5861; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Heckelsmiller K, 2002, EUR J IMMUNOL, V32, P3235, DOI 10.1002/1521-4141(200211)32:11<3235::AID-IMMU3235>3.0.CO;2-J; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Hirano F, 2005, CANCER RES, V65, P1089; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Ichikawa HT, 2002, J IMMUNOL, V169, P2781, DOI 10.4049/jimmunol.169.5.2781; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; JORDAN JT, 2007, CANC IMMUNOL THER; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Katakura K, 2005, J CLIN INVEST, V115, P695, DOI 10.1172/JCI200522996; KIKKAWA F, 1993, EUR J CANCER, V29A, P1542, DOI 10.1016/0959-8049(93)90291-M; Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Kreitman RJ, 2004, EXPERT OPIN BIOL TH, V4, P1115, DOI 10.1517/14712598.4.7.1115; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kubo T, 2004, J IMMUNOL, V173, P7249, DOI 10.4049/jimmunol.173.12.7249; Kudo-Saito C, 2005, CLIN CANCER RES, V11, P4533, DOI 10.1158/1078-0432.CCR-04-2237; Kwon ED, 1997, P NATL ACAD SCI USA, V94, P8099, DOI 10.1073/pnas.94.15.8099; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Lavelle EC, 2003, J IMMUNOL, V171, P2384, DOI 10.4049/jimmunol.171.5.2384; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Lee DC, 2004, CANCER IMMUNOL IMMUN, V53, P275, DOI 10.1007/s00262-003-0432-5; Lin JT, 2006, LANCET, V368, P991, DOI 10.1016/S0140-6736(06)69294-5; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Livingston P O, 1989, Prog Clin Biol Res, V288, P309; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lizee G, 2006, CLIN CANCER RES, V12, P4794, DOI 10.1158/1078-0432.CCR-06-0944; Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; Mellor AL, 2005, J IMMUNOL, V175, P5601, DOI 10.4049/jimmunol.175.9.5601; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Natarajan K, 2003, J INFECT DIS, V187, P914, DOI 10.1086/368173; Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; NORTH RJ, 1982, J EXP MED, V155, P1063, DOI 10.1084/jem.155.4.1063; Obermeier F, 2002, EUR J IMMUNOL, V32, P2084, DOI 10.1002/1521-4141(200207)32:7<2084::AID-IMMU2084>3.0.CO;2-Q; Oldenhove G, 2003, J EXP MED, V198, P259, DOI 10.1084/jem.20030654; Onizuka S, 1999, CANCER RES, V59, P3128; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng G, 2007, IMMUNITY, V27, P334, DOI 10.1016/j.immuni.2007.05.020; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x; Qian C, 2007, BLOOD, V109, P3308, DOI 10.1182/blood-2006-08-040337; Ribas A, 2005, J CLIN ONCOL, V23, P8968, DOI 10.1200/JCO.2005.01.109; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schmidt C, 2007, NAT BIOTECHNOL, V25, P825, DOI 10.1038/nbt0807-825; Sfondrini L, 2006, J IMMUNOL, V176, P6624, DOI 10.4049/jimmunol.176.11.6624; Shimizu J, 1999, J IMMUNOL, V163, P5211; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Smyth MJ, 2000, NAT IMMUNOL, V1, P459, DOI 10.1038/82698; Somasundaram R, 2002, CANCER RES, V62, P5267; Sousa CRE, 2004, CURR OPIN IMMUNOL, V16, P21, DOI 10.1016/j.coi.2003.11.007; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Srivastava PK, 2006, CURR OPIN IMMUNOL, V18, P201, DOI 10.1016/j.coi.2006.01.009; Stary G, 2007, J EXP MED, V204, P1441, DOI 10.1084/jem.20070021; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Toka FN, 2004, J VIROL, V78, P13082, DOI 10.1128/JVI.78.23.13082-13089.2004; Tormo D, 2006, CANCER RES, V66, P5427, DOI 10.1158/0008-5472.CAN-06-0399; Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003; Valenti R, 2006, CANCER RES, V66, P9290, DOI 10.1158/0008-5472.CAN-06-1819; Vicari AP, 2002, J EXP MED, V196, P541, DOI 10.1084/jem.20020732; Viguier M, 2004, J IMMUNOL, V173, P1444, DOI 10.4049/jimmunol.173.2.1444; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; WATANABE Y, 1987, J BIOL RESP MODIF, V6, P169; Weber J, 2007, ONCOLOGIST, V12, P864, DOI 10.1634/theoncologist.12-7-864; Wei S, 2005, CANCER RES, V65, P5020, DOI 10.1158/0008-5472.CAN-04-4043; Whitmore MM, 2004, CANCER RES, V64, P5850, DOI 10.1158/0008-5472.CAN-04-0063; Wilson SB, 2003, NAT REV IMMUNOL, V3, P211, DOI 10.1038/nri1028; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Woo EY, 2001, CANCER RES, V61, P4766; Xu SW, 2006, SURGERY, V140, P170, DOI 10.1016/j.surg.2006.03.006; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Zeytin HE, 2004, CANCER RES, V64, P3668, DOI 10.1158/0008-5472.CAN-03-3878; Zhou G, 2006, BLOOD, V107, P628, DOI 10.1182/blood-2005-07-2737; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806; Zwaveling S, 2002, J IMMUNOL, V169, P350, DOI 10.4049/jimmunol.169.1.350	134	139	152	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					168	180		10.1038/sj.onc.1210910	http://dx.doi.org/10.1038/sj.onc.1210910			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176598	Bronze			2022-12-17	WOS:000252163600003
J	Leupold, JH; Yang, HS; Colburn, NH; Asangani, I; Post, S; Allgayer, H				Leupold, J. H.; Yang, H-S; Colburn, N. H.; Asangani, I.; Post, S.; Allgayer, H.			Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors	ONCOGENE			English	Article						Pdcd4; Sp1; Sp3; invasion; intravasation; u-PAR	PLASMINOGEN-ACTIVATOR SYSTEM; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; PROGNOSTIC IMPACT; BINDING-PROTEIN; GROWTH-FACTOR; CELL-LINE; REQUIREMENT; PROMOTER; INVASION	Tumor suppressor Pdcd4 has recently been shown to inhibit invasion by activating activator protein-1 (AP-1); however, little is known of the functionally significant Pdcd4-target genes. The urokinase receptor (u-PAR) promotes invasion/metastasis, and is associated with poor cancer-patient survival. The present study was conducted (1) to investigate a role for Pdcd4 in intravasation, invasion and u-PAR regulation, and (2) to describe mechanisms by which this is achieved. Fourteen cell lines showed reciprocal expression of u-PAR/Pdcd4. Resected tumor/normal tissues of 29 colorectal cancer patients demonstrated a significant inverse correlation between Pdcd4/u-PAR. siRNA-Pdcd4-transfected GEO cells significantly increased endogenous u-PAR mRNA/protein. A u-PAR-promoter-chloramphenicol acetyl transferase (CAT)-reporter was reduced in activity with increasing Pdcd4 expression in RKO. Deletion of a putative Sp-1-binding site (-402/-350) inhibited u-PAR promoter regulation by Pdcd4, this being paralleled by a reduction of Sp1 binding to this region in pdcd4-transfected cells. Pdcd4-transfected cells showed an increase in Sp3 binding to u-PAR promoter region -152/-135, the deletion of which reduces the ability of Pdcd4 to suppress u- PAR promoter activity. Surprisingly, the u-PAR-AP-1 site was not targeted by Pdcd4. Finally, RKO cells overexpressing Pdcd4 showed an inhibition of invasion/intravasation (chicken embryo metastasis assay). These data suggest Pdcd4 as a new negative regulator of intravasation, and qas the invasion-related gene u-PAR. It is the first study to implicate Pdcd4 regulation of gene expression via Sp1/Sp3.	Heidelberg Univ, DKFZ Heidelberg, Med Fac Mannheim, Dept Expt Surg & Mol Oncol Solid Tumors, D-6900 Heidelberg, Germany; NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD USA; Heidelberg Univ, Med Fac Mannheim, Dept Surg, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg	Allgayer, H (corresponding author), Heidelberg Univ, Med Fac Mannheim, Dept Expt Surg Mol Oncol Solid Tumors, Collaborat Unit German Canc Res Ctr DKFZ Heidelbe, D-68167 Mannheim, Germany.	heike.allgayer@chir.ma.uni-heidelberg.de	Yang, Hsin-Sheng/A-6419-2008; Yang, Hsin-Sheng/AAF-6793-2020	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036; asangani, irfan/0000-0001-5381-1702	NATIONAL CANCER INSTITUTE [ZIABC010026, Z01BC010026] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; ALBINI A, 1987, CANCER RES, V47, P3239; Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOYD D, 1988, CANCER RES, V48, P3112; BOYD D, 1989, CANCER RES, V49, P1948; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DUFFY MJ, 1987, EUR J CANCER CLIN ON, V23, P583, DOI 10.1016/0277-5379(87)90326-9; Fuchs T, 2003, BIOL CHEM, V384, P755, DOI 10.1515/BC.2003.084; GALLI G, 1992, COMPUTER SIMULATION, P261; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Goke R, 2004, ANN NY ACAD SCI, V1014, P220, DOI 10.1196/annals.1294.024; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Heiss MM, 1996, EUR J SURG ONCOL, V22, P74, DOI 10.1016/S0748-7983(96)91649-2; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; MONTE S, 2002, BIOTECHNIQUES, V33, P98; Muehlenweg B, 2001, EXPERT OPIN BIOL TH, V1, P683; NEKARDA H, 1994, CANCER RES, V54, P2900; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schewe DM, 2005, CLIN CANCER RES, V11, P8538, DOI 10.1158/1078-0432.CCR-05-0786; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Shetty S, 2004, AM J RESP CELL MOL, V31, P100, DOI 10.1165/rcmb.2003-0104OC; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Stalberg P, 2001, BIOCHEM BIOPH RES CO, V281, P227, DOI 10.1006/bbrc.2001.4329; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; WAGNER SN, 1995, AM J PATHOL, V147, P183; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588; Zijlstra A, 2002, CANCER RES, V62, P7083	61	139	143	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4550	4562		10.1038/sj.onc.1210234	http://dx.doi.org/10.1038/sj.onc.1210234			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297470				2022-12-17	WOS:000247836100009
J	Yuan, Z; Goetz, JA; Singh, S; Ogden, SK; Petty, WJ; Black, CC; Memoli, VA; Dmitrovsky, E; Robbins, DJ				Yuan, Z.; Goetz, J. A.; Singh, S.; Ogden, S. K.; Petty, W. J.; Black, C. C.; Memoli, V. A.; Dmitrovsky, E.; Robbins, D. J.			Frequent requirement of hedgehog signaling in non-small cell lung carcinoma	ONCOGENE			English	Article						non-small cell lung carcinoma; hedgehog signaling; GLI; hedgehog target genes	SMALL-MOLECULE INHIBITOR; GROWTH-FACTOR RECEPTOR; SONIC HEDGEHOG; STEM-CELLS; PATHWAY; CANCER; TARGET; MEDULLOBLASTOMA; GLI; IDENTIFICATION	Although it had previously been suggested that the hedgehog (HH) pathway might be activated in some lung tumors, the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. During a screen of a panel of 60 human tumor cell lines with an HH antagonist, we observed that the proliferation of a subset of NSCLC cell lines was inhibited. These NSCLC cell lines express HH, as well as key HH target genes, consistent with them being activated through an autocrine mechanism. Interestingly, we also identified a number of NSCLC cell lines that express high levels of the downstream transcription factor GLI1 and harbor enhanced levels of HH activity, but appear insensitive to known HH antagonists. We hypothesized that the high levels of GLI1 in these cells would function downstream of the HH antagonist target, allowing them to bypass the antagonist-mediated block in proliferation. Consistent with this hypothesis, when the levels of GLI1 are knocked down in such cells, they become sensitive to these inhibitors. We go on to show that a large percentage of primary NSCLC samples express GLI1, consistent with constitutive activation of the HH pathway in these samples. Taken together, these results establish the involvement of the HH signaling pathway in a subset of NSCLCs.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA; Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27109 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pathol, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Norris Cotton Canc Ctr, Hanover, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Dartmouth College; Dartmouth College; Wake Forest University; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Robbins, DJ (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	david.j.robbins@dartmouth.edu	Ogden, Stacey K/P-9585-2019; Singh, Samer/H-8468-2013; Ogden, Stacey K/N-2528-2018	Ogden, Stacey K/0000-0001-8991-3065; Singh, Samer/0000-0002-0921-1686; 	NCI NIH HHS [R01 CA111422, T32 CA09658-14, R01 CA87546, T32 CA009658, R01 CA62275, P30 CA023108] Funding Source: Medline; NIGMS NIH HHS [R01 GM64011] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108, R01CA062275, T32CA009658, R01CA087546, R01CA111422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064011] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Borzillo GV, 2005, CURR TOP MED CHEM, V5, P147, DOI 10.2174/1568026053507732; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Goetz JA, 2002, BIOESSAYS, V24, P157, DOI 10.1002/bies.10056; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Ogden SK, 2004, BIOCHEM PHARMACOL, V67, P805, DOI 10.1016/j.bcp.2004.01.002; Petty WJ, 2004, CLIN CANCER RES, V10, P7547, DOI 10.1158/1078-0432.CCR-04-1169; Petty WJ, 2003, LUNG CANCER, V41, pS155, DOI 10.1016/S0169-5002(03)00159-4; Pitha-Rowe I, 2004, CANCER RES, V64, P8109, DOI 10.1158/0008-5472.CAN-03-3938; Robbins DJ, 2005, CURR CANCER THER REV, V1, P277, DOI 10.2174/157339405774574243; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Rusch V, 1997, CLIN CANCER RES, V3, P515; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; SINGH S, 2006, SONIC HEDGEHOG, DOI DOI 10.1038/MP.A002208.01; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watkins DN, 2004, BIOCHEM PHARMACOL, V68, P1055, DOI 10.1016/j.bcp.2004.04.025; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Zhu YH, 2004, CANCER LETT, V207, P205, DOI 10.1016/j.canlet.2003.10.025	47	139	147	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1046	1055		10.1038/sj.onc.1209860	http://dx.doi.org/10.1038/sj.onc.1209860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909105				2022-12-17	WOS:000244245400011
J	Oliveira, C; Velho, S; Moutinho, C; Ferreira, A; Preto, A; Domingo, E; Capelinha, AF; Duval, A; Hamelin, R; Machado, JC; Schwartz, S; Carneiro, F; Seruca, R				Oliveira, C.; Velho, S.; Moutinho, C.; Ferreira, A.; Preto, A.; Domingo, E.; Capelinha, A. F.; Duval, A.; Hamelin, R.; Machado, J. C.; Schwartz, S., Jr.; Carneiro, F.; Seruca, R.			KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression	ONCOGENE			English	Article						KRAS; BRAF; colorectal carcinoma; instability; MAP kinase; lymph node metastases	RAS POINT MUTATIONS; CELL-CYCLE ARREST; K-RAS; COLON-CANCER; WILD-TYPE; EXPRESSION; ASSOCIATION; ACTIVATION; MELANOMA; PATTERNS	In sporadic colorectal cancer (CRC), KRAS are alternative to BRAF mutations and occur, respectively, in 30 and 10% of cases. Few reports addressed the association between KRAS - BRAF mutations and tumour progression specifically in sporadic microsatellite-stable (MSS) CRC. We screened KRAS and BRAF in 250 MSS primary CRC and 45 lymph node (LN) metastases and analysed the pathological features of the cases to understand the involvement of KRAS - BRAF activation in progression and metastasis. Forty-five per cent of primary MSS CRCs carried mutations in at least one of these genes and mutations were associated with wall invasion (P = 0.02), presence and number of LN metastases (P = 0.02 and P = 0.03, respectively), distant metastases (P = 0.004) and advanced stage (P = 0.01). We demonstrated that KRAS and BRAF are alternative events in Tis and T1 MSS CRC and, KRAS rather than BRAF mutations, contributed to the progression of MSS CRC. The frequency of KRAS and/or BRAF mutations was higher in LN metastases than in primary carcinomas (P = 0.0002). Mutated LN metastases displayed KRAS associated or not with BRAF mutations. BRAF mutations were never present as a single event. Concomitant KRAS and BRAF mutations increased along progression of MSS CRCs, suggesting that activation of both genes is likely to harbour a synergistic effect.	Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4200465 Oporto, Portugal; Hosp Univ Vall Hebron, CIBBIM, Barcelona, Spain; Hosp Sao Joao, Dept Pathol, Oporto, Portugal; INSERM, U762, CEPH, Paris, France; Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Hospital Universitari Vall d'Hebron; Sao Joao Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade do Porto	Seruca, R (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.	rseruca@ipatimup.pt	Oliveira, Carla/F-8188-2011; seruca, raquel/F-8187-2011; Preto, Ana/H-8112-2012; Velho, Sérgia/B-8501-2013; Schwartz, Simo/H-7776-2012; Domingo, Enric/A-9099-2018; Carneiro, Fatima/J-6432-2013; Carneiro, Fatima/AAV-8677-2021; Machado, Jose Carlos/C-5907-2009	Oliveira, Carla/0000-0001-8340-2264; Preto, Ana/0000-0002-7302-0630; Velho, Sérgia/0000-0002-7104-8234; Domingo, Enric/0000-0003-4390-8767; Carneiro, Fatima/0000-0002-1964-1006; Carneiro, Fatima/0000-0002-1964-1006; Machado, Jose Carlos/0000-0003-4741-8415; Schwartz, Simo/0000-0001-8297-7971; Ferreira, Ana/0000-0001-6290-1320; Seruca, Raquel/0000-0002-8851-4166				Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, CANCER, V71, P3827, DOI 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N; Fransen K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ikehara N, 2005, INT J CANCER, V115, P943, DOI 10.1002/ijc.20957; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; Kerkhoff E, 1998, CANCER RES, V58, P1636; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; Lipton L, 2003, CANCER RES, V63, P7595; Lubomierski N, 2005, CANCER-AM CANCER SOC, V104, P952, DOI 10.1002/cncr.21266; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; MOERKERK P, 1994, CANCER RES, V54, P3376; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Oliveira C, 2004, HUM MOL GENET, V13, P2303, DOI 10.1093/hmg/ddh238; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Schramm K, 2000, INT J CANCER, V87, P155, DOI 10.1002/1097-0215(20000715)87:2<155::AID-IJC1>3.0.CO;2-J; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Span M, 1996, INT J CANCER, V69, P241, DOI 10.1002/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.3.CO;2-D; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang L, 2003, CANCER RES, V63, P5209; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Yuen ST, 2002, CANCER RES, V62, P6451	52	139	143	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					158	163		10.1038/sj.onc.1209758	http://dx.doi.org/10.1038/sj.onc.1209758			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16953233				2022-12-17	WOS:000243236500016
J	Wicks, SJ; Haros, K; Maillard, M; Song, L; Cohen, RE; ten Dijke, P; Chantry, A				Wicks, SJ; Haros, K; Maillard, M; Song, L; Cohen, RE; ten Dijke, P; Chantry, A			The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-beta signalling	ONCOGENE			English	Article						transforming growth factor-beta; Smads; ubiquitin	UBIQUITIN LIGASE; PATHWAY; DEGRADATION; MEMBRANE; RECEPTOR; TARGETS; BINDS	Disruption of components in the transforming growth factor-beta (TGF-beta) signalling cascade is a common occurrence in human cancers. TGF-beta pathway activation is accomplished via serine/threonine kinase receptors and intracellular Smad transcription factors. A key regulatory step involves specific ubiquitination by Smurfs that mediate the proteasomal degradation of Smads and/or receptors. Here, we report a novel interaction between Smads and ubiquitin C-terminal hydrolase UCH37, a deubiquitinating enzyme that could potentially reverse Smurf-mediated ubiquitination. In GST pull down experiments, UCH37 bound weakly to Smad2 and Smad3, and bound very strongly to Smad7 in a region that is distinct from the -PY- motif in Smad7 that interacts with Smurf ubiquitin ligases. Endogenous Smad7 and UCH37 formed a stable complex in U4A/JAK1 cells, and FLAG-Smad7 co- immunoprecipitated with HA-UCH37 in transfected HEK-293 cells. In addition, we show that UCH37 can deubiquitinate and stabilize the type I TGF-beta receptor. Furthermore, overexpression of UCH37 upregulates TGF-beta-dependent transcription, and this effect is reversed in cells subject to RNAi-mediated knockdown of endogenous UCH37. These findings support a new role for deubiquitinating enzymes in the control of the TGF-beta signalling pathway, and provide a novel molecular target for the design of inhibitors with therapeutic potential in cancer.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands	University of East Anglia; University of Iowa; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Chantry, A (corresponding author), Univ E Anglia, Sch Biol Sci, Earlham Rd, Norwich NR4 7TJ, Norfolk, England.	a.chantry@uea.ac.uk	Dijke, Peter ten/AAG-4660-2021; 高, 雨莉/HGU-8187-2022; Song, Ling/HGA-5011-2022	Dijke, Peter ten/0000-0002-7234-342X; 	NIGMS NIH HHS [R01 GM37666] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	15	139	149	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8080	8084		10.1038/sj.onc.1208944	http://dx.doi.org/10.1038/sj.onc.1208944			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027725				2022-12-17	WOS:000233656600014
J	Huang, HL; Fang, LW; Lu, SP; Chou, CK; Luh, TY; Lai, MZ				Huang, HL; Fang, LW; Lu, SP; Chou, CK; Luh, TY; Lai, MZ			DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation	ONCOGENE			English	Article						Fas; DNA damage; ROS; mitochondria; apoptosis	DEATH DOMAIN; CELL-DEATH; MEDIATED APOPTOSIS; T-LYMPHOCYTES; ACTIVATION; LIGAND; PROTEIN; MITOCHONDRIA; MECHANISM; EXPRESSION	DNA-damaging reagents may kill tumor cells through the generation of reactive oxygen species (ROS). Cytotoxic reagents may also induce apoptosis of cancer cells in Fas-FADD-dependent manners. In this study, we explored the possible link between these two apparently distinct pathways in T leukemia cell Jurkat. Our results demonstrated that gamma-irradiation, similar to cisplatin, induced apoptosis by triggering Fas aggregation and activating FADD-caspase-8 apoptotic cascade. The absence of caspase-8 or Fas greatly reduced the sensitivity to apoptosis mediated by DNA-damaging agents. In addition, apoptosis induced by cisplatin and gamma-irradiation, but not by Fas, was inhibited by ROS scavengers, including N-acetyl cysteine, MnTBAP, and C-60. Importantly, these ROS scavengers effectively prevented the clustering of Fas receptor induced by cisplatin and gamma-irradiation. Our results suggest that cisplatin and gamma-irradiation promote ROS production, which in turn contributes to Fas receptor aggregation and cell death. The novel coupling between ROS and Fas clustering likely plays a significant role in apoptosis triggered by DNA-damaging reagents in Fas-expressing leukemia cells.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Def Med Sch, Grad Inst Life Sci, Taipei, Taiwan; Natl Yang Ming Univ, Dept Life Sci, Taipei, Taiwan; Acad Sinica, Inst Chem, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803; Luh, Tien-Yau/0000-0002-0415-6454				Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Aronis A, 2003, CELL DEATH DIFFER, V10, P335, DOI 10.1038/sj.cdd.4401150; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; Jayanthi S, 1999, MOL BRAIN RES, V72, P158, DOI 10.1016/S0169-328X(99)00216-8; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Lavastre V, 2002, J IMMUNOL, V168, P1419, DOI 10.4049/jimmunol.168.3.1419; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malins DC, 2002, P NATL ACAD SCI USA, V99, P5937, DOI 10.1073/pnas.082111199; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Um HD, 1996, J IMMUNOL, V156, P3469; van Wetering S, 2002, J CELL SCI, V115, P1837; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Wang XD, 2001, GENE DEV, V15, P2922; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795	49	139	145	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8168	8177		10.1038/sj.onc.1206979	http://dx.doi.org/10.1038/sj.onc.1206979			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603257				2022-12-17	WOS:000186403400011
J	Albertoni, M; Shaw, PH; Nozaki, M; Godard, S; Tenan, M; Hamou, MF; Fairlie, DW; Breit, SN; Paralkar, VM; de Tribolet, N; Van Meir, EG; Hegi, ME				Albertoni, M; Shaw, PH; Nozaki, M; Godard, S; Tenan, M; Hamou, MF; Fairlie, DW; Breit, SN; Paralkar, VM; de Tribolet, N; Van Meir, EG; Hegi, ME			Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1	ONCOGENE			English	Article						MIC-1; glioma; anoxia; p53; HIF-1	TGF-BETA SUPERFAMILY; GROWTH-FACTOR-BETA; WILD-TYPE P53; RECEPTOR NUCLEAR TRANSLOCATOR; BONE MORPHOGENETIC PROTEIN; TUMOR ANGIOGENESIS; GENE-EXPRESSION; MAMMALIAN-CELLS; MEMBER; HYPOXIA	Human astrocytic brain tumors select for mutations in the p53 tumor suppressor gene early in malignant progression. p53 is activated upon various kinds of cellular stress leading to apoptosis or cell cycle arrest, but is also implicated in complex biological processes such as inhibition of angiogenesis and metastasis. In an effort to shed light on consequences mediated by p53 inactivation in gliomas, we established the fet-On system for p53 in the LN-Z308 glioblastoma cell line. The macrophage inhibitory cytokine-1 (MIC-1) gene was identified as a most prominent p53 target gene upon gene expression profiling. Oxygen deprivation, an important cellular stress, revealed MIC-1 as an anoxia responsive gene in glioblastoma cell lines. MIC-1 up-regulation by anoxia is mediated through an alternative, p53 and hypoxia inducible factor 1 (HIF-1) independent pathway. Furthermore, ectopic expression of MIC-1 in LN-Z308 cell line completely abolished its inherent tumorigenicity in nude mice, while proliferation in vitro was not affected. In the present experimental model MIC-1 may exert its anti-tumorigenic properties via a paracrine mechanism mediated by host cells in vivo. Taken together, these data suggest that MIC-1 is an important downstream mediator of p53 function, while acting itself as an intercessor of cellular stress signaling and exerting anti-tumorigenic activities.	Univ Lausanne Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Univ Lausanne, Inst Pathol, Expt Oncol Lab, CH-1011 Lausanne, Switzerland; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ S Wales, Sydney, NSW 2010, Australia; Prizer Cent Res, Groton, CT USA; Emory Univ, Mol Neurooncol Lab, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; St Vincents Hospital Sydney; University of New South Wales Sydney; Emory University; Emory University	Hegi, ME (corresponding author), CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, BH19-110, CH-1011 Lausanne, Switzerland.		Fairlie, Walter/M-8401-2015; Hegi, Monika/O-4796-2015	Fairlie, Walter/0000-0002-2498-1160; Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; BONNEKOH B, 1989, ARCH DERMATOL RES, V281, P487, DOI 10.1007/BF00510085; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, GENE, V237, P105, DOI 10.1016/S0378-1119(99)00309-1; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Detmer K, 1999, BLOOD CELL MOL DIS, V25, P310, DOI 10.1006/bcmd.1999.0259; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Fairlie WD, 2001, BIOCHEMISTRY-US, V40, P65, DOI 10.1021/bi001064p; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Hsiao EC, 2000, MOL CELL BIOL, V20, P3742, DOI 10.1128/MCB.20.10.3742-3751.2000; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kessler R, 2000, CANCER RES, V60, P1403; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Schober A, 2001, J COMP NEUROL, V439, P32, DOI 10.1002/cne.1333; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Strelau J, 2000, J NEUROSCI, V20, P8597; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; YAMADA N, 1995, INT J CANCER, V62, P386, DOI 10.1002/ijc.2910620405	43	139	154	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4212	4219		10.1038/sj.onc.1205610	http://dx.doi.org/10.1038/sj.onc.1205610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082608				2022-12-17	WOS:000176174200003
J	Shou, J; Ali-Osman, F; Multani, AS; Pathak, S; Fedi, P; Srivenugopal, KS				Shou, J; Ali-Osman, F; Multani, AS; Pathak, S; Fedi, P; Srivenugopal, KS			Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA	ONCOGENE			English	Article						Wnt antagonist; apoptosis; p53; alkylating agents; brain tumors	MAMMARY EPITHELIAL-CELLS; BETA-CATENIN; DOWN-REGULATION; UP-REGULATION; P53-MEDIATED APOPTOSIS; MEDIATED TRANSCRIPTION; TELOMERASE ACTIVITY; SIGNALING PATHWAY; GLIOMA-CELLS; EXPRESSION	The human Dkk-1 (hDkk-1) gene, a transcriptional target of the p53 tumor suppressor, encodes a powerful inhibitor of the Wnt signaling pathway and regulates the spatial patterning/morphogenesis of the mammalian central nervous system. We investigated the p53-related functions of the hDkk-1 gene by studying its response to DNA damage and its modulation of apoptosis in human glioma cells. Various chemotherapeutic and other agents that induce DNA adducts and compromise its integrity (1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin, H2O2 and UV rays) enhanced the expression of hDkk-1 significantly. The damage-induced increase in hDkk-1 mRNA levels occurred in many human tumor cell lines, irrespective of their p53 gene status. The human glioblastorna cell line, U87MG, which had undetectable hDkk-1 expression, was engineered to express moderate levels of the hDkk protein by stable transfection. The engineered cells did not show any morphological changes, but underwent marked apoptosis after ceramide treatment. Further, the DNA cross-linking drugs BCNU and cisplatin, but not the microtubule poison vincristine, induced significant cell death in U87MG/hDkk cells, and this was accompanied by altered Bcl-2/Bax expression and a reduction in the amount of telomere DNA as visualized by fluorescence in situ hybridization. These results show that hDkk-1 is a pro-apoptotic gene and suggest that it may play important roles in linking the oncogenic Wnt and p53 tumor suppressor pathways.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Srivenugopal, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Box 64,1515 Holcombe Blvd, Houston, TX 77030 USA.	ksrivenu@mdanderson.org			NATIONAL CANCER INSTITUTE [R29CA074321, R01CA079644] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74321, CA 79644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1987, CURRENT PROTOCOLS MO; Barker N, 2000, ADV CANCER RES, V77, P1; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dale TC, 1998, BIOCHEM J, V329, P209; DELANGE T, 1995, TELOMERES, P265; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Howe LR, 1999, CANCER RES, V59, P1572; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; Ishii K, 2000, EXP CELL RES, V255, P95, DOI 10.1006/excr.1999.4777; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kazanskaya O, 2000, DEVELOPMENT, V127, P4981; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MAO B, 2001, NATURE, V411, P255; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Molenaar M, 1999, INT J DEV BIOL, V43, P675; Moon RT, 1997, CELL, V88, P725, DOI 10.1016/S0092-8674(00)81915-7; Mukhopadhyay T, 1998, ONCOGENE, V17, P901, DOI 10.1038/sj.onc.1202011; Multani AS, 1999, ONCOL RES, V11, P455; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; Nagele RG, 2001, J CELL SCI, V114, P377; Naylor S, 2000, J CELL SCI, V113, P2129; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; PATHAK S, 1976, J REPROD MED, V17, P25; Polakis P, 2000, GENE DEV, V14, P1837; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Sawada M, 2001, ONCOGENE, V20, P1368, DOI 10.1038/sj.onc.1204207; Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601; Scotting PJ, 2000, CHILD NERV SYST, V16, P261, DOI 10.1007/s003810050511; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Srivenugopal K. S., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P5; Srivenugopal KS, 1997, INT J ONCOL, V11, P1251; SRIVENUGOPAL KS, 1990, BIOCHEM PHARMACOL, V40, P473, DOI 10.1016/0006-2952(90)90545-V; TATE G, 1999, J BIOCH MOL BIOL BIO, V3, P239; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zinda MJ, 2001, BIOCHEM BIOPH RES CO, V280, P1107, DOI 10.1006/bbrc.2000.4248	69	139	148	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					878	889		10.1038/sj.onc.1205138	http://dx.doi.org/10.1038/sj.onc.1205138			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840333				2022-12-17	WOS:000173427100003
J	Hong, F; Kim, WH; Tian, ZG; Jaruga, B; Ishac, E; Shen, XN; Gao, B				Hong, F; Kim, WH; Tian, ZG; Jaruga, B; Ishac, E; Shen, XN; Gao, B			Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-X-L proteins	ONCOGENE			English	Article						IL-6; Bcl-2; Bax; apoptosis; liver; alcoholic liver disease	NECROSIS-FACTOR-ALPHA; MEDIATED APOPTOSIS; RAT HEPATOCYTES; PLASMA INTERLEUKIN-6; ALCOHOLIC HEPATITIS; REGENERATING LIVER; OXIDATIVE STRESS; IN-VIVO; DISEASE; MICE	Elevation of serum interleukin-6 (IL-6) levels is always associated with alcoholic liver disease (ALD), but the significance of such elevation is not clear. Here we show that chronic ethanol consumption induces significant apoptosis in the liver of IL-6 (-/-) mice but not IL-6 (+/+) mice. IL-6 (-/-) hepatocytes are more susceptible to ethanol- and tumor necrosis factor alpha- (TNF alpha-) induced apoptotic killing, which can be corrected by IL-6. Expression of both anti-apoptotic (such as Bcl-2 and Bcl-X-L) and proapoptotic (such as Bax) proteins is markedly elevated in the liver of human ALD and chronically ethanol-fed IL-6 (+/+) mice. On the contrary, induction of Bcl-2 and Bcl-X-L is not observed in the liver of chronically ethanol-fed IL-6 (-/-) mice, whereas expression of Bax protein remains elevated. Injection of IL-6 markedly induces expression of Bcl-2 and Bcl-XL but not Bax in the liver. Finally, high concentrations of ethanol inhibit IL-6-activated anti-apoptotic signal, but increasing the concentrations of IL-6 is able to overcome such inhibitory effect. These findings suggest that elevated serum IL-6 levels in ALD may overcome the inhibitory effect of ethanol on IL-6-mediated anti-apoptotic signals and prevent alcohol-induced hepatic apoptosis by induction of Bcl-2 and Bcl-X-L.	NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Virginia Commonwealth University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Gao, B (corresponding author), NIAAA, Sect Liver Biol, Lab Physiol Studies, NIH, Pk Bldg,Room 120,12420 Parklawn Dr,MSC 8115, Bethesda, MD 20892 USA.		Tian, Zhigang/J-3512-2013	Kim, Won-Ho/0000-0002-4849-472X	NIAAA NIH HHS [R01AA12637] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000369, Z01AA000369, Z01AA000368, Z01AA000366, R01AA012637, ZIAAA000368] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abittan, 1999, Curr Treat Options Gastroenterol, V2, P72, DOI 10.1007/s11938-999-0022-5; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; BENEDETTI A, 1988, J HEPATOL, V6, P137, DOI 10.1016/S0168-8278(88)80024-2; BIRD G, 1994, ACTA GASTRO-ENT BELG, V57, P255; Chang YC, 2000, CELL RES, V10, P233, DOI 10.1038/sj.cr.7290052; Chen JP, 1999, FEBS LETT, V457, P162, DOI 10.1016/S0014-5793(99)01031-5; Chen JP, 1997, BIOCHEM BIOPH RES CO, V239, P666, DOI 10.1006/bbrc.1997.7531; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; Chen MC, 2000, J BIOL CHEM, V275, P38794, DOI 10.1074/jbc.M003292200; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Deaciuc IV, 1996, ALCOHOL CLIN EXP RES, V20, P293, DOI 10.1111/j.1530-0277.1996.tb01642.x; Deaciuc IV, 2001, HEPATOL RES, V19, P306, DOI 10.1016/S1386-6346(00)00112-1; Diehl AM, 1999, ALCOHOL CLIN EXP RES, V23, P1419, DOI 10.1097/00000374-199909000-00001; Diehl AM, 1999, CLIN BIOCHEM, V32, P571, DOI 10.1016/S0009-9120(99)00057-0; DIEHL AM, 1989, MED CLIN N AM, V73, P815, DOI 10.1016/S0025-7125(16)30640-X; Ezure T, 2000, AM J PATHOL, V156, P1627, DOI 10.1016/S0002-9440(10)65034-1; Fontanilla CV, 2000, ALCOHOL CLIN EXP RES, V24, P1392, DOI 10.1097/00000374-200009000-00010; FUCHS D, 1994, IMMUNOL TODAY, V15, P496, DOI 10.1016/0167-5699(94)90197-X; Galun E, 2000, FASEB J, V14, P1979, DOI 10.1096/fj.99-0913com; GOLDIN RD, 1993, J PATHOL, V171, P73, DOI 10.1002/path.1711710115; Gonzalez-Quintela A, 2000, CYTOKINE, V12, P1437, DOI 10.1006/cyto.2000.0715; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Hall P D, 1994, Alcohol Alcohol Suppl, V2, P303; Halsted CH, 1996, HEPATOLOGY, V23, P497, DOI 10.1002/hep.510230314; Hecht N, 2001, MOL THER, V3, P683, DOI 10.1006/mthe.2001.0313; HILL DB, 1992, J LAB CLIN MED, V119, P547; Hong F, 2001, FASEB J, V15, P1595, DOI 10.1096/fj.00-0908fje; Hong F, 2000, BIOCHEM BIOPH RES CO, V279, P974, DOI 10.1006/bbrc.2000.4044; KAMIMURA S, 1995, HEPATOLOGY, V22, P1304, DOI 10.1002/hep.1840220441; KIM W, 2001, IN PRESS FASEB J, V15; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Kurose I, 1997, HEPATOLOGY, V25, P368; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Laso FJ, 1999, ALCOHOL CLIN EXP RES, V23, P1306, DOI 10.1097/00000374-199908000-00003; Maddrey W C, 2000, Clin Liver Dis, V4, P115, DOI 10.1016/S1089-3261(05)70099-4; MARTINEZ F, 1992, ALCOHOL, V9, P455, DOI 10.1016/0741-8329(92)90080-T; McClain CJ, 1999, SEMIN LIVER DIS, V19, P205, DOI 10.1055/s-2007-1007110; Mi LJ, 2000, ALCOHOL CLIN EXP RES, V24, P207, DOI 10.1111/j.1530-0277.2000.tb04592.x; Panesar N, 1999, J SURG RES, V85, P251, DOI 10.1006/jsre.1999.5648; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Pennington HL, 1997, J GASTROEN HEPATOL, V12, P305, DOI 10.1111/j.1440-1746.1997.tb00426.x; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Rollwagen FM, 1998, CLIN IMMUNOL IMMUNOP, V89, P205, DOI 10.1006/clin.1998.4600; SASAKI Y, 1994, BIOCHEM BIOPH RES CO, V199, P403, DOI 10.1006/bbrc.1994.1243; SHERON N, 1991, CLIN EXP IMMUNOL, V84, P449; Slomiany A, 1999, ALCOHOL CLIN EXP RES, V23, P334, DOI 10.1097/00000374-199902000-00021; Tuma DJ, 1996, ALCOHOL CLIN EXP RES, V20, P579, DOI 10.1111/j.1530-0277.1996.tb01096.x; Walsh K, 2000, POSTGRAD MED J, V76, P280, DOI 10.1136/pmj.76.895.280; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; YACOUB LK, 1995, ALCOHOL CLIN EXP RES, V19, P854, DOI 10.1111/j.1530-0277.1995.tb00958.x; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; Zhang B, 2000, Zhonghua Gan Zang Bing Za Zhi, V8, P215; Zhao M, 1997, VIRCHOWS ARCH, V431, P337, DOI 10.1007/s004280050108	56	139	148	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					32	43		10.1038/sj.onc.1205016	http://dx.doi.org/10.1038/sj.onc.1205016			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791174				2022-12-17	WOS:000172887800004
J	Aydinlik, H; Nguyen, TD; Moennikes, O; Buchmann, A; Schwarz, M				Aydinlik, H; Nguyen, TD; Moennikes, O; Buchmann, A; Schwarz, M			Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors	ONCOGENE			English	Article						beta-catenin; Ha-ras; mouse hepatocarcinogenesis; phenobarbital; tumor promotion	HA-RAS GENE; HEPATOCELLULAR CARCINOMAS; HEPATOCARCINOGENESIS; MUTATIONS; MICE; DIETHYLNITROSAMINE; FREQUENT; CANCER	Tumor promoters are non-mutagenic chemicals which increase the probability of cancer by accelerating the clonal expansion of cells transformed during tumor initiation. Phenobarbital (PB) is an antiepileptic drug which promotes hepatocarcinogenesis in rodents when administered subsequent to an initiating carcinogen like diethylnitrosamine (DEN). Here we have investigated the prevalence and patterns of mutations in two genes, Haras and beta -catenin, both known mutational targets in mouse hepatocarcinogenesis. Liver tumors were generated by a single administration of DEN to 6 week old mice followed by feeding of PB (0.05%) containing or control diet for 39 weeks. Mutations at Ha-ras codon 61 were screened by allele-specific oligonucleotide hybridization; beta -catenin mutations were detected by direct sequencing of PCR products spanning exon 2. In tumors from mice treated with DEN alone, the prevalence of Ha-ras mutations was similar to 30% (6/20), while no beta -catenin mutations (0/13) were detectable in tumors of this treatment group. By contrast, Ha-ras mutations were undetectable in tumors from mice treated with DEN/PB (0/32), while similar to 80% (37/46) of tumors from this group showed beta -catenin mutations. These results demonstrate that PB strongly affects the prevalence of mutations in the two cancer-related genes, presumably by positive and negative selection for cells harboring the respective mutation.	Univ Tubingen, Inst Toxikol, D-72074 Tubingen, Germany	Eberhard Karls University of Tubingen	Schwarz, M (corresponding author), Univ Tubingen, Inst Toxikol, Wilhelmstr 56, D-72074 Tubingen, Germany.							BAUERHOFMANN R, 1992, MOL CARCINOGEN, V6, P60, DOI 10.1002/mc.2940060110; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; DRAGAN YP, 1992, CARCINOGENESIS, V13, P739, DOI 10.1093/carcin/13.5.739; Frey S, 2000, CARCINOGENESIS, V21, P161, DOI 10.1093/carcin/21.2.161; GRASLKRAUPP B, 1990, CANCER RES, V50, P3701; Marshall CJ, 1998, CURR OPIN GENET DEV, V8, P11, DOI 10.1016/S0959-437X(98)80055-5; Moennikes O, 2000, CANCER RES, V60, P5087; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Ogawa K, 1999, CANCER RES, V59, P1830; SCHULTEHERMANN R, 1995, LIVER REGENERATION C, P141; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199	14	139	140	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7812	7816		10.1038/sj.onc.1204982	http://dx.doi.org/10.1038/sj.onc.1204982			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753661				2022-12-17	WOS:000172161700014
J	Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Cheng, WF; Chang, MC; Su, JL; Hsieh, CY				Wei, LH; Kuo, ML; Chen, CA; Chou, CH; Cheng, WF; Chang, MC; Su, JL; Hsieh, CY			The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway	ONCOGENE			English	Article						cervical cancer; interleukin-6; apoptosis; Mcl-1; PI3-K/Akt	AUTOCRINE GROWTH-FACTOR; HUMAN MYELOMA CELLS; IMMUNOHISTOCHEMICAL ANALYSIS; BCL-2 FAMILY; IN-VITRO; IL-6 FUNCTIONS; BONE-MARROW; EXPRESSION; GENE; DIFFERENTIATION	Interleukin-6 (IL-6), a multifunctional cytokine, has recently been implicated in human cervical cancer, though the mechanism remains elusive. This study demonstrates that the anti-apoptotic protein Mcl-1 and IL-6 was concomitantly expressed in human cervical cancer tissues and cell lines, but not in normal cervix tissues. Upon IL-6 treatment, Mcl-1, but not other Bcl-2 family members, was rapidly up-regulated peaking at 4-8 h in human cervical cancer C33A cells. Supporting this observation, using anti-IL-6 or anti-IL-6 receptor antibody to interrupt the IL-6 autocrine loop in SiHa cells significantly reduced cellular level of Mcl-1. This study hypothesizes that the expression of Mcl-1 in cervical cancer cells is regulated by IL-6. The matter of which signaling pathways transduced by IL-6 is responsible for the Mcl-1 up-regulation is further investigated herein. Blocking the STAT3 or MAPK pathway with dominant-negative mutant STAT3F or the MEK inhibitor PD98059 failed to inhibit IL-6-mediated Mcl-1 expression. Meanwhile, the IL-6-induced Mcl-1 up-regulation was effectively abolished by treatment with PI 3-K inhibitors, LY294002. Additionally, overexpression of dominant-negative (dn) Akt in C33A cells could inhibit the IL-6-induced increase of Mcl-1. Finally, overexpression of IL-6 in C33A cells caused a markable resistance to apoptosis induced by doxorubicin or cisplatin. Transient transfection of IL-6-overexpressed cells with a mcl-1 antisense vector, leading to the attenuation of their apoptosis-resistant activity. In conclusion, the data herein suggest that IL-6 regulated the mcl-1 expression via a PI 3-K/Akt-dependent pathway that may facilitate the oncogenesis of human cervical cancer by modulating the apoptosis threshold.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei, Taiwan.		Wei, Lin-Hung/B-1188-2008; Kuo, Min-Liang/C-4872-2009	CHENG, WEN-FANG/0000-0002-3282-6304; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144; CHEN, CHI-AN/0000-0001-6670-7939				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Castrilli G, 1997, BRIT J CANCER, V75, P855, DOI 10.1038/bjc.1997.152; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cervero C, 1999, AM J HEMATOL, V60, P191, DOI 10.1002/(SICI)1096-8652(199903)60:3<191::AID-AJH4>3.0.CO;2-Y; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHOI SS, 1995, ONCOGENE, V11, P1693; Crawford RAF, 1998, BRIT J CANCER, V78, P210, DOI 10.1038/bjc.1998.466; DOLE MG, 1995, CANCER RES, V55, P2576; Elder DJE, 1996, CANCER RES, V56, P2273; EUSTACE D, 1993, GYNECOL ONCOL, V50, P15, DOI 10.1006/gyno.1993.1156; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, J NEUROSCI, V19, P5429; Ogata A, 1997, J IMMUNOL, V159, P2212; Okamoto M, 1997, CANCER RES, V57, P141; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Richter HE, 1999, AM J OBSTET GYNECOL, V181, P940, DOI 10.1016/S0002-9378(99)70329-7; ROBERT ME, 1990, SEMIN DIAGN PATHOL, V7, P173; SCHLAIFER D, 1995, BLOOD, V85, P2671, DOI 10.1182/blood.V85.10.2671.bloodjournal85102671; Tartour E, 1999, CANCER RES, V59, P3698; TARTOUR E, 1994, CANCER RES, V54, P6243; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358; Tlsty TD, 1999, NAT GENET, V21, P64, DOI 10.1038/4998; Wei LH, 2001, GYNECOL ONCOL, V82, P49, DOI 10.1006/gyno.2001.6235; WU S, 1992, AM J OBSTET GYNECOL, V166, P997, DOI 10.1016/0002-9378(92)91379-O; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	47	139	155	1	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5799	5809		10.1038/sj.onc.1204733	http://dx.doi.org/10.1038/sj.onc.1204733			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593385				2022-12-17	WOS:000171037200003
J	Wang, J; Shou, J; Chen, XB				Wang, J; Shou, J; Chen, XB			Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53	ONCOGENE			English	Article						p53; Dickkopf-1; Wnt	GLYCOGEN-SYNTHASE KINASE-3; IN-VIVO; APOPTOTIC RESPONSE; SPEMANN ORGANIZER; MICE DEFICIENT; HEAD INDUCTION; BINDING-SITE; BETA-CATENIN; PROTEIN; DROSOPHILA	Dickkopf-1 (Dkk-1), a secreted glycoprotein, has been found to be necessary and sufficient for inducing amphibian head formation. Interestingly, the mechanism by which Dkk-1 does this is the ability of Dkk-1 to antagonize the Wnt signaling pathway. Wnt, itself a proto-oncoprotein, can promote cell proliferation and transformation when mutated or overexpressed, leading to tumor formation. p53 is a tumor suppressor and loss of p53 function accelerates mammary tumorigenesis by Wnt. In this study, we found that Dkk-1 is induced by wild-type p53 but not mutant p53(R249S). In addition, DNA damage upregulates Dkk-1 in cell lines that harbor an endogenous wild-type p53 gene but not in cell lines that are p53-null or harbor an endogenous mutant p53 gene. We also found a potential p53 responsive element located approximately 2100 nucleotides upstream of the Dkk-1 transcription start site and we show that p53 binds specifically to this element both in vitro and in vivo. Furthermore, we have established several cell lines derived from H1299 lung carcinoma and U118 glioma cells that inducibly express Dkk-1 under a tetracycline-regulated promoter. We found that Dkk-1 has no effect on proliferation of cells that are not transformed by Wnt. Taken together, these results suggest that Dkk-1 may mediate p53 tumor suppression by antagonizing the Wnt signaling pathway.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [CA 76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076069, R01CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pai LM, 1997, DEVELOPMENT, V124, P2255; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THEISEN H, 1994, DEVELOPMENT, V120, P347; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	54	139	153	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1843	1848		10.1038/sj.onc.1203503	http://dx.doi.org/10.1038/sj.onc.1203503			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777218				2022-12-17	WOS:000086292500012
J	Banyard, J; Anand-Apte, B; Symons, M; Zetter, BR				Banyard, J; Anand-Apte, B; Symons, M; Zetter, BR			Motility and invasion are differentially modulated by Rho family GTPases	ONCOGENE			English	Article						cell migration; invasion; Rac; Rho; Cdc42; PDGF	GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; GROWTH-FACTOR; RAS TRANSFORMATION; CELL MOTILITY; PHOSPHOINOSITIDE 3-KINASE; 3-DIMENSIONAL CONTACT; EXTRACELLULAR-MATRIX; INDEPENDENT PATHWAYS; GENE-EXPRESSION	Cell migration in vivo often requires invasion through tissue matrices. Currently little is known regarding the signaling pathways that regulate cell invasion through three-dimensional matrices. The small GTPases Cdc42, Rac and Rho are key regulators of actin cytoskeletal and adhesive structures. We now show that expression of dominant negative forms of either Cdc42, Rac or Rho inhibited PDGF-BB-stimulated Rat1 fibroblast invasion into 3D collagen matrices, indicating that the activity of each of these GTPases is necessary for cell. invasion, In contrast, only Rac activation was required for PDGF-BB-stimulated locomotion across a planar substrate in the Boyden chamber. Interestingly, PDGF-induced invasion was also strongly inhibited by expression of constitutively active forms of Cdc42 or Rho, and to a lesser extent by constitutively active Rac, We also show that constitutively active V12-Rac significantly stimulated basal Rat1 fibroblast invasion, independent of PI-3-kinase activity, and that this effect was suppressed by the effector mutant V12/N40-Rac. These results suggest that cellular invasion may require an optimal level of activation of Cdc42, Rho and Rac, and that migration and invasion are differentially modulated by Rho family GTPases.	Harvard Univ, Childrens Hosp, Sch Med, Dept Surg Res, Boston, MA 02115 USA; Picower Inst Med Res, Mol Oncol Lab, Manhasset, NY 11030 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Northwell Health	Zetter, BR (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Surg Res, Enders 1074, Boston, MA 02115 USA.				NCI NIH HHS [CA37393, CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393, P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Allen WE, 1997, J CELL SCI, V110, P707; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUNDRA V, 1994, ONCOGENE, V9, P1429; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MAUCH C, 1989, FEBS LETT, V250, P301, DOI 10.1016/0014-5793(89)80743-4; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; OHagan RC, 1996, ONCOGENE, V13, P1323; OLSEN MF, 1995, SCIENCE, V269, P1270; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROECKEL D, 1994, EXP CELL RES, V211, P42, DOI 10.1006/excr.1994.1056; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SCHOR SL, 1980, J CELL SCI, V41, P159; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tang Y, 1999, MOL CELL BIOL, V19, P1881; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Xu JH, 1997, J CELL BIOL, V136, P473, DOI 10.1083/jcb.136.2.473; YAMADA KM, 1990, CANCER RES, V50, P4485; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	62	139	139	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					580	591		10.1038/sj.onc.1203338	http://dx.doi.org/10.1038/sj.onc.1203338			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698528				2022-12-17	WOS:000085104200012
J	Klugbauer, S; Rabes, HM				Klugbauer, S; Rabes, HM			The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas	ONCOGENE			English	Article						Chernobyl; dimerization domain; new RET rearrangements; RT-PCR; transcriptional regulatory proteins	CHERNOBYL REACTOR ACCIDENT; NUCLEAR RECEPTORS; RET/PTC1 ONCOGENE; REARRANGEMENT; CHILDREN; PROTOONCOGENE; EXPRESSION; ACTIVATION; GENE; CANCER	Children exposed to radioactive iodine as a consequence of the Chernobyl reactor accident ha ce an increased risk of papillary thyroid carcinomas (PTC), The predominant molecular lesions in these tumors are rearrangements of the RET receptor tyrosine kinase (tk), Here me report on two novel types of RET rearrangement, PTC6 and 7, and describe the fusion products and the ret fused gene (rfg) proteins, Like the other rfg proteins identified so far they are ubiquitously expressed, not membrane-bound and contain coiled coil domains required for constitutive activation of the ret tk domain. In the PTC6 rearrangement the ret tk domain is fused to the aminoterminal part of the human transcription intermediary factor htif 1, In the PTC7 rearrangement the ret tk domain is fused to a novel protein that is strongly related to htif1, Like htif1 it contains a RBCC motif (ring finger, B boxes, coiled coil domain) located in the aminoterminal part and a phd finger and a bromodomain in the carboxyterminal part. Htif1 and related proteins are transcription coactivators for nuclear receptors, thus participating in controlling cellular development, differentiation and homeostasis, This is the first report on their involvement in human thyroid carcinogenesis.	Univ Munich, Inst Pathol, D-80337 Munich, Germany	University of Munich	Rabes, HM (corresponding author), Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.							Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; Klugbauer S, 1998, ONCOGENE, V16, P671, DOI 10.1038/sj.onc.1201526; Klugbauer S, 1998, CANCER RES, V58, P198; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEHRACH H., 1990, GENOME ANAL, P39; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Rabes H M, 1997, Verh Dtsch Ges Pathol, V81, P139; Rabes HM, 1998, RECENT RES CANCER, V154, P248; Sagartz JE, 1997, LAB INVEST, V76, P307; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; Tong Q, 1997, J BIOL CHEM, V272, P9043; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	35	139	158	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4388	4393		10.1038/sj.onc.1202824	http://dx.doi.org/10.1038/sj.onc.1202824			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439047				2022-12-17	WOS:000081732700012
J	Jiang, WD; Ananthaswamy, HN; Muller, HK; Kripke, ML				Jiang, WD; Ananthaswamy, HN; Muller, HK; Kripke, ML			p53 protects against skin cancer induction by UV-B radiation	ONCOGENE			English	Article						sunlight; photocarcinogenesis; transgenic mice; tumor suppressor gene; mutation	SQUAMOUS-CELL CARCINOMA; P53-DEFICIENT MICE; MOUSE SKIN; MUTATIONS; TUMORS; ABNORMALITIES; SUNLIGHT	To assess the role of the p53 tumor suppressor gene in skin carcinogenesis by UV radiation, mice constitutively lacking one or both copies of the functional p53 gene were compared to wild-type mice for their susceptibility to UV carcinogenesis. Heterozygous mice showed greatly increased susceptibility to skin cancer induction, and homozygous p53 knockout mice mere even more susceptible, Accelerated tumor development in the heterozygotes was not associated with loss of the remaining wild-type allele of p53, as reported for tumors induced by other carcinogens, but in many cases was associated with UV-induced mutations in p53, Tumors arose on the ears and dorsal skin of mice of all three genotypes, and homozygous knockout mice also developed ocular tumors, mainly melanomas, Skin tumors in the p53 knockout mice were predominately squamous cell carcinomas and were associated with premalignant lesions resembling actinic keratoses, whereas those in the heterozygous and wild-type mice were mainly sarcomas, These results demonstrate the importance of p53 in protecting against UV-induced cancers, particularly in the eye and epidermis.	Univ Texas, MD Anderson Canc Ctr, Acad Programs, Dept Immunol, Houston, TX 77030 USA; Univ Tasmania, Dept Pathol, Hobart, Tas 7000, Australia	University of Texas System; UTMD Anderson Cancer Center; University of Tasmania	Kripke, ML (corresponding author), Univ Texas, MD Anderson Canc Ctr, Acad Programs, Dept Immunol, 1515 Holcombe Blvd,Box 147, Houston, TX 77030 USA.				NCI NIH HHS [R01CA46523, CA16672, P01CA68233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA068233, R01CA046523] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Cheo DL, 1996, CURR BIOL, V6, P1691, DOI 10.1016/S0960-9822(02)70794-X; DONAWHO CK, 1991, CANCER METAST REV, V10, P177, DOI 10.1007/BF00049413; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KANJILAL S, 1993, CANCER RES, V53, P2961; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; KRIPKE ML, 1977, CANCER RES, V37, P1395; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	19	139	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4247	4253		10.1038/sj.onc.1202789	http://dx.doi.org/10.1038/sj.onc.1202789			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435637				2022-12-17	WOS:000081542400008
J	Denissenko, MF; Pao, A; Pfeifer, GP; Tang, MS				Denissenko, MF; Pao, A; Pfeifer, GP; Tang, MS			Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers	ONCOGENE			English	Article						BPDE; DNA repair; mutation; p53	BENZO<A>PYRENE DIOL EPOXIDE; TUMOR-SUPPRESSOR GENE; HUMAN FIBROBLASTS; SKIN-CANCER; HPRT GENE; CHO CELLS; TRANSCRIPTION; SPECIFICITY; CARCINOGEN; BINDING	Using UvrABC incision in combination with ligation-mediated PCR (LMPCR) we have previously shown that benzo(a)pyrene diol epoxide (BPDE) adduct formation along the nontranscribed strand of the human p53 gene is highly selective; the preferential binding sites coincide with the major mutation hotspots found in human lung cancers. Both sequence-dependent adduct formation and repair may contribute to these mutation hotspots in tumor tissues. To test this possibility, we have extended our previous studies by mapping the BPDE adduct distribution in the transcribed strand of the p53 gene and quantifying the rates of repair for individual damaged bases in exons 5, 7, and 8 for both DNA strands of this gene in normal human fibroblasts. We found that: (i) on both strands, BPDE adducts preferentially form at CpG sequences, and (ii) repair of BPDE adducts in the transcribed DIVA strand is consistently faster than repair of adducts in the nontranscribed strand, while repair at the major damage hotspots (guanines at codons 157, 248 and 273) in the nontranscribed strand is two to four times slower than repair at other damage sites. These results strongly suggest that both preferential adduct formation and slow repair lead to hotspots for mutations at codons 157, 248 and 273, and that the strand bias of bulky adduct repair is primarily responsible for the strand bias of G to T transversion mutations observed in the p53 gene in human cancers.	Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA	University of Texas System; UTMD Anderson Cancer Center; City of Hope; Beckman Research Institute of City of Hope	Tang, MS (corresponding author), Univ Texas, Md Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA.				NATIONAL CANCER INSTITUTE [R01CA065652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008389, R01ES003124] Funding Source: NIH RePORTER; NCI NIH HHS [CA65652] Funding Source: Medline; NIEHS NIH HHS [ES08389, ES03124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELAND FA, 1989, PATHOBIOLOGY NEOPLAS, P57; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOLES TC, 1984, P NATL ACAD SCI-BIOL, V81, P5623, DOI 10.1073/pnas.81.18.5623; Butler AP, 1997, CARCINOGENESIS, V18, P239, DOI 10.1093/carcin/18.2.239; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY RG, 1981, ACCOUNTS CHEM RES, V14, P218, DOI 10.1021/ar00067a004; Harvey RG, 1991, POLYCYCLIC AROMATIC; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; JONES PA, 1991, CANCER RES, V51, P3617; KANEKO M, 1982, CHEM-BIOL INTERACT, V38, P261, DOI 10.1016/0009-2797(82)90057-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACLEOD MC, 1985, CANCER RES, V45, P51; MACLEOD MC, 1988, MUTAT RES, V199, P243, DOI 10.1016/0027-5107(88)90252-7; Maxam A M, 1980, Methods Enzymol, V65, P499; OSBORNE MR, 1990, CHEM-BIOL INTERACT, V75, P131, DOI 10.1016/0009-2797(90)90113-2; PELKONEN O, 1982, PHARMACOL REV, V34, P189; Ruddon R. W., 1995, CANC BIOL; SMITH BL, 1993, J BIOL CHEM, V268, P20620; STEVENS CW, 1985, MUTAT RES, V152, P5, DOI 10.1016/0027-5107(85)90040-5; Tang Moon-Shong, 1996, P139; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; TANG MS, 1994, J BIOL CHEM, V269, P12749; THRALL BD, 1994, BIOCHEMISTRY-US, V33, P2210, DOI 10.1021/bi00174a030; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1995, ONCOGENE, V10, P1493; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204; WEINSTEIN IB, 1981, J SUPRAMOL STR CELL, V17, P99, DOI 10.1002/jsscb.380170202	43	139	145	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1241	1247		10.1038/sj.onc.1201647	http://dx.doi.org/10.1038/sj.onc.1201647			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546425				2022-12-17	WOS:000072422000002
J	Vorechovsky, I; Tingby, O; Hartman, M; Stromberg, B; Nister, M; Collins, VP; Toftgard, R				Vorechovsky, I; Tingby, O; Hartman, M; Stromberg, B; Nister, M; Collins, VP; Toftgard, R			Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours	ONCOGENE			English	Article						medulloblastoma; mutation; nevoid basal cell carcinoma syndrome; chromosome 9; patched; PTCH	CELL CARCINOMA SYNDROME; P53 GENE-MUTATIONS; GORLIN SYNDROME; APC GENE; MEDULLOBLASTOMA; LINE; ESTABLISHMENT; PROTEIN	The naevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple developmental defects and cancer susceptibility, in particular to basal cell carcinomas (BCCs). Medulloblastomas,primitive neuroectodermal tumours (PNETs) arising in childhood, occur in about 3-5% of NBCCS patients and a subset of PNETs was previously found with allelic imbalance at 9q22-q23, the region containing the gene for NBCCS (PTCH). We have analysed tumour DNA samples from 37 unrelated patients with sporadic PNETs and five medulloblastoma cell lines for PTCH mutations using an exon-by-exon single strand conformation polymorphism assay. We found three missense mutations, which affect conserved residues in transmembrane domains of the gene product and in the extracellular loop implicated in binding sonic hedgehog, one 2 bp deletion and an exon skipping splice site mutation. Most mutations were associated with the absence of the wild-type allele and were found in tumours exhibiting loss of heterozygosity (LOH) at loci flanking PTCH. The finding of LOH at 9q22-q23 in most mutated tumours while present in only three out of 26 tumours, in which a mutation was not identified, implicates PTCH as the target gene in PNETs with LOH at 9q22-q23 and deficient PTCH in the development of a subset of these tumours. Since all observed mutations were absent in the germ-line, a sporadic medulloblastoma developing as the first symptom of NBCCS is likely to be a very uncommon event.	UNIV LONDON, ROYAL FREE HOSP, SCH MED, LONDON NW3 2PF, ENGLAND; KAROLINSKA HOSP, GUSTAV V RES INST, DEPT PATHOL & ONCOL, S-17176 STOCKHOLM, SWEDEN; UNIV UPPSALA HOSP, DEPT PATHOL, S-75185 UPPSALA, SWEDEN; UNIV UPPSALA HOSP, DEPT PAEDIAT, S-75185 UPPSALA, SWEDEN	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital	Vorechovsky, I (corresponding author), KAROLINSKA INST, NOVUM, DEPT BIOSCI, CTR NUTR & TOXICOL, S-14157 HUDDINGE, SWEDEN.							Acqui M, 1989, J Neurosurg Sci, V33, P263; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; BADIALI M, 1993, DIAGN MOL PATHOL, V2, P23, DOI 10.1097/00019606-199303000-00004; Beaudet AL, 1996, HUM MUTAT, V8, P197; BELAMARIC J, 1969, J NEUROSURG, V30, P76, DOI 10.3171/jns.1969.30.1.0076; Bhat KM, 1996, DEVELOPMENT, V122, P2921; BICKERSTAFF ER, 1967, ACTA NEUROPATHOL, V8, P104, DOI 10.1007/BF00686656; Blaeker H, 1996, GENE CHROMOSOME CANC, V15, P54, DOI 10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.3.CO;2-4; Chidambaram A, 1996, CANCER RES, V56, P4599; COGEN PH, 1992, AM J HUM GENET, V50, P584; David KM, 1997, J NEUROSURG, V86, P13, DOI 10.3171/jns.1997.86.1.0013; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EVANS DGR, 1993, J MED GENET, V30, P460, DOI 10.1136/jmg.30.6.460; EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FRIEDMAN HS, 1985, J NEUROPATH EXP NEUR, V44, P592, DOI 10.1097/00005072-198511000-00005; FRIEDMAN HS, 1988, AM J PATHOL, V130, P472; FULTS D, 1992, J NEUROPATH EXP NEUR, V51, P272, DOI 10.1097/00005072-199205000-00005; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HE XM, 1991, LAB INVEST, V64, P833; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HUNG KL, 1990, SURG NEUROL, V33, P341, DOI 10.1016/0090-3019(90)90203-2; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kleihues P, 1993, HISTOLOGICAL TYPING; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LACOMBE D, 1990, Genetic Counseling, V1, P273; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Merchant TE, 1996, INT J RADIAT ONCOL, V36, P29, DOI 10.1016/S0360-3016(96)00274-X; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; REIS A, 1992, LANCET, V339, P617, DOI 10.1016/0140-6736(92)90903-G; SAYLORS RL, 1991, CANCER RES, V51, P4721; Scheurlen W, 1996, EUR J PEDIATR, V155, P880; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; SCHOFIELD D, 1995, AM J PATHOL, V146, P472; Sidransky D, 1996, NAT GENET, V14, P7, DOI 10.1038/ng0996-7; Simoneau AR, 1996, CANCER RES, V56, P5039; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; VORECHOVSKY I, 1994, GENOMICS, V21, P517, DOI 10.1006/geno.1994.1310; Vorechovsky I, 1996, CANCER RES, V56, P2726; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wicking C, 1997, AM J HUM GENET, V60, P21; WICKING C, 1994, GENOMICS, V22, P505, DOI 10.1006/geno.1994.1423; YAMASHITA J, 1975, Surgical Neurology, V4, P225; YONG WH, 1995, NEW ENGL J MED, V333, P524	55	139	144	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					361	366		10.1038/sj.onc.1201340	http://dx.doi.org/10.1038/sj.onc.1201340			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233770				2022-12-17	WOS:A1997XK99900012
J	Warbrick, E; Lane, DP; Glover, DM; Cox, LS				Warbrick, E; Lane, DP; Glover, DM; Cox, LS			Homologous regions of Fen1 and p21(Cip1) compete for binding to the same site on PCNA: A potential mechanism to co-ordinate DNA replication and repair	ONCOGENE			English	Article						Fen1; p21(Cip1); PCNA; DNA replication; DNA repair	CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; SCHIZOSACCHAROMYCES-POMBE; MOLECULAR-CLONING; AUXILIARY PROTEIN; ESCHERICHIA-COLI; RAD2 GENE	Following genomic damage, the cessation of DNA replication is co-ordinated with onset of DNA repair; this co-ordination is essential to avoid mutation and genomic instability, To investigate these phenomena, we have analysed proteins that interact with PCNA, which is required for both DNA replication and repair, One such protein is p21(Cip1), which inhibits DNA replication through its interaction with PCNA, while allowing repair to continue, We have identified an interaction between PCNA and the structure specific nuclease, Fen1, which is involved in DNA replication, Deletion analysis suggests that p21(Cip1) and Fen1 bind to the same region of PCNA, Within Fen1 and its homologues a small region (10 amino acids) is sufficient for PCNA binding, which contains an 8 amino acid conserved PCNA-binding motif, This motif shares critical residues with the PCNA-binding region of p21(Cip1), A PCNA binding peptide from p21(Cip1) competes with Fen1 peptides for binding to PCNA, disrupts the Fen1-PCNA complex in replicating cell extracts, and concomitantly inhibits DNA synthesis, Competition between homologous regions of Fen1 and p21(Cip1) for binding to the same site on PCNA may provide a mechanism to co-ordinate the functions of PCNA in DNA replication and repair.	UNIV DUNDEE,DEPT BIOCHEM,CRC LABS,DUNDEE DD1 4HN,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,CRC LABS,DUNDEE DD1 4HN,SCOTLAND	University of Dundee; University of Dundee			Cox, Lynne/AAT-2047-2021; Warbrick, Emma/C-6424-2008; Lane, David P/C-4920-2008	Cox, Lynne/0000-0002-5306-285X; Lane, David/0000-0003-0551-3545; Glover, David/0000-0003-0956-0103				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORES RH, 1994, P NATL ACAD SCI USA, V91, P8655; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GULBIS JM, 1996, CELL, V87, P1; HALL PA, 1995, ONCOGENE, V10, P2427; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HUPPI K, 1994, ONCOGENE, V9, P3017; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; ROSE MD, 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LAB MANU; Savio M, 1996, ONCOGENE, V13, P1591; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WASEEM NH, 1990, J CELL SCI, V96, P121; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; XIONG Y, 1992, CELL, V71, P504	54	139	141	16	126	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2313	2321		10.1038/sj.onc.1201072	http://dx.doi.org/10.1038/sj.onc.1201072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178907				2022-12-17	WOS:A1997WY88300008
J	Shao, NS; Chai, YL; Shyam, E; Reddy, P; Rao, NV				Shao, NS; Chai, YL; Shyam, E; Reddy, P; Rao, NV			Induction of apoptosis by the tumor suppressor protein BRCA1	ONCOGENE			English	Article						BRCA1 proteins; tumor suppressor; breast and ovarian cancers; apoptosis; therapy		The breast and ovarian cancer susceptibility gene BRCA1, is a nuclear phosphoprotein which functions as a tumor suppressor, To investigate the role of BRCA1 in apoptosis, we have developed mouse fibroblast cell lines and human breast cancer cell lines expressing BRCA1, The expression of BRCA1 protein in the BRCA1 transfectants were analysed by immunofluorescence and immunohistochemistry. The BRCA1 transfectants showed a flattened morphology compared to the parental cells, We show that serum deprivation or calcium ionophore treatment of BRCA1 transfectants resulted in programmed cell death, These results indicate that BRCA1 genes may play a critical role in the regulation of apoptosis, Thus, since a wide variety of human malignancies like breast and ovarian cancers have a decreased ability to undergo apoptosis, this could be due to lack/decreased levels of functional BRCA1 proteins, Treatments that are aimed at increasing the apoptotic threshold by BRCA1 gene therapy may have the potential to prevent the progression of these malignancies.	JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA58642, CA57322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDALL LJ, 1994, EXP HEMATOL, V22, P1252; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GUDAS JM, 1995, CANCER RES, V55, P4561; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JIMENEZ B, 1995, ONCOGENE, V10, P811; KONDO S, 1995, ONCOGENE, V10, P2001; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Rao VN, 1996, ONCOGENE, V12, P523; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	16	139	145	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					1	7						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700535				2022-12-17	WOS:A1996UX31900001
J	Levkowitz, G; Klapper, LN; Tzahar, E; Freywald, A; Sela, M; Yarden, Y				Levkowitz, G; Klapper, LN; Tzahar, E; Freywald, A; Sela, M; Yarden, Y			Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins	ONCOGENE			English	Article						tyrosine kinase; growth factor; signal transduction; Neu differentiation factor	GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; EGF RECEPTOR; V-CBL; NEU RECEPTOR; SH2 DOMAINS; BINDING; KINASE; GENE	The ErbB family of transmembrane tyrosine kinases includes the receptor for EGF (ErbB-1), two receptors for NDF/heregulin (ErbB-3 and ErbB-4) and an orphan receptor (ErbB-2). In order to examine the possibility that distinct signal transduction pathways are coupled to each ErbB protein, we examined the interaction of individual ligand-stimulated receptors with the c-Cbl protein, a protooncogene-encoded signaling molecule previously identified in hematopoietic cells. We report that c-Cbl undergoes rapid and sustained phosphorylation on tyrosine residues upon stimulation of fibroblast and epithelial cell lines with ligands of ErbB-1. By contrast, activation of either ErbB-3 or ErbB-4 by NDF did not affect tyrosine phosphorylation of c-Cbl. Likewise, activation of a chimeric ligand-stimulatable ErbB-2 by a heterologous ligand was ineffective. Despite rapidity of the EGF effect, we observed no association of c-Cbl with activated ErbB-1, implying that the interaction is indirect. Our in vitro experiments suggest that a candidate mediator of the interaction is the Grb-2/Ash adaptor protein, which is constitutively bound to c-Cbl. These results indicate that different ErbB proteins can couple to distinct signaling pathways, and therefore their physiological functions are probably non-redundant.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; 	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BATEWELL DDL, 1995, ONCOGENE, V11, P1561; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EAGAN SE, 1993, NATURE, V363, P45; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; KEANE MM, 1995, ONCOGENE, V10, P2367; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SEGATTO O, 1993, ONCOGENE, V8, P2105; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	61	139	142	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1117	1125						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649804				2022-12-17	WOS:A1996UA88400021
J	Guha, A; Lau, N; Huvar, I; Gutmann, D; Provias, J; Pawson, T; Boss, G				Guha, A; Lau, N; Huvar, I; Gutmann, D; Provias, J; Pawson, T; Boss, G			Ras-GTP levels are elevated in human NF1 peripheral nerve tumors	ONCOGENE			English	Article						NF1; Ras-GDP; Ras	NEUROFIBROMATOSIS TYPE-1 GENE; NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; ACTIVATING PROTEIN; GRB2; PRODUCT; CELLS; TRANSFORMATION; NEUROBLASTOMA; ONCOGENES	Neurofibromin, the gene product of NF1, is a Pas GTPase Activating Protein. The absence of neurofibromin leads to increased levels of Ras-GTP, which contributes to the proliferation of NF1 neurogenic sarcoma cell lines. Whether this pathogenic mechanism is applicable to benign and malignant peripheral nerve tumours from NF1 and non NF1 patients is not known, due to lack of a tissue based assay, We have adapted a colorimetric enzymatic assay for determining levels of Pas bound guanine nucleotides in tissues, Ras-GTP levels were increased in NF1 neurogenic sarcomas (15 times) and benign NF1 neurofibromas (four times), compared to non NF1 schwannomas. Neurofibromin was not expressed in NF1 sarcomas, in support of its important negative Ras regulatory role in the pathogenesis of NF1 peripheral nerve tumors.	UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,TORONTO HOSP,DIV NEUROPATHOL,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A1,CANADA; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; WASHINGTON UNIV,SCH MED,DEPT NEUROL PEDIAT & GENET,ST LOUIS,MO 63130; UNIV TORONTO,TORONTO HOSP,DIV NEUROSURG & SURG ONCOL,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of California System; University of California San Diego; Washington University (WUSTL); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Guha, A (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOLEC BIOL & CANC,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Pawson, Tony J/E-4578-2013	Boss, Gerry/0000-0002-9758-8714; Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49360] Funding Source: Medline; NINDS NIH HHS [NS-01590-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1992, CANCER BIOL, V3, P199; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GUHA A, 1995, NEUROLOGICAL SURGERY; GUTMANN DH, 1994, GENE CHROMOSOME CANC, V10, P55, DOI 10.1002/gcc.2870100109; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; GUTMANN DH, 1994, METABOLIC MOL BASIS; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWENSTEIN E, 1942, CELL, V70, P431; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NUREKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; PELTONEN J, 1983, ACTA NEUROPATHOL, V61, P275, DOI 10.1007/BF00691998; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; XU G, 1990, CELL, V463, P835; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	40	139	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					507	513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637706				2022-12-17	WOS:A1996TV59700006
J	BACKER, JM; MENDOLA, CE; KOVESDI, I; FAIRHURST, JL; OHARA, B; EDDY, RL; SHOWS, TB; MATHEW, S; MURTY, VVVS; CHAGANTI, RSK				BACKER, JM; MENDOLA, CE; KOVESDI, I; FAIRHURST, JL; OHARA, B; EDDY, RL; SHOWS, TB; MATHEW, S; MURTY, VVVS; CHAGANTI, RSK			CHROMOSOMAL LOCALIZATION AND NUCLEOSIDE DIPHOSPHATE KINASE-ACTIVITY OF HUMAN METASTASIS-SUPPRESSOR GENES NM23-1 AND NM23-2	ONCOGENE			English	Note							HUMAN BREAST-CANCER; INSITU HYBRIDIZATION; BINDING-PROTEINS; TUMOR-METASTASIS; GOOD PROGNOSIS; HUMAN GENOME; EXPRESSION; ASSOCIATION; IDENTIFICATION; AMPLIFICATION	Human metastasis-suppressor genes nm23-1 (NME1) and nm23-2 (NME2) are implicated in control of the metastatic potential of malignant cells. Using somatic cell hybrid analysis and fluorescence in situ hybridization we co-localized both genes to 17q21.3. The 17q21 region carries the locus responsible for early-onset familial breast-ovarian cancer and several other genes that are involved in tumorigenesis and differentiation and undergo frequent rearrangements during neoplastic development. Thus, our mapping places the NME genes in a region that may be subjected to multiple selection pressures. NME1 and NME2 genes were expressed as soluble proteins in a T7 bacterial expression system. Both proteins are independently active nucleoside diphosphate kinases and readily form intra- and intermolecular disulfide bonds. The biochemical properties of these proteins may explain the diversity of mature eucaryotic nucleoside diphosphate kinases.	NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Roswell Park Cancer Institute; Memorial Sloan Kettering Cancer Center	BACKER, JM (corresponding author), AMER CYANAMID CO,LEDERLE LABS,MOLEC BIOL RES SECT,PEARL RIVER,NY 10965, USA.			Kovesdi, Imre/0000-0002-0322-3969				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BACKER JM, 1991, AIDS RES HUM RETROV, V7, P1015, DOI 10.1089/aid.1991.7.1015; BARNES R, 1991, AM J PATHOL, V139, P245; BEVILACQUA G, 1990, PATHOL BIOL, V38, P774; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CLARK GM, 1991, CANCER RES, V51, P944; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRANCIS B, 1989, MOL CARCINOGEN, V2, P168, DOI 10.1002/mc.2940020310; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAUT M, 1991, J NATL CANCER I, V83, P712, DOI 10.1093/jnci/83.10.712; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HENNESSY C, 1991, BRIT J CANCER, V63, P1024, DOI 10.1038/bjc.1991.223; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MCALPINE PJ, 1991, CYTOGENET CELL GENET, V58, P5, DOI 10.1159/000133160; NAROD SA, 1991, LANCET, V338, P82; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; OHTSUKI K, 1987, BIOCHEM BIOPH RES CO, V148, P300, DOI 10.1016/0006-291X(87)91110-7; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1989, CANCER METASTASIS, P48; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VARESCO L, 1992, GENE CHROMOSOME CANC, V4, P84, DOI 10.1002/gcc.2870040113; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932	47	139	144	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					497	502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381224				2022-12-17	WOS:A1993KN00600030
J	JONVEAUX, P; FENAUX, P; QUIQUANDON, I; PIGNON, JM; LAI, JL; LOUCHEUXLEFEBVRE, MH; GOOSSENS, M; BAUTERS, F; BERGER, R				JONVEAUX, P; FENAUX, P; QUIQUANDON, I; PIGNON, JM; LAI, JL; LOUCHEUXLEFEBVRE, MH; GOOSSENS, M; BAUTERS, F; BERGER, R			MUTATIONS IN THE P53-GENE IN MYELODYSPLASTIC SYNDROMES	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; CHRONIC MYELOGENOUS LEUKEMIA; P53 GENE-MUTATIONS; TUMOR-ANTIGEN; POINT MUTATIONS; CDNA SEQUENCE; RAS ONCOGENES; BLAST CRISIS; DNA; EXPRESSION	We have examined p53 alleles in 151 DNAs from patients with myelodysplastic syndrome using single-strand conformation polymorphism analysis of polymerase chain reaction products. We focused our study on the four highly conserved regions of the p53 gene and detected five patients with aberrantly migrating fragments. We confirmed the putative mutation in each case by direct sequencing analysis. Of these five patients, three had chromosome 17 monosomy associated with p53 mutation, one patient showed one mutated p53 allele and one wild-type allele, and the last patient demonstrated only the mutant allele, suggesting a homozygous state. Unlike many other types of human cancers, point mutations in the p53 tumor-suppressor gene appear to be a rare event in myelodysplastic syndromes.	INSERM,U124,INST RECH CANC,F-59045 LILLE,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; CHU LILLE,SERV HEMATOL & CYTOGENET,F-59037 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille	JONVEAUX, P (corresponding author), INSERM,U301,INST GENET MOLEC,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.							AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; AINSWORTH PJ, 1991, NUCLEIC ACIDS RES, V19, P405, DOI 10.1093/nar/19.2.405; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HARNDEN DG, 1985, CYTOGENET CELL GENET; HARNDEN DG, 1985, ISCN 1985 INT SYSTEM; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KELMAN Z, 1989, BLOOD, V74, P2318; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P284; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LYONS J, 1988, BLOOD, V71, P1707; Maniatis T., 1982, MOL CLONING; MASHAL R, 1990, BLOOD, V75, P180; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; ROMANO JW, 1989, ONCOGENE, V4, P1483; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SOUSSI T, 1990, ONCOGENE, V5, P945; SUGIMOTO K, 1991, BLOOD, V77, P1153; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VARLEY JM, 1991, ONCOGENE, V6, P413; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	42	139	142	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2243	2247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766671				2022-12-17	WOS:A1991GX73500010
J	Cohen, N; Shani, O; Raz, Y; Sharon, Y; Hoffman, D; Abramovitz, L; Erez, N				Cohen, N.; Shani, O.; Raz, Y.; Sharon, Y.; Hoffman, D.; Abramovitz, L.; Erez, N.			Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; INFLAMMATION; CELLS; EXPRESSION; YKL-40; PROGRESSION; METASTASIS; CHI3L1; CHEMOTHERAPY; RESPONSES	Cancer-Associated Fibroblasts (CAFs) are the most prominent stromal cell type in breast tumors. CAFs promote tumor growth and metastasis by multiple mechanisms, including by mediating tumor-promoting inflammation. Immune modulation in the tumor microenvironment plays a central role in determining disease outcome. However, the functional interactions of CAFs with immune cells are largely unknown. Here we report a novel signaling axis between fibroblasts, cancer cells and immune cells in breast tumors that drives an immunosuppressive microenvironment, mediated by CAF-derived Chi3L1. We demonstrate that Chi3L1 is highly upregulated in CAFs isolated from mammary tumors and pulmonary metastases of transgenic mice, and in the stroma of human breast carcinomas. Genetic ablation of Chi3L1 in fibroblasts in vivo attenuated tumor growth, macrophage recruitment and reprogramming to an M2-like phenotype, enhanced tumor infiltration by CD8(+) and CD4(+) T cells and promoted a Th1 phenotype. These results indicate that CAF-derived Chi3L1 promotes tumor growth and shifts the balance of the immune milieu towards type 2 immunity. Taken together, our findings implicate fibroblast-derived Chi3L1 as a novel key player in the complex reciprocal interactions of stromal cells that facilitate tumor progression and metastasis, and suggest that targeting Chi3L1 may be clinically beneficial in breast cancer.	[Cohen, N.; Shani, O.; Raz, Y.; Sharon, Y.; Hoffman, D.; Abramovitz, L.; Erez, N.] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; [Raz, Y.] Tel Aviv Sourasky Med Ctr, Dept Obstet & Gynecol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Erez, N (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel.	netaerez@post.tau.ac.il	Yana, Yael Raz/S-7100-2019	Abramovitz, Lilach/0000-0001-9961-9986; Erez, Neta/0000-0001-6506-9074	European Research Council under the European Union's Horizon research and innovation programme [637069 MetCAF]; Israel Science Foundation [813/12]; Israel Cancer Association; Israel Cancer Research Fund (Research Career Development Award)	European Research Council under the European Union's Horizon research and innovation programme; Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Israel Cancer Research Fund (Research Career Development Award)	This research was supported by grants to NE from the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 637069 MetCAF), from the Israel Science Foundation (#813/12), the Israel Cancer Association and The Israel Cancer Research Fund (Research Career Development Award). We would like to thank Dr Yaron Carmi for scientific discussions, Shahar Biechonski and Hila Schwartz for their help with data analysis and helpful discussions, and Elad Yana for graphical assistance. We thank Dr Ariel Munitz for critical reading of the manuscript. This work was performed in partial fulfillment of the requirements for a PhD of Noam Cohen, Sackler School of Medicine, Tel Aviv University.	Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Bigg HF, 2006, J BIOL CHEM, V281, P21082, DOI 10.1074/jbc.M601153200; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Erez N, 2013, BIOCHEM BIOPH RES CO, V437, P397, DOI 10.1016/j.bbrc.2013.06.089; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Eurich K, 2009, WORLD J GASTROENTERO, V15, P5249, DOI 10.3748/wjg.15.5249; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; Johansen JS, 2003, BREAST CANCER RES TR, V80, P15, DOI 10.1023/A:1024431000710; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karo-Atar D, 2015, J ASTHMA, V52, P545, DOI 10.3109/02770903.2014.988222; Kawada M, 2012, ONCOGENE, V31, P3111, DOI 10.1038/onc.2011.498; Komohara Y, 2017, J PATHOL, V241, P313, DOI 10.1002/path.4824; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Libreros S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00392; Libreros S, 2013, IMMUNOL RES, V57, P99, DOI 10.1007/s12026-013-8459-y; Libreros S, 2012, INT J CANCER, V131, P377, DOI 10.1002/ijc.26379; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Ma B, 2015, CANCER RES, V75, P487, DOI 10.1158/0008-5472.CAN-13-3339; Mantovani A, 2007, BREAST, V16, pS27, DOI 10.1016/j.breast.2007.07.013; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Martey CA, 2004, AM J PHYSIOL-LUNG C, V287, pL981, DOI 10.1152/ajplung.00239.2003; Mizrachy-Schwartz S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000628; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003; Pollard JW, 2008, J LEUKOCYTE BIOL, V84, P623, DOI 10.1189/jlb.1107762; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Schwartz H, 2016, CANCER RES, V76, P4359, DOI 10.1158/0008-5472.CAN-16-0485; Servais C, 2013, J PATHOL, V229, P198, DOI 10.1002/path.4103; Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; Sharon Y, 2013, JOVE-J VIS EXP, DOI 10.3791/4425; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Walker RA, 2001, BREAST CANCER RES, V3, P143, DOI 10.1186/bcr287; Zhou Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007096	53	138	146	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4457	4468		10.1038/onc.2017.65	http://dx.doi.org/10.1038/onc.2017.65			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368410	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000406806000008
J	Khongkow, P; Gomes, AR; Gong, C; Man, EPS; Tsang, JWH; Zhao, F; Monteiro, LJ; Coombes, RC; Medema, RH; Khoo, US; Lam, EWF				Khongkow, P.; Gomes, A. R.; Gong, C.; Man, E. P. S.; Tsang, J. W-H; Zhao, F.; Monteiro, L. J.; Coombes, R. C.; Medema, R. H.; Khoo, U. S.; Lam, E. W-F			Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance	ONCOGENE			English	Article							EPIRUBICIN RESISTANCE; MICROTUBULE MOTORS; KINESIN; PROTEINS; CYTOKINESIS; EXPRESSION; FOXO3A; CELLS; INHIBITION; MECHANISMS	FOXM1 has been implicated in taxane resistance, but the molecular mechanism involved remains elusive. In here, we show that FOXM1 depletion can sensitize breast cancer cells and mouse embryonic fibroblasts into entering paclitaxel-induced senescence, with the loss of clonogenic ability, and the induction of senescence-associated beta-galactosidase activity and flat cell morphology. We also demonstrate that FOXM1 regulates the expression of the microtubulin-associated kinesin KIF20A at the transcriptional level directly through a Forkhead response element (FHRE) in its promoter. Similar to FOXM1, KIF20A expression is downregulated by paclitaxel in the sensitive MCF-7 breast cancer cells and deregulated in the paclitaxel-resistant MCF-7Tax(R) cells. KIF20A depletion also renders MCF-7 and MCF-7Tax(R) cells more sensitive to paclitaxel-induced cellular senescence. Crucially, resembling paclitaxel treatment, silencing of FOXM1 and KIF20A similarly promotes abnormal mitotic spindle morphology and chromosome alignment, which have been shown to induce mitotic catastrophe-dependent senescence. The physiological relevance of the regulation of KIF20A by FOXM1 is further highlighted by the strong and significant correlations between FOXM1 and KIF20A expression in breast cancer patient samples. Statistical analysis reveals that both FOXM1 and KIF20A protein and mRNA expression significantly associates with poor survival, consistent with a role of FOXM1 and KIF20A in paclitaxel action and resistance. Collectively, our findings suggest that paclitaxel targets the FOXM1-KIF20A axis to drive abnormal mitotic spindle formation and mitotic catastrophe and that deregulated FOXM1 and KIF20A expression may confer paclitaxel resistance. These findings provide insights into the underlying mechanisms of paclitaxel resistance and have implications for the development of predictive biomarkers and novel chemotherapeutic strategies for paclitaxel resistance.	[Khongkow, P.; Gomes, A. R.; Gong, C.; Zhao, F.; Monteiro, L. J.; Coombes, R. C.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Gong, C.; Man, E. P. S.; Zhao, F.; Khoo, U. S.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, J. W-H] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	Imperial College London; University of Hong Kong; University of Hong Kong; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Khoo, Ui Soon/C-1345-2014; Khoo, Ui Soon/K-2041-2019; Khoo, Ui Soon/C-4293-2009; Lam, Eric W-F/AAW-8566-2020; Monteiro, Lara J/AAU-8518-2020	Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; Khongkow, Pasarat/0000-0003-3068-2412; Coombes, Raoul Charles/0000-0002-4811-1100; Medema, Rene/0000-0002-6754-0381	Cancer Research UK; Breast Cancer Campaign; Royal Thai Government Scholarships; Committee on Research and Conference Grants from the University of Hong Kong (CRCG) [201007176118]; MRC [MR/N012097/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Engineering and Physical Sciences Research Council [1234732] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish; Breast Cancer Campaign [2012MayPR070, 2012NovPhD016] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Royal Thai Government Scholarships; Committee on Research and Conference Grants from the University of Hong Kong (CRCG); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Breast Cancer Campaign	EW-F Lam, AR Gomes and RC Coombes were supported by grants from Cancer Research UK; EW-F Lam by grants from Breast Cancer Campaign; P Khongkow, from the Royal Thai Government Scholarships. US Khoo received funding from Committee on Research and Conference Grants from the University of Hong Kong (CRCG) (201007176118). We also thank Muhammad Zaini, Marios Poullas and Laura Bella for help with this work.	Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293; Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Cortes J, 2007, ONCOLOGIST, V12, P271, DOI 10.1634/theoncologist.12-3-271; Dean-Colomb W, 2008, SEMIN ONCOL, V35, pS31, DOI 10.1053/j.seminoncol.2008.02.008; Exertier P, 2013, ONCOTARGET, V4, P2302, DOI 10.18632/oncotarget.1490; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098; Khongkow P, 2014, ONCOGENE, V33, P4144, DOI 10.1038/onc.2013.457; Kitagawa M, 2014, CELL REP, V7, P166, DOI 10.1016/j.celrep.2014.02.034; Kline-Smith SL, 2004, MOL CELL, V15, P317, DOI 10.1016/j.molcel.2004.07.012; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu J, 2013, REPROD BIOL ENDOCRIN, V11, DOI 10.1186/1477-7827-11-117; Misiukiewicz K, 2014, ANTI-CANCER DRUG, V25, P561, DOI 10.1097/CAD.0000000000000086; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; Myatt SS, 2014, ONCOGENE, V33, P4316, DOI 10.1038/onc.2013.546; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Neef R, 2005, METHOD ENZYMOL, V403, P618, DOI 10.1016/S0076-6879(05)03054-5; Nguyen PA, 2014, SCIENCE, V346, P244, DOI 10.1126/science.1256773; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Okuyama R, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27010; Rohena CC, 2014, NAT PROD REP, V31, P335, DOI 10.1039/c3np70092e; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tcherniuk S, 2010, ANGEW CHEM INT EDIT, V49, P8228, DOI 10.1002/anie.201003254; Verhey KJ, 2009, NAT REV MOL CELL BIO, V10, P765, DOI 10.1038/nrm2782; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059	41	138	143	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					990	1002		10.1038/onc.2015.152	http://dx.doi.org/10.1038/onc.2015.152			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961928	Green Published, hybrid, Green Accepted, Green Submitted			2022-12-17	WOS:000370823300005
J	Kohlhapp, FJ; Mitra, AK; Lengyel, E; Peter, ME				Kohlhapp, F. J.; Mitra, A. K.; Lengyel, E.; Peter, M. E.			MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment	ONCOGENE			English	Review							MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; STROMAL FIBROBLASTS; SUPPRESSOR-CELLS; DOWN-REGULATION; HUMAN BREAST; OVARIAN-CANCER; DUAL ROLE	Cancer cells grow in an environment comprised of multiple components that support tumor growth and contribute to therapy resistance. Major cell types in the tumor microenvironment are fibroblasts, endothelial cells and infiltrating immune cells all of which communicate with cancer cells. One way that these cell types promote cancer progression is by altering the expression of microRNAs (miRNAs), small noncoding RNAs that negatively regulate protein expression, either in the cancer cells or in the associated normal cells. Changes in miRNA expression can be brought about by direct interaction between the stromal cells and cancer cells, by paracrine factors secreted by any of the cell types or even through direct communication between cells through secreted miRNAs. Understanding the role of miRNAs in the complex interactions between the tumor and cells in its microenvironment is necessary if we are to understand tumor progression and devise new treatments.	[Kohlhapp, F. J.; Peter, M. E.] Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Mitra, A. K.] Indiana Univ, Indiana Univ Sch Med, Med Sci Program, Bloomington, IN USA; [Lengyel, E.] Univ Chicago, Dept Gynecol & Obstet, Gynecol Oncol Sect, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University Bloomington; University of Chicago	Peter, ME (corresponding author), Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, 303 East Super St,Lurie 6-123, Chicago, IL 60611 USA.	m-peter@northwestern.edu	; Lengyel, Ernst/D-9220-2014	Peter, Marcus Ernst/0000-0003-3216-036X; Lengyel, Ernst/0000-0001-8624-1507	OCRF program [FP049318/PPD/UC];  [T32 CA070085];  [F32 CA180677]; NATIONAL CANCER INSTITUTE [T32CA070085, P30CA060553, F32CA180677] Funding Source: NIH RePORTER	OCRF program; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	FK was supported by grants T32 CA070085 and F32 CA180677. MEP and EL were supported by an OCRF program project development grant FP049318/PPD/UC.	Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Almog N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044001; Aprelikova O, 2013, ONCOGENE, V32, P3246, DOI 10.1038/onc.2012.351; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Aucher A, 2013, J IMMUNOL, V191, P6250, DOI 10.4049/jimmunol.1301728; Barroso-delJesus A, 2008, MOL CELL BIOL, V28, P6609, DOI 10.1128/MCB.00398-08; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Bullock MD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.213; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chang SH, 2013, J BIOL CHEM, V288, P4908, DOI 10.1074/jbc.M112.423871; Chaudhuri AA, 2011, J IMMUNOL, V187, P5062, DOI 10.4049/jimmunol.1102001; Chen L, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-489; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Connolly J. L., 2003, TUMOR STRUCTURE TUMO; Cubillos-Ruiz JR, 2012, CANCER RES, V72, P1683, DOI 10.1158/0008-5472.CAN-11-3160; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Du J, 2012, MED ONCOL, V29, P2814, DOI 10.1007/s12032-012-0175-2; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; El Chartouni C, 2010, IMMUNOBIOLOGY, V215, P821, DOI 10.1016/j.imbio.2010.05.031; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670; Gatto G, 2008, NUCLEIC ACIDS RES, V36, P6608, DOI 10.1093/nar/gkn666; Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Guduric-Fuchs J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-357; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hu S, MOL ONCOL, P44; Huffaker TB, 2012, CELL REP, V2, P1697, DOI 10.1016/j.celrep.2012.10.025; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Jusufovic E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045577; Kadera BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071978; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Ke G, 2013, ONCOGENE, V32, P3019, DOI 10.1038/onc.2012.323; Kong D, 2012, ONCOGENE, V31, P3949, DOI 10.1038/onc.2011.558; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Kosaka Nobuyoshi, 2013, Frontiers in Genetics, V4, P173, DOI 10.3389/fgene.2013.00173; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Lee JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084256; Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850; Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036; Liu QF, 2011, INT J CANCER, V129, P2662, DOI 10.1002/ijc.25921; Liu Y, 2012, J IMMUNOL, V188, P5500, DOI 10.4049/jimmunol.1103505; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Lwin T, 2010, BLOOD, V116, P5228, DOI 10.1182/blood-2010-03-275925; Mitra AK, 2015, ONCOGENE, V34, P5923, DOI 10.1038/onc.2015.43; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Mongiat M, 2010, NEOPLASIA, V12, P294, DOI 10.1593/neo.91930; Morello M, 2013, CELL CYCLE, V12, P3526, DOI 10.4161/cc.26539; Muramatsu F, 2013, ONCOGENE, V32, P414, DOI 10.1038/onc.2012.68; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Naito Y, 2014, CANCER SCI, V105, P228, DOI 10.1111/cas.12329; Nielsen BS, 2011, CLIN EXP METASTAS, V28, P27, DOI 10.1007/s10585-010-9355-7; Nilsson S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036051; Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658; Nouraee N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073009; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Plummer PN, 2013, CANCER RES, V73, P341, DOI 10.1158/0008-5472.CAN-12-0271; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Rappa G, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-62; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Roybal JD, 2011, MOL CANCER RES, V9, P25, DOI 10.1158/1541-7786.MCR-10-0497; Sasaki K, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-17; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Senst C, 2013, BREAST CANCER RES TR, V137, P69, DOI 10.1007/s10549-012-2321-0; Shih TC, 2012, J HEPATOL, V57, P584, DOI 10.1016/j.jhep.2012.04.031; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smits M, 2012, FASEB J, V26, P2639, DOI 10.1096/fj.11-202820; Sonda N, 2013, IMMUNITY, V38, P1236, DOI 10.1016/j.immuni.2013.06.004; Squadrito ML, 2014, CELL REP, V8, P1432, DOI 10.1016/j.celrep.2014.07.035; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Subramani A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02392; Sugiyama K, 2014, MOL CANCER THER, V13, P2081, DOI 10.1158/1535-7163.MCT-14-0135; Tang B, 2014, J BIOL CHEM, V289, P34595, DOI 10.1074/jbc.M114.614503; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Tuhkanen H, 2006, INT J CANCER, V119, P1345, DOI 10.1002/ijc.21785; Ueda R, 2009, P NATL ACAD SCI USA, V106, P10746, DOI 10.1073/pnas.0811817106; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vecchione A, 2013, P NATL ACAD SCI USA, V110, P9845, DOI 10.1073/pnas.1305472110; Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248; Wang M, 2014, BRIT J CANCER, V110, P1199, DOI 10.1038/bjc.2014.14; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wang RZ, 2013, HEPATOLOGY, V58, P642, DOI 10.1002/hep.26373; Wei J, 2013, CANCER RES, V73, P3913, DOI 10.1158/0008-5472.CAN-12-4318; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Xu QL, 2012, INT J ONCOL, V41, P959, DOI 10.3892/ijo.2012.1541; Yamamichi N, 2009, CLIN CANCER RES, V15, P4009, DOI 10.1158/1078-0432.CCR-08-3257; Yan XL, 2013, HEPATOLOGY, V57, P2274, DOI 10.1002/hep.26257; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yao Q, 2011, INT J CANCER, V128, P1783, DOI 10.1002/ijc.25506; Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323; Zhai HY, 2011, J NEUROSCI, V31, P14346, DOI 10.1523/JNEUROSCI.3299-11.2011; Zhang MM, 2011, J IMMUNOL, V186, P4716, DOI 10.4049/jimmunol.1002989; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690; Zhao LY, 2012, INT J BIOCHEM CELL B, V44, P2051, DOI 10.1016/j.biocel.2012.08.005; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhu K, 2013, CARCINOGENESIS, V34, P2071, DOI 10.1093/carcin/bgt160; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183; Zonari E, 2013, BLOOD, V122, P243, DOI 10.1182/blood-2012-08-449306	116	138	143	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5857	5868		10.1038/onc.2015.89	http://dx.doi.org/10.1038/onc.2015.89			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25867073	Bronze, Green Accepted			2022-12-17	WOS:000365434000001
J	Sagiv, A; Biran, A; Yon, M; Simon, J; Lowe, SW; Krizhanovsky, V				Sagiv, A.; Biran, A.; Yon, M.; Simon, J.; Lowe, S. W.; Krizhanovsky, V.			Granule exocytosis mediates immune surveillance of senescent cells	ONCOGENE			English	Article						cellular senescence; perforin; liver fibrosis	NATURAL-KILLER-CELLS; ACTIVATED STELLATE CELLS; PERFORIN-DEFICIENT MICE; CELLULAR SENESCENCE; LIVER FIBROSIS; TUMOR-SUPPRESSOR; GRANZYME-B; NK CELLS; T-CELLS; CYTOTOXICITY	Senescence is a stable cell cycle arrest program that contributes to tumor suppression, organismal aging and certain wound healing responses. During liver fibrosis, for example, hepatic stellate cells initially proliferate and secrete extracellular matrix components that produce fibrosis; however, these cells eventually senesce and are cleared by immune cells, including natural killer (NK) cells. Here, we examine how NK cells target senescent cells and assess the impact of this process on liver fibrosis. We show that granule exocytosis, but not death-receptor-mediated apoptosis, is required for NK-cell-mediated killing of senescent cells. This pathway bias is due to upregulation of the decoy death receptor, Dcr2, an established senescence marker that attenuates NK-mediated cell death. Accordingly, mice with defects in granule exocytosis accumulate senescent stellate cells and display more liver fibrosis in response to a fibrogenic agent. Our results thus provide new insights into the immune surveillance of senescent cells and reveal how granule exocytosis has a protective role against liver fibrosis. Oncogene (2013) 32, 1971-1977; doi:10.1038/onc.2012.206; published online 2 July 2012	[Sagiv, A.; Biran, A.; Krizhanovsky, V.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Yon, M.; Simon, J.; Lowe, S. W.; Krizhanovsky, V.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Yon, M.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508 Sao Paulo, Brazil; [Simon, J.; Lowe, S. W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA	Weizmann Institute of Science; Cold Spring Harbor Laboratory; Universidade de Sao Paulo; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute	Lowe, SW (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.	lowes@mskcc.org; valery.krizhanovsky@weizmann.ac.il	Krizhanovsky, Valery/D-1336-2010	Krizhanovsky, Valery/0000-0002-3977-5482	Binational Israel-USA Science foundation; National Institutes of Health [AG16379]; Israel Science Foundation; Abisch-Frenkel foundation; Simms/Mann Family foundation; EU; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG016379, R01AG016379] Funding Source: NIH RePORTER	Binational Israel-USA Science foundation(US-Israel Binational Science Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Israel Science Foundation(Israel Science Foundation); Abisch-Frenkel foundation; Simms/Mann Family foundation; EU(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We gratefully acknowledge O Mandelboim from Hadassah Medical Center for providing us with primary human NK cells; D Sabah-Israel for editorial suggestions; members of the Lowe and Krizhanovsky laboratories for stimulating discussions; K Lehet, L Bianco and the CSHL animal facility for help with animals; T Berkutzki from the Histology Facility at the Weizmann Institute for assistance with histology. This work was supported by a Binational Israel-USA Science foundation (VK and SWL) and grant AG16379 from the National Institutes of Health (SWL). VK was supported by Israel Science Foundation, Abisch-Frenkel foundation, Simms/Mann Family foundation and Marie Curie RG grant from EU FP7. VK is an incumbent of The Karl and Frances Korn Career Development Chair. SWL is a Howard Hughes Medical Institute investigator and Geoffrey Beene Chair for Cancer Biology (MSKCC).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Bottino C, 2005, TRENDS IMMUNOL, V26, P221, DOI 10.1016/j.it.2005.02.007; Chahroudi A, 2003, METHODS, V31, P120, DOI 10.1016/S1046-2023(03)00121-X; Chan CW, 2008, CELL DEATH DIFFER, V15, P58, DOI 10.1038/sj.cdd.4402235; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Choy JC, 2003, MODERN PATHOL, V16, P460, DOI 10.1097/01.MP.0000067424.12280.BC; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Colucci S, 2009, LEUKEMIA, V23, P2139, DOI 10.1038/leu.2009.136; Cullen SP, 2008, CELL DEATH DIFFER, V15, P251, DOI 10.1038/sj.cdd.4402244; Davis ID, 2007, CLIN CANCER RES, V13, P3630, DOI 10.1158/1078-0432.CCR-07-0410; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Guo JS, 2007, SEMIN LIVER DIS, V27, P413, DOI 10.1055/s-2007-991517; Hanna J, 2003, BLOOD, V102, P1569, DOI 10.1182/blood-2003-02-0517; Hayakawa Y, 2006, SEMIN IMMUNOL, V18, P176, DOI 10.1016/j.smim.2006.03.005; Ishiyama K, 2006, HEPATOLOGY, V43, P362, DOI 10.1002/hep.21035; Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Krizhanovsky V, 2008, COLD SH Q B, V73, P513, DOI 10.1101/sqb.2008.73.048; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Melhem A, 2006, J HEPATOL, V45, P60, DOI 10.1016/j.jhep.2005.12.025; Miyazaki H, 2004, J CLIN PATHOL, V57, P1292, DOI 10.1136/jcp.2003.015495; MONTEL AH, 1995, CELL IMMUNOL, V166, P236, DOI 10.1006/cimm.1995.9974; Muhanna N, 2007, CLIN EXP IMMUNOL, V148, P338, DOI 10.1111/j.1365-2249.2007.03353.x; Muta H, 2000, J IMMUNOL, V165, P5105, DOI 10.4049/jimmunol.165.9.5105; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Ogata K, 1997, CLIN IMMUNOL IMMUNOP, V84, P269, DOI 10.1006/clin.1997.4401; Park O, 2009, HEPATOLOGY, V49, P1683, DOI 10.1002/hep.22813; Pinkoski MJ, 2000, AM J PHYSIOL-GASTR L, V278, pG354, DOI 10.1152/ajpgi.2000.278.3.G354; Pitiyage GN, 2011, J PATHOL, V223, P604, DOI 10.1002/path.2839; Radaeva S, 2006, GASTROENTEROLOGY, V130, P435, DOI 10.1053/j.gastro.2005.10.055; Rukavina D, 1998, BLOOD, V92, P2410, DOI 10.1182/blood.V92.7.2410.2410_2410_2420; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soriani A, 2009, BLOOD, V113, P3503, DOI 10.1182/blood-2008-08-173914; Street SEA, 2001, BLOOD, V97, P192, DOI 10.1182/blood.V97.1.192; Takeda K, 2005, BLOOD, V105, P2082, DOI 10.1182/blood-2004-08-3262; vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x	51	138	145	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 11	2013	32	15					1971	1977		10.1038/onc.2012.206	http://dx.doi.org/10.1038/onc.2012.206			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22751116	hybrid, Green Published			2022-12-17	WOS:000317599900011
J	Peschiaroli, A; Giacobbe, A; Formosa, A; Markert, EK; Bongiorno-Borbone, L; Levine, AJ; Candi, E; D'Alessandro, A; Zolla, L; Agro, AF; Melino, G				Peschiaroli, A.; Giacobbe, A.; Formosa, A.; Markert, E. K.; Bongiorno-Borbone, L.; Levine, A. J.; Candi, E.; D'Alessandro, A.; Zolla, L.; Agro, A. Finazzi; Melino, G.			miR-143 regulates hexokinase 2 expression in cancer cells	ONCOGENE			English	Article						miRNAs; hexokinases; prostate cancer; breast cancer; glucose metabolism	DOWN-REGULATION; II HEXOKINASE; GLUCOSE CATABOLISM; GENE; METABOLISM; WARBURG; MICRORNAS; CARCINOMA; TARGET; MITOCHONDRIA	Tumor cells activate pathways that facilitate and stimulate glycolysis even in the presence of adequate levels of oxygen in order to satisfy their continuous need of molecules, such as nucleotides, ATP and fatty acids, necessary to support their rapid proliferation. Accordingly, a variety of human tumors are characterized by elevated expression levels of the hexokinase 2 isoform (HK2). Although different molecular mechanisms, including genetic and epigenetic mechanisms, have been suggested to account for the altered expression of HK2 in tumors, the potential role of microRNAs (miRNAs) in the regulation of HK2 expression has not been evaluated. Here, we report that miR-143 inhibits HK2 expression via a conserved miR-143 recognition motif located in the 3'-untranslated region (3'UTR) of HK2 mRNA. We demonstrate that miR143 inhibits HK2 expression both in primary keratinocytes and in head and neck squamous cell carcinoma (HNSCC)-derived cell lines. Importantly, we found that miR-143 inversely correlates with HK2 expression in HNSCC-derived cell lines and in primary tumors. We also report that the miRNA-dependent regulation of hexokinase expression is not limited to HK2 as miR-138 targets HK1 via a specific recognition motif located in its 3'UTR. All these data unveil a new miRNA-dependent mechanism of regulation of hexokinase expression potentially important in the regulation of glucose metabolism of cancer cells.	[Peschiaroli, A.] CNR, Inst Cellular Biol & Neurobiol, Rome, Italy; [Peschiaroli, A.; Formosa, A.; Melino, G.] Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; [Giacobbe, A.; Bongiorno-Borbone, L.; Candi, E.; Agro, A. Finazzi] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; [Markert, E. K.; Levine, A. J.] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [D'Alessandro, A.; Zolla, L.] Univ Tuscia, Dept Environm Sci, Viterbo, Italy; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata; University of Rome Tor Vergata; Institute for Advanced Study - USA; Tuscia University; University of Leicester	Melino, G (corresponding author), Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	peschiaroli@med.uniroma2.it; melino@uniroma2.it	D'Alessandro, Angelo/AAA-4695-2019	D'Alessandro, Angelo/0000-0002-2258-6490; Giacobbe, Arianna/0000-0002-5874-1851; PESCHIAROLI, ANGELO/0000-0001-6311-2382	Medical Research Council, UK; Alleanza contro il Cancro [ACC12]; MIUR/PRIN [20078P7T3K_001)/FIRB, RBIP06LCA9_0023, RBIP06LCA9_0C, 2008MRLSNZ_004]; AIRC [5471, 2011-IG11955]; Telethon Grant [GGPO9133]; AIRC 5xmille [9979, RF06, c.73, RF08 c.15, RF07 c.57]; Ric. Finalizzata [08-GIOV_RIC]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alleanza contro il Cancro; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon Grant(Fondazione Telethon); AIRC 5xmille(Fondazione AIRC per la ricerca sul cancro); Ric. Finalizzata; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by the Medical Research Council, UK; grants from 'Alleanza contro il Cancro' Grant (ACC12), MIUR/PRIN (20078P7T3K_001)/FIRB (RBIP06LCA9_0023, RBIP06LCA9_0C), AIRC grant no. 5471; 2011-IG11955), Telethon Grant GGPO9133 to GM, MIUR/PRIN 2008MRLSNZ_004, AIRC 5xmille (no. 9979), RF06 c.73, RF08 c.15, RF07 c.57 awarded to GM and EC. Research described in this article was also supported by Ric. Finalizzata 08-GIOV_RIC awarded to AP.	Aberdam D, 2008, TRENDS BIOCHEM SCI, V33, P583, DOI 10.1016/j.tibs.2008.09.002; Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85; Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864; Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787; Cook CC, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.141; Davis-Dusenbery BN, 2011, J BIOL CHEM, V286, P28097, DOI 10.1074/jbc.M111.236950; Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Israel M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-70; Jiang L, 2011, HUM GENET, V129, P189, DOI 10.1007/s00439-010-0915-3; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Liu XQ, 2009, CANCER LETT, V286, P217, DOI 10.1016/j.canlet.2009.05.030; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x; Morton SU, 2008, P NATL ACAD SCI USA, V105, P17830, DOI 10.1073/pnas.0804673105; Munoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123; Noguchi S, 2011, CANCER LETT, V307, P211, DOI 10.1016/j.canlet.2011.04.005; Pedersen PL, 2008, J BIOENERG BIOMEMBR, V40, P123, DOI 10.1007/s10863-008-9165-7; Rempel A, 1996, CANCER RES, V56, P2468; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Siegel G, 2009, NAT CELL BIOL, V11, P705, DOI 10.1038/ncb1876; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Chunmei, 2007, Journal of Genetics and Genomics, V34, P966, DOI 10.1016/S1673-8527(07)60109-X; WARBURG O, 1956, SCIENCE, V124, P269; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470	40	138	147	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					797	802		10.1038/onc.2012.100	http://dx.doi.org/10.1038/onc.2012.100			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22469988				2022-12-17	WOS:000315746700013
J	Zhou, Z; Hao, Y; Liu, N; Raptis, L; Tsao, MS; Yang, X				Zhou, Z.; Hao, Y.; Liu, N.; Raptis, L.; Tsao, M-S; Yang, X.			TAZ is a novel oncogene in non-small cell lung cancer	ONCOGENE			English	Article						TAZ; lung cancer; Hippo-LATS pathway; transcriptional coactivator; cell proliferation; transformation	EPITHELIAL-MESENCHYMAL TRANSITION; ORGAN SIZE CONTROL; HIPPO PATHWAY; TUMOR-SUPPRESSOR; CONTACT INHIBITION; YAP; PROLIFERATION; PATHOGENESIS; PROGRESSION; EXPRESSION	Transcriptional coactivator with PDZ-binding motif (TAZ) is a transcriptional coactivator involved in the differentiation of stem cell as well as the development of multiple organs. Recently, TAZ has also been identified as a major component of the novel Hippo-LATS tumor suppressor pathway and to function as an oncogene in breast cancer. We show for the first time that TAZ is an oncogene in non-small cell lung cancer (NSCLC). Our results show that TAZ is overexpressed in NSCLC cells and that lentivirus-mediated overexpression of TAZ in HBE135 immortalized human bronchial epithelial cells causes increased cell proliferation and transformation, which can be restored back to its original levels by knockdown of TAZ. In addition, short-hairpin RNA (shRNA)-mediated knockdown of TAZ expression in NSCLC cells suppresses their proliferation and anchorage-independent growth in vitro, and tumor growth in mice in vivo, which can be reversed by re-introduction of shRNA-resistant TAZ into TAZ-knockdown NSCLC cells. These results indicate that TAZ is an oncogene and has an important role in tumorigenicity of NSCLC cells. Therefore, TAZ may present a novel target for the future diagnosis, prognosis and therapy of lung cancer. Oncogene (2011) 30, 2181-2186; doi:10.1038/onc.2010.606; published online 24 January 2011	[Yang, X.] Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, Kingston, ON K7L 3N6, Canada; [Liu, N.; Tsao, M-S] Princess Margaret Hosp, Dept Pathol, Toronto, ON M4X 1K9, Canada; [Raptis, L.] Queens Univ, Dept Immunol & Microbiol, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Queens University - Canada	Yang, X (corresponding author), Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, 88 Stuart St, Kingston, ON K7L 3N6, Canada.	yang@cliff.path.queensu.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405	Canadian Institute of Health Research; Clinical Trust Fund at Queen's University; Ontario Ministry of Research and Innovation, Canada; Canadian Cancer Society [CCSRI-020527]	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Clinical Trust Fund at Queen's University; Ontario Ministry of Research and Innovation, Canada(Ministry of Research and Innovation, Ontario); Canadian Cancer Society(Canadian Cancer Society (CCS))	This work was supported by a grant from the Canadian Institute of Health Research, a grant from the Clinical Trust Fund at Queen's University, a New Investigator Award from the Canadian Institute of Health Research and an Early Researcher Award from the Ontario Ministry of Research and Innovation, Canada to Xiaolong Yang, and a grant from the Canadian Cancer Society (CCSRI-020527) to Ming-Sound Tsao. We thank Dulcie Lai and Stacy Visser for reading the manuscript.	Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Brambilla E, 2009, EUR RESPIR J, V33, P1485, DOI 10.1183/09031936.00014009; Cai D, 2010, CANCER RES, V70, P6477, DOI 10.1158/0008-5472.CAN-10-0005; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chow A, 2010, INT J CANCER, V126, P2079, DOI 10.1002/ijc.24878; Dutt A, 2006, CLIN CANCER RES, V12, p4396S, DOI 10.1158/1078-0432.CCR-06-0414; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Hergovich A, 2009, BIOFACTORS, V35, P338, DOI 10.1002/biof.47; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Kim YH, 2010, ONCOGENE, V29, P1421, DOI 10.1038/onc.2009.437; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Lo KC, 2008, LUNG CANCER, V59, P315, DOI 10.1016/j.lungcan.2007.08.037; Mitani A, 2009, AM J RESP CRIT CARE, V180, P326, DOI 10.1164/rccm.200812-1827OC; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Strazisar M, 2009, LUNG CANCER, V64, P257, DOI 10.1016/j.lungcan.2008.09.011; Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Visser S, 2010, CELL CYCLE, V9, P3892, DOI 10.4161/cc.9.19.13386; Wang KN, 2009, BIOCHEM CELL BIOL, V87, P77, DOI 10.1139/O08-114; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	32	138	146	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	18					2181	2186		10.1038/onc.2010.606	http://dx.doi.org/10.1038/onc.2010.606			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21258416				2022-12-17	WOS:000290249600009
J	El Mjiyad, N; Caro-Maldonado, A; Ramirez-Peinado, S; Munoz-Pinedo, C				El Mjiyad, N.; Caro-Maldonado, A.; Ramirez-Peinado, S.; Munoz-Pinedo, C.			Sugar-free approaches to cancer cell killing	ONCOGENE			English	Review						cancer; apoptosis; glucose; tumor metabolism; Bcl-2 proteins	BH3-ONLY PROTEIN BIM; GLUCOSE-METABOLISM; C-MYC; INDUCED APOPTOSIS; GLIOBLASTOMA-MULTIFORME; GLYCOLYTIC INHIBITORS; GLUTAMINE-METABOLISM; DEPENDENT APOPTOSIS; AEROBIC GLYCOLYSIS; TRIGGERS APOPTOSIS	Tumors show an increased rate of glucose uptake and utilization. For this reason, glucose analogs are used to visualize tumors by the positron emission tomography technique, and inhibitors of glycolytic metabolism are being tested in clinical trials. Upregulation of glycolysis confers several advantages to tumor cells: it promotes tumor growth and has also been shown to interfere with cell death at multiple levels. Enforcement of glycolysis inhibits apoptosis induced by cytokine deprivation. Conversely, antiglycolytic agents enhance cell death induced by radio- and chemotherapy. Synergistic effects are likely due to regulation of the apoptotic machinery, as glucose regulates activation and levels of proapoptotic BH3-only proteins such as Bim, Bad, Puma and Noxa, as well as the antiapoptotic Bcl-2 family of proteins. Moreover, inhibition of glucose metabolism sensitizes cells to death ligands. Glucose deprivation and antiglycolytic drugs induce tumor cell death, which can proceed through necrosis or through mitochondrial or caspase-8-mediated apoptosis. We will discuss how oncogenic pathways involved in metabolic stress signaling, such as p53, AMPK (adenosine monophosphate-activated protein kinase) and Akt/mTOR (mammalian target of rapamycin), influence sensitivity to inhibition of glucose metabolism. Finally, we will analyze the rationale for the use of antiglycolytic inhibitors in the clinic, either as single agents or as a part of combination therapies. Oncogene (2011) 30, 253-264; doi:10.1038/onc.2010.466; published online 25 October 2010	[El Mjiyad, N.; Caro-Maldonado, A.; Ramirez-Peinado, S.; Munoz-Pinedo, C.] IDIBELL Bellvitage Biomed Res Inst, Cell Death Regulat Grp, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Munoz-Pinedo, C (corresponding author), Hosp Duran & Reynals, IDIBELL, 3A Planta,Gran Via Hosp 199, Barcelona 08907, Spain.	cmunoz@idibell.cat	Caro-Maldonado, Alfredo/D-3288-2014; Caro-Maldonado, Alfredo/A-7364-2010; Munoz-Pinedo, Cristina/B-6118-2008	Caro-Maldonado, Alfredo/0000-0002-5431-7949; Munoz-Pinedo, Cristina/0000-0002-9120-664X	AICR [08-0621]; Fondo de Investigaciones Sanitarias-ISCIII [PI071027, RTICC RD06/0020]	AICR; Fondo de Investigaciones Sanitarias-ISCIII(Instituto de Salud Carlos III)	We thank Ameeta Kelekar for sharing unpublished data and Oscar M. Tirado for critical reading of this manuscript. Research in our group is supported by AICR grant 08-0621 and by grants PI071027 and RTICC RD06/0020 from the Fondo de Investigaciones Sanitarias-ISCIII.	Aft RL, 2002, BRIT J CANCER, V87, P805, DOI 10.1038/sj.bjc.6600547; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Caro-Maldonado A, 2010, CELL DEATH DIFFER, V17, P1335, DOI 10.1038/cdd.2010.21; Chiaradonna F, 2006, ONCOGENE, V25, P5391, DOI 10.1038/sj.onc.1209528; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Concannon CG, 2010, J CELL BIOL, V189, P83, DOI 10.1083/jcb.200909166; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Di Cosimo S, 2003, DRUGS TODAY, V39, P157, DOI 10.1358/dot.2003.39.3.799451; DiPaola RS, 2008, PROSTATE, V68, P1743, DOI 10.1002/pros.20837; Dwarakanath B. S., 1999, Indian Journal of Experimental Biology, V37, P865; Dwarkanath BS, 2001, INT J RADIAT ONCOL, V50, P1051, DOI 10.1016/S0360-3016(01)01534-6; Egler V, 2008, CLIN CANCER RES, V14, P3132, DOI 10.1158/1078-0432.CCR-07-4182; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fan YJ, 2010, J BIOL CHEM, V285, P7324, DOI 10.1074/jbc.M109.035584; Frenzel A, 2009, APOPTOSIS, V14, P584, DOI 10.1007/s10495-008-0300-z; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Geschwind JFH, 2002, CANCER RES, V62, P3909; Gonin-Giraud S, 2002, CELL DEATH DIFFER, V9, P1147, DOI 10.1038/sj.cdd.4401079; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haga N, 1998, INT J CANCER, V76, P86, DOI 10.1002/(SICI)1097-0215(19980330)76:1<86::AID-IJC14>3.0.CO;2-E; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernlund E, 2009, MOL CANCER THER, V8, P1916, DOI 10.1158/1535-7163.MCT-09-0179; Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842; JAIN VK, 1985, INT J RADIAT ONCOL, V11, P943, DOI 10.1016/0360-3016(85)90117-8; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; KALIA VK, 1982, INDIAN J EXP BIOL, V20, P884; Kang HT, 2006, LIFE SCI, V78, P1392, DOI 10.1016/j.lfs.2005.07.001; KAPLAN O, 1990, CANCER RES, V50, P544; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; KERN KA, 1987, SURGERY, V102, P380; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Latz D., 1993, Strahlentherapie und Onkologie, V169, P405; Lee YJ, 1997, J CELL SCI, V110, P681; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu HP, 2002, BIOCHEM PHARMACOL, V64, P1745, DOI 10.1016/S0006-2952(02)01456-9; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Michalek RD, 2010, IMMUNOL REV, V236, P190, DOI 10.1111/j.1600-065X.2010.00911.x; Munoz-Pinedo C, 2004, FEBS LETT, V570, P205, DOI 10.1016/j.febslet.2004.06.044; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Papaldo P, 2003, J CLIN ONCOL, V21, P3462, DOI 10.1200/JCO.2003.03.034; Pathania D, 2009, ADV DRUG DELIVER REV, V61, P1250, DOI 10.1016/j.addr.2009.05.010; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Raez LE, 2007, J CLIN ONCOL, V25; Raez LE, 2005, J CLIN ONCOL, V23, p238S; Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; ROSBE KW, 1989, CANCER CHEMOTH PHARM, V25, P32, DOI 10.1007/BF00694335; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; SINGH SP, 1990, INT J RADIAT BIOL, V58, P791, DOI 10.1080/09553009014552171; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Swamy R. K., 2005, Indian Journal of Experimental Biology, V43, P686; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; TEICHER BA, 1991, CANCER RES, V51, P780; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; THAKKAR NS, 1993, CANCER RES, V53, P2057; Tomida A, 1996, INT J CANCER, V68, P391, DOI 10.1002/(SICI)1097-0215(19961104)68:3<391::AID-IJC19>3.0.CO;2-B; Tong XM, 2009, P NATL ACAD SCI USA, V106, P21660, DOI 10.1073/pnas.0911316106; Uyeda K, 2006, CELL METAB, V4, P107, DOI 10.1016/j.cmet.2006.06.008; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang X, 2009, TRENDS CELL BIOL, V19, P260, DOI 10.1016/j.tcb.2009.03.005; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wood TE, 2008, MOL CANCER THER, V7, P3546, DOI 10.1158/1535-7163.MCT-08-0569; Xu RH, 2005, CANCER RES, V65, P613; Yamada M, 1999, CANCER CHEMOTH PHARM, V44, P59, DOI 10.1007/s002800050945; Yang CD, 2009, CANCER RES, V69, P7986, DOI 10.1158/0008-5472.CAN-09-2266; Yi CH, 2007, J CELL BIOL, V179, P619, DOI 10.1083/jcb.200708090; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yun J, 1995, ONCOL RES, V7, P583; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XD, 2006, ANTICANCER RES, V26, P3561; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zhao YX, 2008, J BIOL CHEM, V283, P36344, DOI 10.1074/jbc.M803580200	101	138	141	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					253	264		10.1038/onc.2010.466	http://dx.doi.org/10.1038/onc.2010.466			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20972457				2022-12-17	WOS:000286418800001
J	Liu, DP; Song, H; Xu, Y				Liu, D. P.; Song, H.; Xu, Y.			A common gain of function of p53 cancer mutants in inducing genetic instability	ONCOGENE			English	Article						p53; tumorigenesis; gain of function; genetic instability	LI-FRAUMENI-SYNDROME; DNA-DAMAGE; COMPLEX; ATM; SUPPRESSOR; MUTATIONS; REVEALS; GENOME; SITES; MODEL	The critical tumor suppressor p53 is mutated in over half of all human cancers. The majority of p53 cancer mutations are missense mutations, which can be classified into contact mutations that directly disrupt the DNA-binding of p53 but have modest impact on p53 conformation and structural mutations that greatly disrupt p53 conformation. Many p53 cancer mutants, including the hot spot mutations (R175H, R248W and R273H), not only lose p53-dependent tumor-suppressor activities, but also acquire new oncogenic activities to promote cancer. Therefore, it is critical to elucidate the gain of oncogenic function of p53 cancer mutants. Using humanized p53-mutant knock-in mouse models, we have identified a gain of oncogenic function shared by the most common p53 contact mutants (R273H and R248W) and structural mutant (R175H). This gain of function inactivates Mre11/ATM-dependent DNA damage responses, leading to chromosomal translocation and defective G(2)/M checkpoint. Considering the critical roles of ATM in maintaining genetic stability and therapeutic responses to many cancer treatments, the identification of this common gain of function of p53 cancer mutants will have important implication on the drug resistance of a significant portion of human cancers that express either the contact or structural p53 cancer mutants. Oncogene (2010) 29, 949-956; doi:10.1038/onc.2009.376; published online 2 November 2009	[Liu, D. P.; Song, H.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Song, Hoseok/0000-0001-5723-3057; Xu, Yang/0000-0001-5574-921X	NIH [R01 CA94254]; DOD Breast Cancer Research Program [W81XWH-08-10381]; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr M Hollstein for the HUPKI construct. This work was supported by Grants from the NIH (R01 CA94254) and DOD Breast Cancer Research Program (W81XWH-08-10381) to YX.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hainaut P, 2000, ADV CANCER RES, V77, P81; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lavin MF, 2007, ONCOGENE, V26, P7749, DOI 10.1038/sj.onc.1210880; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Lista F, 1997, CANCER RES, V57, P4408; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sigal A, 2000, CANCER RES, V60, P6788; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804	20	138	142	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					949	956		10.1038/onc.2009.376	http://dx.doi.org/10.1038/onc.2009.376			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19881536	Green Accepted, Bronze			2022-12-17	WOS:000274604400002
J	Kelber, JA; Panopoulos, AD; Shani, G; Booker, EC; Belmonte, JC; Vale, WW; Gray, PC				Kelber, J. A.; Panopoulos, A. D.; Shani, G.; Booker, E. C.; Belmonte, J. C.; Vale, W. W.; Gray, P. C.			Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways	ONCOGENE			English	Article						Cripto; GRP78; TGF-beta; MAPK; Akt; stem cell; cancer	MAMMARY EPITHELIAL-CELLS; CANCER-CELLS; TGF-BETA; TYROSINE PHOSPHORYLATION; CHAPERONE GRP78/BIP; ACTIVIN RECEPTOR; GROWTH; IDENTIFICATION; PROLIFERATION; SUPPRESSES	Cripto is a developmental oncoprotein that signals via mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Smad2/3 pathways. However, the molecular basis for Cripto coupling to these pathways during embryogenesis and tumorigenesis is not fully understood. In this regard, we recently demonstrated that Cripto forms a cell surface complex with the HSP70 family member glucose-regulated protein-78 (GRP78). Here, we provide novel functional evidence demonstrating that cell surface GRP78 is a necessary mediator of Cripto signaling in human tumor, mammary epithelial and embryonic stem cells. We show that targeted disruption of the cell surface Cripto/GRP78 complex using shRNAs or GRP78 immunoneutralization precludes Cripto activation of MAPK/PI3K pathways and modulation of activin-A, activin-B, Nodal and transforming growth factor-beta 1 signaling. We further demonstrate that blockade of Cripto binding to cell surface GRP78 prevents Cripto from increasing cellular proliferation, downregulating E-Cadherin, decreasing cell adhesion and promoting proproliferative responses to activin-A and Nodal. Thus, disrupting the Cripto/GRP78 binding interface blocks oncogenic Cripto signaling and may have important therapeutic value in the treatment of cancer. Oncogene (2009) 28, 2324-2336; doi:10.1038/onc.2009.97; published online 4 May 2009	[Gray, P. C.] Salk Inst Biol Studies, Vale Lab, Clayton Fdn Labs Peptide Biol, PBL, La Jolla, CA 92037 USA; [Kelber, J. A.] Univ San Diego, Dept Chem & Biochem, La Jolla, CA USA; [Panopoulos, A. D.; Belmonte, J. C.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Shani, G.] Burnham Inst Med Res, Tumor Microenvironm Program, La Jolla, CA USA; [Booker, E. C.] Univ San Diego, Dept Biol, La Jolla, CA USA	Salk Institute; University of San Diego; Salk Institute; Sanford Burnham Prebys Medical Discovery Institute; University of San Diego	Gray, PC (corresponding author), Salk Inst Biol Studies, Vale Lab, Clayton Fdn Labs Peptide Biol, PBL, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gray@salk.edu		Panopoulos, Athanasia/0000-0002-9610-2604; Kelber, Jonathan/0000-0002-4606-1445	NCI, National Institutes of Health [R01CA107420]; Foundation for Medical research, Inc.; Robert J Jr and Helen Kleberg Foundaton; NIH [T32 CA009370]; G Harold and Leila Y Mathers Charitable Foundation; Foundation for Medical Research, Inc; NATIONAL CANCER INSTITUTE [R01CA107420, T32CA009370] Funding Source: NIH RePORTER	NCI, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Foundation for Medical research, Inc.; Robert J Jr and Helen Kleberg Foundaton; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); G Harold and Leila Y Mathers Charitable Foundation; Foundation for Medical Research, Inc; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI, National Institutes of Health, Grant R01CA107420, the Foundation for Medical research, Inc., and the Robert J Jr and Helen Kleberg Foundaton. A portion of this work was also supported by an NIH training grant T32 CA009370 (to ADP) and the G Harold and Leila Y Mathers Charitable Foundation (to JCIB). Wylie W Vale is a senior investigator of the Foundation for Medical Research, Inc. and is a cofounder, consultant, equity holder and member of the Board of Directors of Neurocrine Biosciences and Acceleron Pharma. We thank Dr Travis Berggren and Margaret Lutz of The Salk Institute Stem Cell Core for valuable technical assistance.	Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bianco C, 1999, J BIOL CHEM, V274, P8624, DOI 10.1074/jbc.274.13.8624; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gonzalez-Gronow M, 2006, CANCER RES, V66, P11424, DOI 10.1158/0008-5472.CAN-06-1721; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gray PC, 2006, MOL CELL BIOL, V26, P9268, DOI 10.1128/MCB.01168-06; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Jakobsen CG, 2007, CANCER RES, V67, P9507, DOI 10.1158/0008-5472.CAN-06-4686; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kelber JA, 2008, J BIOL CHEM, V283, P4490, DOI 10.1074/jbc.M704960200; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Liu Y, 2007, MOL PHARMACEUT, V4, P435, DOI 10.1021/mp060122j; Minchiotti G, 2005, ONCOGENE, V24, P5668, DOI 10.1038/sj.onc.1208917; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Misra UK, 2004, CELL SIGNAL, V16, P929, DOI 10.1016/j.cellsig.2004.01.003; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Philippova M, 2008, MOL CELL BIOL, V28, P4004, DOI 10.1128/MCB.00157-08; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Shani G, 2008, MOL CELL BIOL, V28, P666, DOI 10.1128/MCB.01716-07; Shen MM, 2007, DEVELOPMENT, V134, P1023, DOI 10.1242/dev.000166; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shukla A, 2008, MOL CANCER RES, V6, P509, DOI 10.1158/1541-7786.MCR-07-0396; Strizzi L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Wechselberger C, 2005, ONCOGENE, V24, P4094, DOI 10.1038/sj.onc.1208417; Xing PX, 2004, CANCER RES, V64, P4018, DOI 10.1158/0008-5472.CAN-03-3888; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0	39	138	143	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2324	2336		10.1038/onc.2009.97	http://dx.doi.org/10.1038/onc.2009.97			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421146	Green Accepted			2022-12-17	WOS:000267089100003
J	Ho, KK; Myatt, SS; Lam, EWF				Ho, K. K.; Myatt, S. S.; Lam, E. W-F			Many forks in the path: cycling with FoxO	ONCOGENE			English	Review						FoxO; cell cycle; cancer; senescence; development; apoptosis	FORKHEAD TRANSCRIPTION FACTOR; BREAST-CANCER CELLS; MESSENGER-RNA EXPRESSION; ESTROGEN-RECEPTOR-ALPHA; OXIDATIVE STRESS; DNA-DAMAGE; BOX M1B; PHOSPHOINOSITIDE 3-KINASE; TUMOR SUPPRESSION; NUCLEAR TRANSLOCATION	FoxO transcription factors are an evolutionary conserved subfamily of the forkhead transcription factors, characterized by the forkhead DNA-binding domain. FoxO factors regulate a number of cellular processes involved in cell-fate decisions in a cell-type-and environment-specific manner, including metabolism, differentiation, apoptosis and proliferation. A key mechanism by which FoxO determines cell fate is through regulation of the cell cycle machinery, and as such the cellular consequence of FoxO deregulation is often manifested through perturbation of the cell cycle. Consequently, the deregulation of FoxO factors is implicated in the development of numerous proliferative diseases, in particular cancer.	[Ho, K. K.; Myatt, S. S.; Lam, E. W-F] Imperial Coll London, Canc Res UK Labs, Dept Oncol, London W12 0NN, England	Cancer Research UK; Imperial College London	Lam, EWF (corresponding author), Imperial Coll London, Canc Res UK Labs, Dept Oncol, MRC Bldg Cyclotron Bldg,Hosp Campus,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576	Biotechnology and Biological Sciences Research Council [BBS/B/03785] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Adachi M, 2007, GASTROENTEROLOGY, V132, P1434, DOI 10.1053/j.gastro.2007.01.033; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BATES S, 1994, ONCOGENE, V9, P71; Baugh LR, 2006, CURR BIOL, V16, P780, DOI 10.1016/j.cub.2006.03.021; Bhonde MR, 2006, J BIOL CHEM, V281, P8675, DOI 10.1074/jbc.M511333200; Bhonde MR, 2006, ONCOGENE, V25, P165, DOI 10.1038/sj.onc.1209017; Birkenkamp KU, 2007, J BIOL CHEM, V282, P2211, DOI 10.1074/jbc.M606669200; Boxem M, 2001, DEVELOPMENT, V128, P4349; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Delpuech O, 2007, MOL CELL BIOL, V27, P4917, DOI 10.1128/MCB.01789-06; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Giles GI, 2006, CURR PHARM DESIGN, V12, P4427, DOI 10.2174/138161206779010549; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Holz George G, 2005, Sci STKE, V2005, ppe2; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; KATAYAMA K, 2007, ONCOGENE, V2007, pP15, DOI DOI 10.1038/SJ.0NC1210813; KAUFMANN WK, 1995, CANCER METAST REV, V14, P31, DOI 10.1007/BF00690209; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Kokkinakis DM, 2006, MOL CANCER RES, V4, P575, DOI 10.1158/1541-7786.MCR-05-0240; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Krol J, 2007, MOL CANCER THER, V6, P3169, DOI 10.1158/1535-7163.MCT-07-0507; Krupczak-Hollis K, 2003, HEPATOLOGY, V38, P1552, DOI 10.1016/j.hep.2003.08.052; Kushner JA, 2005, MOL CELL BIOL, V25, P3752, DOI 10.1128/MCB.25.9.3752-3762.2005; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Luscher-Firzlaff JM, 2006, FEBS LETT, V580, P1716, DOI 10.1016/j.febslet.2006.02.021; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Martinez SC, 2006, DIABETES, V55, P1581, DOI 10.2337/db05-0678; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Myatt SS, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-6; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Park Y, 2005, J BIOL CHEM, V280, P9135, DOI 10.1074/jbc.M409486200; Pinkston-Gosse J, 2007, NAT GENET, V39, P1403, DOI 10.1038/ng.2007.1; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Schmitt E, 2007, ONCOGENE, V26, P5851, DOI 10.1038/sj.onc.1210396; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Soeiro I, 2006, MOL CELL BIOL, V26, P6170, DOI 10.1128/MCB.02182-05; Stark GR, 2006, MOL BIOTECHNOL, V32, P227, DOI 10.1385/MB:32:3:227; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; Takano M, 2007, MOL ENDOCRINOL, V21, P2334, DOI 10.1210/me.2007-0058; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teh MT, 2002, CANCER RES, V62, P4773; Teyssier F, 1999, B CANCER, V86, P345; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Vogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2003, GENE EXPRESSION, V11, P149, DOI 10.3727/000000003108749044; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; Wierstra I, 2006, BIOL CHEM, V387, P949, DOI 10.1515/BC.2006.119; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu J, 1999, BRIT J CANCER, V79, P1572, DOI 10.1038/sj.bjc.6690250; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	128	138	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2008	27	16					2300	2311		10.1038/onc.2008.23	http://dx.doi.org/10.1038/onc.2008.23			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE					2022-12-17	WOS:000254782700005
J	Dow, LE; Kauffman, JS; Caddy, J; Peterson, AS; Jane, SM; Russell, SM; Humbert, PO				Dow, L. E.; Kauffman, J. S.; Caddy, J.; Peterson, A. S.; Jane, S. M.; Russell, S. M.; Humbert, P. O.			The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge	ONCOGENE			English	Article						scribble; polarity; migration; wound healing; epithelium	DISCS LARGE; DIFFERENTIAL EXPRESSION; CDC42 CONTROLS; HUMAN HOMOLOG; PROTEIN; DROSOPHILA; ACTIVATION; COMPLEX; ACTIN; MOUSE	Altered expression of human Scribble is associated with invasive epithelial cancers, however, its role in tumour development remains unclear. Mutations in Drosophila Scribble result in loss of polarity, overproliferation and 3D-tumourous overgrowth of epithelial cells. Using complementation studies in Drosophila we recently demonstrated that expression of human Scribble can also regulate polarity and restrict tissue overgrowth. Here, we have undertaken a detailed study of human Scribble function in the polarized mammary cell line, MCF10A. We show that although Scribble does not seem to be required for apical-basal polarity or proliferation control in MCF10A cells, Scribble is essential for the control of polarity associated with directed epithelial cell migration. Scribble-depleted MCF10A cells show defective in vitro wound closure and chemotactic movement. The cells at the wound edge fail to polarize, show reduced lamellipodia formation and impaired recruitment of Cdc42 and Rac1 to the leading edge. Furthermore, we show that this function is relevant in vivo as Scribble mutant mice show defective epidermal wound healing. This data identifies an essential role for mammalian Scribble in the regulation of the polarity specifically involved in directed epithelial migration.	Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic 8006, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic, Australia; Rotary Bone Marrow Res Labs, Parkville, Vic, Australia; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Peter MacCallum Canc Ctr, Immune Signalling Lab, Melbourne, Vic, Australia; Swinburne Univ Technol, Fac Engn & Ind Sci, Ctr Microphoton, Cell Biol Lab, Hawthorn, Vic 3122, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; University of Melbourne; Roche Holding; Genentech; Peter Maccallum Cancer Center; Swinburne University of Technology; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	patrick.humbert@petermac.org	Humbert, Patrick O/L-4264-2016; Russell, Sarah M/B-9341-2009; Jane, Stephen/D-6659-2011	Humbert, Patrick O/0000-0002-1366-6691; Russell, Sarah M/0000-0001-5826-9641; Dow, Lukas/0000-0001-7048-1418; Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL53749-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Berkowitz EA, 1996, CELL GROWTH DIFFER, V7, P1271; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Boussioutas A, 2003, CANCER RES, V63, P2569; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; HUMBERT PO, 2006, IN PRESS TRENDS CELL; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; MCCLUSKEY J, 1993, TISSUE CELL, V25, P173, DOI 10.1016/0040-8166(93)90017-F; Mine N, 2005, DEVELOPMENT, V132, P4317, DOI 10.1242/dev.02030; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pinheiro EM, 2004, DEVELOPMENT, V131, P5243, DOI 10.1242/dev.01412; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Redvers RP, 2004, METH MOL B, V289, P15; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	48	138	140	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2272	2282		10.1038/sj.onc.1210016	http://dx.doi.org/10.1038/sj.onc.1210016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043654				2022-12-17	WOS:000245466000003
J	He, B; Mirza, M; Weber, GF				He, B; Mirza, M; Weber, GF			An osteopontin splice variant induces anchorage independence in human breast cancer cells	ONCOGENE			English	Article						breast cancer; alternative splicing; cell adhesion; metastasis; soft agar	FALSE DISCOVERY RATE; METASTATIC PHENOTYPE; SIGNALING PATHWAY; MOUSE OSTEOPONTIN; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; GENE; ACTIVATION; LIGAND	In malignant tumors, metastasis genes are typically deregulated by aberrant expression or splicing. Osteopontin is expressed at high levels by various cancers and contributes importantly to their invasive potential. In contrast, osteopontin derived from host cells induces cellular immunity and could bolster antitumor protection by cytotoxic T lymphocytes. Here we show that breast cancer cells express multiple splice variants of osteopontin. According to RT-PCR analysis of human breast tissue specimens, the splice variant osteopontin-c is a highly specific marker for transformed cells, which is not expressed in their surrounding normal tissue. The full-length form of osteopontin aggregates in the presence of physiologic amounts of calcium and, in this state, leads to enhanced cell adhesion. Ostensibly, this effect is inhibitory for tumor cell dissemination. The shortest splice variant, osteopontin-c, does not aggregate in the presence of calcium and enhances clone formation in soft agar. According to microarray analysis, osteopontin-c induces the expression of oxidoreductases, consistent with protection from anoikis during anchorage-independent growth. These studies de. ne a third functional domain of osteopontin, beside the C-terminal CD44-binding site and the central integrin-binding site. They also provide evidence for a bifunctional character of osteopontin, with the soluble form supporting invasiveness and the aggregated form promoting adhesion.	Univ Cincinnati, Med Ctr, Coll Pharm, Cincinnati, OH 45267 USA; Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA USA	University System of Ohio; University of Cincinnati; Tufts Medical Center	Weber, GF (corresponding author), Univ Cincinnati, Med Ctr, Coll Pharm, 3225 Eden Ave, Cincinnati, OH 45267 USA.	georg.weber@uc.edu			NCI NIH HHS [CA76176] Funding Source: Medline; NCRR NIH HHS [M01 RR 08084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR008084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adler B, 2001, CELL IMMUNOL, V210, P30, DOI 10.1006/cimm.2001.1800; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Barraclough R, 1998, BIOCHEM SOC SYMP, P273; Bayless KJ, 1998, J CELL SCI, V111, P1165; BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; CHACKALAPARAMPIL I, 1985, J VIROL, V53, P841, DOI 10.1128/JVI.53.3.841-850.1985; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Chen PW, 1996, ANN NY ACAD SCI, V795, P325, DOI 10.1111/j.1749-6632.1996.tb52683.x; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani MK, 2001, ONCOGENE, V20, P1793, DOI 10.1038/sj.onc.1204358; Goldsmith HL, 2002, ANN BIOMED ENG, V30, P840, DOI 10.1114/1.1497383; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo JH, 2004, TOXICOL APPL PHARM, V194, P79, DOI 10.1016/j.taap.2003.09.002; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; HWANG S, 1994, J BIOL CHEM, V269, P711; KARYALA S, 2003, CARDIOVASC TOXICOL, V4, P47; KASUGAI S, 1991, BONE MINER, V13, P235, DOI 10.1016/0169-6009(91)90071-7; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; Kon S, 2000, J CELL BIOCHEM, V77, P487; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; O'Regan AW, 2000, J LEUKOCYTE BIOL, V68, P495; Oates AJ, 1996, ONCOGENE, V13, P97; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rittling SR, 1998, BIOCHEM BIOPH RES CO, V250, P287, DOI 10.1006/bbrc.1998.9306; Rudland PS, 2002, CANCER RES, V62, P3417; SAITOH Y, 1995, LAB INVEST, V72, P55; Sartor M, 2004, BIOTECHNIQUES, V36, P790, DOI 10.2144/04365ST02; Seraj MJ, 2000, CANCER RES, V60, P2764; Singhal H, 1997, CLIN CANCER RES, V3, P605; Sung V, 1998, EXP CELL RES, V241, P273, DOI 10.1006/excr.1998.4029; TANABE KK, 1995, ANN SURG, V222, P493; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Weber GF, 2000, J MOL MED-JMM, V78, P404, DOI 10.1007/s001090000138; WEBER GF, 1995, IMMUNITY, V2, P363, DOI 10.1016/1074-7613(95)90144-2; Weber GF, 2000, BRAIN RES BULL, V53, P421, DOI 10.1016/S0361-9230(00)00379-8; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WEBER GF, 1999, INFLAMMATORY CELLS M, P97; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zitvogel L, 1996, ANN NY ACAD SCI, V795, P284, DOI 10.1111/j.1749-6632.1996.tb52678.x	48	138	148	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2192	2202		10.1038/sj.onc.1209248	http://dx.doi.org/10.1038/sj.onc.1209248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288209				2022-12-17	WOS:000236581200006
J	Itoh, M; Murata, T; Suzuki, T; Shindoh, M; Nakajima, K; Imai, K; Yoshida, K				Itoh, M; Murata, T; Suzuki, T; Shindoh, M; Nakajima, K; Imai, K; Yoshida, K			Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells	ONCOGENE			English	Article						STAT3; EGF; MMP; c-JUN; migration; tumorigenesis	MATRIX-METALLOPROTEINASE; CONSTITUTIVE ACTIVATION; ONCOSTATIN-M; IN-VITRO; SIGNAL TRANSDUCER; C-JUN; EXPRESSION; TRANSCRIPTION; INHIBITOR; PROTEIN	Signal transducers and activators of transcription (STATs) are latent transcription factors that mediate cytokine- and growth factor-induced transcription. Constitutive activation of STAT3 has been shown in human cancers and transformed cell lines. We report that STAT3, but not STAT1 and STAT5, becomes phosphorylated in response to epidermal growth factor (EGF) and achieves maximal induction of collagenase-1 (MMP1) transcription by interacting with c-JUN. Phosphorylation of STAT3 protein is biphasic: the first peak within 30 min and the second peak between 4 and 8 h. Association of STAT3 with c-JUN is detected and its constituting STAT3 is increasingly phosphorylated. The STAT and AP-1 elements are necessary for effective induction of MMP-1 promoter by EGF. Mutation of AP-1 element closely located at the STAT site abolishes the binding not only of c-JUN but also of STAT3 to MMP-1 promoter, resulting in the loss of the responsiveness to EGF. By blocking STAT3 activity with the dominant-negative form, we show the requirement of STAT3 for EGF induction of MMP-1 and MMP-10 (stromelysin-2). Furthermore, expression of the dominant-negative STAT3 is sufficient to inhibit the constitutive and EGF-inducible cell migration and invasion and the tumor formation in nude mice. These results demonstrate that STAT3 phosphorylation and its possible interaction with c-JUN are required for the strong responsiveness of MMP-1 to EGF, and STAT3 activation is crucial for exhibition of malignant characteristics in T24 bladder cancer cells.	Sapporo Med Univ, Sch Med, Dept Biol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Hokkaido Univ, Grad Sch Dent Med, Dept Oral Pathobiol Sci, Kita Ku, Sapporo, Hokkaido, Japan; Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, Osaka 558, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido, Japan	Sapporo Medical University; Hokkaido University; Osaka Metropolitan University; Sapporo Medical University	Yoshida, K (corresponding author), Sapporo Med Univ, Sch Med, Dept Biol, Chuo Ku, S1,W17, Sapporo, Hokkaido 0608556, Japan.	kyoshida@sapmed.ac.jp	Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catterall JB, 2001, ARTHRITIS RHEUM-US, V44, P2296, DOI 10.1002/1529-0131(200110)44:10<2296::AID-ART392>3.0.CO;2-9; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dominguez-Escrig JL, 2004, CLIN CANCER RES, V10, P4874, DOI 10.1158/1078-0432.CCR-04-0034; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Higashino F, 2005, J CELL BIOL, V170, P15, DOI 10.1083/jcb.200405112; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Horton R M, 1997, Methods Mol Biol, V67, P141; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; KOOP S, 1994, CANCER RES, V54, P4791; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Masuda M, 2002, CANCER RES, V62, P3351; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shibata T, 1996, TUMOR BIOL, V17, P168, DOI 10.1159/000217979; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	46	138	162	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1195	1204		10.1038/sj.onc.1209149	http://dx.doi.org/10.1038/sj.onc.1209149			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205632				2022-12-17	WOS:000235537500007
J	Grutzmann, R; Boriss, H; Ammerpohl, O; Luttges, J; Kalthoff, H; Schackert, HK; Kloppel, G; Saeger, HD; Pilarsky, C				Grutzmann, R; Boriss, H; Ammerpohl, O; Luttges, J; Kalthoff, H; Schackert, HK; Kloppel, G; Saeger, HD; Pilarsky, C			Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes	ONCOGENE			English	Article						pancreatic ductal carcinoma; expression profiling; microarray; meta-analysis	DUCTAL ADENOCARCINOMA; EXPRESSION PROFILES; CDNA MICROARRAY; PROGNOSTIC-FACTOR; CARCINOMA; IDENTIFICATION; TECHNOLOGY; RESISTANCE; DISCOVERY; CELLS	Pancreatic ductal adenocarcinoma is the eighth most common cancer with the lowest overall 5-year relative survival rate of any tumor type today. Expression pro. ling using microarrays has been widely used to identify genes associated with pancreatic cancer development. To extract maximum value from the available gene expression data, we applied a meta-analysis to search for commonly differentially expressed genes in pancreatic ductal adenocarcinoma. We obtained data sets from four different gene expression studies on pancreatic cancer. We selected a consensus set of 2984 genes measured in all four studies and applied a meta-analysis approach to evaluate the combined data. Of the genes identified as differentially expressed, several were validated using RT-PCR and immunohistochemistry. Additionally, we used a class discovery algorithm to identify a gene expression signature. Our meta-analysis revealed that the pancreatic cancer gene expression data sets shared a significant number of up- and downregulated genes, independent of the technology used. This interstudy crossvalidation approach generated a set of 568 genes that were consistently and significantly dysregulated in pancreatic cancer. Of these, 364 (64.1%) were upregulated and 204 (35.9%) were downregulated in pancreatic cancer. Only 127 (22%) were described in the published individual analyses. Functional annotation of the genes revealed that genes presumably associated with the cell adhesion-mediated drug resistance pathway are frequently overexpressed in pancreatic cancer. Meta-analysis is an important tool for the identification and validation of differentially expressed genes. These could represent good candidates for novel diagnostic and therapeutic approaches to pancreatic cancer.	Tech Univ Dresden, Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, D-8027 Dresden, Germany; Interdisciplinary Ctr Bioinformat, Leipzig, Germany; Univ Kiel, Clin Gen Surg & Thorac Surg, Dept Mol Oncol, D-24098 Kiel, Germany; Univ Kiel, Dept Pathol, D-24098 Kiel, Germany; Tech Univ Dresden, Hosp Carl Gustav Carus, Dept Surg Res, D-8027 Dresden, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; University of Kiel; University of Kiel; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Pilarsky, C (corresponding author), Tech Univ Dresden, Hosp Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, D-8027 Dresden, Germany.	pilarsky@mailbox.tu-dresden.de	Kalthoff, Holger/B-1618-2010; Ammerpohl, Ole/G-2691-2010	Pilarsky, Christian/0000-0002-7968-3283				Alexakis N, 2004, BRIT J SURG, V91, P1410, DOI 10.1002/bjs.4794; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; COLLINS R, 1997, NONRANDOM REFLECTION, P197; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Ding Xian-Zhong, 2003, Mol Cancer, V2, P10, DOI 10.1186/1476-4598-2-10; EYSENCK HJ, 1995, SYSTEMATIC REV, P64, DOI DOI 10.1007/S11121-005-553-Y; Friess H, 2003, CELL MOL LIFE SCI, V60, P1180, DOI 10.1007/s00018-003-3036-5; Friess H, 2001, ANN SURG, V234, P769, DOI 10.1097/00000658-200112000-00008; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grutzmann R, 2004, INT J COLORECTAL DIS, V19, P401, DOI 10.1007/s00384-003-0563-3; Grutzmann R, 2004, BRIT J CANCER, V90, P1053, DOI 10.1038/sj.bjc.6601645; Grutzmann R, 2003, VIRCHOWS ARCH, V443, P508, DOI 10.1007/s00428-003-0884-1; Han HY, 2002, CANCER RES, V62, P2890; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Ito H, 2004, CANCER RES, V64, P7439, DOI 10.1158/0008-5472.CAN-04-1177; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Logsdon CD, 2003, CANCER RES, V63, P2649; Luttges J, 2000, J PATHOL, V191, P154; Luttges J, 2001, AM J SURG PATHOL, V25, P942; Nakamura T, 2004, ONCOGENE, V23, P2385, DOI 10.1038/sj.onc.1207392; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Storey John D, 2003, Methods Mol Biol, V224, P149; Sutton AJAK, 2000, METHODS METAANALYSIS; Tan ZJ, 2003, WORLD J GASTROENTERO, V9, P818, DOI 10.3748/wjg.v9.i4.818; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105	33	138	143	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5079	5088		10.1038/sj.onc.1208696	http://dx.doi.org/10.1038/sj.onc.1208696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897887				2022-12-17	WOS:000230816900007
J	Zhang, R; Luo, DH; Miao, R; Bai, LF; Ge, QY; Sessa, WC; Min, W				Zhang, R; Luo, DH; Miao, R; Bai, LF; Ge, QY; Sessa, WC; Min, W			Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis	ONCOGENE			English	Article						Hsp90; Akt; ASK1; hydrogen peroxide; 17-allyamino-17-demethoxygeldanamycin (17-AAG); apoptosis	REGULATING KINASE 1; NITRIC-OXIDE SYNTHASE; KAPPA-B; ACTIVATION; STRESS; DISSOCIATION; SURVIVAL; NECROSIS; DOMAIN; TRANSCRIPTION	Hsp90 client protein Akt has been shown to inhibit cell apoptosis in part by inhibiting proapoptotic kinase ASK1 (apoptosis signal-regulating kinase 1) activity. In the present study, we show that Hsp90 inhibits hydrogen peroxide (H2O2)-induced ASK1-p38 activation in endothelial cells (EC). The inhibitory effect of Hsp90 on ASK1-p38 activities is diminished when the Akt phosphorylation site on ASK1 (pSer83) is absent or when Akt is genetically deleted in cells, suggesting that Hsp90 and Akt function together to inhibit ASK1-p38 signaling. Thus, inhibition of Hsp90 by 17-allyamino-17-demethoxy-geldanamycin (17-AAG) or phosphatidylinositol 3-kinase (PI3K) LY294002 induced and synergized ASK1 activation and ASK1-mediated EC apoptosis. Furthermore, we show that in resting EC Hsp90, Akt and ASK1 form a ternary complex in which both Akt and ASK1 bind to the middle domain of Hsp90, suggesting that Hsp90 may hold Akt and ASK1 in close proximity. The N-terminal domain of ASK1 containing the Akt phosphorylation site (pSer83) associates with Akt in resting state. However, Akt is released from the N-terminal domain concomitant with binding to the C-terminal domain of ASK1 in response to ASK1 activator H2O2, inhibitor of Hsp90 17-AAG and Akt inhibitor LY294002, leading to a more stable Hsp90Akt-ASK1 complex. We conclude that Hsp90-Akt forms a complex with ASK1 and protect EC from stress-induced apoptosis.	Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06510 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Yale University; Yale University; Yale University	Min, W (corresponding author), Yale Univ, Sch Med, Interdepartmental Program Vasc Biol & Transplanta, 295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NHLBI NIH HHS [HL 61371, P01 HL 70295, HL 67793, HL 57665, HL 65978] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL061371, R01HL057665, R01HL061371, P01HL070295, R01HL065978] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Min W, 1997, J IMMUNOL, V159, P3508; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Zhang BM, 1999, SMART MATER STRUCT, V8, P515, DOI 10.1088/0964-1726/8/4/310; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	41	138	146	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3954	3963		10.1038/sj.onc.1208548	http://dx.doi.org/10.1038/sj.onc.1208548			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782121				2022-12-17	WOS:000229435300011
J	Singh, A; Karnoub, AE; Palmby, TR; Lengyel, E; Sondek, J; Der, CJ				Singh, A; Karnoub, AE; Palmby, TR; Lengyel, E; Sondek, J; Der, CJ			Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation	ONCOGENE			English	Article						Rho GTPase; Rho GDI; Tiam1; cyclin D1; NF-kappa B	RHO-FAMILY GTPASES; CRYSTAL-STRUCTURE; NIH3T3 CELLS; INDEPENDENT PATHWAYS; RAS TRANSFORMATION; DEPENDENT PATHWAY; GENE-EXPRESSION; ACTIVATION; PROTEINS; TIAM1	A novel splice variant of Rac1, designated Rac1b, is expressed in human breast and colon carcinoma cells. Rac1b contains an additional 19 amino-acid insert immediately behind the switch II domain, a region important for Rac1 interaction with regulators and effectors. Recent studies showed that Rac1b exhibited the biochemical properties of a constitutively activated GTPase, yet it showed impaired interaction with downstream effectors, suggesting that Rac1b may be defective in biological activity. Whether Rac1b is a biologically active protein was not addressed. Therefore, we evaluated the biochemical, signaling and growth-promoting properties of authentic Rac1b. Similar to previous observations, we found that Rac1b showed enhanced intrinsic guanine nucleotide exchange activity, impaired intrinsic GTPase activity, and failed to interact with RhoGDI. Surprisingly, we found that Rac1b, like the constitutively-activated and transforming Rac1(Q61L) mutant, promoted growth transformation of NIH3T3 cells. Rac1b-expressing cells also showed a loss of density-dependent and anchorage-dependent growth. Surprisingly, unlike activated Rac1(61L), Rac1b did not show enhanced activation of the nuclear factor kappaB (NF-kappaB) transcription factor or stimulate cyclin D1 expression, the signaling activities that best correlate with Rac1 transforming activity. However, Rac1b did promote activation of the AKTserine/threonine kinase. Therefore, we suggest that Rac1b selectively activates a subset of Rac1 downstream signaling pathways to facilitate cellular transformation.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Chicago, Dept Obstet & Gynecol, Div Gynecol Oncol, Chicago, IL 60637 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Chicago	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu	Lengyel, Ernst/D-9220-2014; Singh, Anurag/C-7347-2014	Lengyel, Ernst/0000-0001-8624-1507; Singh, Anurag/0000-0003-4705-8683; Der, Channing/0000-0002-7751-2747; Sondek, John/0000-0002-1127-8310	NCI NIH HHS [CA63071] Funding Source: Medline; NIGMS NIH HHS [GM62299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiegen D, 2004, J BIOL CHEM, V279, P4743, DOI 10.1074/jbc.M310281200; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Grizot S, 2001, BIOCHEMISTRY-US, V40, P10007, DOI 10.1021/bi010288k; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kimple RJ, 2003, COMB CHEM HIGH T SCR, V6, P399; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Matos P, 2003, J BIOL CHEM, V278, P50442, DOI 10.1074/jbc.M308215200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Rul W, 2002, ANN NY ACAD SCI, V973, P145, DOI 10.1111/j.1749-6632.2002.tb04624.x; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; VAN AL, 1997, GENE DEV, V11, P2295; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h	46	138	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9369	9380		10.1038/sj.onc.1208182	http://dx.doi.org/10.1038/sj.onc.1208182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516977				2022-12-17	WOS:000225764100008
J	Takahashi, Y; Lallemand-Breitenbach, V; Zhu, J; de The, H				Takahashi, Y; Lallemand-Breitenbach, V; Zhu, J; de The, H			PML nuclear bodies and apoptosis	ONCOGENE			English	Review						SUMO; p53; HIPK2; CHK2; DAXX	ACUTE PROMYELOCYTIC LEUKEMIA; INTERACTING PROTEIN KINASE-2; SUMO-1 INTERACTION MOTIF; PREMATURE SENESCENCE; GROWTH-SUPPRESSOR; P53 ACTIVITY; TRANSCRIPTIONAL ACTIVATION; T(15-17) TRANSLOCATION; SUMO-1-MODIFIED PML; ONCOGENIC DOMAINS	Promyelocytic leukaemia nuclear bodies (PML NBs) are structured protein complexes associated with the nuclear matrix. PML constitutes the scaffold component of NBs and recruits onto these domains a striking variety of proteins, many of which are involved in apoptosis control. Several reports have directly implicated PML in apoptosis and senescence, but the mechanisms by which these are conveyed are still largely unsettled. Recruitment of partner proteins onto NBs is regulated by PML sumolation, a specific post-translational modification also found in many NB-associated proteins. Among these, several are implicated in transcription repression or activation, like the transcriptional repressor Daxx or the transcriptional activator P53. Whether NBs constitute platforms where active sites of enzymatic modifications are carried out, as suggested for P53, sites of intranuclear protein sequestration, as proposed for Daxx or organelles specialized in catabolism, is still debated. A variety of stress-related signalling pathways dramatically modulate the formation of PML NBs, which may provide a clue as to their physiological function.	Univ Paris 07, Hop St Louis, Ctr Hayem,CNRS, UPR 9051,Lab Associe 11,Comite Paris Ligue Canc, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Univ Paris 07, Hop St Louis, Ctr Hayem,CNRS, UPR 9051,Lab Associe 11,Comite Paris Ligue Canc, 1 Av C Vellefaux, F-75475 Paris 10, France.	dethe@chu-stlouis.fr		Lallemand, Valerie/0000-0001-9852-204X				Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Eskiw CH, 2002, BIOCHEM CELL BIOL, V80, P301, DOI 10.1139/O02-079; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; Everett RD, 1999, J CELL SCI, V112, P4581; Ferbeyre G, 2000, GENE DEV, V14, P2015; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moller A, 2003, CANCER RES, V63, P4310; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Puccetti E, 2003, ONCOGENE, V22, P6900, DOI 10.1038/sj.onc.1206747; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; ROTH MB, 1995, CURR OPIN CELL BIOL, V7, P325, DOI 10.1016/0955-0674(95)80086-7; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Spector DL, 2001, J CELL SCI, V114, P2891; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; STUURMAN N, 1992, J CELL SCI, V101, P773; STUURMAN N, 1997, CELL MOL BIOL LETT, V2, P137; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200; Zhu J, 2002, NAT REV CANCER, V2, P705, DOI 10.1038/nrc887; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	77	138	143	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2819	2824		10.1038/sj.onc.1207533	http://dx.doi.org/10.1038/sj.onc.1207533			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077145				2022-12-17	WOS:000220799600009
J	Jang, ER; Lim, SJ; Lee, ES; Jeong, G; Kim, TY; Bang, YJ; Lee, JS				Jang, ER; Lim, SJ; Lee, ES; Jeong, G; Kim, TY; Bang, YJ; Lee, JS			The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen	ONCOGENE			English	Article						estrogen receptor alpha, beta; tamoxifen responsiveness; HDAC inhibitor; ER alpha-negative breast cancer	ER-BETA; TRANSCRIPTIONAL REPRESSION; ACTIVATION FUNCTION-2; BRCA1 INHIBITION; GENE-EXPRESSION; COACTIVATORS; ACETYLATION; MODULATION; PREVENTION; ESTRADIOL	Many cases of breast cancer show loss of estrogen receptor (ER) alpha expression, which leads to unresponsiveness to antihormonal treatment even though there is no loss of the structurally and biochemically similar ER beta. ER activity is positively and negatively regulated by transcriptional regulators such as histone deacetylase (HDAC), which is known to be a negative ER regulator. Here, we evaluated using ER beta as an alternative target for tamoxifen therapy by treating ER alpha-negative, beta-positive breast cancer cells with the HDAC inhibitor trichostatin A (TSA), and testing whether tamoxifen responsiveness increased following upregulation of ER beta. TSA enhanced the overall ER transcriptional activity in these cells, as visualized by estrogen response element-regulated reporter and the expression of progesterone receptor, a known ER target, without ER alpha restoration. Additionally, TSA induced the expression and nuclear translocation of ER beta but not alpha, suggesting that these actions leading to increase of ER transcriptional activity are mediated through ER beta rather than alpha. Furthermore, following treatment with TSA, the formerly unresponsive MDA-MB-231 and Hs578T breast cancer cells became responsive to tamoxifen. However, reduction of ER beta expression by short interfering RNA abrogated this TSA-induced sensitization effect in these cells. Together, these results show that the HDAC inhibitor TSA sensitized ER alpha-negative, antihormone-unresponsive breast cancer cells to tamoxifen treatment possibly by upregulating ER beta activity.	Natl Canc Ctr, Hosp, Goyang Si 411764, Gyeonggi Do, South Korea; Seoul Natl Univ, Coll Nat Sci, Seoul 110799, South Korea; Seoul Natl Univ, Natl Res Lab Canc Epigenet, Inst Canc Res, Coll Med, Seoul 110799, South Korea	National Cancer Center - Korea (NCC); Seoul National University (SNU); Seoul National University (SNU)	Lee, JS (corresponding author), Natl Canc Ctr, Res Inst, 809 Madu 1 Dong, Goyang Si 411764, Gyeonggi Do, South Korea.	leejs@ncc.re.kr	Bang, Yung Jue/J-2759-2012; Kim, Tae-You/J-2750-2012	Bang, Yung Jue/0000-0001-6000-4597; 				Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chang J, 2000, CLIN CANCER RES, V6, P616; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HEDDEN A, 1995, ANN NY ACAD SCI, V761, P109, DOI 10.1111/j.1749-6632.1995.tb31373.x; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; Jordan VC, 2001, ANN NY ACAD SCI, V949, P72; Jung DJ, 2001, J BIOL CHEM, V276, P37280, DOI 10.1074/jbc.M106860200; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Levenson AS, 2002, CANCER RES, V62, P4419; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Matsuda KI, 2002, MOL ENDOCRINOL, V16, P2215, DOI 10.1210/me.2002-0110; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; Noh EJ, 2003, BIOCHEM BIOPH RES CO, V310, P267, DOI 10.1016/j.bbrc.2003.09.013; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7; Powles TJ, 2002, NAT REV CANCER, V2, P787, DOI 10.1038/nrc908; Scott GK, 2002, MOL CANCER THER, V1, P385; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890	42	138	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1724	1736		10.1038/sj.onc.1207315	http://dx.doi.org/10.1038/sj.onc.1207315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14676837				2022-12-17	WOS:000220029300008
J	Mingo-Sion, AM; Marietta, PM; Koller, E; Wolf, DM; Van Den Berg, CL				Mingo-Sion, AM; Marietta, PM; Koller, E; Wolf, DM; Van Den Berg, CL			Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells	ONCOGENE			English	Article						JNK; proliferation; apoptosis; cell cycle; stress signaling	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; INSULIN-RECEPTOR SUBSTRATE-1; GROWTH SUPPRESSION; CYCLE ARREST; JUN; PHOSPHORYLATION; CHECKPOINT; EXPRESSION; PATHWAY	c-Jun N-terminal kinase (JNK) is activated by diverse cell stimuli, including stress, growth factors, and cytokines. Traditionally, activation of JNK by stress treatment is thought to induce cell death. However, our recent data indicate that JNK's ability to sensitize cells to apoptosis may be, in part, cell cycle dependent. Here, we show that the majority of both paclitaxel- and UV-induced apoptosis can be inhibited by the pharmacological JNK inhibitor, SP600125, in MCF-7 cells. However, inhibition of JNK does little to reverse doxorubicin-induced apoptosis in MCF-7 cells or doxorubicin- and UV-mediated death in MDA MB-231 cells. SP treatment causes G2/M arrest of three breast cancer cell lines and results in the endoreduplication (cellular DNA content >4N) of MCF-7 and MDA MB-231 cells. These effects on cell cycle and apoptosis are not significantly altered by the inhibition of p53, indicating that JNK is functioning independently of p53. Lastly, inhibition of JNK using both SP and antisense oligonucleotides targeted to JNK1 and JNK2 reduced proliferation of all three breast cancer cell lines. Taken together, these results suggest that the activation of JNK is important for the induction of apoptosis following stresses that function at different cell cycle phases, and that basal JNK activity is necessary to promote proliferation and maintain diploidy in breast cancer cells.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Isis Pharmaceuticals Inc	Van Den Berg, CL (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, 4200 E 9th Ave,Campus Box C238, Denver, CO 80262 USA.	carla.vandenberg@UCHSC.edu						Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BAND V, 1990, CANCER RES, V50, P7351; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Haq R, 2002, CANCER RES, V62, P5076; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hildesheim J, 2002, CANCER RES, V62, P7305; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; MacCorkle-Chosnek RA, 2001, BIOCHEM BIOPH RES CO, V289, P173, DOI 10.1006/bbrc.2001.5948; Mamay CL, 2003, ONCOGENE, V22, P602, DOI 10.1038/sj.onc.1206186; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Motwani M, 2000, CLIN CANCER RES, V6, P924; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Patel R, 1998, J CELL SCI, V111, P2247; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Woodgett JR, 1996, CANCER SURV, V27, P127; Xue Y, 2003, MOL CARCINOGEN, V36, P38, DOI 10.1002/mc.10096; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200	42	138	143	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					596	604		10.1038/sj.onc.1207147	http://dx.doi.org/10.1038/sj.onc.1207147			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724588				2022-12-17	WOS:000188098300031
J	Nakagawachi, T; Soejima, H; Urano, T; Zhao, W; Higashimoto, K; Satoh, Y; Matsukura, S; Kudo, S; Kitajima, Y; Harada, H; Furukawa, K; Matsuzaki, H; Emi, M; Nakabeppu, Y; Miyazaki, K; Sekiguchi, M; Mukai, T				Nakagawachi, T; Soejima, H; Urano, T; Zhao, W; Higashimoto, K; Satoh, Y; Matsukura, S; Kudo, S; Kitajima, Y; Harada, H; Furukawa, K; Matsuzaki, H; Emi, M; Nakabeppu, Y; Miyazaki, K; Sekiguchi, M; Mukai, T			Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer	ONCOGENE			English	Article						MGMT; DNA methylation; histone modification; histone methylation; chromatin; gene silencing	O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; DNA METHYLATION; BINDING-PROTEIN; PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; LYSINE-9 METHYLATION; CHROMATIN-STRUCTURE; H3 LYSINE-9; REPAIR; TRANSCRIPTION	O6-methylguanine-DNA methyltransferase (MGMT) repairs the cytotoxic and mutagenic O6-alkylguanine produced by alkylating agents such as chemotherapeutic agents and mutagens. Recent studies have shown that in a subset of tumors, MGMT expression is inversely linked to hypermethylation of the CpG island in the promoter region; however, how the epigenetic silencing mechanism works, as it relates to hypermethylation, was still unclear. To understand the mechanism, we examined the detailed methylation status of the whole island with bisulfite-sequencing in 19 MGMT non-expressed cancer cell lines. We found two highly methylated regions in the island. One was upstream of exon 1, including minimal promoter, and the other was downstream, including enhancer. Reporter gene assay showed that methylation of both the upstream and downstream regions suppressed luciferase activity drastically. Chromatin immunoprecipitation assay revealed that histone H3 lysine 9 was hypermethylated throughout the island in the MGMT negative line, whereas acetylation on H3 and H4 and methylation on H3 lysine 4 were at significantly high levels outside the minimal promoter in the MGMT-expressed line. Furthermore, MeCP2 preferentially bound to the CpG-methylated island in the MGMT negative line. Given these results, we propose a model for gene silencing of MGMT that is dependent on the epigenetic state in cancer.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Nagoya, Aichi, Japan; Hokkaido Inst Publ Hlth, Sapporo, Hokkaido, Japan; Saga Med Sch, Dept Surg, Saga, Japan; Int Med Ctr Japan Res Inst, Dept Pathol, Div Histol, Tokyo, Japan; RIKEN, Spring 8, Harima Inst, Synchrotron Radiat Res Network,Membrane Dynam Pro, Tokyo, Japan; Nippon Med Coll, Inst Gerontol, Dept Mol Biol, Tokyo, Japan; Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Fukuoka 812, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan	Saga University; Nagoya University; Saga University; National Center for Global Health & Medicine - Japan; RIKEN; Nippon Medical School; Kyushu University; Japan Science & Technology Agency (JST)	Soejima, H (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.	soejimah@post.saga-med.ac.jp	Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X; Urano, Takeshi/0000-0003-3383-3554; Soejima, Hidenobu/0000-0001-5076-6563				Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Becker K, 1996, CANCER RES, V56, P3244; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Chen FY, 1997, P NATL ACAD SCI USA, V94, P4348, DOI 10.1073/pnas.94.9.4348; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Danam RP, 2001, INT J ONCOL, V18, P1187; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, CANCER RES, V60, P2368; Fahrner JA, 2002, CANCER RES, V62, P7213; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1994, NUCLEIC ACIDS RES, V22, P4614, DOI 10.1093/nar/22.22.4614; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Herfarth KKF, 1999, MOL CARCINOGEN, V24, P90, DOI 10.1002/(SICI)1098-2744(199902)24:2<90::AID-MC3>3.0.CO;2-B; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Matsukura S, 2003, BRIT J CANCER, V88, P521, DOI 10.1038/sj.bjc.6600743; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nguyen CT, 2002, CANCER RES, V62, P6456; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; OLSSON M, 1980, J BIOL CHEM, V255, P569; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; PEGG AE, 1983, J BIOL CHEM, V258, P2327; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Pieper RO, 1996, J BIOL CHEM, V271, P13916, DOI 10.1074/jbc.271.23.13916; Qian XLC, 1997, CANCER RES, V57, P3672; Roder K, 2002, J BIOL CHEM, V277, P30543, DOI 10.1074/jbc.M111891200; Sakumi K, 1997, CANCER RES, V57, P2415; Satoh Y, 2003, J BIOCHEM, V133, P303, DOI 10.1093/jb/mvg041; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; URANO T, 1993, ONCOGENE, V8, P1371; VONWRONSKI MA, 1992, ONCOL RES, V4, P167; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Whitehall VLJ, 2001, CANCER RES, V61, P827; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469	52	138	145	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8835	8844		10.1038/sj.onc.1207183	http://dx.doi.org/10.1038/sj.onc.1207183			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14647440				2022-12-17	WOS:000186982200004
J	Lee, CGL; Ren, JW; Cheong, ISY; Ban, KHK; Ooi, LLPJ; Tan, SY; Kan, A; Nuchprayoon, I; Jin, RX; Lee, KH; Choti, M; Lee, LA				Lee, CGL; Ren, JW; Cheong, ISY; Ban, KHK; Ooi, LLPJ; Tan, SY; Kan, A; Nuchprayoon, I; Jin, RX; Lee, KH; Choti, M; Lee, LA			Expression of the FAT 10 gene is highly upregulated in hepatocellular carcinoma and other gastrointestinal and gynecological cancers	ONCOGENE			English	Article						diubiquitin; FAT10; ubiquitin-like modifier (UBL); hepatocellular carcinoma; gastrointestinal cancers	UBIQUITIN-LIKE PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; MAD2; IDENTIFICATION; CELLS; DEGRADATION; PROTECTION; APOPTOSIS; ANAPHASE; COMPLEX	The ubiquitin-like modifier (UBL) family has recently generated much interest in the scientific community, as it is implicated to play important regulatory roles via novel protein-protein modification. FAT10 (diubiquitin) belongs to this family of proteins, comprising two ubiquitin-like moieties fused in tandem, and has been implicated to be involved in the maintenance of spindle integrity during mitosis. As FAT10 may play a role in the regulation of genomic stability, we examined if there is an association between FAT10 expression and hepatocellular carcinoma (HCC) or other cancers. Northern blot analyses revealed upregulation of FAT10 expression in the tumors of 90% of HCC patients. In situ hybridization as well as immunohistochemistry utilizing anti-FAT10 antibodies localized highest FAT10 expression in the nucleus of HCC hepatocytes rather than the surrounding immune and non-HCC cells. FAT10 expression was also found to be highly upregulated in other cancers of the gastrointestinal tract and female reproductive system. In conclusion, we demonstrated upregulation of FAT10 expression in various gastrointestinal and gynecological cancers. Its overexpression is unrelated to the general increase in protein synthesis or a general immune/inflammatory response to cancer. Rather, FAT10 may modulate tumorigenesis through its reported interaction with the MAD2 spindle-assembly checkpoint protein.	Natl Canc Ctr, Div Med Sci, Lab 5, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; Johns Hopkins Singapore, Singapore, Singapore; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; Natl Canc Ctr, Dept Surg Oncol, Singapore, Singapore; Singapore Gen Hosp, Dept Surg, Singapore 0316, Singapore; Tan Tock Seng Hosp, Dept Pathol & Lab Med, Singapore, Singapore; Chulalongkorn Univ, Fac Med, Dept Pediat, Bangkok 10330, Thailand; Natl Univ Singapore Hosp, Dept Med, Singapore 117548, Singapore; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21218 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Cancer Centre Singapore (NCCS); Singapore General Hospital; Tan Tock Seng Hospital; Chulalongkorn University; National University of Singapore; Johns Hopkins University	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Lab 5, Level 6,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Ooi, London Lucien/AGK-1395-2022; Lee, Caroline G/M-8918-2019; Ban, Kenneth/A-1243-2012	Lee, Caroline G/0000-0002-4323-3635; Ban, Kenneth/0000-0001-7165-8713; Tan, Soo-Yong/0000-0002-6348-2823; Nuchprayoon, Issarang/0000-0002-4014-5082; Cheong, Ian/0000-0002-3062-6878				Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Biggins S, 2001, GENETICS, V159, P453; Boddy MN, 1996, ONCOGENE, V13, P971; Braissant O, 1998, BIOCHEMICA, V1, P10; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Gemma A, 2001, LUNG CANCER-J IASLC, V32, P289, DOI 10.1016/S0169-5002(00)00223-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hooi SC, 1997, MOL BRAIN RES, V51, P15, DOI 10.1016/S0169-328X(97)00191-5; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; KOMMINOTH P, 1992, HISTOCHEMISTRY, V98, P217, DOI 10.1007/BF00271035; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okura T, 1996, J IMMUNOL, V157, P4277; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293	29	138	157	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2592	2603		10.1038/sj.onc.1206337	http://dx.doi.org/10.1038/sj.onc.1206337			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730673				2022-12-17	WOS:000182569000007
J	Wang-Johanning, F; Frost, AR; Jian, BX; Epp, L; Lu, DW; Johanning, GL				Wang-Johanning, F; Frost, AR; Jian, BX; Epp, L; Lu, DW; Johanning, GL			Quantitation of HERV-K env gene expression and splicing in human breast cancer	ONCOGENE			English	Article						breast carcinoma; retrovirus; HERV envelope; and real-time RT-PCR	ENDOGENOUS RETROVIRUS-K; MAMMARY-TUMOR VIRUS; HTDV/HERV-K; IDENTIFICATION; GENOME; CORF; TRANSCRIPTS; PROTEIN; LOCALIZATION; CARCINOMAS	Human endogenous retroviruses (HERVs) comprise up to 8% of the human genome. In previous studies, we demonstrated that type I HERV-K envelope (env) transcripts are expressed in most human breast cancers, but not in normal breast tissues. In the current study, we report that type 2 HERV-K env transcripts are also present in human breast cancers. By real-time RT-PCR, the expression of HERV-K env transcripts was 5-10-fold higher in breast cancer cell lines treated with estradiol and progesterone than in cells without treatment, and expression was significantly higher in most breast cancer tissues than in normal breast tissues. Furthermore, both types of HERV-K env transcripts were capable of being spliced into subgenomic env transcripts and various splice donor and acceptor sites were detected in breast cancers. The selective expression and distribution of multiple HERV-K endogenous retroviral element splice variants in breast cancer, but not in normal controls, suggests that they are novel breast tumor markers.	Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA; Washington Univ, Med Ctr, Dept Pathol & Immunol, Lauren V Ackerman Lab Surg Pathol, St Louis, MO USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Washington University (WUSTL)	Wang-Johanning, F (corresponding author), Univ Alabama, Dept Med, 1824 6th Ave S, Birmingham, AL 35294 USA.	fengj@uab.edu						Armbruester V, 2002, CLIN CANCER RES, V8, P1800; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; Barbulescu M, 1999, CURR BIOL, V9, P861, DOI 10.1016/S0960-9822(99)80390-X; Boese A, 2000, ONCOGENE, V19, P4328, DOI 10.1038/sj.onc.1203794; Boese A, 2000, FEBS LETT, V468, P65, DOI 10.1016/S0014-5793(00)01197-2; Etkind PR, 1997, VIROLOGY, V234, P304, DOI 10.1006/viro.1997.8670; FRANKLIN GC, 1988, J VIROL, V62, P1203, DOI 10.1128/JVI.62.4.1203-1210.1988; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480; Magin C, 2000, VIROLOGY, V274, P11, DOI 10.1006/viro.2000.0438; Magin C, 1999, J VIROL, V73, P9496, DOI 10.1128/JVI.73.11.9496-9507.1999; Mayer J, 1999, NAT GENET, V21, P257, DOI 10.1038/6766; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; Natoli F, 1996, CANCER LETT, V99, P121, DOI 10.1016/0304-3835(95)04060-9; ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; Schiavetti F, 2002, CANCER RES, V62, P5510; Sugimoto J, 2001, GENOMICS, V72, P137, DOI 10.1006/geno.2001.6473; Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000; Wang-Johanning F, 2002, CANCER-AM CANCER SOC, V94, P2199, DOI 10.1002/cncr.10439; Wang-Johanning F, 2001, CLIN CANCER RES, V7, P1553; Yang J, 1999, P NATL ACAD SCI USA, V96, P13404, DOI 10.1073/pnas.96.23.13404; Yin H, 1997, AIDS RES HUM RETROV, V13, P507, DOI 10.1089/aid.1997.13.507	24	138	165	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1528	1535		10.1038/sj.onc.1206241	http://dx.doi.org/10.1038/sj.onc.1206241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629516				2022-12-17	WOS:000181411900010
J	Fujioka, S; Sclabas, GM; Schmidt, C; Niu, JG; Frederick, WA; Dong, QG; Abbruzzese, JL; Evans, DB; Baker, C; Chiao, PJ				Fujioka, S; Sclabas, GM; Schmidt, C; Niu, JG; Frederick, WA; Dong, QG; Abbruzzese, JL; Evans, DB; Baker, C; Chiao, PJ			Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis	ONCOGENE			English	Article						I kappa B alpha; NF-kappa B; tumorigenesis; angiogenesis; pancreatic cancer	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; ANGIOGENESIS; EXPRESSION; INTERLEUKIN-8; APOPTOSIS; ADENOCARCINOMA; METASTASIS; INDUCTION; PROTEINS	We have demonstrated that nuclear factor-kappaB (NF-kappaB) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized, nontumorigenic pancreatic epithelial cells, suggesting that NF-kappaB plays a critical role in the development of pancreatic adenocarcinoma. To elucidate the role of constitutive NF- kappaB activity in human pancreatic cancer cells, we generated pancreatic tumor cell lines that express a phosphorylation defective IkappaBalpha (S32, 36A) (IkappaBalphaM) that blocks NF-kappaB, activity. In this study, we showed that inhibiting constitutive NF-kappaB activity by expressing IkappaBalphaM suppressed the tumorigenicity of a nonmetastatic human pancreatic cancer cell line, PANC-1, in an orthotopic nude mouse model. Immunohistochemical analysis showed that PANC-1-derived tumors expressed vascular endothelial growth factor (VEGF) and induced angiogenesis. Inhibiting NF-kappaB signaling by expressing licBaM significantly reduced expression of Bcl-x(L) and Bcl-2. The cytokine-induced expression of VEGF and Interleukin-8 in PANC-1 cells is also decreased. Taken together, these results suggest that the inhibition of NF-kappaB signaling can suppress tumorigenesis of pancreatic cancer cells and that the NF-kappaB signaling pathway is a potential target for anticancer agents.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Texas, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas System; University of Texas System; University of Texas System	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Schmidt, Christian/0000-0002-1260-9732	NATIONAL CANCER INSTITUTE [R01CA075517, R29CA073675, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [CA78778, CA73675, CA 75517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRAMHALL SR, 1995, BRIT J SURG, V82, P111, DOI 10.1002/bjs.1800820137; Breslin TM, 2001, ANN SURG ONCOL, V8, P123, DOI 10.1007/s10434-001-0123-4; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gilmore TD, 1996, ONCOGENE, V13, P1367; Grau AM, 1997, CANCER RES, V57, P3929; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Huang S, 2000, CANCER RES, V60, P5334; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Leek RD, 1996, CANCER RES, V56, P4625; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LU D, 1991, ONCOGENE, V6, P1235; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Mohammad RM, 2001, ANTI-CANCER DRUG, V12, P735, DOI 10.1097/00001813-200110000-00005; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Parborell F, 2002, BIOL REPROD, V67, P481, DOI 10.1095/biolreprod67.2.481; PASSANITI A, 1992, LAB INVEST, V67, P519; Sawai H, 2001, PANCREAS, V23, P399, DOI 10.1097/00006676-200111000-00011; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shono T, 1996, MOL CELL BIOL, V16, P4231; STRIETER RM, 1992, AM J PATHOL, V141, P1279; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; Teraoka H, 2001, BRIT J CANCER, V85, P612, DOI 10.1054/bjoc.2001.1941; Tsai LC, 2000, ANTICANCER RES, V20, P2441; Tsuzuki Y, 2001, LAB INVEST, V81, P1439, DOI 10.1038/labinvest.3780357; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Xu ZW, 2001, INT J CANCER, V94, P268, DOI 10.1002/ijc.1447; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yoshida A, 1999, INVEST OPHTH VIS SCI, V40, P1624; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	52	138	152	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1365	1370		10.1038/sj.onc.1206323	http://dx.doi.org/10.1038/sj.onc.1206323			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618762				2022-12-17	WOS:000181360900011
J	Zhang, DL; Brodt, P				Zhang, DL; Brodt, P			Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling	ONCOGENE			English	Article						IGF-I; MT1-MMP; PI 3-kinase; Akt; PTEN; invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; ACTIVATED PROTEIN-KINASE; HEPATIC STELLATE CELLS; HUMAN GLIOMA-CELLS; FACTOR-I; CARCINOMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR RECEPTOR; EXTRACELLULAR-MATRIX; INHIBITS APOPTOSIS	The membrane type I matrix metalloproteinase (MT1-MMP) has been identified as a major activator of MMP-2 - a process involving the formation of a trimolecular complex with TIMP-2. We previously identified the IGF-I receptor as a positive regulator of MMP-2 synthesis. Here, we investigated the role of IGF-IR in the regulation of MT1-MMP. Highly invasive Lewis lung carcinoma subline H-59 cells express MT1-MMP and utilize it to activate their major extracellular matrix degrading proteinase-MMP-2. These cells were transiently transfected with a plasmid vector expressing a luciferase reporter gene downstream of the mouse MT1-MMP promoter. IGF-I treatment increased luciferase activity in the transfected cells by up to 10-fold and augmented endogenous MT1-MMP mRNA and protein synthesis by up to 2-3-fold, relative to controls. MT1-MMP induction and invasion were blocked by the PI 3-kinase inhibitors LY294002 and wortmannin and by rapamycin, but not by the MEK inhibitor PD98059. Overexpression of a dominant negative Akt mutant or of the tumor suppressor phosphatase and tensin homologue, PTEN, in these cells also caused a significant reduction in MT1-MMP expression and invasion. The results demonstrate that IGF-IR controls tumor cell invasion by coordinately regulating MMP-2 expression and its MT1-MMP-mediated activation and identify PI 3-kinase/Akt/mTOR signaling as critical to this regulation.	McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Surg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Brodt, P (corresponding author), McGill Univ, Royal Victoria Hosp, Div Surg Res, Hlth Ctr,Dept Surg, Room H6-25,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	pnina.brodt@muhc.mcgill.ca						Allgayer H, 1998, ONCOLOGY-BASEL, V55, P152, DOI 10.1159/000011850; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; Blum S, 2001, J BIOL CHEM, V276, P33428, DOI 10.1074/jbc.M105474200; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; BRODT P, 1986, CANCER RES, V46, P2442; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; Cha HJ, 2001, CLIN EXP METASTAS, V18, P675, DOI 10.1023/A:1013190118556; Davies MA, 1998, CANCER RES, V58, P5285; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanemaaijer R, 2000, INT J CANCER, V86, P204, DOI 10.1002/(SICI)1097-0215(20000415)86:2<204::AID-IJC9>3.0.CO;2-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kanayama Hiro-omi, 2001, Journal of Medical Investigation, V48, P31; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Khatib AM, 1999, CANCER RES, V59, P1356; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Lavandero S, 1998, FEBS LETT, V422, P193, DOI 10.1016/S0014-5793(98)00008-8; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1994, CANCER RES, V54, P3732; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Parrizas M, 1997, J BIOL CHEM, V272, P154; Penninger JM, 2001, SCIENCE, V294, P2116, DOI 10.1126/science.1067931; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Samani A A, 2001, Surg Oncol Clin N Am, V10, P289; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Sato T, 1999, BRIT J CANCER, V80, P1137, DOI 10.1038/sj.bjc.6690477; Seddighzadeh M, 1999, CLIN EXP METASTAS, V17, P649, DOI 10.1023/A:1006741228402; Shimada T, 2000, CLIN EXP METASTAS, V18, P179, DOI 10.1023/A:1006749501682; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; Skrtic S, 1999, ENDOCRINOLOGY, V140, P5729, DOI 10.1210/en.140.12.5729; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; Sugiyama H, 1998, KIDNEY INT, V54, P1188, DOI 10.1046/j.1523-1755.1998.00116.x; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; TRUMPER K, 2002, ANN NY ACAD SCI, V921, P242; Wang H, 2000, BIOCHEM BIOPH RES CO, V272, P900, DOI 10.1006/bbrc.2000.2852; Weng LP, 1999, CANCER RES, V59, P5808; WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0	60	138	153	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2003	22	7					974	982		10.1038/sj.onc.1206197	http://dx.doi.org/10.1038/sj.onc.1206197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592384	Bronze			2022-12-17	WOS:000180926100003
J	Marquez, DC; Pietras, RJ				Marquez, DC; Pietras, RJ			Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast cancer; plasma membrane; MAP kinase; Akt kinase	ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; RECEPTOR-ALPHA; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; MCF-7 CELLS; FACTOR-I; ESTRADIOL; IDENTIFICATION	Membrane-associated binding sites for estrogen may mediate rapid effects of estradiol-17 beta that contribute to proliferation of human breast cancers. After controlled homogenization and fractionation of MCF-7 breast cancer cells, the bulk of specific estradiol binding is found in nuclear fractions. However, a significant portion of specific, high-affinity estradiol-17 beta binding-sites are also enriched in plasma membranes. These estradiol binding-sites co-purify with 5'-nucleotidase, a plasma membrane-marker enzyme, and are free from major contamination by cytosol or nuclei. Electrophoresis of membrane fractions allowed detection of a primary 67-kDa protein and a secondary 46-kDa protein recognized by estradiol-17 beta and by a monoclonal antibody directed to the ligand-binding domain of the nuclear form of estrogen receptor. Estrogen-induced growth of MCF-7 breast cancer cells in vitro was blocked by treatment with the antibody to estrogen receptor and correlated closely with acute hormonal activation of mitogen-activated protein kinase and Akt kinase signaling. Estrogen-promoted growth of human breast cancer xenografts in nude mice was also significantly reduced by treatment in vivo with the estrogen receptor antibody. Thus, membrane-associated forms of estrogen receptor may play a role in promoting intracellular signaling for hormone-mediated proliferation and survival of breast cancers and offer a new target for antitumor therapy.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pietras, RJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, 10833 Le Conte Ave,11-934 Factor Bldg, Los Angeles, CA 90095 USA.		Marquez-Garban, Diana/M-4660-2014	Marquez-Garban, Diana/0000-0002-7866-5323; Pietras, Richard/0000-0002-2846-3192				Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERTHOIS Y, 1986, J STEROID BIOCHEM, V25, P963, DOI 10.1016/0022-4731(86)90330-4; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen FH, 1999, J CELL BIOCHEM, V74, P430, DOI 10.1002/(SICI)1097-4644(19990901)74:3<430::AID-JCB11>3.0.CO;2-5; Chun TY, 1998, P NATL ACAD SCI USA, V95, P2325, DOI 10.1073/pnas.95.5.2325; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Flouriot G, 2000, EMBO J, V19, P4688, DOI 10.1093/emboj/19.17.4688; Fuqua SAW, 1999, CANCER RES, V59, P5425; GERMAIN PS, 1993, ANTICANCER RES, V13, P2347; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Gu Q, 1999, ENDOCRINOLOGY, V140, P660, DOI 10.1210/en.140.2.660; Hawkins MB, 2000, P NATL ACAD SCI USA, V97, P10751, DOI 10.1073/pnas.97.20.10751; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; HENDERSON BE, 1988, CANCER RES, V48, P246; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Levin ER, 1999, TRENDS ENDOCRIN MET, V10, P374, DOI 10.1016/S1043-2760(99)00192-7; Luconi M, 1999, J CLIN ENDOCR METAB, V84, P1670, DOI 10.1210/jc.84.5.1670; McKenna N, 2000, NAT MED, V6, P960, DOI 10.1038/79637; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Monje P, 1999, MOL CELL ENDOCRINOL, V147, P75, DOI 10.1016/S0303-7207(98)00212-3; MURDOCH FE, 1991, MOL CELL ENDOCRINOL, V78, pC103, DOI 10.1016/0303-7207(91)90114-8; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NENCI I, 1981, J STEROID BIOCHEM, V14, P1139, DOI 10.1016/0022-4731(81)90043-1; Norfleet AM, 2000, FASEB J, V14, P157, DOI 10.1096/fasebj.14.1.157; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1984, BIOCHEM BIOPH RES CO, V123, P84, DOI 10.1016/0006-291X(84)90383-8; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PIETRAS RJ, 1975, NATURE, V253, P357, DOI 10.1038/253357a0; PIETRAS RJ, 1980, BIOCHEM J, V191, P743, DOI 10.1042/bj1910743; Ramirez VD, 1996, FRONT NEUROENDOCRIN, V17, P402, DOI 10.1006/frne.1996.0011; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Register TC, 1998, J STEROID BIOCHEM, V64, P187, DOI 10.1016/S0960-0760(97)00155-6; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; SICA V, 1973, NATURE-NEW BIOL, V244, P36, DOI 10.1038/newbio244036a0; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; SZEGO CM, 1984, INT REV CYTOL, V88, P1, DOI 10.1016/S0074-7696(08)62759-X; SZEGO CM, 1967, P NATL ACAD SCI USA, V58, P1711, DOI 10.1073/pnas.58.4.1711; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Weiler PJ, 2000, BIOCHEM BIOPH RES CO, V272, P731, DOI 10.1006/bbrc.2000.2847; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WELSHONS WV, 1993, MOL CELL ENDOCRINOL, V94, P183, DOI 10.1016/0303-7207(93)90167-I; ZYZEK E, 1981, BIOCHEM BIOPH RES CO, V102, P1151, DOI 10.1016/S0006-291X(81)80132-5	57	138	144	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5420	5430		10.1038/sj.onc.1204729	http://dx.doi.org/10.1038/sj.onc.1204729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571639				2022-12-17	WOS:000170781100002
J	Damiens, E; Baratte, B; Marie, D; Eisenbrand, G; Meijer, L				Damiens, E; Baratte, B; Marie, D; Eisenbrand, G; Meijer, L			Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest	ONCOGENE			English	Article						cyclin-dependent kinase; glycogen synthase kinase; GSK-3 beta; indirubin; kinase inhibitor; cancer	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; CHEMICAL INHIBITORS; SODIUM-BUTYRATE; CANCER CELLS; DNA; STAUROSPORINE; APOPTOSIS; MEDICINE; MITOSIS	The bis-indole indirubin is the active ingredient of the Traditional Chinese Medicine recipe Danggui Longhui Wan used against chronic myelocytic leukemia, We have previously shown that indirubins are potent inhibitors of cyclin-dependent kinases and glycogen synthase kinase-3, We here investigated the anti-mitotic properties of this class of compounds using the cell permeable indirubin-3 ' -monoxime and the HBL-100 cell line. Indirubin-3 ' -monoxime reversibly arrests asynchronous HBL-100 cells in G2, This arrest is not accompanied by any significant change in expression of the major cell cycle regulators, However indirubin-3 ' -monoxime inhibits the phosphorylation of consensus CDK phosphorylation sites as well as of nucleolin at a specific CDK1/cyclin B phosphorylation site, suggesting a direct action on the mitotic CDK1/cyclin B, When indirubin-3 ' -monoxime is added to HBL-100 cells synchronized in M phase by nocodazole, cells undergo an endoreplication leading to an 8n DNA content. As soon as indirubin-3 ' -monoxime is washed away, these polyploid cells become aneuploid and later die from necrosis, This mechanism of endoreplication followed by cell death may contribute to the antitumour properties of indirubins.	CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, France; Univ Kaiserslautern, Div Food Chem & Environm Toxicol, Dept Chem, D-67663 Kaiserslautern, Germany; CNRS, Phytoplankton Ocean Grp, Biol Stn, F-29682 Roscoff, France	Centre National de la Recherche Scientifique (CNRS); University of Kaiserslautern; Centre National de la Recherche Scientifique (CNRS)	Meijer, L (corresponding author), CNRS, Biol Stn, Cell Cycle Grp, BP 74, F-29682 Roscoff, France.		Eisenbrand, Gerhard/AEQ-0284-2022	Eisenbrand, Gerhard/0000-0003-4079-2463; , laurent/0000-0003-3511-4916				Akiyama T, 1999, ANTI-CANCER DRUG, V10, P67, DOI 10.1097/00001813-199901000-00009; [Anonymous], 1992, CHIN DRUGS PLANT ORI; Atienza C, 2000, INT J MOL MED, V6, P55; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bible KC, 1997, CANCER RES, V57, P3375; Borgne A, 1999, M S-MED SCI, V15, P496, DOI 10.4267/10608/1375; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; Chang CN, 1985, ADV CHINESE MED MAT, P369; CHEN DH, 1984, CHINESE TRAD HERBAL, V15, P6; Edamatsu H, 2000, ONCOGENE, V19, P3059, DOI 10.1038/sj.onc.1203625; Hall LL, 1996, CANCER RES, V56, P3551; HAN R, 1994, STEM CELLS, V12, P53, DOI 10.1002/stem.5530120110; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Ikegami Y, 1996, ARZNEIMITTEL-FORSCH, V46, P201; Institute of Haematology Chinese Academy of Medical Sciences, 1979, CHIN J INT MED, V18, P83; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lallemand F, 1999, EXP CELL RES, V247, P432, DOI 10.1006/excr.1998.4370; Ma M Z, 1983, J Tradit Chin Med, V3, P245; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; ONGKEKO W, 1995, J CELL SCI, V108, P2897; Roberge M, 1998, CANCER RES, V58, P5701; *SICH I TRAD CHIN, 1981, CHIN TRAD HERB DRUGS, V12, P27; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; WANG JH, 1981, ACTA PHARM SINICA, V2, P241; Wu K M, 1985, Yao Xue Xue Bao, V20, P821; WU LM, 1979, COMM CHINESE HERBAL, V9, P6; YAMADA K, 1985, J CELL PHYSIOL, V122, P59, DOI 10.1002/jcp.1041220110; Zhang Z N, 1985, J Tradit Chin Med, V5, P246; ZHU YP, 1995, PHARM WORLD SCI, V17, P103, DOI 10.1007/BF01872386	36	138	157	0	13	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3786	3797		10.1038/sj.onc.1204503	http://dx.doi.org/10.1038/sj.onc.1204503			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439342	Bronze			2022-12-17	WOS:000169494700004
J	Kranenburg, O; Moolenaar, WH				Kranenburg, O; Moolenaar, WH			Res-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists	ONCOGENE			English	Article						lysophosphatidic acid; sphingosine-1-phosphate; G protein coupled receptors; Ras; Rho; MAP kinase	FACTOR RAS-GRF; EPIDERMAL GROWTH-FACTOR; CELL-CYCLE PROGRESSION; TYROSINE KINASE; EXCHANGE FACTOR; PLASMA-MEMBRANE; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE-3 KINASE; MEDIATED ENDOCYTOSIS	Lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are extracellular lipid mediators that signal through distinct members of the Edg/LP subfamily of G protein-coupled receptors (GPCRs), LPA and S1P receptors are expressed in almost every cell type and can couple to multiple G proteins (G(i), G(q) and G(12/13)) to mediate a great variety of responses, ranging from rapid morphological changes to long-term stimulation of cell proliferation. LPA serves as the prototypic GPCR agonist that activates the small GTPases Pas (via G(i)) and RhoA (via G(12/13)), leading to activation of the mitogen-activated protein kinase (MAPK) cascade and reorganization of the actin cytoskeleton, respectively. This review focuses on our current insights into how Ras-MAPK signaling is regulated by GPCR agonists in general, and by LPA in particular.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Moolenaar, WH (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Alblas J, 1996, EMBO J, V15, P3351, DOI 10.1002/j.1460-2075.1996.tb00700.x; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANDREEV J, 2001, IN PRESS J BIOL CHEM; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Chun J, 1999, CRIT REV NEUROBIOL, V13, P151, DOI 10.1615/CritRevNeurobiol.v13.i2.20; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kranenburg O, 1999, BIOCHEM J, V339, P11, DOI 10.1042/0264-6021:3390011; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mattingly RR, 1999, CELL SIGNAL, V11, P603, DOI 10.1016/S0898-6568(99)00034-0; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Razani B, 2000, J CELL SCI, V113, P2103; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Scheel J, 1999, NAT CELL BIOL, V1, P127, DOI 10.1038/10100; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAN BT, 1995, NATURE, V376, P781; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xu Y, 1995, CLIN CANCER RES, V1, P1223; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Yuryev A, 1998, Cell Res, V8, P81; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	96	138	142	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1540	1546		10.1038/sj.onc.1204187	http://dx.doi.org/10.1038/sj.onc.1204187			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313900				2022-12-17	WOS:000168089800003
J	Oh, S; Song, YH; Yim, J; Kim, TK				Oh, S; Song, YH; Yim, J; Kim, TK			Identification of Mad as a repressor of the human telomerase (hTERT) gene	ONCOGENE			English	Article						telomerase; hTERT; Myc; Mad; repression	CATALYTIC SUBUNIT GENE; NORMAL HUMAN-CELLS; CELLULAR SENESCENCE; LIFE-SPAN; MYC; HUMAN-CHROMOSOME-3; IMMORTALIZATION; COMPLEX	Activation of telomerase, which has been frequently associated with cellular immortality, may constitute a key step in the development of human cancer. Derepression in the expression of its catalytic subunit hTERT gene has been proposed to directly link to the telomerase activation in tumor cells. Little is known about the mechanism how the hTERT gene is repressed in telomerase-negative mortal cells. This study was conducted, using an expression cloning approach, with the aim of identifying the gene(s) responsible for repressing the hTERT gene expression. Using this genetic screen, we isolated the transcription factor Mad as a repressor. Mutation of its DNA binding sites caused significant de-repression of hTERT promoter activity in mortal cells. This Mad-mediated repression of the hTERT promoter in mortal cells was counteracted by ectopic expression of Myc, The antagonism between Mad and Myc was also observed with an endogenous hTERT promoter. Their potential roles in differential hTERT promoter activities were further supported by the relative amounts of Mad and Myc proteins detected in immortal and mortal cells. Thus, Mad may be a direct negative regulator of hTERT in mortal cells and this repression mechanism can be inhibited by induction of Myc in immortal cells.	Harvard Univ, Sch Med, Inst Chem & Cell Biol, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Seoul Natl Univ, Natl Creat Res Initiat, Inst Mol Biol & Genet, Ctr Genet Reprogramming, Seoul 151742, South Korea	Harvard University; Harvard Medical School; Seoul National University (SNU)	Kim, TK (corresponding author), Harvard Univ, Sch Med, Inst Chem & Cell Biol, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.							AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dang CV, 1999, MOL CELL BIOL, V19, P1; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Horikawa I, 1998, MOL CARCINOGEN, V22, P65, DOI 10.1002/(SICI)1098-2744(199806)22:2<65::AID-MC1>3.0.CO;2-J; Horikawa I, 1999, CANCER RES, V59, P826; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OGATA T, 1995, JPN J CANCER RES, V86, P35, DOI 10.1111/j.1349-7006.1995.tb02985.x; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Takakura M, 1999, CANCER RES, V59, P551; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	32	138	149	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1485	1490		10.1038/sj.onc.1203439	http://dx.doi.org/10.1038/sj.onc.1203439			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723141				2022-12-17	WOS:000085942700015
J	Callahan, R; Smith, GH				Callahan, R; Smith, GH			MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways	ONCOGENE			English	Review						MMTV; Wnt; Fgf; notch; elF3p48/INT6	HUMAN BREAST-CANCER; TUMOR VIRUS-DNA; TRANSGENIC MICE; PROVIRAL INSERTION; EPITHELIAL-CELLS; GROWTH-FACTORS; NOTCH-GENE; IN-VIVO; MOUSE DEVELOPMENT; STEM-CELL	The study of the mouse mammary tumor virus (MMTV) has provided important insights into the mechanisms of gene transcription regulation by steroid hormones, the mode of action of heritable super antigens and the progressive nature of neoplastic transformation in the mammary gland, Here we describe the current situation with respect to the latter aspect of MMTV biology and the prospects for further advance in our understanding of breast cancer in humans that may be expected from a continued study of MMTV-induced mammary neoplasia, MMTV is a heritable somatic mutagen whose target range is limited, Commonly, the tumorigenic capacity of MMTV is restricted to mammary gland, whereas infection is found in a variety of cell types, In order to replicate, proviral DNA must be inserted into the cell DNA and cell division is required to fix the mutation. Yet only in the mammary epithelium does this lead to neoplastic transformation. This suggests a unique relationship between MMTV and mammary epithelium. In evaluating this relationship, we and others have discovered genes and potential gene pathways that are pertinent in mammary differentiation and neoplasia, In addition, the clonal nature of these progressive events from normal to malignant phenotype has become increasingly clear, The weight of these observations compel us to conclude that mammary neoplasms arise from multipotent mammary epithelial cells through a process of acquired mutations that are reflected in the increasingly malignant nature of the population of progeny produced by these damaged stem cells.	NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA.							ANDERVONT HB, 1952, ANN NY ACAD SCI, V54, P1004, DOI 10.1111/j.1749-6632.1952.tb39975.x; ANDERVONT HB, 1962, J NATL CANCER I, V28, P1153; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Callahan R, 1996, BREAST CANCER RES TR, V39, P33, DOI 10.1007/BF01806076; CALLAHAN R, 1986, CURR TOP MICROBIOL, V127, P362; CALLAHAN R, 1982, P NATL ACAD SCI-BIOL, V79, P4113, DOI 10.1073/pnas.79.13.4113; CARDIFF RD, 1983, J NATL CANCER I, V71, P1011; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; COHEN JC, 1979, CELL, V16, P333; COHEN JC, 1979, J VIROL, V32, P483, DOI 10.1128/JVI.32.2.483-496.1979; DANIEL CW, 1968, P NATL ACAD SCI USA, V61, P53, DOI 10.1073/pnas.61.1.53; DANIEL CW, 1971, EXP GERONTOL, V6, P95, DOI 10.1016/0531-5565(71)90053-2; DANIEL CW, 1971, EXP CELL RES, V65, P27, DOI 10.1016/S0014-4827(71)80046-0; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEOME K.B., 1959, JNCI-J NATL CANCER I, V78, P751; DEOME KB, 1978, CANCER RES, V38, P2103; DEOME KB, 1978, CANCER RES, V38, P4050; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Diella F, 1997, DNA CELL BIOL, V16, P839, DOI 10.1089/dna.1997.16.839; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; DIEVART A, 1999, IN PRESS ONCOGENE; ESCOT C, 1986, J VIROL, V58, P619, DOI 10.1128/JVI.58.2.619-625.1986; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FELLUGA B, 1969, J NATL CANCER I, V43, P319; FOULDS L, 1956, J NATL CANCER I, V17, P713; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; Golovkina TV, 1998, J VIROL, V72, P3066, DOI 10.1128/JVI.72.4.3066-3071.1998; HELD W, 1994, IMMUNOL TODAY, V15, P184, DOI 10.1016/0167-5699(94)90317-4; HILGERS J, 1981, MAMMARY TUMORS MOUSE; HILKENS J, 1983, J VIROL, V45, P140, DOI 10.1128/JVI.45.1.140-147.1983; HUGUET EL, 1994, CANCER RES, V54, P2615; IMAI S, 1994, J VIROL, V68, P3437, DOI 10.1128/JVI.68.5.3437-3442.1994; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Kordon EC, 1998, DEVELOPMENT, V125, P1921; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE AE, 1968, BRIT J CANCER, V22, P77, DOI 10.1038/bjc.1968.11; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARCHETTI A, 1991, J VIROL, V65, P4550, DOI 10.1128/JVI.65.8.4550-4554.1991; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MEDINA D, 1990, PROTOPLASMA, V159, P77, DOI 10.1007/BF01322591; MEDINA D, 1973, METHOD CANCER RES, V7, P3; MICHALIDES R, 1981, CELL, V23, P165, DOI 10.1016/0092-8674(81)90281-6; MICHALIDES R, 1985, VIROLOGY, V142, P278, DOI 10.1016/0042-6822(85)90336-8; Miyazaki S, 1999, GENE, V233, P241, DOI 10.1016/S0378-1119(99)00130-4; Morimoto Y, 1985, Crit Rev Ther Drug Carrier Syst, V2, P19; Morse H., 1978, ORIGINS INBRED MICE; MUHLBOCK O, 1950, J NATL CANCER I, V10, P861; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NICOLL CHARLES S., 1965, LIFE SCI, V4, P993, DOI 10.1016/0024-3205(65)90203-1; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; Qin W, 1999, J VIROL, V73, P368, DOI 10.1128/JVI.73.1.368-376.1999; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RINGOLD GM, 1979, P NATL ACAD SCI USA, V76, P665, DOI 10.1073/pnas.76.2.665; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RONGEY RW, 1973, J NATL CANCER I, V50, P1581, DOI 10.1093/jnci/50.6.1581; Rosenberg CL, 1997, HUM PATHOL, V28, P214, DOI 10.1016/S0046-8177(97)90109-X; Ross SR, 1998, IMMUNOL RES, V17, P209, DOI 10.1007/BF02786445; ROUBINIAN JR, 1980, J NATL CANCER I, V65, P795, DOI 10.1093/jnci/65.4.795; SARKAR NH, 1994, VIROLOGY, V203, P52, DOI 10.1006/viro.1994.1454; SCHLOM J, 1978, JNCI-J NATL CANCER I, V61, P66; SCHWARTZ MS, 1992, INT J CANCER, V51, P805, DOI 10.1002/ijc.2910510523; SELL S, 1994, LAB INVEST, V70, P6; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; SIRACUSA LD, 1991, GENOMICS, V10, P313, DOI 10.1016/0888-7543(91)90314-5; SMITH GH, 1991, J VIROL, V65, P6365, DOI 10.1128/JVI.65.11.6365-6370.1991; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; SMITH GH, 1982, INT J CANCER, V29, P587, DOI 10.1002/ijc.2910290516; SMITH GH, 1984, CANCER RES, V44, P3426; SMITH GH, 1966, JNCI-J NATL CANCER I, V36, P685, DOI 10.1093/jnci/36.4.685; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; SMITH GH, 1967, CANCER RES, V27, P2179; SMITH GH, 1988, J CELL SCI, V90, P173; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; SQUARTINI F, 1961, J NATL CANCER I, V26, P813; SQUARTINI F, 1963, NATURE, V197, P505, DOI 10.1038/197505a0; SQUARTINI F, 1983, CANCER RES, V43, P5879; Squartini F, 1979, IARC Sci Publ, V23, P43; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; TERAMOTO YA, 1980, J NATL CANCER I, V64, P967; Tsai YC, 1996, CANCER RES, V56, P402; TSUBURA Y, 1981, GANN, V72, P424; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; VANDEVIJVER MJ, 1989, MOL DIAGNOSTICS HUMA; VANNIE R, 1975, INT J CANCER, V16, P922, DOI 10.1002/ijc.2910160606; VANNIE R, 1977, INT J CANCER, V19, P383, DOI 10.1002/ijc.2910190316; VARMUS HE, 1982, CANCER SURV, V1, P309; VLAHAKIS G, 1970, SCIENCE, V170, P185, DOI 10.1126/science.170.3954.185; WAINSCOAT JS, 1990, CANCER RES, V50, P1355; Wang Y, 1998, CLIN CANCER RES, V4, P2565; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WELLINGS SR, 1980, PATHOL RES PRACT, V166, P515, DOI 10.1016/S0344-0338(80)80248-2; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOUNG LJT, 1971, EXP GERONTOL, V6, P49, DOI 10.1016/0531-5565(71)90048-9	123	138	142	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		992	1001		10.1038/sj.onc.1203276	http://dx.doi.org/10.1038/sj.onc.1203276			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713682				2022-12-17	WOS:000085796400004
J	Marchetti, A; Doglioni, C; Barbareschi, M; Buttitta, F; Pellegrini, S; Bertacca, G; Chella, A; Merlo, G; Angeletti, CA; DallaPalma, P; Bevilacqua, G				Marchetti, A; Doglioni, C; Barbareschi, M; Buttitta, F; Pellegrini, S; Bertacca, G; Chella, A; Merlo, G; Angeletti, CA; DallaPalma, P; Bevilacqua, G			p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation	ONCOGENE			English	Article						p21/WAF1/CIP1/SDI1/mda-6; p53; lung cancer; histology; differentiation	P53; PROLIFERATION; INHIBITOR; MARKERS; KINASES	p21, the product of the WAF1/CIP1/SDI1/mda-6 gene, is an inhibitor of cyclin-dependent kinases. In cell cultures p21 is induced by p53-dependent and p53-independent pathways by DNA damage and induction of differentiation. We investigated p21 RNA and immunohistochemical expression in 43 non-small cell lung carcinomas and corresponding normal lung samples previously investigated for p53 and WAF1 gene status and p53 protein expression. p21 RNA and protein expression in normal and neoplastic tissues were strictly associated (P=0.0001). In normal tissue p21 RNA was expressed at low levels and p21 immunoreactivity was seen in scattered differentiated bronchial, alveolar and stromal cells. In the majority of neoplasms p21 protein and RNA were expressed at higher levels than in the corresponding normal tissues: p21 overexpression was seen in 27 (63%) and 28 (65%) cases respectively. p21 was expressed independently from p53 gene/protein alterations. p21 overexpression was more frequent in well differentiated tumors (P=0.01 and P=0.022 for RNA and protein respectively), and p21 immunoreactivity was usually seen in foci of more pronounced differentiation. We conclude that p21 expression is related to tumor differentiation, and that p53-independent p21 expression is a common feature of in vivo neoplasms.	UNIV PISA,SERV THORAC SURG,I-56100 PISA,ITALY; CITY HOSP BELLUNO,DEPT HISTOPATHOL,BELLUNO,ITALY; SANTA CHIARA HOSP,DEPT HISTOPATHOL,TRENT,ITALY; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	University of Pisa; ULSS 1 Dolomiti; Ospedale di Belluno; Santa Chiara Hospital; Friedrich Miescher Institute for Biomedical Research	Marchetti, A (corresponding author), UNIV PISA,INST PATHOL & HISTOL,VIA ROME 57,I-56100 PISA,ITALY.		Pellegrini, Silvia/C-3770-2011; PELLEGRINI, SILVIA/ABG-8822-2021; Barbareschi, Mattia/AAF-2043-2020	PELLEGRINI, SILVIA/0000-0003-0556-0165; BEVILACQUA, GENEROSO/0000-0001-8857-2609; DOGLIONI, Claudio/0000-0002-4969-5216				[Anonymous], 1982, Am J Clin Pathol, V77, P123; BARBARESCHI M, 1992, J PATHOL, V166, P343, DOI 10.1002/path.1711660405; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; CHEDID M, 1994, ONCOGENE, V9, P3021; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARCHETTI A, 1993, CANCER RES, V53, P4665; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARCHETTI A, 1995, INT J ONCOL, V6, P187; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STEINMAN RA, 1994, ONCOGENE, V9, P3389; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	138	145	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1319	1324						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649834				2022-12-17	WOS:A1996UC06700017
J	TEODORO, JG; SHORE, GC; BRANTON, PE				TEODORO, JG; SHORE, GC; BRANTON, PE			ADENOVIRUS E1A PROTEINS INDUCE APOPTOSIS BY BOTH P53-DEPENDENT AND P53-INDEPENDENT MECHANISMS	ONCOGENE			English	Article						APOPTOSIS; P53; ADENOVIRUS; E1A; E1B	E2F TRANSCRIPTION FACTOR; REGION 1A PROTEINS; RAT-KIDNEY CELLS; CELLULAR PROTEINS; 19-KILODALTON PROTEIN; FUNCTIONAL DOMAINS; TUMOR-ANTIGENS; INFECTED-CELLS; GENE-PRODUCT; DNA-BINDING	E1A of human adenovirus type 5 (Ad5) encodes proteins of 289 and 243 residues (289R and 243R) which differ only by the 46 amino acid CR3 region known to activate expression of certain cellular and early viral genes. E1A proteins also induce DNA synthesis and cell transformation, but as well can stimulate apoptosis. Two adenovirus E1B products act to protect cells from E1A-induced cell death, including a 19 kDa protein which is functionally similar to the cellular Bcl-2 suppressor of apoptosis, and a 55 kDa species which binds to and inhibits p53. Previous studies suggested that E1A-induced cell death occurs via a p53-dependent mechanism requiring regions of E1A proteins linked to induction of DNA synthesis and cell transformation. We report here that the 289R E1A protein induces apoptosis in cell lines lacking p53, whereas the 243R product was dependent upon p53. We also show that this p53-independent process involves the expression of one or more additional viral proteins which are presumably synthesized in response to transactivation by 289R. Thus E1A proteins induce cell death by both p53-dependent and p53-independent mechanisms involving separate E1A functions.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University			Teodoro, Joe/AFT-2440-2022	Teodoro, Joe/0000-0002-3713-6839				Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BACCHETTI S, 1993, INT J ONCOL, V3, P781; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BARBEAU D, 1994, ONCOGENE, V9, P359; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT DJ, 1989, J VIROL, V63, P987, DOI 10.1128/JVI.63.2.987-991.1989; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOROWITZ MS, 1990, VIROLOGY, P1679; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; ROWE DT, 1983, VIROLOGY, V129, P456, DOI 10.1016/0042-6822(83)90183-6; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SHENK T, 1991, ADV CANCER RES, V57, P47; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHANG S, 1992, J VIROL, V66, P2302, DOI 10.1128/JVI.66.4.2302-2309.1992	80	138	145	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					467	474						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630630				2022-12-17	WOS:A1995RN53000006
J	PRASAD, DDK; OUCHIDA, M; LEE, L; RAO, VN; REDDY, ESP				PRASAD, DDK; OUCHIDA, M; LEE, L; RAO, VN; REDDY, ESP			TLS FUS FUSION DOMAIN OF TLS FUS-ERG CHIMERIC PROTEIN RESULTING FROM THE T(1621) CHROMOSOMAL TRANSLOCATION IN HUMAN MYELOID-LEUKEMIA FUNCTIONS AS A TRANSCRIPTIONAL ACTIVATION DOMAIN	ONCOGENE			English	Article							ETS-RELATED GENE; SERUM RESPONSE FACTOR; RNA-BINDING PROTEIN; DNA-BINDING; FLI-1 GENE; FAMILY; ELK-1; C-ETS-1; MEMBER; ERYTHROLEUKEMIA	EWS and TLS/FUS genes, which code for RNA binding proteins are involved in a wide variety of human solid tumors. The TLS/FUS gene is involved both in human myxoid liposarcomas which carry a characteristic chromosomal translocation, t(12;16)(q13;p11) and in human myeloid leukemias with recurrent chromosomal translocation, t(16;21)(p11:q22). The TLS/FUS gene is fused to a transcriptional repressor, CHOP (in human myxoid liposarcomas) or transcriptional activator, erg (in human myeloid leukemias). To understand better the functional role of TLS/FUS-erg in human myeloid leukemias, we have cloned the TLS/FUS and TLS/FUS-erg cDNAs and studied the functional properties of their gene products. TLS/FUS protein binds to RNA in vitro and shows preferential binding to poly G. Both the amino- and the carboxy- terminal regions of TLS/FUS containing the conserved RNA binding motifs are needed for poly G specific RNA binding activity. The TLS/FUS fusion domain (TFD) appears to regulate the DNA binding activity of TLS/FUS-erg chimeric protein which shows weaker transcriptional activation properties compared to normal erg proteins. Mutational analysis of the TLS/FUS-erg chimeric protein reveals TFD to function as a transcriptional activation domain thus replacing the amino terminal transcriptional activation domain of the erg protein. Therefore alterations in both DNA binding and transcriptional activation properties of aberrant erg proteins may be responsible for the genesis of t(16;21) chromosomal translocation-bearing human myeloid leukemias.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA 58642, CA 57157, CA 51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057157, P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; HAYNES SR, 1992, NEW BIOL, V4, P421; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1992, CANCER RES, V52, P5833; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; [No title captured]	51	138	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3717	3729						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970732				2022-12-17	WOS:A1994PT39200038
J	WIMMEL, A; LUCIBELLO, FC; SEWING, A; ADOLPH, S; MULLER, R				WIMMEL, A; LUCIBELLO, FC; SEWING, A; ADOLPH, S; MULLER, R			INDUCIBLE ACCELERATION OF G(1) PROGRESSION THROUGH TETRACYCLINE-REGULATED EXPRESSION OF HUMAN CYCLIN-E	ONCOGENE			English	Note							CELL-CYCLE; PHASE	Cyclin E is a cell cycle-regulated protein that activates the cdc2-related protein kinases cdk2 shortly before S-phase entry. In order to analyse the biological role of cyclin E, we have generated HeLa cells that allow the conditional expression of ectopic human cyclin E. In these cells, a cyclin E cDNA is under the control of a bacterial tetracycline repressor-VP16 activator hybrid protein. In the absence of tetracycline, the endogenous gene becomes activated and leads to the synthesis of elevated levels of cyclin E. Concomitant with this increase in cyclin E expression we show by a combined time-lapse video recording/5-bromo-deoxyuridine labelling procedure a significant acceleration of G(1) transition by approximately 1.5 hours. This observation is consistent with the idea that cyclin E is a rate-limiting factor with respect to the control of G(1)-->S transition. The experimental system described here should also prove useful to address the function of cyclin E in further detail.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ADOLPH S, 1993, J CELL SCI, V105, P113; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	19	138	150	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					995	997						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108147				2022-12-17	WOS:A1994MW55100041
J	PUPA, SM; MENARD, S; MORELLI, D; POZZI, B; DEPALO, G; COLNAGHI, MI				PUPA, SM; MENARD, S; MORELLI, D; POZZI, B; DEPALO, G; COLNAGHI, MI			THE EXTRACELLULAR DOMAIN OF THE C-ERBB-2 ONCOPROTEIN IS RELEASED FROM TUMOR-CELLS BY PROTEOLYTIC CLEAVAGE	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; HUMAN-BREAST-CARCINOMA; PLASMINOGEN-ACTIVATOR ACTIVITY; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; PROTO-ONCOGENE; TRUNCATED RECEPTOR; MAMMARY-TUMOR; CATHEPSIN-B	A molecule that is immunologically related to the c-erbB-2 oncogene product (p185HER2/neu) was detected in the conditioned culture medium from neu-overexpressing tumor cell lines and in sera of advanced-stage breast carcinoma patients. Using a sensitive (in the range of 0.5 ng ml-1) double-determinant radioimmunoassay (DDIRMA) with two monoclonal antibodies (MAbs) directed against the neu extracellular domain (ECD), soluble oncoproteins were detected in supernatants from several neu-positive tumor cell lines, independent of the levels of membrane p185HER2 expression. The molecule detected did not react with a MAb directed against an intracytoplasmic epitope of the p185HER2. Western blot analysis of the concentrated supernatant revealed a protein of approximately 110 kDa molecular mass, which closely matches the predicted size of the glycosylated p185HER2 ECD. Immunoprecipitation of culture supernatant from cell surface-radioiodinated cells confirmed the 110 kDa molecular mass of the glycosylated shed protein, which migrated to 86 kDa after deglycosylation. Proteolytic cleavage of the p185HER2 molecule was demonstrated in release assays carried out with protease inhibitors. The combined use of leupeptin and EDTA completely inhibited release of the molecule. Analysis of sera from breast carcinoma patients and healthy donors by DDIRMA revealed the presence of soluble neu in 15% of pathologic sera but none of the normal sera. A good correlation was found between neu-overexpression in the primary tumor and the soluble marker in serum of patients with advanced disease; sera of early-stage patients were always negative, independent of neu-overexpression in the tumor. These results suggest the usefulness of soluble neu as an indicator of tumor aggressiveness but not as a diagnostic marker of breast cancer.	IST NAZL TUMORI,DIV DIAGNOST SURG,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan	PUPA, SM (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL E,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		Pupa, Serenella/K-6388-2016; Morelli, Daniele/I-4113-2017; menard, sylvie mm/C-7940-2011	Pupa, Serenella/0000-0002-4592-6830; Morelli, Daniele/0000-0002-1823-3764; 				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALPER O, 1990, CELL GROWTH DIFFER, V1, P591; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; CARNEY W P, 1991, Journal of Tumor Marker Oncology, V6, P53; CENTIS F, 1992, HYBRIDOMA, V11, P267, DOI 10.1089/hyb.1992.11.267; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Diotti A, 1987, Int J Biol Markers, V2, P161; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EISEMANN A, 1991, ONCOGENE, V6, P1195; ETO I, 1992, BIOCHEM J, V283, P209, DOI 10.1042/bj2830209; EVERS JL, 1982, CANCER RES, V42, P219; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; KAMITANI H, 1992, Neurological Research, V14, P236; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGTON BC, 1991, CANCER RES, V51, P2593; LEITZEL K, 1992, J CLIN ONCOL, V10, P1436, DOI 10.1200/JCO.1992.10.9.1436; LIN YZJ, 1991, ONCOGENE, V6, P639; MAIER LA, 1991, CANCER RES, V51, P5361; MARIANICOSTANTINI R, 1984, VIRCHOWS ARCH A, V402, P389, DOI 10.1007/BF00734636; MENARD S, 1983, CANCER RES, V43, P1295; MORI S, 1990, JPN J CANCER RES, V81, P489, DOI 10.1111/j.1349-7006.1990.tb02596.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NYGREN PA, 1988, J MOL RECOG, V1, P540; PARK JB, 1989, CANCER RES, V49, P6605; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; POOLE AR, 1978, NATURE, V273, P545, DOI 10.1038/273545a0; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RECKLIES AD, 1982, BIOCHEM J, V207, P633, DOI 10.1042/bj2070633; RECKLIES AD, 1980, CANCER RES, V40, P550; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHI ZR, 1983, CANCER RES, V43, P4045; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUTHERLAND DJA, 1980, JNCI-J NATL CANCER I, V64, P3; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; THORSEN T, 1982, EUR J CANCER CLIN ON, V18, P129, DOI 10.1016/0277-5379(82)90055-4; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WALDMANN TA, 1985, CANCER RES, V45, P4559; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	53	138	147	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2917	2923						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8105438				2022-12-17	WOS:A1993MC09300004
J	WANG, J; ZINDY, F; CHENIVESSE, X; LAMAS, E; HENGLEIN, B; BRECHOT, C				WANG, J; ZINDY, F; CHENIVESSE, X; LAMAS, E; HENGLEIN, B; BRECHOT, C			MODIFICATION OF CYCLIN-A EXPRESSION BY HEPATITIS-B VIRUS-DNA INTEGRATION IN A HEPATOCELLULAR-CARCINOMA	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; PROTEIN-KINASE; M-PHASE; SCHIZOSACCHAROMYCES-POMBE; TRANSGENIC MICE; G1 PHASE; CDC2	We have previously reported the identification of a hepatitis B virus (HBV) DNA integration in an intron of the cyclin A gene in an early hepatocellular carcinoma (HCC) and the isolation of human cyclin A cDNA. We have now constructed a cDNA library from the tumor and isolated several hybrid HBV-cyclin A cDNAs from it. The hybrid cDNAs encode an HBV-cyclin A fusion protein. In the chimeric protein, the N-terminus of cyclin A, including the signals for cyclin degradation, is deleted and replaced by viral PreS2/S sequences, transcription being initiated from the viral PreS2/S promoter. This chimeric protein is undegradable in an in vitro cyclin degradation assay. Northern blot analyses showed strong expression of the hybrid transcripts in the tumor, while cyclin A- or HBV-specific transcripts were not detected in the non-tumorous liver of the same patient. Thus, HBV DNA integration in the cyclin A gene resulted in a strong expression of hybrid HBV-cyclin A transcripts encoding a stabilized cyclin A. This chimeric protein may play an important role in the development of the tumor.	CHU NECKER ENFANTS MALAD, INSERM, U75, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE; INST PASTEUR, HYBRIDOTEST, F-75724 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GANEM D, 1990, NATURE, V347, P230, DOI 10.1038/347230b0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; INES J, 1991, CELL, V66, P1071; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORCA T, 1991, MOL CELL BIOL, V11, P1171, DOI 10.1128/MCB.11.2.1171; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SIMONSEN CC, 1983, MOL CELL BIOL, V3, P2250, DOI 10.1128/MCB.3.12.2250; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	46	138	145	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1653	1656						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321406				2022-12-17	WOS:A1992JE81300024
J	KACINSKI, BM; SCATA, KA; CARTER, D; YEE, LD; SAPI, E; KING, BL; CHAMBERS, SK; JONES, MA; PIRRO, MH; STANLEY, ER; ROHRSCHNEIDER, LR				KACINSKI, BM; SCATA, KA; CARTER, D; YEE, LD; SAPI, E; KING, BL; CHAMBERS, SK; JONES, MA; PIRRO, MH; STANLEY, ER; ROHRSCHNEIDER, LR			FMS (CSF-1 RECEPTOR) AND CSF-1 TRANSCRIPTS AND PROTEIN ARE EXPRESSED BY HUMAN BREAST CARCINOMAS INVIVO AND INVITRO	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; CHORIOCARCINOMA CELL-LINES; FACTOR-I RECEPTOR; GROWTH-FACTOR; MESSENGER-RNA; OVARIAN ADENOCARCINOMAS; PLACENTAL DEVELOPMENT; INSITU HYBRIDIZATION; GENE-EXPRESSION; MAMMARY-GLAND	The expression in vivo of FMS transcripts and antigen by neoplastic epithelial cells was demonstrated immunohistochemically or by in situ hybridization in sixteen of seventeen human breast carcinoma specimens and one case of sclerosing adenosis. Expression of CSF-1 receptor (FMS) transcripts and protein was also observed in vitro in two or three breast carcinoma-derived cell lines and was dramatically increased by dexamethasone, a potent glucocorticoid and inducer of mammary epithelial cell differentiation. Immunohistochemical staining with an anti-CSF-1 antibody identified neoplastic epithelial cell co-expression of fms and CSF-1 antigens in more than one-third of the fms-positive invasive carcinoma specimens. These results suggest that autocrine and paracrine interactions of the lymphohematopoietic cytokine CSF-1 and its receptor may participate in the biology of human mammary neoplasms.	YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,BRONX,NY 10461; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Yale University; Yale University; Yeshiva University; Albert Einstein College of Medicine; Fred Hutchinson Cancer Center	KACINSKI, BM (corresponding author), YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NCI NIH HHS [CA-26504, CA-47292, CA-08341] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA026504, R29CA047292, P01CA008341, R01CA047292, R01CA026504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BOLIVAR F, 1977, GENE, V26, P197; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DEDHAR S, 1988, P NATL ACAD SCI USA, V85, P9253, DOI 10.1073/pnas.85.23.9253; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DISORBO D, 1977, ANN NY ACAD SCI, V286, P355, DOI 10.1111/j.1749-6632.1977.tb29429.x; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; FELDMAN M, 1988, SCI AM           NOV, P60; GODARD CM, 1983, HISTOCHEMISTRY, V77, P123, DOI 10.1007/BF00496643; HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006-291X(88)80060-3; HORWITZ KB, 1978, CANCER RES, V38, P2434; HUHN RD, 1989, J CELL BIOCHEM, V39, P129, DOI 10.1002/jcb.240390205; KACINSKI B M, 1989, Cancer Bulletin (Houston), V41, P44; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1990, PROG LEUC B, V10, P393; KACINSKI BM, 1989, YALE J BIOL MED, V62, P379; KACINSKI BM, 1990, INT J RADIAT ONCOL, V19, P619, DOI 10.1016/0360-3016(90)90488-6; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1989, CANCER CEL, V7, P333; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KAMPS MP, 1988, ONCOGENE, V2, P305; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KASUKABE T, 1977, GANN, V68, P765; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; MANIATIS T, 1982, MOL CLONING LABORATO, P75; MCDIVITT RW, 1968, ATLAS TUMOR PATHOLOG; MELAMED MR, 1961, CANCER, V14, P699, DOI 10.1002/1097-0142(199007/08)14:4<699::AID-CNCR2820140404>3.0.CO;2-3; MUELLER R, MOL CELL BIOL, V3, P1062; PATTILLO RA, 1968, CANCER RES, V28, P1231; PETERS GN, 1981, ANN SURG, V193, P138, DOI 10.1097/00000658-198102000-00003; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; QUIRK SJ, 1990, J STEROID BIOCHEM, V35, P623, DOI 10.1016/0022-4731(90)90208-A; QUIRK SJ, 1989, MOL CELL ENDOCRINOL, V66, P135, DOI 10.1016/0303-7207(89)90025-7; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; RAMAKRISHNAN S, 1989, J CLIN INVEST, V83, P921, DOI 10.1172/JCI113977; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAITO M, 1989, AM J REPROD IMMUNOL, V19, P114, DOI 10.1111/j.1600-0897.1989.tb00558.x; SCHAISON G, 1989, ANN ENDOCRINOL-PARIS, V50, P200; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1986, CIBA F SYMP, V118, P29, DOI 10.1002/9780470720998.ch3; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANG RP, 1990, J CELL BIOCHEM, V44, P189, DOI 10.1002/jcb.240440307; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TAYLOR HB, 1967, CANCER, V20, P2245, DOI 10.1002/1097-0142(196712)20:12<2245::AID-CNCR2820201227>3.0.CO;2-0; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WALKER C, 1987, P NATL ACAD SCI USA, V84, P1804, DOI 10.1073/pnas.84.7.1804; WHITTAKER JL, 1986, INT J CANCER, V38, P651, DOI 10.1002/ijc.2910380506; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORD J, 1985, MOL CELL BIOL, V5, P458; [No title captured]	67	138	140	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					941	952						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829808				2022-12-17	WOS:A1991GU62200008
J	XU, HJ; HU, SX; HASHIMOTO, T; TAKAHASHI, R; BENEDICT, WF				XU, HJ; HU, SX; HASHIMOTO, T; TAKAHASHI, R; BENEDICT, WF			THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT - A CHARACTERISTIC PATTERN IN NORMAL-CELLS AND ABNORMAL EXPRESSION IN MALIGNANT-CELLS	ONCOGENE			English	Article									BAYLOR COLL MED, CTR BIOTECHNOL, 4000 RES FOREST DR, WOODLANDS, TX 77381 USA	Baylor College of Medicine					NEI NIH HHS [EYO6195, EYO2715] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002715] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOKOTA J, 1988, ONCOGENE, V3, P471	17	138	147	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					807	812						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2471953				2022-12-17	WOS:A1989AA66000019
J	Qian, MY; Wang, SB; Guo, XF; Wang, J; Zhang, ZP; Qiu, W; Gao, X; Chen, ZH; Xu, JY; Zhao, RR; Xue, H; Li, G				Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang			Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-kappa B pathways	ONCOGENE			English	Article							EXTRACELLULAR VESICLES; GENE-EXPRESSION; TUMOR-GROWTH; CANCER; CELLS; GLIOBLASTOMA; MICROVESICLES; MEDIATE	Exosomes are emerging as important elements that participate in intercellular communication and tumor microenvironment modulation, but the exact mechanisms by which tumor exosomes facilitate the generation of the immunosuppressive microenvironment remain unclear. Here we investigated the effects of glioma-derived exosomes (GDEs) on macrophage polarization and glioma progression. We also performed microRNA sequencing analysis of GDEs to identify the microRNA that mediated macrophage polarization. The microRNA-associated intracellular signaling pathway in macrophages was further investigated. Compared with normoxic glioma-derived exosomes (N-GDEs), hypoxic glioma-derived exosomes (H-GDEs) markedly induced M2 macrophage polarization, which subsequently promoted glioma proliferation, migration and invasion in vitro and in vivo. MicroRNA sequencing analysis identified miR-1246 as the most enriched microRNA in H-GDEs. Moreover, miR-1246 was enriched in the CSF of GBM patients and decreased after tumor resection. Further investigation determined that miR-1246 mediated H-GDE-induced M2 macrophage polarization by targeting TERF2IP to activate the STAT3 signaling pathway and inhibit the NF-kappa B signaling pathway. Our study elucidated a mechanism by which hypoxia and glioma influence M2 macrophage polarization via exosomes, which could facilitate the formation of the immunosuppressive microenvironment. Moreover, our results suggested that miR-1246 in the CSF of GBM patients may be a novel biomarker for GBM diagnosis and that treatment targeting microRNA-1246 may contribute to antitumor immunotherapy.	[Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China; [Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China; [Qian, Mingyu; Wang, Shaobo; Guo, Xiaofan; Wang, Jian; Zhang, Zongpu; Qiu, Wei; Gao, Xiao; Chen, Zihang; Xu, Jianye; Zhao, Rongrong; Xue, Hao; Li, Gang] Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China; [Wang, Jian] Univ Bergen, Dept Biomed, Brain Tumor Res Ctr, Bergen, Norway	Shandong University; Shandong University; University of Bergen	Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Key Lab Brain Funct Remodeling, Jinan, Shandong, Peoples R China.	xuehao@sdu.edu.cn; ligangqiluhospital@163.com	Xu, Jianye/AAO-5514-2020; Wang, Shaobo/AAI-4190-2020; Xue, Hao/GXV-4717-2022	Xu, Jianye/0000-0001-7241-6994; Wang, Shaobo/0000-0001-7759-1687; Li, Gang/0000-0003-3184-1032; Wang, Jian/0000-0002-9482-5227	National Natural Science Foundation of China [30872645, 81372719, 81172403, 81571284, 91542115, 81874083, 81702468]; Natural Science Foundation of Shandong Province of China [2017CXGC1203, 2013GGE27006, 2017G006012]; Taishan Scholars of Shandong Province of China [ts201511093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province); Taishan Scholars of Shandong Province of China	This work was supported by grants from the National Natural Science Foundation of China (grant No.30872645, 81372719, 81172403, 81571284, 91542115, 81874083, 81702468), Natural Science Foundation of Shandong Province of China (grant No.2017CXGC1203, 2013GGE27006, 2017G006012) and the Taishan Scholars of Shandong Province of China (grant No. ts201511093).	Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Bott A, 2017, ONCOTARGET, V8, P43897, DOI 10.18632/oncotarget.14915; Brat DJ, 2003, ANN INTERN MED, V138, P659, DOI 10.7326/0003-4819-138-8-200304150-00014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai Y, 2015, CELL CYCLE, V14, P3580, DOI 10.1080/15384101.2015.1100771; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Colwell N, 2017, NEURO-ONCOLOGY, V19, P887, DOI 10.1093/neuonc/now258; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; De Beule N, 2017, J PATHOL, V241, P534, DOI 10.1002/path.4860; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Gabrusiewicz K, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412909; Giurisato E, 2018, P NATL ACAD SCI USA, V115, pE2801, DOI 10.1073/pnas.1707929115; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; Guo XF, 2016, ONCOTARGET, V7, P80521, DOI 10.18632/oncotarget.11825; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lee JH, 2018, NATURE, V560, P243, DOI 10.1038/s41586-018-0389-3; Li H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01175; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087; Qi L, 2016, ONCOTARGET, V7, P71673, DOI 10.18632/oncotarget.12317; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Sakha S, 2016, SCI REP-UK, V6, DOI 10.1038/srep38750; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Whiteside TL, 2013, BIOCHEM SOC T, V41, P245, DOI 10.1042/BST20120265; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489	42	137	146	16	118	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					428	442		10.1038/s41388-019-0996-y	http://dx.doi.org/10.1038/s41388-019-0996-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31485019				2022-12-17	WOS:000507766400013
J	Cai, H; Liu, XB; Zheng, J; Xue, YX; Ma, J; Li, Z; Xi, Z; Li, ZQ; Bao, M; Liu, YH				Cai, Heng; Liu, Xiaobai; Zheng, Jian; Xue, Yixue; Ma, Jun; Li, Zhen; Xi, Zhuo; Li, Zhiqing; Bao, Min; Liu, Yunhui			Long non-coding RNA taurine upregulated 1 enhances tumor-induced angiogenesis through inhibiting microRNA-299 in human glioblastoma	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; GLIOMA-CELLS; EXPRESSION; CANCER; TUG1; GROWTH; PROLIFERATION; APOPTOSIS; DIFFERENTIATION; PROMOTE	Angiogenesis is one of the critical biological elements affecting the development and progression of cancer. Long non-coding RNAs (lncRNAs) are important regulators and aberrantly expressed in various types of human cancer. Our previous studies indicated that lncRNA taurine upregulated 1 (TUG1) implicated in the regulation of blood-tumor barrier permeability; however, its role in glioblastoma angiogenesis still unclear. Here we demonstrated that TUG1 was up-expressed in human glioblastoma tissues and glioblastoma cell lines. Knockdown of TUG1 remarkably suppressed tumor-induced endothelial cell proliferation, migration and tube formation as well as reducing spheroid-based angiogenesis ability in vitro, which are the critical steps for tumor angiogenesis. Besides, knockdown of TUG1 significantly increased the expression of mircroRNA-299 (miR-299), which was down-expressed in glioblastoma tissues and glioblastoma cell lines. Bioinformatics analysis and luciferase reporter assay revealed that TUG1 influenced tumor angiogenesis via directly binding to the miR-299 and there was a reciprocal repression between TUG1 and miR-299 in the same RNA-induced silencing complex. Moreover, knockdown of TUG1 reduced the expression of vascular endothelial growth factor A (VEGFA), which was defined as a functional downstream target of miR-299. In addition, knockdown of TUG1, shown in the in vivo studies, has effects on suppressing tumor growth, reducing tumor microvessel density and decreasing the VEGFA expression by upregulating miR-299 in xenograft glioblastoma model. Overall, the results demonstrated that TUG1 enhances tumor-induced angiogenesis and VEGF expression through inhibiting miR-299. Also, the inhibition of TUG1 could provide a novel therapeutic target for glioblastoma treatment.	[Cai, Heng; Liu, Xiaobai; Zheng, Jian; Xi, Zhuo; Li, Zhiqing; Bao, Min; Liu, Yunhui] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110004, Peoples R China; [Xue, Yixue; Ma, Jun; Li, Zhen] China Med Univ, Dept Neurobiol, Coll Basic Med, Shenyang, Peoples R China	China Medical University; China Medical University	Liu, YH (corresponding author), China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110004, Peoples R China.	sj_neurosurgery@126.com			Natural Science Foundation of China [81172197, 81272564, 81272795, 81372484, 81573010]; Shenyang Science and Technology Plan Projects [F15-199-1-30, F15-199-1-57]; outstanding scientific fund of Shengjing hospital [201304]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenyang Science and Technology Plan Projects; outstanding scientific fund of Shengjing hospital	This work is supported by grants from the Natural Science Foundation of China (81172197, 81272564, 81272795, 81372484 and 81573010) and Shenyang Science and Technology Plan Projects (nos F15-199-1-30 and F15-199-1-57), and outstanding scientific fund of Shengjing hospital (no. 201304).	Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Bai RY, 2011, TRENDS MOL MED, V17, P301, DOI 10.1016/j.molmed.2011.01.011; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Cai H, 2015, ONCOTARGET, V6, P19759, DOI 10.18632/oncotarget.4331; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chi AS, 2009, ONCOLOGIST, V14, P621, DOI 10.1634/theoncologist.2008-0272; Dunn IF, 2000, J NEURO-ONCOL, V50, P121, DOI 10.1023/A:1006436624862; Ezhilarasan R, 2007, INT J ONCOL, V30, P701; Folkerth RD, 2000, J NEURO-ONCOL, V50, P165, DOI 10.1023/A:1006499824379; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Formosa A, 2014, ONCOGENE, V33, P5173, DOI 10.1038/onc.2013.451; Gaiser T, 2009, NEUROCHEM INT, V54, P458, DOI 10.1016/j.neuint.2009.01.016; Han XR, 2015, FASEB J, V29, P3054, DOI 10.1096/fj.14-259952; Han YH, 2013, J SURG ONCOL, V107, P555, DOI 10.1002/jso.23264; Isin M, 2014, CLIN CHIM ACTA, V431, P255, DOI 10.1016/j.cca.2014.02.010; Jafarifar F, 2011, EMBO J, V30, P1324, DOI 10.1038/emboj.2011.38; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Jiang XC, 2016, J NEUROSURG, V124, P129, DOI [10.3171/2014.12.JNS1426.test, 10.3171/2014.12.JNS1426]; Jiao F, 2015, INT J MOL SCI, V16, P6677, DOI 10.3390/ijms16046677; Jouanneau E, 2008, NEUROSURGERY, V62, P31, DOI 10.1227/01.NEU.0000311060.65002.4E; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Ke J, 2015, ONCOTARGET, V6, P21934, DOI 10.18632/oncotarget.4290; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kobayashi H, 2016, BBA-GENE REGUL MECH, V1859, P71, DOI 10.1016/j.bbagrm.2015.08.007; Leon SP, 1996, CANCER-AM CANCER SOC, V77, P362, DOI 10.1002/(SICI)1097-0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z; Liu Q, 2015, J NEURO-ONCOL, V122, P283, DOI 10.1007/s11060-015-1718-0; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Rapicavoli NA, 2009, DEV DYNAM, V238, P2103, DOI 10.1002/dvdy.21844; Saharinen P, 2011, TRENDS MOL MED, V17, P347, DOI 10.1016/j.molmed.2011.01.015; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shevde LA, 2010, J CELL MOL MED, V14, P1693, DOI 10.1111/j.1582-4934.2009.00821.x; Shi ZM, 2014, NEURO-ONCOLOGY, V16, P1341, DOI 10.1093/neuonc/nou084; Tate MC, 2009, NEUROTHERAPEUTICS, V6, P447, DOI 10.1016/j.nurt.2009.04.001; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wang L, 2014, ONCOTARGET, V5, P5416, DOI 10.18632/oncotarget.2116; Wang P, 2015, CELL SIGNAL, V27, P275, DOI 10.1016/j.cellsig.2014.11.011; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Xu YT, 2015, TUMOR BIOL, V36, P1643, DOI 10.1007/s13277-014-2763-6; Yoon JH, 2014, SEMIN CELL DEV BIOL, V34, P9, DOI 10.1016/j.semcdb.2014.05.015; Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027; Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201; Zhang Q, 2013, ASIAN PAC J CANCER P, V14, P2311, DOI 10.7314/APJCP.2013.14.4.2311; Zhang Z, 2013, CELL DEATH DIFFER, V20, P1558, DOI 10.1038/cdd.2013.110; Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008	54	137	143	3	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					318	331		10.1038/onc.2016.212	http://dx.doi.org/10.1038/onc.2016.212			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345398				2022-12-17	WOS:000394166000003
J	Li, J; Gu, D; Lee, SSY; Song, B; Bandyopadhyay, S; Chen, S; Konieczny, SF; Ratliff, TL; Liu, X; Xie, J; Cheng, JX				Li, J.; Gu, D.; Lee, S. S-Y; Song, B.; Bandyopadhyay, S.; Chen, S.; Konieczny, S. F.; Ratliff, T. L.; Liu, X.; Xie, J.; Cheng, J-X			Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer	ONCOGENE			English	Article							ACYL-COENZYME; TUMOR PROGRESSION; INHIBITION; CAVEOLIN-1; MIGRATION; PATHWAY; CELLS; ACYLTRANSFERASE; ACCUMULATION; METABOLISM	Cancer cells are known to execute reprogramed metabolism of glucose, amino acids and lipids. Here, we report a significant role of cholesterol metabolism in cancer metastasis. By using label-free Raman spectromicroscopy, we found an aberrant accumulation of cholesteryl ester in human pancreatic cancer specimens and cell lines, mediated by acyl-CoA cholesterol acyltransferase-1 (ACAT-1) enzyme. Expression of ACAT-1 showed a correlation with poor patient survival. Abrogation of cholesterol esterification, either by an ACAT-1 inhibitor or by shRNA knockdown, significantly suppressed tumor growth and metastasis in an orthotopic mouse model of pancreatic cancer. Mechanically, ACAT-1 inhibition increased intracellular free cholesterol level, which was associated with elevated endoplasmic reticulum stress and caused apoptosis. Collectively, our results demonstrate a new strategy for treating metastatic pancreatic cancer by inhibiting cholesterol esterification.	[Li, J.; Lee, S. S-Y; Song, B.; Cheng, J-X] Purdue Univ, Weldon Sch Biomed Engn, 206 S Martin Jischke Dr, W Lafayette, IN 47907 USA; [Gu, D.; Xie, J.] Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, IU Simon Canc Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA; [Bandyopadhyay, S.; Konieczny, S. F.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; [Chen, S.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Konieczny, S. F.; Ratliff, T. L.; Liu, X.; Cheng, J-X] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA; [Ratliff, T. L.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Liu, X.] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University Bloomington; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University Bloomington; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cheng, JX (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, 206 S Martin Jischke Dr, W Lafayette, IN 47907 USA.; Xie, J (corresponding author), Indiana Univ Sch Med, Dept Pediat, Wells Ctr Pediat Res, IU Simon Canc Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.	jinxie@iupui.edu; jcheng@purdue.edu	Liu, Bingya/GMW-5655-2022; Li, Junjie/B-1424-2017; Xie, J/AAR-7259-2020	Li, Junjie/0000-0003-4542-300X; Bandyopadhyay, Shovik/0000-0003-3919-3914	Indiana State CTSI grant [106564]; NIH [CA182608, CA124586, CA155086, P30CA023168]; NCI [R25CA128770]; NATIONAL CANCER INSTITUTE [R25CA128770, R21CA182608, R01CA196835, R01CA124586, P30CA023168, R01CA155086] Funding Source: NIH RePORTER	Indiana State CTSI grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We greatly appreciate the help from Dr Tian Shao, Dr Zhiguo Li for their technical support. This work was supported by Indiana State CTSI grant 106564 to JX and JXC, NIH CA182608 to JXC, NCI R25CA128770 CPIP fellowship to JL, NIH CA124586 to SFK, and CA155086 to JX, and NIH grant P30CA023168 to Purdue University Center for Cancer Research for publications.	Antalis CJ, 2010, BREAST CANCER RES TR, V122, P661, DOI 10.1007/s10549-009-0594-8; Bemlih S, 2010, CANCER BIOL THER, V9, P1025, DOI 10.4161/cbt.9.12.11875; Bonovas S, 2008, AM J GASTROENTEROL, V103, P2646, DOI 10.1111/j.1572-0241.2008.02051.x; Campbell L, 2008, BRIT J CANCER, V98, P931, DOI 10.1038/sj.bjc.6604243; Cao S, 2005, J BIOL CHEM, V280, P1901, DOI 10.1074/jbc.M407941200; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; Gu DS, 2013, MOL CANCER THER, V12, P1038, DOI 10.1158/1535-7163.MCT-12-1030; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Jakobisiak M, 2003, INT J ONCOL, V23, P1055; KRITCHEVSKY SB, 1992, ANNU REV NUTR, V12, P391, DOI 10.1146/annurev.nu.12.070192.002135; Lee SSY, 2015, ACS NANO, V9, P2420, DOI 10.1021/nn504025a; Li JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06807; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Liu L., 2014, INT J PHOTOENERGY, V2014, P1, DOI DOI 10.1371/J0URNAL.P0NE.0094160; Llaverias G, 2003, CARDIOVASC DRUG REV, V21, P33; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; Movasaghi Z, 2007, APPL SPECTROSC REV, V42, P493, DOI 10.1080/05704920701551530; Mulas MF, 2011, CELL PROLIFERAT, V44, P360, DOI 10.1111/j.1365-2184.2011.00758.x; Murai Toshiyuki, 2012, Int J Cell Biol, V2012, P763283, DOI 10.1155/2012/763283; Murai T, 2011, J BIOL CHEM, V286, P1999, DOI 10.1074/jbc.M110.184010; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Ramprasad OG, 2007, CELL MOTIL CYTOSKEL, V64, P199, DOI 10.1002/cm.20176; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Sounni NE, 2014, CELL METAB, V20, P280, DOI 10.1016/j.cmet.2014.05.022; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Tanase CP, 2009, J MOL HISTOL, V40, P23, DOI 10.1007/s10735-008-9209-7; Thysell E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014175; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	43	137	145	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6378	6388		10.1038/onc.2016.168	http://dx.doi.org/10.1038/onc.2016.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27132508	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000390247600003
J	Poirier, JT; Gardner, EE; Connis, N; Moreira, AL; de Stanchina, E; Hann, CL; Rudin, CM				Poirier, J. T.; Gardner, E. E.; Connis, N.; Moreira, A. L.; de Stanchina, E.; Hann, C. L.; Rudin, C. M.			DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2	ONCOGENE			English	Article							GENE; INACTIVATION; LANDSCAPE; CARCINOMA; MODEL; LINES	Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis, rapid development of resistance to chemotherapy and genetic instability. This study profiles DNA methylation in SCLC, patient-derived xenografts (PDX) and cell lines at single-nucleotide resolution. DNA methylation patterns of primary samples are distinct from those of cell lines, whereas PDX maintain a pattern closely consistent with primary samples. Clustering of DNA methylation and gene expression of primary SCLC revealed distinct disease subtypes among histologically indistinguishable primary patient samples with similar genetic alterations. SCLC is notable for dense clustering of high-level methylation in discrete promoter CpG islands, in a pattern clearly distinct from other lung cancers and strongly correlated with high expression of the E2F target and histone methyltransferase gene EZH2. Pharmacologic inhibition of EZH2 in a SCLC PDX markedly inhibited tumor growth.	[Poirier, J. T.; Gardner, E. E.; Rudin, C. M.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Gardner, E. E.] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD USA; [Connis, N.; Hann, C. L.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA; [Moreira, A. L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [de Stanchina, E.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Rudin, CM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 300 E 66th St,Room 1203, New York, NY 10065 USA.	rudinc@mskcc.org	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; Connis, Nick/0000-0001-5725-0674; Poirier, John/0000-0001-9795-5644; Gardner, Eric/0000-0002-1552-2675	 [SU2C];  [P30 CA008748]; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Inna Kodos in the Sloan Kettering Antitumor Assessment Core for her technical expertise. We are grateful to all members of the Rudin and Hann labs for thoughtful discussions. SU2C, P30 CA008748 gave financial support.	Bady P, 2012, ACTA NEUROPATHOL, V124, P547, DOI 10.1007/s00401-012-1016-2; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; CARNEY DN, 1985, CANCER RES, V45, P2913; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Daniel VC, 2009, CANCER RES, V69, P3364, DOI 10.1158/0008-5472.CAN-08-4210; Gardner EE, 2014, CANCER RES, V74, P2846, DOI 10.1158/0008-5472.CAN-13-3460; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hann CL, 2007, TRENDS MOL MED, V13, P150, DOI 10.1016/j.molmed.2007.02.003; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kalari S, 2013, ONCOGENE, V32, P3559, DOI 10.1038/onc.2012.362; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lara PN, 2009, J CLIN ONCOL, V27, P2530, DOI 10.1200/JCO.2008.20.1061; Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108; MADRIGAL PA, 1982, CANCER CHEMOTH PHARM, V7, P203; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Oze I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007835; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Poirier JT, 2013, JNCI-J NATL CANCER I, V105, P1059, DOI 10.1093/jnci/djt130; Rauch T, 2005, LAB INVEST, V85, P1172, DOI 10.1038/labinvest.3700311; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wee ZN, 2014, CELL REP, V8, P204, DOI 10.1016/j.celrep.2014.05.045; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Wilkerson MD, 2010, CLIN CANCER RES, V16, P4864, DOI 10.1158/1078-0432.CCR-10-0199; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433; Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504	38	137	139	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5869	5878		10.1038/onc.2015.38	http://dx.doi.org/10.1038/onc.2015.38			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25746006	Green Accepted			2022-12-17	WOS:000365434000002
J	Lengyel, E; Burdette, JE; Kenny, HA; Matei, D; Pilrose, J; Haluska, P; Nephew, KP; Hales, DB; Stack, MS				Lengyel, E.; Burdette, J. E.; Kenny, H. A.; Matei, D.; Pilrose, J.; Haluska, P.; Nephew, K. P.; Hales, D. B.; Stack, M. S.			Epithelial ovarian cancer experimental models	ONCOGENE			English	Review						ovarian cancer; mouse model; cell lines; hen; organotypic models; metastasis	TYPE-1 MATRIX-METALLOPROTEINASE; GENE-EXPRESSION PATTERNS; IN-VITRO MODEL; MOUSE-MODEL; FALLOPIAN-TUBE; CELL-LINES; CARCINOMA CELLS; MESOTHELIAL CELLS; EXTRACELLULAR-MATRIX; MICROENVIRONMENTAL REGULATION	Epithelial ovarian cancer (OvCa) is associated with high mortality and, as the majority (> 75%) of women with OvCa have metastatic disease at the time of diagnosis, rates of survival have not changed appreciably over 30 years. A mechanistic understanding of OvCa initiation and progression is hindered by the complexity of genetic and/or environmental initiating events and lack of clarity regarding the cell(s) or tissue(s) of origin. Metastasis of OvCa involves direct extension or exfoliation of cells and cellular aggregates into the peritoneal cavity, survival of matrix-detached cells in a complex ascites fluid phase and subsequent adhesion to the mesothelium lining covering abdominal organs to establish secondary lesions containing host stromal and inflammatory components. Development of experimental models to recapitulate this unique mechanism of metastasis presents a remarkable scientific challenge, and many approaches used to study other solid tumors (for example, lung, colon and breast) are not transferable to OvCa research given the distinct metastasis pattern and unique tumor microenvironment (TME). This review will discuss recent progress in the development and refinement of experimental models to study OvCa. Novel cellular, three-dimensional organotypic, and ex vivo models are considered and the current in vivo models summarized. The review critically evaluates currently available genetic mouse models of OvCa, the emergence of xenopatients and the utility of the hen model to study OvCa prevention, tumorigenesis, metastasis and chemoresistance. As these new approaches more accurately recapitulate the complex TME, it is predicted that new opportunities for enhanced understanding of disease progression, metastasis and therapeutic response will emerge.	[Lengyel, E.; Kenny, H. A.] Univ Chicago, Dept Obstet & Gynecol, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Burdette, J. E.] Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA; [Matei, D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Pilrose, J.; Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Bloomington, IN USA; [Haluska, P.] Mayo Clin, Div Med Oncol, Rochester, MN USA; [Hales, D. B.] So Illinois Univ, Dept Physiol, Carbondale, IL 62901 USA; [Stack, M. S.] Univ Notre Dame, Dept Chem & Biochem, Harper Canc Res Inst, South Bend, IN USA	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Mayo Clinic; Southern Illinois University System; Southern Illinois University; University of Notre Dame	Lengyel, E (corresponding author), Univ Chicago, Dept Obstet & Gynecol, 5841 South Maryland Ave,MC 2050, Chicago, IL 60637 USA.	elengyel@uchicago.edu; sstack@nd.edu	Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507; Matei, Daniela/0000-0003-2169-5035; Haluska, Paul/0000-0003-3283-4512	National Institutes of Health/National Cancer Institute Research [CA086984, CA109545, CA085289]; Integrative Cancer Biology Program [CA1113001]; Ovarian Cancer Research Fund (PPD/IU); NIH/National Center for Complementary and Alternative Medicine [AT00408, AT005295]; National Cancer Institute Award [CA133915]; American Institute for Cancer Research [06-A043]; Ovarian Cancer Research Fund (PPD/UofC) [NIH/NCI CA111882]; Ovarian Cancer Research Fund Liz Tilberis Ovarian Cancer Scholar Award (L/T UIC); American Cancer Society Illinois Division Research [RSG-12-230-01-TBG]; Department of Defense [OC110133]; Mayo Clinic SPORE in Ovarian Cancer [CA136393]; NATIONAL CANCER INSTITUTE [P50CA136393, R03CA133915, R01CA109545, R01CA111882, R01CA085289, R01CA169604, R01CA086984] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT005295] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute Research; Integrative Cancer Biology Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund (PPD/IU); NIH/National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Cancer Institute Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Institute for Cancer Research; Ovarian Cancer Research Fund (PPD/UofC); Ovarian Cancer Research Fund Liz Tilberis Ovarian Cancer Scholar Award (L/T UIC); American Cancer Society Illinois Division Research; Department of Defense(United States Department of Defense); Mayo Clinic SPORE in Ovarian Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The impetus for this collaborative compendium arose from the inaugural workshop of the Indiana-Illinois End Epithelial Ovarian Cancer Coalition (IIEEOC) held at the University of Notre Dame in 2012. The IIEEOCC Workshop was supported by the Harper Cancer Research Institute, the University of Notre Dame, the Indiana University Simon Cancer Center and the Indiana Clinical and Translational Sciences Institute. We gratefully acknowledge the lively and informative discussion contributed by all workshop participants. Funding for our work was provided by National Institutes of Health/National Cancer Institute Research Grants, CA086984 (MSS), CA109545 (MSS); CA085289 (KN), CA085289 (KN), the Integrative Cancer Biology Program CA1113001 (KN) and an Ovarian Cancer Research Fund (PPD/IU) to KN and DM; NIH/National Center for Complementary and Alternative Medicine grants AT00408 and AT005295 (BH); National Cancer Institute Award CA133915 (BH); American Institute for Cancer Research 06-A043 (BH); NIH/NCI CA111882 (EL) and an Ovarian Cancer Research Fund (PPD/UofC) to EL. JB was supported by the Ovarian Cancer Research Fund Liz Tilberis Ovarian Cancer Scholar Award (L/T UIC), the American Cancer Society Illinois Division Research Grant RSG-12-230-01-TBG and the Department of Defense OC110133. PH was supported by the Mayo Clinic SPORE in Ovarian Cancer-CA136393.	ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Alfonso M, 2005, AVIAN DIS, V49, P430, DOI 10.1637/0005-2086(2005)49[430:MAITLO]2.0.CO;2; ALLEN HJ, 1987, EXP CELL BIOL, V55, P194; Ando H, 2000, HUM REPROD, V15, P1597, DOI 10.1093/humrep/15.7.1597; ANDREWS PA, 1985, CANCER RES, V45, P6250; Ansenberger K, 2010, GYNECOL ONCOL, V117, P341, DOI 10.1016/j.ygyno.2010.01.021; Ansenberger K, 2009, GYNECOL ONCOL, V113, P362, DOI 10.1016/j.ygyno.2009.02.011; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Awadhiya R P, 1967, Indian Vet J, V44, P917; Bai F, 2006, INT J GYNECOL CANCER, V16, P202, DOI 10.1111/j.1525-1438.2006.00296.x; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barbolina MV, 2007, J BIOL CHEM, V282, P4924, DOI 10.1074/jbc.M608428200; Barbolina MV, 2009, CANCER TREAT RES, V149, P319, DOI 10.1007/978-0-387-98094-2_15; Barker SD, 2001, GYNECOL ONCOL, V82, P57, DOI 10.1006/gyno.2001.6226; Barnes MN, 2002, GYNECOL ONCOL, V87, P57, DOI 10.1006/gyno.2002.6806; Barry CP, 2013, CANC PREV RES, V2, P114; Barua A, 2006, AACR INT C 2006; Barua A, 2010, J ULTRAS MED, V29, P173, DOI 10.7863/jum.2010.29.2.173; Barua A, 2009, INT J GYNECOL CANCER, V19, P500, DOI 10.1111/IGC.0b013e3181a39db1; Barua A, 2009, INT J GYNECOL CANCER, V19, P531, DOI 10.1111/IGC.0b013e3181a41613; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bijron JG, 2012, AACR ANN M; Bosquet JG, 2011, GYNECOL ONCOL, V120, P256, DOI 10.1016/j.ygyno.2010.10.030; BUICK RN, 1985, CANCER RES, V45, P3668; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Burleson KM, 2004, GYNECOL ONCOL, V93, P170, DOI 10.1016/j.ygyno.2003.12.034; Burnside J, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-13; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Carver DK, 2011, CANCER PREV RES, V4, P562, DOI 10.1158/1940-6207.CAPR-10-0294; CASAGRANDE JT, 1979, LANCET, V2, P170; Casey RC, 2003, CLIN EXP METASTAS, V20, P343, DOI 10.1023/A:1024009131191; Cheng LH, 2010, GYNECOL ONCOL, V117, P159, DOI 10.1016/j.ygyno.2010.01.041; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chodankar R, 2005, CURR BIOL, V15, P561, DOI 10.1016/j.cub.2005.01.052; Clark-Knowles KV, 2007, EXP CELL RES, V313, P133, DOI 10.1016/j.yexcr.2006.09.026; Clauss A, 2010, NEOPLASIA, V12, P161, DOI 10.1593/neo.91542; Connolly DC, 2003, CANCER RES, V63, P1389; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Drew AF, 2004, GYNECOL ONCOL, V95, P437, DOI 10.1016/j.ygyno.2004.08.032; Duan ZF, 1999, GENE, V229, P75, DOI 10.1016/S0378-1119(99)00042-6; Dunfield Lesley D., 2002, Biol Proced Online, V4, P55; Eilati E, 2012, PROSTAG LEUKOTR ESS, V87, P177, DOI 10.1016/j.plefa.2012.09.003; Elkas JC, 2002, GYNECOL ONCOL, V87, P200, DOI 10.1006/gyno.2002.6819; Evans CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023434; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; FREDRICKSON TN, 1987, ENVIRON HEALTH PERSP, V73, P35, DOI 10.2307/3430596; FREEDMAN RS, 1978, CANCER, V42, P2352, DOI 10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#; FU XY, 1993, ANTICANCER RES, V13, P283; Garson K, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-39; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gilead Assaf, 1999, Neoplasia (New York), V1, P226, DOI 10.1038/sj.neo.7900032; Giles JR, 2006, EXP BIOL MED, V231, P1718, DOI 10.1177/153537020623101108; Giles JR, 2010, INT J GYNECOL CANCER, V20, P738, DOI 10.1111/IGC.0b013e3181da2c49; Giles JR, 2004, GYNECOL ONCOL, V95, P530, DOI 10.1016/j.ygyno.2004.07.061; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GORAI I, 1995, GYNECOL ONCOL, V57, P33, DOI 10.1006/gyno.1995.1097; GREEN JA, 1984, CANCER RES, V44, P5427; Greenaway J, 2008, GYNECOL ONCOL, V108, P385, DOI 10.1016/j.ygyno.2007.10.035; Hales DB, 2008, ENDOCRINE, V33, P235, DOI 10.1007/s12020-008-9080-z; Hoekstra A, 2009, CANCER TREAT RES, V149, P3, DOI 10.1007/978-0-387-98094-2_1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Hu LM, 2005, CLIN CANCER RES, V11, P6966, DOI 10.1158/1078-0432.CCR-05-0910; Hu LM, 2002, CANCER RES, V62, P1087; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Iwanicki M, 2011, CANCER DISCOV, V2, pOF1, DOI Cancer Discov; Jackson E, 2007, GYNECOL ONCOL, V104, P192, DOI 10.1016/j.ygyno.2006.07.024; Jackson KS, 2009, ENDOCRINOLOGY, V150, P3921, DOI 10.1210/en.2008-1674; Johnson PA, 2013, NAT REV CANCER, V13, P432, DOI 10.1038/nrc3535; JOHNSON SW, 1994, CANCER RES, V54, P5911; JONES LMH, 1995, CLIN EXP METASTAS, V13, P373; KARLAN BY, 1994, GYNECOL ONCOL, V53, P70; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Kaur S, 2009, AM J PATHOL, V175, P2184, DOI 10.2353/ajpath.2009.090028; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Kenny HA, 2011, CANCER DISCOV, V1, P100, DOI 10.1158/2159-8290.CD-11-0117; Khabele D, 2012, INT J CLIN EXP PATHO, V5, P37; Khan SM, 2012, CLIN EXP METASTAS, V27, P185; Kim J, 2013, AACR ANN M 2013; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; King SM, 2011, JOVE-J VIS EXP, DOI 10.3791/2804; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309; KISHIKAWA T, 1995, INVAS METAST, V15, P11; Klein OJ, 2012, MOL PHARMACEUT, V9, P3171, DOI 10.1021/mp300262x; Ko SY, 2012, J CLIN INVEST, V122, P3603, DOI 10.1172/JCI62229; Kong BW, 2008, ANIM GENET, V39, P180, DOI 10.1111/j.1365-2052.2008.01702.x; Korch C, 2012, GYNECOL ONCOL, V127, P241, DOI 10.1016/j.ygyno.2012.06.017; KRUK PA, 1990, LAB INVEST, V63, P132; Kuo KT, 2009, AM J PATHOL, V174, P1597, DOI 10.2353/ajpath.2009.081000; Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; LAU DHM, 1991, CANCER RES, V51, P5181; Laviolette LA, 2010, ENDOCRINOLOGY, V151, P929, DOI 10.1210/en.2009-0602; Lee CH, 2005, GYNECOL ONCOL, V96, P48, DOI 10.1016/j.ygyno.2004.09.025; Lessan K, 1999, AM J PATHOL, V154, P1525, DOI 10.1016/S0002-9440(10)65406-5; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Li QH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019428; Li XY, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-60; Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228; Lorenzi PL, 2009, MOL CANCER THER, V8, P713, DOI 10.1158/1535-7163.MCT-08-0921; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; MIYAJIMA Y, 1995, ANN OTO RHINOL LARYN, V104, P678, DOI 10.1177/000348949510400902; Miyoshi I, 2002, MOL REPROD DEV, V63, P168, DOI 10.1002/mrd.10175; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; Mullany LK, 2011, ONCOGENE, V30, P3522, DOI 10.1038/onc.2011.70; Mullen P, 1996, INT J CANCER, V67, P816, DOI 10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#; Nature, 2004, FOC CHICK GEN 2004; NCBI, 2013, GALL GALL CHICK GEN; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; NIEDBALA MJ, 1985, EXP CELL RES, V160, P499, DOI 10.1016/0014-4827(85)90197-1; NIEDBALA MJ, 1987, CLIN EXP METASTAS, V5, P181, DOI 10.1007/BF00058063; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; PAPASOLOMONTOS PA, 1969, VET REC, V85, P459, DOI 10.1136/vr.84.17.459; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Pommier Y, 2013, CELLMINER 2013; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Quinn BA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008404; Rieppi M, 1999, INT J CANCER, V80, P303, DOI 10.1002/(SICI)1097-0215(19990118)80:2<303::AID-IJC21>3.3.CO;2-N; Roberts PC, 2005, NEOPLASIA, V7, P944, DOI 10.1593/neo.05358; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rodriguez-Burford C, 2001, GYNECOL ONCOL, V81, P373, DOI 10.1006/gyno.2001.6191; Romero IL, 2009, CANCER PREV RES, V2, P792, DOI 10.1158/1940-6207.CAPR-08-0236; RUNNEBAUM IB, 1994, FEBS LETT, V353, P29, DOI 10.1016/0014-5793(94)00953-8; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; SAWADA M, 1994, LAB INVEST, V70, P333; SELBY PJ, 1980, BRIT J CANCER, V41, P52, DOI 10.1038/bjc.1980.7; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328; SIMON WE, 1983, J NATL CANCER I, V70, P839; Stakleff KDS, 2005, INT J GYNECOL CANCER, V15, P246; Stewart C Allison, 2012, Results Probl Cell Differ, V55, P247, DOI 10.1007/978-3-642-30406-4_14; Suzuki N, 2004, GYNECOL ONCOL, V95, P290, DOI 10.1016/j.ygyno.2004.06.024; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Szabova L, 2012, CANCER RES, V72, P4141, DOI 10.1158/0008-5472.CAN-11-3834; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Trevino LS, 2012, CANCER PREV RES, V5, P343, DOI 10.1158/1940-6207.CAPR-11-0344; Trevino Lindsey S., 2010, Hormones & Cancer, V1, P177, DOI 10.1007/s12672-010-0024-8; Tseng CL, 2013, J BIOMATER APPL, V27, P1055, DOI 10.1177/0885328211434089; Urick ME, 2009, GYNECOL ONCOL, V112, P166, DOI 10.1016/j.ygyno.2008.09.032; VANDENBERGBAKKER CAM, 1993, INT J CANCER, V53, P613, DOI 10.1002/ijc.2910530415; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Weroha SJ, 2013, ANN ONCOL, V24, P16; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson AP, 1996, BRIT J CANCER, V74, P722, DOI 10.1038/bjc.1996.428; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Wu R, 2013, AM J PATHOL, V182, P1391, DOI 10.1016/j.ajpath.2012.12.031; Xing DY, 2006, CANCER RES, V66, P8949, DOI 10.1158/0008-5472.CAN-06-1495; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Xu Y, 1999, GYNECOL ONCOL, V72, P161, DOI 10.1006/gyno.1998.5238; Yip KW, 2006, MOL CANCER THER, V5, P2234, DOI 10.1158/1535-7163.MCT-06-0134; Yu D, 1992, CANCER RES, V53, P891; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zietarska M, 2007, MOL CARCINOGEN, V46, P872, DOI 10.1002/mc.20315	163	137	141	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3619	3633		10.1038/onc.2013.321	http://dx.doi.org/10.1038/onc.2013.321			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23934194	Green Accepted, Green Submitted			2022-12-17	WOS:000338942900001
J	Muller, P; Ruckova, E; Halada, P; Coates, PJ; Hrstka, R; Lane, DP; Vojtesek, B				Muller, P.; Ruckova, E.; Halada, P.; Coates, P. J.; Hrstka, R.; Lane, D. P.; Vojtesek, B.			C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances	ONCOGENE			English	Article						Hsp70; Hsp90; CHIP; HOP; chaperone; folding	HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONES; UBIQUITIN LIGASE; DEGRADATION; COMPLEXES; PATHWAYS; RESIDUES; PEPTIDE; DOMAIN; SITES	Heat shock proteins Hsp90 and Hsp70 facilitate protein folding but can also direct proteins for ubiquitin-mediated degradation. The mechanisms regulating these opposite activities involve Hsp binding to co-chaperones including CHIP and HOP at their C-termini. We demonstrated that the extreme C-termini of Hsp70 and Hsp90 contain phosphorylation sites targeted by kinases including CK1, CK2 and GSK3-beta in vitro. The phosphorylation of Hsp90 and Hsp70 prevents binding to CHIP and thus enhances binding to HOP. Highly proliferative cells contain phosphorylated chaperones in complex with HOP and phospho-mimetic and non-phosphorylable Hsp mutant proteins show that phosphorylation is directly associated with increased proliferation rate. We also demonstrate that primary human cancers contain high levels of phosphorylated chaperones and show increased levels of HOP protein and mRNA. These data identify C-terminal phosphorylation of Hsp70 and Hsp90 as a switch for regulating co-chaperone binding and indicate that cancer cells possess an elevated protein folding environment by the concerted action of co-chaperone expression and chaperone modifications. In addition to identifying the pathway responsible for regulating chaperone-mediated protein folding/degradation balances in normal cells, the data provide novel mechanisms to account for the aberrant chaperone activities observed in human cancer cells and have implications for the application of anti-chaperone therapies in cancer treatment.	[Muller, P.; Ruckova, E.; Hrstka, R.; Vojtesek, B.] Masaryk Mem Canc Inst, Brno 65653, Czech Republic; [Halada, P.] Acad Sci Czech Republic, Inst Microbiol, Prague, Czech Republic; [Coates, P. J.] Univ Dundee, Ctr Oncol & Mol Med, Dundee DD1 4HN, Scotland; [Lane, D. P.] p53 Lab A STAR, Immunos, Singapore	Masaryk Memorial Cancer Institute; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Dundee	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Muller, Petr/F-7762-2015; Coates, Philip J/H-6854-2019; Hrstka, Roman/AAM-4430-2020; Halada, Petr/H-3330-2014; Muller, Petr/AAK-5014-2021	Muller, Petr/0000-0002-8404-4494; Coates, Philip J/0000-0003-1518-6306; Hrstka, Roman/0000-0002-6139-2664; Halada, Petr/0000-0002-7229-3450; Muller, Petr/0000-0002-8404-4494; Lane, David/0000-0003-0551-3545	European Regional Development Fund [GACR P301/11/1678, GACR P206/12/G151, IGA NT/13794-4/2012]; State Budget of the Czech Republic [RECAMO CZ.1.05/2.1.00/03.0101]; Ministry of Health of the Czech Republic [FUNDIN MZ0MOU2005]	European Regional Development Fund(European Commission); State Budget of the Czech Republic; Ministry of Health of the Czech Republic(Ministry of Health, Czech Republic)	This work was supported by grants from GACR P301/11/1678, GACR P206/12/G151, IGA NT/13794-4/2012, by the European Regional Development Fund and the State Budget of the Czech Republic RECAMO CZ.1.05/2.1.00/03.0101 and research program of the Ministry of Health of the Czech Republic FUNDIN MZ0MOU2005.	Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hutt D, 2010, SCIENCE, V329, P766, DOI 10.1126/science.1194160; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Keefe AD, 2001, PROTEIN EXPRES PURIF, V23, P440, DOI 10.1006/prep.2001.1515; Krukenberg KA, 2011, Q REV BIOPHYS, V44, P229, DOI 10.1017/S0033583510000314; Kundrat L, 2010, BIOCHEMISTRY-US, V49, P7428, DOI 10.1021/bi100386w; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; Li J, 2011, BIOCHIM BIOPHYS ACTA, V1823, P624; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Mayer MP, 2010, MOL CELL, V39, P321, DOI 10.1016/j.molcel.2010.07.012; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; Miyata Y, 2009, CELL MOL LIFE SCI, V66, P1840, DOI 10.1007/s00018-009-9152-0; Mollapour M, 2010, MOL CELL, V37, P333, DOI 10.1016/j.molcel.2010.01.005; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927; Peterson LB, 2009, FUTURE MED CHEM, V1, P267, DOI 10.4155/FMC.09.17; Powers MV, 2010, CELL CYCLE, V9, P1542, DOI 10.4161/cc.9.8.11204; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zhang RM, 2004, ANAL BIOCHEM, V331, P138, DOI 10.1016/j.ab.2004.03.009	31	137	139	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2013	32	25					3101	3110		10.1038/onc.2012.314	http://dx.doi.org/10.1038/onc.2012.314			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22824801				2022-12-17	WOS:000320705700010
J	Sutendra, G; Dromparis, P; Kinnaird, A; Stenson, TH; Haromy, A; Parker, JMR; McMurtry, MS; Michelakis, ED				Sutendra, G.; Dromparis, P.; Kinnaird, A.; Stenson, T. H.; Haromy, A.; Parker, J. M. R.; McMurtry, M. S.; Michelakis, E. D.			Mitochondrial activation by inhibition of PDKII suppresses HIF1 alpha signaling and angiogenesis in cancer	ONCOGENE			English	Article						mitochondria; angiogenesis; hypoxia-inducible-factor; stem cell; tumor perfusion; vascularity	DICHLOROACETATE INDUCES APOPTOSIS; TUMOR-ASSOCIATED FIBROBLASTS; BONE-MARROW; PYRUVATE-KINASE; STROMAL CELLS; HEXOKINASE-II; DNA-DAMAGE; STEM-CELLS; IN-VITRO; HYPOXIA	Most solid tumors are characterized by a metabolic shift from glucose oxidation to glycolysis, in part due to actively suppressed mitochondrial function, a state that favors resistance to apoptosis. Suppressed mitochondrial function may also contribute to the activation of hypoxia-inducible factor 1 alpha (HIF1 alpha) and angiogenesis. We have previously shown that the inhibitor of pyruvate dehydrogenase kinase (PDK) dichloroacetate (DCA) activates glucose oxidation and induces apoptosis in cancer cells in vitro and in vivo. We hypothesized that DCA will also reverse the 'pseudohypoxic' mitochondrial signals that lead to HIF1 alpha activation in cancer, even in the absence of hypoxia and inhibit cancer angiogenesis. We show that inhibition of PDKII inhibits HIF1 alpha in cancer cells using several techniques, including HIF1 alpha luciferase reporter assays. Using pharmacologic and molecular approaches that suppress the prolyl-hydroxylase (PHD)-mediated inhibition of HIF1 alpha, we show that DCA inhibits HIF1 alpha by both a PHD-dependent mechanism (that involves a DCA-induced increase in the production of mitochondria-derived alpha-ketoglutarate) and a PHD-independent mechanism, involving activation of p53 via mitochondrial-derived H2O2, as well as activation of GSK3 beta. Effective inhibition of HIF1 alpha is shown by a decrease in the expression of several HIF1 alpha regulated gene products as well as inhibition of angiogenesis in vitro in matrigel assays. More importantly, in rat xenotransplant models of non-small cell lung cancer and breast cancer, we show effective inhibition of angiogenesis and tumor perfusion in vivo, assessed by contrast-enhanced ultrasonography, nuclear imaging techniques and histology. This work suggests that mitochondria-targeting metabolic modulators that increase pyruvate dehydrogenase activity, in addition to the recently described pro-apoptotic and anti-proliferative effects, suppress angiogenesis as well, normalizing the pseudo-hypoxic signals that lead to normoxic HIF1 alpha activation in solid tumors. Oncogene (2013) 32, 1638-1650; doi:10.1038/onc.2012.198; published online 21 May 2012	[Sutendra, G.; Dromparis, P.; Kinnaird, A.; Stenson, T. H.; Haromy, A.; Parker, J. M. R.; McMurtry, M. S.; Michelakis, E. D.] Univ Alberta, Dept Med, Edmonton, AB T6G 2B7, Canada	University of Alberta	Michelakis, ED (corresponding author), Univ Alberta, Dept Med, Edmonton, AB T6G 2B7, Canada.	em2@ualberta.ca	; Kinnaird, Adam/O-3969-2017	Stenson, Trevor/0000-0001-7164-1137; Kinnaird, Adam/0000-0002-4115-4327	Canadian Institutes for Health Research (CIHR); Alberta Innovates Health Solutions (AIHS)	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates Health Solutions (AIHS)	This study was funded by grants from the Canadian Institutes for Health Research (CIHR) and Alberta Innovates Health Solutions (AIHS) to EDM. We would like to thank Dr Gregg Semenza for his help, providing materials and advice.	Aghi M, 2006, CANCER RES, V66, P9054, DOI 10.1158/0008-5472.CAN-05-3759; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Babu E, 2011, ONCOGENE, V30, P4026, DOI 10.1038/onc.2011.113; Bhattacharyya A, 2010, AM J PHYSIOL-GASTR L, V299, pG1177, DOI 10.1152/ajpgi.00372.2010; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; Chen YJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007033; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dekker PBD, 2003, J PATHOL, V201, P480, DOI 10.1002/path.1461; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dromparis P, 2010, J MOL MED, V88, P1003, DOI 10.1007/s00109-010-0670-x; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Francia G, 2009, CANCER CELL, V15, P3, DOI 10.1016/j.ccr.2008.12.011; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Honczarenko M, 2006, STEM CELLS, V24, P1030, DOI 10.1634/stemcells.2005-0319; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Karshovska E, 2007, ARTERIOSCL THROM VAS, V27, P2540, DOI 10.1161/ATVBAHA.107.151050; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s; Li J, 2009, J BIOL CHEM, V284, P34458, DOI 10.1074/jbc.M109.065557; Lu CT, 2008, INT J ARTIF INTELL T, V17, P1; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Muangnoi P, 2007, PLANTA MED, V73, P748, DOI 10.1055/s-2007-981542; Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200; Pan James G, 2007, Sci STKE, V2007, ppe14; Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ravi R, 2000, GENE DEV, V14, P34; Rebelatto CK, 2008, EXP BIOL MED, V233, P901, DOI 10.3181/0712-RM-356; Saed GM, 2011, REPROD SCI, V18, P1253, DOI 10.1177/1933719111411731; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sanchez-Arago M, 2010, CARCINOGENESIS, V31, P567, DOI 10.1093/carcin/bgq012; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza G.L., 2007, SCI STKE, V2007, pcm8; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Sutendra G, 2010, SCI TRANSL MED, V2; Sutendra G, 2011, J MOL MED, V89, P771, DOI 10.1007/s00109-011-0762-2; Sutendra G, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002194; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Vella S, 2012, INT J CANCER, V130, P1484, DOI 10.1002/ijc.26173; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; Wang SW, 2000, AM J PHYSIOL-CELL PH, V279, pC868, DOI 10.1152/ajpcell.2000.279.3.C868; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	75	137	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1638	1650		10.1038/onc.2012.198	http://dx.doi.org/10.1038/onc.2012.198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614004				2022-12-17	WOS:000316855800004
J	Andradas, C; Caffarel, MM; Perez-Gomez, E; Salazar, M; Lorente, M; Velasco, G; Guzman, M; Sanchez, C				Andradas, C.; Caffarel, M. M.; Perez-Gomez, E.; Salazar, M.; Lorente, M.; Velasco, G.; Guzman, M.; Sanchez, C.			The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK	ONCOGENE			English	Article						G protein-coupled receptors; GPR55; cancer; cannabinoids	L-ALPHA-LYSOPHOSPHATIDYLINOSITOL; CANNABINOID RECEPTOR; LIGAND; IDENTIFICATION; TRANSCRIPTION; ACTIVATION; PATHWAYS; BRAIN	GPR55 is an orphan G protein-coupled receptor that may be engaged by some lipid ligands such as lysophosphatidylinositol and cannabinoid-type compounds. Very little is known about its expression pattern and physio-pathological relevance, and its pharmacology and signaling are still rather controversial. Here we analyzed the expression and function of GPR55 in cancer cells. Our data show that GPR55 expression in human tumors from different origins correlates with their aggressiveness. Moreover, GPR55 promotes cancer cell proliferation, both in cell cultures and in xenografted mice, through the overactivation of the extracellular signal-regulated kinase cascade. These findings reveal the importance of GPR55 in human cancer, and suggest that it could constitute a new biomarker and therapeutic target in oncology. Oncogene (2011) 30, 245-252; doi:10.1038/onc.2010.402; published online 6 September 2010	[Andradas, C.; Caffarel, M. M.; Perez-Gomez, E.; Salazar, M.; Lorente, M.; Velasco, G.; Guzman, M.; Sanchez, C.] Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, E-28040 Madrid, Spain	Complutense University of Madrid	Sanchez, C (corresponding author), Univ Complutense, Dept Biochem & Mol Biol 1, Sch Biol, C Jose Antonio Novais 2, E-28040 Madrid, Spain.	cristina.sanchez@quim.ucm.es	Sanchez, Cristina/H-4980-2017; Roa, Maria Salazar/I-1168-2015; Velasco, Guillermo/H-5260-2012; Velasco, Guillermo/AAU-9189-2020; Lorente, Mar/K-2401-2014; Pérez-Gómez, Eduardo/GYA-5856-2022; Lorente, Mar/O-5106-2017; Perez-gomez, Eduardo/F-5906-2015; Sanchez, Cristina/AFQ-4745-2022	Sanchez, Cristina/0000-0002-1428-3078; Roa, Maria Salazar/0000-0001-6784-9541; Velasco, Guillermo/0000-0002-1994-2386; Velasco, Guillermo/0000-0002-1994-2386; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Lorente, Mar/0000-0003-0982-0956; Perez-gomez, Eduardo/0000-0003-0160-5565; Caffarel, Maria/0000-0002-7442-6827; Guzman, Manuel/0000-0001-7475-118X	Ministerio de Ciencia e Innovacion; Fundacion Ferrer para la Investigacion; Comunidad de Madrid; Fondo de Investigaciones Sanitarias; Fundacion Mutua Madrilena; GW Pharmaceuticals/Otsuka Pharmaceuticals	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion Ferrer para la Investigacion; Comunidad de Madrid(Comunidad de Madrid); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); GW Pharmaceuticals/Otsuka Pharmaceuticals(Otsuka Pharmaceutical)	We are indebted to the members of our laboratory for technical support and critical discussions on this work. CA and MMC were recipients of fellowships from Ministerio de Ciencia e Innovacion and from Fundacion Ferrer para la Investigacion, respectively. MS and ML were recipients of contracts (Research Formation and Postdoctoral, respectively) from Comunidad de Madrid. This work was supported by grants from Fondo de Investigaciones Sanitarias (C Sanchez), Fundacion Mutua Madrilena (C Sanchez), Ministerio de Ciencia e Innovacion (G Velasco and M Guzman), Comunidad de Madrid (M Guzman) and GW Pharmaceuticals/Otsuka Pharmaceuticals (C Sanchez).	Brown AJ, 2009, VITAM HORM, V81, P111, DOI 10.1016/S0083-6729(09)81005-4; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Caffarel MM, 2006, CANCER RES, V66, P6615, DOI 10.1158/0008-5472.CAN-05-4566; Daly CJ, 2010, BRIT J PHARMACOL, V159, P787, DOI 10.1111/j.1476-5381.2009.00608.x; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; ELSTON EW, 1993, J CLIN PATHOL, V46, P189; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Henstridge CM, 2010, BRIT J PHARMACOL, V160, P604, DOI 10.1111/j.1476-5381.2009.00625.x; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Murph M, 2006, CLIN CANCER RES, V12, P6598, DOI 10.1158/1078-0432.CCR-06-1721; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; Oka S, 2009, J BIOCHEM, V145, P13, DOI 10.1093/jb/mvn136; Pietr M, 2009, FEBS LETT, V583, P2071, DOI 10.1016/j.febslet.2009.05.028; Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169-328X(98)00277-0; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Waldeck-Weiermair M, 2008, J CELL SCI, V121, P1704, DOI 10.1242/jcs.020958; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106; Worzfeld T, 2008, TRENDS PHARMACOL SCI, V29, P582, DOI 10.1016/j.tips.2008.08.002; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200	31	137	144	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	2					245	252		10.1038/onc.2010.402	http://dx.doi.org/10.1038/onc.2010.402			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709LG	20818416				2022-12-17	WOS:000286438900012
J	Fritz, V; Fajas, L				Fritz, V.; Fajas, L.			Metabolism and proliferation share common regulatory pathways in cancer cells	ONCOGENE			English	Review						cancer; metabolism; cell-cycle regulators; glycolysis; de novo lipogenesis	FATTY-ACID SYNTHASE; ATP-CITRATE LYASE; RESPONSIVE TRANSCRIPTION FACTOR; ACTIVATED-RECEPTOR-GAMMA; C-MYC; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; MITOCHONDRIAL BIOGENESIS; PROMOTES ADIPOGENESIS; HISTONE DEACETYLASE	Cancer development involves major alterations in cells' metabolism. Enhanced glycolysis and de novo fatty acids synthesis are indeed characteristic features of cancer. Cell proliferation and metabolism are tightly linked cellular processes. Others and we have previously shown a close relationship between metabolic responses and proliferative stimuli. In addition to trigger proliferative and survival signaling pathways, most oncoproteins also trigger metabolic changes to transform the cell. We present herein the view that participation of cell-cycle regulators and oncogenic proteins to cancer development extend beyond the control of cell proliferation, and discuss how these new functions may be implicated in metabolic alterations concomitant to the pathogenesis of human cancers. Oncogene (2010) 29, 4369-4377; doi: 10.1038/onc.2010.182; published online 31 May 2010	[Fritz, V.; Fajas, L.] INSERM, U896, Montpellier, France; [Fritz, V.; Fajas, L.] Univ Montpellier I, Montpellier, France; [Fritz, V.; Fajas, L.] IRCM, CRLC Val Aurelle Paul Lamarque, Montpellier, France; [Fritz, V.; Fajas, L.] Inst Rech Cancerol Montpellier, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Fajas, L (corresponding author), IRCM, CRLC Val Aurelle, Parc Euromed, F-34298 Montpellier, France.	lluis.fajas@inserm.fr	Coll, Lluis Fajas/C-8567-2014	Fajas, Lluis/0000-0002-1283-9503	Fajas' lab; Agence Nationale pour la Recherche (ANR physio); Association pour la Recherche contre le Cancer; Institut National du Cancer (INCA); Fondation pour la Recherche Medicale	Fajas' lab; Agence Nationale pour la Recherche (ANR physio)(French National Research Agency (ANR)); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer (INCA)(Institut National du Cancer (INCA) France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Members of the Fajas' lab are acknowledged for support and discussions. This work was supported by grants from Agence Nationale pour la Recherche (ANR physio), Association pour la Recherche contre le Cancer, Institut National du Cancer (INCA) and Fondation pour la Recherche Medicale. VF was supported by a grant from the INCA.	Abella A, 2005, CELL METAB, V2, P239, DOI 10.1016/j.cmet.2005.09.003; Annicotte JS, 2009, NAT CELL BIOL, V11, P1017, DOI 10.1038/ncb1915; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Cam H, 2004, MOL CELL, V16, P399, DOI 10.1016/j.molcel.2004.09.037; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chiaradonna F, 2006, ONCOGENE, V25, P5391, DOI 10.1038/sj.onc.1209528; Dali-Youcef N, 2007, P NATL ACAD SCI USA, V104, P10703, DOI 10.1073/pnas.0611568104; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Denechaud PD, 2008, FEBS LETT, V582, P68, DOI 10.1016/j.febslet.2007.07.084; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; Fajas L, 2004, J CLIN INVEST, V113, P1288, DOI 10.1172/JCI200418555; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITZ V, 2010, MOL CANC TH IN PRESS; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Iankova I, 2006, MOL ENDOCRINOL, V20, P1494, DOI 10.1210/me.2005-0222; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Jezek P, 2010, INT J BIOCHEM CELL B, V42, P604, DOI 10.1016/j.biocel.2009.11.008; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Lewis BC, 2000, CANCER RES, V60, P6178; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li FX, 2003, P NATL ACAD SCI USA, V100, P12935, DOI 10.1073/pnas.2231861100; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722; Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2005, MED HYPOTHESES, V64, P342, DOI 10.1016/j.mehy.2004.07.022; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Moon YA, 1999, EXP MOL MED, V31, P108, DOI 10.1038/emm.1999.18; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Nadolski MJ, 2007, FEBS J, V274, P5202, DOI 10.1111/j.1742-4658.2007.06056.x; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; Porstmann T, 2009, BIOCHEM SOC T, V37, P278, DOI 10.1042/BST0370278; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; SABINE JR, 1967, CANCER RES, V27, P793; Sarruf DA, 2005, MOL CELL BIOL, V25, P9985, DOI 10.1128/MCB.25.22.9985-9995.2005; Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tong XM, 2009, P NATL ACAD SCI USA, V106, P21660, DOI 10.1073/pnas.0911316106; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WARBURG O, 1930, METABOLISM TUMORS; Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wofford JA, 2008, BLOOD, V111, P2101, DOI 10.1182/blood-2007-06-096297; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Xue LL, 2004, CELL, V117, P761, DOI 10.1016/j.cell.2004.05.016; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamashita H, 2001, P NATL ACAD SCI USA, V98, P9116, DOI 10.1073/pnas.161284298; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600	79	137	141	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4369	4377		10.1038/onc.2010.182	http://dx.doi.org/10.1038/onc.2010.182			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514019	Green Accepted, Green Submitted			2022-12-17	WOS:000280559100001
J	Petersen, M; Pardali, E; van der Horst, G; Cheung, H; van den Hoogen, C; van der Pluijm, G; ten Dijke, P				Petersen, M.; Pardali, E.; van der Horst, G.; Cheung, H.; van den Hoogen, C.; van der Pluijm, G.; ten Dijke, P.			Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis	ONCOGENE			English	Article						angiogenesis; breast cancer; metastasis; Smad; TGF-beta	BETA TYPE-I; TGF-BETA; SUPPRESSES METASTASIS; ENHANCES TUMORIGENESIS; MESENCHYMAL TRANSITION; KINASE INHIBITOR; VEGF PRODUCTION; MAMMARY-TUMOR; GROWTH; TGF-BETA-1	Transforming growth factor (TGF)-beta can suppress and promote breast cancer progression. How TGF-beta elicits these dichotomous functions and which roles the principle intracellular effector proteins Smad2 and Smad3 have therein, is unclear. Here, we investigated the specific functions of Smad2 and Smad3 in TGF-beta-induced responses in breast cancer cells in vitro and in a mouse model for breast cancer metastasis. We stably knocked down Smad2 or Smad3 expression in MDA-MB-231 breast cancer cells. The TGF-beta-induced Smad3-mediated transcriptional response was mitigated and enhanced by Smad3 and Smad2 knockdown, respectively. This response was also seen for TGF-beta-induced vascular endothelial growth factor (VEGF) expression. TGF-beta induction of key target genes involved in bone metastasis, were found to be dependent on Smad3 but not Smad2. Strikingly, whereas knockdown of Smad3 in MDA-MB-231 resulted in prolonged latency and delayed growth of bone metastasis, Smad2 knockdown resulted in a more aggressive phenotype compared with control MDA-MB-231 cells. Consistent with differential effects of Smad knockdown on TGF-beta-induced VEGF expression, these opposing effects of Smad2 versus Smad3 could be directly correlated with divergence in the regulation of tumor angiogenesis in vivo. Thus, Smad2 and Smad3 differentially affect breast cancer bone metastasis formation in vivo. Oncogene (2010) 29, 1351-1361; doi:10.1038/onc.2009.426; published online 14 December 2009	[Petersen, M.; Pardali, E.; ten Dijke, P.] Dept Mol Cell Biol, Leiden, Netherlands; [Petersen, M.; Pardali, E.; ten Dijke, P.] Ctr Biomed Genet, Leiden, Netherlands; [Petersen, M.; van der Horst, G.; Cheung, H.; van den Hoogen, C.; van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Urol, NL-2300 RC Leiden, Netherlands; [van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van der Pluijm, G (corresponding author), Leiden Univ, Med Ctr, Dept Urol & Endocrinol, J3-100,POB 9600, NL-2300 RC Leiden, Netherlands.	G.van_der_Pluijm@lumc.nl	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; van der Horst, Geertje/0000-0003-1696-160X	Dutch Cancer Society [UL 2005-3371]; Ludwig Institute for Cancer Research; European Union [005428, 504743, 503224, 518198]	Dutch Cancer Society(KWF Kankerbestrijding); Ludwig Institute for Cancer Research; European Union(European Commission)	We thank Martine Deckers and Maarten van Dinther for their initial studies and members of our research group for help and suggestions during the course of this work. We are grateful to Lukas Hawinkels and Hein Verspaget for assistance with VEGF ELISA measurements, Kuber Sampath (Genzyme) for BMP6, Ken Iwata (OSI Pharmaceuticals) for TGF-beta 3 and Dr Philippe Clezardin for the MDA-MB-231 subclone BO2. This work was supported by the Dutch Cancer Society (UL 2005-3371), Ludwig Institute for Cancer Research and grants from the Sixth European Union Framework Programme, that is, the EpiplastCarcinoma Marie Curie RTN (project 005428), Angiotargeting (project 504743), BRECOSM (project 503224) and Tumor-Host Genomics (project 518198).	Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044; Burdette JE, 2005, CANCER RES, V65, P7968, DOI 10.1158/0008-5472.CAN-04-3553; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Desruisseau S, 2006, BRIT J CANCER, V94, P239, DOI 10.1038/sj.bjc.6602920; Donovan D, 1997, ANN SURG ONCOL, V4, P621, DOI 10.1007/BF02303745; Dzwonek J, 2009, MOL CANCER RES, V7, P1342, DOI 10.1158/1541-7786.MCR-08-0558; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Ge RR, 2006, CLIN CANCER RES, V12, P4315, DOI 10.1158/1078-0432.CCR-06-0162; Ghellal A, 2000, ANTICANCER RES, V20, P4413; Heffelfinger SC, 1999, CLIN CANCER RES, V5, P2867; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Isogai C, 2001, CANCER RES, V61, P5587; Ivanovic V, 2003, EUR J CANCER, V39, P454, DOI 10.1016/S0959-8049(02)00502-6; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Kirkbride KC, 2003, EXPERT OPIN BIOL TH, V3, P251; Kobayashi T, 2005, BIOCHEM BIOPH RES CO, V327, P393, DOI 10.1016/j.bbrc.2004.12.032; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; LaGamba D, 2005, DEV DYNAM, V234, P132, DOI 10.1002/dvdy.20489; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nam JS, 2008, CANCER RES, V68, P3835, DOI 10.1158/0008-5472.CAN-08-0215; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Petersen M, 2008, KIDNEY INT, V73, P705, DOI 10.1038/sj.ki.5002717; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Sheen-Chen SM, 2001, ARCH SURG-CHICAGO, V136, P937, DOI 10.1001/archsurg.136.8.937; Tannehill-Gregg SH, 2004, VET PATHOL, V41, P278, DOI 10.1354/vp.41-3-278; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian F, 2003, CANCER RES, V63, P8284; Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Xie W, 2002, CANCER RES, V62, P497; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523	51	137	140	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1351	1361		10.1038/onc.2009.426	http://dx.doi.org/10.1038/onc.2009.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	20010874				2022-12-17	WOS:000275170600010
J	Flahaut, M; Meier, R; Coulon, A; Nardou, KA; Niggli, FK; Martinet, D; Beckmann, JS; Joseph, JM; Muhlethaler-Mottet, A; Gross, N				Flahaut, M.; Meier, R.; Coulon, A.; Nardou, K. A.; Niggli, F. K.; Martinet, D.; Beckmann, J. S.; Joseph, J-M; Muehlethaler-Mottet, A.; Gross, N.			The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway	ONCOGENE			English	Article						neuroblastoma; chemoresistance; FZD1; MDR1; Wnt signalling	MULTIDRUG-RESISTANCE; GENE-EXPRESSION; BETA-CATENIN; CELL-LINES; INDUCED APOPTOSIS; CYCLIN D1; CANCER; CARCINOMA; TARGET; AMPLIFICATION	The development of chemoresistance represents a major obstacle in the successful treatment of cancers such as neuroblastoma (NB), a particularly aggressive childhood solid tumour. The mechanisms underlying the chemoresistant phenotype in NB were addressed by gene expression profiling of two doxorubicin (DoxR)-resistant vs sensitive parental cell lines. Not surprisingly, the MDR1 gene was included in the identified upregulated genes, although the highest overexpressed transcript in both cell lines was the frizzled-1 Wnt receptor (FZD1) gene, an essential component of the Wnt/beta-catenin pathway. FZD1 upregulation in resistant variants was shown to mediate sustained activation of the Wnt/b-catenin pathway as revealed by nuclear beta-catenin translocation and target genes transactivation. Interestingly, specific micro-adapted short hairpin RNA (shRNAmir)-mediated FZD1 silencing induced parallel strong decrease in the expression of MDR1, another beta-catenin target gene, revealing a complex, Wnt/beta-catenin-mediated implication of FZD1 in chemoresistance. The significant restoration of drug sensitivity in FZD1-silenced cells confirmed the FZD1-associated chemoresistance. RNA samples from 21 patient tumours (diagnosis and postchemotherapy), showed a highly significant FZD1 and/or MDR1 overexpression after treatment, underlining a role for FZD1-mediated Wnt/beta-catenin pathway in clinical chemoresistance. Our data represent the first implication of the Wnt/beta-catenin pathway in NB chemoresistance and identify potential new targets to treat aggressive and resistant NB. Oncogene (2009) 28, 2245-2256; doi:10.1038/onc.2009.80; published online 4 May 2009	[Flahaut, M.; Coulon, A.; Nardou, K. A.; Joseph, J-M; Muehlethaler-Mottet, A.; Gross, N.] Univ Hosp CHUV, Dept Paediat, CH-1011 Lausanne, Switzerland; [Meier, R.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; [Niggli, F. K.] Univ Children Hosp, Dept Paediat, Zurich, Switzerland; [Martinet, D.; Beckmann, J. S.] Univ Hosp CHUV, Med Genet Serv, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University Children's Hospital Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Flahaut, M (corresponding author), Univ Hosp CHUV, Dept Paediat, CH-1011 Lausanne, Switzerland.	Marjorie.Flahaut@chuv.ch	Beckmann, Jacques S/A-9772-2008; Niggli, Felix/L-6547-2017; , Mühlethaler-Mottet/H-2848-2019	Beckmann, Jacques S/0000-0002-9741-1900; Niggli, Felix/0000-0002-7553-3712; , Mühlethaler-Mottet/0000-0001-8274-0907	Schweizer Forschungsstiftung Kind und Krebs; Swiss National Science foundation; FORCE foundation	Schweizer Forschungsstiftung Kind und Krebs; Swiss National Science foundation(Swiss National Science Foundation (SNSF)European Commission); FORCE foundation	We thank M Wicht and N Besuchet Schmutz ( Medical Genetic Service, CHUV) for their skillful help. This study was supported by the Schweizer Forschungsstiftung Kind und Krebs, the Swiss National Science foundation and the FORCE foundation.	Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bedrnicek J, 2005, NEOPLASMA, V52, P415; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Duhem, 1996, Oncologist, V1, P151; Eisenmann David M, 2005, WormBook, P1, DOI 10.1895/wormbook.1.7.1; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Flahaut M, 2006, GENE CHROMOSOME CANC, V45, P495, DOI 10.1002/gcc.20312; Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Haber M, 1997, EUR J CANCER, V33, P2031, DOI 10.1016/S0959-8049(97)00229-3; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Johnsson A, 2005, ANTICANCER RES, V25, P2661; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Ludwig JA, 2006, CANCER RES, V66, P4808, DOI 10.1158/0008-5472.CAN-05-3322; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Merle P, 2005, J HEPATOL, V43, P854, DOI 10.1016/j.jhep.2005.05.018; Milovanovic T, 2004, INT J ONCOL, V25, P1337; Modok S, 2006, CURR OPIN PHARMACOL, V6, P350, DOI 10.1016/j.coph.2006.01.009; Muhlethaler-Mottet A, 2004, ONCOGENE, V23, P5415, DOI 10.1038/sj.onc.1207704; Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Norris MD, 1997, EUR J CANCER, V33, P1911, DOI 10.1016/S0959-8049(97)00284-0; Polakis P, 2000, GENE DEV, V14, P1837; Psarros M, 2005, NUCLEIC ACIDS RES, V33, pW638, DOI 10.1093/nar/gki490; SEEGER RC, 1977, CANCER RES, V37, P1364; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueno K, 2008, NEOPLASIA, V10, P697, DOI 10.1593/neo.08320; Valent A, 1999, CANCER GENET CYTOGEN, V112, P124, DOI 10.1016/S0165-4608(98)00264-7; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yamada T, 2000, CANCER RES, V60, P4761	44	137	145	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2245	2256		10.1038/onc.2009.80	http://dx.doi.org/10.1038/onc.2009.80			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421142				2022-12-17	WOS:000266886300001
J	Uemura, T; Shiozaki, K; Yamaguchi, K; Miyazaki, S; Satomi, S; Kato, K; Sakuraba, H; Miyagi, T				Uemura, T.; Shiozaki, K.; Yamaguchi, K.; Miyazaki, S.; Satomi, S.; Kato, K.; Sakuraba, H.; Miyagi, T.			Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta 4	ONCOGENE			English	Article						sialidase; integrin beta 4; sialic acid; metastasis; invasion; MMP-7	MEMBRANE-ASSOCIATED SIALIDASE; TYPE-1 MATRIX-METALLOPROTEINASE; PLASMA-MEMBRANE; LYSOSOMAL SIALIDASE; APOPTOSIS SUPPRESSION; COLORECTAL-CANCER; GLYCOSYLATION; EXPRESSION; PROGRESSION; LAMININ-5	We previously found an inverse relationship between sialidase Neu1 expression and metastatic potential of murine cancer cells. To elucidate the mechanism underlying the cellular events, the human sialidase gene NEU1 was overexpressed or silenced in colon cancer HT-29 cells. When NEU1-overexpressing cells were injected transsplenically into mice, in vivo liver metastasis was significantly reduced. NEU1 suppressed cell migration, invasion and adhesion in vitro, whereas the silencing resulted in the opposite. One of the major molecular changes by NEU1 was decreased sialylation of integrin beta 4, assessed by PNA- and MAL-II-lectin blotting of immunoprecipitates with anti-integrin beta 4 antibody. The desialylation was accompanied by decreased phosphorylation of the integrin followed by attenuation of focal adhesion kinase and Erk1/2 pathway. Moreover, NEU1 caused downregulation of matrix metalloproteinase-7, overexpression of which is associated with cancer metastasis. Treatment of the cells with GalNAc-alpha-O-benzyl, an inhibitor of O-glycosylation, showed increased PNA-positive integrin beta 4 with its decreased phosphorylation, indicating that sialic acid removal from the integrin O-glycans results in the decreased phosphorylation. Biotinylation and immunofluorescence staining exhibited some NEU1 molecules to be at the cell surface accessible to the integrin. These results suggest that NEU1 is important in regulation of integrin beta 4-mediated signaling, leading to suppression of metastasis.	[Uemura, T.; Shiozaki, K.; Yamaguchi, K.; Kato, K.; Miyagi, T.] Miyagi Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; [Uemura, T.; Shiozaki, K.; Yamaguchi, K.; Kato, K.; Miyagi, T.] JST, CREST, Kawaguchi, Saitama, Japan; [Uemura, T.; Miyazaki, S.; Satomi, S.] Tohoku Univ, Grad Sch Med, Dept Adv Surg Sci & Technol, Sendai, Miyagi 980, Japan; [Sakuraba, H.] Meiji Pharmaceut Univ, Dept Analyt Biochem, Tokyo, Japan	Miyagi Cancer Center; Japan Science & Technology Agency (JST); Tohoku University; Meiji Pharmaceutical University	Miyagi, T (corresponding author), Miyagi Canc Ctr, Res Inst, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	miyagi-ta173@pref.miyagi.jp		Shiozaki, Kazuhiro/0000-0002-0523-838X	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We appreciate the expert technical assistance of Ms Setsuko Moriya. This study was supported in part by Grants-in-Aid for Scientific Research on Priority Areas Cancer from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Duca L, 2007, J BIOL CHEM, V282, P12484, DOI 10.1074/jbc.M609505200; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giannelli G, 2002, CLIN EXP METASTAS, V19, P217, DOI 10.1023/A:1015579204607; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hinek A, 2006, J BIOL CHEM, V281, P3698, DOI 10.1074/jbc.M508736200; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kato T, 2001, INT J CANCER, V92, P797, DOI 10.1002/ijc.1268; Koshikawa N, 2005, J BIOL CHEM, V280, P88, DOI 10.1074/jbc.M411824200; LI K, 1992, J CHROMATOGR-BIOMED, V579, P209, DOI 10.1016/0378-4347(92)80384-3; Liang F, 2006, J BIOL CHEM, V281, P27526, DOI 10.1074/jbc.M605633200; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Mimori K, 2004, CLIN CANCER RES, V10, P8243, DOI 10.1158/1078-0432.CCR-04-0849; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; MIYAGI T, 1984, EUR J BIOCHEM, V141, P75, DOI 10.1111/j.1432-1033.1984.tb08159.x; MIYAGI T, 1994, FEBS LETT, V349, P255, DOI 10.1016/0014-5793(94)00682-2; Miyagi T., 2007, COMPREHENSIVE GLYCOS, V3, P297; Miyagi T, 2008, BBA-GEN SUBJECTS, V1780, P532, DOI 10.1016/j.bbagen.2007.09.016; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; Remacle AG, 2006, J BIOL CHEM, V281, P16897, DOI 10.1074/jbc.M600295200; Remy L, 2006, CANCER RES, V66, P11228, DOI 10.1158/0008-5472.CAN-06-1187; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; TRAINER DL, 1998, INT J CANCER, V41, P287; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Xia YP, 1996, J CELL BIOL, V132, P727, DOI 10.1083/jcb.132.4.727; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; Zeng ZS, 2002, CLIN CANCER RES, V8, P144	35	137	142	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1218	1229		10.1038/onc.2008.471	http://dx.doi.org/10.1038/onc.2008.471			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19151752				2022-12-17	WOS:000263906200006
J	Takafuji, V; Forgues, M; Unsworth, E; Goldsmith, P; Wang, XW				Takafuji, V.; Forgues, M.; Unsworth, E.; Goldsmith, P.; Wang, X. W.			An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma	ONCOGENE			English	Article						osteopontin; hepatocellular carcinoma; metastasis; cellular invasion; MMP-9; CD44	METASTASIS FORMATION; PROTEIN EXPRESSION; PLASMA OSTEOPONTIN; SURVIVAL; CANCER; CD44; TRANSGLUTAMINASE; BREAST; OVEREXPRESSION; PROGRESSION	Tumor cell invasion is a primary event in the metastatic progression of hepatocellular carcinoma (HCC). Our recent results indicate a concordant elevated expression of osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in primary metastatic HCC. This study hypothesizes an MMP-9-directed cleavage of OPN that biologically contributes to HCC metastasis. We found that MMP-9 cleaved OPN into specific fragments in vitro, of which three could be identified by Edman degradation amino-acid sequencing. On e of these fragments (OPN-5 kDa, residues 167-210) induced low-metastatic HCC cellular invasion via CD44 receptors, which was effectively blocked by the addition of small peptides within the region of OPN-5 kDa. In creased expression of an OPN splice variant (OPN-c) was associated with clinical metastatic HCC. Overexpression of OPN-c with physiological levels of MMP-9 enhanced cellular invasion and coincided with elevated OPN-5 kDa levels. Our data suggest that an alternative splicing event (OPN-c) promotes extracellular cleavage of OPN by MMP-9, thus releasing a distinct region of OPN (OPN-5 kDa) that is essential for HCC cellular invasion and appears to correlate with metastatic potential. The findings of this study may help to improve advanced-stage HCC prognosis and suggest the utility of small peptides for novel therapies.	NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Antibody & Protein Purificat Grp, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, 37-3044A,37 Convent Dr MSC 4258, Bethesda, MD 20892 USA.	xw3u@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X	NATIONAL CANCER INSTITUTE [ZIABC010313, Z01BC010313] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Ashida K, 1996, AM J PATHOL, V149, P1803; Blum HE, 2005, EUR J GASTROEN HEPAT, V17, P475, DOI 10.1097/00042737-200505000-00001; BUTLER WT, 1995, ANN NY ACAD SCI, V760, P6, DOI 10.1111/j.1749-6632.1995.tb44615.x; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Endo K, 2000, J HEPATOL, V32, P78, DOI 10.1016/S0168-8278(00)80192-0; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; FRANCO D, 1990, GASTROENTEROLOGY, V98, P733, DOI 10.1016/0016-5085(90)90296-D; Harada N, 2001, INT J CANCER, V91, P67, DOI 10.1002/1097-0215(20010101)91:1<67::AID-IJC1011>3.0.CO;2-D; He B, 2006, ONCOGENE, V25, P2192, DOI 10.1038/sj.onc.1209248; Hotte SJ, 2002, CANCER-AM CANCER SOC, V95, P506, DOI 10.1002/cncr.10709; Kaartinen MT, 1999, J BIOL CHEM, V274, P1729, DOI 10.1074/jbc.274.3.1729; Kaneyoshi T, 2001, CLIN CANCER RES, V7, P4027; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Lin LI, 1998, ONCOLOGY-BASEL, V55, P349, DOI 10.1159/000011876; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; McKenna GJ, 2002, AM J SURG, V183, P588, DOI 10.1016/S0002-9610(02)00833-4; Pan HW, 2003, CANCER-AM CANCER SOC, V98, P119, DOI 10.1002/cncr.11487; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudzki Z, 1997, J CLIN PATHOL-MOL PA, V50, P57, DOI 10.1136/mp.50.2.57; SAITOH Y, 1995, LAB INVEST, V72, P55; SENGER DR, 1988, CANCER RES, V48, P5770; Si MS, 2003, AM SURGEON, V69, P879; Singhal H, 1997, CLIN CANCER RES, V3, P605; SORENSEN ES, 1994, BIOCHEM J, V304, P13, DOI 10.1042/bj3040013; Takahashi K, 1998, BIOCHEM MOL BIOL INT, V46, P1081; Theret N, 2001, HEPATOLOGY, V34, P82, DOI 10.1053/jhep.2001.25758; Turpeenniemi-Hujanen T, 2005, BIOCHIMIE, V87, P287, DOI 10.1016/j.biochi.2005.01.014; van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang XW, 2005, HEPATOLOGY, V42, p391A; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	39	137	146	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6361	6371		10.1038/sj.onc.1210463	http://dx.doi.org/10.1038/sj.onc.1210463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452979				2022-12-17	WOS:000249737600001
J	Peschard, P; Park, M				Peschard, P.; Park, M.			From Tpr-Met to Met, tumorigenesis and tubes	ONCOGENE			English	Review						signaling; downregulation; ubiquitination; mutations; oncogenic activation	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; DOMAIN BINDING-SITE; EPITHELIAL MORPHOGENESIS DOWNSTREAM; SIGNAL-REGULATED KINASE; MESENCHYMAL STEM-CELLS; C-MET; EGF RECEPTOR; FACTOR/SCATTER FACTOR	The receptor for hepatocyte growth factor (HGF)/scatter factor (SF), Met, controls a program of invasive epithelial growth through the coordination of cell proliferation and survival, cell migration and epithelial morphogenesis. This process is important during embryogenesis and for organ regeneration in the adult. However, when deregulated the HGF/SF-Met signaling axis contributes to tumorigenesis and metastasis. Studies on the oncogenic activation of the Met receptor have shed light on the molecular mechanisms underlying the oncogenic activation of receptor tyrosine kinase (RTKs). More than a decade ago, work on the Met related oncogene, Tpr-Met, revealed the mechanism for activation of RTK-derived oncogenes generated following chromosomal translocation. More recently, studies on the mechanisms of downregulation of the Met RTK highlight a role for loss of downregulation in RTK oncogenic activation.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Dept Biochem, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca		Peschard, Pascal/0000-0001-6395-5566				Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Davies GC, 2004, ONCOGENE, V23, P7104, DOI 10.1038/sj.onc.1207952; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Forte G, 2006, STEM CELLS, V24, P23, DOI 10.1634/stemcells.2004-0176; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Graveel C, 2004, P NATL ACAD SCI USA, V101, P17198, DOI 10.1073/pnas.0407651101; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; HERBST R, 1995, ONCOGENE, V10, P369; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lamorte L, 2002, J BIOL CHEM, V277, P37904, DOI 10.1074/jbc.M201743200; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Machide M, 2006, J BIOL CHEM, V281, P8765, DOI 10.1074/jbc.M512298200; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 2003, MOL BIOL CELL, V14, P1691, DOI 10.1091/mbc.E02-06-0352; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto K, 2001, KIDNEY INT, V59, P2023, DOI 10.1046/j.1523-1755.2001.00717.x; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakamura T, 2000, J CLIN INVEST, V106, P1511, DOI 10.1172/JCI10226; Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Otsuka T, 1998, CANCER RES, V58, P5157; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RONSIN C, 1993, ONCOGENE, V8, P1195; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sangwan V, 2006, J BIOL CHEM, V281, P221, DOI 10.1074/jbc.M507858200; Saucier C, 2004, P NATL ACAD SCI USA, V101, P2345, DOI 10.1073/pnas.0308065101; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1998, CANCER RES, V58, P1719; Schmidt PR, 1997, J ANTHROPOL ARCHAEOL, V16, P73, DOI 10.1006/jaar.1997.0305; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Sun H, 2005, CELL MICROBIOL, V7, P443, DOI 10.1111/j.1462-5822.2004.00475.x; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; YANG XM, 1995, LAB INVEST, V73, P483; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359; ZHU H, 1994, J BIOL CHEM, V269, P29943	114	137	147	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1276	1285		10.1038/sj.onc.1210201	http://dx.doi.org/10.1038/sj.onc.1210201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322912				2022-12-17	WOS:000244558700004
J	Aung, PP; Oue, N; Mitani, Y; Nakayama, H; Yoshida, K; Noguchi, T; Bosserhoff, AK; Yasui, W				Aung, PP; Oue, N; Mitani, Y; Nakayama, H; Yoshida, K; Noguchi, T; Bosserhoff, AK; Yasui, W			Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer	ONCOGENE			English	Article						gastric cancer; MIA; MMP10; DKK4; SAGE; tumor serum marker	SQUAMOUS-CELL CARCINOMA; CLINICAL-IMPLICATIONS; MALIGNANT-MELANOMA; METASTATIC CANCER; TISSUE INHIBITORS; SERIAL ANALYSIS; FUNCTIONAL-ROLE; PHASE-I; EXPRESSION; PROTEIN	Gastric cancer ( GC) is one of the most common malignancies worldwide. Genes expressed only in cancer tissue will be useful molecular markers for diagnosis and may also be good therapeutic targets. However, little is known about cancer-specific genes, at least in GC. In this study, we searched for GC-specific genes by serial analysis of gene expression ( SAGE) data analysis and quantitative reverse transcription (RT)-PCR. Comparing GC SAGE libraries with those of various normal tissues in the SAGEmap database, we identified 54 candidate GC-specific genes. Quantitative RT-PCR analysis of these candidates revealed that APin protein (APIN), taxol resistance-associated gene 3 (TRAG3), cytochrome P450, family 2, subfamily W, polypeptide 1 (CYP2W1), melanoma inhibitory activity (MIA), matrix metalloproteinase-10 (MMP-10), dickkopf homolog 4 (DKK4), GW112, regenerating islet-derived family, member 4 (REGIV), and HORMA domain-containing 1 (HOR-MAD1) were expressed much more highly in GC than in 14 kinds of normal tissues. Immunohistochemical staining for MIA, MMP-10, and DKK4 was found in 47 (31.1%), 68 (45.0%), and two (1.3%) of 151 GCs, respectively, and staining for both MIA and MMP-10 was correlated with poor prognosis in advanced GC (P = 0.0001 and 0.0141, respectively). Moreover, enzyme-linked immunosorbent assay showed high levels of MMP-10 (65/69, 94.2%) in serum samples from patients with GC. Levels of MIA were raised in a small proportion of serum samples from patients with GC (4/69, 5.8%). In Boyden chamber invasion assays, MIA-transfected GC cells were up to three times more invasive than cells transfected with empty vector. Taken together, these results suggest that MMP-10 is a good marker for the detection of GC and that MIA and MMP-10 are prognostic factors for GC. As expression of MIA and MMP-10 is narrowly restricted in cancer, these two molecules may be good therapeutic targets for GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Surg Oncol, Hiroshima, Japan; Oita Univ, Fac Med, Dept Oncol Sci, Oita, Japan; Univ Regensburg, Inst Pathol, Regensburg, Germany	Hiroshima University; Hiroshima University; Oita University; University of Regensburg	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Mitani, Yoshitsugu/ABA-2736-2021; Bosserhoff, Anja/GNH-4801-2022	Mitani, Yoshitsugu/0000-0002-8661-4702; Bosserhoff, Anja/0000-0001-8147-394X; Aung, Phyu/0000-0002-3398-0573				ALLEY MC, 1988, CANCER RES, V48, P589; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Bando E, 1999, AM J SURG, V178, P256, DOI 10.1016/S0002-9610(99)00162-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BLESCH A, 1994, CANCER RES, V54, P5695; Bodey B, 2000, ANTICANCER RES, V20, P4585; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Buckhaults P, 2001, CANCER RES, V61, P6996; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; El Fitori J, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-3; Hau P, 2004, ONCOL REP, V12, P1355; Hau P, 2002, ANTICANCER RES, V22, P577; HEMBRY RM, 1995, ANN RHEUM DIS, V54, P25, DOI 10.1136/ard.54.1.25; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; KOGA T, 1987, JPN J SURG, V17, P342, DOI 10.1007/BF02470632; Kondo T, 2004, CANCER RES, V64, P523, DOI 10.1158/0008-5472.CAN-03-1196; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Lal A, 1999, CANCER RES, V59, P5403; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; MOLNAR IG, 1976, GASTROENTEROLOGY, V70, P513; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Nakamura H, 1998, EUR J BIOCHEM, V253, P67, DOI 10.1046/j.1432-1327.1998.2530067.x; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8; OHGAKI H, 2003, WORLD CANC REPORT, P197; Oue N, 2005, J PATHOL, V207, P185, DOI 10.1002/path.1827; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Ramos MC, 2004, BIOL CHEM, V385, P75, DOI 10.1515/BC.2004.010; Rizvi NA, 2004, CLIN CANCER RES, V10, P1963, DOI 10.1158/1078-0432.CCR-1183-02; Rudek MA, 2001, J CLIN ONCOL, V19, P584, DOI 10.1200/JCO.2001.19.2.584; Saghizadeh M, 2001, AM J PATHOL, V158, P723, DOI 10.1016/S0002-9440(10)64015-1; Sharma R, 2004, ONCOLOGY-BASEL, V67, P300, DOI 10.1159/000081331; SHIMIZU N, 1987, ONCOLOGY, V44, P240, DOI 10.1159/000226486; SOBIN LH, 2002, TNM CLASSIFICATION M, P65; Solomon A, 2003, J LAB CLIN MED, V142, P348, DOI 10.1016/S0022-2143(03)00149-5; Thorns V, 2003, ANTICANCER RES, V23, P3937; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Yamashita K, 1998, INT J CANCER, V79, P187; Yasui W, 2004, CANCER SCI, V95, P385, DOI 10.1111/j.1349-7006.2004.tb03220.x; Yasui Wataru, 2000, Journal of Gastroenterology, V35, P111; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443; Zucker S, 1999, ANN NY ACAD SCI, V878, P212, DOI 10.1111/j.1749-6632.1999.tb07687.x	51	137	153	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2546	2557		10.1038/sj.onc.1209279	http://dx.doi.org/10.1038/sj.onc.1209279			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331256				2022-12-17	WOS:000236948000013
J	Wang, L; Weinshilboum, R				Wang, L; Weinshilboum, R			Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions	ONCOGENE			English	Review						TPMT; 6-mercaptopurine; azathioprine; pharmacogenomics; proteasome degradation; aggresome	ACUTE LYMPHOBLASTIC-LEUKEMIA; INFLAMMATORY-BOWEL-DISEASE; GENETIC-POLYMORPHISM; BIOCHEMICAL-PROPERTIES; ERYTHROCYTE CORRELATION; FUNCTIONAL GENOMICS; AGGRESOME FORMATION; CATALYTIC ACTIVITY; DRUG RESPONSE; TANDEM REPEAT	The thiopurine S-methyltransferase (TPMT) genetic polymorphism is one of the most 'mature' examples in pharmacogenetics. That is true because of its importance clinically for the individualization of thiopurine drug therapy and also because TPMT has provided novel insights into molecular mechanisms responsible for the functional effects of common genetic polymorphisms. This review will summarize the development of our understanding of the role of inheritance in the regulation of TPMT as well as the clinical implications of that genetic regulation. It will also summarize recent studies in which TPMT pharmacogenetics has enhanced our understanding of molecular mechanisms by which common polymorphisms influence or alter function. TPMT pharmacogenetics highlights the potential clinical importance of the translation of pharmacogenetics from bench to bedside, the potential for basic pharmacogenetic research to provide insight into mechanisms by which genetic polymorphisms can alter function, and the challenges associated with the achievement of both of those goals.	Mayo Clin Rochester, Coll Med, Dept Mol Pharmaceut & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA	Mayo Clinic	Wang, L (corresponding author), Mayo Clin Rochester, Coll Med, Dept Mol Pharmaceut & Expt Therapeut, Div Clin Pharmacol, 200 1st St SW, Rochester, MN 55905 USA.	wang.liewei@mayo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028157, U01GM061388] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM35720, R01 GM28157, U01 GM61388] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adjei AA, 2003, BRIT J PHARMACOL, V139, P1373, DOI 10.1038/sj.bjp.0705369; Branca MA, 2005, NAT REV DRUG DISCOV, V4, P615, DOI 10.1038/nrd1812; Cheng Q, 2005, NAT GENET, V37, P878, DOI 10.1038/ng1612; Collie-Duguid ESR, 1999, PHARMACOGENETICS, V9, P37, DOI 10.1097/00008571-199902000-00006; Coulthard SA, 1998, BLOOD, V92, P2856, DOI 10.1182/blood.V92.8.2856.420k05_2856_2862; de la Moureyre CSV, 1999, PHARMACOGENETICS, V9, P189; de la Moureyre CSV, 1998, BRIT J PHARMACOL, V125, P879, DOI 10.1038/sj.bjp.0702152; Dervieux T, 2001, CANCER RES, V61, P5810; Dubinsky MC, 2002, GASTROENTEROLOGY, V122, P904, DOI 10.1053/gast.2002.32420; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; Fessing MY, 1998, EUR J BIOCHEM, V256, P510, DOI 10.1046/j.1432-1327.1998.2560510.x; Freimuth RR, 2001, PHARMACOGENETICS, V11, P747, DOI 10.1097/00008571-200112000-00002; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Gearry RB, 2005, J GASTROEN HEPATOL, V20, P1149, DOI 10.1111/j.1440-1746.2005.03832.x; GUERCIOLINI R, 1989, FASEB Journal, V3, pA428; Hamdan-Khalil R, 2005, BIOCHEM PHARMACOL, V69, P525, DOI 10.1016/j.bcp.2004.10.011; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hon YY, 1999, HUM MOL GENET, V8, P371, DOI 10.1093/hmg/8.2.371; HONCHEL R, 1993, MOL PHARMACOL, V43, P878; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Ji Y, 2005, J NEUROCHEM, V95, P1766, DOI 10.1111/j.1471-4159.2005.03453.x; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Krynetski E, 2003, ONCOGENE, V22, P7403, DOI 10.1038/sj.onc.1206944; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; *LAB MED, 1991, LAB MED B MAYO FDN, V14, P1; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1992, EUR J CLIN PHARMACOL, V43, P329, DOI 10.1007/BF02220605; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1989, CLIN PHARMACOL THER, V46, P149, DOI 10.1038/clpt.1989.119; LENNARD L, 1983, BRIT J CLIN PHARMACO, V16, P359, DOI 10.1111/j.1365-2125.1983.tb02178.x; Lindqvist M, 2004, PHARMACOGENETICS, V14, P261, DOI 10.1097/00008571-200404000-00006; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Nebert Daniel W, 2003, Am J Pharmacogenomics, V3, P361, DOI 10.2165/00129785-200303060-00002; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Otterness D, 1997, CLIN PHARMACOL THER, V62, P60, DOI 10.1016/S0009-9236(97)90152-1; Otterness DM, 1998, J CLIN INVEST, V101, P1036, DOI 10.1172/JCI1004; PATERSON ARP, 1975, 6 THIOPURINES; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; REMY CN, 1963, J BIOL CHEM, V238, P1078; Salavaggione OE, 2005, PHARMACOGENET GENOM, V15, P801, DOI 10.1097/01.fpc.0000174788.69991.6b; Schaeffeler E, 2003, LEUKEMIA, V17, P1422, DOI 10.1038/sj.leu.2402981; Schaeffeler E, 2004, PHARMACOGENETICS, V14, P407, DOI 10.1097/01.fpc.0000114745.08559.db; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; SZUMLANSKI CL, 1992, PHARMACOGENETICS, V2, P148, DOI 10.1097/00008571-199208000-00002; Tai HL, 1999, PHARMACOGENETICS, V9, P641, DOI 10.1097/01213011-199910000-00011; Tai HL, 1996, AM J HUM GENET, V58, P694; Tai HL, 1997, P NATL ACAD SCI USA, V94, P6444, DOI 10.1073/pnas.94.12.6444; TAY BS, 1969, BIOCHEM PHARMACOL, V18, P934, DOI 10.1016/0006-2952(69)90069-0; Thomae B. A., 2002, Pharmacogenomics Journal, V2, P48, DOI 10.1038/sj.tpj.6500089; Thomae BA, 2003, J NEUROCHEM, V87, P809, DOI 10.1046/j.1471-4159.2003.02027.x; VANLOON JA, 1982, BIOCHEM GENET, V20, P637, DOI 10.1007/BF00483962; Wang LW, 2003, PHARMACOGENETICS, V13, P555, DOI 10.1097/00008571-200309000-00004; Wang LW, 2005, P NATL ACAD SCI USA, V102, P9394, DOI 10.1073/pnas.0502352102; Weinshilboum R, 2004, NAT REV DRUG DISCOV, V3, P739, DOI 10.1038/nrd1497; Weinshilboum R, 2001, DRUG METAB DISPOS, V29, P601; Weinshilboum R, 2004, CLIN PHARMACOL THER, V75, P253, DOI 10.1016/j.clpt.2003.12.002; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEINSHILBOUM RM, 1978, CLIN CHIM ACTA, V85, P323, DOI 10.1016/0009-8981(78)90311-X; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOODSON LC, 1982, J PHARMACOL EXP THER, V222, P174; WOODSON LC, 1983, BIOCHEM PHARMACOL, V32, P819, DOI 10.1016/0006-2952(83)90582-8; Yan L, 2000, CLIN PHARMACOL THER, V68, P210, DOI 10.1067/mcp.2000.108674; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003; [No title captured]	69	137	152	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1629	1638		10.1038/sj.onc.1209372	http://dx.doi.org/10.1038/sj.onc.1209372			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550163				2022-12-17	WOS:000235904700005
J	Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR				Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR			Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma	ONCOGENE			English	Article						erythropoietin; erythropoietin receptor; head and neck cancer; invasion; HNSCC; JAK-STAT	PLACEBO-CONTROLLED TRIAL; RECEPTOR EXPRESSION; CYTOKINE RECEPTORS; CANCER-PATIENTS; BREAST-CANCER; DOUBLE-BLIND; GROWTH; BIOLOGY; LINES; REQUIREMENT	Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. EPO and the EPO receptor (EPOR) are expressed in nonhematopoietic cells and cancers. However, the role of EPO and EPOR within nonhematopoietic cancer cells remains incompletely understood. Although a recent clinical trial demonstrated worse tumor control and survival in head and neck cancer patients treated with EPO, the role of EPO and EPOR in head and neck squamous cell carcinoma (HNSCC) has not been examined. In the present study, we demonstrate the previously unrecognized EPO-mediated invasion by HNSCC cells through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. Furthermore, we confirmed the expression of EPO and EPOR in a panel of human HNSCC cell lines and tissue specimens. Pharmacological doses of EPO also had a limited proliferation effect in these cell lines. These results de. ne a novel role for EPO in mediating tumor cell invasion. Increased levels of EPO and EPOR in lymph node metastases as compared to primary tumors from HNSCC patients further support the role of EPO/EPOR in HNSCC disease progression and metastasis.	Univ Pittsburgh, Inst Canc, Inst Eye & Ear, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Biostat Facil, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lai, SY (corresponding author), Univ Pittsburgh, Inst Canc, Inst Eye & Ear, Dept Otolaryngol Head & Neck Surg, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.	laisy@upmc.edu		Lai, Stephen/0000-0001-8301-7286; Wells, Alan/0000-0002-1637-8150	NIDCD NIH HHS [T32 DC000066-01A2] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000066] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Acs G, 2002, CANCER-AM CANCER SOC, V95, P969, DOI 10.1002/cncr.10787; Acs G, 2003, AM J PATHOL, V162, P1789, DOI 10.1016/S0002-9440(10)64314-3; Acs G, 2001, CANCER RES, V61, P3561; ALBINI A, 1987, CANCER RES, V47, P3239; Arcasoy MO, 2005, CLIN CANCER RES, V11, P20; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Gall RM, 2000, J OTOLARYNGOL, V29, P131; Glaser CM, 2001, INT J RADIAT ONCOL, V50, P705, DOI 10.1016/S0360-3016(01)01488-2; Godfrey TE, 2000, J MOL DIAGN, V2, P84, DOI 10.1016/S1525-1578(10)60621-6; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Guo YL, 2004, MOL ENDOCRINOL, V18, P1033, DOI 10.1210/me.2003-0231; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; HEO DS, 1989, CANCER RES, V49, P5167; Hwa V, 2004, J BIOL CHEM, V279, P2728, DOI 10.1074/jbc.M310495200; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Lacombe C, 1999, NEPHROL DIAL TRANSPL, V14, P22, DOI 10.1093/ndt/14.suppl_2.22; Leong PL, 2002, ONCOGENE, V21, P2846, DOI 10.1038/sj.onc.1205385; Leyland-Jones B, 2003, LANCET ONCOL, V4, P459, DOI 10.1016/S1470-2045(03)01163-X; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Liu WM, 2004, ONCOGENE, V23, P981, DOI 10.1038/sj.onc.1207294; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Opdam FJM, 2004, ONCOGENE, V23, P6647, DOI 10.1038/sj.onc.1207887; Pajonk F, 2004, ONCOGENE, V23, P8987, DOI 10.1038/sj.onc.1208140; SACKS PG, 1988, CANCER RES, V48, P2858; Shasha D, 2001, SEMIN HEMATOL, V38, P8; TABBARA IA, 1993, ARCH INTERN MED, V153, P298, DOI 10.1001/archinte.153.3.298; Thatcher N, 1998, SEMIN ONCOL, V25, P23; Thomas SM, 2003, CANCER RES, V63, P5629; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VIROLAINEN E, 1983, OTOLARYNG HEAD NECK, V91, P126, DOI 10.1177/019459988309100204; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Xi SC, 2003, CANCER RES, V63, P6763; Yasuda Y, 2003, CARCINOGENESIS, V24, P1021, DOI 10.1093/carcin/bgg060; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yokomizo R, 2002, MOL HUM REPROD, V8, P441, DOI 10.1093/molehr/8.5.441; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719	46	137	150	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2005	24	27					4442	4449		10.1038/sj.onc.1208635	http://dx.doi.org/10.1038/sj.onc.1208635			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15856028				2022-12-17	WOS:000229976900013
J	Nakshatri, H; Rice, SE; Bhat-Nakshatri, P				Nakshatri, H; Rice, SE; Bhat-Nakshatri, P			Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase	ONCOGENE			English	Article						parthenolide; TRAIL; apoptosis; JNK; NF-kappa B; breast cancer	KAPPA-B ACTIVATION; SESQUITERPENE LACTONE PARTHENOLIDE; ALPHA-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; GROWTH-FACTOR RECEPTOR; MEDIATED APOPTOSIS; DEATH RECEPTORS; SIGNAL-TRANSDUCTION; SERINE-PROTEASE; IN-VIVO	The antitumor activity of the sesquiterpene lactone parthenolide, an active ingredient of medicinal plants, is believed to be due to the inhibition of DNA binding of transcription factors NF-kappaB and STAT-3, reduction in MAP kinase activity and the generation of reactive oxygen. In this report, we show that parthenolide activates c-Jun N-terminal kinase (JNK), which is independent of inhibition of NF-kappaB DNA binding and generation of reactive oxygen species. Parthenolide reversed resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Cancer cells treated with a combination of TRAIL and parthenolide underwent massive typical apoptosis and atypical apoptosis involving the loss of plasma membrane integrity. JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis. Parthenolide induced phosphorylation of Bid and increased TRAIL-dependent cleavage of Bid without affecting caspase 8 activities. Cytochrome c but not Smac/DIABLO was released from the mitochondria in cells treated with parthenolide alone. Parthenolide through JNK increased the TRAIL-mediated degradation of the antiapoptotic protein X-linked inhibitor of apoptosis ( XIAP). Enhanced XIAP cleavage correlated with increased and prolonged caspase 3 activity and PARP cleavage, suggesting that the sensitization to TRAIL involves 'feed forward' activation of caspase 3. These results identify a new antitumor activity of parthenolide, which can be exploited to reverse resistance of cancer cells to TRAIL, particularly those with elevated XIAP levels.	Indiana Univ, Sch Med, Dept Surg, Indiana Canc Res Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Univ, Sch Med, Dept Surg, Indiana Canc Res Inst, 1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu	Gelfand, Vladimir I/D-2545-2013	Gelfand, Vladimir I/0000-0002-6361-2798; Nakshatri, Harikrishna/0000-0001-8876-0052	NCI NIH HHS [R01-CA89153] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089153] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berman PA, 1997, FREE RADICAL BIO MED, V22, P1283, DOI 10.1016/S0891-5849(96)00508-4; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Berns EMJJ, 2000, CANCER RES, V60, P2155; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Bratton SB, 2003, CELL DEATH DIFFER, V10, P4, DOI 10.1038/sj.cdd.4401176; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Eid MA, 2002, INT J ONCOL, V21, P111; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hell K, 2003, CELL DEATH DIFFER, V10, P1234, DOI 10.1038/sj.cdd.4401298; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pozarowski P, 2003, CYTOM PART A, V54A, P118, DOI 10.1002/cyto.a.10057; Pozarowski P, 2003, CELL CYCLE, V2, P377, DOI 10.4161/cc.2.4.420; Reuther-Madrid JY, 2002, MOL CELL BIOL, V22, P8175, DOI 10.1128/MCB.22.23.8175-8183.2002; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Sah NK, 2003, J BIOL CHEM, V278, P20593, DOI 10.1074/jbc.M211010200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Singh TR, 2003, CANCER RES, V63, P5390; Sobota R, 2000, BIOCHEM BIOPH RES CO, V267, P329, DOI 10.1006/bbrc.1999.1948; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VANHAMME L, 1988, CARCINOGENESIS, V9, P653, DOI 10.1093/carcin/9.4.653; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 2001, CANCER RES, V61, P7339; Zhou Q, 2000, CANCER RES, V60, P2611	65	137	147	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7330	7344		10.1038/sj.onc.1207995	http://dx.doi.org/10.1038/sj.onc.1207995			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286701				2022-12-17	WOS:000224021400004
J	Koziczak, M; Holbro, T; Hynes, NE				Koziczak, M; Holbro, T; Hynes, NE			Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins	ONCOGENE			English	Article						FGFR; cyclin D; breast cancer; tyrosine kinase inhibitor	FIBROBLAST-GROWTH-FACTOR; TRANSCRIPTIONAL REGULATION; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR GENES; PROTEIN-KINASE; EXPRESSION; AMPLIFICATION; ERBB2; OVEREXPRESSION; ANGIOGENESIS	Overexpression of fibroblast growth factor receptor ( FGFR) tyrosine kinases has been found in many human breast cancers and has been associated with poor patient prognosis. In order to understand the mechanism by which FGFR mediates breast cancer cell proliferation, we used a low molecular weight compound, PD173074, that selectively inhibits FGFR tyrosine kinase activity and autophosphorylation. This potential anticancer agent caused a G1 growth arrest of MDA-MB-415, MDA-MB-453 and SUM 52 breast cancer cells. Our analyses revealed that FGFR signaling links to the cell cycle machinery via D-type cyclins. PD173074-mediated inhibition of FGFR activity caused downregulation of cyclin D1 and cyclin D2 expression, inhibition of cyclin D/cdk4 activity and, as a consequence, reduction of pRB phosphorylation. Retroviral-mediated ectopic expression of cyclin D1 prevented pRB hypophosphorylation and the cell cycle G1 block in PD173074-treated cells, suggesting a central role for D cyclins in proliferation of FGFR-driven breast cancer cells. The repression of FGFR activity caused downregulation of MAPK in MDA-MB-415 and MDA-MB453 cells. In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	nancy.hynes@fmi.ch						ADNANE J, 1991, ONCOGENE, V6, P659; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Chodosh LA, 2000, DEV BIOL, V219, P259, DOI 10.1006/dbio.2000.9614; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cross MJ, 2000, J CELL SCI, V113, P643; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Cuny M, 2000, CANCER RES, V60, P1077; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ETHIER SP, 1993, CANCER RES, V53, P627; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Giri D, 1999, CLIN CANCER RES, V5, P1063; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jang JH, 2001, CANCER RES, V61, P3541; Kim I, 2001, BBA-GENE STRUCT EXPR, V1518, P152, DOI 10.1016/S0167-4781(00)00282-7; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lavia P, 1999, BIOESSAYS, V21, P221; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 2001, GENOME BIOL, V2; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; RIMOKH R, 1994, BLOOD, V83, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	51	137	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3501	3508		10.1038/sj.onc.1207331	http://dx.doi.org/10.1038/sj.onc.1207331			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116089				2022-12-17	WOS:000221101700001
J	Leu, CM; Wong, FH; Chang, CM; Huang, SF; Hu, CP				Leu, CM; Wong, FH; Chang, CM; Huang, SF; Hu, CP			Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways	ONCOGENE			English	Article						IL-6; esophageal carcinoma; apoptosis; MAPK; STAT3	PROSTATE-CANCER CELLS; GROWTH-FACTOR-I; SERINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; IMMUNE-RESPONSE; MYELOMA CELLS; RISK-FACTORS; EXPRESSION; RECEPTOR	The production of interleukin-6 (IL-6) has been discovered in a variety of human tumors. Here we report the expression of IL-6, IL-6 receptor alpha (IL- 6Ralpha), and gp130 in human esophageal carcinoma tissues. We further demonstrate that IL- 6 protects an esophageal carcinoma cell line CE48T/VGH from apoptosis induced by staurosporine. IL-6 stimulation induced a rapid phosphorylation of gp130 and STAT3, and a dominant-negative STAT3 completely abolished the antiapoptotic effect. IL-6 also activated ERK 1/2 in CE48T/VGH cells. Inhibition of the ERK activation by PD98059 and transfection of a dominant-negative ERK2 completely blocked the protection of IL- 6 against apoptosis. Thus, both STAT and MAP kinase pathways are responsible for the IL-6-delivered survival signal in human esophageal carcinoma cells. In contrast, PI3-K inhibitors only partially attenuated the effect of IL-6, suggesting that PI3-K does not play a major role in the antiapoptotic signal of IL- 6 in our system. To investigate whether IL- 6 could induce the production of antiapoptotic molecules, proteins of the Bcl-2 family were measured. While Bcl-2, Bcl- x(L),, and Bax were not affected, Mcl-1 was induced by IL-6 in human esophageal carcinoma cells. Our results suggest that IL- 6 may contribute to the progression of esophageal cancers in an autocrine or paracrine manner.	Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; Natl Hlth Res Inst, Dept Intramural Res Affairs, Taipei, Taiwan; Natl Hlth Res Inst, Div Mol & Gen Med, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital	Hu, CP (corresponding author), Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan.	cphu@vghtpe.gov.tw	Huang, Shiu-Feng Kathy/E-3977-2010; Chang, Chung-Ming/E-3945-2010					Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; BLOT WJ, 1994, SEMIN ONCOL, V21, P403; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHEN T, 2001, CANCER RES, V60, P2132; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Enzinger PC, 1999, SEMIN ONCOL, V26, P12; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gallo RL, 1997, J INVEST DERMATOL, V109, P597, DOI 10.1111/1523-1747.ep12337529; Halapi E, 1998, MED ONCOL, V15, P203, DOI 10.1007/BF02787202; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HU CP, 1984, J NATL CANCER I, V72, P577; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Lauta VM, 2001, CYTOKINE, V16, P79, DOI 10.1006/cyto.2001.0982; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Ma YX, 1999, APMIS, V107, P514, DOI 10.1111/j.1699-0463.1999.tb01587.x; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; MEIR EV, 1990, CANCER RES, V50, P6683; Minshall C, 1996, J IMMUNOL, V156, P939; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Oka M, 1996, CANCER RES, V56, P2776; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Okamoto M, 1997, CANCER RES, V57, P141; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Ribeiro U, 1996, BRIT J SURG, V83, P1174, DOI 10.1002/bjs.1800830905; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takeda K, 1998, J IMMUNOL, V161, P4652; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WONG FH, 1994, CANCER INVEST, V12, P121, DOI 10.3109/07357909409024867; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200	46	137	147	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7809	7818		10.1038/sj.onc.1207084	http://dx.doi.org/10.1038/sj.onc.1207084			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586407				2022-12-17	WOS:000186240200011
J	Rasheed, ZA; Rubin, EH				Rasheed, ZA; Rubin, EH			Mechanisms of resistance to topoisomerase I-targeting drugs	ONCOGENE			English	Review						topoisomerase I; camptothecin; topotecan; irinotecan; drug resistance	TERNARY CLEAVABLE COMPLEX; HUMAN-COLON-CANCER; HUMAN TUMOR-CELLS; BREAST-CANCER; WERNER-SYNDROME; HUMAN LIVER; DNA-DAMAGE; CAMPTOTHECIN RESISTANCE; CELLULAR ACCUMULATION; MULTIDRUG-RESISTANCE	DNA topoisomerases are a class of enzymes that alter the topology of DNA and are targets of several anticancer drugs. Camptothecins (CPTs) are a relatively new family of compounds that specifically target topoisomerase I (Top1). These compounds 'poison' Top1 by binding to the Top1 - DNA complex in a manner that prevents the religation of DNA. Topotecan and irinotecan are two CPTs that are approved for the treatment of a variety of malignancies, including colorectal, ovarian, and small cell lung cancers, as well as myeloid malignancies. Although CPTs have proven to be effective anticancer drugs, resistance is still a critical clinical problem. The mechanisms underlying de novo and acquired clinical resistance to CPTs and the newer classes of Top1 poisons are unclear. However, based on preclinical studies, it is likely that clinical resistance to these drugs is the result of: ( 1) inadequate accumulation of drug in the tumor, ( 2) resistance-conferring alterations in Top1, or ( 3) alterations in the cellular response to the Top1 - CPT interaction. This review will focus on the current knowledge regarding mechanisms of resistance to CPTs and other Top1-targeting drugs.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol & Cellular Pharmacol, Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rasheed, ZA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol & Cellular Pharmacol, Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.	rasheeze@umdnj.edu						Ahmed F, 1999, ANTICANCER RES, V19, P2067; Allen JD, 2002, CANCER RES, V62, P2294; Allen JD, 1999, CANCER RES, V59, P4237; Bailly C, 1999, BIOCHEMISTRY-US, V38, P8605, DOI 10.1021/bi983052y; Bearden DT, 2001, PHARMACOTHERAPY, V21, p224S, DOI 10.1592/phco.21.16.224S.33997; BENEDETTI P, 1993, CANCER RES, V53, P4343; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Brangi M, 1999, CANCER RES, V59, P5938; Buckwalter CA, 1996, CANCER RES, V56, P1674; Byrne Lee James, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P415; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang JY, 2002, CANCER RES, V62, P3716; CHEN AY, 1991, CANCER RES, V51, P6039; Ciotti M, 1999, BIOCHEM BIOPH RES CO, V260, P199, DOI 10.1006/bbrc.1999.0453; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cummings J, 2002, BIOCHEM PHARMACOL, V63, P607, DOI 10.1016/S0006-2952(01)00812-7; Cusack JC, 2001, CANCER RES, V61, P3535; Danks MK, 1998, CANCER RES, V58, P20; Danks MK, 1996, CANCER RES, V56, P1664; DARPA P, 1990, CANCER RES, V50, P6919; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; Edwards TK, 2000, J BIOL CHEM, V275, P36181, DOI 10.1074/jbc.M006628200; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; Faneyte IF, 2002, CLIN CANCER RES, V8, P1068; Fiorani Paola, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P717; FUJIMORI A, 1995, CANCER RES, V55, P1339; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Gounder Murugesan K., 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P805; Gupta E, 2000, ANTICANCER RES, V20, P1013; GUPTA E, 1998, CANC THER, V1, P292; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hanioka N, 2001, XENOBIOTICA, V31, P687, DOI 10.1080/00498250110057341; HARKER WG, 1995, CANCER RES, V55, P1707; HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038; Honjo Y, 2001, CANCER RES, V61, P6635; HOUGHTON PJ, 1995, CANCER CHEMOTH PHARM, V36, P393; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huinink WTB, 1997, J CLIN ONCOL, V15, P2183, DOI 10.1200/JCO.1997.15.6.2183; Humerickhouse R, 2000, CANCER RES, V60, P1189; Kanzaki A, 2001, JPN J CANCER RES, V92, P452, DOI 10.1111/j.1349-7006.2001.tb01115.x; Kawabata S, 2001, BIOCHEM BIOPH RES CO, V280, P1216, DOI 10.1006/bbrc.2001.4267; Kerrigan JE, 2001, BIOCHEMISTRY-US, V40, P9792, DOI 10.1021/bi010913l; Khanna R, 2000, CANCER RES, V60, P4725; Koike K, 1997, CANCER RES, V57, P5475; Komatani H, 2001, CANCER RES, V61, P2827; Komatani H, 1999, CANCER RES, V59, P2701; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Ma J, 1998, BRIT J CANCER, V77, P1645, DOI 10.1038/bjc.1998.270; Maliepaard M, 1999, CANCER RES, V59, P4559; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Meijer M, 2002, J BIOL CHEM, V277, P4050, DOI 10.1074/jbc.M109383200; MIRSKI SEL, 1995, CANCER RES, V55, P2129; MO YY, 2001, J BIOL CHEM, V14, P14; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Ohashi N, 1996, JPN J CANCER RES, V87, P1280, DOI 10.1111/j.1349-7006.1996.tb03144.x; Pandit B, 2001, CANCER CHEMOTH PHARM, V48, P312, DOI 10.1007/s002800100352; Park SY, 2002, CANCER RES, V62, P459; Perego P, 2001, CANCER RES, V61, P6034; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Rajendra R, 2003, CANCER RES, V63, P3228; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; RASHEED ZA, 2000, P AM ASSOC CANC RES, V41, P210; Rasheed Zeshaan A., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1156; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; Rothenberg ML, 1996, J CLIN ONCOL, V14, P1128, DOI 10.1200/JCO.1996.14.4.1128; RUBIN E, 1995, CLIN CANCER RES, V1, P269; RUBIN E, 1994, J BIOL CHEM, V269, P2433; Saleem A, 2000, ANN NY ACAD SCI, V922, P46; SALEEM A, 2002, P AM ASS CANC RES S, V43, P74; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Simon JA, 2000, CANCER RES, V60, P328; SMITH PJ, 1989, INT J RADIAT BIOL, V55, P217, DOI 10.1080/09553008914550271; SQUIRES S, 1993, CANCER RES, V53, P2012; Stewart L., 2001, P AM ASS CANC RES S, V42, P80; Takahashi T, 1997, JPN J CANCER RES, V88, P1211, DOI 10.1111/j.1349-7006.1997.tb00351.x; Takatani H, 1997, JPN J CANCER RES, V88, P160, DOI 10.1111/j.1349-7006.1997.tb00361.x; Takenaga N, 2002, DRUG METAB DISPOS, V30, P494, DOI 10.1124/dmd.30.5.494; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Tsurutani J, 2002, LUNG CANCER-J IASLC, V35, P299, DOI 10.1016/S0169-5002(01)00425-1; Urasaki Y, 2001, CANCER RES, V61, P1964; Urasaki Y, 2001, CANCER RES, V61, P504; Valkov NI, 2000, BRIT J HAEMATOL, V108, P331; VANWARDENBURG R, 2002, P AM ASSOC CANC RES, V43, P793; WALL ME, 1995, CANCER RES, V55, P753; Walowsky C, 1999, J BIOL CHEM, V274, P7302, DOI 10.1074/jbc.274.11.7302; WALTON MI, 1993, CANCER RES, V53, P1853; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Wang HY, 2002, CANCER RES, V62, P2483; Wang J C, 1985, Harvey Lect, V81, P93; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LF, 1997, CANCER RES, V57, P1516; Wessel I, 1997, CANCER RES, V57, P4451; Wierdl M, 2001, CANCER RES, V61, P5078; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; Yang CH, 2000, BIOCHEM PHARMACOL, V60, P831, DOI 10.1016/S0006-2952(00)00396-8; Zamboni WC, 1998, CLIN CANCER RES, V4, P743; Zhang XW, 2000, ANTI-CANCER DRUG, V11, P747, DOI 10.1097/00001813-200010000-00012; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6	119	137	148	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7296	7304		10.1038/sj.onc.1206935	http://dx.doi.org/10.1038/sj.onc.1206935			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576839				2022-12-17	WOS:000186112500004
J	Voltz, JW; Weinman, EJ; Shenolikar, S				Voltz, JW; Weinman, EJ; Shenolikar, S			Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation	ONCOGENE			English	Article						NHERF; PDZ; ERM; epithelium; mitogen; cancer	TRANSMEMBRANE CONDUCTANCE REGULATOR; CAMP-MEDIATED INHIBITION; NA+/H+ EXCHANGER NHE3; KINASE-A; BETA(2)-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; ALLELIC LOSS; EZRIN; ASSOCIATION; BINDING	NHERF (Na+/H+ exchanger regulatory factor or NHERF-1) and E3KARP (NHE3 kinase A regulatory protein or NHERF-2) are structurally related protein adapters that are highly expressed in epithelial tissues. NHERF proteins contain two tandem PDZ domains and a C-terminal sequence that binds several members of the ERM (ezrin-radixin-moesin) family of membrane-cytoskeletal adapters. Although identified as a regulator of NHE3, recent evidence points to a broadening role for NHERF in the function, localization and/or turnover of G-protein coupled receptors, platelet-derived growth factor receptor and ion transporters such as CFTR, Na/Pi cotransporter, Na/HCO3 cotransporter and Trp (calcium) channels. NHERF also recruits non-membrane proteins such as the c-Yes/YAP-65 complex, members of the phospholipase Cp family and the GRK6A protein kinase to apical surface of polarized epithelial cells where they regulate or respond to membrane signals. While two distinct models have been proposed for NHERF's role in signal transduction, the common theme is NHERF's ability to bring together membrane and non-membrane proteins to regulate cell metabolism and growth. NHERF overexpression in human breast cancers and mutations in NHERF targets, such as CFTR and merlin, the product of Neurofibromatosis NF2 tumor suppressor gene, that impair NHERF binding suggest that aberrant NHERF function contributes to human disease.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Maryland, Sch Med, Div Nephrol, Dept Med, Baltimore, MD 21202 USA	Duke University; University System of Maryland; University of Maryland Baltimore	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	sheno001@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055881] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55881] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; BARBER DL, 1992, J BIOL CHEM, V267, P20607; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; JAY DG, 1999, BIOCHIM BIOPHYS ACTA, V1424, P39; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; Lagana A, 2000, J CELL SCI, V113, P3649; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Shao ZM, 2000, ONCOGENE, V19, P4337, DOI 10.1038/sj.onc.1203785; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shimizu K, 2000, GENOMICS, V65, P113, DOI 10.1006/geno.2000.6154; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Stokowski RP, 2000, AM J HUM GENET, V66, P873, DOI 10.1086/302812; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Tokunou M, 2000, LAB INVEST, V80, P1643, DOI 10.1038/labinvest.3780174; WADE JB, 2001, AM J PHYSIOL, V280, P192; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Weinman EJ, 1999, BBA-GENE STRUCT EXPR, V1447, P71, DOI 10.1016/S0167-4781(99)00100-1	44	137	141	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6309	6314		10.1038/sj.onc.1204774	http://dx.doi.org/10.1038/sj.onc.1204774			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607833				2022-12-17	WOS:000171640600006
J	Cruzalegui, FH; Cano, E; Treisman, R				Cruzalegui, FH; Cano, E; Treisman, R			ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry	ONCOGENE			English	Article						TCF; SRE; ERK; MAP kinase; Elk-1; SAP-1	SERUM RESPONSE FACTOR; TERNARY COMPLEX FACTORS; MAP KINASE PATHWAYS; C-FOS EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PROTEIN-KINASE; TRANSACTIVATION DOMAIN; ELEMENT; BINDING; CASCADES	Elk-1, a member of the TCF family of Ets domain proteins, contains a C-terminal transcriptional activation domain with multiple copies of the MAPK core consensus sequence S/T-P. This region is phosphorylated by MAP kinases in vitro and in vivo, but the extent and kinetics of phosphorylation at the different sites have not been investigated in detail. We prepared antisera against the phosphorylated forms of residues T353, T363, T368, S383, S389 and T417. The antisera specifically recognize the phosphorylated Elk-1 C terminus and are specific for their cognate sites, as assessed by peptide competition and mutagenesis experiments. Analysis of cells stably expressing Elk-1 in vivo shows that following serum or TPA stimulation, residues T353, T363, T368, S383, S389 and T417 become phosphorylated with similar kinetics. Mutation of any one site does not prevent phosphorylation of the others. Mutation to alanine of S383, F378 or W379, which virtually abolishes transcriptional activation by Elk-1, does not affect phosphorylation of any sites tested. Analysis of Elk-1 using two-dimensional gel electrophoresis shows that following ERK activation Elk-1 receives at least six phosphates in addition to those present prior to stimulation. We propose that the Elk-1 C-terminal regulatory domain becomes stoichiometrically phosphorylated following growth factor stimulation.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135; Treisman, Richard/0000-0002-9658-0067				Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Shen F, 1996, J BIOL CHEM, V271, P4827; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	34	137	140	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7948	7957		10.1038/sj.onc.1203362	http://dx.doi.org/10.1038/sj.onc.1203362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637505				2022-12-17	WOS:000084634600003
J	Matise, MP; Joyner, AL				Matise, MP; Joyner, AL			Gli genes in development and cancer	ONCOGENE			English	Article						Ci; Gli1; Gli2; Gli3; hedgehog; nervous system	HEDGEHOG SIGNALING PATHWAY; PROTEIN-KINASE-A; GREIG CEPHALOPOLYSYNDACTYLY SYNDROME; CUBITUS-INTERRUPTUS PROTEIN; KINESIN-RELATED PROTEIN; BASAL-CELL CARCINOMA; SONIC-HEDGEHOG; FLOOR PLATE; LIMB DEVELOPMENT; TRANSDUCING HEDGEHOG	With the realization that many proto-oncogenes and tumor suppressor genes are expressed and have important functions during mammalian development, it is clear that cancer often involves the inappropriate activation of genetic pathways used during normal development. A signaling cascade that has been of considerable interest to both developmental and cancer biologists involves the Hedgehog (Hh) family of secreted proteins. To date, the only transcription factors shown to be directly downstream of Hh are the zinc-finger containing proteins Cubitus interruptus (Ci) and Gli, in flies and vertebrates, respectively, The identification of many of the genes and proteins involved in Hh signaling has come largely from genetic and biochemical studies in Drosophila. Ci mediates Hh signaling through a Hh-dependent set of protein modifications that alter the activity of Ci on Hh target genes, Recent evidence suggests vertebrate Gli proteins may be similarly regulated. The interest in this pathway has taken on added importance with the identification of mutations in Hh pathway genes, including Gli genes, in several human developmental disorders and cancers. We discuss models for how Gli proteins mediate Hh signaling in both vertebrate development and cancers.	NYU, Sch Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol Neurosci, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University; New York University; New York University	Matise, MP (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, 675 Hoes Lane,Room R325, Piscataway, NJ 08854 USA.							Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; ALBERLE H, 1997, EMBO J, V16, P3797; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Biesecker LG, 1997, NAT GENET, V17, P259, DOI 10.1038/ng1197-259; Buscher D, 1997, MECH DEVELOP, V62, P175, DOI 10.1016/S0925-4773(97)00656-4; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1999, DEVELOPMENT, V126, P3607; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Ding Q, 1998, DEVELOPMENT, V125, P2533; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Grindley JC, 1997, DEV BIOL, V188, P337, DOI 10.1006/dbio.1997.8644; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; IALTABA AR, 1998, DEVELOPMENT, V125, P2203; IALTABA AR, 1997, CELL, V90, P193; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1997, COLD SPRING HARB SYM, V62, P205; Kalderon D, 1997, CURR BIOL, V7, pR759, DOI 10.1016/S0960-9822(06)00398-8; Kalff-Suske M, 1999, HUM MOL GENET, V8, P1769, DOI 10.1093/hmg/8.9.1769; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Lee J, 1997, DEVELOPMENT, V124, P2537; Lessing D, 1998, DEVELOPMENT, V125, P1469; Lewis KE, 1999, DEVELOPMENT, V126, P2397; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Matise MP, 1998, DEVELOPMENT, V125, P2759; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Mo R, 1997, DEVELOPMENT, V124, P113; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Motoyama J, 1998, MECH DEVELOP, V78, P81, DOI 10.1016/S0925-4773(98)00149-X; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Platt KA, 1997, MECH DEVELOP, V62, P121, DOI 10.1016/S0925-4773(96)00648-X; Price MA, 1999, DEVELOPMENT, V126, P4331; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; ROBERTS WM, 1989, CANCER RES, V49, P5407; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCHWARTZ C, 1995, DEVELOPMENT, V121, P1625; Shin SH, 1999, P NATL ACAD SCI USA, V96, P2880, DOI 10.1073/pnas.96.6.2880; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; VORTKAMP A, 1992, MAMM GENOME, V3, P461, DOI 10.1007/BF00356157; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	78	137	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7852	7859		10.1038/sj.onc.1203243	http://dx.doi.org/10.1038/sj.onc.1203243			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630638				2022-12-17	WOS:000084405900002
J	Piret, B; Schoonbroodt, S; Piette, J				Piret, B; Schoonbroodt, S; Piette, J			The ATM protein is required for sustained activation of NF-kappa B following DNA damage	ONCOGENE			English	Article						NF-kappa B; camptothecin; ataxia-telangiectasia; DNA damage; DNA-PK; ATM	DAUNORUBICIN-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION PATHWAY; ATAXIA-TELANGIECTASIA CELLS; NIJMEGEN BREAKAGE SYNDROME; NUCLEAR TYROSINE KINASE; ALPHA-INDUCED APOPTOSIS; LONG TERMINAL REPEAT; TRANSCRIPTION FACTOR; C-ABL; IONIZING-RADIATION	Cells lacking an intact ATM gene are hypersensitive to ionizing radiation and show multiple defects in the cell cycle-coupled checkpoints. DNA damage usually triggers cell cycle arrest through, among other things, the Another DNA-damage responsive factor is NF-kappa B. It is activated by various stress situations, including oxidative stress, and by DNA-damaging compounds such as topoisomerase poisons. We found that cells from Ataxia Telangiectasia patients exhibit a defect in NF-kappa B activation in response to treatment with camptothecin, a topoisomerase I poison. In AT cells, this activation is shortened or suppressed, compared to that observed in normal cells. Ectopic expression of the ATM protein in AT cells increases the activation of NF-kappa B in response to camptothecin. M059J glioblastoma cells that do not express the DNA-PK catalytic subunit respond normally to camptothecin. These results support the hypothesis that NF-kappa B is a DNA damage-responsive transcription factor and that its activation pathway by DNA damage shares some components with the one leading to p53 activation.	Univ Liege, Lab Fundamental Virol & Immunol, B-4000 Liege, Belgium	University of Liege	Piette, J (corresponding author), Univ Liege, Lab Fundamental Virol & Immunol, B23, B-4000 Liege, Belgium.							Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BERTONCINI CRA, 1995, NUCLEIC ACIDS RES, V23, P2995, DOI 10.1093/nar/23.15.2995; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Brown L, 1997, NATURE, V387, P450, DOI 10.1038/387450a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P14; Fritz E, 1997, P NATL ACAD SCI USA, V94, P4538, DOI 10.1073/pnas.94.9.4538; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOGA A, 1995, ONCOGENE, V11, P791; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jung M, 1997, CANCER RES, V57, P24; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Le Page C, 1998, BIOCHEM BIOPH RES CO, V243, P451; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; Liu WM, 1998, INT J ONCOL, V12, P793; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1993, AM J HUM GENET, V53, P1206; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; Piette J, 1997, BIOL CHEM, V378, P1237; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; PLANCHON SM, 1995, CANCER RES, V55, P3706; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; QUINTO I, 1993, J BIOL CHEM, V268, P26719; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright J, 1996, AM J HUM GENET, V59, P839; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	96	137	142	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2261	2271		10.1038/sj.onc.1202541	http://dx.doi.org/10.1038/sj.onc.1202541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327072				2022-12-17	WOS:000079525100010
J	Khanna, M; Park, P; Zirvi, M; Cao, WG; Picon, A; Day, J; Paty, P; Barany, F				Khanna, M; Park, P; Zirvi, M; Cao, WG; Picon, A; Day, J; Paty, P; Barany, F			Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors	ONCOGENE			English	Article						colorectal cancer; K-ras mutations; polymerase chain reaction; ligase detection reaction; thermostable ligase; microdissection	POLYMERASE CHAIN-REACTION; OLIGONUCLEOTIDE LIGATION ASSAY; SEQUENCE-CODED SEPARATION; THERMOPHILUS DNA-LIGASE; COLORECTAL-CANCER; GENE-MUTATIONS; POINT MUTATIONS; PANCREATIC ADENOCARCINOMA; MOLECULAR DIAGNOSIS; CODON-12 MUTATIONS	Point mutations in codons 12, 13, and 61 of the K-ras gene occur early in the development of colorectal cancer and are preserved throughout the course of tumor progression. These mutations can serve as biomarkers for shed or circulating tumor cells and may be useful for diagnosis of early, curable tumors and for staging of advanced cancers. We have developed a multiplex polymerase chain reaction/ligase detection reaction (PCR/LDR) method which identifies all 19 possible single-base mutations in K-ras codons 12, 13, and 61, with a sensitivity of 1 in 500 wild-type sequences. In a blinded study, 144 paraffin-embedded archival colon carcinomas were microdissected and K-ras mutations determined by both dideoxy-sequencing and multiplex PCR/LDR. Results were concordant for 134 samples. The ten discordant samples were re-evaluated using higher sensitivity uniplex PCR/LDR, and the original multiplex PCR/LDR result was confirmed in nine of these ten cases. Multiplex PCR/LDR was able to identify mutations in solid tumors or paraffin-embedded tissues containing a majority of wild-type stromal cells, with or without microdissection. The technique is well suited for large scale studies and for analysis of clinical samples containing a minority population of mutated cells.	Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Barany, F (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, Box 62,1300 York Ave, New York, NY 10021 USA.				NCI NIH HHS [CA65930-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA065930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; BARANY F, 1991, GENE, V109, P1, DOI 10.1016/0378-1119(91)90582-V; Barany F, 1991, PCR Methods Appl, V1, P5, DOI 10.1101/gr.1.1.5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Belgrader P, 1996, GENOME SCI TECHNOLOG, V1, P77, DOI [DOI 10.1089/GST.1996.1.77, 10.1089/gst.1996.1.77]; BENHATTAR J, 1993, GASTROENTEROLOGY, V104, P1044, DOI 10.1016/0016-5085(93)90272-E; BERTHELEMY P, 1995, ANN INTERN MED, V123, P188, DOI 10.7326/0003-4819-123-3-199508010-00005; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOYLE JO, 1994, AM J SURG, V168, P429, DOI 10.1016/S0002-9610(05)80092-3; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CALDAS C, 1994, CANCER RES, V54, P3568; CAPELLA G, 1991, ENVIRON HEALTH PERSP, V93, P125, DOI 10.2307/3431180; Cha R S, 1992, PCR Methods Appl, V2, P14; CHEHAB FF, 1989, P NATL ACAD SCI USA, V86, P9178, DOI 10.1073/pnas.86.23.9178; CHEN J, 1991, ANAL BIOCHEM, V195, P51, DOI 10.1016/0003-2697(91)90293-3; CHEN J, 1994, ENV HLTH PERSPECT, V3, P227; Day DJ, 1996, HUM MOL GENET, V5, P2039, DOI 10.1093/hmg/5.12.2039; DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226; DIGIUSEPPE JA, 1994, AM J PATHOL, V144, P889; EGGERDING FA, 1995, HUM MUTAT, V5, P153, DOI 10.1002/humu.1380050209; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEERO WG, 1993, NEUROLOGY, V43, P668, DOI 10.1212/WNL.43.4.668; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GROSSMAN PD, 1994, NUCLEIC ACIDS RES, V22, P4527, DOI 10.1093/nar/22.21.4527; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HASEGAWA H, 1995, ONCOGENE, V10, P1413; HAYASHI N, 1994, CANCER RES, V54, P3853; HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2; HORN T, 1986, TETRAHEDRON LETT, V27, P4705, DOI 10.1016/S0040-4039(00)85043-1; Jacobson D R, 1992, PCR Methods Appl, V1, P299; JEN J, 1994, CANCER RES, V54, P5523; KAHN SM, 1991, ONCOGENE, V6, P1079; KHRAPKO K, 1994, NUCLEIC ACIDS RES, V22, P364, DOI 10.1093/nar/22.3.364; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KORN SH, 1993, J CLIN PATHOL, V46, P621, DOI 10.1136/jcp.46.7.621; KWOK S, 1990, NUCLEIC ACIDS RES, V18, P999, DOI 10.1093/nar/18.4.999; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVI S, 1991, CANCER RES, V51, P3497; LI HH, 1990, P NATL ACAD SCI USA, V87, P4580, DOI 10.1073/pnas.87.12.4580; LO YMD, 1991, NUCLEIC ACIDS RES, V19, P3561, DOI 10.1093/nar/19.13.3561; LOSI L, 1992, EUR J CANCER, V28A, P1115, DOI 10.1016/0959-8049(92)90468-H; LU ZB, 1993, PCR METH APPL, V3, P176; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3071, DOI 10.1093/nar/24.15.3071; MANSFIELD V, 1992, PCR METH APPL, V1, P211; Mao L, 1996, SCIENCE, V271, P659, DOI 10.1126/science.271.5249.659; MAO L, 1994, CANCER RES, V54, P1634; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MOERKERK P, 1994, CANCER RES, V54, P3376; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK P, 1998, UNPUB; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravin J S, 1995, GUT, V36, P81; REDSTON MS, 1995, GASTROENTEROLOGY, V108, P383, DOI 10.1016/0016-5085(95)90064-0; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P8392, DOI 10.1093/nar/17.20.8392; RUST S, 1993, NUCLEIC ACIDS RES, V21, P3623, DOI 10.1093/nar/21.16.3623; SATO Y, 1990, AM J PATHOL, V136, P267; SEYAMA T, 1992, NUCLEIC ACIDS RES, V20, P2493, DOI 10.1093/nar/20.10.2493; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMITH AJ, 1994, CANCER RES, V54, P5527; TADA M, 1993, CANCER RES, V53, P2472; TORIBARA NW, 1995, NEW ENGL J MED, V332, P861, DOI 10.1056/NEJM199503303321306; TRUMPER LH, 1994, BRIT J CANCER, V70, P278, DOI 10.1038/bjc.1994.292; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; WINNDEEN E, 1993, AM J HUM GENET, V53, P1512; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757; WU S, 1994, EARLY DETECTION CANC, P237; Zhu D, 1997, CANCER RES, V57, P2485	80	137	161	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					27	38		10.1038/sj.onc.1202291	http://dx.doi.org/10.1038/sj.onc.1202291			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926917				2022-12-17	WOS:000078166000004
J	Jager, R; Herzer, U; Schenkel, J; Weiher, H				Jager, R; Herzer, U; Schenkel, J; Weiher, H			Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice	ONCOGENE			English	Article						bcl-2; transgenic mice; mammary gland; involution; tumorigenesis	HUMAN BREAST; CHROMOSOMAL BREAKPOINT; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; PROTEIN; DEATH; GENE; TISSUE	Expression of the apoptosis-inhibitory protein Bcl-2 has frequently been detected in human cancer including mammary carcinoma. The functional significance of its expression has been well established in experimental tumors of the lymphoid system, however, remains to be elucidated for epithelial tumors. In order to assess the role of Bcl-2 in mammary tumorigenesis me have generated WAP-bcl-2 transgenic mice. The strong overexpression of Bcl-2 in lactating mammary glands was preserved during early postlactational involution and apoptosis of alveolar epithelial cells was prevented without influencing the dedifferentiation of the milk-producing epithelium. Although Bcl-2 overexpression was not sufficient to induce spontaneous tumors it, however, led to an accelerated development of MMTVmyc transgene-induced mammary tumors. In the mammary glands of MMTVmyc transgenic mice, a high proportion of apoptotic cells was detected which was significantly reduced in the mammary glands of WAP-bcl-2/MMTVmyc double transgenic mice. Taken together, these results suggest that Bcl-2 contributes to mammary tumorigenesis by inhibiting apoptosis.	FORSCHUNGSZENTRUM KARLSRUHE,GENET INST,D-76021 KARLSRUHE,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology			Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; ANDRES AC, 1991, ONCOGENE, V6, P771; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BCHINI O, 1991, ENDOCRINOLOGY, V128, P539, DOI 10.1210/endo-128-1-539; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; BURDON T, 1991, J BIOL CHEM, V266, P6909; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HAGUE A, 1994, ONCOGENE, V9, P3367; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hogan B., 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; JIANG SX, 1995, J PATHOL, V177, P135, DOI 10.1002/path.1711770206; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LI B, 1996, MOL CARCINOG, V14, P75; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pullan S, 1996, J CELL SCI, V109, P631; SANDGREN EP, 1995, CANCER RES, V55, P3915; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WANG TTY, 1995, CANCER RES, V55, P2487; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	56	137	140	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1787	1795		10.1038/sj.onc.1201353	http://dx.doi.org/10.1038/sj.onc.1201353			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362445				2022-12-17	WOS:A1997XZ72500005
J	Algar, EM; Khromykh, T; Smith, SI; Blackburn, DM; Bryson, GJ; Smith, PJ				Algar, EM; Khromykh, T; Smith, SI; Blackburn, DM; Bryson, GJ; Smith, PJ			A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines	ONCOGENE			English	Article						WT1; leukaemia; apoptosis	WILMS-TUMOR; GENE; IDENTIFICATION; MUTATIONS; PROTEINS	The response of the CML-BC cell line, K562, the myelomonocytic cell line MM6 and the promyelocytic leukaemia cell line HL-60, to a 15 mer WT1 antisense oligonucleotide, targeted to the translation initiation site of the WT1 mRNA was examined. K562 cells exposed to 0.4 mu M antisense oligonucleotide showed markedly reduced proliferation which was associated with reduced cell viability. Sense, scrambled and mutant antisense oligonucleotides had no effect on the proliferation of K562 cells. MM6 cells exposed to 0.4 mu M antisense oligonucleotide also showed significantly reduced cellular proliferation which was also accompanied by loss of cell viability. In the K562 and MM6 antisense cultures that exhibited reduced cell viability, both DNA fragmentation and morphological features consistent with apoptosis could be identified. In contrast the growth of HL-60 cells was unaffected by exposure to oligonucleotide. In each of the cell WT1 antisense oligonucleotide abrogated WT1 protein expression, and analysis of WT1 coding sequence in these cells showed that no oncogenic point mutations in the gene were present. We propose therefore that in some myeloid leukaemia cell lines, the expression of a normal WT1 protein is necessary for cell proliferation and that it plays a role in maintaining the viability of some leukaemia cells.	UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT PATHOL,HERSTON,QLD 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT HAEMATOL & ONCOL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Brisbane & Women's Hospital; University of Queensland; Royal Children's Hospital Melbourne	Algar, EM (corresponding author), UNIV QUEENSLAND,SCH MED,DEPT PATHOL,HERSTON RD,HERSTON,QLD 4006,AUSTRALIA.		Algar, Elizabeth/B-3770-2012; Khromykh, Tatiana/D-3952-2017	Khromykh, Tatiana/0000-0001-6629-6885				BAIRD PN, 1992, ONCOGENE, V7, P2141; CHANDLER D, 1994, HUM PATHOL, V25, P789, DOI 10.1016/0046-8177(94)90248-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HABER DA, 1992, CANCER SURV, V12, P105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOTEM J, 1991, BLOOD, V78, P953; LOTEM J, 1989, BLOOD, V74, P579; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIYAGI T, 1993, LEUKEMIA, V7, P970; MORRIS JF, 1991, ONCOGENE, V6, P2339; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SEKIYA M, 1994, BLOOD, V83, P1876; SIMMS L, 1996, IN PRESS EUR J CANC; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WANG ZY, 1995, ONCOGENE, V10, P1243; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	27	137	149	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1005	1014						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649791				2022-12-17	WOS:A1996UA88400008
J	HENNIG, G; BEHRENS, J; TRUSS, M; FRISCH, S; REICHMANN, E; BIRCHMEIER, W				HENNIG, G; BEHRENS, J; TRUSS, M; FRISCH, S; REICHMANN, E; BIRCHMEIER, W			PROGRESSION OF CARCINOMA-CELLS IS ASSOCIATED WITH ALTERATIONS IN CHROMATIN STRUCTURE AND FACTOR-BINDING AT THE E-CADHERIN PROMOTER IN-VIVO	ONCOGENE			English	Article						E-CADHERIN PROMOTER; CARCINOMA PROGRESSION; IN VIVO FOOTPRINTING; GENE REGULATION; CHROMATIN STRUCTURE; DNA METHYLATION	LIGATION MEDIATED PCR; GENE-EXPRESSION; HYPERSENSITIVE SITES; ADHESION MOLECULE; DNA INTERACTIONS; INVIVO PROTEIN; METHYLATION; ACTIVATION; ENHANCER; IDENTIFICATION	E-cadherin has been identified as a tumor (invasion) suppressor gene, which is mutated in 50% of diffuse-type human gastric carcinomas. In other carcinomas, the expression of E-cadherin is down-regulated in the poorly differentiated cells such as from breast, bladder, lung and colon. We have here examined the in vivo properties of the genomic E-cadherin promoter in well and poorly differentiated carcinoma cell lines in order to gain insights into the mechanisms of E-cadherin downregulation in tumors. In vivo footprinting analysis revealed that positive regulatory elements of the E-cadherin promoter (a GC-rich region, the CCAAT-box and a palindromic element) are specifically bound by transcription factors in E-cadherin-expressing but not in non-expressing cells. The tested cell systems include more than a dozen carcinomas cell lines as well as mammary epithelial cells where E-cadherin expression can be switched off by activation of a Fos-estrogen receptor fusion protein and rhabdomyosarcoma cells where E-cadherin expression was induced by transfection with E1A. Mapping of DNase I hypersensitive sites showed that the chromatin structure in the promoter region is loosened in expressing but condensed in nonexpressing cells. Furthermore, the endogenous E-cadherin promoter is specifically methylated at CpG sites in the undifferentiated cells. We also show that the in vivo properties of the promoter in E-cadherin-negative carcinoma cells are similar as in mesenchymal cells, i.e. fibroblasts or sarcoma cells. These data suggest that silencing of the E-cadherin promoter during epithelial-mensenchymal transition and tumor progression is due to a loss of factor binding in vivo and to chromatin rearrangement in the regulatory region.	MAX DELBRUCK CENTRUM MOLEK MED,D-13125 BERLIN,GERMANY; INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Sanford Burnham Prebys Medical Discovery Institute; Swiss Institute Experimental Cancer Research								BECKER KF, 1994, CANCER RES, V54, P3845; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRABANT G, 1994, CANCER RES, V53, P4987; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DORUDI S, 1993, AM J PATHOL, V142, P981; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SALUZ HP, 1987, LABORATORY GUIDE GEN; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SORKIN BC, 1993, P NATL ACAD SCI USA, V90, P11356, DOI 10.1073/pnas.90.23.11356; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1994, CURR OPIN CELL BIOL, V5, P806; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VALLES AM, 1991, CELL MOTILITY FACTOR, P17; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WU C, 1978, J CELL BIOL, V79, P113	54	137	141	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					475	484						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630631				2022-12-17	WOS:A1995RN53000007
J	MANNE, V; YAN, N; CARBONI, JM; TUOMARI, AV; RICCA, CS; BROWN, JG; ANDAHAZY, ML; SCHMIDT, RJ; PATEL, D; ZAHLER, R; WEINMANN, R; DER, CJ; COX, AD; HUNT, JT; GORDON, EM; BARBACID, M; SEIZINGER, BR				MANNE, V; YAN, N; CARBONI, JM; TUOMARI, AV; RICCA, CS; BROWN, JG; ANDAHAZY, ML; SCHMIDT, RJ; PATEL, D; ZAHLER, R; WEINMANN, R; DER, CJ; COX, AD; HUNT, JT; GORDON, EM; BARBACID, M; SEIZINGER, BR			BISUBSTRATE INHIBITORS OF FARNESYLTRANSFERASE - A NOVEL CLASS OF SPECIFIC INHIBITORS OF RAS TRANSFORMED-CELLS	ONCOGENE			English	Article						P21 RAS PROTEINS; TRANSFORMATION; POSTTRANSLATIONAL MODIFICATIONS; MEVALONATE; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLTRANSFERASE	FARNESYL-PROTEIN TRANSFERASE; GERANYLGERANYL TRANSFERASE; SELECTIVE-INHIBITION; CDNA CLONING; POSTTRANSLATIONAL MODIFICATION; PRENYLATED PROTEINS; ALPHA-SUBUNIT; BETA-SUBUNIT; GTP-BINDING; P21RAS	We describe the biological properties of a new class of potent farnesyltransferase (FT) inhibitors designed as bisubstrate analog inhibitors. These inhibitors incorporate the structural motifs of both farnesyl pyrophosphate and the CAAX tetrapeptide, the two substrates of the reaction catalyzed by FT. Both the phosphinate inhibitor, EMS-185878, and the phosphonate inhibitor, BMS-184467, exhibited higher in vitro FT selectivity than some of the previously reported CVFM peptidomimentics and benzodiazepine analogs. Xenopus oocyte maturation induced by microinjected oncogenic Ras proteins was blocked by coinjected EMS-184467 and EMS-185878. However, both inhibitors showed poor cell activity presumably because of the doubly charged nature of the compounds. Thus, masking the charge on the carboxylate ion markedly improved the cell permeability of EMS-185878, leading to EMS-186511, the methyl carboxyl ester prodrug. EMS-186511 inhibited FT activity in whole cells as determined by inhibition of p21 Ras protein processing, inhibition of farnesylation of proteins including Ras and the accumulation of unfarnesylated Ras proteins in the cytosolic fraction. While the cellular effects of these bisubstrate analog inhibitors had no significant effect on growth of untransformed NIH3T3 cells, they produced pronounced inhibition of Ras transformed cell growth. Both the anchorage dependent and independent growth of ras transformed cells were severely curtailed by micromolar concentrations of EMS-186511, We also found that both H-ras and K-pas transformed cells are affected by this bisubstrate inhibitor. However, K-ras transformed cells appear to be less sensitive. The inhibition of FT activity in cells and the ensuing inhibition of ras transformed cell growth is further manifested in distinct morphological changes in cells. Cells flattened, became less refractile and grew in contact inhibited monolayer. Moreover, the highly diffused character of the actin cytoskeleton in the ras transformed cells was dramatically reverted to an organized network of stress cables crisscrossing the entire cells upon treatment with EMS-186511. All of these effects of EMS-186511 are limited to ras transformed cells that utilize farnesylated Ras, but are not seen in transformed cells that use geranylgeranyl Ras or myristoyl Ras. Significantly, these FT inhibitors did not produce any signs of gross cytotoxicity in untransformed, ras transformed cells or other oncogene transformed cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DIV DISCOVERY CHEM,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT BIOL MOLEC,PRINCETON,NJ 08543; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Bristol-Myers Squibb; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill	MANNE, V (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543, USA.		manne, veeraswamy/B-1954-2010	Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454; Hunt, John/0000-0001-6389-1021; manne, veeraswamy/0000-0002-1179-5529				AARONSON SA, 1971, J GEN VIROL, V13, P245, DOI 10.1099/0022-1317-13-2-245; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUENGER E, 1986, BIOCHEM BIOPH RES CO, V139, P209, DOI 10.1016/S0006-291X(86)80100-0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; CROWELL PL, 1994, BIOCHEM PHARMACOL, V47, P1405, DOI 10.1016/0006-2952(94)90341-7; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GEORGES RN, 1993, CANCER RES, V53, P1743; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; GRAY GD, 1993, CANCER RES, V53, P577; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P14182; KASHANISABET M, 1994, CANCER RES, V54, P900; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOIZUMI M, 1993, BIOL PHARM BULL, V16, P879; KOTHAPALLI R, 1993, LIPIDS, V28, P969, DOI 10.1007/BF02537116; LEFTHERIS K, 1994, BIOORG MED CHEM LETT, V4, P887, DOI 10.1016/S0960-894X(01)80257-2; LIU WC, 1992, J ANTIBIOT, V45, P454, DOI 10.7164/antibiotics.45.454; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MANNE V, 1991, MOL BASIS CANCER, P27; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; OMURA S, 1993, J ANTIBIOT, V46, P222, DOI 10.7164/antibiotics.46.222; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802; WALLACE RA, 1973, J EXP ZOOL, V18, P321; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	82	137	141	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1763	1779						17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753553				2022-12-17	WOS:A1995QX46900010
J	CARDER, P; WYLLIE, AH; PURDIE, CA; MORRIS, RG; WHITE, S; PIRIS, J; BIRD, CC				CARDER, P; WYLLIE, AH; PURDIE, CA; MORRIS, RG; WHITE, S; PIRIS, J; BIRD, CC			STABILIZED P53 FACILITATES ANEUPLOID CLONAL DIVERGENCE IN COLORECTAL-CANCER	ONCOGENE			English	Note							MUTATIONS; TUMORS; TUMORIGENESIS; EXPRESSION; ADENOMAS; MODEL	Mutations in the p53 tumour suppressor gene are amongst the most frequent genetic abnormalities acquired in tumours. Recent studies in vitro suggest that mutant p53 destabilises the genome and facilitates development of aneuploidy. Here, in a study of 83 colorectal carcinomas, we demonstrate that alterations in p53 (detected by immunocytochemical stabilisation) precede and apparently facilitate divergence of aneuploid sub-clones. Aneuploidy in these tumours (but not those with normal p53) is predominantly in the subtetraploid range, suggesting that endoreduplication is important in its origin. This association with a specific phase of carcinoma progression is not shared by other commonly acquired genetic abnormalities in these tumours. These observations highlight the critical role of p53 in the regulation of abnormal chromosome replication and afford an explanation for the association between p53 abnormalities, aneuploidy and biological aggression in cancer.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANCER RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; GEN INFIRM,DEPT HISTOPATHOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	University of Edinburgh; Leeds General Infirmary				Purdie, Colin/0000-0002-1258-4010				AHSTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BAKER SJ, 1990, CANCER RES, V50, P7717; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BODNER SM, 1992, ONCOGENE, V7, P743; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEDLANDER ML, 1984, J CLIN PATHOL, V37, P961, DOI 10.1136/jcp.37.9.961; FRITSCHE M, 1993, ONCOGENE, V8, P307; GIARETTI W, 1991, CANCER, V67, P1921, DOI 10.1002/1097-0142(19910401)67:7<1921::AID-CNCR2820670717>3.0.CO;2-X; HIDDEMANN W, 1986, CANCER, V58, P258, DOI 10.1002/1097-0142(19860715)58:2<258::AID-CNCR2820580210>3.0.CO;2-H; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JARVIS LR, 1987, J CLIN PATHOL, V40, P26, DOI 10.1136/jcp.40.1.26; JASS JR, 1989, J CLIN PATHOL, V42, P254, DOI 10.1136/jcp.42.3.254; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PURDIE CA, 1991, AM J PATHOL, V138, P807; QUIRKE P, 1986, BRIT J CANCER, V53, P477, DOI 10.1038/bjc.1986.75; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STARZYNSKA T, 1992, BRIT J CANCER, V66, P558, DOI 10.1038/bjc.1992.314; VANDENINGH HF, 1985, CANCER RES, V45, P3392; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	30	137	137	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1397	1401						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479757				2022-12-17	WOS:A1993KY32800035
J	DREBIN, JA; LINK, VC; GREENE, MI				DREBIN, JA; LINK, VC; GREENE, MI			MONOCLONAL-ANTIBODIES REACTIVE WITH DISTINCT DOMAINS OF THE NEU ONCOGENE-ENCODED P185 MOLECULE EXERT SYNERGISTIC ANTI-TUMOR EFFECTS INVIVO	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV IMMUNOL,PHILADELPHIA,PA 19104	University of Pennsylvania								CERIANI RL, 1987, CANCER RES, V47, P532; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, IN PRESS ONCOGENE; HERLYN D, 1985, J IMMUNOL, V134, P1300; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; Hudson L, 1980, PRACTICAL IMMUNOLOGY, V2nd; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOKAI Y, IN PRESS P NATL ACAD; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; REISFELD RA, 1986, SEMIN ONCOL, V13, P153; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SIBINGA EM, 1987, DEV RECOGNITION TRAN, P59; Slamon D, 1987, SCIENCE, V235, P117; TROWBRIDGE IS, 1981, NATURE, V294, P171, DOI 10.1038/294171a0; VOLLMERS HP, 1983, P NATL ACAD SCI-BIOL, V80, P6863, DOI 10.1073/pnas.80.22.6863	20	137	190	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					273	277						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	2451200				2022-12-17	WOS:A1988M593100010
J	Guo, XF; Qiu, W; Liu, QL; Qian, MY; Wang, SB; Zhang, ZP; Gao, X; Chen, ZH; Xue, H; Li, G				Guo, Xiaofan; Qiu, Wei; Liu, Qinglin; Qian, Mingyu; Wang, Shaobo; Zhang, Zongpu; Gao, Xiao; Chen, Zihang; Xue, Hao; Li, Gang			Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways	ONCOGENE			English	Article							NF-KAPPA-B; BLOOD-BRAIN-BARRIER; TUMOR MICROENVIRONMENT; LINKING INFLAMMATION; ROR-ALPHA; GLIOBLASTOMA; ACTIVATION; CANCER; MIGRATION; DIFFERENTIATION	While immunosuppressive environments mediated by myeloid-derived suppressor cells (MDSCs) have been well documented in glioma patients, the mechanisms of MDSC development and activation have not been clearly defined. Here, we elucidated a role for glioma-derived exosomes (GDEs) in potentiating an MDSC pathway. We isolated normoxiastimulated and hypoxia-stimulated GDEs and studied their MDSC induction abilities in vivo and in vitro. Analyses of spleen and bone marrow MDSC proportions (flow cytometry) and reactive oxygen species (ROS), arginase activity, nitric oxide (NO), T-cell proliferation and immunosuppressive cytokine (IL-10 and TGF-beta, ELISA) levels were used to assess MDSC expansion and functional capacity. We also performed microRNA (miRNA) sequencing analysis of two types of GDEs to find miRNAs that potentially mediate the development and activation of MDSCs. GDE miRNA intracellular signaling in MDSCs was also studied. Hypoxia promoted the secretion of GDEs, and mouse MDSCs could uptake GDEs. Hypoxia-stimulated GDEs had a stronger ability to induce MDSCs than N-GDEs. The hypoxia-inducible expression of miR-10a and miR-21 in GDEs mediated GDE-induced MDSC expansion and activation by targeting RAR-related orphan receptor alpha (RORA) and phosphatase and tensin homolog (PTEN). Mice inoculated with miR-10a or miR-21 knockout glioma cells generated fewer MDSCs than those inoculated with normal glioma cells. These data elucidated a mechanism by which glioma cells influence the differentiation and activation of MDSCs via exosomes and demonstrated how local glioma hypoxia affects the entirety of tumor immune environments.	[Guo, Xiaofan; Qiu, Wei; Qian, Mingyu; Wang, Shaobo; Zhang, Zongpu; Gao, Xiao; Chen, Zihang; Xue, Hao; Li, Gang] Shandong Univ, Brain Sci Res Inst, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Liu, Qinglin; Xue, Hao; Li, Gang] Shandong Univ, Qilu Hosp, Dept Neurosurg, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University	Xue, H; Li, G (corresponding author), Shandong Univ, Brain Sci Res Inst, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Xue, H; Li, G (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurosurg, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	undeadadams@163.com; ligangqiluhospital@163.com	liu, qingqing/HHD-0360-2022; Liu, Qing/GWC-9222-2022; Wang, Shaobo/AAI-4190-2020; Xue, Hao/GXV-4717-2022	Wang, Shaobo/0000-0001-7759-1687; Li, Gang/0000-0003-3184-1032	National Natural Science Foundation of China [81101594, 81372719, 81172403, 81300510, 81402077, 81571284, 91542115, 81702468]; National Natural Science Foundation of Shandong Province of China [2017CXGC1203]; Taishan Scholars of Shandong Province of China [ts201511093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Shandong Province of China; Taishan Scholars of Shandong Province of China	This work was supported by grants from the National Natural Science Foundation of China (Nos. 81101594; 81372719; 81172403; 81300510; 81402077; 81571284; 91542115; 81702468), National Natural Science Foundation of Shandong Province of China (No. 2017CXGC1203) and Taishan Scholars of Shandong Province of China (No. ts201511093).	Ajibade AA, 2012, IMMUNITY, V36, P43, DOI 10.1016/j.immuni.2011.12.010; Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Bott A, 2017, ONCOTARGET, V8, P43897, DOI 10.18632/oncotarget.14915; Chen CC, 2016, CELL MOL BIOENG, V9, P509, DOI 10.1007/s12195-016-0458-3; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; Dubois LG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00418; Dunn-Pirio AM, 2017, CANCER-AM CANCER SOC, V123, P734, DOI 10.1002/cncr.30371; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garcia JA, 2015, FASEB J, V29, P3863, DOI 10.1096/fj.15-273656; Gieryng A, 2016, WSPOLCZESNA ONKOL, V20, P345, DOI 10.5114/wo.2016.64592; Guo XF, 2016, ONCOTARGET, V7, P80521, DOI 10.18632/oncotarget.11825; Guo X, 2015, ONCOTARGET, V6, P41620, DOI 10.18632/oncotarget.5871; Hannafon BN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0753-x; Hellwinkel JE, 2016, NEURO-ONCOLOGY, V18, P497, DOI 10.1093/neuonc/nov170; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Jeker LT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036684; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330; Nduom EK, 2015, NEURO-ONCOLOGY, V17, P9, DOI 10.1093/neuonc/nov151; Noman MZ, 2015, CANCER RES, V75, P3771, DOI 10.1158/0008-5472.CAN-15-0405; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Otvos B, 2016, STEM CELLS, V34, P2026, DOI 10.1002/stem.2393; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Tadokoro H, 2013, J BIOL CHEM, V288, P34343, DOI 10.1074/jbc.M113.480822; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van der Vos KE, 2016, NEURO-ONCOLOGY, V18, P58, DOI 10.1093/neuonc/nov244; Whiteside TL, 2013, BIOCHEM SOC T, V41, P245, DOI 10.1042/BST20120265; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Wu W, 2015, GUT, V64, P1755, DOI 10.1136/gutjnl-2014-307980; Xiang XY, 2009, INT J CANCER, V124, P2621, DOI 10.1002/ijc.24249; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Xue H, 2016, ONCOTARGET, V7, P4785, DOI 10.18632/oncotarget.6735; Yang TZ, 2015, PHARM RES-DORDR, V32, P2003, DOI 10.1007/s11095-014-1593-y; Yu SH, 2007, J IMMUNOL, V178, P6867, DOI 10.4049/jimmunol.178.11.6867; Zaidi AH, 2016, BIOCHEM J, V473, P859, DOI 10.1042/BJ20150624; Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489	49	136	143	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4239	4259		10.1038/s41388-018-0261-9	http://dx.doi.org/10.1038/s41388-018-0261-9			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29713056				2022-12-17	WOS:000440566100004
J	Cao, C; Zhang, T; Zhang, D; Xie, L; Zou, X; Lei, L; Wu, D; Liu, L				Cao, C.; Zhang, T.; Zhang, D.; Xie, L.; Zou, X.; Lei, L.; Wu, D.; Liu, L.			The long non-coding RNA, SNHG6-003, functions as a competing endogenous RNA to promote the progression of hepatocellular carcinoma	ONCOGENE			English	Article							METASTASIS; CELLS; TAK1; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; SPONGES; GROWTH	The expression of long non-coding RNAs (lncRNAs) is dysregulated in hepatocellular carcinoma (HCC). However, the functions and contributions of lncRNAs remain largely unknown. Here, we identified a critical role of SNHG6-003 in HCC. We found that five SNHG6 transcripts were differentially expressed in HCC tissues while only the SNHG6-003 had an oncogenic function. Ectopic expression of SNHG6-003 in HCC cells promoted cell proliferation and induced drug resistance, whereas SNHG6-003 knockdown promoted apoptosis. Moreover, SNHG6-003 functioned as a competitive endogenous RNA (ceRNA), effectively becoming sponge for miR-26a/b and thereby modulating the expression of transforming growth factor-beta-activated kinase 1 (TAK1). Importantly, expression analysis revealed that both SNHG6-003 and TAK1 were upregulated in human cancers, exhibiting a co-expression pattern. In HCC patients, high expression of SNHG6-003 closely correlated with tumor progression and shorter survival. Thus, targeting the ceRNA network involving SNHG6-003 may be used as a treatment strategy against HCC.	[Cao, C.; Zhang, D.; Lei, L.; Wu, D.] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, T.; Zou, X.; Liu, L.] Guangdong Prov Key Lab Viral Hepatitis Res, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, T.; Liu, L.] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China; [Xie, L.] Univ Georgia, Ctr Mol Med, Athens, GA USA	Southern Medical University - China; Southern Medical University - China; University System of Georgia; University of Georgia	Wu, D (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China.; Liu, L (corresponding author), Guangdong Prov Key Lab Viral Hepatitis Res, Guangzhou 510515, Guangdong, Peoples R China.	wudehua.gd@gmail.com; liuli.fimmu@gmail.com		Wu, De-Hua/0000-0003-0560-0016; Liu, Li/0000-0002-5265-4159; Zou, Xuejing/0000-0001-6360-204X	National Nature Science Foundation of China [81172586, 81401180, 81372283, 91540111]; Guangdong Province Universities and Colleges Pearl River Scholar Funded Schem; Natural Science Funding of Guangdong Province [2014A030311013]; postdoctoral fellowship from American Heart Association [16POST26400005]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Province Universities and Colleges Pearl River Scholar Funded Schem; Natural Science Funding of Guangdong Province; postdoctoral fellowship from American Heart Association	This work was supported by the National Nature Science Foundation of China (Grant Nos. 81172586, 81401180, 81372283 and 91540111), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2015), Natural Science Funding of Guangdong Province (Grant No. 2014A030311013) and postdoctoral fellowship from American Heart Association 16POST26400005 (to XL). LX thanks Dr Hang Yin (University of Georgia) for support of the studies proposed in this manuscript.	Bak RO, 2014, WIRES RNA, V5, P317, DOI 10.1002/wrna.1213; Bodzin AS, 2015, WORLD J HEPATOL, V7, P1157, DOI 10.4254/wjh.v7.i9.1157; Cai PCH, 2014, ONCOTARGET, V5, P7549, DOI 10.18632/oncotarget.2273; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chen FC, 2014, EVOL BIOINFORM, V10, P219, DOI 10.4137/EBO.S20772; Chen IT, 2015, SCI REP-UK, V5, DOI 10.1038/srep12300; Fan YH, 2013, APOPTOSIS, V18, P1224, DOI 10.1007/s10495-013-0864-0; Ge D, 2014, AUTOPHAGY, V10, P957, DOI 10.4161/auto.28363; Ghosal S, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00249; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Jalali S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053823; Joo JH, 2014, MOL VIS, V20, P1629; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785; Li L, 2014, SCI REP-UK, V4, DOI 10.1038/srep05406; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu M, 2012, HEPATOLOGY, V55, P1754, DOI 10.1002/hep.25584; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Ma MZ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.541; Ng SY, 2013, MOL CELL, V51, P349, DOI 10.1016/j.molcel.2013.07.017; Pilyugin M, 2014, INT J BIOCHEM CELL B, V54, P356, DOI 10.1016/j.biocel.2014.06.018; Tang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.518; Tay FC, 2015, ADV DRUG DELIVER REV, V81, P117, DOI 10.1016/j.addr.2014.05.010; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Volders PJ, 2013, NUCLEIC ACIDS RES, V41, pD246, DOI 10.1093/nar/gks915; Wang P, 2015, NUCLEIC ACIDS RES, V43, P3478, DOI 10.1093/nar/gkv233; Wu XF, 2014, P NATL ACAD SCI USA, V111, P13870, DOI 10.1073/pnas.1414358111; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang YC, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0512-1; Zheng LF, 2015, BREAST CANCER RES TR, V150, P105, DOI 10.1007/s10549-015-3298-2; Zhou X, 2014, GYNECOL ONCOL, V133, P333, DOI 10.1016/j.ygyno.2014.02.033	34	136	138	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1112	1122		10.1038/onc.2016.278	http://dx.doi.org/10.1038/onc.2016.278			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27530352				2022-12-17	WOS:000395371500009
J	Gao, P; Xing, AY; Zhou, GY; Zhang, TG; Zhang, JP; Gao, C; Li, H; Shi, DB				Gao, P.; Xing, A-Y; Zhou, G-Y; Zhang, T-G; Zhang, J-P; Gao, C.; Li, H.; Shi, D-B			The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer	ONCOGENE			English	Article						gastric carcinoma; miR-145; metastasis; N-cadherin	N-CADHERIN; TUMOR-METASTASIS; BREAST-CANCER; CELL INVASION; COLON-CANCER; EXPRESSION; GROWTH; METALLOPROTEINASES; PROGRESSION; SIGNATURES	Invasion and metastasis are the major features of malignant tumors that are responsible for 90% of cancer-related deaths. Recently, microRNAs have been discovered to have a role in suppressing tumor metastasis. This study's aim was to clarify the roles of miR-145 in gastric carcinomas and its underlying molecular mechanism in regulating tumor metastasis. Here, we demonstrate a stepwise downregulation of miR-145 level in nontumorous gastric mucosa, primary gastric cancers-and their secondary metastases. In vitro analysis of miR-145's ectopic expression and loss-of-function suggests that it suppresses gastric cancer cell migration and invasion. In vivo spontaneous metastasis and experimental metastasis assay further confirm its function in suppressing the invasion-metastasis cascade, including impairing local invasion and inhibiting hematogenous metastasis in gastric cancers. Furthermore, we identified a novel mechanism of miR-145 to suppress metastasis. N-cadherin (CDH2) was proved to be a direct target of miR-145, using luciferase assay and western blot. Re-expressing N-cadherin in miR-145-transfected cells reverses their migration and invasion defects. Although not a direct target of miR-145, matrix metallopeptidase 9 (MMP9), but not MMP2, was also significantly decreased in miR-145-expressing cells. We suggest that miR-145 suppresses tumor metastasis by inhibiting N-cadherin protein translation, and then indirectly downregulates its downstream effector MMP9. Oncogene (2013) 32, 491-501; doi:10.1038/onc.2012.61; published online 27 February 2012	[Gao, P.; Xing, A-Y; Zhou, G-Y; Zhang, T-G; Zhang, J-P; Gao, C.] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Li, H.; Shi, D-B] Shandong Univ, Sch Med, Dept Pathol, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University	Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan Wen Hua Xi Rd 107, Jinan 250012, Shandong, Peoples R China.	gaopeng@sdu.edu.cn	邢, 爱艳/AAC-6576-2021		National Natural Science Foundation of China [30972929, 81172351]; Natural Science Foundation of Shandong Province of China [ZR2010HM075]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province of China(Natural Science Foundation of Shandong Province)	This work was supported by the National Natural Science Foundation of China (No. 30972929, 81172351) and the Natural Science Foundation of Shandong Province of China (No. ZR2010HM075). We thank Chun-Ming Wong and Irene Oi-Lin Ng of Department of Pathology, Li Ka Shing Faculty Medicine, University of Hong Kong for useful advice and discussion. Peng Gao was a Cheng Yu Tung Fellow at the University of Hong Kong. The study was approved by the Ethics Committee of Shandong University.	Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Coghlin C, 2010, J PATHOL, V222, P1, DOI 10.1002/path.2727; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; de Krijger I, 2011, J PATHOL, V224, P438, DOI 10.1002/path.2922; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Desiderio MA, 2007, CELL MOL LIFE SCI, V64, P1341, DOI 10.1007/s00018-007-7050-x; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gao P, 2011, J HEPATOL, V54, P1177, DOI 10.1016/j.jhep.2010.09.023; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hartland SN, 2009, LIVER INT, V29, P966, DOI 10.1111/j.1478-3231.2009.02070.x; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Parmo-Cabanas M, 2006, J PATHOL, V208, P108, DOI 10.1002/path.1876; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406	32	136	144	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					491	501		10.1038/onc.2012.61	http://dx.doi.org/10.1038/onc.2012.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370644				2022-12-17	WOS:000315551300010
J	Chu, Y; Yang, X				Chu, Y.; Yang, X.			SUMO E3 ligase activity of TRIM proteins	ONCOGENE			English	Article						TRIM proteins; SUMO E3 ligase; sumoylation; PML; Mdm2; p53	RET FINGER PROTEIN; REGULATES P53; TUMOR-SUPPRESSOR; FAMILY PROTEINS; NUCLEAR-BODIES; C-JUN; PML; UBIQUITIN; SUMOYLATION; RING	SUMOylation governs numerous cellular processes and is essential to most eukaryotic life. Despite increasing recognition of the importance of this process, an extremely limited number of small ubiquitin-like modifier (SUMO) protein ligases (E3s) have been identified. Here we show that at least some members of the functionally diverse tripartite motif (TRIM) superfamily are SUMO E3s. These TRIM proteins bind both the SUMO-conjugating enzyme Ubc9 and substrates and strongly enhance transfer of SUMOs from Ubc9 to these substrates. Among the substrates of TRIM SUMO E3s are the tumor suppressor p53 and its principal antagonist Mdm2. The E3 activity depends on the TRIM motif, suggesting it to be the first widespread SUMO E3 motif. Given the large number of TRIM proteins, our results may greatly expand the identified SUMO E3s. Furthermore, TRIM E3 activity may be an important contributor to SUMOylation specificity and the versatile functions of TRIM proteins. Oncogene (2011) 30, 1108-1116; doi:10.1038/onc.2010.462; published online 25 October 2010	[Yang, X.] Univ Penn, Sch Med, Dept Canc Biol, 610 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19096 USA; [Yang, X.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19096 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Yang, X (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, 610 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19096 USA.	xyang@mail.med.upenn.edu			NIH [CA088868, GM060911]; NATIONAL CANCER INSTITUTE [R01CA088868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr PP Pandolfi for providing Pml<SUP>-/-</SUP> MEF cells and Drs V Yu, A-M Herr, F Rauscher III and TC Cox for TRIM-expressing plasmids. We also thank E Fischer and S Slattery for technical assistance and A Stonestrom for help with manuscript preparation. Supported by NIH (CA088868 and GM060911) to XY.	Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Cao TY, 1998, J CELL SCI, V111, P1319; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Duprez E, 1999, J CELL SCI, V112, P381; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; GILLOT I, 2009, INT J CELL BIOL; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lee MH, 2006, NAT CELL BIOL, V8, P1424, DOI 10.1038/ncb1512; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Quimby BB, 2006, ONCOGENE, V25, P2999, DOI 10.1038/sj.onc.1209335; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Townson SM, 2006, BIOCHEM BIOPH RES CO, V349, P540, DOI 10.1016/j.bbrc.2006.08.063; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wolf D, 2007, CELL, V131, P46, DOI 10.1016/j.cell.2007.07.026; Zhu SS, 2009, MOL CELL, V33, P570, DOI 10.1016/j.molcel.2009.02.008	43	136	141	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1108	1116		10.1038/onc.2010.462	http://dx.doi.org/10.1038/onc.2010.462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	20972456	Green Accepted			2022-12-17	WOS:000287964100009
J	Bartkova, J; Hamerlik, P; Stockhausen, MT; Ehrmann, J; Hlobilkova, A; Laursen, H; Kalita, O; Kolar, Z; Poulsen, HS; Broholm, H; Lukas, J; Bartek, J				Bartkova, J.; Hamerlik, P.; Stockhausen, M-T; Ehrmann, J.; Hlobilkova, A.; Laursen, H.; Kalita, O.; Kolar, Z.; Poulsen, H. S.; Broholm, H.; Lukas, J.; Bartek, J.			Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas	ONCOGENE			English	Article						glioblastoma multiforme; DNA replication stress; oxidative DNA lesions; DNA damage checkpoints; p53 aberrations	ONCOGENE-INDUCED SENESCENCE; CANCER; REPAIR; CHECKPOINT; 53BP1; RADIORESISTANCE; PATHWAYS; BARRIER; BIOLOGY	Malignant gliomas, the deadliest of brain neoplasms, show rampant genetic instability and resistance to genotoxic therapies, implicating potentially aberrant DNA damage response (DDR) in glioma pathogenesis and treatment failure. Here, we report on gross, aberrant constitutive activation of DNA damage signalling in low-and high-grade human gliomas, and analyze the sources of such endogenous genotoxic stress. Based on analyses of human glioblastoma multiforme (GBM) cell lines, normal astrocytes and clinical specimens from grade II astrocytomas (n=41) and grade IV GBM (n=60), we conclude that the DDR machinery is constitutively activated in gliomas, as documented by phosphorylated histone H2AX (gamma H2AX), activation of the ATM-Chk2-p53 pathway, 53BP1 foci and other markers. Oxidative DNA damage (8-oxoguanine) was high in some GBM cell lines and many GBM tumors, while it was low in normal brain and grade II astrocytomas, despite the degree of DDR activation was higher in grade II tumors. Markers indicative of ongoing DNA replication stress (Chk1 activation, Rad17 phosphorylation, replication protein A foci and single-stranded DNA) were present in GBM cells under high-or low-oxygen culture conditions and in clinical specimens of both low-and high-grade tumors. The observed global checkpoint signaling, in contrast to only focal areas of overabundant p53 (indicative of p53 mutation) in grade II astrocytomas, are consistent with DDR activation being an early event in gliomagenesis, initially limiting cell proliferation (low Ki-67 index) and selecting for mutations of p53 and likely other genes that allow escape (higher Ki-67 index) from the checkpoint and facilitate tumor progression. Overall, these results support the potential role of the DDR machinery as a barrier to gliomagenesis and indicate that replication stress, rather than oxidative stress, fuels the DNA damage signalling in early stages of astrocytoma development. Oncogene (2010) 29, 5095-5102; doi:10.1038/onc.2010.249; published online 28 June 2010	[Bartkova, J.; Hamerlik, P.; Lukas, J.; Bartek, J.] Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; [Bartkova, J.; Hamerlik, P.; Lukas, J.; Bartek, J.] Danish Canc Soc, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark; [Hamerlik, P.; Bartek, J.] Palacky Univ, Inst Mol & Translat Med, Lab Genome Integr, CR-77147 Olomouc, Czech Republic; [Stockhausen, M-T; Poulsen, H. S.] Copenhagen Univ Hosp, Dept Radiat Biol, Copenhagen, Denmark; [Laursen, H.; Broholm, H.] Copenhagen Univ Hosp, Dept Neuropathol, Copenhagen, Denmark; [Kalita, O.] Univ Hosp, Dept Neurosurg, Olomouc, Czech Republic	Danish Cancer Society; Danish Cancer Society; Palacky University Olomouc; University of Copenhagen; University of Copenhagen; University Hospital Olomouc	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jil@cancer.dk; jb@cancer.dk	Bartek, Jiri/G-5870-2014; Ehrmann, Jiri/C-9074-2009; , Petra/U-2260-2019; Kolar, Zdenek/A-4597-2008; Kalita, Ondrej/I-8815-2016	Ehrmann, Jiri/0000-0002-8419-3414; , Petra/0000-0002-5856-0161; Kolar, Zdenek/0000-0003-1838-5925; Kalita, Ondrej/0000-0002-1356-023X; Lukas, Jiri/0000-0001-9087-506X	Danish Cancer Society; Danish National Research Foundation; Danish Research Council; Vilhelm Pedersen and Hustrus Mindelegat; Czech Ministry of Education [MSMT6198959216]; Grant Agency of the Czech Ministry of Health [NS10282-3/2009]; Lundbeck Foundation [R13-A1287]; European Commission [CZ.1.05/2.1.00/01.0030]	Danish Cancer Society(Danish Cancer Society); Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Research Council(Det Frie Forskningsrad (DFF)); Vilhelm Pedersen and Hustrus Mindelegat; Czech Ministry of Education(Ministry of Education, Youth & Sports - Czech Republic); Grant Agency of the Czech Ministry of Health; Lundbeck Foundation(Lundbeckfonden); European Commission(European CommissionEuropean Commission Joint Research Centre)	We thank J Darling, University of Wolverhampton and CV Bree, University of Amsterdam for donating the SS859 and Gli-6 cells, respectively and MyungHee Lee for excellent technical assistance. Grant support was obtained from Danish Cancer Society, Danish National Research Foundation, Danish Research Council, Vilhelm Pedersen and Hustrus Mindelegat, Czech Ministry of Education (MSMT6198959216), Grant Agency of the Czech Ministry of Health (NS10282-3/2009), Lundbeck Foundation (R13-A1287) and European Commission (projects: CZ.1.05/2.1.00/01.0030, Active p53, Infla-Care, GENICA).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2007, ONCOGENE, V26, P7414, DOI 10.1038/sj.onc.1210553; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Knizetova P, 2008, CELL CYCLE, V7, P2553, DOI 10.4161/cc.7.16.6442; Li DD, 2005, EUR J NEUROSCI, V22, P1319, DOI 10.1111/j.1460-9568.2005.04335.x; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Martin SA, 2008, CURR OPIN GENET DEV, V18, P80, DOI 10.1016/j.gde.2008.01.016; Mistrik M, 2009, CELL CYCLE, V8, P2592, DOI 10.4161/cc.8.16.9331; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	30	136	137	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5095	5102		10.1038/onc.2010.249	http://dx.doi.org/10.1038/onc.2010.249			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581868				2022-12-17	WOS:000281620100009
J	Chinnadurai, G; Vijayalingam, S; Gibson, SB				Chinnadurai, G.; Vijayalingam, S.; Gibson, S. B.			BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions	ONCOGENE			English	Review						BNIP3; BNIP3L; apoptosis; autophagy; cancer; cardiomyopathies	AUTOPHAGIC CELL-DEATH; MALIGNANT GLIOMA-CELLS; CARDIAC MYOCYTE DEATH; BCL-2 FAMILY-MEMBER; BREAST-CANCER CELLS; NF-KAPPA-B; PANCREATIC-CANCER; VENTRICULAR MYOCYTES; UP-REGULATION; BH3 DOMAIN	The BNIP3 subfamily of BH3-only proteins consists of BNIP3 and BNIP3-like (BNIP3L) proteins. These proteins form stable homodimerization complexes that localize to the outer membrane of the mitochondria after cellular stress. This promotes either apoptotic or non-apoptotic cell death such as autophagic cell death. Although the mammalian cells contain both members of this subfamily, the genome of Caenorhabditis elegans codes for a single BNIP3 ortholog, ceBNIP3, which shares homology in the transmembrane (TM) domain and in a conserved region close to the BH3 domain of mammalian BNIP3 protein. The cell death activities of BNIP3 and BNIP3L are determined by either the BH3 domain or the C-terminal TM domain. The TM domain of BNIP3 is unique, as it is capable of autonomous stable dimerization and contributes to mitochondrial localization of BNIP3. In knockout mouse models, BNIP3L was shown to be essential for normal erythrocyte differentiation and hematopoietic homeostasis, whereas BNIP3 plays a role in cellular responses to ischemia/reperfusion injury in the heart. Both BNIP3 and BNIP3L play a role in cellular responses to stress. Under hypoxia, both BNIP3 and BNIP3L expression levels are elevated and contribute to hypoxia-induced cell death. In addition, these proteins play critical roles in disease states. In heart disease, both BNIP3 and BNIP3L play a critical role in cardiomyocyte cell death following ischemic and non-ischemic injuries. In cancer, expression of BNIP3 and BNIP3L is downregulated by promoter hypermethylation or by homozygous deletion of the gene locus in certain cancers, whereas their expression was increased in other cancers. In addition, BNIP3 expression has been correlated with poor prognosis in some cancers. The results reviewed here suggest that BNIP3 and BNIP3L may be novel therapeutic targets for intervention because of their pathological roles in regulating cell death in disease states. Oncogene (2009) 27, S114-S127; doi: 10.1038/onc.2009.49	[Chinnadurai, G.] St Louis Univ, Sch Med, Inst Mol Virol, Doisy Res Ctr,Med Ctr, St Louis, MO 63104 USA; [Gibson, S. B.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada	Saint Louis University; University of Manitoba	Chinnadurai, G (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, Doisy Res Ctr,Med Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu		Gibson, Spencer/0000-0003-0119-732X	National Cancer Institute [CA-33616, CA-116262, CA-73803]; Canadian Institutes for Health Research [MOP-64330]; Manitoba Health Research Council; NATIONAL CANCER INSTITUTE [R01CA033616, R21CA116262, R01CA073803] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Manitoba Health Research Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	GC received grant support from the National Cancer Institute (grants CA-33616, CA-116262 and CA-73803). SBG was supported by a grant from the Canadian Institutes for Health Research MOP-64330 and is a Manitoba Research Chair supported by the Manitoba Health Research Council. We thank Lorrie Kirshenbaum for comments on this review and Teralee Burton for assistance in writing the review.	Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1; Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039; Aerbajinai W, 2003, BLOOD, V102, P712, DOI 10.1182/blood-2002-11-3324; Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761; Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHEN JC, 1997, SOFT COMPUT, V1, P19; Chen L, 2005, DIFFERENTIATION, V73, P350, DOI 10.1111/j.1432-0436.2005.00038.x; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Diwan A, 2008, APOPTOSIS, V13, P1022, DOI 10.1007/s10495-008-0236-3; Diwan A, 2008, CIRCULATION, V117, P396, DOI 10.1161/CIRCULATIONAHA.107.727073; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Erkan M, 2005, ONCOGENE, V24, P4421, DOI 10.1038/sj.onc.1208642; Farooq M, 2001, EXP MOL MED, V33, P169, DOI 10.1038/emm.2001.29; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Galvez AS, 2006, J BIOL CHEM, V281, P1442, DOI 10.1074/jbc.M509056200; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Ha SD, 2007, J BIOL CHEM, V282, P26275, DOI 10.1074/jbc.M703668200; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Ishida M, 2007, WORLD J GASTROENTERO, V13, P4593, DOI 10.3748/wjg.v13.i34.4593; Itoh T, 2003, J NEUROCHEM, V85, P1500, DOI 10.1046/j.1471-4159.2003.01795.x; Kammouni W, 2007, ARTHRITIS RHEUM, V56, P2854, DOI 10.1002/art.22853; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; KENT G, 1966, AM J PATHOL, V48, P831; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Knowles HJ, 2008, J PATHOL, V215, P56, DOI 10.1002/path.2319; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kubl DA, 2007, BIOCHEM J, V405, P407, DOI 10.1042/BJ20070319; Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008; Liu WN, 2008, NEOPLASIA, V10, P897, DOI 10.1593/neo.08428; Mahon PC, 2007, CANCER RES, V67, P6786, DOI 10.1158/0008-5472.CAN-07-0440; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Manka D, 2006, CELL CYCLE, V5, P343, DOI 10.4161/cc.5.4.2474; Manka D, 2005, CANCER RES, V65, P11689, DOI 10.1158/0008-5472.CAN-05-3091; Martin-Rendon E, 2007, STEM CELLS, V25, P1003, DOI 10.1634/stemcells.2006-0398; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0; Metcalf DG, 2007, PROTEINS, V67, P375, DOI 10.1002/prot.21265; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422; Murai M, 2005, CLIN CANCER RES, V11, P1021; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Niedergethmann M, 2007, BRIT J CANCER, V97, P1432, DOI 10.1038/sj.bjc.6604031; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Real PJ, 2005, CANCER RES, V65, P8151, DOI 10.1158/0008-5472.CAN-05-1134; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Reynolds TY, 1996, CANCER RES, V56, P5754; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Shaw J, 2008, AUTOPHAGY, V4, P427, DOI 10.4161/auto.5901; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Sulistijo ES, 2006, J MOL BIOL, V364, P974, DOI 10.1016/j.jmb.2006.09.065; Sulistijo ES, 2003, J BIOL CHEM, V278, P51950, DOI 10.1074/jbc.M308429200; SUN JL, 2004, ZHENG, V23, P8; Syed F, 2004, CIRC RES, V95, P1200, DOI 10.1161/01.RES.0000150366.08972.7f; Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466; Theodorakis P, 1996, ONCOGENE, V12, P1707; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang J, 2008, AUTOPHAGY, V4, P354, DOI 10.4161/auto.5552; Zhang ZF, 2007, STROKE, V38, P1606, DOI 10.1161/STROKEAHA.106.475129; Zhaorigetu S, 2008, AUTOPHAGY, V4, P1079, DOI 10.4161/auto.7066; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	105	136	139	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S114	S127		10.1038/onc.2009.49	http://dx.doi.org/10.1038/onc.2009.49			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641497	Green Accepted			2022-12-17	WOS:000268566800010
J	Banerjee, T; DuHadaway, JB; Gaspari, P; Sutanto-Ward, E; Munn, DH; Mellor, AL; Malachowski, WP; Prendergast, GC; Muller, AJ				Banerjee, T.; DuHadaway, J. B.; Gaspari, P.; Sutanto-Ward, E.; Munn, D. H.; Mellor, A. L.; Malachowski, W. P.; Prendergast, G. C.; Muller, A. J.			A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase	ONCOGENE			English	Article						IDO; INDO; tumoral immune tolerance; immunotherapy; targeted therapeutics; tryptophan	CANCER CHEMOPREVENTIVE ACTIVITY; SULFUR-CONTAINING PHYTOALEXINS; SSP PEKINENSIS CRUCIFERAE; TRYPTOPHAN CATABOLISM; DENDRITIC CELLS; T-CELLS; EXPRESSION; PREVENTION; CABBAGE; TOLERANCE	Agents that interfere with tumoral immune tolerance may be useful to prevent or treat cancer. Brassinin is a phytoalexin, a class of natural products derived from plants that includes the widely known compound resveratrol. Brassinin has been demonstrated to have chemopreventive activity in preclinical models but the mechanisms underlying its anticancer properties are unknown. Here, we show that brassinin and a synthetic derivative 5-bromo-brassinin (5-Br-brassinin) are bioavailable inhibitors of indoleamine 2,3-dioxygenase (IDO), a pro-toleragenic enzyme that drives immune escape in cancer. Like other known IDO inhibitors, both of these compounds combined with chemotherapy to elicit regression of autochthonous mammary gland tumors in MMTV-Neu mice. Furthermore, growth of highly aggressive melanoma isograft tumors was suppressed by single agent treatment with 5-Br-brassinin. This response to treatment was lost in athymic mice, indicating a requirement for active host T-cell immunity, and in IDO-null knockout mice, providing direct genetic evidence that IDO inhibition is essential to the antitumor mechanism of action of 5-Br-brassinin. The natural product brassinin thus provides the structural basis for a new class of compounds with in vivo anticancer activity that is mediated through the inhibition of IDO.	[DuHadaway, J. B.; Sutanto-Ward, E.; Prendergast, G. C.; Muller, A. J.] Lankenau Inst Med Res, Wynnewood, PA 19096 USA; [Banerjee, T.] NewLink Genet Corp, Ames, IA USA; [Gaspari, P.; Malachowski, W. P.] Bryn Mawr Coll, Dept Chem, Bryn Mawr, PA 19010 USA; [Munn, D. H.; Mellor, A. L.] Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; [Munn, D. H.] Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; [Mellor, A. L.] Med Coll Georgia, Dept Med, Augusta, GA 30912 USA; [Prendergast, G. C.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Prendergast, G. C.; Muller, A. J.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Muller, A. J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Bryn Mawr College; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Jefferson University; Jefferson University; Jefferson University	Muller, AJ (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	mullera@mlhs.org	Malachowski, Bill/AAD-7744-2022	Malachowski, William/0000-0003-1215-3808; Munn, David/0000-0002-7711-2858; Muller, Alexander/0000-0001-7854-6933	NCI NIH HHS [R01 CA109542, R01 CA100123, R01 CA82222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100123, R01CA082222, R01CA109542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts DS, 1999, CANCER RES, V59, P4743; Baban B, 2004, J REPROD IMMUNOL, V61, P67, DOI 10.1016/j.jri.2003.11.003; Brandacher G, 2006, CLIN CANCER RES, V12, P1144, DOI 10.1158/1078-0432.CCR-05-1966; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Csomos P, 2006, BIOORG MED CHEM LETT, V16, P6273, DOI 10.1016/j.bmcl.2006.09.016; Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576; Gaspari P, 2006, J MED CHEM, V49, P684, DOI 10.1021/jm0508888; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hayaishi O, 1984, PROGR TRYPTOPHAN SER, P33; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Ino K, 2006, BRIT J CANCER, V95, P1555, DOI 10.1038/sj.bjc.6603477; MALABADI RB, 2005, S AFRICA NEWS PA MAR, V2, P3; MEHTA RG, 1995, CARCINOGENESIS, V16, P399, DOI 10.1093/carcin/16.2.399; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mezencev R, 2003, NEOPLASMA, V50, P239; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Muller AJ, 2006, NAT REV CANCER, V6, P613, DOI 10.1038/nrc1929; MULLER K. O., 1958, AUSTRALIAN JOUR BIOL SCI, V11, P275; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 2004, J CLIN INVEST, V114, P280, DOI 10.1172/JCI200421583; Murillo G, 2001, NUTR CANCER, V41, P17, DOI 10.1207/S15327914NC41-1&amp;2_2; Okamoto A, 2005, CLIN CANCER RES, V11, P6030, DOI 10.1158/1078-0432.CCR-04-2671; Park EJ, 2002, CANCER METAST REV, V21, P231, DOI 10.1023/A:1021254725842; Pilatova M, 2005, LEUKEMIA RES, V29, P415, DOI 10.1016/j.leukres.2004.09.003; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Sabol M, 2000, BIOLOGIA, V55, P701; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; TAKASUGI M, 1988, B CHEM SOC JPN, V61, P285, DOI 10.1246/bcsj.61.285; TAKASUGI M, 1986, J CHEM SOC CHEM COMM, P1077, DOI 10.1039/c39860001077; THOMSON JA, 1993, IMMUNOLOGY, V78, P185	31	136	146	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2851	2857		10.1038/sj.onc.1210939	http://dx.doi.org/10.1038/sj.onc.1210939			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026137				2022-12-17	WOS:000255502500006
J	Beach, S; Tang, H; Park, S; Dhillon, AS; Keller, ET; Kolch, W; Yeung, KC				Beach, S.; Tang, H.; Park, S.; Dhillon, A. S.; Keller, E. T.; Kolch, W.; Yeung, K. C.			Snail is a repressor of RK1P transcription in metastatic prostate cancer cells	ONCOGENE			English	Article						regulation of RKIP expression; EMT; prostate cancer metastasis	KINASE INHIBITOR PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; UP-REGULATION; EXPRESSION; HYPERMETHYLATION	Diminished expression of the metastasis suppressor protein RKIP was previously reported in a number of cancers. The underlying mechanism remains unknown. Here, we show that the expression of RKIP negatively correlates with that of Snail zinc-transcriptional repressor, a key modulator of normal and neoplastic epithelial-mesenchymal transition (EMT) program. With a combination of loss-of-function and gain-of-function approaches, we showed that Snail repressed the expression of RKIP in metastatic prostate cancer cell lines. The effect of Snail on RKIP was on the level of transcriptional initiation and mediated by a proximal E-box on the RKIP promoter. Our results therefore suggest that RKIP is a novel component of the Snail transcriptional regulatory network important for the progression and metastasis of cancer.	[Beach, S.; Tang, H.; Park, S.; Yeung, K. C.] Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; [Keller, E. T.] Univ Michigan Hlth Syst, Ctr Comprehens Canc, Ann Arbor, MI USA; [Keller, E. T.; Kolch, W.] Univ Michigan Hlth Syst, Dept Urol, Ann Arbor, MI USA; [Dhillon, A. S.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Kolch, W.] Univ Glasgow, Sir Henry Wellcome Funct Genom Facil, Glasgow G12 8QQ, Lanark, Scotland	University System of Ohio; University of Toledo; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Beatson Institute; University of Glasgow	Yeung, KC (corresponding author), Univ Toledo, Coll Med, Dept Biochem & Canc Biol, Hlth Sci Campus,BHSB Room 469,3035 Arlington Ave, Toledo, OH 43614 USA.	kam.yeung@utoledo.edu	Kolch, Walter/ABF-2102-2021; Keller, Evan T/M-1446-2016; Admin, SBI/HGB-2738-2022	Keller, Evan T/0000-0002-7592-7535; Dhillon, Amardeep/0000-0002-6065-663X; Kolch, Walter/0000-0001-5777-5016	Cancer Research UK Funding Source: Medline; NCI NIH HHS [R01 CA098513, R01 CA098513-05] Funding Source: Medline; NIGMS NIH HHS [R01 GM64767, R01 GM064767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064767] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Knight S.W., 2001, SCIENCE, V2, P2; Lee HC, 2006, GASTROENTEROLOGY, V131, P1208, DOI 10.1053/j.gastro.2006.07.012; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Schuierer MM, 2006, ONCOL REP, V16, P451; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2; Zhang LZ, 2004, SURGERY, V136, P708, DOI 10.1016/j.surg.2003.12.013; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	31	136	148	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2243	2248		10.1038/sj.onc.1210860	http://dx.doi.org/10.1038/sj.onc.1210860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17952120	Green Accepted			2022-12-17	WOS:000254621300015
J	Endo, Y; Marusawa, H; Kinoshita, K; Morisawa, T; Sakurai, T; Okazaki, IM; Watashi, K; Shimotohno, K; Honjo, T; Chiba, T				Endo, Y.; Marusawa, H.; Kinoshita, K.; Morisawa, T.; Sakurai, T.; Okazaki, I-M; Watashi, K.; Shimotohno, K.; Honjo, T.; Chiba, T.			Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappa B signaling	ONCOGENE			English	Article						activation-induced cytidine deaminase; TNF-alpha; NF-kappa B; hepatocellular carcinoma; hepatitis C virus; chronic hepatitis	CLASS-SWITCH RECOMBINATION; SOMATIC HYPERMUTATION; HEPATOCELLULAR-CARCINOMA; FACTOR-ALPHA; MEDIATED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA; MOUSE MODEL; C-MYC; AID	Activation-induced cytidine deaminase (AID) is involved in somatic DNA alterations of the immunoglobulin gene for amplification of immune diversity. The fact that constitutive expression of AID in mice causes tumors in various organs, including lymphoid tissues and lungs, suggests the important role of the aberrant editing activity of AID on various tumor-related genes for carcinogenesis. AID expression, however, is restricted to activated B cells under physiological conditions. We demonstrate here that ectopic AID expression is induced in response to tumor necrosis factor-alpha stimulation in cultured human hepatocytes. The proinflammatory cytokine-mediated expression of AID is achieved by I kappa B kinase-dependent nuclear factor (NF)-kappa B signaling pathways. Hepatitis C virus, one of the leading causes of hepatocellular carcinoma (HCC), enhanced AID expression via NF-kappa B activation through expression of viral core protein. The aberrant expression of AID in hepatoma-derived cells resulted in accumulation of genetic alterations in the c-myc and pim1 genes, suggesting that inappropriate expression of AID acts as a DNA mutator that enhances the genetic susceptibility to mutagenesis in human hepatocytes. Our current findings indicate that the inappropriate expression of AID is induced by proinflammatory cytokine stimulation and may provide the link between hepatic inflammation and the development of HCC.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Shiga Med Ctr Res Inst, Moriyama, Japan; Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Kyoto, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University	Chiba, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawara Cho,Shogoin, Kyoto 6068507, Japan.	chiba@kuhp.kyoto-u.ac.jp	Honjo, Tasuku/N-4470-2016	Marusawa, Hiroyuki/0000-0002-4286-2712				Aly HH, 2007, J HEPATOL, V46, P26, DOI 10.1016/j.jhep.2006.08.018; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Coulouarn C, 2006, HEPATOLOGY, V44, P1003, DOI 10.1002/hep.21293; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; Feitelson MA, 2006, CANCER LETT, V239, P10, DOI 10.1016/j.canlet.2005.07.009; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Heintel D, 2004, LEUKEMIA, V18, P756, DOI 10.1038/sj.leu.2403294; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Ishii N, 2006, J VIROL, V80, P4510, DOI 10.1128/JVI.80.9.4510-4520.2006; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kinoshita K, 2006, INT J HEMATOL, V83, P201, DOI 10.1532/IJH97.06011; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Kotani A, 2005, P NATL ACAD SCI USA, V102, P4506, DOI 10.1073/pnas.0500830102; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Machida K, 2004, P NATL ACAD SCI USA, V101, P4262, DOI 10.1073/pnas.0303971101; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Marusawa H, 2000, HEPATOLOGY, V31, P488, DOI 10.1002/hep.510310232; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Marusawa H, 2001, MICROBIOL IMMUNOL, V45, P483, DOI 10.1111/j.1348-0421.2001.tb02648.x; Matsumoto T, 2006, FEBS LETT, V580, P731, DOI 10.1016/j.febslet.2005.12.081; MURAKAMI H, 1993, CANCER RES, V53, P1719; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Tanaka Y, 2006, BIOCHEM BIOPH RES CO, V341, P314, DOI 10.1016/j.bbrc.2005.12.192; Tateno C, 2000, HEPATOLOGY, V31, P65, DOI 10.1002/hep.510310113; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556	44	136	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5587	5595		10.1038/sj.onc.1210344	http://dx.doi.org/10.1038/sj.onc.1210344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17404578	Green Submitted			2022-12-17	WOS:000248801900004
J	Bond, GL; Levine, AJ				Bond, G. L.; Levine, A. J.			A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans	ONCOGENE			English	Review						MDM2; polymorphism; cancer; gender; stress; mutation	MDM2 PROMOTER POLYMORPHISM; ESTROGEN-RECEPTOR-ALPHA; SQUAMOUS-CELL CARCINOMA; LI-FRAUMENI-SYNDROME; BREAST-CANCER; LUNG-CANCER; COLORECTAL-CANCER; CHINESE POPULATION; PROTEIN EXPRESSION; NO ASSOCIATION	Cancer biology finds itself in a post-genomic era and the hopes of using inherited genetic variants to improve prevention and treatment strategies are widespread. One of the largest types of inherited genetic variation is the single nucleotide polymorphism (SNP), of which there are at least 4.5 million. The challenge now becomes how to discover which polymorphisms alter cancer in humans and how to begin to understand their mechanism of action. In this report, a series of recent publications will be reviewed that have studied a polymorphism in the p53 tumor suppressor pathway, MDM2 SNP309. These reports have lent insights into how germline genetic variants of the p53 pathway could interact with gender, environmental stresses and tumor genetics to affect cancer in humans. Importantly, these observations have also exposed potential nodes of intervention, which could prove valuable in both the prevention and treatment of this disease in humans.	Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; Canc Inst New Jersey, New Brunswick, NJ USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Levine, AJ (corresponding author), Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA.	alevine@ias.edu						Alhopuro P, 2005, J MED GENET, V42, P694, DOI 10.1136/jmg.2005.031260; ALLAZZOUZI H, 2006, J MED GENET; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; Boersma BJ, 2006, J NATL CANCER I, V98, P911, DOI 10.1093/jnci/djj245; Bond GL, 2006, J MED GENET, V43, P950, DOI 10.1136/jmg.2006.043539; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bougeard G, 2006, J MED GENET, V43, P531, DOI 10.1136/jmg.2005.037952; Campbell IG, 2006, CANCER LETT, V240, P195, DOI 10.1016/j.canlet.2005.09.003; Copson ER, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-80; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; Dharel N, 2006, CLIN CANCER RES, V12, P4867, DOI 10.1158/1078-0432.CCR-06-0111; Elledge RM, 2000, INT J CANCER, V89, P111, DOI 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.3.CO;2-N; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; Hong Y, 2005, CANCER RES, V65, P9582, DOI 10.1158/0008-5472.CAN-05-1460; Hu ZB, 2006, INT J CANCER, V118, P1275, DOI 10.1002/ijc.21463; Johnson TM, 2006, CELL DEATH DIFFER, V13, P902, DOI 10.1038/sj.cdd.4401902; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Lane DP, 2005, COLD SH Q B, V70, P489, DOI 10.1101/sqb.2005.70.049; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Li GJ, 2006, CARCINOGENESIS, V27, P2028, DOI 10.1093/carcin/bgl047; Lind H, 2006, INT J CANCER, V119, P718, DOI 10.1002/ijc.21872; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Ma HX, 2006, CANCER LETT, V240, P261, DOI 10.1016/j.canlet.2005.09.019; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Menin C, 2006, J NATL CANCER I, V98, P285, DOI 10.1093/jnci/djj054; Millikan RC, 2006, CANCER EPIDEM BIOMAR, V15, P175, DOI 10.1158/1055-9965.EPI-05-0692; Ohkubo S, 2006, J BIOL CHEM, V281, P16943, DOI 10.1074/jbc.M601388200; Ohmiya N, 2006, J CLIN ONCOL, V24, P4434, DOI 10.1200/JCO.2005.04.1459; Okumura N, 2002, ONCOL REP, V9, P557; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Onel K, 2004, MOL CANCER RES, V2, P1; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Park SH, 2006, LUNG CANCER, V54, P19, DOI 10.1016/j.lungcan.2006.06.008; Petz LN, 2004, J STEROID BIOCHEM, V88, P113, DOI 10.1016/j.jsbmb.2003.11.008; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Phelps M, 2003, CANCER RES, V63, P2616; Pine SR, 2006, CANCER EPIDEM BIOMAR, V15, P1559, DOI 10.1158/1055-9965.EPI-06-0217; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Ruijs MWG, 2007, EUR J HUM GENET, V15, P110, DOI 10.1038/sj.ejhg.5201715; SHEIKH MS, 1993, CANCER RES, V53, P3226; Sotamaa K, 2005, CLIN CANCER RES, V11, P6840, DOI 10.1158/1078-0432.CCR-05-1139; Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201; Swinney RM, 2005, LEUKEMIA, V19, P1996, DOI 10.1038/sj.leu.2403941; Wilkening S, 2006, CANCER RES, V66, P646, DOI 10.1158/0008-5472.CAN-05-3168; Zhang XM, 2006, HUM MUTAT, V27, P110, DOI 10.1002/humu.20277	56	136	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1317	1323		10.1038/sj.onc.1210199	http://dx.doi.org/10.1038/sj.onc.1210199			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322917				2022-12-17	WOS:000244558700009
J	Altomare, DA; You, HH; Xiao, GH; Ramos-Nino, ME; Skele, KL; De Rienzo, A; Jhanwar, SC; Mossman, BT; Kane, AB; Testa, JR				Altomare, DA; You, HH; Xiao, GH; Ramos-Nino, ME; Skele, KL; De Rienzo, A; Jhanwar, SC; Mossman, BT; Kane, AB; Testa, JR			Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth	ONCOGENE			English	Article						AKT; mTOR; asbestos; mesothelioma	PROSTATE INTRAEPITHELIAL NEOPLASIA; FACTOR SCATTER FACTOR; HUMAN OVARIAN; PHOSPHATIDYLINOSITOL 3-KINASE; AKT ACTIVATION; KINASE-B; C-MET; CANCER; GENE; EXPRESSION	Malignant mesotheliomas ( MMs) are very aggressive tumors that respond poorly to standard chemotherapeutic approaches. The phosphatidylinositol 3- kinase ( PI3K)/AKT pathway has been implicated in tumor aggressiveness, in part by mediating cell survival and reducing sensitivity to chemotherapy. Using antibodies recognizing the phosphorylated/activated form of AKT kinases, we observed elevated phospho-AKT staining in 17 of 26 ( 65%) human MM specimens. In addition, AKT phosphorylation was consistently observed in MMs arising in asbestos-treated mice and in MM cell xenografts. Consistent with reports implicating hepatocyte growth factor (HGF)/Met receptor signaling in MM, all 14 human and murine MM cell lines had HGF- inducible AKT activity. One of nine human MM cell lines had elevated AKT activity under serum-starvation conditions, which was associated with a homozygous deletion of PTEN, the first reported in MM. Treatment of this cell line with the mTOR inhibitor rapamycin resulted in growth arrest in G1 phase. Treatment of MM cells with the PI3K inhibitor LY294002 in combination with cisplatin had greater efficacy in inhibiting cell proliferation and inducing apoptosis than either agent alone. Collectively, these data indicate that MMs frequently express elevated AKT activity, which may be targeted pharmacologically to enhance chemotherapeutic efficacy. These findings also suggest that mouse models of MM maybe useful for future preclinical studies of pharmaceuticals targeting the PI3K/AKT pathway.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA	Fox Chase Cancer Center; University of Vermont; Memorial Sloan Kettering Cancer Center; Brown University	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	jr_testa@fccc.edu			NATIONAL CANCER INSTITUTE [P30CA006927, R01CA077429, R01CA045745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003721] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA045745, CA-06927, P30 CA006927, R01 CA077429, CA-45745, CA-77429] Funding Source: Medline; NIEHS NIH HHS [ES-003721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; BELLACOSA A, IN PRESS CANC RES; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Bowers DC, 2000, CANCER RES, V60, P4277; Britton M, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.30237; Brognard J, 2001, CANCER RES, V61, P3986; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Cao XBX, 2001, AM J RESP CELL MOL, V25, P562, DOI 10.1165/ajrcmb.25.5.4539; CRAIGHEAD JE, 1982, NEW ENGL J MED, V306, P1446, DOI 10.1056/NEJM198206173062403; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Goodglick LA, 1997, TOXICOL PATHOL, V25, P565, DOI 10.1177/019262339702500605; Harvey P, 2000, BRIT J CANCER, V83, P1147, DOI 10.1054/bjoc.2000.1445; Hu LM, 2002, CANCER RES, V62, P1087; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Liu AX, 1998, CANCER RES, V58, P2973; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234; Papp T, 2001, ONCOL REP, V8, P1375; Philp AJ, 2001, CANCER RES, V61, P7426; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Rusch VW, 2003, J CLIN ONCOL, V21, P2629, DOI 10.1200/JCO.2003.02.043; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; TAGUCHI T, 1993, CANCER RES, V53, P4349; Tanno S, 2001, CANCER RES, V61, P589; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	45	136	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6080	6089		10.1038/sj.onc.1208744	http://dx.doi.org/10.1038/sj.onc.1208744			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15897870				2022-12-17	WOS:000231718100002
J	Wakeford, R				Wakeford, R			The cancer epidemiology of radiation	ONCOGENE			English	Review						ionizing; nonionizing; risk; dose-response	ATOMIC-BOMB SURVIVORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; X-RAY TREATMENT; CHERNOBYL EMERGENCY WORKERS; CANADIAN FLUOROSCOPY COHORT; NONMELANOMA SKIN-CANCER; 2ND MALIGNANT NEOPLASMS; RATE IONIZING-RADIATION; FEMALE BREAST-CANCER; RADIUM DIAL WORKERS	Ionizing radiation has been the subject of intense epidemiological investigation. Studies have demonstrated that exposure to moderate-to-high levels can cause most forms of cancer, leukaemia and cancers of the breast, lung and thyroid being particularly sensitive to induction by radiation, especially at young ages at exposure. Predominant among these studies is the Life Span Study of the cohort of survivors of the atomic bombings of Japan in 1945, but substantial evidence is derived from groups exposed for medical reasons, occupationally or environmentally. Notable among these other groups are underground hard rock miners who inhaled radioactive radon gas and its decay products, large numbers of patients irradiated therapeutically and workers who received high doses in the nuclear weapons programme of the former USSR. The degree of carcinogenic risk arising from low levels of exposure is more contentious, but the available evidence points to an increased risk that is approximately proportional to the dose received. Epidemiological investigations of nonionizing radiation have established ultraviolet radiation as a cause of skin cancer. However, the evidence for a carcinogenic effect of other forms of nonionizing radiation, such as those associated with mobile telephones or electricity transmission lines, is not convincing, although the possibility of a link between childhood leukaemia and extremely low-frequency electromagnetic fields cannot be dismissed entirely.	BNFL, Warrington WA4 4BG, Cheshire, England		Wakeford, R (corresponding author), BNFL, 1100 Daresbury Pk, Warrington WA4 4BG, Cheshire, England.	R.Wakeford@bnfl.com	Wakeford, Richard/I-1978-2019	Wakeford, Richard/0000-0002-2934-0987				ADAMS EE, 1980, J OCCUP ENVIRON MED, V22, P583; Advisory Group on Non-Ionising Radiation (AGNIR), 2003, DOC NRPB, V14, P1; *AGIR, 2000, DOC NRPB, V11; *AGNIR, 2002, DOC NRPB, V13, P1; *AGNIR, 2001, DOC NRPB, V12; *AGNIR, 1994, DOC NRPB, V5, P77; *AGNIR, 1992, DOC NRPB, V3; Ahlbom A, 2001, ENVIRON HEALTH PERSP, V109, P911, DOI 10.2307/3454653; Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; [Anonymous], 1999, Lancet, V354, P1925; [Anonymous], 1994, SOURC EFF ION RAD, P16; Astakhova LN, 1998, RADIAT RES, V150, P349, DOI 10.2307/3579983; Atkinson W. D., 1994, Journal of Radiological Protection, V14, P109, DOI 10.1088/0952-4746/14/2/001; Atkinson WD, 2002, P 4 INT C HLTH EFF L; Band PR, 1996, AM J EPIDEMIOL, V143, P137; Bataille V, 2004, EUR J CANCER, V40, P429, DOI 10.1016/j.ejca.2003.09.030; BAVERSTOCK KF, 1989, BIR REPORT, V21, P72; BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 2001, HLTH HAZARDS DEPLE 1, P75; Berrington A, 2001, BRIT J RADIOL, V74, P507, DOI 10.1259/bjr.74.882.740507; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; Blettner M, 2003, INT J CANCER, V106, P946, DOI 10.1002/ijc.11328; BOICE JD, 1988, RADIAT RES, V116, P3, DOI 10.2307/3577477; BOICE JD, 1985, J NATL CANCER I, V74, P955; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BOICE JD, 1991, RADIAT RES, V125, P214, DOI 10.2307/3577890; Boice JD, 1999, TERATOLOGY, V59, P227, DOI 10.1002/(SICI)1096-9926(199904)59:4<227::AID-TERA7>3.0.CO;2-E; Boice JD, 2000, HEALTH PHYS, V79, P576, DOI 10.1097/00004032-200011000-00016; BOICE JD, 2002, J RADIOL PROT, V22, P102; BOICE JD, 2002, 200216 SSI SWED RAD; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Brenner DJ, 2001, RADIAT RES, V155, P402, DOI 10.1667/0033-7587(2001)155[0402:TBEIRO]2.0.CO;2; BRENNER DJ, 2003, NATURE, V421, P691; CARDIS E, 1995, RADIAT RES, V142, P117, DOI 10.2307/3579020; CARPENTER L M, 1990, Radiation Research, V124, P351; Carpenter LM, 1998, BRIT J CANCER, V78, P1224, DOI 10.1038/bjc.1998.659; Carr ZA, 2002, RADIAT RES, V157, P668, DOI 10.1667/0033-7587(2002)157[0668:MNARTF]2.0.CO;2; Cartwright RA, 2002, BRIT J CANCER, V86, P1721, DOI 10.1038/sj.bjc.6600276; Cartwright RA, 2002, BRIT J CANCER, V86, P1727, DOI 10.1038/sj.bjc.6600277; Cheng KK, 2000, BRIT J CANCER, V83, P1573, DOI 10.1054/bjoc.2000.1550; COHEN BL, 1995, HEALTH PHYS, V68, P157, DOI 10.1097/00004032-199502000-00002; *COMARE, 1988, 2 COMARE; *COMARE, 1996, 4 COMARE; [COMARE (Committee on Medical Aspects of Radiation in the Environment) Crown], 2002, 7 COMARE; Cox DR, 2003, J ROY STAT SOC A STA, V166, P241, DOI 10.1111/1467-985X.00272; Dalager NA, 2000, J OCCUP ENVIRON MED, V42, P798, DOI 10.1097/00043764-200008000-00006; DARBY SC, 1995, JNCI-J NATL CANCER I, V87, P378, DOI 10.1093/jnci/87.5.378; Darby SC, 2003, RADIAT PROT DOSIM, V104, P321, DOI 10.1093/oxfordjournals.rpd.a006195; DARBY SC, 1992, BRIT MED J, V304, P1005, DOI 10.1136/bmj.304.6833.1005; DAVIS FG, 1989, CANCER RES, V49, P6130; Davis S., 2002, HANFORD THYROID DIS; de Vathaire F, 1999, BRIT J CANCER, V79, P1884, DOI 10.1038/sj.bjc.6690300; Dennis LK, 2003, ANN INTERN MED, V139, P966, DOI 10.7326/0003-4819-139-12-200312160-00006; Dickman PW, 2003, INT J CANCER, V106, P580, DOI 10.1002/ijc.11258; Dolk H, 1997, AM J EPIDEMIOL, V145, P10, DOI 10.1093/oxfordjournals.aje.a009026; Dolk H, 1997, AM J EPIDEMIOL, V145, P1, DOI 10.1093/oxfordjournals.aje.a009025; Doll R, 1999, BRIT J CANCER, V81, P3, DOI 10.1038/sj.bjc.6690642; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; Doll R, 1997, BRIT J RADIOL, V70, P130, DOI 10.1259/bjr.70.830.9135438; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; Elwood JM, 1999, ENVIRON HEALTH PERSP, V107, P155, DOI 10.2307/3434480; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Fears TR, 2002, CANCER RES, V62, P3992; FOLLEY JH, 1952, AM J MED, V13, P311, DOI 10.1016/0002-9343(52)90285-4; Freedman DM, 2002, OCCUP ENVIRON MED, V59, P257, DOI 10.1136/oem.59.4.257; Fry SA, 1998, RADIAT RES, V150, pS21, DOI 10.2307/3579805; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; Garwicz S, 2000, INT J CANCER, V88, P672, DOI 10.1002/1097-0215(20001115)88:4<672::AID-IJC24>3.0.CO;2-N; GIBSON BES, 1988, LANCET, V2, P630; Gilbert ES, 1998, JNCI-J NATL CANCER I, V90, P1654, DOI 10.1093/jnci/90.21.1654; Gilbert ES, 2000, RADIAT RES, V154, P246, DOI 10.1667/0033-7587(2000)154[0246:LCIMW]2.0.CO;2; Gilliland FD, 2000, HEALTH PHYS, V79, P365, DOI 10.1097/00004032-200010000-00004; Gilman EA, 1998, BRIT J CANCER, V77, P842, DOI 10.1038/bjc.1998.137; Grosche B, 2002, RADIAT ENVIRON BIOPH, V41, P75, DOI 10.1007/s00411-001-0136-1; Groves FD, 2002, AM J EPIDEMIOL, V155, P810, DOI 10.1093/aje/155.9.810; Guizard AV, 2001, J EPIDEMIOL COMMUN H, V55, P469, DOI 10.1136/jech.55.7.469; Gundestrup M, 1999, LANCET, V354, P2029, DOI 10.1016/S0140-6736(99)05093-X; Hahn K, 2001, RADIAT RES, V156, P61, DOI 10.1667/0033-7587(2001)156[0061:TCADAO]2.0.CO;2; HAMILTON TE, 1987, JAMA-J AM MED ASSOC, V258, P629, DOI 10.1001/jama.258.5.629; Harrison JD, 2003, INT J RADIAT BIOL, V79, P1, DOI 10.1080/0955300021000038671; *HARV CTR CANC PRE, 1996, CANC CAUS CONTR S1, V7, pS41; Hatch EE, 2000, EPIDEMIOLOGY, V11, P189, DOI 10.1097/00001648-200003000-00019; HATCH MC, 1990, AM J EPIDEMIOL, V132, P397, DOI 10.1093/oxfordjournals.aje.a115673; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; Hocking B, 1996, MED J AUSTRALIA, V165, P601, DOI 10.5694/j.1326-5377.1996.tb138661.x; HOLLINGSWORTH DR, 1963, MEDICINE, V42, P47, DOI 10.1097/00005792-196301000-00003; Howard JE, 1997, HEALTH PHYS, V73, P190, DOI 10.1097/00004032-199707000-00016; HOWE GR, 1995, RADIAT RES, V142, P295, DOI 10.2307/3579139; Howe GR, 1996, RADIAT RES, V145, P694, DOI 10.2307/3579360; Huncharek M, 2002, AM J PUBLIC HEALTH, V92, P1173, DOI 10.2105/AJPH.92.7.1173; *IARC, 1992, IARC MON EV CARC RIS, V55; *IARC, 2002, IARC MON EV CARC R 1, V80; IARC, 2001, IARC MON EV CARC R 2, V78; *ICRP, 1998, PUBL ICRP, V79; ICRP, 1991, ANN ICRP, V22; *ICRP, 1991, PUBL ICRP, V60; *IEGMP, 2000, MOB PHON HLTH; Institute of Medicine, 2000, 5 SER STUD MORT MIL; International Agency for Research on Cancer (IARC), 2000, IARC MON EV CARC R 1, V75; Ivanov EP, 1998, RADIAT ENVIRON BIOPH, V37, P53, DOI 10.1007/s004110050092; Ivanov V. K., 1997, Journal of Radiological Protection, V17, P137, DOI 10.1088/0952-4746/17/3/003; Ivanov VK, 2004, RADIAT ENVIRON BIOPH, V43, P35, DOI 10.1007/s00411-003-0223-6; Ivanov VK, 1997, RADIAT ENVIRON BIOPH, V36, P9, DOI 10.1007/s004110050049; Ivanov VK, 2003, HEALTH PHYS, V84, P46, DOI 10.1097/00004032-200301000-00004; Ivanov VK, 2002, RADIAT ENVIRON BIOPH, V41, P195, DOI 10.1007/s00411-002-0163-6; Ivanov VK, 2001, HEALTH PHYS, V81, P514, DOI 10.1097/00004032-200111000-00005; Izumi S, 2003, INT J CANCER, V107, P292, DOI 10.1002/ijc.11400; Jacob P, 2000, RADIAT ENVIRON BIOPH, V39, P25, DOI 10.1007/PL00007681; Karagas MR, 2002, J NATL CANCER I, V94, P224, DOI 10.1093/jnci/94.3.224; KERBER RA, 1993, JAMA-J AM MED ASSOC, V270, P2076; Kesminiene A, 2002, J Radiol Prot, V22, pA137, DOI 10.1088/0952-4746/22/3A/324; KINLEN LJ, 2000, RADIOL PROT B, V226, P9; Kleinerman RA, 2000, AM J EPIDEMIOL, V151, P512, DOI 10.1093/oxfordjournals.aje.a010237; Koshurnikova NA, 2000, RADIAT RES, V154, P237, DOI 10.1667/0033-7587(2000)154[0237:BCIMW]2.0.CO;2; Kossenko MM, 2002, RADIAT ENVIRON BIOPH, V41, P45, DOI 10.1007/s00411-001-0132-5; Kreisheimer M, 2003, RADIAT ENVIRON BIOPH, V42, P129, DOI 10.1007/s00411-003-0198-3; Lagarde F, 2001, EPIDEMIOLOGY, V12, P396, DOI 10.1097/00001648-200107000-00009; Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082; LAND CE, 1993, LANCET, V342, P237, DOI 10.1016/0140-6736(93)92324-M; LAND CE, 1994, CANCER CAUSE CONTROL, V5, P167, DOI 10.1007/BF01830263; Langner I, 2004, RADIAT ENVIRON BIOPH, V42, P247, DOI 10.1007/s00411-003-0214-7; Laurier D, 2001, HEALTH PHYS, V81, P272, DOI 10.1097/00004032-200109000-00009; Linet MS, 1997, NEW ENGL J MED, V337, P1, DOI 10.1056/NEJM199707033370101; Little MP, 2001, RADIAT RES, V156, P695, DOI 10.1667/0033-7587(2001)156[0695:TBEICC]2.0.CO;2; Little MP, 2002, INT J RADIAT BIOL, V78, P145, DOI 10.1080/09553000110095714; Little MP, 2002, INT J RADIAT BIOL, V78, P1001, DOI 10.1080/0955300021000013803; Little MP, 1999, RADIAT RES, V151, P218, DOI 10.2307/3579773; Little MP, 1997, INT J RADIAT BIOL, V71, P589, DOI 10.1080/095530097143923; Little MP, 1999, RADIAT RES, V152, P280, DOI 10.2307/3580328; LITTLE MP, 1990, HEALTH PHYS, V59, P765, DOI 10.1097/00004032-199012000-00001; Little MP, 2001, INT J RADIAT BIOL, V77, P431, DOI 10.1080/09553000010022634; Lubin JH, 2004, INT J CANCER, V109, P132, DOI 10.1002/ijc.11683; Lubin JH, 2003, RADIAT PROT DOSIM, V104, P315, DOI 10.1093/oxfordjournals.rpd.a006194; Lubin JH, 1997, J NATL CANCER I, V89, P49, DOI 10.1093/jnci/89.1.49; Lubin JH, 1998, JNCI-J NATL CANCER I, V90, P294, DOI 10.1093/jnci/90.4.294; LUBIN JH, 1995, J NATL CANCER I, V87, P817, DOI 10.1093/jnci/87.11.817; Lubin JH, 1997, RADIAT RES, V147, P126, DOI 10.2307/3579412; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; March HC., 1944, RADIOLOGY, V43, P275, DOI DOI 10.1148/43.3.275; McKenzie DR, 1998, AUST NZ J PUBL HEAL, V22, P360, DOI 10.1111/j.1467-842X.1998.tb01392.x; Michelozzi P, 2002, AM J EPIDEMIOL, V155, P1096, DOI 10.1093/aje/155.12.1096; Milan T, 2002, BRIT J DERMATOL, V147, P509, DOI 10.1046/j.1365-2133.2002.04870.x; Mohan AK, 2003, INT J CANCER, V103, P259, DOI 10.1002/ijc.10811; Mohan AK, 2002, J NATL CANCER I, V94, P943, DOI 10.1093/jnci/94.12.943; Morgan RW, 2000, EPIDEMIOLOGY, V11, P118, DOI 10.1097/00001648-200003000-00007; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; Muirhead C. R., 1999, Journal of Radiological Protection, V19, P3, DOI 10.1088/0952-4746/19/1/002; Muirhead CR, 2003, OCCUP ENVIRON MED, V60, P165, DOI 10.1136/oem.60.3.165; National Council on Radiation Protection and Measurements [NCRP], 2001, 135 NCRP; Naumburg E, 2000, BMJ-BRIT MED J, V320, P282, DOI 10.1136/bmj.320.7230.282; *NCR COMM HLTH RIS, 1999, HLTH EFF EXP RAD BEI; *NCRP, 2001, 136 NCRP; [NCRP] National Council on Radiation Protection and Measurements, 1993, 115 NCRP; Nekolla EA, 2000, RADIAT RES, V153, P93, DOI 10.1667/0033-7587(2000)153[0093:IOMBTI]2.0.CO;2; Nicholas JS, 1998, J OCCUP ENVIRON MED, V40, P980, DOI 10.1097/00043764-199811000-00008; *NRC COMM BIOL EFF, 1990, HLTH EFF EXP LOW LEV; *NRPB, 1995, DOC NRPB, V6; NRPB, 1993, DOC NRPB; Omar RZ, 1999, BRIT J CANCER, V79, P1288, DOI 10.1038/sj.bjc.6690207; Parkin DM, 1996, BRIT J CANCER, V73, P1006, DOI 10.1038/bjc.1996.197; Pearce N, 1997, CANCER CAUSE CONTROL, V8, P139, DOI 10.1023/A:1018407927076; Petridou E, 1996, NATURE, V382, P352, DOI 10.1038/382352a0; Pierce DA, 2003, RADIAT RES, V159, P511, DOI 10.1667/0033-7587(2003)159[0511:JEORAS]2.0.CO;2; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; Pierce DA, 2000, RADIAT RES, V154, P178, DOI 10.1667/0033-7587(2000)154[0178:RRCRAL]2.0.CO;2; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Preston DL, 2002, RADIAT RES, V158, P220, DOI 10.1667/0033-7587(2002)158[0220:REOBCR]2.0.CO;2; PRESTON DL, 1994, RADIAT RES, V137, pS68, DOI 10.2307/3578893; Preston RJ, 2003, J RADIOL PROT, V23, P263, DOI 10.1088/0952-4746/23/3/303; Puskin JS, 2003, HEALTH PHYS, V84, P526, DOI 10.1097/00004032-200304000-00012; Ron E, 1998, CANCER CAUSE CONTROL, V9, P393, DOI 10.1023/A:1008867617415; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; RON E, 1994, RADIAT RES, V137, pS98, DOI 10.2307/3578894; ROONEY C, 1993, BRIT MED J, V307, P1391, DOI 10.1136/bmj.307.6916.1391; Rothman KJ, 2000, LANCET, V356, P1837, DOI 10.1016/S0140-6736(00)03244-X; Scotto J, 1996, CANC EPIDEMIOLOGY PR, P355; Shakhtarin VV, 2003, INT J EPIDEMIOL, V32, P584, DOI 10.1093/ije/dyg205; Shilnikova NS, 2003, RADIAT RES, V159, P787, DOI 10.1667/0033-7587(2003)159[0787:CMRAWA]2.0.CO;2; Shore RE, 2002, RADIAT RES, V157, P410, DOI 10.1667/0033-7587(2002)157[0410:SCAXRT]2.0.CO;2; Shu XO, 2002, CANCER EPIDEM BIOMAR, V11, P177; Sigurdson AJ, 2003, CANCER-AM CANCER SOC, V97, P3080, DOI 10.1002/cncr.11444; Simonsen LC, 2000, HEALTH PHYS, V79, P515, DOI 10.1097/00004032-200011000-00008; SKINNER J, 2000, BRIT J CANCER, V87, P1257; SORAHAN T, 1995, BRIT J OBSTET GYNAEC, V102, P831, DOI 10.1111/j.1471-0528.1995.tb10851.x; Steiner M, 1998, RADIAT ENVIRON BIOPH, V37, P87, DOI 10.1007/s004110050099; STEVENS W, 1990, JAMA-J AM MED ASSOC, V264, P585, DOI 10.1001/jama.264.5.585; Stewart AM, 2000, INT J EPIDEMIOL, V29, P708, DOI 10.1093/ije/29.4.708; Straume T, 2003, NATURE, V424, P539, DOI 10.1038/nature01815; Takahashi T, 2003, J EPIDEMIOL, V13, P99, DOI 10.2188/jea.13.99; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; TOKUNAGA M, 1994, RADIAT RES, V138, P209, DOI 10.2307/3578591; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465; Travis LB, 1996, J CLIN ONCOL, V14, P565, DOI 10.1200/JCO.1996.14.2.565; Travis LB, 2003, RADIAT RES, V160, P691, DOI 10.1667/RR3095; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; Travis LB, 2001, RADIAT RES, V156, P136, DOI 10.1667/0033-7587(2001)156[0136:MACAWO]2.0.CO;2; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, UNSCEAR 2000 REPORT; Vajdic CM, 2003, INT J CANCER, V105, P117, DOI 10.1002/ijc.11057; van Leeuwen FE, 2003, JNCI-J NATL CANCER I, V95, P971, DOI 10.1093/jnci/95.13.971; Veierod MB, 2003, J NATL CANCER I, V95, P1530, DOI 10.1093/jnci/djg075; Wakeford R, 2003, INT J RADIAT BIOL, V79, P293, DOI 10.1080/0955300031000114729; Wang JX, 2002, HEALTH PHYS, V82, P455, DOI 10.1097/00004032-200204000-00004; Wang ZY, 2002, AM J EPIDEMIOL, V155, P554, DOI 10.1093/aje/155.6.554; Wei L, 2000, J Radiat Res, V41 Suppl, P1; WEISS HA, 1994, INT J CANCER, V59, P327, DOI 10.1002/ijc.2910590307; WEISS HA, 1995, RADIAT RES, V142, P1, DOI 10.2307/3578960; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WHELDON TE, 1989, J ROY STAT SOC A STA, V152, P327, DOI 10.2307/2983130; Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; WHO World Health Organization, 1994, ENV HLTH CRIT, V160; Wick RR, 1999, RADIAT RES, V152, pS8, DOI 10.2307/3580103; Williams D, 2002, NAT REV CANCER, V2, P543, DOI 10.1038/nrc845; Wing S, 1997, ENVIRON HEALTH PERSP, V105, P52, DOI 10.2307/3433062; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041; Zeeb H, 2003, AM J EPIDEMIOL, V158, P35, DOI 10.1093/aje/kwg107	217	136	143	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6404	6428		10.1038/sj.onc.1207896	http://dx.doi.org/10.1038/sj.onc.1207896			25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322514				2022-12-17	WOS:000223468800008
J	Conrotto, P; Corso, S; Gamberini, S; Comoglio, PM; Giordano, S				Conrotto, P; Corso, S; Gamberini, S; Comoglio, PM; Giordano, S			Interplay between scatter factor receptors and B plexins controls invasive growth	ONCOGENE			English	Article						Scatter Factor Receptors; B plexins; invasive growth; tyrosine phosphorylation	MACROPHAGE-STIMULATING PROTEIN; TYROSINE KINASE; SEMAPHORIN RECEPTORS; MET PROTOONCOGENE; SOMATIC MUTATIONS; EPITHELIAL-CELLS; GENE-PRODUCT; ACTIVE RAC; RON GENE; HGF	Met and Ron tyrosine kinases are members of the Scatter Factor Receptor family. Met is the receptor for hepatocyte growth factor while Ron is that for macrophage stimulating protein. On ligand stimulation, activation of these receptors induces 'invasive growth', a complex biological response involved in tissue morphogenesis and, when deregulated, in tumor progression and metastasis. Scatter Factor Receptors share structural homology with Plexins, transmembrane receptors for Semaphorins, a family of ligands originally identified as axon guidance molecules. A physical and functional association between Met and Plexin B1, the prototype of class B Plexin subfamily, has been previously demonstrated. Here, we show that both Met and Ron receptors can interact with each of the three members of class B Plexins, even in the absence of their ligands and that Plexin B1 ligand, Sema 4D, can induce activation of Met and Ron receptors, promoting an invasive response. Furthermore, in some human neoplastic cell lines Plexin B1 is overexpressed, constitutively tyrosine phosphorylated, and associated with Scatter Factor Receptors. These data extend the crosstalk previously described between Met and Plexin B1 to the entire families of Scatter Factor Receptors and class B Plexins and show that interaction with multiple upstream activators can finely tune the invasive growth process both in physiological conditions and in tumor growth and metastatization.	Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy	University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Turin, Italy.	silvia.giordano@ircc.it	Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; CORSO, Simona/0000-0002-5069-1503				Artigiani S, 2003, J BIOL CHEM, V278, P10094, DOI 10.1074/jbc.M210156200; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chen YQ, 2002, ONCOGENE, V21, P6382, DOI 10.1038/sj.onc.1205783; Danilkovitch A, 1999, EXP CELL RES, V248, P575, DOI 10.1006/excr.1999.4429; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Park WS, 1999, CANCER RES, V59, P307; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	38	136	153	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5131	5137		10.1038/sj.onc.1207650	http://dx.doi.org/10.1038/sj.onc.1207650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15184888				2022-12-17	WOS:000222382500003
J	Castedo, M; Perfettini, JL; Roumier, T; Yakushijin, K; Horne, D; Medema, R; Kroemer, G				Castedo, M; Perfettini, JL; Roumier, T; Yakushijin, K; Horne, D; Medema, R; Kroemer, G			The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe	ONCOGENE			English	Article						aneuploidy; cancer; caspases; Chk-2; programmed cell death	DNA-DAMAGE CHECKPOINT; GLYCOPROTEIN COMPLEX; APOPTOSIS; ACTIVATION; P53; PHOSPHORYLATION; LOCALIZATION; CHECKING; CDC25C; DEATH	Fusion between nonsynchronized cells leads to the formation of heterokarya which transiently activate Cyclin-dependent kinase 1 (Cdk1)/cyclin B1 and enter the prophase of the cell cycle, where they arrest due to a loss of Cdk1/cyclin B1 activity, activate p53, disorganize centrosomes, and undergo apoptosis. Here, we show that the down regulation of Cdk1/cyclin B is secondary to the activation of the DNA structure checkpoint kinase Chk2. Thus, syncytia generated by the fusion of asynchronous HeLa cells contain elevated levels of active Chk2 but not Chk1. Chk2 bearing the activating phosphorylation on threonine-68 accumulates in BRCA1 nuclear bodies when the cells arrest at the G2/M boundary. Inhibition of Chk2 by transfection of a dominant-negative Chk2 mutant or a chemical inhibitor, debromohymenialdesine, stabilizes centrosomes, maintains high cyclin B1 levels, and allows for a prolonged activation of Cdk1. Under these conditions, multinuclear HeLa syncytia do not arrest at the G2/M boundary and rather enter mitotis and subsequently die during the metaphase of the cell cycle. This mitotic catastrophe is associated with the activation of the proapoptotic caspase-3. Inhibition of caspases allows the cells to go beyond the metaphase arrest, indicating that apoptosis is responsible for cell death by mitotic catastrophe. In another, completely different model of mitotic catastrophe, namely 14.3.3sigma-deficient HCT116 colon carcinoma cells treated with doxorubicin, Chk2 activation was also found to be deficient as compared to 14.3.3sigma-sufficient controls. Inhibition of Chk2 again facilitated the induction of mitotic catastrophe in HCT116 wild-type cells. In conclusion, a conflict in cell cycle progression or DNA damage can lead to mitotic catastrophe, provided that the checkpoint kinase Chk2 is inhibited. Inhibition of Chk2 thus can sensitize proliferating cells to chemotherapy-induced apoptosis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Netherlands Canc Inst, Div Mol Biol H8, NL-1066 CX Amsterdam, Netherlands	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Oregon State University; Netherlands Cancer Institute	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Medema, Rene H/E-2981-2013; KROEMER, Guido/B-4263-2013; PERFETTINI, Jean-Luc/N-4699-2017; Medema, Rene H/G-5415-2011; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Medema, Rene/0000-0002-6754-0381				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chehab NH, 2000, GENE DEV, V14, P278; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferri KF, 2000, CELL DEATH DIFFER, V7, P1137, DOI 10.1038/sj.cdd.4400748; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hirose Y, 2001, CANCER RES, V61, P5843; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lock RB, 1996, CANCER RES, V56, P4006; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mackey MA, 1996, CANCER RES, V56, P1770; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; PERFETTINI JL, 2004, IN PRESS J EXP MED; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roumier T, 2003, BIOCHEM PHARMACOL, V66, P1321, DOI 10.1016/S0006-2952(03)00480-5; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Shieh SY, 2000, GENE DEV, V14, P289; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Sosa ACB, 2000, J ORG CHEM, V65, P610, DOI 10.1021/jo991277o; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takada S, 2003, CELL, V113, P87, DOI 10.1016/S0092-8674(03)00202-2; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Xu JH, 2003, FEBS LETT, V545, P209, DOI 10.1016/S0014-5793(03)00536-2; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yu Q, 2002, CANCER RES, V62, P5743	46	136	144	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4353	4361		10.1038/sj.onc.1207573	http://dx.doi.org/10.1038/sj.onc.1207573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15048074				2022-12-17	WOS:000221661300001
J	Chien, J; Staub, J; Hu, SI; Erickson-Johnson, MR; Couch, FJ; Smith, DI; Crowl, RM; Kaufmann, SH; Shridhar, V				Chien, J; Staub, J; Hu, SI; Erickson-Johnson, MR; Couch, FJ; Smith, DI; Crowl, RM; Kaufmann, SH; Shridhar, V			A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer	ONCOGENE			English	Article						serine protease; HtrA; ovarian cancer; down-regulation; loss of heterozygosity	SERINE-PROTEASE; EPITHELIAL TUMORS; CELL-DEATH; GENE; DMBT1; IDENTIFICATION; APOPTOSIS; GROWTH; EXPRESSION; INHIBITOR	We report here that HtrA1, a candidate tumor suppressor, is downregulated in ovarian cancer. Expression of HtrA1 is downregulated in five of seven ovarian cancer cell lines. In total, 59% of primary ovarian tumors have either a complete absence or markedly reduced levels of HtrA1 expression compared to the brushings of ovarian surface epithelium. Primary ovarian tumors show high frequencies of loss of an allele at microsatellite markers near htrA1 locus on 10q26. Downregulation of HtrA1 in SKOV3 by antisense transfection promotes anchorage-independent growth, while exogenous expression of HtrA1 in OV202 induces cell death. HtrA1-induced cell death is not inhibited by the broad caspase inhibitor, zVAD(O-Me) fmk, but instead reflects serine protease activity associated with HtrA1. These observations raise the possibility of HtrA1 as a candidate tumor suppressor involved in promoting serine-protease-mediated cell death and that downregulation of HtrA1 in ovarian cancer may contribute to malignant phenotype.	Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Novartis Pharmaceut, Arthrit Biol Unit, E Hanover, NJ 07936 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Novartis; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	shridv@exrch.mayo.edu	Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374; Kaufmann, Scott/0000-0002-4900-7145				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Deichmann M, 2002, ONCOLOGY-BASEL, V63, P166, DOI 10.1159/000063802; ENOMOTO T, 1991, AM J PATHOL, V139, P777; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kato MV, 2000, MOL MED, V6, P126, DOI 10.1007/BF03401780; KATSAROS D, 1995, ANTICANCER RES, V15, P1501; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mueller W, 2002, ONCOGENE, V21, P5956, DOI 10.1038/sj.onc.1205733; Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Ross JS, 1999, AM J CLIN PATHOL, V111, P311; Sasaki H, 2002, CANCER RES, V62, P1790; Schwartz DI, 1999, BREAST CANCER RES TR, V58, P25, DOI 10.1023/A:1006237031070; Shridhar V, 2002, CANCER RES, V62, P262; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	32	136	145	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1636	1644		10.1038/sj.onc.1207271	http://dx.doi.org/10.1038/sj.onc.1207271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716297				2022-12-17	WOS:000189219500019
J	Bauvois, B				Bauvois, B			Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?	ONCOGENE			English	Review						ACE; ADAM; APN; DPPIV; MT-MMP; TACE	NECROSIS-FACTOR-ALPHA; ANGIOTENSIN-CONVERTING ENZYME; MEMBRANE-TYPE-MATRIX; DIPEPTIDYL PEPTIDASE-IV; MICROVASCULAR ENDOTHELIAL-CELLS; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; TNF-ALPHA; AMINOPEPTIDASE-N; TISSUE LOCALIZATION	Transmembrane proteases (TPs) are proteins anchored in the plasma membrane with their catalytic site exposed to the external surface of the membrane. TPs are widely expressed, and their dysregulated expression is associated with cancer, infection, inflammation, autoimmune and cardiovascular diseases, all diseases where angiogenesis is part of the pathology. TPs participate in extracellular proteolysis (degradation of extracellular matrix components, regulation of chemokine activity, release of membrane-anchored cytokines, cytokine receptors and adhesion molecules) and influence cell functions (growth, secretion of angiogenic molecules, motility). Recent attention has been focused on the ADAM-17 (a disintegrin and metalloprotease)/TACE/CD156q, the MT1-MMP (membrane-type-1 matrix metallo proteinase)/MMP-14, and the ectopeptidases aminopeptidase N (APN/CD13), dipeptidyl peptidase IV (DPPIV/CD26) and angiotensin-converting enzyme (ACE/CD143), that appear to have a critical role in angiogenesis. This article summarizes current knowledge on these TPs, and reviews recent investigations that document their participation during angiogenic-related events. Through their multiple roles, TPs may thereby provide critical links in angiogenesis.	Hop Necker Enfants Malad, INSERM, U507, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bauvois, B (corresponding author), Hop Necker Enfants Malad, INSERM, U507, Batiment Lavoisier,161 Rue Sevres, F-75015 Paris, France.	bauvois@necker.fr	Bauvois, Brigitte/F-6776-2013	Bauvois, Brigitte/0000-0002-1751-6922				Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; AHMAD S, 1990, J PHARMACOL EXP THER, V252, P643; ALHENCGELAS F, 1997, CELL SURFACE PEPTIDA, P119; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Antczak C, 2001, BIOESSAYS, V23, P251, DOI 10.1002/1521-1878(200103)23:3<251::AID-BIES1035>3.0.CO;2-O; Antczak C, 2001, J BIOL REG HOMEOS AG, V15, P130; Asher J R, 2000, Curr Hypertens Rep, V2, P384, DOI 10.1007/s11906-000-0042-y; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; Bauvois B, 2001, J LEUKOCYTE BIOL, V70, P11; Beckner ME, 1999, CANCER INVEST, V17, P594, DOI 10.3109/07357909909032845; Bermpohl F, 1998, FEBS LETT, V428, P152, DOI 10.1016/S0014-5793(98)00515-8; Bernardi C, 1998, B BELG MATH SOC-SIM, V5, P7; Bernardini G, 2003, J IMMUNOL METHODS, V273, P83, DOI 10.1016/S0022-1759(02)00420-9; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bischof P, 2002, J REPROD IMMUNOL, V55, P3, DOI 10.1016/S0165-0378(01)00142-5; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Bueno C, 2002, J IMMUNOL METHODS, V264, P77, DOI 10.1016/S0022-1759(02)00083-2; BURNETT JC, 1999, J HYPERTENS S1, V17, P537; Burrell LM, 2000, AM J HYPERTENS, V13, P1110, DOI 10.1016/S0895-7061(00)01185-7; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cambien Francois, 1995, P1667; Cerretti DP, 1999, BIOCHEM SOC T, V27, P219, DOI 10.1042/bst0270219; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chen WT, 2003, CANCER METAST REV, V22, P259, DOI 10.1023/A:1023055600919; CHOMARAT P, 1995, J IMMUNOL, V155, P3645; Collen A, 2003, BLOOD, V101, P1810, DOI 10.1182/blood-2002-05-1593; Colon AL, 2001, CYTOKINE, V16, P220, DOI 10.1006/cyto.2001.0969; Comte L, 1997, EUR J CLIN INVEST, V27, P788, DOI 10.1046/j.1365-2362.1997.1980737.x; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Constantinescu CS, 1998, IMMUNOL LETT, V62, P25, DOI 10.1016/S0165-2478(98)00025-X; Conway JG, 2001, J PHARMACOL EXP THER, V298, P900; Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; Danilov S, 1996, J HYPERTENS, V14, P719, DOI 10.1097/00004872-199606000-00007; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; DIAZFLORES L, 1994, HISTOL HISTOPATHOL, V9, P807; Doggrell SA, 2002, EXPERT OPIN INV DRUG, V11, P1003, DOI 10.1517/13543784.11.7.1003; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellis LM, 2001, SEMIN ONCOL, V28, P94, DOI 10.1053/sonc.2001.28560; Emanueli C, 2002, AM J HYPERTENS, V15, P410, DOI 10.1016/S0895-7061(01)02332-9; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; FUJII H, 1995, CLIN EXP METASTAS, V13, P337; Glicklich D, 1999, TRANSPLANTATION, V68, P62, DOI 10.1097/00007890-199907150-00012; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Gonzalez-Gronow M, 2001, BIOCHEM J, V355, P397, DOI 10.1042/0264-6021:3550397; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hadjadj S, 2001, J AM SOC NEPHROL, V12, P541, DOI 10.1681/ASN.V123541; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Harada T, 1998, J HEPATOL, V28, P231, DOI 10.1016/0168-8278(88)80010-2; Hashida H, 2002, GASTROENTEROLOGY, V122, P376, DOI 10.1053/gast.2002.31095; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiscox S, 1997, IN VIVO, V11, P125; HOCKEL M, 1993, ARCH SURG-CHICAGO, V128, P423; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Honda S, 2001, CLIN EXP IMMUNOL, V126, P131, DOI 10.1046/j.1365-2249.2001.01624.x; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Ishii K, 2001, BIOL PHARM BULL, V24, P226, DOI 10.1248/bpb.24.226; ISHII N, 1994, ENZYME PROTEIN, V48, P174, DOI 10.1159/000474984; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Karkkainen I, 2000, MOL CELL NEUROSCI, V15, P547, DOI 10.1006/mcne.2000.0848; Kawai M, 2003, CLIN CHIM ACTA, V330, P141, DOI 10.1016/S0009-8981(03)00002-0; Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Koike T, 2002, J CELL BIOCHEM, V86, P748, DOI 10.1002/jcb.10257; Korom S, 1999, TRANSPLANT P, V31, P873, DOI 10.1016/S0041-1345(98)01812-0; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Kuro T, 2000, BIOL PHARM BULL, V23, P820; Kuroi K, 2001, INT J BIOL MARKER, V16, P5, DOI 10.1177/172460080101600102; Lafleur MA, 2002, J CELL SCI, V115, P3427; Laurent S, 2000, HYPERTENSION, V35, P1148, DOI 10.1161/01.HYP.35.5.1148; Lever AF, 1998, LANCET, V352, P179, DOI 10.1016/S0140-6736(98)03228-0; Li L, 1998, BBA-MOL CELL RES, V1405, P110, DOI 10.1016/S0167-4889(98)00091-3; Lohn M, 2002, LEUKEMIA LYMPHOMA, V43, P407, DOI 10.1080/10428190290006233; Lucas A, 1998, CARDIOVASC RES, V38, P237, DOI 10.1016/S0008-6363(97)00315-5; Ludwig A, 2002, J LEUKOCYTE BIOL, V72, P183; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; Mattei MG, 1997, GENOMICS, V40, P168, DOI 10.1006/geno.1996.4559; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McClean DR, 2001, AM J CARDIOL, V87, P565, DOI 10.1016/S0002-9149(00)01432-6; Meissner A, 1999, MOL HUM REPROD, V5, P252, DOI 10.1093/molehr/5.3.252; Mishima Y, 2002, J NATL CANCER I, V94, P1020; Moehler TM, 2001, ANN HEMATOL, V80, P695, DOI 10.1007/s00277-001-0398-3; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Napoleone E, 2000, CIRC RES, V86, P139, DOI 10.1161/01.RES.86.2.139; Neal B, 2000, LANCET, V356, P1955; NEWTON RC, 2001, ANN RHEUM DIS     S3, V60, P25; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohta S, 2001, J RHEUMATOL, V28, P1756; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Opdenakker G, 2002, Verh K Acad Geneeskd Belg, V64, P105; Pap T, 2000, ARTHRITIS RHEUM, V43, P1226, DOI 10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4; Papies B, 1991, Cor Vasa, V33, P218; Pasqualini R, 2000, CANCER RES, V60, P722; Patel IR, 1998, J IMMUNOL, V160, P4570; Phillips M Ian, 2002, Curr Opin Investig Drugs, V3, P569; PIEPHO RW, 2000, AM J HEALTH-SYST PH, V57, P53; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proost P, 2001, BLOOD, V98, P3554, DOI 10.1182/blood.V98.13.3554; Prud'homme GJ, 2000, J AUTOIMMUN, V14, P23, DOI 10.1006/jaut.1999.0339; Rajavashisth TB, 1999, CIRCULATION, V99, P3103, DOI 10.1161/01.CIR.99.24.3103; Ribatti D, 2000, J HEMATOTH STEM CELL, V9, P13, DOI 10.1089/152581600319577; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; Rouleau JL, 2000, LANCET, V356, P615, DOI 10.1016/S0140-6736(00)02602-7; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; SANTOS A, 2000, THROMB HAEMOSTASIS, V78, P497; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; SCHEELTOELLNER D, 1995, LAB INVEST, V73, P685; Schonermarck U, 2000, CLIN EXP RHEUMATOL, V18, P457; Schwartz JD, 1998, SURGERY, V124, P232, DOI 10.1067/msy.1998.90566; Seifert T, 2002, MULT SCLER, V8, P447, DOI 10.1191/1352458502ms830oa; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Silvestre JS, 2001, CIRC RES, V89, P678, DOI 10.1161/hh2001.097691; Simpson K, 2000, DRUGS, V59, P1149, DOI 10.2165/00003495-200059050-00012; Skopinski P, 2001, INT J CLIN PHARM RES, V21, P73; Skovronsky DM, 2001, J NEUROBIOL, V49, P40, DOI 10.1002/neu.1064; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Soderstrom M, 2001, APMIS, V109, P305, DOI 10.1034/j.1600-0463.2001.d01-125.x; Spinale FG, 2000, CARDIOVASC RES, V46, P225, DOI 10.1016/S0008-6363(99)00431-9; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Takeshita S, 2001, CARDIOVASC RES, V52, P314, DOI 10.1016/S0008-6363(01)00372-8; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Trifilieff A, 2002, BRIT J PHARMACOL, V135, P1655, DOI 10.1038/sj.bjp.0704616; Tschesche H, 2000, ADV EXP MED BIOL, V477, P217; Ueno H, 1997, CANCER RES, V57, P2055; Vivian EM, 2002, CLIN THER, V24, P1741, DOI 10.1016/S0149-2918(02)80076-5; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Vranes D, 1995, J DIABETES COMPLICAT, V9, P296, DOI 10.1016/1056-8727(95)80026-B; WANG DH, 1990, HYPERTENSION, V15, P68, DOI 10.1161/01.HYP.15.1.68; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; WRIGHT JW, 1991, BRAIN RES BULL, V27, P545, DOI 10.1016/0361-9230(91)90027-H; Xu P, 2002, J CLIN ENDOCR METAB, V87, P1353, DOI 10.1210/jc.87.3.1353; Xue CB, 2001, J MED CHEM, V44, P2636, DOI 10.1021/jm010127e; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4; Yamanaka H, 2000, LAB INVEST, V80, P677, DOI 10.1038/labinvest.3780071; Yoshiji H, 2002, INT J ONCOL, V20, P1227; Yoshiji H, 2002, ANTI-CANCER DRUG, V13, P221, DOI 10.1097/00001813-200203000-00003; Yoshiji H, 2001, CLIN CANCER RES, V7, P1073; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang XY, 1999, J MASS SPECTROM, V34, P255, DOI 10.1002/(SICI)1096-9888(199904)34:4<255::AID-JMS752>3.3.CO;2-Z; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968; Zukowska Z, 2003, CAN J PHYSIOL PHARM, V81, P89, DOI 10.1139/Y03-006; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; 2000, LANCET, V356, P1955	170	136	146	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					317	329		10.1038/sj.onc.1207124	http://dx.doi.org/10.1038/sj.onc.1207124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724562				2022-12-17	WOS:000188098300001
